EDITORS

Anthony S. Fauci, MD, ScD(HON)
Chief, Laboratory of Immunoregulation; Director,
National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda

Eugene Braunwald, MD, ScD(HON)
Distinguished Hersey Professor of Medicine,
Harvard Medical School; Chairman, TIMI Study Group,
Brigham and Women’s Hospital, Boston

Dennis L. Kasper, MD, MA(HON)
William Ellery Channing Professor of Medicine,
Professor of Microbiology and Molecular Genetics,
Harvard Medical School; Director, Channing Laboratory,
Department of Medicine, Brigham and Women’s Hospital, Boston

Stephen L. Hauser, MD
Robert A. Fishman Distinguished Professor and Chairman,
Department of Neurology, University of California, San Francisco,
San Francisco

Dan L. Longo, MD
Scientific Director, National Institute on Aging,
National Institutes of Health, Bethesda and Baltimore

J. Larry Jameson, MD, PhD
Professor of Medicine;
Vice President for Medical Affairs and Lewis Landsberg Dean,
Northwestern University Feinberg School of Medicine, Chicago

Joseph Loscalzo, MD, PhD
Hersey Professor of the Theory and Practice of Medicine,
Harvard Medical School; Chairman, Department of Medicine;
Physician-in-Chief, Brigham and Women’s Hospital, Boston
CONTENTS

Contributors ................................................. xiii
Preface ...................................................... xv
Acknowledgments ........................................ xvii

SECTION 1 CARE OF THE HOSPITALIZED PATIENT

1 Initial Evaluation and Admission Orders for the General Medicine Patient ............. 1
2 Electrolytes/Acid-Base Balance .......................................... 3
3 Diagnostic Imaging in Internal Medicine ........................................ 22
4 Procedures Commonly Performed by Internists ...................................... 25
5 Principles of Critical Care Medicine .................................................. 30
6 Pain and Its Management ............................................................... 34
7 Assessment of Nutritional Status ...................................................... 39
8 Enteral and Parenteral Nutrition ....................................................... 41
9 Transfusion and Pheresis Therapy ..................................................... 44
10 Palliative and End-of-Life Care ......................................................... 46

SECTION 2 MEDICAL EMERGENCIES

11 Cardiovascular Collapse and Sudden Death ....................................... 55
12 Shock ......................................................................................... 58
13 Sepsis and Septic Shock ................................................................. 63
14 Acute Pulmonary Edema ................................................................ 66
15 Acute Respiratory Distress Syndrome ................................................. 69
16 Respiratory Failure ........................................................................ 71
17 Confusion, Stupor, and Coma ............................................................. 74
18 Stroke ......................................................................................... 79
19 Subarachnoid Hemorrhage ............................................................... 88
20 Increased Intracranial Pressure and Head Trauma .................................. 90
21 Spinal Cord Compression .................................................................. 94
22 Hypoxic-Ischemic Encephalopathy .................................................... 96
23 Status Epilepticus ........................................................................... 98
24 Diabetic Ketoacidosis and Hyperosmolar Coma ..................................... 100
25 Hypoglycemia ............................................................................... 103
26 Infectious Disease Emergencies ........................................................ 105
27 Oncologic Emergencies ................................................................... 112
28 Anaphylaxis .................................................................................... 116
29 Bites, Venoms, Stings, and Marine Poisonings ....................................... 117
30 Hypothermia and Frostbite ............................................................... 127
## CONTENTS

### SECTION 3 COMMON PATIENT PRESENTATIONS

<table>
<thead>
<tr>
<th>Section</th>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td>Poisoning and Drug Overdose</td>
<td>130</td>
</tr>
<tr>
<td>32</td>
<td>Bioterrorism</td>
<td>160</td>
</tr>
<tr>
<td>33</td>
<td>Chest Pain</td>
<td>175</td>
</tr>
<tr>
<td>34</td>
<td>Abdominal Pain</td>
<td>179</td>
</tr>
<tr>
<td>35</td>
<td>Headache</td>
<td>183</td>
</tr>
<tr>
<td>36</td>
<td>Back and Neck Pain</td>
<td>189</td>
</tr>
<tr>
<td>37</td>
<td>Fever, Hyperthermia, Chills, and Rash</td>
<td>199</td>
</tr>
<tr>
<td>38</td>
<td>Pain and Swelling of Joints</td>
<td>203</td>
</tr>
<tr>
<td>39</td>
<td>Syncope</td>
<td>207</td>
</tr>
<tr>
<td>40</td>
<td>Dizziness and Vertigo</td>
<td>211</td>
</tr>
<tr>
<td>41</td>
<td>Acute Visual Loss and Double Vision</td>
<td>215</td>
</tr>
<tr>
<td>42</td>
<td>Weakness and Paralysis</td>
<td>218</td>
</tr>
<tr>
<td>43</td>
<td>Tremor and Movement Disorders</td>
<td>222</td>
</tr>
<tr>
<td>44</td>
<td>Aphasia and Related Disorders</td>
<td>224</td>
</tr>
<tr>
<td>45</td>
<td>Sleep Disorders</td>
<td>226</td>
</tr>
<tr>
<td>46</td>
<td>Dyspnea</td>
<td>231</td>
</tr>
<tr>
<td>47</td>
<td>Cough and Hemoptysis</td>
<td>233</td>
</tr>
<tr>
<td>48</td>
<td>Cyanosis</td>
<td>239</td>
</tr>
<tr>
<td>49</td>
<td>Edema</td>
<td>240</td>
</tr>
<tr>
<td>50</td>
<td>Nausea, Vomiting, and Indigestion</td>
<td>244</td>
</tr>
<tr>
<td>51</td>
<td>Weight Loss</td>
<td>247</td>
</tr>
<tr>
<td>52</td>
<td>Dysphagia</td>
<td>249</td>
</tr>
<tr>
<td>53</td>
<td>Diarrhea, Constipation, and Malabsorption</td>
<td>253</td>
</tr>
<tr>
<td>54</td>
<td>Gastrointestinal Bleeding</td>
<td>259</td>
</tr>
<tr>
<td>55</td>
<td>Jaundice and Evaluation of Liver Function</td>
<td>263</td>
</tr>
<tr>
<td>56</td>
<td>Ascites</td>
<td>271</td>
</tr>
<tr>
<td>57</td>
<td>Azotemia and Urinary Abnormalities</td>
<td>274</td>
</tr>
<tr>
<td>58</td>
<td>Anemia and Polycythemia</td>
<td>280</td>
</tr>
<tr>
<td>59</td>
<td>Lymphadenopathy and Splenomegaly</td>
<td>283</td>
</tr>
<tr>
<td>60</td>
<td>Generalized Fatigue</td>
<td>288</td>
</tr>
</tbody>
</table>

### SECTION 4 OPHTHALMOLOGY AND OTOLARYNGOLOGY

<table>
<thead>
<tr>
<th>Section</th>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>61</td>
<td>Common Disorders of Vision and Hearing</td>
<td>293</td>
</tr>
<tr>
<td>62</td>
<td>Sinusitis, Pharyngitis, Otitis, and Other Upper Respiratory Infections</td>
<td>301</td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
<td>Page</td>
</tr>
<tr>
<td>---------</td>
<td>------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>5</td>
<td>General Examination of the Skin</td>
<td>309</td>
</tr>
<tr>
<td></td>
<td>Common Skin Conditions</td>
<td>314</td>
</tr>
<tr>
<td>6</td>
<td>Examination of Blood Smears and Bone Marrow</td>
<td>321</td>
</tr>
<tr>
<td>66</td>
<td>Red Blood Cell Disorders</td>
<td>323</td>
</tr>
<tr>
<td>67</td>
<td>Leukocytosis and Leukopenia</td>
<td>329</td>
</tr>
<tr>
<td>68</td>
<td>Bleeding and Thrombotic Disorders</td>
<td>332</td>
</tr>
<tr>
<td>69</td>
<td>Cancer Chemotherapy</td>
<td>339</td>
</tr>
<tr>
<td>70</td>
<td>Myeloid Leukemias, Myelodysplasia, and Myeloproliferative Syndromes</td>
<td>344</td>
</tr>
<tr>
<td>71</td>
<td>Lymphoid Malignancies</td>
<td>352</td>
</tr>
<tr>
<td>72</td>
<td>Skin Cancer</td>
<td>364</td>
</tr>
<tr>
<td>73</td>
<td>Head and Neck Cancer</td>
<td>367</td>
</tr>
<tr>
<td>74</td>
<td>Lung Cancer</td>
<td>368</td>
</tr>
<tr>
<td>75</td>
<td>Breast Cancer</td>
<td>374</td>
</tr>
<tr>
<td>76</td>
<td>Tumors of the Gastrointestinal Tract</td>
<td>379</td>
</tr>
<tr>
<td>77</td>
<td>Genitourinary Tract Cancer</td>
<td>391</td>
</tr>
<tr>
<td>78</td>
<td>Gynecologic Cancer</td>
<td>395</td>
</tr>
<tr>
<td>79</td>
<td>Prostate Hyperplasia and Carcinoma</td>
<td>399</td>
</tr>
<tr>
<td>80</td>
<td>Cancer of Unknown Primary Site</td>
<td>401</td>
</tr>
<tr>
<td>81</td>
<td>Paraneoplastic Endocrine Syndromes</td>
<td>405</td>
</tr>
<tr>
<td>82</td>
<td>Neurologic Paraneoplastic Syndromes</td>
<td>407</td>
</tr>
<tr>
<td>83</td>
<td>Diagnosis of Infectious Diseases</td>
<td>411</td>
</tr>
<tr>
<td>84</td>
<td>Antibacterial Therapy</td>
<td>422</td>
</tr>
<tr>
<td>85</td>
<td>Health Care–Associated Infections</td>
<td>428</td>
</tr>
<tr>
<td>86</td>
<td>Infections in the Immunocompromised Host</td>
<td>432</td>
</tr>
<tr>
<td>87</td>
<td>Infective Endocarditis</td>
<td>440</td>
</tr>
<tr>
<td>88</td>
<td>Intraabdominal Infections</td>
<td>448</td>
</tr>
<tr>
<td>89</td>
<td>Infectious Diarrheas</td>
<td>451</td>
</tr>
<tr>
<td>90</td>
<td>Sexually Transmitted Diseases and Reproductive Tract Infections</td>
<td>462</td>
</tr>
<tr>
<td>91</td>
<td>Infections of the Skin, Soft Tissues, Joints, and Bones</td>
<td>477</td>
</tr>
<tr>
<td>92</td>
<td>Pneumococcal Infections</td>
<td>486</td>
</tr>
<tr>
<td>Page</td>
<td>Section Title</td>
<td>Page</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>93</td>
<td>Staphylococcal Infections</td>
<td>489</td>
</tr>
<tr>
<td>94</td>
<td>Streptococcal/Enterococcal Infections, Diphtheria, and Other Infections Caused by Corynebacteria and Related Species</td>
<td>496</td>
</tr>
<tr>
<td>95</td>
<td>Meningococcal and Listerial Infections</td>
<td>504</td>
</tr>
<tr>
<td>96</td>
<td>Infections Caused by <em>Haemophilus</em>, <em>Bordetella</em>, <em>Moraxella</em>, and HACEK Group Organisms</td>
<td>508</td>
</tr>
<tr>
<td>97</td>
<td>Diseases Caused by Gram-Negative Enteric Bacteria, <em>Pseudomonas</em>, and <em>Legionella</em></td>
<td>513</td>
</tr>
<tr>
<td>98</td>
<td>Infections Caused by Miscellaneous Gram-Negative Bacilli</td>
<td>522</td>
</tr>
<tr>
<td>99</td>
<td>Anaerobic Infections</td>
<td>528</td>
</tr>
<tr>
<td>100</td>
<td>Nocardiosis and Actinomycosis</td>
<td>535</td>
</tr>
<tr>
<td>101</td>
<td>Tuberculosis and Other Mycobacterial Infections</td>
<td>538</td>
</tr>
<tr>
<td>102</td>
<td>Lyme Disease and Other Nonsyphilitic Spirochetal Infections</td>
<td>549</td>
</tr>
<tr>
<td>103</td>
<td>Rickettsial Diseases</td>
<td>554</td>
</tr>
<tr>
<td>104</td>
<td><em>Mycoplasma</em> Infections</td>
<td>560</td>
</tr>
<tr>
<td>105</td>
<td>Chlamydial Infections</td>
<td>561</td>
</tr>
<tr>
<td>106</td>
<td>Herpesvirus Infections</td>
<td>564</td>
</tr>
<tr>
<td>107</td>
<td>Cytomegalovirus and Epstein-Barr Virus Infections</td>
<td>572</td>
</tr>
<tr>
<td>108</td>
<td>Influenza and Other Viral Respiratory Diseases</td>
<td>577</td>
</tr>
<tr>
<td>109</td>
<td>Rubella, Rubella, Mumps, and Parvovirus Infections</td>
<td>584</td>
</tr>
<tr>
<td>110</td>
<td>Enteroviral Infections</td>
<td>588</td>
</tr>
<tr>
<td>111</td>
<td>Insect- and Animal-Borne Viral Infections</td>
<td>592</td>
</tr>
<tr>
<td>112</td>
<td>HIV Infection and AIDS</td>
<td>600</td>
</tr>
<tr>
<td>113</td>
<td>Fungal Infections</td>
<td>618</td>
</tr>
<tr>
<td>114</td>
<td><em>Pneumocystis</em> Infections</td>
<td>633</td>
</tr>
<tr>
<td>115</td>
<td>Protozoal Infections</td>
<td>636</td>
</tr>
<tr>
<td>116</td>
<td>Helminthic Infections and Ectoparasite Infestations</td>
<td>648</td>
</tr>
<tr>
<td>117</td>
<td>Physical Examination of the Heart</td>
<td>661</td>
</tr>
<tr>
<td>118</td>
<td>Electrocardiography</td>
<td>665</td>
</tr>
<tr>
<td>119</td>
<td>Noninvasive Examination of the Heart</td>
<td>669</td>
</tr>
<tr>
<td>120</td>
<td>Congenital Heart Disease in the Adult</td>
<td>674</td>
</tr>
<tr>
<td>121</td>
<td>Valvular Heart Disease</td>
<td>678</td>
</tr>
<tr>
<td>122</td>
<td>Cardiomyopathies and Myocarditis</td>
<td>684</td>
</tr>
<tr>
<td>123</td>
<td>Pericardial Disease</td>
<td>688</td>
</tr>
<tr>
<td>124</td>
<td>Hypertension</td>
<td>693</td>
</tr>
<tr>
<td>125</td>
<td>Metabolic Syndrome</td>
<td>699</td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
<td>Page</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>126</td>
<td>ST-Segment Elevation Myocardial Infarction (STEMI)</td>
<td>700</td>
</tr>
<tr>
<td>127</td>
<td>Unstable Angina and Non-ST-Elevation Myocardial Infarction</td>
<td>709</td>
</tr>
<tr>
<td>128</td>
<td>Chronic Stable Angina</td>
<td>712</td>
</tr>
<tr>
<td>129</td>
<td>Bradyarrhythmias</td>
<td>717</td>
</tr>
<tr>
<td>130</td>
<td>Tachyarrhythmias</td>
<td>720</td>
</tr>
<tr>
<td>131</td>
<td>Congestive Heart Failure and Cor Pulmonale</td>
<td>730</td>
</tr>
<tr>
<td>132</td>
<td>Diseases of the Aorta</td>
<td>736</td>
</tr>
<tr>
<td>133</td>
<td>Peripheral Vascular Disease</td>
<td>739</td>
</tr>
<tr>
<td>134</td>
<td>Pulmonary Hypertension</td>
<td>742</td>
</tr>
<tr>
<td>135</td>
<td>Respiratory Function and Pulmonary Diagnostic Procedures</td>
<td>747</td>
</tr>
<tr>
<td>136</td>
<td>Asthma</td>
<td>753</td>
</tr>
<tr>
<td>137</td>
<td>Environmental Lung Diseases</td>
<td>756</td>
</tr>
<tr>
<td>138</td>
<td>Chronic Obstructive Pulmonary Disease</td>
<td>759</td>
</tr>
<tr>
<td>139</td>
<td>Pneumonia and Lung Abscess</td>
<td>764</td>
</tr>
<tr>
<td>140</td>
<td>Pulmonary Thromboembolism and Deep-Vein Thrombosis</td>
<td>769</td>
</tr>
<tr>
<td>141</td>
<td>Interstitial Lung Disease</td>
<td>772</td>
</tr>
<tr>
<td>142</td>
<td>Diseases of the Pleura and Mediastinum</td>
<td>777</td>
</tr>
<tr>
<td>143</td>
<td>Disorders of Ventilation</td>
<td>781</td>
</tr>
<tr>
<td>144</td>
<td>Sleep Apnea</td>
<td>783</td>
</tr>
<tr>
<td>145</td>
<td>Approach to the Patient with Renal Disease</td>
<td>785</td>
</tr>
<tr>
<td>146</td>
<td>Acute Renal Failure</td>
<td>789</td>
</tr>
<tr>
<td>147</td>
<td>Chronic Kidney Disease and Uremia</td>
<td>794</td>
</tr>
<tr>
<td>148</td>
<td>Dialysis</td>
<td>796</td>
</tr>
<tr>
<td>149</td>
<td>Renal Transplantation</td>
<td>798</td>
</tr>
<tr>
<td>150</td>
<td>Glomerular Diseases</td>
<td>801</td>
</tr>
<tr>
<td>151</td>
<td>Renal Tubular Disease</td>
<td>808</td>
</tr>
<tr>
<td>152</td>
<td>Urinary Tract Infections</td>
<td>815</td>
</tr>
<tr>
<td>153</td>
<td>Renovascular Disease</td>
<td>820</td>
</tr>
<tr>
<td>154</td>
<td>Nephrolithiasis</td>
<td>826</td>
</tr>
<tr>
<td>155</td>
<td>Urinary Tract Obstruction</td>
<td>829</td>
</tr>
</tbody>
</table>
# CONTENTS

## SECTION 11  GASTROENTEROLOGY

<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>156</td>
<td>Peptic Ulcer and Related Disorders</td>
</tr>
<tr>
<td>157</td>
<td>Inflammatory Bowel Diseases</td>
</tr>
<tr>
<td>158</td>
<td>Colonic and Anorectal Diseases</td>
</tr>
<tr>
<td>159</td>
<td>Cholelithiasis, Cholecystitis, and Cholangitis</td>
</tr>
<tr>
<td>160</td>
<td>Pancreatitis</td>
</tr>
<tr>
<td>161</td>
<td>Acute Hepatitis</td>
</tr>
<tr>
<td>162</td>
<td>Chronic Hepatitis</td>
</tr>
<tr>
<td>163</td>
<td>Cirrhosis and Alcoholic Liver Disease</td>
</tr>
<tr>
<td>164</td>
<td>Portal Hypertension</td>
</tr>
</tbody>
</table>

## SECTION 12 ALLERGY, CLINICAL IMMUNOLOGY, AND RHEUMATOLOGY

<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>165</td>
<td>Diseases of Immediate Type Hypersensitivity</td>
</tr>
<tr>
<td>166</td>
<td>Primary Immune Deficiency Diseases</td>
</tr>
<tr>
<td>167</td>
<td>SLE, RA, and Other Connective Tissue Diseases</td>
</tr>
<tr>
<td>168</td>
<td>Vasculitis</td>
</tr>
<tr>
<td>169</td>
<td>Ankylosing Spondylitis</td>
</tr>
<tr>
<td>170</td>
<td>Psoriatic Arthritis</td>
</tr>
<tr>
<td>171</td>
<td>Reactive Arthritis</td>
</tr>
<tr>
<td>172</td>
<td>Osteoarthritis</td>
</tr>
<tr>
<td>173</td>
<td>Gout, Pseudogout, and Related Diseases</td>
</tr>
<tr>
<td>174</td>
<td>Other Musculoskeletal Disorders</td>
</tr>
<tr>
<td>175</td>
<td>Sarcoidosis</td>
</tr>
<tr>
<td>176</td>
<td>Amyloidosis</td>
</tr>
</tbody>
</table>

## SECTION 13 ENDOCRINOLOGY AND METABOLISM

<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>177</td>
<td>Disorders of the Anterior Pituitary and Hypothalamus</td>
</tr>
<tr>
<td>178</td>
<td>Diabetes Insipidus and SIADH</td>
</tr>
<tr>
<td>179</td>
<td>Thyroid Gland Disorders</td>
</tr>
<tr>
<td>180</td>
<td>Adrenal Gland Disorders</td>
</tr>
<tr>
<td>181</td>
<td>Obesity</td>
</tr>
<tr>
<td>182</td>
<td>Diabetes Mellitus</td>
</tr>
<tr>
<td>183</td>
<td>Disorders of the Male Reproductive System</td>
</tr>
<tr>
<td>184</td>
<td>Disorders of the Female Reproductive System</td>
</tr>
<tr>
<td>185</td>
<td>Hypercalcemia and Hypocalcemia</td>
</tr>
<tr>
<td>186</td>
<td>Osteoporosis and Osteomalacia</td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>187</td>
<td>Hypercholesterolemia and Hypertriglyceridemia</td>
</tr>
<tr>
<td>188</td>
<td>Hemochromatosis, Porphyrias, and Wilson’s Disease</td>
</tr>
<tr>
<td>189</td>
<td>The Neurologic Examination</td>
</tr>
<tr>
<td>190</td>
<td>Neuroimaging</td>
</tr>
<tr>
<td>191</td>
<td>Seizures and Epilepsy</td>
</tr>
<tr>
<td>192</td>
<td>Alzheimer’s Disease and Other Dementias</td>
</tr>
<tr>
<td>193</td>
<td>Parkinson’s Disease</td>
</tr>
<tr>
<td>194</td>
<td>Ataxic Disorders</td>
</tr>
<tr>
<td>195</td>
<td>ALS and Other Motor Neuron Diseases</td>
</tr>
<tr>
<td>196</td>
<td>Autonomic Nervous System Disorders</td>
</tr>
<tr>
<td>197</td>
<td>Trigeminal Neuralgia, Bell’s Palsy, and Other Cranial Nerve Disorders</td>
</tr>
<tr>
<td>198</td>
<td>Spinal Cord Diseases</td>
</tr>
<tr>
<td>199</td>
<td>Tumors of the Nervous System</td>
</tr>
<tr>
<td>200</td>
<td>Multiple Sclerosis (MS)</td>
</tr>
<tr>
<td>201</td>
<td>Acute Meningitis and Encephalitis</td>
</tr>
<tr>
<td>202</td>
<td>Chronic Meningitis</td>
</tr>
<tr>
<td>203</td>
<td>Peripheral Neuropathies, Including Guillain-Barré Syndrome (GBS)</td>
</tr>
<tr>
<td>204</td>
<td>Myasthenia Gravis (MG)</td>
</tr>
<tr>
<td>205</td>
<td>Muscle Diseases</td>
</tr>
<tr>
<td>206</td>
<td>Psychiatric Disorders</td>
</tr>
<tr>
<td>207</td>
<td>Psychiatric Medications</td>
</tr>
<tr>
<td>208</td>
<td>Eating Disorders</td>
</tr>
<tr>
<td>209</td>
<td>Alcoholism</td>
</tr>
<tr>
<td>210</td>
<td>Narcotic Abuse</td>
</tr>
<tr>
<td>211</td>
<td>Routine Disease Screening</td>
</tr>
<tr>
<td>212</td>
<td>Immunization and Advice to Travelers</td>
</tr>
<tr>
<td>213</td>
<td>Cardiovascular Disease Prevention</td>
</tr>
<tr>
<td>214</td>
<td>Prevention and Early Detection of Cancer</td>
</tr>
<tr>
<td>215</td>
<td>Smoking Cessation</td>
</tr>
<tr>
<td>216</td>
<td>Women’s Health</td>
</tr>
<tr>
<td>SECTION 17 ADVERSE DRUG REACTIONS</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>217</strong> Adverse Drug Reactions</td>
<td>1131</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SECTION 18 LABORATORY VALUES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>218</strong> Laboratory Values of Clinical Importance</td>
</tr>
</tbody>
</table>

Index ........................................................................ 1173
ASSOCIATE EDITORS

TAMAR F. BARLAM, MD
Associate Professor of Medicine
Boston University School of Medicine, Boston

ANNE R. CAPPOLA, MD, SCM
Assistant Professor of Medicine
Division of Endocrinology, Diabetes, and Metabolism
University of Pennsylvania School of Medicine
Philadelphia

S. ANDREW JOSEPHSON, MD
Assistant Professor of Neurology, Director, Neurohospitalist Program
University of California, San Francisco
San Francisco

CAROL A. LANGFORD, MD, MHS
Director, Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Cleveland Clinic Foundation, Cleveland

LEONARD S. LILLY, MD
Associate Professor of Medicine
Harvard Medical School
Chief, Brigham/Faulkner Cardiology
Brigham & Women’s Hospital, Boston

DAVID B. MOUNT, MD
Assistant Professor of Medicine
Harvard Medical School
Associate Physician, Brigham & Women’s Hospital
Renal Division Staff Physician, VA Boston Healthcare System, Boston

EDWIN K. SILVERMAN, MD, PHD
Associate Professor of Medicine
Channing Laboratory and Pulmonary and Critical Care Division
Department of Medicine, Brigham & Women’s Hospital
Harvard Medical School, Boston

Numbers indicate the chapters written or co-written by the contributor.

TAMAR F. BARLAM, MD
13, 26, 29, 37, 62, 83–111, 113–116, 139, 152, 212

EUGENE BRAUNWALD, MD
11, 12, 14, 33, 46–49, 117–124, 126–131, 134, 143, 144, 217

ANNE R. CAPPOLA, MD, SCM
7, 8, 24, 25, 30, 51, 177–188, 216

ANTHONY S. FAUCI, MD
28, 32, 38, 55, 56, 63, 64, 112, 159–176

STEPHEN L. HAUSER, MD

J. LARRY JAMESON, MD, PHD
1, 3, 4, 7, 8, 24, 25, 30, 31, 51, 60, 125, 177–188, 208, 211, 216, 218
S. ANDREW JOSEPHSON, MD

DENNIS L. KASPER, MD
13, 26, 29, 37, 62, 83–111, 113–116, 139, 152, 212

CAROL A. LANGFORD, MD
28, 32, 38, 55, 56, 63, 64, 112, 159–176

LEONARD S. LILLY, MD
11, 33, 117–124, 127–133, 213

DAN L. LONGO, MD
9, 10, 27, 34, 50, 52–54, 58, 59, 65–81, 156–158, 214

JOSEPH LOSCALZO, MD, PHD
2, 5, 15, 16, 57, 132, 133, 135–138, 140–142, 145–151, 153–155

DAVID B. MOUNT, MD
2, 57, 145–151, 153–155

EDWIN K. SILVERMAN, MD, PHD
5, 15, 16, 135–138, 140–142
Harrison’s Principles of Internal Medicine (HPIM) provides a comprehensive body of information important to an understanding of the biological and clinical aspects of quality patient care. It remains the premier medical textbook for students and clinicians. With the rapidly expanding base of medical knowledge and the time constraints associated with heavy patient-care responsibilities in modern health care settings, it is not always possible to read a comprehensive account of diseases and their presentations, clinical manifestations, and treatments before or even immediately after encountering the patient. It was for these reasons, among others, that in 1988 the Editors first condensed the clinical portions of HPIM into a pocket-sized volume, Harrison’s Manual of Medicine. Similar to the prior 6 editions, this new edition of the Manual, drawn from the 17th edition of HPIM, presents the key features of the diagnosis, clinical manifestations, and treatment of the major diseases that are likely to be encountered on a medical service.

The Editors stress that the Manual should not substitute for in-depth analysis of the clinical problem, but should serve as a ready source of well-crafted and informative summaries that will be useful “on-the-spot” and that will prepare the reader for a more in-depth analysis drawn from more extensive reading at a later time. The Manual has met with increasing popularity over the years; its popularity and value relate in part to its abbreviated format, which has proven to be extremely useful for initial diagnosis, brief description of pathogenesis, and outline of management in time-restricted clinical settings. The most obvious change in this new edition of the Manual is its appearance: full-color format will increase the speed with which readers can locate and use information within its chapters. The Manual has been written for easy and seamless reference to the full text of the 17th edition of HPIM, and the Editors recommend that the full textbook—or Harrison’s On Line—be consulted as soon as time allows.

As with previous editions, this latest edition of the Manual attempts to keep up with the continual and sometimes rapid evolution of internal medicine practices. In this regard, every chapter has received a close review and has been updated from the prior edition, with substantial revisions and new chapters provided where appropriate. In Section 1 on Care of the Hospitalized Patient, a new chapter entitled “End-of-Life Care” has been added. Section 2 on Medical Emergencies now includes a chapter entitled “Spinal Cord Compression.” Chapters on “Tremor and Movement Disorders” and “Generalized Fatigue” appear in Section 3 on Common Patient Presentations. In Section 7 on Infectious Diseases, the chapter on “HIV Infection and AIDS” has been extensively revised to reflect important advances in therapy since the last edition. In Section 8 on Cardiology, there are new chapters on “Noninvasive Examination of the Heart,” “Congenital Heart Disease in the Adult,” and “Metabolic Syndrome.” In Section 9 on Pulmonology, there is a new chapter on “Sleep Apnea,” and in Section 16 on Disease Prevention and Health Maintenance, there are important new chapters on “Cardiovascular Disease Prevention” and “Smoking Cessation.”

In full recognition of the important role of digital information delivery in alleviating the increasing time demands put on clinicians, the last 3 editions of the Manual, including the current edition, have been made.
available in PDA format. In addition, a version of the Manual for use with the iPhone platform is available for the 17th edition.

In 2006, in recognition of the increasing use of electronic health records systems in hospitals, Harrison’s Practice made its debut. This innovative, digital point-of-care resource delivers substantial clinical reference data to the bedside. Its outline format and telescopic nature make it an ideal tool for finding and employing complex medical reference information quickly. Taken as a complete portfolio, Harrison’s is now available in a variety of formats designed to be suitable for all levels of medical training and for all varieties of health care settings.
The Editors and McGraw-Hill wish to thank their editorial staff whose assistance and patience made this edition come out in a timely manner:

From the Editors’ offices: Pat Duffey; Gregory K. Folkers; Julie McCoy; Elizabeth Robbins, MD; Kathryn Saxon; Kristine Shontz; and Stephanie Tribuna.

From McGraw-Hill: James F. Shanahan, Mariapaz Ramos Englis, Catherine Saggese, M. Lorraine Andrews, and Eileen Scott who has been a part of HMOM since the 11th edition.

The Editors also wish to acknowledge contributors to past editions of this Manual, whose work formed the basis for many of the chapters herein: Joseph B. Martin, MD, PhD; Kurt Isselbacher, MD; Jean Wilson, MD; Daryl R. Gress, MD; Michael Sneller, MD; John W. Engstrom, MD; Kenneth Tyler, MD; Sophia Vinogradov, MD; Dan B. Evans, MD; Punit Chadha, MD; Glenn Chertow, MD; James Woodrow Weiss, MD.
Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.
Patients are admitted to the hospital when (1) they present the physician with a complex diagnostic challenge that cannot be safely or efficiently performed in the outpatient setting; or (2) they are acutely ill and require inpatient diagnostic tests, interventions, and treatments. The decision to admit a patient includes identifying the optimal clinical service (e.g., medicine, urology, neurology), the level of care (observation, general floor, telemetry, ICU), and necessary consultants. Admission should always be accompanied by clear communication with the patient and family, both to obtain information and to outline the anticipated events in the hospital. Patients often have multiple physicians, and based on the nature of the clinical problems, they should be contacted to procure relevant medical history and to assist with clinical care during or after admission.

The scope of illnesses cared for by internists is enormous. During a single day on a typical general medical service, it is not unusual for physicians, especially residents in training, to admit ten patients with ten different diagnoses affecting ten different organ systems. Given this diversity of disease, it is important to be systematic and consistent in the approach to any new admission.

Physicians are often concerned about making errors of commission. Examples would include prescribing an improper antibiotic for a patient with pneumonia or miscalculating the dose of heparin for a patient with new deep venous thrombosis (DVT). However, errors of omission are also common and can result in patients being denied life-saving interventions. Simple examples include: not checking a lipid panel for a patient with coronary heart disease, not prescribing an angiotensin-converting enzyme (ACE) inhibitor to a diabetic with documented albuminuria, or forgetting to give a patient with an osteoporotic hip fracture calcium, vitamin D, and an oral bisphosphonate.

Inpatient medicine typically focuses on the diagnosis and treatment of acute medical problems. However, most patients have multiple medical problems affecting different organ systems, and it is equally important to prevent nosocomial complications. Prevention of common hospital complications, such as DVT, peptic ulcers, line infections, falls, delirium, and pressure ulcers, is an important aspect of the care of all general medicine patients.

A consistent approach to the admission process helps to ensure comprehensive and clear orders that can be written and implemented in a timely manner. Several mnemonics serve as useful reminders when writing admission orders. A suggested checklist for admission orders is shown below and it includes several interventions targeted to prevent common nosocomial complications. Computerized order entry systems are also useful when designed to prompt structured sets of admission orders. However, these should not be used to the exclusion of orders tailored for the needs of an individual patient.
Checklist mnemonic: ADMIT VITALS AND PHYSICAL EXAM

- Admit to: service (Medicine, Oncology, ICU); provide status (acute or observation).
- Diagnosis: state the working diagnosis prompting this particular hospitalization.
- MD: name the attending, resident, intern, student, primary care MD, and consultants.
- Isolation requirements: state respiratory or contact isolation and reason for order.
- Telemetry: state indications for telemetry and specify monitor parameters.
- Vital signs (VS): frequency of VS; also specify need for pulse oximetry and orthostatic VS.
- IV access and IV fluid or TPN orders (see Chap. 2).
- Therapists: respiratory, speech, physical, and/or occupational therapy needs.
- Allergies: also specify type of adverse reaction.
- Labs: blood count, chemistries, coagulation tests, type & screen, UA, special tests.
- Studies: CT scans (also order contrast), ultrasounds, angiograms, endoscopies, etc.
- Activity: weight bear/ambulating instructions, fall/seizure precautions and restraints.
- Nursing Orders: call intern if (x/y/z), also order I/Os, daily weights, and blood glucose.
- Diet: include NPO orders and tube feeding. State whether to resume diet after tests.
- Peptic ulcer prevention: proton-pump inhibitor or misoprostil for high-risk patients.
- Heparin or other modality (warfarin, compression boots, support hose) for DVT prophylaxis.
- Yank all Foley catheters and nonessential central lines to prevent iatrogenic infections.
- Skin care: prevent pressure sores with heel guards, air mattresses, and RN wound care.
- Incentive spirometry: prevent atelectasis and hospital-acquired pneumonia.
- Calcium, vitamin D, and bisphosphonates if steroid use, bone fracture, or osteoporosis.
- ACE inhibitor and aspirin: use for nearly all patients with coronary disease or diabetes.
- Lipid panel: assess and treat all cardiac and vascular patients for hyperlipidemia.
- ECG: for nearly every patient >50 years at the time of admission.
- X-rays: chest x-ray, abdominal series; evaluate central lines and endotracheal tubes.
- Advanced directives: Full code or DNR; specify whether to rescind for any procedures.
- Medications: be specific with your medication orders.

It may be helpful to remember the medication mnemonic “Stat DRIP” for different routes of administration (stat, daily, round-the-clock, IV, and prn medications). For the sake of cross-covering colleagues, provide relevant prn orders for acetaminophen, diphenhydramine, stool softeners or laxatives, and sleeping pills. Specify any stat medications since routine medication orders entered as “once daily” may not be dispensed until the following day unless ordered as stat or “first dose now.”
SODIUM

Disturbances of sodium concentration [Na+] result in most cases from abnormalities of H2O homeostasis, which change the relative ratio of Na+ to H2O. Disorders of Na+ balance per se are, in contrast, associated with changes in extracellular fluid volume, either hypo- or hypervolemia. Maintenance of the “effective circulating volume” is achieved in large part by changes in urinary sodium excretion, whereas H2O balance is achieved by changes in both H2O intake and urinary H2O excretion (Table 2-1). Confusion can result from the coexistence of defects in both H2O and Na+ balance. For example, a hypovolemic pt may have an appropriately low urinary Na+ due to increased renal tubular reabsorption of filtered NaCl; a concomitant increase in circulating arginine vasopressin (AVP)—part of the defense of effective circulating volume (Table 2-1)—will cause the renal retention of ingested H2O and the development of hyponatremia.

Hyponatremia This is defined as a serum [Na+] <135 mmol/L and is among the most common electrolyte abnormalities encountered in hospitalized pts. Symptoms include nausea, vomiting, confusion, lethargy, and disorientation; if severe (<120 mmol/L) and/or abrupt, seizures, central herniation, coma, or death may result (see Acute Symptomatic Hyponatremia, below). Hyponatremia is almost always the result of an increase in circulating AVP and/or increased renal sensitivity to AVP; a notable exception is in the setting of low solute intake (“beer potomania”), wherein a markedly reduced urinary solute excretion is inadequate to support the excretion of sufficient free H2O. The serum [Na+] by itself does not yield diagnostic information regarding total-body Na+ content; hyponatremia is primarily a disorder of H2O homeostasis. Pts with hyponatremia are thus categorized diagnostically into three groups, depending on their clinical volume status: hypovolemic, euvolemic, and hypervolemic hyponatremia (Fig. 2-1). All three forms of hyponatremia share an

### Table 2-1: Osmoregulation Versus Volume Regulation

<table>
<thead>
<tr>
<th>Osmoregulation</th>
<th>Volume Regulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>What is sensed</td>
<td>“Effective” circulating volume</td>
</tr>
<tr>
<td>Sensors</td>
<td>Carotid sinus</td>
</tr>
<tr>
<td>Plasma osmolality</td>
<td>Afferent arteriole</td>
</tr>
<tr>
<td>Hypothalamic osmoreceptors</td>
<td>Atria</td>
</tr>
<tr>
<td>Effectors</td>
<td>Sympathetic nervous system</td>
</tr>
<tr>
<td>AVP</td>
<td>Renin-angiotensin-aldosterone system</td>
</tr>
<tr>
<td>Thirst</td>
<td>ANP/BNP</td>
</tr>
<tr>
<td>What is affected</td>
<td>AVP</td>
</tr>
<tr>
<td>Urine osmolality</td>
<td>Urinary sodium excretion</td>
</tr>
<tr>
<td>H2O intake</td>
<td>Vascular tone</td>
</tr>
</tbody>
</table>

FIGURE 2-1 The diagnostic approach to hyponatremia. See text for details. (From Schrier RW: Atlas of Diseases of the Kidney. Philadelphia, Blackwell Science, 1999; with permission.)
Electrolytes/Acid-Base Balance

CHAPTER 2

exaggerated, “nonosmotic” increase in circulating AVP, in the setting of reduced serum osmolality. Notably, hyponatremia is often multifactorial; clinically important nonosmotic stimuli that can cause a release of AVP and increase the risk of hyponatremia include drugs, pain, nausea, and strenuous exercise.

Laboratory investigation of a pt with hyponatremia should include a measurement of serum osmolality to exclude “pseudohyponatremia” due to hyperlipidemia or hyperproteinemia. Serum glucose also should be measured; serum Na⁺ falls by 1.4 mM for every 100-mg/dL increase in glucose, due to glucose-induced H₂O efflux from cells. Hyperkalemia may suggest adrenal insufficiency or hypoaldosteronism; increased blood urea nitrogen (BUN) and creatinine may suggest a renal cause. Urine electrolytes and osmolality are also critical tests in the initial evaluation of hyponatremia. In particular, a urine Na⁺ <20 meq/L is consistent with hypovolemic hyponatremia in the clinical absence of a “hypervolemic,” Na⁺-avid syndrome such as congestive heart failure (CHF) (Fig. 2-1). Urine osmolality <100 mosmol/kg is suggestive of polydipsia or, in rare cases, of decreased solute intake; urine osmolality >400 mosmol/kg suggests that AVP excess is playing a more dominant role, whereas intermediate values are more consistent with multifactorial pathophysiology (e.g., AVP excess with a component of polydipsia). Finally, in the right clinical setting, thyroid, adrenal, and pituitary function should also be tested.

Hypovolemic Hyponatremia

Hypovolemia from both renal and extrarenal causes is associated with hyponatremia. Renal causes of hypovolemia include primary adrenal insufficiency and hypoaldosteronism, salt-losing nephropathies (e.g., reflux nephropathy, nonoliguric acute tubular necrosis), diuretics, and osmotic diuresis. Random “spot” urine Na⁺ is typically >20 meq/L in these cases but may be <20 meq/L in diuretic-associated hyponatremia if tested long after administration of the drug. Nonrenal causes of hypovolemic hyponatremia include GI loss (e.g., vomiting, diarrhea, tube drainage) and integumentary loss (sweating, burns); urine Na⁺ is typically <20 meq/L in these cases.

Hypovolemia causes profound neurohumoral activation, inducing systems that preserve effective circulating volume, such as the renin-angiotensin-aldosterone axis (RAA), the sympathetic nervous system, and AVP (Table 2-1). The increase in circulating AVP serves to increase the retention of ingested free H₂O, leading to hyponatremia. The optimal treatment of hypovolemic hyponatremia is volume administration, generally as isotonic crystalloid, i.e., 0.9% NaCl (“normal saline”). If the history suggests that hyponatremia has been “chronic,” i.e., present for 48 hours, care should be taken to avoid overcorrection (see below), which can easily occur as AVP levels plummet in response to volume-resuscitation; if necessary, the administration of desmopressin (DDAVP) and free water can reinduce or arrest the correction of hyponatremia (see below).

Hypervolemic Hyponatremia

The edematous disorders (CHF, hepatic cirrhosis, and nephrotic syndrome) are often associated with mild to moderate degrees of hyponatremia ([Na⁺] = 125–135 mmol/L); occasionally, pts with severe CHF or cirrhosis may present with serum [Na⁺] <120 mmol/L. The pathophysiology is similar to that in hypovolemic hyponatremia, except that “effective circulating volume” is decreased due to the specific etiologic factors, i.e., cardiac dysfunction, peripheral vasodilation in cirrhosis, and hypoalbuminemia in nephrotic syndrome. The degree of hyponatremia is an indirect index of the associated neurohumoral activation (Table 2-1) and an important prognostic indicator in hypervolemic hyponatremia.

Management consists of treatment of the underlying disorder (e.g., afterload reduction in heart failure, large-volume paracentesis in cirrhosis, immunomod-
ulatory therapy in some forms of nephrotic syndrome), Na+ restriction, diuretic therapy, and, in some pts, H2O restriction. Vasopressin antagonists (e.g., tolvaptan and conivaptan) are also effective in normalizing hyponatremia associated with both cirrhosis and CHF.

**Euvolemic Hyponatremia** The syndrome of inappropriate ADH secretion (SIADH) characterizes most cases of euvolemic hyponatremia. Other causes of euvolemic hyponatremia include hypothyroidism and secondary adrenal insufficiency due to pituitary disease; notably, repletion of glucocorticoid levels in the latter may cause a rapid drop in circulating AVP levels and overcorrection of serum [Na+] (see below).

Common causes of SIADH include pulmonary disease (e.g., pneumonia, tuberculosis, pleural effusion) and central nervous system (CNS) diseases (e.g., tumor, subarachnoid hemorrhage, meningitis); SIADH also occurs with malignancies (e.g., small cell carcinoma of the lung) and drugs (e.g., selective serotonin reuptake inhibitors, tricyclic antidepressants, nicotine, vincristine, chlorpropamide, carbamazepine, narcotic analgesics, antipsychotic drugs, cyclophosphamide, ifosfamide). Optimal treatment of euvolemic hyponatremia includes treatment of the underlying disorder. H2O restriction to <1 L/d is a cornerstone of therapy but may be ineffective or poorly tolerated. However, vasopressin antagonists are predictably effective in normalizing serum [Na+] in SIADH. Alternatives include the coadministration of loop diuretics to inhibit the countercurrent mechanism and reduce urinary concentration, combined with oral salt tablets to abrogate diuretic-induced salt loss and attendant hypovolemia.

**Acute Symptomatic Hyponatremia** Acute symptomatic hyponatremia is a medical emergency; a sudden drop in serum [Na+] can overwhelm the capacity of the brain to regulate cell volume, leading to cerebral edema, seizures, and death. Women, particularly premenopausal women, are particularly prone to such sequelae; neurologic consequences are comparatively rare in male pts. Many of these pts develop hyponatremia from iatrogenic causes, including hypotonic fluids in the postoperative period, prescription of a thiazide diuretic, colonoscopy preparation, or intraoperative use of glycine irrigants. Polydipsia with an associated cause of increased AVP may also cause acute hyponatremia, as can increased H2O intake in the setting of strenuous exercise, e.g., a marathon. The recreational drug ecstasy [methylenedioxymethamphetamine (MDMA)] can cause acute hyponatremia, rapidly inducing both AVP release and increased thirst.

Severe symptoms may occur at relatively modest levels of serum [Na+], e.g., in the mid-120s. Nausea and vomiting are common premonitory symptoms of more severe sequelae. An important concomitant is respiratory failure, which may be hypercapnic due to CNS depression or normocapnic due to neurogenic, noncardiogenic pulmonary edema; the attendant hypoxia amplifies the impact of hyponatremic encephalopathy.

**Hyponatremia**

Three considerations are critical in the therapy of hyponatremia. First, the presence, absence, and/or severity of symptoms determine the urgency of therapy (see above for acute symptomatic hyponatremia). Second, pts with hyponatremia that has been present for >48 h (“chronic hyponatremia”) are at risk for osmotic demyelination syndrome, typically central pontine myelinolysis, if serum Na+ is corrected by >10–12 mM within the first 24 h and/or by >18 mM within the first 48 h. Third, the response to interventions, such as hypotonic saline or vasopressin antagonists, can be highly unpredictable, such that frequent monitoring of serum Na+ (every 2–4 h) is imperative.
Treatment of acute symptomatic hyponatremia should include hypertonic saline to acutely increase serum Na\(^+\) by 1–2 mM/h to a total increase of 4–6 mM; this increase is typically sufficient to alleviate acute symptoms, after which corrective guidelines for “chronic” hyponatremia are appropriate (see below). A number of equations and algorithms have been developed to estimate the required rate of hypertonic solution; one popular approach is to calculate a “Na\(^+\) deficit,” where the Na\(^+\) deficit = 0.6 × body weight × (target [Na\(^+\)] – starting [Na\(^+\)]). Regardless of the method used to determine the rate of administered hypertonic saline, the increase in serum [Na\(^+\)] can be highly unpredictable, as the underlying physiology rapidly changes; serum [Na\(^+\)] should be monitored every 2–4 h during and after treatment with hypertonic saline. The administration of supplemental O\(_2\) and ventilatory support can also be critical in acute hyponatremia, if pts develop acute pulmonary edema or hypercapnic respiratory failure. IV loop diuretics will help treat acute pulmonary edema and will also increase free H\(_2\)O excretion by interfering with the renal countercurrent multiplier system. It is noteworthy that vasopressin antagonists do not have a role in the management of acute hyponatremia.

The rate of correction should be comparatively slow in chronic hyponatremia (<10–12 mM in the first 24 h and <18 mM in the first 48 h), so as to avoid osmotic demyelination syndrome. Vasopressin antagonists are highly effective in SIADH and in hypervolemic hyponatremia due to heart failure or cirrhosis. Should pts overcorrect serum [Na\(^+\)] in response to vasopressin antagonists, hypertonic saline, or isotonic saline (in chronic hypovolemic hyponatremia), hyponatremia can be safely reinduced or stabilized by the administration of the vasopressin agonist DDA VP and the administration of free H\(_2\)O, typically IV D\(_3\)W; again, close monitoring of the response of serum [Na\(^+\)] is essential to adjust therapy.

Hypernatremia

This is rarely associated with hypervolemia, where the association is typically iatrogenic, e.g., administration of hypertonic sodium bicarbonate. More commonly, hypernatremia is the result of a combined H\(_2\)O and volume deficit, with losses of H\(_2\)O in excess of Na\(^+\). Elderly individuals with reduced thirst and/or diminished access to fluids are at the highest risk of hypernatremia due to decreased free H\(_2\)O intake. Common causes of renal H\(_2\)O loss are osmotic diuresis secondary to hyperglycemia, postobstructive diuresis, or drugs (radiocontrast, mannitol, etc.); H\(_2\)O diuresis occurs in central or nephrogenic diabetes insipidus (DI) (Chap. 58). In pts with hypernatremia due to renal loss of H\(_2\)O, it is critical to quantify ongoing daily losses in addition to calculation of the baseline H\(_2\)O deficit (Table 2-2). The approach to correction of hypernatremia is outlined in Table 2-2. As with hyponatremia, it is advisable to correct the H\(_2\)O deficit slowly to avoid neurologic compromise, decreasing the serum [Na\(^+\)] over 48–72 h. Depending on the blood pressure or clinical volume status, it may be appropriate to initially treat with hypotonic saline solutions (1/4 or 1/2 normal saline); blood glucose should be monitored in pts treated with large volumes of D\(_3\)W, should hyperglycemia ensue. Calculation of urinary electrolyte-free H\(_2\)O clearance is helpful to estimate daily, ongoing loss of free H\(_2\)O in pts with nephrogenic or central DI (Table 2-2). Other forms of therapy may be helpful in selected cases of hypernatremia. Pts with central DI may respond to the administration of intranasal DDAVP. Stable pts with nephrogenic DI due to lithium may reduce
Their polyuria with amiloride (2.5–10 mg/d) or hydrochlorothiazide (12.5–50 mg/d) or both in combination. These diuretics are thought to increase proximal H₂O reabsorption and decrease distal solute delivery, thus reducing polyuria; amiloride may also decrease entry of lithium into principal cells in the distal nephron by inhibiting the amiloride-sensitive epithelial sodium channel (ENaC). Notably, however, most patients with lithium-induced nephrogenic DI can adequately accommodate by increasing their H₂O intake. Occasionally, nonsteroidal anti-inflammatory drugs (NSAIDs) have also been used to treat polyuria associated with nephrogenic DI, reducing the negative effect of local prostaglandins on urinary concentration; however, the nephrotoxic potential of NSAIDs typically makes them a less attractive therapeutic option.

**Potassium**

Since potassium (K⁺) is the major intracellular cation, discussion of disorders of K⁺ balance must take into consideration changes in the exchange of intra- and extracellular K⁺ stores. (Extracellular K⁺ constitutes <2% of total-body K⁺ content.) Insulin, β₂-adrenergic agonists, and alkalosis tend to promote K⁺ uptake by cells; acidosis, insulinopenia, or acute hyperosmolality (e.g., after treatment with mannitol or D50W) promote the efflux or reduced uptake of K⁺. A corollary is that tissue necrosis and the attendant release of K⁺ can cause severe hypokalemia, particularly in the setting of acute kidney injury. Hyperkalemia due to rhabdomyolysis is thus particularly common, due to the enormous store of K⁺ in muscle; hyperkalemia may also be prominent in tumor lysis syndrome.

The kidney plays a dominant role in K⁺ excretion. Although K⁺ is transported along the entire nephron, it is the principal cells of the connecting segment and cortical collecting duct that play a dominant role in K⁺ excretion. Apical Na⁺ entry into principal cells via the amiloride-sensitive epithelial Na⁺ channel (ENaC) generates a lumen-negative potential difference, which drives passive

<table>
<thead>
<tr>
<th>TABLE 2-2</th>
<th>CORRECTION OF HYPERNATREMIA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>H₂O Deficit</strong></td>
<td></td>
</tr>
<tr>
<td>1. Estimate total-body water (TBW): 50–60% body weight (kg) depending on body composition</td>
<td></td>
</tr>
<tr>
<td>2. Calculate free-water deficit: [(Na⁺ 140)/140] × TBW</td>
<td></td>
</tr>
<tr>
<td>3. Administer deficit over 48–72 h</td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing H₂O Losses</strong></td>
<td></td>
</tr>
<tr>
<td>4. Calculate free-water clearance, CₑH₂O:</td>
<td></td>
</tr>
<tr>
<td>[ CₑH₂O = V \left(1 - \frac{U_{Na} + U_K}{S_{Na}}\right) ]</td>
<td></td>
</tr>
<tr>
<td>where V is urinary volume, Uₙa is urinary [Na⁺], Uₙ is urinary [K⁺], and Sₙa is serum [Na⁺].</td>
<td></td>
</tr>
<tr>
<td><strong>Insensible Losses</strong></td>
<td></td>
</tr>
<tr>
<td>5. ~10 mL/kg per day: less if ventilated, more if febrile</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
</tr>
<tr>
<td>6. Add components to determine H₂O deficit and ongoing H₂O loss; correct the H₂O deficit over 48–72 h and replace daily H₂O loss.</td>
<td></td>
</tr>
</tbody>
</table>
K⁺ exit through apical K⁺ channels. This relationship is key to the bedside understanding of potassium disorders. For example, decreased distal delivery of Na⁺ tends to blunt the ability to excrete K⁺, leading to hyperkalemia. Abnormalities in the RAA can cause both hypokalemia and hyperkalemia; aldosterone has a major influence on potassium excretion, increasing the activity of ENaC channels and thus amplifying the driving force for K⁺ secretion across the luminal membrane of principal cells.

**Hypokalemia** Major causes of hypokalemia are outlined in Table 2-3. Atrial and ventricular arrhythmias are the most serious health consequences of hypokalemia. Pts with concurrent Mg deficit and/or digoxin therapy are at a particularly increased risk of arrhythmias. Other clinical manifestations include muscle weakness, which may be profound at serum [K⁺] <2.5 mmol/L, and, if hypokalemia is sustained, hypertension, ileus, polyuria, renal cysts, and even renal failure.

### Table 2-3 Causes of Hypokalemia

<table>
<thead>
<tr>
<th>I. Decreased intake</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Starvation</td>
</tr>
<tr>
<td>B. Clay ingestion</td>
</tr>
<tr>
<td>II. Redistribution into cells</td>
</tr>
<tr>
<td>A. Acid-base</td>
</tr>
<tr>
<td>1. Metabolic alkalosis</td>
</tr>
<tr>
<td>B. Hormonal</td>
</tr>
<tr>
<td>1. Insulin</td>
</tr>
<tr>
<td>2. β₂-Adrenergic agonists (endogenous or exogenous)</td>
</tr>
<tr>
<td>3. α-Adrenergic antagonists</td>
</tr>
<tr>
<td>C. Anabolic state</td>
</tr>
<tr>
<td>1. Vitamin B₁₂ or folic acid administration (red blood cell production)</td>
</tr>
<tr>
<td>2. Granulocyte-macrophage colony-stimulating factor (white blood cell production)</td>
</tr>
<tr>
<td>3. Total parenteral nutrition</td>
</tr>
<tr>
<td>D. Other</td>
</tr>
<tr>
<td>1. Pseudohypokalemia</td>
</tr>
<tr>
<td>2. Hypothermia</td>
</tr>
<tr>
<td>3. Hypokalemic periodic paralysis</td>
</tr>
<tr>
<td>4. Thyrotoxic periodic paralysis</td>
</tr>
<tr>
<td>5. Barium toxicity</td>
</tr>
<tr>
<td>II. Increased loss</td>
</tr>
<tr>
<td>A. Nonrenal</td>
</tr>
<tr>
<td>1. Gastrointestinal loss (diarrhea)</td>
</tr>
<tr>
<td>2. Integumentary loss (sweat)</td>
</tr>
<tr>
<td>B. Renal</td>
</tr>
<tr>
<td>1. Increased distal flow: diuretics, osmotic diuresis, salt-wasting nephropathies</td>
</tr>
<tr>
<td>2. Increased secretion of potassium</td>
</tr>
<tr>
<td>a. Mineralocorticoid excess: primary hyperaldosteronism, secondary hyperaldosteronism (malignant hypertension, renin-secreting tumors, renal artery stenosis, hypovolemia), apparent mineralocorticoid excess (hereditary, licorice, chewing tobacco, carbenoxolone), congenital adrenal hyperplasia, Cushing’s syndrome, Bartter’s syndrome, Gitelman’s syndrome</td>
</tr>
<tr>
<td>b. Distal delivery of non-reabsorbed anions: vomiting, nasogastric suction, proximal (type 2) renal tubular acidosis, diabetic ketoacidosis, glue-sniffing (toluene abuse), penicillin derivatives</td>
</tr>
<tr>
<td>c. Other: amphotericin B, Liddle’s syndrome, hypomagnesemia</td>
</tr>
</tbody>
</table>
The cause of hypokalemia is usually obvious from history, physical examination, and/or basic laboratory tests. However, persistent hypokalemia may require a more thorough, systematic evaluation (Fig. 2-2). Initial laboratory evaluation should include electrolytes, BUN, creatinine, serum osmolality, Mg²⁺, and Ca²⁺, a complete blood count, and urinary pH, osmolality, creatinine, and electrolytes. Serum and urine osmolality are required for calculation of the transtubular K⁺ gradient (TTKG), which should be <3 in the presence of hypokalemia (see also Hyperkalemia). Further tests such as urinary Mg²⁺ and Ca²⁺ and/or plasma renin and aldosterone levels may be necessary in specific cases.

### Hypokalemia

Hypokalemia can generally be managed by correction of the underlying disease process (e.g., diarrhea) or withdrawal of an offending medication (e.g., loop or thiazide diuretic), combined with oral KCl supplementation. However, hypokalemia is refractory to correction in the presence of Mg deficiency, which should also be corrected when present; renal wasting of both cations may be particularly prominent after renal tubular injury, e.g., from cisplatin nephrotoxicity. If loop or thiazide diuretic therapy cannot be discontinued, a distal tubular K-sparing agent, such as amiloride or spironolactone, can be added to the regimen. Angiotensin-converting enzyme (ACE) inhibition in pts with CHF attenuates diuretic-induced hypokalemia and protects against cardiac arrhythmia. If hypokalemia is severe (<2.5 mmol/L) and/or if oral supplementation is not feasible or tolerated, IV KCl can be administered through a central vein with cardiac monitoring in an intensive care setting, at rates that should not exceed 20 mmol/h. KCl should always be administered in saline solutions, rather than dextrose; the dextrose-induced increase in insulin can acutely exacerbate hypokalemia.

### Hyperkalemia

Causes are outlined in Table 2-4; in most cases, hyperkalemia is due to decreased renal K⁺ excretion. However, increases in dietary K⁺ intake can have a major effect in susceptible pts, e.g., diabetics with hyporeninemic hypoaldosteronism and chronic kidney disease. Drugs that impact on the renin-angiotensin-aldosterone axis are also a major cause of hyperkalemia, particularly given recent trends to coadminister these agents, e.g., spironolactone or angiotensin receptor blockers with an ACE inhibitor in cardiac and/or renal disease.

The first priority in the management of hyperkalemia is to assess the need for emergency treatment (ECG changes and/or K⁺ ≥6.0 mEq/L). This should be followed by a comprehensive workup to determine the cause (Fig. 2-3). History and physical examination should focus on medications (e.g., ACE inhibitors, NSAIDs, trimethoprim/sulfamethoxazole), diet and dietary supplements (e.g., salt substitute), risk factors for acute kidney failure, reduction in urine output, blood pressure, and volume status. Initial laboratory tests should include electrolytes, BUN, creatinine, serum osmolality, Mg²⁺, and Ca²⁺, a complete blood count, and urinary pH, osmolality, creatinine, and electrolytes. A urine [Na⁺] <20 meq/L suggests that distal Na⁺ delivery is a limiting factor in K⁺ excretion; volume repletion with 0.9% saline or treatment with furosemide may then be effective in reducing serum [K⁺] by increasing distal Na⁺ delivery. Serum and urine osmolality are required for calculation of the TTKG. The expected values of the TTKG are largely based on historic data: <3 in the presence of hypokalemia and >7–8 in the presence of hyperkalemia.

\[
\text{TTKG} = \frac{[K^+]_{\text{urine}} \times \text{Osm}_{\text{serum}}}{[K^+]_{\text{serum}} \times \text{Osm}_{\text{urine}}}
\]
FIGURE 2-2 The diagnostic approach to hypokalemia. See text for details. FHPP, familial hypokalemic periodic paralysis; GI, gastrointestinal; TTKG, transtubular potassium gradient; CCD, cortical collecting duct; BP, blood pressure; RTA, renal tubular acidosis; DKA, diabetic ketoacidosis; RAS, renal artery stenosis; RST, renin-secreting tumor; HTN, hypertension; PA, primary aldosteronism; GRA, glucocorticoid-remediable aldosteronism; AME, apparent mineralocorticoid excess. [From Mount DB, Zandi-Nejad K: Disorders of potassium balance, in The Kidney, 8th ed, BM Brenner (ed). Philadelphia, Saunders, 2008; with permission.]
Hyperkalemia

The most important consequence of hyperkalemia is altered cardiac conduction, with the risk of bradycardic cardiac arrest. Figure 2-4 shows serial ECG patterns of hyperkalemia; ECG manifestations of hyperkalemia should be considered a true medical emergency and treated urgently. However, ECG changes of hyperkalemia are notoriously insensitive, particularly in pts with

### Table 2-4 Major Causes of Hyperkalemia

<table>
<thead>
<tr>
<th>Category</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. &quot;Pseudo&quot;-hyperkalemia</td>
<td>A. Cellular efflux; thrombocytosis, leukocytosis, in vitro hemolysis</td>
</tr>
<tr>
<td></td>
<td>B. Hereditary defects in red cell membrane transport</td>
</tr>
<tr>
<td>II. Intracellular to extracellular shift</td>
<td>A. Acidosis</td>
</tr>
<tr>
<td></td>
<td>B. Hyperosmolality; radiocast, hypertonic dextrose, mannitol</td>
</tr>
<tr>
<td></td>
<td>C. β2-adrenergic antagonists (noncardioselective agents)</td>
</tr>
<tr>
<td></td>
<td>D. Digoxin or ouabain poisoning</td>
</tr>
<tr>
<td></td>
<td>E. Hyperkalemic periodic paralysis</td>
</tr>
<tr>
<td>III. Inadequate excretion</td>
<td>A. Inhibition of the renin-angiotensin-aldosterone axis; ↑ risk of hyperkalemia when used in combination</td>
</tr>
<tr>
<td></td>
<td>1. ACE inhibitors</td>
</tr>
<tr>
<td></td>
<td>2. Renin inhibitors; aliskiren (in combination with ACE inhibitors or ARBs)</td>
</tr>
<tr>
<td></td>
<td>3. ARBs</td>
</tr>
<tr>
<td></td>
<td>4. Blockade of the mineralocorticoid receptor; spironolactone, eplerenone</td>
</tr>
<tr>
<td></td>
<td>5. Blockade of the ENaC; amiloride, triamterene, trimethoprim, pentamidine</td>
</tr>
<tr>
<td></td>
<td>B. Decreased distal delivery</td>
</tr>
<tr>
<td></td>
<td>1. Congestive heart failure</td>
</tr>
<tr>
<td></td>
<td>2. Volume depletion</td>
</tr>
<tr>
<td></td>
<td>3. NSAIDs, cyclosporine</td>
</tr>
<tr>
<td></td>
<td>C. Hyporeninemic hypaldosteronism</td>
</tr>
<tr>
<td></td>
<td>1. Tubulointerstitial diseases; SLE, sickle cell anemia, obstructive uropathy</td>
</tr>
<tr>
<td></td>
<td>2. Diabetes, diabetic nephropathy</td>
</tr>
<tr>
<td></td>
<td>3. Drugs; NSAIDs, beta blockers, cyclosporine</td>
</tr>
<tr>
<td></td>
<td>4. Chronic kidney disease, advanced age</td>
</tr>
<tr>
<td></td>
<td>D. Renal resistance to mineralocorticoid</td>
</tr>
<tr>
<td></td>
<td>1. Tubulointerstitial diseases; SLE, amyloidosis, sickle cell anemia, obstructive uropathy, post-ATN</td>
</tr>
<tr>
<td></td>
<td>2. Hereditary; pseudohypaldosteronism type I—defects in the mineralocorticoid receptor or ENaC</td>
</tr>
<tr>
<td></td>
<td>E. Advanced renal insufficiency with low GFR</td>
</tr>
<tr>
<td></td>
<td>F. Primary adrenal insufficiency</td>
</tr>
<tr>
<td></td>
<td>1. Autoimmune; Addison’s disease, polyglandular endocrinopathy</td>
</tr>
<tr>
<td></td>
<td>2. Infectious; HIV, CMV, TB, disseminated fungal infection</td>
</tr>
<tr>
<td></td>
<td>3. Infiltrative; amyloidosis, malignancy, metastatic cancer</td>
</tr>
<tr>
<td></td>
<td>4. Drug-associated; heparin, low-molecular-weight heparin</td>
</tr>
<tr>
<td></td>
<td>5. Hereditary; adrenal hypoplasia congenita, congenital lipid adrenal hyperplasia, aldosterone synthase deficiency</td>
</tr>
<tr>
<td></td>
<td>6. Adrenal hemorrhage or infarction; may occur in antiphospholipid syndrome</td>
</tr>
</tbody>
</table>

**Note:** ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockers; ATN, acute tubular necrosis; CMV, cytomegalovirus; ENaC, epithelial sodium channel; GFR, glomerular filtration rate; HIV, human immunodeficiency virus; NSAIDs, nonsteroidal anti-inflammatory drugs; SLE, systemic lupus erythematosus; TB, tuberculosis.
FIGURE 2-3  The diagnostic approach to hyperkalemia. See text for details. ECG, electrocardiogram; TTKG, transtubular potassium gradient; GFR, glomerular filtration rate; ECV, effective circulatory volume; GN, glomerulonephritis; NSAIDs, nonsteroidal anti-inflammatory drugs; LMW heparin, low-molecular-weight heparin; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; PHA, pseudohypoaldosteronism; SLE, systemic lupus erythematosus. [From Mount DB, Zandi-Nejad K: Disorders of potassium balance, in The Kidney, 8th ed, BM Brenner (ed). Philadelphia, Saunders, 2008; with permission.]
chronic kidney disease; given these limitations, pts with significant hyperkalemia (K+ ≥6–6.5 mmol/L) in the absence of ECG changes should also be aggressively managed.

Urgent management of hyperkalemia constitutes a 12-lead ECG, admission to the hospital, continuous cardiac monitoring, and immediate treatment. Treatment of hyperkalemia is divided into three categories: (1) antagonism of the cardiac effects of hyperkalemia, (2) rapid reduction in [K+] by redistribution into cells, and (3) removal of K+ from the body. Treatment of hyperkalemia is summarized in Table 2-5.

**ACID-BASE DISORDERS** *(Fig. 2-5)*

Regulation of normal pH (7.35–7.45) depends on both the lungs and kidneys. By the Henderson-Hasselbalch equation, pH is a function of the ratio of HCO₃⁻ (regulated by the kidney) to PCO₂ (regulated by the lungs). The HCO₃⁻/PCO₂ relationship is useful in classifying disorders of acid-base balance. Acidosis is due to gain of acid or loss of alkali; causes may be metabolic (fall in serum HCO₃⁻) or respiratory (rise in PCO₂). Alkalosis is due to loss of acid or addition of base and is either metabolic (↑ serum [HCO₃⁻]) or respiratory (↓ PCO₂).

To limit the change in pH, metabolic disorders evoke an immediate compensatory response in ventilation; full renal compensation for respiratory disorders is a slower process, such that “acute” compensations are of lesser magnitude than “chronic” compensations. Simple acid-base disorders consist of one primary disturbance and its compensatory response. In mixed disorders, a combination of primary disturbances is present.

The cause of simple acid-base disorders is usually obvious from history, physical examination, and/or basic laboratory tests. Initial laboratory evaluation
<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Therapy</th>
<th>Dose</th>
<th>Onset</th>
<th>Duration</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stabilize membrane potential</td>
<td>Calcium</td>
<td>10% Ca gluconate, 10 mL over 10 min</td>
<td>1–3 min</td>
<td>30–60 min</td>
<td>Repeat in 5 min if persistent electrocardiographic changes; avoid in digoxin toxicity.</td>
</tr>
<tr>
<td>Cellular K⁺ uptake</td>
<td>Insulin</td>
<td>10 U R with 50 mL of D50, if blood sugar &lt;250</td>
<td>30 min</td>
<td>4–6 h</td>
<td>Can repeat in 15 min; initiate D10W IV at 50–75 mL/h to avoid rebound hypoglycemia.</td>
</tr>
<tr>
<td></td>
<td>β₂-agonist</td>
<td>Nebulized albuterol, 10–20 mg in 4 mL saline</td>
<td>30 min</td>
<td>2–4 h</td>
<td>Can be synergistic/additive to insulin; should not be used as sole therapy; use with caution in cardiac disease; may cause tachycardia/hyperglycemia.</td>
</tr>
<tr>
<td>K⁺ removal</td>
<td>Kayexalate</td>
<td>30–60 g PO in 20% sorbitol</td>
<td>1–2 h</td>
<td>4–6 h</td>
<td>May cause ischemic colitis and colonic necrosis, particularly in enema form and postoperative state.</td>
</tr>
<tr>
<td></td>
<td>Furosemide</td>
<td>20–250 mg IV</td>
<td>15 min</td>
<td>4–6 h</td>
<td>Depends on adequate renal response/function. Efficacy depends on pretreatment of hyperkalemia (with attendant decrease in serum K⁺), the dialyzer used, blood flow and dialysate flow rates, duration, and serum to dialysate K⁺ gradient.</td>
</tr>
<tr>
<td></td>
<td>Hemodialysis</td>
<td></td>
<td>Immediate</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
depends on the dominant acid-base disorder, but for metabolic acidosis and alkalosis this should include electrolytes, BUN, creatinine, albumin, urinary pH, and urinary electrolytes. An arterial blood gas (ABG) is not always required for pts with a simple acid-base disorder, e.g., mild metabolic acidosis in the context of chronic renal failure. However, concomitant ABG and serum electrolytes are necessary to fully evaluate more complex acid-base disorders. The compensatory response should be estimated from the ABG; Winter’s formula \[ P_{acCO_2} = (1.5 \times [HCO_3^-]) + 8 \pm 2 \] is particularly useful for assessing the respiratory response to metabolic acidosis. The anion gap should also be calculated; the anion gap = [Na⁺] – ([HCO_3⁻] + [Cl⁻]) = unmeasured anions – unmeasured cations. The anion gap should be adjusted for changes in the concentration of albumin, a dominant unmeasured anion; the “adjusted anion gap” = anion gap + ~2.5 \times (4 – albumin mg/dL). Other supportive tests will elucidate the specific form of anion-gap acidosis (see below).

**Metabolic Acidosis** The low HCO₃⁻ in metabolic acidosis results from the addition of acids (organic or inorganic) or from a loss of HCO₃⁻; causes of metabolic acidosis are classically categorized by presence or absence of an increase in the anion gap (Table 2-6). Increased anion-gap acidosis (>12 mmol/L) is due to addition of acid (other than HCl) and unmeasured anions to the body. Com-
<table>
<thead>
<tr>
<th>Cause</th>
<th>Clue</th>
<th>Cause</th>
<th>Clue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>Hx; ↑ K⁺</td>
<td>DKA</td>
<td>Hyperglycemia, ketones</td>
</tr>
<tr>
<td>Enterostomy</td>
<td>Drainage</td>
<td>RF</td>
<td>Late chronic kidney disease</td>
</tr>
<tr>
<td>RTA</td>
<td>Early chronic kidney disease</td>
<td>Lactic acidosis</td>
<td>Clinical setting + ↑ serum lactate</td>
</tr>
<tr>
<td>Proximal</td>
<td>↓ K⁺, presence of other proximal tubular</td>
<td>Alcoholic ketoacidosis</td>
<td>Hx; weak + ketones; + osm gap</td>
</tr>
<tr>
<td></td>
<td>defects (Fanconi Syndrome)</td>
<td>Starvation</td>
<td>Hx; mild acidosis; + ketones</td>
</tr>
<tr>
<td>Distal—hypokalemic</td>
<td>↑ K⁺; hypercalciuria; UpH &gt; 5.5</td>
<td>Salicylates</td>
<td>Hx; tinnitus; high serum level; + ketones; + lactate</td>
</tr>
<tr>
<td>Distal—hyperkalemic</td>
<td>↑ K⁺; nl PRA/aldo; UpH &gt; 5.5</td>
<td>Methanol</td>
<td>Large AG; concomitant respiratory alkalosis; retinitis; + toxic screen; + osm gap</td>
</tr>
<tr>
<td>Distal—hyporeninemic</td>
<td>↑ K⁺; ↓ PRA/aldo; UpH &lt; 5.5</td>
<td>Ethylene glycol</td>
<td>RF; CNS symptoms; + toxic screen; crystal-</td>
</tr>
<tr>
<td>hypodosteronism</td>
<td></td>
<td></td>
<td>luria; + osm gap</td>
</tr>
<tr>
<td>Dilutional</td>
<td>Massive volume expansion with saline</td>
<td>D-lactic acidosis</td>
<td>Small-bowel disease; prominent neuro</td>
</tr>
<tr>
<td>Ureterosigmoidostomy</td>
<td>Obstructed ileal loop</td>
<td>Propylene glycol</td>
<td>symptoms</td>
</tr>
<tr>
<td>Hyperalimentation</td>
<td>Amino acid infusion</td>
<td>Pyroglutamic aciduria,</td>
<td>IV infusions, e.g., lorazepam; + osm gap</td>
</tr>
<tr>
<td>Acetazolamide, NH₄Cl, lysine</td>
<td>Hx of administration of these agents</td>
<td>5-oxoprolinuria</td>
<td>RF</td>
</tr>
<tr>
<td>HCl, arginine HCl, sevelamer-HCl</td>
<td></td>
<td></td>
<td>Large AG; chronic acetaminophen</td>
</tr>
</tbody>
</table>

Note: RTA, renal tubular acidosis; PRA, plasma renin activity; UpH, urinary pH; DKA, diabetic ketoacidosis; RF, renal failure; CNS, central nervous system; AG, anion gap; osm gap, osmolar gap.
mon causes include ketoacidosis [diabetes mellitus (DKA), starvation, alcohol], lactic acidosis, poisoning (salicylates, ethylene glycol, and methanol), and renal failure.

Rare and newly appreciated causes of anion-gap acidosis include D-lactic acidosis, propylene glycol toxicity, and 5-oxoprolinuria (also known as pyroglutamic aciduria). D-Lactic acidosis (an increase in the D-enantiomer of lactate) can occur in pts with removal, disease, or bypass of the short bowel, leading to increased delivery of carbohydrates to colon. Intestinal overgrowth of organisms that metabolize carbohydrate to D-lactate results in D-lactic acidosis; a wide variety of neurologic symptoms can ensue, with resolution following treatment with appropriate antibiotics to change the intestinal flora. Propylene glycol is a common solvent for IV preparations of a number of drugs, most prominently lorazepam. Pts receiving high rates of these drugs may develop a hyperosmolar anion-gap metabolic acidosis, due mostly to increased lactate, often accompanied by acute kidney failure. Pyroglutamic aciduria (5-oxoprolinuria) is a high anion-gap acidosis caused by dysfunction of the \( \gamma \)-glutamyl cycle that replenishes intracellular glutathione; 5-oxoproline is an intermediate product of the cycle. Hereditary defects in the \( \gamma \)-glutamyl cycle are associated with 5-oxoprolinuria; acquired defects occur in the context of acetaminophen therapy, due to derepression of the cycle by reduced glutathione and overproduction of 5-oxoproline. Resolution occurs after withdrawal of acetaminophen; treatment with N-acetyl cysteine to replenish glutathione stores may hasten recovery.

The differentiation of the various anion-gap acidoses depends on the clinical scenario and routine laboratory tests (Table 2-6) in conjunction with measurement of serum lactate, ketones, toxicology screens (if ethylene glycol or methanol ingestion are suspected), and serum osmolality. D-Lactic acidosis can be diagnosed by a specific assay for the D-enantiomer; 5-oxoprolinuria can be diagnosed by the clinical scenario and confirmed by gas chromatographic/mass spectroscopic (GC/MS) analysis of urine, a widely available pediatric screening test for inborn errors of metabolism (typically “urine for organic acids”).

Pts with ethylene glycol, methanol, or propylene glycol toxicity may have an “osmolar gap,” defined as a >10-mosm/kg difference between calculated and measured serum osmolality. Calculated osmolality = \( 2 \times Na^+ + \text{glucose}/18 + \text{BUN}/2.8 \). Of note, pts with alcoholic ketoacidosis and lactic acidosis may also exhibit a modest elevation in the osmolar gap; pts may alternatively metabolize ethylene glycol or methanol to completion by presentation, with an increased anion gap and no increase in the osmolar gap. However, the rapid availability of a measured serum osmolality may aid in the urgent assessment and management of pts with these medical emergencies.

Normal anion-gap acidosis can result from \( \text{HCO}_3^- \) loss from the GI tract. Diarrhea is by far the most common cause, but other GI conditions associated with external losses of bicarbonate-rich fluids may lead to large alkali losses—e.g., in ileus secondary to intestinal obstruction, in which liters of alkaline fluid may accumulate within the intestinal lumen. Various forms of kidney disease are associated with non-anion-gap acidosis due to reduced tubular reabsorption of filtered bicarbonate and/or reduced excretion of ammonium (\( \text{NH}_4^+ \)). The early stages of progressive renal disease are frequently associated with a non-anion-gap acidosis, with development of an anion-gap component in more advanced renal failure. Non-anion-gap acidosis is also seen in renal tubular acidosis or in the context of tubulointerstitial injury, e.g., after acute tubular necrosis, allergic interstitial nephritis, or urinary tract obstruction. Finally, non-anion-gap acidosis due to exogenous acid loads may occur after rapid volume expansion with saline-containing solutions, the administration of \( \text{NH}_4\text{Cl} \) (a
component of cough syrup), lysine HCl, or treatment with the phosphate binder sevelamer hydrochloride.

Calculation of the urinary anion gap may be helpful in the evaluation of hyperchloremic metabolic acidosis, along with a measurement of urine pH. The urinary anion gap is defined as urinary ([Na+] + [K +]) – [Cl –] = [unmeasured anions] – [unmeasured cations]); the NH₄⁺ ion is the major unmeasured urinary cation in metabolic acidosis, wherein the urinary anion gap should be strongly negative. A negative anion gap thus suggests GI losses of bicarbonate, with appropriate renal response and increased NH₄⁺ excretion; a positive anion gap suggests altered urinary acidification, as seen in renal failure or distal renal tubular acidoses. An important caveat is that the rapid renal excretion of unmeasured anions in anion-gap acidosis, classically seen in DKA, may reduce the serum anion gap and generate a positive value for the urinary anion gap, despite the adequate excretion of urinary NH₄⁺; this may lead to misdiagnosis as a renal tubular acidosis.

**Metabolic Acidosis**

Treatment of metabolic acidosis depends on the cause and severity. DKA responds to insulin therapy and aggressive hydration; close attention to serum [K+] and administration of KCl is essential, given that the correction of insulinopenia can cause profound hypokalemia. The administration of alkali in anion-gap acidoses is controversial and is rarely appropriate in DKA. It is reasonable to treat severe lactic acidosis with IV HCO₃⁻ at a rate sufficient to maintain a pH >7.20; treatment of moderate lactic acidosis with HCO₃⁻ is controversial. IV HCO₃ is however appropriate to reduce acidosis in D-lactic acidosis, ethylene glycol and methanol toxicity, and 5-oxoprolinuria.

Chronic metabolic acidosis should be treated when HCO₃⁻ is <18–20 mmol/L. In pts with chronic kidney disease, there is some evidence that acidosis promotes protein catabolism and may worsen bone disease. Sodium citrate may be more palatable than oral NaHCO₃, although the former should be avoided in pts with advanced renal insufficiency, as it augments aluminum absorption. Oral therapy with NaHCO₃ usually begins with 650 mg tid and is titrated upward to maintain serum [HCO₃⁻].

**Metabolic Alkalosis**

Metabolic alkalosis is due to a primary increase in serum [HCO₃⁻], distinguished from chronic respiratory acidosis—with a compensatory increase in renal HCO₃⁻ reabsorption—by the associated increase in arterial pH (normal or decreased in chronic respiratory acidosis). Administered, exogenous alkali (HCO₃⁻, acetate, citrate, or lactate) may cause alkalosis if the normal capacity to excrete HCO₃⁻ is reduced or if renal HCO₃⁻ reabsorption is enhanced. A recently resurgent problem is “milk alkali syndrome,” a triad of hypercalcemia, metabolic alkalosis, and acute renal failure due to ingested calcium carbonate, typically taken for the treatment or prevention of osteoporosis.

Metabolic alkalosis is primarily caused by renal retention of HCO₃⁻ and is due to a variety of underlying mechanisms. Pts are typically separated into two major subtypes: Cl⁻-responsive and Cl⁻-resistant. Measurement of urine Cl⁻ affords this separation in the clinical setting (Fig. 2-6). The quintessential causes of Cl⁻-responsive alkalosis are GI-induced from vomiting or gastric aspiration through a nasogastric tube, and renal-induced from diuretic therapy. Hypovolemia, chloride deficiency, activation of the renin-angiotensin-aldosterone axis, and hypokalemia play interrelated roles in the maintenance of this hypochloremic or “contraction” alkalosis. The various syndromes of true or apparent
mineralocorticoid excess cause Cl\textsuperscript{−}-resistant metabolic alkalosis (Fig. 2-6); most of these pts are hypokalemic, volume-expanded, and/or hypertensive.

Common forms of metabolic alkalosis are generally diagnosed from the history, physical examination, and/or basic laboratory tests. ABGs will help determine whether an elevated [HCO\textsubscript{3}\textsuperscript{−}] is reflective of metabolic alkalosis or chronic respiratory acidosis; ABGs are required for the diagnosis of mixed acid-base disorders. Measurement of urinary electrolytes will aid in separating Cl\textsuperscript{−}-responsive and Cl\textsuperscript{−}-resistant forms. Urinary [Na\textsuperscript{+}] may thus be >20 meq/L in Cl\textsuperscript{−}-responsive alkalosis despite the presence of hypovolemia; however, urinary [Cl\textsuperscript{−}] will be very low. Notably, urinary [Cl\textsuperscript{−}] may be variable in pts with diuretic-associated alkalosis, depending on the temporal relationship to diuretic administration. Other diagnostic tests—e.g., plasma renin, aldosterone, cortisol—may be appropriate in Cl\textsuperscript{−}-resistant forms with high urinary [Cl\textsuperscript{−}] (Fig. 2-6).

**Metabolic Alkalosis**

The acid-base disorder in Cl\textsuperscript{−}-responsive alkalosis will typically respond to saline infusion; however, the associated hypokalemia should also be corrected. Pts with true or apparent mineralocorticoid excess require specific treatment of the underlying disorder. For example, hyperactive amiloride-sensitive ENaC channels cause Liddle’s syndrome, which can respond to therapy with amiloride and related drugs; pts with hyperaldosteronism may in turn respond...
to blockade of the mineralocorticoid receptor with spironolactone or eplerenone. Finally, severe alkalosis in the critical care setting may require treatment with acidifying agents such as acetazolamide or HCl.

**Respiratory Acidosis**  Respiratory acidosis is characterized by CO₂ retention due to ventilatory failure. Causes include sedatives, stroke, chronic pulmonary disease, airway obstruction, severe pulmonary edema, neuromuscular disorders, and cardiopulmonary arrest. Symptoms include confusion, asterixis, and obtundation.

The goal is to improve ventilation through pulmonary toilet and reversal of bronchospasm. Intubation or noninvasive positive pressure ventilation (NP-PV) may be required in severe acute cases. Acidosis due to hypercapnia is usually mild; however, combined respiratory and metabolic acidosis may cause a profound reduction in pH. Respiratory acidosis may accompany low tidal volume ventilation in ICU pts and may require metabolic “overcorrection” to maintain a neutral pH.

**Respiratory Alkalosis**  Excessive ventilation causes a primary reduction in CO₂ and ↑ pH in pneumonia, pulmonary edema, interstitial lung disease, and asthma. Pain and psychogenic causes are common; other etiologies include fever, hypoxemia, sepsis, delirium tremens, salicylates, hepatic failure, mechanical overventilation, and CNS lesions. Pregnancy is associated with a mild respiratory alkalosis. Severe respiratory alkalosis may acutely cause seizures, tetany, cardiac arrhythmias, or loss of consciousness.

Treatment should be directed at the underlying disorders. In psychogenic cases, sedation or a rebreathing bag may be required.

**“Mixed” Disorders**  In many circumstances, more than a single acid-base disturbance exists. Examples include combined metabolic and respiratory acidosis with cardiogenic shock; metabolic alkalosis and anion-gap acidosis in pts with vomiting and diabetic ketoacidosis; and anion-gap metabolic acidosis with respiratory alkalosis in pts with salicylate toxicity. The diagnosis may be clinically evident and/or suggested by relationships between the P_CO₂ and [HCO₃⁻] that diverge from those found in simple disorders. For example, the P_{CO₂} in a pt with metabolic acidosis and respiratory alkalosis will be considerably less than that predicted from the [HCO₃⁻] and Winter’s formula \[ P_{CO₂} = (1.5 \times [HCO₃⁻]) + 8 ± 2 \].

In “simple” anion-gap acidosis, the anion gap increases in proportion to the fall in [HCO₃⁻]. A lesser drop in serum [HCO₃⁻] than in the anion gap suggests a coexisting metabolic alkalosis. Conversely, a proportionately larger drop in [HCO₃⁻] than in the anion gap suggests the presence of a mixed anion-gap and non-anion-gap metabolic acidosis. Notably, however, these interpretations assume 1:1 relationships between unmeasured anions and the fall in [HCO₃⁻], which are not uniformly present in individual pts or as acidoses evolve. For example, volume resuscitation of pts with DKA will typically increase glomerular filtration and the urinary excretion of ketones, resulting in a decrease in the anion gap in the absence of a supervening non-anion-gap acidosis.
Clinicians have a wide array of radiologic modalities at their disposal to aid them in noninvasive diagnosis. Despite the introduction of highly specialized imaging modalities, radiologic tests such as chest radiographs and ultrasound continue to serve a vital role in the diagnostic approach to patient care. At most institutions, CT is available on an emergent basis and is invaluable for initial evaluation of patients with trauma, stroke, suspected CNS hemorrhage, or ischemic stroke. MRI and related techniques (MR angiography, functional MRI, MR spectroscopy) provide remarkable resolution of many tissues including the brain, vascular system, joints, and most large organs.

This chapter will review the indications and utility of the most commonly utilized radiologic studies used by internists.

**CHEST RADIOGRAPHY**  See Fig. 3-1.

- Can be obtained quickly and should be part of the standard evaluation for patients with cardiopulmonary complaints.
- Is able to identify life-threatening conditions such as pneumothorax, intraperitoneal air, pulmonary edema, and aortic dissection.
- Is most often normal in a patient with an acute pulmonary embolus.
- Should be repeated in 4–6 weeks in a patient with an acute pneumonic process to document resolution of the radiographic infiltrate.
- Is used in conjunction with the physical exam to support the diagnosis of congestive heart failure. Radiographic findings supporting the diagnosis of heart failure include cardiomegaly, cephalization, Kerley B lines, and pleural effusions.
- Should be obtained daily in intubated patients to examine endotracheal tube position and the possibility of barotrauma.
- Helps to identify alveolar or airspace disease. Radiographic features of such diseases include inhomogeneous, patchy opacities and air-bronchograms.
- Helps to document the free-flowing nature of pleural effusions. Decubitus views should be obtained to exclude loculated pleural fluid prior to attempts to extract such fluid.

**ABDOMINAL RADIOGRAPHY**

- Should be the initial imaging modality in a patient with suspected bowel obstruction. Signs of small-bowel obstruction on plain radiographs include
multiple air-fluid levels, absence of colonic distention, and a “stepladder” appearance of small-bowel loops.

- Should not be performed with barium enhancement when perforated bowel, portal venous gas, or toxic megacolon is suspected.
- Is used to evaluate the size of bowel:
  1. Normal small bowel is <3 cm in diameter.
  2. Normal caliber of the cecum is up to 9 cm, with the rest of the large bowel up to 6 cm in diameter.

**ULTRASOUND**

- Is more sensitive and specific than CT scanning in evaluating for the presence of gallstone disease.
- Can readily identify the size of the kidneys in a patient with renal insufficiency and can exclude the presence of hydronephrosis.
- Can expeditiously evaluate for the presence of peritoneal fluid in a patient with blunt abdominal trauma.
- Is used in conjunction with doppler studies to evaluate for the presence of arterial atherosclerotic disease.
- Is used to evaluate cardiac valves and wall motion.
- Should be used to localize loculated pleural and peritoneal fluid prior to draining such fluid.
- Can determine the size of thyroid nodules and guide fine-needle aspiration biopsy.
- Is the modality of choice for assessing known or suspected scrotal pathology.
- Should be the first imaging modality utilized when evaluating the ovaries.

**COMPUTED TOMOGRAPHY**

- CT of the brain should be initial radiographic modality in evaluating a patient with a potential stroke.
- Is highly sensitive for diagnosing an acute subarachnoid hemorrhage and in the acute setting is more sensitive than MRI.
- CT of the brain is an essential test in evaluating a patient with mental status changes to exclude entities such as intracranial bleeding, mass effect, subdural or epidural hematomas, and hydrocephalus.
- Is better than MRI for evaluating osseous lesions of the skull and spine.
- CT of the chest should be considered in the evaluation of a patient with chest pain to rule out entities such as pulmonary embolus or aortic dissection.
- CT of the chest is essential for evaluating lung nodules to assess for the presence of thoracic lymphadenopathy.
- CT with high-resolution cuts through the lungs is the imaging modality of choice for evaluating the lung interstitium in a patient with interstitial lung disease.
- Can be used to evaluate for presence of pleural and pericardial fluid and to localize loculated effusions.
- Is useful in a patient with unexplained abdominal pain to evaluate for conditions such as appendicitis, mesenteric ischemia or infarction, diverticulitis, or pancreatitis.
- CT of the abdomen is also the test of choice for evaluating for nephrolithiasis in a patient with renal colic.
- Is the test of choice for evaluating for the presence of an abscess in the chest or abdomen.
- In conjunction with abdominal radiography, CT can help identify the cause of bowel obstruction.
• Can identify abdominal conditions such as intussusception and volvulus in a patient with abdominal pain.
• Is the imaging modality of choice for evaluating the retroperitoneum.
• Should be obtained expeditiously in a patient with abdominal trauma to evaluate for the presence of intraabdominal hemorrhage and to assess injury to abdominal organs.

**MAGNETIC RESONANCE IMAGING**

- Is more useful than CT in the evaluation of ischemic infarction, dementia, mass lesions, demyelinating diseases, and most nonosseous spinal disorders.
- Provides excellent imaging of large joints including the knee, hip, and shoulder.
- Can be used, often with CT or angiography, to assess possible dissecting aortic aneurysms and congenital anomalies of the cardiovascular system.
- Cardiac MRI is proving useful to evaluate cardiac wall motion and for assessing cardiac muscle viability in ischemic heart disease.
- Is preferable to CT for evaluating adrenal masses such as pheochromocytoma and for helping to distinguish benign and malignant adrenal masses.

**Procedures Commonly Performed by Internists**

Internists perform a wide range of medical procedures, although practices vary widely among institutions and by specialty. Internists, nurses, or other ancillary health care professionals perform venipuncture for blood testing, arterial puncture for blood gases, endotracheal intubation, and flexible sigmoidoscopy, and insert IV lines, nasogastric (NG) tubes, and urinary catheters. These procedures are not covered here but require skill and practice to minimize patient discomfort and potential complications. Here, we review more invasive diagnostic and therapeutic procedures performed by internists—thoracentesis, lumbar puncture, and paracentesis. Many additional procedures are performed by specialists and require additional training and credentialing, including the following:

- Allergy—skin testing, rhinoscopy
- Cardiology—stress testing, echocardiograms, coronary catheterization, angioplasty, stent insertion, pacemakers, electrophysiology testing and ablation, implantable defibrillators, cardioversion
- Endocrinology—thyroid biopsy, dynamic hormone testing, bone densitometry
- Gastroenterology—upper and lower endoscopy, esophageal manometry, endoscopic retrograde cholangiopancreatography, stent insertion, endoscopic ultrasound, liver biopsy
- Hematology/Oncology—bone marrow biopsy, stem cell transplant, lymph node biopsy, plasmapheresis
- Pulmonary—intubation and ventilator management, bronchoscopy
- Renal—kidney biopsy, dialysis
- Rheumatology—joint aspiration

Increasingly, ultrasound, CT, and MRI are being used to guide invasive procedures, and flexible fiberoptic instruments are extending the reach into the
body. For most invasive medical procedures, including those reviewed below, informed consent should be obtained in writing before beginning the procedure.

## THORACENTESIS

Drainage of the pleural space can be performed at the bedside. Indications for this procedure include diagnostic evaluation of pleural fluid, removal of pleural fluid for symptomatic relief, and instillation of sclerosing agents in pts with recurrent, usually malignant pleural effusions.

### Preparatory Work

Familiarity with the components of a thoracentesis tray is a prerequisite to performing a thoracentesis successfully. Recent PA and lateral chest radiographs with bilateral decubitus views should be obtained to document the free-flowing nature of the pleural effusion. Loculated pleural effusions should be localized by ultrasound or CT prior to drainage.

### Technique

A posterior approach is the preferred means of accessing pleural fluid. Comfortable positioning is a key to success for both pt and physician. The pt should sit on the edge of the bed, leaning forward with the arms abducted onto a pillow on a bedside stand. Pts undergoing thoracentesis frequently have severe dyspnea, and it is important to assess if they can maintain this positioning for at least 10 min. The entry site for the thoracentesis is based on the physical exam and radiographic findings. Percussion of dullness is utilized to ascertain the extent of the pleural effusion with the site of entry being the first or second highest interspace in this area. The entry site for the thoracentesis is at the superior aspect of the rib, thus avoiding the intercostal nerve, artery, and vein, which run along the inferior aspect of the rib (Fig. 4-1).

The site of entry should be marked with a pen to guide the thoracentesis. The skin is then prepped and draped in a sterile fashion with the operator observing sterile technique at all times. A small-gauge needle is used to anesthetize the skin, and a larger-gauge needle is used to anesthetize down to the superior aspect of the rib.

![FIGURE 4-1](image-url) In thoracentesis, the needle is passed over the top of the rib to avoid the neurovascular bundle. (From LG Gomella, SA Haist: Clinician’s Pocket Reference, 11th ed. New York, McGraw-Hill, 2007.)
of the rib. The needle should then be directed over the upper margin of the rib to anesthetize down to the parietal pleura. The pleural space should be entered with the anesthetizing needle, all the while using liberal amounts of lidocaine.

A dedicated thoracentesis needle with an attached syringe should next be utilized to penetrate the skin. This needle should be advanced to the superior aspect of the rib. While maintaining gentle negative pressure, the needle should be slowly advanced into the pleural space. If a diagnostic tap is being performed, aspiration of only 30–50 mL of fluid is necessary before termination of the procedure. If a therapeutic thoracentesis is being performed, a three-way stopcock is utilized to direct the aspirated pleural fluid into collection bottles or bags. No more than 1 L of pleural fluid should be withdrawn at any given time as quantities >1–1.5 L can result in reexpansion pulmonary edema.

After all specimens have been collected, the thoracentesis needle should be withdrawn and the needle site occluded for at least 1 min.

**Specimen Collection** The diagnostic evaluation of pleural fluid depends on the clinical situation. All pleural fluid samples should be sent for cell count and differential, Gram stain, and bacterial cultures. LDH and protein determinations should also be made to differentiate between exudative and transudative pleural effusions. The pH should be determined if empyema is a diagnostic consideration. Other studies on pleural fluid include mycobacterial and fungal cultures, glucose, triglyceride level, amylase, and cytologic determination.

**Post-Procedure** A post-procedural chest radiograph should be obtained to evaluate for a pneumothorax, and the pt should be instructed to notify the physician if new shortness of breath develops.

---

**LUMBAR PUNCTURE**

Evaluation of CSF is essential for the diagnosis of suspected meningeal infection, subarachnoid hemorrhage, leptomeningeal neoplastic disease, and noninfectious meningoencephalitis. Relative contraindications to LP include local skin infection in the lumbar area, suspected spinal cord mass lesion, and a suspected intracranial mass lesion. Any bleeding diathesis should also be corrected prior to performing LP to prevent the possible occurrence of an epidural hematoma. A functional platelet count > 50,000/μL and an INR < 1.5 are advisable to perform LP safely.

**Preparatory Work** Familiarity with the components of a lumbar puncture tray is a prerequisite to performing LP successfully. In pts with focal neurologic deficits or with evidence of papilledema on physical exam, a CT scan of the head should be obtained prior to performing LP.

**Technique** Proper positioning of the pt is important to ensure a successful LP. Two different pt positions can be used: the lateral decubitus position and the sitting position. Most routine LPs should be performed using the lateral decubitus position (Fig. 4-2). The sitting position may be preferable in obese pts. With either position, the pt should be instructed to flex the spine as much as possible. In the lateral decubitus position, the pt is instructed to assume the fetal position with the knees flexed toward the abdomen. In the sitting position, the pt should bend over a bedside table with the head resting on folded arms.

The entry site for a LP is below the level of the conus medullaris, which extends to L1-L2 in most adults. Thus, either the L3-L4 or L4-L5 interspace can be utilized as the entry site. The posterior superior iliac crest should be identified and the spine palpated at this level. This represents the L3-L4 interspace, with the other interspaces referenced from this landmark. The midpoint of the interspace be-
SECTION 1 Care of the Hospitalized Patient

The entry site for the thoracentesis needle between the spinous processes represents the entry point for the thoracentesis needle. This entry site should be marked with a pen to guide the LP. The skin is then prepped and draped in a sterile fashion with the operator observing sterile technique at all times. A small-gauge needle is then used to anesthetize the skin and subcutaneous tissue. The spinal needle should be introduced perpendicular to the skin in the midline and should be advanced slowly. The needle stylette should be withdrawn frequently as the spinal needle is advanced. As the needle enters the subarachnoid space, a “popping” sensation can sometimes be felt. If bone is encountered, the needle should be withdrawn to just below the skin and then redirected more caudally. Once CSF begins to flow, the opening pressure can be measured. This should be measured in the lateral decubitus position with the pt shifted to this position if the procedure was begun with the pt in the sitting position. After the opening pressure is measured, the CSF should be collected in a series of specimen tubes for various tests. At a minimum, a total of 10–15 mL of CSF should be collected in the different specimen tubes.

Once the required spinal fluid is collected, the stylette should be replaced and the spinal needle removed.

**Specimen Collection**  Diagnostic evaluation of CSF is based on the clinical scenario. In general, spinal fluid should always be sent for cell count with differential, protein, glucose, and bacterial cultures. Other specialized studies that can be obtained on CSF include viral cultures, fungal and mycobacterial cultures, VDRL, cryptococcal antigen, oligoclonal bands, and cytology.

**Post-Procedure**  To reduce the chance of a post-LP headache, the pt should be instructed to lie prone for at least 3 h. If a headache does develop, bedrest, hydration, and oral analgesics are often helpful. If an intractable post-LP headache ensues, the pt may have a persistent CSF leak. In this case, consultation with an anesthesiologist should be considered for the placement of a blood patch.

**PARACENTESIS**

Removal and analysis of peritoneal fluid is invaluable in evaluating pts with new-onset ascites or ascites of unknown etiology. It is also requisite in pts with

---

**FIGURE 4-2** Proper positioning of a patient in the lateral decubitus position. Note that the shoulders and hips are in a vertical plane; the torso is perpendicular to the bed. (From SE Strauss et al: JAMA 296:2012, 2006; with permission.)
known ascites who have a decompensation in their clinical status. Relative con-
traindications include bleeding diathesis, prior abdominal surgery, distended
bowel, or known loculated ascites.

**Preparatory Work**  Prior to performing a paracentesis, any severe bleeding dia-
thesis should be corrected. Bowel distention should also be relieved by place-
ment of a nasogastric tube, and the bladder should also be emptied before
beginning the procedure. If a large-volume paracentesis is being performed,
large vacuum bottles with the appropriate connecting tubing should be obtained.

**Technique**  Proper pt positioning greatly improves the ease with which a para-
centesis can be performed. The pt should be instructed to lie supine with the head
of the bed elevated to 45°. This position should be maintained for ~15 min to
allow ascitic fluid to accumulate in the dependent portion of the abdomen.

The preferred entry site for paracentesis is a midline puncture halfway be-
tween the pubic symphysis and the umbilicus; this correlates with the loca-
tion of the relatively avascular linea alba. The midline puncture should be
avoided if there is a previous midline surgical scar, as neovascularization may
have occurred. Alternative sites of entry include the lower quadrants, lateral
to the rectus abdominis, but caution should be used to avoid collateral blood
vessels that may have formed in patients with portal hypertension.

The skin is prepped and draped in a sterile fashion. The skin, subcutaneous
 tissue, and the abdominal wall down to the peritoneum should be infiltrated
with an anesthetic agent. The paracentesis needle with an attached syringe is
then introduced in the midline perpendicular to the skin. To prevent leaking of
ascitic fluid, “Z-tracking” can sometimes be helpful: after penetrating the skin,
the needle is inserted 1–2 cm before advancing further. The needle is then ad-
vanced slowly while continuous aspiration is performed. As the peritoneum is
pierced, the needle will give noticeably. Fluid should flow freely into the sy-
ringe soon thereafter. For a diagnostic paracentesis, removal of 50 mL of ascitic
fluid is adequate. For a large-volume paracentesis, direct drainage into large
vacuum containers using connecting tubing is a commonly utilized option.

After all samples have been collected, the paracentesis needle should be re-
moved and firm pressure applied to the puncture site.

**Specimen Collection**  Peritoneal fluid should be sent for cell count with differ-
ential, Gram stain, and bacterial cultures. Albumin measurement of ascitic fluid
is also necessary for calculating the serum–ascitic albumin gradient. Depending
on the clinical scenario, other studies that can be obtained include mycobacterial
cultures, amylase, adenosine deaminase, triglycerides, and cytology.

**Post-Procedure**  The pt should be monitored carefully post-procedure and
should be instructed to lie supine in bed for several hours. If persistent fluid leak-
age occurs, continued bedrest with pressure dressings at the puncture site can be
helpful. For pts with hepatic dysfunction undergoing large-volume paracentesis,
the sudden reduction in intravascular volume can precipitate hepatorenal syn-
drome. Administration of 25 g IV albumin following large-volume paracentesis
has been shown to decrease the incidence of renal failure post-procedure. Final-
ly, if the ascites fluid analysis shows evidence of spontaneous bacterial perito-
nitis, then antibiotics (directed toward gram-negative gut bacteria) and IV
albumin should be administered as soon as possible.
INITIAL EVALUATION OF THE CRITICALLY ILL PATIENT

Initial care of critically ill pts must often be performed rapidly and before a thorough medical history has been obtained. Physiologic stabilization begins with the principles of advanced cardiovascular life support and frequently involves invasive techniques such as mechanical ventilation and renal replacement therapy to support organ systems that are failing. A variety of severity-of-illness scoring systems, such as APACHE II, have been developed. Although these tools are useful for ensuring similarity among groups of pts involved in clinical trials or in quality assurance monitoring, their relevance to individual pts is less clear. These scoring systems are not typically used to guide clinical management.

SHOCK

Shock, which is characterized by multisystem end-organ hypoperfusion and tissue hypoxia, is a frequent problem requiring ICU admission. A variety of clinical indicators of shock exist, including reduced mean arterial pressure, tachycardia, tachypnea, cool extremities, altered mental status, oliguria, and lactic acidosis. Although hypotension is usually observed in shock, there is not a specific blood pressure threshold that is used to define it. Shock can result from decreased cardiac output, decreased systemic vascular resistance, or both. The three main categories of shock are hypovolemic, cardiogenic, and high cardiac output/low systemic vascular resistance. Clinical evaluation can be useful to assess the adequacy of cardiac output, with narrow pulse pressure, cool extremities, and delayed capillary refill suggestive of reduced cardiac output. Indicators of high cardiac output (e.g., widened pulse pressure, warm extremities) associated with shock suggest reduced systemic vascular resistance. Reduced cardiac output can be due to intravascular volume depletion (e.g., hemorrhage) or cardiac dysfunction. Reduced systemic vascular resistance is often caused by sepsis, but high cardiac output hypotension is also seen in pancreatitis, burns, anaphylaxis, peripheral arteriovenous shunts, and thyrotoxicosis. Early resuscitation of septic and cardiogenic shock may improve survival; objective assessments such as echocardiography and/or invasive vascular monitoring should be used to complement clinical evaluation. The approach to the pt in shock is outlined in Fig. 5-1.

MECHANICAL VENTILATORY SUPPORT

Critically ill pts often require mechanical ventilation. During initial resuscitation, standard principles of advanced cardiovascular life support should be followed. Mechanical ventilation should be considered for acute hypoxemic respiratory failure, which may occur with cardiogenic shock, pulmonary edema (cardiogenic or noncardiogenic), or pneumonia. Mechanical ventilation should also be considered with ventilatory failure, which can result from an increased load on the respiratory system—often manifested by lactic acidosis or decreased lung compliance. Mechanical ventilation may decrease respiratory work, improve arterial oxygenation with improved tissue O₂ delivery, and reduce acidosis. Reduction in mean arterial pressure after institution of mechanical ventilation commonly occurs due to reduced venous return from positive pressure ventilation, reduced en-
Principles of Critical Care Medicine

CHAPTER 5

Dedogenous catecholamine secretion, and administration of drugs used to facilitate intubation. Since hypovolemia often contributes to postintubation hypotension, IV volume administration should be considered. The major types of respiratory failure are discussed in Chap. 16.

The Mechanically Ventilated Patient

Many pts receiving mechanical ventilation require treatment for pain (typically with narcotics) and for anxiety (typically with benzodiazepines, which also have the benefit of providing amnesia). Less commonly, neuromuscular blocking agents are required to facilitate ventilation when there is extreme dyssynchrony between the pt’s respiratory efforts and the ventilator that cannot be corrected with manipulation of the ventilator settings; aggressive sedation is required during treatment with neuromuscular blockers. Neuromuscular blocking agents should be used with caution because a myopathy associated with prolonged weakness can result.

FIGURE 5-1 Approach to patient in shock. JVP, jugular venous pulse; EGDT, early goal-directed therapy.
Weaning from mechanical ventilation should be considered when the disease process prompting intubation has improved. Daily screening of intubated pts for weaning potential should be performed. Stable oxygenation (at low PEEP levels), intact cough and airway reflexes, and lack of (or substantial reduction in) requirement for vasopressor agents are required before considering a trial of weaning from mechanical ventilation. The most effective approach for weaning is usually a spontaneous breathing trial, which involves 30–120 min of breathing without significant ventilatory support. Either an open T-piece breathing system or minimal amounts of ventilatory support (pressure support to overcome resistance of the endotracheal tube and/or low levels of CPAP) can be used. Failure of a spontaneous breathing trial has occurred if tachypnea (respiratory rate >35 breaths/min for >5 min), hypoxemia (O₂ saturation <90%), tachycardia (>140 beats/min or 20% increase from baseline), bradycardia (20% reduction from baseline), hypotension (<90 mmHg), hypertension (>180 mmHg), or increased anxiety or diaphoresis develop. At the end of the spontaneous breathing trial, the rapid shallow breathing index (RSBI or f/VT), which is calculated as respiratory rate in breaths/min divided by tidal volume in liters, can be used to predict weanability. A f/VT <105 at the end of the spontaneous breathing test warrants a trial of extubation.

MULTIORGAN SYSTEM FAILURE

Multiorgan system failure is a syndrome defined by the simultaneous dysfunction or failure of two or more organs in pts with critical illness. Multiorgan system failure is a common consequence of systemic inflammatory conditions (e.g., sepsis, pancreatitis, and trauma). To meet the criteria for multiorgan system failure, organ failure must persist for >24 h. Prognosis worsens with increased duration of organ failure and increased number of organ systems involved.

MONITORING IN THE ICU

With critical illness, close and often continuous monitoring of multiple organ systems is required. In addition to pulse oximetry, frequent arterial blood gas analysis can reveal evolving acid-base disturbances and assess the adequacy of ventilation. Intra-arterial pressure monitoring is frequently performed to follow blood pressure and to provide arterial blood gases and other blood samples. Pulmonary artery (Swan-Ganz) catheters can provide pulmonary artery pressure, cardiac output, and systemic vascular resistance measurements. However, no morbidity or mortality benefit from pulmonary artery catheter use has been demonstrated, and rare but significant complications from placement of central venous access (e.g., pneumothorax, infection) or the pulmonary artery catheter (e.g., cardiac arrhythmias, pulmonary artery rupture) can result. Thus, routine pulmonary artery catheterization in critically ill pts is not recommended.

For intubated pts receiving volume-controlled modes of mechanical ventilation, respiratory mechanics can be followed easily. The peak airway pressure is regularly measured by mechanical ventilators, and the plateau pressure can be assessed by including an end-inspiratory pause. The inspiratory airway resistance is calculated as the difference between the peak and plateau airway pressures (with adjustment for flow rate). Increased airway resistance can result from bronchospasm, respiratory secretions, or a kinked endotracheal tube. Static compliance of the respiratory system is calculated as the tidal volume divided by the gradient in airway pressure (plateau pressure minus PEEP). Reduced respiratory system compliance can result from pleural effusions, pneumothorax, pneumonia, pulmonary edema, or auto-PEEP.
PREVENTION OF CRITICAL ILLNESS COMPLICATIONS

Critically ill pts are prone to a number of complications, including the following:

- Sepsis—Often is related to the invasive monitoring performed of critically ill pts.
- Anemia—Usually is due to chronic inflammation as well as iatrogenic blood loss.
- Deep-venous thrombosis—May occur despite standard prophylaxis with SC heparin or sequential compression devices and may occur at the site of central venous catheters.
- GI bleeding—Stress ulcers of the gastric mucosa frequently develop in pts with bleeding diatheses, shock, or respiratory failure, necessitating prophy- lactic acid neutralization in such pts.
- Acute renal failure—A tendency exacerbated by nephrotoxic medications and dye studies. The most common etiology is acute tubular necrosis. Low-dose dopamine treatment does not protect against the development of acute renal failure.
- Hyperglycemia—Frequently occurs with parenteral nutrition; intensive insulin therapy to provide normoglycemia improves survival in surgical ICU pts.
- ICU-acquired weakness—Neuropathies and myopathies have been described; they are especially common in sepsis.

NEUROLOGIC DYSFUNCTION IN CRITICALLY ILL PATIENTS

A variety of neurologic problems can develop in critically ill pts. Most ICU pts develop delirium, which is characterized by acute changes in mental status, inattention, disorganized thinking, and an altered level of consciousness. Less common but important neurologic complications include anoxic brain injury, stroke, and status epilepticus.

LIMITATION OR WITHDRAWAL OF CARE

Withholding or withdrawing care commonly occurs in the ICU. Technological advances have allowed many pts to be maintained in the ICU with little or no chance of recovery. Increasingly, pts, families, and caregivers have acknowledged the ethical validity of withdrawal of care when the pt or surrogate decision-maker determines that the pt’s goals for care are no longer achievable with the clinical situation.

For a more detailed discussion, see Kress JP, Hall JB: Principles of Critical Care Medicine, Chap. 261, p. 1673, in HPIM-17.
SECTION 1  Care of the Hospitalized Patient

Pain and Its Management

APPROACH TO THE PATIENT: PAIN

Pain is the most common symptom of disease. Management depends on determining its cause, alleviating triggering and potentiating factors, and providing rapid relief whenever possible. Pain may be of somatic (skin, joints, muscles), visceral, or neuropathic (injury to nerves, spinal cord pathways, or thalamus) origin. Characteristics of each are summarized in Table 6-1.

Neuropathic Pain

Definitions: neuralgia: pain in the distribution of a single nerve, as in trigeminal neuralgia; dysesthesia: spontaneous, unpleasant, abnormal sensations; hyperalgesia and hyperesthesia: exaggerated responses to nociceptive or touch stimulus, respectively; allodynia: perception of light mechanical stimuli as painful, as when vibration evokes painful sensation. Reduced pain perception is called hypalgesia or, when absent, analgesia. Causalgia is continuous severe burning pain with indistinct boundaries and accompanying sympathetic nervous system dysfunction (sweating; vascular, skin, and hair changes—sympathetic dystrophy) that occurs after injury to a peripheral nerve.

Sensitization refers to a lowered threshold for activating primary nociceptors following repeated stimulation in damaged or inflamed tissues; inflammatory mediators play a role. Sensitization contributes to tenderness, soreness, and hyperalgesia (as in sunburn).

Referred pain results from the convergence of sensory inputs from skin and viscera on single spinal neurons that transmit pain signals to the brain. Because of this convergence, input from deep structures is mislocalized to a region of skin innervated by the same spinal segment.

---

TABLE 6-1  CHARACTERISTICS OF SOMATIC AND NEUROPATHIC PAIN

<table>
<thead>
<tr>
<th>Category</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Somatic pain</td>
<td>Nociceptive stimulus usually evident</td>
</tr>
<tr>
<td></td>
<td>Usually well localized</td>
</tr>
<tr>
<td></td>
<td>Similar to other somatic pains in pt’s experience</td>
</tr>
<tr>
<td></td>
<td>Relieved by anti-inflammatory or narcotic analgesics</td>
</tr>
<tr>
<td>Visceral pain</td>
<td>Most commonly activated by inflammation</td>
</tr>
<tr>
<td></td>
<td>Pain poorly localized and usually referred</td>
</tr>
<tr>
<td></td>
<td>Associated with diffuse discomfort, e.g., nausea, bloating</td>
</tr>
<tr>
<td></td>
<td>Relieved by narcotic analgesics</td>
</tr>
<tr>
<td>Neuropathic pain</td>
<td>No obvious nociceptive stimulus</td>
</tr>
<tr>
<td></td>
<td>Associated evidence of nerve damage, e.g., sensory impairment, weakness</td>
</tr>
<tr>
<td></td>
<td>Unusual, dissimilar from somatic pain, often shooting or electrical quality</td>
</tr>
<tr>
<td></td>
<td>Only partially relieved by narcotic analgesics, may respond to antidepressants or anticonvulsants</td>
</tr>
</tbody>
</table>
Chronic Pain
The problem is often difficult to diagnose, and pts may appear emotionally distraught. Several factors can cause, perpetuate, or exacerbate chronic pain: (1) painful disease for which there is no cure (e.g., arthritis, cancer, migraine headaches, diabetic neuropathy); (2) neural factors initiated by a bodily disease that persist after the disease has resolved (e.g., damaged sensory or sympathetic nerves); (3) psychological conditions. Pay special attention to the medical history and to depression. Major depression is common, treatable, and potentially fatal (suicide).

PATHOPHYSIOLOGY: ORGANIZATION OF PAIN PATHWAYS
Pain-producing (nociceptive) sensory stimuli in skin and viscera activate peripheral nerve endings of primary afferent neurons, which synapse on second-order neurons in spinal cord or medulla (Fig. 6-1). These second-order neurons form crossed ascending pathways that reach the thalamus and are projected to somatosensory cortex. Parallel ascending neurons connect with brainstem nuclei and ventrocaudal and medial thalamic nuclei. These parallel pathways project to the limbic system and underlie the emotional aspect of pain. Pain transmission is

---

**FIGURE 6-1** Pain transmission and modulatory pathways. A. Transmission system for nociceptive messages. Noxious stimuli activate the sensitive peripheral ending of the primary afferent nociceptor by the process of transduction. The message is then transmitted over the peripheral nerve to the spinal cord, where it synapses with cells of origin of the major ascending pain pathway, the spinothalamic tract. The message is relayed in the thalamus to the anterior cingulate (C), frontal insular (F), and somatosensory cortex (SS). B. Pain-modulation network. Inputs from frontal cortex and hypothalamus activate cells in the midbrain that control spinal pain-transmission cells via cells in the medulla.
### TABLE 6-2 DRUGS FOR RELIEF OF PAIN

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Dose, mg</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nonnarcotic Analgesics: Usual Doses and Intervals</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetylsalicylic acid</td>
<td>650 PO</td>
<td>q 4 h</td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>650 PO</td>
<td>q 4 h</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>400 PO</td>
<td>q 4–6 h</td>
</tr>
<tr>
<td>Naproxen</td>
<td>250–500 PO</td>
<td>q 12 h</td>
</tr>
<tr>
<td>Fenoprofen</td>
<td>200 PO</td>
<td>q 4–6 h</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>25–50 PO</td>
<td>q 8 h</td>
</tr>
<tr>
<td>Ketorolac</td>
<td>15–60 IM/IV</td>
<td>q 4–6 h</td>
</tr>
<tr>
<td>Celecoxib</td>
<td>100–200 PO</td>
<td>q 12–24 h</td>
</tr>
<tr>
<td>Valdecoxib</td>
<td>10–20 PO</td>
<td>q 12–24 h</td>
</tr>
<tr>
<td><strong>Narcotic Analgesics: Usual Doses and Intervals</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Codeine</td>
<td>30–60 q 4 h</td>
<td>30–60 q 4 h</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>—</td>
<td>5–10 q 4–6 h</td>
</tr>
<tr>
<td>Morphine</td>
<td>10 q 4 h</td>
<td>60 q 4 h</td>
</tr>
<tr>
<td>Morphine sustained release</td>
<td>—</td>
<td>30–200 bid to tid</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>1–2 q 4 h</td>
<td>2–4 q 4 h</td>
</tr>
<tr>
<td>Levorphanol</td>
<td>2 q 6–8 h</td>
<td>4 q 6–8 h</td>
</tr>
<tr>
<td>Methadone</td>
<td>10 q 6–8 h</td>
<td>20 q 6–8 h</td>
</tr>
<tr>
<td>Meperidine</td>
<td>75–100 q 3–4 h</td>
<td>300 q 4 h</td>
</tr>
<tr>
<td>Butorphanol</td>
<td>—</td>
<td>1–2 q 4 h</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>25–100 µg/h</td>
<td>—</td>
</tr>
<tr>
<td>Tramadol</td>
<td>—</td>
<td>50–100 q 4–6 h</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Parenteral Dose, mg</th>
<th>PO Dose, mg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antidepressants</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doxepin</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>++++</td>
<td>++</td>
</tr>
<tr>
<td>Imipramine</td>
<td>++++</td>
<td>++</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Desipramine</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>+++</td>
<td>+++</td>
</tr>
</tbody>
</table>

| **Anticonvulsants and Antiarrhythmics** |              |             |
| Phenytoin              | 300              | daily/qhs  |
| Carbamazepine          | 200–300           | q 6 h      |
| Oxcarbazine            | 300               | bid        |

*Antidepressants, anticonvulsants, and antiarrhythmics have not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of pain.*
Enteric-coated preparations available
Side effects uncommon
Available without prescription
Delayed effects may be due to long half-life
Contraindicated in renal disease
Gastrointestinal side effects common
Available for parenteral use
Useful for arthritis
Removed from U.S. market in 2005

Nausea common
Usually available with acetaminophen or aspirin
Oral slow-release preparation
Shorter acting than morphine sulfate
Longer acting than morphine sulfate; absorbed well PO
Delayed sedation due to long half-life
Poorly absorbed PO; normeperidine a toxic metabolite
Intranasal spray
72 h Transdermal patch
Mixed opioid/adrenergic action

<table>
<thead>
<tr>
<th>Orthostatic Hypotension</th>
<th>Cardiac Arrhythmia</th>
<th>Ave. Dose, mg/d</th>
<th>Range, mg/d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate</td>
<td>Less</td>
<td>200</td>
<td>75–400</td>
</tr>
<tr>
<td>Moderate</td>
<td>Yes</td>
<td>150</td>
<td>25–300</td>
</tr>
<tr>
<td>High</td>
<td>Yes</td>
<td>200</td>
<td>75–400</td>
</tr>
<tr>
<td>Low</td>
<td>Yes</td>
<td>100</td>
<td>40–150</td>
</tr>
<tr>
<td>Low</td>
<td>Yes</td>
<td>150</td>
<td>50–300</td>
</tr>
<tr>
<td>None</td>
<td>No</td>
<td>150</td>
<td>75–400</td>
</tr>
<tr>
<td>None</td>
<td>No</td>
<td>40</td>
<td>30–60</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>PO Dose, mg</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clonazepam</td>
<td>1</td>
<td>q 6 h</td>
</tr>
<tr>
<td>Gabapentin&lt;sup&gt;b&lt;/sup&gt;</td>
<td>600–1200</td>
<td>q 8 h</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>150–600</td>
<td>bid</td>
</tr>
</tbody>
</table>

<sup>b</sup>Gabapentin in doses up to 1800 mg/d is FDA approved for postherpetic neuralgia.

Note: 5-HT, serotonin; NE, norepinephrine.
regulated at the dorsal horn level by descending bulboспinal pathways that con-
tain serotonin, norepinephrine, and several neuropeptides.

Agents that modify pain perception may act to reduce tissue inflammation
(NSAIDs, prostaglandin synthesis inhibitors), to interfere with pain transmission
(narcotics), or to enhance descending modulation (narcotics and antidepres-
sants). Anticonvulsants (gabapentin, carbamazepine) may be effective for aber-
rant pain sensations arising from peripheral nerve injury.

**Pain**

**ACUTE SOMATIC PAIN**

If moderate, it can usually be treated effectively with nonnarcotic analgesics,
e.g., aspirin, acetaminophen, and NSAIDs (Table 6-2). All inhibit cyclooxy-
genase (COX) and, except for acetaminophen, all have anti-inflammatory ac-
tions, especially at high dosages. For subacute musculoskeletal pain and
arthritis, selective COX-2 inhibitors such as celecoxib are useful but are asso-
ociated with increased cardiovascular risk. Narcotic analgesics are usually re-
quired for relief of severe pain; the dose should be titrated to produce effective
analgesia.

**CHRONIC PAIN**

After evaluation, an explicit treatment plan should be developed, including
specific and realistic goals for therapy, e.g., getting a good night’s sleep, being
able to go shopping, or returning to work. A multidisciplinary approach that
utilizes medications, counseling, physical therapy, nerve blocks, and even sur-
gery may be required to improve the pt’s quality of life. Psychological evalua-
tion is key; behaviorally based treatment paradigms are frequently helpful.
Some pts may require referral to a pain clinic; for others, pharmacologic man-
agement alone can provide significant help.

The tricyclic antidepressants are useful in management of chronic pain
from many causes, including headache, diabetic neuropathy, postherpetic
neuralgia, atypical facial pain, chronic low back pain, and post-stroke pain.
Anticonvulsants or antiarrhythmics benefit pts with neuropathic pain and little
or no evidence of sympathetic dysfunction (e.g., diabetic neuropathy, trigemi-
nal neuralgia). The combination of the anticonvulsant gabapentin and an anti-
depressant such as nortriptyline may be effective for chronic neuropathic
pain.

The long-term use of opioids is accepted for pain due to malignant disease
but is controversial for chronic pain of nonmalignant origin. When other ap-
proaches fail, long-acting opioid compounds such as levorphanol, methadone,
sustained-release morphine, or transdermal fentanyl may be considered for
these pts (Table 6-2).

For a more detailed discussion, see Fields HL, Martin JB: Pain: Pa-
thophysiology and Management, Chap. 12, p. 81, in HPIM-17.
Stability of body weight requires that energy intake and expenditures are balanced over time. The major categories of energy output are resting energy expenditure (REE) and physical activity; minor sources include the energy cost of metabolizing food (thermic effect of food or specific dynamic action) and shivering thermogenesis. The average energy intake is about 2800 kcal/d for men and about 1800 kcal/d for women, though these estimates vary with age, body size, and activity level. Basal energy expenditure (BEE), measured in kcal/d, may be estimated by the Harris and Benedict formula (Fig. 7-1).

Dietary reference intakes (DRI) and recommended dietary allowances (RDA) have been defined for many nutrients, including 9 essential amino acids, 4 fat-soluble and 10 water-soluble vitamins, several minerals, fatty acids, choline, and water (Tables 70-1 and 70-2, pp. 438 and 439, in HPIM-17). The usual water requirements are 1.0–1.5 mL/kcal energy expenditure in adults, with adjustments for excessive losses. The RDA for protein is 0.6 g/kg ideal body weight, representing 15% of total caloric intake. Fat should comprise \( \leq 30\% \) of calories, and saturated fat should be \(<10\% \) of calories. At least 55% of calories should be derived from carbohydrates.

MALNUTRITION

Malnutrition results from inadequate intake or abnormal gastrointestinal assimilation of dietary calories, excessive energy expenditure, or altered metabolism of energy supplies by an intrinsic disease process.

Both outpatients and inpatients are at risk for malnutrition if they meet one or more of the following criteria:

- Unintentional loss of \( >10\% \) of usual body weight in the preceding 3 months
- Body weight \(< 90\% \) of ideal for height (Table 7-1)
- Body mass index (BMI: weight/height\(^2 \) in kg/m\(^2 \)) \(< 18.5\)

**Calculate BEE**
- BEE (men) = 66.47 + (13.75 \times W) + (5.00 \times H) – (6.76 \times A) kcal/d
- BEE (women) = 655.10 + (9.56 \times W) + (1.85 \times H) – (4.68 \times A) kcal/d

**Account for the stress of illness**
- BEE \times 1.1 for patients without significant physiologic stress
- BEE \times 1.4 for patients with marked stress, such as sepsis or trauma

**FIGURE 7-1** Basal energy expenditure (BEE) calculation in kcal/d, estimated by the Harris and Benedict formula. W, Weight in kg; H, height in cm; A, age in years.
Two forms of severe malnutrition can be seen: marasmus, which refers to generalized starvation that occurs in the setting of chronically decreased energy intake, and kwashiorkor, which refers to selective protein malnutrition due to decreased protein intake and catabolism in the setting of acute, life-threatening illnesses or chronic inflammatory disorders. Aggressive nutritional support is indicated in kwashiorkor to prevent infectious complications and poor wound healing.

**Etiology**

The major etiologies of malnutrition are starvation, stress from surgery or severe illness, and mixed mechanisms. Starvation results from decreased dietary intake (from poverty, chronic alcoholism, anorexia nervosa, fad diets, severe depression, neurodegenerative disorders, dementia, or strict vegetarianism; abdominal pain from intestinal ischemia or pancreatitis; or anorexia associated with AIDS, disseminated cancer, or renal failure) or decreased assimilation of the diet (from pancreatic insufficiency; short bowel syndrome; celiac disease; or esophageal, gastric, or intestinal obstruction). Contributors to physical stress include fever, acute trauma, major surgery, burns, acute sepsis, hyperthyroidism, and inflammation as occurs in pancreatitis, collagen vascular diseases, and chronic infectious diseases such as tuberculosis or AIDS opportunistic infections. Mixed mechanisms occur in AIDS, disseminated cancer, chronic obstructive pulmonary disease, chronic liver disease, Crohn’s disease, ulcerative colitis, and renal failure.

<table>
<thead>
<tr>
<th>Height</th>
<th>Weight</th>
<th>Height</th>
<th>Weight</th>
<th>Height</th>
<th>Weight</th>
<th>Height</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>145</td>
<td>51.9</td>
<td>166</td>
<td>64.0</td>
<td>140</td>
<td>44.9</td>
<td>161</td>
<td>56.9</td>
</tr>
<tr>
<td>146</td>
<td>52.4</td>
<td>167</td>
<td>64.6</td>
<td>141</td>
<td>45.4</td>
<td>162</td>
<td>57.6</td>
</tr>
<tr>
<td>147</td>
<td>52.9</td>
<td>168</td>
<td>65.2</td>
<td>142</td>
<td>45.9</td>
<td>163</td>
<td>58.3</td>
</tr>
<tr>
<td>148</td>
<td>53.5</td>
<td>169</td>
<td>65.9</td>
<td>143</td>
<td>46.4</td>
<td>164</td>
<td>58.9</td>
</tr>
<tr>
<td>149</td>
<td>54.0</td>
<td>170</td>
<td>66.6</td>
<td>144</td>
<td>47.0</td>
<td>165</td>
<td>59.5</td>
</tr>
<tr>
<td>150</td>
<td>54.5</td>
<td>171</td>
<td>67.3</td>
<td>145</td>
<td>47.5</td>
<td>166</td>
<td>60.1</td>
</tr>
<tr>
<td>151</td>
<td>55.0</td>
<td>172</td>
<td>68.0</td>
<td>146</td>
<td>48.0</td>
<td>167</td>
<td>60.7</td>
</tr>
<tr>
<td>152</td>
<td>55.6</td>
<td>173</td>
<td>68.7</td>
<td>147</td>
<td>48.6</td>
<td>168</td>
<td>61.4</td>
</tr>
<tr>
<td>153</td>
<td>56.1</td>
<td>174</td>
<td>69.4</td>
<td>148</td>
<td>49.2</td>
<td>169</td>
<td>62.1</td>
</tr>
<tr>
<td>154</td>
<td>56.6</td>
<td>175</td>
<td>70.1</td>
<td>149</td>
<td>49.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>155</td>
<td>57.2</td>
<td>176</td>
<td>70.8</td>
<td>150</td>
<td>50.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>156</td>
<td>57.9</td>
<td>177</td>
<td>71.6</td>
<td>151</td>
<td>51.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>157</td>
<td>58.6</td>
<td>178</td>
<td>72.4</td>
<td>152</td>
<td>51.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>158</td>
<td>59.3</td>
<td>179</td>
<td>73.3</td>
<td>153</td>
<td>52.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>159</td>
<td>59.9</td>
<td>180</td>
<td>74.2</td>
<td>154</td>
<td>52.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>160</td>
<td>60.5</td>
<td>181</td>
<td>75.0</td>
<td>155</td>
<td>53.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>161</td>
<td>61.1</td>
<td>182</td>
<td>75.8</td>
<td>156</td>
<td>53.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>162</td>
<td>61.7</td>
<td>183</td>
<td>76.5</td>
<td>157</td>
<td>54.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>163</td>
<td>62.3</td>
<td>184</td>
<td>77.3</td>
<td>158</td>
<td>54.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>164</td>
<td>62.9</td>
<td>185</td>
<td>78.1</td>
<td>159</td>
<td>55.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>165</td>
<td>63.5</td>
<td>186</td>
<td>78.9</td>
<td>160</td>
<td>56.2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Values are expressed in cm for height and kg for weight. To obtain height in inches, divide by 2.54. To obtain weight in pounds, multiply by 2.2.

Clinical Features

• **General**—weight loss, temporal and proximal muscle wasting, decreased skin-fold thickness

• **Skin, hair, and nails**—easily plucked hair (protein); sparse hair (protein, biotin, zinc); coiled hair, easy bruising, petechiae, and perifollicular hemorrhages (vit. C); “flaky paint” rash of lower extremities (zinc); hyperpigmentation of skin in exposed areas (niacin, tryptophan); spooning of nails (iron)

• **Eyes**—conjunctival pallor (anemia); night blindness, dryness, and Bitot spots (vit. A); ophthalmoplegia (thiamine)

• **Mouth and mucous membranes**—glossitis and/or cheilosis (riboflavin, niacin, vit. B₁₂, pyridoxine, folate), diminished taste (zinc), inflamed and bleeding gums (vit. C)

• **Neurologic**—disorientation (niacin, phosphorus); confabulation, cerebellar gait, or past pointing (thiamine); peripheral neuropathy (thiamine, pyridoxine, vit. E); lost vibratory and position sense (vit. B₁₂)

• **Other**—edema (protein, thiamine), heart failure (thiamine, phosphorus), hepatomegaly (protein)

Laboratory findings in protein malnutrition include a low serum albumin, low total iron-binding capacity, and anergy to skin testing. Specific vitamin deficiencies may also be present.

For a more detailed discussion, see Dwyer J: Nutritional Requirements and Dietary Assessment, Chap. 70, p. 437; Heimberger DC: Malnutrition and Nutritional Assessment, Chap. 72, p. 450; and Russell RM and Suter PM: Vitamin and Trace Mineral Deficiency and Excess, Chap. 71, p. 450, in HPIM-17.

**8 Enteral and Parenteral Nutrition**

Nutritional support should be initiated in pts with malnutrition or in those at risk for malnutrition (e.g., conditions that preclude adequate oral feeding or pts in catabolic states, such as sepsis, burns, or trauma). An approach for deciding when to use various types of specialized nutrition support (SNS) is summarized in Fig. 8-1.

**Enteral therapy** refers to feeding via the gut, using oral supplements or infusion of formulas via various feeding tubes (nasogastric, nasoduodenal, gastrostomy, jejunostomy, or combined gastrojejunostomy). **Parenteral therapy** refers to the infusion of nutrient solutions into the bloodstream via a peripherally inserted central catheter (PICC), a centrally inserted externalized catheter, or a centrally inserted tunneled catheter or subcutaneous port. When feasible, enteral nutrition is the preferred route because it sustains the digestive, absorptive, and immunologic functions of the GI tract. Parenteral nutrition is often indicated in severe pancreatitis, necrotizing enterocolitis, prolonged ileus, and distal bowel obstruction.
ENTERAL NUTRITION

The components of a standard enteral formula are as follows:

- Caloric density: 1 kcal/mL
- Protein: ~14% cals; caseinates, soy, lactalbumin
Enteral and Parenteral Nutrition

CHAPTER 8

- Fat: ~30% cals; corn, soy, safflower oils
- Carbohydrate: ~60% cals; hydrolyzed corn starch, maltodextrin, sucrose
- Recommended daily intake of all minerals and vitamins in ≥1500 kcal/d
- Osmolality (mosmol/kg): ~300

However, modification of the enteral formula may be required based on various clinical indications and/or associated disease states. After elevation of the head of the bed and confirmation of correct tube placement, continuous gastric infusion is initiated using a half-strength diet at a rate of 25–50 mL/h. This can be advanced to full strength as tolerated to meet the energy target. The major risks of enteral tube feeding are aspiration, diarrhea, electrolyte imbalance, warfarin resistance, sinusitis, and esophagitis.

PARENTERAL NUTRITION

The components of parenteral nutrition include adequate fluid (30 mL/kg body weight for adults, plus any abnormal loss); energy from glucose, amino acids, and lipid solutions; nutrients essential in severely ill pts, such as glutamine, nucleotides, and products of methionine metabolism; electrolytes, vitamins, and minerals. The risks of parenteral therapy include mechanical complications from insertion of the infusion catheter, catheter sepsis, fluid overload, hyperglycemia, hypophosphatemia, hypokalemia, acid-base and electrolyte imbalance, cholestasis, metabolic bone disease, and micronutrient deficiencies.

The following parameters should be monitored in all patients receiving supplemental nutrition, whether enteral or parenteral:
- Fluid balance (weight, intake vs. output)
- Glucose, electrolytes, BUN (daily until stable, then 2× per week)
- Serum creatinine, albumin, phosphorus, calcium, magnesium, Hb/Hct, WBC (baseline, then 2× per week)
- INR (baseline, then weekly)
- Micronutrient tests as indicated

TABLE 8-1

<table>
<thead>
<tr>
<th>Nutrient</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin A&lt;sup&gt;a,b,c&lt;/sup&gt;</td>
<td>60 mg PO, repeated 1 and 14 days later if ocular changes; 30 mg for ages 6–11 mo 15 mg PO qd × 1 month if chronic malabsorption</td>
</tr>
<tr>
<td>Vitamin C</td>
<td>200 mg PO qd</td>
</tr>
<tr>
<td>Vitamin E&lt;sup&gt;a&lt;/sup&gt;</td>
<td>800–1200 mg PO qd</td>
</tr>
<tr>
<td>Vitamin K&lt;sup&gt;a&lt;/sup&gt;</td>
<td>10 mg IV × 1 1–2 mg PO qd or 1–2 mg IV weekly in chronic malabsorption</td>
</tr>
<tr>
<td>Thiamine&lt;sup&gt;b&lt;/sup&gt;</td>
<td>100 mg IV qd × 7 days, followed by 10 mg PO qd</td>
</tr>
<tr>
<td>Niacin</td>
<td>100–200 mg PO tid for 5 days</td>
</tr>
<tr>
<td>Pyridoxine</td>
<td>50 mg PO qd, 100–200 mg PO qd if deficiency related to medication</td>
</tr>
<tr>
<td>Zinc&lt;sup&gt;b,c&lt;/sup&gt;</td>
<td>60 mg PO bid</td>
</tr>
</tbody>
</table>

<sup>a</sup>Associated with fat malabsorption, along with vitamin D deficiency.
<sup>b</sup>Associated with chronic alcoholism; always replete thiamine before carbohydrates in alcoholics to avoid precipitation of acute thiamine deficiency.
<sup>c</sup>Associated with protein-calorie malnutrition.
SPECIFIC MICRONUTRIENT DEFICIENCY

Appropriate therapies for micronutrient deficiencies are outlined in Table 8-1.

For a more detailed discussion, see Russell RM and Suter PM: Vitamin and Trace Mineral Deficiency and Excess, Chap. 71, p. 441; and Bistrian BR and Driscoll DF: Enteral and Parenteral Nutrition Therapy, Chap. 73, p. 455, HPIM-17.

9 Transfusion and Pheresis Therapy

TRANSFUSIONS

WHOLE BLOOD TRANSFUSION

Indicated when acute blood loss is sufficient to produce hypovolemia, whole blood provides both oxygen-carrying capacity and volume expansion. In acute blood loss, hematocrit may not accurately reflect degree of blood loss for 48 h until fluid shifts occur.

RED BLOOD CELL TRANSFUSION

Indicated for symptomatic anemia unresponsive to specific therapy or requiring urgent correction. Packed red blood cell (RBC) transfusions may be indicated in pts who are symptomatic from cardiovascular or pulmonary disease when Hb is between 70 and 90 g/L (7 and 9 g/dL). Transfusion is usually necessary when Hb is <70 g/L (<7 g/dL). One unit of packed RBCs raises the Hb by approximately 10 g/L (1 g/dL). In the setting of acute hemorrhage, packed RBCs, fresh-frozen plasma (FFP), and platelets in an approximate ratio of 3:1:10 units are an adequate replacement for whole blood. Removal of leukocytes reduces risk of alloimmunization and transmission of cytomegalovirus. Washing to remove donor plasma reduces risk of allergic reactions. Irradiation prevents graft-versus-host disease in immunocompromised recipients by killing alloreactive donor lymphocytes. Avoid related donors.

Other Indications

(1) Hypertransfusion therapy to block production of defective cells, e.g., thalassemia, sickle cell anemia; (2) exchange transfusion—hemolytic disease of newborn, sickle cell crisis; (3) transplant recipients—decreases rejection of cadaveric kidney transplants.

Complications

(See Table 9-1) (1) Transfusion reaction—immediate or delayed, seen in 1–4% of transfusions; IgA-deficient pts at particular risk for severe reaction; (2) infection—bacterial (rare); hepatitis C, 1 in 1,600,000 transfusions; HIV transmission, 1 in 1,960,000; (3) circulatory overload; (4) iron overload—each unit contains 200–250 mg iron; hemochromatosis may develop after 100 U of RBCs (less in children), in absence of blood loss; iron chelation therapy with deferoxamine indicated; (5) graft-versus-host disease; (6) alloimmunization.
CHAPTER 9

AUTOLOGOUS TRANSFUSION

Use of pt’s own stored blood avoids hazards of donor blood; also useful in pts with multiple RBC antibodies. Pace of autologous donation may be accelerated using erythropoietin (50–150 U/kg SC three times a week) in the setting of normal iron stores.

PLATELET TRANSFUSION

Prophylactic transfusions usually reserved for platelet count < 10,000/μL (<20,000/μL in acute leukemia). One unit elevates the count by about 10,000/μL if no platelet antibodies are present as a result of prior transfusions. Efficacy assessed by 1-h and 24-h posttransfusion platelet counts. HLA-matched single-donor platelets may be required in pts with platelet alloantibodies.

TRANSFUSION OF PLASMA COMPONENTS

FFP is a source of coagulation factors, fibrinogen, antithrombin, and proteins C and S. It is used to correct coagulation factor deficiencies, rapidly reverse warfarin effects, and treat thrombotic thrombocytopenic purpura (TTP). Cryoprecipitate is a source of fibrinogen, factor VIII, and von Willebrand factor; it may be used when recombinant factor VIII or factor VIII concentrates are not available.

---

**TABLE 9-1 RISKS OF TRANSFUSION COMPLICATIONS**

<table>
<thead>
<tr>
<th>Reactions</th>
<th>Frequency, Episodes:Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Febrile (FNHTR)</td>
<td>1–4:100</td>
</tr>
<tr>
<td>Allergic</td>
<td>1–4:100</td>
</tr>
<tr>
<td>Delayed hemolytic</td>
<td>1:1000</td>
</tr>
<tr>
<td>TRALI</td>
<td>1:5000</td>
</tr>
<tr>
<td>Acute hemolytic</td>
<td>1:12,000</td>
</tr>
<tr>
<td>Fatal hemolytic</td>
<td>1:100,000</td>
</tr>
<tr>
<td>Anaphylactic</td>
<td>1:150,000</td>
</tr>
<tr>
<td>Infections</td>
<td>1:63,000</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>1:1,600,000</td>
</tr>
<tr>
<td>HIV-1</td>
<td>1:1,960,000</td>
</tr>
<tr>
<td>HIV-2</td>
<td>None reported</td>
</tr>
<tr>
<td>HTLV-I and -II</td>
<td>1:641,000</td>
</tr>
<tr>
<td>Malaria</td>
<td>1:4,000,000</td>
</tr>
<tr>
<td>Other complications</td>
<td></td>
</tr>
<tr>
<td>RBC allosensitization</td>
<td>1:100</td>
</tr>
<tr>
<td>HLA allosensitization</td>
<td>1:10</td>
</tr>
<tr>
<td>Graft-versus-host disease</td>
<td>Rare</td>
</tr>
</tbody>
</table>

**Note:** FNHTR, febrile nonhemolytic transfusion reaction; TRALI, transfusion-related acute lung injury; HTLV, human T lymphotropic virus; RBC, red blood cell; HLA, human leukocyte antigen.

---

*Infectious agents rarely associated with transfusion, theoretically possible, or of unknown risk, include hepatitis A virus, parvovirus B-19, Babesia microti (babesiosis), Borrelia burgdorferi (Lyme disease), Trypanosoma cruzi (Chagas’ disease), Treponema pallidum, human herpesvirus-8, and hepatitis G virus.*

Infectious agents rarely associated with transfusion, theoretically possible, or of unknown risk, include hepatitis A virus, parvovirus B-19, Babesia microti (babesiosis), Borrelia burgdorferi (Lyme disease), Trypanosoma cruzi (Chagas’ disease), Treponema pallidum, human herpesvirus-8, and hepatitis G virus.
THERAPEUTIC HEMAPHERESIS

Hemapheresis is removal of a cellular or plasma constituent of blood; the specific procedure is referred to by the blood fraction removed.

LEUKAPHERESIS

Removal of WBCs; most often used in acute leukemia, esp. acute myeloid leukemia (AML) in cases complicated by marked elevation (>100,000/μL) of the peripheral blast count, to lower risk of leukostasis (blast-mediated vasoocclusive events resulting in central nervous system or pulmonary infarction, hemorrhage). Leukapheresis is replacing bone marrow aspiration to obtain hematopoietic stem cells. After treatment with a chemotherapeutic agent and granulocyte-macrophage colony-stimulating factor, hematopoietic stem cells are mobilized from marrow to the peripheral blood; such cells are leukapheresed and then used for hematopoietic reconstitution after high-dose myeloablative therapy.

PLATELETHERESIS

Used in some pts with thrombocytosis associated with myeloproliferative disorders with bleeding and/or thrombotic complications. Other treatments are generally used first. Plateletpheresis also enhances platelet yield from blood donors.

PLASMAPHERESIS

Indications  (1) Hyperviscosity states—e.g., Waldenström’s macroglobulinemia; (2) TTP; (3) immune-complex and autoantibody disorders—e.g., Goodpasture’s syndrome, rapidly progressive glomerulonephritis, myasthenia gravis; possibly Guillain-Barré, systemic lupus erythematosus, idiopathic thrombocytopenic purpura; (4) cold agglutinin disease, cryoglobulinemia.

For a more detailed discussion, see Dzieczkowski JS, Anderson KC: Transfusion Biology and Therapy, Chap. 107, p. 707, in HPIM-17

Palliative and End-of-Life Care

In 2006, 2,425,901 people died in the United States; death rates are declining. Heart disease and cancer are the two leading causes of death and together account for nearly half of all deaths. About 70% of deaths occur in people who have a condition that is known to be leading to their death; thus, planning for terminal care is relevant and important. An increasing fraction of deaths are occurring in hospices or at home rather than in the hospital.

Optimal care depends on a comprehensive assessment of pt needs in all four domains affected by illness: physical, psychological, social, and spiritual. A variety of assessment tools are available to assist in the process.
Communication and continuous assessment of management goals are key components to addressing end-of-life care. Physicians must be clear about the likely outcome of the illness(es) and provide an anticipated schedule with goals and landmarks in the care process. When the goals of care have changed from cure to palliation, that transition must be clearly explained and defended. Seven steps are involved in establishing goals:

1. Ensure that the medical information is as complete as possible and understood by all relevant parties.
2. Explore the pt’s goals while making sure the goals are achievable.
3. Explain the options.
4. Show empathy as the pt and the family adjust to changing expectations.
5. Make a plan with realistic goals.
6. Follow through with the plan.
7. Review and revise the plan periodically as the pt’s situation changes.

**Advance Directives** Only 29% of pts (and less than one-third of physicians) have executed advance directives that define the level of intervention the pt is willing to accept. It is useful to have the pt’s wishes for level of intervention defined before a medical crisis occurs. Two types of legal documents can be used: the advance directive, in which specific instructions from the pt may be made known, and the durable attorney for health care, in which a person is designated as having the pt’s authority to make health decisions on the pt’s behalf. Forms are available free of charge from the National Hospice and Palliative Care Organization (www.nhpco.org).

**Physical Symptoms and Their Management** The most common physical and psychological symptoms among terminally ill pts are shown in Table 10-1. Studies of pts with advanced cancer have shown that pts experience an average of 11.5 symptoms.

**Pain** Pain is noted in 36–90% of terminally ill pts. The various types of pain and their management are discussed in Chap. 6.

### Table 10-1: Common Physical and Psychological Symptoms of Terminally Ill Patients

<table>
<thead>
<tr>
<th>Physical Symptoms</th>
<th>Psychological Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td>Anxiety</td>
</tr>
<tr>
<td>Fatigue and weakness</td>
<td>Depression</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>Hopelessness</td>
</tr>
<tr>
<td>Insomnia</td>
<td>Meaninglessness</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>Irritability</td>
</tr>
<tr>
<td>Anorexia</td>
<td>Impaired concentration</td>
</tr>
<tr>
<td>Nausea and vomiting</td>
<td>Confusion</td>
</tr>
<tr>
<td>Constipation</td>
<td>Delirium</td>
</tr>
<tr>
<td>Cough</td>
<td>Loss of libido</td>
</tr>
<tr>
<td>Swelling of arms or legs</td>
<td></td>
</tr>
<tr>
<td>Itching</td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td></td>
</tr>
<tr>
<td>Dysphagia</td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td></td>
</tr>
<tr>
<td>Fecal and urinary incontinence</td>
<td></td>
</tr>
<tr>
<td>Numbness/tingling in hands/feet</td>
<td></td>
</tr>
</tbody>
</table>
**Constipation**  Constipation is noted in up to 90% of terminally ill pts. Medications commonly contribute to constipation, including opioids used to manage pain and dyspnea, and tricyclic antidepressants with their anticholinergic effects. Inactivity, poor diet, and hypercalcemia may contribute. GI tract obstruction also may play a role in some settings.

**Interventions**  Improved physical activity (if possible), adequate hydration; opioid effects can be antagonized by the μ-opioid receptor blocker methylnaltrexone; rule out surgically correctable obstruction; laxatives and stool softeners (Table 10-2).

**Nausea**  Up to 70% of pts with advanced cancer have nausea. Nausea may result from uremia, liver failure, hypercalcemia, bowel obstruction, severe constipation, infection, gastroesophageal reflux disease, vestibular disease, brain metastases, medications (cancer chemotherapy, antibiotics, nonsteroidal anti-inflammatory drugs, opioids, proton pump inhibitors), and radiation therapy.

**Interventions**  Treatment should be tailored to the cause. Offending medications should be stopped. Underlying conditions should be alleviated, if possible. If decreased bowel motility is suspected, metoclopramide may help. Nausea from cancer chemotherapy agents can generally be prevented with glucocorticoids and serotonin receptor blockers like ondansetron or dolasetron. Aprepitant is useful in controlling nausea from highly emetogenic agents like cisplatin. Vestibular nausea may respond to antihistamines (meclizine) or anticholinergics (scopolamine). Anticipatory nausea may be prevented with a benzodiazepine.

---

**TABLE 10-2 MEDICATIONS FOR THE MANAGEMENT OF CONSTIPATION**

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Dose</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Stimulant laxatives</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prune juice</td>
<td>120–240 mL/d</td>
<td>These agents directly stimulate peristalsis and may reduce colonic absorption of water. Work in 6–12 h.</td>
</tr>
<tr>
<td>Senna (Senokot)</td>
<td>2–8 tablets PO bid</td>
<td></td>
</tr>
<tr>
<td>Bisacodyl</td>
<td>5–15 mg/d PO, PR</td>
<td></td>
</tr>
<tr>
<td><strong>Osmotic laxatives</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lactulose</td>
<td>15–30 mL PO q4–8h</td>
<td>These agents are not absorbed. They attract and retain water in the gastrointestinal tract. Lactulose may cause flatulence and bloating. Lactulose works in 1 day; magnesium products in 6 h.</td>
</tr>
<tr>
<td>Magnesium hydroxide (Milk of Magnesia)</td>
<td>15–30 mL/d PO</td>
<td></td>
</tr>
<tr>
<td>Magnesium citrate</td>
<td>125–250 mL/d PO</td>
<td></td>
</tr>
<tr>
<td><strong>Stool softeners</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium docusate (Colace)</td>
<td>300–600 mg/d PO</td>
<td>These agents work by increasing water secretion and as detergents increasing water penetration into the stool.</td>
</tr>
<tr>
<td>Calcium docusate</td>
<td>300–600 mg/d PO</td>
<td></td>
</tr>
<tr>
<td><strong>Suppositories and enemas</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bisacodyl</td>
<td>10–15 PR qd, PR</td>
<td>Fixed dose, 4.5 oz, Fleet’s.</td>
</tr>
<tr>
<td>Sodium phosphate enema</td>
<td>qd</td>
<td></td>
</tr>
</tbody>
</table>
such as lorazepam. Haloperidol is sometimes useful when the nausea does not have a single specific cause.

**Dyspnea** Up to 75% of dying pts experience dyspnea. Dyspnea exerts perhaps the greatest adverse effect on the pt, often even more distressing than pain. It may be caused by parenchymal lung disease, infection, effusions, pulmonary emboli, pulmonary edema, asthma, or compressed airway. While many of the causes may be treated, often the underlying cause cannot be reversed.

**Interventions** Underlying causes should be reversed, where possible, as long as the intervention is not more unpleasant (e.g. repeated thoracenteses) than the dyspnea. Most often the treatment is symptomatic (Table 10-3).

**Fatigue** Fatigue is nearly a universal symptom in terminally ill pts. It is often a direct consequence of the disease process (and the cytokines produced in response to that process) and may be complicated by inanition, dehydration, anemia, infection, hypothryoidism, and drug effects. Depression may also contribute to fatigue. Functional assessments include the Karnofsky performance status or the Eastern Cooperative Oncology Group system based on how much time the pt spends in bed each day: 0, normal activity; 1, symptomatic without being bedridden; 2, in bed <50% of the day; 3, in bed >50% of the day; 4, bedbound.

**Interventions** Modest exercise and physical therapy may reduce muscle wasting and depression and improve mood; discontinue medications that worsen fatigue, if possible; glucocorticoids may increase energy and enhance mood; dextroamphetamine (5–10 mg/d) or methylphenidate (2.5–5 mg/d) in the morning may enhance energy levels but should be avoided at night because they may produce insomnia; modafinil and L-carnitine have shown some early promise.

**Depression** Up to 75% of terminally ill pts experience depression. The inexperienced physician may feel that depression is an appropriate response to terminal illness; however, in a substantial fraction of pts the depression is more intense and

### Table 10-3 Medications for the Management of Dyspnea

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Dose</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Weak opioids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Codeine (or codeine with 325 mg acetaminophen)</td>
<td>30 mg PO q4h</td>
<td>For patients with mild dyspnea</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>5 mg PO q4h</td>
<td>For opioid-naïve patient</td>
</tr>
<tr>
<td><strong>Strong opioids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine</td>
<td>5–10 mg PO q4h, 30–50% of baseline opioid dose q4h</td>
<td>For opioid-naïve patients with moderate to severe dyspnea</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>5–10 mg PO q4h, 1–2 mg PO q4h</td>
<td>For patients already taking opioids for pain or other symptoms</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anxiolytics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lorazepam</td>
<td>0.5–2.0 mg PO/SL/IV qh then q4–6h</td>
<td>Give a dose every hour until the patient is relaxed, then provide a dose for maintenance</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>0.25–2.0 mg PO q12h</td>
<td></td>
</tr>
<tr>
<td>Midazolam</td>
<td>0.5 mg IV q15min</td>
<td></td>
</tr>
</tbody>
</table>
disabling than usual. Pts with a previous history of depression are at greater risk. A number of treatable conditions can cause depression-like symptoms including hypothyroidism, Cushing’s syndrome, electrolyte abnormalities (e.g., hypercalcaemia), and drugs including dopamine blockers, interferon, tamoxifen, interleukin 2, vincristine, and glucocorticoids.

**Interventions**  Dextroamphetamine or methylphenidate (see above); serotonin reuptake inhibitors such as fluoxetine, paroxetine, and citalopram; modafinil 100 mg/d; pemoline 18.75 mg in the A.M. and at noon.

**Delirium**  Delirium is a global cerebral dysfunction associated with altered cognition and consciousness; it is frequently preceded by anxiety. Unlike dementia, it is of sudden onset, is characterized by fluctuating consciousness and inattention, and may be reversible. It is generally manifested in the hours before death. It may be caused by metabolic encephalopathy in renal or liver failure, hypoxemia, infection, hypercalcemia, paraneoplastic syndromes, dehydration, constipation, urinary retention, and central nervous system spread of cancer. It is also a common medication side effect; offending agents include those commonly used in dying pts including opioids, glucocorticoids, anticholinergics, antihistamines, antiemetics, and benzodiazepines. Early recognition is key because the pt should be encouraged to use the periods of lucidity for final communication with loved ones. Day-night reversal with changes in mentation may be an early sign.

**Interventions**  Stop any and all unnecessary medications that may have this side effect; provide a calendar, clock, newspaper, or other orienting signals; gently correct hallucinations or cognitive mistakes; pharmacologic interventions are shown in Table 10-4.

**Care during the Last Hours**  The clinical course of a dying pt may largely be predictable. Figure 10-1 shows common and uncommon changes during the last days of life. Informing families that these changes might occur can help minimize the distress that they cause. In particular, the physician needs to be sensitive to the sense of guilt and helplessness that family members feel. They should be reassured that the illness is taking its course and their care of the pt is not at fault in any way. The pt stops eating because they are dying; they are not dying because they have stopped eating. Families and caregivers should be encouraged to communicate directly with the dying pt whether or not the pt is unconscious.

<table>
<thead>
<tr>
<th>Medications for the Management of Delirium</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Interventions</strong></td>
</tr>
<tr>
<td>Neuroleptics</td>
</tr>
<tr>
<td>Anxiolytics</td>
</tr>
<tr>
<td>Anesthetics</td>
</tr>
</tbody>
</table>
Holding the pt’s hand may be a source of comfort to both the pt and the family member/caregiver. Table 10-5 provides a listing of some changes in the pt’s condition in the final hours and advice on how to manage the changes.

Additional resources for managing terminally ill pts may be found at the following websites: www.epec.net, www.eperc.mcw.edu, www.capc.org, and www.nhpco.org.

For a more detailed discussion, see Emanuel EJ, Hauser J, Emanuel LL: Palliative and End-of-Life Care, Chap. 11, p. 66, in HPIM-17.
<table>
<thead>
<tr>
<th>Changes in the Patient’s Condition</th>
<th>Potential Complication</th>
<th>Family’s Possible Reaction and Concern</th>
<th>Advice and Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Profound fatigue</td>
<td>Bedbound with development of pressure ulcers that are prone to infection, malodor, and pain, and joint pain</td>
<td>Patient is lazy and giving up.</td>
<td>Reassure family and caregivers that terminal fatigue will not respond to interventions and should not be resisted. Use an air mattress if necessary.</td>
</tr>
<tr>
<td>Anorexia</td>
<td>None</td>
<td>Patient is giving up; patient will suffer from hunger and will starve to death.</td>
<td>Reassure family and caregivers that the patient is not eating because he or she is dying; not eating at the end of life does not cause suffering or death. Forced feeding, whether oral, parenteral, or enteral, does not reduce symptoms or prolong life. Forcing feeding may cause distress, pain, nausea, vomiting, and aspiration.</td>
</tr>
<tr>
<td>Dehydration</td>
<td>Dry mucosal membranes (see below)</td>
<td>Patient will suffer from thirst and die of dehydration.</td>
<td>Reassure family and caregivers that dehydration at the end of life does not cause suffering because patients lose consciousness before any symptom distress. Intravenous hydration can worsen symptoms of dyspnea by pulmonary edema and peripheral edema as well as prolong dying process.</td>
</tr>
<tr>
<td>Dysphagia</td>
<td>Inability to swallow oral medications needed for palliative care</td>
<td></td>
<td>Do not force oral intake. Discontinue unnecessary medications that may have been continued including antibiotics, diuretics, anti-depressants, and laxatives. If swallowing pills is difficult, convert essential medications (analgesics, antiemetics, anxiolytics, and psychotropics) to oral solutions, buccal, sublingual, or rectal administration.</td>
</tr>
<tr>
<td>“Death rattle”—noisy breathing</td>
<td>Patient is choking and suffocating.</td>
<td></td>
<td>Reassure the family and caregivers that this is caused by secretions in the oropharynx and the patient is not choking. Reduce secretions with scopolamine (0.2–0.4 mg SC q4h or 1–3 patches q3d). Reposition patient to permit drainage of secretions. Do not suction. Suction can cause patient and family discomfort, and is usually ineffective.</td>
</tr>
<tr>
<td>Condition</td>
<td>Description</td>
<td>Management</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Apnea, Cheyne-Stokes respirations, dyspnea</td>
<td>Patient is suffocating.</td>
<td>Reassure family and caregivers that unconscious patients do not experience suffocation or air hunger. Apneic episodes are frequently a premorbid change. Opioids or anxiolytics may be used for dyspnea. Oxygen is unlikely to relieve dyspneic symptoms and may prolong the dying process.</td>
<td></td>
</tr>
<tr>
<td>Urinary or fecal incontinence</td>
<td>Skin breakdown if days until death</td>
<td>Remind family and caregivers to use universal precautions.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Potential transmission of infectious agents to caregivers</td>
<td>Frequent changes of bedclothes and bedding.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Use diapers, urinary catheter, or rectal tube if diarrhea or high urine output.</td>
<td></td>
</tr>
<tr>
<td>Agitation or delirium</td>
<td>Day/night reversal</td>
<td>Reassure family and caregivers that agitation and delirium do not necessarily connote physical pain. Depending upon the prognosis and goals of treatment, consider evaluating for causes of delirium and modify medications. Manage symptoms with haloperidol, chlorpromazine, diazepam, or midazolam.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hurt self or caregivers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry mucosal membranes</td>
<td>Cracked lips, mouth sores, and candidiasis can also cause pain. Odor</td>
<td>Use baking soda mouthwash or saliva preparation q15–30min.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Use topical nystatin for candidiasis.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coat lips and nasal mucosa with petroleum jelly q60–90min.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Use ophthalmic lubricants q4h or artificial tears q30min.</td>
<td></td>
</tr>
</tbody>
</table>
Unexpected cardiovascular collapse and death most often result from ventricular fibrillation in pts with underlying coronary artery disease, with or without acute MI. Other common causes are listed in Table 11-1. The arrhythmic causes may be provoked by electrolyte disorders (primarily hypokalemia), hypoxemia, acidosis, or massive sympathetic discharge, as may occur in CNS injury. Immediate institution of cardiopulmonary resuscitation (CPR) followed by advanced life support measures (see below) are mandatory. Ventricular fibrillation, or asystole, without institution of CPR within 4–6 min is usually fatal.

**MANAGEMENT OF CARDIAC ARREST**

Basic life support (BLS) must commence immediately (Fig. 11-1):

- Phone 911 (or emergency line); Get automated external defibrillator (AED) if quickly available on site.
- Open mouth of patient and remove visible debris or dentures. If there is respiratory stridor, consider aspiration of a foreign body and perform Heimlich maneuver.
- Tilt head backward, lift chin, and begin mouth-to-mouth respiration if rescue equipment is not available (pocket mask is preferable to prevent trans-

**TABLE 11-1 DIFFERENTIAL DIAGNOSIS OF CARDIOVASCULAR COLLAPSE AND SUDDEN DEATH**

1. Ventricular fibrillation due to:
   - Myocardial ischemia (severe coronary artery disease, acute MI)
   - Heart failure
   - Dilated or hypertrophic cardiomyopathy
   - Myocarditis
   - Right ventricular dysplasia
   - Valvular disease [aortic stenosis, mitral valve prolapse (rare)]
   - Cardiac infiltrative diseases
   - Preexcitation syndromes (Wolff-Parkinson-White)
   - Prolonged QT syndromes (congenital, drug-induced)
   - Brugada syndrome
2. Asystole or severe bradycardia
3. Sudden marked decrease in LV stroke volume from:
   - Massive pulmonary embolism
   - Cardiac tamponade
   - Severe aortic stenosis
4. Sudden marked decrease in intravascular volume, e.g.:
   - Ruptured aortic aneurysm
   - Aortic dissection
Medical Emergencies

SECTION 2

The lungs should be inflated twice in rapid succession for every 30 chest compressions.

• If carotid pulse is absent, perform chest compressions (depressing sternum 4–5 cm) at rate of 100 per min. For one rescuer, 30 compressions are performed before returning to ventilating twice.

• As soon as resuscitation equipment is available, begin advanced life support with continued chest compressions and ventilation.

• Although performed as simultaneously as possible, defibrillation takes highest priority (Fig. 11-2), followed by placement of intravenous access and intubation. 100% O₂ should be administered by endotracheal tube or, if rapid

---

FIGURE 11-1 Major steps in cardiopulmonary resuscitation. A. Make certain that the victim has an open airway. B. Start respiratory resuscitation immediately. C. Feel for the carotid pulse in the groove alongside the “Adam’s apple” or thyroid cartilage. D. If pulse is absent, begin cardiac massage. Use 100 compressions/min with two lung inflations in rapid succession for every 30 compressions. (From J Henderson, Emergency Medical Guide, 4th ed, New York, McGraw-Hill, 1978.)

“Adam’s apple” (thyroid cartilage)
intubation cannot be accomplished, by bag-valve-mask device; respirations should not be interrupted for more than 30 s while attempting to intubate.

- Initial intravenous access should be through the antecubital vein, but if drug administration is ineffective, a central line (internal jugular or subclavian) should be placed. Intravenous NaHCO₃ should be administered only if there is persistent severe acidosis (pH < 7.15) despite adequate ventilation. Calcium is not routinely administered but should be given to pts with known hypocalcemia, those who have received toxic doses of calcium channel antagonists, or if acute hyperkalemia is thought to be the triggering event for resistant ventricular fibrillation.

- The approach to cardiovascular collapse caused by bradyarrhythmias, asystole, or pulseless electrical activity is shown in Fig. 11-3.

**FOLLOW-UP**

If cardiac arrest was due to ventricular fibrillation in initial hours of an acute MI, follow-up is standard post-MI care (Chap. 126). For other survivors of a ventricular fibrillation arrest, extensive assessment, including evaluation of coronary anatomy, left ventricular function, and invasive electrophysiologic test-
ing, is often recommended. In absence of a transient or reversible cause, placement of an implantable cardioverter defibrillator is usually indicated.

For a more detailed discussion, see Myerburg RJ, Castellanos A: Cardiovascular Collapse, Cardiac Arrest, and Sudden Cardiac Death, Chap. 267, p. 1707, in HPIM-17.

**DEFINITION**

Condition of severe impairment of tissue perfusion leading to cellular injury and dysfunction. Cell membrane dysfunction is a common end stage for various forms of shock. Rapid recognition and treatment are essential to prevent irreversible organ damage. Common causes are listed in Table 12-1.
CLINICAL MANIFESTATIONS

- Hypotension (systolic bp < 90, mean bp < 60), tachycardia, tachypnea, pallor, restlessness, and altered sensorium.
- Signs of intense peripheral vasoconstriction, with weak pulses and cold clammy extremities. In distributive (e.g., septic) shock, vasodilatation predominates and extremities are warm.
- Oliguria (<20 mL/h) and metabolic acidosis common.
- Acute lung injury and acute respiratory distress syndrome (ARDS; see Chap. 15) with noncardiogenic pulmonary edema, hypoxemia, and diffuse pulmonary infiltrates.

APPROACH TO THE PATIENT

Obtain history for underlying cause, including
- Known cardiac disease (coronary disease, CHF, pericarditis)
- Recent fever or infection (leading to sepsis)
- Drugs, e.g., excess diuretics or antihypertensives
- Conditions predisposing for pulmonary embolism (Chap. 140)
- Possible bleeding from any site, particularly GI tract.

PHYSICAL EXAMINATION

- Jugular veins are flat in oligemic or distributive shock; jugular venous distention (JVD) suggests cardiogenic shock; JVD in presence of paradoxical pulse (Chap. 117) may reflect cardiac tamponade (Chap. 123).
- Look for evidence of CHF (Chap. 131), murmurs of aortic stenosis, acute regurgitation (mitral or aortic), ventricular septal defect.
- Check for asymmetry of pulses (aortic dissection) (Chap. 132).
- Tenderness or rebound in abdomen may indicate peritonitis or pancreatitis; high-pitched bowel sounds suggest intestinal obstruction. Perform stool guaiac to rule out GI bleeding.
• Fever and chills usually accompany septic shock. Sepsis may not cause fever in elderly, uremic, or alcoholic patients.
• Skin lesion may suggest specific pathogens in septic shock: petechiae or purpura (*Neisseria meningitidis*), erythema gangrenosum (*Pseudomonas aeruginosa*), generalized erythroderma (toxic shock due to *Staphylococcus aureus* or *Streptococcus pyogenes*).

**LABORATORY**

• Obtain hematocrit, WBC, electrolytes. If actively bleeding, check platelet count, PT, PTT, DIC screen.
• Arterial blood gas usually shows metabolic acidosis (in septic shock, respiratory alkalosis precedes metabolic acidosis). If sepsis suspected, draw blood cultures, perform urinalysis, and obtain Gram stain and cultures of sputum, urine, and other suspected sites.
• Obtain ECG (myocardial ischemia or acute arrhythmia), chest x-ray (CHF, tension pneumothorax, aortic dissection, pneumonia). Echocardiogram may be helpful (cardiac tamponade, CHF).
• Central venous pressure or pulmonary capillary wedge (PCW) pressure measurements may be necessary to distinguish between different categories of shock (Table 12-2): Mean PCW < 6 mmHg suggests oligemic or distributive shock; PCW > 20 mmHg suggests left ventricular failure. Cardiac output (thermodilution) is decreased in cardiogenic and oligemic shock, and usually increased initially in septic shock.

---

**TABLE 12-2  HEMODYNAMIC PROFILES IN SHOCK STATES**

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>PCW Pressure</th>
<th>Cardiac Output (CO)</th>
<th>Systemic Vascular Resistance</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiogenic shock</td>
<td>↑</td>
<td>↓</td>
<td>↑</td>
<td>PCW is normal or ↓ in RV infarction</td>
</tr>
<tr>
<td>Cardiac tamponade</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Equalization of intra-cardiac diastolic pressures</td>
</tr>
<tr>
<td>Massive pulmonary embolus</td>
<td>Normal or ↓</td>
<td>↓</td>
<td>↑</td>
<td>Right-sided cardiac pressures may be elevated</td>
</tr>
<tr>
<td>Oligemic shock</td>
<td>↓</td>
<td>↓</td>
<td>↑</td>
<td>CO may ↓ later if sepsis results in LV dysfunction or if intravascular volume is inadequate</td>
</tr>
<tr>
<td>Distributive shock</td>
<td>↓</td>
<td>↑</td>
<td>↓</td>
<td></td>
</tr>
</tbody>
</table>

---

Aimed at rapid improvement of tissue hypoperfusion and respiratory impairment:

• Serial measurements of bp (intraarterial line preferred), heart rate, continuous ECG monitor, urine output, pulse oximetry, blood studies: Hct, electrolytes, creatinine, BUN, ABGs, pH, calcium, phosphate, lactate, urine Na

---

Shock See Fig. 12-1.
**Shock**

**CHAPTER 12**

Concentration (<20 mmol/L suggests volume depletion). Consider continuous monitoring of CVP and/or pulmonary artery pressure, with serial PCW pressures in pts with ongoing blood loss or suspected cardiac dysfunction.

- Insert Foley catheter to monitor urine flow.
- Assess mental status frequently.

![FIGURE 12-1](image-url) An algorithm for the resuscitation of the patient in shock. VS, vital signs; HR, heart rate; SBP, systolic blood pressure; W/U, workup; CVP, central venous pressure; Hct, hematocrit; ECHO, echocardiogram; PAC, pulmonary artery catheter; CI, cardiac index in (L/min)/m²; PCWP, pulmonary capillary wedge pressure in mmHg.

*Monitor SVO₂, SVRI, and RVEDVI as additional markers of correction for perfusion and hypovolemia. Consider age-adjusted CI. SVO₂, saturation of hemoglobin with O₂ in venous blood; SVRI, systemic vascular resistance index; RVEDVI, right-ventricular end-diastolic volume index.

Hypotension and/or Tachycardia

- Airway control
- Ensure ventilation
- Augment circulation (crystalloid +/- blood)

**VS Normalized**

Definitive W/U

**Central monitoring**

- CVP <15

**Administer crystalloid +/- blood**
- Hct >30
- CVP >15

**VS unstable or acidosis worsens**

- Insert PAC

**CI <3.5; PCWP <15**

- Administer crystalloid +/- blood
- PCWP >15, Hct >30

**CI <3.5; 15< PCWP <25**

- Administer 500 mL crystalloid boluses until preload — maximal CI (Starling curve)

**CI <3.5; PCWP >25**

- Inotrope as indicated
- Consider ECHO

**Maintain optimal PCWP**
- Crystalloid
- Blood (Hct ≥30)

*Monitor CI deterioration

**Maintain optimal PCWP**

- Crystalloid
- Blood (Hct ≥30)
**SECTION 2**

Medical Emergencies

**Augment systolic bp to >100 mmHg:** (1) place in reverse Trendelenburg position; (2) IV volume infusion (500- to 1000-mL bolus), unless cardio-
genic shock suspected (begin with normal saline, then whole blood, dex-
tran, or packed RBCs, if anemic); continue volume replacement as needed to restore vascular volume.

- Add vasoactive drugs after intravascular volume is optimized; administer va-
  sopressors (Table 12-3) if systemic vascular resistance (SVR) is decreased
  (begin with norepinephrine or dopamine; for persistent hypotension add
  phenylephrine or vasopressin).

- **If CHF present, add inotropic agents (usually dobutamine)** (Table 12-3); aim
to maintain cardiac index > 2.2(L/m²)/min [>4.0(L/m²)/min in septic shock].

- **Administer 100% O₂; intubate with mechanical ventilation if P_O₂ < 70 mmHg.**

- **If severe metabolic acidosis present (pH < 7.15), administer NaHCO₃ (44.6–
  89.2 mmol).**

- **Identify and treat underlying cause of shock. Cardiogenic shock in acute MI is
discussed in Chap. 126. Emergent coronary revascularization may be lifesaving
if persistent ischemia is present. Consider cardiac tamponade (see Chap. 123).**

### TABLE 12-3 VASOPRESSORS USED IN SHOCK STATES

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose, (μg/kg)/min</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dopamine</td>
<td>1–5</td>
<td>Facilitates diuresis</td>
</tr>
<tr>
<td></td>
<td>5–10</td>
<td>Positive inotropic and chronotropic effects;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>may increase O₂ consumption as well as O₂ delivery; use may be limited by tachycardia</td>
</tr>
<tr>
<td></td>
<td>10–20</td>
<td>Generalized vasoconstriction (decrease renal perfusion)</td>
</tr>
<tr>
<td>Norepinephrine</td>
<td>2–8</td>
<td>Potent vasoconstrictor; moderate inotropic effect; in septic shock is thought to increase tissue O₂ consumption as well as O₂ delivery; may be chosen over dopamine in sepsis due to less chronotropic effect; may be useful in cardiogenic shock with reduced SVR but should generally be reserved for refractory hypotension</td>
</tr>
</tbody>
</table>
| Dobutamine      | 1–20              | Primarily for cardiogenic shock (Chap. 126): positive inotrope; lacks vasoconstrictor activity; most useful when only mild hy-
  potension present and avoidance of tachycardia desired |
| Phenylephrine   | 20–200            | Potent vasoconstrictor without inotropic effect; may be useful in distributive (septic) shock |
| Vasopressin     | 0.01–0.04 U/min   | Occasionally used in refractory septic (distributive) shock; restores vascular tone in vasopressin-deficient states (e.g., sepsis) |

---

**Isoproterenol not recommended in shock states because of potential hypotension and arrhythmogenic effects.**

**Dose not based on weight.**

**Note:** SVR, systemic vascular resistance.
Sepsis and Septic Shock

DEFINITIONS
Systemic inflammatory response syndrome (SIRS)—Two or more of the following:
• Fever (oral temperature >38°C) or hypothermia (oral temperature <36°C)
• Tachypnea (>24 breaths/min)
• Tachycardia (>90 beats/min)
• Leukocytosis (>12,000/μL), leukopenia (<4000/μL), or >10% bands; may have a noninfectious etiology

Sepsis—SIRS with a proven or suspected microbial etiology
Severe sepsis—Sepsis with one or more signs of organ dysfunction
Septic shock—Sepsis with arterial blood pressure <90 mmHg or 40 mmHg below pt’s normal blood pressure for at least 1 h despite fluid resuscitation or need for vasopressors to maintain systolic blood pressure ≥90 mmHg or mean arterial pressure ≥70 mmHg

ETIOLOGY
Blood cultures are positive in 20–40% of sepsis cases and in 40–70% of septic shock cases. Of cases with positive blood cultures, a single gram-positive or gram-negative bacterial species accounts for ~70% of isolates; the remainder are fungi or a mixture of microorganisms.

EPIDEMIOLOGY AND RISK FACTORS
The incidence of severe sepsis and septic shock is increasing in the United States, with >700,000 cases each year. Two-thirds of cases occur in pts with significant underlying disease. Sepsis is a contributing factor in >200,000 deaths each year in the United States.

The higher incidence of sepsis is due to the aging of the population, longer survival of pts with chronic diseases, a relatively high frequency of sepsis among AIDS patients, medical treatments (e.g., with glucocorticoids or antibiotics), invasive procedures (e.g., catheter placement), and mechanical ventilation.

Invasive bacterial infections are a prominent cause of death around the world, especially among young children. In sub-Saharan Africa, at least one-quarter of deaths of children >1 year of age are due to community-acquired bacteremia (e.g., with nontyphoidal Salmonella species, Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli).

PATHOGENESIS AND PATHOLOGY
Local and Systemic Host Responses
• Cytokines and other mediators that increase blood flow to the infected site, enhance the permeability of local blood vessels, attract neutrophils to the infected site, and elicit pain are released.
• Key features of the systemic immune response include intravascular fibrin deposition, thrombosis, and disseminated intravascular coagulation (DIC); the underlying mechanisms are the activation of intrinsic and extrinsic clotting pathways, impaired function of the protein C–protein S inhibitory pathway, depletion of antithrombin and protein C, and prevention of fibrinolysis by increased plasma levels of plasminogen activator inhibitor 1.

Organ Dysfunction and Shock
• Endothelial injury: Widespread endothelial injury is believed to be the major mechanism for multiorgan dysfunction.
• Septic shock is characterized by a decrease in peripheral vascular resistance despite increased levels of vasopressor catecholamines. Although blood flow to peripheral tissues increases, oxygen utilization by these tissues is greatly impaired.

Clinical Features
• Hyperventilation
• Encephalopathy (disorientation, confusion)
• Acrocyanosis, ischemic necrosis of peripheral tissues (e.g., digits) due to DIC
• Skin: hemorrhagic lesions, bullae, cellulitis. Skin lesions may suggest specific pathogens—e.g., petechiae and purpura with Neisseria meningitidis, ecthyma gangrenosum in pts with Pseudomonas aeruginosa.
• Gastrointestinal: nausea, vomiting, diarrhea, ileus, cholestatic jaundice

Major Complications
• Cardiopulmonary manifestations
• Ventilation-perfusion mismatch, increased alveolar capillary permeability, increased pulmonary water content, and decreased pulmonary compliance impede oxygen exchange and lead to acute respiratory distress syndrome (progressive diffuse pulmonary infiltrates and arterial hypoxemia) in ~50% of pts.
• Hypotension: Normal or increased cardiac output and decreased systemic vascular resistance distinguish septic shock from cardiogenic or hypovolemic shock.
• Myocardial function is depressed with decreased ejection fraction.
• Renal manifestations: oliguria, azotemia, proteinuria, renal failure due to acute tubular necrosis
• Coagulopathy
• Neurologic manifestations: polyneuropathy with distal motor weakness in prolonged sepsis

Laboratory Findings
• Leukocytosis with a left shift, thrombocytopenia
• Prolonged thrombin time, decreased fibrinogen, presence of D-dimers, suggestive of DIC. With DIC, platelet counts usually fall below 50,000/μL.
• Hyperbilirubinemia, increase in hepatic aminotransferases, azotemia, proteinuria, hypoalbuminemia
• Metabolic acidosis, elevated anion gap, elevated lactate levels, hypoxemia

Diagnosis
Definitive diagnosis requires isolation of the microorganism from blood or a local site of infection. Culture of infected cutaneous lesions may help establish the diagnosis.

Rx Sepsis and Septic Shock
Patients in whom sepsis is suspected must be managed expeditiously, if possible within 1 h of presentation.
1. Antibiotic treatment: See Table 13-1.
2. Removal or drainage of a focal source of infection
   a. Remove indwelling intravascular catheters; replace Foley and other drainage catheters; drain local sources of infection.
   b. Rule out sinusitis in pts with nasal intubation.
   c. Perform CT or MRI to rule out abscess.
3. Hemodynamic, respiratory, and metabolic support
   a. Maintain intravascular volume with IV fluids. Initiate treatment with 1–2 L of normal saline administered over 1–2 h, keeping pulmonary capillary wedge pressure at 12–16 mmHg or central venous pressure at 8–12

**TABLE 13-1  INITIAL ANTIMICROBIAL THERAPY FOR SEVERE SEPSIS WITH NO OBVIOUS SOURCE IN ADULTS WITH NORMAL RENAL FUNCTION**

<table>
<thead>
<tr>
<th>Clinical Condition</th>
<th>Antimicrobial Regimens (IV Therapy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunocompetent adult</td>
<td>The many acceptable regimens include (1) ceftriaxone (2 g q24h) or ticarcillin-clavulanate (3.1 g q4–6h) or piperacillin-tazobactam (3.375 g q4–6h); (2) imipenem-cilastatin (0.5 g q6h) or meropenem (1 g q8h) or cefepime (2 g q12h). Gentamicin or tobramycin (5–7 mg/kg q24h) may be added to either regimen. If the pt is allergic to β-lactam agents, use ciprofloxacin (400 mg q12h) or levofloxacin (500–750 mg q12h) plus clindamycin (600 mg q8h). If the institution has a high incidence of MRSA infections, add vancomycin (15 mg/kg q12h) to each of the above regimens.</td>
</tr>
<tr>
<td>Neutropenia&lt;sup&gt;a&lt;/sup&gt; (&lt;500 neutrophils/μL)</td>
<td>Regimens include (1) imipenem-cilastatin (0.5 g q6h) or meropenem (1 g q8h) or cefepime (2 g q8h); (2) ticarcillin-clavulanate (3.1 g q4h) or piperacillin-tazobactam (3.375 g q4h) plus tobramycin (5–7 mg/kg q24h). Vancomycin (15 mg/kg q12h) should be used if the pt has an infected vascular catheter, if staphyloccoci are suspected, if the pt has received quinolone prophylaxis, if the pt has received intensive chemotherapy that produces mucosal damage, if the institution has a high incidence of MRSA infections, or if MRSA isolates are highly prevalent in the community.</td>
</tr>
<tr>
<td>Splenectomy</td>
<td>Cefotaxime (2 g q6–8h) or ceftriaxone (2 g q12h) should be used. If the local prevalence of cephalosporin-resistant pneumococci is high, add vancomycin. If the pt is allergic to beta-lactam drugs, vancomycin (15 mg/kg q12h) plus ciprofloxacin (400 mg q12h) or levofloxacin (750 mg q12h) or aztreonam (2 g q8h) should be used.</td>
</tr>
<tr>
<td>IV drug user</td>
<td>Nafcillin or oxacillin (2 g q8h) plus gentamicin (5–7 mg/kg q24h). If the local prevalence of MRSA is high or if the pt is allergic to beta-lactam drugs, vancomycin (15 mg/kg q12h) with gentamicin should be used.</td>
</tr>
<tr>
<td>AIDS</td>
<td>Cefepime (2 g q8h), ticarcillin-clavulanate (3.1 g q4h), or piperacillin-tazobactam (3.375 g q4h) plus tobramycin (5–7 mg/kg q24h) should be used. If the pt is allergic to beta-lactam drugs, ciprofloxacin (400 mg q12h) or levofloxacin (750 mg q12h) plus vancomycin (15 mg/kg q12h) plus tobramycin should be used.</td>
</tr>
</tbody>
</table>


**Note:** MRSA, methicillin-resistant *Staphylococcus aureus.*
cmH₂O, urine output at >0.5 mL/kg per hour, mean arterial blood pressure at >65 mmHg, and cardiac index at ≥4 (L/min)/m². Add vasopressor therapy if needed. A study of early goal-directed therapy (EGDT) found that prompt resuscitation based on maintenance of oxygen saturation at >70% was associated with significant improvement in survival in patients with severe sepsis. Therapy included rapid administration of IV fluids, antibiotics, and vasopressor support; erythrocyte transfusions to maintain hematocrit above 30%; and use of dobutamine if other measures did not result in a central venous oxygen saturation >70%.

b. Maintain oxygenation with ventilator support as indicated. Recent studies favor the use of low tidal volumes.

c. Monitor for adrenal insufficiency or reduced adrenal reserve. Survival rates may be improved among pts with a plasma cortisol level <15 μg/dL if hydrocortisone (50 mg q6h IV) is administered. If clinical improvement results within 24–48 h, most experts would continue hydrocortisone treatment for 5–7 days.

4. Recombinant activated protein C (aPC), given as a constant infusion of 24 μg/kg per hour for 96 h, has been approved for treatment of severe sepsis or septic shock in pts with APACHE II scores of ≥25 prior to aPC infusion and low risk of hemorrhagic complications.

5. General support: Nutritional supplementation should be given to pts with prolonged sepsis (i.e., that lasting >2–3 days). Prophylactic heparin should be administered to prevent deep-venous thrombosis if no active bleeding or coagulopathy is present. Tight control of blood glucose levels in pts who have just undergone major surgery may improve survival rates.

PROGNOSIS

In all, 20–35% of pts with severe sepsis and 40–60% of pts with septic shock die within 30 days, and further deaths occur within the first 6 months. The severity of underlying disease most strongly influences the risk of dying.

PREVENTION

Nosocomial infections cause most episodes of severe sepsis and septic shock in the United States. Measures to reduce those infections could reduce the incidence of sepsis.

For a more detailed discussion, see Munford RS: Severe Sepsis and Septic Shock, Chap. 265, p. 1695, in HPIM-17.

14 Acute Pulmonary Edema

Life-threatening, acute development of alveolar lung edema often due to:

- Elevation of hydrostatic pressure in the pulmonary capillaries (left heart failure, mitral stenosis)
CHAPTER 14

Acute Pulmonary Edema

Specific precipitants (Table 14-1), resulting in cardiogenic pulmonary edema in pts with previously compensated CHF or without previous cardiac history. Increased permeability of pulmonary alveolar-capillary membrane (noncardiogenic pulmonary edema). For common causes, see Table 14-2.

**PHYSICAL FINDINGS**

Patient appears severely ill, sitting bolt upright, tachypneic, dyspneic, with marked perspiration; cyanosis may be present. Bilateral pulmonary rales; third heart sound may be present. Frothy and blood-tinged sputum.

**LABORATORY**

Early arterial blood gases show reductions of both PaO₂ and PaCO₂. Later, with progressive respiratory failure, hypercapnia develops with progressive acidemia. CXR shows pulmonary vascular redistribution, diffuse haziness in lung fields with perihilar “butterfly” appearance.

**EVALUATION** See Fig. 14-1.

### Acute Pulmonary Edema

Immediate, aggressive therapy is mandatory for survival. The following measures should be instituted nearly simultaneously for cardiogenic pulmonary edema:

<table>
<thead>
<tr>
<th>TABLE 14-1</th>
<th>PRECIPITANTS OF ACUTE PULMONARY EDEMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute tachy- or bradyarrhythmia</td>
<td></td>
</tr>
<tr>
<td>Infection, fever</td>
<td></td>
</tr>
<tr>
<td>Acute MI</td>
<td></td>
</tr>
<tr>
<td>Severe hypertension</td>
<td></td>
</tr>
<tr>
<td>Acute mitral or aortic regurgitation</td>
<td></td>
</tr>
<tr>
<td>Increased circulating volume (Na ingestion, blood transfusion, pregnancy)</td>
<td></td>
</tr>
<tr>
<td>Increased metabolic demands (exercise, hyperthyroidism)</td>
<td></td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td></td>
</tr>
<tr>
<td>Noncompliance (sudden discontinuation) of chronic CHF medications</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TABLE 14-2</th>
<th>COMMON CAUSES OF NONCARDIOGENIC PULMONARY EDEMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct Injury to Lung</td>
<td></td>
</tr>
<tr>
<td>Chest trauma, pulmonary contusion</td>
<td>Pneumonia</td>
</tr>
<tr>
<td>Aspiration</td>
<td>Oxygen toxicity</td>
</tr>
<tr>
<td>Smoke inhalation</td>
<td>Pulmonary embolism, reperfusion</td>
</tr>
<tr>
<td>Hematogenous Injury to Lung</td>
<td></td>
</tr>
<tr>
<td>Sepsis</td>
<td>Multiple transfusions</td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>Intravenous drug use, e.g., heroin</td>
</tr>
<tr>
<td>Nonthoracic trauma</td>
<td>Cardiopulmonary bypass</td>
</tr>
<tr>
<td>Possible Lung Injury Plus Elevated Hydrostatic Pressures</td>
<td></td>
</tr>
<tr>
<td>High altitude pulmonary edema</td>
<td>Reexpansion pulmonary edema</td>
</tr>
<tr>
<td>Neurogenic pulmonary edema</td>
<td></td>
</tr>
</tbody>
</table>
Medical Emergencies

SECTION 2

• Seat pt upright to reduce venous return.
• Administer 100% O₂ by mask to achieve PaO₂ > 60 mmHg; in pts who can tolerate it, continuous positive airway pressure (10 cmH₂O pressure) by mask improves outcome. Assisted ventilation by mask or endotracheal tube is frequently necessary.

• Intravenous loop diuretic (furosemide, 40–100 mg, or bumetanide, 1 mg); use lower dose if pt does not take diuretics chronically.
• Morphine 2–4 mg IV (repetitively); assess frequently for hypotension or respiratory depression; naloxone should be available to reverse effects of morphine if necessary.

Additional therapy may be required if rapid improvement does not ensue:

• The precipitating cause of cardiogenic pulmonary edema (Table 14-1) should be sought and treated, particularly acute arrhythmias or infection.
• Several noncardiogenic conditions may result in pulmonary edema in the absence of left heart dysfunction; therapy is directed toward the primary condition.
• Inotropic agents, e.g., dobutamine (Chap. 12), in cardiogenic pulmonary edema with shock.

FIGURE 14-1 An algorithm for the evaluation of the patient with dyspnea. JVP, jugular venous pulse; CHF, congestive heart failure; ECG, electrocardiogram; CT, computed tomography. (From RM Schwartzstein: HPIM-17, p. 224.)
• Reduce intravascular volume by phlebotomy (removal of ~250 mL through antecubital vein) if rapid diuresis does not follow diuretic administration.
• Nitroglycerin (sublingual 0.4 mg × 3 q5min) followed by 5–10 μg/min IV. Alternatively, nesiritide [2-μg/kg bolus IV followed by 0.01 (μg/kg)/min] may be used.
• For refractory pulmonary edema associated with persistent cardiac ischemia, early coronary revascularization may be life-saving.
• For noncardiac pulmonary edema, identify and treat/remove cause (Table 14-2).

For a more detailed discussion, see Schwartzstein RM: Dyspnea and Pulmonary Edema, Chap. 33, p. 221; and Hochman JS, Ingbar D: Cardiogenic Shock and Pulmonary Edema, Chap. 266, p. 1702, in HPIM-17.

**Acute Respiratory Distress Syndrome**

**DEFINITION AND ETIOLOGY**

Acute respiratory distress syndrome (ARDS) develops rapidly and includes severe dyspnea and hypoxemia; it typically causes respiratory failure. Key diagnostic criteria for ARDS include (1) diffuse bilateral pulmonary infiltrates on chest x-ray (CXR); (2) \( \text{PaO}_2 \) (arterial partial pressure of oxygen in mmHg) \( \text{FiO}_2 \) (inspired \( \text{O}_2 \) fraction) \( \leq 200 \) mmHg; and (3) absence of elevated left atrial pressure (pulmonary capillary wedge pressure \( \leq 18 \) mmHg). Acute lung injury is a related but milder syndrome, with less profound hypoxemia (\( \text{PaO}_2/\text{FiO}_2 \) \( \leq 300 \) mmHg), that can develop into ARDS. Although many medical and surgical conditions can cause ARDS, most cases (>80%) result from sepsis, bacterial pneumonia, trauma, multiple transfusions, gastric acid aspiration, and drug overdose. Individuals with more than one predisposing factor have a greater risk of developing ARDS. Other risk factors include older age, chronic alcohol abuse, metabolic acidosis, and overall severity of critical illness.

**CLINICAL COURSE AND PATHOPHYSIOLOGY**

There are three phases in the natural history of ARDS:

1. **Exudative phase**—Characterized by alveolar edema and leukocytic inflammation, with subsequent development of hyaline membranes from diffuse alveolar damage. The alveolar edema is most prominent in the dependent portions of the lung; this causes atelectasis and reduced lung compliance. Hypoxemia, tachypnea, and progressive dyspnea develop, and increased pulmonary dead space can also lead to hypercarbia. CXR reveals bilateral, diffuse alveolar and interstitial opacities. The differential diagnosis is broad, but common alternative etiologies to consider are cardiogenic pulmonary edema, pneumonia, and alveolar hemorrhage. Unlike cardiogenic pulmonary edema, the CXR in ARDS rarely shows cardiomegaly, pleural effusions, or pulmo-
nary vascular redistribution. The exudative phase duration is typically up to 7 days in length and usually begins within 12–36 h after the inciting insult.

2. **Proliferative phase**—This phase can last from approximately days 7 to 21 after the inciting insult. Although most pts recover, some will develop progressive lung injury and evidence of pulmonary fibrosis. Even among pts who show rapid improvement, dyspnea and hypoxemia often persist during this phase.

3. **Fibrotic phase**—Although the majority of pts recover within 3–4 weeks of the initial pulmonary injury, some experience progressive fibrosis, necessitating prolonged ventilatory support and/or supplemental O₂.

### Acute Respiratory Distress Syndrome

Progress in recent therapy has emphasized the importance of general critical care of pts with ARDS in addition to lung protective ventilator strategies. General care requires treatment of the underlying medical or surgical problem that caused lung injury, minimizing iatrogenic complications (e.g., procedure-related), prophylaxis to prevent venous thromboembolism and GI hemorrhage, prompt treatment of infections, and adequate nutritional support. An algorithm for the initial management of ARDS is presented in Fig. 15-1.

### MECHANICAL VENTILATORY SUPPORT

Pts with ARDS typically require mechanical ventilatory support due to hypoxemia and increased work of breathing. A substantial improvement in outcomes from ARDS occurred with the recognition that mechanical ventilator–related overdistention of normal lung units with positive pressure can produce or exacerbate lung injury, causing or worsening ARDS. Currently recommended ventilator strategies limit alveolar distention but maintain adequate tissue oxygenation.

**FIGURE 15-1** Algorithm for the initial management of ARDS. Clinical trials have provided evidence-based therapeutic goals for a step-wise approach to the early mechanical ventilation, oxygenation, correction of acidosis and diuresis of critically ill patients with ARDS.
It has been clearly shown that low tidal volumes (≤ 6 mL/kg predicted body weight) provide reduced mortality compared with higher tidal volumes (12 mL/kg predicted body weight). In ARDS, alveolar collapse can occur due to alveolar/interstitial fluid accumulation and loss of surfactant, thus worsening hypoxemia. Therefore, low tidal volumes are combined with the use of positive end-expiratory pressure (PEEP) at levels that strive to minimize alveolar collapse and achieve adequate oxygenation with the lowest FIO₂. Use of PEEP levels higher than required to optimize oxygenation has not been proven to be of benefit. Other techniques that may improve oxygenation while limiting alveolar distention include extending the time of inspiration on the ventilator (inverse ratio ventilation) and placing the pt in the prone position. However, these approaches are not of proven benefit in reducing mortality from ARDS.

ANCILLARY THERAPIES
Pts with ARDS have increased pulmonary vascular permeability leading to interstitial and alveolar edema. Therefore, they should receive IV fluids only as needed to achieve adequate cardiac output and tissue O₂ delivery as assessed by urine output, acid-base status, and arterial pressure. There is not convincing evidence currently to support the use of glucocorticoids or nitric oxide in ARDS.

OUTCOMES
Mortality from ARDS has declined with improvements in general critical care treatment and with the introduction of low tidal volume ventilation. Current mortality from ARDS is 41–65%, with most deaths due to sepsis and nonpulmonary organ failure. Increased risk of mortality from ARDS is associated with advanced age, preexisting organ dysfunction (e.g., chronic liver disease, chronic immunosuppression, chronic renal disease), and direct lung injury (e.g., pneumonia, aspiration) compared with indirect lung injury (e.g., sepsis, trauma, pancreatitis). Most surviving ARDS pts do not have significant long-term pulmonary disability.

For a more detailed discussion, see Levy BD, Shapiro SD: Acute Respiratory Distress Syndrome, Chap. 262, p. 1680, in HPIM-17.
Hypercarbic respiratory failure is characterized by respiratory acidosis with pH <7.30. Hypercarbic respiratory failure results from decreased minute ventilation and/or increased physiologic dead space. Common conditions associated with hypercarbic respiratory failure include neuromuscular diseases, such as myasthenia gravis, and respiratory diseases associated with respiratory muscle fatigue, such as asthma and chronic obstructive pulmonary disease (COPD). In acute hypercarbic respiratory failure, PaCO₂ is typically >50 mmHg. With acute-on-chronic respiratory failure, as is often seen with COPD exacerbations, considerably higher PaCO₂ values may be observed. The degree of respiratory acidosis, the pt’s mental status, and the pt’s degree of respiratory distress are better indicators of the need for mechanical ventilation than a specific PaCO₂ level in acute-on-chronic respiratory failure.

MODES OF MECHANICAL VENTILATION

Respiratory failure often requires treatment with mechanical ventilation. Various modes of mechanical ventilation are commonly used; different modes are characterized by a trigger (what the ventilator senses to initiate a machine-delivered breath), a cycle (what determines the end of inspiration), and limiting factors (specified values for key parameters that are monitored by the ventilator and not allowed to be exceeded). Four of the common modes of mechanical ventilation are described below; additional information is provided in Table 16-1:

- **Assist-control ventilation**: The trigger for a machine delivered breath is the pt’s inspiratory effort, which causes a synchronized breath to be delivered. If no effort is detected over a prespecified time interval, a timer-triggered machine breath is delivered. Assist control is volume-cycled with an operator-determined tidal volume. Limiting factors include the minimum respiratory rate, which is specified by the operator; pt efforts can lead to higher rates. Other limiting factors include the airway pressure limit, which is also set by the operator. Because the pt will receive a full tidal breath with each inspiratory effort, tachypnea due to nonrespiratory drive (such as pain) can lead to respiratory alkalosis. In pts with airflow obstruction (e.g., asthma or COPD), auto-PEEP can develop.

- **Synchronized intermittent mandatory ventilation (SIMV)**: As with Assist-control, SIMV is volume-cycled, with similar limiting factors. As with Assist-control, the trigger for a machine-delivered breath can be either pt effort or a specified time interval. However, if the pt’s next inspiratory effort occurs before the time interval for another mandatory breath has elapsed, only their spontaneous respiratory effort (without machine support) is delivered. Thus, the number of machine-delivered breaths is limited in SIMV.

- **Pressure-control ventilation (PCV)**: PCV is triggered by a specified time interval, and the inspiratory pressure that is delivered after that time trigger is time-cycled. The level of inspiratory pressure is an operator-specified limiting factor in this mode of ventilation; the achieved tidal volume and inspiratory flow rate result from this prespecified pressure limit, and a specific tidal volume or minute ventilation may not be achieved. For pts in whom limiting airway pressure is desired (e.g., barotrauma), PCV is often used.

- **Pressure-support ventilation (PSV)**: PSV is triggered by the pt’s inspiratory effort. The cycle of PSV is determined by the inspiratory flow rate. Because a specific respiratory rate is not provided, this mode of ventilation may be combined with SIMV to ensure that an adequate respiratory rate is achieved in pts with respiratory depression.

**MANAGEMENT OF MECHANICALLY VENTILATED PATIENTS**

General care of mechanically ventilated pts is reviewed in Chap. 5, along with weaning from mechanical ventilation. A cuffed endotracheal tube is often used...
### TABLE 16-1 CLINICAL CHARACTERISTICS OF COMMONLY USED MODES OF MECHANICAL VENTILATION

<table>
<thead>
<tr>
<th>Ventilator Mode</th>
<th>Independent Variables (Set by User)</th>
<th>Dependent Variables (Monitored by User)</th>
<th>Trigger/Cycle Limit</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Initial Settings</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACMV*a</td>
<td>$FIO_2$, Tidal volume, Ventilator rate, Level of PEEP, Inspiratory flow pattern, Peak inspiratory flow, Pressure limit</td>
<td>Peak airway pressure, $P_{A\text{O}<em>2}$, $P</em>{A\text{CO}_2}$, Mean airway pressure, I/E ratio</td>
<td>Patient/timer, Pressure limit</td>
<td>Timer backup, Patient-vent synchrony, Patient controls minute ventilation</td>
<td>Not useful for weaning, Potential for dangerous respiratory alkalosis</td>
<td>$FIO_2 = 1.0^b$, $V_t = 10–15 \text{ mL/kg}^a$, $f = 12–15/\text{min}$, PEEP = 0–5 cmH$_2$O, Inspiratory flow = 60 L/min</td>
</tr>
<tr>
<td>SIMV*a</td>
<td>Same as for ACMV</td>
<td>Same as for ACMV</td>
<td>Same as for ACMV</td>
<td>Timer backup useful for weaning</td>
<td>Potential dyssynchrony</td>
<td>Same as for ACMV*a</td>
</tr>
<tr>
<td>PCV*a</td>
<td>$FIO_2$, Inspiratory pressure level, Ventilator rate, Level of PEEP, Pressure limit, I/E ratio</td>
<td>Tidal volume, Flow rate, pattern, Minute ventilation, $P_{A\text{O}<em>2}$, $P</em>{A\text{CO}_2}$</td>
<td>Timer/patient, Timer/pressure limit</td>
<td>System pressures regulated, Useful for barotrauma treatment, Timer backup</td>
<td>Requires heavy sedation, Not useful for weaning</td>
<td>$FIO_2 = 1.0^b$, PC = 20–40 cmH$_2$O*a, PEEP = 5–10 cmH$_2$O, $f = 12–15/\text{min}$, I/E = 0.7/1–4/1</td>
</tr>
<tr>
<td>PSV</td>
<td>$FIO_2$, Inspiratory pressure level, PEEP, Pressure limit</td>
<td>Same as for PCV + I/E ratio</td>
<td>Inspiratory flow, Pressure limit</td>
<td>Assures synchrony, Good for weaning</td>
<td>No timer backup</td>
<td>$FIO_2 = 0.5–1.0^b$, PS = 10–30 cmH$_2$O, 5 cmH$_2$O usually the level used, PEEP = 0–5 cmH$_2$O</td>
</tr>
</tbody>
</table>

*aOpen lung ventilation (OLV) involves the use of any of these specific modes with tidal volumes (or applied pressures) to achieve 5–6 mL/kg, and positive end-expiratory pressures achieve maximal alveolar recruitment.

*b$FIO_2$ is usually set to 1.0 initially, unless there is a specific clinical indication to minimize $FIO_2$, such as history of chemotherapy with bleomycin. Once adequate oxygenation is documented by blood gas analysis, $FIO_2$ should be decreased in decrements of 0.1–0.2 as tolerated, until the lowest $FIO_2$ required for an $SA_{O_2} > 90\%$ is achieved.

**Abbreviations:** $f$, frequency; I/E, inspiration/expiration; $FIO_2$, inspired O$_2$; PEEP, positive end-expiratory pressure; for ventilator modes, see text; $V_t$, tidal ventilation.
to provide positive pressure ventilation with conditioned gas. After an endotra-
cheal tube has been in place for an extended period of time, tracheostomy
should be considered, primarily to improve pt comfort and management of res-
piratory secretions. No absolute time frame for tracheostomy placement exists,
but pts who are likely to require mechanical ventilatory support for >3 weeks
should be considered for a tracheostomy.

A variety of complications can result from mechanical ventilation. Barotrau-
ma, overdistention and damage of lung tissue, typically occurs at high airway
pressures (>50 cmH2O). Barotrauma can cause pneumomediastinum, subcutane-
ous emphysema, and pneumothorax; pneumothorax typically requires treatment
with tube thoracostomy. Ventilator-associated pneumonia is a major complica-
tion of mechanical ventilation; common pathogens include *Pseudomonas aeruginosa*
and other gram-negative bacilli, as well as *Staphylococcus aureus*.

In some circumstances, noninvasive positive pressure ventilation (NPPV)
delivered through a tightly fitting nasal or full facemask should be considered
for treatment of impending respiratory failure. Pressure support ventilation
is typically used with noninvasive ventilation, and positive end-expiratory pres-
sure (PEEP) can also be included. NPPV has been used quite successfully in
the management of COPD exacerbations (Chap. 139), and it appears to reduce
the risk of ventilator-associated pneumonia.

For a more detailed discussion, see Ingenito EP: Mechanical Ven-
tilatory Support, Chap. 263, p. 1684, in HPIM-17.

**Confusion, Stupor, and Coma**

**APPROACH TO THE PATIENT:
DISORDERS OF CONSCIOUSNESS**

Disorders of consciousness are common; these always signify a disorder of the
nervous system. Assessment should determine whether there is a change
in level of consciousness (drowsy, stuporous, comatose) and/or content of
consciousness (confusion, perseveration, hallucinations). *Confusion* is a
lack of clarity in thinking with inattentiveness; *delirium* is used to describe
an acute confusional state; *stupor*, a state in which vigorous stimuli are
needed to elicit a response; *coma*, a condition of unresponsiveness. Patients
in such states are usually seriously ill, and etiologic factors must be assessed
*(Tables 17-1 and 17-2)*.

**DELIRIUM**

Delirium is a clinical diagnosis made at the bedside; a careful history and phys-
ical exam are necessary, focusing on common etiologies of delirium, especially
toxins and metabolic conditions. Observation will usually reveal an altered lev-
el of consciousness or a deficit of attention. Attention can be assessed through a
simple bedside test of digits forward—pts are asked to repeat successively longer random strings of digits beginning with two digits in a row; a digit span of four digits or less usually indicates an attentional deficit unless hearing or language barriers are present. Delirium is vastly underrecognized, especially in pts presenting with a quiet, hypoactive state.

A cost-effective approach to the evaluation of delirium allows the history and physical exam to guide tests. No single algorithm will fit all pts due to the

---

**TABLE 17-1 COMMON ETIOLOGIES OF DELIRIUM**

<table>
<thead>
<tr>
<th>Category</th>
<th>Etiologies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxins</td>
<td>Prescription medications: especially those with anticholinergic properties, narcotics and benzodiazepines</td>
</tr>
<tr>
<td></td>
<td>Drugs of abuse: alcohol intoxication and alcohol withdrawal, opiates, ecstasy, LSD, GHB, PCP, ketamine, cocaine</td>
</tr>
<tr>
<td></td>
<td>Poisons: inhalants, carbon monoxide, ethylene glycol, pesticides</td>
</tr>
<tr>
<td>Metabolic conditions</td>
<td>Electrolyte disturbances: hypoglycemia, hyperglycemia, hyponatremia, hypernatremia, hypercalcemia, hypocalcemia, hypomagnesemia</td>
</tr>
<tr>
<td></td>
<td>Hypothermia and hyperthermia</td>
</tr>
<tr>
<td></td>
<td>Pulmonary failure: hypoxemia and hypercarbia</td>
</tr>
<tr>
<td></td>
<td>Liver failure/hepatic encephalopathy</td>
</tr>
<tr>
<td></td>
<td>Renal failure/uremia</td>
</tr>
<tr>
<td></td>
<td>Cardiac failure</td>
</tr>
<tr>
<td></td>
<td>Vitamin deficiencies: B₁₂, thiamine, folate, niacin</td>
</tr>
<tr>
<td></td>
<td>Dehydration and malnutrition</td>
</tr>
<tr>
<td></td>
<td>Anemia</td>
</tr>
<tr>
<td>Infections</td>
<td>Systemic infections: urinary tract infections, pneumonia, skin and soft tissue infections, sepsis</td>
</tr>
<tr>
<td></td>
<td>CNS infections: meningitis, encephalitis, brain abscess</td>
</tr>
<tr>
<td>Endocrinologic conditions</td>
<td>Hyperthyroidism, hypothyroidism</td>
</tr>
<tr>
<td></td>
<td>Hyperparathyroidism</td>
</tr>
<tr>
<td></td>
<td>Adrenal insufficiency</td>
</tr>
<tr>
<td>Cerebrovascular disorders</td>
<td>Global hypoperfusion states</td>
</tr>
<tr>
<td></td>
<td>Hypertensive encephalopathy</td>
</tr>
<tr>
<td></td>
<td>Focal ischemic strokes and hemorrhages: especially nondominant parietal and thalamic lesions</td>
</tr>
<tr>
<td>Autoimmune disorders</td>
<td>CNS vasculitis</td>
</tr>
<tr>
<td></td>
<td>Cerebral lupus</td>
</tr>
<tr>
<td>Seizure-related disorders</td>
<td>Nonconvulsive status epilepticus</td>
</tr>
<tr>
<td></td>
<td>Intermittent seizures with prolonged post-ictal states</td>
</tr>
<tr>
<td>Neoplastic disorders</td>
<td>Diffuse metastases to the brain</td>
</tr>
<tr>
<td></td>
<td>Gliomatosis cerebri</td>
</tr>
<tr>
<td></td>
<td>Carcinomatous meningitis</td>
</tr>
<tr>
<td>Hospitalization</td>
<td>Terminal end of life delirium</td>
</tr>
</tbody>
</table>

**Abbreviations:** LSD, lysergic acid diethylamide; GHB, γ-hydroxybutyrate; PCP, phencyclidine; CNS, central nervous system.
large number of potential etiologies, but one step-wise approach is shown in Table 17-3.

Management of the delirious pt begins with treatment of the underlying inciting factor (e.g., pts with systemic infections should be given appropriate antibiotics, and electrolyte disturbances judiciously corrected). Relatively simple methods of supportive care can be quite effective, such as frequent reorientation by staff, preservation of sleep-wake cycles, and attempting to mimic the home environment as much as possible. Chemical restraints exacerbate delirium and should be used only when necessary to protect pt or staff from possible injury; antipsychotics at low dose are usually the treatment of choice.
COMA

Because coma demands immediate attention, the physician must employ an organized approach. Almost all instances of coma can be traced to widespread abnormalities of the bilateral cerebral hemispheres or to reduced activity of the reticular activating system in the brainstem.

**History**  
Pt should be aroused, if possible, and questioned regarding use of insulin, narcotics, anticoagulants, other prescription drugs, suicidal intent, recent trauma, headache, epilepsy, significant medical problems, and preceding symptoms. Witnesses and family members should be interviewed, often by phone. History of sudden headache followed by loss of consciousness suggests intracranial hemorrhage; preceding vertigo, nausea, diplopia, ataxia, hemisensory disorder suggest basilar insufficiency; chest pain, palpitations, and faintness suggest a cardiovascular cause.

**Immediate Assessment**  
Acute respiratory and cardiovascular problems should be attended to prior to the neurologic assessment. Vital signs should be evaluated, and appropriate support initiated. Thiamine, glucose, and naloxone should be administered if the etiology of coma is not immediately apparent.

---

**TABLE 17-3**  
**STEP-WISE EVALUATION OF A PATIENT WITH DELIRIUM**

<table>
<thead>
<tr>
<th>Initial evaluation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>History with special attention to medications (including over-the-counter and herbals)</td>
<td></td>
</tr>
<tr>
<td>General physical examination and neurologic examination</td>
<td></td>
</tr>
<tr>
<td>Complete blood count</td>
<td></td>
</tr>
<tr>
<td>Electrolyte panel including calcium, magnesium, phosphorus</td>
<td></td>
</tr>
<tr>
<td>Liver function tests including albumin</td>
<td></td>
</tr>
<tr>
<td>Renal function tests</td>
<td></td>
</tr>
<tr>
<td><strong>First-tier further evaluation guided by initial evaluation</strong></td>
<td></td>
</tr>
<tr>
<td>Systemic infection screen</td>
<td></td>
</tr>
<tr>
<td>Urinalysis and culture</td>
<td></td>
</tr>
<tr>
<td>Chest radiograph</td>
<td></td>
</tr>
<tr>
<td>Blood cultures</td>
<td></td>
</tr>
<tr>
<td>Electrocardiogram</td>
<td></td>
</tr>
<tr>
<td>Arterial blood gas</td>
<td></td>
</tr>
<tr>
<td>Serum and/or urine toxicology screen (perform earlier in young persons)</td>
<td></td>
</tr>
<tr>
<td>Brain imaging with MRI with diffusion and gadolinium (preferred) or CT</td>
<td></td>
</tr>
<tr>
<td>Suspected CNS infection: lumbar puncture following brain imaging</td>
<td></td>
</tr>
<tr>
<td>Suspected seizure-related etiology: electroencephalogram (EEG) (if high suspicion should be performed immediately)</td>
<td></td>
</tr>
<tr>
<td><strong>Second-tier further evaluation</strong></td>
<td></td>
</tr>
<tr>
<td>Vitamin levels: B12, folate, thiamine</td>
<td></td>
</tr>
<tr>
<td>Endocrinologic laboratories: thyroid-stimulating hormone (TSH) and free T4; cortisol</td>
<td></td>
</tr>
<tr>
<td>Serum ammonia</td>
<td></td>
</tr>
<tr>
<td>Sedimentation rate</td>
<td></td>
</tr>
<tr>
<td>Autoimmune serologies: antinuclear antibodies (ANA), complement levels; p-ANCA, c-ANCA</td>
<td></td>
</tr>
<tr>
<td>Infectious serologies: rapid plasmin reagin (RPR); fungal and viral serologies if high suspicion; HIV antibody</td>
<td></td>
</tr>
<tr>
<td>Lumbar puncture (if not already performed)</td>
<td></td>
</tr>
<tr>
<td>Brain MRI with and without gadolinium (if not already performed)</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** p-ANCA, perinuclear antineutrophil cytoplasmic antibody; c-ANCA, cytoplasmic antineutrophil cytoplasmic antibody.
Blood should be drawn for glucose, electrolytes, calcium, and renal (BUN, creatinine) and hepatic (ammonia, transaminases) function; also screen for presence of alcohol and other toxins. Arterial blood-gas analysis is helpful in pts with lung disease and acid-base disorders. Fever, especially with petechial rash, suggests meningitis. Examination of CSF is essential in diagnosis of meningitis and encephalitis; lumbar puncture should not be deferred if meningitis is a possibility, but CT scan should be obtained first to exclude a mass lesion. Empirical antibiotic coverage for meningitis may be instituted until CSF results are available. Fever with dry skin suggests heat shock or intoxication with anticholinergics. Hypothermia suggests myxedema, intoxication, sepsis, exposure, or hypoglycemia. Marked hypertension occurs with increased intracranial pressure (ICP) and hypertensive encephalopathy.

**Neurologic Examination** Focus on establishing pt’s best level of function and uncovering signs that enable a specific diagnosis. Comatose pt’s best motor and sensory function should be assessed by testing reflex responses to noxious stimuli; carefully note any asymmetric responses, which suggest a focal lesion. Multifocal myoclonus indicates that a metabolic disorder is likely; intermittent twitching may be the only sign of a seizure.

**Responsiveness** Stimuli of increasing intensity are applied to gauge the degree of unresponsiveness and any asymmetry in sensory or motor function. Motor responses may be purposeful or reflexive. Spontaneous flexion of elbows with leg extension, termed *decortication*, accompanies severe damage to contralateral hemisphere above midbrain. Internal rotation of the arms with extension of elbows, wrists, and legs, termed *decerebration*, suggests damage to midbrain or diencephalon. These postural reflexes occur in profound encephalopathic states.

**Pupillary Signs** In comatose pts, equal, round, reactive pupils exclude midbrain damage as cause and suggest a metabolic abnormality. Pinpoint pupils occur in narcotic overdose (except meperidine, which causes midsize pupils), pontine damage, hydrocephalus, or thalamic hemorrhage; the response to naloxone and presence of reflex eye movements (usually intact with drug overdose) can distinguish these. A unilateral, enlarged, often oval, poorly reactive pupil is caused by midbrain lesions or compression of third cranial nerve, as occurs in transtentorial herniation. Bilaterally dilated, unreactive pupils indicate severe bilateral midbrain damage, anticholinergic overdose, or ocular trauma.

**Ocular Movements** Examine spontaneous and reflex eye movements. Intermittent horizontal divergence is common in drowsiness. Slow, to-and-fro horizontal movements suggest bihemispheric dysfunction. Conjugate eye deviation to one side indicates damage to the pons on the opposite side or a lesion in the frontal lobe on the same side (“The eyes look toward a hemispherical lesion and away from a brainstem lesion”). An adducted eye at rest with impaired ability to turn eye laterally indicates an abducens (VI) nerve palsy, common in raised ICP or pontine damage. The eye with a dilated, unreactive pupil is often abducted at rest and cannot adduct fully due to third nerve dysfunction, as occurs with transtentorial herniation. Vertical separation of ocular axes (skew deviation) occurs in pontine or cerebellar lesions. Doll’s head maneuver (oculocephalic reflex) and cold caloric–induced eye movements allow diagnosis of gaze or cranial nerve palsies in pts who do not move their eyes purposefully. Doll’s head maneuver is tested by observing eye movements in response to lateral rotation of head (this should not be performed in pts with possible neck injury); full conjugate movement of eyes occurs in bihemispheric dysfunction. In comatose pts with intact brainstem function, raising head to 60° above the horizontal and irrigating external auditory ca-
nal with cool water causes tonic deviation of gaze to side of irrigated ear (“cold calorics”). In conscious pts, it causes nystagmus, vertigo, and emesis.

**Respiratory Patterns**  Respiratory pattern may suggest site of neurologic damage. Cheyne-Stokes (periodic) breathing occurs in bihemispheric dysfunction and is common in metabolic encephalopathies. Respiratory patterns composed of gasps or other irregular breathing patterns are indicative of lower brainstem damage; such pts usually require intubation and ventilatory assistance.

**Radiologic Examination**  Lesions causing raised ICP commonly cause impaired consciousness. CT or MRI scan of the brain is often abnormal in coma but may not be diagnostic; appropriate therapy should not be postponed while awaiting a CT or MRI scan. Pts with disordered consciousness due to high ICP can deteriorate rapidly; emergent CT study is necessary to confirm presence of mass effect and to guide surgical decompression. CT scan is normal in some pts with subarachnoid hemorrhage; the diagnosis then rests on clinical history combined with RBCs or xanthrochromia in spinal fluid. MR angiography or cerebral angiography may be necessary to establish basilar artery stroke as cause of coma in pts with brainstem signs. The EEG is useful in metabolic or drug-induced states but is rarely diagnostic; exceptions are coma due to seizures or herpesvirus encephalitis.

**BRAIN DEATH**

This results from total cessation of cerebral function while somatic function is maintained by artificial means and the heart continues to pump. It is legally and ethically equivalent to cardiorespiratory death. The pt is unresponsive to all forms of stimulation (widespread cortical destruction), brainstem reflexes are absent (global brainstem damage), and there is complete apnea (destruction of the medulla). Demonstration of apnea requires that the $P_{CO_2}$ be high enough to stimulate respiration, while $P_{O_2}$ and bp are maintained. EEG is isoelectric at high gain. The absence of deep tendon reflexes is not required because the spinal cord may remain functional. Special care must be taken to exclude drug toxicity and hypothermia prior to making a diagnosis of brain death. Diagnosis should be made only if the state persists for some agreed-upon period, usually 6–24 h.

For a more detailed discussion, see Josephson SA, Miller BL: Confusion and Delirium, Chap. 26, p. 158, in HPIM-17. and Ropper AH: Coma, Chap. 268, p. 1714, in HPIM-17.

### Stroke

Sudden onset of a neurologic deficit from a vascular mechanism: 85% are ischemic; 15% are primary hemorrhages [subarachnoid (Chap. 19) and intraparenchymal]. An ischemic deficit that resolves rapidly is termed a *transient ischemic attack* (TIA); 24 h is a commonly used boundary between TIA and stroke whether or not a new infarction has occurred, although most TIAs last between 5 and 15 min. Stroke is the leading cause of neurologic disability in
adults; 200,000 deaths annually in the United States. Much can be done to limit morbidity and mortality through prevention and acute intervention.

PATHOPHYSIOLOGY

Ischemic stroke is most often due to embolic occlusion of large cerebral vessels; source of emboli may be heart, aortic arch, or other arterial lesions such as the carotid arteries. Small, deep ischemic lesions are most often related to intrinsic small-vessel disease (lacunar strokes). Low-flow strokes are seen with severe proximal stenosis and inadequate collaterals challenged by systemic hypotensive episodes. Hemorrhages most frequently result from rupture of aneurysms or small vessels within brain tissue. Variability in stroke recovery is influenced by collateral vessels, blood pressure, and the specific site and mechanism of vessel occlusion; if blood flow is restored prior to significant cell death, the pt may experience only transient symptoms, i.e., a TIA.

CLINICAL FEATURES

Ischemic Stroke  Abrupt and dramatic onset of focal neurologic symptoms is typical of ischemic stroke. Pts may not seek assistance on their own because they are rarely in pain and may lose appreciation that something is wrong (anosagnosia). Symptoms reflect the vascular territory involved (Table 18-1). Transient monocular blindness (amaurosis fugax) is a particular form of TIA due to retinal ischemia; pts describe a shade descending over the visual field.

Lacunar Syndromes (Small-Vessel Strokes)  Most common are:
• Pure motor hemiparesis of face, arm, and leg (internal capsule or pons)
• Pure sensory stroke (ventral thalamus)
• Ataxic hemiparesis (pons or internal capsule)
• Dysarthria—clumsy hand (pons or genu of internal capsule).

Intracranial Hemorrhage  Vomiting and drowsiness occur in some cases, and headache in about one-half. Signs and symptoms are often not confined to a single vascular territory. Etiologies are diverse but hypertension-related is the most common (Table 18-2). Hypertensive hemorrhages typically occur in the following locations:
• Putamen: Contralateral hemiparesis.
• Thalamus: Hemiparesis with prominent sensory deficit.
• Pons: Quadriplegic, “pinpoint” pupils, impaired horizontal eye movements.
• Cerebellum: Headache, vomiting, gait ataxia.

A neurologic deficit that evolves relentlessly over 5–30 min strongly suggests intracerebral bleeding.

EX  Stroke

Principles of management are outlined in Fig. 18-1. Stroke needs to be distinguished from potential mimics, including seizure, migraine, tumor, and metabolic derangements. After initial stabilization, an emergency noncontrast head CT scan is necessary to differentiate ischemic from hemorrhagic stroke. With large ischemic strokes, CT abnormalities are usually evident within the first few hours, but small infarcts can be difficult to visualize by CT. CT or MR angiography (CTA/MRA) and perfusion may help reveal vascular occlusions and tissue at risk for infarction. Diffusion-weighted MRI has a high sensitivity for identifying ischemic stroke even minutes after onset.
ACUTE ISCHEMIC STROKE

Patient care in comprehensive stroke centers followed by rehabilitation services improves neurologic outcomes and reduces mortality. Treatments designed to reverse or lessen tissue infarction include: (1) medical support, (2) thrombolysis and endovascular techniques, (3) antiplatelet agents, (4) anticoagulation, and (5) neuroprotection.

<table>
<thead>
<tr>
<th>TABLE 18-1</th>
<th>ANATOMIC LOCALIZATION IN STROKE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Signs and Symptoms</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Cerebral Hemisphere, Lateral Aspect (Middle Cerebral A.)</strong></td>
<td></td>
</tr>
<tr>
<td>Hemiparesis</td>
<td></td>
</tr>
<tr>
<td>Mismatch sensory decit</td>
<td></td>
</tr>
<tr>
<td>Motor aphasia (Broca’s)—hesitant speech with word-finding difficulty and preserved comprehension</td>
<td></td>
</tr>
<tr>
<td>Central aphasia (Wernicke’s)—anomia, poor comprehension, jargon speech</td>
<td></td>
</tr>
<tr>
<td>Unilateral neglect, apraxias</td>
<td></td>
</tr>
<tr>
<td>Homonymous hemianopia or quadrantanopia</td>
<td></td>
</tr>
<tr>
<td>Gaze preference with eyes deviated to side of lesion</td>
<td></td>
</tr>
<tr>
<td><strong>Cerebral Hemisphere, Medial Aspect (Anterior Cerebral A.)</strong></td>
<td></td>
</tr>
<tr>
<td>Paralysis of foot and leg with or without paresis of arm</td>
<td></td>
</tr>
<tr>
<td>Cortical sensory loss over leg</td>
<td></td>
</tr>
<tr>
<td>Grasp and sucking reflexes</td>
<td></td>
</tr>
<tr>
<td>Urinary incontinence</td>
<td></td>
</tr>
<tr>
<td>Gait apraxia</td>
<td></td>
</tr>
<tr>
<td><strong>Cerebral Hemisphere, Posterior Aspect (Posterior Cerebral A.)</strong></td>
<td></td>
</tr>
<tr>
<td>Homonymous hemianopia</td>
<td></td>
</tr>
<tr>
<td>Cortical blindness</td>
<td></td>
</tr>
<tr>
<td>Memory deficit</td>
<td></td>
</tr>
<tr>
<td>Dense sensory loss, spontaneous pain, dysesthesias, choreoathetosis</td>
<td></td>
</tr>
<tr>
<td><strong>Brainstem, Midbrain (Posterior Cerebral A.)</strong></td>
<td></td>
</tr>
<tr>
<td>Third nerve palsy and contralateral hemiplegia</td>
<td></td>
</tr>
<tr>
<td>Paralysis/paresis of vertical eye movement</td>
<td></td>
</tr>
<tr>
<td>Convergence nystagmus, disorientation</td>
<td></td>
</tr>
<tr>
<td><strong>Brainstem, Pontomedullary Junction (Basilar A.)</strong></td>
<td></td>
</tr>
<tr>
<td>Facial paralysis</td>
<td></td>
</tr>
<tr>
<td>Paresis of abduction of eye</td>
<td></td>
</tr>
<tr>
<td>Paresis of conjugate gaze</td>
<td></td>
</tr>
<tr>
<td>Hemifacial sensory deficit</td>
<td></td>
</tr>
<tr>
<td>Horner’s syndrome</td>
<td></td>
</tr>
<tr>
<td>Diminished pain and thermal sense over half body (with or without face)</td>
<td></td>
</tr>
<tr>
<td>Ataxia</td>
<td></td>
</tr>
<tr>
<td><strong>Brainstem, Lateral Medulla (Vertebral A.)</strong></td>
<td></td>
</tr>
<tr>
<td>Vertigo, nystagmus</td>
<td></td>
</tr>
<tr>
<td>Horner’s syndrome (miosis, ptosis, decreased sweating)</td>
<td></td>
</tr>
<tr>
<td>Ataxia, falling toward side of lesion</td>
<td></td>
</tr>
<tr>
<td>Impaired pain and thermal sense over half body with or without face</td>
<td></td>
</tr>
<tr>
<td>Cause</td>
<td>Location</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Head trauma</td>
<td>Intraparenchymal: frontal lobes, anterior temporal lobes; subarachnoid</td>
</tr>
<tr>
<td>Hypertensive hemorrhage</td>
<td>Putamen, globus pallidus, thalamus, cerebellar hemisphere, pons</td>
</tr>
<tr>
<td>Transformation of prior ischemic infarction</td>
<td>Basal ganglion, subcortical regions, lobar</td>
</tr>
<tr>
<td>Metastatic brain tumor</td>
<td>Lobar</td>
</tr>
<tr>
<td>Coagulopathy</td>
<td>Any</td>
</tr>
<tr>
<td>Drug</td>
<td>Lobar, subarachnoid</td>
</tr>
<tr>
<td>Drug</td>
<td>Lobar, intraventricular, subarachnoid</td>
</tr>
<tr>
<td>Arteriovenous malformation</td>
<td>Lobar</td>
</tr>
<tr>
<td>Arteriovenous malformation</td>
<td>Lobar, subarachnoid</td>
</tr>
<tr>
<td>Aneurysm</td>
<td>Subarachnoid, intraparenchymal, rarely subdural</td>
</tr>
<tr>
<td>Amyloid angiopathy</td>
<td>Lobar</td>
</tr>
<tr>
<td>Cavernous angioma</td>
<td>Intraparenchymal</td>
</tr>
<tr>
<td>Dural arteriovenous fistula</td>
<td>Lobar, subarachnoid</td>
</tr>
<tr>
<td>Capillary telangiectasias</td>
<td>Usually brainstem</td>
</tr>
</tbody>
</table>
Immediate goal is to optimize perfusion in ischemic penumbra surrounding the infarct. Blood pressure should never be lowered precipitously (exacerbates the underlying ischemia), and only in the most extreme situations should gradual lowering be undertaken (e.g., malignant hypertension with bp > 220/120 or, if thrombolysis planned, bp > 185/110 mmHg). Intravascular volume should be maintained with isotonic fluids as volume restriction is rarely helpful. Osmotic therapy with mannitol may be necessary to control edema in large infarcts, but isotonic volume must be replaced to avoid hypovolemia. In cerebellar infarction (or hemorrhage), rapid deterioration can occur from brainstem compression and hydrocephalus, requiring neurosurgical intervention.

**Thrombolysis and Endovascular Techniques**

Ischemic deficits of <3 h duration, with no hemorrhage by CT criteria, may benefit from thrombolytic therapy with IV recombinant tissue plasminogen activator (Table 18-3). Ischemic stroke from large-vessel intracranial occlusion...
Medical Emergencies

SECTION 2

Thrombotic Occlusion

Sion results in high rates of morbidity and mortality; pts with such occlusions may benefit from intraarterial thrombolysis (<6 h duration) or embolectomy (<8 h duration) administered at the time of an urgent cerebral angiogram at specialized centers. Only a small percentage of stroke pts are seen early enough to receive treatment with these techniques.

Antiplatelet Agents

Aspirin (up to 325 mg/d) is safe and has a small but definite benefit in acute stroke.

Anticoagulation

Trials do not support the use of heparin or other anticoagulants for pts with acute stroke although some physicians continue to use this treatment in specific situations such as TIA in the setting of atrial fibrillation.

Neuroprotection

Hypothermia is effective in coma following cardiac arrest but has not been adequately studied in pts with stroke. Other neuroprotective agents have shown no benefit in human trials despite promising animal data.

ACUTE INTRACEREBRAL HEMORRHAGE

Noncontrast head CT will confirm diagnosis. Rapidly identify and correct any coagulopathy. Nearly 50% of pts die; prognosis is determined by volume and

---

### TABLE 18-3
ADMINISTRATION OF INTRAVENOUS RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (RTPA) FOR ACUTE ISCHEMIC STROKE

<table>
<thead>
<tr>
<th>Indication</th>
<th>Contraindication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical diagnosis of stroke</td>
<td>Sustained BP &gt;185/110 despite treatment</td>
</tr>
<tr>
<td>Onset of symptoms to time of drug administration ≤3 h</td>
<td>Platelets &lt;100,000; HCT &lt;25%; glucose &lt;50 or &gt;400 mg/dL</td>
</tr>
<tr>
<td>CT scan showing no hemorrhage or edema of &gt; 1/3 of the MCA territory</td>
<td>Use of heparin within 48 h and prolonged PTT, or elevated INR</td>
</tr>
<tr>
<td>Age ≥18 years</td>
<td>Rapidly improving symptoms</td>
</tr>
<tr>
<td>Consent by patient or surrogate</td>
<td>Prior stroke or head injury within 3 months; prior intracranial hemorrhage</td>
</tr>
<tr>
<td></td>
<td>Major surgery in preceding 14 days</td>
</tr>
<tr>
<td></td>
<td>Minor stroke symptoms</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal bleeding in preceding 21 days</td>
</tr>
<tr>
<td></td>
<td>Recent myocardial infarction</td>
</tr>
<tr>
<td></td>
<td>Coma or stupor</td>
</tr>
</tbody>
</table>

Administration of rtPA

- Intravenous access with two peripheral IV lines (avoid arterial or central line placement)
- Review eligibility for rtPA
- Administer 0.9 mg/kg intravenously (maximum 90 mg) IV as 10% of total dose by bolus, followed by remainder of total dose over 1 h
- Frequent cuff blood pressure monitoring
- No other antithrombotic treatment for 24 h
- For decline in neurologic status or uncontrolled blood pressure, stop infusion, give cryoprecipitate, and reimage brain emergently
- Avoid urethral catheterization for ≥2 h

*See Activase (tissue plasminogen activator) package insert for complete list of contraindications and dosing.

**Note:** BP, blood pressure; HCT, hematocrit; INR, international normalized ratio; MCA, middle cerebral artery; PTT, partial thromboplastin time.
location of hematoma. Stuporous or comatose patients generally are treated presumptively for elevated ICP. Neurosurgical consultation should be sought for possible urgent evacuation of cerebellar hematoma; in other locations, data do not support surgical intervention. Treatment for edema and mass effect with osmotic agents may be necessary; glucocorticoids not helpful.

**EVALUATION: DETERMINING THE CAUSE OF STROKE**

Although initial management of acute ischemic stroke or TIA does not depend on the etiology, establishing a cause is essential to reduce risk of recurrence (Table 18-4); particular attention should be on atrial fibrillation and carotid atherosclerosis as these etiologies have proven secondary prevention strategies. Nearly 30% of strokes remain unexplained despite extensive evaluation.

Clinical examination should be focused on the peripheral and cervical vascular system. Routine studies include CXR and ECG, urinalysis, CBC/platelets, electrolytes, glucose, ESR, lipid profile, PT, PTT, and serologic tests for syphilis. If a hypercoagulable state is suspected, further studies of coagulation are indicated.

Imaging evaluation may include brain MRI (compared with CT, increased sensitivity for small infarcts of cortex and brainstem); MR or CT angiography (evaluate patency of intracranial vessels and extracranial carotid and vertebral vessels); noninvasive carotid tests (“duplex” studies, combine ultrasound imaging of the vessel with Doppler evaluation of blood flow characteristics); or cerebral angiography (“gold standard” for evaluation of intracranial and extracranial vascular disease). For suspected cardiogenic source, cardiac echocardiogram with attention to right-to-left shunts, and 24-h Holter or long-term cardiac event monitoring indicated.

**PRIMARY AND SECONDARY PREVENTION OF STROKE**

**Risk Factors**  Atherosclerosis is a systemic disease affecting arteries throughout the body. Multiple factors including hypertension, diabetes, hyperlipidemia, and family history influence stroke and TIA risk (Table 18-5). Cardioembolic risk factors include atrial fibrillation, MI, valvular heart disease, and cardiomyopathy. Hypertension and diabetes are also specific risk factors for lacunar stroke and intraparenchymal hemorrhage. Smoking is a potent risk factor for all vascular mechanisms of stroke. Identification of modifiable risk factors and prophylactic interventions to lower risk is probably the best approach to stroke overall.

**Antiplatelet Agents**  Platelet antiaggregation agents can prevent atherothrombotic events, including TIA and stroke, by inhibiting the formation of intraarterial platelet aggregates. Aspirin (50–325 mg/d) inhibits thromboxane A2, a platelet aggregating and vasoconstricting prostaglandin. Aspirin, clopidogrel (blocks the platelet ADP receptor), and the combination of aspirin plus extended-release dipyridamole (inhibits platelet uptake of adenosine) are the antiplatelet agents most commonly used. In general, antiplatelet agents reduce new stroke events by 25–30%. Every patient who has experienced an atherothrombotic stroke or TIA and has no contraindication should take an antiplatelet agent regularly because the average annual risk of another stroke is 8–10%.

**Embolic Stroke**  In pts with atrial fibrillation, the choice between warfarin or aspirin prophylaxis is determined by age and risk factors; the presence of any risk factor tips the balance in favor of anticoagulation (Table 18-6). Anticoagulation reduces the risk of embolism in acute MI; most clinicians recommend a 3-month course of therapy when there is anterior Q-wave infarction or other complica-
tions. For prosthetic heart valve pts, a combination of aspirin and warfarin may be indicated depending on the type and location of the prosthetic valve.

**Anticoagulation Therapy for Noncardiogenic Stroke** Data do not support the use of long-term warfarin for preventing atherothrombotic stroke for either intracranial or extracranial cerebrovascular disease.

**Surgical Therapy** Carotid endarterectomy benefits many pts with **symptomatic** severe (>70%) **carotid stenosis**; the relative risk reduction is ~65%. However, if the perioperative stroke rate is >6% for any surgeon, the benefit is lost. Endovascular stenting is an emerging option which has thus far been shown to be

### TABLE 18-4  CAUSES OF ISCHEMIC STROKE

<table>
<thead>
<tr>
<th>Common Causes</th>
<th>Uncommon Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombosis</td>
<td>Hypercoagulable disorders</td>
</tr>
<tr>
<td>Lacunar stroke (small vessel)</td>
<td>Protein C deficiency</td>
</tr>
<tr>
<td>Large vessel thrombosis</td>
<td>Protein S deficiency</td>
</tr>
<tr>
<td>Dehydration</td>
<td>Antithrombin III deficiency</td>
</tr>
<tr>
<td>Embolic occlusion</td>
<td>Antiphospholipid syndrome</td>
</tr>
<tr>
<td>Artery-to-artery</td>
<td>Factor V Leiden mutationa</td>
</tr>
<tr>
<td>Carotid bifurcation</td>
<td>Prothrombin G20210 mutationa</td>
</tr>
<tr>
<td>Aortic arch</td>
<td>Systemic malignancy</td>
</tr>
<tr>
<td>Arterial dissection</td>
<td>Sickle cell anemia</td>
</tr>
<tr>
<td>Cardioembolic</td>
<td>ß-Thalassemia</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>Polycythemia vera</td>
</tr>
<tr>
<td>Mural thrombus</td>
<td>Systemic lupus erythematosus</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>Homocysteinemia</td>
</tr>
<tr>
<td>Dilated cardiomyopathy</td>
<td>Thrombotic thrombocytopenic purpura</td>
</tr>
<tr>
<td>Valvular lesions</td>
<td>Disseminated intravascular coagulation</td>
</tr>
<tr>
<td>Mitral stenosis</td>
<td>Dysproteinemias</td>
</tr>
<tr>
<td>Mechanical valve</td>
<td>Nephrotic syndrome</td>
</tr>
<tr>
<td>Bacterial endocarditis</td>
<td>Inflammatory bowel disease</td>
</tr>
<tr>
<td>Paradoxical embolus</td>
<td>Oral contraceptives</td>
</tr>
<tr>
<td>Atrial septal defect</td>
<td>Venous sinus thrombosisb</td>
</tr>
<tr>
<td>Patent foramen ovale</td>
<td>Fibromuscular dysplasia</td>
</tr>
<tr>
<td>Atrial septal aneurysm</td>
<td>Vasculitis</td>
</tr>
<tr>
<td>Spontaneous echo contrast</td>
<td>Systemic vasculitis (PAN, Wegener’s, Takayasu’s, giant cell arteritis)</td>
</tr>
<tr>
<td></td>
<td>Primary CNS vasculitis</td>
</tr>
<tr>
<td></td>
<td>Meningitis (syphilis, tuberculosis, fungal, bacterial, zoster)</td>
</tr>
<tr>
<td>Cardiogenic</td>
<td>Drugs: cocaine, amphetamine</td>
</tr>
<tr>
<td></td>
<td>Moyamoya disease</td>
</tr>
<tr>
<td></td>
<td>Eclampsia</td>
</tr>
</tbody>
</table>

*aChiefly cause venous sinus thrombosis.

bMay be associated with any hypercoagulable disorder.

**Note:** CNS, central nervous system; PAN, polyarteritis nodosa.
Stroke
CHAPTER 18

noninferior to endarterectomy only in very high-risk patients. Surgical results in pts with asymptomatic carotid stenosis are less robust, and medical therapy for reduction of atherosclerosis risk factors plus antiplatelet medications is generally recommended in this group.

### TABLE 18-5 RISK FACTORS FOR STROKE

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Relative Risk</th>
<th>Relative Risk Reduction with Treatment</th>
<th>Number Needed to Treat&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>2–5</td>
<td>38%</td>
<td>100–300</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>1.8–2.9</td>
<td>68% warfarin, 21% aspirin</td>
<td>50–100</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1.8–6</td>
<td>No proven effect</td>
<td>20–83</td>
</tr>
<tr>
<td>Smoking</td>
<td>1.8</td>
<td>50% at 1 year, baseline risk at 5 years post cessation</td>
<td>13</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>1.8–2.6</td>
<td>16–30%</td>
<td>560</td>
</tr>
<tr>
<td>Asymptomatic carotid stenosis</td>
<td>2.0</td>
<td>53%</td>
<td>85</td>
</tr>
<tr>
<td>Symptomatic carotid stenosis (70–99%)</td>
<td></td>
<td>65% at 2 years</td>
<td>N/A</td>
</tr>
<tr>
<td>Symptomatic carotid stenosis (50–69%)</td>
<td></td>
<td>29% at 5 years</td>
<td>77</td>
</tr>
</tbody>
</table>

<sup>a</sup>Number needed to treat to prevent one stroke annually. Prevention of other cardiovascular outcomes is not considered here.

**Note:** N/A, not applicable.

### TABLE 18-6 CONSENSUS RECOMMENDATION FOR ANTITHROMBOTIC PROPHYLAXIS IN ATRIAL FIBRILLATION

<table>
<thead>
<tr>
<th>Age</th>
<th>Risk Factors&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≤65</td>
<td>≥1</td>
<td>Warfarin INR 2–3</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Age 65–75</td>
<td>≥1</td>
<td>Warfarin INR 2–3</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>Warfarin INR 2–3 or aspirin</td>
</tr>
<tr>
<td>Age &gt;75</td>
<td></td>
<td>Warfarin INR 2–3</td>
</tr>
</tbody>
</table>

<sup>a</sup>Risk factors include previous transient ischemic attack or stroke, hypertension, heart failure, diabetes, systemic embolism, mitral stenosis, or prosthetic heart valve.

**Source:** Modified from DE Singer et al: Antithrombotic therapy in atrial fibrillation. Chest 126:429S, 2004; with permission.

For a more detailed discussion, see Smith WS, English JD, Johnston SC: Cerebrovascular Diseases, Chap. 364, p. 2513, in HPIM-17.
Excluding head trauma, most common cause of subarachnoid hemorrhage (SAH) is rupture of an intracranial (saccular) aneurysm; other etiologies include bleeding from a vascular malformation (arteriovenous malformation or dural arterial-venous fistula), infective (mycotic) aneurysms, and extension into the subarachnoid space from a primary intracerebral hemorrhage. Approximately 2% of the population harbor aneurysms, and 25,000–30,000 cases of aneurysmal rupture producing SAH occur each year in the United States; rupture risk for aneurysms ≥10 mm in size is 0.5–1% per year.

Clinical Presentation  Sudden, severe headache, often with transient loss of consciousness at onset; vomiting is common. Bleeding may injure adjacent brain tissue and produce focal neurologic deficits. A progressive third nerve palsy, usually involving the pupil, along with headache suggests posterior communicating artery aneurysm. In addition to dramatic presentations, aneurysms can undergo small ruptures with leaks of blood into the subarachnoid space (sentinel bleeds). The initial clinical manifestations of SAH can be graded using established scales (Table 19-1); prognosis for good outcome falls as the grade increases.

Initial Evaluation  
- Noncontrast CT is the initial study of choice and usually demonstrates the hemorrhage if obtained within 72 h. LP is required for diagnosis of suspected SAH if the CT is nondiagnostic; xanthrochromia of the spinal fluid is seen within 6–12 h after rupture and lasts for 1–4 weeks.
- Cerebral angiography is necessary to localize and define the anatomic details of the aneurysm and to determine if other unruptured aneurysms exist; angiography should be performed as soon as possible after the diagnosis of SAH is made.

<table>
<thead>
<tr>
<th>Grade</th>
<th>Hunt-Hess Scale</th>
<th>World Federation of Neurosurgical Societies (WFNS) Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mild headache, normal mental status, no cranial nerve or motor findings</td>
<td>Glasgow Coma Scale&lt;sup&gt;a&lt;/sup&gt; (GCS) score 15, no motor deficits</td>
</tr>
<tr>
<td>2</td>
<td>Severe headache, normal mental status, may have cranial nerve deficit</td>
<td>GCS 13–14, no motor deficits</td>
</tr>
<tr>
<td>3</td>
<td>Somnolent, confused, may have cranial nerve or mild motor deficit</td>
<td>GCS 13–14, with motor deficits</td>
</tr>
<tr>
<td>4</td>
<td>Stupor, moderate to severe motor deficit, may have intermittent reflex posturing</td>
<td>GCS 7–12, with or without motor deficits</td>
</tr>
<tr>
<td>5</td>
<td>Coma, reflex posturing or flaccid</td>
<td>GCS 3–6, with or without motor deficits</td>
</tr>
</tbody>
</table>

<sup>a</sup>Glasgow Coma Scale: See Fig. 373-2, HPIM 17.
• ECG may reveal ST-segment and T-wave changes similar to those associated with cardiac ischemia; caused by circulating catecholamines and excessive discharge of sympathetic neurons. A reversible cardiomyopathy producing shock or congestive heart failure may result.
• Studies of coagulation and platelet count should be obtained, and rapid correction should ensue if SAH is documented.

Subarachnoid Hemorrhage

Aneurysm Repair
Early aneurysm repair prevents rerupture and allows the safe application of techniques used to improve blood flow should symptomatic vasospasm develop. The International Subarachnoid Aneurysm Trial (ISAT) demonstrated improved outcomes with endovascular therapy compared to surgery; however, some aneurysms have a morphology not amenable to endovascular treatment, and therefore surgery is still an important treatment option.

Medical Management
Closely follow serum electrolytes and osmolality; hyponatremia (“cerebral salt wasting”) frequently develops several days after SAH, and supplemental oral salt plus IV normal saline or hypertonic saline may be used to overcome renal losses. Anticonvulsants may be begun at diagnosis and continued at least until the aneurysm is treated, although some experts reserve this therapy only for patients in whom a seizure has occurred. Blood pressure should be carefully controlled initially, while preserving cerebral blood flow, in order to decrease the risk of rerupture until the aneurysm is repaired. All patients should have pneumatic compression stockings applied to prevent pulmonary embolism; unfractionated heparin administered subcutaneously for DVT prophylaxis can be initiated immediately following endovascular treatment and within days following craniotomy and surgical clipping.

Hydrocephalus
Severe hydrocephalus may require urgent placement of a ventricular catheter for external CSF drainage; some patients will require permanent shunt placement. Deterioration of a SAH patient in the first hours to days should prompt repeat CT scanning to evaluate ventricular size.

Vasospasm
Symptomatic vasospasm is the leading cause of mortality and morbidity following initial rupture; may occur by day 4 and continue through day 14, leading to focal ischemia and possibly stroke. Medical treatment with the calcium channel antagonist nimodipine (60 mg PO every 4 h) improves outcome, probably by preventing ischemic injury rather than reducing the risk of vasospasm. Cerebral perfusion can be improved in symptomatic vasospasm by increasing mean arterial pressure with vasopressor agents such as phenylephrine or norepinephrine, and intravascular volume can be expanded with crystalloid, augmenting cardiac output and reducing blood viscosity by reducing the hematocrit; this so-called “triple-H” (hypertension, hemodilution, and hypervolemic) therapy is widely used. If symptomatic vasospasm persists despite optimal medical therapy, intrarterial vasodilators and angioplasty of the cerebral vessels can be effective.

For a more detailed discussion, see Hemphill JC III and Smith WS: Neurologic Critical Care, Including Hypoxic-Ischemic Encephalopathy and Subarachnoid Hemorrhage. Chap. 269, p. 1720, in HPIM-17.
Increased Intracranial Pressure and Head Trauma

INCREASED INTRACRANIAL PRESSURE

A limited volume of extra tissue, blood, CSF, or edema can be added to the intracranial contents without raising the intracranial pressure (ICP). Clinical deterioration or death may follow increases in ICP that shift intracranial contents, distort vital brainstem centers, or compromise cerebral perfusion. Cerebral perfusion pressure (CPP), defined as the mean arterial pressure (MAP) minus the ICP, is the driving force for circulation across capillary beds of the brain; decreased CPP is a fundamental mechanism of secondary ischemic brain injury and constitutes an emergency that requires immediate attention. In general, ICP should be maintained at $<20$ mmHg and CPP should be maintained at $\geq 60$ mmHg.

Clinical Features Elevated ICP may occur in a wide range of disorders including head trauma, intracerebral hemorrhage, subarachnoid hemorrhage (SAH) with hydrocephalus, and fulminant hepatic failure.

Symptoms of high ICP include drowsiness, headache (especially a constant ache that is worse upon awakening), nausea, emesis, diplopia, and blurred vision. Papilledema and sixth nerve palsies are common. If not controlled, then cerebral hypoperfusion, pupillary dilation, coma, focal neurologic deficits, posturing, abnormal respirations, systemic hypertension, and bradycardia may result.

Masses that cause raised ICP also distort midbrain and diencephalic anatomy, leading to stupor and coma. Brain tissue is pushed away from the mass against fixed intracranial structures and into spaces not normally occupied. Posterior fossa masses, which may initially cause ataxia, stiff neck, and nausea, are especially dangerous because they can both compress vital brainstem structures and cause obstructive hydrocephalus.

Herniation syndromes (Fig. 20-1) include:

- **Uncal**: Medial temporal lobe displaced through the tentorium, compressing the third cranial nerve and pushing the cerebral peduncle against the tentorium, leading to ipsilateral pupillary dilation, contralateral hemiparesis, and posterior cerebral artery occlusion.
- **Central**: Downward displacement of the thalamus through the tentorium; miotic pupils and drowsiness are early signs.
- **Transfalcial**: Cingulate gyrus displaced under the midline falx, leading to anterior cerebral artery occlusion and stroke.
- **Foraminal**: Cerebellar tonsils displaced into the foramen magnum, causing medullary compression and cardiorespiratory collapse.

Increased Intracranial Pressure

A number of different interventions may lower ICP, and ideally the selection of treatment will be based on the underlying mechanism responsible for the elevated ICP (Table 20-1). For example, in hydrocephalus from SAH, the principal cause of elevated ICP is impaired CSF drainage; in this setting, ventricular drainage of CSF is likely to be sufficient. In head trauma and stroke, cytotoxic edema may be most responsible, and the use of osmotic diuretics such as mannitol becomes an appropriate early step. Elevated ICP may cause
tissue ischemia; the resulting vasodilatation can lead to a cycle of worsening ischemia. Paradoxically, administration of vasopressor agents to increase mean arterial pressure may actually lower ICP by increasing perfusion; therefore, hypertension should be treated carefully, if at all. Free water should be restricted, and fever treated aggressively. Hyperventilation is best used for only short periods of time until a more definitive treatment can be instituted. ICP monitoring can be an important tool to guide medical and surgical decisions in selected pts with cerebral edema (Fig. 20-2).

After stabilization and initiation of the above therapies, a CT scan (or MRI, if feasible) is performed to delineate the cause of the elevated ICP. Emergency surgical intervention is sometimes necessary to decompress the intracranial contents. Hydrocephalus, cerebellar stroke with edema, surgically accessible tumor, and subdural or epidural hemorrhage often require lifesaving neurosurgery.

**HEAD TRAUMA**

Almost 10 million head injuries occur annually in the United States, about 20% of which are serious enough to cause brain damage.

**Clinical Features**  Head trauma can cause immediate loss of consciousness. If transient and unaccompanied by other serious brain pathology other than a short period of amnesia, it is called *concussion*. Prolonged alterations in consciousness may be due to parenchymal, subdural, or epidural hematoma or to diffuse shearing of axons in the white matter. Skull fracture should be suspected in pts with CSF rhinorrhea, hemotympanum, and periorbital or mastoid ecchymoses.
TABLE 20-1  
STEPWISE APPROACH TO TREATMENT OF ELEVATED INTRACRANIAL PRESSURE

Insert ICP monitor—ventriculostomy versus parenchymal device  
General goals: maintain ICP < 20 mmHg and CPP ≥ 60 mmHg  
For ICP > 20–25 mmHg for >5 min:  
1. Drain CSF via ventriculostomy (if in place)  
2. Elevate head of the bed; midline head position  
3. Osmotherapy—mannitol 25–100 g q4h as needed (maintain serum osmolality < 320 mosmol) or hypertonic saline (30 mL, 23.4% NaCl bolus)  
4. Glucocorticoids—dexamethasone 4 mg q6h for vasogenic edema from tumor, abscess (avoid glucocorticoids in head trauma, ischemic and hemorrhagic stroke)  
5. Sedation (e.g., morphine, propofol, or midazolam); add neuromuscular paralysis if necessary (patient will require endotracheal intubation and mechanical ventilation at this point, if not before)  
6. Hyperventilation—to PaCO₂ 30–35 mmHg  
7. Pressor therapy—phenylephrine, dopamine, or norepinephrine to maintain adequate MAP to ensure CPP ≥ 60 mmHg (maintain euvolemia to minimize deleterious systemic effects of pressors)  
8. Consider second-tier therapies for refractory elevated ICP  
   a. High-dose barbiturate therapy (“pentobarb coma”)  
   b. Aggressive hyperventilation to PaCO₂ < 30 mmHg  
   c. Hypothermia  
   d. Hemicraniectomy  

Throughout ICP treatment algorithm, consider repeat head CT to identify mass lesions amenable to surgical evacuation.  

Note: CPP, cerebral perfusion pressure; CSF, cerebrospinal fluid; MAP, mean arterial pressure; PaCO₂, arterial partial pressure of carbon dioxide.

FIGURE 20-2  
Intracranial pressure and brain tissue oxygen monitoring. A ventriculostomy allows for drainage of cerebrospinal fluid to treat elevated intracranial pressure (ICP). Fiberoptic ICP and brain tissue oxygen monitors are usually secured using a screwlike skull bolt. Cerebral blood flow and microdialysis probes (not shown) may be placed in a manner similar to the brain tissue oxygen probe.
Medical personnel caring for head injury patients should be aware that:

- Spinal injury often accompanies head injury and care must be taken to prevent compression of the spinal cord due to instability of the spinal column.
- Intoxication is a frequent accompaniment of traumatic brain injury and, when appropriate, testing should be carried out for drugs and alcohol.
- Accompanying systemic injuries, including ruptures of abdominal organs, may produce vascular collapse or respiratory compromise requiring immediate attention.

**Minor Concussive Injury**  The pt with minor head injury who is alert and attentive after a short period of unconsciousness (<1 min) may have headache, dizziness, faintness, nausea, a single episode of emesis, difficulty with concentration, or slight blurring of vision. Such patients have usually sustained a concussion and are expected to have a brief amnestic period. After several hours of observation, pts with this category of injury can be accompanied home and observed for a day by family or friends. Persistent severe headache and repeated vomiting are usually benign if the neurologic exam remains normal, but in such situations radiologic studies should be obtained and hospitalization is justified.

Older age, two or more episodes of vomiting, >30 min of retrograde or persistent anterograde amnesia, seizure, and concurrent drug or alcohol intoxication are sensitive (but not specific) indicators of intracranial hemorrhage that justify CT scanning; it is appropriate to be more liberal in obtaining CT scans in children.

**Injury of Intermediate Severity**  Pts who are not comatose but who have persistent confusion, behavioral changes, subnormal alertness, extreme dizziness, or focal neurologic signs such as hemiparesis should be admitted to the hospital and soon thereafter have a CT scan. Usually a cerebral contusion or subdural hematoma is found. Pts with intermediate head injury require medical observation to detect increasing drowsiness, respiratory dysfunction, and pupillary enlargement or other changes in the neurologic exam. Abnormalities of attention, intellect, spontaneity, and memory tend to return to normal weeks or months after the injury, although some cognitive deficits may be persistent.

**Severe Injury**  Patients who are comatose from onset require immediate neurologic attention and often resuscitation. After intubation (with care taken to avoid deforming the cervical spine), the depth of coma, pupillary size and reactivity, limb movements, and Babinski responses are assessed. As soon as vital functions permit and cervical spine x-rays and a CT scan have been obtained, the pt should be transported to a critical care unit. CT scan may be normal in comatose pts with axonal shearing lesions in cerebral white matter.

The finding of an epidural or subdural hematoma or large intracerebral hemorrhage requires prompt decompressive surgery in otherwise salvageable pts. Subsequent treatment is probably best guided by direct measurement of ICP. All potentially exacerbating factors should be eliminated; hypoxia, hyperthermia, hypercarbia, awkward head positions, and high mean airway pressures from mechanical ventilation all increase ICP. Persistently raised ICP after treatment of these factors generally indicates a poor outcome. The use of prophylactic anticonvulsants has been recommended by some neurosurgeons but there are few supportive data.
Spinal Cord Compression

APPROACH TO THE PATIENT: SPINAL CORD INJURY

The initial symptoms of spinal cord injury, focal neck or back pain, evolve over days to weeks. These are followed by various combinations of paresthesias, sensory loss, motor weakness, and sphincter disturbance evolving over hours to several days. Partial lesions may selectively involve one or more tracts and may be limited to one side of the cord. In severe or abrupt cases, areflexia reflecting spinal shock may be present, but hyperreflexia supervenes over days to weeks. A sensory level to pain may be present on the trunk, indicating localization to the cord at that dermatomal level.

The first priority is to exclude a treatable compression of the spinal cord by a mass. Compressive disease is more likely to be preceded by warning signs of neck or back pain, bladder disturbances, and sensory symptoms prior to development of weakness; noncompressive etiologies such as infarction and hemorrhage are more likely to produce myelopathy without antecedent symptoms.

MRI with gadolinium, centered on the clinically suspected level, is the initial diagnostic procedure (CT myelography may be helpful in patients who have contraindications to MRI). It may be useful to image the entire spine to search for additional clinically silent lesions. Infectious etiologies, unlike tumor, often cross the disc space to involve adjacent vertebral bodies.

NEOPLASTIC SPINAL CORD COMPRESSION

Occurs in 5–10% of pts with cancer and is the first manifestation of malignancy in about 10% of these pts. Most neoplasms are epidural in origin, resulting from metastases to the adjacent spinal bones. Almost any malignant tumor can metastasize to the spinal column with breast, lung, prostate, kidney, lymphoma, and plasma cell dyscrasia being particularly frequent. The thoracic cord is most commonly involved; exceptions include prostate and ovarian tumors, which preferentially involve the lumbar and sacral segments from spread through veins in the anterior epidural space. The most common presenting symptom is localized back pain and tenderness followed by symptoms of neurologic compromise. Urgent MRI is indicated when the diagnosis is suspected; up to 40% of patients with neoplastic cord compression at one level are found to have asymptomatic epidural disease elsewhere, so the entire spine should be imaged.
Neoplastic Spinal Cord Compression

Management includes glucocorticoids to reduce edema (dexamethasone, up to 40 mg daily), local radiotherapy (initiated as soon as possible), and specific therapy for the underlying tumor type. Glucocorticoids can be administered before the imaging study if the clinical suspicion is high, and continued at a lower dose until radiotherapy (generally 3000 cGy administered in 15 daily fractions) is completed. Biopsy is needed if there is no history of underlying malignancy; a simple workup including chest imaging, mammography, measurement of prostate-specific antigen (PSA), and abdominal CT may reveal the diagnosis. Radiotherapy appears to be as effective as surgical treatments. Surgery, either decompression by laminectomy or vertebral body resection, should be considered when signs of cord compression worsen despite radiotherapy, when the maximum tolerated dose of radiotherapy has been delivered previously to the site, or when a vertebral compression fracture or spinal instability contributes to cord compression. Time is of the essence in treatment; fixed motor deficits (paraplegia or quadriplegia) once established for >12 h do not usually improve, and beyond 48 h the prognosis for substantial motor recovery is poor; those who start treatment while ambulatory, usually (75%) remain so.

SPINAL EPIDURAL ABSCESS

Presents as a triad of pain, fever, and progressive limb weakness. Aching pain is almost always present, either over the spine or in a radicular pattern. The duration of pain prior to presentation is generally <2 weeks but may be several months or longer. Fever is usually present along with elevated white blood cell count and sedimentation rate. Risk factors include an impaired immune status (diabetes mellitus, HIV, renal failure, alcoholism, malignancy), intravenous drug abuse, and infections of the skin or other soft tissues. Most cases are due to Staphylococcus aureus; other important causes include gram-negative bacilli, Streptococcus, anaerobes, fungi, and tuberculosis (Pott’s disease).

MRI localizes the abscess. Lumbar puncture (LP) is only required if encephalopathy or other clinical signs raise the question of associated meningitis, a feature found in <25% of cases. The level of the LP should be planned to minimize risk of meningitis due to passage of the needle through infected tissue.

Spinal Epidural Abscess

Decompressive laminectomy with debridement combined with long-term antibiotic treatment. Surgical evacuation is unlikely to improve deficits of more than several days’ duration. Antibiotics should be started empirically before surgery and then modified on the basis of culture results and continued for at least 4 weeks.

SPINAL EPIDURAL HEMATOMA

Hemorrhage into the epidural (or subdural) space causes acute focal or radicular pain followed by variable signs of a spinal cord disorder. Therapeutic anticoagulation, trauma, tumor, or blood dyscrasia are predisposing conditions; rarely complication of LP or epidural anesthesia. Treatment consists of prompt reversal of any underlying bleeding disorder and surgical decompression.
HEMATOMYELIA

Hemorrhage into the substance of the spinal cord is a rare result of trauma, vasculitis, bleeding disorders, spinal cord neoplasm, or intraparenchymal vascular malformation. Usually presents as a painful myelopathy. Diagnosis is by MRI or CT. Therapy is supportive, and surgical intervention is generally not useful; an exception is hematomyelia due to an underlying vascular malformation, for which selective spinal angiography may be indicated, followed by surgery to evacuate the thrombus and remove the underlying vascular lesion.


Hypoxic-Ischemic Encephalopathy

Results from lack of delivery of oxygen to the brain because of hypotension or respiratory failure. Most common causes are MI, cardiac arrest, shock, asphyxiation, paralysis of respiration, and carbon monoxide or cyanide poisoning. In some circumstances, hypoxia may predominate. Carbon monoxide and cyanide poisoning are termed histotoxic hypoxia since they cause a direct impairment of the respiratory chain.

CLINICAL MANIFESTATIONS

Mild degrees of pure hypoxia (e.g., high altitude) cause impaired judgment, inattentiveness, motor incoordination, and, at times, euphoria. However, with hypoxia-ischemia, such as occurs with circulatory arrest, consciousness is lost within seconds. If circulation is restored within 3–5 min, full recovery may occur, but with longer periods permanent cerebral damage is the rule. It may be difficult to judge the precise degree of hypoxia-ischemia, and some pts make a relatively full recovery even after 8–10 min of global ischemia. The distinction between pure hypoxia and hypoxia-ischemia is important, since a PaO$_2$ as low as 2.7 kPa (20 mmHg) can be well tolerated if it develops gradually and normal blood pressure is maintained, but short periods of very low or absent cerebral circulation may result in permanent impairment.

Clinical examination at different time points after an insult (especially cardiac arrest) helps to assess prognosis (Fig. 22-1). The prognosis is better for pts with intact brainstem function, as indicated by normal pupillary light responses, intact oculocephalic (doll’s eyes) reflexes, and oculovestibular (caloric) and corneal reflexes (Chap. 18). Absence of these reflexes and the presence of persistently dilated pupils that do not react to light are grave prognostic signs. A uniformly dismal prognosis is conveyed by the absence of pupillary light reflex or absence of a motor response to pain on day 3 following the injury. Bilateral absence of the cortical somatosensory evoked potentials (SSEP) in the first sev-
eral days also conveys a poor prognosis, as does a very elevated serum level (>33 μg/L) of the biochemical marker neuron-specific enolase (NSE); currently these two ancillary tests are limited by the ability to obtain them in a timely fashion along with the need for expert interpretation (SSEP) and lack of standardization in laboratory methods (NSE measurements).

Long-term consequences include persistent coma or vegetative state, dementia, visual agnosia, parkinsonism, choreoathetosis, ataxia, myoclonus, seizures, and an amnestic state. Delayed postanoxic encephalopathy is an uncommon phenomenon where patients appear to make an initial recovery following an insult and then have a relapse with a progressive course often characterized by widespread demeylination on imaging studies.

**FIGURE 22-1** Prognostication of outcome in comatose survivors of cardiopulmonary resuscitation. Numbers in parentheses are 95% confidence intervals. Confounders could include use of sedatives or neuromuscular blocking agents, hypothermia therapy, organ failure, or shock. Tests denoted with an * may not be available in a timely and standardized manner. SSEP, somatosensory evoked potentials; NSE, neuron-specific enolase; FPR, false-positive rate. [From EFM Wijdicks et al: Practice parameter: Prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review). Neurology 67:203, 2006; with permission.]
Hypoxic-Ischemic Encephalopathy

- Initial treatment is directed at restoring normal cardiorespiratory function. This includes securing a clear airway, ensuring adequate oxygenation and ventilation, and restoring cerebral perfusion, whether by cardiopulmonary resuscitation, fluids, pressors, or cardiac pacing.
- Mild hypothermia (33°C), initiated as early as possible and continued for 12–24 h, may improve outcome in pts who remain comatose after cardiac arrest, based on trials in pts whose initial rhythm was primarily ventricular fibrillation or pulseless ventricular tachycardia. Potential complications include coagulopathy and an increased risk of infection.
- Anticonvulsants are not usually given prophylactically but may be used to control seizures.
- Myoclonic status epilepticus after a hypoxic-ischemic insult portends a universally poor prognosis, even if seizures are controlled.
- Severe carbon monoxide intoxication may be treated with hyperbaric oxygen.
- Posthypoxic myoclonus can be controlled with clonazepam (1.5–10 mg/d) or valproate (300–1200 mg/d) in divided doses.

For a more detailed discussion, see Hemphill JC Smith WS: Neurologic Critical Care, Including Hypoxic-Ischemic Encephalopathy and Subarachnoid Hemorrhage, Chap. 269, p. 1720, in HPIM-17.

Status Epilepticus

Defined as continuous seizures or repetitive, discrete seizures with impaired consciousness in the interictal period. The duration of seizure activity to meet the definition has traditionally been 15–30 min. A more practical definition is any situation requiring the acute use of anticonvulsants; in generalized convulsive status epilepticus (GCSE), this is typically when seizures last >5 min.

CLINICAL FEATURES

Has numerous subtypes: GCSE (e.g., persistent, generalized electrographic seizures, coma, and tonic-clonic movements), and nonconvulsive status epilepticus (e.g., persistent absence seizures or partial seizures, confusion, or partially impaired consciousness, and minimal motor abnormalities). GCSE is obvious when overt convulsions are present, but after 30–45 min of uninterrupted seizures, the signs may become increasingly subtle (mild clonic movements of the fingers; fine, rapid movements of the eyes; or paroxysmal episodes of tachycardia, pupillary dilatation, and hypertension). EEG may be the only method of diagnosis with these subtle signs; therefore, if a patient remains comatose after a seizure, EEG should be performed to exclude ongoing status epilepticus. GCSE is life-threatening when accompanied by hyperpyrexia, acidosis (from prolonged muscle activity), respiratory or cardiovascular compromise. Irreversible
neuronal injury may occur from persistent seizures, even when pt is paralyzed from neuromuscular blockade.

**ETIOLOGY**

Principal causes of GCSE are antiepileptic drug withdrawal or noncompliance, metabolic disturbances, drug toxicity, CNS infections, CNS tumors, refractory epilepsy, and head trauma.

GCSE is a medical emergency. First attend to any acute cardiorespiratory problems or hyperthermia, perform a brief medical and neurologic exam, establish venous access, and send lab studies to screen for metabolic abnormalities including anticonvulsant levels if pt has a history of epilepsy. Anticonvulsant therapy should then begin without delay (Fig. 23-1). In parallel, it is essential to determine the cause of the seizures to prevent recurrence and treat any underlying abnormalities.

The treatment of nonconvulsive status epilepticus is somewhat less urgent since the ongoing seizures are not accompanied by the severe metabolic disturbances of GCSE; however, evidence points to local cellular injury in the region of the seizure focus, so the condition should be treated as promptly as possible using the general approach for GCSE.

---

**FIGURE 23-1** Pharmacologic treatment of generalized tonic-clonic status epilepticus in adults. The horizontal bars indicate the approximate duration of drug infusions. IV, intravenous; PE, phenytoin equivalents.
PROGNOSIS

The mortality rate is 20% in GCSE, and the incidence of permanent neurologic sequelae is 10–30%.

For a more detailed discussion, see Lowenstein DH: Seizures and Epilepsy, Chap. 363, p. 2498, in HPIM-17.

Diabetic Ketoacidosis and Hyperosmolar Coma

Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) are acute complications of diabetes mellitus (DM). DKA is seen primarily in individuals with type 1 DM and HHS in individuals with type 2 DM. Both disorders are associated with absolute or relative insulin deficiency, volume depletion, and altered mental status. The metabolic similarities and differences in DKA and HHS are summarized in Table 24-1.

**DIABETIC KETOACIDOSIS**

**Etiology**  DKA results from insulin deficiency with a relative or absolute increase in glucagon and may be caused by inadequate insulin administration, infection

**TABLE 24-1**  LABORATORY VALUES IN DIABETIC KETOACIDOSIS (DKA) AND HYPERGLYCEMIC HYPEROSMOLAR STATE (HHS) (REPRESENTATIVE RANGES AT PRESENTATION)

<table>
<thead>
<tr>
<th></th>
<th>DKA</th>
<th>HHS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose, mmol/L (mg/dL)</td>
<td>13.9–33.3 (250–600)</td>
<td>33.3–66.6 (600–1200)</td>
</tr>
<tr>
<td>Sodium, meq/L</td>
<td>125–135</td>
<td>135–145</td>
</tr>
<tr>
<td>Potassium, meq/L</td>
<td>Normal to ↑</td>
<td>Normal</td>
</tr>
<tr>
<td>Magnesium a</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Chloride a</td>
<td>↓</td>
<td></td>
</tr>
<tr>
<td>Phosphate a</td>
<td>Slightly ↑</td>
<td>Moderately ↑</td>
</tr>
<tr>
<td>Creatinine, µmol/L (mg/dL)</td>
<td>300–320</td>
<td>330–380</td>
</tr>
<tr>
<td>Osmolality (mOsm/mL)</td>
<td>++++</td>
<td>±</td>
</tr>
<tr>
<td>Plasma ketones a</td>
<td>&lt;15 meq/L</td>
<td>Normal to slightly ↓</td>
</tr>
<tr>
<td>Arterial pH</td>
<td>6.8–7.3</td>
<td>&gt;7.3</td>
</tr>
<tr>
<td>Arterial P&lt;sub&gt;CO2&lt;/sub&gt;, mmHg</td>
<td>20–30</td>
<td>Normal</td>
</tr>
<tr>
<td>Anion gap a [Na – (Cl + HCO₃⁻)], meq/L</td>
<td>↑</td>
<td>Normal to slightly ↑</td>
</tr>
</tbody>
</table>

aLarge changes occur during treatment of DKA.

bAlthough plasma levels may be normal or high at presentation, total-body stores are usually depleted.
Diabetic Ketoacidosis and Hyperosmolar Coma

CHAPTER 24

Clinical Features

The initial symptoms of DKA include anorexia, nausea, vomiting, polyuria, and thirst. Abdominal pain, altered mental function, or frank coma may ensue. Classic signs of DKA include Kussmaul respirations and an acetone odor on the pt’s breath. Volume depletion can lead to dry mucous membranes, tachycardia, and hypotension. Fever and abdominal tenderness may also be present. Laboratory evaluation reveals hyperglycemia, ketosis (β-hydroxybutyrate > acetoacetate), and metabolic acidosis (arterial pH 6.8–7.3) with an increased anion gap (Table 24-1). The fluid deficit is often 3–5 L. Despite a total-body potassium deficit, the serum potassium at presentation may be normal or mildly high as a result of acidosis. Leukocytosis, hypertriglyceridemia, and hyperlipoproteinemia are common. Hyperamylasemia is usually of salivary origin but may suggest a diagnosis of pancreatitis. The measured serum sodium is reduced as a consequence of hyperglycemia [1.6-meq reduction for each 5.6-mmol/L (100-mg/dL) rise in the serum glucose].

The management of DKA is outlined in Table 24-2.

Hyperglycemic Hyperosmolar State

Etiology

Relative insulin deficiency and inadequate fluid intake are the underlying causes of HHS. Hyperglycemia induces an osmotic diuresis that leads to profound intravascular volume depletion. HHS is often precipitated by a serious, concurrent illness such as myocardial infarction or sepsis and compounded by conditions that impede access to water.

Clinical Features

Presenting symptoms include polyuria, thirst, and altered mental state, ranging from lethargy to coma. Notably absent are symptoms of nausea, vomiting, and abdominal pain and the Kussmaul respirations characteristic of DKA. The prototypical pt is an elderly individual with a several week history of polyuria, weight loss, and diminished oral intake. The laboratory features are summarized in Table 24-1. In contrast to DKA, acidosis and ketonemia are usually not found; however, a small anion gap may be due to lactic acidosis, and moderate ketonuria may occur from starvation. Though the measured serum sodium may be normal or slightly low, the corrected serum sodium is usually increased [add 1.6 meq to measured sodium for each 5.6-mmol/L (100-mg/dL) rise in the serum glucose].

The precipitating problem should be sought and treated. Sufficient IV fluids (1–3 L of 0.9% normal saline over the first 2–3 h) must be given to stabilize the hemodynamic status. The calculated free water deficit (usually 9–10 L) should be reversed over the next 1–2 days, using 0.45% saline initially then 5% dextrose in water. Potassium repletion is usually necessary. The plasma glucose may drop precipitously with hydration alone, though insulin therapy with an IV bolus of 0.1 units/kg followed by a constant infusion rate (0.1 units/kg per hour) is usually required. If the serum glucose does not fall, the insulin infusion rate should be doubled. Glucose should be added to IV fluid.
and the insulin infusion rate decreased when the plasma glucose falls to 13.9 mmol/L (250 mg/dL). The insulin infusion should be continued until the patient has resumed eating and can be transitioned to a subcutaneous insulin regimen.

For a more detailed discussion, see Powers AC: Diabetes Mellitus, Chap. 338, p. 2275, in HPIM-17.
Glucose is an obligate metabolic fuel for the brain. Hypoglycemia should be considered in any patient with confusion, altered level of consciousness, or seizures. Counterregulatory responses to hypoglycemia include insulin suppression and the release of catecholamines, glucagon, growth hormone, and cortisol.

The laboratory diagnosis of hypoglycemia is usually defined as a plasma glucose level <2.5–2.8 mmol/L (<45–50 mg/dL), although the absolute glucose level at which symptoms occur varies among individuals. For this reason, Whipple’s triad should be present: (1) symptoms consistent with hypoglycemia, (2) a low plasma glucose concentration measured by precise method (not a glucose monitor), and (3) relief of symptoms after the plasma glucose level is raised.

**ETIOLOGY**

Hypoglycemia occurs most commonly as a result of treating patients with diabetes mellitus. Additional factors to be considered in any pt with hypoglycemia are listed below.

1. **Drugs:** insulin, insulin secretagogues (especially chlorpropamide, repaglinide, nateglinide), alcohol, high doses of salicylates, sulfonamides, pentamidine, quinine, quinolones
2. **Critical illness:** hepatic, renal, or cardiac failure; sepsis; prolonged starvation
3. **Hormone deficiencies:** adrenal insufficiency, hypopituitarism
4. **Insulinoma:** pancreatic β cell tumor, β cell hyperplasia (a.k.a. nesidioblastosis; congenital or after gastric or bariatric surgery)
5. **Other rare etiologies:** Non-β cell tumors (large mesenchymal or epithelial tumors producing IGF-II, other non-pancreatic tumors), insulin or insulin receptor antibodies, inherited enzymatic defects

**CLINICAL FEATURES**

Symptoms of hypoglycemia can be divided into autonomic (adrenergic: palpitations, tremor, and anxiety; cholinergic: sweating, hunger, and paresthesia) and neuroglycopenic (behavioral changes, confusion, fatigue, seizure, loss of consciousness, and, if hypoglycemia is severe and prolonged, death). Tachycardia, elevated systolic blood pressure, pallor, and diaphoresis may be present on physical examination.

Recurrent hypoglycemia shifts thresholds for the autonomic symptoms and counterregulatory responses to lower glucose levels, leading to hypoglycemic unawareness. Under these circumstances, the first manifestation of hypoglycemia is neuroglycopenia, placing patients at risk of being unable to treat themselves.

**DIAGNOSIS**

Diagnosis of the hypoglycemic mechanism is critical for choosing a treatment that prevents recurrent hypoglycemia (Fig. 25-1). Urgent treatment is often necessary in patients with suspected hypoglycemia. Nevertheless, blood should be drawn at the time of symptoms, whenever possible before the administration of glucose, to allow documentation of the glucose level. If the glucose level is low and the cause of hypoglycemia is unknown, additional assays should be
Medical Emergencies

SECTION 2

performed on blood obtained at the time of a low plasma glucose. These should include insulin, C-peptide, sulfonylurea levels, cortisol, and ethanol. In the absence of documented spontaneous hypoglycemia, overnight fasting or food deprivation during observation in the outpatient setting will sometimes elicit hypoglycemia and allow diagnostic evaluation. An extended (up to 72 h) fast under careful supervision in the hospital may otherwise be required—the test should be terminated if plasma glucose drops below 2.5 mmol/L (45 mg/dL) and the patient has symptoms.

Interpretation of fasting test results is shown in Table 25-1.

**Hypoglycemia**

The syndrome of hypoglycemic unawareness in patients with diabetes mellitus is reversible after as little as 2 weeks of scrupulous avoidance of hypoglycemia. This involves a shift of glycemic thresholds back to higher glucose concentrations.
CHAPTER 26

Acute therapy of hypoglycemia requires administration of oral glucose or 25 g of a 50% solution IV followed by a constant infusion of 5 or 10% dextrose if parenteral therapy is necessary. Hypoglycemia from sulfonylureas is often prolonged, requiring treatment and monitoring for 24 h or more. Subcutaneous or intramuscular glucagon can be used in diabetics. Prevention of recurrent hypoglycemia requires treatment of the underlying cause of hypoglycemia, including discontinuation or dose reduction of offending drugs, treatment of critical illnesses, replacement of hormonal deficiencies, and surgery of insulinomas or other tumors. Treatment of other forms of hypoglycemia is dietary, with avoidance of fasting and ingestion of frequent small meals.

For a more detailed discussion, see Cryer PE: Hypoglycemia, Chap. 339, p. 2305, in HPIM-17.

Infectious Disease Emergencies

GENERAL CONSIDERATIONS

- Acutely ill infected febrile pts requiring emergent attention must be appropriately evaluated and treated at presentation to improve outcome. A quick assessment of general appearance provides a subjective sense of whether the pt is septic or toxic.
- **History**: The physician should assess:
  
  - Onset and duration of symptoms, changes in severity or rate of progression over time
  - Host factors (e.g., alcoholism, IV drug use) and comorbid conditions (e.g., asplenia, diabetes)
  - Potential nidus for invasive infection (e.g., URI or influenza, trauma, burn, foreign body)
Exposure history (e.g., travel, pets, diet, medication use, vaccination history, sick contacts, menstruation history, sexual contacts)

- **Physical examination**
  - General appearance (e.g., agitation or lethargy, vital signs)
  - Special attention to skin and soft tissue exam, neurologic examination, assessment of mental status

- **Diagnostic workup**
  - Bloodwork: cultures, CBC with differential, electrolytes, BUN, creatinine, LFTs, blood smear examination, buffy coat
  - CSF cultures if meningitis is possible. With focal neurologic signs, papilledema, or abnormal mental status, obtain blood cultures, begin antibiotics, perform brain imaging, and then consider LP.
  - CT or MRI to evaluate focal abscesses; cultures of wounds or scraping of skin lesions as indicated. No diagnostic procedure should delay treatment for more than minutes.

- **Treatment**
  - See Table 26-1. Adjunctive therapy (e.g., glucocorticoids or IV immunoglobulin) can decrease morbidity and mortality rates. Dexamethasone for bacterial meningitis must be given before or with the first dose of antibiotic. Urgent surgical attention may be indicated.

**SPECIFIC PRESENTATIONS** (Table 26-1)

**Sepsis without an Obvious Focus of Primary Infection**

1. Septic shock: primary site may not be identified initially; bacteremia and shock are evident.
2. Overwhelming infection in asplenic pts
   a. The risk of severe sepsis remains increased throughout life, but 50–70% of cases occur in the first 2 years after splenectomy.
   b. *Streptococcus pneumoniae* is the most common etiologic agent, with mortality rates up to 80%.
3. Babesiosis: history of travel to endemic areas, tick bite 1–4 weeks previously
   a. *Babesia divergens* are risk factors for severe disease.
   b. *Babesia microti* is transmitted by the *Ixodes scapularis* tick, which also transmits *Borrelia burgdorferi* (Lyme disease) and ehrlichiae. Co-infections can result in more severe disease.
   c. Nonspecific symptoms can progress to hemolysis, jaundice, and renal and respiratory failure.
4. Tularemia and plague can produce typhoidal or septic syndromes with mortality rates ~30%.

**Sepsis with Skin Manifestations**

1. Maculopapular rashes: usually not emergent but can occur in early meningococcemia or rickettsial disease
2. Petechiae
   a. Meningococcemia: young children and their household contacts are at greatest risk; outbreaks occur in schools and army barracks. Serogroup A meningococcal disease is endemic in sub-Saharan Africa; epidemic outbreaks occur every 8–12 years.
   - Headache, nausea, myalgias, altered mental status, meningismus
   - Petechiae begin at ankles, wrists, axillae, and mucosal surfaces and progress to purpura and DIC.
<table>
<thead>
<tr>
<th>Clinical Syndrome</th>
<th>Possible Etiologies</th>
<th>Treatment</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sepsis without a Clear Focus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Septic shock</td>
<td><em>Pseudomonas</em> spp., gram-negative enteric bacilli, <em>Staphylococcus</em> spp., <em>Streptococcus</em> spp.</td>
<td>Vancomycin (1 g q12h) <strong>plus</strong> Gentamicin (5 mg/kg per day) <strong>plus either</strong> Piperacillin/tazobactam (3.375 g q4h) <strong>or</strong> Cefepime (2 g q12h)</td>
<td>Adjust treatment when culture data become available. Drotrecogin alfa (activated) or low-dose hydrocortisone and fludrocortisone may improve outcome in patients with septic shock.</td>
</tr>
<tr>
<td>Overwhelming post-splenectomy sepsis</td>
<td><em>Streptococcus pneumoniae</em>, <em>Haemophilus influenzae</em>, <em>Neisseria meningitidis</em></td>
<td>Ceftriaxone (2 g q12h) <strong>plus</strong> Vancomycin (1 g q12h)</td>
<td>If a β-lactam–sensitive strain is identified, vancomycin can be discontinued.</td>
</tr>
<tr>
<td>Babesiosis</td>
<td><em>Babesia microti</em> (U.S.), <em>B. divergens</em> (Europe)</td>
<td>Either: Clindamycin (600 mg tid) <strong>plus</strong> Quinine (650 mg tid) <strong>or</strong> Atovaquone (750 mg q12h) <strong>plus</strong> Azithromycin (500-mg loading dose, then 250 mg/d)</td>
<td>Atovaquone and azithromycin are as effective as clindamycin and quinine and are associated with fewer side effects. Treatment with doxycycline (100 mg bid) for potential co-infection with <em>Borrelia burgdorferi</em> or <em>Ehrlichia</em> spp. may be prudent.</td>
</tr>
<tr>
<td>Sepsis with Skin Findings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcemia</td>
<td><em>N. meningitidis</em></td>
<td>Penicillin (4 mU q4h) <strong>or</strong> Ceftriaxone (2 g q12h)</td>
<td>Consider protein C replacement in fulminant meningococcemia.</td>
</tr>
<tr>
<td>Clinical Syndrome</td>
<td>Possible Etiologies</td>
<td>Treatment</td>
<td>Comments</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>-----------------------------------</td>
<td>----------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Rocky Mountain spotted fever (RMSF)</td>
<td><em>Rickettsia rickettsii</em></td>
<td>Doxycycline (100 mg bid)</td>
<td>If both meningococcemia and RMSF are being considered, use chloramphenicol alone (50–75 mg/kg per day in four divided doses) or ceftriaxone (2 g q12h) plus doxycycline (100 mg bid) If RMSF is diagnosed, doxycycline is the proven superior agent.</td>
</tr>
<tr>
<td>Purpura fulminans</td>
<td><em>S. pneumoniae, H. influenzae, N. meningitidis</em></td>
<td>Ceftriaxone (2 g q12h) plus Vancomycin (1 g q12h)</td>
<td>If a β-lactam–sensitive strain is identified, vancomycin can be discontinued. If a penicillin- or oxacillin-sensitive strain is isolated, those agents are superior to vancomycin (penicillin, 2 mU q4h; or oxacillin, 2 g q4h). The site of toxigenic bacteria should be debrided; IV immunoglobulin can be used in severe cases.</td>
</tr>
<tr>
<td>Erythoderma: toxic shock syndrome</td>
<td>Group A <em>Streptococcus, Staphylococcus aureus</em></td>
<td>Vancomycin (1 g q12h) plus Clindamycin (600 mg q8h)</td>
<td>Urgent surgical evaluation is critical. If community-acquired meticillin-resistant <em>S. aureus</em> is a concern, vancomycin (1 g q12h) can be substituted for penicillin while culture data are pending.</td>
</tr>
<tr>
<td>Sepsis with Soft Tissue Findings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Necrotizing fasciitis</td>
<td>Group A <em>Streptococcus</em>, mixed aerobic/anaerobic flora</td>
<td>Penicillin (2 mU q4h) plus Clindamycin (600 mg q8h) plus Gentamicin (5 mg/kg per day)</td>
<td>Urgent surgical evaluation is critical. If community-acquired meticillin-resistant <em>S. aureus</em> is a concern, vancomycin (1 g q12h) can be substituted for penicillin while culture data are pending.</td>
</tr>
<tr>
<td>Clostridial myonecrosis</td>
<td><em>Clostridium perfringens</em></td>
<td>Penicillin (2 mU q4h) plus Clindamycin (600 mg q8h)</td>
<td></td>
</tr>
<tr>
<td>Neurologic Infections</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacterial meningitis</td>
<td><em>S. pneumoniae, N. meningitidis</em></td>
<td>Ceftriaxone (2 g q12h) plus Vancomycin (1 g q12h)</td>
<td>If a β-lactam–sensitive strain is identified, vancomycin can be discontinued. If the patient is &gt;50 years old or has comorbid disease, add ampicillin (2 g q4h) for <em>Listeria</em> coverage. Dexamethasone (10 mg q6h × 4 days) improves outcome in adult patients with meningitis (especially pneumococcal) and cloudy CSF, positive CSF Gram’s stain, or a CSF leukocyte count &gt;1000/μL.</td>
</tr>
<tr>
<td>Condition</td>
<td>Pathogens</td>
<td>Treatments</td>
<td>Notes</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Brain abscess, suppurative intracranial infections</strong></td>
<td><em>Streptococcus</em> spp., <em>Staphylococcus</em> spp., anaerobes, gram-negative bacilli</td>
<td>Vancomycin (1 g q12h) plus Metronidazole (500 mg q8h) plus Ceftriaxone (2 g q12h)</td>
<td>Urgent surgical evaluation is critical. If a penicillin- or oxacillin-sensitive strain is isolated, those agents are superior to vancomycin (penicillin, 4 mU q4h; or oxacillin, 2 g q4h).</td>
</tr>
<tr>
<td><strong>Cerebral malaria</strong></td>
<td><em>Plasmodium falciparum</em></td>
<td>Quinine (650 mg tid) plus Tetracycline (250 mg tid)</td>
<td>Do not use glucocorticoids.</td>
</tr>
<tr>
<td><strong>Spinal epidural abscess</strong></td>
<td><em>Staphylococcus</em> spp., gram-negative bacilli</td>
<td>Vancomycin (1 g q12h) plus Ceftriaxone (2 g q24h)</td>
<td>Surgical evaluation is essential. If a penicillin- or oxacillin-sensitive strain is isolated, those agents are superior to vancomycin (penicillin, 4 mU q4h; or oxacillin, 2 g q4h).</td>
</tr>
</tbody>
</table>

**Focal Infections**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Pathogens</th>
<th>Treatments</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute bacterial endocarditis</strong></td>
<td><em>S. aureus</em>, β-hemolytic streptococci, HACEK group, <em>Neisseria</em> spp., <em>S. pneumoniae</em></td>
<td>Ceftriaxone (2 g q12h) plus Vancomycin (1 g q12h)</td>
<td>Adjust treatment when culture data become available. Surgical evaluation is essential.</td>
</tr>
</tbody>
</table>

---

*a* Drotrecogin alfa (activated) is administered at a dose of 24 μg/kg per hour for 96 h. It has been approved for use in patients with severe sepsis and a high risk of death as defined by an Acute Physiology and Chronic Health Evaluation II (APACHE II) score of ≥25 and/or multiorgan failure.

*b* Hydrocortisone (50-mg IV bolus q6h) with fludrocortisone (50-μg tablet daily for 7 days) may improve outcomes of severe sepsis, particularly in the setting of relative adrenal insufficiency.

*c* Tetracyclines can be antagonistic in action to β-lactam agents. Adjust treatment as soon as the diagnosis is confirmed.

*d* The optimal dose of IV immunoglobulin has not been determined, but the median dose in observational studies is 2 g/kg (total dose administered over 1–5 days).

*e* *Haemophilus aphrophilus*, *H. paraphrophilus*, *H. parainfluenzae*, *Actinobacillus actino-mycetemcomitans*, *Cardiobacterium hominis*, *Eikenella corrodens*, and *Kingella kingae*. 
Mortality rates exceed 90% among pts without meningitis who have rash, hypotension, and a normal or low WBC count and ESR.

b. Rocky Mountain spotted fever: history of tick bite and/or travel or outdoor activity
   Headache, malaise, myalgias, nausea, vomiting, anorexia
   In progressive disease: hypotension, noncardiogenic pulmonary edema, confusion, encephalitis, coma
   Rash by day 3: blanching macules that become hemorrhagic, starting at wrists and ankles and spreading to legs and trunk, then palms and soles

c. Other rickettsial diseases: Mediterranean spotted fever (Africa) can be severe in the elderly or pts with comorbid illness; mortality rates in these populations approach 50%. Epidemic typhus occurs in louse-infested areas, usually in a setting of poverty, war, or natural disaster; mortality rates are 10–15%. In scrub typhus (Southeast Asia), death occurs in 1–35% of cases.

d. Purpura fulminans: cutaneous manifestation of DIC; large ecchymotic areas and hemorrhagic bullae; associated with CHF, septic shock, acute renal failure, acidosis

3. Ecthyma gangrenosum: hemorrhagic vesicles with central necrosis and ulceration in septic shock with *Pseudomonas aeruginosa* or *Aeromonas hydrophila*

4. Other emergent infections associated with rash
   a. *Vibrio vulnificus* and other noncholera vibrios: Bacteremic infections and sepsis with lower-extremity bullous or hemorrhagic lesions develop after contaminated shellfish ingestion, typically in hosts with liver disease.
   b. *Capnocytophaga canimorsus*: septic shock in asplenic pts, typically after dog bite. Skin manifestations: exanthem, erythema multiforme, peripheral cyanosis, petechiae

5. Erythroderma and toxic shock syndrome (TSS): diffuse sunburn-like rash that desquamates after 1–2 weeks; hypotension; multiorgan failure; renal failure (may precede hypotension)
   a. *Staphylococcus aureus* TSS: colonization of vagina or postoperative wound; usually no primary focal infection; 5–15% mortality
   b. Streptococcal TSS: less frequent desquamation, 30–70% mortality

6. Viral hemorrhagic fevers: zoonotic viral illness from animal reservoirs or arthropod vectors—e.g., Lassa fever in Africa, hantavirus hemorrhagic fever with renal syndrome in Asia, Ebola and Marburg virus infections in Africa, and yellow fever in Africa and South America. Dengue is the most common arboviral disease worldwide. Dengue hemorrhagic fever is the more severe form, with a triad of hemorrhagic manifestations, plasma leakage, and platelet counts <100,000/μL. Mortality is 10–20% but approaches 40% if dengue shock syndrome develops. Supportive care and volume replacement therapy are life-saving.

**Sepsis with a Soft Tissue/Muscle Primary Focus**

1. Necrotizing fasciitis
   a. Risk factors: minimal trauma, surgical incision, varicella, comorbid conditions (diabetes, peripheral vascular disease, IV drug use)
   b. Bacteremia, hypotension, physical findings minimal compared to degree of pain, fever, toxicity; infected area red, hot, shiny, exquisitely tender
   c. Progression to bullae, necrosis; decreased pain due to peripheral nerve destruction an ominous sign
   d. Mortality: 100% without surgery, 70% in setting of TSS, 25–30% overall
2. Clostridial myonecrosis
   a. Either secondary to trauma or surgery or spontaneous (associated with *Clostridium septicum* infection and underlying malignancy)
   b. Pain and toxicity are out of proportion to physical findings. Pts are apathetic, tachycardic, and tachypneic, with a sense of impending doom.
   c. Mottled, bronze-colored overlying skin or bullous lesions; crepitus; drainage with mousy or sweet odor; massive necrotizing gangrene, toxicity, shock, death within hours
   d. Mortality: 12% (extremity myonecrosis) to 63–65% (trunk or spontaneous myonecrosis)

Neurologic Infections with or without Septic Shock
1. Bacterial meningitis
   a. Classic triad of headache, meningismus, and fever in one-half to two-thirds of pts
   b. Blood cultures positive in 50–60% of pts
   c. Death associated with coma, respiratory distress, shock, CSF protein >2.5 g/L, peripheral WBC count <5000/μL, serum Na level <135 mmol/L

2. Brain abscess
   a. Often without systemic signs, can present as space-occupying lesion
   b. Headache, focal neurologic signs, papilledema
   c. From contiguous foci or hematogenous infection (e.g., endocarditis)
   d. Prognosis worsens with fulminant course, delayed diagnosis, rupture into ventricles, multiple abscesses, and/or abnormal mental status at presentation.

Focal Syndromes with a Fulminant Course
1. Rhinocerebral mucormycosis
   a. Seen in patients with diabetes, malignancy
   b. Low-grade fever, dull sinus pain, diplopia, decreased mental status, chemosis, proptosis, hard-palate lesions that respect the midline

2. Acute bacterial endocarditis
   a. Seen in patients with malignancy, diabetes, IV drug use, alcoholism
   b. Etiologies include *S. aureus, S. pneumoniae, Haemophilus* spp., and group A, B, or G streptococci.
   c. Rapid valvular destruction, pulmonary edema, hypotension, myocardial abscesses, conduction abnormalities and arrhythmias, large friable vegetations, major arterial emboli with tissue infarction
   d. Mortality: 10–40%

3. Respiratory illnesses
   a. Inhalational anthrax: mediastinal widening, pulmonary infiltrates, pleural effusions
   b. Avian influenza (H5N1): Southeast Asia; poultry contact; progressive dyspnea and ARDS, multiorgan failure, and ultimately (within 9–10 days) death
   c. Hantavirus pulmonary syndrome: rural U.S., Canada, and South America; rodent exposure. Nonspecific viral prodrome can progress to pulmonary edema, respiratory failure, myocardial depression, and death.

For a more detailed discussion, see Barlam TF, Kasper DL: Approach to the Acutely Ill Infected Febrile Patient, Chap. 115, p. 761, in HPIM-17.
Oncologic Emergencies

Emergencies in the cancer pt may be classified into three categories: effects from tumor expansion, metabolic or hormonal effects mediated by tumor products, and treatment complications.

STRUCTURAL/OBSTRUCTIVE ONCOLOGIC EMERGENCIES

The most common problems are superior vena cava syndrome; pericardial effusion/tamponade; spinal cord compression; seizures (Chap. 191) and/or increased intracranial pressure; and intestinal, urinary, or biliary obstruction. The last three conditions are discussed in Chap. 270 in HPIM-17.

SUPERIOR VENA CAVA SYNDROME

Obstruction of the superior vena cava reduces venous return from the head, neck, and upper extremities. About 85% of cases are due to lung cancer; lymphoma and thrombosis of central venous catheters are also causes. Pts often present with facial swelling, dyspnea, and cough. In severe cases, the mediastinal mass lesion may cause tracheal obstruction. Dilated neck veins and increased collateral veins on anterior chest wall are noted on physical exam. Chest x-ray (CXR) documents widening of the superior mediastinum; 25% of pts have a right-sided pleural effusion.

Superior Vena Cava Syndrome

Radiation therapy is the treatment of choice for non-small cell lung cancer; addition of chemotherapy to radiation therapy is effective in small cell lung cancer and lymphoma. Symptoms recur in 10–30% and can be palliated by venous stenting. Clotted central catheters producing this syndrome should be removed and anticoagulation therapy initiated. Catheter clots may be prevented with warfarin, 1 mg/d.

PERICARDIAL EFFUSION/TAMPONADE

Accumulation of fluid in the pericardium impairs filling of the heart and decreases cardiac output. Most commonly seen in pts with lung or breast cancers, leukemias, or lymphomas, pericardial tamponade may also develop as a late complication of mediastinal radiation therapy (constrictive pericarditis). Common symptoms are dyspnea, cough, chest pain, orthopnea, and weakness. Pleural effusion, sinus tachycardia, jugular venous distention, hepatomegaly, and cyanosis are frequent physical findings. Paradoxical pulse, decreased heart sounds, pulsus alternans, and friction rub are less common with malignant than nonmalignant pericardial disease. Echocardiography is diagnostic; pericardiocentesis may show serous or bloody exudate, and cytology usually shows malignant cells.
Pericardial Effusion/Tamponade

Drainage of fluid from the pericardial sac may be lifesaving until a definitive surgical procedure (pericardial stripping or window) can be performed.

SPINAL CORD COMPRESSION

Primary spinal cord tumors occur rarely, and cord compression is most commonly due to epidural metastases from vertebral bodies involved with tumor, especially from prostate, lung, breast, lymphoma, and myeloma primaries. Pts present with back pain, worse when recumbent, with local tenderness. Loss of bowel and bladder control may occur. On physical exam, pts have a loss of sensation below a horizontal line on the trunk, called a *sensory level*, that usually corresponds to one or two vertebrae below the site of compression. Weakness and spasticity of the legs and hyperactive reflexes with upgoing toes on Babinski testing are often noted. Spine radiographs may reveal erosion of the pedicles (winking owl sign), lytic or sclerotic vertebral body lesions, and vertebral collapse. Collapse alone is not a reliable indicator of tumor; it is a common manifestation of a more common disease, osteoporosis. MRI can visualize the cord throughout its length and define the extent of tumor involvement.

Radiation therapy plus dexamethasone, 4 mg IV or PO q4h, is successful in arresting and reversing symptoms in about 75% of pts who are diagnosed while still ambulatory. Only 10% of pts made paraplegic by the tumor recover the ability to ambulate.

EMERGENT PARANEOPLASTIC SYNDROMES

Most paraneoplastic syndromes have an insidious onset (Chap. 81). Hypercalcemia, syndrome of inappropriate antidiuretic hormone secretion (SIADH), and adrenal insufficiency may present as emergencies.

HYPERCALCEMIA

The most common paraneoplastic syndrome, it occurs in about 10% of cancer pts, particularly those with lung, breast, head and neck, and kidney cancer and myeloma. Bone resorption mediated by parathormone-related protein is the most common mechanism; interleukin 1 (IL-1), IL-6, tumor necrosis factor, and transforming growth factor β may act locally in tumor-involved bone. Pts usually present with nonspecific symptoms: fatigue, anorexia, constipation, weakness. Hypoalbuminemia associated with malignancy may make symptoms worse for any given serum calcium level because more calcium will be free rather than protein bound.

Saline hydration, antiresorptive agents (e.g., pamidronate, 60–90 mg IV over 4 h, or zoledronate, 4–8 mg IV), and glucocorticoids usually lower calcium levels significantly within 1–3 days. Treatment effects usually last several weeks. Treatment of the underlying malignancy is also important.
SIADH

Induced by the action of arginine vasopressin produced by certain tumors (especially small cell cancer of the lung), SIADH is characterized by hyponatremia, inappropriately concentrated urine, and high urine sodium excretion in the absence of volume depletion. Most pts with SIADH are asymptomatic. When serum sodium falls to <115 meq/L, pts may experience anorexia, depression, lethargy, irritability, confusion, weakness, and personality changes.

Water restriction controls mild forms. Demeclocycline (150–300 mg PO tid or qid) inhibits the effects of vasopressin on the renal tubule but has a slow onset of action (1 week). Treatment of the underlying malignancy is also important. If the patient has mental status changes with sodium levels <115 meq/L, normal saline infusion plus furosemide to increase free water clear-
ance may provide more rapid improvement. Rate of correction should not exceed 0.5–1 meq/L per h. More rapid change can produce fluid shifts that lead to brain damage.

**ADRENAL INSUFFICIENCY**

The infiltration of the adrenals by tumor and their destruction by hemorrhage are the two most common causes. Symptoms such as nausea, vomiting, anorexia, and orthostatic hypotension may be attributed to progressive cancer or to treatment side effects. Certain treatments (e.g., ketoconazole, aminoglutethimide) may directly interfere with steroid synthesis in the adrenal.

---

**Adrenal Insufficiency**

In emergencies, a bolus of 100 mg IV hydrocortisone is followed by a continuous infusion of 10 mg/h. In nonemergent but stressful circumstances, 100–200 mg/d oral hydrocortisone is the beginning dose, tapered to maintenance of 15–37.5 mg/d. Fludrocortisone (0.1 mg/d) may be required in the presence of hyperkalemia.

---

**TREATMENT COMPLICATIONS**

Complications from treatment may occur acutely or emerge only many years after treatment. Toxicity may be either related to the agents used to treat the cancer or from the response of the cancer to the treatment (e.g., leaving a perforation in a hollow viscus or causing metabolic complications such as tumor lysis syndrome). Several treatment complications present as emergencies. Fever and neutropenia and tumor lysis syndrome will be discussed here; others are discussed in Chap. 270 in HPIM-17.

---

**FEVER AND NEUTROPENIA**

Many cancer pts are treated with myelotoxic agents. When peripheral blood granulocyte counts are <1000/μL, the risk of infection is substantially increased (48 infections/100 pts). A neutropenic pt who develops a fever (>38°C) should undergo physical exam with special attention to skin lesions, mucous membranes, IV catheter sites, and perirectal area. Two sets of blood cultures from different sites should be drawn and a CXR performed, and any additional tests should be guided by findings from the history and physical exam. Any fluid collections should be tapped, and urine and/or fluids should be examined under the microscope for evidence of infection.

---

**Fever and Neutropenia**

After cultures are obtained, all pts should receive IV broad-spectrum antibiotics (e.g., ceftazidime, 1 g q8h). If an obvious infectious site is found, the antibiotic regimen is designed to cover organisms that may cause the infection. Usually therapy should be started with an agent or agents that cover both gram-positive and -negative organisms. If the fever resolves, treatment should continue until neutropenia resolves. Persistence of febrile neutropenia after 7 days should lead to addition of amphotericin B to the antibiotic regimen.
TUMOR LYSIS SYNDROME

When rapidly growing tumors are treated with effective chemotherapy regimens, the dying tumor cells can release large amounts of nucleic acid breakdown products (chiefly uric acid), potassium, phosphate, and lactic acid. The phosphate elevations can lead to hypocalcemia. The increased uric acid, especially in the setting of acidosis, can precipitate in the renal tubules and lead to renal failure. The renal failure can exacerbate the hyperkalemia.

Prevention is the best approach. Maintain hydration with 3 L/d of saline, keep urine pH > 7.0 with bicarbonate administration, and start allopurinol, 300 mg/m² per day, 24 h before starting chemotherapy. Once chemotherapy is given, monitor serum electrolytes every 6 h. If after 24 h, uric acid (>8 mg/dL) and serum creatinine (>1.6 mg/dL) are elevated, rasburicase (recombinant urate oxidase), 0.2 mg/kg IV daily, may lower uric acid levels. If serum potassium is >6.0 meq/L and renal failure ensues, hemodialysis may be required. Maintain normal calcium levels.

For a more detailed discussion, see Finberg R: Infections in Patients with Cancer, Chap. 82, p. 533; and Gucalp R, Dutcher J: Oncologic Emergencies, Chap. 270, p. 1730, in HPIM-17.

Anaphylaxis

DEFINITION

A life-threatening systemic hypersensitivity reaction to contact with an allergen; it may appear within minutes of exposure to the offending substance. Manifestations include respiratory distress, pruritus, urticaria, mucous membrane swelling, gastrointestinal disturbances (including nausea, vomiting, pain, and diarrhea), and vascular collapse. Virtually any allergen may incite an anaphylactic reaction, but among the more common agents are proteins such as antiserum, hormones, pollen extracts, Hymenoptera venom, foods; drugs (especially antibiotics); and diagnostic agents. Atopy does not seem to predispose to anaphylaxis from penicillin or venom exposures. Anaphylactic transfusion reactions are covered in Chap. 9.

CLINICAL PRESENTATION

Time to onset is variable, but symptoms usually occur within seconds to minutes of exposure to the offending antigen:

- Respiratory: mucous membrane swelling, hoarseness, stridor, wheezing
- Cardiovascular: tachycardia, hypotension
- Cutaneous: pruritus, urticaria, angioedema
DIAGNOSIS
Made by obtaining history of exposure to offending substance with subsequent development of characteristic complex of symptoms.

Anaphylaxis
Mild symptoms such as pruritus and urticaria can be controlled by administration of 0.3–0.5 mL of 1:1000 (1.0 mg/mL) epinephrine SC or IM, with repeated doses as required at 5- to 20-min intervals for a severe reaction.

An IV infusion should be initiated for administration of 2.5 mL of 1:10,000 epinephrine solution at 5- to 10-min intervals, volume expanders such as normal saline, and vasopressor agents, e.g., dopamine, if intractable hypotension occurs.

Epinephrine provides both α- and β-adrenergic effects, resulting in vasoconstriction and bronchial smooth-muscle relaxation. Beta blockers are relatively contraindicated in persons at risk for anaphylactic reactions.

The following should also be used as necessary:

- Antihistamines such as diphenhydramine 50–100 mg IM or IV
- Aminophylline 0.25–0.5 g IV for bronchospasm
- Oxygen
- Glucocorticoids (medrol 0.5–1.0 mg/kg IV); not useful for acute manifestations but may help control persistent hypotension or bronchospasm
- For antigenic material injected into an extremity consider: use of a tourniquet proximal to the site, 0.2 mL of 1:1000 epinephrine into the site, removal of an insect stinger if present.

PREVENTION
Avoidance of offending antigen, where possible; skin testing and desensitization to materials such as penicillin and Hymenoptera venom, if necessary. Individuals should wear an informational bracelet and have immediate access to an unexpired epinephrine kit.

For a more detailed discussion, see Austen KF: Allergies, Anaphylaxis, and Systemic Mastocytosis, Chap. 311, p. 2061, in HPIM-17.

29 Bites, Venoms, Stings, and Marine Poisonings

MAMMALIAN BITES
Each year, there are ~300 dog and cat bites per 100,000 population in the United States.

DOG BITES
Epidemiology Of all mammalian bite wounds, 80% are inflicted by dogs, and 15–20% of these wounds become infected.
Etiology (See Table 29-1.) In addition to bacterial infections, dog bites may transmit rabies (Chap. 111) and may lead to tetanus (Chap. 99) or tularemia (Chap. 98).

Clinical Features
- Pain, cellulitis, and a purulent, sometimes foul-smelling discharge may develop 8–24 h after the bite.
- Infection is usually localized, but systemic spread (e.g., bacteremia, endocarditis, brain abscess) can occur.
- *Capnocytophaga canimorsus* infection can present as sepsis syndrome, DIC, and renal failure, particularly in pts who are splenectomized, have hepatic dysfunction, or are otherwise immunosuppressed.

CAT BITES

Epidemiology In >50% of cases, infection occurs as a result of deep tissue penetration of narrow, sharp feline incisors. Cat bites are more likely than dog bites to cause septic arthritis or osteomyelitis.

Etiology The microflora is usually mixed, although *Pasteurella multocida* is the most important pathogen. Cat bites may transmit rabies or may lead to tetanus. Cat bites and scratches may also transmit *Bartonella henselae*, the agent of cat-scratch disease (Chap. 98), as well as *Francisella tularensis*, the agent of tularemia (Chap. 98).

Clinical Features *P. multocida* can cause rapidly advancing, painful inflammation within a few hours after the bite as well as purulent discharge. Dissemination may occur.

OTHER NONHUMAN MAMMALIAN BITES
- Bite infections reflect oral flora. Bites from Old World monkeys (*Macaca* spp.) may transmit herpes B virus (*Herpesvirus simiae*), which can cause CNS infections with high mortality rates.
- Small rodents and the animals that prey on them may transmit rat-bite fever, caused by *Streptobacillus moniliformis* (in the United States) or *Spirillum minor* (in Asia). Infection with *S. moniliformis* manifests 3–10 days after the bite as fever, chills, myalgias, headache, and migratory arthralgias; these manifestations are followed by a maculopapular rash. Complications can include metastatic abscesses, endocarditis, meningitis, or pneumonia. Diagnosis can be made by culture on enriched media and serologic testing. Infection with *S. minor* causes local pain, purple swelling with lymphangitis, and regional lymphadenopathy 1–4 weeks after the bite, with evolution into a systemic illness. Diagnosis can be made by detection of spirochetes on microscopic examination.

HUMAN BITES

Human bites become infected more frequently than bite wounds from other animals. *Occlusional* injuries are inflicted by actual biting. *Clenched-fist* injuries result when the fist of one individual strikes the teeth of another and are particularly prone to serious infection.

Etiology See Table 29-1.
<table>
<thead>
<tr>
<th>Biting Species</th>
<th>Commonly Isolated Pathogens</th>
<th>Preferred Antibiotic(s)</th>
<th>Alternative Agent(s) for Penicillin-Allergic Patients</th>
<th>Prophylaxis Advised for Early Uninfected Wounds</th>
<th>Other Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dog</td>
<td><em>Staphylococcus aureus</em>, <em>Pasteurella multocida</em>, anaerobes, <em>Capnocytophaga canimorsus</em></td>
<td>Amoxicillin/clavulanate (250–500 mg PO tid) or ampicillin/sulbactam (1.5–3.0 g IV q6h)</td>
<td>Clindamycin (150–300 mg PO qid) plus either TMP-SMX (1 double-strength tablet bid) or ciprofloxacin (500 mg PO bid)</td>
<td>Sometimes&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Consider rabies prophylaxis.</td>
</tr>
<tr>
<td>Cat</td>
<td><em>P. multocida</em>, <em>S. aureus</em>, anaerobes</td>
<td>Amoxicillin/clavulanate or ampicillin/sulbactam, as for dog bite</td>
<td>Clindamycin plus either TMP-SMX (as for dog bite) or a fluoroquinolone</td>
<td>Usually</td>
<td>Consider rabies prophylaxis. Carefully evaluate for joint or bone penetration.</td>
</tr>
<tr>
<td>Human, occlusional bite</td>
<td><em>Viridans streptococci</em>, <em>S. aureus</em>, <em>Haemophilus influenzae</em>, anaerobes</td>
<td>Amoxicillin/clavulanate or ampicillin/sulbactam, as for dog bite</td>
<td>Erythromycin (500 mg PO qid) or a fluoroquinolone</td>
<td>Always</td>
<td>—</td>
</tr>
<tr>
<td>Human, clenched-fist injury</td>
<td>As for occlusional plus <em>Eikenella corrodens</em></td>
<td>Amoxicillin/sulbactam, as for dog bite</td>
<td>Cefoxitin&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Always</td>
<td>—</td>
</tr>
<tr>
<td>Monkey</td>
<td>As for human bite</td>
<td>As for human bite</td>
<td>As for human bite</td>
<td>Always</td>
<td>Examine for tendon, nerve, or joint involvement. For macaque monkeys, consider herpes B virus prophylaxis with acyclovir.</td>
</tr>
</tbody>
</table>
### Table 29-1  Management of Wound Infections Following Animal and Human Bites (Continued)

<table>
<thead>
<tr>
<th>Biting Species</th>
<th>Commonly Isolated Pathogens</th>
<th>Preferred Antibiotic(s)(^a)</th>
<th>Alternative Agent(s) for Penicillin-Allergic Patients</th>
<th>Prophylaxis Advised for Early Uninfected Wounds</th>
<th>Other Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Snake(^d)</td>
<td><em>Pseudomonas aeruginosa</em>, <em>Proteus</em> spp., <em>Bacteroides fragilis</em>, <em>Clostridium</em> spp., <em>Streptobacillus moniliformis</em>, <em>Leptospira</em> spp., <em>P. multocida</em></td>
<td>Ampicillin/sulbactam, as for dog bite</td>
<td>Clindamycin plus either TMP-SMX (as for dog bite) or a fluoroquinolone</td>
<td>Sometimes, especially for venomous snakebites</td>
<td>Antivenom for venomous snakebite</td>
</tr>
<tr>
<td>Rodent</td>
<td></td>
<td>Penicillin VK (500 mg PO qid)</td>
<td>Doxycycline (100 mg PO bid)</td>
<td>Sometimes</td>
<td>—</td>
</tr>
</tbody>
</table>

\(^a\)Antibiotic choices should be based on culture data when available. These are suggestions for empirical therapy and need to be tailored to individual circumstances and local conditions. IV regimens should be used for hospitalized pts. A single IV dose of antibiotic may be given to pts who will be discharged after initial management.

\(^b\)Prophylactic antibiotics are suggested for severe or extensive wounds, facial wounds, and crush injuries; when bone or joint may be involved; or when comorbidity is present.

\(^c\)May be hazardous to pts with immediate-type hypersensitivity reaction to penicillin.

\(^d\)See Chap. 391 in HPIM-17.

**Note:** TMP-SMX, trimethoprim-sulfamethoxazole.
Mammalian Bites

- **Wound management**: Wound closure is controversial in bite injuries. After thorough cleansing, facial wounds are usually sutured for cosmetic reasons and because the abundant facial blood supply lessens the risk of infection. For wounds elsewhere on the body, many authorities do not attempt primary closure, preferring instead to irrigate the wound copiously, debride devitalized tissue, remove foreign bodies, and approximate the margins. Delayed primary closure may be undertaken after the risk of infection has passed.

- **Antibiotic therapy**: See Table 29-1. If prophylactic antibiotics are given, the course is 3–5 days long.

- **Other prophylaxis**: Rabies prophylaxis (passive immunization with rabies immune globulin and active immunization with rabies vaccine) should be given in consultation with local and regional public health authorities. A tetanus booster for pts immunized previously but not boosted within 5 years should be considered, as should primary immunization and tetanus immune globulin administration for pts not previously immunized.

VENOMOUS SNAKEBITES

**Etiology and Epidemiology** Worldwide, >125,000 people die each year from venomous snakebite injuries, most often in temperate and tropical regions. Snake venoms are complex mixtures of enzymes and other substances that promote vascular leaking and bleeding, tissue necrosis, and neurotoxicity and affect the coagulation cascade.

**FIELD MANAGEMENT**

- Get the victim to definitive care as soon as possible.
- Keep the victim inactive to minimize the systemic spread of venom.
- Splint a bitten extremity and keep it at heart level.
- Pressure immobilization (wrapping of the entire limb in a bandage at a pressure of 40–70 mmHg and splinting) can be used if the venom is primarily neurotoxic without local tissue effects, if the rescuer is skilled in this technique, and if the victim can be carried to medical care.
- Avoid incisions into the bite wound, cooling, consumption of alcoholic beverages by the victim, and electric shock.
- Best first aid: Do it RIGHT: Reassure victim, Immobilize extremity, Get to the Hospital, inform physician of Telltale signs and symptoms.

**HOSPITAL MANAGEMENT**

- Monitor vital signs, cardiac rhythm, and O₂ saturation closely, and watch for evidence of difficulty swallowing or respiratory insufficiency.
- Note the level of erythema and swelling and the limb circumference every 15 min until swelling has stabilized.
- Treat shock initially by crystalloid fluid resuscitation with isotonic saline. If hypotension persists, try 5% albumin and vasopressors.
- Begin the search for appropriate, specific antivenom early in all cases of known venomous snakebite. In the United States, round-the-clock assistance is available from regional poison control centers.
1. Any evidence of systemic envenomation (systemic symptoms or signs, laboratory abnormalities) and (possibly) significant, progressive local finding are indications for antivenom administration.

2. Treating physicians should seek advice from snakebite experts regarding indications and dosing of antivenom. Antivenom administration should be continued until the victim shows definite improvement. However, neurotoxicity from the bite of an elapid (e.g., a cobra) is harder to reverse with antivenom. Once neurotoxicity is established and intubation is required, further antivenom is unlikely to help.

3. CroFab, an antivenom used in the United States against North American pit viper species, has a low risk of allergy elicitation. Worldwide, antivenom quality varies, and rates of anaphylactoid reaction can exceed 50%.

4. If the risk of allergy is significant, pts should be premedicated with IV antihistamines (e.g., diphenhydramine, 1 mg/kg up to a maximum dose of 100 mg; plus cimetidine, 5–10 mg/kg up to a maximum dose of 300 mg) and given IV crystalloids to expand intravascular volume. Epinephrine should be immediately available. The antivenom in dilute solution should be administered slowly by the IV route, with a physician present in case of an acute reaction.

5. Acetylcholinesterase inhibitors may cause neurologic improvement in pts bitten by snakes with postsynaptic neurotoxins.

- Elevate the bitten extremity once antivenom administration has been initiated.
- Update tetanus immunization.
- Observe pt for muscle-compartment syndrome.
- Observe pts with signs of envenomation in the hospital for at least 24 h. Pts with “dry” bites should be watched for at least 8 h because symptoms are commonly delayed.

The overall mortality rate for venomous snakebite is <1% among U.S. victims who receive antivenom. Eastern and western diamondback rattlesnakes are responsible for most deaths from snakebite in the United States.

**MARINE ENVENOMATIONS**

**INVERTEBRATES**

Injuries from nematocysts (stinging cells) of hydroids, fire coral, jellyfish, Portuguese man-of-wars, and sea anemones cause similar clinical symptoms that differ in severity.

**Clinical Features**  Pain (prickling, burning, and throbbing), pruritus, and paresthesia develop immediately at the site of the bite. Neurologic, GI, renal, cardiovascular, respiratory, rheumatologic, and ocular symptoms have been described.

![Rx Marine Invertebrate Envenomations](image)

- Decontaminate the skin immediately with vinegar (5% acetic acid) or rubbing alcohol (40–70% isopropanol). Baking soda, unseasoned meat tenderizer (papain), lemon or lime juice, household ammonia, olive oil, or sugar may be effective.
- Shaving the skin may help remove nematocysts.
- After decontamination, topical anesthetics, antihistamines, or steroid lotions may be helpful.
• Narcotics may be necessary for persistent pain.
• Muscle spasms may respond to IV 10% calcium gluconate (5–10 mL) or diazepam (2–5 mg titrated upward as needed).

**VERTEBRATES**

Marine vertebrates, including stingrays, scorpionfish, and catfish, are capable of envenomating humans.

**Clinical Features**

- Immediate and intense pain at the site can last up to 48 h.
- Systemic symptoms include weakness, diaphoresis, nausea, vomiting, diarrhea, dysrhythmia, syncope, hypotension, muscle cramps, muscle fasciculations, and paralysis. Fatal cases are rare.
- Stingray wounds can become ischemic and heal poorly.
- The sting of a stonefish is the most serious marine vertebrate envenomation and can be life-threatening.

**Marine Vertebrate Envenomations**

- Immerse the affected part immediately in nonscalding hot water (113°F/45°C) for 30–90 min.
- Explore, debride, and vigorously irrigate the wound.
- Antivenom is available for stonefish and scorpionfish envenomations.
- Leave wounds to heal by secondary intention or to be treated by delayed primary closure.
- Update tetanus immunization.
- Consider empirical antibiotics to cover *Staphylococcus* and *Streptococcus* spp. for serious wounds or envenomations in immunocompromised hosts.

**SOURCES OF ANTIVENOMS AND OTHER ASSISTANCE**

To locate a specific antivenom in the United States, contact the nearest regional poison control center. Divers Alert Network is a source of helpful information (round-the-clock at 919-684-8111 or www.diversalertnetwork.org). Antivenom for stonefish and severe scorpionfish envenomation is made in Australia at the Commonwealth Serum Laboratories (www.csl.com.au, 61-3-389-1911).

**MARINE POISONINGS**

**Ciguatera**

Ciguatera poisoning is the most common nonbacterial food poisoning associated with fish in the United States. Tropical and semitropical marine coral reef fish are usually the source; 75% of cases involve barracuda, snapper, jack, or grouper. Toxins may not affect the appearance or taste of the fish and are resistant to heat, cold, freeze-drying, and gastric acid.

**Clinical Features** Most victims experience diarrhea, vomiting, and abdominal pain (typically 2–6 h after ingestion of contaminated fish), and symptoms increase in severity over the ensuing 4–6 h. The myriad manifestations include neurologic signs (e.g., paresthesia, weakness, fasciculations, ataxia), maculopapular or vesicular rash, and hemodynamic instability. A pathognomonic symp-
Ciguatera Poisoning

Therapy is supportive and based on symptoms. Cool showers, hydroxyzine (25 mg PO q6–8h), or amitriptyline (25 mg PO bid) may ameliorate pruritus and dysesthesias. During recovery, the pt should avoid ingestion of fish, shellfish, fish oils, fish or shellfish sauces, alcohol, nuts, and nut oils.

PSP is induced by ingestion of contaminated clams, oysters, scallops, mussels, and other species that concentrate water-soluble, heat- and acid-stable chemical toxins. Pts develop oral paresthesias that progress to the neck and extremities and that change to numbness within minutes to hours after ingestion of contaminated shellfish. Flaccid paralysis and respiratory insufficiency may follow 2–12 h later. Treatment is supportive. If pts present within hours of ingestion, gastric lavage and stomach irrigation with 2 L of a 2% sodium bicarbonate solution may help, as may administration of activated charcoal (50–100 g) and a cathartic (sorbitol, 20–50 g). The pt should be monitored for respiratory paralysis for at least 24 h.

Scombroid poisoning is a histamine intoxication due to inadequately preserved or refrigerated scombroid fish (e.g., tuna, mackerel, saury, needlefish, wahoo, skipjack, and bonito); it can also occur with exposure to nonscombroid fish, including sardines and herring. Within 15–90 min of ingestion, victims present with flushing, pruritus or urticaria, bronchospasm, GI symptoms, tachycardia, and hypotension. Symptoms generally resolve within 8–12 h.

Scombroid Poisoning

Treatment consists of antihistamine (H₁ or H₂) administration.

ARThROPOD BITES AND STINGS

TICK BITES AND TICK PARALYSIS

Etiology and Clinical Features

- Ticks are important carriers of vector-borne diseases in the United States.
- Ticks attach and feed painlessly on blood from their hosts, but tick secretions may produce local reactions. Tick bites may cause a small area of induration and erythema. A necrotic ulcer occasionally develops; chronic nodules or tick granulomas may require surgical excision. Tick-induced fever and malaise resolve within 36 h after tick removal.
- Tick paralysis is an ascending flaccid paralysis due to a toxin in tick saliva that causes neuromuscular block and decreased nerve conduction. Paralysis begins in the lower extremities within 6 days after the tick’s attachment and ascends symmetrically, causing complete paralysis of the extremities and cranial nerves. Deep tendon reflexes are decreased or absent, but sensory
examination and LP yield normal findings. Tick removal results in improvement within hours. Failure to remove the tick may lead ultimately to respiratory paralysis and death. The tick is often hidden beneath hair.

**Tick Bites and Tick Paralysis**

Ticks should be removed with forceps applied close to the point of attachment, and the site of attachment should then be disinfected. Removal within 48 h of attachment usually prevents transmission of the agents of Lyme disease, babesiosis, anaplasmosis, and ehrlichiosis. Protective clothing and DEET application are protective measures that can be effective against ticks.

**SPIDER BITES**

**Recluse Spider Bites**  
Severe necrosis of skin and SC tissue follows a bite by the brown recluse spider. Spiders seek dark, undisturbed spots and bite only if threatened or pressed against the skin. The venoms contain enzymes that produce necrosis and hemolysis.

**Clinical Features**
- Initially the bite is painless or stings, but within hours the site becomes painful, pruritic, and indurated, with zones of ischemia and erythema.
- Fever and other nonspecific systemic symptoms may develop within 3 days of the bite.
- Lesions typically resolve within 2–3 days, but severe cases can leave a large ulcer and a depressed scar that take months to years to heal. Deaths are rare and are due to hemolysis and renal failure.

**Recluse Spider Bites**
- Wound care, cold compress application, elevation and loose immobilization of the affected limb, and administration of analgesics, antihistamines, antibiotics, and tetanus prophylaxis should be undertaken as indicated.
- Dapsone administration within 48–72 h (50–100 mg PO bid after G6PD deficiency has been ruled out) may halt progression of necrotic lesions.

**Widow Spider Bites**  
**Etiology and Clinical Features**  
The black widow spider is most abundant in the southeastern United States. It measures up to 1 cm in body length and 5 cm in leg span, is shiny black, and has a red hourglass marking on the ventral abdomen. Female widow spiders produce a potent neurotoxin that binds irreversibly to nerves and causes release and depletion of acetylcholine and other neurotransmitters from presynaptic terminals. Within 60 min, painful cramps spread from the bite site to large muscles of the extremities and trunk. Extreme abdominal muscular rigidity and pain may mimic peritonitis, but the abdomen is nontender. Other features include salivation, diaphoresis, vomiting, hypertension, tachycardia, and myriad neurologic signs. Respiratory arrest, cerebral hemorrhage, or cardiac failure may occur.

**Widow Spider Bites**
- Treatment consists of local cleansing of the wound, application of ice packs to slow the spread of the venom, and tetanus prophylaxis. Analgesics, anti-spasmodics, and other supportive care should be given. Equine antivenom is
available; rapid IV administration relieves pain and can be life-saving. However, because of the risk of anaphylaxis and serum sickness, antivenom use should be reserved for severe cases involving respiratory arrest, refractory hypertension, seizures, or pregnancy.

**SCORPION STINGS**

**Etiology and Clinical Features** Among the venoms of scorpions in the United States, only the venom of the bark scorpion (*Centruroides sculpturatus* or *C. exilicauda*) is potentially lethal. The scorpion’s neurotoxin opens sodium channels, and neurons fire repetitively. The sting causes little swelling, but pain, paraesthesia, and hyperesthesia are prominent. Cranial nerve dysfunction and skeletal muscle hyperexcitability develop within hours. Symptoms include restlessness, blurred vision, abnormal eye movements, profuse salivation, slurred speech, diaphoresis, nausea, and vomiting. Complications include tachycardia, arrhythmias, hypertension, hyperthermia, rhabdomyolysis, and acidosis. Manifestations peak at 5 h and subside within a day or two, although paresthesias can last for weeks. Outside the United States, scorpion envenomations can cause massive release of endogenous catecholamines with hypertensive crises, arrhythmias, pulmonary edema, and myocardial damage.

**Scorpion Stings**

Aggressive supportive care should include pressure dressings and cold packs to decrease the absorption of venom. Continuous IV administration of midazolam to decrease agitation and involuntary muscle movements may be needed. The benefit of scorpion antivenom has not been established in controlled trials.

**HYMENOPTERA STINGS**

The hymenoptera include apids (bees and bumblebees), vespids (wasps, hornets, and yellow jackets), and ants. About 100 deaths from hymenoptera stings occur annually in the United States, nearly all due to allergic reactions to venoms.

**Clinical Features**

- Honeybees can sting only once; other bees, vespids, and ants can sting many times in succession.
- Uncomplicated stings cause pain, a wheal-and-flare reaction, and local edema that subsides within hours.
- Multiple stings can lead to vomiting, diarrhea, generalized edema, dyspnea, hypotension, rhabdomyolysis, renal failure, and death.
- Large (>10 cm) local reactions progressing over 1–2 days are not uncommon and resemble cellulitis but are hypersensitivity reactions.
- About 0.4–4% of the U.S. population exhibits immediate-type hypersensitivity to insect stings. Serious reactions occur within 10 min of the sting and include upper airway edema, bronchospasm, hypotension, shock, and death.

**Hymenoptera Stings**

- Stingers embedded in skin should be removed promptly by any method.
- The site should be cleansed and ice packs applied. Elevation of the bite site and administration of analgesics, oral antihistamines, and topical calamine lotion may ease symptoms.
• Oral glucocorticoids are indicated for large local reactions.
• Anaphylaxis is treated with epinephrine hydrochloride (0.3–0.5 mL of a 1:1000 solution, given SC q20–30min as needed). For profound shock, epinephrine (2–5 mL of a 1:10,000 solution by slow IV push) is indicated. Pts should be observed for 24 h because of the risk of recurrence.
• Pts with a history of allergy to insect stings should carry a sting kit and seek medical attention immediately after the kit is used. Adults with a history of anaphylaxis should undergo desensitization.

For a more detailed discussion, see Madoff LC, Pereyra F: Infectious Complications of Burns and Bites, Chap. e15 in Harrison’s DVD and in Harrison’s Online; and Auerbach PS, Norris RL: Disorders Caused by Reptile Bites and Marine Animal Exposures, Chap. 391, p. 2741; and Pollack RJ, Maguire JH: Ectoparasite Infestations and Arthropod Bites and Stings, Chap. 392, p. 2748, in HPIM-17.

Hypothermia and Frostbite

HYPOTHERMIA

Hypothermia is defined as a core body temperature of ≤35°C and is classified as mild (32.2°–35°C), moderate (28°–32.2°C), or severe (<28°C).

Etiology Most cases occur during the winter in cold climates, but hypothermia may occur in mild climates and is usually multifactorial. Heat is generated in most tissues of the body and is lost by radiation, conduction, convection, evaporation, and respiration. Factors that impede heat generation and/or increase heat loss lead to hypothermia (Table 30-1).

Clinical Features Acute cold exposure causes tachycardia, increased cardiac output, peripheral vasoconstriction, and increased peripheral vascular resistance. As body temperature drops below 32°C, cardiac conduction becomes impaired, the heart rate slows, and cardiac output decreases. Atrial fibrillation with slow ventricular response is common. Other ECG changes include Osborn (J) waves. Additional manifestations of hypothermia include volume depletion, hypotension, increased blood viscosity (which can lead to thrombosis), coagulopathy, thrombocytopenia, DIC, acid-base disturbances, and bronchospasm. CNS abnormalities are diverse and can include ataxia, amnesia, hallucinations, hyporeflexia, and (in severe hypothermia) an isoelectric EEG. Hypothermia may mask other concurrent disorders, such as an acute abdomen, drug toxicity, or spinal cord injury.

Diagnosis Hypothermia is confirmed by measuring the core temperature, preferably at two sites. Since oral thermometers are usually calibrated only as low as 34.4°C, the exact temperature of a patient whose initial reading is <35°C should be determined with a rectal thermocouple probe inserted to ≥15 cm and not adjacent to cold feces. Simultaneously, an esophageal probe should be placed 24 cm below the larynx.
Medical Emergencies

SECTION 2

Hypothermia

Cardiac monitoring and supplemental oxygen should be instituted, along with attempts to limit further heat loss. Mild hypothermia is managed by passive external rewarming and insulation. The pt should be placed in a warm environment and covered with blankets to allow endogenous heat production to restore normal body temperature. With the head also covered, the rate of rewarming is usually 0.5°–2.0°C/h. Active rewarming is necessary for moderate to severe hypothermia, cardiovascular instability, age extremes, CNS dysfunction, endocrine insufficiency, or hypothermia due to complications from systemic disorders. Active rewarming may be external (forced-air heating blankets, radiant heat sources, and hot packs) or internal (by inspiration of heated, humidified oxygen warmed to 40°–45°C, by administration of IV fluids warmed to 40°–42°C, or by peritoneal or pleural lavage with dialysate or saline warmed to 40°–45°C). The most efficient active internal rewarming techniques are extracorporeal rewarming by hemodialysis and cardiopulmonary bypass. External rewarming may cause a fall in blood pressure by relieving peripheral vasoconstriction. Volume should be repleted with warmed isotonic solutions; lactated Ringer’s solution should be avoided because of impaired lactate metabolism in hypothermia. If sepsis is a possibility, empirical broad-spectrum antibiotics should be administered after sending blood cultures. Atrial arrhythmias usually require no specific treatment. Ventricular fibrillation is often refractory. Only a single sequence of 3 defibrillation attempts (2 J/kg) should be attempted when the temperature is <30°C. Since it is sometimes difficult to distinguish profound hypothermia from death, cardiopulmonary resuscitation efforts and active internal rewarming should continue until the core temperature is >32°C or cardiovascular status has been stabilized.

FROSTBITE

Frostbite occurs when the tissue temperature drops below 0°C. Clinically, it is most practical to classify frostbite as superficial (involves skin only) or deep

### TABLE 30-1 RISK FACTORS FOR HYPOTHERMIA

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Risk Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age extremes</td>
<td>Neurologic-related</td>
</tr>
<tr>
<td>Elderly</td>
<td>Stroke</td>
</tr>
<tr>
<td>Neonates</td>
<td>Hypothalamic disorders</td>
</tr>
<tr>
<td>Outdoor exposure</td>
<td>Parkinson’s disease</td>
</tr>
<tr>
<td>Occupational</td>
<td>Spinal cord injury</td>
</tr>
<tr>
<td>Sports-related</td>
<td>Multisystem</td>
</tr>
<tr>
<td>Inadequate clothing</td>
<td>Malnutrition</td>
</tr>
<tr>
<td>Cold-water immersion</td>
<td>Sepsis</td>
</tr>
<tr>
<td>Drugs and intoxicants</td>
<td>Shock</td>
</tr>
<tr>
<td>Ethanol</td>
<td>Hepatic or renal failure</td>
</tr>
<tr>
<td>Phenothiazines</td>
<td>Diabetic ketoacidosis</td>
</tr>
<tr>
<td>Barbiturates</td>
<td>Lactic acidosis</td>
</tr>
<tr>
<td>Anesthetics</td>
<td>Burns and exfoliative dermatologic disorders</td>
</tr>
<tr>
<td>Neuromuscular blockers</td>
<td>Immobility or debilitation</td>
</tr>
<tr>
<td>Endocrine-related</td>
<td></td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td></td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td></td>
</tr>
<tr>
<td>Adrenal insufficiency</td>
<td></td>
</tr>
<tr>
<td>Hypopituitarism</td>
<td></td>
</tr>
</tbody>
</table>
Hypothermia and Frostbite

CHAPTER 30

(Hypothermia and Frostbite) involves deep tissues, muscle, and bone. Classically, frostbite is retrospectively graded like a burn (first- to fourth-degree) once the resultant pathology is demarcated over time.

Clinical Features

The initial presentation of frostbite can be deceptively benign. The symptoms always include a sensory deficit affecting light touch, pain, and temperature perception. Deep frostbitten tissue can appear waxy, mottled, yellow, or violaceous-white. Favorable presenting signs include some warmth or sensation with normal color. Hemorrhagic vesicles reflect a serious injury to the microvasculature and indicate third-degree frostbite. Differential diagnosis of frostbite includes chilblain and immersion (trench) foot.

Frostbite

A treatment protocol for frostbite is summarized in Table 30-2. Frozen tissue should be rapidly and completely thawed by immersion in circulating water at 37°–40°C. Thawing should not be terminated prematurely due to pain from reperfusion; ibuprofen, 400 mg, should be given, and parenteral narcotics are often required. If cyanosis persists after rewarming, the tissue compartment pressures should be monitored carefully. Patients with parts showing no flow on 99mTc scintiscan may be candidates for tissue plasminogen activator (tPA).

For a more detailed discussion, see Danzl DF: Hypothermia and Frostbite, Chap. 20, p. 135, in HPIM-17.

Table 30-2: Treatment for Frostbite

<table>
<thead>
<tr>
<th>Before Thawing</th>
<th>During Thawing</th>
<th>After Thawing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remove from environment</td>
<td>Consider parenteral analgesia and ketorolac</td>
<td>Gently dry and protect part; elevate; pledges between toes, if macerated</td>
</tr>
<tr>
<td>Prevent partial thawing and re-freezing</td>
<td>Administer ibuprofen, 400 mg PO</td>
<td>If clear vesicles are intact, the fluid will reabsorb in days; if broken, debride and dress with antibiotic or sterile aloe vera ointment</td>
</tr>
<tr>
<td>Stabilize core temperature and treat hypothermia</td>
<td>Immerse part in 37°–40°C (thermometer-monitored) circulating water containing an antiseptic soap until distal flush (10–45 min)</td>
<td>Leave hemorrhagic vesicles intact to prevent infection</td>
</tr>
<tr>
<td>Protect frozen part—no friction or massage</td>
<td>Encourage patient to gently move part</td>
<td>Continue ibuprofen 400 mg PO (12 mg/kg per day) q8–12h</td>
</tr>
<tr>
<td>Address medical or surgical conditions</td>
<td>If pain is refractory, reduce water temperature to 33°–37°C and administer parenteral narcotics</td>
<td>Consider tetanus and streptococcal prophylaxis; elevate part</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hydrotherapy at 37°C</td>
</tr>
</tbody>
</table>

For a more detailed discussion, see Danzl DF: Hypothermia and Frostbite, Chap. 20, p. 135, in HPIM-17.
Poisoning refers to the development of harmful effects following exposure to chemicals. Overdosage is exposure to excessive amounts of a substance normally intended for consumption and does not necessarily imply poisoning. Chemical exposures result in an estimated 5 million requests in the United States for medical advice or treatment each year, and about 5% of victims of chemical exposure require hospitalization. Suicide attempts account for most serious or fatal poisonings. Up to 30% of psychiatric admissions are prompted by attempted suicide via overdosage.

Carbon monoxide (CO) poisoning is the leading cause of death. Acetaminophen toxicity is the most common pharmaceutical agent causing fatalities. Other drug-related fatalities are commonly due to analgesics, antidepressants, sedative-hypnotics, neuroleptics, stimulants and street drugs, cardiovascular drugs, anticonvulsants, antihistamines, and asthma therapies. Nonpharmaceutical agents implicated in fatal poisoning include alcohols and glycols, gases and fumes, chemicals, cleaning substances, pesticides, and automotive products. The diagnosis of poisoning or drug overdose must be considered in any pt who presents with coma, seizure, or acute renal, hepatic, or bone marrow failure.

DIAGNOSIS

The correct diagnosis can usually be reached by history, physical exam, and routine and toxicologic laboratory evaluation. All available sources should be used to determine the exact nature of the ingestion or exposure. The history should include the time, route, duration, and circumstances (location, surrounding events, and intent) of exposure; time of onset, nature, and severity of symptoms; relevant past medical and psychiatric history. The Physicians Desk Reference, regional poison control centers, and local/hospital pharmacies may be useful for identification of ingredients and potential effects of toxins.

The diagnosis of poisoning in cases of unknown etiology primarily relies on pattern recognition. The first step is a physical exam with initial focus on the pulse, blood pressure, respiratory rate, temperature, and neurologic status and then characterization of the overall physiologic state as stimulated, depressed, discordant, or normal (Table 31-1).

Examination of the eyes (for nystagmus, pupil size, and reactivity), abdomen (for bowel activity and bladder size), and skin (for burns, bullae, color, warmth, moisture, pressure sores, and puncture marks) may narrow the diagnosis to a particular disorder. The pt should also be examined for evidence of trauma and underlying illnesses. When the history is unclear, all orifices should be examined for the presence of chemical burns and drug packets. The odor of breath or vomitus and the color of nails, skin, or urine may provide diagnostic clues.

Initial laboratory studies should include glucose, serum electrolytes, serum osmolality, BUN/creatinine, LFTs, PT/PTT, and ABGs. An increased anion-gap metabolic acidosis is characteristic of advanced methanol, ethylene glycol, and salicylate intoxication but can occur with other agents and in any poisoning that results in hepatic, renal, or respiratory failure; seizures; or shock. An increased osmolar gap—the difference between the serum osmolality (measured by freezing point depression) and that calculated from the serum sodium, glucose, and
<table>
<thead>
<tr>
<th>Stimulated</th>
<th>Depressed</th>
<th>Discordant</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sympathetics</td>
<td>Sympatholytics</td>
<td>Asphyxiants</td>
<td>Nontoxic exposure</td>
</tr>
<tr>
<td>Sympathomimetics</td>
<td>α₁-Adrenergic antagonists</td>
<td>Cytochrome oxidase inhibitors</td>
<td>Psychogenic illness</td>
</tr>
<tr>
<td>Ergot alkaloids</td>
<td>α₂-Adrenergic agonists</td>
<td>Inert gases</td>
<td>Toxic time-bombs</td>
</tr>
<tr>
<td>Methylxanthines</td>
<td>ACE inhibitors</td>
<td>Irritant gases</td>
<td>Slow absorption</td>
</tr>
<tr>
<td>MAO inhibitors</td>
<td>Angiotensin receptor blockers</td>
<td>Methemoglobin inducers</td>
<td>Anticholinergics</td>
</tr>
<tr>
<td>Thyroid hormones</td>
<td>Antipsychotics</td>
<td>Oxidative phosphorylation inhibitors</td>
<td>Carbamazepine</td>
</tr>
<tr>
<td>Anticholinergics</td>
<td>β-Adrenergic blockers</td>
<td>AGMA inducers</td>
<td>Concretion formers</td>
</tr>
<tr>
<td>Antihistamines</td>
<td>Calcium channel blockers</td>
<td>Alcohol (ketoacidosis)</td>
<td>Dilantin Kapseals</td>
</tr>
<tr>
<td>Antiparkinsonian agents</td>
<td>Cardiac glycosides</td>
<td>Ethylene glycol</td>
<td>Drug packets</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>Cyclic antidepressants</td>
<td>Iron</td>
<td>Enteric-coated pills</td>
</tr>
<tr>
<td>Antispasmodics</td>
<td>Cholinergics</td>
<td>Methanol</td>
<td>Lomotil</td>
</tr>
<tr>
<td>Belladonna alkaloids</td>
<td>Acetylcholinesterase inhibitors</td>
<td>Salicylate</td>
<td>Opioids</td>
</tr>
<tr>
<td>Cyclic antidepressants</td>
<td>Muscarinic agonists</td>
<td>Toluene</td>
<td>Salicylates</td>
</tr>
<tr>
<td>Muscle relaxants</td>
<td>Nicotinic agonists</td>
<td>CNS syndromes</td>
<td>Sustained-release pills</td>
</tr>
<tr>
<td>Mushrooms and plants</td>
<td>Opioids</td>
<td>Extrapyramidal reactions</td>
<td>Slow distribution</td>
</tr>
<tr>
<td>Hallucinogens</td>
<td>Analgesics</td>
<td>Hydrocarbon inhalation</td>
<td>Cardiac glycosides</td>
</tr>
<tr>
<td>Cannabinoids (marijuana)</td>
<td>GI antispasmodics</td>
<td>Isoniazid</td>
<td>Lithium</td>
</tr>
<tr>
<td>LSD and analogues</td>
<td>Heroin</td>
<td>Lithium</td>
<td>Metals</td>
</tr>
<tr>
<td>Mescaline and analogues</td>
<td>Sedative-hypnotics</td>
<td>Neuroleptic malignant syndrome</td>
<td>Salicylate</td>
</tr>
<tr>
<td>Mushrooms</td>
<td>Alcohols</td>
<td>Serotonin syndrome</td>
<td>Toxic metabolite</td>
</tr>
<tr>
<td>Phencyclidine and analogues</td>
<td>Anticonvulsants</td>
<td>Stycnine</td>
<td>Acetaminophen</td>
</tr>
<tr>
<td>Withdrawal syndromes</td>
<td>Membrane-active agents</td>
<td>Membrane-active agents</td>
<td>Carbon tetrachloride</td>
</tr>
<tr>
<td>Barbiturates</td>
<td>Benzodiazepines</td>
<td>Amantidine</td>
<td>Cyanogenic glycosides</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>GABA precursors</td>
<td>Antiarrhythmics</td>
<td>Ethylene glycol</td>
</tr>
</tbody>
</table>

(continued)
### TABLE 31-1  DIFFERENTIAL DIAGNOSIS OF POISONING BASED ON PHYSIOLOGIC STATE (CONTINUED)

<table>
<thead>
<tr>
<th>Stimulated</th>
<th>Depressed</th>
<th>Discordant</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethanol</td>
<td>Muscle relaxants</td>
<td>Antihistamines</td>
<td>Methanol</td>
</tr>
<tr>
<td>Opioids</td>
<td>Other agents</td>
<td>Antipsychotics</td>
<td>Methemoglobin inducers</td>
</tr>
<tr>
<td>Sedative-hypnotics</td>
<td>GHB Products</td>
<td>Carbamazepine</td>
<td>Mushroom toxins</td>
</tr>
<tr>
<td>Sympatholytics</td>
<td></td>
<td>Cyclic antidepressants</td>
<td>Organophosphate insecticides</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Local anesthetics</td>
<td>Paraquat</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Opioids (some)</td>
<td>Metabolism disruptors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Orphenadrine</td>
<td>Antineoplastic agents</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quinoline antimalarials</td>
<td>Antiviral agents</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Colchicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hypoglycemic agents</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Immunosuppressive agents</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MAO inhibitors</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Metals</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Salicylate</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Warfarins</td>
</tr>
</tbody>
</table>

**Note:** AGMA, anion-gap metabolic alkalosis; GHB, γ-hydroxybutyric; LSD, lysergic acid diethylamide; GABA, γ-aminobutyric acid; MAO, monoamine oxidase.
BUN of >10 mmol/L—suggests the presence of a low-molecular-weight solute such as an alcohol, glycol, or ketone or an unmeasured electrolyte or sugar. Ketosis suggests acetone, isopropyl alcohol, or salicylate poisoning. Hypoglycemia may be due to poisoning with β-adrenergic blockers, ethanol, insulin, oral hypoglycemic agents, quinine, and salicylates, whereas hyperglycemia can occur in poisoning with acetone, β-adrenergic agonists, calcium channel blockers, iron, theophylline, or Vacor.

Radiologic studies should include a chest x-ray to exclude aspiration or ARDS. Radiopaque densities may be visible on abdominal x-rays. Head CT or MRI is indicated in stuporous or comatose pts to exclude structural lesions or subarachnoid hemorrhage, and LP should be performed when CNS infection is suspected. The ECG can be useful to assist with the differential diagnosis and to guide treatment. Toxicologic analysis of urine and blood (and occasionally of gastric contents and chemical samples) may be useful to confirm or rule out suspected poisoning. Although rapid screening tests for a limited number of drugs of abuse are available, comprehensive screening tests require 2–6 h for completion, and immediate management must be based on the history, physical exam, and routine ancillary tests. Quantitative analysis is useful for poisoning with acetaminophen, acetone, alcohol (including ethylene glycol), antiarrhythmics, anticonvulsants, barbiturates, digoxin, heavy metals, lithium, salicylate, and theophylline, as well as for carboxyhemoglobin and methemoglobin. Results can often be available within an hour.

The response to antidotes may be useful for diagnostic purposes. Resolution of altered mental status and abnormal vital signs within minutes of intravenous administration of dextrose, naloxone, or flumazenil is virtually diagnostic of hypoglycemia, narcotic poisoning, and benzodiazepine intoxication, respectively. The prompt reversal of acute dystonic (extrapyramidal) reactions following an intravenous dose of benztropine or diphenhydramine confirms a drug etiology. Although physostigmine reversal of both central and peripheral manifestations of anticholinergic poisoning is diagnostic, it may cause arousal in patients with CNS depression of any etiology.

Goals of therapy include support of vital signs, prevention of further absorption, enhancement of elimination, administration of specific antidotes, and prevention of reexposure. Fundamentals of poisoning management are listed in Table 31-2. Treatment is usually initiated before routine and toxicologic data are known. All symptomatic pts need large-bore IV access, supplemental O₂, cardiac monitoring, continuous observation, and, if mental status is altered, 100 mg thiamine (IM or IV), 1 ampule of 50% dextrose in water, and 4 mg of naloxone along with specific antidotes as indicated. Unconscious pts should be intubated. Activated charcoal may be given PO or via a large-bore gastric tube; gastric lavage requires an orogastric tube. Severity of poisoning determines the management. Admission to an ICU is indicated for pts with severe poisoning (coma, respiratory depression, hypotension, cardiac conduction abnormalities, arrhythmias, hypothermia or hyperthermia, seizures); those needing close monitoring, antidotes, or enhanced elimination therapy; and those with progressive clinical deterioration or significant underlying medical problems. Suicidal pts require constant observation by qualified personnel.

Supportive Care
Airway protection is mandatory. Gag reflex alone is not a reliable indicator of the need for intubation. Need for O₂ supplementation and ventilatory support
Supraventricular tachycardia (SVT) with hypertension and CNS excitation is almost always due to sympathetic, anticholinergic, or hallucinogenic stimulation or to drug withdrawal. Treatment is indicated if associated with hemodynamic instability, chest pain, or ischemia on ECG. Treatment with combined alpha and beta blockers or combinations of beta blocker and vasodilator is indicated in severe sympathetic hyperactivity. Physostigmine is useful for anticholinergic hyperactivity. SVT without hypertension usually responds to fluid administration.

Ventricular tachycardia (VT) can be caused by sympathetic stimulation, myocardial membrane destabilization, or metabolic derangements. Lidocaine and phenytoin are generally safe. Drugs that prolong the QT interval (quinidine, procainamide) should not be used in VT due to tricyclic antidepressant
overdose. Magnesium sulfate and overdrive pacing (by isoproterenol or a pacemaker) may be useful for torsades de pointes. Arrhythmias may be resistant to therapy until underlying acid-base and electrolyte derangements, hypoxia, and hypothermia are corrected. It is acceptable to observe hemodynamically stable pts without pharmacologic intervention.

Seizures are best treated with γ-aminobutyric acid agonists such as benzodiazepines or barbiturates. Barbiturates should be given only after intubation. Seizures caused by isoniazid overdose may respond only to large doses of pyridoxine IV. Seizures from beta blockers or tricyclic antidepressants may require phenytoin and benzodiazepines.

**Prevention of Poison Absorption**

Whether or not to perform GI decontamination, and which procedure to use, depends on the time since ingestion; the existing and predicted toxicity of the ingestant; the availability, efficacy, and contraindications of the procedure; and the nature, severity, and risk of complications. The efficacy of activated charcoal and gastric lavage decreases with time, and there are insufficient data to support or exclude a beneficial effect when they are used >1 h after ingestion. Activated charcoal has comparable or greater efficacy, fewer contraindications and complications, and is less invasive than gastric lavage and is the preferred method of GI decontamination in most situations.

Activated charcoal is prepared as a suspension in water, either alone or with a cathartic. It is given orally via a nipped bottle (for infants), or via a cup, straw, or small-bore nasogastric tube. The recommended dose is 1 g/kg body weight, using 8 mL of diluent per gram of charcoal if a premixed formulation is not available. Charcoal may inhibit absorption of other orally administered agents and is contraindicated in pts with corrosive ingestion.

When indicated, gastric lavage is performed using a 28F orogastric tube in children and a 40F orogastric tube in adults. Saline or tap water may be used in adults or children (use saline in infants). Place pt in Trendelenburg and left lateral decubitus position to minimize aspiration (occurs in 10% of pts). Lavage is contraindicated with corrosives and petroleum distillate hydrocarbons because of risk of aspiration-induced pneumonia and gastroesophageal perforation.

Whole-bowel irrigation may be useful with ingestions of foreign bodies, drug packets, and slow-release medications. Golytely is given orally or by gastric tube up to a rate of 2 L/h. Cathartic salts (magnesium citrate) and saccharides (sorbitol, mannitol) promote evacuation of the rectum. Dilution of corrosive acids and alkali is accomplished by having pt drink 5 mL water/kg. Endoscopy or surgical intervention may be required in large foreign-body ingestion, heavy metal ingestion, and when ingested drug packets leak or rupture.

Syrup of ipecac, once the most commonly used decontamination procedure, has no role in the hospital setting. The American Academy of Pediatrics (AAP) issued a policy statement in 2003 recommending that ipecac should no longer be routinely considered in poisoning treatment. Some argue it can still be considered for the home management of patients with accidental ingestions, reliable histories, and mild predicted toxicity when transport to a hospital site is prolonged. It is administered orally in doses of 30 mL for adults, 15 mL for children, and 10 mL for infants. Vomiting should occur within 20 min. Ipecac is contraindicated with marginal airway patency, CNS depression, recent GI surgery, seizures, corrosive (lye) ingestion, petroleum hydrocarbon ingestion, and rapidly acting CNS poisons (camphor, cyanide, tricyclic antidepressants, propoxyphene, strychnine).

Skin and eyes are decontaminated by washing with copious amounts of water or saline.
<table>
<thead>
<tr>
<th>Physiologic Condition, Causes</th>
<th>Examples</th>
<th>Mechanism of Action</th>
<th>Clinical Features</th>
<th>Specific Treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stimulated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sympathetics (see also Chap. 389)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sympathomimetics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>α₁-Adrenergic agonists (decongestants): phenylephrine, phenylpropanolamine</td>
<td></td>
<td>Stimulation of central and peripheral sympathetic receptors directly or indirectly (by promoting the release or inhibiting the reuptake of norepinephrine and sometimes dopamine)</td>
<td>Physiologic stimulation (Table e35-2); reflex bradycardia can occur with selective α₁ agonists; β agonists can cause hypotension and hypokalemia.</td>
<td>Phentolamine, a nonselective α₁-adrenergic receptor antagonist, for severe hypertension due to α₁-adrenergic agonists; propranolol, a nonselective β blocker, for hypotension and tachycardia due to β₂ agonists; labetalol, a β blocker with α-blocking activity, or phentolamine with esmolol, metoprolol, or other cardioselective β blocker for hypertension with tachycardia due to nonselective agents (β blockers, if used alone, can exacerbate hypertension and vasospasm due to unopposed α stimulation); benzodiazepines; propofol.</td>
</tr>
<tr>
<td>β₂-Adrenergic agonists (bronchodilators): albuterol, terbutaline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonspecific adrenergic agonists: amphetamines, cocaine, ephedrine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class</td>
<td>Drugs</td>
<td>Effects</td>
<td>Treatment</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Ergot alkaloids</td>
<td>Ergotine, methysergide, bromocriptine, pergolide</td>
<td>Stimulation and inhibition of serotonergic and α-adrenergic receptors; stimulation of dopamine receptors</td>
<td>Physiologic stimulation (Table e35-2); formation; vasospasm with limb (isolated or generalized), myocardial, and cerebral ischemia progressing to gangrene or infarction; hypotension, bradycardia, and involuntary movements can also occur.</td>
<td>Nitroprusside or nitroglycerine for severe vasospasm; prazocin (an α₁ blocker), captopril, nifedipine, and cyproheptadene (a serotonin receptor antagonist) for mild to moderate limb ischemia; dopamine receptor antagonists (antipsychotics) for hallucinations and movement disorders</td>
</tr>
<tr>
<td>Methylxanthines</td>
<td>Caffeine, theophylline</td>
<td>Inhibition of adenosine synthesis and adenosine receptor antagonism; stimulation of epinephrine and norepinephrine release; inhibition of phosphodiesterase resulting in increased intracellular cyclic adenosine and guanosine monophosphate</td>
<td>Physiologic stimulation (Table e35-2); pronounced gastrointestinal symptoms and β agonist effects (see above). Toxicity occurs at lower drug levels in chronic poisoning than in acute poisoning.</td>
<td>Propranolol, a nonselective β blocker, for tachycardia with hypotension; any β blocker for supraventricular or ventricular tachycardia without hypotension; elimination enhanced by multiple-dose charcoal, hemoperfusion, and hemodialysis; indications for hemoperfusion or hemodialysis include unstable vital signs, seizures, and a theophylline level of 80–100 μg/mL after acute overdose and 40–60 μg/mL with chronic exposure.</td>
</tr>
<tr>
<td>Physiologic Condition, Causes</td>
<td>Examples</td>
<td>Mechanism of Action</td>
<td>Clinical Features</td>
<td>Specific Treatments</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Monoamine oxidase inhibitors</td>
<td>Phenelzine, tranylcypromine, selegiline</td>
<td>Inhibition of monoamine oxidase resulting in impaired metabolism of endogenous catecholamines and exogenous sympathomimetic agents</td>
<td>Delayed or slowly progressive physiologic stimulation (Table e35-2); terminal hypotension and bradycardia in severe cases.</td>
<td>Short-acting agents (e.g., nitroprusside, esmolol) for severe hypertension and tachycardia; direct-acting sympathomimetics (e.g., norepinephrine, epinephrine) for hypotension and bradycardia</td>
</tr>
<tr>
<td>Anticholinergics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antihistamines</td>
<td>Diphenhydramine, doxylamine, pyrilamine</td>
<td>Inhibition of central and postganglionic parasympathetic muscarinic cholinergic receptors. At high doses, amantidine, diphenhydramine, orphenadrine, phenothiazines, and tricyclic antidepressants have additional nonanticholinergic activity (see below).</td>
<td>Physiologic stimulation (Table e35-2); dry skin and mucous membranes, decreased bowel sounds, flushing, and urinary retention; myoclonus and picking activity. Central effects may occur without significant autonomic dysfunction.</td>
<td>Physostigmine, an acetylcholinesterase inhibitor (see below) for delirium, hallucinations, and neuromuscular hyperactivity. Contraindications include nonanticholinergic cardiovascular toxicity (e.g., cardiac conduction abnormalities, hypotension, and ventricular arrhythmias).</td>
</tr>
<tr>
<td>Antiparkinsonian agents</td>
<td>Amantidine, trihexyphenidyl</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>Chlorpromazine, olanzapine, quetiapine, thioridazine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antispasmodics</td>
<td>Clinidium, dicyclomine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belladonna alkaloids</td>
<td>Atropine, hyoscyamine, scopolamine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclic antidepressants</td>
<td>Amitriptyline, doxepin, imipramine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscle relaxants</td>
<td>Cyclobenzaprine, orphenadrine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mushrooms and plants</td>
<td>Amanita muscaria and A. pantherina, henbane, jimson weed, nightshade</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Depressed

<table>
<thead>
<tr>
<th>Sympatholytics</th>
<th>Clonidine, guanabenz, tetrahydrozoline and other imidazoline decongestants, tizanidine and other imidazoline muscle relaxants</th>
<th>Stimulation of $\alpha_2$-adrenergic receptors leading to inhibition of CNS sympathetic outflow; activity at nonadrenergic imidazoline binding sites also contributes to CNS effects.</th>
<th>Physiologic depression (Table e35-2), miosis. Transient initial hypertension may be seen.</th>
<th>Dopamine and norepinephrine for hypotension. Atropine for symptomatic bradycardia. Naloxone for CNS depression (inconsistently effective).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antipsychotics</td>
<td>Chlorpromazine, clozapine, haloperidol, risperidone, thioridazine</td>
<td>Inhibition of $\alpha$-adrenergic, dopaminergic, histaminergic, muscarinic, and serotonergic receptors. Some agents also inhibit sodium, potassium, and calcium channels.</td>
<td>Physiologic depression (Table e35-2), miosis, anticholinergic effects (see above), extrapyramidal reactions (see below), tachycardia. Cardiac conduction delays (increased PR, QRS, JT, and QT intervals) with ventricular tachydysrhythmias, including torsades des pointes, can sometimes develop.</td>
<td>Sodium bicarbonate and lidocaine for ventricular tachydysrhythmias associated with QRS prolongation. Magnesium, isoproterenol, and overdrive pacing for torsades de pointes. Avoid class IA, IC, and III antiarrhythmics.</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Physiologic Condition, Causes</th>
<th>Examples</th>
<th>Mechanism of Action</th>
<th>Clinical Features</th>
<th>Specific Treatments</th>
</tr>
</thead>
</table>
| **β-Adrenergic blockers**     | Cardioselective (β₁) blockers: atenolol, esmolol, metoprolol  
Nonselective (β₁ and β₂) blockers: nadolol, propranolol, timolol  
Partial β agonists: acebutolol, pindolol  
α₁ Antagonists: carvedilol, labetalol  
Membrane-active agents: acebutolol, propranolol, sotalol | Inhibition of β-adrenergic receptors (class II antiarrhythmic effect). Some agents have activity at additional receptors or have membrane effects (see below). | Physiologic depression (Table e35-2), atrioventricular block, hypoglycemia, hyperkalemia, seizures. Partial agonists can cause hypertension and tachycardia. Sotalol can cause increased QT interval and ventricular tachydysrhythmias. Onset may be delayed after sotalol and sustained-release formulation overdose. | Glucagon and calcium for hypotension and symptomatic bradycardia. Atropine, isoproterenol, amrinone, dopamine, dobutamine, epinephrine, and norepinephrine may sometimes be effective. High-dose insulin (with glucose and potassium to maintain euglycemia and normokalemia), electrical pacing, and mechanical cardiovascular support for refractory cases. |
| **Calcium channel blockers**  | Diltiazem, nifedipine and other dihydropyridine derivatives, verapamil | Inhibition of slow (type L) cardiovascular calcium channels (class IV antiarrhythmic effect). | Physiologic depression (Table e35-2), atrioventricular block, organ ischemia and infarction, hyperglycemia, seizures. Hypotension is usually due to decreased vascular resistance rather than to decreased cardiac output. Onset may be delayed for ≥12 h after overdose of sustained-release formulations. | Calcium and glucagon for hypotension and symptomatic bradycardia. Dopamine, epinephrine, norepinephrine, atropine, and isoproterenol are less often effective but can be used adjunctively. Amrinone, high-dose insulin (with glucose and potassium to maintain euglycemia and normokalemia), electrical pacing, and mechanical cardiovascular support for refractory cases. |
Cardiac glycosides

Digoxin, endogenous cardioactive steroids, foxglove and other plants, toad skin secretions (*Bufo*onidae sp.)

Inhibition of cardiac Na⁺, K⁺-ATPase membrane pump.

Physiologic depression (Table e35-2); gastrointestinal, psychiatric, and visual symptoms; atrioventricular block with or without concomitant supraventricular tachyarrhythmia; ventricular tachyarrhythmias. Hyperkalemia in acute poisoning. Toxicity occurs at lower drug levels in chronic poisoning than in acute poisoning.

Digoxin-specific antibody fragments for hemodynamically compromising dysrhythmias, Mobitz II or third-degree atrioventricular block, hyperkalemia (>5.5 meq/L; in acute poisoning only). Temporizing measures include atropine, dopamine, epinephrine, phenytoin, and external cardiac pacing for bradydysrhythmias and magnesium, lidocaine, phenytoin, and bretylium for ventricular tachydysrhythmias. Internal cardiac pacing and cardioversion can increase ventricular irritability and should be reserved for refractory cases.

Cyclic antidepressants

Amitriptyline, doxepin, imipramine

Inhibition of α-adrenergic, dopaminergic, GABA-ergic, histaminergic, muscarinic, and serotonergic receptors; inhibition of sodium channels (see membrane-active agents); inhibition of norepinephrine and serotonin reuptake.

Physiologic depression (Table e35-2), seizures, tachycardia, cardiac conduction delays (increased PR, QRS, JT, and QT intervals; terminal QRS right axis deviation) with aberrancy and ventricular tachydysrhythmias. Anticholinergic toxidrome (see above).

Hypertonic sodium bicarbonate (or hypertonic saline) and lidocaine for ventricular tachydysrhythmias associated with QRS prolongation. Use of phenytoin is controversial. Avoid class IA, IC, and III antiarrhythmics.

(continued)
<table>
<thead>
<tr>
<th>Physiologic Condition, Causes</th>
<th>Examples</th>
<th>Mechanism of Action</th>
<th>Clinical Features</th>
<th>Specific Treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cholinergics</strong>&lt;br&gt;Acetylcholinesterase inhibitors</td>
<td>Carbamate insecticides (aldicarb, carbaryl, propoxur) and medicinals (neostigmine, physostigmine, tacrine); nerve gases (sarin, soman, tabun, VX) organophosphate insecticides (diazinon, chlorpyrifos, malathion)</td>
<td>Inhibition of acetylcholinesterase leading to increased synaptic acetylcholine at muscarinic and nicotinic cholinergic receptor sites</td>
<td>Physiologic depression (Table e35-2). Muscarinic signs and symptoms: seizures, excessive secretions (lacrimation, salivation, bronchorrhea and wheezing, diaphoresis), and increased bowel and bladder activity with nausea, vomiting, diarrhea, abdominal cramps, and incontinence of feces and urine. Nicotinic signs and symptoms: hypertension, tachycardia, muscle cramps, fasciculations, weakness, and paralysis. Death is usually due to respiratory failure. Cholinesterase activity in plasma and red cells &lt;50% of normal in acetylcholinesterase inhibitor poisoning.</td>
<td>Atropine for muscarinic signs and symptoms. Pralidoxime (2-PAM), a cholinesterase reactivator, for nicotinic signs and symptoms due to organophosphates, nerve gases, or an unknown anticholinesterase.</td>
</tr>
<tr>
<td><strong>Muscarinic agonists</strong></td>
<td>Bethanecol, mushrooms (Boletus, Clitocybe, Inocybe sp.), pilocarpine</td>
<td>Stimulation of CNS and postganglionic parasympathetic cholinergic (muscarinic) receptors</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nicotinic agonists</strong></td>
<td>Lobeline, nicotine (tobacco)</td>
<td>Stimulation of preganglionic sympathetic and parasympathetic and striated muscle (neuromuscular junction) cholinergic (nicotine) receptors</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Sedative-hypnotics (see also Chap. 388)

#### Anticonvulsants
- Carbamazepine, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, tiagabine, topiramate, valproate, zonisamide

#### Anticonvulsants
- Potentiation of the inhibitory effects of GABA by binding to the neuronal GABA-A chloride channel receptor complex and increasing the frequency or duration of chloride channel opening in response to GABA stimulation. Baclofen and, to some extent, GHB act at the GABA-B receptor complex; meprobamate, its metabolite carisoprodol, felbamate, and orphenadrine antagonize N-methyl-D-aspartate (NDMA) excitatory receptors; ethosuximide, valproate, and zonisamide decrease conduction through T-type calcium channels; valproate

#### Physiologic depression (Table e35-2), nystagmus. Delayed absorption can occur with carbamazepine, phenytoin, and valproate. Myoclonus, seizures, hypertension, and tachyarrhythmias can occur with baclofen, carbamazepine, and orphenadrine.

Tachyarrhythmias can also occur with chloral hydrate. AGMA, hypernatremia, hyperosmolality, hyperammonemia, chemical hepatitis, and hypoglycemia can be seen in valproate poisoning. Carbamazepine and oxcarbazepine may produce hyponatremia from SIADH.

Flumazenil for benzodiazepine and zolpidem poisoning. Benzodiazepines and barbiturates for seizures. Elimination of phenobarbital and possibly other long-acting agents enhanced by multiple-dose charcoal. Hemodialysis and hemoperfusion may be indicated for severe poisoning by some agents (see Extracorporeal Removal, in text). See above and below for treatment of anticholinergic and sodium channel (membrane) blocking effects.
<table>
<thead>
<tr>
<th>Physiologic Condition, Causes</th>
<th>Examples</th>
<th>Mechanism of Action</th>
<th>Clinical Features</th>
<th>Specific Treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>GABA precursors</td>
<td>γ-Hydroxybutyrate (sodium oxybate; GHB), γ-butyrolactone (GBL), 1,4-butanediol.</td>
<td>Decreases GABA degradation, and tiagabine blocks GABA reuptake; carbamazepine, lamotrigine, oxcarbazepine, phenytoin, topiramate, valproate, and zonisamide slow the rate of recovery of inactivated sodium channels. Some agents also have α2 agonist, anticholinergic, and sodium channel blocking activity (see above and below).</td>
<td>Some agents can cause anti-cholinergic and sodium channel (membrane) blocking effects (see above and below).</td>
<td></td>
</tr>
<tr>
<td>Muscle relaxants</td>
<td>Baclofen, carisoprodol, cyclobenzaprine, etomidate, metaxalone, methocarbamol, orphenadrine, propofol, tizanidine and other imidazoline muscle relaxants.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other agents</td>
<td>Chloral hydrate, ethchlorvynol, glutethimide, meprobamate, methaqualone, methyprylon.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asphyxiants</td>
<td>Carbon monoxide, cyanide, hydrogen sulfide</td>
<td>Inhibition of mitochondrial cytochrome oxidase, thereby blocking electron transport and oxidative metabolism. Carbon monoxide also binds to hemoglobin and myoglobin and prevents oxygen binding, transport, and tissue uptake (binding to hemoglobin shifts the oxygen dissociation curve to the left).</td>
<td>Signs and symptoms of hypoxia with initial physiologic stimulation and subsequent depression (Table e35-2); lactic acidosis; normal ( P_O_2 ) and calculated oxygen saturation but decreased oxygen saturation by co-oximetry (that measured by pulse oximetry is falsely elevated but is less than normal and less than the calculated value). Headache and nausea are common with carbon monoxide. Sudden collapse may occur with cyanide and hydrogen sulfide exposure. A bitter almond breath odor may be noted with cyanide ingestion, and hydrogen sulfide smells like rotten eggs.</td>
<td>High-dose oxygen. Inhaled amyl nitrite and IV sodium nitrite and sodium thiosulfate (Lilly cyanide antidote kit) for coma, metabolic acidosis, and cardiovascular dysfunction in cyanide poisoning. Amyl and sodium nitrite (without thiosulfate) for similar toxicity in hydrogen sulfide poisoning. Hyperbaric oxygen for moderate to severe carbon monoxide poisoning and for cyanide or hydrogen sulfide poisoning unresponsive to other measures.</td>
</tr>
<tr>
<td>Physiologic Condition, Causes</td>
<td>Examples</td>
<td>Mechanism of Action</td>
<td>Clinical Features</td>
<td>Specific Treatments</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Methemoglobin inducers</td>
<td>Aniline derivatives, dapsone, local anesthetics, nitrates, nitrites, nitrogen oxides, nitro- and nitrosohydrocarbons, phenazopyridine, primaquine-type antimalarials, sulfonamides.</td>
<td>Oxidation of hemoglobin iron from ferrous (Fe2+) to ferric (Fe3+) state prevents oxygen binding, transport, and tissue uptake (methemoglobinemia shifts oxygen dissociation curve to the left). Oxidation of hemoglobin protein causes hemoglobin precipitation and hemolytic anemia (manifest as Heinz bodies and “bite cells” on peripheral blood smear).</td>
<td>Signs and symptoms of hypoxia with initial physiologic stimulation and subsequent depression (Table e35-2), gray-brown cyanosis unresponsive to oxygen at methemoglobin fractions &gt; 15–20%, headache, lactic acidosis (at methemoglobin fractions &gt; 45%), normal PO2 and calculated oxygen saturation but decreased oxygen saturation and increased methemoglobin fraction by co-oximetry (oxygen saturation by pulse oximetry may be falsely increased or decreased but is less than normal and less than the calculated value).</td>
<td>High-dose oxygen. Intravenous methylene blue for methemoglobin fraction &gt; 30%, symptomatic hypoxia, or ischemia (contraindicated in G6PD deficiency). Exchange transfusion and hyperbaric oxygen for severe or refractory cases.</td>
</tr>
<tr>
<td>AGMA inducers</td>
<td>Ethylene glycol</td>
<td>Ethylene glycol causes CNS depression and increased serum osmolality. Metabolites (primarily glycolic acid) cause AGMA, CNS depression, and renal failure. Precipitation of oxalic acid metabolite as calcium salt in tissues and urine results in hypocalcemia, tissue edema, and crystalluria. Initial ethanol-like intoxication, nausea, vomiting, increased osmolar gap, calcium oxylate crystalluria. Delayed AGMA, back pain, renal failure. Coma, seizures, hypotension, ARDS in severe cases. Gastric aspiration for recent ingestions. Sodium bicarbonate to correct acidemia. Thiamine, folic acid, magnesium, and high-dose pyridoxine to facilitate metabolism. Ethanol or fomepizole for AGMA, crystalluria or renal dysfunction, ethylene glycol level &gt; 3 mmol/L (20 mg/dL), and for ethanol-like intoxication or increased osmolar gap if level not readily obtainable. Hemodialysis for persistent AGMA, lack of clinical improvement, and renal dysfunction. Hemodialysis also useful for enhancing ethylene glycol elimination and shortening duration of treatment when ethylene glycol level &gt; 8 mmol/L (50 mg/dL).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGMA inducers</td>
<td>Iron</td>
<td>Hydration of ferric (Fe³⁺) ion generates H⁺. Non-transferin-bound iron catalyzes formation of free radicals that cause mitochondrial injury, lipid peroxidation, increased capillary permeability, vasodilation, and organ toxicity. Initial nausea, vomiting, abdominal pain, diarrhea. AGMA, cardiovascular and CNS depression, hepatitis, coagulopathy, and seizures in severe cases. Radiopaque iron tablets may be seen on abdominal x-ray. Whole-bowel irrigation for large ingestions. Endoscopy and gastrotomy if clinical toxicity and large number of tablets still visible on x-ray. IV hydration. Sodium bicarbonate for acidemia. IV deferoxamine for systemic toxicity, iron level &gt; 90 μmol/L (500 μg/dL).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physiologic Condition, Causes</td>
<td>Examples</td>
<td>Mechanism of Action</td>
<td>Clinical Features</td>
<td>Specific Treatments</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Methanol</td>
<td></td>
<td>Methanol causes ethanol-like CNS depression and increased serum osmolality. Formic acid metabolite causes AGMA and retinal toxicity.</td>
<td>Initial ethanol-like intoxication, nausea, vomiting, increased osmolar gap. Delayed AGMA, visual (clouding, spots, blindness) and retinal (edema, hyperemia) abnormalities. Coma, seizures, cardiovascular depression in severe cases. Possible pancreatitis.</td>
<td>Gastric aspiration for recent ingestions. Sodium bicarbonate to correct acidemia. High-dose folic acid or folate to facilitate metabolism. Ethanol or fomepizole for AGMA, visual symptoms, methanol level &gt; 6 mmol/L (20 mg/dL), and for ethanol-like intoxication or increased osmolar gap if level not readily obtainable. Hemodialysis for persistent AGMA, lack of clinical improvement, and renal dysfunction. Hemodialysis also useful for enhancing methanol elimination and shortening duration of treatment when methanol level &gt; 15 mmol/L (50 mg/dL).</td>
</tr>
<tr>
<td><strong>CNS syndromes</strong></td>
<td><strong>Extrapyramidal reactions</strong></td>
<td><strong>Antipsychotics (see above), some cyclic antidepressants and antihistamines.</strong></td>
<td><strong>Decreased CNS dopaminergic activity with relative excess of cholinergic activity.</strong></td>
<td><strong>Akathisia, dystonia, parkinsonism</strong></td>
</tr>
<tr>
<td>-------------------</td>
<td>----------------------------</td>
<td>-----------------------------------------------------------------</td>
<td>-----------------------------------------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>Salicylate</td>
<td>Increased sensitivity of CNS respiratory center to changes in $P_{O_2}$ and $P_{CO_2}$ stimulates respiration. Uncoupling of oxidative phosphorylation, inhibition of Kreb’s cycle enzymes, and stimulation of carbohydrate and lipid metabolism generate unmeasured endogenous anions and cause AGMA.</td>
<td>Initial nausea, vomiting, hyperventilation, alkalemia, alkaluria. Subsequent alkalemia with both respiratory alkalosis and AGMA, and paradoxical aciduria. Late acidemia with CNS and respiratory depression. Cerebral and pulmonary edema in severe cases. Hypoglycemia, hypocalcemia, hypokalemia, and seizures can occur.</td>
<td>IV hydration and supplemental glucose. Sodium bicarbonate to correct acidemia. Alkaline diuresis for systemic toxicity. Hemodialysis for coma, cerebral edema, seizures, pulmonary edema, renal failure, progressive acid-base disturbances or clinical toxicity, salicylate level &gt; 7 mmol/L (100 mg/dL) following acute overdose.</td>
<td>(continued)</td>
</tr>
<tr>
<td>Physiologic Condition, Causes</td>
<td>Examples</td>
<td>Mechanism of Action</td>
<td>Clinical Features</td>
<td>Specific Treatments</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Isoniazid</td>
<td></td>
<td>Interference with activation and supply of pyridoxal-5-phosphate, a cofactor for glutamic acid decarboxylase, which converts glutamic acid to GABA, results in decreased levels of this inhibitory CNS neurotransmitter; complexation with and depletion of pyridoxine itself; inhibition of nicotinamide adenine dinucleotide dependent lactate and hydroxybutyrate dehydrogenases resulting in substrate accumulation.</td>
<td>Nausea, vomiting, agitation, confusion; coma, respiratory depression, seizures, lactic and ketoacidosis in severe cases.</td>
<td>High-dose intravenous pyridoxine (vitamin B6) for agitation, confusion, coma, and seizures. Diazepam or barbiturates for seizures.</td>
</tr>
</tbody>
</table>
Lithium

Interference with cell membrane ion transport, adenylate cyclase and $\text{Na}^+$, $\text{K}^+$-ATPase activity, and neurotransmitter release.

Nausea, vomiting, diarrhea, ataxia, choreoathetosis, encephalopathy, hyperreflexia, myoclonus, nystagmus, nephrogenic diabetes insipidus, falsely elevated serum chloride with low anion gap, tachycardia. Coma, seizures, arrhythmias, hyperthermia, and prolonged or permanent encephalopathy and movement disorders in severe cases. Delayed onset after acute overdose, particularly with delayed-release formations. Toxicity occurs at lower drug levels in chronic poisoning than in acute poisoning.

Whole-bowel irrigation for large ingestions. Consider endoscopic removal if high and rising drug level with progressive clinical toxicity. IV hydration. Hemodialysis for coma, seizures, severe, progressive, or persistent encephalopathy or neuromuscular dysfunction, peak lithium level $> 8$ meq/L (mmol/L) following acute overdose.

(continued)
### TABLE 31-3 PATHOPHYSIOLOGIC FEATURES AND TREATMENT OF SPECIFIC TOXIC SYNDROMES AND POISONINGS (CONTINUED)

<table>
<thead>
<tr>
<th>Physiologic Condition, Causes</th>
<th>Examples</th>
<th>Mechanism of Action</th>
<th>Clinical Features</th>
<th>Specific Treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serotonin syndrome</td>
<td>Amphetamines, cocaine, dextromethorphan, meperidine, MAO inhibitors, selective serotonin (5HT) reuptake inhibitors, tricyclic antidepressants, tramadol, triptans, tryptophan.</td>
<td>Promotion of serotonin release, inhibition of serotonin reuptake, or direct stimulation of CNS and peripheral serotonin receptors (primarily 5HT-1a and 5HT-2), alone or in combination.</td>
<td>Altered mental status (agitation, confusion, mutism, coma, seizures), neuromuscular hyperactivity (hyperreflexia, myoclonus, rigidity, tremors), and autonomic dysfunction (abdominal pain, diarrhea, diaphoresis, fever, flushing, labile hypertension, mydriasis, tearing, salivation, tachycardia). Complications include hyperthermia, lactic acidosis, rhabdomyolysis, and multisystem organ failure.</td>
<td>Serotonin receptor antagonist such as cyproheptadine or chlorpromazine.</td>
</tr>
</tbody>
</table>
Membrane-active agents

Amantidine, antiarrhythmics (class I and III agents; some β blockers), antipsychotics (see above), antihistamines (particularly diphenhydramine), carbamazepine, local anesthetics (including cocaine), opioids (meperidine, propoxyphene), orphenadrine, quinoline antimalarials (chloroquine, hydroxychloroquine, quinine), cyclic antidepressants (see above).

Blockade of fast sodium membrane channels prolongs phase 0 (depolarization) of the cardiac action potential, which prolongs the QRS duration and promotes reentrant (monomorphic) ventricular tachycardia. Class Ia, Ic, and III antiarrhythmics also block potassium channels during phases 2 and 3 (repolarization) of the action potential, prolonging the JT interval and promoting early after-depolarizations and polymorphic (torsades des pointes) ventricular tachycardia. Similar effects on neuronal membrane channels cause CNS dysfunction. Some agents also block α-adrenergic and cholinergic receptors or have opioid effects (see above and Chap. 388).

QRS and JT prolongation (or both) with hypotension, ventricular tachyarrhythmias, CNS depression, seizures. Anti-cholinergic effects with amantidine, antihistamines, carbamazepine, disopyramide, antipsychotics, and cyclic antidepressants (see above). Opioid effects with meperidine and propoxyphene (see Chap. 388). Cinchonism (hearing loss, tinnitus, nausea, vomiting, vertigo, ataxia, headache, flushing, diaphoresis) and blindness with quinoline antimalarials.

Hypertonic sodium bicarbonate (or hypertonic saline) for cardiac conduction delays and monomorphic ventricular tachycardia. Lidocaine for monomorphic ventricular tachycardia (except when due to class Ib antiarrhythmics). Magnesium, isoproterenol, and overdrive pacing for polymorphic ventricular tachycardia. Phystostigmine for anticholinergic effects (see above). Naloxone for opioid effects (see Chap. 388). Extracorporeal removal for some agents (see text).

Note: AGMA, anion-gap metabolic acidosis; ARDS, adult respiratory distress syndrome; CNS, central nervous system; GABA, γ-aminobutyric acid; G6PD, glucose-6-phosphate dehydrogenase; MAO, monoamine oxidase; SIADH, syndrome of inappropriate antidiuretic hormone.
# TABLE 31-4 HEAVY METALS

<table>
<thead>
<tr>
<th>Main Sources</th>
<th>Metabolism</th>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Arsenic</strong></td>
<td>Organic arsenic (arsenobetaine, arsenocholine) is ingested in seafood and fish, but is nontoxic; inorganic arsenic is readily absorbed (lung and GI); sequesters in liver, spleen, kidneys, lungs, and GI tract; residues persist in skin, hair, and nails; biomethylation results in detoxification, but this process saturates.</td>
<td>Acute arsenic poisoning results in necrosis of intestinal mucosa with hemorrhagic gastroenteritis, fluid loss, hypotension, delayed cardiomyopathy, acute tubular necrosis, and hemolysis. Chronic arsenic exposure causes diabetes, vasospasm, peripheral vascular insufficiency and gangrene, peripheral neuropathy, and cancer of skin, lung, liver (angiosarcoma), bladder, kidney. Lethal dose: 120–200 mg (adults); 2 mg/kg (children).</td>
</tr>
<tr>
<td>Smelting and microelectronics industries; wood preservatives, pesticides, herbicides, fungicides; contaminant of deep-water wells; folk remedies; and coal; incineration of these products</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cadmium</strong></td>
<td>Absorbed through ingestion or inhalation; bound by metallothionein, filtered at the glomerulus, but reabsorbed by proximal tubules (thus, poorly excreted). Biologic 1/2 life: 10–30 y. Binds cellular sulfhydryl groups, competes with zinc, calcium for binding sites. Concentrates in liver and kidneys.</td>
<td>Acute cadmium inhalation causes pneumonitis after 4–24 h; acute ingestion causes gastroenteritis. Chronic exposure causes anosmia, yellowing of teeth, emphysema, minor LFT elevations, microcytic hypochromic anemia unresponsive to iron therapy, proteinuria, increased urinary β2-microglobulin, calcification, leading to chronic renal failure, osteomalacia, and fractures.</td>
</tr>
<tr>
<td>Metal-plating, pigment, smelting, battery, and plastics industries; tobacco; incineration of these products; ingestion of food that concentrates cadmium (grains, cereals).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Diagnosis**

Nausea, vomiting, diarrhea, abdominal pain, delirium, coma, seizures; garlicky odor on breath; hyperkeratosis, hyperpigmentation, exfoliative dermatitis, and Mees’ lines (transverse white striae of the fingernails); sensory and motor polyneuritis, distal weakness. Radiopaque sign on abdominal x-ray; ECG–QRS broadening, QT prolongation, ST depression, T-wave flattening; 24-h urinary arsenic >67 μmol/d or 50 μg/d; (no seafood × 24 h); if recent exposure, serum arsenic >0.9 μmol/L (7 μg/dL). High arsenic in hair or nails.

**Treatment**

If acute ingestion, gastric lavage, activated charcoal with a cathartic. Supportive care in ICU. Dimercaprol 3–5 mg/kg IM q4h × 2 days; q6h × 1 day, then q12h × 10 days; alternative: oral succimer.

With inhalation: pleuritic chest pain, dyspnea, cyanosis, fever, tachycardia, nausea, noncardiogenic pulmonary edema. With ingestion: nausea, vomiting, cramps, diarrhea. Bone pain, fractures with osteomalacia. If recent exposure, serum cadmium >500 nmol/L (5 μg/dL). Urinary cadmium >100 nmol/L (10 μg/g creatinine) and/or urinary β2-microglobulin >750 μg/g creatinine (but urinary β2-microglobulin also increased in other renal diseases such as pyelonephritis).

**Treatment**

There is no effective treatment for cadmium poisoning (chelation not useful; dimercaprol can exacerbate nephrotoxicity). Avoidance of further exposure, supportive therapy, vitamin D for osteomalacia.

(continued)
### TABLE 31-4 HEAVY METALS (CONTINUED)

<table>
<thead>
<tr>
<th>Main Sources</th>
<th>Metabolism</th>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lead</strong></td>
<td>Absorbed through ingestion or inhalation; organic lead (e.g., tetraethyl lead) absorbed dermally. In blood, 95–99% sequestered in RBCs—thus, must measure lead in whole blood (not serum). Distributed widely in soft tissue, with $\frac{1}{2}$ life ~30 days; 15% of dose sequestered in bone with $\frac{1}{2}$ life of &gt;20 years. Excreted mostly in urine, but also appears in other fluids including breast milk. Interferes with mitochondrial oxidative phosphorylation, ATPases, calcium-dependent messengers; enhances oxidation and cell apoptosis.</td>
<td>Acute exposure with blood lead levels (BPb) of &gt; 60–80 μg/dL can cause impaired neurotransmission and neuronal cell death (with central and peripheral nervous system effects); impaired hematopoiesis and renal tubular dysfunction. At higher levels of exposure (e.g., BPb &gt; 80–120 μg/dL), acute encephalopathy with convulsions, coma, and death may occur. Subclinical exposures in children (BPb 25–60 μg/dL) are associated with anemia; mental retardation; and deficits in language, motor function, balance, hearing, behavior, and school performance. Impairment of IQ appears to occur at even lower levels of exposure with no measurable threshold above the limit of detection in most assays of 1 μg/dL. In adults, chronic subclinical exposures (BPb &gt; 40 μg/dL) are associated with an increased risk of anemia, demyelinating peripheral neuropathy (mainly motor), impairments of reaction time, hypertension, ECG conduction delays, interstitial nephritis and chronic renal failure, diminished sperm counts, spontaneous abortions.</td>
</tr>
</tbody>
</table>
Abdominal pain, irritability, lethargy, anorexia, anemia, Fanconi’s syndrome, pyuria, azotemia in children with blood lead level (BPb) >80 μg/dL; may also see epiphyseal plate “lead lines” on long bone x-rays. Convulsions, coma at BPb > 120 μg/dL. Noticeable neurodevelopmental delays at BPb of 40–80 μg/dL; may also see symptoms associated with higher BPb levels. In the U.S., screening of all children when they begin to crawl (~6 months) is recommended by the CDC; source identification and intervention is begun if the BPb > 10 μg/dL. In adults, acute exposure causes similar symptoms as in children as well as headaches, arthralgias, myalgias, depression, impaired short-term memory, loss of libido. Physical exam may reveal a “lead line” at the gingiva-tooth border, pallor, wrist drop, and cognitive dysfunction (e.g., declines on the mini-mental status exam); lab tests may reveal a normocytic, normochromic anemia, basophilic stippling, an elevated blood protoporphyrin level (free erythrocyte or zinc), and motor delays on nerve conduction. In the U.S., OSHA requires regular testing of lead-exposed workers with removal if BPb > 40 μg/dL.

Identification and correction of exposure sources is critical. In some U.S. states, screening and reporting to local health boards of children with BPb > 10 μg/dL and workers with BPb > 40 μg/dL is required. In the highly exposed individual with symptoms, chelation is recommended with oral DMSA (succimer); if acutely toxic, hospitalization and IV or IM chelation with edentate calcium disodium (CaEDTA) may be required, with the addition of dimercaprol to prevent worsening of encephalopathy. It is uncertain whether children with asymptomatic lead exposure (e.g., BPb 20–40 μg/dL) benefit from chelation. Correction of dietary deficiencies in iron, calcium, magnesium, and zinc will lower lead absorption and may also improve toxicity. Vitamin C is a weak but natural chelating agent.
### TABLE 31-4  HEAVY METALS (CONTINUED)

<table>
<thead>
<tr>
<th>Main Sources</th>
<th>Metabolism</th>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mercury</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metallic, mercurous, and mercuric mercury ((Hg^0, Hg^+, Hg^{2+})) exposures occur in some chemical, metal-processing, electrical-equipment, automotive industries; they are also in thermometers, dental amalgams, batteries. Mercury is dispersed by waste incineration. Environmental bacteria convert inorganic to organic mercury, which then bioconcentrates up the aquatic food chain to contaminate tuna, swordfish, and other pelagic fish.</td>
<td>Elemental mercury ((Hg^0)) is not well absorbed; however, it will volatilize into highly absorbable vapor. Inorganic mercury is absorbed through the gut and skin. Organic mercury is well absorbed through inhalation and ingestion. Elemental and organic mercury cross the blood-brain barrier and placenta. Mercury is excreted in urine and feces and has a (1/2) life in blood of (\sim 60) days; however, deposits will remain in the kidney and brain for years. Exposure to mercury stimulates the kidney to produce metallothionein, which provides some detoxification benefit. Mercury binds sulfhydryl groups and interferes with a wide variety of critical enzymatic processes.</td>
<td>Acute inhalation of (Hg^0) vapor causes pneumonitis and noncardiogenic pulmonary edema leading to death, CNS symptoms, and polyneuropathy. Chronic high exposure causes CNS toxicity (mercurial); lower exposures impair renal function, motor speed, memory, coordination. Acute ingestion of inorganic mercury causes gastroenteritis, the nephritic syndrome, or acute renal failure, hypertension, tachycardia, and cardiovascular collapse, with death at a dose of 10–42 mg/kg. Ingestion of organic mercury causes gastroenteritis, arrhythmias, and lesions in the basal ganglia, gray matter, and cerebellum at doses &gt;1.7 mg/kg. High exposure during pregnancy causes derangement of fetal neuronal migration resulting in severe mental retardation. Mild exposures during pregnancy (from fish consumption) are associated with declines in neurobehavioral performance in offspring. Dimethylmercury, a compound only found in research labs, is “supertoxic”—a few drops of exposure via skin absorption or inhaled vapor can cause severe cerebellar degeneration and death.</td>
</tr>
</tbody>
</table>

*Note: IQ, intelligence quotient; CDC, Centers for Disease Control and Prevention; OSHA, Occupational Safety and Health Administration; CNS.*
Chronic exposure to metallic mercury vapor produces a characteristic intention tremor and mercurial erethism: excitability, memory loss, insomnia, timidity, and delirium (“mad as a hatter”). On neurobehavioral tests: decreased motor speed, visual scanning, verbal and visual memory, visuomotor coordination. Children exposed to mercury in any form may develop acrodynia (“pink disease”): flushing, itching, swelling, tachycardia, hypertension, excessive salivation or perspiration, irritability, weakness, morbilliform rashes, desquamation of palms and soles.

Toxicity from elemental or inorganic mercury exposure begins when blood levels >180 nmol/L (3.6 μg/dL) and urine levels >0.7 μmol/L (15 μg/dL). Exposures that ended years ago may result in a >20-μg increase in 24-h urine after a 2-g dose of succimer.

Organic mercury exposure is best measured by levels in blood (if recent) or hair (if chronic); CNS toxicity in children may derive from fetal exposures associated with maternal hair Hg > 30 nmol/g (6 μg/g).

Treat acute ingestion of mercuric salts with induced emesis or gastric lavage and polythiol resins (to bind mercury in the GI tract). Chelate with dimercaprol (up to 24 mg/kg per day IM in divided doses), DMSA (succimer), or penicillamine, with 5-day courses separated by several days of rest. If renal failure occurs, treat with peritoneal dialysis, hemodialysis, or extracorporeal regional complexing hemodialysis and succimer.

Chronic inorganic mercury poisoning is best treated with N-acetyl penicillamine.
Enhancement of Elimination

Activated charcoal in repeated doses of 1 g/kg q2–4h is useful for ingestions of drugs with enteral circulation such as carbamazepine, dapsone, diazepam, digoxin, glutethimide, meprobamate, methotrexate, phenobarbital, phenytoin, salicylate, theophylline, and valproic acid.

Forced urinary alkalinization enhances the elimination of chlorphenoxyacetic acid herbicides, chlorpropamide, diflunisal, fluoride, methotrexate, phenobarbital, sulfonamides, and salicylates. Sodium bicarbonate, 1–2 ampules per liter of 0.45% NaCl, is given at a rate sufficient to maintain urine pH ≥ 7.5 and urine output at 3–6 mL/kg per h. Acidiuresis is no longer recommended.

Peritoneal dialysis or hemodialysis may be useful in severe poisoning due to barbiturates, bromide, chloral hydrate, ethanol, ethylene glycol, isopropyl alcohol, lithium, heavy metals, methanol, procainamide, and salicylate. Hemo-perfusion may be indicated for chloramphenicol, disopyramide, and hypnotic-sedative overdose. Exchange transfusion removes poisons affecting red blood cells.

The features of specific toxic syndromes and approaches to treatment are summarized in Table 31-3. The features of selected heavy metal toxicity and approaches to treatment are summarized in Table 31-4. Readers are encouraged to contact poison control centers for additional information (http://www.aapcc.org/DNN/).

For a more detailed discussion, see Linden CH, Burns MJ: Poisoning and Drug Overdosage, Chap. 377, p. 2580; and Hu H: Heavy Metal Poisoning, Chap. 376, p. 2577, in HPIM-16.

32 Bioterrorism

MICROBIAL BIOTERRORISM

Microbial bioterrorism refers to the use of microbial pathogens as weapons of terror that target civilian populations. A primary goal of bioterrorism is not necessarily to produce mass casualties but to destroy the morale of a society through creating fear and uncertainty. The events of September 11, 2001, followed by the anthrax attacks through the U.S. Postal Service illustrate the vulnerability of the American public to terrorist attacks, including those that use microbes. The key to combating bioterrorist attacks is a highly functioning system of public health surveillance and education that rapidly identifies and effectively contains the attack.

Agents of microbial bioterrorism may be used in their natural form or may be deliberately modified to maximize their deleterious effect. Modifications that increase the deleterious effect of a biologic agent include genetic alteration of microbes to produce antimicrobial resistance, creation of fine-particle aerosols, chemical treatment to stabilize and prolong infectivity, and alteration of the host range through changes in surface protein receptors. Certain of these approaches
fall under the category of weaponization, a term that describes the processing of microbes or toxins in a manner that enhances their deleterious effect after release. The key features that characterize an effective biologic weapon are summarized in Table 32-1.

The U.S. Centers for Disease Control and Prevention (CDC) has classified microbial agents that could potentially be used in bioterrorism attacks into three categories: A, B, and C (Table 32-2). Category A agents are the highest-priority

---

**TABLE 32-1**  
KEY FEATURES OF BIOLOGIC AGENTS USED AS BIOWEAPONS

<table>
<thead>
<tr>
<th>Feature</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. High morbidity and mortality</td>
<td></td>
</tr>
<tr>
<td>2. Potential for person-to-person spread</td>
<td></td>
</tr>
<tr>
<td>3. Low infective dose and highly infectious by aerosol</td>
<td></td>
</tr>
<tr>
<td>4. Lack of rapid diagnostic capability</td>
<td></td>
</tr>
<tr>
<td>5. Lack of universally available effective vaccine</td>
<td></td>
</tr>
<tr>
<td>6. Potential to cause anxiety</td>
<td></td>
</tr>
<tr>
<td>7. Availability of pathogen and feasibility of production</td>
<td></td>
</tr>
<tr>
<td>8. Environmental stability</td>
<td></td>
</tr>
<tr>
<td>9. Database of prior research and development</td>
<td></td>
</tr>
<tr>
<td>10. Potential to be “weaponized”</td>
<td></td>
</tr>
</tbody>
</table>

*Source: From L. Borio et al: JAMA 287:2391, 2002; with permission.*

**TABLE 32-2**  
CDC CATEGORY A, B, AND C AGENTS

**Category A**  
- Anthrax (*Bacillus anthracis*)  
- Botulism (*Clostridium botulinum* toxin)  
- Plague (*Yersinia pestis*)  
- Smallpox (Variola major)  
- Tularemia (*Francisella tularensis*)  
- Viral hemorrhagic fevers  
  - Arenaviruses: Lassa, New World (Machupo, Junin, Guanarito, and Sabia)  
  - Bunyaviridae: Crimean Congo, Rift Valley  
  - Filoviridae: Ebola, Marburg  
  - Flaviviridae: Yellow fever; Omsk fever; Kyasanur Forest

**Category B**  
- Brucellosis (*Brucella* spp.)  
- Epsilon toxin of *Clostridium perfringens*  
- Food safety threats (e.g., *Salmonella* spp., *Escherichia coli* 0157:H7, *Shigella*)  
- Glanders (*Burkholderia mallei*)  
- Melioidosis (*B. pseudomallei*)  
- Psittacosis (*Chlamydia psittaci*)  
- Q fever (*Coxiella burnetii*)  
- Ricin toxin from *Ricinus communis* (castor beans)  
- Staphylococcal enterotoxin B  
- Typhus fever (*Rickettsia prowazekii*)  
- Viral encephalitis [alphaviruses (e.g., Venezuelan, eastern, and western equine encephalitis)]  
- Water safety threats (e.g., *Vibrio cholerae*, *Cryptosporidium parvum*)

**Category C**  
- Emerging infectious diseases threats such as Nipah, hantavirus, SARS coronaviruses, and pandemic influenza.

*Source: Centers for Disease Control and Prevention and the National Institute of Allergy and Infectious Diseases.*
pathogens. They pose the greatest risk to national security because they (1) can be easily disseminated or transmitted from person to person, (2) are associated with high case-fatality rates, (3) have potential to cause significant public panic and social disruption, and (4) require special action and public health preparedness.

**CATEGORY A AGENTS**

**Anthrax (Bacillus anthracis)**  
**Anthrax as a Bioweapon**  
Anthrax in many ways is the prototypic bioweapon. Although it is only rarely spread by person-to-person contact, it has many of the other features of an ideal biologic weapon listed in Table 32-1. The potential impact of anthrax as a bioweapon is illustrated by the apparent accidental release in 1979 of anthrax spores from a Soviet bioweapons facility in Sverdlosk, Russia. As a result of this atmospheric release of anthrax spores, at least 77 cases of anthrax (of which 66 were fatal) occurred in individuals within an area 4 km downwind of the facility. Deaths were noted in livestock up to 50 km from the facility. The interval between probable exposure and onset of symptoms ranged from 2–43 days, with the majority of cases occurring within 2 weeks. In September of 2001 the American public was exposed to anthrax spores delivered through the U.S. Postal Service. There were 22 confirmed cases: 11 cases of inhaled anthrax (5 died) and 11 cases of cutaneous anthrax (no deaths). Cases occurred in individuals who opened contaminated letters as well as in postal workers involved in processing the mail.

**Microbiology and Clinical Features**  
(See also Chaps. 214 and 131, HPIM-17)

- Anthrax is caused by infections with *B. anthracis*, a gram-positive, nonmotile, spore-forming rod that is found in soil and predominantly causes disease in cattle, goats, and sheep.
- Spores can remain viable for decades in the environment and be difficult to destroy with standard decontamination procedures. These properties make anthrax an ideal bioweapon.
- Naturally occurring human infection generally results from exposure to infected animals or contaminated animal products.

There are three major clinical forms of anthrax:

1. **Gastrointestinal anthrax** is rare and is unlikely to result from a bioterrorism event.
2. **Cutaneous anthrax** follows introduction of spores through an opening in the skin. The lesion begins as a papule followed by the development of a black eschar. Prior to the availability of antibiotics, about 20% of cutaneous anthrax cases were fatal.
3. **Inhalation anthrax** is the form most likely to result in serious illness and death in a bioterrorism attack. It occurs following inhalation of spores that become deposited in the alveolar spaces. The spores are phagocytosed by alveolar macrophages and are transported to regional lymph nodes where they germinate. Following germination, rapid bacterial growth and toxin production occur. Subsequent hematologic dissemination leads to cardiovascular collapse and death. The earliest symptoms are typically those of a viral-like prodrome with fever, malaise, and abdominal/chest symptoms that rapidly progress to a septic shock picture. Widening of the mediastinum and pleural effusions are typical findings on chest radiography. Once considered 100% fatal, experience from the Sverdlosk and U.S. Postal outbreaks indicate that with prompt initiation of appropriate antibiotic therapy, survival may be >50%. Awareness of the possibility of the diagnosis of anthrax is critical to the prompt initiation of therapy.
Anthrax (See Table 32-3)

Anthrax can be successfully treated if the disease is promptly recognized and appropriate antibiotic therapy is initiated.

- Penicillin, ciprofloxacin, and doxycycline are currently licensed for the treatment of anthrax.
- Clindamycin and rifampin have in vitro activity against the organism and may be used as part of the treatment regimen.
- Patients with inhalation anthrax are not contagious and do not require special isolation procedures.

Vaccination and Prevention

- Currently there is a single vaccine licensed for use; produced from a cell-free culture supernatant of an attenuated strain of *B. anthracis* (Stern strain).
- Current recommendation for postexposure prophylaxis is 60 days of antibiotics (see Table 32-1); recent animal studies have suggested that postexposure vaccination may be of some additional benefit.

Plague (*Yersinia pestis*) (See also Chap. 98)

**Plague as a Bioweapon** Although plague lacks the environmental stability of anthrax, the highly contagious nature of the infection and the high mortality rate make it a potentially important agent of bioterrorism. As a bioweapon, plague would likely be delivered via an aerosol leading to primary pneumonic plague. In such an attack, person-to-person transmission of plague via respiratory aerosol could lead to large numbers of secondary cases.

**Microbiology and Clinical Features** See Chap. 98.

Smallpox (*Variola major* and *V. minor*) (See also Chap. 176, HPIM-17)

**Smallpox as a Bioweapon** Smallpox as a disease was globally eradicated by 1980 through a worldwide vaccination program. However, with the cessation of smallpox immunization programs in the United States in 1972 (and worldwide in 1980), close to half the U.S. population is fully susceptible to smallpox today. Given the infectious nature and the 10–30% mortality of smallpox in unimmunized individuals, the deliberate release of virus could have devastating effects on the population. In the absence of effective containment measures, an initial infection of 50–100 persons in a first generation of cases could expand by a factor of 10 to 20 with each succeeding generation. These considerations make smallpox a formidable bioweapon.

**Microbiology and Clinical Features** The disease smallpox is caused by one of two closely related double-strand DNA viruses, *V. major* and *V. minor*. Both viruses are members of the Orthopoxvirus genus of the Poxviridae family. Infection with *V. minor* is generally less severe, with low mortality rates; thus, *V. major* is the only one considered as a potential bioweapon. Infection with *V. major* typically occurs following contact with an infected person from the time that a maculopapular rash appears through scabbing of the pustular lesions. Infection is thought to occur from inhalation of virus-containing saliva droplets from oropharyngeal lesions. Contaminated clothing or linen can also spread infection. About 12–14 days following initial exposure the patient develops high fever, malaise, vomiting, headache, back pain, and a maculopapular rash that
<table>
<thead>
<tr>
<th>Agent</th>
<th>Diagnosis</th>
<th>Treatment</th>
<th>Prophylaxis</th>
</tr>
</thead>
</table>
| *Bacillus anthracis* (anthrax) | Culture, Gram stain, PCR, Wright stain of peripheral smear | **Postexposure:**
Ciprofloxacin, 500 mg, PO bid × 60 d or
Doxycycline, 100 mg PO bid × 60 d
(Amoxicillin, 500 mg PO q8h, likely to be effective if strain penicillin sensitive)
**Active disease:**
Ciprofloxacin, 400 mg IV q12h or
Doxycycline, 100 mg IV q12 plus
Clindamycin, 900 mg IV q8h and/or rifampin, 300 mg IV q12h;
switch to PO when stable × 60 d total
**Antitoxin strategies:**
Neutralizing monoclonal and polyclonal antibodies are under study | Anthrax vaccine adsorbed
Recombinant protective antigen vaccines are under study |
| *Yersinia pestis* (pneumonic plague) | Culture, Gram stain, direct fluorescent antibody, PCR | Gentamicin, 2.0 mg/kg IV loading then 1.7 mg/kg q8h IV or
Streptomycin, 1.0 g q12h IM or IV
Alternatives include doxycycline, 100 mg bid PO or IV; chloramphenicol 500 mg qid PO or IV | Doxycycline, 100 mg PO bid (ciprofloxacin may also be active)
Formalin-fixed vaccine (FDA licensed; not available) |
<p>| Variola major (smallpox)     | Culture, PCR, electron microscopy               | Supportive measures; consideration for cidofovir, antivaccinia immunoglobulin | Vaccinia immunization |</p>
<table>
<thead>
<tr>
<th><strong>Francisella tularensis (tularemia)</strong></th>
<th>Gram stain, culture, immunochemistry, PCR</th>
<th>Streptomycin, 1 g IM bid or Gentamicin, 5 mg/kg per day div q8h IV for 14 days</th>
<th>Doxycycline, 100 mg PO bid × 14 days or Ciprofloxacin, 500 mg PO bid × 14 days</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Viral hemorrhagic fevers</strong></td>
<td>RT-PCR, serologic testing for antigen or antibody Viral isolation by CDC or U.S. Army Medical Institute of Infectious Diseases (US-AMRIID)</td>
<td>Ribavirin 30 mg/kg up to 2 g × 1, followed by 16 mg/kg IV up to 1 g q6h for 4 days, followed by 8 mg/kg IV up to 0.5 g q8h × 6 days</td>
<td>No known chemoprophyaxis Consideration for ribavirin in high-risk situations Vaccine exists for yellow fever</td>
</tr>
<tr>
<td><strong>Botulinum toxin (Clostridium botulinum)</strong></td>
<td>Mouse bioassay, toxin immunoassay</td>
<td>Supportive measures including ventilation 5000–9000 IU equine antitoxin</td>
<td>Administration of antitoxin</td>
</tr>
</tbody>
</table>

**Note:** CDC, U.S. Centers for Disease Control and Prevention; FDA, U.S. Food and Drug Administration; PCR, polymerase chain reaction; RT-PCR, reverse transcriptase PCR.
begins on the face and extremities and spreads to the trunk. The skin lesions evolve into vesicles that eventually become pustular with scabs. The oral mucosa also develops macular lesions that progress to ulcers. Smallpox is associated with a 10–30% mortality. Historically, about 5–10% of naturally occurring cases manifest as highly virulent atypical forms, classified as hemorrhagic and malignant. These are difficult to recognize due to their atypical manifestations. Both forms have similar onset of a severe prostrating illness characterized by high fever, severe headache, and abdominal and back pain. In the hemorrhagic form, cutaneous erythema develops followed by petechiae and hemorrhage into the skin and mucous membranes. In the malignant form, confluent skin lesions develop but never progress to the pustular stage. Both of these forms are often fatal, with death occurring in 5–6 days.

**Vaccination and Prevention** Smallpox is a preventable disease following immunization with vaccinia. Past and current experience indicates that the smallpox vaccine is associated with a very low incidence of severe complications (see Table 214-4, p. 1349, HPIM-17). The current dilemma facing our society regarding assessment of the risk/benefit of smallpox vaccination is that, while the risks of vaccination are known, the risk of someone deliberately and effectively releasing smallpox into the general population is unknown. Given the rare, but potentially severe complications associated with smallpox vaccination using the currently available vaccine together with the current level of threat, it has been decided by public health authorities that vaccination of the general population is not indicated.

**Tularemia (Francisella tularensis)** (See also Chap. 98)

**Tularemia as a Bioweapon** Tularemia has been studied as a biologic agent since the mid-twentieth century. Reportedly, both the United States and the former Soviet Union had active programs investigating this organism as a possible bioweapon. It has been suggested that the Soviet program extended into the era of molecular biology and that some strains of *F. tularensis* may have been genetically engineered to be resistant to commonly used antibiotics. *F. tularensis* is extremely infectious and can cause significant morbidity and mortality. These facts make it reasonable to consider this organism as a possible bioweapon that could be disseminated by either aerosol or contamination of food or drinking water.

**Microbiology and Clinical Features** See Chap. 98.

**Viral Hemorrhagic Fevers** (See also Chap. 111)

**Hemorrhagic Fever Viruses as Bioweapons** Several of the hemorrhagic fever viruses have been reported to have been weaponized by the former Soviet Union and the United States. Nonhuman primate studies indicate that infection
can be established with very few virions and that infectious aerosol preparations can be produced.

**Microbiology and Clinical Features**  See Chap. 111.

**Botulinum Toxin (Clostridium botulinum)**  (See also Chap. 99)

**Botulinum Toxin as a Bioweapon**  In a bioterrorism attack, botulinum toxin would likely be dispersed as an aerosol or used to contaminate food. Contamination of the water supply is possible, but the toxin would likely be degraded by chlorine used to purify drinking water. The toxin can also be inactivated by heating food to >85°C for >5 min. The United States, the former Soviet Union, and Iraq have all acknowledged studying botulinum toxin as a potential bioweapon. Unique among the Category A agents for not being a live organism, botulinum toxin is one of the most potent and lethal toxins known to man. It has been estimated that 1 g of toxin is sufficient to kill 1 million people if adequately dispersed.

**Microbiology and Clinical Features**  See Chap. 99.

**CATEGORY B AND C AGENTS**  (See Table 32-2)

Category B agents are the next highest priority and include agents that are moderately easy to disseminate, produce moderate morbidity and low mortality, and require enhanced diagnostic capacity.

Category C agents are the third highest priority agents in the biodefence agenda. These agents include emerging pathogens, such as SARS (severe acute respiratory syndrome) coronavirus or a pandemic influenza virus, to which the general population lacks immunity. Category C agents could be engineered for mass dissemination in the future. It is important to note that these categories are empirical, and, depending on future circumstances, the priority ratings for a given microbial agent may change.

**PREVENTION AND PREPAREDNESS**

As indicated above, a diverse array of agents have the potential to be used against a civilian population in a bioterrorism attack. The medical profession must maintain a high index of suspicion that unusual clinical presentations or clustering of rare diseases may not be a chance occurrence, but rather the first sign of a bioterrorism attack. Possible early indicators of a bioterrorism attack could include:

- The occurrence of rare diseases in healthy populations
- The occurrence of unexpectedly large numbers of a rare infection
- The appearance in an urban population of an infectious disease that is usually confined to rural settings

Given the importance of rapid diagnosis and early treatment for many of these diseases, it is important that the medical care team report any suspected cases of bioterrorism immediately to local and state health authorities and/or the CDC (888-246-2675).
CHEMICAL BIOTERRORISM

The use of chemical warfare agents (CWAs) as weapons of terror against civilian populations is a potential threat that must be addressed by public health officials and the medical profession. The use of both nerve agents and sulfur mustard by Iraq against Iranian military and Kurdish civilians and the sarin attacks in 1994–1995 in Japan underscore this threat.

A detailed description of the various CWAs can be found in Chap. 215, HPIM-17, and on the CDC website at www.bt.cdc.gov/agent/agentlistchem.asp. In this section only vesicants and nerve agents will be discussed as these are considered the most likely agents to be used in a terrorist attack.

VESICANTS (SULFUR MUSTARD, NITROGEN MUSTARD, LEWISITE)

Sulfur mustard is the prototype for this group of CWAs and was first used on the battlefields of Europe in World War I. This agent constitutes both a vapor and liquid threat to exposed epithelial surfaces. The organs most commonly affected are the skin, eyes, and airways. Exposure to large quantities of sulfur mustard can result in bone marrow toxicity. Sulfur mustard dissolves slowly in aqueous media such as sweat or tears, but once dissolved it forms reactive compounds that react with cellular proteins, membranes, and importantly DNA. Much of the biologic damage from this agent appears to result from DNA alkylation and cross-linking in rapidly dividing cells in the corneal epithelium, skin, bronchial mucosal epithelium, GI epithelium, and bone marrow. Sulfur mustard reacts with tissue within minutes of entering the body.

Clinical Features

The topical effects of sulfur mustard occur in the skin, airways, and eyes. Absorption of the agent may produce effects in the bone marrow and GI tract (direct injury to the GI tract may occur if sulfur mustard is ingested in contaminated food or water).

- **Skin**: erythema is the mildest and earliest manifestation; involved areas of skin then develop vesicles that coalesce to form bullae; high-dose exposure may lead to coagulation necrosis within bullae.
- **Airways**: initial and, with mild exposures, the only airway manifestations are burning of the nares, epistaxis, sinus pain, and pharyngeal pain. With exposure to higher concentrations, damage to the trachea and lower airways may occur, producing laryngitis, cough, and dyspnea. With large exposures, necrosis of the airway mucosa occurs leading to pseudomembrane formation and airway obstruction. Secondary infection may occur due to bacterial invasion of denuded respiratory mucosa.
- **Eyes**: the eyes are the most sensitive organ to injury by sulfur mustard. Exposure to low concentrations may produce only erythema and irritation. Exposure to higher concentrations produces progressively more severe conjunctivitis, photophobia, blepharospasm pain, and corneal damage.
- **GI tract manifestations** include nausea and vomiting, lasting up to 24 h.
- **Bone marrow suppression**, with peaks at 7–14 days following exposure, may result in sepsis due to leukopenia.

RX **Sulfur Mustard**

Immediate decontamination is essential to minimize damage. Immediately remove clothing and gently wash skin with soap and water. Eyes should be flushed with copious amounts of water or saline. Subsequent medical care is supportive. Cutaneous vesicles should be left intact. Larger bullae should be
Debrided and treated with topical antibiotic preparations. Intensive care similar to that given to severe burn patients is required for pts with severe exposure. Oxygen may be required for mild/moderate respiratory exposure. Intubation and mechanical ventilation may be necessary for laryngeal spasm and severe lower airway damage. Pseudomembranes should be removed by suctioning; bronchodilators are of benefit for bronchospasm. The use of granulocyte colony-stimulating factor and/or stem cell transplantation may be effective for severe bone marrow suppression.

**NERVE AGENTS**

The organophosphorus nerve agents are the deadliest of the CWAs and work by inhibiting synaptic acetylcholinesterase, creating an acute cholinergic crisis. The “classic” organophosphorus nerve agents are tabun, sarin, soman, cyclosarin, and VX. All agents are liquid at standard temperature and pressure. With the exception of VX, all these agents are highly volatile, and the spilling of even a small amount of liquid agent represents a serious vapor hazard.

**Mechanism** Inhibition of acetylcholinesterase accounts for the major life-threatening effects of these agents. At the cholinergic synapse, the enzyme acetylcholinesterase functions as a “turn off” switch to regulate cholinergic synaptic transmission. Inhibition of this enzyme allows released acetylcholine to accumulate, resulting in end-organ overstimulation and leading to what is clinically referred to as cholinergic crisis.

**Clinical Features** The clinical manifestations of nerve agent exposure are identical for vapor and liquid exposure routes. Initial manifestations include miosis, blurred vision, headache, and copious oropharyngeal secretions. Once the agent enters the bloodstream (usually via inhalation of vapors) manifestations of cholinergic overload include nausea, vomiting, abdominal cramping, muscle twitching, difficulty breathing, cardiovascular instability, loss of consciousness, seizures, and central apnea. The onset of symptoms following vapor exposure is rapid (seconds to minutes). Liquid exposure to nerve agents results in differences in speed of onset and order of symptoms. Contact of a nerve agent with intact skin produces localized sweating followed by localized muscle fasciculations. Once in the muscle, the agent enters the circulation and causes the symptoms described above.

**Rx Nerve Agents**

Since nerve agents have a short circulating half-life, improvement should be rapid if exposure is terminated and supportive care and appropriate antidotes are given. Thus, the treatment of acute nerve agent poisoning involves decontamination, respiratory support, antidotes.

1. **Decontamination**: Procedures are the same as those described above for sulfur mustard.
2. **Respiratory support**: Death from nerve agent exposure is usually due to respiratory failure. Ventilation will be complicated by increased airway resistance and secretions. Atropine should be given before mechanical ventilation is instituted.
3. **Antidotal therapy** (see Table 32-4):
   a. **Atropine**: Generally the preferred anticholinergic agent of choice for treating acute nerve agent poisoning. Atropine rapidly reverses cholin-
<table>
<thead>
<tr>
<th>Patient Age</th>
<th>Mild/Moderate Effects&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Severe Effects&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Other Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants (0–2 yrs)</td>
<td>Atropine: 0.05 mg/kg IM, or 0.02 mg/kg IV; and 2-PAM chloride: 15 mg/kg IM or IV slowly</td>
<td>Atropine: 0.1 mg/kg IM, or 0.02 mg/kg IV; and 2-PAM chloride: 25 mg/kg IM, or 15 mg/kg IV slowly</td>
<td>Assisted ventilation after antidotes for severe exposure. Repeat atropine (2 mg IM, or 1 mg IM for infants) at 5- to 10-min intervals until secretions have diminished and breathing is comfortable or airway resistance has returned to near normal. Phentolamine for 2-PAM-induced hypertension: (5 mg IV for adults; 1 mg IV for children). Diazepam for convulsions: (0.2–0.5 mg IV for infants &lt;5 years; 1 mg IV for children &gt;5 years; 5 mg IV for adults).</td>
</tr>
<tr>
<td>Child (2–10 yrs)</td>
<td>Atropine: 1 mg IM, or 0.02 mg/kg IV; and 2-PAM chloride&lt;sup&gt;c&lt;/sup&gt;: 15 mg/kg IM or IV slowly</td>
<td>Atropine: 2 mg IM, or 0.02 mg/kg IV; and 2-PAM chloride&lt;sup&gt;c&lt;/sup&gt;: 25 mg/kg IM, or 15 mg/kg IV slowly</td>
<td></td>
</tr>
<tr>
<td>Adolescent (&gt;10 yrs)</td>
<td>Atropine: 2 mg IM, or 0.02 mg/kg IV; and 2-PAM chloride&lt;sup&gt;c&lt;/sup&gt;: 15 mg/kg IM or IV slowly</td>
<td>Atropine: 4 mg IM, or 0.02 mg/kg IV; and 2-PAM chloride&lt;sup&gt;c&lt;/sup&gt;: 25 mg/kg IM, or 15 mg/kg IV slowly</td>
<td></td>
</tr>
<tr>
<td>Adult</td>
<td>Atropine: 2–4 mg IM or IV; and 2-PAM chloride: 600 mg IM, or 15 mg/kg IV slowly</td>
<td>Atropine: 6 mg IM; and 2-PAM chloride: 1800 mg IM, or 15 mg/kg IV slowly</td>
<td></td>
</tr>
<tr>
<td>Elderly, frail</td>
<td>Atropine: 1 mg IM; and 2-PAM chloride: 10 mg/kg IM, or 5–10 mg/kg IV slowly</td>
<td>Atropine: 2–4 mg IM; and 2-PAM chloride: 25 mg/kg IM, or 5–10 mg/kg IV slowly</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>Mild/moderate effects include localized sweating, muscle fasciculations, nausea, vomiting, weakness, dyspnea.

<sup>b</sup>Severe effects include unconsciousness, convulsions, apnea, flaccid paralysis.

<sup>c</sup>If calculated dose exceeds the adult IM dose, adjust accordingly.

*Note:* 2-PAM chloride is pralidoxime chloride or protopam chloride.

*Source:* State of New York, Department of Health.
ergic overload at muscarinic synapses but has little effect at nicotinic synapses. Thus, atropine can rapidly treat the life-threatening respiratory effects of nerve agents but will probably not help neuromuscular effects. The field loading dose is 2–6 mg IM, with repeat doses given every 5–10 min until breathing and secretions improve. In the mildly affected pt with miosis and no systemic symptoms, atropine or homatropine eye drops may suffice.

b. Oxime therapy: Oximes are nucleophiles that help restore normal enzyme function by reactivating the cholinesterase whose active site has been occupied and bound by the nerve agent. The oxime available in the United States is 2-pralidoxime chloride (2-PAM Cl). Treatment with 2-PAM may cause blood pressure elevation.

c. Anticonvulsant: Seizures caused by nerve agents do not respond to the usual anticonvulsants such as phenytoin, phenobarbital, carbamazepine, valproate, and lamotrigine. The only class of drugs known to have efficacy in treating nerve agent–induced seizures are the benzodiazepines. Diazepam is the only benzodiazepine approved by the U.S. Food and Drug Administration for the treatment of seizures (although other benzodiazepines have been shown to work well in animal models of nerve agent–induced seizures).

RADIATION BIOTERRORISM

Nuclear or radiation-related devices represent a third category of weapon that could be used in a terrorism attack. There are two major types of attacks that could occur. The first is the use of radiologic dispersal devices that cause the dispersal of radioactive material without detonation of a nuclear explosion. Such devices could use conventional explosives to disperse radionuclides. The second, and less probable, scenario would be the use of actual nuclear weapons by terrorists against a civilian target.

TYPES OF RADIATION

Alpha radiation consists of heavy, positively charged particles containing two protons and two neutrons. Due to their large size, alpha particles have limited penetrating power. Cloth and human skin can usually prevent alpha particles from penetrating into the body. If alpha particles are internalized, they can cause significant cellular damage.

Beta radiation consists of electrons and can travel only short distances in tissue. Plastic layers and clothing can stop most beta particles. Higher energy beta particles can cause injury to the basal stratum of skin similar to a thermal burn.

Gamma radiation and x-rays are forms of electromagnetic radiation discharged from the atomic nucleus. Sometimes referred to as penetrating radiation, both gamma and x-rays easily penetrate matter and are the principle type of radiation to cause whole-body exposure (see below).

Neutron particles are heavy and uncharged; often emitted during a nuclear detonation. Their ability to penetrate tissues is variable, depending upon their energy. They are less likely to be generated in various scenarios of radiation bioterrorism.

The commonly used units of radiation are the rad and the gray. The rad is the energy deposited within living matter and is equal to 100 ergs/g of tissue. The rad has been replaced by the SI unit of the gray (Gy). 100 rad = 1 Gy.
TYPES OF EXPOSURE

Whole-body exposure represents deposition of radiation energy over the entire body. Alpha and beta particles have limited penetration power and do not cause significant whole-body exposure unless they are internalized in large amounts. Whole-body exposure from gamma rays, x-rays, or high-energy neutron particles can penetrate the body, causing damage to multiple tissues and organs.

External contamination results from fallout of radioactive particles landing on the body surface, clothing, and hair. This is the dominant form of contamination likely to occur in a terrorist strike that utilizes a dispersal device. The most likely contaminants would emit alpha and beta radiation. Alpha particles do not penetrate the skin and thus would produce minimal systemic damage. Beta emitters can cause significant cutaneous burns. Gamma emitters not only cause cutaneous burns but can also cause significant internal damage.

Internal contamination will occur when radioactive material is inhaled, ingested, or is able to enter the body via a disruption in the skin. The respiratory tract is the main portal of entrance for internal contamination, and the lung is the organ at greatest risk. Radioactive material entering the GI tract will be absorbed according to its chemical structure and solubility. Penetration through the skin usually occurs when wounds or burns have disrupted the cutaneous barrier. Absorbed radioactive materials will travel throughout the body. Liver, kidney, adipose tissue, and bone tend to bind and retain radioactive material more than do other tissues.

Localized exposure results from close contact between highly radioactive material and a part of the body, resulting in discrete damage to the skin and deeper structures.

ACUTE RADIATION SICKNESS

Radiation interactions with atoms can result in ionization and free radical formation that damages tissue by disrupting chemical bonds and molecular structures in the cell, including DNA. Radiation can lead to cell death; cells that recover may have DNA mutations that pose a higher risk for malignant transformation. Cell sensitivity to radiation damage increases as replication rate increases. Bone marrow and mucosal surfaces in the GI tract have high mitotic activity and thus are significantly more prone to radiation damage than slowly dividing tissues such as bone and muscle. Acute radiation sickness (ARS) can develop following exposure of all or most of the human body to ionizing radiation. The clinical manifestation of ARS reflect the dose and type of radiation as well as the parts of the body that are exposed.

Clinical Features ARS produces signs and symptoms related to damage of three major organ systems: GI tract, bone marrow, and neurovascular. The type and dose of radiation and the part of the body exposed will determine the dominant clinical picture.

- There are four major stages of ARS:
  1. **Prodrome** occurs between hours to 4 days after exposure and lasts from hours to days. Manifestations include: nausea, vomiting, anorexia, and diarrhea.
  2. The **latent stage** follows the prodrome and is associated with minimal or no symptoms. It most commonly lasts up to 2 weeks but can last as long as 6 weeks.
  3. **Illness** follows the latent stage.
  4. **Death or recovery** is the final stage of ARS.
• The higher the radiation dose, the shorter and more severe the stage.
• At low radiation doses (0.7–4 Gy), bone marrow suppression occurs and constitutes the main illness. The pt may develop bleeding or infection secondary to thrombocytopenia and leukopenia. The bone marrow will generally recover in most pts. Care is supportive (transfusion, antibiotics, colony-stimulating factors).
• With exposure to 6–8 Gy, the clinical picture is more complicated; the bone marrow may not recover and death will ensue. Damage to the GI mucosa producing diarrhea, hemorrhage, sepsis, fluid and electrolyte imbalance may occur and complicate the clinical picture.
• Whole-body exposure to >10 Gy is usually fatal. In addition to severe bone marrow and GI tract damage, a neurovascular syndrome characterized by vascular collapse, seizures, and death may occur (especially at doses >20 Gy).

Treatment of ARS is largely supportive (Fig. 32-1).
1. Persons contaminated either externally or internally should be decontaminated as soon as possible. Contaminated clothes should be removed; showering or washing the entire skin and hair is very important. A radiation
Medical Emergencies

2. Treatment for the hematopoietic system includes appropriate therapy for neutropenia and infection, transfusion of blood products as needed, and hematopoietic growth factors. The value of bone marrow transplantation in this situation is unknown.

3. Partial or total parenteral nutrition is appropriate supportive therapy for pts with significant injury to the GI mucosa.

4. Treatment of internal radionuclide contamination is aimed at reducing absorption and enhancing elimination of the ingested material (Table 216-2, HPIM-17).
   a. Clearance of the GI tract may be achieved by gastric lavage, emetics, or purgatives, laxatives, ion exchange resins, and aluminum-containing antacids.
   b. Administration of blocking agents is aimed at preventing the entrance of radioactive materials into tissues (e.g., potassium iodide, which blocks the uptake of radioactive iodine by the thyroid).
   c. Diluting agents decrease the absorption of the radionuclide (e.g., water in the treatment of tritium contamination).
   d. Mobilizing agents are most effective when given immediately; however, they may still be effective for up to 2 weeks following exposure. Examples include antithyroid drugs, glucocorticoids, ammonium chloride, diuretics, expectorants, and inhalants. All of these should induce the release of radionuclides from tissues.
   e. Chelating agents bind many radioactive materials, after which the complexes are excreted from the body.

For a more detailed discussion, see Lane HC, Fauci AS: Microbial Bioterrorism, Chap. 214, p. 1343; Hurst CG, Newmark J, Romano JA: Chemical Bioterrorism, Chap. 215, p. 1352; Tochner ZA, Glatstein E: Radiation Bioterrorism, Chap. 216, p. 1358; in HPIM-17.
SECTION 3 COMMON PATIENT PRESENTATIONS

33 Chest Pain

There is little correlation between the severity of chest pain and the seriousness of its cause. The range of disorders that cause chest discomfort is shown in Table 33-1.

**POTENTIALLY SERIOUS CAUSES**

The differential diagnosis of chest pain is shown in Figs. 33-1 and 33-2. It is useful to characterize the chest pain as (1) new, acute, and ongoing; (2) recurrent, episodic; and (3) persistent, sometimes for days.

*Myocardial Ischemia*  *Angina Pectoris*  Substernal pressure, squeezing, constriction, with radiation typically to left arm; usually on exertion, especially after meals or with emotional arousal. Characteristically relieved by rest and nitroglycerin.

*Acute Myocardial Infarction*  (Chaps. 126 and 127) Similar to angina but usually more severe, of longer duration (≥30 min), and not immediately relieved by rest or nitroglycerin. S₃ and S₄ common.

**TABLE 33-1 DIFFERENTIAL DIAGNOSES OF PATIENTS ADMITTED TO HOSPITAL WITH ACUTE CHEST PAIN RULED NOT MYOCARDIAL INFARCTION**

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastroesophageal disease*</td>
<td>42</td>
</tr>
<tr>
<td>Gastroesophageal reflux</td>
<td></td>
</tr>
<tr>
<td>Esophageal motility disorders</td>
<td></td>
</tr>
<tr>
<td>Peptic ulcer</td>
<td></td>
</tr>
<tr>
<td>Gallstones</td>
<td></td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>31</td>
</tr>
<tr>
<td>Chest wall syndromes</td>
<td>28</td>
</tr>
<tr>
<td>Pericarditis</td>
<td>4</td>
</tr>
<tr>
<td>Pleuritis/pneumonia</td>
<td>2</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>2</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>1.5</td>
</tr>
<tr>
<td>Aortic aneurysm</td>
<td>1</td>
</tr>
<tr>
<td>Aortic stenosis</td>
<td>1</td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>1</td>
</tr>
</tbody>
</table>

*In order of frequency.

Pulmonary Embolism  (Chap. 140)  May be substernal or lateral, pleuritic in nature, and associated with hemoptysis, tachycardia, and hypoxemia.

Aortic Dissection  (Chap. 132)  Very severe, in center of chest, a sharp “ripping” quality, radiates to back, not affected by changes in position. May be associated with weak or absent peripheral pulses.

Mediastinal Emphysema  Sharp, intense, localized to substernal region; often associated with audible crepitus.
<table>
<thead>
<tr>
<th>Description of pain</th>
<th>Background history</th>
<th>Key Physical findings</th>
<th>Consider</th>
<th>Confirmatory tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oppressive, constrictive, or squeezing; may radiate to arm(s), neck, back</td>
<td>Less severe, similar pain on exertion; + coronary risk factors</td>
<td>Diaphoresis, pallor; S4 common; S3 less common</td>
<td>Acute myocardial infarction (Chaps. 126 and 127)</td>
<td>• Serial ECGs • Serial cardiac markers (esp. troponins, CK)</td>
</tr>
<tr>
<td>“Tearing” or “ripping”; may travel from anterior chest to mid-back</td>
<td>Hypertension or Marfan syndrome (Chap. 169)</td>
<td>Weak, asymmetric peripheral pulses; possible diastolic murmur of aortic insufficiency (Chap. 121)</td>
<td>Aortic dissection (Chap. 132)</td>
<td>• CXR – widened mediastinal silhouette • MRI, CT, or transesophageal echogram: intimal flap visualized • Aortic angiogram: definitive diagnosis</td>
</tr>
<tr>
<td>Crushing, sharp, pleuritic; relieved by sitting forward</td>
<td>Recent upper respiratory tract infection, or other conditions which predispose to pericarditis (Chap. 123)</td>
<td>Pericardial friction rub (usually 3 components, best heard by sitting patient forward)</td>
<td>Acute pericarditis (Chap. 140)</td>
<td>• ECG: diffuse ST elevation and PR segment depression • Echogram: pericardial effusion often visualized</td>
</tr>
<tr>
<td>Pleuritic, sharp; possibly accompanied by cough/hemoptysis</td>
<td>Recent surgery or other immobilization</td>
<td>Tachypnea; possible pleural friction rub</td>
<td>Pulmonary embolism (Chap. 140)</td>
<td>• Normal d-dimer makes diagnosis unlikely • CT angiography or lung scan: V/Q mismatch • Pulmonary angiogram: arterial luminal filling defects</td>
</tr>
<tr>
<td>Very sharp, pleuritic</td>
<td>Recent chest trauma, or history of chronic obstructive lung disease</td>
<td>Tachypnea; breath sounds &amp; hyperresonance over affected lung field</td>
<td>Acute pneumothorax (Chap. 142)</td>
<td>• CXR: radiolucency within pleural space; pos. collapse of adjacent lung segment; if tension pneumothorax, mediastinum is shifted to opp. side</td>
</tr>
<tr>
<td>Intense substernal and epigastric; accompanied by vomiting = hematemesis</td>
<td>Recent recurrent vomiting/retinghing</td>
<td>Subcutaneous emphysema; audible crepitus adjacent to the sternum</td>
<td>Rupture of esophagus</td>
<td>• CXR: pneumo-mediastinum • Esophageal endoscopy is diagnostic</td>
</tr>
</tbody>
</table>

**FIGURE 33-2** Differential diagnosis of acute chest pain.
Acute Pericarditis  (Chap. 123) Usually steady, crushing, substernal; often has pleuritic component aggravated by cough, deep inspiration, supine position, and relieved by sitting upright; one-, two-, or three-component pericardial friction rub often audible.

Pleurisy  Due to inflammation; less commonly tumor and pneumothorax. Usually unilateral, knifelike, superficial, aggravated by cough and respiration.

**LESS SERIOUS CAUSES**

Costochondral Pain  In anterior chest, usually sharply localized, may be brief and darting or a persistent dull ache. Can be reproduced by pressure on costochondral and/or chondrosternal junctions. In Tietze’s syndrome (costochondritis), joints are swollen, red, and tender.

Chest Wall Pain  Due to strain of muscles or ligaments from excessive exercise or rib fracture from trauma; accompanied by local tenderness.

Esophageal Pain  Deep thoracic discomfort; may be accompanied by dysphagia and regurgitation.

Emotional Disorders  Prolonged ache or dartlike, brief, flashing pain; associated with fatigue, emotional strain.

**OTHER CAUSES**

(1) Cervical disk; (2) osteoarthritis of cervical or thoracic spine; (3) abdominal disorders: peptic ulcer, hiatus hernia, pancreatitis, biliary colic; (4) tracheobronchitis, pneumonia; (5) diseases of the breast (inflammation, tumor); (6) intercostal neuritis (herpes zoster).

**APPRAOCH TO THE PATIENT WITH CHEST PAIN**

A meticulous history of the behavior of pain, what precipitates it and what relieves it, aids diagnosis of recurrent chest pain. Figure 33-2 presents clues to diagnosis and workup of acute, life-threatening chest pain.

An ECG is key to the initial evaluation to rapidly distinguish patients with acute ST elevation MI, who typically warrant immediate reperfusion therapies (Chap. 126).

For a more detailed discussion, see Lee TH: Chest Discomfort, Chap. 13, p. 87, in HPIM-17.
Abdominal Pain

CHAPTER 34

Numerous causes, ranging from acute, life-threatening emergencies to chronic functional disease and disorders of several organ systems, can generate abdominal pain. Evaluation of acute pain requires rapid assessment of likely causes and early initiation of appropriate therapy. A more detailed and time-consuming approach to diagnosis may be followed in less acute situations. Table 34-1 lists the common causes of abdominal pain.

<table>
<thead>
<tr>
<th>Table 34-1</th>
<th>COMMON ETIOLOGIES OF ABDOMINAL PAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mucosal or muscle inflammation in hollow viscera:</strong> Peptic disease (ulcers, erosions, inflammation), hemorrhagic gastritis, gastroesophageal reflux, appendicitis, diverticulitis, cholecystitis, cholangitis, inflammatory bowel diseases (Crohn’s, ulcerative colitis), infectious gastroenteritis, mesenteric lymphadenitis, colitis, cystitis, or pyelonephritis</td>
<td></td>
</tr>
<tr>
<td><strong>Visceral spasm or distention:</strong> Intestinal obstruction (adhesions, tumor, intussusception), appendiceal obstruction with appendicitis, strangulation of hernia, irritable bowel syndrome (muscle hypertrophy and spasm), acute biliary obstruction, pancreatic ductal obstruction (chronic pancreatitis, stone), uterine obstruction (kidney stone, blood clot), fallopian tubes (tubal pregnancy)</td>
<td></td>
</tr>
<tr>
<td><strong>Vascular disorders:</strong> Mesenteric thromboembolic disease (arterial or venous), arterial dissection or rupture (e.g., aortic aneurysm), occlusion from external pressure or torsion (e.g., volvulus, hernia, tumor, adhesions, intussusception), hemoglobinopathy (esp. sickle cell disease)</td>
<td></td>
</tr>
<tr>
<td><strong>Distention or inflammation of visceral surfaces:</strong> Hepatic capsule (hepatitis, hemorrhage, tumor, Budd-Chiari syndrome, Fitz-Hugh-Curtis syndrome), renal capsule (tumor, infection, infarction, venous occlusion), splenic capsule (hemorrhage, abscess, infarction), pancreas (pancreatitis, pseudocyst, abscess, tumor), ovary (hemorrhage into cyst, ectopic pregnancy, abscess)</td>
<td></td>
</tr>
<tr>
<td><strong>Peritoneal inflammation:</strong> Bacterial infection (perforated viscus, pelvic inflammatory disease, infected ascites), intestinal infarction, chemical irritation, pancreatitis, perforated viscus (esp. stomach and duodenum), reactive inflammation (neighboring abscess, incl. diverticulitis, pleuropulmonary infection or inflammation), serositis (collagen-vascular diseases, familial Mediterranean fever), ovulation (mittelschmerz).</td>
<td></td>
</tr>
<tr>
<td><strong>Abdominal wall disorders:</strong> Trauma, hernias, muscle inflammation or infection, hematoma (trauma, anticoagulant therapy), traction from mesentery (e.g., adhesions)</td>
<td></td>
</tr>
<tr>
<td><strong>Toxins:</strong> Lead poisoning, black widow spider bite</td>
<td></td>
</tr>
<tr>
<td><strong>Metabolic disorders:</strong> Uremia, ketoacidosis (diabetic, alcoholic), Addisonian crisis, porphyria, angioedema (C1 esterase deficiency), narcotic withdrawal</td>
<td></td>
</tr>
<tr>
<td><strong>Neurologic disorders:</strong> Herpes zoster, tabes dorsalis, causalgia, compression or inflammation of spinal roots, (e.g., arthritis, herniated disk, tumor, abscess), psychogenic</td>
<td></td>
</tr>
<tr>
<td><strong>Referred pain:</strong> From heart, lungs, esophagus, genitalia (e.g., cardiac ischemia, pneumonia, pneumothorax, pulmonary embolism, esophagitis, esophageal spasm, esophageal rupture)</td>
<td></td>
</tr>
</tbody>
</table>
SECTION 3

APPROACH TO THE PATIENT: ABDOMINAL PAIN

HISTORY
History is of critical diagnostic importance. Physical exam may be unrevealing or misleading, and laboratory and radiologic exams delayed or unhelpful.

CHARACTERISTIC FEATURES OF ABDOMINAL PAIN

Duration and Pattern
These provide clues to nature and severity, although acute abdominal crisis may occasionally present insidiously or on a background of chronic pain.

Type and location provide a rough guide to nature of disease. Visceral pain (due to distention of a hollow viscus) localizes poorly and is often perceived in the midline. Intestinal pain tends to be crampy; when originating proximal to the ileocecal valve, it usually localizes above and around the umbilicus. Pain of colonic origin is perceived in the hypogastrum and lower quadrants. Pain from biliary or ureteral obstruction often causes pts to writhe in discomfort. Somatic pain (due to peritoneal inflammation) is usually sharper and more precisely localized to the diseased region (e.g., acute appendicitis; capsular distention of liver, kidney, or spleen), exacerbated by movement, causing pts to remain still. Pattern of radiation may be helpful: right shoulder (hepatobiliary origin), left shoulder (spleenic), midback (pancreatic), flank (proximal urinary tract), groin (genital or distal urinary tract).

Factors That Precipitate or Relieve Pain
Ask about its relationship to eating (e.g., upper GI, biliary, pancreatic, ischemic bowel disease), defecation (colorectal), urination (genitourinary or colorectal), respiratory (pleuropulmonary, hepatobiliary), position (pancreatic, gastroesophageal reflux, musculoskeletal), menstrual cycle/menarche (tuboovarian, endometrial, including endometriosis), exertion (coronary/intestinal ischemia, musculoskeletal), medication or specific foods (motility disorders, food intolerance, gastroesophageal reflux, porphyria, adrenal insufficiency, ketoacidosis, toxins), and stress (motility disorders, nonulcer dyspepsia, irritable bowel syndrome).

Associated Symptoms
Look for fevers/chills (infection, inflammatory disease, infarction), weight loss (tumor, inflammatory disease, malabsorption, ischemia), nausea/vomiting (obstruction, infection, inflammatory disease, metabolic disease), dysphagia/odynophagia (esophageal), early satiety (gastric), hematemesis (esophageal, gastric, duodenal), constipation (colorectal, perianal, genitourinary), jaundice (hepatobiliary, hemolytic), diarrhea (inflammatory disease, infection, malabsorption, secretory tumors, ischemia, genitourinary), dysuria/hematuria/vaginal or penile discharge (genitourinary), hematochezia (colorectal or, rarely, urinary), skin/joint/eye disorders (inflammatory disease, bacterial or viral infection).

Predisposing Factors
Inquire about family history (inflammatory disease, tumors, pancreatitis), hypertension and atherosclerotic disease (ischemia), diabetes mellitus (motility disorders, ketoacidosis), connective tissue disease (motility disorders, serositis), depression (motility disorders, tumors), smoking (ischemia), recent smoking cessation (inflammatory disease), ethanol use (motility disorders, hepatobiliary, pancreatic, gastritis, peptic ulcer disease).
PHYSICAL EXAMINATION

Evaluate abdomen for prior trauma or surgery, current trauma; abdominal distention, fluid, or air; direct, rebound, and referred tenderness; liver and spleen size; masses, bruits, altered bowel sounds, hernias, arterial masses. Rectal examination assesses presence and location of tenderness, masses, blood (gross or occult). Pelvic examination in women is essential. General examination: evaluate for evidence of hemodynamic instability, acid-base disturbances, nutritional deficiency, coagulopathy, arterial occlusive disease, stigmata of liver disease, cardiac dysfunction, lymphadenopathy, and skin lesions.

ROUTINE LABORATORY AND RADIOLOGIC STUDIES

Choices depend on clinical setting (esp. severity of pain, rapidity of onset) and may include complete blood count, serum electrolytes, coagulation parameters, serum glucose, and biochemical tests of liver, kidney, and pancreatic function; chest x-ray to determine the presence of diseases involving heart, lung, mediastinum, and pleura; electrocardiogram is helpful to exclude referred pain from cardiac disease; plain abdominal radiographs to evaluate bowel displacement, intestinal distention, fluid and gas pattern, free peritoneal air, liver size, and abdominal calcifications (e.g., gallstones, renal stones, chronic pancreatitis).

SPECIAL STUDIES

These include abdominal ultrasonography (to visualize biliary ducts, gallbladder, liver, pancreas, and kidneys); CT to identify masses, abscesses, evidence of inflammation (bowel wall thickening, mesenteric “stranding,” lymphadenopathy), aortic aneurysm; barium contrast radiographs (barium swallow, upper GI series, small-bowel follow-through, barium enema); upper GI endoscopy, sigmoidoscopy, or colonoscopy; cholangiography (endoscopic, percutaneous, or via MRI), angiography (direct or via CT or MRI), and radionuclide scanning. In selected cases, percutaneous biopsy, laparoscopy, and exploratory laparotomy may be required.

ACUTE, CATASTROPHIC ABDOMINAL PAIN

Intense abdominal pain of acute onset or pain associated with syncope, hypotension, or toxic appearance necessitates rapid yet orderly evaluation. Consider obstruction, perforation, or rupture of hollow viscus; dissection or rupture of major blood vessels (esp. aortic aneurysm); ulceration; abdominal sepsis; ketoacidosis; and adrenal crisis.

Brief History and Physical Examination

Historic features of importance include age; time of onset of the pain; activity of the pt when the pain began; location and character of the pain; radiation to other sites; presence of nausea, vomiting, or anorexia; temporal changes; changes in bowel habits; and menstrual history. Physical exam should focus on the pt’s overall appearance [writhing in pain (ureteral lithiasis) vs. still (peritonitis, perforation)], position (a pt leaning forward may have pancreatitis or gastric perforation into the lesser sac), presence of fever or hypothermia, hyperventilation, cyanosis, bowel sounds, direct or rebound abdominal tenderness, pulsating abdominal mass, abdominal bruits, ascites, rectal blood, rectal or pelvic tenderness, and evidence of coagulopathy. Useful laboratory studies include hematocrit (may be normal with acute hemorrhage or misleadingly high with dehydration), WBC with differential count, arterial blood gases, serum electrolytes, BUN, creatinine, glucose, lipase or amylase, and UA. Females of reproductive age should have a
pregnancy test. Radiologic studies should include supine and upright abdominal films (left lateral decubitus view if upright unobtainable) to evaluate bowel caliber and presence of free peritoneal air, cross-table lateral film to assess aortic diameter; CT (when available) to detect evidence of bowel perforation, inflammation, solid organ infarction, retroperitoneal bleeding, abscess, or tumor. Abdominal paracentesis (or peritoneal lavage in cases of trauma) can detect evidence of bleeding or peritonitis. Abdominal ultrasound (when available) reveals evidence of abscess, cholecystitis, biliary or ureteral obstruction, or hematoma and is used to determine aortic diameter.

Diagnostic Strategies  The initial decision point is based on whether the pt is hemodynamically stable. If not, one must suspect a vascular catastrophe such as a leaking abdominal aortic aneurysm. Such pts receive limited resuscitation and move immediately to surgical exploration. If the pt is hemodynamically stable, the next decision point is whether the abdomen is rigid. Rigid abdomens are most often due to perforation or obstruction. The diagnosis can generally be made by a chest and plain abdominal radiograph.

If the abdomen is not rigid, the causes may be grouped based on whether the pain is poorly localized or well localized. In the presence of poorly localized pain, one should assess whether an aortic aneurysm is possible. If so, a CT scan can make the diagnosis; if not, early appendicitis, early obstruction, mesenteric ischemia, inflammatory bowel disease, pancreatitis, and metabolic problems are all in the differential diagnosis.

Pain localized to the epigastrium may be of cardiac origin or due to esophageal inflammation or perforation, gastritis, peptic ulcer disease, biliary colic or cholecystitis, or pancreatitis. Pain localized to the right upper quadrant includes those same entities plus pyelonephritis or nephrolithiasis, hepatic abscess, subdiaphragmatic abscess, pulmonary embolus, or pneumonia, or it may be of musculoskeletal origin. Additional considerations with left upper quadrant localization are infarcted or ruptured spleen, splenomegaly, and gastric or peptic ulcer. Right lower quadrant pain may be from appendicitis, Meckel’s diverticulum, Crohn’s disease, diverticulitis, mesenteric adenitis, rectus sheath hematoma, psoas abscess, ovarian abscess or torsion, ectopic pregnancy, salpingitis, familial fever syndromes, urolithiasis, or herpes zoster. Left lower quadrant pain may be due to diverticulitis, perforated neoplasm, or other entities previously mentioned.

Acute, Catastrophic Abdominal Pain

IV fluids, correction of life-threatening acid-base disturbances, and assessment of need for emergent surgery are the first priority; careful follow-up with frequent reexamination (when possible, by the same examiner) is essential. Relieve the pain. The use of narcotic analgesia is controversial. Traditionally, narcotic analgesics were withheld pending establishment of diagnosis and therapeutic plan, since masking of diagnostic signs may delay needed intervention. However, evidence that narcotics actually mask a diagnosis is sparse.
APPROACH TO THE PATIENT: HEADACHE

Headache is among the most common reasons that pts seek medical attention. Headache can be either primary or secondary (Table 35-1). First step—distinguish serious from benign etiologies. Symptoms that raise suspicion for a serious cause are listed in Table 35-2. Intensity of head pain rarely has diagnostic value; most pts who present to emergency ward with worst headache of their lives have migraine. Headache location can suggest involvement of local structures (temporal pain in giant cell arteritis, facial pain in sinusitis). Ruptured aneurysm (instant onset), cluster headache (peak over 3–5 min), and migraine (onset over minutes to hours) differ in time to peak intensity. Provocation by environmental factors suggests a benign cause.

Complete neurologic exam is important in the evaluation of headache. If exam is abnormal or if serious underlying cause is suspected, an imaging study (CT or MRI) is indicated as a first step. Lumbar puncture (LP) is required when meningitis (stiff neck, fever) or subarachnoid hemorrhage (after negative imaging) is a possibility. The psychological state of the patient should also be evaluated since a relationship exists between pain and depression.

MIGRAINE

A benign and recurring syndrome of headache associated with other symptoms of neurologic dysfunction in varying admixtures. The second most common cause of headache; afflicts ~15% of women and 6% of men. Diagnostic criteria for migraine are listed in Table 35-3. Onset usually in childhood, adolescence, or early adulthood; however, initial attack may occur at any age. Family history often positive. Women may have increased sensitivity to attacks during menstrual cycle. Classic triad: premonitory visual (scotoma or scintillations) sensory or motor symptoms, unilateral throbbing headache, nausea and vomiting. Most do not have visual aura and are therefore referred to as having “common migraine.” Photo- and phonophobia common. Vertigo may occur. Focal neurologic disturbances without headache or vomiting (migraine equivalents) may also occur. An

<table>
<thead>
<tr>
<th>PRIMARY HEADACHE</th>
<th>SECONDARY HEADACHE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type</strong></td>
<td><strong>%</strong></td>
</tr>
<tr>
<td>Migraine</td>
<td>16</td>
</tr>
<tr>
<td>Tension-type</td>
<td>69</td>
</tr>
<tr>
<td>Cluster</td>
<td>0.1</td>
</tr>
<tr>
<td>Idiopathic stabbing</td>
<td>2</td>
</tr>
<tr>
<td>Exertional</td>
<td>1</td>
</tr>
</tbody>
</table>

Common Patient Presentations

SECTION 3

Attack lasting 4–72 h is typical, as is relief after sleep. Attacks may be triggered by wine, cheese, chocolate, contraceptives, stress, exercise, or travel.

**Migraine**

Three approaches to migraine treatment: nonpharmacologic (such as the avoidance of patient-specific triggers; information for pts is available at [www.achenet.org](http://www.achenet.org)); drug treatment of acute attacks ([Tables 35-4 and 35-5](#)); and prophylaxis ([Table 35-6](#)). Drug treatment necessary for most migraine pts, but avoidance or management of environmental triggers is sufficient for some. General principles of pharmacologic treatment: (1) response rates vary from 60–90%; (2) initial drug choice is empirical— influenced by age, coexisting illnesses, and side effect profile; (3) efficacy of prophylactic treatment may take several months to assess with each drug; (4) when an acute attack requires additional medication 60 min after the first dose, then the initial drug dose should be increased for subsequent attacks. Mild-to-moderate acute migraine attacks often respond to over-the-counter (OTC) NSAIDs when taken early in the attack. Triptans are widely used also but many have recurrence of pain after initial relief. There is less frequent headache recurrence when using ergots, but more frequent side effects. For prophylaxis, tricyclic antidepressants are a good first choice for young people with difficulty falling asleep; verapamil is often a first choice for prophylaxis in the elderly.

**TABLE 35-2  HEADACHE SYMPTOMS THAT SUGGEST A SERIOUS UNDERLYING DISORDER**

<table>
<thead>
<tr>
<th>Symptom</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Worst” headache ever</td>
</tr>
<tr>
<td>First severe headache</td>
</tr>
<tr>
<td>Subacute worsening over days or weeks</td>
</tr>
<tr>
<td>Abnormal neurologic examination</td>
</tr>
<tr>
<td>Fever or unexplained systemic signs</td>
</tr>
<tr>
<td>Vomiting that precedes headache</td>
</tr>
<tr>
<td>Pain induced by bending, lifting, cough</td>
</tr>
<tr>
<td>Pain that disturbs sleep or presents immediately upon awakening</td>
</tr>
<tr>
<td>Known systemic illness</td>
</tr>
<tr>
<td>Onset after age 55</td>
</tr>
<tr>
<td>Pain associated with local tenderness, e.g., region of temporal artery</td>
</tr>
</tbody>
</table>

**TABLE 35-3  SIMPLIFIED DIAGNOSTIC CRITERIA FOR MIGRAINE**

Repeated attacks of headache lasting 4–72 h in patients with a normal physical examination, no other reasonable cause for the headache, and:

<table>
<thead>
<tr>
<th>At least 2 of the following features:</th>
<th>Plus at least 1 of the following features:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unilateral pain</td>
<td>Nausea/vomiting</td>
</tr>
<tr>
<td>Throbbing pain</td>
<td>Photophobia and phonophobia</td>
</tr>
<tr>
<td>Aggravation by movement</td>
<td></td>
</tr>
<tr>
<td>Moderate or severe intensity</td>
<td></td>
</tr>
</tbody>
</table>

*Source:* Adapted from the International Headache Society Classification (Headache Classification Committee of the International Headache Society, 2004).
TABLE 35-4 TREATMENT OF ACUTE MIGRAINE

<table>
<thead>
<tr>
<th>Drug</th>
<th>Trade Name</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Simple Analgesics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetaminophen, aspirin, caffeine</td>
<td>Excedrin Migraine</td>
<td>Two tablets or caplets q6h (max 8 per day)</td>
</tr>
<tr>
<td><strong>NSAIDs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naproxen</td>
<td>Aleve, Anaprox, generic</td>
<td>220–550 mg PO bid</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>Advil, Motrin, Nuprin, generic</td>
<td>400 mg PO q3–4h</td>
</tr>
<tr>
<td>Tolfenamic acid</td>
<td>Clotam Rapid</td>
<td>200 mg PO. May repeat x 1 after 1–2 h</td>
</tr>
<tr>
<td><strong>5-HT&lt;sub&gt;1 &lt;/sub&gt; Agonists</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ergotamine</td>
<td>Ergomar</td>
<td>One 2 mg sublingual tablet at onset and q1/2h (max 3 per day, 5 per week)</td>
</tr>
<tr>
<td>Ergotamine 1 mg, caffeine 100 mg</td>
<td>Ercaf, Wigraine</td>
<td>One or two tablets at onset, then one tablet q1/2h (max 6 per day, 10 per week)</td>
</tr>
<tr>
<td>Naratriptan</td>
<td>Amerge</td>
<td>2.5 mg tablet at onset; may repeat once after 4 h</td>
</tr>
<tr>
<td>Rizatriptan</td>
<td>Maxalt</td>
<td>5–10 mg tablet at onset; may repeat after 2 h (max 30 mg/d)</td>
</tr>
<tr>
<td></td>
<td>Maxalt-MLT</td>
<td></td>
</tr>
<tr>
<td>Sumatriptan</td>
<td>Imitrex</td>
<td>50–100 mg tablet at onset; may repeat after 2 h (max 200 mg/d)</td>
</tr>
<tr>
<td>Frovatriptan</td>
<td>Frova</td>
<td>2.5 mg tablet at onset, may repeat after 2 h (max 5 mg/d)</td>
</tr>
<tr>
<td>Almotriptan</td>
<td>Axert</td>
<td>12.5 mg tablet at onset, may repeat after 2 h (max 25 mg/d)</td>
</tr>
<tr>
<td>Eletriptan</td>
<td>Relpax</td>
<td>40 or 80 mg</td>
</tr>
<tr>
<td>Zolmitriptan</td>
<td>Zomig</td>
<td>2.5 mg tablet at onset; may repeat after 2 h (max 10 mg/d)</td>
</tr>
<tr>
<td></td>
<td>Zomig Rapimelt</td>
<td></td>
</tr>
<tr>
<td><strong>Nasal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dihydroergotamine</td>
<td>Migranal Nasal Spray</td>
<td>Prior to nasal spray, the pump must be primed 4 times; 1 spray (0.5 mg) is administered, followed in 15 min by a second spray</td>
</tr>
<tr>
<td>Sumatriptan</td>
<td>Imitrex Nasal Spray</td>
<td>5–20 mg intranasal spray as 4 sprays of 5 mg or a single 20 mg spray (may repeat once after 2 h, not to exceed a dose of 40 mg/d)</td>
</tr>
<tr>
<td>Zolmitriptan</td>
<td>Zomig</td>
<td>5 mg intranasal spray as one spray (may repeat once after 2 h, not to exceed a dose of 10 mg/d)</td>
</tr>
</tbody>
</table>

(continued)
Common Patient Presentations

SECTION 3

Tension Headache

Common in all age groups. Pain is holocephalic, described as bilateral pressure or a tight band. May persist for hours or days; usually builds slowly. Pain can be managed generally with simple analgesics such as acetaminophen, aspirin, or NSAIDs. Often related to stress; responds to behavioral approaches including relaxation. Amitriptyline may be helpful for chronic tension-type headache prophylaxis.

Cluster Headache

Rare form of primary headache; population frequency 0.1%. Characterized by episodes of recurrent, deep, nocturnal, unilateral, retroorbital searing pain. Typically, a young male (three times more common in males) awakens 2–4 h after sleep onset with severe pain, unilateral lacrimation, and nasal and conjunctival congestion. Visual complaints, nausea, or vomiting are rare. Unlike

---

### TABLE 35-4 TREATMENT OF ACUTE MIGRAINE (CONTINUED)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Trade Name</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Parenteral</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dihydroergotamine</td>
<td>DHE-45</td>
<td>1 mg IV, IM, or SC at onset and q1h (max 3 mg/d, 6 mg per week)</td>
</tr>
<tr>
<td>Sumatriptan</td>
<td>Imitrex Injection</td>
<td>6 mg SC at onset (may repeat once after 1 h for max of 2 doses in 24 h)</td>
</tr>
</tbody>
</table>

**Dopamine Antagonists**

<table>
<thead>
<tr>
<th>Oral</th>
<th>Trade Name</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metoclopramide</td>
<td>Reglan, a generic</td>
<td>5–10 mg/d</td>
</tr>
<tr>
<td>Prochlorperazine</td>
<td>Compazine, a generic</td>
<td>1–25 mg/d</td>
</tr>
</tbody>
</table>

**Parenteral**

| Chlorpromazine        | Generic             | 0.1 mg/kg IV at 2 mg/min; max 35 mg/d       |
| Metoclopramide        | Reglan, a generic   | 10 mg IV                                    |
| Prochlorperazine       | Compazine, a generic | 10 mg IV                                    |

**Other**

<table>
<thead>
<tr>
<th>Oral</th>
<th>Midrin, Duradrin, generic</th>
<th>Two capsules at onset followed by 1 capsule q1h (max 5 capsules)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen, 325 mg, plus dichloralphenazone, 100 mg, plus isometheptene, 65 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Nasal**

| Butorphanol           | Stadol a               | 1 mg (1 spray in 1 nostril), may repeat if necessary in 1–2 h |

**Parenteral**

| Narcotics             | Generic                | Multiple preparations and dosages; see Table 6-2             |

---

*aNot all drugs are specifically indicated by the FDA for migraine. Local regulations and guidelines should be consulted.

Note: Antiemetics (e.g., domperidone 10 mg or ondansetron) or prokinetics (e.g., metoclopramide 10 mg) are sometimes useful adjuncts.

Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; 5-HT, 5-hydroxytryptamine.
migraine, patients with cluster tend to move about during attacks. A core feature is periodicity. Pain lasts 30–120 min but tends to recur at the same time of night or several times each 24 h over 4–8 weeks (a cluster). A pain-free period of months or years may be followed by another cluster of headaches. Alcohol provokes attacks in 70%. Prophylaxis with verapamil (40–80 mg twice daily to start), lithium (600–900 mg/d), prednisone (60 mg/d for 7 days followed by a rapid taper), or ergotamine (1–2 mg suppository 1–2 h before expected attack). High-flow oxygen (10–12 L/min for 15–20 min) or sumatriptan (6 mg SC or 20-mg nasal spray) is useful for the acute attack. Deep-brain stimulation of the posterior hypothalamic gray matter is successful for refractory cases.

**Post-Concussion Headache** Common following motor vehicle collisions, other head trauma; severe injury or loss of consciousness often not present. Symptoms of headache, dizziness, vertigo, impaired memory, poor concentration, irritability; typically remits after several weeks to months. Neurologic examina-

<table>
<thead>
<tr>
<th>Clinical Situation</th>
<th>Treatment Options</th>
</tr>
</thead>
<tbody>
<tr>
<td>Failed NSAIDS/analgesics</td>
<td><strong>First tier</strong></td>
</tr>
<tr>
<td></td>
<td>Sumatriptan 50 mg or 100 mg PO</td>
</tr>
<tr>
<td></td>
<td>Almotriptan 12.5 mg PO</td>
</tr>
<tr>
<td></td>
<td>Rizatriptan 10 mg PO</td>
</tr>
<tr>
<td></td>
<td>Eletriptan 40 mg PO</td>
</tr>
<tr>
<td></td>
<td>Zolmitriptan 2.5 mg PO</td>
</tr>
<tr>
<td><strong>Slower effect/better tolerability</strong></td>
<td>Naratriptan 2.5 mg PO</td>
</tr>
<tr>
<td></td>
<td>Frovatriptan 2.5 mg PO</td>
</tr>
<tr>
<td><strong>Infrequent headache</strong></td>
<td>Ergotamine 1–2 mg PO</td>
</tr>
<tr>
<td></td>
<td>Dihydroergotamine nasal spray 2 mg</td>
</tr>
<tr>
<td>Early nausea or difficulties taking tablets</td>
<td>Zolmitriptan 5 mg nasal spray</td>
</tr>
<tr>
<td></td>
<td>Sumatriptan 20 mg nasal spray</td>
</tr>
<tr>
<td></td>
<td>Rizatriptan 10 mg MLT wafer</td>
</tr>
<tr>
<td>Headache recurrence</td>
<td>Ergotamine 2 mg (most effective PR/usually with caffeine)</td>
</tr>
<tr>
<td></td>
<td>Naratriptan 2.5 mg PO</td>
</tr>
<tr>
<td></td>
<td>Almotriptan 12.5 mg PO</td>
</tr>
<tr>
<td></td>
<td>Eletriptan 40 mg</td>
</tr>
<tr>
<td>Tolerating acute treatments poorly</td>
<td>Naratriptan 2.5 mg</td>
</tr>
<tr>
<td>Early vomiting</td>
<td>Almotriptan 12.5 mg</td>
</tr>
<tr>
<td></td>
<td>Zolmitriptan 5 mg nasal spray</td>
</tr>
<tr>
<td></td>
<td>Sumatriptan 25 mg PR</td>
</tr>
<tr>
<td></td>
<td>Sumatriptan 6 mg SC</td>
</tr>
<tr>
<td>Menses-related headache</td>
<td><strong>Prevention</strong></td>
</tr>
<tr>
<td></td>
<td>Ergotamine PO at night</td>
</tr>
<tr>
<td></td>
<td>Estrogen patches</td>
</tr>
<tr>
<td>Very rapidly developing symptoms</td>
<td><strong>Treatment</strong></td>
</tr>
<tr>
<td></td>
<td>Triptans</td>
</tr>
<tr>
<td></td>
<td>Dihydroergotamine nasal spray</td>
</tr>
<tr>
<td></td>
<td>Zolmitriptan 5 mg nasal spray</td>
</tr>
<tr>
<td></td>
<td>Sumatriptan 6 mg SC</td>
</tr>
<tr>
<td></td>
<td>Dihydroergotamine 1 mg IM</td>
</tr>
</tbody>
</table>
# Table 35-6 Preventive Treatments in Migraine

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Selected Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pizotifen[^b]</td>
<td>0.5–2 mg qd</td>
<td>Weight gain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drowsiness</td>
</tr>
<tr>
<td>Beta blocker</td>
<td></td>
<td>Reduced energy</td>
</tr>
<tr>
<td>Propranolol</td>
<td>40–120 mg bid</td>
<td>Tiredness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Postural symptoms</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td></td>
<td>Contraindicated in asthma</td>
</tr>
<tr>
<td>Topiramate</td>
<td>25–200 mg/d</td>
<td>Paresthesias</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cognitive symptoms</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weight loss</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Glaucoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caution with nephrolithias</td>
</tr>
<tr>
<td>Valproate</td>
<td>400–600 mg bid</td>
<td>Drowsiness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weight gain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tremor</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>900–3600 mg qd</td>
<td>Dizziness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sedation</td>
</tr>
<tr>
<td>Serotonergic drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methysergide</td>
<td>1–4 mg qd</td>
<td>Drowsiness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Leg cramps</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hair loss</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Retropertitoneal fibrosis (1-month drug holiday is required every 6 months)</td>
</tr>
<tr>
<td>Flunarizine[^b]</td>
<td>5–15 mg qd</td>
<td>Drowsiness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weight gain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Depression</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Parkinsonism</td>
</tr>
<tr>
<td>No convincing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>evidence from</td>
<td></td>
<td></td>
</tr>
<tr>
<td>controlled trials</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verapamil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controlled trials</td>
<td>demonstrate no effect</td>
<td></td>
</tr>
<tr>
<td>Nimodipine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clonidine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSRIs: fluoxetine</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[^a]: Commonly used preventives are listed with reasonable doses and common side effects. Not all listed medicines are approved by the FDA; local regulations and guidelines should be consulted.

[^b]: Not available in the United States.
tion and neuroimaging studies normal. Not a functional disorder; cause unknown and treatment usually not satisfactory.

**Lumbar Puncture Headache**  Typical onset 24–48 h after LP; follows 10–30% of LPs. Positional: onset when pt sits or stands, relief by lying flat. Most cases remit spontaneously in ≤1 week. Intravenous caffeine (500 mg IV, repeat in 1 h if dose ineffective) successful in 85%; epidural blood patch effective immediately in refractory cases.

**Cough Headache**  Transient severe head pain with coughing, bending, lifting, sneezing, or stooping; lasts from seconds to several minutes; men > women. Usually benign, but posterior fossa mass lesion in ~25%. Consider brain MRI.

**Indomethacin-Responsive Headaches**  A diverse set of disorders that respond often exquisitely to indomethacin include:

- **Paroxysmal hemicrania**: Frequent unilateral, severe, short-lasting episodes of headache that are often retroorbital and associated with autonomic phenomena such as lacrimation and nasal congestion.
- **Hemicrania continua**: Moderate and continuous unilateral pain associated with fluctuations of severe pain that may be associated with autonomic features.
- **Primary stabbing headache**: Stabbing pain confined to the head or rarely the face lasting from 1 to many seconds or minutes.
- **Primary cough headache**
- **Primary exertional headache**: Has features similar to cough headache and migraine; usually precipitated by any form of exercise.

**FACIAL PAIN**

Most common cause of facial pain is dental; triggered by hot, cold, or sweet foods. Exposure to cold repeatedly induces dental pain. Trigeminal neuralgia consists of paroxysmal, electric shock–like episodes of pain in the distribution of trigeminal nerve; occipital neuralgia presents as lancinating occipital pain. These disorders are discussed in Chap. 197.

> For a more detailed discussion, see Goadsby PJ and Raskin NH: Headache, Chap. 15, p. 95, in HPIM-17.

**LOW BACK PAIN**

The cost of low back pain (LBP) in the United States is ~$100 billion annually. Back symptoms are the most common cause of disability in those <45 years; ~1% of the United States population is disabled because of back pain.
Types of Low Back Pain

• **Local pain**—caused by stretching of pain-sensitive structures that compress or irritate nerve endings; pain (i.e., tears, stretching) located near the affected part of the back.

• **Pain referred to the back**—abdominal or pelvic origin; back pain unaffected by routine movements.

• **Pain of spine origin**—restricted to the back or referred to lower limbs or buttock. Diseases of upper lumbar spine refer pain to upper lumbar region, groin, or anterior thighs. Diseases of lower lumbar spine refer pain to buttocks or posterior thighs.

• **Radicular back pain**—radiates from spine to leg in specific nerve root territory. Coughing, sneezing, lifting heavy objects, or straining may elicit pain.

• **Pain associated with muscle spasm**—diverse causes; accompanied by taut paraspinal muscles and abnormal posture.

**Examination** Include abdomen, pelvis, and rectum to search for visceral sources of pain. Inspection may reveal scoliosis or muscle spasm. Palpation may elicit pain over a diseased spine segment. Pain from hip may be confused with spine pain; manual internal/external rotation of leg at hip (knee and hip in flexion) reproduces the hip pain.

Straight leg raising (SLR) sign—elicited by passive flexion of leg at the hip with pt in supine position; maneuver stretches L5/S1 nerve roots and sciatic nerve passing posterior to the hip; SLR sign is positive if maneuver reproduces the pain. Crossed SLR sign—positive when SLR on one leg reproduces symptoms in opposite leg or buttocks; nerve/nerve root lesion is on the painful side. Reverse SLR sign—passive extension of leg backwards with pt standing; maneuver stretches L2–L4 nerve roots and femoral nerve passing anterior to the hip.

Neurologic exam—search for focal atrophy, weakness, reflex loss, diminished sensation in a dermatomal distribution. Findings with radiculopathy are summarized in Table 36-1.

**Laboratory Evaluation** “Routine” laboratory studies and lumbar spine x-rays are rarely needed for acute LBP (<3 months) but indicated when risk factors for serious underlying disease are present (Table 36-2). MRI and CT-myelography are tests of choice for anatomic definition of spine disease. Electromyography (EMG) and nerve conduction studies useful for functional assessment of peripheral nervous system.

**Etiology** **Lumbar Disk Disease** Common cause of low back and leg pain; usually at L4-L5 or L5-S1 levels. Dermatomal sensory loss, reduction or loss of deep tendon reflexes, or myotomal pattern of weakness more informative than pain pattern for localization. Usually unilateral; can be bilateral with large central disk herniations compressing multiple nerve roots and causing cauda equina syndrome (Chap. 198). Indications for lumbar disk surgery: (1) progressive motor weakness from nerve root injury, (2) progressive motor impairment by EMG, (3) abnormal bowel or bladder function, (4) incapacitating nerve root pain despite conservative treatment for at least 4 weeks, and (5) recurrent incapacitating pain despite conservative treatment. The latter two criteria are controversial.

**Spinal Stenosis** A narrowed spinal canal producing neurogenic claudication, i.e., back, buttock, and/or leg pain induced by walking or standing and relieved by sitting. Symptoms are usually bilateral. Unlike vascular claudication, symptoms are provoked by standing without walking. Unlike lumbar disk disease, symptoms are relieved by sitting. Focal neurologic deficits common; severe neurologic deficits (paralysis, incontinence) rare. Stenosis results from acquired
<table>
<thead>
<tr>
<th>Lumbosacral Nerve Roots</th>
<th>Reflex</th>
<th>Sensory</th>
<th>Motor</th>
<th>Pain Distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>L2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>—</td>
<td>Upper anterior thigh</td>
<td>Psoas (hip flexion)</td>
<td>Anterior thigh</td>
</tr>
<tr>
<td>L3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>—</td>
<td>Lower anterior thigh Anterior knee</td>
<td>Psoas (hip flexion) Quadriceps (knee extension) Thigh adduction</td>
<td>Anterior thigh Anterior thigh, knee</td>
</tr>
<tr>
<td>L4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Quadriceps (knee)</td>
<td>Medial calf</td>
<td>Quadriceps (knee extension)&lt;sup&gt;b&lt;/sup&gt; Tibialis anterior (foot dorsiflexion) Thigh adduction</td>
<td>Knee, medial calf Anterolateral thigh</td>
</tr>
<tr>
<td>L5&lt;sup&gt;c&lt;/sup&gt;</td>
<td>—</td>
<td>Dorsal surface—foot Lateral calf</td>
<td>Peroneii (foot eversion)&lt;sup&gt;b&lt;/sup&gt; Tibialis anterior (foot dorsiflexion) Gluteus medius (hip abduction) Toe dorsiflexors</td>
<td>Lateral calf, dorsal foot, posterolateral thigh, buttocks</td>
</tr>
<tr>
<td>S1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Gastrocnemius/soleus (ankle)</td>
<td>Plantar surface—foot Lateral aspect—foot</td>
<td>Gastrocnemius/soleus (foot plantar flexion)&lt;sup&gt;b&lt;/sup&gt; Abductor hallucis (toe flexors)&lt;sup&gt;b&lt;/sup&gt; Gluteus maximus (hip extension)</td>
<td>Bottom foot, posterior calf, posterior thigh, buttocks</td>
</tr>
</tbody>
</table>

<sup>a</sup>Reverse straight leg-raise sign present—see “Examination of the Back.”
<sup>b</sup>These muscles receive the majority of innervation from this root.
<sup>c</sup>Straight leg-raise sign present—see “Examination of the Back.”
Common Patient Presentations

(75%), congenital, or mixed acquired/congenital factors. Symptomatic treatment adequate for mild disease; surgery indicated when pain interferes with activities of daily living or focal neurologic signs present. Most patients treated surgically experience at least 75% relief of back and leg pain; 25% develop recurrent stenosis within 5 years.

Trauma  Low back strain or sprain used to describe minor, self-limited injuries associated with LBP. Vertebral fractures from trauma result in anterior wedging or compression of vertebral bodies; burst fractures involving vertebral body and posterior spine elements can occur. Neurologic impairment common with vertebral fractures; early surgical intervention indicated. CT scans are used as a screening tool for spine disease in moderate to severe trauma as they are superior to routine x-rays for bony disease. Most common cause of nontraumatic fracture is osteoporosis; others are osteomalacia, hyperparathyroidism, hyperthyroidism, multiple myeloma, or metastatic carcinoma; glucocorticoid use may predispose vertebral body to fracture. Clinical context, exam findings, and imaging establish diagnosis.

Spondylolisthesis  Slippage of anterior spine forward, leaving posterior elements behind; L4-L5 > L5-S1 levels; can produce LBP or radiculopathy/cauda equina syndrome (see Chap. 198).

Osteoarthritis  Back pain induced by spine movement and associated with stiffness. Increases with age; radiologic findings do not correlate with severity of pain. Facet syndrome—radicular symptoms and signs, nerve root compression by unilateral facet hypertrophy and osteophytes. Loss of intervertebral disk height reduces vertical dimensions of intervertebral foramen; descending pedicle can compress the exiting nerve root.

Vertebral Metastases  Back pain most common neurologic symptom in patients with systemic cancer and may be presenting complaint; pain typically unrelieved by rest. Metastatic carcinoma, multiple myeloma, and lymphomas frequently involve spine. MRI or CT-myelography demonstrates vertebral body metastasis; disk space is spared.

---

**TABLE 36-2 ACUTE LOW BACK PAIN: RISK FACTORS FOR AN IMPORTANT STRUCTURAL CAUSE**

<table>
<thead>
<tr>
<th>History</th>
<th>Examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain worse at rest or at night</td>
<td>Unexplained fever</td>
</tr>
<tr>
<td>Prior history of cancer</td>
<td>Unexplained weight loss</td>
</tr>
<tr>
<td>History of chronic infection (esp. lung, urinary tract, skin)</td>
<td>Percussion tenderness over the spine</td>
</tr>
<tr>
<td>History of trauma</td>
<td>Abdominal, rectal, or pelvic mass</td>
</tr>
<tr>
<td>Incontinence</td>
<td>Patrick’s sign or heel percussion sign</td>
</tr>
<tr>
<td>Age &gt; 50 years</td>
<td>Straight leg– or reverse straight leg–raising signs</td>
</tr>
<tr>
<td>Intravenous drug use</td>
<td>Progressive focal neurologic deficit</td>
</tr>
<tr>
<td>Glucocorticoid use</td>
<td></td>
</tr>
</tbody>
</table>
### Vertebral Osteomyelitis
Back pain unrelieved by rest; focal spine tenderness, elevated ESR. Primary source of infection (lung, urinary tract, or skin) found in fewer than half of cases; IV drug abuse a risk factor. Destruction of the vertebral bodies and disk space common. Lumbar spinal epidural abscess presents as back pain and fever; exam may be normal or show radicular findings, spinal cord involvement, or cauda equina syndrome. Extent of abscess best defined by MRI.

### Lumbar Arachnoiditis
May follow inflammation within subarachnoid space; fibrosis results in clumping of nerve roots, best seen by MRI; treatment is unsatisfactory.

### Immune Disorders
Ankylosing spondylitis, rheumatoid arthritis, Reiter’s syndrome, psoriatic arthritis, and chronic inflammatory bowel disease. Ankylosing spondylitis—typically male <40 years with nocturnal back pain and morning stiffness; pain unrelieved by rest but improves with exercise.

### Osteoporosis
Loss of bone substance resulting from hyperparathyroidism, chronic glucocorticoid use, immobilization, other medical disorders, or increasing age (particularly in females). Sole manifestation may be back pain exacerbated by movement. Can also occur in the upper back.

### Visceral Diseases
(Table 36-3) Pelvis refers pain to sacral region, lower abdomen to mid-lumbar region, upper abdomen to lower thoracic or upper lumbar region. Local signs are absent; normal movements of the spine are painless. A contained rupture of an abdominal aortic aneurysm may produce isolated back pain.

### Other
Chronic LBP with no clear cause; psychiatric disorders, substance abuse may be associated.

### Table 36-3  Visceral Causes of Low Back Pain

<table>
<thead>
<tr>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stomach (posterior wall)—gallbladder—gallstones</td>
</tr>
<tr>
<td>Pancreas—tumor, cyst, pancreatitis</td>
</tr>
<tr>
<td>Retropertitoneal—hemorrhage, tumor, pyelonephritis</td>
</tr>
<tr>
<td>Vascular—abdominal aortic aneurysm, renal artery and vein thrombosis</td>
</tr>
<tr>
<td>Colon—colitis, diverticulitis, neoplasm</td>
</tr>
<tr>
<td>Uterosacral ligaments—endometriosis, carcinoma</td>
</tr>
<tr>
<td>Uterine malposition</td>
</tr>
<tr>
<td>Menstrual pain</td>
</tr>
<tr>
<td>Neoplastic infiltration of nerves</td>
</tr>
<tr>
<td>Radiation neurosis of tumors/nerves</td>
</tr>
<tr>
<td>Prostate—carcinoma, prostatitis</td>
</tr>
<tr>
<td>Kidney—renal stones, inflammatory disease, neoplasm, infection</td>
</tr>
</tbody>
</table>

### Low Back Pain

#### Acute Low Back Pain (ALBP)

Pain of <3 months’ duration; full recovery occurs in 85%. Management controversial; few well-controlled clinical trials exist. Algorithms are presented in Fig. 36-1. If “risk factors” (Table 36-2) are absent, initial treatment is symptomatic and no diagnostic tests necessary. Spine infections, fractures, tumors, or rapidly progressive neurologic deficits require urgent diagnostic evaluation.

Clinical trials do not show benefit from bed rest >2 days. Possible benefits of early activity—cardiovascular conditioning, disk and cartilage nutrition, bone and muscle strength, increased endorphin levels. Studies of traction or posture...
SECTION 3

Common Patient Presentations

FIGURE 36-1 Algorithms for management of acute low back pain, age ≥ 18 years. A. Symptoms <3 months, first 4 weeks. B. Management weeks 4–12. ( ) entry point from Algorithm C postoperatively or if patient declines surgery. C. Surgical options. (NSAIDs, nonsteroidal anti-inflammatory drugs; CBC, complete blood count; ESR, erythrocyte sedimentation rate; UA, urinalysis; EMG, electromyography; NCV, nerve conduction velocity studies; MRI, magnetic resonance imaging; CT, computed tomography; CNS, central nervous system.)
modification fail to show benefit. Proof lacking to support acupuncture, ultrasound, diathermy, transcutaneous electrical nerve stimulation, massage, biofeedback, magnets, or electrical stimulation. Self-application of ice or heat or use of shoe insoles is optional given low cost and risk. A short course of lumbar spinal manipulation or physical therapy is a reasonable option. Temporary sus-

FIGURE 36-1 (Continued)
Pension of activities known to increase mechanical stress on the spine (heavy lifting, straining at stool, prolonged sitting/bending/twisting) may relieve symptoms. Value of education (“back school”) in long-term prevention is unclear.

Pharmacologic treatment of ALBP includes NSAIDs and acetaminophen (Chap 6). Muscle relaxants (cyclobenzaprine) provide short-term benefit (4–7 days), but drowsiness limits use. Opioids are not superior to NSAIDs or acetaminophen for ALBP. Epidural glucocorticoids may occasionally produce short-term pain relief, but proof is lacking for a benefit beyond 1 month. Systemic glucocorticoids, opioids, or tricyclic antidepressants are not indicated as initial treatment.

**CHRONIC LOW BACK PAIN (CLBP)**

Pain lasting >3 months; differential diagnosis includes most conditions described above. CLBP causes can be clarified by neuroimaging and EMG/nerve conduction studies; diagnosis of radiculopathy secure when results concordant with findings on neurologic exam. Treatment should not be based on neuroimaging alone: up to one-third of asymptomatic young adults have a herniated lumbar disk by CT or MRI.

Management is not amenable to a simple algorithmic approach. Treatment based upon identification of underlying cause; when specific cause not found, conservative management necessary. Pharmacologic and comfort measures similar to those described for ALBP. Exercise (“work hardening”) regimens effective in returning some pts to work, diminishing pain, and improving walking distances. Hydrotherapy may be useful. Some pts report short-term pain relief with percutaneous electrical nerve stimulation, which has not been adequately studied. An unblinded study in patients with chronic sciatica found that surgery could hasten relief of symptoms by ~2 months; however, at 1 year there was no advantage of surgery over conservative medical therapy; nearly all (95%) pts in both groups made a full recovery.

**NECK AND SHOULDER PAIN**

Usually arises from diseases of the cervical spine and soft tissues of the neck; typically precipitated by movement and may be accompanied by focal tenderness and limitation of motion.

**Etiology**  

**Trauma to the Cervical Spine**  

Trauma to the cervical spine (fractures, subluxation) places the spine at risk for compression; immediate immobilization of the neck is essential to minimize movement of unstable cervical spine segments.

*Whiplash injury* is due to trauma (usually automobile accidents) causing cervical musculoligamental sprain or strain due to hyperflexion or hyperextension. This diagnosis is not applied to pts with fractures, disk herniation, head injury, or altered consciousness.

**Cervical Disk Disease**  

Herniation of a lower cervical disk is a common cause of neck, shoulder, arm, or hand pain or tingling. Neck pain (worse with movement), stiffness, and limited range of neck motion are common. With nerve root compression, pain may radiate into a shoulder or arm. Extension and lateral rotation of the neck narrows the intervertebral foramen and may reproduce radicular symptoms (Spurling’s sign). In young individuals, acute radiculopathy from a ruptured disk is often traumatic. *Subacute radiculopathy* is less likely to be related to a specific traumatic incident and may involve both disk disease and spondylosis. Clinical features of cervical nerve root lesions are summarized in Table 36-4.
<table>
<thead>
<tr>
<th>Cervical Nerve Roots</th>
<th>Examination Findings</th>
<th>Pain Distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Reflex</td>
<td>Sensory</td>
</tr>
<tr>
<td>C5</td>
<td>Biceps</td>
<td>Over lateral deltoid</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C6</td>
<td>Biceps</td>
<td>Thumb, index fingers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radial hand/forearm</td>
</tr>
<tr>
<td>C7</td>
<td>Triceps</td>
<td>Middle fingers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dorsum forearm</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C8</td>
<td>Finger flexors</td>
<td>Little finger</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medial hand and forearm</td>
</tr>
<tr>
<td>T1</td>
<td>Finger flexors</td>
<td>Axilla and medial arm</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>These muscles receive the majority of innervation from this root.
Cervical Spondylosis  Osteoarthritis of the cervical spine may produce neck pain that radiates into the back of the head, shoulders, or arms; can also be source of headaches in the posterior occipital region. A combined radiculopathy and myelopathy may occur. An electrical sensation elicited by neck flexion and radiating down the spine from the neck (Lhermitte’s symptom) usually indicates spinal cord involvement. MRI or CT-myelography can define the anatom-ic abnormalities, and EMG and nerve conduction studies can quantify the severity and localize the levels of nerve root injury.

Other Causes of Neck Pain  Includes rheumatoid arthritis of the cervical apophyseal joints, ankylosing spondylitis, herpes zoster (shingles), neoplasms metastatic to the cervical spine, infections (osteomyelitis and epidural abscess), and metabolic bone diseases. Neck pain may also be referred from the heart with coronary artery ischemia (cervical angina syndrome).

Thoracic Outlet  An anatomic region containing the first rib, the subclavian artery and vein, the brachial plexus, the clavicle, and the lung apex. Injury may result in posture- or task-related pain around the shoulder and supraclavicular region. True neurogenic thoracic outlet syndrome results from compression of the lower trunk of the brachial plexus by an anomalous band of tissue; treatment consists of surgical division of the band. Arterial thoracic outlet syndrome results from compression of the subclavian artery by a cervical rib; treatment is with thrombolysis or anticoagulation, and surgical excision of the cervical rib. Disputed thoracic outlet syndrome includes a large number of patients with chronic arm and shoulder pain of unclear cause; surgery is controversial, and treatment is often unsuccessful.

Brachial Plexus and Nerves  Pain from injury to the brachial plexus or peripheral nerves can mimic pain of cervical spine origin. Neoplastic infiltration can produce this syndrome, as can postradiation fibrosis (pain less often present). Acute brachial neuritis consists of acute onset of severe shoulder or scapular pain followed over days by weakness of proximal arm and shoulder girdle muscles innervated by the upper brachial plexus; onset often preceded by an infec-tion or immunization.

Shoulder  If signs of radiculopathy are absent, differential diagnosis includes mechanical shoulder pain (tendinitis, bursitis, rotator cuff tear, dislocation, adhesive capsulitis, and cuff impingement under the acromion) and referred pain (subdiaphragmatic irritation, angina, Pancoast tumor). Mechanical pain is often worse at night, associated with shoulder tenderness, and aggravated by abduction, internal rotation, or extension of the arm.

Neck and Shoulder Pain  
Symptomatic treatment of neck pain includes analgesic medications and/or a soft cervical collar. Indications for cervical disk and lumbar disk surgery are similar; however, with cervical disease, an aggressive approach is indicated if spinal cord injury is threatened. Surgery of cervical herniated disks consists of an anterior approach with diskectomy followed by anterior interbody fusion; a simple posterior partial laminectomy with diskectomy is an acceptable alternative. Another surgical approach involves implantation of an artificial disk, which is not yet approved for use in the United States. The cumulative risk of subsequent radiculopathy or myelopathy at cervical segments adjacent to the fusion is 3% per year. Nonprogressive cervical radiculopathy due to a herniated cervical disk may be treated conservatively with a high rate of suc-
Cervical spondylosis with bony, compressive cervical radiculopathy is generally treated with surgical decompression to interrupt the progression of neurologic signs. Spondylotic myelopathy is managed with either anterior decompression and fusion or laminectomy because myelopathy progresses in 20–30% of untreated patients. One prospective study comparing surgery versus conservative treatment for mild cervical spondylotic myelopathy showed no difference in outcome after 2 years of follow-up.

For more detailed discussion, see Engstrom JW: Back and Neck Pain, Chap. 16, p. 107, in HPIM-17.

37 Fever, Hyperthermia, Chills, and Rash

FEVER

Definitions  

Temperature: Normal body temperature is maintained (≤37.2°C/98.9°F in the morning and ≤37.7°C/99.9°F in the evening) because the hypothalamic thermoregulatory center balances excess heat production from metabolic activity in muscle and liver with heat dissipation from the skin and lungs.

Fever: an elevation of normal body temperature in conjunction with an increase in the hypothalamic set point. Infectious causes are common.

Fever of unknown origin (FUO):

1. Classic FUO: three outpt visits or 3 days in the hospital without elucidation of a cause of fever; or 1 week of unproductive intelligent and invasive ambulatory investigation, temperatures >38.3°C (>101°F) on several occasions, and duration of fever for >3 weeks

2. Nosocomial FUO: at least 3 days of investigation and 2 days of culture incubation failing to elucidate a cause of fever in a hospitalized pt with temperatures >38.3°C (>101°F) on several occasions and no infection on admission

3. Neutropenic FUO: at least 3 days of investigation and 2 days of culture incubation failing to elucidate a cause of fever in a pt with temperatures >38.3°C (>101°F) on several occasions whose neutrophil count is <500/μL or is expected to fall to that level within 1–2 days

4. HIV-associated FUO: failure of appropriate investigation to reveal a cause of fever in an HIV-infected pt with temperatures >38.3°C (>101°F) on several occasions over a period of >4 weeks for outpts and >3 days for hospitalized pts

Hyperpyrexia: temperatures >41.5°C (>106.7°F) that can occur with severe infections but more commonly occur with CNS hemorrhages

Etiology  

Most fevers are associated with self-limited infections (usually viral) and have causes that are easily identified.

- Classic FUO: As the duration of fever increases, the likelihood of an infectious etiology decreases. Etiologies to consider include:
Common Patient Presentations

SECTION 3

1. Infection—e.g., extrapulmonary tuberculosis; EBV, CMV, or HIV infection; occult abscesses; endocarditis; fungal disease
2. Neoplasm—e.g., lymphoma and hematologic malignancies, hepatoma, renal cell carcinoma
3. Miscellaneous noninfectious inflammatory diseases
   a. Systemic rheumatologic disease or vasculitis—e.g., Still’s disease, lupus erythematosus
   b. Granulomatous disease—e.g., granulomatous hepatitis, sarcoidosis, Crohn’s disease
   c. Miscellaneous diseases—e.g., pulmonary embolism, hereditary fever syndromes, drug fever, factitious fevers

• *Nosocomial FUO*
  Infectious—e.g., infected foreign bodies or catheters, *Clostridium difficile* colitis, sinusitis
  Noninfectious—e.g., drug fever, pulmonary embolism

• *Neutropenic FUO*: Neutropenic pts are susceptible to focal bacterial and fungal infections, bacteremic infections, perianal infections, and catheter-associated infections. More than 50–60% of pts with febrile neutropenia are infected, and 20% are bacteremic.

• *HIV-associated FUO*: More than 80% of pts are infected, but drug fever and lymphoma are also possible etiologies.

Pathogenesis

The hypothalamic set point increases. The pt feels cold as a result of the peripheral vasoconstriction and shivering that are needed to raise body temperature to a new set point. Peripheral vasodilation and sweating commence when the set point is lowered again by resolution or treatment of the fever.

Fever caused by:

• Exogenous pyrogens (e.g., lipopolysaccharide endotoxin)
• Endogenous pyrogens [e.g., interleukin (IL) 1, tumor necrosis factor] induced by exogenous pyrogens
• Prostaglandin E₂ (in CNS, raises hypothalamic set point; in peripheral tissues, causes myalgias and arthralgias)

**APPROACH TO THE PATIENT: FEVER**

A meticulous history is essential. Attention must be paid to the chronology of events (e.g., in the case of rash: the site of onset and the direction and rate of spread; see below) and the relation of symptoms to medications, pet exposure, sick contacts, sexual contacts, travel, trauma, and the presence of prosthetic materials. A thorough physical examination should be performed. The temperature can be taken orally or rectally, but a consistent site should be used.

Skin examination can be especially revealing in pts with fever. Close attention should be paid to any rash, with a precise definition of its salient features.

1. Type of lesion (e.g., macule, papule, nodule, vesicle, pustule, purpura, ulcer)
2. Classification of rash
   a. Centrally distributed maculopapular eruptions (e.g., measles, rubella)
   b. Peripheral eruptions (e.g., Rocky Mountain spotted fever, secondary syphilis)
   c. Confluent desquamative erythemas (e.g., toxic shock syndrome)
   d. Vesiculobullous eruptions (e.g., varicella, primary herpes simplex infection, rickettsialpox)
CHAPTER 37

Fever, Hyperthermia, Chills, and Rash

e. Urticarial eruptions: Hypersensitivity reactions usually are not associated with fever. The presence of fever suggests serum sickness, connective-tissue disease, or infection (hepatitis B, enteroviral or parasitic infection).

f. Nodular eruptions (e.g., disseminated candidiasis, cryptococcosis, erythema nodosum, Sweet’s syndrome)

g. Purpuric eruptions (e.g., acute meningococcemia, echovirus 9 infection, disseminated gonococcemia)

h. Eruptions with ulcers or eschars (e.g., rickettsial diseases, such as scrub typhus; tularemia; anthrax)

Diagnosis

In most cases, initial history, physical examination, and laboratory tests (including CBC with differential, ESR, C-reactive protein) lead to a diagnosis or the pt recovers spontaneously. For the pt with FUO, an approach to diagnosis is found in Fig. 37-1.

**Fever**

The diagnosed infection should be treated appropriately. In pts with FUO, “shotgun” empirical therapy should be avoided if vital signs are stable and the pt is not neutropenic. Cirrhosis, asplenia, immunosuppressive drug use, or recent exotic travel may be appropriate settings for empirical treatment.

Treatment of fever and its symptoms with antipyretics does no harm and does not slow the resolution of common viral and bacterial infections. Treatment of fever is appropriate to relieve symptoms and reduce oxygen demand in pts with underlying cardiovascular or pulmonary disease and to prevent seizures in children with a history of febrile seizures. Antipyretic treatment should be given on a regular schedule rather than intermittently; otherwise, it will aggravate chills and sweats.

However, withholding antipyretics may be helpful in evaluating the therapeutic effectiveness of a particular antibiotic or in allowing observation of important clinical indicators such as a relapsing pattern in malaria or a reversal of the usual times of peak and trough temperatures in typhoid fever and disseminated tuberculosis.

Aspirin, NSAIDs, and glucocorticoids are effective antipyretics. Acetaminophen is preferred because it does not mask signs of inflammation, does not impair platelet function, and is not associated with Reye’s syndrome.

Recurrent fever occurs in most autoimmune and in all autoinflammatory diseases. These fevers respond dramatically to anticytokine therapy that blocks IL-1β activity. However, chronic anticytokine therapy (e.g., for rheumatoid arthritis or Crohn’s disease) may reduce the febrile response while increasing susceptibility to certain infections, such as tuberculosis.

**Prognosis**

Failure of efforts to identify the source of FUO for >6 months is generally associated with a good prognosis. Debilitating symptoms can be treated with antipyretics.

**HYPERTHERMIA**

**Definitions and Etiology**

*Hyperthermia*: an unchanged setting of the hypothalamic set point in conjunction with an uncontrolled increase in body temper-
Common Patient Presentations

**Hyperthermia**: does not involve pyrogenic molecules.

Heat stroke: thermoregulatory failure in association with a warm environment
- Exertional: caused by exercise in high heat or humidity

**Hyperthermia**
- Thermoregulatory failure in association with a warm environment
  - Exertional: caused by exercise in high heat or humidity

**Figure 37-1** Approach to the pt with classic FUO. "Potentially diagnostic clues," as outlined by EMHA DeKleijn and colleagues (Medicine 76:401, 1997), may be key findings in the history, localizing signs, or key symptoms. Abbreviations: CRP, C-reactive protein; Diff, differential; RF, rheumatoid factor; SPEP, serum protein electrophoresis; TB, tuberculosis; TIBC, total iron-binding capacity.

**Laboratory Testing**
- CBC, Diff, smear, ESR, CRP, urinalysis, liver function tests, muscle enzymes, VDRL, HIV, CMV, EBV, ANA, RF, SPEP, PPD, control skin tests, creatinine, electrolytes, Ca, Fe, transferrin, TIBC, vitamin B₁₂; acute/convalescent serum set aside
- Cultures: Blood, urine, sputum, fluids as appropriate

**Fever > 38°C x 3 weeks; 1 week of “intelligent and invasive investigation”**

- Physical exam
- Repeat history

**Laboratory Testing**
- Directed exam
  - Potentially diagnostic clue*
  - No potentially diagnostic clue*
  - Directed exam
    - CT of chest, abdomen, pelvis with IV or PO contrast; colonoscopy
    - Needle biopsy, invasive testing
      - Diagnosis
      - Specific therapy
      - Anti-TB therapy, antimicrobial therapy
      - Steroids
    - No diagnosis
      - Empiric therapy
      - Watchful waiting
      - Colchicine, NSAIDs
Pain and Swelling of Joints

CHAPTER 38

Nonexertional: typically occurs in either very young or elderly individuals, particularly during heat waves. In the United States, 7000 deaths were attributed to heat injury in 1979–1997. The elderly, the bedridden, persons confined to poorly ventilated or non-air-conditioned areas, and those taking anticholinergic, antiparkinsonian, or diuretic drugs are most susceptible.

Drug-induced: caused by drugs such as monoamine oxidase inhibitors, tricyclic antidepressants, amphetamines, and cocaine and other illicit agents

Malignant hyperthermia: hyperthermic and systemic response to halothane and other inhalational anesthetics in pts with genetic abnormality

Neuroleptic malignant syndrome: syndrome caused by use of neuroleptic agents (e.g., haloperidol) and consisting of lead-pipe muscle rigidity, extrapyramidal side effects, autonomic dysregulation, and hyperthermia

Clinical Features/Diagnosis

High core temperature in association with an appropriate history (heat exposure, certain drug treatments) and dry skin, hallucinations, pupil dilation, muscle rigidity, and/or elevated levels of creatine phosphokinase. Unlike pts with fever, hyperthermic pts have a history of heat exposure or treatment with drugs that interfere with thermoregulation; their skin is hot but dry; and antipyretic agents do not lower the body temperature. Febrile pts can have cold skin as a result of vasoconstriction or hot, moist skin; antipyretics usually result in some lowering of the body temperature of pts with fever.

Hyperthermia

Physical cooling:
- Sponging, fans, cooling blankets, ice baths
- IV fluids, internal cooling by gastric or peritoneal lavage with iced saline
- In extreme cases, hemodialysis or cardiopulmonary bypass

For malignant hyperthermia: cessation of anesthesia and administration of dantrolene (1–2.5 mg/kg q6h for at least 24–48 h) plus procainamide administration because of the risk of ventricular fibrillation. Dantrolene is also useful in neuroleptic malignant syndrome and drug-induced hyperthermia and may be helpful in serotonin syndrome and thyrotoxicosis.

For a more detailed discussion, see Kaye KM, Kaye ET: Atlas of Rashes Associated with Fever, Chap. e5 in Harrison’s DVD and Harrison’s Online; and Dinarello CA, Porat R: Fever and Hyperthermia, Chap. 17, p. 117; Kaye ET, Kaye KM: Fever and Rash, Chap. 18, p. 121; and Gelland JA, Callahan MV: Fever of Unknown Origin, Chap. 19, p. 130, in HPIM-17.

Pain and Swelling of Joints

Musculoskeletal complaints are extremely common in outpatient medical practice and are among the leading causes of disability and absenteeism from work. Pain in the joints must be evaluated in a uniform, thorough, and logical fashion.
Common Patient Presentations

SECTION 3

to ensure the best chance of accurate diagnosis and to plan appropriate follow-up testing and therapy. Joint pain and swelling may be manifestations of disorders affecting primarily the musculoskeletal system or may reflect systemic disease.

INITIAL ASSESSMENT OF A MUSCULOSKELETAL COMPLAINT  (See Fig. 38-1)

1. **Articular versus nonarticular.** Is the pain located in a joint or in a periarticular structure such as soft tissue or muscle?

![Algorithm for the diagnosis of musculoskeletal complaints. An approach to formulating a differential diagnosis (shown in italics). ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DIP, distal interphalangeal; CMC, carpometacarpal; PIP, proximal interphalangeal; MCP, metacarpophalangeal; MTP, metatarsophalangeal; SLE, systemic lupus erythematosus; JA, juvenile arthritis.](image-url)
2. **Inflammatory versus noninflammatory.** Inflammatory disease is suggested by local signs of inflammation (erythema, warmth, swelling); systemic features (morning stiffness, fatigue, fever, weight loss); or laboratory evidence of inflammation (thrombocytosis, elevated ESR or C-reactive protein).

3. **Acute (≤ 6 weeks) versus chronic.**

4. **Localized versus systemic.**

**HISTORIC FEATURES**

- Age, sex, race, and family history
- Symptom onset (abrupt or indolent), evolution (chronic constant, intermittent, migratory, additive), and duration (acute versus chronic)
- Number and distribution of involved structures: monarticular (one joint), oligoarticular (2–3 joints), polyarticular (>3 joints); symmetry
- Other articular features: morning stiffness, effect of movement, features that improve/worsen Sx
- Extraarticular Sx: e.g., fever, rash, weight loss, visual change, dyspnea, diarrhea, dysuria, numbness, weakness
- Recent events: e.g., trauma, drug administration, travel, other illnesses

**PHYSICAL EXAMINATION**

Complete examination is essential: particular attention to skin, mucous membranes, nails (may reveal characteristic pitting in psoriasis), eyes. Careful and thorough examination of involved and uninvolved joints and periarticular structures; this should proceed in an organized fashion from head to foot or from extremities inward toward axial skeleton; special attention should be paid to identifying the presence or absence of:

- Warmth and/or erythema
- Swelling
- Synovial thickening
- Subluxation, dislocation, joint deformity
- Joint instability
- Limitations to active and passive range of motion
- Crepitus
- Periarticular changes
- Muscular changes including weakness, atrophy

**LABORATORY INVESTIGATIONS**

Additional evaluation usually indicated for monarticular, traumatic, inflammatory, or chronic conditions or for conditions accompanied by neurologic changes or systemic manifestations.

- For all evaluations: include CBC, ESR, or C-reactive protein
- Where there are suggestive clinical features, include: rheumatoid factor, ANA, antineutrophilic cytoplasmic antibodies (ANCA), antistreptolysin O titer, Lyme antibodies
- Where systemic disease is present or suspected: renal/hepatic function tests, UA
- Uric acid–useful only when gout diagnosed and therapy contemplated
- CPK, aldolase–consider with muscle pain, weakness
- Synovial fluid aspiration and analysis: always indicated for acute monarthritits or when infectious or crystal-induced arthropathy is suspected. Should be examined for (1) appearance, viscosity; (2) cell count and differential (sus-
pect septic joint if WBC count > 50,000/μL; (3) crystals using polarizing microscope; (4) Gram’s stain, cultures (Fig. 38-2).

DIAGNOSTIC IMAGING

Conventional radiography using plain x-rays is a valuable tool in the diagnosis and staging of articular disorders (Table 38-1).

FIGURE 38-2 Algorithmic approach to the use and interpretation of synovial fluid aspiration and analysis.
Additional imaging procedures, including ultrasound, radionuclide scintigraphy, CT, and MRI, may be helpful in selected clinical settings.

**SPECIAL CONSIDERATIONS IN THE ELDERLY PATIENT**

The evaluation of joint and musculoskeletal disorders in the elderly patient presents a special challenge given the frequently insidious onset and chronicity of disease in this age group, the confounding effect of other medical conditions, and the increased variability of many diagnostic tests in the geriatric population. Although virtually all musculoskeletal conditions may afflict the elderly, certain disorders are especially frequent. Special attention should be paid to identifying the potential rheumatic consequences of intercurrent medical conditions and therapies when evaluating the geriatric patient with musculoskeletal complaints.

For a more detailed discussion, see CushJJ, Lipsky PE: Approach to Articular and Musculoskeletal Disorders, Chap. 325, p. 2149, in HPIM-17.

**Syncope**

*Syncope* is a transient loss of consciousness and postural tone due to reduced cerebral blood flow. It may occur suddenly, without warning, or may be preceded by presyncopal symptoms such as lightheadedness, weakness, nausea, dimming vision, ringing in ears, or sweating. *Faintness* refers to prodromal symptoms that precede the loss of consciousness in syncope. The syncope patient appears pale, has a faint, rapid, or irregular pulse, and breathing may be almost imperceptible; transient myoclonic or clonic movements may occur. Recovery of consciousness is prompt if the patient is maintained in a horizontal position and cerebral perfusion is restored.

**APPROACH TO THE PATIENT WITH SYNCOPE**

The cause of syncope may be apparent only at the time of the event, leaving few, if any, clues when the patient is seen by the physician. First consider serious
underlying etiologies; among these are massive internal hemorrhage or myocardial infarction, which may be painless, and cardiac arrhythmias. In elderly persons, a sudden faint without obvious cause should raise the question of complete heart block or a tachyarrhythmia. Loss of consciousness in particular situations, such as during venipuncture or micturition, suggests a benign abnormality of vascular tone. The position of the pt at the time of the syncopal episode is important; syncope in the supine position is unlikely to be vasovagal and suggests an arrhythmia or a seizure. Medications must be considered, including nonprescription drugs or health store supplements, with particular attention to recent changes. Symptoms of impotence, bowel and bladder difficulties, disturbed sweating, or an abnormal neurologic exam, suggest a primary neurogenic cause. An algorithmic approach to syncope is presented in Fig. 39-1.

**ETIOLOGY**

Transiently decreased cerebral blood flow is usually due to disorders of vascular tone or blood volume including vasovagal syncope and postural hypotension, cardiovascular disorders including cardiac arrhythmias, or uncommonly cerebrovascular disease (Table 39-1). Not infrequently the cause of syncope is multifactorial.

**Neurocardiogenic (Vasovagal and Vasodepressor) Syncope**  The common faint, experienced by normal persons, accounts for approximately half of all episodes of syncope. It is frequently recurrent and may be provoked by hot or crowded environment, alcohol, fatigue, pain, hunger, prolonged standing, or stressful situations.
<table>
<thead>
<tr>
<th>TABLE 39-1</th>
<th>CAUSES OF SYNCOPE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>I. Disorders of Vascular Tone or Blood Volume</strong></td>
<td></td>
</tr>
<tr>
<td>A. Reflex synapses</td>
<td></td>
</tr>
<tr>
<td>1. Neurocardiogenic</td>
<td></td>
</tr>
<tr>
<td>2. Situational</td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td></td>
</tr>
<tr>
<td>Micturition</td>
<td></td>
</tr>
<tr>
<td>Defecation</td>
<td></td>
</tr>
<tr>
<td>Valsalva</td>
<td></td>
</tr>
<tr>
<td>Deglutition</td>
<td></td>
</tr>
<tr>
<td>3. Carotid sinus hypersensitivity</td>
<td></td>
</tr>
<tr>
<td>B. Orthostatic hypotension</td>
<td></td>
</tr>
<tr>
<td>1. Drug-induced (antihypertensive or vasodilator drugs)</td>
<td></td>
</tr>
<tr>
<td>2. Pure autonomic failure (idiopathic orthostatic hypotension)</td>
<td></td>
</tr>
<tr>
<td>3. Multisystem atrophies</td>
<td></td>
</tr>
<tr>
<td>4. Peripheral neuropathy (diabetic, alcoholic, nutritional, amyloid)</td>
<td></td>
</tr>
<tr>
<td>5. Physical deconditioning</td>
<td></td>
</tr>
<tr>
<td>6. Sympathectomy</td>
<td></td>
</tr>
<tr>
<td>7. Decreased blood volume</td>
<td></td>
</tr>
<tr>
<td><strong>II. Cardiovascular Disorders</strong></td>
<td></td>
</tr>
<tr>
<td>A. Structural and obstructive causes</td>
<td></td>
</tr>
<tr>
<td>1. Pulmonary embolism</td>
<td></td>
</tr>
<tr>
<td>2. Pulmonary hypertension</td>
<td></td>
</tr>
<tr>
<td>3. Atrial myxoma</td>
<td></td>
</tr>
<tr>
<td>4. Mitral valvular stenosis</td>
<td></td>
</tr>
<tr>
<td>5. Myocardial disease (massive acute myocardial infarction)</td>
<td></td>
</tr>
<tr>
<td>6. Left ventricular myocardial restriction or constriction</td>
<td></td>
</tr>
<tr>
<td>7. Pericardial constriction or tamponade</td>
<td></td>
</tr>
<tr>
<td>8. Aortic outflow tract obstruction</td>
<td></td>
</tr>
<tr>
<td>9. Aortic valvular stenosis</td>
<td></td>
</tr>
<tr>
<td>10. Hypertrophic obstructive cardiomyopathy</td>
<td></td>
</tr>
<tr>
<td>B. Cardiac arrhythmias</td>
<td></td>
</tr>
<tr>
<td>1. Bradyarrhythmias</td>
<td></td>
</tr>
<tr>
<td>a. Sinus bradycardia, sinoatrial block, sinus arrest, sick-sinus syndrome</td>
<td></td>
</tr>
<tr>
<td>b. Atrioventricular block</td>
<td></td>
</tr>
<tr>
<td>2. Tachyarrhythmias</td>
<td></td>
</tr>
<tr>
<td>a. Supraventricular tachycardia with structural cardiovascular disease</td>
<td></td>
</tr>
<tr>
<td>b. Atrial fibrillation with the Wolff-Parkinson-White syndrome</td>
<td></td>
</tr>
<tr>
<td>c. Atrial flutter with 1:1 atrioventricular conduction</td>
<td></td>
</tr>
<tr>
<td>d. Ventricular tachycardia</td>
<td></td>
</tr>
<tr>
<td><strong>III. Cerebrovascular Disease</strong></td>
<td></td>
</tr>
<tr>
<td>A. Vertebrobasilar insufficiency</td>
<td></td>
</tr>
<tr>
<td>B. Basilar artery migraine</td>
<td></td>
</tr>
<tr>
<td><strong>IV. Other Disorders that May Resemble Syncope</strong></td>
<td></td>
</tr>
<tr>
<td>A. Metabolic</td>
<td></td>
</tr>
<tr>
<td>1. Hypoxia</td>
<td></td>
</tr>
<tr>
<td>2. Anemia</td>
<td></td>
</tr>
<tr>
<td>3. Diminished carbon dioxide due to hyperventilation</td>
<td></td>
</tr>
<tr>
<td>4. Hypoglycemia</td>
<td></td>
</tr>
<tr>
<td>B. Psychogenic</td>
<td></td>
</tr>
<tr>
<td>1. Anxiety attacks</td>
<td></td>
</tr>
<tr>
<td>2. Hysterical fainting</td>
<td></td>
</tr>
<tr>
<td>C. Seizures</td>
<td></td>
</tr>
</tbody>
</table>
Common Patient Presentations

Postural (Orthostatic) Hypotension  Sudden rising from a recumbent position or standing quietly are precipitating circumstances. Cause of syncope in 30% of elderly; polypharmacy with antihypertensive or antidepressant drugs often a contributor; physical deconditioning may also play a role. Also occurs with autonomic nervous system disorders, either peripheral (diabetes, nutritional, or amyloid polyneuropathy) or central (multiple system atrophy, Parkinson’s disease). Some cases are idiopathic.

DIFFERENTIAL DIAGNOSIS

Anxiety Attacks  Frequently resembles presyncope although the symptoms are not accompanied by facial pallor and are not relieved by recumbency. Attacks can often be reproduced by hyperventilation and have associated symptoms of panic attacks such as a feeling of impending doom, air hunger, palpitations, and tingling of the fingers and perioral region.

Seizures  The differential diagnosis is often between syncope and a generalized seizure. Syncope is more likely if the event was provoked by acute pain or anxiety or occurred immediately after arising from a lying or sitting position. Seizures are typically not related to posture. Pts with syncope often describe a stereotyped transition from consciousness to unconsciousness that develops over a few seconds. Seizures occur either very abruptly without a transition or are preceded by premonitory symptoms such as an epigastric rising sensation, perception of odd odors, or racing thoughts. Pallor is seen during syncope; cyanosis is usually seen during a seizure. The duration of unconsciousness is usually very brief (i.e., seconds) in syncope and more prolonged (i.e., >5 min) in a seizure. Injury from falling and incontinence are common in seizure, rare in syncope. Headache and drowsiness, which with mental confusion are the usual sequelae of a seizure, do not follow a syncopal attack.

Hypoglycemia  Severe hypoglycemia is usually due to a serious disease. The glucose level at the time of a spell is diagnostic.

Hysterical Fainting  The attack is usually unattended by an outward display of anxiety. Lack of change in pulse and blood pressure or color of the skin distinguishes it from a vasodepressor faint.

Rx  Syncope

Therapy is determined by the underlying cause. Pts with vasovagal syncope should be instructed to avoid situations or stimuli that provoke attacks. Episodes associated with intravascular volume depletion may be prevented by salt and fluid preloading prior to provocative events.

Drug therapy may be necessary for resistant vasovagal syncope. β-Adrenergic antagonists (metoprolol 25–50 mg twice daily; atenolol 25–50 m/d; or nadolol 10–20 mg twice daily; all starting doses) are the most widely used agents; serotonin reuptake inhibitors (paroxetine 20–40 mg/d, or sertraline 25–50 mg/d) and bupropion SR (150 mg/d) are also effective. The mineralocorticoid hydrofludrocortisone (0.1–0.2 mg/d) or the α-agonist proamatine (2.5–10 mg twice or three times a day) may be helpful for refractory pts with recurrent vasovagal syncope, but side effects, including increases in resting bp, limit their usefulness. Recent trials suggest that there may be significant age-related differences in response to pharmacologic therapy. Permanent car-
Dizziness and Vertigo

CHAPTER 40

Diastolic pacing may be effective for pts whose episodes of vasovagal syncope are frequent or associated with prolonged asystole.

Management of orthostatic hypotension is discussed in Chap. 196.

For a more detailed discussion, see Carlson MD: Syncope, Chap. 21, p. 139, in HPIM-17.

40 Dizziness and Vertigo

APPROACH TO THE PATIENT WITH DIZZINESS OR VERTIGO

The term dizziness is used by pts to describe a variety of head sensations or gait unsteadiness. With a careful history, distinguishing between faintness (presyncope; Chap. 39) and vertigo (an illusory or hallucinatory sense of movement of the body or the environment, most often a feeling of spinning) is usually possible.

When the meaning of “dizziness” is uncertain, provocative tests to reproduce the symptoms may be helpful. Valsalva maneuver, hyperventilation, or postural changes leading to orthostasis may reproduce faintness. Rapid rotation in a swivel chair is a simple provocative test to reproduce vertigo. Benign positional vertigo is identified by positioning the turned head of a recumbent patient in extension over the edge of the bed to elicit vertigo and the characteristic nystagmus. If a central cause for the vertigo is suspected (e.g., signs of peripheral vertigo are absent or other neurologic abnormalities are present), then prompt evaluation for central pathology is required. The initial test is usually an MRI scan of the posterior fossa, and, depending upon the results, vertebrobasilar angiography or evoked potentials may be indicated. Vestibular function tests, including electronystagmography (calorics), can help distinguish between central and peripheral etiologies.

FAINTNESS

Faintness is usually described as light-headedness followed by visual blurring and postural swaying along with a feeling of warmth, diaphoresis, and nausea. It is a symptom of insufficient blood, oxygen, or, rarely, glucose supply to the brain. It can occur prior to a syncopal event of any etiology (Chap. 39) and with hyperventilation or hypoglycemia. Lightheadedness can rarely occur as an aura before a seizure. Chronic lightheadedness is a common somatic complaint in patients with depression.

VERTIGO

Usually due to a disturbance in the vestibular system; abnormalities in the visual or somatosensory systems may also contribute to vertigo. Frequently accompanied by nausea, postural unsteadiness, and gait ataxia; may be provoked or worsened by head movement.
**Physiologic vertigo** results from unfamiliar head movement (seasickness) or a mismatch between visual-proprioceptive-vestibular system inputs (height vertigo, visual vertigo during motion picture chase scenes). True vertigo almost never occurs as a presyncopal symptom.

**Pathologic vertigo** may be caused by a peripheral (labyrinth or eighth nerve) or central CNS lesion. Distinguishing between these causes is the essential first step in diagnosis (Table 40-1).

### Peripheral Vertigo

Usually severe, accompanied by nausea and emesis. Tinnitus, a feeling of ear fullness, or hearing loss may occur. A characteristic jerk nystagmus is almost always present. The nystagmus does not change direction with a change in direction of gaze, it is usually horizontal with a torsional component and has its fast phase away from the side of the lesion. It is inhibited by visual fixation. The pt senses spinning motion away from the lesion and tends to have difficulty walking, with falls towards the side of the lesion, particularly in the darkness or with eyes closed. No other neurologic abnormalities are present.

**Acute unilateral labyrinthine dysfunction** may be caused by infection, trauma, or ischemia. Often no specific etiology is uncovered, and the nonspecific term *acute labyrinthitis* (or *vestibular neuritis*) is used to describe the event; herpes simplex virus type 1 infection has been implicated. The attacks are brief and leave the patient for some days with a mild vertigo: recurrent episodes may occur. **Acute bilateral labyrinthine dysfunction** is usually due to drugs (ami-
Dizziness and Vertigo

CHAPTER 40

noglycoside antibiotics) or alcohol. Recurrent labyrinthine dysfunction with signs and symptoms of cochlear disease is usually due to Ménière’s disease (recurrent vertigo accompanied by tinnitus and deafness). Positional vertigo is usually precipitated by a recumbent head position. Benign paroxysmal positional vertigo (BPPV) of the posterior semicircular canal is particularly common; the pattern of nystagmus is distinctive (Table 40-2). BPPV may follow trauma but is usually idiopathic; it generally abates spontaneously after weeks or months. Schwannomas of the eighth cranial nerve (acoustic neuroma) usually present as auditory symptoms of hearing loss and tinnitus, sometimes accompanied by facial weakness and sensory loss due to involvement of cranial nerves VII and V.

Psychogenic vertigo should be suspected in pts with chronic incapacitating vertigo who also have agoraphobia, panic attacks, a normal neurologic exam, and no nystagmus.

Central Vertigo Identified by associated abnormal brainstem or cerebellar signs such as dysarthria, diplopia, dysphagia, hiccups, other cranial nerve abnormalities, weakness, or limb ataxia; depending on the cause, headache may be present. The nystagmus can take almost any form (i.e., vertical or multidirectional) but is often purely horizontal without a torsional component and changes direction with different directions of gaze. Central nystagmus is not inhibited by fixation. Central vertigo may be chronic, mild, and is usually unaccompanied by tinnitus or hearing loss. It may be due to vascular, demyelinating, or neoplastic disease. Vertigo may be a manifestation of migraine or, rarely, of temporal lobe epilepsy.

Vertigo

Treatment of acute vertigo consists of bed rest (1–2 days maximum) and vestibular suppressant drugs (Table 40-3). If the vertigo persists more than a few days, most authorities advise ambulation in an attempt to induce central compensatory mechanisms, despite the short-term discomfort to the patient. BPPV may respond dramatically to repositioning exercises such as the Epley procedure designed to empty particulate debris from the posterior semicircular canal (www.charite.de/ch/neuro/vertigo.html). Ménière’s disease may respond to a low-salt diet (1 g/d) or to a diuretic. Recurrent episodes of migraine-associated vertigo should be treated with antimigraine therapy (Chap. 35). Some data suggest that glucocorticoids improve the likelihood of recovery in vestibular neuritis.

<table>
<thead>
<tr>
<th>TABLE 40-2</th>
<th>BENIGN PAROXYSMAL POSITIONAL VERTIGO AND CENTRAL POSITIONAL VERTIGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Features</td>
<td>BPPV</td>
</tr>
<tr>
<td>Latencya</td>
<td>3–40 s</td>
</tr>
<tr>
<td>Fatigabilityb</td>
<td>Yes</td>
</tr>
<tr>
<td>Habituationc</td>
<td>Yes</td>
</tr>
<tr>
<td>Intensity of vertigo</td>
<td>Severe</td>
</tr>
<tr>
<td>Reproducibilityd</td>
<td>Variable</td>
</tr>
</tbody>
</table>

aTime between attaining head position and onset of symptoms.
bDisappearance of symptoms with maintenance of offending position.
cLessening of symptoms with repeated trials.
dLikelihood of symptom production during any examination session.
### TABLE 40-3 TREATMENT OF VERTIGO

<table>
<thead>
<tr>
<th>Agent</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antihistamines</strong></td>
<td></td>
</tr>
<tr>
<td>Meclizine</td>
<td>25–50 mg 3 times/day</td>
</tr>
<tr>
<td>Dimenhydrinate</td>
<td>50 mg 1–2 times/day</td>
</tr>
<tr>
<td>Promethazine</td>
<td>25–50-mg suppository or IM</td>
</tr>
<tr>
<td><strong>Benzodiazepines</strong></td>
<td></td>
</tr>
<tr>
<td>Diazepam</td>
<td>2.5 mg 1–3 times/day</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>0.25 mg 1–3 times/day</td>
</tr>
<tr>
<td><strong>Phenothiazines</strong></td>
<td></td>
</tr>
<tr>
<td>Prochlorperazine</td>
<td>5 mg IM or 25 mg suppository</td>
</tr>
<tr>
<td><strong>Benzodiazepines</strong></td>
<td></td>
</tr>
<tr>
<td>Diazepam</td>
<td>2.5 mg 1–3 times/day</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>0.25 mg 1–3 times/day</td>
</tr>
<tr>
<td><strong>Phenothiazines</strong></td>
<td></td>
</tr>
<tr>
<td>Prochlorperazine</td>
<td>5 mg IM or 25 mg suppository</td>
</tr>
<tr>
<td><strong>Anticholinergic</strong></td>
<td></td>
</tr>
<tr>
<td>Scopolamine transdermal</td>
<td>Patch</td>
</tr>
<tr>
<td><strong>Sympathomimetics</strong></td>
<td></td>
</tr>
<tr>
<td>Ephedrine</td>
<td>25 mg/d</td>
</tr>
<tr>
<td><strong>Combination preparations</strong></td>
<td></td>
</tr>
<tr>
<td>Ephedrine and promethazine</td>
<td>25 mg/d of each</td>
</tr>
<tr>
<td><strong>Exercise therapy</strong></td>
<td></td>
</tr>
<tr>
<td>Repositioning maneuvers</td>
<td></td>
</tr>
<tr>
<td>Vestibular rehabilitation</td>
<td></td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
</tr>
<tr>
<td>Diuretics or low-salt (1 g/d) diet</td>
<td></td>
</tr>
<tr>
<td>Antimigrainous drugs</td>
<td></td>
</tr>
<tr>
<td>Inner ear surgery</td>
<td></td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>100 mg/d for 3 days, tapered by 20 mg</td>
</tr>
<tr>
<td></td>
<td>every 3 days</td>
</tr>
</tbody>
</table>

*aAll listed drugs are U.S. Food and Drug Administration approved, but most are not approved for the treatment of vertigo.

*bUsual oral (unless otherwise stated) starting dose in adults; maintenance dose can be reached by a gradual increase.

*cFor acute vertigo only.

*dFor motion sickness only.

*eFor benign paroxysmal positional vertigo.

*fFor vertigo other than Ménière’s and positional.

*gFor Ménière’s disease.

*hFor migraine-associated vertigo (see Chap. 35 for a listing of prophylactic antimigrainous drugs).

*iFor perilymphatic fistula and refractory cases of Ménière’s disease.

For a more detailed discussion, see Daroff RB: Dizziness, and Vertigo, Chap. 22, p. 144, in HPIM-17.
CHAPTER 41

Acute Visual Loss and Double Vision

APPROACH TO THE PATIENT

Accurate measurement of visual acuity in each eye (with glasses) is of primary importance. Additional assessments include testing of pupils, eye movements, ocular alignment, and visual fields. Slit-lamp examination can exclude corneal infection, trauma, glaucoma, uveitis, and cataract. Ophthalmoscopic exam to inspect the optic disc and retina often requires pupillary dilation using 1% topical amide and 2.5% phenylephrine; risk of provoking an attack of narrow-angle glaucoma is remote.

Visual field mapping by finger confrontation localizes lesions in the visual pathway (Fig. 41-1); formal testing using a perimeter may be necessary. The goal is to determine whether the lesion is anterior, at, or posterior to the optic chiasm. A scotoma confined to one eye is caused by an anterior lesion affecting the optic nerve or globe; swinging flashlight test may reveal an afferent pupil defect. History and ocular exam are usually sufficient for diagnosis. If a bitemporal hemianopia is present, lesion is located at optic chiasm (e.g., pituitary adenoma, meningioma). Homonymous visual field loss signals a retrochiasmal lesion affecting the optic tract, lateral geniculate body, optic radiations, or visual cortex (e.g., stroke, tumor, abscess). Neuroimaging is recommended for any pt with a bitemporal or homonymous hemianopia.

TRANSIENT OR SUDDEN VISUAL LOSS

1. **Amaurosis fugax** (transient monocular blindness; a TIA of the retina) usually occurs from a retinal embolus or severe ipsilateral carotid stenosis. Prolonged occlusion of the central retinal artery results in classic fundus appearance of a milky, infarcted retina with cherry-red fovea. Any pt with compromise of the retinal circulation should be evaluated promptly for stroke risk factors (e.g., carotid atheroma, heart disease, atrial fibrillation).

2. **Vertebrobasilar insufficiency** or emboli to the posterior circulation can be confused with amaurosis fugax, because many pts mistakenly ascribe symptoms to their left or right eye, when in fact they are occurring in the left or right hemifield of both eyes. Interruption of blood flow to the visual cortex causes sudden graying of vision, occasionally with flashing lights or other symptoms that mimic migraine. The history may be the only guide to the correct diagnosis. Pts should be questioned about the precise pattern and duration of visual loss and other neurologic symptoms such as diplopia, vertigo, numbness, or weakness.

3. **Malignant hypertension** can cause visual loss from exudates, hemorrhages, cotton-wool spots (focal nerve fiber layer infarcts), and optic disc edema.

4. In central or branch retinal vein occlusion, the fundus exam reveals engorged, phlebitic veins with extensive retinal hemorrhages.

5. In age-related macular degeneration, characterized by extensive drusen and scarring of the pigment epithelium, leakage of blood or fluid from subretinal neovascular membranes can produce sudden central visual loss.

6. Flashing lights and floaters may indicate a fresh vitreous detachment. Separation of the vitreous from the retina is a frequent involutional event in
Common Patient Presentations

SECTION 3

7. Vitreous hemorrhage may occur in diabetic pts from retinal neovascularization.
8. Papilledema refers to optic disc edema from raised intracranial pressure. Transient visual obscurations are common, but visual acuity is not affected unless the papilledema is severe, long-standing, or accompanied by macular edema or hemorrhage. Neuroimaging should be obtained to exclude an intracranial mass. If negative, an LP is required to confirm elevation of the intracranial pressure. Pseudotumor cerebri (idiopathic intracranial hy-
Acute Visual Loss and Double Vision

CHAPTER 41

pertension) is a diagnosis of exclusion. Most pts are young, female, and obese; some are found to have occult cerebral venous sinus thrombosis. Treatment is with acetazolamide, repeated LPs, and weight loss; some pts require lumboperitoneal shunting or optic nerve sheath fenestration.

9. **Optic neuritis** is a common cause of monocular optic disc swelling and visual loss. If site of inflammation is retrobulbar, fundus will appear normal on initial exam. The typical pt is female, age 15–45, with pain provoked by eye movements. Glucocorticoids, consisting of intravenous methylprednisolone (1 g daily for 3 days) followed by oral prednisone (1 mg/kg daily for 11 days), may hasten recovery in severely affected patients but makes no difference in final acuity (measured 6 months after the attack). If an MR scan shows multiple demyelinating lesions, treatment for multiple sclerosis (Chap. 200) should be considered. Optic neuritis involving both eyes simultaneously or sequentially suggests neuromyelitis optica.

10. **Anterior ischemic optic neuropathy (AION)** is an infarction of the optic nerve head due to inadequate perfusion via the posterior ciliary arteries. Pts have sudden visual loss, often upon awakening, and painless swelling of the optic disc. It is important to differentiate between nonarteritic (idiopathic) AION and arteritic AION. The latter is caused by giant cell (temporal) arteritis and requires immediate glucocorticoid therapy to prevent blindness. The ESR should be checked in any elderly pt with acute optic disc swelling or symptoms suggestive of polymyalgia rheumatica.

DOUBLE VISION (DIPLOPIA)

First step—clarify whether diplopia persists in either eye after covering the opposite eye; if it does the diagnosis is monocular diplopia usually caused by disease intrinsic to the eye with no dire implications for the patient.

If pt has diplopia while being examined, motility testing will usually reveal an abnormality in ocular excursions. However, if the degree of angular separation between the double images is small, the limitation of eye movements may be subtle and difficult to detect. In this situation, the cover test is useful. While the pt is fixating upon a distant target, one eye is covered while observing the other eye for a movement of redress as it takes up fixation. If none is seen, the procedure is repeated with the other eye. With genuine diplopia, this test should reveal ocular malalignment, especially if the head is turned or tilted in the position that gives rise to the worst symptoms.

Common causes of diplopia are summarized in Table 41-1. The physical findings in isolated ocular motor nerve palsies are:

- **CN III**: Ptosis and deviation of the eye down and outwards, causing vertical and horizontal diplopia. A dilated pupil suggests direct compression of the third nerve; if present, the possibility of an aneurysm of the posterior communicating artery must be considered urgently.
- **CN IV**: Vertical diplopia with cyclotorsion; the affected eye is slightly elevated, and limitation of depression is seen when the eye is held in adduction. The pt may assume a head tilt to the opposite side (e.g., left head tilt in right fourth nerve paresis).
- **CN VI**: Horizontal diplopia with crossed eyes; the affected eye cannot abduct.

Isolated ocular motor nerve palsies often occur in pts with hypertension or diabetes. They usually resolve spontaneously over several months. The apparent occurrence of multiple ocular motor nerve palsies, or diffuse ophthalmoplegia, raises the possibility of myasthenia gravis. In this disease, the pupils are always normal. Systemic weakness may be absent. Multiple ocular
motor nerve palsies should be investigated with neuroimaging focusing on the cavernous sinus, superior orbital fissure, and orbital apex where all three nerves are in close proximity. Diplopia that cannot be explained by a single ocular motor nerve palsy may also be caused by carcinomatous or fungal meningitis, Graves’ disease, Guillain-Barré syndrome, Fisher syndrome, or Tolosa-Hunt syndrome.

For a more detailed discussion, see Horton JC: Disorders of the Eye, Chap. 29, p. 180, in HPIM-17.

**Weakness and Paralysis**

**APPROACH TO THE PATIENT**

*Weakness* is a reduction of power in one or more muscles. *Paralysis* indicates weakness that is so severe that the muscle cannot be contracted at all, whereas *paresis* refers to weakness that is mild or moderate. The prefix “hemi-” refers to one half of the body, “para-” to both legs, and “quadri-” to all four limbs. The suffix “-plegia” signifies severe weakness or paralysis.

Increased *fatigability* or limitation in function due to pain or articular stiffness is often confused with weakness by pts. Increased time is sometimes required for full power to be exerted, and this *bradykinesia* may be misinterpreted as weakness. Severe proprioceptive sensory loss may also lead to complaints of weakness because adequate feedback information...
about the direction and power of movements is lacking. Finally, apraxia, a disorder of planning and initiating a skilled or learned movement, is sometimes mistaken for weakness.

The history should focus on the tempo of development of weakness, presence of sensory and other neurologic symptoms, medication history, predisposing medical conditions, and family history.

Weakness or paralysis is typically accompanied by other neurologic abnormalities that help to indicate the site of the responsible lesion (Table 42-1). It

<table>
<thead>
<tr>
<th>TABLE 42-1</th>
<th>SIGNS THAT DISTINGUISH ORIGIN OF WEAKNESS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sign</td>
<td>Upper Motor Neuron</td>
</tr>
<tr>
<td>Atrophy</td>
<td>None</td>
</tr>
<tr>
<td>Fasciculations</td>
<td>None</td>
</tr>
<tr>
<td>Tone</td>
<td>Spastic</td>
</tr>
<tr>
<td>Distribution of weakness</td>
<td>Pyramidal/ regional</td>
</tr>
<tr>
<td>Tendon reflexes</td>
<td>Hyperactive</td>
</tr>
<tr>
<td>Babinski’s sign</td>
<td>Present</td>
</tr>
</tbody>
</table>

### Table 42-2: Common Causes of Weakness

**Upper Motor Neuron**

- **Cortex**: ischemia; hemorrhage; intrinsic mass lesion (primary or metastatic cancer, abscess); extrinsic mass lesion (subdural hematoma); degenerative (amyotrophic lateral sclerosis)
- **Subcortical white matter/internal capsule**: ischemia; hemorrhage; intrinsic mass lesion (primary or metastatic cancer, abscess); immunologic (multiple sclerosis); infectious (progressive multifocal leukoencephalopathy)
- **Brainstem**: ischemia; immunologic (multiple sclerosis)
- **Spinal cord**: extrinsic compression (cervical spondylosis, metastatic cancer, epidural abscess); immunologic (multiple sclerosis, transverse myelitis); infectious (AIDS-associated myelopathy, HTLV-I–associated myelopathy, tabes dorsalis); nutritional deficiency (subacute combined degeneration)

**Motor Unit**

- **Spinal motor neuron**: degenerative (amyotrophic lateral sclerosis); infectious (poliomyelitis)
- **Spinal root**: compressive (degenerative disc disease); immunologic (Guillain-Barré syndrome); infectious (AIDS-associated polyradiculopathy, Lyme disease)
- **Peripheral nerve**: metabolic (diabetes mellitus, uremia, porphyria); toxic (ethanol, heavy metals, many drugs, diphtheria); nutritional ($B_{12}$ deficiency); inflammatory (polyarteritis nodosa); hereditary (Charcot-Marie-Tooth); immunologic (paraneoplastic, paraproteinemia); infectious (AIDS-associated polyneuropathies and mononeuritis multiplex); compressive (entrapment)
- **Neuromuscular junction**: immunologic (myasthenia gravis); toxic (botulism, aminoglycosides)
- **Muscle**: inflammatory (polymyositis, inclusion body myositis); degenerative ( muscular dystrophy); toxic (glucocorticoids, ethanol, AZT); infectious (trichinosis); metabolic (hypothyroid, periodic paralyses); congenital (central core disease)
is important to distinguish weakness arising from disorders of upper motor neurons (i.e., motor neurons in the cerebral cortex and their axons that descend through the subcortical white matter, internal capsule, brainstem, and spinal cord) from disorders of the motor unit (i.e., lower motor neurons in the

<table>
<thead>
<tr>
<th>Location of Lesion</th>
<th>Pattern of Weakness</th>
<th>Associated Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Upper Motor Neuron</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebral cortex</td>
<td>Hemiparesis (face and arm predominantly, or leg predominantly)</td>
<td>Hemisensory loss, seizures, homonymous hemianopia or quadrantanopia, aphasia, apraxias, gaze preference</td>
</tr>
<tr>
<td>Internal capsule</td>
<td>Hemiparesis (face, arm, leg may be equally affected)</td>
<td>Hemisensory deficit; homonymous hemianopia or quadrantanopia</td>
</tr>
<tr>
<td>Brainstem</td>
<td>Hemiparesis (arm and leg; face may not be involved at all)</td>
<td>Vertigo, nausea and vomiting, ataxia and dysarthria, eye movement abnormalities, cranial nerve dysfunction, altered level of consciousness, Horner’s syndrome</td>
</tr>
<tr>
<td>Spinal cord</td>
<td>Quadriparesis if mid-cervical or above Paraparesis if low cervical or thoracic Hemiparesis below level of lesion (Brown-Séquard)</td>
<td>Sensory level; bowel and bladder dysfunction; contralateral pain/temperature loss below level of lesion</td>
</tr>
<tr>
<td><strong>Motor Unit</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spinal motor neuron</td>
<td>Diffuse weakness, may involve control of speech and swallowing</td>
<td>Muscle fasciculations and atrophy; no sensory loss</td>
</tr>
<tr>
<td>Spinal root</td>
<td>Radicular pattern of weakness</td>
<td>Dermatomal sensory loss; radicular pain common with compressive lesions</td>
</tr>
<tr>
<td>Peripheral nerve</td>
<td>Distal weakness, usually feet more than hands; usually symmetric</td>
<td>Distal sensory loss, usually feet more than hands</td>
</tr>
<tr>
<td>Polyneuropathy</td>
<td>Weakness in distribution of single nerve</td>
<td>Sensory loss in distribution of single nerve</td>
</tr>
<tr>
<td>Mononeuropathy</td>
<td>Fattigable weakness, usually with ocular involvement producing diplopia and ptosis</td>
<td>No sensory loss; no reflex changes</td>
</tr>
<tr>
<td>Neuromuscular junction</td>
<td>Proximal weakness</td>
<td>No sensory loss; diminished reflexes only when severe; may have muscle tenderness</td>
</tr>
</tbody>
</table>
ventral horn of the spinal cord and their axons in the spinal roots and peripheral nerves, neuromuscular junction, and skeletal muscle).

Table 42-2 lists common causes of weakness by the primary site of pathology. Table 42-3 summarizes patterns with lesions of different parts of the nervous system.

An algorithm for the initial workup of weakness is shown in Fig. 42-1.
**APPROACH TO THE PATIENT WITH TREMOR AND MOVEMENT DISORDERS**

Divided into akinetic rigid forms, with muscle rigidity and slowness of movement, and hyperkinetic forms, with involuntary movements. In both types, preservation of strength is the rule. Most movement disorders arise from disruption of basal ganglia circuits; common causes are degenerative diseases (hereditary and idiopathic), drug-induced, organ system failure, CNS infection, and ischemia. Clinical features of the various movement disorders are summarized below.

**Bradykinesia**  Inability to initiate changes in activity or perform ordinary volitional movements rapidly and easily. There is a slowness of movement and a paucity of automatic motions such as eye blinking and arm swinging while walking. Usually due to Parkinsonism (Chap. 193).

**Tremor**  Rhythmic oscillation of a part of the body due to intermittent muscle contractions, usually involving the distal limbs and less commonly the head, tongue, or jaw. A coarse tremor at rest, 4–5 beats/s, is usually due to Parkinson’s disease. A fine postural tremor of 8–10 beats/s may be an exaggeration of normal physiologic tremor or indicate familial essential tremor. An intention tremor, most pronounced during voluntary movement towards a target, is found with cerebellar pathway disease.

**Essential Tremor (ET)**  This is the most common involuntary movement disorder. The tremor of ET must be distinguished from that of early Parkinson’s disease (Table 43-1). The pathophysiology of ET is unknown. Approximately 50% of cases have a positive family history with an autosomal dominant pattern of inheritance. Many cases are mild and require no treatment. When activities of daily living such as eating and writing are impaired, therapy with primidone (25–100 mg/d) or propranolol (20–80 mg/d) leads to benefit in 50% of patients. Surgical therapies may be effective in refractory cases.

<table>
<thead>
<tr>
<th>TABLE 43-1</th>
<th>ADVANCED EXAMINATION PEARLS: DIFFERENTIATING ESSENTIAL TREMOR FROM PARKINSONIAN TREMOR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Essential Tremor</td>
</tr>
<tr>
<td>Speed</td>
<td>5–10 Hz</td>
</tr>
<tr>
<td>Symmetry</td>
<td>Bilateral</td>
</tr>
<tr>
<td>Most common component</td>
<td>Postural</td>
</tr>
<tr>
<td>Other Parkinsonian symptoms</td>
<td>Absent</td>
</tr>
<tr>
<td>Helped with alcohol</td>
<td>Usually</td>
</tr>
<tr>
<td>Family history</td>
<td>Present often</td>
</tr>
</tbody>
</table>
Dystonia  Consists of sustained or repetitive involuntary muscle contractions, frequently causing twisting movements with abnormal posture. Dystonias may be generalized or focal.

Focal dystonias are common and include blepharospasm of the eyelids; spasmodic dysphonia involving the vocal cords; oromandibular dystonia of the face, lips, tongue, and jaw; cervical dystonia of the neck musculature (torticollis); and limb dystonias that are often task-specific such as writer’s cramp, playing a musical instrument, or putting in golf (yips).

Idiopathic torsional dystonia is a predominantly childhood-onset form of generalized dystonia with an autosomal dominant pattern of inheritance that mainly affects Ashkenazi Jewish families; most are linked to a mutation in the \textit{DYT1} gene on chromosome 9. Other generalized dystonias occur as a consequence of drugs such as antiepileptics and treatments for Parkinson’s disease.

Therapy for focal dystonias usually involves botulinum toxin injections into the affected musculature. All forms of dystonia may respond to anticholinergic medications (e.g., trihexyphenidyl 20–120 mg/d), benzodiazepines, baclofen, or anticonvulsants. Surgical therapies, including deep brain stimulation (DBS), may be effective in refractory cases.

Choreoathetosis  A combination of chorea (rapid, jerky movements) and athetosis (slow writhing movements). The two usually exist together, though one may be more prominent. Chorea movements are the predominant involuntary movements in rheumatic (Sydenham’s) chorea and Huntington’s disease. Systemic lupus erythematosus is the most common systemic disorder that causes chorea, but it can also be seen in patients with hyperthyroidism, various autoimmune disorders, infections including HIV, metabolic alterations, and in association with a wide variety of medications. Hemiballismus is a violent form of chorea that comprises wild, flinging movements on one side of the body; the most common cause is a lesion (often infarct or hemorrhage) of the subthalamic nucleus. Athetosis is prominent in some forms of cerebral palsy. Chronic neuroleptic use may lead to tardive dyskinesia, in which choreoathetotic movements are usually restricted to the buccal, lingual, and mandibular areas.

Huntington’s Disease (HD)  This is a progressive, fatal, autosomal dominant disorder characterized by motor, behavioral, and cognitive dysfunction. Onset is typically between the ages of 25 and 45 years. Rapid, nonpatterned, semipurposeful, involuntary choriform movements are the hallmark feature with dysarthria, gait disturbance, and oculomotor abnormalities commonly seen. Late stages of the disease feature a reduction in chorea and emergence of dystonia, rigidity, bradykinesia, myoclonus, and spasticity. HD patients eventually develop behavioral and cognitive disturbances that can be a major source of disability. HD is inherited as an autosomal dominant disorder and is caused by an expansion in the number of polyglutamine (CAG) repeats in the coding sequence of the \textit{Huntington} gene on chromosome 4.

Treatment involves a multidisciplinary approach with medical, neuropsychiatric, social, and genetic counseling for patients and their families. Dopamine-blocking agents may control the chorea but may aggravate motor symptoms and often have an unfavorable side-effect profile. Psychosis can be treated with atypical neuroleptic agents. No disease-modifying agents currently exist.

Tics  Brief, rapid, recurrent, and seemingly purposeless stereotyped muscle contractions. Gilles de la Tourette syndrome (TS) is a neurobehavioral, multiple tic disorder that may involve motor tics (especially twitches of the face, neck, and shoulders), vocal tics (grunts, words), and “behavioral tics” (coprolalia, echolalia). Patients may experience an irresistible urge to express tics but char-
acteristically can voluntarily suppress them for short periods of time. Onset is usually between 2 and 15 years of age, and tics often lessen or even disappear in adulthood. Drug treatment is only indicated when tics are disabling and interfere with quality of life. Therapy is generally initiated with clonidine, starting at low dose, or guanfacine (0.5–2 mg/d). If these agents are not effective, neuroleptics may be used.

**Asterixis**  
Brief, arrhythmic interruptions of sustained voluntary muscle contraction, usually observed as a brief lapse of posture of wrists in dorsiflexion with arms outstretched. This “liver flap” may be seen in any encephalopathy related to drug intoxication, organ system failure, or CNS infection. Therapy is correction of underlying disorder.

**Myoclonus**  
Rapid (<100 ms), brief, shocklike, jerky, irregular movements that are usually multifocal. Like asterixis, often indicates a diffuse encephalopathy. Following cardiac arrest, diffuse cerebral hypoxia may produce multifocal myoclonus. Spinal cord injury can also cause myoclonus. Myoclonus occurs in normal individuals when waking up or falling asleep. Treatment of myoclonus, indicated only when function is impaired, consists of treating the underlying condition or removing an offending agent. Drug therapies include valproic acid (1200–3000 mg/d), piracetam (8–20 g/d), clonazepam (2–15 mg/d), or primidone (500–1000 mg/d).

For a more detailed discussion, see Olanow CW: Hyperkinetic Movement Disorders, Chap. 367, p. 2560, in HPIM-17.

### Aphasias and Related Disorders

Aphasias are disturbances in the comprehension or production of spoken or written language. Clinical examination should assess spontaneous speech (fluency), comprehension, repetition, naming, reading, and writing. A classification scheme is presented in Table 44-1. In nearly all right-handed individuals and many left-handed patients, language localization is in the left hemisphere.

#### CLINICAL FEATURES

**Wernicke’s Aphasia**  
Although speech sounds grammatical, melodic, and effortless (fluent), it is virtually incomprehensible due to errors in word usage, structure, and tense and the presence of paraphasic errors and neologisms (“jargon”). Comprehension of written and spoken material is severely impaired, as are reading, writing, and repetition. The pt usually seems unaware of the deficit. Associated symptoms can include parietal lobe sensory deficits and homonymous hemianopia. Motor disturbances are rare.

Lesion is located in posterior perisylvian region. Most common cause is embolism to the inferior division of dominant middle cerebral artery (MCA); less commonly intracerebral hemorrhage, severe head trauma, or tumor is responsible.
Broca’s Aphasia  Speech output is sparse (nonfluent), slow, labored, interrupted by many word-finding pauses, and usually dysarthric; output may be reduced to a grunt or single word. Naming and repetition also impaired. Most pts have severe writing impairment. Comprehension of written and spoken language is relatively preserved. Patient is often aware of and visibly frustrated by deficit. With large lesions, a dense hemiparesis may occur, and eyes may deviate toward the side of lesion. More commonly, lesser degrees of contralateral face and arm weakness are present. Sensory loss is rarely found, and visual fields are intact.

Lesion involves dominant inferior frontal gyrus (Broca’s area), although cortical and subcortical areas along superior sylvian fissure and insula are often involved. Commonly caused by vascular lesions involving the superior division of the MCA; less commonly due to tumor, intracerebral hemorrhage, or abscess.

Global Aphasia  All aspects of speech and language are impaired. Pt cannot read, write, or repeat and has poor auditory comprehension. Speech output is minimal and nonfluent. Hemiplegia, hemisensory loss, and homonymous hemianopia are usually present. Syndrome represents the combined dysfunction of Wernicke’s and Broca’s areas, usually resulting from proximal occlusion of MCA supplying dominant hemisphere (less commonly due to tumor, intracerebral hemorrhage, or abscess).

Conduction Aphasia  Speech output is fluent but paraphasic, comprehension of spoken language is intact, and repetition is severely impaired, as are naming and writing. Lesion spares, but functionally disconnects, Wernicke’s and Bro-
Common Patient Presentations

SECTION 3

cas’s areas. Most cases are embolic, involving supramarginal gyrus of dominant parietal lobe, dominant superior temporal lobe, or arcuate fasciculus.

LABORATORY EVALUATION

CT scan or MRI usually identifies the location and nature of the causative lesion.

Aphasia

Speech therapy may be helpful in treatment of certain types of aphasia. When the lesion is caused by a stroke, recovery of language function generally peaks within 2–6 months, after which time further progress is limited.

For a more detailed discussion, see Mesulam M-M: Aphasia, Memory Loss, and Other Focal Cerebral Disorders, Chap. 27, p. 162, in HPIM-17.

Sleep Disorders

Disorders of sleep are among the most common problems seen by clinicians. More than one-half of adults experience at least intermittent sleep disturbances, and 50–70 million Americans suffer from a chronic sleep disturbance.

APPROACH TO THE PATIENT

Pts may complain of (1) difficulty in initiating and maintaining sleep (insomnia); (2) excessive daytime sleepiness, fatigue, or tiredness; (3) behavioral phenomena occurring during sleep [sleepwalking, rapid eye movement (REM) behavioral disorder, periodic leg movements of sleep, etc.]; or (4) circadian rhythm disorders associated with jet lag, shift work, and delayed sleep phase syndrome. A careful history of sleep habits and reports from the sleep partner (e.g., heavy snoring, falling asleep while driving) are a cornerstone of diagnosis. Pts with excessive sleepiness should be advised to avoid all driving until effective therapy has been achieved. Completion of a day-by-day sleep-work-drug log for at least 2 weeks is often helpful. Work and sleep times (including daytime naps and nocturnal awakenings) as well as drug and alcohol use, including caffeine and hypnotics, should be noted each day. Objective sleep laboratory recording is necessary to evaluate sleep apnea, narcolepsy, REM behavior disorder, periodic leg movements, and other suspected disorders.

INSOMNIA

Insomnia, or the complaint of inadequate sleep, may be subdivided into difficulty falling asleep (sleep-onset insomnia), frequent or sustained awakenings
(sleep-offset insomnia), or persistent sleepiness despite sleep of adequate duration (nonrestorative sleep). An insomnia complaint lasting one to several nights is termed transient insomnia and is typically due to situational stress or a change in sleep schedule or environment (e.g., jet lag). Short-term insomnia lasts from a few days up to 3 weeks; it is often associated with more protracted stress such as recovery from surgery or short-term illness. Long-term (chronic) insomnia lasts for months or years and, in contrast to short-term insomnia, requires a thorough evaluation for underlying causes. Chronic insomnia is often a waxing and waning disorder, with spontaneous or stress-induced exacerbations.

Adjustment Insomnia (Acute Insomnia) Acute insomnia can occur after a change in the sleeping environment (e.g., in an unfamiliar hotel or hospital bed) or before or after a significant life event or anxiety-provoking situation. Treatment is symptomatic, with intermittent use of hypnotics and resolution of the underlying stress. Inadequate sleep hygiene is characterized by a behavior pattern prior to sleep and/or a bedroom environment that is not conducive to sleep. In preference to hypnotic medications, the pt should attempt to avoid stressful activities before bed, reserve the bedroom environment for sleeping, and maintain regular rising times.

Psychophysiologic Insomnia These pts are preoccupied with a perceived inability to sleep adequately at night. Rigorous attention should be paid to sleep hygiene and correction of counterproductive, arousing behaviors before bedtime. Behavioral therapies are the treatment of choice.

Drugs and Medications Caffeine is probably the most common pharmacologic cause of insomnia. Alcohol and nicotine can also interfere with sleep, despite the fact that many pts use these agents to relax and promote sleep. A number of prescribed medications, including antidepressants, sympathomimetics, and glucocorticoids, can produce insomnia. In addition, severe rebound insomnia can result from the acute withdrawal of hypnotics, especially following use of high doses of benzodiazepines with a short half-life. For this reason, doses of hypnotics should be low to moderate and prolonged drug tapering is encouraged.

Movement Disorders Pts with restless legs syndrome complain of creeping dyesthesias deep within the calves or feet associated with an irresistible urge to move the affected limbs; symptoms are typically worse at night. One-third of pts have multiple affected family members. Treatment is with dopaminergic drugs (pramipexole 0.25–1.0 mg daily at 8 P.M. or ropinirole 0.5–4.0 mg daily at 8 P.M.). Periodic limb movements of sleep (PLMS) consists of stereotyped extensions of the great toe and dorsiflexion of the foot recurring every 20–40 s during non-REM sleep. Treatment options include dopaminergic medications or benzodiazepines.

Other Neurologic Disorders A variety of neurologic disorders produce sleep disruption through both indirect, nonspecific mechanisms (e.g., neck or back pain) or by impairment of central neural structures involved in the generation and control of sleep itself. Common disorders to consider include dementia from any cause, epilepsy, Parkinson’s disease, and migraine.

Psychiatric Disorders Approximately 80% of pts with mental disorders complain of impaired sleep. The underlying diagnosis may be depression, mania, an anxiety disorder, or schizophrenia.

Medical Disorders In asthma, daily variation in airway resistance results in marked increases in asthmatic symptoms at night, especially during sleep. Treat-
ment of asthma with theophylline-based compounds, adrenergic agonists, or glucocorticoids can independently disrupt sleep. Inhaled glucocorticoids that do not disrupt sleep may provide a useful alternative to oral drugs. Cardiac ischemia is also associated with sleep disruption; the ischemia itself may result from increases in sympathetic tone as a result of sleep apnea. Pts may present with complaints of nightmares or vivid dreams. Paroxysmal nocturnal dyspnea can also occur from cardiac ischemia that causes pulmonary congestion exacerbated by the recumbent posture. Chronic obstructive pulmonary disease, cystic fibrosis, hyperthyroidism, menopause, gastroesophageal reflux, chronic renal failure, and liver failure are other causes.

**Insomnia**

**Insomnia without Identifiable Cause**

Primary insomnia is a diagnosis of exclusion. Treatment is directed toward behavior therapies for anxiety and negative conditioning; pharmacotherapy and/or psychotherapy for mood/anxiety disorders; an emphasis on good sleep hygiene; and intermittent hypnotics for exacerbations of insomnia. Cognitive therapy emphasizes understanding the nature of normal sleep, the circadian rhythm, the use of light therapy, and visual imagery to block unwanted thought intrusions. Behavioral modification involves bedtime restriction, set schedules, and careful sleep environment practices. Judicious use of benzodiazepine receptor agonists with short half-lives can be effective; options include zaleplon (5–20 mg), zolpidem (5–10 mg), or triazolam (0.125–0.25 mg). Limit use to 2–4 weeks maximum for acute insomnia or intermittent use for chronic. Some pts benefit from low-dose sedating antidepressants.

**Hypersomnias (Disorders of Excessive Daytime Sleepiness)**

Differentiation of sleepiness from subjective complaints of fatigue may be difficult. Quantification of daytime sleepiness can be performed in a sleep laboratory using a multiple sleep latency test (MSLT), the repeated daytime measurement of sleep latency under standardized conditions. Common causes are summarized in Table 45-1.

**Sleep Apnea Syndromes**

Respiratory dysfunction during sleep is a common cause of excessive daytime sleepiness and/or disturbed nocturnal sleep, affecting an estimated 2–5 million individuals in the United States. Episodes may be due to occlusion of the airway (obstructive sleep apnea), absence of respiratory effort (central sleep apnea), or a combination of these factors (mixed sleep apnea). Obstruction is exacerbated by obesity, supine posture, sedatives (especially alcohol), nasal obstruction, and hypothyroidism. Sleep apnea is particularly prevalent in overweight men and in the elderly and is undiagnosed in 80–90% of affected individuals. Treatment consists of correction of the above factors, positive airway pressure devices, oral appliances, and sometimes surgery (Chap. 142).

**Narcolepsy**

A disorder of excessive daytime sleepiness and intrusion of REM-related sleep phenomena into wakefulness (cataplexy, hypnagogic hallucinations, and sleep paralysis). Cataplexy, the abrupt loss of muscle tone in arms, legs, or face, is precipitated by emotional stimuli such as laughter or sadness. Symptoms of narcolepsy (Table 45-2) typically begin in the second decade, although the onset ranges from ages 5–50. The prevalence is 1 in 4000 and narcolepsy has a genetic basis; almost all narcoleptics with cataplexy are positive for HLA DQB1*0602. Hypothalamic neurons containing the neuropeptide hypocre-
# Evaluation of the Patient with the Complaint of Excessive Daytime Somnolence

<table>
<thead>
<tr>
<th>Findings on History and Physical Examination</th>
<th>Diagnostic Evaluation</th>
<th>Diagnosis</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity, snoring, hypertension</td>
<td>Polysomnography with respiratory monitoring</td>
<td>Obstructive sleep apnea</td>
<td>Continuous positive airway pressure; ENT surgery (e.g., uvulopalatopharyngoplasty); dental appliance; pharmacologic therapy (e.g., protriptyline); weight loss</td>
</tr>
<tr>
<td>Cataplexy, hypnagogic hallucinations, sleep paralysis, family history</td>
<td>Polysomnography with multiple sleep latency testing</td>
<td>Narcolepsy-cataplexy syndrome</td>
<td>Stimulants (e.g., modafinil, methylphenidate); REM-suppressant antidepressants (e.g., protriptyline); genetic counseling</td>
</tr>
<tr>
<td>Restless legs, disturbed sleep, predisposing medical condition (e.g., iron deficiency or renal failure)</td>
<td>Assessment for predisposing medical conditions</td>
<td>Restless legs syndrome</td>
<td>Treatment of predisposing condition, if possible; dopamine agonists (e.g., pramipexole, ropinirole)</td>
</tr>
<tr>
<td>Disturbed sleep, predisposing medical conditions (e.g., asthma) and/or predisposing medical therapies (e.g., theophylline)</td>
<td>Sleep-wake diary record- ing</td>
<td>Insomnias (see text)</td>
<td>Treatment of predisposing condition and/or change in therapy, if possible; behavioral therapy; short-acting benzodiazepine receptor agonist (e.g., zolpidem)</td>
</tr>
</tbody>
</table>

*Note:* ENT, ears, nose, throat; REM, rapid eye movement; EMG, electromyogram.

tin (orexin) regulate the sleep/wake cycle and have been implicated in narcolepsy. Sleep studies confirm a short daytime sleep latency and a rapid transition to REM sleep.

**Hypersomnias**

Somnolence is treated with modafinil, a novel wake-promoting agent; the usual dose is 200–400 mg/d given as a single dose. Older stimulants such as methylphenidate (10 mg twice a day to 20 mg four times a day) or dextroamphetamine are alternatives, particularly in refractory pts. Cataplexy, hypnagogic hallucinations, and sleep paralysis respond to the tricyclic antidepressants protriptyline (10–40 mg/d) and clomipramine (25–50 mg/d) and to the selective serotonin uptake inhibitor fluoxetine (10–20 mg/d). Alternatively, γ-hydroxybutyrate (GHB) given at bedtime, and 4 h later, is effective in reducing daytime cataplectic episodes. Adequate nocturnal sleep time and the use of short naps are other useful preventative measures.

**DISORDERS OF CIRCADIAN RHYTHMICITY**

Insomnia or hypersomnia may occur in disorders of sleep timing rather than sleep generation. Such conditions may be (1) organic—due to a defect in the hypothalamic circadian pacemaker or its input from entraining stimuli, or (2) environmental—due to a disruption of exposure to entraining stimuli (light/dark cycle). Examples of the latter include jet-lag disorder and shift work. Shift work sleepiness can be treated with modafinil (200 mg, taken 30–60 min before the start of each night shift) as well as properly timed exposure to bright light. Safety programs should promote education about sleep and increase awareness of the hazards associated with night work.

*Delayed sleep phase syndrome* is characterized by late sleep onset and awakening with otherwise normal sleep architecture. Bright-light phototherapy in the morning hours or melatonin therapy during the evening hours may be effective. *Advanced sleep phase syndrome* moves sleep onset to the early evening hours with early morning awakening. These pts may benefit from bright-light phototherapy during the evening hours.

---

**TABLE 45-2 PREVALENCE OF SYMPTOMS IN NARCOLEPSY**

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Prevalence, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excessive daytime somnolence</td>
<td>100</td>
</tr>
<tr>
<td>Disturbed sleep</td>
<td>87</td>
</tr>
<tr>
<td>Cataplex</td>
<td>76</td>
</tr>
<tr>
<td>Hypnagogic hallucinations</td>
<td>68</td>
</tr>
<tr>
<td>Sleep paralysis</td>
<td>64</td>
</tr>
<tr>
<td>Memory problems</td>
<td>50</td>
</tr>
</tbody>
</table>


For a more detailed discussion, see Czeisler CA, Winkleman JW, Richardson GS: Sleep Disorders, Chap. 28, p. 171, in *HPIM-17*.
Dyspnea

CHAPTER 46

DEFINITION
Abnormally uncomfortable awareness of breathing; intensity quantified by establishing the amount of physical exertion necessary to produce the sensation. Dyspnea occurs when work of breathing is excessive.

CAUSES

Heart Disease
- Dyspnea most commonly due to ↑ pulmonary capillary pressure, and sometimes fatigue of respiratory muscles. Vital capacity and lung compliance are ↓ and airway resistance ↑.
- Begins as exertional breathlessness → orthopnea → paroxysmal nocturnal dyspnea and dyspnea at rest.
- Diagnosis depends on recognition of heart disease, e.g., Hx of MI, presence of S₃, S₄, murmurs, cardiomegaly, jugular vein distention, hepatomegaly, and peripheral edema (Chap. 131). Objective quantification of ventricular function (echocardiography, radionuclide ventriculography) is often helpful.

Airway Obstruction  (Chap. 138)
- May occur with obstruction anywhere from extrathoracic airways to lung periphery.
- Acute dyspnea with difficulty inhaling suggests upper airway obstruction. Physical exam may reveal inspiratory stridor and retraction of supraclavicular fossae.
- Acute intermittent dyspnea with expiratory wheezing suggests reversible intrathoracic obstruction due to asthma.
- Chronic, slowly progressive exertional dyspnea characterizes emphysema and CHF.
- Exertional dyspnea with chronic cough and expectoration is typical of chronic bronchitis and bronchiectasis.

Diffuse Parenchymal Lung Diseases  (Chap. 141) Many parenchymal lung diseases, from sarcoidosis to pneumoconioses, may cause dyspnea. Dyspnea is usually related to exertion early in the course of the illness. Physical exam typically reveals tachypnea and late inspiratory rales.

Pulmonary Embolism  (Chap. 140) Dyspnea is most common symptom of pulmonary embolism. Repeated discrete episodes of dyspnea may occur with recurrent pulmonary emboli; tachypnea is frequent.

Disease of the Chest Wall or Respiratory Muscles  (Chap. 142) Severe kyphoscoliosis may produce chronic dyspnea, often with chronic cor pulmonale. Spinal deformity must be severe before respiratory function is compromised.
- Pts with bilateral diaphragmatic paralysis appear normal while standing, but complain of severe orthopnea and display paradoxical abnormal respiratory movement when supine.
Algorithm for the Evaluation of the Patient with Dyspnea

**History**
- Quality of sensation, timing, positional disposition
- Persistent vs. intermittent

**Physical Exam**
- General appearance: Speak in full sentences? Accessory muscles? Color?
- Chest: Wheezes, rales, rhonchi, diminished breath sounds? Hyperinflated?
- Cardiac exam: JVP elevated? Precordial impulse? Gallop? Murmur?
- Extremities: Edema? Cyanosis?

At this point, diagnosis may be evident—if not, proceed to further evaluation

**Chest radiograph**
- Assess cardiac size, evidence of CHF
- Assess for hyperinflation
- Assess for pneumonia, interstitial lung disease, pleural effusions

**Suspect low cardiac output, myocardial ischemia, or pulmonary vascular disease**
- ECG and echocardiogram to assess left ventricular function and pulmonary artery pressure

**Suspect respiratory pump or gas exchange abnormality**
- Pulmonary function testing—if diffusing capacity reduced, consider CT angiogram to assess for interstitial lung disease and pulmonary embolism

**Suspect high cardiac output**
- Hematocrit, thyroid function tests

If diagnosis still uncertain, obtain cardiopulmonary exercise test

**TABLE 46-1 DIFFERENTIATION BETWEEN CARDIAC AND PULMONARY DYSPNEA**

- **Careful history:** Dyspnea of lung disease usually more gradual in onset than that of heart disease; nocturnal exacerbations common with each.
- **Examination:** Usually obvious evidence of cardiac or pulmonary disease. Findings may be absent at rest when symptoms are present only with exertion.
- **Brain natriuretic peptide (BNP):** Elevated in cardiac but not pulmonary dyspnea.
- **Pulmonary function tests:** Pulmonary disease rarely causes dyspnea unless tests of obstructive disease (FEV₁, FEV₁/FVC) or restrictive disease (total lung capacity) are reduced (<80% predicted).
- **Ventricular performance:** LV ejection fraction at rest and/or during exercise usually depressed in cardiac dyspnea.
Elicit a description of the amount of physical exertion necessary to produce the sensation and whether it varies under different conditions.

- If acute upper airway obstruction is suspected, lateral neck films or fiberoptic exam of upper airway may be helpful.
- With chronic upper airway obstruction the respiratory flow-volume curve may show inspiratory cutoff of flow, suggesting variable extrathoracic obstruction.
- Dyspnea due to emphysema is reflected in a reduction in expiratory flow rates ($FEV_1$), and often by a reduction in diffusing capacity for carbon monoxide ($DL_{CO}$).
- Pts with intermittent dyspnea due to asthma may have normal pulmonary function if tested when asymptomatic.
- Cardiac dyspnea usually begins as breathlessness on strenuous exertion with gradual (months-to-years) progression to dyspnea at rest.
- Pts with dyspnea due to both cardiac and pulmonary diseases may report orthopnea. Paroxysmal nocturnal dyspnea occurring after awakening from sleep is characteristic of CHF.
- Dyspnea of chronic obstructive lung disease tends to develop more gradually than that of heart disease.
- PFTs should be performed when etiology is not clear. When the diagnosis remains obscure a pulmonary stress test is often useful.
- Management depends on elucidating etiology.

Differentiation between cardiac and pulmonary dyspnea is summarized in Table 46-1.

**Cough**

Produced by inflammatory, mechanical, chemical, and thermal stimulation of cough receptors.

**Etiology**

- **Inflammatory**—edema and hyperemia of airways and alveoli due to laryngitis, tracheitis, bronchitis, bronchiolitis, pneumonitis, lung abscess.
- **Mechanical**—inhalation of particulates (dust) or compression of airways (pulmonary neoplasms, foreign bodies, granulomas, bronchospasm).
- **Chemical**—inhalation of irritant fumes, including cigarette smoke.
- **Thermal**—inhalation of cold or very hot air.
Common Patient Presentations

SECTION 3

APPROACH TO THE PATIENT WITH COUGH

DIAGNOSIS  (Fig. 47-1)

*History should consider:

- **Duration**—acute or chronic
- **Presence of fever or wheezing**
- **Sputum quantity and character**—change in sputum character, color, or volume in a smoker with “smoker’s cough” necessitates investigation.

![Diagram of Approach to the Patient with Cough](image)

**FIGURE 47-1** An algorithm for the evaluation of chronic cough. ACEI, angiotensin-converting enzyme inhibitor; BaE, barium esophagography; GERD, gastroesophageal reflux disease; HRCT, high-resolution CT; PE, physical examination; PNDS, postnasal drip syndrome. *Treatment is either targeted to a presumptive diagnosis or given empirically. [Adapted from RS Irwin: Chest 114(Suppl):1335, 1998, with permission.]
• **Temporal or seasonal pattern**—seasonal cough may indicate “cough asthma.”
• **Risk factors for underlying disease**—environmental exposures may suggest occupational asthma or interstitial lung disease.
• **Past medical history**—past history of recurrent pneumonias may indicate bronchiectasis, particularly if associated with purulent or copious sputum production. A change in the character of chronic cigarette cough raises suspicion of bronchogenic carcinoma. Chronic CHF causes cough.
• **Drugs**—is pt. on ACE inhibitor? Causes chronic cough in 5–20%.

Short duration with associated fever suggests acute viral or bacterial infection. Persistent cough after viral illness suggests postinflammatory cough. Postnasal drip is common cause of chronic cough. Nocturnal cough may indicate chronic sinus drainage or esophageal reflux.

**Physical exam** should assess upper and lower airways and lung parenchyma.

• Stridor suggests upper airway obstruction; wheezing suggests bronchospasm as the cause of cough.
• Midinspiratory crackles indicate airways disease (e.g., chronic bronchitis).
• Fine end-inspiratory crackles occur in interstitial fibrosis and heart failure.
• CXR may show neoplasm, infection, interstitial disease, or the hilar adenopathy of sarcoidosis.
• High-resolution CT (HRCT) helpful in unexplained chronic cough.
• PFTs may reveal obstruction or restriction.
• Sputum exam can indicate malignancy or infection.
• Fiberoptic bronchoscopy helpful in defining endobronchial causes.

**Complications**
(1) Syncope, due to transient decrease in venous return; (2) rupture of an emphysematous bleb with pneumothorax; (3) rib fractures—may occur in otherwise normal individuals.

**Cough** (See Fig. 47-2)

• When possible, therapy of cough is that of underlying disease. Eliminate ACE inhibitors and cigarette smoking.
• If no cause can be found, a trial of an inhaled anticholinergic agent (e.g., ipratropium 2–4 puffs four times daily), an inhaled β agonist (e.g., albuterol) or an inhaled steroid (e.g., triamcinolone) can be attempted. Inhaled steroids may take 7–10 days to be effective when used for an irritative cough.
• Cough productive of significant volumes of sputum should generally not be suppressed. Sputum clearance can be facilitated with adequate hydration, expectorants, and mechanical devices. Iodinated glycerol (30 mg four times daily) may be useful in asthma or chronic bronchitis.
• When symptoms from an irritative cough are severe, the cough may be suppressed with a narcotic antitussive agent such as codeine, 15–30 mg up to four times a day, or a nonnarcotic such as dextromethorphan (15 mg four times a day).

**HEMOPTYSIS**

Includes both streaked sputum and coughing up of gross blood.
**Etiology**  (Table 47-1) Bronchitis and pneumonia are common causes. Neoplasm may be the cause, particularly in smokers and when hemoptysis is persistent. Hemoptysis rare in metastatic neoplasm to lung. Pulmonary thromboembolism and infection are other causes. Diffuse hemoptysis may occur with vasculitis involving the lung. Five to 15% of cases with hemoptysis remain undiagnosed.

**Approach to the Patient with Hemoptysis**

**Diagnosis**  (Fig. 47-3)
Essential to determine that blood is coming from respiratory tract. Often frothy, may be preceded by a desire to cough.
Cough and Hemoptysis

CHAPTER 47

History may suggest diagnosis: chronic hemoptysis in otherwise asymptomatic young woman suggests bronchial adenoma.

Hemoptysis, weight loss, and anorexia in a smoker suggest carcinoma.

Hemoptysis with acute pleuritic pain suggests infarction; fever or chills with blood-streaked sputum suggests pneumonia.

Physical exam may also suggest diagnosis: pleural friction rub raises possibility of pulmonary embolism or some other pleural-based lesion (lung abscess, coccidioidomycosis cavity, vasculitis); diastolic rumbling murmur suggests mitral stenosis; localized wheeze suggests bronchogenic carcinoma.

Initial evaluation includes CXR. A normal CXR does not exclude tumor or bronchiectasis as a source of bleeding. The CXR may show an air-fluid level suggesting an abscess or atelectasis distal to an obstructing carcinoma. Follow with chest CT.

Most pts should be assessed by fiberoptic bronchoscopy. Rigid bronchoscopy helpful when bleeding is massive or from proximal airway lesion and when endotracheal intubation is contemplated.

### TABLE 47-1 DIFFERENTIAL DIAGNOSIS OF HEMOPTYSIS

<table>
<thead>
<tr>
<th>Source other than the lower respiratory tract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper airway (nasopharyngeal) bleeding</td>
</tr>
<tr>
<td>Gastrointestinal bleeding</td>
</tr>
<tr>
<td>Tracheobronchial source</td>
</tr>
<tr>
<td>Neoplasm (bronchogenic carcinoma, endobronchial metastatic tumor, Kaposi’s sarcoma, bronchial carcinoid)</td>
</tr>
<tr>
<td>Bronchitis (acute or chronic)</td>
</tr>
<tr>
<td>Bronchiectasis</td>
</tr>
<tr>
<td>Broncholithiasis</td>
</tr>
<tr>
<td>Airway trauma</td>
</tr>
<tr>
<td>Foreign body</td>
</tr>
<tr>
<td>Pulmonary parenchymal source</td>
</tr>
<tr>
<td>Lung abscess</td>
</tr>
<tr>
<td>Pneumonia</td>
</tr>
<tr>
<td>Tuberculosis</td>
</tr>
<tr>
<td>Mycetoma (“fungus ball”)</td>
</tr>
<tr>
<td>Goodpasture’s syndrome</td>
</tr>
<tr>
<td>Idiopathic pulmonary hemosiderosis</td>
</tr>
<tr>
<td>Wegener’s granulomatosis</td>
</tr>
<tr>
<td>Lupus pneumonitis</td>
</tr>
<tr>
<td>Lung contusion</td>
</tr>
<tr>
<td>Primary vascular source</td>
</tr>
<tr>
<td>Arteriovenous malformation</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
</tr>
<tr>
<td>Elevated pulmonary venous pressure (esp. mitral stenosis)</td>
</tr>
<tr>
<td>Pulmonary artery rupture secondary to balloon-tip pulmonary artery catheter manipulation</td>
</tr>
<tr>
<td>Miscellaneous/rare causes</td>
</tr>
<tr>
<td>Pulmonary endometriosis</td>
</tr>
<tr>
<td>Systemic coagulopathy or use of anticoagulants or thrombolytic agents</td>
</tr>
</tbody>
</table>

Common Patient Presentations

SECTION 3

Hemoptysis

- Treat the underlying condition
- Mainstays are bed rest and cough suppression with an opiate (codeine, 15–30 mg, or hydrocodone, 5 mg q4–6h).
- Pts with massive hemoptysis (>600 mL/d) and pts with respiratory compromise due to aspiration of blood should be monitored intensively with suction and intubation equipment close by so that selective intubation to isolate the bleeding lung can be accomplished. In massive hemoptysis, highest priority is to maintain gas exchange, and this may require intubation with double-lumen endotracheal tubes.
- Choice of medical or surgical therapy often relates to the anatomic site of hemorrhage and the pt’s baseline pulmonary function.
- Localized peripheral bleeding sites may be tamponaded by bronchoscopic placement of a balloon catheter in a lobar or segmental airway. Central bleeding sites may be managed with laser coagulation. Pts with severely compromised pulmonary function may be candidates for bronchial artery catheterization and embolization.

For a more detailed discussion, see Weinberger SE, Lipson DA: Cough and Hemoptysis, Chap. 34, p. 225, in HPIM-17.
Cyanosis

CHAPTER 48

The circulating quantity of reduced hemoglobin is elevated \( [>50 \text{ g/L (}>5 \text{ g/dL})] \) resulting in bluish discoloration of the skin and/or mucous membranes.

CENTRAL CYANOSIS

Results from arterial desaturation. Usually evident when arterial saturation is \( \leq 85\% \) or \( \leq 75\% \) in dark-skinned individuals.

- **Impaired pulmonary function**: Poorly ventilated alveoli or impaired oxygen diffusion; most frequent in pneumonia, pulmonary edema, and chronic obstructive pulmonary disease (COPD); in COPD with cyanosis, polycythemia is often present.
- **Anatomic vascular shunting**: Shunting of desaturated venous blood into the arterial circulation may result from congenital heart disease or pulmonary AV fistula.
- **Decreased inspired \( O_2 \)**: Cyanosis may develop in ascents to altitudes \( >2400 \text{ m (}>8000 \text{ ft}) \).
- **Abnormal hemoglobins**: Methemoglobinemia, sulfhemoglobinemia, and mutant hemoglobins with low oxygen affinity (see HPIM-17, Chap. 99).

PERIPHERAL CYANOSIS

Occurs with normal arterial \( O_2 \) saturation with increased extraction of \( O_2 \) from capillary blood caused by decreased localized blood flow. Vasoconstriction due to cold exposure, decreased cardiac output (in shock, Chap. 12), heart failure (Chap. 131), and peripheral vascular disease (Chap. 133) with arterial obstruction or vasospasm (Table 48-1). Local (e.g., thrombophlebitis) or central (e.g., constrictive pericarditis) venous hypertension intensifies cyanosis.

APPREACH TO THE PATIENT WITH CYANOSIS

- Inquire about duration (cyanosis since birth suggests congenital heart disease) and exposures (drugs or chemicals that result in abnormal hemoglobins).
- Differentiate central from peripheral cyanosis by examining nailbeds, lips, and mucous membranes. Peripheral cyanosis most intense in nailbeds and may resolve with gentle warming of extremities.
- Check for clubbing, i.e., selective enlargement of the distal segments of fingers and toes. Clubbing may be hereditary, idiopathic, or acquired and is associated with a variety of disorders, including primary and metastatic lung cancer, infective endocarditis, bronchiectasis, and hepatic cirrhosis. Combination of clubbing and cyanosis is frequent in congenital heart disease and occasionally with pulmonary disease (lung abscess, pulmonary AV shunts but not with uncomplicated obstructive lung disease).
- Examine chest for evidence of pulmonary disease, pulmonary edema, or murmurs associated with congenital heart disease.
- If cyanosis is localized to an extremity, evaluate for peripheral vascular obstruction.
Common Patient Presentations

SECTION 3

• Obtain arterial blood gas to measure systemic O₂ saturation. Repeat while pt inhales 100% O₂; if saturation fails to increase to >95%, intra-vascular shunting of blood bypassing the lungs is likely (e.g., right-to-left intracardiac shunts).

• Evaluate abnormal hemoglobins by hemoglobin electrophoresis, spectroscopy, and measurement of methemoglobin level.

For a more detailed discussion, see Braunwald E: Hypoxia and Cyanosis, Chap. 35, p. 229, in HPIM-17.

EDema

DEFINITION

Soft tissue swelling due to abnormal expansion of interstitial fluid volume. Edema fluid is a plasma transudate that accumulates when movement of fluid from vascular to interstitial space is favored. Since detectable generalized edema in

<table>
<thead>
<tr>
<th>TABLE 48-1</th>
<th>CAUSES OF CYANOSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Central Cyanosis</strong></td>
<td></td>
</tr>
<tr>
<td>Decreased arterial oxygen saturation</td>
<td></td>
</tr>
<tr>
<td>Decreased atmospheric pressure—high altitude</td>
<td></td>
</tr>
<tr>
<td>Impaired pulmonary function</td>
<td></td>
</tr>
<tr>
<td>Alveolar hypoventilation</td>
<td></td>
</tr>
<tr>
<td>Uneven relationships between pulmonary ventilation and perfusion (perfusion of hypoventilated alveoli)</td>
<td></td>
</tr>
<tr>
<td>Impaired oxygen diffusion</td>
<td></td>
</tr>
<tr>
<td>Anatomic shunts</td>
<td></td>
</tr>
<tr>
<td>Certain types of congenital heart disease</td>
<td></td>
</tr>
<tr>
<td>Pulmonary arteriovenous fistulas</td>
<td></td>
</tr>
<tr>
<td>Multiple small intrapulmonary shunts</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin with low affinity for oxygen</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin abnormalities</td>
<td></td>
</tr>
<tr>
<td>Methemoglobinemia—hereditary, acquired</td>
<td></td>
</tr>
<tr>
<td>Sulfhemoglobinemia—acquired</td>
<td></td>
</tr>
<tr>
<td>Carboxyhemoglobinemia (not true cyanosis)</td>
<td></td>
</tr>
<tr>
<td><strong>Peripheral Cyanosis</strong></td>
<td></td>
</tr>
<tr>
<td>Reduced cardiac output</td>
<td></td>
</tr>
<tr>
<td>Cold exposure</td>
<td></td>
</tr>
<tr>
<td>Redistribution of blood flow from extremities</td>
<td></td>
</tr>
<tr>
<td>Arterial obstruction</td>
<td></td>
</tr>
<tr>
<td>Venous obstruction</td>
<td></td>
</tr>
</tbody>
</table>

49
the adult reflects a gain of \( \geq 3 \) L, renal retention of salt and water is necessary for edema to occur. Distribution of edema can be an important guide to cause.

**Localized Edema**  Limited to a particular organ or vascular bed; easily distinguished from generalized edema. Unilateral extremity edema is usually due to venous or lymphatic obstruction (e.g., deep venous thrombosis, tumor obstruction, primary lymphedema). Stasis edema of a paralyzed lower extremity may also occur. Allergic reactions ("angioedema") and superior vena caval obstruction are causes of localized facial edema. Bilateral lower extremity edema may have localized causes, e.g., inferior vena cava obstruction, compression due to ascites, abdominal mass. Ascites (fluid in peritoneal cavity) and hydrothorax (in pleural space) may also present as isolated localized edema, due to inflammation or neoplasm.

**Generalized Edema**  Soft tissue swelling of most or all regions of the body. Bilateral lower extremity swelling, more pronounced after standing for several hours, and pulmonary edema are usually cardiac in origin. Periorbital edema noted on awakening often results from renal disease and impaired Na excretion. Ascites and edema of lower extremities and scrotum are frequent in cirrhosis or CHF. In CHF, diminished cardiac output and effective arterial blood volume result in both decreased renal perfusion and increased venous pressure with resultant renal Na retention due to renal vasoconstriction, intrarenal blood flow redistribution, direct Na-retentive effects of norepinephrine and angiotensin II, and secondary hyperaldosteronism.

In *cirrhosis*, arteriovenous shunts lower renal perfusion, resulting in Na retention. Ascites accumulates when increased intrahepatic vascular resistance produces portal hypertension. Reduced serum albumin and increased abdominal pressure also promote lower extremity edema.

**TABLE 49-1**  **DRUGS ASSOCIATED WITH EDEMA FORMATION**

<table>
<thead>
<tr>
<th>Category</th>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonsteroidal anti-inflammatory drugs</td>
<td>Hydralazine, Clonidine, Methylprednisolone</td>
</tr>
<tr>
<td>Antihypertensive agents</td>
<td>Hydralazine</td>
</tr>
<tr>
<td>Direct arterial/arteriolar vasodilators</td>
<td>Clonidine</td>
</tr>
<tr>
<td>Calcium channel antagonists</td>
<td>Methylprednisolone</td>
</tr>
<tr>
<td>( \alpha )-Adrenergic antagonists</td>
<td>Guanethidine</td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>Minoxidil</td>
</tr>
<tr>
<td>Steroid hormones</td>
<td>Calcium channel antagonists</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>( \alpha )-Adrenergic antagonists</td>
</tr>
<tr>
<td>Anabolic steroids</td>
<td>Thiazolidinediones</td>
</tr>
<tr>
<td>Estrogens</td>
<td>Steroid hormones</td>
</tr>
<tr>
<td>Progestins</td>
<td>Glucocorticoids</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Anabolic steroids</td>
</tr>
<tr>
<td>Growth hormone</td>
<td>Estrogens</td>
</tr>
<tr>
<td>Immunotherapies</td>
<td>Progestins</td>
</tr>
<tr>
<td>Interleukin 2</td>
<td>Cyclosporine</td>
</tr>
<tr>
<td>OKT3 monoclonal antibody</td>
<td>Growth hormone</td>
</tr>
</tbody>
</table>

In acute or chronic renal failure, edema occurs if Na intake exceeds kidney's ability to excrete Na secondary to marked reductions in glomerular filtration. Severe hypoalbuminemia [<25 g/L (2.5 g/dL)] of any cause (e.g., nephrotic syndrome, nutritional deficiency, chronic liver disease) may lower plasma oncotic pressure, promoting fluid transudation into interstitium; lowering of effective blood volume stimulates renal Na retention, and causes edema.

Less common causes of generalized edema: idiopathic edema, a syndrome of recurrent rapid weight gain and edema in women of reproductive age; hypothyroidism, in which myxedema is typically located in the pretibial region; drugs (see Table 49-1).

**Edema**

Primary management is to identify and treat the underlying cause of edema (Fig. 49-1).
Dietary Na restriction (<500 mg/d) may prevent further edema formation. Bed rest enhances response to salt restriction in CHF and cirrhosis. Supportive stockings and elevation of edematous lower extremities help to mobilize interstitial fluid. If severe hyponatremia (<132 mmol/L) is present, water intake should also be reduced (<1500 mL/d). Diuretics (Table 49-2) are indicated for marked peripheral edema, pulmonary edema, CHF, inadequate dietary salt restriction. Complications are listed in Table 49-3. Weight loss by diuretics should be limited to 1–1.5 kg/d. Distal (“potassium sparing”) diuretics or metolazone may be added to loop diuretics for enhanced effect. Note that intestinal edema may impair absorption of oral diuretics and reduce effectiveness. When desired weight is achieved, diuretic doses should be reduced.

In CHF (Chap. 131), avoid overdiuresis because it may bring a fall in cardiac output and prerenal azotemia. Avoid diuretic-induced hypokalemia, which predisposes to digitalis toxicity.

In cirrhosis and other hepatic causes of edema, spironolactone is the diuretic of choice but may produce acidosis and hyperkalemia. Thiazides or small doses of loop diuretics may also be added. However, renal failure may result from volume depletion. Overdiuresis may result in hyponatremia, hypokalemia, and alkalosis, which may worsen hepatic encephalopathy (Chap. 163).

### Table 49-2: Diuretics for Edema

<table>
<thead>
<tr>
<th>Drug</th>
<th>Usual Dose</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Loop (May Be Administered PO or IV)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furosemide</td>
<td>40–120 mg qd or bid</td>
<td>Short-acting; potent; effective with low GFR</td>
</tr>
<tr>
<td>Bumetanide</td>
<td>0.5–2 mg qd or bid</td>
<td>May be used if allergic to furosemide</td>
</tr>
<tr>
<td>Ethacrynic acid</td>
<td>50–200 mg qd</td>
<td>Longer-acting</td>
</tr>
<tr>
<td><strong>Distal, K-Losing</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>25–200 mg qd</td>
<td>First choice; causes hypokalemia; need GFR &gt; 25 mL/min</td>
</tr>
<tr>
<td>Chlorthalidone</td>
<td>100 mg qd or qod</td>
<td>Long-acting (up to 72 h); hypokalemia; need GFR &gt; 25 mL/min</td>
</tr>
<tr>
<td>Metolazone</td>
<td>1–10 mg qd</td>
<td>Long-acting; hypokalemia; effective with low GFR, especially when combined with a loop diuretic</td>
</tr>
<tr>
<td><strong>Distal, K-Sparing</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spironolactone</td>
<td>25–100 mg qd to qid</td>
<td>Hyperkalemia; acidosis; blocks aldosterone; gynecomastia, impotence, amenorrhea; onset takes 2–3 days; avoid use in renal failure or in combination with ACE inhibitors or potassium supplements</td>
</tr>
<tr>
<td>Amiloride</td>
<td>5–10 mg qd or bid</td>
<td>Hyperkalemia; once daily; less potent than spironolactone</td>
</tr>
<tr>
<td>Triamterene</td>
<td>100 mg bid</td>
<td>Hyperkalemia; less potent than spironolactone; renal stones</td>
</tr>
</tbody>
</table>
NAUSEA AND VOMITING

Nausea refers to the imminent desire to vomit and often precedes or accompanies vomiting. Vomiting refers to the forceful expulsion of gastric contents through the mouth. Retching refers to labored rhythmic respiratory activity that precedes emesis. Regurgitation refers to the gentle expulsion of gastric contents in the absence of nausea and abdominal diaphragmatic muscular contraction. Rumination refers to the regurgitation, rechewing, and reswallowing of food from the stomach.

Pathophysiology Gastric contents are propelled into the esophagus when there is relaxation of the gastric fundus and gastroesophageal sphincter followed by a rapid increase in intraabdominal pressure produced by contraction of the abdominal and diaphragmatic musculature. Increased intrathoracic pressure results in further movement of the material to the mouth. Reflex elevation of the soft palate and closure of the glottis protect the nasopharynx and trachea and complete the act of vomiting. Vomiting is controlled by two brainstem areas, the vomiting center and chemoreceptor trigger zone. Activation of the chemoreceptor trigger zone results in impulses to the vomiting center, which controls the physical act of vomiting.

Etiology Nausea and vomiting are manifestations of a large number of disorders (Table 50-1).

<table>
<thead>
<tr>
<th>TABLE 49-3 COMPLICATIONS OF DIURETICS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common</strong></td>
</tr>
<tr>
<td>Volume depletion</td>
</tr>
<tr>
<td>Prerenal azotemia</td>
</tr>
<tr>
<td>Potassium depletion</td>
</tr>
<tr>
<td>Hyponatremia (thiazides)</td>
</tr>
<tr>
<td>Metabolic alkalosis</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
</tr>
<tr>
<td>Hyperglycemia (thiazides)</td>
</tr>
<tr>
<td>Hyperkalemia (K-sparing)</td>
</tr>
<tr>
<td>Hypomagnesemia</td>
</tr>
<tr>
<td>Hyperuricemia</td>
</tr>
<tr>
<td>Hypercalcemia (thiazides)</td>
</tr>
<tr>
<td>GI complaints</td>
</tr>
<tr>
<td>Rash (thiazides)</td>
</tr>
</tbody>
</table>

For a more detailed discussion, see Braunwald E, Loscalzo J: Edema, Chap. 36, p. 231, in HPIM-17.
### Evaluation

The history, including a careful drug history, and the timing and character of the vomitus can be helpful. For example, vomiting that occurs predominantly in the morning is often seen in pregnancy, uremia, and alcoholic gastritis; feculent emesis implies distal intestinal obstruction or gastrocolic fistula; projectile vomiting suggests increased intracranial pressure; vomiting during or shortly after a meal may be due to psychogenic causes or peptic ulcer disease. Associated symptoms may also be helpful: vertigo and tinnitus in Ménière’s disease, relief of abdominal pain with vomiting in peptic ulcer, and early satiety in gastroparesis. Plain radiographs can suggest diagnoses such as intestinal obstruction. The upper GI series assesses motility of the proximal GI tract as well as the mucosa. Other studies may be indicated, such as gastric emptying scans (diabetic gastroparesis) and CT scan of the brain.

### Complications

Rupture of the esophagus (Boerhaave’s syndrome), hematemeisis from a mucosal tear (Mallory-Weiss syndrome), dehydration, malnutrition, dental caries and erosions, metabolic alkalosis, hypokalemia, and aspiration pneumonia.

---

### Nausea and Vomiting

Treatment is aimed at correcting the specific cause. The effectiveness of antiemetic medications depends on etiology of symptoms, pt responsiveness, and side effects. Antihistamines such as meclizine and dimenhydrinate are effective for nausea due to inner ear dysfunction. Anticholinergics such as scopolamine are effective for nausea associated with motion sickness. Haloperidol...
and phenothiazine derivatives such as prochlorperazine are often effective in controlling mild nausea and vomiting, but sedation, hypotension, and parkinsonian symptoms are common side effects. Selective dopamine antagonists such as metoclopramide may be superior to the phenothiazines in treating severe nausea and vomiting and are particularly useful in treatment of gastroparesis. IV metoclopramide may be effective as prophylaxis against nausea when given before chemotherapy. Ondansetron and granisetron, serotonin receptor blockers, and glucocorticoids are used for treating nausea and vomiting associated with cancer chemotherapy. Aprepitant, a neurokinin receptor blocker, is effective at controlling nausea from highly emetic drugs like cisplatin. Erythromycin is effective in some pts with gastroparesis.

### INDIGESTION

*Indigestion* is a nonspecific term that encompasses a variety of upper abdominal complaints including heartburn, regurgitation, and dyspepsia (upper abdominal discomfort or pain). These symptoms are overwhelmingly due to gastroesophageal reflux disease (GERD).

#### Pathophysiology

GERD occurs as a consequence of acid reflux into the esophagus from the stomach, gastric motor dysfunction, or visceral afferent hypersensitivity. A wide variety of situations promote GERD: increased gastric contents (from a large meal, gastric stasis, or acid hypersecretion), physical factors (lying down, bending over), increased pressure on the stomach (tight clothes, obesity, ascites, pregnancy), and loss (usually intermittent) of lower esophageal sphincter tone (diseases such as scleroderma, smoking, anticholinergics, calcium antagonists). Hiatal hernia also promotes acid flow into the esophagus.

#### Natural History

Heartburn is reported once monthly by 40% of Americans and daily by 7%. Functional dyspepsia is defined as >3 months of dyspepsia without an organic cause. Functional dyspepsia is the cause of symptoms in 60% of pts with dyspeptic symptoms. However, peptic ulcer disease from either *Helicobacter pylori* infection or ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs) is present in 15% of cases.

In most cases, the esophagus is not damaged, but 5% of pts develop esophageal ulcers and some form strictures; 8–20% develop glandular epithelial cell metaplasia, termed Barrett's esophagus, which can progress to adenocarcinoma.

Extraesophageal manifestations include asthma, laryngitis, chronic cough, aspiration pneumonitis, chronic bronchitis, sleep apnea, dental caries, halitosis, and hiccups.

#### Evaluation

The presence of dysphagia, odynophagia, unexplained weight loss, recurrent vomiting leading to dehydration, occult or gross bleeding, or a palpable mass or adenopathy are “alarm” signals that demand directed radiographic, endoscopic, and surgical evaluation. Pts without alarm features are generally treated empirically. Individuals >45 years can be tested for the presence of *H. pylori*. Pts positive for the infection are treated to eradicate the organism. Pts who fail to respond to *H. pylori* treatment, those >45 years old, and those with alarm features generally undergo upper GI endoscopy.

### Rx Indigestion

Weight reduction; elevation of the head of the bed; and avoidance of large meals, smoking, caffeine, alcohol, chocolate, fatty food, citrus juices, and
NSAIDs may prevent GERD. Antacids are widely used. Clinical trials suggest that proton pump inhibitors (omeprazole) are more effective than histamine receptor blockers (ranitidine) in patients with or without esophageal erosions. *H. pylori* eradication regimens are discussed in Chap. 156. Motor stimulants like metoclopramide and erythromycin may be useful in a subset of patients with postprandial distress.

Surgical techniques (Nissen fundoplication, Belsey procedure) work best in young individuals whose symptoms have improved on proton pump inhibitors and who otherwise may require lifelong therapy. They can be used in the rare pts who are refractory to medical management. Clinical trials have not documented the superiority of one over another.

For a more detailed discussion, see Hasler WL: Nausea, Vomiting, and Indigestion, Chap. 39, p. 240, in HPIM-17.

51 Weight Loss

Significant unintentional weight loss in a previously healthy individual is often a harbinger of underlying systemic disease. The routine medical history should always include inquiry about changes in weight. Rapid fluctuations of weight over days suggest loss or gain of fluid, whereas long-term changes usually involve loss of tissue mass. Loss of 5% of body weight over 6–12 months should prompt further evaluation.

**ETIOLOGY**

A list of possible causes of weight loss is extensive (Table 51-1). In older persons the most common causes of weight loss are depression, cancer, and benign gastrointestinal disease. Lung and GI cancers are the most common malignancies in pts presenting with weight loss. In younger individuals diabetes mellitus, hyperthyroidism, anorexia nervosa, and infection, especially with HIV, should be considered.

**CLINICAL FEATURES**

Before extensive evaluation is undertaken, it is important to confirm that weight loss has occurred. In the absence of documentation, changes in belt notch size or the fit of clothing may help to determine loss of weight.

The *history* should include questions about fever, pain, shortness of breath or cough, palpitations, and evidence of neurologic disease. A history of GI symptoms should be obtained, including difficulty eating, dysphagia, anorexia, nausea, and change in bowel habits. Travel history, use of cigarettes, alcohol, and all medications should be reviewed, and pts should be questioned about previous illness or surgery as well as diseases in family members. Risk factors for HIV should be assessed. Signs of depression, evidence of dementia, and social factors, including financial issues that might affect food intake, should be considered.
SECTION 3

Physical examination should begin with weight determination and documentation of vital signs. The skin should be examined for pallor, jaundice, turgor, surgical scars, and stigmata of systemic disease. Evaluation for oral thrush, dental disease, thyroid gland enlargement, and adenopathy and for respiratory, cardiac, or abdominal abnormalities should be performed. All men should have a rectal examination, including the prostate; all women should have a pelvic examination; and both should have testing of the stool for occult blood. Neurologic examination should include mental status assessment and screening for depression.

Initial laboratory evaluation is shown in Table 51-2, with appropriate treatment based on the underlying cause of the weight loss. If an etiology of weight loss is not found, careful clinical follow-up, rather than persistent undirected testing, is reasonable.

**TABLE 51-1** CAUSES OF WEIGHT LOSS

<table>
<thead>
<tr>
<th>Causes of Weight Loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer</td>
</tr>
<tr>
<td>Endocrine and metabolic causes</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>Pheochromocytoma</td>
</tr>
<tr>
<td>Adrenal insufficiency</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
</tr>
<tr>
<td>Malabsorption</td>
</tr>
<tr>
<td>Obstruction</td>
</tr>
<tr>
<td>Pernicious anemia</td>
</tr>
<tr>
<td>Cardiac disorders</td>
</tr>
<tr>
<td>Chronic ischemia</td>
</tr>
<tr>
<td>Chronic congestive heart failure</td>
</tr>
<tr>
<td>Respiratory disorders</td>
</tr>
<tr>
<td>Emphysema</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>Renal insufficiency</td>
</tr>
<tr>
<td>Rheumatologic disease</td>
</tr>
<tr>
<td>Infections</td>
</tr>
<tr>
<td>HIV</td>
</tr>
<tr>
<td>Tuberculosis</td>
</tr>
<tr>
<td>Parasitic infection</td>
</tr>
<tr>
<td>Subacute bacterial endocarditis</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Treatment of weight loss should be directed at correcting the underlying physical cause or social circumstance. In specific situations, nutritional supplements and medications (megastrol acetate, dronabinol, or growth hormone) may be effective for stimulating appetite or increasing weight.
DYSPHAGIA

Dysphagia is difficulty moving food or liquid through the mouth, pharynx, and esophagus. The pt senses swallowed material sticking along the path. Odynophagia is pain on swallowing. Globus pharyngeus is the sensation of a lump lodged in the throat, with swallowing unaffected.

Pathophysiology  Dysphagia is caused by two main mechanisms: mechanical obstruction or motor dysfunction. Mechanical causes of dysphagia can be luminal (e.g., large food bolus, foreign body), intrinsic to the esophagus (e.g., inflammation, webs and rings, strictures, tumors), or extrinsic to the esophagus (e.g., cervical spondylitis, enlarged thyroid or mediastinal mass, vascular compression). The motor function abnormalities that cause dysphagia may be related to defects in initiating the swallowing reflex (e.g., tongue paralysis, lack of saliva, lesions affecting sensory components of cranial nerves X and XI), disorders of the pharyngeal and esophageal striated muscle (e.g., muscle disorders such as polymyositis and dermatomyositis, neurologic lesions such as myasthenia gravis, polio, or amyotrophic lateral sclerosis), and disorders of the esophageal smooth muscle (e.g., achalasia, scleroderma, myotonic dystrophy).

APPRAOCH TO THE PATIENT: DYSPHAGIA

History can provide a presumptive diagnosis in about 80% of pts. Difficulty only with solids implies mechanical dysphagia. Difficulty with both solids and liquids may occur late in the course of mechanical dysphagia but is an early sign of motor dysphagia. Pts can sometimes pinpoint the site of food sticking. Weight loss out of proportion to the degree of dysphagia may be a sign of underlying malignancy. Hoarseness may be related to involvement

<table>
<thead>
<tr>
<th>TABLE 51-2</th>
<th>SCREENING TESTS FOR EVALUATION OF INVOLUNTARY WEIGHT LOSS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial testing</td>
<td>Additional testing</td>
</tr>
<tr>
<td>CBC</td>
<td>HIV test</td>
</tr>
<tr>
<td>Electrolytes, calcium, glucose</td>
<td>Upper and/or lower gastrointestinal endoscopy</td>
</tr>
<tr>
<td>Renal and liver function tests</td>
<td>Abdominal CT scan or MRI</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>Chest CT scan</td>
</tr>
<tr>
<td>Thyroid-stimulating hormone</td>
<td></td>
</tr>
<tr>
<td>Chest x-ray</td>
<td></td>
</tr>
<tr>
<td>Recommended cancer screening</td>
<td></td>
</tr>
</tbody>
</table>
of the larynx in the primary disease process (e.g., neuromuscular disorders), neoplastic disruption of the recurrent laryngeal nerve, or laryngitis from gastroesophageal reflux.

Physical exam may reveal signs of skeletal muscle, neurologic, or oropharyngeal diseases. Neck exam can reveal masses impinging on the esophagus. Skin changes might suggest the systemic nature of the underlying disease (e.g., scleroderma).

Dysphagia is nearly always a symptom of organic disease rather than a functional complaint. If oropharyngeal dysphagia is suspected, video-fluoroscopy of swallowing may be diagnostic. Mechanical dysphagia can be evaluated by barium swallow and esophagogastroscopy with endoscopic biopsy. Barium swallow and esophageal motility studies can show the presence of motor dysphagia.

Oropharyngeal Dysphagia  Pt has difficulty initiating the swallow; food sticks at the level of the suprasternal notch; nasopharyngeal regurgitation and aspiration may be present.

Causes include the following: for solids only, carcinoma, aberrant vessel, congenital or acquired web (Plummer-Vinson syndrome in iron deficiency), cervical osteophyte; for solids and liquids, cricopharyngeal bar (e.g., hypertensive or hypotensive upper esophageal sphincter), Zenker’s diverticulum (outpouching in the posterior midline at the intersection of the pharynx and the cricopharyngeus muscle), myasthenia gravis, glucocorticoid myopathy, hyperthyroidism, hypothyroidism, myotonic dystrophy, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, stroke, bulbar palsy, pseudobulbar palsy.

Esophageal Dysphagia  Food sticks in the mid or lower sternal area; can be associated with regurgitation, aspiration, odynophagia. Causes include the following: for solids only, lower esophageal ring (Schatzki’s ring—symptoms are usually intermittent), peptic stricture (heartburn accompanies this), carcinoma, lye stricture; for solids and liquids, diffuse esophageal spasm (occurs with chest pain and is intermittent), scleroderma (progressive and occurs with heartburn), achalasia (progressive and occurs without heartburn).

NONCARDIAC CHEST PAIN

Of pts presenting with chest pain, 30% have an esophageal source rather than angina. History and physical exam often cannot distinguish cardiac from noncardiac pain. Exclude cardiac disease first. Causes include the following: gastroesophageal reflux disease, esophageal motility disorders, peptic ulcer disease, gallstones, psychiatric disease (anxiety, panic attacks, depression).

Evaluation  Consider a trial of antireflux therapy (omeprazole); if no response, 24-h ambulatory luminal pH monitoring; if negative, esophageal manometry may show motor disorder. Trial of imipramine, 50 mg PO qhs, may be worthwhile. Consider psychiatric evaluation in selected cases.

ESOPHAGEAL MOTILITY DISORDERS

Pts may have a spectrum of manometric findings ranging from nonspecific abnormalities to defined clinical entities.
Achalasia  Motor obstruction caused by hypertensive lower esophageal sphincter (LES), incomplete relaxation of LES, or loss of peristalsis in smooth-muscle portion of esophagus. Causes include the following: primary (idiopathic) or secondary due to Chagas’ disease, lymphoma, carcinoma, chronic idiopathic intestinal pseudoobstruction, ischemia, neurotropic viruses, drugs, toxins, radiation therapy, postvagotomy.

Evaluation  Chest x-ray shows absence of gastric air bubble. Barium swallow shows dilated esophagus with distal beaklike narrowing and air-fluid level. Endoscopy is done to rule out cancer, particularly in persons >50 years. Manometry shows normal or elevated LES pressure, decreased LES relaxation, absent peristalsis.

### Achalasia

Pneumatic balloon dilatation is effective in 85%, with 3–5% risk of perforation or bleeding. Injection of botulinum toxin at endoscopy to relax LES is safe and effective, but effects last only ~12 months. Myotomy of LES (Heller procedure) is effective, but 10–30% of pts develop gastroesophageal reflux. Nifedipine, 10–20 mg, or isosorbide dinitrate, 5–10 mg S/L ac, may avert need for dilatation or surgery. Sildenafil may also augment swallow-induced relaxation of the LES.

Spastic Disorders  Diffuse esophageal spasm involves multiple spontaneous and swallow-induced contractions of the esophageal body that are of simultaneous onset and long duration and are recurrent. Causes include the following: primary (idiopathic) or secondary due to gastroesophageal reflux disease, emotional stress, diabetes, alcoholism, neuropathy, radiation therapy, ischemia, or collagen vascular disease.

An important variant is nutcracker esophagus: high-amplitude (>180 mm-Hg) peristaltic contractions; particularly associated with chest pain or dysphagia, but correlation between symptoms and manometry is inconsistent. Condition may resolve over time or evolve into diffuse spasm; associated with increased frequency of depression, anxiety, and somatization.

Evaluation  Barium swallow shows corkscrew esophagus, pseudodiverticula, and diffuse spasm. Manometry shows spasm with multiple simultaneous esophageal contractions of high amplitude and long duration. In nutcracker esophagus, the contractions are peristaltic and of high amplitude. If heart disease has been ruled out, edrophonium, ergonovine, or bethanechol can be used to provoke spasm.

### Spastic Disorders

Anticholinergics are usually of limited value; nitrates (isosorbide dinitrate, 5–10 mg PO ac) and calcium antagonists (nifedipine, 10–20 mg PO ac) are more effective. Those refractory to medical management may benefit from balloon dilatation. Rare pts require surgical intervention: longitudinal myotomy of esophageal circular muscle. Treatment of concomitant depression or other psychological disturbance may help.

Scleroderma  Atrophy of the esophageal smooth muscle and fibrosis can make the esophagus aperistaltic and lead to an incompetent LES with attendant reflux.
esophagitis and stricture. Treatment of gastroesophageal reflux disease is discussed in Chap. 50.

**ESOPHAGEAL INFLAMMATION**

**Viral Esophagitis**  Herpesviruses I and II, varicella-zoster virus, and cytomegalovirus (CMV) can all cause esophagitis; particularly common in immunocompromised pts (e.g., AIDS). Odynophagia, dysphagia, fever, and bleeding are symptoms and signs. Diagnosis is made by endoscopy with biopsy, brush cytology, and culture.

**Viral Esophagitis**  Disease is usually self-limited in the immunocompetent person; viscous lidocaine can relieve pain; in prolonged cases and in immunocompromised hosts, herpes and varicella esophagitis are treated with acyclovir, 5–10 mg/kg IV q8h for 10–14 d, then 200–400 mg PO 5 times a day. CMV is treated with ganciclovir, 5 mg/kg IV q12h, until healing occurs, which may take weeks. Oral valganciclovir (900 mg bid) is an effective alternative to parenteral treatment. In nonresponders, foscarnet, 60 mg/kg IV q12h for 21 days, may be effective.

**Candida Esophagitis**  In immunocompromised hosts, or those with malignancy, diabetes, hypoparathyroidism, hemoglobinopathy, systemic lupus erythematosus, corrosive esophageal injury, candidal esophageal infection may present with odynophagia, dysphagia, and oral thrush (50%). Diagnosis is made on endoscopy by identifying yellow-white plaques or nodules on friable red mucosa. Characteristic hyphae are seen on KOH stain. In pts with AIDS, the development of symptoms may prompt an empirical therapeutic trial.

**Candida Esophagitis**  Oral nystatin (100,000 U/mL), 5 mL q6h, or clotrimazole, 10-mg tablet sucked q6h, is effective. In immunocompromised hosts, fluconazole, 100–200 mg PO daily for 1–3 weeks, is treatment of choice; alternatives include itraconazole, 200 mg PO bid, or ketoconazole, 200–400 mg PO daily; long-term maintenance therapy is often required. Poorly responsive pts may respond to higher doses of fluconazole (400 mg/d) or to amphotericin, 10–15 mg IV q6h for a total dose of 300–500 mg.

**Pill-Related Esophagitis**  Doxycycline, tetracycline, aspirin, nonsteroidal anti-inflammatory drugs, KCl, quinidine, ferrous sulfate, clindamycin, alprenolol, and alendronate can induce local inflammation in the esophagus. Predisposing factors include recumbency after swallowing pills with small sips of water and anatomic factors impinging on the esophagus and slowing transit.

**Pill-Related Esophagitis**  Withdraw offending drug, use antacids, and dilate any resulting stricture.

**Eosinophilic Esophagitis**  Mucosal inflammation with eosinophils with submucosal fibrosis can be seen especially in pts with food allergies. This diagno-
sis relies on the presence of symptoms of esophagitis with the appropriate findings on esophageal biopsy. Eotaxin 3, an eosinophil chemokine, has been implicated in its etiology. Treatment involves a 12-week course of swallowed fluticasone (440 μg bid) using a metered-dose inhaler.

Other Causes of Esophagitis in AIDS  Mycobacteria, Cryptosporidium, Pneumocystis carinii, idiopathic esophageal ulcers, and giant ulcers (possible cytopathic effect of HIV) can occur. Ulcers may respond to systemic glucocorticoids.

For a more detailed discussion, see Goyal RK: Dysphagia, Chap. 38, p. 237; and Diseases of the Esophagus, Chap. 286, p. 1847, in HPIM-17.

53 Diarrhea, Constipation, and Malabsorption

NORMAL GASTROINTESTINAL FUNCTION

Absorption of Fluid and Electrolytes  Fluid delivery to the GI tract is 8–10 L/d, including 2 L/d ingested; most is absorbed in small bowel. Colonic absorption is normally 0.05–2 L/d, with capacity for 6 L/d if required. Intestinal water absorption passively follows active transport of Na⁺, Cl⁻, glucose, and bile salts. Additional transport mechanisms include Cl⁻/HCO₃⁻ exchange, Na⁺/H⁺ exchange, H⁺, K⁺, Cl⁻, and HCO₃⁻ secretion, Na⁺-glucose cotransport, and active Na⁺ transport across the basolateral membrane by Na⁺,K⁺-ATPase.

Nutrient Absorption
1. Proximal small intestine: iron, calcium, folate, fats (after hydrolysis of triglycerides to fatty acids by pancreatic lipase and colipase), proteins (after hydrolysis by pancreatic and intestinal peptidases), carbohydrates (after hydrolysis by amylases and disaccharidases); triglycerides absorbed as micelles after solubilization by bile salts; amino acids and dipeptides absorbed via specific carriers; sugars absorbed by active transport.
2. Distal small intestine: vitamin B₁₂, bile salts, water.

Intestinal Motility  Allows propulsion of intestinal contents from stomach to anus and separation of components to facilitate nutrient absorption. Propulsion is controlled by neural, myogenic, and hormonal mechanisms; mediated by migrating motor complex, an organized wave of neuromuscular activity that originates in the distal stomach during fasting and migrates slowly down the small intestine. Colonic motility is mediated by local peristalsis to propel feces. Defecation is effected by relaxation of internal anal sphincter in response to rectal distention, with voluntary control by contraction of external anal sphincter.
Inflammation, necrosis, and sloughing of colonic mucosa; may include component of secretory diarrhea due to prostaglandin release by inflammatory cells; stools usually contain polymorphonuclear leukocytes as well as occult or gross blood. Causes include bacterial infections (e.g., Campylobacter, Salmonella, Shigella, Yersinia), invasive or enterotoxigenic E. coli, Vibrio parahaemolyticus, Clostridium difficile colitis (frequently antibiotic-induced), colonic parasites (e.g., Entamoeba histolytica), Crohn’s disease, ulcerative proctocolitis, idiopathic inflammatory bowel disease, radiation enterocolitis, cancer chemotherapeutic agents, and intestinal ischemia.

Altered Intestinal Motility Alteration of coordinated control of intestinal propulsion; diarrhea often intermittent or alternating with constipation. Causes include diabetes mellitus, adrenal insufficiency, hyperthyroidism, collagen-vascular diseases, parasitic infestations, gastrin and VIP hypersecretory states, amylodosis, laxatives (esp. magnesium-containing agents), antibiotics (esp. erythromycin), cholinergic agents, primary neurologic dysfunction (e.g., Parkinson’s disease, traumatic neuropathy), fecal impaction, diverticular disease, and irritable bowel syndrome. Blood in intestinal lumen is cathartic, and major upper GI bleeding leads to diarrhea from increased motility.

Decreased Absorptive Surface Usually arises from surgical manipulation (e.g., extensive bowel resection or rearrangement) that leaves inadequate absorptive surface for fat and carbohydrate digestion and fluid and electrolyte absorption; occurs spontaneously from enteroenteric fistulas (esp. gastrocolic).

Evaluation History Diarrhea must be distinguished from fecal incontinence, change in stool caliber, rectal bleeding, and small, frequent, but otherwise nor-
Diarrhea, Constipation, and Malabsorption

CHAPTER 53

Diarrhea, Constipation, and Malabsorption

Normal stools. Careful medication history is essential. Alternating diarrhea and constipation suggests fixed colonic obstruction (e.g., from carcinoma) or irritable bowel syndrome. A sudden, acute course, often with nausea, vomiting, and fever, is typical of viral and bacterial infections, diverticulitis, ischemia, radiation enterocolitis, or drug-induced diarrhea and may be the initial presentation of inflammatory bowel disease. More than 90% of acute diarrheal illnesses are infectious in etiology. A longer (>4 weeks), more insidious course suggests malabsorption, inflammatory bowel disease, metabolic or endocrine disturbance, pancreatic insufficiency, laxative abuse, ischemia, neoplasm (hypersecretory state or partial obstruction), or irritable bowel syndrome. Parasitic and certain forms of bacterial enteritis can also produce chronic symptoms. Particularly foul-smelling or oily stool suggests fat malabsorption. Fecal impaction may cause apparent diarrhea because only liquids pass partial obstruction. Several infectious causes of diarrhea are associated with an immunocompromised state (Table 53-1).

Physical Examination Signs of dehydration are often prominent in severe, acute diarrhea. Fever and abdominal tenderness suggest infection or inflammatory disease but are often absent in viral enteritis. Evidence of malnutrition suggests chronic course. Certain signs are frequently associated with specific deficiency states secondary to malabsorption (e.g., cheilosis with riboflavin or iron deficiency, glossitis with B₁₂, folate deficiency). Questions to address in patients with chronic diarrhea are shown in Table 53-2.

### Table 53-1 Infectious Causes of Diarrhea in Patients with AIDS

<table>
<thead>
<tr>
<th>Nonopportunistic Pathogens</th>
<th>Opportunistic Pathogens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shigella</td>
<td>Protozoa</td>
</tr>
<tr>
<td>Salmonella</td>
<td>Cryptosporidium</td>
</tr>
<tr>
<td>Campylobacter</td>
<td>Isospora belli</td>
</tr>
<tr>
<td>Entamoeba histolytica</td>
<td>Microsporidia</td>
</tr>
<tr>
<td>Chlamydia</td>
<td>Blastocystis hominis</td>
</tr>
<tr>
<td>Neisseria gonorrhoeae</td>
<td>Viruses</td>
</tr>
<tr>
<td>Treponema pallidum and other spirochetes</td>
<td>Cytomegalovirus</td>
</tr>
<tr>
<td>Giardia lamblia</td>
<td>Herpes simplex</td>
</tr>
<tr>
<td></td>
<td>Adenovirus</td>
</tr>
<tr>
<td></td>
<td>HIV</td>
</tr>
<tr>
<td></td>
<td>Bacteria</td>
</tr>
<tr>
<td></td>
<td>Mycobacterium avium complex</td>
</tr>
</tbody>
</table>

### Table 53-2 Physical Examination in Patients with Chronic Diarrhea

1. Are there general features to suggest malabsorption or inflammatory bowel disease (IBD) such as anemia, dermatitis herpetiformis, edema, or clubbing?
2. Are there features to suggest underlying autonomic neuropathy or collagen-vascular disease in the pupils, orthostasis, skin, hands, or joints?
3. Is there an abdominal mass or tenderness?
4. Are there any abnormalities of rectal mucosa, rectal defects, or altered anal sphincter functions?
5. Are there any mucocutaneous manifestations of systemic disease such as dermatitis herpetiformis (celiac disease), erythema nodosum (ulcerative colitis), flushing (carcinoid), or oral ulcers for IBD or celiac disease?
**Stool Examination**  Culture for bacterial pathogens, examination for leukocytes, measurement of *C. difficile* toxin, and examination for ova and parasites are important components of evaluation of pts with severe, protracted, or bloody diarrhea. Presence of blood (fecal occult blood test) or leukocytes (Wright’s stain) suggests inflammation (e.g., ulcerative colitis, Crohn’s disease, infection, or ischemia). Gram’s stain of stool can be diagnostic of *Staphylococcus, Campylobacter*, or *Candida* infection. Gram’s stain of stool can be diagnostic of *Staphylococcus, Campylobacter*, or *Candida* infection. Steatorrhea (determined with Sudan III stain of stool sample or 72-h quantitative fecal fat analysis) suggests malabsorption or pancreatic insufficiency. Measurement of Na+ and K+ levels in fecal water helps to distinguish osmotic from other types of diarrhea; osmotic diarrhea is implied by stool osmolar gap > 40, where stool osmolar gap = osmol<sub>serum</sub> \[2 \times (\text{Na}^+ + \text{K}^+)\]<sub>stool</sub>.

**Laboratory Studies**  Complete blood count may indicate anemia (acute or chronic blood loss or malabsorption of iron, folate, or B<sub>12</sub>), leukocytosis (inflammation), eosinophilia (parasitic, neoplastic, and inflammatory bowel diseases). Serum levels of calcium, albumin, iron, cholesterol, folate, B<sub>12</sub>, vitamin D, and carotene; serum iron-binding capacity; and prothrombin time can provide evidence of intestinal malabsorption or malnutrition.

**Other Studies**  D-Xylose absorption test is a convenient screen for small-bowel absorptive function. Small-bowel biopsy is especially useful for evaluating intestinal malabsorption. Specialized studies include Schilling test (B<sub>12</sub> malabsorption), lactose H<sub>2</sub> breath test (carbohydrate malabsorption), [14C]xylose and lactulose H<sub>2</sub> breath tests (bacterial overgrowth), glycocholic breath test (ileal malabsorption), triolein breath test (fat malabsorption), and betaniomide and secretin tests (pancreatic insufficiency). Sigmoidoscopy or colonoscopy with biopsy is useful in the diagnosis of colitis (esp. pseudomembranous, ischemic, microscopic); it may not allow distinction between infectious and noninfectious (esp. idiopathic ulcerative) colitis. Barium contrast x-ray studies may suggest malabsorption (thickened bowel folds), inflammatory bowel disease (ileitis or colitis), tuberculosis (ileocecal inflammation), neoplasm, intestinal fistula, or motility disorders.

**Diarrhea**  An approach to the management of acute diarrheal illnesses is shown in Fig. 53-1. Symptomatic therapy includes vigorous rehydration (IV or with oral glucose-electrolyte solutions), electrolyte replacement, binders of osmotically active substances (e.g., kaolin-pectin), and opiates to decrease bowel motility (e.g., loperamide, diphenoxylate); opiates may be contraindicated in infectious or inflammatory causes of diarrhea. An approach to the management of chronic diarrhea is shown in Fig. 53-2.

**MALABSORPTION SYNDROMES**

Intestinal malabsorption of ingested nutrients may produce osmotic diarrhea, steatorrhea, or specific deficiencies (e.g., iron; folate; B<sub>12</sub>; vitamins A, D, E, and K). Table 53-3 lists common causes of intestinal malabsorption. Protein-losing enteropathy may result from several causes of malabsorption; it is associated with hypoalbuminemia and can be detected by measuring stool α<sub>1</sub>-antitrypsin or radiolabeled albumin levels. Therapy is directed at the underlying disease.
CONSTIPATION

Defined as decrease in frequency of stools to <1 per week or difficulty in defe-
cation; may result in abdominal pain, distention, and fecal impaction, with con-
sequent obstruction or, rarely, perforation. Constipation is a frequent and often
subjective complaint. Contributory factors may include inactivity, low-fiber di-
et, and inadequate allotment of time for defecation.

Specific Causes  Altered colonic motility due to neurologic dysfunction (dia-
abetes mellitus, spinal cord injury, multiple sclerosis, Chagas’ disease, Hirsch-
sprung’s disease, chronic idiopathic intestinal pseudoobstruction, idiopathic
megacolon), scleroderma, drugs (esp. anticholinergic agents, opiates, alumi-
num- or calcium-based antacids, calcium channel blockers, iron supplements,
sucralfate), hypothyroidism, Cushing’s syndrome, hypokalemia, hypercalce-
mia, dehydration, mechanical causes (colorectal tumors, diverticulitis, volvu-
Common Patient Presentations

SECTION 3

lus, hernias, intussusception), and anorectal pain (from fissures, hemorrhoids, abscesses, or proctitis) leading to retention, constipation, and fecal impaction.

**Constipation**

In absence of identifiable cause, constipation may improve with reassurance, exercise, increased dietary fiber, bulking agents (e.g., psyllium), and increased fluid intake. Specific therapies include removal of bowel obstruction (fecalith, tumor), discontinuance of nonessential hypomotility agents (esp. aluminum-

---

**FIGURE 53-2** Algorithm for the management of chronic diarrhea based on accompanying symptoms or features (A) or based on a limited screening for organic disease (B). p.r., per rectum; bm, bowel movement; IBS, irritable bowel syndrome; Hb, hemoglobin; Alb, albumin; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; OSM, osmolality. *(Reprinted from M Camilleri: Clin Gastro Hepatol. 2:198, 2004.)*
or calcium-containing antacids, opiates), or substitution of magnesium-based antacids for aluminum-based antacids. For symptomatic relief, magnesium-containing agents or other cathartics are occasionally needed. With severe hypo- or dysmotility or in presence of opiates, osmotically active agents (e.g., oral lactulose, intestinal polyethylene glycol–containing lavage solutions) and oral or rectal emollient laxatives (e.g., docusate salts) and mineral oil are most effective.

For a more detailed discussion, see Camilleri M, Murray JA: Diarrhea and Constipation, Chap. 40, p. 245; and Binder HJ: Disorders of Absorption, Chap. 288, p. 1872, in HPIM-17.

54 Gastrointestinal Bleeding

PRESENTATION

1. Hematemesis: Vomiting of blood or altered blood (“coffee grounds”) indicates bleeding proximal to ligament of Treitz.

2. Melena: Altered (black) blood per rectum (>100 mL blood required for one melemic stool) usually indicates bleeding proximal to ligament of Treitz but may be as distal as ascending colon; pseudomelena may be caused by ingestion of iron, bismuth, licorice, beets, blueberries, charcoal.
3. Hematochezia: Bright red or maroon rectal bleeding usually implies bleeding beyond ligament of Treitz but may be due to rapid upper GI bleeding (>1000 mL).

4. Positive fecal occult blood test with or without iron deficiency.

5. Symptoms of blood loss: e.g., light-headedness or shortness of breath.

**Hemodynamic Changes** Orthostatic drop in BP > 10 mmHg usually indicates >20% reduction in blood volume (± syncope, light-headedness, nausea, sweating, thirst).

**Shock** BP < 100 mmHg systolic usually indicates <30% reduction in blood volume (± pallor, cool skin).

**Laboratory Changes** Hematocrit may not reflect extent of blood loss because of delayed equilibration with extravascular fluid. Mild leukocytosis and thrombocytosis. Elevated blood urea nitrogen is common in upper GI bleeding.

**Adverse Prognostic Signs** Age >60, associated illnesses, coagulopathy, immunosuppression, presentation with shock, rebleeding, onset of bleeding in hospital, variceal bleeding, endoscopic stigmata of recent bleeding [e.g., “visible vessel” in ulcer base (see below)].

### UPPER GI BLEEDING

**Causes Common** Peptic ulcer (accounts for ~50%), gastropathy [alcohol, aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), stress], esophagitis, Mallory-Weiss tear (mucosal tear at gastroesophageal junction due to retching), gastroesophageal varices.

**Less Common** Swallowed blood (nosebleed); esophageal, gastric, or intestinal neoplasm; anticoagulant and fibrinolytic therapy; hypertrophic gastropathy (Ménétrier’s disease); aortic aneurysm; aortoenteric fistula (from aortic graft); arteriovenous malformation; telangiectases (Osler-Rendu-Weber syndrome); Dieulafoy lesion (ectatic submucosal vessel); vasculitis; connective tissue disease (pseudoxanthoma elasticum, Ehlers-Danlos syndrome); blood dyscrasias; neurofibroma; amyloidosis; hemobilia (biliary origin).

**Evaluation** After hemodynamic resuscitation (see below and Fig. 54-1).

- History and physical examination: Drugs (increased risk of upper and lower GI tract bleeding with aspirin and NSAIDs), prior ulcer, bleeding history, family history, features of cirrhosis or vasculitis, etc. Hyperactive bowel sounds favor upper GI source.
- Nasogastric aspirate for gross blood, if source (upper versus lower) not clear from history; may be falsely negative in up to 16% of pts if bleeding has ceased or duodenum is the source. Testing aspirate for occult blood is meaningless.
- Upper endoscopy: Accuracy >90%; allows visualization of bleeding site and possibility of therapeutic intervention; mandatory for suspected varices, aortoenteric fistulas; permits identification of “visible vessel” (protruding artery in ulcer crater), which connotes high (~50%) risk of rebleeding.
- Upper GI barium radiography: Accuracy ~80% in identifying a lesion, though does not confirm source of bleeding; acceptable alternative to endoscopy in resolved or chronic low-grade bleeding.
- Selective mesenteric arteriography: When brisk bleeding precludes identification of source at endoscopy.
• Radioisotope scanning (e.g., $^{99}$Tc tagged to red blood cells or albumin); used primarily as screening test to confirm bleeding is rapid enough for arteriography to be of value or when bleeding is intermittent and of unclear origin.

**LOWER GI BLEEDING**

**Causes**  Anal lesions (hemorrhoids, fissures), rectal trauma, proctitis, colitis (ulcerative colitis, Crohn’s disease, infectious colitis, ischemic colitis, radiation), colonic polyps, colonic carcinoma, angiodysplasia (vascular ectasia), diverticulosis, intussusception, solitary ulcer, blood dyscrasias, vasculitis, connective tissue disease, neurofibroma, amyloidosis, anticoagulation.
Common Patient Presentations

**Evaluation**  See below and Fig. 54-2.

- History and physical examination.
- In the presence of hemodynamic changes, perform upper endoscopy followed by colonoscopy. In the absence of hemodynamic changes, perform anoscopy and either flexible sigmoidoscopy or colonoscopy: Exclude hemorrhoids, fissure, ulcer, proctitis, neoplasm.
- Colonoscopy: Often test of choice, but may be impossible if bleeding is massive.
- Barium enema: No role in active bleeding.
- Arteriography: When bleeding is severe (requires bleeding rate >0.5 mL/min; may require prestudy radioisotope bleeding scan as above); defines site of bleeding or abnormal vasculature.
- Surgical exploration (last resort).

**Bleeding of Obscure Origin**  Often small-bowel source. Consider small-bowel enteroclysis x-ray (careful barium radiography via peroral intubation of small

---

**FIGURE 54-2**  Suggested algorithm for patients with acute lower GI bleeding. Sequential recommendations under “Hemodynamic instability” assume a test is found to be nondiagnostic before the next test is performed. *Some suggest colonoscopy for any degree of rectal bleeding in patients <40 years as well. †If massive bleeding does not allow time for colonic lavage, proceed to angiography. Tc-RBC, 99mtechnetium-labeled red blood cell.
Jaundice and Evaluation of Liver Function

CHAPTER 55

bowel), Meckel’s scan, enteroscopy (small-bowel endoscopy), or exploratory laparotomy with intraoperative enteroscopy.

**Upper and Lower GI Bleeding**

- Venous access with large-bore IV (14–18 gauge); central venous line for major bleed and pts with cardiac disease; monitor vital signs, urine output, Hct (fall may lag). Gastric lavage of unproven benefit but clears stomach before endoscopy. Iced saline may lyse clots; room-temperature tap water may be preferable. Intubation may be required to protect airway.
- Type and cross-match blood (6 units for major bleed).
- Surgical standby when bleeding is massive.
- Support blood pressure with isotonic fluids (normal saline); albumin and fresh-frozen plasma in cirrhotics. Packed red blood cells when available (whole blood if massive bleeding); maintain Hct >25–30. Fresh-frozen plasma and vitamin K (10 mg SC or IV) in cirrhotics with coagulopathy.
- IV calcium (e.g., up to 10–20 mL 10% calcium gluconate IV over 10–15 min) if serum calcium falls (due to transfusion of citrated blood). Empirical drug therapy (antacids, H2 receptor blockers, omeprazole) of unproven benefit.

- Specific measures:
  - **Varices**: octreotide (50-μg bolus, 50-μg/h infusion for 2–5 days), Blakemore-Sengstaken tube tamponade, endoscopic sclerosis, or band ligation; propranolol or nadolol in doses sufficient to cause beta blockade reduces risk of recurrent or initial variceal bleeding (do not use in acute bleed) (Chap. 164);
  - **ulcer with visible vessel or active bleeding**: endoscopic bipolar, heater-probe, or laser coagulation or injection of epinephrine; **gastritis**: embolization or vasopressin infusion of left gastric artery; **GI telangiectases**: ethinylestradiol/norethisterone (0.05/1.0 mg PO qd) may prevent recurrent bleeding, particularly in pts with chronic renal failure; **diverticulosis**: mesenteric arteriography with intraarterial vasopressin; **angiodysplasia**: colonoscopic bipolar or laser coagulation, may regress with replacement of stenotic aortic valve.
- Indications for emergency surgery: Uncontrolled or prolonged bleeding, severe reblooding, aortoenteric fistula. For intractable variceal bleeding, consider transjugular intrahepatic portosystemic shunt (TIPS).

For a more detailed discussion, see Laine L: Gastrointestinal Bleeding, Chap. 42, p. 257, in HPIM-17.

55 Jaundice and Evaluation of Liver Function

**JAUNDICE**

**Definition** Yellow skin pigmentation caused by elevation in serum bilirubin level (also termed icterus); often more easily discernible in sclerae. Scleral icterus becomes clinically evident at a serum bilirubin level of ≥51 μmol/L (≥3
mg/dL); yellow skin discoloration also occurs with elevated serum carotene levels but without pigmentation of the sclerae.

**Bilirubin Metabolism** Bilirubin is the major breakdown product of hemoglobin released from senescent erythrocytes. Initially, it is bound to albumin, transported into the liver, conjugated to a water-soluble form (glucuronide) by glucuronosyl transferase, excreted into the bile, and converted to urobilinogen in the colon. Urobilinogen is mostly excreted in the stool; a small portion is reabsorbed and excreted by the kidney. Bilirubin can be filtered by the kidney only in its conjugated form (measured as the “direct” fraction); thus, increased *direct* serum bilirubin level is associated with bilirubinuria. Increased bilirubin production and excretion (even without hyperbilirubinemia, as in hemolysis) produce elevated urinary urobilinogen levels.

**Etiology** Hyperbilirubinemia occurs as a result of (1) overproduction; (2) impaired uptake, conjugation, or excretion of bilirubin; (3) regurgitation of unconjugated or conjugated bilirubin from damaged hepatocytes or bile ducts (*Table 55-1*).

**Evaluation** The initial steps in evaluating the pt with jaundice are to determine whether (1) hyperbilirubinemia is conjugated or unconjugated, and (2) other biochemical liver tests are abnormal (*Figs. 55-1 and 55-2, Tables 55-2 and 55-3*). Essential clinical examination includes history (especially duration of jaundice, pruritus, associated pain, risk factors for parenterally transmitted diseases, medications, ethanol use, travel history, surgery, pregnancy, presence of any accompanying symptoms), physical examination (hepatomegaly, tenderness over liver, palpable gallbladder, splenomegaly, gynecomastia, testicular atrophy, other stigmata of chronic liver disease), blood liver tests (see below), and complete blood count.

---

**TABLE 55-1  CAUSES OF ISOLATED HYPERBILIRUBINEMIA**

I. Indirect hyperbilirubinemia  
   A. Hemolytic disorders  
      1. Inherited  
         a. Spherocytosis, elliptocytosis  
         b. Glucose-6-phosphate dehydrogenase and pyruvate kinase deficiencies  
         c. Sickle cell anemia  
      2. Acquired  
         a. Microangiopathic hemolytic anemias  
         b. Paroxysmal nocturnal hemoglobinuria  
         c. Spur cell anemia  
         d. Immune hemolysis  
   B. Ineffective erythropoiesis  
      1. Cobalamin, folate, thalassemia, and severe iron deficiencies  
   C. Drugs  
      1. Rifampicin, probenecid, ribavirin  
   D. Inherited conditions  
      1. Crigler-Najjar types I and II  
      2. Gilbert’s syndrome  

II. Direct hyperbilirubinemia  
   A. Inherited conditions  
      1. Dubin-Johnson syndrome  
      2. Rotor’s syndrome
Gilbert’s Syndrome  Impaired conjugation of bilirubin due to reduced bilirubin UDP glucuronosyl transferase activity. Results in mild unconjugated hyperbilirubinemia, almost always <103 μmol/L (<6 mg/dL). Affects 3–7% of the population; males/females 2–7:1.
**FIGURE 55-2** Algorithm for evaluation of abnormal liver tests.

**TABLE 55-2** HEPATOCELLULAR CONDITIONS THAT MAY PRODUCE JAUNDICE

<table>
<thead>
<tr>
<th>Hepatocellular Conditions</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral hepatitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Hepatitis A, B, C, D, and E</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epstein-Barr virus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytomegalovirus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herpes simplex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug toxicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Predictable, dose-dependent, e.g., acetaminophen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Unpredictable, idiosyncratic, e.g., isoniazid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Environmental toxins</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Vinyl chloride</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Jamaica bush tea—pyrrolizidine alkaloids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Kava Kava</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Wild mushrooms—<em>Amanita phalloides</em> or <em>A. verna</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wilson’s disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoimmune hepatitis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
BLOOD TESTS OF LIVER FUNCTION

Used to detect presence of liver disease (Fig. 55-2), discriminate among different types of liver disease (Table 55-4), gauge the extent of known liver damage, follow response to treatment.

Bilirubin Provides indication of hepatic uptake, metabolic (conjugation) and excretory functions; conjugated fraction (direct) distinguished from unconjugated by chemical assay (Table 55-1).

### TABLE 55-3 CHOLESTATIC CONDITIONS THAT MAY PRODUCE JAUNDICE

<table>
<thead>
<tr>
<th>Intrahepatic</th>
<th>Extrahepatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Viral hepatitis</td>
<td>A. Malignant</td>
</tr>
<tr>
<td>1. Fibrosing cholestatic hepatitis—hepatitis B and C</td>
<td>1. Cholangiocarcinoma</td>
</tr>
<tr>
<td>B. Alcoholic hepatitis</td>
<td>3. Gallbladder cancer</td>
</tr>
<tr>
<td>C. Drug toxicity</td>
<td>4. Ampullary cancer</td>
</tr>
<tr>
<td>1. Pure cholestasis—anabolic and contraceptive steroids</td>
<td>5. Malignant involvement of the porta hepatis lymph nodes</td>
</tr>
<tr>
<td>2. Cholestatic hepatitis—chlorpromazine, erythromycin estolate</td>
<td></td>
</tr>
</tbody>
</table>
Aminotransferases (Transaminases)  Aspartate aminotransferase (AST; SGOT) and alanine aminotransferase (ALT; SGPT); sensitive indicators of liver cell injury; greatest elevations seen in hepatocellular necrosis (e.g., viral hepatitis, toxic or ischemic liver injury, acute hepatic vein obstruction), occasionally with sudden, complete biliary obstruction (e.g., from gallstone); milder abnormalities in cholestatic, cirrhotic, and infiltrative disease; poor correlation between degree of liver cell damage and level of aminotransferases; ALT more specific measure of liver injury, since AST also found in striated muscle and other organs; ethanol-induced liver injury usually produces modest increases with more prominent elevation of AST than ALT.

Alkaline Phosphatase  Sensitive indicator of cholestasis, biliary obstruction (enzyme increases more quickly than serum bilirubin), and liver infiltration; mild elevations in other forms of liver disease; limited specificity because of wide tissue distribution; elevations also seen in normal childhood, pregnancy, and bone diseases; tissue-specific isoenzymes can be distinguished by fractionation or by differences in heat stability (liver enzyme activity stable under conditions that destroy bone enzyme activity).

5’-Nucleotidase (5’-NT)  Pattern of elevation in hepatobiliary disease similar to alkaline phosphatase; has greater specificity for liver disorders; used to determine whether liver is source of elevation in serum alkaline phosphatase, esp. in children, pregnant women, pts with possible concomitant bone disease.
Jaundice and Evaluation of Liver Function

CHAPTER 55

\(\gamma\)-Glutamyltranspeptidase (GGT)\) Correlates with serum alkaline phosphatase activity. Elevation is less specific for cholestasis than alkaline phosphatase or 5-NT.

**Coagulation Factors** (See also Chap. 68) Measure of clotting factor activity; prolongation results from clotting factor deficiency or inactivity; all clotting factors except factor VIII are synthesized in the liver, and deficiency can occur rapidly from widespread liver disease as in hepatitis, toxic injury, or cirrhosis; single best acute measure of hepatic synthetic function; helpful in Dx and prognosis of acute liver disease. Clotting factors II, VII, IX, X function only in the presence of the fat-soluble vitamin K; PT prolongation from fat malabsorption distinguished from hepatic disease by rapid and complete response to vitamin K replacement.

**Albumin** Decreased serum levels result from decreased hepatic synthesis (chronic liver disease or prolonged malnutrition) or excessive losses in urine or stool; insensitive indicator of acute hepatic dysfunction, since serum half-life is 2–3 weeks; in pts with chronic liver disease, degree of hypoalbuminemia correlates with severity of liver dysfunction.

**Globulin** Mild polyclonal hyperglobulinemia often seen in chronic liver diseases; marked elevation frequently seen in autoimmune chronic active hepatitis.

**Ammonia** Elevated blood levels result from deficiency of hepatic detoxification pathways and portal-systemic shunting, as in fulminant hepatitis, hepatotoxin exposure, and severe portal hypertension (e.g., from cirrhosis); elevation

<table>
<thead>
<tr>
<th>Alkaline Phosphatase</th>
<th>Albumin</th>
<th>Prothrombin Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Normal to &lt;3 times normal elevation</td>
<td>Normal</td>
<td>Usually normal. If &gt;5 × above control and not corrected by parenteral vitamin K, suggests poor prognosis</td>
</tr>
<tr>
<td>Normal to &lt;3 times normal elevation</td>
<td>Often decreased</td>
<td>Often prolonged Fails to correct with parenteral vitamin K</td>
</tr>
<tr>
<td>Normal to &lt;3 times normal elevation</td>
<td>Often decreased</td>
<td>Often prolonged Fails to correct with parenteral vitamin K</td>
</tr>
<tr>
<td>Elevated, often &gt;4 times normal elevation</td>
<td>Normal, unless chronic</td>
<td>Normal If prolonged, will correct with parenteral vitamin K</td>
</tr>
<tr>
<td>Elevated, often &gt;4 times normal elevation Fractionate, or confirm liver origin with 5’ nucleotide or (\gamma)glutamyl transpeptidase</td>
<td>Normal</td>
<td>Normal</td>
</tr>
</tbody>
</table>
of blood ammonia does not correlate well with hepatic function or the presence or degree of acute encephalopathy.

**HEPATOBILIARY IMAGING PROCEDURES**

**Ultrasonography (US)** Rapid, noninvasive examination of abdominal structures; no radiation exposure; relatively low cost, equipment portable; images and interpretation strongly dependent on expertise of examiner; particularly valuable for detecting biliary duct dilatation and gallbladder stones (>95%); much less sensitive for intraductal stones (~60%); most sensitive means of detecting ascites; moderately sensitive for detecting hepatic masses but excellent for discriminating solid from cystic structures; useful in directing percutaneous needle biopsies of suspicious lesions; Doppler US useful to determine patency and flow in portal, hepatic veins and portal-systemic shunts; imaging improved by presence of ascites but severely hindered by bowel gas; endoscopic US less affected by bowel gas and is sensitive for determination of depth of tumor invasion through bowel wall.

**CT** Particularly useful for detecting, differentiating, and directing percutaneous needle biopsy of abdominal masses, cysts, and lymphadenopathy; imaging enhanced by intestinal or intravenous contrast dye and unaffected by intestinal gas; somewhat less sensitive than US for detecting stones in gallbladder but more sensitive for cholelithiasis; may be useful in distinguishing certain forms of diffuse hepatic disease (e.g., fatty infiltration, iron overload).

**MRI** Most sensitive detection of hepatic masses and cysts; allows easy differentiation of hemangiomas from other hepatic tumors; most accurate noninvasive means of assessing hepatic and portal vein patency, vascular invasion by tumor; useful for monitoring iron, copper deposition in liver (e.g., in hemochromatosis, Wilson’s disease). Magnetic resonance cholangiography (MRCP) can be useful for visualizing the head of the pancreas and the pancreatic and biliary ducts.

**Radionuclide Scanning** Using various radiolabeled compounds, different scanning methods allow sensitive assessment of biliary excretion (HIDA, PIPIDA, DISIDA scans), parenchymal changes (technetium sulfur colloid liver/spleen scan), and selected inflammatory and neoplastic processes (gallium scan); HIDA and related scans particularly useful for assessing biliary patency and excluding acute cholecystitis in situations where US is not diagnostic; CT, MRI, and colloid scans have similar sensitivity for detecting liver tumors and metastases; CT and combination of colloidal liver and lung scans sensitive for detecting right subphrenic (suprahepatic) abscesses.

**Cholangiography** Most sensitive means of detecting biliary ductal calculi, biliary tumors, sclerosing cholangitis, choledochal cysts, fistulas, and bile duct leaks; may be performed via endoscopic (transampullary) or percutaneous (transhepatic) route; allows sampling of bile and ductal epithelium for cytologic analysis and culture; allows placement of biliary drainage catheter and stricture dilatation; endoscopic route (ERCP) permits manometric evaluation of sphincter of Oddi, sphincterotomy, and stone extraction.

**Angiography** Most accurate means of determining portal pressures and assessing patency and direction of flow in portal and hepatic veins; highly sensitive for detecting small vascular lesions and hepatic tumors (esp. primary hepatocellular carcinoma); “gold standard” for differentiating hemangiomas from solid tumors; most accurate means of studying vascular anatomy in preparation for complicated hepatobiliary surgery (e.g., portal-systemic shunting, biliary reconstruction).
and determining resectability of hepatobiliary and pancreatic tumors. Similar anatomic information (but not intravascular pressures) can often be obtained noninvasively by CT- and MR-based techniques.

**Percutaneous Liver Biopsy**  Most accurate in disorders causing diffuse changes throughout the liver; subject to sampling error in focal infiltrative disorders such as metastasis; should not be the initial procedure in the Dx of cholestasis.

---

**56 Ascites**

**DEFINITION**

Accumulation of fluid within the peritoneal cavity. Small amounts may be asymptomatic; increasing amounts cause abdominal distention and discomfort, anorexia, nausea, early satiety, heartburn, flank pain, and respiratory distress.

**DETECTION**

**Physical Examination**  Bulging flanks, fluid wave, shifting dullness, “puddle sign” (dullness over dependent abdomen with pt on hands and knees). May be associated with penile or scrotal edema, umbilical or inguinal herniation, pleural effusion. Evaluation should include rectal and pelvic examination, assessment of liver and spleen. Palmar erythema and spider angiomata seen in cirrhosis. Periumbilical nodule (*Sister Mary Joseph’s nodule*) suggests metastatic disease from a pelvic or GI tumor.

**Ultrasonography/CT**  Very sensitive; able to distinguish fluid from cystic masses.

**EVALUATION**

Diagnostic paracentesis (50–100 mL) essential. Routine evaluation includes gross inspection, protein, albumin, glucose, cell count and differential, Gram’s and acid-fast stains, culture, cytology; in selected cases check amylase, LDH, triglycerides, culture for tuberculosis (TB). Rarely, laparoscopy or even exploratory laparotomy may be required. Ascites due to CHF (e.g., pericardial constriction) may require evaluation by right-sided heart catheterization.

**Differential Diagnosis**  More than 90% of cases due to cirrhosis, neoplasm, CHF, TB.

* Diseases of peritoneum: Infections (bacterial, tuberculous, fungal, parasitic), neoplasms, connective tissue disease, miscellaneous (Whipple’s disease, familial Mediterranean fever, endometriosis, starch peritonitis, etc.).
Common Patient Presentations

Diseases not involving peritoneum: Cirrhosis, CHF, Budd-Chiari syndrome, hepatic venoocclusive disease, hypoalbuminemia (nephrotic syndrome, protein-losing enteropathy, malnutrition), miscellaneous (myxedema, ovarian diseases, pancreatic disease, chylous ascites).

Pathophysiologic Classification Using Serum-Ascites Albumin Gradient

Difference in albumin concentrations between serum and ascites as a reflection of imbalances in hydrostatic pressures:

1. Low gradient (serum-ascites albumin gradient < 1.1): 2° bacterial peritonitis, neoplasm, pancreatitis, vasculitis, nephrotic syndrome.
2. High gradient (serum-ascites albumin gradient > 1.1 suggests ascites is due to portal hypertension): cirrhosis, CHF, Budd-Chiari syndrome.

Representative Fluid Characteristics

See Table 56-1.

CIRRHTIC ASCITES

Pathogenesis

Contributing factors: (1) portal hypertension, (2) hypoalbuminemia, (3) hepatic lymph, (4) renal sodium retention—secondary to hyperaldosteronism, increased sympathetic nervous system activity (renin-angiotensin production). Initiating event may be peripheral arterial vasodilation triggered by endotoxin and cytokines and mediated by nitric oxide.

Cirrhotic Ascites

Maximum mobilization ~700 mL/d (peripheral edema may be mobilized faster).

1. Rigid salt restriction (<2 g Na/d).
2. For moderate ascites, diuretics usually necessary; spironolactone 100–200 mg/d PO (can be increased to 400–600 mg/d if low-sodium diet is confirmed and fluid not mobilized); furosemide 40–80 mg/d PO or IV may be added if necessary (greater risk of hepatorenal syndrome, encephalopathy), can increase to maximum of 120–160 mg/d until effect achieved or complication occurs.

If ascites is still present with the above measures this is defined as refractory ascites. Treatment modalities include:

1. Repeated large-volume paracentesis (5 L) with IV infusions of albumin (10 g/L ascites removed).
2. Consider transjugular intrahepatic portosystemic shunt (TIPS). While TIPS manages the ascites, it has not been found to improve survival and is often associated with encephalopathy.

Prognosis for pts with cirrhotic ascites is poor with <50% survival 2 years after onset of ascites. Consider liver transplantation in appropriate candidates with the onset of ascites (Chap. 163).

COMPLICATIONS

Spontaneous Bacterial Peritonitis

Suspect in cirrhotic pt with ascites and fever, abdominal pain, worsening ascites, ileus, hypotension, worsening jaundice, or encephalopathy; low ascitic protein concentration (low opsonic activity) is predisposing factor. Diagnosis suggested by ascitic fluid PMN cell count >250/μL; confirmed by positive culture (usually Escherichia coli and other gut bacte-
<table>
<thead>
<tr>
<th>Condition</th>
<th>Gross Appearance</th>
<th>Protein, g/L</th>
<th>Serum-Ascites Albumin Gradient, g/dL</th>
<th>Red Blood Cells, &gt;10,000/μL</th>
<th>White Blood Cells, per μL</th>
<th>Other Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cirrhosis</td>
<td>Straw-colored or bile-stained</td>
<td>&lt;25 (95%)</td>
<td>&gt;1.1</td>
<td>1%</td>
<td>&lt;250 (90%)&lt;sup&gt;a&lt;/sup&gt;; predominantly mesothelial</td>
<td></td>
</tr>
<tr>
<td>Neoplasm</td>
<td>Straw-colored, hemorrhagic, mucinous, or chylous</td>
<td>&gt;25 (75%)</td>
<td>&lt;1.1</td>
<td>20%</td>
<td>&gt;1000 (50%); variable cell types</td>
<td></td>
</tr>
<tr>
<td>Tuberculous peritonitis</td>
<td>Clear, turbid, hemorrhagic, chylous</td>
<td>&gt;25 (50%)</td>
<td>&lt;1.1</td>
<td>7%</td>
<td>&gt;1000 (70%); usually &gt;70% lymphocytes</td>
<td></td>
</tr>
<tr>
<td>Pyogenic peritonitis</td>
<td>Turbid or purulent</td>
<td>If purulent, &gt;25</td>
<td>&lt;1.1</td>
<td>Unusual</td>
<td>Predominantly polymorphonuclear leukocytes</td>
<td></td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>Straw-colored</td>
<td>Variable, 15–53</td>
<td>&gt;1.1</td>
<td>10%</td>
<td>&lt;1000 (90%); usually mesothelial, mononuclear</td>
<td></td>
</tr>
<tr>
<td>Nephrosis</td>
<td>Straw-colored or chylous</td>
<td>&lt;25 (100%)</td>
<td>&lt;1.1</td>
<td>Unusual</td>
<td>&lt;250; mesothelial, mononuclear</td>
<td></td>
</tr>
<tr>
<td>Pancreatic ascites</td>
<td>Turbid, hemorrhagic, or chylous</td>
<td>Variable, often &gt;25</td>
<td>&lt;1.1</td>
<td>Variable, may be blood-stained</td>
<td>Variable</td>
<td></td>
</tr>
<tr>
<td>(pancreatitis, pseudocyst)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Increased amylase in ascitic fluid and serum</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>Because the conditions of examining fluid and selecting patients were not identical in each series, the percentage figures (in parentheses) should be taken as an indication of the order of magnitude rather than as the precise incidence of any abnormal finding.
ria; however, gram-positive bacteria including *Streptococcus viridans*, *Staphylococcus aureus*, and *Enterococcus* spp. can also be found). Initial treatment: Cefotaxime 2 g IV q8h. Risk is increased in pts with variceal bleeding and prophylaxis against spontaneous bacterial peritonitis is recommended when a pt presents with upper GI bleeding.

**Hepatorenal Syndrome (HRS)**  
Functional renal failure without renal pathology; occurs in 10% of pts with advanced cirrhosis or acute liver failure. Thought to result from altered renal hemodynamics. Two types: type 1 HRS—decrease in renal function within 1–2 weeks of presentation; type 2 HRS—associated with a rise in serum creatinine but is associated with a better outcome. Often seen in pts with refractory ascites. Treatment: midodrine along with octreotide and IV albumin. For either type 1 or 2 HRS, prognosis is poor in the absence of liver transplantation.

For a more detailed discussion, see Glickman RM, Rajapaksa R: Abdominal Swelling and Ascites, Chap. 44, p. 266; and Bacon BR: Cirrhosis and Its Complications, Chap. 302, p. 1971, in HPIM-17.

## 57 Azotemia and Urinary Abnormalities

### ABNORMALITIES OF RENAL FUNCTION, AZOTEMIA

Azotemia is the retention of nitrogenous waste products excreted by the kidney. Increased levels of blood urea nitrogen (BUN) (>10.7 mmol/L (>30 mg/dL)) and creatinine (>133 μmol/L (>1.5 mg/dL)) are ordinarily indicative of impaired renal function. Renal function can be estimated by determining the clearance of creatinine (CL\textsubscript{cr}) (normal > 100 mL/min); this can be directly measured from a 24-h urine collection using the following equation:

\[
\text{Creatinine Clearance (mL/min)} = \frac{\text{uCr} \times \text{uV}}{\text{sCr} \times 1440}
\]

1. Where uCr is urine creatinine in mg/dL  
2. Where sCr is serum creatinine in mg/dL  
3. Where uV is 24-h urine volume in mL  
4. Where 1440 represents number of minutes in 24 h

The “adequacy” or “completeness” of the collection is estimated by the urinary volume and creatinine content; creatinine is produced from muscle and excreted at a relatively constant rate. For a 20- to 50-year-old man, creatinine excretion should be 18.5–25.0 mg/kg body weight; for a woman of the same age, it should be 16.5–22.4 mg/kg body weight. For example, an 80-kg man should excrete between ~1500 and 2000 mg of creatinine in an “adequate” collection. Creatinine excretion is also influenced by age and muscle mass. Notably, creatinine is an imperfect measure of glomerular filtration rate (GFR), since it is both filtered by glomeruli and secreted by proximal tubular cells; the relative contribution of tubular secretion increases with advancing renal dys-

<table>
<thead>
<tr>
<th>Kidney Damage Stage</th>
<th>Description</th>
<th>eGFR (mL/min per 1.73 m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>With risk factors for CKD&lt;sup&gt;a&lt;/sup&gt;</td>
<td>&gt;90</td>
</tr>
<tr>
<td>1</td>
<td>With evidence of kidney damage&lt;sup&gt;b&lt;/sup&gt;</td>
<td>&gt;90</td>
</tr>
<tr>
<td>2</td>
<td>Mild decrease in GFR</td>
<td>60–89</td>
</tr>
<tr>
<td>3</td>
<td>Moderate decrease in GFR</td>
<td>30–59</td>
</tr>
<tr>
<td>4</td>
<td>Severe decrease in GFR</td>
<td>15–29</td>
</tr>
<tr>
<td>5</td>
<td>Kidney failure</td>
<td>&lt;15</td>
</tr>
</tbody>
</table>

<sup>a</sup>Diabetes, high blood pressure, family history, older age, African ancestry.

<sup>b</sup>Abnormal urinalysis, hematuria, proteinuria, albuminuria.

**Note:** eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; GFR, glomerular filtration rate.

**AZOTEMIA**

![Diagram of azotemia and urinary abnormalities](From Denker BM, Brenner BM in HPIM-16.)

**FIGURE 57-1** Approach to the patient with azotemia. WBC, white blood cell; RBC, red blood cell; GBM, glomerular basement membrane. *(From Denker BM, Brenner BM in HPIM-16.)*
Common Patient Presentations

SECTION 3

function, such that creatinine clearance will provide an overestimate of the “true” GFR in pts with chronic kidney disease. Isotopic markers that are filtered and not secreted (e.g., iothalamate) provide more accurate estimates of GFR.

A formula that allows for an estimate of creatinine clearance in men that accounts for age-related decreases in GFR, body weight, and sex has been derived by Cockcroft-Gault:

\[
\text{Creatinine clearance (mL/min) } = \frac{(140 - \text{age}) \times \text{lean body weight (kg)}}{\text{plasma creatinine (mg/dL) \times 72}}
\]

This value should be multiplied by 0.85 for women.

GFR may also be estimated using serum creatinine–based equations derived from the Modification of Diet in Renal Disease Study. This “eGFR” is now reported with serum creatinine by most clinical laboratories in the United States and is the basis for the National Kidney Foundation classification of chronic kidney disease (Table 57-1).

Manifestations of impaired renal function include volume overload, hypertension, electrolyte abnormalities (e.g., hyperkalemia, hypocalcemia, hyperphosphatemia), metabolic acidosis, and hormonal disturbances (e.g., insulin resistance, functional vitamin D deficiency, secondary hyperparathyroidism). When severe, the symptom complex of “uremia” may develop, encompassing one or more of the following symptoms and signs: anorexia, dysgeusia, nausea, vomiting, lethargy, confusion, asterixis, pleuritis, pericarditis, enteritis, pruritus, sleep and taste disturbance, nitrogenous fetor.

An approach to the pt with azotemia is shown in Fig. 57-1.

**ABNORMALITIES OF URINE VOLUME**

**Oliguria** This refers to reduced urine output, usually defined as <400 mL/d. **Oligoanuria** refers to a more marked reduction in urine output, i.e., <100 mL/d. **Anuria** indicates the complete absence of urine output. Oliguria most often occurs in the setting of volume depletion and/or renal hypoperfusion, resulting in “prerenal azotemia” and acute renal failure (Chap. 146). Anuria can be caused by complete bilateral urinary tract obstruction; a vascular catastrophe (dissection or arterial occlusion); renal vein thrombosis; renal cortical necrosis; severe acute tubular necrosis; nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme (ACE) inhibitors, and/or angiotensin receptor blockers; and hypovolemic, cardiogenic, or septic shock. Oliguria is never normal, since at least

**TABLE 57-2** MAJOR CAUSES OF POLYURIA

<table>
<thead>
<tr>
<th>Excessive fluid intake</th>
<th>Nephrogenic diabetes insipidus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary polydipsia</td>
<td>Lithium exposure</td>
</tr>
<tr>
<td>Iatrogenic (IV fluids)</td>
<td>Urinary tract obstruction</td>
</tr>
<tr>
<td>Therapeutic</td>
<td>Papillary necrosis</td>
</tr>
<tr>
<td>Diuretic agents</td>
<td>Reflux nephropathy</td>
</tr>
<tr>
<td>Osmotic diuresis</td>
<td>Interstitial nephritis</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td>Hypercalcemia</td>
</tr>
<tr>
<td>Azotemia</td>
<td>Central diabetes insipidus</td>
</tr>
<tr>
<td>Mannitol</td>
<td>Tumor</td>
</tr>
<tr>
<td>Radiocontrast</td>
<td>Postoperative</td>
</tr>
<tr>
<td></td>
<td>Head trauma</td>
</tr>
<tr>
<td></td>
<td>Basilar meningitis</td>
</tr>
<tr>
<td></td>
<td>Neurosarcoidiosis</td>
</tr>
</tbody>
</table>

**TABLE 57-1** MAJOR CAUSES OF POLYURIA

<table>
<thead>
<tr>
<th>Major Causes of Polyuria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excessive fluid intake</td>
</tr>
<tr>
<td>Primary polydipsia</td>
</tr>
<tr>
<td>Iatrogenic (IV fluids)</td>
</tr>
<tr>
<td>Therapeutic</td>
</tr>
<tr>
<td>Diuretic agents</td>
</tr>
<tr>
<td>Osmotic diuresis</td>
</tr>
<tr>
<td>Hyperglycemia</td>
</tr>
<tr>
<td>Azotemia</td>
</tr>
<tr>
<td>Mannitol</td>
</tr>
<tr>
<td>Radiocontrast</td>
</tr>
</tbody>
</table>

**TABLE 57-2** MAJOR CAUSES OF POLYURIA

<table>
<thead>
<tr>
<th>Major Causes of Polyuria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excessive fluid intake</td>
</tr>
<tr>
<td>Primary polydipsia</td>
</tr>
<tr>
<td>Iatrogenic (IV fluids)</td>
</tr>
<tr>
<td>Therapeutic</td>
</tr>
<tr>
<td>Diuretic agents</td>
</tr>
<tr>
<td>Osmotic diuresis</td>
</tr>
<tr>
<td>Hyperglycemia</td>
</tr>
<tr>
<td>Azotemia</td>
</tr>
<tr>
<td>Mannitol</td>
</tr>
<tr>
<td>Radiocontrast</td>
</tr>
</tbody>
</table>

**TABLE 57-2** MAJOR CAUSES OF POLYURIA

<table>
<thead>
<tr>
<th>Major Causes of Polyuria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excessive fluid intake</td>
</tr>
<tr>
<td>Primary polydipsia</td>
</tr>
<tr>
<td>Iatrogenic (IV fluids)</td>
</tr>
<tr>
<td>Therapeutic</td>
</tr>
<tr>
<td>Diuretic agents</td>
</tr>
<tr>
<td>Osmotic diuresis</td>
</tr>
<tr>
<td>Hyperglycemia</td>
</tr>
<tr>
<td>Azotemia</td>
</tr>
<tr>
<td>Mannitol</td>
</tr>
<tr>
<td>Radiocontrast</td>
</tr>
</tbody>
</table>
Azotemia and Urinary Abnormalities

CHAPTER 57

400 mL of maximally concentrated urine must be produced to excrete the obli-
gate daily osmolar load.

Polyuria Polyuria is defined as a urine output >3 L/d. It is often accompanied
by nocturia and urinary frequency and must be differentiated from other more
common conditions associated with lower urinary tract pathology and urinary
urgency or frequency (e.g., cystitis, prostatism). It is often accompanied by hy-
pernatremia (Chap. 2). Polyuria (Table 57-2) can occur as a response to a sol-
ute load (e.g., hyperglycemia) or to an abnormality in arginine vasopressin
[AVP; also known as antidiuretic hormone (ADH)] action. Diabetes insipidus is
termed central if due to the insufficient hypothalamic production of AVP and
nephrogenic if the result of renal insensitivity to the action of AVP. Excess fluid
intake can lead to polyuria, but primary polydipsia rarely results in changes in plasma osmolality unless urinary diluting capacity is impaired. Tubulointerstitial diseases, lithium therapy, and resolving acute tubular necrosis or urinary tract obstruction can be associated with nephrogenic diabetes insipidus, which is more rarely caused by mutations in the V2 AVP receptor or the AVP-regulated water channel, aquaporin 2.

The approach to the pt with polyuria is shown in Fig. 57-2.

### ABNORMALITIES OF URINE COMPOSITION

#### Proteinuria

This is the hallmark of glomerular disease. Levels up to 150 mg/d are considered within normal limits. Typical measurements are semiquantitative, using a moderately sensitive dipstick that estimates protein concentration; therefore, the degree of hydration may influence the dipstick protein determination. Most commercially available urine dipsticks detect albumin and do not detect smaller proteins, such as light chains, that require testing with sulfosalicylic acid. More sensitive assays can in turn be used to detect microalbuminuria, an important screening tool for diabetic nephropathy. A urine albumin to creatinine ratio >30 mg/g defines the presence of microalbuminuria.

Formal assessment of urinary protein excretion requires a 24-h urine protein collection (see “Abnormalities of Renal Function, Azotemia,” above). The ratio of protein to creatinine in a random, “spot” urine can also provide a rough estimate of protein excretion; for example, a protein/creatinine ratio of 3.0 correlates to ~3.0 g of proteinuria per day.

Urinary protein excretion rates between 500 mg/d and 3 g/d are nonspecific and can be seen in a variety of renal diseases (including hypertensive nephrosclerosis, interstitial nephritis, vascular disease, and other primary renal diseases with little or no glomerular involvement). Transient, lesser degrees of proteinuria (500 mg/d to 1.5 g/d) may be seen after vigorous exercise, changes

### TABLE 57-3 MAJOR CAUSES OF HEMATURIA

<table>
<thead>
<tr>
<th>Lower Urinary Tract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial cystitis</td>
</tr>
<tr>
<td>Interstitial cystitis</td>
</tr>
<tr>
<td>Urethritis (infectious or inflammatory)</td>
</tr>
<tr>
<td>Passed or passing kidney stone</td>
</tr>
<tr>
<td>Transitional cell carcinoma of bladder or structures proximal to it</td>
</tr>
<tr>
<td>Squamous cell carcinoma of bladder (e.g., following schistosomiasis)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Upper Urinary Tract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal cell carcinoma</td>
</tr>
<tr>
<td>Age-related renal cysts</td>
</tr>
<tr>
<td>Other neoplasms (e.g., oncocytoma, hamartoma)</td>
</tr>
<tr>
<td>Acquired renal cystic disease</td>
</tr>
<tr>
<td>Congenital cystic disease, including autosomal dominant form</td>
</tr>
<tr>
<td>Glomerular diseases</td>
</tr>
<tr>
<td>Interstitial renal diseases, including interstitial nephritis</td>
</tr>
<tr>
<td>Nephrolithias</td>
</tr>
<tr>
<td>Pyelonephritis</td>
</tr>
<tr>
<td>Renal infarction</td>
</tr>
<tr>
<td>Hypercalciuria</td>
</tr>
<tr>
<td>Hyperuricosuria</td>
</tr>
</tbody>
</table>
in body position, fever, or congestive heart failure. Protein excretion rates >3 g/d are termed nephrotic range proteinuria in that they may be accompanied by hypalbuminemia, hypercholesterolemia, and edema (the nephrotic syndrome). Nephrotic syndrome can be associated with a variety of extrarenal complications (Chap. 150). Massive degrees of proteinuria (>10 g/d) can be seen with minimal change disease, primary focal segmental sclerosis (FSGS), membranous nephropathy, collapsing glomerulopathy (a subtype of primary FSGS), and HIV-associated nephropathy.

Pharmacologic inhibition of ACE or blockade of angiotensin II should be employed to reduce proteinuria; successful reduction of proteinuria decreases the rate of progression to end-stage renal disease in diabetic nephropathy and other glomerulopathies. Specific therapy for a variety of causes of nephrotic syndrome is discussed in Chap. 150.
Common Patient Presentations

**Hematuria**
Gross hematuria refers to the presence of frank blood in the urine and is more characteristic of lower urinary tract disease and/or bleeding diatheses than intrinsic renal disease (Table 57-3). Cyst rupture in polycystic kidney disease and postpharyngitic flares of IgA nephropathy are exceptions. Microscopic hematuria (>1–2 red blood cells (RBCs) per high-powered field) accompanied by proteinuria, hypertension, and an active urinary sediment (the “nephritic syndrome”) is most likely related to an inflammatory glomerulonephritis, classically poststreptococcal glomerulonephritis (Chap. 150).

Free hemoglobin and myoglobin are detected by dipstick; a negative urinary sediment with strongly heme-positive dipstick is characteristic of either hemolysis or rhabdomyolysis, which can be differentiated by clinical history and laboratory testing. RBC casts are not a sensitive finding but when seen are highly specific for glomerulonephritis. Specificity of urinalysis can be enhanced by examining urine with a phase contrast microscope capable of detecting dysmorphic red cells (“acanthocytes”) associated with glomerular disease.

The approach to the pt with hematuria is shown in Fig. 57-3.

**Pyuria**
This may accompany hematuria in inflammatory glomerular diseases. Isolated pyuria is most commonly observed in association with an infection of the upper or lower urinary tract. Pyuria may also occur with allergic interstitial nephritis (often with a preponderance of eosinophils), transplant rejection, and noninfectious, nonallergic tubulointerstitial diseases, including atheroembolic renal disease. The finding of “sterile” pyuria (i.e., urinary white blood cells without bacteria) in the appropriate clinical setting should raise suspicion of renal tuberculosis.

For a more detailed discussion, see Denker BM, Brenner BM: Azotemia and Urinary Abnormalities, Chap. 45, p. 268, in HPIM-17.

**58 Anemia and Polycythemia**

**ANEMIA**

According to World Health Organization criteria, anemia is defined as blood hemoglobin (Hb) concentration < 130 g/L (<13 g/dL) or hematocrit (Hct) < 39% in adult males; Hb < 120 g/L (<12 g/dL) or Hct < 37% in adult females.

Signs and symptoms of anemia are varied, depending on the level of anemia and the time course over which it developed. Acute anemia is nearly always due to blood loss or hemolysis. In acute blood loss, hypovolemia dominates the clinical picture; hypotension and decreased organ perfusion are the main issues. Symptoms associated with more chronic onset vary with the age of the pt and the adequacy of blood supply to critical organs. Moderate anemia is associated with fatigue, loss of stamina, breathlessness, and tachycardia. The pt’s skin and mucous membranes may appear pale. If the palmar creases are lighter in color than the surrounding skin with the fingers extended, Hb level is often <80 g/L (8 g/dL). In pts with coronary artery disease, anginal episodes may appear or
increase in frequency and severity. In pts with carotid artery disease, lightheadedness or dizziness may develop.

A physiologic approach to anemia diagnosis is based on the understanding that a decrease in circulating red blood cells (RBCs) can be related to either inadequate production of RBCs or increased RBC destruction or loss. Within the category of inadequate production, erythropoiesis can be either ineffective, due to an erythrocyte maturation defect (which usually results in RBCs that are too small or too large), or hypoproliferative (which usually results in RBCs of normal size, but too few of them).

Basic evaluations include (1) reticulocyte index (RI), and (2) review of blood smear and RBC indices [chiefly mean corpuscular volume (MCV)] (Fig. 58-1).

The RI is a measure of RBC production. The reticulocyte count is corrected for the Hct level and for early release of marrow reticulocytes into the circulation, which leads to an increase in the lifespan of the circulating reticulocyte beyond the usual 1 day. Thus, RI = (% reticulocytes × pt Hct/45%) × (1/shift correction factor). The shift correction factor varies with the Hct: 1.5 for Hct = 35%, 2 for Hct = 25%, 2.5 for Hct = 15%. RI < 2–2.5% implies inadequate RBC production for the particular level of anemia; RI > 2.5% implies excessive RBC destruction or loss.

---

**FIGURE 58-1** The physiologic classification of anemia. CBC, complete blood count.
If the anemia is associated with a low RI, RBC morphology helps distinguish a maturation disorder from hypoproliferative marrow states. Cytoplasmic maturation defects such as iron deficiency or Hb synthesis problems produce smaller RBCs, MCV < 80; nuclear maturation defects such as B12 and folate deficiency and drug effects produce larger RBCs, MCV > 100. In hypoproliferative marrow states, RBCs are generally normal in morphology but too few are produced. Bone marrow examination is often helpful in the evaluation of anemia but is done most frequently to diagnose hypoproliferative marrow states.

Other laboratory tests indicated to evaluate particular forms of anemia depend on the initial classification based on the pathophysiology of the defect. These are discussed in more detail in Chap. 66.

**POLYCYTHEMIA (ERYTHROCYTOSIS)**

This is an increase above the normal range of RBCs in the circulation. Concern that the Hb level may be abnormally high should be triggered at a level of 170 g/L (17 g/dL) in men and 150 g/L (15 g/dL) in women. Polycythemia is usually found incidentally at routine blood count. Relative erythrocytosis, due to plasma volume loss (e.g., severe dehydration, burns), does not represent a true in-
crease in total RBC mass. Absolute erythrocytosis is a true increase in total RBC mass.

**Causes**  Polycythemia vera (a clonal myeloproliferative disorder), erythropoietin-producing neoplasms (e.g., renal cancer, cerebellar hemangioma), chronic hypoxemia (e.g., high altitude, pulmonary disease), carboxyhemoglobin excess (e.g., smokers), high-affinity hemoglobin variants, Cushing’s syndrome, androgen excess. Polycythemia vera is distinguished from secondary polycythemia by the presence of splenomegaly, leukocytosis, thrombocytosis, and elevated vitamin B₁₂ levels, and by decreased erythropoietin levels. An approach to evaluate polycythemic pts is shown in Fig. 58-2.

**Complications**  Hyperviscosity (with diminished O₂ delivery) with risk of ischemic organ injury and thrombosis (venous or arterial) are most common.

<table>
<thead>
<tr>
<th><strong>Polycythemia</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Phlebotomy recommended for Hct ≥ 55%, regardless of cause, to low-normal range.</td>
</tr>
</tbody>
</table>

For a more detailed discussion, see Adamson JW, Longo DL: Anemia and Polycythemia, Chap. 58, p. 355, in HPIM-17.

**Lymphadenopathy and Splenomegaly**

**LYMPHADENOPATHY**

Exposure to antigen through a break in the skin or mucosa results in antigen being taken up by an antigen-presenting cell and carried via lymphatic channels to the nearest lymph node. Lymph channels course throughout the body except for the brain and the bones. Lymph enters the node through the afferent vessel and leaves through an efferent vessel. As antigen-presenting cells pass through lymph nodes, they present antigen to lymphocytes residing there. Lymphocytes in a node are constantly being replaced by antigen-naïve lymphocytes from the blood. They are retained in the node via special homing receptors. B cells populate the lymphoid follicles in the cortex; T cells populate the paracortical regions. When a B cell encounters an antigen to which its surface immunoglobulin can bind, it stays in the follicle for a few days and forms a germinal center where the immunoglobulin gene is mutated in an effort to make an antibody with higher affinity for the antigen. The B cell then migrates to the medullary region, differentiates into a plasma cell, and secretes immunoglobulin into the efferent lymph.

When a T cell in the node encounters an antigen it recognizes, it proliferates and joins the efferent lymph. The efferent lymph laden with antibodies and T cells specific for the inciting antigen passes through several nodes on its way to the thoracic duct, which drains lymph from most of the body. From the thoracic duct, lymph enters the bloodstream at the left subclavian vein. Lymph from the
head and neck and the right arm drain into the right subclavian vein. From the bloodstream, the antibody and T cells localize to the site of infection.

Lymphadenopathy may be caused by infections, immunologic diseases, malignancies, lipid storage diseases, or a number of disorders of uncertain etiology (e.g., sarcoidosis, Castleman’s disease; Table 59-1). The two major mechanisms of lymphadenopathy are hyperplasia, in response to immunologic or in-

**Table 59-1 DISEASES ASSOCIATED WITH LYMPHADENOPATHY**

1. Infectious diseases
   a. Viral—infectious mononucleosis syndromes (EBV, CMV), infectious hepatitis, herpes simplex, herpesvirus 6, varicella-zoster virus, rubella, measles, adenovirus, HIV, epidemic keratoconjunctivitis, vaccinia, herpesvirus 8
   b. Bacterial—streptococci, staphylococci, cat-scratch disease, brucellosis, tuberculosis, yersinia, plague, chancroid, melioidosis, glanders, tuberculosis, atypical mycobacterial infection, primary and secondary syphilis, diphtheria, leprosy
   c. Fungal—histoplasmosis, coccidioidomycosis, paracoccidioidomycosis
   d. Chlamydial—lymphogranuloma venereum, trachoma
   e. Parasitic—toxoplasmosis, leishmaniasis, trypanosomiasis, filariasis
   f. Rickettsial—scrub typhus, rickettsialpox
2. Immunologic diseases
   a. Rheumatoid arthritis
   b. Juvenile rheumatoid arthritis
   c. Mixed connective tissue disease
   d. Systemic lupus erythematosus
   e. Dermatomyositis
   f. Sjögren’s syndrome
   g. Serum sickness
   h. Drug hypersensitivity—diphenylhydantoin, hydralazine, allopurinol, primidone, gold, carbamazepine, etc.
   i. Angioimmunoblastic lymphadenopathy
   j. Primary biliary cirrhosis
   k. Graft-versus-host disease
   l. Silicone-associated
3. Malignant diseases
   a. Hematologic—Hodgkin’s disease, non-Hodgkin’s lymphomas, acute or chronic lymphocytic leukemia, hairy cell leukemia, malignant histiocytosis, amyloidosis
   b. Metastatic—from numerous primary sites
4. Lipid storage diseases—Gaucher’s, Niemann-Pick, Fabry, Tangier
5. Endocrine diseases—hyperthyroidism
6. Other disorders
   a. Castleman’s disease (giant lymph node hyperplasia)
   b. Sarcomas
   c. Dermatopathic lymphadenitis
   d. Lymphomatoid granulomatosis
   e. Histiocytic necrotizing lymphadenitis (Kikuchi’s disease)
   f. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease)
   g. Mucocutaneous lymph node syndrome (Kawasaki’s disease)
   h. Histiocytosis X
   i. Familial Mediterranean fever
   j. Severe hypertriglycerideremia
   k. Vascular transformation of sinuses
   l. Inflammatory pseudotumor of lymph node

*Note*: EBV, Epstein-Barr virus; CMV, cytomegalovirus.
fectious stimuli, and infiltration, by cancer cells or lipid- or glycoprotein-laden macrophages.

**APPROACH TO THE PATIENT: LYMPHADENOPATHY**

**HISTORY**

Age, occupation, animal exposures, sexual orientation, substance abuse history, medication history, and concomitant symptoms influence diagnostic workup. Adenopathy is more commonly malignant in origin in those over age 40. Farmers have an increased incidence of brucellosis and lymphoma. Male homosexuals may have AIDS-associated adenopathy. Alcohol and tobacco abuse increase risk of malignancy. Phenytoin may induce adenopathy. The concomitant presence of cervical adenopathy with sore throat or with fever, night sweats, and weight loss suggests particular diagnoses (mononucleosis in the former instance, Hodgkin’s disease in the latter).

**PHYSICAL EXAMINATION**

Location of adenopathy, size, node texture, and the presence of tenderness are important in differential diagnosis. Generalized adenopathy (three or more anatomic regions) implies systemic infection or lymphoma. Subclavian or scalene adenopathy is always abnormal and should be biopsied. Nodes > 4 cm should be biopsied immediately. Rock-hard nodes fixed to surrounding soft tissue are usually a sign of metastatic carcinoma. Tender nodes are most often benign.

**LABORATORY TESTS**

Usually lab tests are not required in the setting of localized adenopathy. If generalized adenopathy is noted, an excisional node biopsy should be performed for diagnosis, rather than a panoply of laboratory tests.

---

**Lymphadenopathy**

Pts over age 40, those with scalene or supraclavicular adenopathy, those with lymph nodes > 4 cm in diameter, and those with hard nontender nodes should undergo immediate excisional biopsy. In younger pts with smaller nodes that are rubbery in consistency or tender, a period of observation for 7–14 days is reasonable. Empirical antibiotics are not indicated. If the nodes shrink, no further evaluation is necessary. If they enlarge, excisional biopsy is indicated.

---

**SPLENOMEGALY**

Just as the lymph nodes are specialized to fight pathogens in the tissues, the spleen is the lymphoid organ specialized to fight bloodborne pathogens. It has no afferent lymphatics. The spleen has specialized areas like the lymph node for making antibodies (follicles) and amplifying antigen-specific T cells (periarteriolar lymphatic sheath, or PALS). In addition, it has a well-developed reticuloendothelial system for removing particles and antibody-coated bacteria. The flow of blood through the spleen permits it to filter pathogens from the blood and to maintain quality control over erythrocytes (RBCs)—those that are old and nondeformable are destroyed, and intracellular inclusions (sometimes including pathogens such as *Babesia* and *Plasmodium* are culled from the cells in
### TABLE 59-2  
**DISEASES ASSOCIATED WITH SPLENOMEGALY GROUPED BY PATHOGENIC MECHANISM**

#### Enlargement Due to Increased Demand for Splenic Function

- **Reticuloendothelial system hyperplasia** *(for removal of defective erythrocytes)*
  - Spherocytosis
  - Early sickle cell anemia
  - Ovalocytosis
  - Thalassemia major
  - Hemoglobinopathies
  - Paroxysmal nocturnal hemoglobinuria
  - Nutritional anemias

- **Immune hyperplasia**
  - Response to infection (viral, bacterial, fungal, parasitic)
    - Infectious mononucleosis
    - AIDS
    - Viral hepatitis
    - Cytomegalovirus
    - Subacute bacterial endocarditis
    - Bacterial septicemia
    - Congenital syphilis
    - Splenic abscess
    - Tuberculosis
    - Histoplasmosis
    - Malaria
    - Leishmaniasis
    - Trypanosomiasis
    - Ehrlichiosis

- **Disordered immunoregulation**
  - Rheumatoid arthritis (Felty’s syndrome)
  - Systemic lupus erythematosus
  - Collagen vascular diseases
  - Serum sickness
  - Immune hemolytic anemias
  - Immune thrombocytopenias
  - Immune neutropenias
  - Drug reactions
  - Angioimmunoblastic lymphadenopathy
  - Sarcoidosis
  - Thyrotoxicosis (benign lymphoid hypertrophy)
  - Interleukin 2 therapy

- **Extramedullary hematopoiesis**
  - Myelofibrosis
  - Marrow damage by toxins, radiation, strontium
  - Marrow infiltration by tumors, leukemias, Gaucher’s disease

#### Enlargement Due to Abnormal Splenic or Portal Blood Flow

- Cirrhosis
- Hepatic vein obstruction
- Portal vein obstruction, intrahepatic or extrahepatic
- Cavernous transformation of the portal vein
- Splenic vein obstruction
- Splenic artery aneurysm
- Hepatic schistosomiasis

(continued)
Lymphadenopathy and Splenomegaly

### CHAPTER 59

![Image](https://via.placeholder.com/150)

A process called pitting. Under certain conditions, the spleen can generate hematopoietic cells in place of the marrow.

The normal spleen is about 12 cm in length and 7 cm in width and is not normally palpable. Dullness from the spleen can be percussed between the ninth and eleventh ribs with the pt lying on the right side. Palpation is best performed with the pt supine with knees flexed. The spleen may be felt as it descends when the pt inspires. Physical diagnosis is not sensitive. CT or ultrasound are superior tests.

Spleen enlargement occurs by three basic mechanisms: (1) hyperplasia or hypertrophy due to an increase in demand for splenic function (e.g., hereditary spherocytosis where demand for removal of defective RBCs is high or immune hyperplasia in response to systemic infection or immune diseases); (2) passive vascular congestion due to portal hypertension; and (3) infiltration with malignant cells, lipid- or glycoprotein-laden macrophages, or amyloid (Table 59-2).

Massive enlargement, with spleen palpable >8 cm below the left costal margin, usually signifies a lymphoproliferative or myeloproliferative disorder.

Peripheral blood RBC count, white blood cell count, and platelet count may be normal, decreased, or increased depending on the underlying disorder. Decreases in one or more cell lineages could indicate hypersplenism, increased destruction. In cases with hypersplenism, the spleen is removed and the cytopenia is generally reversed. In the absence of hypersplenism, most causes of splenomegaly are diag-

<table>
<thead>
<tr>
<th>TABLE 59-2</th>
<th>DISEASES ASSOCIATED WITH SPLENOMEGALY GROUPED BY PATHOGENIC MECHANISM (CONTINUED)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infiltration of the Spleen</strong></td>
<td></td>
</tr>
<tr>
<td><em>Intracellular or extracellular depositions</em></td>
<td></td>
</tr>
<tr>
<td>Amyloidosis</td>
<td></td>
</tr>
<tr>
<td>Gaucher’s disease</td>
<td></td>
</tr>
<tr>
<td>Niemann-Pick disease</td>
<td></td>
</tr>
<tr>
<td>Tangier disease</td>
<td></td>
</tr>
<tr>
<td>Hurler’s syndrome and other mucopolysaccharidoses</td>
<td></td>
</tr>
<tr>
<td>Hyperlipidemias</td>
<td></td>
</tr>
<tr>
<td><em>Benign and malignant cellular infiltrations</em></td>
<td></td>
</tr>
<tr>
<td>Leukemias (acute, chronic, lymphoid, myeloid, monocytic)</td>
<td></td>
</tr>
<tr>
<td>Lymphomas</td>
<td></td>
</tr>
<tr>
<td>Hodgkin’s disease</td>
<td></td>
</tr>
<tr>
<td>Myeloproliferative syndromes (e.g., polycythemia vera)</td>
<td></td>
</tr>
<tr>
<td>Angiosarcomas</td>
<td></td>
</tr>
<tr>
<td>Metastatic tumors (melanoma is most common)</td>
<td></td>
</tr>
<tr>
<td>Eosinophilic granuloma</td>
<td></td>
</tr>
<tr>
<td>Histiocytosis X</td>
<td></td>
</tr>
<tr>
<td>Hamartomas</td>
<td></td>
</tr>
<tr>
<td>Hemangiomas, fibromas, lymphangiomas</td>
<td></td>
</tr>
<tr>
<td>Splenic cysts</td>
<td></td>
</tr>
<tr>
<td><strong>Unknown Etiology</strong></td>
<td></td>
</tr>
<tr>
<td>Idiopathic splenomegaly</td>
<td></td>
</tr>
<tr>
<td>Berylliosis</td>
<td></td>
</tr>
<tr>
<td>Iron-deficiency anemia</td>
<td></td>
</tr>
</tbody>
</table>

Congestive heart failure
Hepatic echinococcosis
Portal hypertension (any cause including the above): “Banti’s disease”
nosed on the basis of signs and symptoms and laboratory abnormalities associated with the underlying disorder. Splenectomy is rarely performed for diagnostic purposes.

Individuals who have had splenectomy are at increased risk of sepsis from a variety of organisms including pneumococcus and *Haemophilus influenzae*. Vaccines for these agents should be given before splenectomy is performed. Splenectomy compromises the immune response to these T-independent antigens.

For a more detailed discussion, see Henry PH, Longo DL: Enlargement of Lymph Nodes and Spleen, Chap. 60, p. 370, in HPIM-17.

### Generalized Fatigue

*Fatigue* is one of the most common complaints related by pts. It usually refers to nonspecific sense of a low energy level, or the feeling that near exhaustion is reached after relatively little exertion. Fatigue should be distinguished from true neurologic *weakness*, which describes a reduction in the normal power of one or more muscles (Chap. 42). It is not uncommon for pts, especially the elderly, to present with generalized failure to thrive, which may include components of fatigue and weakness, depending on the cause.

#### CLINICAL MANIFESTATIONS

Because the causes of generalized fatigue are numerous, a thorough history, review of systems (ROS), and physical examination are paramount to narrow the focus to likely causes. The history and ROS should focus on the temporal onset of fatigue and its progression. Has it lasted days, weeks, or months? Activities of daily living, exercise, sexual practices, and sleep habits should be reviewed. Features of depression or dementia should be sought. Travel history and possible exposures to infectious agents should be reviewed, along with the medication list. The ROS may elicit important clues as to organ system involvement. The past medical history may elucidate potential precursors to the current presentation, such as previous malignancy or cardiac problems. The physical exam should specifically assess lymphadenopathy, hepatosplenomegaly, abdominal masses, pallor, rash, heart failure, new murmurs, painful joints or trigger points, and evidence of weakness or neurologic abnormalities. A finding of true weakness or paralysis should prompt consideration of neurologic disorders (Chap. 42).

#### DIFFERENTIAL DIAGNOSIS

Determining the cause of fatigue can be one of the most challenging diagnostic problems in medicine because the differential diagnosis is very broad, including infection, malignancy, cardiac disease, endocrine disorders, neurologic disease, or serious abnormalities of virtually any organ system, as well as side effects of many medications (Table 60-1). Symptoms of fever and weight loss will focus attention on infectious causes, whereas symptoms of progressive...
dyspnea might point toward cardiac, pulmonary, or renal causes. A presentation that includes arthralgia suggests the possibility of a rheumatologic disorder. A previous malignancy, thought to be cured or in remission, may have recurred or metastasized widely. A previous history of valvular heart disease or cardiomyopathy may identify a condition that has decompensated. Treatment for Graves’ disease may have resulted in hypothyroidism. Changes in medication should always be pursued, whether discontinued or recently started. Almost any new medication has the potential to cause fatigue. However, a temporal association with a new medication should not eliminate other causes, as many patients may have received new medications in an effort to address their complaints. The time course for presentation is also valuable. Indolent presentations over months to years are more likely to be associated with slowly progressive organ failure or endocrinopathies, whereas a more rapid course over weeks to months suggests infection or malignancy.

**LABORATORY TESTING**

Laboratory testing and imaging should be guided by the history and physical exam. However, a CBC with differential, electrolytes, BUN, creatinine, glucose, calcium, and LFTs are useful in most pts with undifferentiated fatigue, as these tests will rule out many causes and may provide clues to unsuspected disorders. Similarly, a CXR is useful to evaluate many possible disorders rapidly, including heart failure, pulmonary disease, or occult malignancy that may be detected in the lungs or bony structures. Subsequent testing should be based on the initial re-
r

Common Patient Presentations

SECTION 3

sults and clinical assessment of the likely differential diagnoses. For example, a finding of anemia would dictate the need to assess whether it has features of iron deficiency or hemolysis, thereby narrowing potential causes. Hyponatremia might be caused by SIADH, hypothyroidism, adrenal insufficiency, or medications or by underlying cardiac, pulmonary, liver, or renal dysfunction. An elevated WBC count would raise the possibility of infection or malignancy. Thus, the approach is generally one of gathering information in a serial but cost-effective manner to narrow the differential diagnosis progressively.

Generalized Fatigue

Treatment should be based on the diagnosis, if known. Many conditions, such as metabolic, nutritional, or endocrine disorders, can be corrected quickly by appropriate treatment of the underlying causes. Specific treatment can also be initiated for many infections, such as TB, sinusitis, or endocarditis. Pts with chronic conditions such as COPD, heart failure, renal failure, or liver disease may benefit from interventions that enhance organ function or correct associated metabolic problems, and it may be possible to gradually improve physical conditioning. In patients with cancer, fatigue may be caused by chemotherapy or radiation and may resolve with time; treatment of associated anemia, nutritional deficiency, hyponatremia, or hypercalcemia may increase energy levels. Treatment of depression or sleep disorders, whether a primary cause of fatigue or secondary to a medical disorder, may be beneficial. Withdrawal of medications that potentially contribute to fatigue should be considered, recognizing that other medications may need to be substituted for the underlying condition.

CHRONIC FATIGUE SYNDROME

Chronic fatigue syndrome (CFS) is characterized by debilitating fatigue and several associated physical, constitutional, and neuropsychological complaints. Pts are twice as likely to be women as men and are generally 25–45 years old. The CDC has developed diagnostic criteria for CFS based upon symptoms and the exclusion of other illnesses (Table 60-2). The cause is uncertain, although

<table>
<thead>
<tr>
<th>TABLE 60-2</th>
<th>CDC® CRITERIA FOR DIAGNOSIS OF CHRONIC FATIGUE SYNDROME</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Clinically evaluated, unexplained, persistent or relapsing fatigue that is of new or definite onset; is not the result of ongoing exertion; is not alleviated by rest; and results in substantial reduction of previous levels of occupational, educational, social, or personal activities; and</td>
<td></td>
</tr>
<tr>
<td>2. Four or more of the following symptoms that persist or recur during six or more consecutive months of illness and that do not predate the fatigue:</td>
<td></td>
</tr>
<tr>
<td>• Self-reported impairment in short-term memory or concentration</td>
<td></td>
</tr>
<tr>
<td>• Sore throat</td>
<td></td>
</tr>
<tr>
<td>• Tender cervical or axillary nodes</td>
<td></td>
</tr>
<tr>
<td>• Muscle pain</td>
<td></td>
</tr>
<tr>
<td>• Multijoint pain without redness or swelling</td>
<td></td>
</tr>
<tr>
<td>• Headaches of a new pattern or severity</td>
<td></td>
</tr>
<tr>
<td>• Unrefreshing sleep</td>
<td></td>
</tr>
<tr>
<td>• Postexertional malaise lasting ≥24 h</td>
<td></td>
</tr>
</tbody>
</table>

*CDC, U.S. Centers for Disease Control and Prevention.  
clinical manifestations often follow a viral illness. Many studies have attempted, without success, to link CFS to infection with EBV, a retrovirus, or an enterovirus. Depression is present in half to two-thirds of pts, and some experts believe that CFS is fundamentally a psychiatric disorder.

CFS remains a diagnosis of exclusion, and no laboratory test can establish the diagnosis or measure its severity. Fortunately, CFS does not appear to progress. On the contrary, many pts experience gradual improvement, and a minority recover fully.

NSAIDs alleviate headache, diffuse pain, and feverishness. Antihistamines or decongestants may be helpful for symptoms of rhinitis and sinusitis. Although the pt may be averse to psychiatric diagnoses, features of depression and anxiety may justify treatment. Nonsedating antidepressants improve mood and disordered sleep and may attenuate the fatigue.

For a more detailed discussion, see Aminoff MJ: Weakness and Paralysis, Chap. 23, p. 147; Czeisler CA, Winkelman JW, Richardson GS: Sleep Disorders, Chap. 28, p. 171; Reife CM: Weight Loss, Chap. 41, p. 255; Straus SE: Chronic Fatigue Syndrome, Chap. 384, p. 2703; Reus VJ: Mental Disorders, Chap. 386, p. 2710, in HPIM-17.
This page intentionally left blank
SECTION 4 OPHTHALMOLOGY AND OTOLARYNGOLOGY

61 Common Disorders of Vision and Hearing

DISORDERS OF THE EYE

APPROACH TO THE PATIENT WITH EYE DISORDERS

The history and examination permit accurate diagnosis of most eye disorders, without need for laboratory or imaging studies. The essential ocular exam includes assessment of the visual acuity, pupil reactions, eye movements, eye alignment, visual fields, and intraocular pressure. The lids, conjunctiva, cornea, anterior chamber, iris, and lens are examined with a slit lamp. The fundus is viewed with an ophthalmoscope.

Acute visual loss or double vision in a pt with quiet, uninflamed eyes often signifies a serious ocular or neurologic disorder and should be managed emergently (Chap. 41). Ironically, the occurrence of a red eye, even if painful, has less dire implications as long as visual acuity is spared.

SPECIFIC DISORDERS

Red or Painful Eye  Common causes listed in Table 61-1.

Minor Trauma  This may result in corneal abrasion, subconjunctival hemorrhage, or foreign body. The integrity of the corneal epithelium is assessed by placing a drop of fluorescein in the eye and looking with a slit lamp (using cobalt-blue light) or a blue penlight. The conjunctival fornices should be searched carefully for foreign bodies by pulling the lower lid down and evertting the upper lid.

<table>
<thead>
<tr>
<th>TABLE 61-1  CAUSES OF A RED OR PAINFUL EYE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blunt or penetrating trauma</td>
</tr>
<tr>
<td>Chemical exposure</td>
</tr>
<tr>
<td>Corneal abrasion</td>
</tr>
<tr>
<td>Foreign body</td>
</tr>
<tr>
<td>Contact lens (overuse or infection)</td>
</tr>
<tr>
<td>Corneal exposure (5th, 7th nerve palsy, ectropion)</td>
</tr>
<tr>
<td>Subconjunctival hemorrhage</td>
</tr>
<tr>
<td>Blepharitis</td>
</tr>
<tr>
<td>Conjunctivitis (infectious or allergic)</td>
</tr>
<tr>
<td>Corneal ulcer</td>
</tr>
<tr>
<td>Herpes keratitis</td>
</tr>
<tr>
<td>Herpes zoster ophthalmicus</td>
</tr>
<tr>
<td>Keratoconjunctivitis sicca (dry eye)</td>
</tr>
</tbody>
</table>
Minor Trauma

Chemical splashes and foreign bodies are treated by copious saline irrigation. Corneal abrasions may require application of a topical antibiotic, a mydriatic agent (1% cyclopentolate), and an eye patch.

Infection

Infection of the eyelids and conjunctiva (blepharoconjunctivitis) produces redness and irritation but should not cause visual loss or pain. Adenovirus is the most common viral cause of “pink eye.” It produces a thin, watery discharge, whereas bacterial infection causes a more mucopurulent exudate. On slit-lamp exam one should confirm that the cornea is not affected, by observing that it remains clear and lustrous. Corneal infection (keratitis) is a more serious condition than blepharoconjunctivitis because it can cause scarring and permanent visual loss. Worldwide, the two leading causes of blindness from keratitis are trachoma from chlamydial infection and Vitamin A deficiency from malnutrition; in the United States, contact lenses play a major role. A dendritic pattern of corneal fluorescein staining is pathognomonic of herpes simplex keratitis but is seen in only a minority of cases.

Infection

Strict handwashing and broad-spectrum topical antibiotics for blepharoconjunctivitis (sulfacetamide 10%, polymyxin-bacitracin-neomycin, or trimethoprim-polymyxin). Keratitis requires empirical antibiotics (usually topical and subconjunctival) pending culture results from corneal scrapings. Herpes keratitis is treated with topical antiviral agents, cycloplegics, and oral acyclovir.

Inflammation

Eye inflammation, without infection, can produce episcleritis, scleritis, or uveitis (iritis or iridocyclitis). Most cases are idiopathic, but some occur in conjunction with autoimmune disease. There is no discharge. A ciliary flush results from injection of deep conjunctival and episcleral vessels near the corneal limbus. The diagnosis of uveitis hinges on the slit-lamp observation of inflammatory cells floating in the aqueous humor of the anterior chamber or deposited on the corneal endothelium (keratic precipitates).

Inflammation

Mydriatic agents (to reduce pain and prevent the formation of synechiae), NSAIDs, and topical glucocorticoids. (Note: prolonged treatment with ocular glucocorticoids can cause cataract and glaucoma).

Acute Angle-Closure Glaucoma

This is a rare but frequently misdiagnosed cause of a red, painful eye. Because the anterior chamber is shallow, aqueous outflow via the anterior chamber angle becomes blocked by the peripheral iris. Intraocular pressure rises abruptly, causing ocular pain, injection, corneal edema, obscurations, headache, nausea, and blurred vision. The key diagnostic step is measurement of the intraocular pressure during an attack.

Acute Angle-Closure Glaucoma

The acute attack is broken by constricting the pupil with a drop of pilocarpine and by lowering the intraocular pressure with acetazolamide (PO or IV), topi-
cal beta blockers, prostaglandin analogues, and \( \alpha_2 \)-adrenergic agonists. If these measures fail, laser therapy can be used to create a hole in the peripheral iris to relieve papillary block.

**Chronic Visual Loss**  Most common causes are listed in Table 61-2.

**Cataract**  A cloudy lens, due principally to aging. The formation of cataract occurs more rapidly in patients with a history of ocular trauma, uveitis, or diabetes mellitus. Radiation and glucocorticoid treatment can induce a cataract as a side effect. It is treated by surgical extraction and replacement with an artificial intraocular lens.

**Glaucoma**  An insidious optic neuropathy that leads to slowly progressive visual loss, usually associated with elevated intraocular pressure. Angle closure accounts for only a few cases; most pts have open angles and no identifiable cause for their pressure elevation. The diagnosis is made by documenting arcuate (nerve fiber bundle) scotomas on visual field exam, by observing “cupping” of the optic disc (Fig. 61-1), and measuring intraocular pressure.

**TABLE 61-2 CAUSES OF CHRONIC, PROGRESSIVE VISUAL LOSS**

<table>
<thead>
<tr>
<th>Cataract</th>
<th>Intraocular tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glaucoma</td>
<td>Retinitis pigmentosa</td>
</tr>
<tr>
<td>Macular degeneration</td>
<td>Epiretinal membrane</td>
</tr>
<tr>
<td>Diabetic retinopathy</td>
<td>Macular hole</td>
</tr>
<tr>
<td>Optic nerve or optic chiasm tumor</td>
<td></td>
</tr>
</tbody>
</table>

**FIGURE 61-1**  Glaucoma results in “cupping” as the neural rim is destroyed and the central cup becomes enlarged and excavated. The cup-to-disc ratio is about 0.7/1.0 in this patient. *(From JC Horton, in HPIM-17, p. 190.)*
Macular Degeneration

This occurs in both a “dry” and “wet” form. In the dry form, clumps of extracellular material, called drusen, are deposited beneath the retinal pigment epithelium (Fig. 61-2). As they accumulate, vision is slowly lost. In the wet form, neovascular proliferation occurs beneath the retinal pigment epithelium. Bleeding from these neovascular vessels can cause sudden, central visual loss in the elderly, although usually blurring of vision is more gradual. Macular exam shows drusen and subretinal hemorrhage.

Treatment with vitamins C and E, beta carotene, and zinc may retard dry macular degeneration. Wet macular degeneration can be treated with either photodynamic therapy or intraocular injection of vascular endothelial growth factor antagonists.

Diabetic Retinopathy

A leading cause of blindness in the United States. Appears in most pts 10–15 years after onset of diabetes. Background diabetic retinopathy consists of intraretinal hemorrhage, exudates, nerve fiber layer infarcts (cotton-wool spots), and macular edema. Proliferative diabetic retinopathy is characterized by ingrowth of neovascular vessels on the retinal surface, causing blindness from vitreous hemorrhage, retinal detachment, and glaucoma (Fig. 61-3).

All diabetics should be examined regularly by an ophthalmologist for surveillance of diabetic retinopathy. Macular edema is treated by focal or grid laser application. Neovascularization is treated by panretinal laser photocoagulation.

Tumors

Tumors of the optic nerve or chiasm are comparatively rare but often escape detection because they produce insidious visual loss and few physical findings, except for optic disc pallor. Pituitary tumor is the most common lesion. It causes bitemporal or monocular visual loss. Melanoma is the most common primary tumor of the eye itself.
Tumors

Large pituitary tumors producing chiasm compression are removed transphenoidally. In some cases, small tumors can be observed or controlled pharmacologically (e.g., bromocriptine for prolactinoma).

HEARING DISORDERS

Nearly 10% of the adult population has some hearing loss; up to one-third of individuals over the age of 65 have hearing loss of sufficient magnitude to require a hearing aid. Hearing loss can result from disorders of the auricle, external auditory canal, middle ear, inner ear, or central auditory pathways. In general, lesions in the auricle, external auditory canal, or middle ear cause conductive hearing losses, while lesions in the inner ear or eighth nerve cause sensorineural hearing losses.

APPROACH TO THE PATIENT WITH HEARING IMPAIRMENT

The goal is to determine (1) the nature of the hearing impairment (sensorineural vs. conductive vs. mixed), (2) the severity of the impairment, (3) the anatomy of the impairment, and (4) the etiology. Ascertain onset (sudden vs. insidious), progression (rapid vs. slow), and whether symptoms are unilateral or bilateral. Ask about tinnitus, vertigo, imbalance, aural fullness, otorrhea, headache, and facial or other cranial nerve symptoms. Prior head trauma, exposure to ototoxins, occupational or recreational noise exposure, or family history of hearing impairment also important.

Exam should include the auricle, external ear canal, and tympanic membrane. The external ear canal of the elderly is often dry and fragile; it is preferable to clean cerumen with wall-mounted suction and cerumen loops and to avoid irrigation. Inspect the nose, nasopharynx, cranial nerves, and upper respiratory tract. Unilateral serous effusion should prompt a fiberoptic exam of the nasopharynx to exclude neoplasm.
The Weber and Rinne tests differentiate conductive from sensorineural hearing losses. *Rinne test*: the tines of a vibrating tuning fork (512 Hz) are held near the opening of the external auditory canal, and then the stem is placed on the mastoid process. Normally, and with sensorineural hearing loss, air conduction is louder than bone conduction; however, with conductive hearing loss, bone conduction is louder. *Weber test*: the stem of a vibrating tuning fork is placed on the forehead in the midline. With a unilateral conductive hearing loss, the tone is perceived in the affected ear; with a unilateral sensorineural hearing loss, the tone is perceived in the unaffected ear.

**LABORATORY EVALUATION**

**Audiologic Assessment**  
*Pure tone audiometry* assesses hearing acuity for pure tones. Speech recognition requires greater synchronous neural firing than necessary for appreciation of pure tones; clarity of hearing is tested in *speech audiometry*. *Tympanometry* measures impedance of middle ear to sound; useful in diagnosis of middle-ear effusions. *Otoacoustic emissions* (OAE), measured with microphones inserted in external auditory canal, indicate that outer hair cells of the organ of Corti are intact; useful to assess auditory thresholds and distinguish sensory from neural hearing loss. *Electrocochleography* measures earliest evoked potentials generated in cochlea and auditory nerve; useful in diagnosis of Ménière’s disease. *Brainstem auditory evoked responses* (BAER) localize site of sensorineural hearing loss.

**Imaging Studies**  
CT of temporal bone with fine 1-mm cuts can define the caliber of the external auditory canal, integrity of the ossicular chain, presence of middle ear or mastoid disease, inner-ear malformations, and bone erosion (chronic otitis media and cholesteatoma). MRI superior to CT for imaging of retrocochlear structures including cerebellopontine angle (vestibular schwannoma) and brainstem.

**CAUSES OF HEARING LOSS**  
(Fig. 61-4)

**Conductive Hearing Loss**  
May result from obstruction of the external auditory canal by cerumen, debris, and foreign bodies; swelling of the lining of the canal; atresia of the ear canal; neoplasms of the canal; perforations of the tympanic membrane; disruption of the ossicular chain, as occurs with necrosis of the long process of the incus in trauma or infection; otosclerosis; and fluid, scarring, or neoplasms in the middle ear. Hearing loss with otorrhea most likely due to otitis media or cholesteatoma.

*Cholesteatoma*, i.e., stratified squamous epithelium in the middle ear or mastoid, is a benign, slowly growing lesion that destroys bone and normal ear tissue. A chronically draining ear that fails to respond to appropriate antibiotic therapy suggests cholesteatoma; surgery is required.

Conductive hearing loss with a normal ear canal and intact tympanic membrane suggests ossicular pathology. Fixation of the stapes from *otosclerosis* is a common cause of low-frequency conductive hearing loss; onset is between the late teens to the forties. In women, the hearing loss is often first noticeable during pregnancy. A hearing aid or a surgical stapedectomy can provide auditory rehabilitation.

*Eustachian tube dysfunction* is common and may predispose to acute otitis media (AOM) or serous otitis media (SOM). Trauma, AOM, or chronic otitis media are the usual factors responsible for tympanic membrane perforation.
FIGURE 61-4  An algorithm for the approach to hearing loss. HL, hearing loss; SNHL, sensorineural hearing loss; TM, tympanic membrane; SOM, serous otitis media; AOM, acute otitis media; *, CT scan of temporal bone; †, MRI scan. (From AK Lalwani, in HPIM-17, p. 201.)
While small perforations often heal spontaneously, larger defects usually require surgical tympanoplasty (>90% effective). Otoscopy is usually sufficient to diagnose AOM, SOM, chronic otitis media, cerumen impaction, tympanic membrane perforation, and eustachian tube dysfunction.

Sensorineural Hearing Loss Damage to hair cells of the organ of Corti may be caused by intense noise, viral infections, ototoxic drugs (e.g., salicylates, quinine and its analogues, aminoglycoside antibiotics, diuretics such as furosemide and ethacrynic acid, and chemotherapeutic agents such as cisplatin), fractures of the temporal bone, meningitis, cochlear otosclerosis, Ménière’s disease, and aging. Congenital malformations of the inner ear may cause hearing loss in some adults. Genetic predisposition alone or in concert with environmental influences may also be responsible.

Presbycusis (age-associated hearing loss) is the most common cause of sensorineural hearing loss in adults. In early stages, symmetric high frequency hearing loss is typical; with progression, the hearing loss involves all frequencies. The hearing impairment is associated with loss in clarity. Hearing aids provide limited rehabilitation; cochlear implants are treatment of choice for severe cases.

Ménière’s disease is characterized by episodic vertigo, fluctuating sensorineural hearing loss, tinnitus, and aural fullness. It is caused by an increase in endolymphatic fluid pressure due to endolymphatic sac dysfunction. Low-frequency, unilateral sensorineural hearing impairment is usually present. MRI should be obtained to exclude retrocochlear pathology such as cerebellopontine angle tumor or demyelinating disorder. Therapy directed toward control of vertigo; a low-salt diet, diuretics, a short course of glucocorticoids, and intratympanic gentamicin may be useful. For unresponsive cases, endolymphatic sac decompression, labyrinthectomy, and vestibular nerve section abolish rotatory vertigo. There is no effective therapy for hearing loss, tinnitus, or aural fullness.

Vestibular schwannomas present with asymmetric hearing impairment, tinnitus, imbalance (rarely vertigo); cranial neuropathy (trigeminal or facial nerve) may accompany larger tumors.

Sensorineural hearing loss may also result from any neoplastic, vascular, demyelinating, infectious (including HIV), or degenerative disease or trauma affecting the central auditory pathways.

Tinnitus Defined as the perception of a sound when there is no sound in the environment. It may have a buzzing, roaring, or ringing quality and may be pulsatile (synchronous with the heartbeat). Tinnitus is often associated with either a conductive or sensorineural hearing loss and may be the first symptom of a serious condition such as a vestibular schwannoma. Pulsatile tinnitus requires evaluation of the vascular system of the head to exclude vascular tumors such as glomus jugulare tumors, aneurysms, arteriovenous fistulae, and stenotic arterial lesions; it may also occur with SOM.

Tinnitus Treatment is problematic. Relief of the tinnitus may be obtained by masking it with background music. Hearing aids are also helpful in tinni-
tus suppression, as are tinnitus maskers, devices that present a sound to the af-
fected ear that is more pleasant to listen to than the tinnitus. Antidepressants 
have also shown some benefit.

Hard-of-hearing individuals often benefit from a reduction in unnecessary 
noise to enhance the signal-to-noise ratio. Speech comprehension is aided by 
lip-reading; the face of the speaker should be well-illuminated and easily seen.

**PREVENTION**

Conductive hearing losses may be prevented by prompt antibiotic therapy for 
acute otitis media and by ventilation of the middle ear with tympanostomy 
tubes in middle-ear effusions lasting ≥12 weeks. Loss of vestibular function and 
deafness due to aminoglycoside antibiotics can largely be prevented by moni-
toring of serum peak and trough levels.

Ten million Americans have noise-induced hearing loss, and 20 million are 
exposed to hazardous noise in their employment. Noise-induced hearing loss 
can be prevented by avoidance of exposure to loud noise or by regular use of 
ear plugs or fluid-filled muff s to attenuate intense sound.

For a more detailed discussion, see Horton JC: Disorders of the 
Eye, Chap. 29, p. 180; and Lalwani AK: Disorders of Smell, Taste, 
and Hearing, Chap. 30, p. 196, in HPIM-17.

### 62 Sinusitis, Pharyngitis, Otitis, and Other 
Upper Respiratory Infections

Upper respiratory tract infections (URIs) are common illnesses that are often 
treated with antibiotics even though bacteria cause only 25% of cases. Inappropri-
ate prescribing of antibiotics for URIs is a leading cause of antibiotic resistance in 
common community-acquired pathogens such as *Streptococcus pneumoniae*.

### NONSPECIFIC URIs

The “common cold” is an acute, mild, catarrhal syndrome that lasts ~1 week and 
is caused by a wide variety of viruses, including rhinoviruses, coronaviruses, 
parainfluenza viruses, influenza viruses, adenoviruses, and respiratory syncytial 
ivirus. Symptoms include rhinorrhea, nasal congestion, cough, sore throat, 
hoarseness, malaise, sneezing, and fever. Because secondary bacterial infection 
complicates only 0.5–2% of colds, antibiotics are not indicated. Only symptom-
based treatments should be used.

### SINUS INFECTIONS

Sinusitis is an inflammatory condition most commonly involving the maxillary 
sinus; the next most common sites are the ethmoid, frontal, and sphenoid sinuses.
ACUTE SINUSITIS

Etiology and Epidemiology  Acute sinusitis, defined as disease of <4 weeks’ duration, is usually caused by the same viruses that cause nonspecific URIs. S. pneumoniae, nontypable Haemophilus influenzae, and (in children) Moraxella catarrhalis cause acute bacterial sinusitis. Nosocomial cases, which are associated with nasotracheal intubation, are commonly caused by Staphylococcus aureus and gram-negative bacilli and are often polymicrobial and highly resistant to antibiotics. Acute fungal sinusitis occurs in compromised hosts (e.g., rhinocerebral mucormycosis in diabetic pts or aspergillosis in neutropenic pts).

Clinical Features  Common manifestations include nasal drainage, congestion, facial pain or pressure, headache, thick purulent nasal discharge, and tooth pain. Pain localizes to the involved sinus and is often worse when the pt bends over or is supine. Rarely, sphenoid or ethmoid sinusitis causes severe frontal or retroorbital pain, cavernous sinus thrombosis, and orbital cellulitis. Advanced frontal sinusitis can present as “Pott’s puffy tumor”: swelling and edema over the frontal bone. Life-threatening complications include meningitis, epidural abscess, and brain abscess.

Diagnosis  It is difficult to distinguish viral from bacterial sinusitis clinically. Disease of <7 days’ duration is considered viral. Of pts with symptoms of >7 days’ duration, 40–50% have bacterial sinusitis. If fungal sinusitis is a consideration, biopsies of involved areas should be performed. Nosocomial sinusitis should be confirmed with a CT scan of the sinuses.

Rx Acute Sinusitis

Most pts improve without therapy. Treatment to facilitate drainage (e.g., oral and topical decongestants) should be used. Pts without improvement or with severe disease at presentation should be given antibiotics. See Table 62-1 for recommended regimens for adults. (Regimens for children can be found in Table 31-1 in HPIM-17.) Lack of response may mandate surgical drainage or lavage. Surgery should be considered for pts with severe disease or intracranial complications. Extensive debridement is usually needed for invasive fungal sinusitis in immunocompromised pts. Nosocomial disease requires agents active against S. aureus and gram-negative bacilli, including Pseudomonas aeruginosa.

CHRONIC SINUSITIS

Sinusitis of >12 weeks’ duration is considered chronic.

• Chronic bacterial sinusitis: repeated infections due to impaired mucociliary clearance. Pts have constant nasal congestion and sinus pressure with periods of increased severity. Sinus CT scans can define the extent of disease and response to treatment. Tissue samples for histology and culture should be obtained to guide treatment. Repeated courses of antibiotics are required for 3–4 weeks at a time. Adjunctive treatments include intranasal administration of glucocorticoids, sinus irrigation, and surgical evaluation. Recurrence is common.

• Chronic fungal sinusitis: a noninvasive disease in immunocompetent hosts. Mild, indolent disease is usually curable without antifungal agents by endoscopic surgery. Unilateral disease with a mycetoma within the sinus (fungus ball) is treated with surgery and—if bony erosion has occurred—antifungal agents. Allergic fungal sinusitis is seen in pts with nasal polyps and asthma.
**TABLE 62-1**

GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF SELECTED UPPPER RESPIRATORY TRACT INFECTIONS IN ADULTS

<table>
<thead>
<tr>
<th>Syndrome, Diagnostic Criteria</th>
<th>Treatment Recommendations</th>
</tr>
</thead>
</table>
| **Acute sinusitis**<sup>b</sup>  
Moderate symptoms (e.g., nasal purulence/congestion or cough) for >7 d or  
Severe symptoms of any duration, including unilateral/focal facial swelling or tooth pain | **Initial therapy**  
Amoxicillin, 500 mg PO tid or 875 mg PO bid, or  
TMP-SMX, 1 DS tablet PO bid for 10–14 d  
**Exposure to antibiotics within 30 d or >30% prevalence of penicillin-resistant S. pneumoniae**  
Amoxicillin, 1000 mg PO tid, or  
Amoxicillin/clavulanate (extended release), 2000 mg PO bid, or  
Antipneumococcal fluoroquinolone (e.g., levofloxacin, 500 mg PO qd)  
**Recent treatment failure**<sup>d</sup>  
Amoxicillin/clavulanate (extended release), 2000 mg PO bid, or  
Amoxicillin, 1500 mg bid, plus clindamycin, 300 mg PO qid, or  
Antipneumococcal fluoroquinolone (e.g., levofloxacin, 500 mg PO qd) |
| **Acute otitis media**<sup>c</sup>  
Fluid in the middle ear, evidenced by decreased tympanic membrane mobility, air/liquid level behind tympanic membrane, bulging tympanic membrane, purulent otorrhea; and  
Acute onset of signs and symptoms of middle-ear inflammation, including fever, otalgia, decreased hearing, tinnitus, vertigo, erythematous tympanic membrane | **Initial therapy**  
Observation alone (symptom relief only) or  
Amoxicillin, 80–90 mg/kg qd (up to 2 g) PO in divided doses (bid or tid), or  
Cefdinir, 14 mg/kg qd PO in 1 dose or divided doses (bid), or  
Cefuroxime, 30 mg/kg qd PO in divided doses (bid), or  
Azithromycin, 10 mg/kg qd PO on day 1 followed by 5 mg/kg qd PO for 4 d  
**Antibiotic exposure within 30 d,<sup>c,d</sup> recent treatment failure,<sup>c,d</sup> or severe disease<sup>c,e</sup>**  
Amoxicillin, 90 mg/kg qd (up to 2 g) PO in divided doses (bid), plus clavulanate, 6.4 mg/kg qd PO in divided doses (bid), or  
Ceftriaxone, 50 mg/kg IV/IM qd for 3 d, or  
Clindamycin, 30–40 mg/kg qd PO in divided doses (tid) or  
Consider tympanocentesis with culture |

(continued)
INFECTIONS OF THE EAR AND MASTOID

EXTERNAL EAR INFECTIONS

Consider noninfectious causes of inflammation—such as trauma, insect bite, autoimmune diseases (e.g., lupus), and vasculitides (e.g., Wegener’s granulomatosis)—especially in the absence of local or regional adenopathy.

- **Auricular cellulitis:** Tenderness, erythema, and swelling of the external ear, particularly the lobule, follow minor trauma. Treat with warm compresses, and give antibiotics active against *S. aureus* and streptococci (e.g., dicloxacillin).
- **Perichondritis:** Infection of the perichondrium of the auricular cartilage follows minor trauma (e.g., ear piercing). Treatment should be directed at the most common etiologic agents, *P. aeruginosa* and *S. aureus*, and may consist of an antipseudomonal penicillin or a penicillinase-resistant penicillin (e.g., nafcillin) plus an antipseudomonal quinolone (e.g., ciprofloxacin). Surgical drainage may be needed; resolution can take weeks. If perichondritis fails to respond to adequate therapy, consider noninfectious inflammatory etiologies.
- **Otitis externa**
  1. **Acute localized otitis externa,** furunculosis in the outer third of the ear canal, is usually due to *S. aureus*.
  2. **Acute diffuse otitis externa** is known as “swimmer’s ear.” *P. aeruginosa* or other gram-negative or gram-positive bacteria cause infection in macerated, irritated canals. Pts have severe pain, erythema and swelling of...
the canal and white clumpy discharge from the ear. Treatment includes cleansing of the canal and use of topical antibiotics (e.g., preparations with neomycin and polymyxin), with or without glucocorticoids to reduce inflammation.

3. **Chronic otitis externa** usually arises from persistent drainage from a chronic middle-ear infection, repeated irritation, or rare chronic infections such as tuberculosis or leprosy. Pts have pruritus rather than pain.

4. **Malignant or necrotizing otitis externa** is an aggressive, potentially life-threatening disease occurring primarily in elderly diabetic or immunocompromised pts. The disease progresses over weeks to months. Severe otalgia and purulent otorrhoea and erythema of the ear and canal are evident. On exam, granulation tissue in the posteroinferior wall of the canal, near the junction of bone and cartilage, is seen. Untreated, this condition has a high mortality rate and can involve the base of the skull, meninges, cranial nerves, and brain. *P. aeruginosa* is the most common etiologic agent, but other gram-negative bacilli, *S. aureus*, *Staphylococcus epidermidis*, and *Aspergillus* can also cause the disease. Biopsy should be performed for diagnostic purposes. IV antipseudomonal agents (e.g., piperacillin, ceftazidime) with an aminoglycoside or fluoroquinolone plus antibiotic drops active against *Pseudomonas* should be given along with glucocorticoids.

### MIDDLE EAR INFECTIONS

Eustachian tube dysfunction, often in association with URIs, causes sterile inflammation. Infection results when viral or bacterial superinfection occurs.

- **Acute otitis media**: A viral URI can cause otitis media or predispose to bacterial otitis media. *S. pneumoniae* is the most common bacterial cause; next in frequency are nontypable *H. influenzae* and *M. catarrhalis*. Concern is increasing about community-acquired methicillin-resistant *S. aureus* (MRSA) as an emerging etiologic agent. Pts have fluid in the middle ear. The tympanic membrane is immobile, erythematous, and bulging or retracted and can perforate spontaneously. Other findings include otalgia, otorrhoea, decreased hearing, fever, and irritability. Pts with mild to moderate disease will do well if given analgesic and anti-inflammatory agents initially, with antibiotics reserved for pts who do not improve in 2–3 days. Most cases resolve within 1 week without treatment. Amoxicillin remains the drug of choice, despite rising antibiotic resistance. See Table 62-1 for treatment options. (Regimens for children can be found in Table 31-2 in HPIM-17.)

- **Serous otitis media**: Otitis media with effusion can persist for months without signs of infection. Antibiotic therapy or myringotomy with tympanostomy tubes is reserved for pts with bilateral effusions that have persisted for at least 3 months and are associated with bilateral hearing loss.

- **Chronic otitis media**: persistent or recurrent purulent otorrhoea with tympanic membrane perforation. Active disease may lead to erosion of bone, meningitis, and brain abscess and is treated surgically. Inactive disease is treated with repeated courses of topical antibiotic drops during periods of drainage.

- **Mastoiditis** has been uncommon in the antibiotic era. Mastoid air cells connect with the middle ear, and purulent exudates can cause erosion of surrounding bone and abscess-like cavities. Pts have pain, erythema, and mastoid process swelling along with the signs and symptoms of otitis media. Rare complications include subperiosteal abscess, deep neck abscess, and septic thrombosis of the lateral sinus. Cultures should be performed and used to direct therapy.
INFECTIONS OF THE PHARYNX AND ORAL CAVITY

ACUTE PHARYNGITIS

- **Viral:** Respiratory viruses typically cause mild disease associated with nonspecific URI symptoms, tender cervical adenopathy, and minimal fever. Influenza virus and adenovirus can cause severe exudative pharyngitis with fever. Herpes simplex virus (HSV) causes pharyngeal inflammation and exudes with vesicles and ulcers on the palate. Coxsackievirus A causes small vesicles on the soft palate and uvula that form shallow white ulcers. Epstein-Barr virus and cytomegalovirus cause exudative pharyngitis in association with other signs of infectious mononucleosis. HIV causes fever, myalgias, malaise, and sometimes a maculopapular rash.

- **Bacterial:** Group A Streptococcus (GAS) accounts for ~5–15% of cases of pharyngitis in adults but is primarily a disease of children 5–15 years old. Other bacterial causes include streptococci of groups C and G, Neisseria gonorrhoeae, Corynebacterium diphtheriae, and anaerobic bacteria. Streptococcal pharyngitis ranges from mild disease to profound pharyngeal pain, fever, chills, abdominal pain, and a hyperemic pharyngeal membrane with tonsillar hypertrophy and exudates. Coryzal symptoms are absent. The diagnosis is made by rapid antigen-detection testing for GAS. Most experts recommend that children have a throat culture performed if rapid testing is negative, but this course is not recommended for adults because of the low incidence of disease. For treatment options in adults, see Table 62-1 and Chap. 94. (Regimens for children can be found in Table 31-3 in HPIM-17.)

ORAL INFECTIONS

Oral-labial herpesvirus infections and oral thrush caused by Candida are discussed in Chaps. 106 and 113, respectively.

INFECTIONS OF THE LARYNX AND EPIGLOTTIS

- **Laryngitis:** a common syndrome caused by nearly all the major respiratory viruses and only rarely by bacteria (e.g., GAS, C. diphtheriae, and M. catarrhalis). Pts are hoarse, exhibit reduced vocal pitch or aphonia, and have coryzal symptoms. Treatment consists of humidification, voice rest, and—if GAS is cultured—antibiotic administration.

- **Croup:** viral disease marked by swelling of the subglottic region and primarily affecting children <6 years old

- **Epiglottitis:** acute, rapidly progressive cellulitis of the epiglottis and adjacent structures. Vaccination against H. influenzae type b has reduced disease rates among children by >90%, but the incidence among adults is stable. Epiglottitis in adults is caused by GAS, S. pneumoniae, Haemophilus parainfluenzae, and S. aureus. Symptoms include fever, severe sore throat, and systemic toxicity, and pts sometimes drool while sitting forward. Signs of respiratory obstruction may develop and progress rapidly. Adolescents and adults have less acute presentations than children. Examination may reveal respiratory distress, inspiratory stridor, and chest wall retractions. Direct fiberoptic laryngoscopy in a controlled environment (e.g., an operating room) may be performed for diagnosis, procurement of specimens for culture, and placement of an endotracheal tube. Treatment focuses on protection of the airway. Blood and, in some cases, the epiglottis should be cultured; after samples are obtained, IV antibiotics active against H. influen-
**INFECTIONS OF DEEP NECK STRUCTURES**

These infections, which include Ludwig’s angina, Lemierre’s syndrome, and retropharyngeal abscess, are discussed in Chap. 99.

For a more detailed discussion, see Rubin MA et al: Pharyngitis, Sinusitis, Otitis, and Other Upper Respiratory Tract Infections, Chap. 31, p. 205, in HPIM-17.
As dermatologic evaluation relies heavily on the objective cutaneous appearance, physical examination is often performed prior to taking a complete history in pts presenting with a skin problem. A differential diagnosis can usually be generated on the basis of a thorough examination with precise descriptions of the skin lesion(s) and narrowed with pertinent facts from the history. Laboratory or diagnostic procedures are then used, when appropriate, to clarify the diagnosis.

**PHYSICAL EXAMINATION**

Examination of skin should take place in a well-illuminated room with pt completely disrobed. Helpful ancillary equipment includes a hand lens and a pocket flashlight to provide peripheral illumination of lesions. An ideal examination includes evaluation of the skin, hair, nails and mucous membranes. The examination often begins with an assessment of the entire skin viewed at a distance, which is then narrowed down to focus on the individual lesions.

**Distribution**  As illustrated in Fig. 63-1, the distribution of skin lesions can provide valuable clues to the identification of the disorder: Generalized (systemic diseases); sun-exposed (SLE, photoallergic, phototoxic, polymorphous light eruption, porphyria cutanea tarda); dermatomal (herpes zoster); extensor surfaces (elbows and knees in psoriasis); flexural surfaces (antecubital and popliteal fossae in atopic dermatitis).

**Arrangement and Shape**  Can describe individual or multiple lesions: *Linear* (contact dermatitis such as poison ivy); *annular*—“ring-shaped” lesion (erythema chronicum migrans, erythema annulare centrificum, tinea corporis); *iris* or *target lesion*—two or three concentric circles of differing hue (erythema multiforme); *nummular*—“coin-shaped” (nummular eczema); *morbilliform*—“measles-like” with small confluent papules coalescing into unusual shapes (measles, drug eruption); *herpetiform*—grouped vesicles, papules, or erosions (herpes simplex).

**Primary Lesions**  Cutaneous changes caused directly by disease process (Table 63-1).

**Secondary Lesions**  Changes in area of primary pathology often due to secondary events, e.g., scratching, secondary infection, bleeding (Table 63-2).

**Other Descriptive Terms**  Color, e.g., violaceous, erythematous; physical characteristics, e.g., warm, tender; sharpness of edge, surface contour—flat-topped, pedunculated (on a stalk), verrucous (wartlike), umbilicated (containing a central depression).
A complete history should be obtained, with special attention being paid to the following points:

1. Evolution of the lesion—site of onset, manner in which eruption progressed or spread, duration, periods of resolution or improvement in chronic eruptions
2. Symptoms associated with the eruption—itching, burning, pain, numbness; what has relieved symptoms; time of day when symptoms are most severe
3. Current or recent medications—both prescription and over-the-counter
4. Associated systemic symptoms (e.g., malaise, fatigue, arthralgias)
5. Ongoing or previous illnesses
6. History of allergies
7. Presence of photosensitivity
8. Review of systems
9. Family history
10. Social, sexual, or travel history
Skin Biopsy  Minor surgical procedure. Choice of site very important.

Potassium Hydroxide Preparation  Useful for detection of dermatophyte or yeast. Scale is collected from advancing edge of a scaling lesion by gently scraping with side of a microscope slide or a scalpel blade. Nail lesions are best sampled by trimming back nail and scraping subungual debris. A drop of 10–20% potassium hydroxide is added to slide, and coverslip is applied. The slide may be gently heated and examined under microscope. This technique can be utilized to identify hyphae in dermatophyte infections, pseudohyphae and budding yeast in Candida infections, and “spaghetti and meatballs” yeast forms in tinea versicolor.

Tzanck Preparation  Useful for determining presence of herpes viruses (herpes simplex virus or herpes zoster virus). Optimal lesion to sample is an early vesicle. Lesion is gently unroofed with no. 15 scalpel blade, and base of vesicle is gently scraped with belly of blade (keep blade perpendicular to skin surface to prevent laceration). Scrapings are transferred to slide and stained with Wright’s
or Giemsa stain. A positive preparation has multinuclear giant cells. Culture or immunofluorescence testing must be performed to identify the specific virus.

**Diascopy**  Assesses whether a lesion blanches with pressure. Done by pressing a magnifying lens or microscope slide on lesion and observing changes in vascularity. For example, hemangiomas will usually blanch; purpuric lesions will not.

**Wood’s Light Examination**  Useful for detecting bacterial or fungal infection or accentuating features of some skin lesions.

**Patch Tests**  To document cutaneous sensitivity to specific antigens.
TABLE 63-1 DESCRIPTION OF PRIMARY SKIN LESIONS

Macule: A flat, colored lesion, <2 cm in diameter, not raised above the surface of the surrounding skin. A “freckle,” or ephelid, is a prototype pigmented macule.

Patch: A large (>2 cm) flat lesion with a color different from the surrounding skin. This differs from a macule only in size.

Papule: A small, solid lesion, <0.5 cm in diameter, raised above the surface of the surrounding skin and hence palpable (e.g., a closed comedone, or whitehead, in acne).

Nodule: A larger (0.5–5.0 cm), firm lesion raised above the surface of the surrounding skin. This differs from a papule only in size (e.g., a dermal nevomelanocytic nevus).

Tumor: A solid, raised growth >5 cm in diameter.

Patch: A large (>1 cm), flat-topped, raised lesion; edges may either be distinct (e.g., in psoriasis) or gradually blend with surrounding skin (e.g., in eczematous dermatitis).

Vesicle: A small, fluid-filled lesion, <0.5 cm in diameter, raised above the plane of surrounding skin. Fluid is often visible, and the lesions are translucent [e.g., vesicles in allergic contact dermatitis caused by Toxicodendron (poison ivy)].

Pustule: A vesicle filled with leukocytes. Note: The presence of pustules does not necessarily signify the existence of an infection.

Bulla: A fluid-filled, raised, often translucent lesion >0.5 cm in diameter.

Wheal: A raised, erythematous, edematous papule or plaque, usually representing short-lived vasodilatation and vasopermeability.

Telangiectasia: A dilated, superficial blood vessel.

TABLE 63-2 DESCRIPTION OF SECONDARY SKIN LESIONS

Lichenification: A distinctive thickening of the skin that is characterized by accentuated skin-fold markings.

Scale: Excessive accumulation of stratum corneum.

Crust: Dried exudate of body fluids that may be either yellow (i.e., serous crust) or red (i.e., hemorrhagic crust).

Erosion: Loss of epidermis without an associated loss of dermis.

Ulcer: Loss of epidermis and at least a portion of the underlying dermis.

Excoriation: Linear, angular erosions that may be covered by crust and are caused by scratching.

Atrophy: An acquired loss of substance. In the skin, this may appear as a depression with intact epidermis (i.e., loss of dermal or subcutaneous tissue) or as sites of shiny, delicate, wrinkled lesions (i.e., epidermal atrophy).

Scar: A change in the skin secondary to trauma or inflammation. Sites may be erythematous, hypopigmented, or hyperpigmented depending on their age or character. Sites on hair-bearing areas may be characterized by destruction of hair follicles.

For a more detailed discussion, see Lawley TJ, Yancey KB: Approach to the Patient with a Skin Disorder, Chap. 52, p. 308, in HPIM-17.
Common Skin Conditions

PAPULOSQUAMOUS DISORDERS

Disorders exhibiting papules and scale.

Psoriasis  A chronic, recurrent disorder. Classic lesion is a well-marginated, erythematous plaque with silvery-white surface scale. Distribution includes extensor surfaces (i.e., knees, elbows, and buttocks); may also involve palms and scalp (particularly anterior scalp margin). Associated findings include psoriatic arthritis (Chap. 170) and nail changes (onycholysis, pitting or thickening of nail plate with accumulation of subungual debris).

Psoriasis

Maintain cutaneous hydration; topical glucocorticoids; topical vitamin D analogue (calcipotriol) and retinoid (tazarotene); UV light (PUVA when UV used in combination with psoralens); for severe disease methotrexate or cyclosporine; acitretin can also be used but is teratogenic. Efalizumab (humanized monoclonal antibody directed against CD11a) or alefacept (dimeric fusion protein: LFA-3/Fc human IgG1) can be considered for chronic, moderate to severe plaque psoriasis. Etanercept (dimeric fusion protein: TNF receptor/Fc human IgG1) is approved for psoriatic arthritis and psoriasis.

Pityriasis Rosea  A self-limited condition lasting 3–8 weeks. Initially, there is a single 2- to 6-cm annular salmon-colored patch (herald patch) with a peripheral rim of scale, followed in days to weeks by a generalized eruption involving the trunk and proximal extremities. Individual lesions are similar to but smaller than the herald patch and are arranged in symmetric fashion with long axis of each individual lesion along skin lines of cleavage. Appearance may be similar to that of secondary syphilis.

Pityriasis Rosea

Disorder is self-limited, so treatment is directed at symptoms; oral antihistamines for pruritus; topical glucocorticoids; UV-B phototherapy in some cases.

Lichen Planus  Disorder of unknown cause; can follow administration of certain drugs and in chronic graft-versus-host disease; lesions are pruritic, polygonal, flat-topped, and violaceous. Course is variable, but most pts have spontaneous remissions 6–24 months after onset of disease.

Lichen Planus

Topical glucocorticoids.
ECZEMATOUS DISORDERS

**Eczema**  
Eczema, or dermatitis, is a reaction pattern that presents with variable clinical and histologic findings; it is the final common expression for a number of disorders.

**Atopic Dermatitis**  
One aspect of atopic triad of hayfever, asthma, and eczema. Usually an intermittent, chronic, severely pruritic, eczematous dermatitis with scaly erythematous patches, vesiculation, crusting, and fissuring. Lesions are most commonly on flexures, with prominent involvement of antecubital and popliteal fossae; generalized erythroderma in severe cases.

 avoidance of irritants; cutaneous hydration; topical glucocorticoids; treatment of infected lesions [often with *Staphylococcus aureus* (SA)—consider community-acquired methicillin-resistant strains (CA-MRSA)]. Systemic glucocorticoids only for severe exacerbations unresponsive to topical conservative therapy.

**Allergic Contact Dermatitis**  
A delayed hypersensitivity reaction that occurs after cutaneous exposure to an antigenic substance. Lesions occur at site of contact and are vesicular, weeping, crusting; linear arrangement of vesicles is common. Most frequent allergens are resin from plants of the genus *Toxicodendron* (poison ivy, oak, sumac), nickel, rubber, and cosmetics.

 avoidance of sensitizing agent; topical glucocorticoids; consideration of systemic glucocorticoids over 2–3 weeks for widespread disease.

**Irritant Contact Dermatitis**  
Inflammation of the skin due to direct injury by an exogenous agent. The most common area of involvement is the hands, where dermatitis is initiated or aggravated by chronic exposure to water and detergents. Features may include skin dryness, cracking, erythema, edema.

 avoidance of irritants; barriers (use of protective gloves); topical glucocorticoids; treatment of secondary bacterial or dermatophyte infection.

**Seborrheic Dermatitis**  
A chronic noninfectious process characterized by erythematous patches with greasy yellowish scale. Lesions are generally on scalp, eyebrows, nasolabial folds, axillae, central chest, and posterior auricular area.

 Nonfluorinated topical glucocorticoids; shampoos containing coal tar, salicylic acid, or selenium sulfide.
**Impetigo**  A superficial infection of skin secondary to either *S. aureus* or group A β-hemolytic streptococci. The primary lesion is a superficial pustule that ruptures and forms a “honey-colored” crust. Tense bullae are associated with *S. aureus* infections (bullous impetigo). Lesions may occur anywhere but commonly involve the face. Impetigo and *furunculosis* (painful erythematous nodule, or boil) have gained prominence because of increasing incidence of CA-MRSA.

**Gentle debridement of adherent crusts with soaks and topical antibiotics; appropriate oral antibiotics depending on organism (Chap. 84).**

**Erysipelas**  Superficial cellulitis, most commonly on face, characterized by a bright red, sharply demarcated, intensely painful, warm plaque. Because of superficial location of infection and associated edema, surface of plaque may exhibit a *peau d’orange* (orange peel) appearance. Most commonly due to infection with group A β-hemolytic streptococci, occurring at sites of trauma or other breaks in skin.

**Appropriate antibiotics depending on organism (Chap. 84).**

**Herpes Simplex**  (See also Chap. 106)

Recurrent eruption characterized by grouped vesicles on an erythematous base that progress to erosions; often secondarily infected with staphylococci or streptococci. Infections frequently involve mucocutaneous surfaces around the oral cavity, genitals, or anus. Can also cause severe visceral disease including esophagitis, pneumonitis, encephalitis, and disseminated herpes simplex virus infection. Tzanck preparation of an unroofed early vesicle reveals multinuclear giant cells.

**Will differ based on disease manifestations and level of immune competence (Chap. 106); appropriate antibiotics for secondary infections, depending on organism.**

**Herpes Zoster**  (See also Chap. 106)

Eruption of grouped vesicles on an erythematous base usually limited to a single dermatome (“shingles”); disseminated lesions can also occur, especially in immunocompromised pts. Tzanck preparation reveals multinucleate giant cells; indistinguishable from herpes simplex except by culture. Postherpetic neuralgia, lasting months to years, may occur, especially in the elderly.

**Will differ based on disease manifestations and level of immune competence (Chap. 106).**
**Dermatophyte Infection**  
Skin fungus, may involve any area of body; due to infection of stratum corneum, nail plate, or hair. Appearance may vary from mild scaliness to florid inflammatory dermatitis. Common sites of infection include the foot (tinea pedis), nails (tinea unguium), groin (tinea cruris), or scalp (tinea capitis). Classic lesion of tinea corporis (“ringworm”) is an erythematous papulosquamous patch, often with central clearing and scale along peripheral advancing border. Hyphae are often seen on KOH preparation, although tinea capitis and tinea corporis may require culture or biopsy.

**Dermatophyte Infection**

Depends on affected site and type of infection. Topical imidazoles, triazoles, and allylamines may be effective. Haloprogin, undecylenic acid, ciclopirox-olamine, and tolnaftate are also effective, but nystatin is not active against dermatophytes. Griseofulvin, 500 mg/d, if systemic therapy required. Itraconazole or terbinaine may be effective for nail infections.

**Candidiasis**  
Fungal infection caused by a related group of yeasts. Manifestations may be localized to the skin or rarely systemic and life-threatening. Predisposing factors include diabetes mellitus, cellular immune deficiencies, and HIV (Chap. 112). Frequent sites include the oral cavity, chronically wet macerated areas, around nails, intertriginous areas. Diagnosed by clinical pattern and demonstration of yeast on KOH preparation or culture.

**Candidiasis**

(See also Chap. 113) Removal of predisposing factors; topical nystatin or azoles; systemic therapy reserved for immunosuppressed patients, unresponsive chronic or recurrent disease; vulvovaginal candidiasis may respond to a single dose of fluconazole, 150 mg.

**Warts**  
Cutaneous neoplasms caused by human papilloma viruses (HPVs). Typically dome-shaped lesions with irregular filamentous surface. Propensity for the face, arms, and legs; often spread by shaving. HPVs are also associated with genital or perianal lesions and play a role in the development of cancer of the uterine cervix and external genitalia in females (Chap. 90).

**Warts**

Cryotherapy with liquid nitrogen, keratinolytic agents (salicylic acid). For genital warts, application of podophyllin solution is effective but can be associated with marked local reactions; topical imiquimod has also been used.

**ACNE**

**Acne Vulgaris**  
Usually a self-limited disorder of teenagers and young adults. Comedones (small cyst formed in hair follicle) are clinical hallmark; often accompanied by inflammatory lesions of papules, pustules, or nodules. May scar in severe cases.
**Acne Vulgaris**
Careful cleaning and removal of oils; oral tetracycline or erythromycin; topical antibacterials (e.g., benzoyl peroxide), topical retinoic acid. Systemic isotretinoin only for unresponsive severe nodulocystic acne (risk of severe adverse events including teratogenicity and possible association with depression).

**Acne Rosacea**
Inflammatory disorder affecting predominantly the central face, rarely affecting pts <30 years of age. Tendency toward exaggerated flushing, with eventual superimposition of papules, pustules, and telangiectases. May lead to rhinophyma and ocular problems.

**Acne Rosacea**
Oral tetracycline, 250–1000 mg/d; topical metronidazole and topical nonfluorinated glucocorticoids may be useful.

**Vascular Disorders**

**Erythema Nodosum**
Septal panniculitis characterized by erythematous, warm, tender subcutaneous nodular lesions typically over anterior tibia. Lesions are usually flush with skin surface but are indurated and have appearance of an erythematous/violaceous bruise. Lesions usually resolve spontaneously in 3–6 weeks without scarring. Commonly seen in sarcoidosis, administration of certain drugs (esp. sulfonamides, oral contraceptives, and estrogens), and a wide range of infections including streptococcal and tubercular; may be idiopathic.

**Erythema Nodosum**
Identification and treatment/removal of underlying cause. NSAID for severe or recurrent lesions; systemic glucocorticoids are effective but dangerous if underlying infection is not appreciated.

**Erythema Multiforme**
A reaction pattern of skin consisting of a variety of lesions but most commonly erythematous papules and bullae. “Target” or “iris” lesion is characteristic and consists of concentric circles of erythema and normal flesh-colored skin, often with a central vesicle or bulla.
Distribution of lesions classically acral, esp. palms and soles. Three most common causes are drug reaction (particularly penicillins and sulfonamides) or concurrent herpetic or *Mycoplasma* infection. Can rarely affect mucosal surfaces and internal organs (erythema multiforme major or Stevens-Johnson syndrome).

**Erythema Multiforme**
Provocative agent should be sought and eliminated if drug-related. In mild cases limited to skin, only symptomatic treatment is needed (antihistamines, NSAID). For Stevens-Johnson, systemic glucocorticoids have been used, but are controversial; prevention of secondary infection and maintenance of nutrition and fluid/electrolyte balance are critical.
Urticaria  A common disorder, either acute or chronic, characterized by evanescent (individual lesions lasting <24 h), pruritic, edematous, pink to erythematous plaques with a whitish halo around margin of individual lesions. Lesions range in size from papules to giant coalescent lesions (10–20 cm in diameter). Often due to drugs, systemic infection, or foods (esp. shellfish). Food additives such as tartrazine dye (FD & C yellow no. 5), benzoate, or salicylates have also been implicated. If individual lesions last >24 h, consider diagnosis of urticarial vasculitis.

See Chap. 165.

Vasculitis  Palpable purpura (nonblanching, elevated lesions) is the cutaneous hallmark of vasculitis. Other lesions include petechiae (esp. early lesions), necrosis with ulceration, bullae, and urticarial lesions (urticarial vasculitis). Lesions usually most prominent on lower extremities. Associations include infections, collagen-vascular disease, primary systemic vasculitides, malignancy, hepatitis B and C, drugs (esp. thiazides), and inflammatory bowel disease. May occur as an idiopathic, predominantly cutaneous vasculitis.

Will differ based on cause. Pursue identification and treatment/elimination of an exogenous cause or underlying disease. If part of a systemic vasculitis, treat based on major organ-threatening features (Chap. 168). Immunosuppressive therapy should be avoided in idiopathic, predominantly cutaneous vasculitis as disease frequently does not respond and rarely causes irreversible organ system dysfunction.

CUTANEOUS DRUG REACTIONS

Cutaneous reactions are among the most frequent medication toxicities. These can have a wide range of severity and manifestations including urticaria, photosensitivity, erythema multiforme, fixed drug reactions, erythema nodosum, vasculitis, lichenoid reactions, bullous drug reactions, Stevens-Johnson syndrome, and toxic epidermal necrolysis (TEN). Diagnosis is usually made by appearance and careful medication history.

Withdrawal of the medication. Treatment based on nature and severity of cutaneous pathology.

For a more detailed discussion, see McCall CO, Lawley TJ: Eczema, Psoriasis, Cutaneous Infections, Acne, and Other Common Skin Disorders, Chap. 53, p. 312; Roujeau J-C, Stern RS, Wintrob BU: Cutaneous Drug Reactions, Chap. 56, p. 343; and Bolognia JL, Braverman IM: Skin Manifestations of Internal Disease, Chap. 54, p. 321, in HPIM-17.
This page intentionally left blank
SECTION 6  HEMATOLOGY AND ONCOLOGY

65 Examination of Blood Smears and Bone Marrow

BLOOD SMEARS

ERYTHROCYTE (RBC) MORPHOLOGY

- Normal: 7.5-μm diameter. Roughly the size of the nucleus of a small lymphocyte.
- Reticulocytes (Wright’s stain)—large, grayish-blue, admixed with pink (polychromasia).
- Anisocytosis—variation in RBC size; large cells imply delay in erythroid precursor DNA synthesis caused by folate or B₁₂ deficiency or drug effect; small cells imply a defect in hemoglobin synthesis caused by iron deficiency or abnormal hemoglobin genes.
- Poikilocytosis—abnormal RBC shapes; the following are examples:
  1. Acanthocytes (spur cells)—irregularly spiculated; abetalipoproteinemia, severe liver disease, rarely anorexia nervosa.
  2. Echinocytes (burr cells)—regularly shaped, uniformly distributed spiny projections; uremia, RBC volume loss.
  3. Elliptocytes—elliptical; hereditary elliptocytosis.
  4. Schistocytes (schizocytes)—fragmented cells of varying sizes and shapes; microangiopathic or macroangiopathic hemolytic anemia.
  5. Sickled cells—elongated, crescentic; sickle cell anemias.
  6. Spherocytes—small hyperchromic cells lacking normal central pallor; hereditary spherocytosis, extravascular hemolysis as in autoimmune hemolytic anemia, G6PD deficiency.
  7. Target cells—central and outer rim staining with intervening ring of pallor; liver disease, thalassemia, hemoglobin C and sickle C diseases.
  8. Teardrop cells—myelofibrosis, other infiltrative processes of marrow (e.g., carcinoma).
  9. Rouleaux formation—alignment of RBCs in stacks; may be artifactual or due to paraproteinemia (e.g., multiple myeloma, macroglobulinemia).

RBC INCLUSIONS

- Howell-Jolly bodies—1-μm-diameter basophilic cytoplasmic inclusion that represents a residual nuclear fragment, usually single; asplenic pts.
- Basophilic stippling—multiple, punctate basophilic cytoplasmic inclusions composed of precipitated mitochondria and ribosomes; lead poisoning, thalassemia, myelofibrosis.
- Pappenheimer (iron) bodies—iron-containing granules usually composed of mitochondria and ribosomes resemble basophilic stippling but also stain with Prussian blue; lead poisoning, other sideroblastic anemias.
• **Heinz bodies**—spherical inclusions of precipitated hemoglobin seen only with supravital stains, such as crystal violet; G6PD deficiency (after oxidant stress such as infection, certain drugs), unstable hemoglobin variants.

• **Parasites**—characteristic intracytoplasmic inclusions; malaria, babesiosis.

### LEUKOCYTE INCLUSIONS AND NUCLEAR CONTOUR ABNORMALITIES

- **Toxic granulations**—dark cytoplasmic granules; bacterial infection.
- **Döhle bodies**—1- to 2-μm blue, oval cytoplasmic inclusions; bacterial infection, Chédiak-Higashi anomaly.
- **Auer rods**—eosinophilic, rodlike cytoplasmic inclusions; acute myeloid leukemia (some cases).
- **Hypersegmentation**—neutrophil nuclei contain more than the usual 2–4 lobes; usually ≥5% have ≥5 lobes or a single cell with 7 lobes is adequate to make the diagnosis; folate or B₁₂ deficiency, drug effects.
- **Hyposegmentation**—neutrophil nuclei contain fewer lobes than normal, either one or two; Pelger-Hüet anomaly, pseudo-Pelger-Hüet or acquired Pelger-Hüet anomaly in acute leukemia.

### PLATELET ABNORMALITIES

*Platelet clumping*—an in vitro artifact—is often readily detectable on smear; can lead to falsely low platelet count by automated cell counters.

### BONE MARROW

Aspiration assesses cell morphology. Biopsy assesses overall marrow architecture, including degree of cellularity. Biopsy should precede aspiration to avoid aspiration artifact (mainly hemorrhage) in the specimen.

### INDICATIONS

**Aspiration** Hypoproliferative or unexplained anemia, leukopenia, or thrombocytopenia, suspected leukemia or myeloma or marrow defect, evaluation of iron stores, workup of some cases of fever of unknown origin.

**Special Tests** Histochemical staining (leukemias), cytogenetic studies (leukemias, lymphomas), microbiology (bacterial, mycobacterial, fungal cultures), Prussian blue (iron) stain (assessment of iron stores, diagnosis of sideroblastic anemias).

**Biopsy** Performed in addition to aspiration for pancytopenia (aplastic anemia), metastatic tumor, granulomatous infection (e.g., mycobacteria, brucellosis, histoplasmosis), myelofibrosis, lipid storage disease (e.g., Gaucher’s, Niemann-Pick), any case with “dry tap” on aspiration; evaluation of marrow cellularity. When biopsy and aspirate are both planned, the biopsy should be performed first because of the risk of bleeding artifact from biopsy of an aspiration site.

**Special Tests** Histochemical staining (e.g., acid phosphatase for metastatic prostate carcinoma), immunoperoxidase staining (e.g., immunoglobulin or cell surface marker detection in multiple myeloma, leukemia, or lymphoma; lysozyme detection in monocytic leukemia), reticulin staining (increased in myelofibrosis), microbiologic staining (e.g., acid-fast staining for mycobacteria).
INTERPRETATION

Cellularity  Defined as percentage of space occupied by hematopoietic cells. Decreases with age after age 65 years from about 50% to 25–30% with a corresponding increase in fat.

Erythroid:Granulocytic (E:G) Ratio  Normally about 1:2, the E:G ratio is decreased in acute and chronic infection, leukemoid reactions (e.g., chronic inflammation, metastatic tumor), acute and chronic myeloid leukemia, myelodysplastic disorders (“preleukemia”), and pure red cell aplasia; increased in agranulocytosis, anemias with erythroid hyperplasia (megaloblastic, iron-deficiency, thalassemia, hemorrhage, hemolysis, sideroblastic), and erythrocytosis (excessive RBC production); normal in aplastic anemia (though marrow hypocellular), myelofibrosis (marrow hypocellular), multiple myeloma, lymphoma, anemia of chronic disease. Some centers use the term M:E (myeloid to erythroid) ratio; normal value is 2:1 and increases with diseases that promote myeloid activity or inhibit erythroid activity and decreases with diseases that inhibit myeloid activity or promote erythroid activity.


Red Blood Cell Disorders

Anemia is a common clinical problem in medicine. A physiologic approach (outlined in Chap. 58) provides the most efficient path to diagnosis and management. Anemias arise either because red blood cell (RBC) production is inadequate or because RBC lifespan is shortened through loss from the circulation or destruction.

HYPOPROLIFERATIVE ANEMIAS

These are the most common anemias. Usually the RBC morphology is normal and the reticulocyte index (RI) is low. Marrow damage, early iron deficiency, and decreased erythropoietin production or action may produce anemia of this type.

Marrow damage may be caused by infiltration of the marrow with tumor or fibrosis that crowds out normal erythroid precursors or by the absence of erythroid precursors (aplastic anemia) as a consequence of exposure to drugs, radiation, chemicals, viruses (e.g., hepatitis), autoimmune mechanisms, or genetic factors, either hereditary (e.g., Fanconi’s anemia) or acquired (e.g., paroxysmal nocturnal hemoglobinuria). Most cases of aplasia are idiopathic. The tumor or fibrosis that infiltrates the marrow may originate in the marrow (as in leukemia
or myelofibrosis) or be secondary to processes originating outside the marrow (as in metastatic cancer or myelophthisis).

Early iron-deficiency anemia (or iron-deficient erythropoiesis) is associated with a decrease in serum ferritin levels (<15 \( \mu g/L \)), moderately elevated total iron-binding capacity (TIBC) (>380 \( \mu g/dL \)), serum iron (SI) level <50 \( \mu g/dL \), and an iron saturation of <30% but >10% (Fig. 66-1). RBC morphology is generally normal until iron deficiency is severe (see below).

Decreased stimulation of erythropoiesis can be a consequence of inadequate erythropoietin production [e.g., renal disease destroying the renal tubular cells that produce it or hypometabolic states (endocrine deficiency or protein starvation) in which insufficient erythropoietin is produced] or of inadequate erythropoietin action. The anemia of chronic disease is a common entity. It is multifactorial in pathogenesis: inhibition of erythropoietin production, inhibition of iron reutilization (which blocks the response to erythropoietin), and inhibition of erythroid colony proliferation by inflammatory cytokines (e.g., tumor necrosis factor, interferon \( \gamma \)). Hepcidin, a small iron-binding molecule produced by the liver during an acute-phase inflammatory response, may bind iron and prevent its reutilization in hemoglobin synthesis. The laboratory tests shown in Table 66-1 may assist in the differential diagnosis of hypoproliferative anemias. Measurement of hepcidin in the urine is not yet practical or widely available.

### Table 66-1 Laboratory studies in the evolution of iron deficiency

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Erythron iron</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marrow iron stores</td>
<td>1–3</td>
<td>0–1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Serum ferritin (( \mu g/L ))</td>
<td>50–200</td>
<td>&lt;20</td>
<td>&lt;15</td>
<td>&lt;15</td>
</tr>
<tr>
<td>TIBC (( \mu g/dL ))</td>
<td>300–360</td>
<td>&gt;360</td>
<td>&gt;380</td>
<td>&gt;400</td>
</tr>
<tr>
<td>SI (( \mu g/dL ))</td>
<td>50–150</td>
<td>NL</td>
<td>&lt;50</td>
<td>&lt;30</td>
</tr>
<tr>
<td>Saturation (%)</td>
<td>30–50</td>
<td>NL</td>
<td>&lt;30</td>
<td>&lt;10</td>
</tr>
<tr>
<td>Marrow sideroblasts (%)</td>
<td>40–60</td>
<td>NL</td>
<td>&lt;10</td>
<td>&lt;10</td>
</tr>
<tr>
<td>RBC protoporphyrin (( \mu g/dL ))</td>
<td>30–50</td>
<td>NL</td>
<td>&gt;100</td>
<td>&gt;200</td>
</tr>
<tr>
<td>RBC morphology</td>
<td>NL</td>
<td>NL</td>
<td>NL</td>
<td>Microcytic/hypochromic</td>
</tr>
</tbody>
</table>

**FIGURE 66-1** Laboratory studies in the evolution of iron deficiency. Measurements of marrow iron stores, serum ferritin, and TIBC are sensitive to early iron-store depletion. Iron-deficient erythropoiesis is recognized from additional abnormalities in the SI, percent saturation of transferrin, the pattern of marrow sideroblasts, and the red blood cell protoporphyrin level. Finally, patients with iron-deficiency anemia demonstrate all of these abnormalities plus an anemia characterized by microcytic hypochromic morphology. (From RS Hillman, CA Finch: Red Cell Manual, 7th ed, Philadelphia, Davis, 1996, with permission.)
MATURATION DISORDERS

These result from either defective hemoglobin synthesis, leading to cytoplasmic maturation defects and small relatively empty red cells, or abnormally slow DNA replication, leading to nuclear maturation defects and large full red cells. Defects in hemoglobin synthesis usually result from insufficient iron supply (iron deficiency) or decreased globin production (thalassemia) or are idiopathic (sideroblastic anemia). Defects in DNA synthesis are usually due to nutritional problems (vitamin B12 and folate deficiency), toxic (methotrexate or other cancer chemotherapeutic agent) exposure, or intrinsic marrow maturation defects (refractory anemia, myelodysplasia).

Laboratory tests useful in the differential diagnosis of the microcytic anemias are shown in Table 66-2. Mean corpuscular volume (MCV) is generally 60–80 fL. Increased lactate dehydrogenase (LDH) and indirect bilirubin levels suggest an increase in RBC destruction and favor a cause other than iron deficiency. Iron status is best assessed by measuring SI, TIBC, and ferritin levels. Macrocytic MCVs are >94 fL. Folate status is best assessed by measuring red blood cell folate levels. Vitamin B12 status is best assessed by measuring serum

### TABLE 66-1 DIAGNOSIS OF HYPOProliferative Anemias

<table>
<thead>
<tr>
<th>Tests</th>
<th>Iron Deficiency</th>
<th>Inflammation</th>
<th>Renal Disease</th>
<th>Hypometabolic States</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anemia</td>
<td>Mild to severe</td>
<td>Mild</td>
<td>Mild to severe</td>
<td>Mild</td>
</tr>
<tr>
<td>MCV (fL)</td>
<td>70–90 Normo-microcytic</td>
<td>80–90 Normocytic</td>
<td>90 Normocytic</td>
<td>90 Normocytic</td>
</tr>
<tr>
<td>SI</td>
<td>&lt;30</td>
<td>&lt;50</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>TIBC</td>
<td>&gt;360</td>
<td>&gt;300</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Saturation (%)</td>
<td>&lt;10</td>
<td>10–20</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Serum ferritin (μg/L)</td>
<td>&lt;15</td>
<td>30–200</td>
<td>115–150</td>
<td>Normal</td>
</tr>
<tr>
<td>Iron stores</td>
<td>0</td>
<td>2–4+</td>
<td>1–4+</td>
<td>Normal</td>
</tr>
</tbody>
</table>

**Note:** MCV, mean corpuscular volume; SI, serum iron; TIBC, total iron-binding capacity.

### TABLE 66-2 DIAGNOSIS OF MICROCYTIC ANEMIA

<table>
<thead>
<tr>
<th>Tests</th>
<th>Iron Deficiency</th>
<th>Thalassemia</th>
<th>Sideroblastic Anemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear</td>
<td>Micro/hypo</td>
<td>Micro/hypo with targeting</td>
<td>Variable</td>
</tr>
<tr>
<td>SI</td>
<td>&lt;30</td>
<td>Normal to high</td>
<td>Normal to high</td>
</tr>
<tr>
<td>TIBC</td>
<td>&gt;360</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Saturation, %</td>
<td>&lt;10</td>
<td>30–80</td>
<td>30–80</td>
</tr>
<tr>
<td>Ferritin, μg/L</td>
<td>&lt;15</td>
<td>50–300</td>
<td>50–300</td>
</tr>
<tr>
<td>Hemoglobin pattern</td>
<td>Normal</td>
<td>Abnormal</td>
<td>Normal</td>
</tr>
</tbody>
</table>

**Note:** SI, serum iron; TIBC, total iron-binding capacity.
B₁₂, homocysteine, and methylmalonic acid levels. Homocysteine and methylmalonic acid levels are elevated in the setting of B₁₂ deficiency.

ANEMIA DUE TO RBC DESTRUCTION OR ACUTE BLOOD LOSS

Blood Loss Trauma, GI hemorrhage (may be occult) are common causes; less common are genitourinary sources (menorrhagia, gross hematuria), internal bleeding such as intraperitoneal from spleen or organ rupture, retroperitoneal, iliopsoas hemorrhage (e.g., in hip fractures). Acute bleeding is associated with manifestations of hypovolemia, reticulocytosis, macrocytosis; chronic bleeding is associated with iron deficiency, hypochromia, microcytosis.

Hemolysis Causes are listed in Table 66-3.

1. **Intracellular RBC abnormalities**—most are inherited enzyme defects [glucose-6-phosphate dehydrogenase (G6PD) deficiency > pyruvate kinase deficiency], hemoglobinopathies, sickle cell anemia and variants, thalassemia, unstable hemoglobin variants.

2. **G6PD deficiency**—leads to episodes of hemolysis precipitated by ingestion of drugs that induce oxidant stress on RBCs. These include antimalarials (chloroquine), sulfonamides, analgesics (phenacetin), and other miscellaneous drugs (Table 66-4).

3. **Sickle cell anemia**—characterized by a single-amino-acid change in β globin (valine for glutamic acid in the 6th residue) that produces a molecule of decreased solubility, especially in the absence of O₂. Although anemia and chronic hemolysis are present, the major disease manifestations relate to vasoocclusion from misshapen sickled RBCs. Infarcts in lung, bone, spleen, retina, brain, and other organs lead to symptoms and dysfunction (Fig. 66-2).

4. **Membrane abnormalities** (rare)—spur cell anemia (cirrhosis, anorexia nervosa), paroxysmal nocturnal hemoglobinuria, hereditary spherocytosis (increased RBC osmotic fragility, spherocytes), hereditary elliptocytosis (causes mild hemolytic anemia).

<table>
<thead>
<tr>
<th>TABLE 66-3</th>
<th>CLASSIFICATION OF HEMOLYTIC ANEMIAS⁶</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intracorpuscular Defects</strong></td>
<td><strong>Extracorpuscular Factors</strong></td>
</tr>
<tr>
<td>Hereditary</td>
<td></td>
</tr>
<tr>
<td>Hemoglobinopathies</td>
<td>Familial hemolytic uremic syndrome (HUS)</td>
</tr>
<tr>
<td>Enzymopathies</td>
<td></td>
</tr>
<tr>
<td>Membrane-cytoskeletal defects</td>
<td></td>
</tr>
<tr>
<td>Acquired</td>
<td>Paroxysmal nocturnal hemoglobinuria (PNH)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

⁶There is a strong correlation between hereditary causes and intracorpuscular defects, because such defects are due to inherited mutations; the one exception is PNH, because the defects are due to an acquired somatic mutation. There is also a strong correlation between acquired causes and extracorpuscular factors; the one exception is familial HUS, because here an inherited abnormality allows excessive complement activation, with bouts of production of membrane attack complex capable of severely damaging normal cells.
5. **Immunohemolytic anemia** (positive Coombs’ test, spherocytes). Two types: (a) **warm antibody** (usually IgG)—idiopathic, lymphoma, chronic lymphocytic leukemia, systemic lupus erythematosus, drugs (e.g., methyldopa, penicillins, quinine, quinidine, isoniazid, sulfonamides); and (b) **cold antibody**—cold agglutinin disease (IgM) due to *Mycoplasma* infection, infectious mononucleosis, lymphoma, idiopathic; paroxysmal cold hemoglobinuria (IgG) due to syphilis, viral infections.

### TABLE 66-4 DRUGS THAT CARRY RISK OF CLINICAL HEMOLYSIS IN PERSONS WITH G6PD DEFICIENCY

<table>
<thead>
<tr>
<th>Definite Risk</th>
<th>Possible Risk</th>
<th>Doubtful Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antimalarials</strong></td>
<td>Primaquine</td>
<td>Chloroquine</td>
</tr>
<tr>
<td></td>
<td>Dapsone/ chloroproguanil</td>
<td></td>
</tr>
<tr>
<td><strong>Sulphonamides/ sulphones</strong></td>
<td>Sulfamethoxazole</td>
<td>Sulfasalazine</td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td>Sulfadimidine</td>
</tr>
<tr>
<td></td>
<td>Dapsone</td>
<td></td>
</tr>
<tr>
<td><strong>Antibacterial/ antibiotics</strong></td>
<td>Cotrimoxazole</td>
<td>Ciprofloxacin</td>
</tr>
<tr>
<td></td>
<td>Nalidixic acid</td>
<td>Nitrofurantoin</td>
</tr>
<tr>
<td></td>
<td>Nitiridazole</td>
<td></td>
</tr>
<tr>
<td><strong>Antipyretic/ analgesics</strong></td>
<td>Nalidixic acid</td>
<td>Acetylsalicylic acid</td>
</tr>
<tr>
<td></td>
<td>Phenazopyridine (Pyridium)</td>
<td>high dose (&gt;3 g/d)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>Naphthalene</td>
<td>Vitamin K analogues</td>
</tr>
<tr>
<td></td>
<td>Methylene blue</td>
<td>Ascorbic acid &gt;1 g</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rasburicase</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FIGURE 66-2** Pathophysiology of sickle cell crisis.
6. **Mechanical trauma** (macro- and microangiopathic hemolytic anemias; schistocytes)—prosthetic heart valves, vasculitis, malignant hypertension, eclampsia, renal graft rejection, giant hemangioma, scleroderma, thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, disseminated intravascular coagulation, march hemoglobinuria (e.g., marathon runners, bongo drummers).

7. **Direct toxic effect**—infections (e.g., malaria, *Clostridium perfringens* toxin, toxoplasmosis).

8. **Hypersplenism** (pancytopenia may be present).

### Laboratory Abnormalities

- Elevated reticulocyte index, polychromasia and nucleated RBCs on smear; also spherocytes, elliptocytes, schistocytes, or target, spur, or sickle cells may be present depending on disorder; elevated unconjugated serum bilirubin and LDH, elevated plasma hemoglobin, low or absent haptoglobin; urine hemosiderin present in intravascular but not extravascular hemolysis, Coombs’ test (immunohemolytic anemias), osmotic fragility test (hereditary spherocytosis), hemoglobin electrophoresis (sickle cell anemia, thalassemia), G6PD assay (best performed after resolution of hemolytic episode to prevent false-negative result).

### Anemia

#### General Approaches

The acuteness and severity of the anemia determine whether transfusion therapy with packed RBCs is indicated. Rapid occurrence of severe anemia (e.g., after acute GI hemorrhage resulting in Hct < 25%, following volume repletion) or development of angina or other symptoms is an indication for transfusion. Hct should increase 3–4% [Hb by 10 g/L (1 g/dL)] with each unit of packed RBCs, assuming no ongoing losses. Chronic anemia (e.g., vitamin B₁₂ deficiency), even when severe, may not require transfusion therapy if the pt is compensated and specific therapy (e.g., vitamin B₁₂) is instituted.

#### Specific Disorders

1. **Iron deficiency**: find and treat cause of blood loss, oral iron (e.g., FeSO₄ 300 mg tid).

2. **Folate deficiency**: common in malnourished, alcoholics; less common now than before folate food supplementation; folic acid 1 mg PO qd (5 mg qd for pts with malabsorption).

3. **Vitamin B₁₂ deficiency**: can be managed either with parenteral vitamin B₁₂ 100 μg IM qd for 7 d, then 100–1000 μg IM per month or with 2 mg oral crystalline vitamin B₁₂ per day. An inhaled formulation is also available.

4. **Anemia of chronic disease**: treat underlying disease; in uremia use recombinant human erythropoietin, 50–150 U/kg three times a week; role of erythropoietin in other forms of anemia of chronic disease is less clear; response more likely if serum erythropoietin levels are low.

5. **Sickle cell anemia**: hydroxyurea 10–30 mg/kg per day PO increases level of HbF and prevents sickling, treat infections early, supplemental folic acid; painful crises treated with oxygen, analgesics (opioids), hydration, and hypertransfusion; consider allogeneic bone marrow transplantation in pts with increasing frequency of crises.

6. **Thalassemia**: transfusion to maintain Hb > 90 g/L (>9 g/dL), folic acid, prevention of Fe overload with deferoxoxine (parenteral) or deferasirox (oral) chelation; consider splenectomy and allogeneic bone marrow transplantation.
7. Aplastic anemia: antithymocyte globulin and cyclosporine leads to improvement in 70%, bone marrow transplantation in young pts with a matched donor.
9. G6PD deficiency: avoid agents known to precipitate hemolysis.

For a more detailed discussion, see Adamson JW, Chap. 98; Benz EJ, Chap. 99; Hoffbrand AV, Chap. 100; Luzzato L, Chap. 101; Young NS, Chap. 102; pp. 628-671, in HPIM-17.

---

**Leukocytosis and Leukopenia**

**LEUKOCYTOSIS**

**APPROACH**

Review smear (? abnormal cells present) and obtain differential count. The normal values for concentration of blood leukocytes are shown in Table 67-1.

**NEUTROPHILIA**

Absolute neutrophil count (polys and bands) > 10,000/μL. The pathophysiology of neutrophilia involves increased production, increased marrow mobilization, or decreased margination (adherence to vessel walls).

**Causes**  (1) Exercise, stress; (2) infections—esp. bacterial; smear shows increased numbers of immature neutrophils (“left shift”), toxic granulations, Döhle bodies; (3) burns; (4) tissue necrosis (e.g., myocardial, pulmonary, renal infarction); (5) chronic inflammatory disorders (e.g., gout, vasculitis); (6) drugs (e.g., glucocorticoids, epinephrine, lithium); (7) cytokines [e.g., granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF)]; (8) myeloproliferative disorders (Chap. 70); (9) metabolic (e.g., ketoacidosis, uremia); (10) other—malignant neoplasms, acute hemorrhage or hemolysis, after splenectomy.

**TABLE 67-1**

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Mean, cells/μL</th>
<th>95% Confidence Intervals, cells/μL</th>
<th>Total WBC, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrophil</td>
<td>3650</td>
<td>1830–7250</td>
<td>30–60%</td>
</tr>
<tr>
<td>Lymphocyte</td>
<td>2500</td>
<td>1500–4000</td>
<td>20–50%</td>
</tr>
<tr>
<td>Monocyte</td>
<td>430</td>
<td>200–950</td>
<td>2–10%</td>
</tr>
<tr>
<td>Eosinophil</td>
<td>150</td>
<td>0–700</td>
<td>0.3–5%</td>
</tr>
<tr>
<td>Basophil</td>
<td>30</td>
<td>0–150</td>
<td>0.6–1.8%</td>
</tr>
</tbody>
</table>
LEUKEMOID REACTION

Extreme elevation of leukocyte count (>50,000/μL) composed of mature and/or immature neutrophils.

Causes  (1) Infection (severe, chronic, e.g., tuberculosis), esp. in children; (2) hemolysis (severe); (3) malignant neoplasms (esp. carcinoma of the breast, lung, kidney); (4) cytokines (e.g., G-CSF, GM-CSF). May be distinguished from chronic myeloid leukemia (CML) by measurement of the leukocyte alkaline phosphatase (LAP) level: elevated in leukemoid reactions, depressed in CML.

LEUKOERYTHROBLASTIC REACTION

Similar to leukemoid reaction with addition of nucleated red blood cells (RBCs) and schistocytes on blood smear.

Causes  (1) Myelophthisis—invasion of the bone marrow by tumor, fibrosis, granulomatous processes; smear shows “teardrop” RBCs; (2) myelofibrosis—same pathophysiology as myelophthisis, but the fibrosis is a primary marrow disorder; (3) hemorrhage or hemolysis (rarely, in severe cases).

LYMPHOCYTOSIS

Absolute lymphocyte count > 5000/μL.

Causes  (1) Infection—infectious mononucleosis, hepatitis, cytomegalovirus, rubella, pertussis, tuberculosis, brucellosis, syphilis; (2) endocrine disorders—thyrotoxicosis, adrenal insufficiency; (3) neoplasms—chronic lymphocytic leukemia (CLL), most common cause of lymphocyte count > 10,000/μL.

MONOCYTOSIS

Absolute monocyte count > 800/μL.

Causes  (1) Infection—subacute bacterial endocarditis, tuberculosis, brucellosis, rickettsial diseases (e.g., Rocky Mountain spotted fever), malaria, leishmaniasis; (2) granulomatous diseases—sarcoidosis, Crohn’s disease; (3) collagen vascular diseases—rheumatoid arthritis, systemic lupus erythematosus (SLE), polyarteritis nodosa, polymyositis, temporal arteritis; (4) hematologic diseases—leukemias, lymphoma, myeloproliferative and myelodysplastic syndromes, hemolytic anemia, chronic idiopathic neutropenia; (5) malignant neoplasms.

EOSINOPHILIA

Absolute eosinophil count > 500/μL.

Causes  (1) Drugs, (2) parasitic infections, (3) allergic diseases, (4) collagen vascular diseases, (5) malignant neoplasms, (6) hypereosinophilic syndromes.

BASOPHILIA

Absolute basophil count > 100/μL.

Causes  (1) Allergic diseases, (2) myeloproliferative disorders (esp. CML), (3) chronic inflammatory disorders (rarely).

LEUKOPENIA

Total leukocyte count < 4300/μL.
NEUTROPENIA

Absolute neutrophil count < 2000/μL (increased risk of bacterial infection with count < 1000/μL). The pathophysiology of neutropenia involves decreased production or increased peripheral destruction.

Causes
(1) Drugs—cancer chemotherapeutic agents are most common cause, also phenytoin, carbamazepine, indomethacin, chloramphenicol, penicillins, sulfonamides, cephalosporins, propylthiouracil, phenothiazines, captopril, methyl-dopa, procaainamide, chlorpropanide, thiazides, cimetidine, allopurinol, colchicine, ethanol, penicillamine, and immunosuppressive agents; (2) infections—viral (e.g., influenza, hepatitis, infectious mononucleosis, HIV), bacterial (e.g., typhoid fever, miliary tuberculosis, fulminant sepsis), malaria; (3) nutritional—B₁₂, folate deficiencies; (4) benign—mild cyclic neutropenia common in blacks, no associated risk of infection; (5) hematologic diseases—cyclic neutropenia (q21d, with recurrent infections common), leukemia, myelodysplasia (preleukemia), aplastic anemia, bone marrow infiltration (uncommon cause), Chédiak-Higashi syndrome; (6) hyper-splenism—e.g., Felty’s syndrome, congestive splenomegaly, Gaucher’s disease; (7) autoimmune diseases—idiopathic, SLE, lymphoma (may see positive antineutrophil antibodies).

The Febrile, Neutropenic Patient

(See Chap. 26) In addition to usual sources of infection, consider paranasal sinuses, oral cavity (including teeth and gums), anorectal region; empirical therapy with broad-spectrum antibiotics (e.g., ceftazidime) is indicated after blood and other appropriate cultures are obtained. Prolonged febrile neutropenia (>7 days) leads to increased risk of disseminated fungal infections; requires addition of antifungal chemotherapy (e.g., amphotericin B). The duration of chemotherapy-induced neutropenia may be shortened by a few days by treatment with the cytokines GM-CSF or G-CSF.

LYMPHOPENIA

Absolute lymphocyte count < 1000/μL.

Causes
(1) Acute stressful illness—e.g., myocardial infarction, pneumonia, sepsis; (2) glucocorticoid therapy; (3) lymphoma (esp. Hodgkin’s disease); (4) immune-deficiency syndromes—ataxia telangiectasia and Wiskott-Aldrich and DiGeorge syndromes; (5) immunsuppressive therapy—e.g., antilymphocyte globulin, cyclophosphamide; (6) large-field radiation therapy (esp. for lymphoma); (7) intestinal lymphangiectasia (increased lymphocyte loss); (8) chronic illness—e.g., congestive heart failure, uremia, SLE, disseminated malignancies; (9) bone marrow failure/replacement—e.g., aplastic anemia, miliary tuberculosis.

MONOCYTOPENIA

Absolute monocyte count < 100/μL.

Causes
(1) Acute stressful illness, (2) glucocorticoid therapy, (3) aplastic anemia, (4) leukemia (certain types, e.g., hairy cell leukemia), (5) chemotherapeutic and immunosuppressive agents.

EOSINOPENIA

Absolute eosinophil count < 50/μL.
Causes

(1) Acute stressful illness, (2) glucocorticoid therapy.

For a more detailed discussion, see Holland SM, Gallin JI: Disorders of Granulocytes and Monocytes, Chap. 61, p. 375; in HPIM-17.

BLEEDING DISORDERS

Bleeding may result from abnormalities of (1) platelets, (2) blood vessel walls, or (3) coagulation. Platelet disorders characteristically produce petechial and purpuric skin lesions and bleeding from mucosal surfaces. Defective coagulation results in ecchymoses, hematomas, and mucosal and, in some disorders, recurrent joint bleeding (hemarthroses).

PLATELET DISORDERS

Thrombocytopenia

Normal platelet count is 150,000–350,000/µL. Thrombocytopenia is defined as a platelet count < 100,000/µL. Bleeding time, a measurement of platelet function, is abnormally increased if platelet count < 100,000/µL; injury or surgery may provoke excess bleeding. Spontaneous bleeding is unusual unless count < 20,000/µL; platelet count < 10,000/µL is often associated with serious hemorrhage. Bone marrow examination shows increased number of megakaryocytes in disorders associated with accelerated platelet destruction; decreased number in disorders of platelet production. Evaluation of thrombocytopenia is shown in Fig. 68-1.

Causes

(1) Production defects such as marrow injury (e.g., drugs, irradiation), marrow failure (e.g., aplastic anemia), marrow invasion (e.g., carcinoma, leukemia, fibrosis); (2) sequestration due to splenomegaly; (3) accelerated destruction—causes include:

- Drugs such as chemotherapeutic agents, thiazides, ethanol, estrogens, sulfonamides, quinidine, quinine, methyldopa.
- Heparin-induced thrombocytopenia is seen in 5% of pts receiving >5 days of therapy and is due to in vivo platelet aggregation often from anti—platelet factor 4 antibodies. Arterial and occasionally venous thromboses may result.
- Autoimmune destruction by an antibody mechanism; may be idiopathic or associated with systemic lupus erythematosus (SLE), lymphoma, HIV.
- Idiopathic thrombocytopenic purpura (ITP) has two forms: an acute, self-limited disorder of childhood requiring no specific therapy, and a chronic disorder of adults (esp. women 20–40 years). Chronic ITP may be due to autoantibodies to glycoprotein IIb-IIIa or glycoprotein Ib-IX complexes.
- Disseminated intravascular coagulation (DIC)—platelet consumption with coagulation factor depletion [prolonged prothrombin time (PT), partial thromboplastin time (PTT)] and stimulation of fibrinolysis [generation of fi-
brin split products (FSPs)]. Blood smear shows microangiopathic hemolysis (schistocytes). Causes include infection (esp. meningococcal, pneumococcal, gram-negative bacteremias), extensive burns, trauma, or thrombosis; giant hemangioma, retained dead fetus, heat stroke, mismatched blood transfusion, metastatic carcinoma, acute promyelocytic leukemia.

- Thrombotic thrombocytopenic purpura (TTP)—rare disorder characterized by microangiopathic hemolytic anemia, fever, thrombocytopenia, renal dysfunction (and/or hematuria), and neurologic dysfunction caused by failure to cleave von Willebrand factor (vWF) normally.
- Hemorrhage with extensive transfusion.

Pseudothrombocytopenia Platelet clumping secondary to collection of blood in EDTA (0.3% of pts). Examination of blood smear establishes diagnosis.

Thrombocytosis Platelet count > 350,000/μL. Either primary (essential thrombocytosis; Chap. 70) or secondary (reactive): latter secondary to severe hemorrhage, iron deficiency, surgery, after splenectomy (transient), malignant neoplasms (esp. Hodgkin’s disease, polycythemia vera), chronic inflammatory diseases (e.g., inflammatory bowel disease), recovery from acute infection, vitamin B₁₂ deficiency, drugs (e.g., vincristine, epinephrine). Rebound thrombocytosis may occur after marrow recovery from cytotoxic agents, alcohol. Primary thrombocytosis may be complicated by bleeding and/or thrombosis; secondary rarely causes hemostatic problems.
Disorders of Platelet Function  Suggested by the finding of prolonged bleeding time with normal platelet count. Defect is in platelet adhesion, aggregation, or granule release. Causes include (1) drugs—aspirin, other nonsteroidal anti-inflammatory drugs, dipyridamole, clopidogrel, heparin, penicillins, esp. carbenicillin, ticarcillin; (2) uremia; (3) cirrhosis; (4) dysproteinemias; (5) myeloproliferative and myelodysplastic disorders; (6) von Willebrand disease (vWD; see below); (7) cardiopulmonary bypass.

HEMOSTATIC DISORDERS DUE TO BLOOD VESSEL WALL DEFECTS

Causes include (1) aging; (2) drugs—e.g., glucocorticoids (chronic therapy), penicillins, sulfonamides; (3) vitamin C deficiency; (4) TTP; (5) hemolytic uremic syndrome; (6) Henoch-Schönlein purpura; (7) paraproteinemias; (8) hereditary hemorrhagic telangiectasia (Osler-Rendu-Weber disease).

DISORDERS OF BLOOD COAGULATION

Congenital Disorders
1. Hemophilia A—incidence 1:5,000; sex-linked recessive deficiency of factor VIII (low plasma factor VIII coagulant activity, but normal amount of factor VIII–related antigen—vWF). Laboratory features: elevated PTT, normal PT.
2. Hemophilia B (Christmas disease)—incidence 1:30,000, sex-linked recessive, due to factor IX deficiency. Clinical and laboratory features similar to hemophilia A.
3. von Willebrand disease—most common inherited coagulation disorder (1:800–1000), usually autosomal dominant; primary defect is reduced synthesis or chemically abnormal factor VIII–related antigen produced by platelets and endothelium, resulting in abnormal platelet function.

Acquired Disorders
1. Vitamin K deficiency—impairs production of factors II (prothrombin), VII, IX, and X; vitamin K is a cofactor in the carboxylation of glutamate residues on prothrombin complex proteins; major source of vitamin K is dietary (esp. green vegetables), with minor production by gut bacteria. Laboratory features: elevated PT and PTT.
2. Liver disease—results in deficiencies of all clotting factors except VIII. Laboratory features: elevated PT, normal or elevated PTT.
3. Other disorders—DIC, fibrinogen deficiency (liver disease, L-asparaginase therapy, rattlesnake bites), other factor deficiencies, circulating anticoagulants (lymphoma, SLE, idiopathic), massive transfusion (dilutional coagulopathy).

Bleeding Disorders

Thrombocytopenia Caused by Drugs
Discontinue use of possible offending agents; expect recovery in 7–10 days. Platelet transfusions may be needed if platelet count < 10,000/μL.

Heparin-Induced Thrombocytopenia
Discontinue heparin promptly. A direct thrombin inhibitor such as lepirudin (0.4-mg/kg bolus, 0.15-mg/kg per hour infusion; PTT target 1.5–2.5 × baseline) or argatroban (2-μg/kg per min infusion; PTT target 1.5–3 × baseline) should be used for treatment of thromboses. Do not use low-molecular-weight heparin (LMWH), as antibodies often cross-react.
**Chronic ITP**
Prednisone, initially 1–2 mg/kg per day, then slow taper to keep the platelet count > 60,000/μL. IV immunoglobulin (2 g/kg in divided doses over 2–5 days) to block phagocytic destruction may be useful. Rituximab is effective in pts refractory to glucocorticoids. Splenectomy, danazol (androgen), or other agents (e.g., vincristine, cyclophosphamide, fludarabine) are indicated for refractory pts or those requiring >5–10 mg prednisone daily.

**DIC**
Control of underlying disease most important; platelets, fresh-frozen plasma (FFP) to correct clotting parameters. Heparin may be beneficial in pts with acute promyelocytic leukemia.

**TTP**
Plasmapheresis and FFP infusions (plasma exchange), possibly IV IgG; recovery in two-thirds of cases. Plasmapheresis removes inhibitors of the vWF cleavage enzyme (ADAMTS13), and FFP replaces the enzyme.

**Disorders of Platelet Function**
Remove or reverse underlying cause. Dialysis and/or cryoprecipitate infusions (10 bags/24 h) may be helpful for platelet dysfunction associated with uremia.

**Hemostatic Disorders**
Withdraw offending drugs, replace vitamin C, plasmapheresis, and plasma infusion for TTP.

**Hemophilia A**
Factor VIII replacement for bleeding or before surgical procedure; degree and duration of replacement depends on severity of bleeding. Give factor VIII (e.g., Recombinate) to obtain a 15% (for mild bleeding) to 50% (for severe bleeding) factor VIII level. The duration should range from a single dose of factor VIII to therapy bid for up to 2 weeks. Dose is calculated as follows:

\[
\text{Factor VIII dose} = (\text{Target level} - \text{baseline level}) \times \text{weight (kg)} \times 0.5 \text{ unit/kg}
\]

**Hemophilia B**
Recombinant factor IX (e.g., Benefix), FFP or factor IX concentrates (e.g., Proplex, Konyne). Because of the longer half-life, once-daily treatment is sufficient. Dose is calculated as follows:

\[
\text{Factor IX dose} = (\text{Target level} - \text{baseline level}) \times \text{weight (kg)} \times 1 \text{ unit/kg}
\]

**von Willebrand Disease**
Desmopressin (1-deamino-8-D-arginine vasopressin) increases release of vWF from endothelial stores in type 1 vWD. It is given IV (0.3 μg/kg) or by nasal spray (2 squirts of 1.5-mg/mL fluid in each nostril). For types 2A, 2M, and 3, cryoprecipitate (plasma product rich in factor VIII) or factor VIII concentrate (Humate-P, Koate HS) is used: up to 10 bags bid for 48–72 h, depending on the severity of bleeding.

**Vitamin K Deficiency**
Vitamin K, 10 mg SC or slow IV.

**Liver Disease**
Fresh-frozen plasma.
Consider in pts with recurrent episodes of venous thrombosis [i.e., deep-venous thrombosis (DVT), pulmonary embolism (PE)]. Causes include (1) venous stasis (e.g., pregnancy, immobilization); (2) vasculitis; (3) cancer and myeloproliferative disorders; (4) oral contraceptives; (5) lupus anticoagulant—antibody to platelet phospholipid, stimulates coagulation; (6) heparin-induced thrombocytopenia; (7) deficiencies of endogenous anticoagulant factors—antithrombin III, protein C, protein S; (8) factor V Leiden—mutation in factor V (Arg → Glu at position 506) confers resistance to inactivation by protein C, accounts for 25% of cases of recurrent thrombosis; (9) prothrombin gene mutation—Glu → Arg at position 20210 results in increased prothrombin levels; accounts for about 6% of thromboses; (10) other—paroxysmal nocturnal hemoglobinuria, dysfibrinogenemias (abnormal fibrinogen).

The approach to the diagnosis of the pt with DVT and/or PE is discussed in Chap. 140.

Correct underlying disorder whenever possible; long-term warfarin therapy is otherwise indicated.

1. Heparin (Table 68-1)—enhances activity of antithrombin III; parenteral agent of choice. LMWH is the preparation of choice (enoxaparin or dalteparin). It can be administered SC, monitoring of the PTT is unnecessary, and it is less likely to induce antibodies and thrombocytopenia. The usual dose is 100 U/kg SC bid. Unfractionated heparin should be given only if LMWH is unavailable. In adults, the dose of unfractionated heparin is 25,000–40,000 U continuous IV infusion over 24 h following initial IV bolus of 5000 U; monitor by following PTT; should be maintained between 1.5 and 2 times upper normal limit. Prophylactic anticoagulation to lower risk of venous thrombosis recommended in some pts (e.g., postoperative, immobilized) (Table 68-1). Prophylactic doses of unfractionated heparin are 5000 U SC bid or tid. Major complication of unfractionated heparin therapy is hemorrhage—manage by discontinuing heparin; for severe bleeding, administer protamine (1 mg/100 U heparin); results in rapid neutralization.

2. Warfarin (Coumadin)—vitamin K antagonist, decreases levels of factors II, VII, IX, X, and anticoagulant proteins C and S. Administered over 2–3 days; initial load of 5–10 mg PO qd followed by titration of daily dose to keep PT 1.5–2 times control PT or 2–3 times if the International Normalized Ratio method is used. Complications include hemorrhage, warfarin-induced skin necrosis (rare, occurs in persons deficient in protein C), teratogenic effects. Warfarin effect reversed by administration of vitamin K; FFP infused if urgent reversal necessary. Numerous drugs potentiate or antagonize warfarin effect. Potentiating agents include chlorpromazine, chloral hydrate, sulfonamides, chloramphenicol, other broad-spectrum antibiotics, allopurinol, cimetidine, tricyclic antidepressants, disulfiram, laxatives, high-dose salicylates, thyroxine, clofibrate. Some pts who are sensitive to warfarin effects have genetic defects metabolizing the drug. Antagonizing agents include vitamin K, barbiturates, rifampin, cholestyramine, oral contraceptives, thiazides.
3. **Fondaparinux**—a pentapeptide that directly inhibits factor Xa. It is given at a dose of 2.5 mg SC daily for prophylaxis and 7.5 mg SC daily for treatment of thrombosis and does not require monitoring. Unlike the heparins, it does not bind to platelet factor 4 and does not elicit the antibodies that produce heparin-induced thrombocytopenia.

4. **Argatroban and lepirudin**—direct thrombin inhibitors. These agents are being compared to LMWH and are commonly used in pts with heparin-induced thrombocytopenia. Both are monitored with the activated PTT.

In-hospital anticoagulation is usually initiated with heparin for 4–10 days, with subsequent maintenance on warfarin after an overlap of 3 days. Duration of therapy depends on underlying condition; calf DVT with clear precipitating cause, 3 months; proximal or idiopathic DVT or PE, 6–12 months; recurrent idiopathic DVT, 12 months minimum; embolic disease with ongoing risk factor, long-term, indefinite.

---

**TABLE 68-1**  
**ANTICOAGULANT THERAPY WITH LOW-MOLECULAR-WEIGHT AND UNFRACTIONATED HEPARIN**

<table>
<thead>
<tr>
<th>Clinical Indication</th>
<th>Heparin Dose and Schedule</th>
<th>Target PTT&lt;sup&gt;a&lt;/sup&gt;</th>
<th>LMWH Dose and Schedule&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Venous thrombosis pulmonary embolism</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>5000 U IV bolus; 1000–1500 U/h</td>
<td>2–2.5</td>
<td>100 U/kg SC bid</td>
</tr>
<tr>
<td>Prophylaxis</td>
<td>5000 U SC q8–12h</td>
<td>&lt;1.5</td>
<td>100 U/kg SC bid</td>
</tr>
<tr>
<td><strong>Acute myocardial infarction</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With thrombolytic therapy</td>
<td>5000 U IV bolus; 1000 U/h</td>
<td>1.5–2.5</td>
<td>100 U/kg SC bid</td>
</tr>
<tr>
<td>With mural thrombus</td>
<td>8000 U SC q8h + warfarin</td>
<td>1.5–2.0</td>
<td>100 U/kg SC bid</td>
</tr>
<tr>
<td>Unstable angina</td>
<td>5000 U IV bolus; 1000 U/h</td>
<td>1.5–2.5</td>
<td>100 U/kg SC bid</td>
</tr>
<tr>
<td><strong>Prophylaxis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General surgery</td>
<td>5000 U SC bid</td>
<td>&lt;1.5</td>
<td>100 U/kg SC before and bid</td>
</tr>
<tr>
<td>Orthopedic surgery</td>
<td>10,000 U SC bid</td>
<td>1.5</td>
<td>100 U/kg SC before and bid</td>
</tr>
<tr>
<td>Medical pts with CHF, MI</td>
<td>10,000 U SC bid</td>
<td>1.5</td>
<td>100 U/kg SC bid</td>
</tr>
</tbody>
</table>

<sup>a</sup>Times normal control; assumes PTT has been standardized to heparin levels so that 1.5–2.5 x normal equals 0.2–0.4 U/mL; if PTT is normal (27–35 s), start with 5000 U bolus 1300 U/h infusion monitoring PTT; if PTT at recheck is <50 s, rebolus with 5000 U and increase infusion by 100 U/h; if PTT at recheck is 50–60 s, increase infusion rate by 100 U/h; if PTT at recheck is 60–85 s, no change; if PTT at recheck is 85–100 s, decrease infusion rate 100 U/h; if PTT at recheck is 100–120 s, stop infusion for 30 min and decrease rate 100 U/h at restart; if PTT at recheck is >120 s, stop infusion for 60 min and decrease rate 200 U/h at restart.

<sup>b</sup>LMWH does not affect PTT, and PTT is not used to adjust dosage.

**Note:** PTT, partial thromboplastin time; LMWH, low-molecular-weight heparin; CHF, congestive heart failure; MI, myocardial infarction.
**Fibrinolytic Agents**

Tissue plasminogen activators mediate clot lysis by activating plasmin, which degrades fibrin. Currently available versions include streptokinase, urokinase, anistreplase (acylated plasminogen streptokinase activator complex), and three modestly distinct forms of recombinant tissue plasminogen activator (tPA): alteplase, tenecteplase, and reteplase. Indications include treatment of DVT, with lower incidence of postphlebitic syndrome (chronic venous stasis, skin ulceration) than with heparin therapy; massive PE, arterial embolic occlusion of an extremity, treatment of acute myocardial infarction (MI), unstable angina pectoris. Dosages for fibrinolytic agents: (1) tPA—for acute MI and massive PE (adult > 65 kg), 10-mg IV bolus over 1–2 min, then 50 mg IV over 1 h and 40 mg IV over next 2 h (total dose = 100 mg). tPA is slightly more effective but more expensive than streptokinase for treatment of acute MI. (2) Streptokinase—for acute MI, 1.5 million IU IV over 60 min; or 20,000 IU as a bolus intracoronary (IC) infusion, followed by 2000 IU/min for 60 min IC. For PE or arterial or deep-venous thrombosis, 250,000 IU over 30 min, then 100,000 IU/h for 24 h (PE) or 72 h (arterial or deep-venous thrombosis). (3) Urokinase—for PE, 4400 IU/kg IV over 10 min, then 4400 (IU/kg)/h IV for 12 h.

Fibrinolytic therapy is usually followed by a period of anticoagulant therapy with heparin. Fibrinolytic agents are contraindicated in pts with (1) active internal bleeding; (2) recent (<2–3 months) cerebrovascular accident; (3) intracranial neoplasm, aneurysm, or recent head trauma.

**Antiplatelet Agents**

Aspirin inhibits platelet function by blocking the ability of cyclooxygenase (COX-1) to synthesize thromboxane A2. The thienopyridines (ticlopidine and clopidogrel) inhibit ADP-induced platelet aggregation by blocking its receptor (P2Y12). Dipyridamole acts by inhibiting phosphodiesterase, which permits cAMP levels to increase and block activation. Glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists block the integrin receptors on the platelet and prevent platelet aggregation. Three such agents are now in use: abciximab, an Fab antibody fragment that binds to the activated form of GPIIb/IIIa; eptifibatide, a cyclic heptapeptide that includes the KGD tripeptide motif that the GPIIb/IIIa receptor recognizes; and tirofiban, a tyrosine derivative that mimics the KGD motif.

Aspirin (160–325 mg/d) plus clopidogrel (400-mg loading dose then 75 mg/d) may be beneficial in lowering incidence of arterial thrombotic events (stroke, MI) in high-risk pts. Antiplatelet agents are useful in preventing strokes, complications from percutaneous coronary interventions, and progression of unstable angina.

For a more detailed discussion, see Konkle BA: Bleeding and Thrombosis, Chap. 59, p. 363; Konkle BA: Disorders of Platelets and Vessel Wall, Chap. 109, p. 718; Arruda V, High KA: Coagulation Disorders, Chap. 110, p. 725; and Weitz JI: Antiplatelet, Anticoagulant, and Fibrinolytic Drugs, Chap. 112, p. 735, in HPIM-17.
Cancer Chemotherapy

CHAPTER 69

BIOLOGY OF TUMOR GROWTH

Two essential features of cancer cells are uncontrolled growth and the ability to metastasize. The malignant phenotype of a cell is the end result of a series of genetic changes that remove safeguards restricting cell growth and induce new features that enable the cell to metastasize, including surface receptors for binding to basement membranes, enzymes to poke holes in anatomic barriers, cytokines to facilitate mobility, and angiogenic factors to develop a new vascular lifeline for nutrients and oxygen. These genetic changes usually involve increased or abnormal expression or activity of certain genes known as proto-oncogenes (often growth factors or their receptors, enzymes in growth pathways, or transcription factors), deletion or inactivation of tumor-suppressor genes, and defects in DNA repair enzymes. These genetic changes may occur by point mutation, gene amplification, gene rearrangement, or epigenetic changes such as altered gene methylation.

Once cells are malignant, their growth kinetics are similar to those of normal cells but lack regulation. For unclear reasons, tumor growth kinetics follow a Gompertizian curve: as the tumor mass increases, the fraction of dividing cells declines. Thus, by the time a cancer is large enough to be detected clinically, its growth fraction is often small. Unfortunately, tumor growth usually does not stop altogether before the tumor reaches a lethal tumor burden. Cancer cells proceed through the same cell-cycle stages as normal cycling cells: G₁ (period of preparation for DNA synthesis), S (DNA synthesis), G₂ (tetraploid phase preceding mitosis in which integrity of DNA replication is assessed), and M (mitosis). Some noncycling cells may remain in a G₀, or resting, phase for long periods. Certain chemotherapeutic agents are specific for cells in certain phases of the cell cycle, a fact that is important in designing effective chemotherapeutic regimens.

DEVELOPMENT OF DRUG RESISTANCE

Drug resistance can be divided into de novo resistance or acquired resistance. De novo resistance refers to the tendency of many of the most common solid tumors to be unresponsive to chemotherapeutic agents. In acquired resistance, tumors initially responsive to chemotherapy develop resistance during treatment, usually because resistant clones appear within tumor cell populations (Table 69-1).

Resistance can be specific to single drugs because of (1) defective transport of the drug, (2) decreased activating enzymes, (3) increased drug inactivation, (4) increases in target enzyme levels, or (5) alterations in target molecules. Multiple drug resistance occurs in cells overexpressing the P glycoprotein, a membrane glycoprotein responsible for enhanced efflux of drugs from cells, but there are other mechanisms as well.

CATEGORIES OF CHEMOTHERAPEUTIC AGENTS AND MAJOR TOXICITIES

A partial list of toxicities is shown in Table 69-2; some toxicities may apply only to certain members of a group of drugs.
While the effects of cancer chemotherapeutic agents may be exerted primarily on the malignant cell population, virtually all currently employed regimens have profound effects on normal tissues as well. Every side effect of treatment must be balanced against potential benefits expected, and pts must always be fully apprised of the toxicities they may encounter. While the duration of certain adverse effects may be short-lived, others, such as sterility and the risk of secondary malignancy, have long-term implications; consideration of these effects is important in the use of regimens as adjuvant therapy. The combined toxicity of regimens involving radiotherapy and chemotherapy is greater than that seen with each modality alone. Teratogenesis is a special concern in treating

### TABLE 69-1 CURABILITY OF CANCERS WITH CHEMOTHERAPY

<table>
<thead>
<tr>
<th>Advanced cancers with possible cure</th>
<th>Cancers possibly cured with “high-dose” chemotherapy with stem cell support</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute lymphoid and acute myeloid leukemia (pediatric/adult)</td>
<td>Relapsed leukemias, lymphoid and myeloid</td>
</tr>
<tr>
<td>Hodgkin’s disease (pediatric/adult)</td>
<td>Relapsed leukemias, lymphoid and myeloid</td>
</tr>
<tr>
<td>Lymphomas—certain types (pediatric/adult)</td>
<td>Relapsed lymphomas, Hodgkin’s and non-Hodgkin’s</td>
</tr>
<tr>
<td>Germ cell neoplasms</td>
<td>Chronic myeloid leukemia</td>
</tr>
<tr>
<td>Embryonal carcinoma</td>
<td>Multiple myeloma</td>
</tr>
<tr>
<td>Teratocarcinoma</td>
<td><strong>Cancers responsive with useful palliation, but not cure, by therapy</strong></td>
</tr>
<tr>
<td>Seminoma or dysgerminoma</td>
<td>Bladder carcinoma</td>
</tr>
<tr>
<td>Choriocarcinoma</td>
<td>Chronic myeloid leukemia</td>
</tr>
<tr>
<td>Gestational trophoblastic neoplasia</td>
<td>Hairy cell leukemia</td>
</tr>
<tr>
<td>Pediatric neoplasms</td>
<td>Chronic lymphocytic leukemia</td>
</tr>
<tr>
<td>Wilms’ tumor</td>
<td>Lymphoma—certain types</td>
</tr>
<tr>
<td>Embryonal rhabdomyocarcinoma</td>
<td>Multiple myeloma</td>
</tr>
<tr>
<td>Ewing’s sarcoma</td>
<td>Gastric carcinoma</td>
</tr>
<tr>
<td>Peripheral neuroepithelioma</td>
<td>Cervix carcinoma</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>Endometrial carcinoma</td>
</tr>
<tr>
<td>Small cell lung carcinoma</td>
<td>Soft tissue sarcoma</td>
</tr>
<tr>
<td>Ovarian carcinoma</td>
<td>Head and neck cancer</td>
</tr>
<tr>
<td>Advanced cancers possibly cured by chemotherapy and radiation</td>
<td>Renal carcinoma</td>
</tr>
<tr>
<td>Squamous carcinoma (head and neck)</td>
<td>Islet-cell neoplasms</td>
</tr>
<tr>
<td>Squamous carcinoma (anus)</td>
<td>Breast carcinoma</td>
</tr>
<tr>
<td>Breast carcinoma</td>
<td>Colorectal carcinoma</td>
</tr>
<tr>
<td>Carcinoma of the uterine cervix</td>
<td>Tumors poorly responsive in advanced stages to therapy</td>
</tr>
<tr>
<td>Non-small cell lung carcinoma (stage III)</td>
<td>Pancreatic carcinoma</td>
</tr>
<tr>
<td>Small-cell lung carcinoma</td>
<td>Biliary-tract neoplasms</td>
</tr>
<tr>
<td><strong>Cancers possibly cured with chemotherapy as adjuvant to surgery</strong></td>
<td>Thyroid carcinoma</td>
</tr>
<tr>
<td>Breast carcinoma</td>
<td>Carcinoma of the vulva</td>
</tr>
<tr>
<td>Colorectal carcinoma</td>
<td>Non-small cell lung carcinoma</td>
</tr>
<tr>
<td>Osteogenic sarcoma</td>
<td>Prostate carcinoma</td>
</tr>
<tr>
<td>Soft tissue sarcoma</td>
<td>Melanoma</td>
</tr>
<tr>
<td><em>Rectum also receives radiation therapy.</em></td>
<td></td>
</tr>
</tbody>
</table>

**COMPLICATIONS OF THERAPY**

While the effects of cancer chemotherapeutic agents may be exerted primarily on the malignant cell population, virtually all currently employed regimens have profound effects on normal tissues as well. Every side effect of treatment must be balanced against potential benefits expected, and pts must always be fully apprised of the toxicities they may encounter. While the duration of certain adverse effects may be short-lived, others, such as sterility and the risk of secondary malignancy, have long-term implications; consideration of these effects is important in the use of regimens as adjuvant therapy. The combined toxicity of regimens involving radiotherapy and chemotherapy is greater than that seen with each modality alone. Teratogenesis is a special concern in treating
TABLE 69-2  TOXICITIES OF CANCER TREATMENTS

<table>
<thead>
<tr>
<th>Agent</th>
<th>Toxicities</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alkylating agents</strong></td>
<td>(add alkyl groups to N-7 or O-6 of guanine)</td>
</tr>
<tr>
<td>Busulfan</td>
<td>Nausea, vomiting, myelosuppression, sterility, alopecia, acute leukemia (rare), hemorrhagic cystitis, pulmonary fibrosis</td>
</tr>
<tr>
<td>Chlorambucil</td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td></td>
</tr>
<tr>
<td>Ifosfamide</td>
<td></td>
</tr>
<tr>
<td>Dacarbazine</td>
<td></td>
</tr>
<tr>
<td>Mechlorethamine</td>
<td></td>
</tr>
<tr>
<td>Nitrosoureas</td>
<td></td>
</tr>
<tr>
<td>Melphalan</td>
<td></td>
</tr>
<tr>
<td>Bendamustine</td>
<td></td>
</tr>
<tr>
<td><strong>Antimetabolites</strong></td>
<td>(inhibit DNA or RNA synthesis)</td>
</tr>
<tr>
<td>5-Fluorouracil</td>
<td>Nausea, vomiting, myelosuppression, oral ulceration, hepatic toxicity, alopecia, neurologic symptoms</td>
</tr>
<tr>
<td>Capecitabine</td>
<td></td>
</tr>
<tr>
<td>Fludarabine</td>
<td></td>
</tr>
<tr>
<td>Cladribine</td>
<td></td>
</tr>
<tr>
<td>Cytarabine</td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td></td>
</tr>
<tr>
<td>Pemetrexed</td>
<td></td>
</tr>
<tr>
<td>Hydroxyurea</td>
<td></td>
</tr>
<tr>
<td>Pentostatin</td>
<td></td>
</tr>
<tr>
<td>Azathioprine</td>
<td></td>
</tr>
<tr>
<td>Thioguanine</td>
<td></td>
</tr>
<tr>
<td><strong>Tubulin poisons</strong></td>
<td>(block tubule polymerization or depolymerization)</td>
</tr>
<tr>
<td>Vincristine</td>
<td>Nausea, vomiting, myelosuppression, vesicant effect, ileus, hypersensitivity reaction, peripheral neuropathy, SIADH</td>
</tr>
<tr>
<td>Vinblastine</td>
<td></td>
</tr>
<tr>
<td>Vinorelbine</td>
<td></td>
</tr>
<tr>
<td>Paclitaxel</td>
<td></td>
</tr>
<tr>
<td>Docetaxel</td>
<td></td>
</tr>
<tr>
<td>Estramustine</td>
<td></td>
</tr>
<tr>
<td><strong>Topoisomerase inhibitors</strong></td>
<td>(interfere with DNA unwinding/repair)</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>Nausea, vomiting, myelosuppression, vesicant effect, cardiac failure, acute leukemia (rare)</td>
</tr>
<tr>
<td>Daunorubicin</td>
<td></td>
</tr>
<tr>
<td>Idarubicin</td>
<td></td>
</tr>
<tr>
<td>Epirubicin</td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td></td>
</tr>
<tr>
<td>Irinotecan</td>
<td></td>
</tr>
<tr>
<td>Topotecan</td>
<td></td>
</tr>
<tr>
<td>Mitoxantrone</td>
<td></td>
</tr>
<tr>
<td><strong>Platinum compounds</strong></td>
<td>(form DNA adducts, disrupt repair)</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>Nausea, vomiting, myelosuppression, renal toxicity, neurotoxicity</td>
</tr>
<tr>
<td>Carboplatin</td>
<td></td>
</tr>
<tr>
<td>Oxaliplatin</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
women of childbearing years with radiation or chemotherapy. The most serious late toxicities are sterility (common; from alkylating agents), secondary acute leukemia (rare; from alkylating agents and topoisomerase inhibitors), secondary solid tumors (0.5–1%/year risk for at least 25 years after treatment; from radiation therapy), premature atherosclerosis (3-fold increased risk of fatal

### Table 69-2: Toxicities of Cancer Treatments (Continued)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Toxicities</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>(diverse mechanisms)</td>
<td></td>
</tr>
<tr>
<td>Bleomycin</td>
<td>Nausea, vomiting, myelosuppression, cardiac toxicity, lung fibrosis, hypo-calcemia, hypersensitivity reaction</td>
</tr>
<tr>
<td>Dactinomycin</td>
<td></td>
</tr>
<tr>
<td>Mithramycin</td>
<td></td>
</tr>
<tr>
<td>Mitomycin</td>
<td></td>
</tr>
<tr>
<td><strong>Hormone and nuclear receptor targeting agents</strong></td>
<td></td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>Nausea, vomiting, hot flashes, gynecmastia, impotence</td>
</tr>
<tr>
<td>Raloxifene</td>
<td></td>
</tr>
<tr>
<td>Anastrozole</td>
<td></td>
</tr>
<tr>
<td>Letrozole</td>
<td></td>
</tr>
<tr>
<td>Exemestane</td>
<td></td>
</tr>
<tr>
<td>Tretinoin</td>
<td></td>
</tr>
<tr>
<td>Bexarotene</td>
<td></td>
</tr>
<tr>
<td>Flutamide</td>
<td></td>
</tr>
<tr>
<td>Leuprolide</td>
<td></td>
</tr>
<tr>
<td>Diethylstilbestrol</td>
<td></td>
</tr>
<tr>
<td>Medroxyprogesterone</td>
<td></td>
</tr>
<tr>
<td><strong>Biologic agents</strong></td>
<td></td>
</tr>
<tr>
<td>Interferon</td>
<td>Nausea, vomiting, fever, chills, vascular leak, respiratory distress, skin rashes, edema</td>
</tr>
<tr>
<td>Interleukin 2</td>
<td></td>
</tr>
<tr>
<td>Rituximab</td>
<td></td>
</tr>
<tr>
<td>Trastuzumab</td>
<td></td>
</tr>
<tr>
<td>Cetuximab</td>
<td></td>
</tr>
<tr>
<td>Bevacizumab</td>
<td></td>
</tr>
<tr>
<td>Gentuzumab ozogamicin</td>
<td></td>
</tr>
<tr>
<td>Denileukin diftitox</td>
<td></td>
</tr>
<tr>
<td>Bortezomib</td>
<td></td>
</tr>
<tr>
<td>Imatinib</td>
<td></td>
</tr>
<tr>
<td>Dasatinib</td>
<td></td>
</tr>
<tr>
<td>Nilotinib</td>
<td></td>
</tr>
<tr>
<td>Gefitinib</td>
<td></td>
</tr>
<tr>
<td>Erlotinib</td>
<td></td>
</tr>
<tr>
<td>Sorafenib</td>
<td></td>
</tr>
<tr>
<td>Sunitinib</td>
<td></td>
</tr>
<tr>
<td>Temsirolimus</td>
<td></td>
</tr>
<tr>
<td><strong>Radiation therapy</strong></td>
<td></td>
</tr>
<tr>
<td>External beam (teletherapy)</td>
<td>Nausea, vomiting, myelosuppression, tissue damage, late second cancers, heart disease, sterility</td>
</tr>
<tr>
<td>Internal implants (brachytherapy)</td>
<td></td>
</tr>
<tr>
<td>Ibritumomab tiuxetan</td>
<td></td>
</tr>
<tr>
<td>Tositumomab</td>
<td></td>
</tr>
<tr>
<td>Samarium-153 EDTMP</td>
<td></td>
</tr>
<tr>
<td>Strontium-89</td>
<td></td>
</tr>
</tbody>
</table>

*Note: SIADH, syndrome of inappropriate antidiuretic hormone secretion.*
myocardial infarction; from radiation therapy that includes the heart), heart failure (rare; from anthracyclines), and pulmonary fibrosis (rare; from bleomycin).

**MANAGEMENT OF ACUTE TOXICITIES**

**Nausea and Vomiting**  Mildly to moderately emetogenic agents—prochlorperazine, 5–10 mg PO or 25 mg PR before chemotherapy; effects are enhanced by also administering dexamethasone, 10–20 mg IV. Highly emetogenic agents (such as cisplatin, mechlorethamine, dacarbazine, streptozocin)—ondansetron, 8 mg PO q6h the day before chemotherapy and IV at time of chemotherapy,

<table>
<thead>
<tr>
<th>TABLE 69-3</th>
<th>INDICATIONS FOR THE CLINICAL USE OF G-CSF OR GM-CSF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preventive Uses</strong></td>
<td>With the first cycle of chemotherapy (so-called primary CSF administration)</td>
</tr>
<tr>
<td></td>
<td>Not needed on a routine basis</td>
</tr>
<tr>
<td></td>
<td>Use if the probability of febrile neutropenia is ≥20%</td>
</tr>
<tr>
<td></td>
<td>Use if patient has preexisting neutropenia or active infection</td>
</tr>
<tr>
<td></td>
<td>Age &gt;65 treated for lymphoma with curative intent or other tumor treated by similar regimens</td>
</tr>
<tr>
<td></td>
<td>Poor performance status</td>
</tr>
<tr>
<td></td>
<td>Extensive prior chemotherapy</td>
</tr>
<tr>
<td></td>
<td>Dose-dense regimens in a clinical trial or with strong evidence of benefit</td>
</tr>
<tr>
<td>With subsequent cycles if febrile neutropenia has previously occurred</td>
<td>(so-called secondary CSF administration)</td>
</tr>
<tr>
<td></td>
<td>Not needed after short duration neutropenia without fever</td>
</tr>
<tr>
<td></td>
<td>Use if patient had febrile neutropenia in previous cycle</td>
</tr>
<tr>
<td></td>
<td>Use if prolonged neutropenia (even without fever) delays therapy</td>
</tr>
<tr>
<td><strong>Therapeutic Uses</strong></td>
<td>Afefrile neutropenic patients</td>
</tr>
<tr>
<td></td>
<td>No evidence of benefit</td>
</tr>
<tr>
<td>Febrile neutropenic patients</td>
<td>No evidence of benefit</td>
</tr>
<tr>
<td></td>
<td>May feel compelled to use in the face of clinical deterioration from sepsis, pneumonia, or fungal infection, but benefit unclear</td>
</tr>
<tr>
<td>In bone marrow or peripheral blood stem cell transplantation</td>
<td>Use to mobilize stem cells from marrow</td>
</tr>
<tr>
<td></td>
<td>Use to hasten myeloid recovery</td>
</tr>
<tr>
<td>In acute myeloid leukemia</td>
<td>G-CSF of minor or no benefit</td>
</tr>
<tr>
<td></td>
<td>GM-CSF of no benefit and may be harmful</td>
</tr>
<tr>
<td>In myelodysplastic syndromes</td>
<td>Not routinely beneficial</td>
</tr>
<tr>
<td></td>
<td>Use intermittently in subset with neutropenia and recurrent infection</td>
</tr>
<tr>
<td><strong>What Dose and Schedule Should Be Used?</strong></td>
<td>G-CSF: 5 µg/kg per day subcutaneously</td>
</tr>
<tr>
<td></td>
<td>GM-CSF: 250 µg/m² per day subcutaneously</td>
</tr>
<tr>
<td></td>
<td>Peg-filgrastim: one dose of 6 mg 24 h after chemotherapy</td>
</tr>
<tr>
<td><strong>When Should Therapy Begin and End?</strong></td>
<td>When indicated, start 24–72 h after chemotherapy</td>
</tr>
<tr>
<td></td>
<td>Continue until absolute neutrophil count is 10,000/µL</td>
</tr>
<tr>
<td></td>
<td>Do not use concurrently with chemotherapy or radiation therapy</td>
</tr>
</tbody>
</table>

**Note:** G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.

**Source:** From the American Society of Clinical Oncology.
plus dexamethasone, 20 mg IV at time of chemotherapy. Aprepitant (125 mg PO day 1, 80 mg PO days 2,3 with or without dexamethasone 8 mg), a substance P/neurokinin 1 receptor blocker, decreases the risk of acute and delayed vomiting from cisplatin.

**Neutropenia** Colony-stimulating factors are often used where they have been shown to have little or no benefit. Specific indications for the use of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor are provided in Table 69-3.

**Anemia** Quality of life is improved by maintaining Hb levels >90 g/L (9 g/dL). This is routinely done with packed red blood cell transfusions. Erythropoietin, 150 U thrice weekly, may improve quality-of-life scores independently of Hb level. Depot forms of erythropoietin may permit less frequent administration. Hb levels may take up to 2 months to increase. Concerns have been raised about the ability of erythropoietin to protect hypoxic cells from dying; studies have found that its use resulted in poorer tumor control.

**Thrombocytopenia** Rarely, treatment may induce a decline in platelet counts. Platelet transfusions are generally triggered at a platelet count of 10,000/μL in pts with solid tumors and at a platelet count of 20,000/μL in pts with acute leukemia.

For a more detailed discussion, see Sausville EA, Longo DL: Principles of Cancer Treatment, Chap. 81, p. 514, in HPIM-17.

### 70 Myeloid Leukemias, Myelodysplasia, and Myeloproliferative Syndromes

#### ACUTE MYELOID LEUKEMIA (AML)

AML is a clonal malignancy of myeloid bone marrow precursors in which poorly differentiated cells accumulate in the bone marrow and circulation.

Signs and symptoms occur because of the absence of mature cells normally produced by the bone marrow, including granulocytes (susceptibility to infection) and platelets (susceptibility to bleeding). In addition, if large numbers of immature malignant myeloblasts circulate, they may invade organs and rarely produce dysfunction. There are distinct morphologic subtypes (Table 70-1) that have largely overlapping clinical features. Of note is the propensity of pts with acute promyelocytic leukemia (APL) (FAB M3) to develop bleeding and disseminated intravascular coagulation, especially during induction chemotherapy, because of the release of procoagulants from their cytoplasmic granules.

**Incidence and Etiology** In the United States about 13,300 cases occur each year. AML accounts for about 80% of acute leukemias in adults. Etiology is unknown for the vast majority. Three environmental exposures increase the risk: chronic benzene exposure, radiation exposure, and prior treatment with alkylating agents (especially in addition to radiation therapy) and topoisomerase II inhibitors (e.g., doxorubicin and etoposide). Chronic myeloid leukemia (CML),
myelodysplasia, and myeloproliferative syndromes may all evolve into AML. Certain genetic abnormalities are associated with particular morphologic variants: t(15;17) with APL, inv(16) with eosinophilic leukemia; others occur in a number of types. Chromosome 11q23 abnormalities are often seen in leukemias developing after exposure to topoisomerase II inhibitors. Chromosome 5 or 7 deletions are seen in leukemias following radiation plus chemotherapy. The particular genetic abnormality has a strong influence on treatment outcome. Ex-

---

### TABLE 70-1 ACUTE MYELOID LEUKEMIA (AML) CLASSIFICATION SYSTEMS

<table>
<thead>
<tr>
<th>World Health Organization Classification&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. AML with recurrent genetic abnormalities</td>
</tr>
<tr>
<td>AML with t(8;21)(q22;q22);RUNX1/RUNX1T1&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>AML with abnormal bone marrow eosinophils [inv(16)(p13q22) or t(16;16)(p13;q22);CBFB/MYH11]&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Acute promyelocytic leukemia [AML with t(15;17)(q22;q12) (PML/RARA) and variants]&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>AML with 11q23 (MLL) abnormalities</td>
</tr>
<tr>
<td>II. AML with multilineage dysplasia</td>
</tr>
<tr>
<td>Following a myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative disorder</td>
</tr>
<tr>
<td>Without antecedent myelodysplastic syndrome</td>
</tr>
<tr>
<td>III. AML and myelodysplastic syndromes, therapy-related</td>
</tr>
<tr>
<td>Alkylating agent–related</td>
</tr>
<tr>
<td>Topoisomerase type II inhibitor–related</td>
</tr>
<tr>
<td>Other types</td>
</tr>
<tr>
<td>IV. AML not otherwise categorized</td>
</tr>
<tr>
<td>AML minimally differentiated</td>
</tr>
<tr>
<td>AML without maturation</td>
</tr>
<tr>
<td>AML with maturation</td>
</tr>
<tr>
<td>Acute myelomonocytic leukemia</td>
</tr>
<tr>
<td>Acute monoblastic and monocytic leukemia</td>
</tr>
<tr>
<td>Acute erythroid leukemia</td>
</tr>
<tr>
<td>Acute megakaryoblastic leukemia</td>
</tr>
<tr>
<td>Acute basophilic leukemia</td>
</tr>
<tr>
<td>Acute panmyelosis with myelofibrosis</td>
</tr>
<tr>
<td>Myeloid sarcoma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>French-American-British (FAB) Classification&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0: Minimally differentiated leukemia</td>
<td>5%</td>
</tr>
<tr>
<td>M1: Myeloblastic leukemia without maturation</td>
<td>20%</td>
</tr>
<tr>
<td>M2: Myeloblastic leukemia with maturation</td>
<td>30%</td>
</tr>
<tr>
<td>M3: Hypergranular promyelocytic leukemia</td>
<td>10%</td>
</tr>
<tr>
<td>M4: Myelomonocytic leukemia</td>
<td>20%</td>
</tr>
<tr>
<td>M4Eo: Variant: Increase in abnormal marrow eosinophils</td>
<td></td>
</tr>
<tr>
<td>M5: Monocytic leukemia</td>
<td>10%</td>
</tr>
<tr>
<td>M6: Erythroleukemia (DiGuglielmo’s disease)</td>
<td>4%</td>
</tr>
<tr>
<td>M7: Megakaryoblastic leukemia</td>
<td>1%</td>
</tr>
</tbody>
</table>

<sup>b</sup>Diagnosis is AML regardless of blast count.
pression of MDR1 (multidrug resistance efflux pump) is common in older pts and adversely affects prognosis.

**Clinical and Laboratory Features** Initial symptoms of acute leukemia have usually been present for <3 months; a preleukemic syndrome may be present in some 25% of pts with AML. Signs of anemia, pallor, fatigue, weakness, palpitations, and dyspnea on exertion are most common. White blood cell count (WBC) may be low, normal, or markedly elevated; circulating blast cells may or may not be present; with WBC > 100 × 10^9 blasts per liter, leukostasis in lungs and brain may occur. Minor pyogenic infections of the skin are common. Thrombocytopenia leads to spontaneous bleeding, epistaxis, petechiae, conjunctival hemorrhage, gingival bleeding, and bruising, especially with platelet count <20,000/μL. Anorexia and weight loss are common; fever may be present.

Bacterial and fungal infection are common; risk is heightened with total neutrophil count <5000/μL, and breakdown of mucosal and cutaneous barriers aggravates susceptibility; infections may be clinically occult in presence of severe leukopenia, and prompt recognition requires a high degree of clinical suspicion.

Hepatosplenomegaly occurs in about one-third of pts; leukemic meningitis may present with headache, nausea, seizures, papilledema, cranial nerve palsies. Metabolic abnormalities may include hyponatremia, hypokalemia, elevated serum lactate dehydrogenase (LDH), hyperuricemia, and (rarely) lactic acidosis. With very high blast cell count in the blood, spurious hyperkalemia and hyperglycemia may occur (potassium released from and glucose consumed by tumor cells after the blood was drawn).

**Acute Myeloid Leukemia**

Leukemic cell mass at time of presentation may be 10^11–10^12 cells; when total leukemic cell numbers fall below ~10^9, they are no longer detectable in blood or bone marrow and pt appears to be in complete remission (CR). Thus aggressive therapy must continue past the point when initial cell bulk is reduced if leukemia is to be eradicated. Typical phases of chemotherapy include remission induction and postremission therapy, with treatment lasting about 1 year.

Supportive care with transfusions of red cells and platelets [from cytomegalovirus (CMV)-seronegative donors, if pt is a candidate for bone marrow transplantation] is very important, as are aggressive prevention, diagnosis, and treatment of infections. Colony-stimulating factors offer little or no benefit; some recommend their use in older pts and those with active infections. Febrile neutropenia should be treated with broad-spectrum antibiotics (e.g., ceftazidime 1 g q8h); if febrile neutropenia persists beyond 7 days, amphotericin B should be added.

60–80% of pts will achieve initial remission when treated with cytarabine 100–200 (mg/m^2)/d by continuous infusion for 7 days, and daunorubicin [45 (mg/m^2)/d] or idarubicin [12–13 (mg/m^2)/d] for 3 days. Addition of etoposide may improve CR duration. Half of treated pts enter CR with the first cycle of therapy, and another 25% require two cycles. 10–30% of pts achieve 5-year disease-free survival and probable cure. Patients achieving a CR who have low risk of relapse [cells contain t(8;21) or inv(16)] receive 3–4 cycles of cytarabine. Those at high risk of relapse may be considered for allogeneic bone marrow transplantation.

Response to treatment after relapse is short, and prognosis for pts who have relapsed is poor. In APL, addition of trans-retinoic acid (tretinoin) to chemotherapy induces differentiation of the leukemic cells and may improve outcome. Arsenic trioxide also induces differentiation in APL cells.

Bone marrow transplantation from identical twin or human leukocyte antigen (HLA)-identical sibling is effective treatment for AML. Typical protocol
uses high-dose chemotherapy ± total-body irradiation to ablate host marrow, followed by infusion of marrow from donor. Risks are substantial (unless marrow is from identical twin). Complications include graft-versus-host disease, interstitial pneumonitis, opportunistic infections (especially CMV). Comparison between transplantation and high-dose cytarabine as postremission therapy has not produced a clear advantage for either approach. Up to 30% of otherwise end-stage pts with refractory leukemia achieve probable cure from transplantation; results are better when transplant is performed during remission. Results are best for children and young adults.

CHRONIC MYELOID LEUKEMIA

CML is a clonal malignancy usually characterized by splenomegaly and production of increased numbers of granulocytes; course is initially indolent but eventuates in leukemic phase (blast crisis) that has a poorer prognosis than de novo AML; rate of progression to blast crisis is variable; overall survival averages 4 years from diagnosis.

Incidence and Etiology In the United States, about 4800 cases occur each year. More than 90% of cases have a reciprocal translocation between chromosomes 9 and 22, creating the Philadelphia (Ph) chromosome and a fusion gene product called BCR-ABL (BCR is from 9, ABL from 22). The chromosome abnormality appears in all bone marrow–derived cells except T cells. The protein made by the chimeric gene is 210 kDa in chronic phase and 190 kDa in acute blast transformation. In some pts, the chronic phase is clinically silent and pts present with acute leukemia with the Ph chromosome.

Clinical and Laboratory Features Symptoms develop gradually; easy fatigability, malaise, anorexia, abdominal discomfort and early satiety from the large spleen, excessive sweating. Occasional pts are found incidentally based on elevated leukocyte count. WBC is usually >25,000/μL with the increase accounted for by granulocytes and their precursors back to the myelocyte stage; bands and mature forms predominate. Basophils may account for 10–15% of the cells in the blood. Platelet count is normal or increased. Anemia is often present. Neutrophil alkaline phosphatase score is low. Marrow is hypercellular with granulocytic hyperplasia. Marrow blast cell count is normal or slightly elevated. Serum levels of vitamin B₁₂, B₁₂-binding proteins, and LDH are elevated in proportion to the WBC. With high blood counts, spurious hyperkalemia and hypoglycemia may be seen.

Natural History Chronic phase lasts 2–4 years. Accelerated phase is marked by anemia disproportionate to the disease activity or treatment. Platelet counts fall. Additional cytogenetic abnormalities appear. Blast cell counts increase. Usually within 6–8 months, overt blast crisis develops in which maturation ceases and blasts predominate. The clinical picture is that of acute leukemia. Half of the cases become AML, one-third have morphologic features of acute lymphoid leukemia, 10% are erythroleukemia, and the rest are undifferentiated. Survival in blast crisis is often <4 months.

Criteria for response are provided in Table 70-2. Allogeneic bone marrow transplantation has the potential to cure the disease in chronic phase. However, the first treatment is imatinib, a molecule that inhibits the chimeric gene product’s tyrosine kinase activity. A daily oral dose of 400 mg produces complete hematologic remission of >90% and cytogenetic remission in 76%. If a
### TABLE 70-2 RESPONSE CRITERIA IN CHRONIC MYELOID LEUKEMIA

<table>
<thead>
<tr>
<th>Category</th>
<th>Hematologic</th>
<th>Cytogenetic</th>
<th>Molecular</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Complete response&lt;sup&gt;a&lt;/sup&gt; White blood cell count &lt;10,000/μL, normal morphology</td>
<td>Complete response&lt;sup&gt;a&lt;/sup&gt; Percentage of bone marrow metaphases with t(9;22) 0</td>
<td>Presence of BCR/ABL transcript by RT-PCR</td>
</tr>
<tr>
<td></td>
<td>Incomplete response White blood cell count ≥10,000/μL</td>
<td>Partial response ≤35</td>
<td>No response</td>
</tr>
<tr>
<td></td>
<td>Cyogenetic</td>
<td>Minor response 36–85&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Complete response None</td>
</tr>
<tr>
<td></td>
<td>Complete response</td>
<td>No response 85–100</td>
<td>Incomplete response Any</td>
</tr>
<tr>
<td></td>
<td>Incomplete response</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Complete hematologic response requires the disappearance of splenomegaly.

<sup>b</sup> Up to 15% normal metaphases are occasionally seen at diagnosis (when 30 metaphases are analyzed).

**Note:** RT-PCR, reverse transcriptase polymerase chain reaction.

### TABLE 70-3 WORLD HEALTH ORGANIZATION CLASSIFICATION OF DISEASE

<table>
<thead>
<tr>
<th>Disease</th>
<th>Frequency</th>
<th>Blood Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refractory anemia (RA)</td>
<td>5–10%</td>
<td>Anemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No or rare blasts</td>
</tr>
<tr>
<td>Refractory anemia with ringed sideroblasts (RARS)</td>
<td>10–12%</td>
<td>Anemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No blasts</td>
</tr>
<tr>
<td>Refractory cytopenia with multilineage dysplasia (RCMD)</td>
<td>24%</td>
<td>Cytopenias (2 or 3 lineages)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No or rare blasts</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No Auer rods &lt;1 × 10⁹/L monocytes</td>
</tr>
<tr>
<td>RCMD with ringed sideroblasts (RCMD-RS)</td>
<td>15%</td>
<td>Cytopenias (2 or 3 lineages)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No or rare blasts</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No Auer rods &lt;1 × 10⁹/L monocytes</td>
</tr>
<tr>
<td>Refractory anemia with excess blasts-1 (RAEB-1)</td>
<td>40% (RAEB-1 +2)</td>
<td>Cytopenias &lt;5% blasts</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No Auer rods &lt;1 × 10⁹/L monocytes</td>
</tr>
<tr>
<td>Refractory anemia with excess blasts-2 (RAEB-2)</td>
<td></td>
<td>Cytopenias 5–19% blasts ±Auer rods &lt;1 × 10⁹/L monocytes</td>
</tr>
<tr>
<td>Myelodysplastic syndrome, unclassified (MDS-U)</td>
<td>Unknown</td>
<td>Cytopenias</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No or rare blasts</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No Auer rods</td>
</tr>
<tr>
<td>MDS with isolated del(5q)</td>
<td>Unknown</td>
<td>Anemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt;5% blasts</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Platelets nl or increased</td>
</tr>
</tbody>
</table>

**Note:** BM, bone marrow.

matched donor is available, it is best to transplant patients in complete remission. Several mechanisms of resistance to imatinib have emerged, and it is unlikely that it leads to permanent remissions when used alone; however, follow-up is not sufficient to draw firm conclusions.

Patients who no longer respond to imatinib may respond to other tyrosine kinase inhibitors such as dasatinib (100 mg PO qd) or nilotinib (400 mg PO bid). The T315I mutation in the BCR/ABL gene conveys resistance to all three kinase inhibitors. Allopurinol, 300 mg/d, prevents urate nephropathy. The only curative therapy for the disease is HLA-matched allogeneic bone marrow transplantation. The optimal timing of transplantation is unclear, but transplantation in chronic phase is more effective than transplantation in accelerated phase or blast crisis. Transplantation appears most effective in pts treated within a year of diagnosis. Long-term disease-free survival may be obtained in 50–60% of transplanted pts. Infusion of donor lymphocytes can restore remission in relapsing pts. In pts without a matched donor, autologous transplantation may be helpful using peripheral blood stem cells. Treatment of pts in blast crisis with imatinib can obtain responses, but their durability has not been established.

### MYELODYSPLASTIC SYNDROMES

<table>
<thead>
<tr>
<th>Bone Marrow Findings</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erythroid dysplasia only</td>
<td>Protracted course</td>
</tr>
<tr>
<td>&lt;5% blasts</td>
<td>Leukemic transformation in ~6%</td>
</tr>
<tr>
<td>&lt;15% ringed sideroblasts</td>
<td></td>
</tr>
<tr>
<td>Erythroid dysplasia only</td>
<td>Protracted course</td>
</tr>
<tr>
<td>≥15% ringed sideroblasts</td>
<td>Leukemia in ~1–2%</td>
</tr>
<tr>
<td>&lt;5% blasts</td>
<td></td>
</tr>
<tr>
<td>Dysplasia in ≥10% of cells in ≥2 lineages</td>
<td>Variable clinical course</td>
</tr>
<tr>
<td>&lt;5% blasts</td>
<td>Leukemia in ~11%</td>
</tr>
<tr>
<td>No Auer rods</td>
<td></td>
</tr>
<tr>
<td>&lt;15% ringed sideroblasts</td>
<td></td>
</tr>
<tr>
<td>Dysplasia in ≥10% of cells in ≥2 lineages</td>
<td>Progressive BM failure</td>
</tr>
<tr>
<td>≥15% ringed sideroblasts</td>
<td>Leukemia in ~25%</td>
</tr>
<tr>
<td>&lt;5% blasts</td>
<td></td>
</tr>
<tr>
<td>No Auer rods</td>
<td></td>
</tr>
<tr>
<td>Unilineage or multilineage dysplasia</td>
<td>Progressive BM failure</td>
</tr>
<tr>
<td>5–9% blasts</td>
<td>Leukemia in ~33%</td>
</tr>
<tr>
<td>No Auer rods</td>
<td></td>
</tr>
<tr>
<td>Unilineage or multilineage dysplasia</td>
<td>Progressive BM failure</td>
</tr>
<tr>
<td>10–19% blasts</td>
<td>Leukemia in ~33%</td>
</tr>
<tr>
<td>±Auer rods</td>
<td></td>
</tr>
<tr>
<td>Dysplasia in myeloid or platelet lineage</td>
<td>Unknown</td>
</tr>
<tr>
<td>&lt;5% blasts</td>
<td></td>
</tr>
<tr>
<td>No Auer rods</td>
<td></td>
</tr>
<tr>
<td>NI or increased megakaryocytes with hypolobated nuclei</td>
<td>Long survival</td>
</tr>
<tr>
<td>&lt;5% blasts</td>
<td></td>
</tr>
<tr>
<td>No Auer rods</td>
<td></td>
</tr>
<tr>
<td>Isolated del(5q)</td>
<td></td>
</tr>
</tbody>
</table>
Hematology and Oncology

Myelodysplastic Syndromes (MDS)

These are clonal abnormalities of marrow cells characterized by varying degrees of cytopenias affecting one or more cell lines. The World Health Organization classification of myelodysplastic syndromes is shown in Table 70-3. Other terms that have been used to describe one or more of the entities include preleukemia and oligoblastic leukemia.

Incidence and Etiology

About 3000 cases occur each year, mainly in persons >50 years old (median age, 68). As in AML, exposure to benzene, radiation, and chemotherapeutic agents may lead to MDS. Chromosome abnormalities occur in up to 80% of cases, including deletion of part or all of chromosomes 5, 7, and 9 (20 or 21 less commonly) and addition of part or all of chromosome 8.

Clinical and Laboratory Features

Symptoms depend on the affected lineages. 85% of pts are anemic, 50% have neutropenia, and about one-third have thrombocytopenia. The pathologic features of MDS are a cellular marrow with varying degrees of cytologic atypia including delayed nuclear maturation, abnormal cytoplasmic maturation, accumulation of ringed sideroblasts (iron-laden mitochondria surrounding the nucleus), uni- or bilobed megakaryocytes, micromegakaryocytes, and increased myeloblasts. Table 70-3 lists features used to identify distinct entities. Prognosis is defined by marrow blast %, karyotype, and lineages affected (Table 70-4).

Myelodysplastic Syndromes

Allogeneic bone marrow transplantation is the only curative therapy and may cure 60% of those so treated. However, the majority of pts with MDS are too old to receive transplantation. 5-Azacytidine (75 mg/m² daily × 7, q 4 weeks) can delay transformation to AML by 8–10 months. Decitabine (15 mg/m² by continuous IV infusion, q8h daily × 3, q 6 weeks) may induce responses lasting a median of 1 year in 20% of pts. Lenalidomide (10 mg/d), a thalidomide analogue with fewer central nervous system effects, causes a substantial frac-

### Table 70-4

**International Prognostic Scoring System for Myelodysplastic Syndromes**

<table>
<thead>
<tr>
<th>Prognostic Factors</th>
<th>Low</th>
<th>Intermediate-1</th>
<th>Intermediate-2</th>
<th>High</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Marrow blasts</td>
<td>&lt;5 = 0 pts; 5–10 = 0.5 pts; 11–20 = 1.5 pts; 21–30 = 2 pts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karyotype&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Good = 0 pts; intermediate = 0.5 pts; poor = 1.5 pts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytophenias&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0/1 = 0 pts; 2/3 = 0.5 pts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk Group</td>
<td>Total points = 0</td>
<td>0.5–1.0</td>
<td>1.5–2.0</td>
<td>≥2.5</td>
</tr>
<tr>
<td></td>
<td>Risk of AML = 19%</td>
<td>30%</td>
<td>33%</td>
<td>45%</td>
</tr>
<tr>
<td></td>
<td>Median survival, years = 5.7</td>
<td>3.5</td>
<td>1.2</td>
<td>0.4</td>
</tr>
</tbody>
</table>

<sup>a</sup> Good karyotypes: normal, Y, del(5q), del(20q)  
Poor karyotypes: ≥3 abnormalities, chr 7 abnormalities  
Intermediate karyotypes: others

<sup>b</sup>Cytophenias defined as Hb < 100 g/L, platelet count < 100,000/μL, absolute neutrophil count < 1500/μL.
tion of patients with the 5q– syndrome to become transfusion-independent. Pts with low erythropoietin levels may respond to erythropoietin, and a minority of pts with neutropenia respond to granulocyte colony-stimulating factor. Supportive care is the cornerstone of treatment.

**MYELOPROLIFERATIVE SYNDROMES**

The three major myeloproliferative syndromes are polycythemia vera, idiopathic myelofibrosis, and essential thrombocytosis. All are clonal disorders of hematopoietic stem cells and all are associated with a mutation in the JAK2 kinase (V617F) that results in activation of the kinase. The mutation is seen in 90% of pts with polycythemia vera and ~45% of pts with idiopathic myelofibrosis and essential thrombocytosis.

**POLYCYTHEMIA VERA**

The most common myeloproliferative syndrome, this is characterized by an increase in red blood cell (RBC) mass, massive splenomegaly, and clinical manifestations related to increased blood viscosity, including neurologic symptoms (vertigo, tinnitus, headache, visual disturbances) and thromboses (myocardial infarction, stroke, peripheral vascular disease; uncommonly, mesenteric and hepatic). It must be distinguished from other causes of increased RBC mass (Chap. 58). This is most readily done by assaying serum erythropoietin levels. Polycythemia vera is associated with very low erythropoietin levels; in other causes of erythrocytosis, erythropoietin levels are high. Pts are effectively managed with phlebotomy. Some pts require splenectomy to control symptoms, and those with severe pruritus may benefit from psoralens and UV light. 20% develop myelofibrosis, <5% acute leukemia.

**IDIOPATHIC MYELOFIBROSIS**

This rare entity is characterized by marrow fibrosis, myeloid metaplasia with extramedullary hematopoiesis, and splenomegaly. Evaluation of a blood smear reveals teardrop-shaped RBC, nucleated RBC, and some early granulocytic forms, including promyelocytes. However, many entities may lead to marrow fibrosis and extramedullary hematopoiesis, and the diagnosis of primary idiopathic myelofibrosis is made only when the many other potential causes are ruled out. The following diseases are in the differential diagnosis: CML, polycythemia vera, Hodgkin's disease, cancer metastatic to the marrow (especially from breast and prostate), infection (particularly granulomatous infections), and hairy cell leukemia. Supportive therapy is generally used; no specific therapy is known.

**ESSENTIAL THROMBOCYTOSIS**

This is usually noted incidentally upon routine platelet count done in an asymptomatic person. Like myelofibrosis, many conditions can produce elevated platelet counts; thus, the diagnosis is one of exclusion. Platelet count must be >500,000/μL, and known causes of thrombocytosis must be ruled out including CML, iron deficiency, splenectomy, malignancy, infection, hemorrhage, polycythemia vera, myelodysplasia, and recovery from vitamin B₁₂ deficiency. Although usually asymptomatic, pts should be treated if they develop migraine headache, transient ischemic attack, or other bleeding or thrombotic disease manifestations. Interferon α is effective therapy, as are anagrelide and hydroxy-
urea. Treatment should not be given just because the absolute platelet count is high in the absence of other symptoms.

For a more detailed discussion, see Young NS: Aplastic Anemia, Myelodysplasia, and Related Bone Marrow Failure Syndromes, Chap. 102, p. 663; Spivak JL: Polycythemia Vera and Other Myeloproliferative Diseases, Chap. 103, p. 671; and Wetzler M et al: Acute and Chronic Myeloid Leukemia, Chap. 104, p. 677, in HPIM-17.

71 Lymphoid Malignancies

Definition Neoplasms of lymphocytes usually represent malignant counterparts of cells at discrete stages of normal lymphocyte differentiation. When bone marrow and peripheral blood involvement dominate the clinical picture, the disease is classified as a lymphoid leukemia. When lymph nodes and/or other extranodal sites of disease are the dominant site(s) of involvement, the tumor is called a lymphoma. The distinction between lymphoma and leukemia is sometimes blurred; for example, small lymphocytic lymphoma and chronic lymphoid leukemia are tumors of the same cell type and are distinguished arbitrarily on the basis of the absolute number of peripheral blood lymphocytes (>5 × 10⁹/L defines leukemia).

Classification Historically, lymphoid tumors have had separate pathologic classifications based on the clinical syndrome—lymphomas according to the Rappaport, Kiel, or Working Formulation systems; acute leukemias according to the French-American-British (FAB) system; Hodgkin’s disease according to the Rye classification. Myelomas have generally not been subclassified by pathologic features of the neoplastic cells. The World Health Organization (WHO) has proposed a unifying classification system that brings together all lymphoid neoplasms into a single framework. Although the new system bases the definitions of disease entities on histology, genetic abnormalities, immunophenotype, and clinical features, its organization is based on cell of origin (B cell vs. T cell) and maturation stage (precursor vs. mature) of the tumor, features that are of limited value to the clinician. Table 71-1 lists the disease entities according to a more clinically useful schema based on the clinical manifestations and natural history of the diseases.

Incidence Lymphoid tumors are increasing in incidence. Nearly 115,000 cases were diagnosed in 2008 in the United States (Fig. 71-1).

Etiology The cause(s) for the vast majority of lymphoid neoplasms is unknown. The malignant cells are monoclonal and often contain numerous genetic abnormalities. Some genetic alterations are characteristic of particular histologic entities: t(8;14) in Burkitt’s lymphoma, t(14;18) in follicular lymphoma, t(11;14) in mantle cell lymphoma, t(2;5) in anaplastic large cell lymphoma, translocations or mutations involving bcl-6 on 3q27 in diffuse large cell lymphoma, and others. In most cases, translocations involve insertion of a distant chromosome segment into the antigen receptor genes (either immunoglob-
ulin or T cell receptor) during the rearrangement of the gene segments that form the receptors.

Three viruses—Epstein-Barr virus (EBV), human herpesvirus 8 (HHV-8) (both herpes family viruses), and human T-lymphotropic virus type I (HTLV-I, a retrovirus)—may cause some lymphoid tumors. EBV has been strongly associated with African Burkitt’s lymphoma and the lymphomas that complicate immunodeiciencies (disease-related or iatrogenic). EBV has an uncertain relationship to mixed cellularity Hodgkin’s disease and angiocentric lymphoma. HHV-8 causes a rare entity, body cavity lymphoma, mainly in pts with AIDS. HTLV-I is associated with adult T cell leukemia/lymphoma. Both the virus and the disease are endemic to southwestern Japan and the Caribbean.

### TABLE 71-1  CLINICAL SCHEMA OF LYMPHOID NEOPLASMS

<table>
<thead>
<tr>
<th>Chronic lymphoid leukemias/lymphomas</th>
<th>Chronic lymphocytic leukemia/small lymphocytic lymphoma (99% B cell, 1% T cell)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prolymphocytic leukemia (90% B cell, 10% T cell)</td>
<td></td>
</tr>
<tr>
<td>Large granular lymphocyte leukemia [80% natural killer (NK) cell, 20% T cell]</td>
<td></td>
</tr>
<tr>
<td>Hairy cell leukemia (99–100% B cell)</td>
<td></td>
</tr>
<tr>
<td><strong>Indolent lymphoma</strong></td>
<td></td>
</tr>
<tr>
<td>Follicular center cell lymphoma, grades I and II (100% B cell)</td>
<td></td>
</tr>
<tr>
<td>Lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia (100% B cell)</td>
<td></td>
</tr>
<tr>
<td>Marginal zone lymphoma (100% B cell)</td>
<td></td>
</tr>
<tr>
<td>Extranaodal [mucosa-associated lymphatic tissue (MALT) lymphoma]</td>
<td></td>
</tr>
<tr>
<td>Nodal (monocytoid B cell lymphoma)</td>
<td></td>
</tr>
<tr>
<td>Splenic marginal zone lymphoma</td>
<td></td>
</tr>
<tr>
<td>Cutaneous T cell lymphoma (mycosis fungoides) (100% T cell)</td>
<td></td>
</tr>
<tr>
<td><strong>Aggressive lymphoma</strong></td>
<td></td>
</tr>
<tr>
<td>Diffuse large cell lymphoma (85% B cell, 15% T cell), includes immunoblastic</td>
<td></td>
</tr>
<tr>
<td>Follicular center cell lymphoma, grade III (100% B cell)</td>
<td></td>
</tr>
<tr>
<td>Mantle cell lymphoma (100% B cell)</td>
<td></td>
</tr>
<tr>
<td>Primary mediastinal (thymic) large B cell lymphoma (100% B cell)</td>
<td></td>
</tr>
<tr>
<td>Peripheral T cell lymphoma (100% T cell)</td>
<td></td>
</tr>
<tr>
<td>Angioimmunoblastic lymphoma (100% T cell)</td>
<td></td>
</tr>
<tr>
<td>Angiocentric lymphoma (80% T cell, 20% NK cell)</td>
<td></td>
</tr>
<tr>
<td>Intestinal T cell lymphoma (100% T cell)</td>
<td></td>
</tr>
<tr>
<td>Anaplastic large cell lymphoma (70% T cell, 30% null cell)</td>
<td></td>
</tr>
<tr>
<td><strong>Acute lymphoid leukemias/lymphomas</strong></td>
<td></td>
</tr>
<tr>
<td>Precursor lymphoblastic leukemia/lymphoma (80% T cell, 20% B cell)</td>
<td></td>
</tr>
<tr>
<td>Burkitt’s leukemia/lymphoma (100% B cell)</td>
<td></td>
</tr>
<tr>
<td>Adult T cell leukemia/lymphoma (100% T cell)</td>
<td></td>
</tr>
<tr>
<td><strong>Plasma cell disorders</strong> (100% B cell)</td>
<td></td>
</tr>
<tr>
<td>Monoclonal gammopathy of uncertain significance</td>
<td></td>
</tr>
<tr>
<td>Solitary plasmacytoma</td>
<td></td>
</tr>
<tr>
<td>Extramedullary plasmacytoma</td>
<td></td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td></td>
</tr>
<tr>
<td>Plasma cell leukemia</td>
<td></td>
</tr>
<tr>
<td><strong>Hodgkin’s disease</strong> (cell of origin mainly B cell)</td>
<td></td>
</tr>
<tr>
<td>Lymphocyte predominant</td>
<td></td>
</tr>
<tr>
<td>Nodular sclerosis</td>
<td></td>
</tr>
<tr>
<td>Mixed cellularity</td>
<td></td>
</tr>
<tr>
<td>Lymphocyte depleted</td>
<td></td>
</tr>
</tbody>
</table>
FIGURE 71-1 Relative frequency of lymphoid malignancies.
Gastric *Helicobacter pylori* infection is associated with gastric mucosa-associated lymphoid tissue (MALT) lymphoma and perhaps gastric large cell lymphoma. Eradication of the infection produces durable remissions in about half of pts with gastric MALT lymphoma. MALT lymphomas of other sites are associated with either infection (ocular adnexae, *Chlamydia psittaci*; small intestine, *Campylobacter jejuni*; skin, *Borrelia*) or autoimmunity (salivary gland, Sjögren’s syndrome; thyroid gland, Hashimoto’s thyroiditis).

Inherited or acquired immunodeficiencies and autoimmune disorders predispose individuals to lymphoma. Lymphoma is 17 times more common in HIV-infected than in HIV-noninfected people. Lymphoma occurs with increased incidence in farmers and meat workers; Hodgkin’s disease is increased in wood workers.

**Diagnosis and Staging** Excisional biopsy is the standard diagnostic procedure; adequate tissue must be obtained. Tissue undergoes three kinds of studies: (1) light microscopy to discern the pattern of growth and the morphologic features of the malignant cells, (2) flow cytometry for assessment of immunophenotype, and (3) genetic studies (cytogenetics, DNA extraction). Needle aspirates of nodal or extranodal masses are not adequate diagnostic procedures. Leukemia diagnosis and lymphoma staging include generous bilateral iliac crest bone marrow biopsies. Differential diagnosis of adenopathy is reviewed in Chap. 59.

Staging varies with the diagnosis. In acute leukemia, peripheral blood blast counts are most significant in assessing prognosis. In chronic leukemia, peripheral blood red blood cell (RBC) and platelet counts are most significant in assessing prognosis. Non-Hodgkin’s lymphomas have five clinical prognostic factors; indolent and aggressive lymphomas share three of these, advanced stage, high lactate dehydrogenase (LDH) levels, and age >60. In follicular lymphoma, the last two factors are Hb <120 g/L (<12 g/dL) and more than four nodal sites of involvement. In aggressive lymphoma, more than one extranodal site and performance status predict outcome. In myeloma, serum levels of para-protein, creatinine, and β2-microglobulin levels predict survival.

### CHRONIC LYMPHOID LEUKEMIAS/LYMPHOMAS

Most of these entities have a natural history measured in years. (Prolymphocytic leukemia is very rare and can be very aggressive.) Chronic lymphocytic leukemia is the most common entity in this group (~15,000 cases/year) and the most common leukemia in the Western world.

**Chronic Lymphocytic Leukemia (CLL)** Usually presents as asymptomatic lymphocytosis in pts >60 years. The malignant cell is a CD5+ B cell that looks like a normal small lymphocyte. Trisomy 12 is the most common genetic abnormality. Prognosis is related to stage; stage is determined mainly by the degree to which the tumor cells crowd out normal hematopoietic elements from the marrow (Table 71-2). Cells may infiltrate nodes and spleen as well as marrow. Nodal involvement may be related to the expression of an adhesion molecule that allows the cells to remain in the node rather than recirculate. Pts often have hypogammaglobulinemia. Up to 20% have autoimmune antibodies that may produce autoimmune hemolytic anemia, thrombocytopenia, or red cell aplasia. Death is from infection, marrow failure, or intercurrent illnesses. In 5%, the disease evolves to aggressive lymphoma (Richter’s syndrome) that is refractory to treatment.

Subsets of CLL may exist based on whether the immunoglobulin expressed by the tumor cell contains mutations (more indolent course, good prognosis) or
Table 71-2: Staging of B Cell CLL and Relation to Survival

<table>
<thead>
<tr>
<th>Stage</th>
<th>Clinical Features</th>
<th>Median Survival, Years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RAI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>Lymphocytosis</td>
<td>12</td>
</tr>
<tr>
<td>I</td>
<td>Lymphocytosis + adenopathy</td>
<td>9</td>
</tr>
<tr>
<td>II</td>
<td>Lymphocytosis + splenomegaly</td>
<td>7</td>
</tr>
<tr>
<td>III</td>
<td>Anemia</td>
<td>1–2</td>
</tr>
<tr>
<td>IV</td>
<td>Thrombocytopenia</td>
<td>1–2</td>
</tr>
<tr>
<td>BINET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>No anemia/thrombocytopenia, &lt;3 involved sites</td>
<td>&gt;10</td>
</tr>
<tr>
<td>B</td>
<td>No anemia/thrombocytopenia, &gt;3 involved sites</td>
<td>5</td>
</tr>
<tr>
<td>C</td>
<td>Anemia and/or thrombocytopenia</td>
<td>2</td>
</tr>
</tbody>
</table>

Chronic Lymphocytic Leukemia

Supportive care is generally given until anemia or thrombocytopenia develops. At that time, tests are indicated to assess the cause of the anemia or thrombocytopenia. Decreased RBC and/or platelet counts related to peripheral destruction may be treated with splenectomy or glucocorticoids without cytotoxic therapy in many cases. If marrow replacement is the mechanism, cytotoxic therapy is indicated. Fludarabine, 25 (mg/m²)/d IV × 5 days every 4 weeks, induces responses in about 75% of pts, complete responses in half. Rituximab (375–500 mg/m² day 1), fludarabine (25 mg/m² days 2–4 on cycle 1 and 1–3 in subsequent cycles), plus cyclophosphamide (250 mg/m² with fludarabine) induces complete responses in nearly 70% of pts but the regimen is associated with significant myelotoxicity. Glucocorticoids increase the risk of infection without adding a substantial antitumor benefit. Monthly IV immunoglobulin (IVIg) significantly reduces risk of serious infection but is expensive and usually reserved for pts who have had a serious infection. Alkylating agents are also active against the tumor. Therapeutic intent is palliative in most pts. Young pts may be candidates for high-dose therapy and autologous or allogeneic hematopoietic cell transplantation; long-term disease-free survival has been noted. Mini-transplant, in which the preparative regimen is immunosuppressive but not myeloablative, may be less toxic and as active or more active in disease treatment than high-dose therapy. Monoclonal antibodies alemtuzumab (anti-CD52) and rituximab (anti-CD20) also are active as single agents.

See Chap. 105 in HPIM-17 for discussion of the rarer entities.
These entities have a natural history measured in years. Median survival is about 10 years. Follicular lymphoma is the most common indolent lymphoma, accounting for about one-third of all lymphoid malignancies.

Follicular Lymphoma

Usually presents with painless peripheral lymphadenopathy, often involving several nodal regions. “B symptoms” (fever, sweats, weight loss) occur in 10%, less common than with Hodgkin’s disease. In about 25%, nodes wax and wane before the pt seeks medical attention. Median age is 55 years. Disease is widespread at diagnosis in 85%. Liver and bone marrow are commonly involved extranodal sites.

The tumor has a follicular or nodular growth pattern reflecting the follicular center origin of the malignant cell. The t(14;18) is present in 85% of cases, resulting in the overexpression of bcl-2, a protein involved in prevention of programmed cell death. The normal follicular center B cell is undergoing active mutation of the immunoglobulin variable regions in an effort to generate antibody of higher affinity for the selecting antigen. Follicular lymphoma cells also have a high rate of mutation that leads to the accumulation of genetic damage. Over time, follicular lymphomas acquire sufficient genetic damage (e.g., mutated p53) to accelerate their growth and evolve into diffuse large B cell lymphomas that are often refractory to treatment. The majority of pts dying from follicular lymphoma have undergone histologic transformation. This transformation occurs at a rate of about 7% per year and is an attribute of the disease, not the treatment.

Follicular Lymphoma

Only 15% of pts have localized disease, but the majority of these pts are curable with radiation therapy. Although many forms of treatment induce tumor regression in advanced-stage pts, it is not clear that treatment of any kind alters the natural history of disease. No therapy, single-agent alkylators, nucleoside analogues (fludarabine, cladribine), combination chemotherapy, radiation therapy, and biologic agents [interferon (IFN) α, monoclonal antibodies such as rituximab, anti-CD20] are all considered appropriate. More than 90% of pts are responsive to treatment; complete responses are seen in about 50–75% of pts treated aggressively. The median duration of remission of pts treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) + rituximab exceeds 6 years. Younger pts are being treated experimentally with high-dose therapy and autologous hematopoietic stem cells or mini-transplant. It is not yet clear whether this is curative. Radioimmunotherapy with isotopes guided by anti-CD20 antibody (ibritumomab tiuxetan, In-111; tositumomab, I-131) may produce durable responses. Combination chemotherapy with or without IFN maintenance may prolong survival and delay or prevent histologic progression, especially in pts with poor prognostic features. Remissions appear to last longer with chemotherapy plus rituximab; some data suggest that the longer remissions are leading to improved survival.

See Chap. 105 in HPIM-17 for discussion of the other indolent lymphomas.

AGGRESSIVE LYMPHOMAS

A large number of pathologic entities share an aggressive natural history; median survival untreated is 6 months, and nearly all untreated pts are dead within 1...
year. Pts may present with asymptomatic adenopathy or symptoms referable to involvement of practically any nodal or extranodal site: mediastinal involvement may produce superior vena cava syndrome or pericardial tamponade; retroperitoneal nodes may obstruct ureters; abdominal masses may produce pain, ascites, or GI obstruction or perforation; central nervous system (CNS) involvement may produce confusion, cranial nerve signs, headache, seizures, and/or spinal cord compression; bone involvement may produce pain or pathologic fracture. About 45% of pts have B symptoms.

Diffuse large B cell lymphoma is the most common histologic diagnosis among the aggressive lymphomas, accounting for 35–45% of all lymphomas. Aggressive lymphomas together account for ~60% of all lymphoid tumors. About 85% of aggressive lymphomas are of mature B cell origin; 15% are derived from peripheral (postthymic) T cells.

**APPROACH TO THE PATIENT: AGGRESSIVE LYMPHOMA**

Early diagnostic biopsy is critical. Pt workup is directed by symptoms and known patterns of disease. Pts with Waldeyer’s ring involvement should undergo careful evaluation of the GI tract. Pts with bone or bone marrow involvement should have a lumbar puncture to evaluate meningeal CNS involvement.

**Aggressive Lymphomas**

Localized aggressive lymphomas are usually treated with four cycles of CHOP combination chemotherapy ± involved-field radiation therapy. About 85% of these pts are cured. CHOP + rituximab appears to be even more effective than CHOP + radiation therapy. The specific therapy used for pts with more advanced disease is controversial. Six cycles of CHOP + rituximab is the treatment of choice for advanced-stage disease. Outcome is influenced by tumor bulk (usually measured by LDH levels, stage, and number of extranodal sites) and physiologic reserve (usually measured by age and Karnofsky status) (Table 71-3). CHOP + rituximab cures about two-thirds of pts. The use of a sequential high-dose chemotherapy regimen in pts with high-intermediate- and

**TABLE 71-3 INTERNATIONAL PROGNOSTIC INDEX FOR NHL**

<table>
<thead>
<tr>
<th>Five clinical risk factors:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 60 years</td>
<td></td>
</tr>
<tr>
<td>Serum lactate dehydrogenase levels elevated</td>
<td></td>
</tr>
<tr>
<td>Performance status ≥ 2 (ECOG) or ≤ 70 (Karnofsky)</td>
<td></td>
</tr>
<tr>
<td>Ann Arbor stage III or IV</td>
<td></td>
</tr>
<tr>
<td>&gt;1 site of extranodal involvement</td>
<td></td>
</tr>
</tbody>
</table>

Patients are assigned a number for each risk factor they have. Patients are grouped differently based upon the type of lymphoma

For diffuse large B cell lymphoma:

- 0, 1 factor = low risk: 35% of cases; 5-year survival, 73%
- 2 factors = low-intermediate risk: 27% of cases; 5-year survival, 51%
- 3 factors = high-intermediate risk: 22% of cases; 5-year survival, 43%
- 4, 5 factors = high risk: 16% of cases; 5-year survival, 26%

For diffuse large B cell lymphoma treated with R-CHOP:

- 0 factor = very good: 10% of cases; 5-year survival, 94%
- 1, 2 factors = good: 45% of cases; 5-year survival, 79%
- 3, 4, 5 factors = poor: 45% of cases; 5-year survival, 55%
high-risk disease has yielded long-term survival in about 75% of pts in some institutions. Other studies fail to confirm a role for high-dose therapy.

About 30–45% of pts not cured with initial standard combination chemotherapy may be salvaged with high-dose therapy and autologous hematopoietic stem cell transplantation.

Specialized approaches are required for lymphomas involving certain sites (e.g., CNS, stomach) or under certain complicating clinical circumstances (e.g., concurrent illness, AIDS). Lymphomas occurring in iatrogenically immunosuppressed pts may regress when immunosuppressive medication is withheld. Lymphomas occurring post-allogeneic marrow transplant may regress with infusions of donor leukocytes.

Pts with rapidly growing bulky aggressive lymphoma may experience tumor lysis syndrome when treated (Chap. 27); prophylactic measures (hydration, urine alkalinization, allopurinol, rasburicase) may be lifesaving.

**ACUTE LYMPHOID LEUKEMIAS/LYMPHOMAS**

**Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma** These are more common in children than adults (~5400 total cases/year). The majority of cases have tumor cells that appear to be of thymic origin, and pts may have mediastinal masses. Pts usually present with recent onset of signs of marrow failure (pallor, fatigue, bleeding, fever, infection). Hepatosplenomegaly and adenopathy are common. Males may have testicular enlargement reflecting leukemic involvement. Meningeal involvement may be present at diagnosis or develop later. Elevated LDH, hyponatremia, and hypokalemia may be present, in addition to anemia, thrombocytopenia, and high peripheral blood blast counts. The leukemic cells are more often FAB type L2 in adults than in children, where L1 predominates. Leukemia diagnosis requires at least 20% lymphoblasts in the marrow. Prognosis is adversely affected by high presenting white count, age >35 years, and the presence of t(9;22), t(1;19), and t(4;11) translocations. HOX11 expression identifies a more favorable subset of T cell acute lymphoblastic leukemia.

**Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma** Successful treatment requires intensive induction phase, CNS prophylaxis, and maintenance chemotherapy that extends for about 2 years. Vincristine, L-asparaginase, cytarabine, daunorubicin, and prednisone are particularly effective agents. Intrathecal or high-dose systemic methotrexate is effective CNS prophylaxis. Long-term survival of 60–65% of pts may be achieved. The role and timing of bone marrow transplantation in primary therapy is debated, but up to 30% of relapsed pts may be cured with salvage transplantation.

**Burkitt’s Lymphoma/Leukemia** This is also more common in children. It is associated with translocations involving the c-myc gene on chromosome 8 rearranging with immunoglobulin heavy or light chain genes. Pts often have disseminated disease with large abdominal masses, hepatomegaly, and adenopathy. If a leukemic picture predominates, it is classified as FAB L3.

**Burkitt’s Lymphoma/Leukemia** Resection of large abdominal masses improves treatment outcome. Aggressive leukemia regimens that include vincristine, cyclophosphamide, 6-mer-
Captopurine, doxorubicin, and prednisone are active. CODOX-M and the BFM regimen are the most effective regimens. Cure may be achieved in 50–60%. The need for maintenance therapy is unclear. Prophylaxis against tumor lysis syndrome is important (Chap. 27).

**Adult T Cell Leukemia/Lymphoma (ATL)** This is very rare; only a small fraction (~2%) of persons infected with HTLV-I go on to develop the disease. Some HTLV-I-infected pts develop spastic paraplegia from spinal cord involvement without developing cancer. The characteristic clinical syndrome of ATL includes high white count without severe anemia or thrombocytopenia, skin infiltration, hepatomegaly, pulmonary infiltrates, meningeal involvement, and opportunistic infections. The tumor cells are CD4+ T cells with cloven hoof– or flower-shaped nuclei. Hypercalcemia occurs in nearly all pts and is related to cytokines produced by the tumor cells.

**Aggressive therapy** is associated with serious toxicity related to the underlying immunodeficiency. Glucocorticoids relieve hypercalcemia. The tumor is responsive to therapy, but responses are generally short-lived. Zidovudine and IFN may be palliative in some pts.

**PLASMA CELL DISORDERS**

The hallmark of plasma cell disorders is the production of immunoglobulin molecules or fragments from abnormal plasma cells. The intact immunoglobulin molecule, or the heavy chain or light chain produced by the abnormal plasma cell clone, is detectable in the serum and/or urine and is called the M (for monoclonal) component. The amount of the M component in any given pt reflects the tumor burden in that pt. In some, the presence of a clonal light chain in the urine (Bence Jones protein) is the only tumor product that is detectable. M components may be seen in pts with other lymphoid tumors, nonlymphoid cancers, and noncancerous conditions such as cirrhosis, sarcoidosis, parasitic infestations, and autoimmune diseases.

**Multiple Myeloma** A malignant proliferation of plasma cells in the bone marrow (notably not in lymph nodes). Nearly 20,000 new cases are diagnosed each year. Disease manifestations result from tumor expansion, local and remote actions of tumor products, and the host response to the tumor. About 70% of pts have bone pain, usually involving the back and ribs, precipitated by movement. Bone lesions are multiple, lytic, and rarely accompanied by an osteoblastic response. Thus, bone scans are less useful than radiographs. The production of osteoclast-activating cytokines by tumor cells leads to substantial calcium mobilization, hypercalcemia, and symptoms related to it. Decreased synthesis and increased catabolism of normal immunoglobulins leads to hypogammaglobulinemia, and a poorly defined tumor product inhibits granulocyte migration. These changes create a susceptibility to bacterial infections, especially the pneumococcus, *Klebsiella pneumoniae*, and *Staphylococcus aureus* affecting the lung and *Escherichia coli* and other gram-negative pathogens affecting the urinary tract. Infections affect at least 75% of pts at some time in their course. Renal failure may affect 25% of pts; its pathogenesis is multifactorial—hypercalcemia, infection, toxic effects of light chains, urate nephropathy, dehydra-
tion. Neurologic symptoms may result from hyperviscosity, cryoglobulins, and rarely amyloid deposition in nerves. Anemia occurs in 80% related to myelophthisis and inhibition of erythropoiesis by tumor products. Clotting abnormalities may produce bleeding.

**Diagnosis**  Marrow plasmacytosis >10%, lytic bone lesions, and a serum and/or urine M component are the classic triad. Monoclonal gammopathy of uncertain significance (MGUS) is much more common than myeloma, affecting about 6% of people over age 70; in general, MGUS is associated with a level of M component <20 g/L, low serum β₂-microglobulin, <10% marrow plasma cells, and no bone lesions. Lifetime risk of progression of MGUS to myeloma is about 25%.

**Staging**  Disease stage influences survival (Table 71-4).

**Multiple Myeloma**  About 10% of pts have very slowly progressive disease and do not require treatment until the paraprotein levels rise above 50 g/L or progressive bone disease occurs. Pts with solitary plasmacytoma and extramedullary plasmacytoma are usually cured with localized radiation therapy. Supportive care includes early treatment of infections; control of hypercalcemia with glucocorticoids, hydration, and natriuresis; chronic administration of bisphosphonates to antagonize skeletal destruction; and prophylaxis against urate nephropathy and dehydration. Therapy aimed at the tumor is usually palliative. Initial therapy is usually one of several approaches, based on whether the pt is a candidate for high-dose therapy and autologous stem cell transplant. Transplant-eligible (avoid alkylating agents): thalidomide, 400 mg/d PO or 200 mg qhs, plus dexamethasone, 40 mg/d on days 1–4 each month, with or without chemotherapy such as liposomal doxorubicin; addition of bortezomib may be even more effective. Transplant-ineligible: melphalan, 8 mg/m² orally for 4–7 days every 4–6 weeks, plus prednisone. About 60% of pts have significant symptomatic improvement plus a 75% decline in the M component. Bortezomib also appears to improve response rates to melphalan. Experimental approaches using sequential high-dose pulses of melphalan plus two successive autologous stem cell transplants have produced complete responses in about 50% of pts <65 years. Long-term follow-up is required to see whether survival is enhanced. Palliatively treated pts generally follow a chronic course for 2–5 years, followed by an acceleration characterized by organ infiltration with myeloma cells and marrow failure. More aggressive treatment may produce median survival of 6 years. New approaches to salvage treatment include bortezomib, 1.3 mg/m² on days 1, 4, 8, and 11 every 3 weeks, often used with dexamethasone, vincristine, and/or liposomal doxorubicin. Lenalidomide is also active.

**Hodgkin’s Disease**  About 8000 new cases are diagnosed each year. Hodgkin’s disease (HD) is a tumor of Reed-Sternberg cells, aneuploid cells that usually express CD30 and CD15 but may also express other B or T cell markers. Most tumors are derived from B cells in that immunoglobulin genes are rearranged but not expressed. Most of the cells in an enlarged node are normal lymphoid, plasma cells, monocytes, and eosinophils. The etiology is unknown, but the incidence in both identical twins is 99-fold increased over the expected concordance, suggesting a genetic susceptibility. Distribution of histologic subtypes is 75% nodular sclerosis, 20% mixed cellularity, with lymphocyte predominant and lymphocyte depleted representing about 5%.
Clinical Manifestations  Usually presents with asymptomatic lymph node enlargement or with adenopathy associated with fever, night sweats, weight loss, and sometimes pruritus. Mediastinal adenopathy (common in nodular sclerosing HD) may produce cough. Spread of disease tends to be to contiguous lymph node groups. Superior vena cava obstruction or spinal cord compression may be presenting manifestation. Involvement of bone marrow and liver is rare.

Differential Diagnosis
- Infection—mononucleosis, viral syndromes, toxoplasma, histoplasma, primary tuberculosis

**TABLE 71-4  MYELOMA STAGING SYSTEMS**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Criteria</th>
<th>Estimated Tumor Burden, $\times 10^{12}$ cells/m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>All of the following: 1. Hemoglobin $&gt;100$ g/L ($&gt;10$ g/dL) 2. Serum calcium $&lt;3$ mmol/L ($&lt;12$ mg/dL) 3. Normal bone x-ray or solitary lesion 4. Low M-component production a. IgG level $&gt;50$ g/L ($&gt;5$ g/dL) b. IgA level $&lt;30$ g/L ($&lt;3$ g/dL) c. Urine light chain $&lt;4$ g/24 h</td>
<td>$&lt;0.6$ (low)</td>
</tr>
<tr>
<td>II</td>
<td>Fitting neither I nor III</td>
<td>0.6–1.20 (intermediate)</td>
</tr>
<tr>
<td>III</td>
<td>One or more of the following: 1. Hemoglobin $&lt;85$ g/L ($&lt;8.5$ g/dL) 2. Serum calcium $&gt;3$ mmol/L ($&gt;12$ mg/dL) 3. Advanced lytic bone lesions 4. High M-component production a. IgG level $&gt;70$ g/L ($&gt;7$ g/dL) b. IgA level $&gt;50$ g/L ($&gt;5$ g/dL) c. Urine light chains $&gt;12$ g/24 h</td>
<td>$&gt;1.20$ (high)</td>
</tr>
</tbody>
</table>

**Level** | **Stage** | **Median Survival, Months** |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Subclassification based on serum creatinine levels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A $&lt;177$ μmol/L ($&lt;2$ mg/dL)</td>
<td>IA</td>
<td>61</td>
</tr>
<tr>
<td>B $&gt;177$ μmol/L ($&gt;2$ mg/dL)</td>
<td>II, B</td>
<td>55</td>
</tr>
<tr>
<td>IIIA</td>
<td></td>
<td>30</td>
</tr>
<tr>
<td>IIIB</td>
<td></td>
<td>15</td>
</tr>
</tbody>
</table>

International Staging System

| $\beta_2$M = 3.5–5.5 | I (28%) | 62 |
| $\beta_2$M = 5.5 | II (39%) | 44 |
| $\beta_2$M $< 3.5$, alb $\geq 5.5$ | | |
| $\beta_2$M $< 3.5$, alb $< 3.5$ or | | |
| $\beta_2$M = 3.5–5.5 | III (33%) | 29 |

*Note*: $\beta_2$M, serum $\beta_2$-microglobulin in mg/L; alb, serum albumin in g/dL; (%), % patients presenting at each stage.
Lymphoid Malignancies

CHAPTER 71

• Other malignancies—especially head and neck cancers
• Sarcoidosis—mediastinal and hilar adenopathy

Immunologic and Hematologic Abnormalities

• Defects in cell-mediated immunity (remains even after successful treatment of lymphoma); cutaneous anergy; diminished antibody production to capsular antigens of *Haemophilus* and pneumococcus
• Anemia; elevated erythrocyte sedimentation rate; leukemoid reaction; eosinophilia; lymphocytopenia; fibrosis and granulomas in marrow

Staging

The Ann Arbor staging classification is shown in Table 71-5. Disease is staged by performing physical exam, chest x-ray, thoracoabdominal CT, bone marrow biopsy; ultrasound examinations, lymphangiogram. Staging laparotomy should be used, especially to evaluate the spleen, if pt has early-stage disease on clinical grounds and radiation therapy is being contemplated. Pathologic staging is unnecessary if the pt is treated with chemotherapy.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Involvement of a single lymph node region or lymphoid structure (e.g., spleen, thymus, Waldeyer’s ring)</td>
</tr>
<tr>
<td>II</td>
<td>Involvement of two or more lymph node regions on the same side of the diaphragm (the mediastinum is a single site; hilar lymph nodes should be considered “lateralized” and, when involved on both sides, constitute stage II disease)</td>
</tr>
<tr>
<td>III</td>
<td>Involvement of lymph node regions or lymphoid structures on both sides of the diaphragm</td>
</tr>
<tr>
<td>III₁</td>
<td>Subdiaphragmatic involvement limited to spleen, splenic hilar nodes, celiac nodes, or portal nodes</td>
</tr>
<tr>
<td>III₂</td>
<td>Subdiaphragmatic involvement includes paraaortic, iliac, or mesenteric nodes plus structures in III₁</td>
</tr>
<tr>
<td>IV</td>
<td>Involvement of extranodal site(s) beyond that designated as “E” More than one extranodal deposit at any location Any involvement of liver or bone marrow</td>
</tr>
</tbody>
</table>

| A     | No symptoms |
| B     | Unexplained weight loss of >10% of the body weight during the 6 months before staging investigation Unexplained, persistent, or recurrent fever with temperatures >38°C during the previous month Recurrent drenching night sweats during the previous month |
| E     | Localized, solitary involvement of extralymphatic tissue, excluding liver and bone marrow |

- Other malignancies—especially head and neck cancers
- Sarcoidosis—mediastinal and hilar adenopathy

**Table 71-5** THE ANN ARBOR STAGING SYSTEM FOR HODGKIN’S DISEASE

Hodgkin’s Disease

About 85% of pts are curable. Therapy should be performed by experienced clinicians in centers with appropriate facilities. Most pts are clinically staged and treated with chemotherapy alone or combined-modality therapy. Those with localized disease may be treated with radiation therapy alone. Those with stage II disease often receive either four cycles of ABVD plus involved-field radiation therapy or Stanford V, a combined-modality program using lower doses of chemotherapy. Those with stage III or IV disease receive six
cycles of combination chemotherapy, usually either ABVD or MOPP-ABV hybrid therapy or MOPP/ABVD alternating therapy. Pts with any stage disease accompanied by a large mediastinal mass (greater than one-third the greatest chest diameter) should receive combined-modality therapy with MOPP/ABVD or MOPP-ABV hybrid followed by mantle field radiation therapy. (Radiation plus ABVD is too toxic to the lung.) A persistently positive midtreatment positron emission tomography scan may be an index of risk of relapse and need for additional therapy. About one-half of pts (or more) not cured by their initial chemotherapy regimen may be rescued by high-dose therapy and autologous stem cell transplant.

With long-term follow-up, it has become clear that more pts are dying of late fatal toxicities related to radiation therapy (myocardial infarction, stroke, second cancers) than from HD. It may be possible to avoid radiation exposure by using combination chemotherapy in early-stage disease as well as in advanced-stage disease.

For a more detailed discussion, see Longo DL: Malignancies of Lymphoid Cells, Chap. 105, p. 687; Munshi NC et al: Plasma Cell Disorders, Chap. 106, p. 700, in HPIM-17.

MALIGNANT MELANOMA

Most dangerous cutaneous malignancy; high metastatic potential; poor prognosis with metastatic spread.

Incidence  Melanoma was diagnosed in 62,480 people in the United States in 2008 and caused 8420 deaths.

Predisposing Factors (Table 72-1)
Fair complexion, sun exposure, family history of melanoma, dysplastic nevus syndrome (autosomal dominant disorder with multiple nevi of distinctive appearance and cutaneous melanoma, may be associated with 9p deletion), and presence of a giant congenital nevus. Blacks have a low incidence.

Prevention  Sun avoidance lowers risk. Sunscreens are not proven effective.

Types  
1. Superficial spreading melanoma: Most common; begins with initial radial growth phase before invasion.
2. Lentigo maligna melanoma: Very long radial growth phase before invasion, lentigo maligna (Hutchinson’s melanotic freckle) is precursor lesion, most common in elderly and in sun-exposed areas (esp. face).
3. Acral lentiginous: Most common form in darkly pigmented pts; occurs on palms and soles, mucosal surfaces, in nail beds and mucocutaneous junc-
4. **Nodular**: Generally poor prognosis because of invasive growth from onset.

**Clinical Appearance**  Generally pigmented (rarely amelanotic); color of lesions varies, but red, white, and/or blue are common, in addition to brown and/or black. Suspicion should be raised by a pigmented skin lesion that is >6 mm in diameter, asymmetric, has an irregular surface or border, or has variation in color.

**Prognosis**  Best with thin lesions without evidence of metastatic spread; with increasing thickness or evidence of spread, prognosis worsens. Stage I and II (primary tumor without spread) have 85% 5-year survival. Stage III (palpable regional nodes with tumor) has a 50% 5-year survival when only one node is involved and 15–20% when four or more are involved. Stage IV (disseminated disease) has <5% 5-year survival.

### Malignant Melanoma

Early recognition and local excision for localized disease is best; 1- to 2-cm margins are as effective as 4- to 5-cm margins and do not usually require skin grafting. Elective lymph node dissection offers no advantage in overall survival compared with deferral of surgery until clinical recurrence. Pts with stage II disease may have improved disease-free survival with adjuvant interferon (IFN) α 3 million units three times weekly for 12–18 months; no overall survival advantage has been shown. In one study, pts with stage III disease had improved survival with adjuvant IFN, 20 million units IV daily × 5 for 4 weeks, then 10 million units SC three times weekly for 11 months. This result was not confirmed in a second study. Metastatic disease may be treated with chemotherapy or immunotherapy. Dacarbazine (250 mg/m² IV daily × 5 q3w) plus tamoxifen (20 mg/m² PO daily) may induce partial responses in one-third of patients. IFN and interleukin 2 (IL-2) at maximum tolerated doses induce partial responses in 15% of pts. Rare long remissions occur with IL-2. Temozolomide is an oral agent related to dacarbazine that has some activity. It can enter the central nervous system (CNS) and is being evaluated with radiation therapy for CNS metastases. No therapy for metastatic disease is curative. Vaccines and adoptive cellular therapies are being tested.

### TABLE 72-1  RISK FACTORS FOR CUTANEOUS MELANOMA

<table>
<thead>
<tr>
<th>High risk (&gt;50-fold increase in risk)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Persistently changing mole</td>
</tr>
<tr>
<td>Clinically atypical moles in patient with two family members with melanoma</td>
</tr>
<tr>
<td>Adulthood (vs. childhood)</td>
</tr>
<tr>
<td>&gt;50 nevi ≥2 mm in diameter</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intermediate risk (~10-fold increase in risk)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family history of melanoma</td>
</tr>
<tr>
<td>Sporadic clinically atypical moles</td>
</tr>
<tr>
<td>Congenital nevi (?)</td>
</tr>
<tr>
<td>White ethnicity (vs. black or East Asian ethnicity)</td>
</tr>
<tr>
<td>Personal history of prior melanoma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Low risk (2- to 4-fold increase in risk)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunosuppression</td>
</tr>
<tr>
<td>Sun sensitivity or excess exposure to sun</td>
</tr>
</tbody>
</table>

**BASAL CELL CARCINOMA (BCC)**

Most common form of skin cancer; most frequently on sun-exposed skin, esp. face.

**Predisposing Factors** Fair complexion, chronic UV exposure, exposure to inorganic arsenic (i.e., Fowler’s solution or insecticides such as Paris green), or exposure to ionizing radiation.

**Prevention** Avoidance of sun exposure and use of sunscreens lower risk.

**Types** Five general types: noduloulcerative (most common), superficial (mimics eczema), pigmented (may be mistaken for melanoma), morpheaform (plaquelike lesion with telangiectasia—with keratotic is most aggressive), keratotic (basosquamous carcinoma).

**Clinical Appearance** Classically a pearly, translucent, smooth papule with rolled edges and surface telangiectasia.

**Rx Basal Cell Carcinoma**

Local removal with electrodesiccation and curettage, excision, cryosurgery, or radiation therapy; metastases are rare but may spread locally. Exceedingly unusual for BCC to cause death.

**SQUAMOUS CELL CARCINOMA (SCC)**

Less common than basal cell but more likely to metastasize.

**Predisposing Factors** Fair complexion, chronic UV exposure, previous burn or other scar (i.e., scar carcinoma), exposure to inorganic arsenic or ionizing radiation. Actinic keratosis is a premalignant lesion.

**Types** Most commonly occurs as an ulcerated nodule or a superficial erosion on the skin. Variants include:

1. *Bowen’s disease*: Erythematous patch or plaque, often with scale; noninvasive; involvement limited to epidermis and epidermal appendages (i.e., SCC in situ).
3. *Verrucous carcinoma*: Most commonly on plantar aspect of foot; low-grade malignancy but may be mistaken for a common wart.

**Clinical Appearance** Hyperkeratotic papule or nodule or erosion; nodule may be ulcerated.

**Rx Squamous Cell Carcinoma**

Local excision and Moh’s micrographic surgery are most common; radiation therapy in selected cases. Metastatic disease may be treated with radiation therapy or with combination biologic therapy; 13-cis-retinoic acid 1 mg/d PO plus IFN 3 million units/d SC.

**Prognosis** Favorable if secondary to UV exposure; less favorable if in sun-protected areas or associated with ionizing radiation.
SKIN CANCER PREVENTION

Most skin cancer is related to sun exposure. Encourage pts to avoid the sun and use sunscreen.

For a more detailed discussion, see Sober AJ et al: Cancer of the Skin, Chap. 83, p. 541, in HPIM-17.

Epithelial cancers may arise from the mucosal surfaces of the head and neck including the sinuses, oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx. These tumors are usually squamous cell cancers. Thyroid cancer is discussed in Chap. 179.

INCIDENCE AND EPIDEMIOLOGY

About 48,000 cases are diagnosed each year. Oral cavity, oropharynx, and larynx are the most frequent sites of primary lesions in the United States; nasopharyngeal primaries are more common in the Far East and Mediterranean countries. Alcohol and tobacco (including smokeless) abuse are risk factors. Human papillomavirus is associated with some of these cancers.

PATHOLOGY

Nasopharyngeal cancer in the Far East has a distinct histology, nonkeratinizing undifferentiated carcinoma with infiltrating lymphocytes called lymphoepithelioma, and a distinct etiology, Epstein-Barr virus. Squamous cell head and neck cancer may develop from premalignant lesions (erythroplakia, leukoplakia), and the histologic grade affects prognosis. Pts who have survived head and neck cancer commonly develop a second cancer of the head and neck, lung, or esophagus, presumably reflecting the exposure of the upper aerodigestive mucosa to similar carcinogenic stimuli.

GENETIC ALTERATIONS

Chromosomal deletions and mutations have been found in chromosomes 3p, 9p, 17p, and 13q; mutations in p53 have been reported. Cyclin D1 may be overexpressed. Epidermal growth factor receptor is commonly overexpressed.

CLINICAL PRESENTATION

Most occur in persons > 50 years. Symptoms vary with the primary site. Nasopharynx lesions do not usually cause symptoms until late in the course and then cause unilateral serous otitis media or nasal obstruction or epistaxis. Oral cavity cancers present as nonhealing ulcers, sometimes painful. Oropharyngeal lesions also present late with sore throat or otalgia. Hoarseness may be an early
sign of laryngeal cancer. Rare pts present with painless, rock-hard cervical or supraclavicular lymph node enlargement. Staging is based on size of primary tumor and involvement of lymph nodes. Distant metastases occur in <10% of pts.

**Treatment**

Three categories of disease are common: localized, locally or regionally advanced, and recurrent or metastatic. **Local disease** occurs in about one-third of pts and is treated with curative intent by surgery or radiation therapy. Radiation therapy is preferred for localized larynx cancer to preserve organ function; surgery is used more commonly for oral cavity lesions. Overall 5-year survival is 60–90%, and most recurrences occur within 2 years. **Locally advanced disease** is the most common presentation (>50%). Combined-modality therapy using induction chemotherapy, then surgery followed by concomitant chemotherapy and radiation therapy, is most effective. The use of three cycles of cisplatin (100 mg/m² IV day 1) plus 5-fluorouracil (5FU) [1000 (mg/m²)/d by 96- to 120-h continuous infusion] before or during radiation therapy is more effective than surgery plus radiation therapy, though mucositis is also more severe; 5-year survival is 34–50%. Cetuximab plus radiation therapy may be more effective than radiation therapy alone. Head and neck cancer pts are frequently malnourished and often have intercurrent illness. Pts with recurrent or metastatic disease (about 10% of pts) are treated palliatively with cisplatin plus 5FU or paclitaxel (200–250 mg/m² with granulocyte colony-stimulating factor support) or with single-agent chemotherapy (a taxane, methotrexate, cisplatin, or carboplatin). Response rates are usually 30–50% and median survival about 3 months.

**PREVENTION**

The most important intervention is to get the pts to stop smoking. Long-term survival is significantly better in those who stop smoking. Chemopreventive therapy with cis-retinoic acid [3 months of 1.5 (mg/kg)/d followed by 9 months of 0.5 (mg/kg)/d PO] may cause regression of leukoplakia but has no consistent effect on development of cancer.

For a more detailed discussion, see Vokes EE: Head and Neck Cancer, Chap. 84, p. 548, in HPIM-17.

**Lung Cancer**

**INCIDENCE**

Lung cancer was diagnosed in about 114,700 men and 100,300 women in the United States in 2008, and 86% of pts die within 5 years. Lung cancer, the leading cause of cancer death, accounts for 31% of all cancer deaths in men and 26% in women. Peak incidence occurs between ages 55 and 65 years. Incidence is decreasing in men and increasing in women.
HISTOLOGIC CLASSIFICATION

Four major types account for 88% of primary lung cancers: epidermoid (squamous), 29%; adenocarcinoma (including bronchioloalveolar), 35%; large cell, 9%; and small cell (or oat cell), 18%. Histology (small cell versus non-small cell types) is a major determinant of treatment approach. Small cell is usually widely disseminated at presentation, while non-small cell may be localized. Epidermoid and small cell typically present as central masses, while adenocarcinomas and large cell usually present as peripheral nodules or masses. Epidermoid and large cell cavitate in 20–30% of pts.

ETIOLOGY

The major cause of lung cancer is tobacco use, particularly cigarette smoking. Lung cancer cells may have ≥10 acquired genetic lesions, most commonly point mutations in ras oncogenes; amplification, rearrangement, or transcriptional activation of myc family oncogenes; overexpression of bcl-2, Her2/neu, and telomerase; and deletions involving chromosomes 1p, 1q, 3p12-13, 3p14 (FHIT gene region), 3p21, 3p24-25, 3q, 5q, 9p (p16 and p15 cyclin-dependent kinase inhibitors), 11p13, 11p15, 13q14 (rb gene), 16q, and 17p13 (p53 gene). Loss of 3p and 9p are the earliest events, detectable even in hyperplastic bronchial epithelium; loss of 9p abnormalities and ras point mutations are usually found only in invasive cancers.

CLINICAL MANIFESTATIONS

Only 5–15% are detected while asymptomatic. Central endobronchial tumors cause cough, hemoptysis, wheeze, stridor, dyspnea, pneumonitis. Peripheral lesions cause pain, cough, dyspnea, symptoms of lung abscess resulting from cavitation. Metastatic spread of primary lung cancer may cause tracheal obstruction, dysphagia, hoarseness, Horner’s syndrome. Other problems of regional spread include superior vena cava syndrome, pleural effusion, respiratory failure. Extrathoracic metastatic disease affects 50% of pts with epidermoid cancer, 80% with adenocarcinoma and large cell, and >95% with small cell. Clinical problems result from brain metastases, pathologic fractures, liver invasion, and spinal cord compression. Paraneoplastic syndromes may be a presenting finding of lung cancer or first sign of recurrence (Chap. 81). Systemic symptoms occur in 30% and include weight loss, anorexia, fever. Endocrine syndromes occur in 12% and include hypercalcemia (epidermoid), syndrome of inappropriate antidiuretic hormone secretion (small cell), gynecomastia (large cell). Skeletal connective tissue syndromes include clubbing in 30% (most often non-small cell) and hypertrophic pulmonary osteoarthropathy in 1–10% (most often adenocarcinomas), with clubbing, swelling, and pain.

STAGING

See Table 74-1.

Two parts to staging are (1) determination of location (anatomic staging) and (2) assessment of pt’s ability to withstand antitumor treatment (physiologic staging). Non-small cell tumors are staged by the TNM/International Staging System (ISS). The T (tumor), N (regional node involvement), and M (presence or absence of distant metastasis) factors are taken together to define different stage groups. Small cell tumors are staged by two-stage system: limited stage disease—confined to one hemithorax and regional lymph nodes; extensive disease—involvement beyond this. General staging procedures include careful ear, nose, and throat examination; chest x-ray (CXR); chest and abdominal CT scanning; and positron emission tomography scan. CT scans may suggest me-
<table>
<thead>
<tr>
<th>Stage</th>
<th>TNM Descriptors</th>
<th>Clinical Stage</th>
<th>Surgical-Pathologic Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>T1 N0 M0</td>
<td>61</td>
<td>67</td>
</tr>
<tr>
<td>IB</td>
<td>T2 N0 M0</td>
<td>38</td>
<td>57</td>
</tr>
<tr>
<td>IIA</td>
<td>T1 N1 M0</td>
<td>34</td>
<td>55</td>
</tr>
<tr>
<td>IIB</td>
<td>T2 N1 M0</td>
<td>24</td>
<td>39</td>
</tr>
<tr>
<td>IIB</td>
<td>T3 N0 M0</td>
<td>22</td>
<td>38</td>
</tr>
<tr>
<td>IIIA</td>
<td>T3 N1 M0</td>
<td>9</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>T1–2–3 N2 M0</td>
<td>13</td>
<td>23</td>
</tr>
<tr>
<td>IIIB</td>
<td>T4 N0–1–2 M0</td>
<td>7</td>
<td>&lt;5</td>
</tr>
<tr>
<td>IV</td>
<td>Any T any N M1</td>
<td>1</td>
<td>&lt;1</td>
</tr>
</tbody>
</table>

**Tumor (T) Status Descriptor**

- **T0**: No evidence of a primary tumor
- **TX**: Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy
- **TIS**: Carcinoma in situ
- **T1**: Tumor <3 cm in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than lobar bronchus (i.e., not in main bronchus)
- **T2**: Tumor with any of following: >3 cm in greatest dimension; involves main bronchus, ≥2 cm distal to the carina; invades visceral pleura; associated with atelectasis or obstructive pneumonitis extending to hilum but does not involve entire lung
- **T3**: Tumor of any size that directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium; or tumor in main bronchus <2 cm distal to carina but without involvement of carina; or associated atelectasis or obstructive pneumonitis of entire lung
- **T4**: Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, esophagus, vertebral body, carina; or tumor with a malignant pleural or pericardial effusion, or with satellite tumor nodule(s) within the ipsilateral primary-tumor lobe of the lung.

**Lymph Node (N) Involvement Descriptor**

- **NX**: Regional lymph nodes cannot be assessed
- **N0**: No regional lymph node metastasis
- **N1**: Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary nodes involved by direct extension of the primary tumor
- **N2**: Metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes(s)
- **N3**: Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)

(continued)
diastinal lymph node involvement and pleural extension in non-small cell lung cancer, but definitive evaluation of mediastinal spread requires histologic examination. Routine radionuclide scans are not obtained in asymptomatic pts. If a mass lesion is on CXR and no obvious contraindications to curative surgical approach are noted, the mediastinum should be investigated. Major contraindications to curative surgery include extrathoracic metastases, superior vena cava syndrome, vocal cord and phrenic nerve paralysis, malignant pleural effusions, metastases to contralateral lung, and histologic diagnosis of small cell cancer.

1. Surgery in pts with localized disease and non-small cell cancer; however, majority initially thought to have curative resection ultimately succumb to metastatic disease. Adjuvant chemotherapy [cisplatin, four cycles at 100 mg/m² plus a second active agent (etoposide, vinblastine, vinorelbine, vinodesine, a taxane)] in pts with total resection of stage IIA and IIB disease may modestly extend survival.

2. Solitary pulmonary nodule: factors suggesting resection include cigarette smoking, age ≥35, relatively large (>2 cm) lesion, lack of calcification, chest symptoms, and growth of lesion compared with old CXR. See Fig. 74-1.

3. For unresectable stage II non-small cell lung cancer, combined thoracic radiation therapy and cisplatin-based chemotherapy reduces mortality by about 25% at 1 year.

4. For unresectable non-small cell cancer, metastatic disease, or refusal of surgery: consider for radiation therapy; addition of cisplatin/taxane-based chemotherapy may reduce death risk by 13% at 2 years and improve quality of life. Pemetrexed has activity in pts with progressive disease.

5. Small cell cancer; combination chemotherapy is standard mode of therapy; response after 6–12 weeks predicts median- and long-term survival.

6. Addition of radiation therapy to chemotherapy in limited-stage small cell lung cancer can increase 5-year survival from about 11% to 20%.

7. Prophylactic cranial irradiation improves survival of limited-stage small cell lung cancer by another 5%.

8. Laser obliteration of tumor through bronchoscopy in presence of bronchial obstruction.

9. Radiation therapy for brain metastases, spinal cord compression, symptomatic masses, bone lesions.
**TABLE 74-2**

**SUMMARY OF TREATMENT APPROACH TO PATIENTS WITH LUNG CANCER**

### Non-Small Cell Lung Cancer

**Stages IA, IB, IIA, IIB, and some IIIA:**
- Surgical resection for stages IA, IB, IIA, and IIB
- Surgical resection with complete mediastinal lymph node dissection and consideration of neoadjuvant CRx for stage IIIA disease with “minimal N2 involvement” (discovered at thoracotomy or mediastinoscopy)
- Consider postoperative RT for patients found to have N2 disease
- Stage IB: discussion of risk/benefits of adjuvant CRx; not routinely given
- Stage II: Adjuvant CRx
- Curative potential RT for “nonoperable” patients

**Stage IIIA with selected types of stage T3 tumors:**
- Tumors with chest wall invasion (T3): en bloc resection of tumor with involved chest wall and consideration of postoperative RT
- Superior sulcus (Pancoast’s) (T3) tumors: preoperative RT (30–45 Gy) and CRx followed by en bloc resection of involved lung and chest wall with postoperative RT
- Proximal airway involvement (<2 cm from carina) without mediastinal nodes: sleeve resection if possible preserving distal normal lung or pneumonectomy
- Stages IIIA “advanced, bulky, clinically evident N2 disease” (discovered preoperatively) and IIIB disease that can be included in a tolerable RT port: Curative potential concurrent RT + CRx if performance status and general medical condition are reasonable; otherwise, sequential CRx followed by RT, or RT alone
- Stage IIIB disease with carinal invasion (T4) but without N2 involvement:
  - Consider pneumonectomy with tracheal sleeve resection with direct reanastomosis to contralateral mainstem bronchus
- Stage IV and more advanced IIIB disease:
  - RT to symptomatic local sites
  - CRx for ambulatory patients; consider CRx and bevacizumab for selected patients
  - Chest tube drainage of large malignant pleural effusions
  - Consider resection of primary tumor and metastasis for isolated brain or adrenal metastases

### Small Cell Lung Cancer

**Limited stage (good performance status):** combination CRx + concurrent chest RT
- Extensive stage (good performance status): combination CRx
- Complete tumor responders (all stages): consider prophylactic cranial RT
- Poor-performance-status patients (all stages):
  - Modified-dose combination CRx
  - Palliative RT

### Broncholoalveolar or Adenocarcinoma with EGF Receptor Mutations

Gefitinib or erlotinib, inhibitors of EGF receptor kinase activity

*(continued)*
TABLE 74-2  SUMMARY OF TREATMENT APPROACH TO PATIENTS WITH LUNG CANCER (CONTINUED)

All Patients

RT for brain metastases, spinal cord compression, weight-bearing lytic bony lesions, symptomatic local lesions (nerve paralyses, obstructed airway, hemothysis, intrathoracic large venous obstruction, in non-small cell lung cancer and in small cell cancer not responding to CRx)

Appropriate diagnosis and treatment of other medical problems and supportive care during CRx

Encouragement to stop smoking

Entrance into clinical trial, if eligible

Abbreviations: CRx, chemotherapy; EGF, epidermal growth factor; RT, radiotherapy.

---

FIGURE 74-1  Algorithm for evaluation of a solitary pulmonary nodule (SPN). CXR, chest x-ray; CT, computed tomography scan; PET, positron emission tomography.
10. Encourage cessation of smoking.

11. Pts with broncholoalveolar carcinoma (3% of all pts with lung cancer) often have activating mutations in the epidermal growth factor (EGF) receptor. These pts often respond to gefitinib or erlotinib, EGF receptor inhibitors.

**PROGNOSIS**

At time of diagnosis, only 20% of pts have localized disease. Overall 5-year survival is 30% for males and 50% for females with localized disease and 5% for pts with advanced disease.

For a more detailed discussion, see Minna JD, Schiller JH: Neoplasms of the Lung, Chap. 85, p. 551, in HPIM-17.

---

**Breast Cancer**

**INCIDENCE AND EPIDEMIOLOGY**

The most common tumor in women: 183,000 women in the United States are diagnosed and 40,000 die each year with breast cancer. Men also get breast cancer; F:M is 150:1. Breast cancer is hormone-dependent. Women with late menarche, early menopause, and first full-term pregnancy by age 18 have a significantly reduced risk. The average American woman has about a 1 in 9 lifetime risk of developing breast cancer. Dietary fat is a controversial risk factor. Oral contraceptives have little, if any, effect on risk and lower the risk of endometrial and ovarian cancer. Voluntary interruption of pregnancy does not increase risk. Estrogen replacement therapy may slightly increase the risk, but the beneficial effects of estrogen on quality of life, bone mineral density, and decreased risk of colorectal cancer appear to be somewhat outnumbered by increases in cardiovascular and thrombotic disease. Women who received therapeutic radiation before age 30 are at increased risk. Breast cancer risk is increased when a sister and mother also had the disease.

**GENETICS**

Perhaps 8–10% of breast cancer is familial. BRCA-1 mutations account for about 5%. BRCA-1 maps to chromosome 17q21 and appears to be involved in transcription-coupled DNA repair. Ashkenazi Jewish women have a 1% chance of having a common mutation (deletion of adenine and guanine at position 185). The BRCA-1 syndrome includes an increased risk of ovarian cancer in women and prostate cancer in men. BRCA-2 on chromosome 11 may account for 2–3% of breast cancer. Mutations are associated with an increased risk of breast cancer in men and women. Germ-line mutations in p53 (Li-Fraumeni syndrome) are very rare, but breast cancer, sarcomas, and other malignancies occur in such families. Germ-line mutations in hCHK2 and PTEN may account...
Breast cancer is usually diagnosed by biopsy of a nodule detected by mammogram or by palpation. Women should be strongly encouraged to examine their breasts monthly. In premenopausal women, questionable or nonsuspicious (small) masses should be reexamined in 2–4 weeks (Fig. 75-1). A mass in a premenopausal woman that persists throughout her cycle and any mass in a postmenopausal woman should be aspirated. If the mass is a cyst filled with non-bloody fluid that goes away with aspiration, the pt is returned to routine screening. If the cyst aspiration leaves a residual mass or reveals bloody fluid, the pt should have a mammogram and excisional biopsy. If the mass is solid, the pt should undergo a mammogram and excisional biopsy. Screening mammograms performed every other year beginning at age 50 have been shown to save lives. The controversy regarding screening mammograms beginning at age 40 relates to the following facts: (1) the disease is much less common in the 40- to 49-year age group, and screening is generally less successful for less common problems; (2) workup of mammographic abnormalities in the 40- to 49-year age group less commonly diagnoses cancer; and (3) about 50% of women...
Hematology and Oncology

who are screened annually during their forties have an abnormality at some point that requires a diagnostic procedure (usually a biopsy), yet very few evaluations reveal cancer. However, many believe in the value of screening mammography beginning at age 40. After 13–15 years of follow-up, women who start screening at age 40 have a small survival benefit. Women with familial breast cancer more often have false-negative mammograms. MRI is a better screening tool in these women.

STAGING

Therapy and prognosis are dictated by stage of disease (Table 75-1). Unless the breast mass is large or fixed to the chest wall, staging of the ipsilateral axilla is performed at the time of lumpectomy (see below). Within pts of a given stage, individual characteristics of the tumor may influence prognosis: expression of estrogen receptor improves prognosis, while overexpression of HER-2/neu, mutations in p53, high growth fraction, and aneuploidy worsen the prognosis. Breast cancer can spread almost anywhere but commonly goes to bone, lungs, liver, soft tissue, and brain.

Breast Cancer

Five-year survival rate by stage is shown in Table 75-2. Treatment varies with stage of disease.

Ductal carcinoma in situ is a noninvasive tumor present in the breast ducts. Treatment of choice is wide excision with breast radiation therapy. In one study, adjuvant tamoxifen further reduced the risk of recurrence.

Invasive breast cancer can be classified as operable, locally advanced, and metastatic. In operable breast cancer, outcome of primary therapy is the same with modified radical mastectomy or lumpectomy followed by breast radiation therapy. Axillary dissection may be replaced with sentinel node biopsy to evaluate node involvement. The sentinel node is identified by injecting a dye in the tumor site at surgery; the first node in which dye appears is the sentinel node. Women with tumors <1 cm and negative axillary nodes require no additional therapy beyond their primary lumpectomy and breast radiation. Adjuvant combination chemotherapy for 6 months appears to benefit premenopausal women with positive lymph nodes, pre- and postmenopausal women with negative lymph nodes but with large tumors or poor prognostic features, and postmenopausal women with positive lymph nodes whose tumors do not express estrogen receptors. Estrogen receptor–positive tumors >1 cm with or without involvement of lymph nodes are treated with aromatase inhibitors. Women who began treatment with tamoxifen before aromatase inhibitors were approved should switch to an aromatase inhibitor after 5 years of tamoxifen and continue for another 5 years.

Adjuvant chemotherapy is added to hormonal therapy in estrogen receptor–positive, node-positive women and is used without hormonal therapy in estrogen receptor–negative node-positive women, whether they are pre- or postmenopausal. Various regimens have been used. The most effective regimen appears to be four cycles of doxorubicin, 60 mg/m², plus cyclophosphamide, 600 mg/m², IV on day 1 of each 3-week cycle followed by four cycles of paclitaxel, 175 mg/m², by 3-h infusion on day 1 of each 3-week cycle. The activity of other combinations is being explored. In premenopausal women, ovarian ablation [e.g., with the luteinizing hormone–releasing hormone (LHRH) inhibitor goserelin] may be as effective as adjuvant chemotherapy.
# TABLE 75-1  STAGING OF BREAST CANCER

## Primary Tumor (T)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0</td>
<td>No evidence of primary tumor</td>
</tr>
<tr>
<td>TIS</td>
<td>Carcinoma in situ</td>
</tr>
<tr>
<td>T1</td>
<td>Tumor ( \leq 2 ) cm</td>
</tr>
<tr>
<td>T1a</td>
<td>Tumor ( &gt;0.1 ) cm but ( \leq 0.5 ) cm</td>
</tr>
<tr>
<td>T1b</td>
<td>Tumor ( &gt;0.5 ) but ( \leq 1 ) cm</td>
</tr>
<tr>
<td>T1c</td>
<td>Tumor ( &gt;1 ) cm but ( \leq 2 ) cm</td>
</tr>
<tr>
<td>T2</td>
<td>Tumor ( &gt;2 ) cm but ( \leq 5 ) cm</td>
</tr>
<tr>
<td>T3</td>
<td>Tumor ( &gt;5 ) cm</td>
</tr>
<tr>
<td>T4</td>
<td>Extension to chest wall, inflammation, satellite lesions, ulcerations</td>
</tr>
</tbody>
</table>

## Regional Lymph Nodes (N)

- **PN0(i-)**: No regional lymph node metastasis histologically, negative IHC
- **PN0(i+)**: No regional lymph node metastasis histologically, positive IHC, no IHC cluster greater than 0.2 mm
- **PN0(mol-)**: No regional lymph node metastasis histologically, negative molecular findings (RT-PCR)<sup>a</sup>
- **PN0(mol+)**: No regional lymph node metastasis histologically, positive molecular findings (RT-PCR)<sup>a</sup>
- **PN1**: Metastasis in one to three axillary lymph nodes, or in internal mammary nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent
- **PN1mi**: Micrometastasis (\( >0.2 \) mm, none \( >2.0 \) mm)
- **PN1a**: Metastasis in one to three axillary lymph nodes
- **PN1b**: Metastasis in internal mammary nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent<sup>b</sup>
- **PN1c**: Metastasis in one to three axillary lymph nodes and in internal mammary lymph nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent<sup>b</sup> (If associated with greater than three positive axillary lymph nodes, the internal mammary nodes are classified as pN3b to reflect increased tumor burden.)
- **pN2**: Metastasis in four to nine axillary lymph nodes, or in clinically apparent internal mammary lymph nodes in the absence of axillary lymph node metastasis
- **pN3**: Metastasis in ten or more axillary lymph nodes, or in infraclavicular lymph nodes, or in clinically apparent ipsilateral internal mammary lymph nodes in the presence of 1 or more positive axillary lymph nodes; or in more than 3 axillary lymph nodes with clinically negative microscopic metastasis in internal mammary lymph nodes; or in ipsilateral SCLNs

## Distant Metastasis (M)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis (includes spread to ipsilateral supraclavicular nodes)</td>
</tr>
</tbody>
</table>

(continued)
Tamoxifen adjuvant therapy (20 mg/d for 5 years) or an aromatase inhibitor (anastrozole, letrozole, exemestane) is used for pre- or postmenopausal women with tumors expressing estrogen receptors whose nodes are positive or whose nodes are negative but with large tumors or poor prognostic features. Breast cancer will recur in about half of pts with localized disease. High-dose adjuvant therapy with marrow support does not appear to benefit even women with high risk of recurrence.

Pts with locally advanced breast cancer benefit from neoadjuvant combination chemotherapy (e.g., CAF: cyclophosphamide 500 mg/m², doxorubicin 50 mg/m², and 5-fluorouracil 500 mg/m² all given IV on days 1 and 8 of a monthly cycle for 6 cycles) followed by surgery plus breast radiation therapy.

Treatment for metastatic disease depends on estrogen receptor status and treatment philosophy. No therapy is known to cure pts with metastatic dis-

### TABLE 75-1

<table>
<thead>
<tr>
<th>Stage Grouping</th>
<th>TIS</th>
<th>N0</th>
<th>M0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIA</td>
<td>T0</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T1</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIB</td>
<td>T2</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIA</td>
<td>T0</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T1</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N1, N2</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIB</td>
<td>T4</td>
<td>Any N</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIC</td>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

*RT-PCR, reverse transcriptase/polymerase chain reaction.

*Clinically apparent is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination.

*T1 includes T1mic.


### TABLE 75-2

<table>
<thead>
<tr>
<th>Stage</th>
<th>5-Year Survival (Percentage of Patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>99</td>
</tr>
<tr>
<td>I</td>
<td>92</td>
</tr>
<tr>
<td>IIA</td>
<td>82</td>
</tr>
<tr>
<td>IIB</td>
<td>65</td>
</tr>
<tr>
<td>IIIA</td>
<td>47</td>
</tr>
<tr>
<td>IIIIB</td>
<td>44</td>
</tr>
<tr>
<td>IV</td>
<td>14</td>
</tr>
</tbody>
</table>

**Source:** Modified from data of the National Cancer Institute—Surveillance, Epidemiology, and End Results (SEER).
Tumors of the Gastrointestinal Tract

CHAPTER 76

Breast Cancer Prevention

Women with breast cancer have a 0.5% per year risk of developing a second breast cancer. Women at increased risk of breast cancer can reduce their risk by 49% by taking tamoxifen for 5 years. Aromatase inhibitors are probably at least as effective as tamoxifen and are under study. Women with \textit{BRCA-1} mutations can reduce the risk by 90% with simple mastectomy.

For a more detailed discussion, see Lippman ME: Breast Cancer, Chap. 86, p. 563, in HPIM-17.

Tumors of the Gastrointestinal Tract

ESOPHAGEAL CARCINOMA

In 2008 in the United States, 16,470 cases and 14,280 deaths; less frequent in women than men. Highest incidence in focal regions of China, Iran, Afghanistan, Siberia, Mongolia. In the United States, blacks more frequently affected than whites; usually presents sixth decade or later; 5-year survival <5% because most pts present with advanced disease.

Pathology 60% squamous cell carcinoma, most commonly in upper two-thirds; <40% adenocarcinoma, usually in distal third, arising in region of columnar metaplasia (Barrett’s esophagus), glandular tissue, or as direct extension of proximal gastric adenocarcinoma; lymphoma and melanoma rare.

Risk Factors Major risk factors for squamous cell carcinoma: ethanol abuse, smoking (combination is synergistic); other risks: lye ingestion and esophageal stricture, radiation exposure, head and neck cancer, achalasia, smoked opiates, Plummer-Vinson syndrome, tylosis, chronic ingestion of extremely hot tea, deficiency of vitamin A, zinc, molybdenum. Barrett’s esophagus is a risk for adenocarcinoma.
**Clinical Features**  Progressive dysphagia (first with solids, then liquids), rapid weight loss common, chest pain (from mediastinal spread), odynophagia, pulmonary aspiration (obstruction, tracheoesophageal fistula), hoarseness (laryngeal nerve palsy), hypercalcemia (parathyroid hormone–related peptide hypersecretion by squamous carcinomas); bleeding infrequent, occasionally severe; examination often unremarkable.

**Diagnosis**  Double-contrast barium swallow useful as initial test in dysphagia; flexible esophagogastroduodenoscopy most sensitive and specific test; pathologic confirmation by combining endoscopic biopsy and cytologic examination of mucosal brushings (neither alone sufficiently sensitive); CT and endoscopic ultrasonography valuable to assess local and nodal spread.

---

**Esophageal Carcinoma**

Surgical resection feasible in only 40% of pts; associated with high complication rate (fistula, abscess, aspiration). Squamous cell carcinoma: Surgical resection after chemotherapy [5-fluorouracil (5FU), cisplatin] plus radiation therapy prolongs survival and may provide improved cure rate. Adenocarcinoma: Curative resection rarely possible; <20% of pts with resectable tumors survive 5 years. Palliative measures include laser ablation, mechanical dilatation, radiotherapy, and a luminal prosthesis to bypass the tumor. Gastrostomy or jejunostomy are frequently required for nutritional support.

---

**GASTRIC CARCINOMA**

Highest incidence in Japan, China, Chile, Ireland; incidence decreasing worldwide, eightfold in the United States over past 60 years; in 2008, 21,500 new cases and 10,880 deaths. Male:female = 2:1; peak incidence sixth and seventh decades; overall 5-year survival <15%.

**Risk Factors**  Increased incidence in lower socioeconomic groups; environmental component is suggested by studies of migrants and their offspring. Several dietary factors correlated with increased incidence: nitrates, smoked foods, heavily salted foods; genetic component suggested by increased incidence in first-degree relatives of affected pts; other risk factors: atrophic gastritis, Helicobacter pylori infection, Billroth II gastrectomy, gastrojejunostomy, adenomatous gastric polyps, pernicious anemia, hyperplastic gastric polyps (latter two associated with atrophic gastritis), Ménétrier’s disease, slight increased risk with blood group A.

**Pathology**  Adenocarcinoma in 85%; usually focal (polypoid, ulcerative), two-thirds arising in antrum or lesser curvature, frequently ulcerative (“intestinal type”); less commonly diffuse infiltrative (linitis plastica) or superficial spreading (diffuse lesions more prevalent in younger pts; exhibit less geographic variation; have extremely poor prognosis); spreads primarily to local nodes, liver, peritoneum; systemic spread uncommon; lymphoma accounts for 15% (most frequent extranodal site in immunocompetent pts), either low-grade tumor of mucosa-associated lymphoid tissue (MALT) or aggressive diffuse large B cell lymphoma; leiomyosarcoma or gastrointestinal stromal tumor (GIST) is rare.

**Clinical Features**  Most commonly presents with progressive upper abdominal discomfort, frequently with weight loss, anorexia, nausea; acute or chronic GI bleeding (mucosal ulceration) common; dysphagia (location in cardia); vomiting
Tumors of the Gastrointestinal Tract

CHAPTER 76

(pyloric and widespread disease); early satiety; examination often unrevealing early in course; later, abdominal tenderness, pallor, and cachexia most common signs; palpable mass uncommon; metastatic spread may be manifest by hepatomegaly, ascites, left supraclavicular or scalene adenopathy, periumbilical, ovarian, or prerectal mass (Blumer’s shelf), low-grade fever, skin abnormalities (nodules, dermatomyositis, acanthosis nigricans, or multiple seborrheic keratoses). Laboratory findings: iron-deficiency anemia in two-thirds of pts; fecal occult blood in 80%; rarely associated with pancytopenia and microangiopathic hemolytic anemia (from marrow infiltration), leukemoid reaction, migratory thrombophlebitis, or acanthosis nigricans.

**Diagnosis**

Double-contrast barium swallow useful; gastroscopy most sensitive and specific test; pathologic confirmation by biopsy and cytologic examination of mucosal brushings; superficial biopsies less sensitive for lymphomas (frequently submucosal); important to differentiate benign from malignant gastric ulcers with multiple biopsies and follow-up examinations to demonstrate ulcer healing.

### Gastric Carcinoma

**Adenocarcinoma:** Gastrectomy offers only chance of cure (only possible in less than one-third); the rare tumors limited to mucosa are resectable for cure in 80%; deeper invasion, nodal metastases decrease 5-year survival to 20% of pts with resectable tumors in absence of obvious metastatic spread (Table 76-1); CT and endoscopic ultrasonography may aid in determining tumor resectability. Subtotal gastrectomy has similar efficacy to total gastrectomy for distal stomach lesions, but with less morbidity; no clear benefit for resection of spleen and a portion of the pancreas, or for radical lymph node removal. Adjuvant chemotherapy (5FU/leucovorin) plus radiation therapy following primary surgery leads to a 7-month increase in median survival. Neoadjuvant chemotherapy with epirubicin, cisplatin, and 5FU may downstage tumors and increase the efficacy of surgery. Palliative therapy for pain, obstruction, and bleeding includes surgery, endoscopic dilatation, radiation therapy, chemotherapy.

**Lymphoma:** Low-grade MALT lymphoma is caused by *H. pylori* infection, and eradication of the infection causes complete remissions in 50% of pts; rest are responsive to combination chemotherapy including cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) plus rituximab. Diffuse large B cell lymphoma may be treated with either CHOP plus rituximab or subtotal gastrectomy followed by chemotherapy; 50–60% 5-year survival.

**Leiomyosarcoma:** Surgical resection curative in most pts. Tumors expressing the *c-kit* tyrosine kinase (CD117)—GIST—respond to imatinib mesylate in a substantial fraction of cases.

### BENIGN GASTRIC TUMORS

Much less common than malignant gastric tumors; hyperplastic polyps most common, with adenomas, hamartomas, and leiomyomas rare; 30% of adenomas and occasional hyperplastic polyps are associated with gastric malignancy; polyposis syndromes include Peutz-Jeghers and familial polyposis (hamartomas and adenomas), Gardner’s (adenomas), and Cronkhite-Canada (cystic polyps). See “Colonic Polyps,” below.

**Clinical Features**

Usually asymptomatic; occasionally present with bleeding or vague epigastric discomfort.
Benign Gastric Tumors

Endoscopic or surgical excision.

SMALL-BOWEL TUMORS

Clinical Features Uncommon tumors (~5% of all GI neoplasms); usually present with bleeding, abdominal pain, weight loss, fever, or intestinal obstruction (intermittent or fixed); increased incidence of lymphomas in pts with gluten-sensitive enteropathy, Crohn’s disease involving small bowel, AIDS, prior organ transplantation, autoimmune disorders.

Pathology Usually benign; most common are adenomas (usually duodenal), leiomyomas (intramural), and lipomas (usually ileal); 50% of malignant tumors are adenocarcinoma, usually in duodenum (at or near ampulla of Vater) or proximal jejunum, commonly coexisting with benign adenomas; primary intestinal lymphomas (non-Hodgkin’s) account for 25% and occur as focal mass (Western type), which is usually a T cell lymphoma associated with prior celiac disease, or diffuse infiltration (Mediterranean type), which is usually immunoproliferative small-intestinal disease (IPSID; α-heavy chain disease), a B cell MALT lymphoma associated with Campylobacter jejuni infection, which can present as

<table>
<thead>
<tr>
<th>Stage</th>
<th>TNM</th>
<th>Features</th>
<th>Number of Cases, %</th>
<th>5-Year Survival, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>TisN0M0</td>
<td>Node negative; limited to mucosa</td>
<td>1</td>
<td>90</td>
</tr>
<tr>
<td>IA</td>
<td>T1N0M0</td>
<td>Node negative; invasion of lamina propria or submucosa</td>
<td>7</td>
<td>59</td>
</tr>
<tr>
<td>IB</td>
<td>T2N0M0</td>
<td>Node negative; invasion of muscularis propria</td>
<td>10</td>
<td>44</td>
</tr>
<tr>
<td>II</td>
<td>T1N2M0 T2N1M0</td>
<td>Node positive; invasion beyond mucosa but within wall or Node negative; extension through wall</td>
<td>17</td>
<td>29</td>
</tr>
<tr>
<td>IIIA</td>
<td>T2N2M0 T3N1–2M0</td>
<td>Node positive; invasion of muscularis propria or through wall</td>
<td>21</td>
<td>15</td>
</tr>
<tr>
<td>IIIB</td>
<td>T4N0–1M0</td>
<td>Node negative; adherence to surrounding tissue</td>
<td>14</td>
<td>9</td>
</tr>
<tr>
<td>IV</td>
<td>T4N2M0</td>
<td>Node positive; adherence to surrounding tissue or Distant metastases</td>
<td>30</td>
<td>3</td>
</tr>
</tbody>
</table>

Note: TNM, tumor, node, metastasis.
intestinal malabsorption; carcinoid tumors (usually asymptomatic) occasionally produce bleeding or intussusception (see below).

**Diagnosis** Endoscopy and biopsy most useful for tumors of duodenum and proximal jejunum; otherwise barium x-ray examination best diagnostic test; direct small-bowel instillation of contrast (enteroclysis) occasionally reveals tumors not seen with routine small-bowel radiography; angiography (to detect plexus of tumor vessels) or laparotomy often required for diagnosis; CT useful to evaluate extent of tumor (esp. lymphomas).

**Small-Bowel Tumors**

Surgical excision; adjuvant chemotherapy appears helpful for focal lymphoma; IPSID appears to be curable with combination chemotherapy used in aggressive lymphoma plus oral antibiotics (e.g., tetracycline); no proven role for chemotherapy or radiation therapy for other small-bowel tumors.

**COLONIC POLYPS**

**TUBULAR ADENOMAS**

Present in ~30% of adults; pedunculated or sessile; usually asymptomatic; ~5% cause occult blood in stool; may cause obstruction; overall risk of malignant degeneration correlates with size (<2% if <1.5 cm diam; >10% if >2.5 cm diam) and is higher in sessile polyps; 65% found in rectosigmoid colon; diagnosis by barium enema, sigmoidoscopy, or colonoscopy. **Treatment:** Full colonoscopy to detect synchronous lesions (present in 30%); endoscopic resection (surgery if polyp large or inaccessible by colonoscopy); follow-up surveillance by colonoscopy every 2–3 years.

**VILLOUS ADENOMAS**

Generally larger than tubular adenomas at diagnosis; often sessile; high risk of malignancy (up to 30% when >2 cm); more prevalent in left colon; occasionally associated with potassium-rich secretory diarrhea. **Treatment:** As for tubular adenomas.

**HYPERPLASTIC POLYPS**

Asymptomatic; usually incidental finding at colonoscopy; rarely >5 mm; no malignant potential. No treatment required.

**HEREDITARY POLYPOSIS SYNDROMES**

See Table 76-2.

1. **Familial polyposis coli** (FPC): Diffuse pancoonic adenomatous polyposis (up to several thousand polyps); autosomal dominant inheritance associated with deletion in adenomatous polyposis coli (APC) gene on chromosome 5; colon carcinoma from malignant degeneration of polyp in 100% by age 40. **Treatment:** Prophylactic total colectomy or subtotal colectomy with ileoproctostomy before age 30; subtotal resection avoids ileostomy but necessitates frequent proctoscopic surveillance; periodic colonoscopic or annual radiologic screening of siblings and offspring of pts with FPC until age 35; sulindac and other nonsteroidal anti-inflammatory drugs (NSAIDs) cause regression of polyps and inhibit their development.
2. **Gardner’s syndrome**: Variant of FPC with associated soft tissue tumors (epidermoid cysts, osteomas, lipomas, fibromas, desmoids); higher incidence of gastroduodenal polyps, ampullary cancers, congenital hypertrophy of retinal pigment epithelium. **Treatment**: As for FPC; surveillance for small-bowel disease with fecal occult blood testing after colectomy.

3. **Turcot’s syndrome**: Rare variant of FPC with associated malignant brain tumors. **Treatment**: As for FPC.

4. **Nonpolyposis syndrome (Lynch syndrome)**: Familial syndrome with up to 50% risk of colon carcinoma; peak incidence in fifth decade; associated with multiple primary cancers (esp. endometrial); autosomal dominant; due to defective DNA mismatch repair.

5. **Juvenile polyposis**: Multiple benign colonic and small-bowel hamartomas; intestinal bleeding common. Other symptoms: abdominal pain, diarrhea; occasional intussusception. Rarely recur after excision; low risk of colon cancer from malignant degeneration of interspersed adenomatous polyps. Prophylactic colectomy controversial.
6. Peutz-Jeghers syndrome: Numerous hamartomatous polyps of entire GI tract, though denser in small bowel than colon; GI bleeding common; somewhat increased risk for the development of cancer at GI and non-GI sites. Prophylactic surgery not recommended.

**COLORECTAL CANCER**

Second most common internal cancer in humans; accounts for 10% of cancer-related deaths in United States; incidence increases dramatically above age 50, nearly equal in men and women. In 2008, 148,810 new cases, 49,960 deaths.

**Etiology and Risk Factors** Most colon cancers arise from adenomatous polyps. Genetic steps from polyp to dysplasia to carcinoma in situ to invasive cancer have been defined, including point mutation in K-ras proto-oncogene, hypomethylation of DNA leading to enhanced gene expression, allelic loss at the APC gene (a tumor suppressor), allelic loss at the DCC (deleted in colon cancer) gene on chromosome 18, and loss and mutation of p53 on chromosome 17. Hereditary nonpolyposis colon cancer arises from mutations in the DNA mismatch repair genes, hMSH2 gene on chromosome 2 and hMLH1 gene on chromosome 3. Mutations lead to colon and other cancers. Diagnosis requires three or more relatives with colon cancer, one of whom is a first-degree relative; one or more cases diagnosed before age 50; and involvement of at least two generations. Environmental factors also play a role; increased prevalence in developed countries, urban areas, advantaged socioeconomic groups; increased risk in pts with hypercholesterolemia, coronary artery disease; correlation of risk with low-fiber, high-animal-fat diets, although direct effect of diet remains unproven; decreased risk with long-term dietary calcium supplementation and, possibly, daily aspirin ingestion. Risk increased in first-degree relatives of pts; families with increased prevalence of cancer; and pts with history of breast or gynecologic cancer, familial polyposis syndromes, >10-year history of ulcerative colitis or Crohn’s colitis, >15-year history of ureterosigmoidostomy. Tumors in pts with strong family history of malignancy are frequently located in right colon and commonly present before age 50; high prevalence in pts with *Streptococcus bovis* bacteremia.

**Pathology** Nearly always adenocarcinoma; 75% located distal to the splenic flexure (except in association with polyposis or hereditary cancer syndromes); may be polyoid, sessile, fungating, or constricting; subtype and degree of differentiation do not correlate with course. Degree of invasiveness at surgery (Dukes’ classification) is single best predictor of prognosis (Fig. 76-1). Rectosigmoid tumors may spread to lungs early because of systemic paravertebral venous drainage of this area. Other predictors of poor prognosis: preoperative serum carcinoembryonic antigen (CEA) >5 ng/mL (>5 μg/L), poorly differentiated histology, bowel perforation, venous invasion, adherence to adjacent organs, aneuploidy, specific deletions in chromosomes 5, 17, 18, and mutation of ras proto-oncogene. 15% have defects in DNA repair.

**Clinical Features** Left-sided colon cancers present most commonly with rectal bleeding, altered bowel habits (narrowing, constipation, intermittent diarrhea, tenesmus), and abdominal or back pain; cecal and ascending colon cancers more frequently present with symptoms of anemia, occult blood in stool, or weight loss; other complications: perforation, fistula, volvulus, inguinal hernia; laboratory findings: anemia in 50% of right-sided lesions.

**Diagnosis** Early diagnosis aided by screening asymptomatic persons with fecal occult blood testing (see below); >50% of all colon cancers are within reach of a
FIGURE 76-1 Staging and prognosis for patients with colorectal cancer.

### Staging of Colorectal Cancer

<table>
<thead>
<tr>
<th>Stage at Presentation</th>
<th>Extent of Tumor</th>
<th>5-Year Survival</th>
<th>Stage II</th>
<th>Stage III</th>
<th>Stage IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon</td>
<td>No deeper than submucosa</td>
<td>&gt;95%</td>
<td>T1</td>
<td>N1</td>
<td>M</td>
</tr>
<tr>
<td>Rectal</td>
<td>Not through muscularis</td>
<td>&gt;90%</td>
<td>T2</td>
<td>N2</td>
<td>Distant Metastases</td>
</tr>
<tr>
<td></td>
<td>Through muscularis</td>
<td>70–85%</td>
<td>T3</td>
<td>≥4 lymph node metastases</td>
<td>&lt;5%</td>
</tr>
<tr>
<td></td>
<td>1–3 lymph node metastases</td>
<td>50–70%</td>
<td>N1</td>
<td>25–60%</td>
<td>20%</td>
</tr>
<tr>
<td></td>
<td>4 lymph node metastases</td>
<td>26%</td>
<td>N2</td>
<td>26%</td>
<td>15%</td>
</tr>
</tbody>
</table>

**Colon**

- **Extent of tumor**: No deeper than submucosa
- **5-Year survival**: >95%

**Rectal**

- **Extent of tumor**: Not through muscularis
- **5-Year survival**: >90%
60-cm flexible sigmoidoscope; air-contrast barium enema will diagnose ~85% of colon cancers not within reach of sigmoidoscope; colonoscopy most sensitive and specific, permits tumor biopsy and removal of synchronous polyps (thus preventing neoplastic conversion), but is more expensive. Radiographic or virtual colonoscopy has not been shown to be a better diagnostic method than colonoscopy.

**Colorectal Cancer**

**Local disease**: Surgical resection of colonic segment containing tumor; preoperative evaluation to assess prognosis and surgical approach includes full colonoscopy, chest films, biochemical liver tests, plasma CEA level, and possible abdominal CT. Resection of isolated hepatic metastases possible in selected cases. Adjuvant radiation therapy to pelvis (with or without concomitant 5FU chemotherapy) decreases local recurrence rate of rectal carcinoma (no apparent effect on survival); radiation therapy without benefit on colon tumors; preoperative radiation therapy may improve resectability and local control in pts with rectal cancer. Total mesorectal excision is more effective than conventional anteroposterior resection in rectal cancer. Adjuvant chemotherapy (5FU/leucovorin plus oxaliplatin, or FOLFOX plus bevacizumab, or 5FU/leucovorin plus irinotecan, or FOLFIRI) decreases recurrence rate and improves survival of stage C (III); survival benefit from adjuvant therapy is not so clear in stage B (II) tumors; periodic determination of serum CEA level useful to follow therapy and assess recurrence. **Follow-up after curative resection**: Yearly liver tests, complete blood count, follow-up radiologic or colonoscopic evaluation at 1 year—if normal, repeat every 3 years, with routine screening interim (see below); if polyps detected, repeat 1 year after resection. **Advanced tumor** (locally unresectable or metastatic): Systemic chemotherapy (5FU/leucovorin plus oxaliplatin plus bevacizumab), irinotecan usually used in second treatment; antibodies to the EGF receptor (cetuximab, panitumumab) appear to enhance the effect of chemotherapy; intraarterial chemotherapy [floxuridine (FUDR)] and/or radiation therapy may palliate symptoms from hepatic metastases.

**Prevention** Early detection of colon carcinoma may be facilitated by routine screening of stool for occult blood (Hemoccult II, ColonCare, Hemosure); however, sensitivity only ~50% for carcinoma; specificity for tumor or polyp ~25–40%. False positives: ingestion of red meat, iron, aspirin; upper GI bleeding. False negatives: vitamin C ingestion, intermittent bleeding. Annual digital rectal exam and fecal occult blood testing recommended for pts over age 40, screening by flexible sigmoidoscopy every 3 years after age 50, in pts at increased risk (see above); careful evaluation of all pts with positive fecal occult blood tests (flexible sigmoidoscopy and air-contrast barium enema or colonoscopy alone) reveals polyps in 20–40% and carcinoma in ~5%; screening of asymptomatic persons allows earlier detection of colon cancer (i.e., earlier Dukes' stage) and achieves greater resectability rate; decreased overall mortality from colon carcinoma seen only after 13 years of follow-up. More intensive evaluation of first-degree relatives of pts with colon carcinoma frequently includes screening air-contrast barium enema or colonoscopy after age 40. NSAIDs and cyclooxygenase 2 inhibitors appear to prevent polyp development and induce regression in high-risk groups but have not been recommended for average-risk pts at this time.

**ANAL CANCER**

Accounts for 1–2% of large-bowel cancer, 5070 cases and 680 deaths in 2008; associated with chronic irritation, e.g., from condyloma acuminata, perianal fis-
sures/fistulae, chronic hemorrhoids, leukoplakia, trauma from anal intercourse. Women are more commonly affected than men. Homosexual men are at increased risk. Human papillomavirus may be etiologic. Presents with bleeding, pain, and perianal mass. Radiation therapy plus chemotherapy (5FU and mitomycin) leads to complete response in 80% when the primary lesion is <3 cm. Abdominoperineal resection with permanent colostomy is reserved for those with large lesions or whose disease recurs after chemoradiotherapy.

**BENIGN LIVER TUMORS**

Hepatocellular adenomas occur most commonly in women in the third or fourth decades who take birth control pills. Most are found incidentally but may cause pain; intratumoral hemorrhage may cause circulatory collapse. 10% may become malignant. Women with these adenomas should stop taking birth control pills. Large tumors near the liver surface may be resected. Focal nodular hyperplasia is also more common in women but seems not to be caused by birth control pills. Lesions are vascular on angiography and have septae and are usually asymptomatic.

**HEPATOCELLULAR CARCINOMA**

About 21,370 cases in the United States in 2008, but worldwide this may be the most common tumor. Male:female = 4:1; tumor usually develops in cirrhotic liver in persons in fifth or sixth decade. High incidence in Asia and Africa is related to etiologic relationship between this cancer and hepatitis B and C infections. Aflatoxin exposure contributes to etiology and leaves a molecular signature, a mutation in codon 249 of the gene for p53.

**Modes of Presentation** A patient with known liver disease develops an abnormality on ultrasound or rising $\alpha$ fetoprotein (AFP) or des-gamma-carboxy prothrombin (DCP) due to absence of vitamin K; abnormal liver function tests; cachexia, abdominal pain, fever.

**Physical Findings** Jaundice, asthenia, itching, tremors, disorientation, hepatomegaly, splenomegaly, ascites, peripheral edema.

**Hepatocellular Carcinoma**

Surgical resection or liver transplantation is therapeutic option but rarely successful. Radiofrequency ablation can cause regression of small tumors. Sorafenib may produce partial responses lasting a few months.

**Screening and Prevention** Screening populations at risk has given conflicting results. Hepatitis B vaccine prevents the disease. Interferon $\alpha$ (IFN-\(\alpha\)) may prevent liver cancer in persons with chronic active hepatitis C disease and possibly in those with hepatitis B. Ribavirin $\pm$ IFN-\(\alpha\) is most effective treatment of chronic hepatitis C.

**PANCREATIC CANCER**

In 2008 in the United States, about 37,680 new cases and 34,290 deaths. The incidence is decreasing somewhat, but nearly all diagnosed cases are fatal. The tumors are ductal adenocarcinomas and are not usually detected until the dis-
ease has spread. About 70% of tumors are in the pancreatic head, 20% in the body, and 10% in the tail. Mutations in K-ras have been found in 85% of tumors, and the p16 cyclin-dependent kinase inhibitor on chromosome 9 may also be implicated. Long-standing diabetes, chronic pancreatitis, and smoking increase the risk; coffee-drinking, alcoholism, and cholelithiasis do not. Pts present with pain and weight loss, the pain often relieved by bending forward. Jaundice commonly complicates tumors of the head, due to biliary obstruction. Curative surgical resections are feasible in about 10%. Adjuvant chemotherapy (5FU) may benefit some patients after resection. Gemcitabine plus erlotinib or capecitabine may palliate symptoms in pts with advanced disease.

ENDOCRINE TUMORS OF THE GI TRACT AND PANCREAS

CARCINOID TUMOR

Carcinoid tumor accounts for 75% of GI endocrine tumors; incidence is about 15 cases per million population. 90% originate in Kulchitsky cells of the GI tract, most commonly the appendix, ileum, and rectum. Carcinoid tumors of the small bowel and bronchus have a more malignant course than tumors of other sites. About 5% of pts with carcinoid tumors develop symptoms of the carcinoid syndrome, the classic triad being cutaneous flushing, diarrhea, and valvular heart disease. For tumors of GI tract origin, symptoms imply metastases to liver.

Diagnosis can be made by detecting the site of tumor or documenting production of >15 mg/d of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in the urine. Octreotide scintigraphy identifies sites of primary and metastatic tumor in about two-thirds of cases.

Carcinoid Tumor

Surgical resection where feasible. Symptoms may be controlled with histamine blockers and octreotide, 150–1500 mg/d in three doses. Hepatic artery embolization and chemotherapy (5FU plus streptozocin or doxorubicin) have been used for metastatic disease. IFN-α at 3–10 million units SC three times a week may relieve symptoms. Prognosis ranges from 95% 5-year survival for localized disease to 20% 5-year survival for those with liver metastases. Median survival of pts with carcinoid syndrome is 2.5 years from the first episode of flushing.

PANCREATIC ISLET-CELL TUMORS

Gastrinoma, insulinoma, VIPoma, glucagonoma, and somatostatinoma account for the vast majority of pancreatic islet-cell tumors; their characteristics are shown in Table 76-3. The tumors are named for the dominant hormone they produce. They are generally slow-growing and produce symptoms related to hormone production. Gastrinomas and peptic ulcer disease constitute the Zollinger-Ellison syndrome. Gastrinomas are rare (4 cases per 10 million population), and in 25–50%, the tumor is a component of a multiple endocrine neoplasia type 1 (MEN 1) syndrome (Chap. 186).

Insulinoma may present with Whipple’s triad: fasting hypoglycemia, symptoms of hypoglycemia, and relief after IV glucose. Normal or elevated serum insulin levels in the presence of fasting hypoglycemia are diagnostic. Insulinomas may also be associated with MEN 1.

Verner and Morrison described a syndrome of watery diarrhea, hypokalemia, achlorhydria, and renal failure associated with pancreatic islet tumors that
### Table 76-3: Gastrointestinal Endocrine Tumor Syndromes

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Cell Type</th>
<th>Clinical Features</th>
<th>Percentage Malignant</th>
<th>Major Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoid syndrome</td>
<td>Enterochromaffin, enterochromaffin-like</td>
<td>Flushing, diarrhea, wheezing, hypotension</td>
<td>~100</td>
<td>Serotonin, histamine, miscellaneous peptides</td>
</tr>
<tr>
<td>Zollinger-Ellison, gastrinoma</td>
<td>Non-β islet cell, duodenal G cell</td>
<td>Peptic ulcers, diarrhea</td>
<td>~70</td>
<td>Gastrin</td>
</tr>
<tr>
<td>Insulinoma</td>
<td>Islet β cell</td>
<td>Hypoglycemia</td>
<td>~10</td>
<td>Insulin</td>
</tr>
<tr>
<td>VIPoma (Verner-Morrison, WDHA)</td>
<td>Islet D₁ cell</td>
<td>Diarrhea, hypokalemia, hypochlorhydria</td>
<td>~60</td>
<td>Vasoactive intestinal peptide</td>
</tr>
<tr>
<td>Glucagonoma</td>
<td>Islet A cell</td>
<td>Mild diabetes mellitus, erythema necrolytica migrans, glossitis</td>
<td>&gt;75</td>
<td>Glucagon</td>
</tr>
<tr>
<td>Somatostatinoma</td>
<td>Islet D cell</td>
<td>Diabetes mellitus, diarrhea, steatorrhea, gallstones</td>
<td>~70</td>
<td>Somatostatin</td>
</tr>
</tbody>
</table>

**Note**: WDHA, watery diarrhea, hypokalemia, achlorhydria.
produce vasoactive intestinal polypeptide (VIP). *VIPomas* are rare (1 case per 10 million) but often grow to a large size before producing symptoms.

*Glucagonoma* is associated with diabetes mellitus and necrolytic migratory erythema, a characteristic red, raised, scaly rash usually located on the face, abdomen, perineum, and distal extremities. Glucagon levels >1000 ng/L not suppressed by glucose are diagnostic.

The classic triad of *somatostatinoma* is diabetes mellitus, steatorrhea, and cholelithiasis.

Provocative tests may facilitate diagnosis of functional endocrine tumors: tolbutamide enhances somatostatin secretion by somatostatinomas; pentagastrin enhances calcitonin secretion from medullary thyroid (C cell) tumors; secretin enhances gastrin secretion from gastrinomas. If imaging techniques fail to detect tumor masses, angiography or selective venous sampling for hormone determination may reveal the site of tumor. Metastases to nodes and liver should be sought by CT or MRI.

## Pancreatic Islet-Cell Tumors

Tumor is surgically removed, if possible. Octreotide inhibits hormone secretion in the majority of cases. IFN-α may reduce symptoms. Streptozotocin plus doxorubicin combination chemotherapy may produce responses in 60–90% of cases. Embolization or chemoembolization of hepatic metastases may be palliative.

For a more detailed discussion, see Mayer RJ: Gastrointestinal Tract Cancer, Chap. 87, p. 570; Carr BI: Tumors of the Liver and Biliary Tree, Chap. 88, p. 580; Chua YJ, Cunningham D: Pancreatic Cancer, Chap. 89, p. 586; and Jensen RT: Endocrine Tumors of the Gastrointestinal Tract and Pancreas, Chap. 344, p. 2347, in HPIM-17.

## Genitourinary Tract Cancer

### BLADDER CANCER

#### Incidence and Epidemiology

Annual incidence in the United States is about 69,810 cases with 14,100 deaths. Median age is 65 years. Smoking accounts for 50% of the risk. Exposure to polycyclic aromatic hydrocarbons increases the risk, especially in slow acetylators. Risk is increased in chimney sweeps, dry cleaners, and those involved in aluminum manufacturing. Chronic cyclophosphamide exposure increases risk ninefold. *Schistosoma haematobium* infection also increases risk, especially of squamous histology.

#### Etiology

Lesions involving chromosome 9q are an early event. Deletions in 17p (p53), 18q (the DCC locus), 13q (RB), 3p, and 5q are characteristic of invasive lesions. Overexpression of epidermal growth factor receptors and *HER2/neu* receptors is common.
Hematology and Oncology

SECTION 6

Pathology  Over 90% of tumors are derived from transitional epithelium; 3% are squamous, 2% are adenocarcinomas, and <1% are neuroendocrine small cell tumors. Field effects are seen that place all sites lined by transitional epithelium at risk including the renal pelvis, ureter, bladder, and proximal two-thirds of the urethra. 90% of tumors are in the bladder, 8% in the renal pelvis, and 2% in the ureter or urethra. Histologic grade influences survival. Lesion recurrence is influenced by size, number, and growth pattern of the primary tumor.

Clinical Presentation  Hematuria is the initial sign in 80–90%; however, cystitis is a more common cause of hematuria (22% of all hematuria) than is bladder cancer (15%). Pts are initially staged and treated by endoscopy. Superficial tumors are removed at endoscopy; muscle invasion requires more extensive surgery.

Bladder Cancer  Management is based on extent of disease: superficial, invasive, or metastatic. Frequency of presentation is 75% superficial, 20% invasive, and 5% metastatic. Superficial lesions are resected at endoscopy. Although complete resection is possible in 80%, 30–80% of cases recur; grade and stage progression occur in 30%. Intravesical instillation of bacille Calmette-Guérin (BCG) reduces the risk of recurrence by 40–45%. Recurrence is monitored every 3 months.

The standard management of muscle-invasive disease is radical cystectomy. 5-year survival is 70% for those without invasion of perivesicular fat or lymph nodes, 50% for those with invasion of fat but not lymph nodes, 35% for those with one node involved, and 10% for those with six or more involved nodes. Pts who cannot withstand radical surgery may have 30–35% 5-year survival with 5000- to 7000-cGy external beam radiation therapy. Bladder sparing may be possible in up to 45% of pts with two cycles of chemotherapy with CMV (methotrexate, 30 mg/m² days 1 and 8, vinblastine, 4 mg/m² days 1 and 8, cisplatin, 100 mg/m² day 2, q21d) followed by 4000-cGy radiation therapy given concurrently with cisplatin.

Metastatic disease is treated with combination chemotherapy. Useful regimens include CMV (see above), M-VAC (methotrexate, 30 mg/m² days 1, 15, 22; vinblastine, 3 mg/m² days 2, 15, 22; doxorubicin, 30 mg/m² day 2; cisplatin, 70 mg/m² day 2; q28d) or cisplatin (70 mg/m² day 2) plus gemcitabine (1000 mg/m² days 1, 8, 15 of a 28-day cycle) or carboplatin plus paclitaxel. About 70% of pts respond to treatment, and 20% have a complete response; 10–15% have long-term disease-free survival.

RENAL CANCER

Incidence and Epidemiology  Annual incidence in the United States is about 54,390 cases with 13,010 deaths. Cigarette smoking accounts for 20–30% of cases. Risk is increased in acquired renal cystic disease. There are two familial forms: a rare autosomal dominant syndrome and von Hippel–Lindau disease. About 35% of pts with von Hippel–Lindau disease develop renal cancer. Incidence is also increased in those with tuberous sclerosis and polycystic kidney disease.

Etiology  Most cases are sporadic; however, the most frequent chromosomal abnormality (occurs in 60%) is deletion or rearrangement of 3p21-26. The von Hippel–Lindau gene has been mapped to that region and appears to have novel activities, regulation of speed of transcription, and participation in turnover of damaged proteins. It is unclear how lesions in the gene lead to cancer.
Pathology  Five variants are recognized: clear cell tumors (75%), chromophilic tumors (15%), chromophobic tumors (5%), oncocytic tumors (3%), and collecting duct tumors (2%). Clear cell tumors arise from cells of the proximal convoluted tubules. Chromophilic tumors tend to be bilateral and multifocal and often show trisomy 7 and/or trisomy 17. Chromophobic and eosinophilic tumors less frequently have chromosomal aberrations and follow a more indolent course.

Clinical Presentation  The classic triad of hematuria, flank pain, and flank mass is seen in only 10–20% of pts; hematuria (40%), flank pain (40%), palpable mass (33%), and weight loss (33%) are the most common individual symptoms. Paraneoplastic syndromes of erythrocytosis (3%), hypercalcemia (5%), and nonmetastatic hepatic dysfunction (Stauffer’s syndrome) (15%) may also occur. Workup should include IV pyelography, renal ultrasonography, CT of abdomen and pelvis, chest x-ray (CXR), urinalysis, and urine cytology. Stage I is disease restricted to the kidney, stage II is disease contained within Gerota’s fascia, stage III is locally invasive disease involving nodes and/or inferior vena cava, stage IV is invasion of adjacent organs or metastatic sites. Prognosis is related to stage: 66% 5-year survival for I, 64% for II, 42% for III, and 11% for IV.

Renal Cancer  Radical nephrectomy is standard for stages I, II, and most stage III pts. Surgery may also be indicated in the setting of metastatic disease for intractable local symptoms (bleeding, pain). Response rates of 40–48% have been noted with three different single agents, sunitinib, sorafenib, and temsirolimus. Sunitinib and sorafenib are thought to be antiangiogenic through inhibition of kinases in tumor cells. Temsirolimus is an inhibitor of mTOR. About 10–15% of pts with advanced-stage disease may benefit from interleukin 2 and/or interferon α (IFN-α). Addition of bevacizumab to IFN-α improves the response rate. Some remissions are durable. Chemotherapy is of little or no benefit.

TESTICULAR CANCER  Incidence and Epidemiology  Annual incidence is about 8090 cases with 380 deaths. Peak age incidence is 20–40. Occurs 4–5 times more frequently in white than black men. Cryptorchid testes are at increased risk. Early orchio-pexy may protect against testis cancer. Risk is also increased in testicular feminization syndromes, and Klinefelter syndrome is associated with mediastinal germ cell tumor.

Etiology  The cause is unknown. Disease is associated with a characteristic cytogenetic defect, isochromosome 12p.

Pathology  Two main subtypes are noted: seminoma and nonseminoma. Each accounts for ~50% of cases. Seminoma has a more indolent natural history and is highly sensitive to radiation therapy. Four subtypes of nonseminoma are defined: embryonal carcinoma, teratoma, choriocarcinoma, and endodermal sinus (yolk sac) tumor.

Clinical Presentation  Painless testicular mass is the classic initial sign. In the presence of pain, differential diagnosis includes epididymitis or orchitis; a brief trial of antibiotics may be undertaken. Staging evaluation includes measurement of serum tumor markers α fetoprotein (AFP) and β-human chorionic gonadotropin (hCG), CXR, and CT scan of abdomen and pelvis. Lymph nodes are
staged at resection of the primary tumor through an inguinal approach. Stage I disease is limited to the testis, epididymis, or spermatic cord; stage II involves retroperitoneal nodes; and stage III is disease outside the retroperitoneum. Among seminoma pts, 70% are stage I, 20% are stage II, and 10% are stage III. Among nonseminoma germ cell tumor pts, 33% are found in each stage. hCG may be elevated in either seminoma or nonseminoma, but AFP is elevated only in nonseminoma. 95% of pts are cured if treated appropriately. Primary non-seminoma in the mediastinum is associated with acute leukemia or other hematologic disorders and has a poorer prognosis than testicular primaries (~33%).

**Testicular Cancer**  
Table 77-1

For stages I and II seminoma, inguinal orchiectomy followed by retroperitoneal radiation therapy to 2500–3000 cGy is effective. For stages I and II nonseminoma germ cell tumors, inguinal orchiectomy followed by retroperitoneal lymph node dissection is effective. For pts of either histology with bulky nodes or stage III disease, chemotherapy is given. Cisplatin (20 mg/m² days 1–5), etoposide (100 mg/m² days 1–5), and bleomycin (30 U days 2, 9, 16) given every 21 days for four cycles is the standard therapy. If tumor markers return to zero, residual masses are resected. Most are necrotic debris or teratomas. Salvage therapy rescues about 25% of those not cured with primary therapy.

For a more detailed discussion, see Scher HI, Motzer RJ: Bladder and Renal Cell Carcinomas, Chap. 90, p. 589; and Motzer RJ, Bosl GJ: Testicular Cancer, Chap. 92, p. 601, in HPIM-17.
Gynecologic Cancer

CHAPTER 78

OVARIAN CANCER

Incidence and Epidemiology Annually in the United States, about 22,000 new cases are found and 15,500 women die of ovarian cancer. Incidence begins to rise in the fifth decade, peaking in the eighth decade. Risk is increased in nulliparous women and reduced by pregnancy (risk decreased about 10% per pregnancy) and oral contraceptives. About 5% of cases are familial.

Genetics Mutations in BRCA-1 predispose women to both breast and ovarian cancer. Cytogenetic analysis of epithelial ovarian cancers that are not familial often reveals complex karyotypic abnormalities including structural lesions on chromosomes 1 and 11 and loss of heterozygosity for loci on chromosomes 3q, 6q, 11q, 13q, and 17. C-myc, H-ras, K-ras, and HER2/neu are often mutated or overexpressed. Unlike in colon cancer, a stepwise pathway to ovarian carcinoma is not apparent.

Screening No benefit has been seen from screening women of average risk. Hereditary ovarian cancer accounts for 10% of all cases. Women with BRCA-1 or -2 mutations should consider prophylactic bilateral salpingo-oophorectomy by age 40.

Clinical Presentation Most pts present with abdominal pain, bloating, urinary symptoms, and weight gain indicative of disease spread beyond the true pelvis. Localized ovarian cancer is usually asymptomatic and detected on routine pelvic examination as a palpable nontender adnexal mass. Most ovarian masses detected incidentally in ovulating women are ovarian cysts that resolve over one to three menstrual cycles. Adnexal masses in postmenopausal women are more often pathologic and should be surgically removed. CA-125 serum levels are ≥35 U/mL in 80–85% of women with ovarian cancer, but other conditions may also cause elevations.

Pathology Half of ovarian tumors are benign, one-third are malignant, and the rest are tumors of low malignant potential. These borderline lesions have cytologic features of malignancy but do not invade. Malignant epithelial tumors may be of five different types: serous (50%), mucinous (25%), endometrioid (15%), clear cell (5%), and Brenner tumors (1%, derived from urothelial or transitional epithelium). The remaining 4% of ovarian tumors are stromal or germ cell tumors, which are managed like testicular cancer in men (Chap. 77). Histologic grade is an important prognostic factor for the epithelial varieties.

Staging Extent of disease is ascertained by a surgical procedure that permits visual and manual inspection of all peritoneal surfaces and the diaphragm. Total abdominal hysterectomy, bilateral salpingo-oophorectomy, partial omentectomy, pelvic and paraaortic lymph node sampling, and peritoneal washings should be performed. The staging system and its influence on survival are shown in Table 78-1. About 23% of pts are stage I, 13% are stage II, 47% are stage III, and 16% are stage IV.
<table>
<thead>
<tr>
<th>Stage</th>
<th>Ovarian</th>
<th>5-Year Survival, %</th>
<th>Endometrial</th>
<th>5-Year Survival, %</th>
<th>Cervical</th>
<th>5-Year Survival, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>I</td>
<td>Confined to ovary</td>
<td>90–95</td>
<td>Confined to corpus</td>
<td>89</td>
<td>Carcinoma in situ</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Confined to pelvis</td>
<td>70–80</td>
<td>Involves corpus and cervix</td>
<td>73</td>
<td>Confined to uterus</td>
<td>85</td>
</tr>
<tr>
<td>II</td>
<td>Intraabdominal spread</td>
<td>25–50</td>
<td>Extends outside the uterus but not outside the true pelvis</td>
<td>52</td>
<td>Invades beyond uterus but not pelvic wall</td>
<td>65</td>
</tr>
<tr>
<td>III</td>
<td>Spread outside abdomen</td>
<td>1–5</td>
<td>Extends outside the true pelvis or involves the bladder or rectum</td>
<td>17</td>
<td>Extends to pelvic wall and/or lower third of vagina, or hydronephrosis</td>
<td>35</td>
</tr>
<tr>
<td>IV</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>
**Ovarian Cancer**

Pts with stage I disease, no residual tumor after surgery, and well- or moderately differentiated tumors need no further treatment after surgery and have a 5-year survival of >95%. For stage II pts totally resected and stage I pts with poor histologic grade, adjuvant therapy with single-agent cisplatin or cisplatin plus paclitaxel produces 5-year survival of 80%. Advanced-stage pts should receive paclitaxel, 175 mg/m² by 3-h infusion, followed by carboplatin dosed to an area under the curve (AUC) of 7.5 every 3 or 4 weeks. Carboplatin dose is calculated by the Calvert formula: dose = target AUC × (glomerular filtration rate + 25). The complete response rate is about 55%, and median survival is 38 months.

**ENDOMETRIAL CANCER**

**Incidence and Epidemiology**  
The most common gynecologic cancer—40,000 cases are diagnosed in the United States and 7500 pts die annually. It is primarily a disease of postmenopausal women. Obesity, altered menstrual cycles, infertility, late menopause, and postmenopausal bleeding are commonly encountered in women with endometrial cancer. Women taking tamoxifen to prevent breast cancer recurrence and those taking estrogen replacement therapy are at a modestly increased risk. Peak incidence is in the sixth and seventh decades.

**Clinical Presentation**  
Abnormal vaginal discharge (90%), abnormal vaginal bleeding (80%), and leukorrhea (10%) are the most common symptoms.

**Pathology**  
Endometrial cancers are adenocarcinomas in 75–80% of cases. The remaining cases include mucinous carcinoma; papillary serous carcinoma; and secretory, ciliate, and clear cell varieties. Prognosis depends on stage, histologic grade, and degree of myometrial invasion.

**Staging**  
Total abdominal hysterectomy and bilateral salpingo-oophorectomy comprise both the staging procedure and the treatment of choice. The staging scheme and its influence on prognosis are shown in Table 78-1. About 75% of pts are stage I, 13% are stage II, 9% are stage III, and 3% are stage IV.

**Endometrial Cancer**

In women with poor histologic grade, deep myometrial invasion, or extensive involvement of the lower uterine segment or cervix, intracavitary or external beam radiation therapy is given. If cervical invasion is deep, preoperative radiation therapy may improve the resectability of the tumor. Stage III disease is managed with surgery and radiation therapy. Stage IV disease is usually treated palliatively. Progestational agents such as hydroxyprogesterone or megestrol and the antiestrogen tamoxifen may produce responses in 20% of pts. Doxorubicin, 60 mg/m² IV day 1, and cisplatin, 50 mg/m² IV day 1, every 3 weeks for 8 cycles produces a 45% response rate.

**CERVICAL CANCER**

**Incidence and Epidemiology**  
In the United States about 11,000 cases of invasive cervical cancer are diagnosed each year and 50,000 cases of carcinoma in situ are detected by Pap smear. Cervical cancer kills 3900 women a year, 85% of
whom never had a Pap smear. It is a major cause of disease in underdeveloped countries and is more common in lower socioeconomic groups, in women with early sexual activity and/or multiple sexual partners, and in smokers. Human papilloma virus (HPV) types 16 and 18 are the major types associated with cervical cancer. The virus attacks the G1 checkpoint of the cell cycle; its E7 protein binds and inactivates Rb protein, and E6 induces the degradation of p53.

**Screening**  Women should begin screening when they begin sexual activity or at age 20. After two consecutive negative annual Pap smears, the test should be repeated every 3 years. Abnormal smears dictate the need for a cervical biopsy, usually under colposcopy, with the cervix painted with 3% acetic acid, which shows abnormal areas as white patches. If there is evidence of carcinoma in situ, a cone biopsy is performed, which is therapeutic.

**Prevention**  Women and children age 9–26 should consider vaccination with Gardasil to prevent infection with two serotypes of virus that cause 70% of the cervical cancer in the United States.

**Clinical Presentation**  Pts present with abnormal bleeding or postcoital spotting or menometrorrhagia or intermenstrual bleeding. Vaginal discharge, low back pain, and urinary symptoms may also be present.

**Staging**  Staging is clinical and consists of a pelvic exam under anesthesia with cystoscopy and proctoscopy. Chest x-ray, IV pyelography, and abdominal CT are used to search for metastases. The staging system and its influence on prognosis are shown in Table 78-1. At presentation, 47% of pts are stage I, 28% are stage II, 21% are stage III, and 4% are stage IV.

<table>
<thead>
<tr>
<th>Rx</th>
<th>Cervical Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Carcinoma in situ is cured with cone biopsy. Stage I disease may be treated with radical hysterectomy or radiation therapy. Stages II–IV disease are usually treated with radiation therapy, often with both brachytherapy and teletherapy, or combined-modality therapy. Pelvic exenteration is used uncommonly to control the disease, especially in the setting of centrally recurrent or persistent disease. Women with locally advanced (stage IIB to IVA) disease usually receive concurrent chemotherapy and radiation therapy. The chemotherapy acts as a radiosensitizer. Hydroxyurea, 5-fluorouracil (5FU), and cisplatin have all shown promising results given concurrently with radiation therapy. Cisplatin, 75 mg/m² IV over 4 h on day 1, and 5FU, 4 g given by 96-h infusion on days 1–5 of radiation therapy, is a common regimen. Relapse rates are reduced 30–50% by such therapy. Advanced-stage disease is treated palliatively with single agents (cisplatin, irinotecan, ifosfamide).</td>
</tr>
</tbody>
</table>
Prostate Hyperplasia and Carcinoma

CHAPTER 79

PROSTATE HYPERPLASIA

Enlargement of the prostate is nearly universal in aging men. Hyperplasia usually begins by age 45 years, occurs in the area of the prostate gland surrounding the urethra, and produces urinary outflow obstruction. Symptoms develop on average by age 65 in whites and 60 in blacks. Symptoms develop late because hypertrophy of the bladder detrusor compensates for ureteral compression. As obstruction progresses, urinary stream caliber and force diminish, hesitancy in stream initiation develops, and postvoid dribbling occurs. Dysuria and urgency are signs of bladder irritation (perhaps due to inflammation or tumor) and are usually not seen in prostate hyperplasia. As the postvoid residual increases, nocturia and overflow incontinence may develop. Common medications such as tranquilizing drugs and decongestants, infections, or alcohol may precipitate urinary retention. Because of the prevalence of hyperplasia, the relationship to neoplasia is unclear.

On digital rectal exam (DRE), a hyperplastic prostate is smooth, firm, and rubbery in consistency; the median groove may be lost. Prostate-specific antigen (PSA) levels may be elevated but are \( \leq 10 \text{ ng/mL} \) unless cancer is also present (see below). Cancer may also be present at lower levels of PSA.

Asymptomatic pts do not require treatment, and those with complications of urethral obstruction such as inability to urinate, renal failure, recurrent urinary tract infection, hematuria, or bladder stones clearly require surgical extirpation of the prostate, usually by transurethral resection (TURP). However, the approach to the remaining pts should be based on the degree of incapacity or discomfort from the disease and the likely side effects of any intervention. If the pt has only mild symptoms, watchful waiting is not harmful and permits an assessment of the rate of symptom progression. If therapy is desired by the pt, two medical approaches may be helpful: terazosin, an \( \alpha_1 \)-adrenergic blocker (1 mg at bedtime, titrated to symptoms up to 20 mg/d), relaxes the smooth muscle of the bladder neck and increases urine flow; finasteride (5 mg/d), an inhibitor of 5α-reductase, blocks the conversion of testosterone to dihydrotestosterone and causes an average decrease in prostate size of \( \sim 24\% \). TURP has the greatest success rate but also the greatest risk of complications. Transurethral microwave thermotherapy (TUMT) may be comparably effective to TURP. Direct comparison has not been made between medical and surgical management.

PROSTATE CARCINOMA

Prostate cancer was diagnosed in 186,320 men in 2008 in the United States—an incidence comparable to that of breast cancer. About 28,660 men died of prostate cancer in 2008. The early diagnosis of cancers in mildly symptomatic men found on screening to have elevated serum levels of PSA has complicated management. Like most other cancers, incidence is age-related. The disease is more common in blacks than whites. Symptoms are generally similar to and in-
distinguishable from those of prostate hyperplasia, but those with cancer more often have dysuria and back or hip pain. On histology, 95% are adenocarcinomas. Biologic behavior is affected by histologic grade (Gleason score).

In contrast to hyperplasia, prostate cancer generally originates in the periphery of the gland and may be detectable on DRE as one or more nodules on the posterior surface of the gland, hard in consistency and irregular in shape. An approach to diagnosis is shown in Fig. 79-1. Those with a negative DRE and PSA ≤4 ng/mL may be followed annually. Those with an abnormal DRE or a PSA >10 ng/mL should undergo transrectal ultrasound (TRUS)-guided biopsy. Those with normal DRE and PSA of 4.1–10 ng/mL may be handled differently in different centers. Some would perform TRUS and biopsy any abnormality or follow if no abnormality were found. Some would repeat the PSA in a year and biopsy if the increase over that period were >0.75 ng/mL. Other methods of using PSA to distinguish early cancer from hyperplasia include quantitating bound and free PSA and relating the PSA to the size of the prostate (PSA density). Perhaps one-third of persons with prostate cancer do not have PSA elevations.

Lymphatic spread is assessed surgically; it is present in only 10% of those with Gleason grade 5 or lower and in 70% of those with grade 9 or 10. PSA level also correlates with spread; only 10% of those with PSA <10 ng/mL have lymphatic spread. Bone is the most common site of distant metastasis. Whitmore-Jewett staging includes A: tumor not palpable but detected at TURP; B: palpable tumor in one (B1) or both (B2) lobes; C: palpable tumor outside capsule; and D: metastatic disease.

**Prostate Carcinoma**

For pts with stages A through C disease, surgery (radical retropubic prostatectomy) and radiation therapy (conformal 3-dimensional fields) are said to have similar outcomes; however, most pts are treated surgically. Both modalities
are associated with impotence. Surgery is more likely to lead to incontinence. Radiation therapy is more likely to produce proctitis, perhaps with bleeding or stricture. Addition of hormonal therapy (goserelin) to radiation therapy of patients with localized disease appears to improve results. Patients usually must have a 5-year life expectancy to undergo radical prostatectomy. Stage A pts have survival identical to age-matched controls without cancer. Stage B and C pts have a 10-year survival of 82% and 42%, respectively.

Pts treated surgically for localized disease who develop rising PSA may undergo Prostascint scanning (antibody to a prostate-specific membrane antigen). If no uptake is seen, the pt is observed. If uptake is seen in the prostate bed, local recurrence is implied and external beam radiation therapy is delivered to the site. (If the pt was initially treated with radiation therapy, this local recurrence may be treated with surgery.) However, in most cases, a rising PSA after local therapy indicates systemic disease. It is not clear when to intervene in such patients.

For pts with metastatic disease, androgen deprivation is the treatment of choice. Surgical castration is effective, but most pts prefer to take leuprolide, 7.5 mg depot form IM monthly (to inhibit pituitary gonadotropin production), plus flutamide, 250 mg PO tid (an androgen receptor blocker). The value of added flutamide is debated. Alternative approaches include adrenalectomy, hypophysectomy, estrogen administration, and medical adrenalectomy with aminoglutethimide. The median survival of stage D pts is 33 months. Pts occasionally respond to withdrawal of hormonal therapy with tumor shrinkage. Rarely a second hormonal manipulation will work, but most pts who progress on hormonal therapy have androgen-independent tumors, often associated with genetic changes in the androgen receptor and new expression of bel-2, which may contribute to chemotherapy resistance. Chemotherapy is used for palliation in prostate cancer. Mitoxantrone, estramustine, and taxanes appear to be active single agents, and combinations of drugs are being tested. Chemotherapy-treated pts are more likely to have pain relief than those receiving supportive care alone. Bone pain from metastases may be palliated with strontium-89 or samarium-153. Bisphosphonates have not been adequately evaluated.

**Prostate Cancer Prevention**

Finasteride has been shown to reduce the incidence of prostate cancer by 25%, but no effect on overall survival has been seen with limited follow-up.
CUPS incidence is declining, probably because of better pathology diagnostic criteria; they account for about 3% of all cancers today, down from 10–15% 15 years ago. Most pts are over age 60. The tumors are often aneuploid. Cell lines derived from such tumors frequently have abnormalities in chromosome 1.

**Clinical Presentation** Pts may present with fatigue, weight loss, pain, bleeding, abdominal swelling, subcutaneous masses, and lymphadenopathy. Once metastatic malignancy is confirmed, diagnostic efforts should be confined to evaluating the presence of potentially curable tumors, such as lymphoma, Hodgkin’s disease, germ cell tumor, ovarian cancer, head and neck cancer, and primitive neuroectodermal tumor, or tumors for which therapy may be of significant value such as breast cancer or prostate cancer. In general, efforts to evaluate the presence of these tumor types depend more on the pathologist than on expensive clinical diagnostic testing. Localizing symptoms, a history of carcinogen exposure, or a history of fulguration of skin lesion may direct some clinical testing; however, the careful light microscopic, ultrastructural, immunologic, karyotypic, and molecular biologic examination of adequate volumes of tumor tissue is the most important feature of the diagnostic workup in the absence of suspicious findings on history and physical exam (Table 80-1).

**Histology** About 60% of CUPS tumors are adenocarcinomas, 5% are squamous cell carcinomas, and 30% are poorly differentiated neoplasms not further classified on light microscopy. Expression of cytokeratin subtypes may narrow the range of possible diagnoses (Fig. 80-1).

**Prognosis** Pts with squamous cell carcinoma have a median survival of 9 months; those with adenocarcinoma or unclassifiable tumors have a median survival of 4–6 months. Pts in whom a primary site is identified usually have a better prognosis. Limited sites of involvement and neuroendocrine histology are favorable prognostic factors. Pts without a primary diagnosis should be treated palliatively with radiation therapy to symptomatic lesions. All-purpose chemotherapy regimens rarely produce responses but always produce toxicity. Certain clinical features may permit individualized therapy.

**SYNDROME OF UNRECOGNIZED EXTRAGONADAL GERM CELL CANCER**

In pts <50 years with tumor involving midline structures, lung parenchyma, or lymph nodes and evidence of rapid tumor growth, germ cell tumor is a possible diagnosis. Serum tumor markers may or may not be elevated. Cisplatin, etoposide, and bleomycin (Chap. 77) chemotherapy may induce complete responses in ≥25%, and ~15% may be cured. A trial of such therapy should probably also be undertaken in pts whose tumors have abnormalities in chromosome 12.

**PERITONEAL CARCINOMATOSIS IN WOMEN**

Women who present with pelvic mass or pain and an adenocarcinoma diffusely throughout the peritoneal cavity, but without a clear site of origin, have primary peritoneal papillary serous carcinoma. The presence of psammoma bodies in the tumor or elevated CA-125 levels may favor ovarian origin. Such pts should undergo debulking surgery followed by paclitaxel plus cisplatin or carboplatin combination chemotherapy (Chap. 78). About 20% of pts will respond, and 10% will survive at least 2 years.

**CARCINOMA IN AN AXILLARY LYMPH NODE IN WOMEN**

Such women should receive adjuvant breast cancer therapy appropriate for their menopausal status even in the absence of a breast mass on physical examination.
### TABLE 80-1 POSSIBLE PATHOLOGIC EVALUATION OF BIOPSY SPECIMENS FROM PATIENTS WITH METASTATIC CANCER OF UNKNOWN PRIMARY SITE

<table>
<thead>
<tr>
<th>Evaluation/Findings</th>
<th>Suggested Primary Site or Neoplasm</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HISTOLOGY (HEMATOXYLIN AND EOSIN STAINING)</strong></td>
<td></td>
</tr>
<tr>
<td>Psammoma bodies, papillary configuration</td>
<td>Ovary, thyroid</td>
</tr>
<tr>
<td>Signet ring cells</td>
<td>Stomach</td>
</tr>
<tr>
<td><strong>IMMUNOHISTOLOGY</strong></td>
<td></td>
</tr>
<tr>
<td>Leukocyte common antigen (LCA, CD45)</td>
<td>Lymphoid neoplasm</td>
</tr>
<tr>
<td>Leu-M1</td>
<td>Hodgkin’s disease</td>
</tr>
<tr>
<td>Epithelial membrane antigen</td>
<td>Carcinoma</td>
</tr>
<tr>
<td>Cytokeratin</td>
<td>Carcinoma</td>
</tr>
<tr>
<td>CEA</td>
<td>Carcinoma</td>
</tr>
<tr>
<td>HMB45</td>
<td>Melanoma</td>
</tr>
<tr>
<td>Desmin</td>
<td>Sarcoma</td>
</tr>
<tr>
<td>Thyroglobulin</td>
<td>Thyroid carcinoma</td>
</tr>
<tr>
<td>Calcitonin</td>
<td>Medullary carcinoma of the thyroid</td>
</tr>
<tr>
<td>Myoglobin</td>
<td>Rhabdomyosarcoma</td>
</tr>
<tr>
<td>PSA/prostatic acid phosphatase</td>
<td>Prostate</td>
</tr>
<tr>
<td>AFP</td>
<td>Liver, stomach, germ cell</td>
</tr>
<tr>
<td>Placental alkaline phosphatase</td>
<td>Germ cell</td>
</tr>
<tr>
<td>B, T cell markers</td>
<td>Lymphoid neoplasm</td>
</tr>
<tr>
<td>S-100 protein</td>
<td>Neuroendocrine tumor, melanoma</td>
</tr>
<tr>
<td>Gross cystic fluid protein</td>
<td>Breast, sweat gland</td>
</tr>
<tr>
<td>Factor VIII</td>
<td>Kaposi’s sarcoma, angiosarcoma</td>
</tr>
<tr>
<td>Thyroid transcription factor 1 (TTF-1)</td>
<td>Lung adenocarcinoma, thyroid</td>
</tr>
<tr>
<td><strong>FLOW CYTOMETRY</strong></td>
<td></td>
</tr>
<tr>
<td>B, T cell markers</td>
<td>Lymphoid neoplasm</td>
</tr>
<tr>
<td><strong>ULTRASTRUCTURE</strong></td>
<td></td>
</tr>
<tr>
<td>Actin-myosin filaments</td>
<td>Rhabdomyosarcoma</td>
</tr>
<tr>
<td>Secretory granules</td>
<td>Neuroendocrine tumors</td>
</tr>
<tr>
<td>Desmosomes</td>
<td>Carcinoma</td>
</tr>
<tr>
<td>Premelanosomes</td>
<td>Melanoma</td>
</tr>
<tr>
<td><strong>CYTOGENETICS</strong></td>
<td></td>
</tr>
<tr>
<td>Isochromosome 12p; 12q(−)</td>
<td>Germ cell</td>
</tr>
<tr>
<td>t(11;22)</td>
<td>Ewing’s sarcoma, primitive neuroectodermal tumor</td>
</tr>
<tr>
<td>t(8;14)a</td>
<td>Lymphoid neoplasm</td>
</tr>
<tr>
<td>3p(−)</td>
<td>Small cell lung carcinoma; renal cell carcinoma, mesothelioma</td>
</tr>
<tr>
<td>t(X;18)</td>
<td>Synovial sarcoma</td>
</tr>
<tr>
<td>t(12;16)</td>
<td>Myxoid liposarcoma</td>
</tr>
<tr>
<td>t(12;22)</td>
<td>Clear cell sarcoma (melanoma of soft parts)</td>
</tr>
<tr>
<td>t(2;13)</td>
<td>Alveolar rhabdomyosarcoma</td>
</tr>
<tr>
<td>1p(−)</td>
<td>Neuroblastoma</td>
</tr>
</tbody>
</table>

(continued)
or mammography and undetermined or negative estrogen and progesterone receptors on the tumor (Chap. 75). Unless the ipsilateral breast is radiated, up to 50% of these pts will later develop a breast mass. Although this is a rare clinical situation, long-term survival similar to women with stage II breast cancer is possible.

**OSTEOBLASTIC BONE METASTASES IN MEN**

The probability of prostate cancer is high; a trial of empirical hormonal therapy (leuprolide and flutamide) is warranted (Chap. 79).

**CERVICAL LYMPH NODE METASTASES**

Even if panendoscopy fails to reveal a head and neck primary, treatment of such pts with cisplatin and 5-fluorouracil chemotherapy may produce a response; some responses are long-lived (Chap. 73).

---

**TABLE 80-1**

**POSSIBLE PATHOLOGIC EVALUATION OF BIOPSY SPECIMENS FROM PATIENTS WITH METASTATIC CANCER OF UNKNOWN PRIMARY SITE (CONTINUED)**

<table>
<thead>
<tr>
<th>Evaluation/Findings</th>
<th>Suggested Primary Site or Neoplasm</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RECEPTOR ANALYSIS</strong></td>
<td></td>
</tr>
<tr>
<td>Estrogen/progesterone receptor</td>
<td>Breast</td>
</tr>
<tr>
<td><strong>MOLECULAR BIOLOGIC STUDIES</strong></td>
<td></td>
</tr>
<tr>
<td>Immunoglobulin, bcl-2, T cell receptor gene rearrangement</td>
<td>Lymphoid neoplasm</td>
</tr>
</tbody>
</table>

*Or any other rearrangement involving an antigen-receptor gene.

**Note:** CEA, carcinoembryonic antigen; PSA, prostate-specific antigen; AFP, α-fetoprotein.

---

**FIGURE 80-1**

Approach to cytokeratin (CK7 and CK20) markers used in CUP.

- **CK7**
- **CK20**

<table>
<thead>
<tr>
<th>CK7+ CK20+</th>
<th>CK7+ CK20−</th>
<th>CK7− CK20+</th>
<th>CK7− CK20−</th>
</tr>
</thead>
</table>
| Urothelial tumors
Ovarian mucinous adenocarcinoma
Pancreatic adenocarcinoma
Cholangiocarcinoma
| Lung adenocarcinoma
Breast carcinoma
Thyroid carcinoma
Endometrial carcinoma
Cervical carcinoma
Syalivary gland carcinoma
Cholangiocarcinoma
Pancreatic carcinoma
| Colorectal carcinoma
Merkel cell carcinoma
| Hepatocellular carcinoma
Renal cell carcinoma
Prostate carcinoma
Squamous cell and small cell lung carcinoma
Head and neck carcinoma |

For a more detailed discussion, see Varadhachary GR, Abbruzzese JL: Carcinoma of Unknown Primary, Chap. 95, p. 614, in HPIM-17.
Both benign and malignant tumors of nonendocrine tissue can secrete a variety of hormones, principally peptide hormones, and many tumors produce more than one hormone (Table 81-1). At the clinical level, ectopic hormone production is important for two reasons. First, endocrine syndromes that result may either be the presenting manifestations of the neoplasm or occur late in the course. The endocrine manifestations in some instances are of greater significance than the tumor itself, as in pts with benign or slowly growing malignancies that secrete corticotropin-releasing hormone and cause fulminant Cushing’s syndrome. The frequency with which ectopic hormone production is recognized varies with the criteria used for diagnosis. The most common syndromes of clinical import are those of adrenocorticotropic hormone (ACTH) hypersecretion, hypercalcemia, and hypoglycemia. Indeed, ectopic ACTH secretion is responsible for 15–20% of pts with Cushing’s syndrome, and ~50% of pts with persistent hypercalcemia have a malignancy rather than hyperparathyroidism. Because of the rapidity of development of hormone secretion in some rapidly growing tumors, diagnosis may require a high index of suspicion, and hormone levels may be elevated out of proportion to the manifestations.

**TABLE 81-1** COMMON PARANEOPLASTIC ENDOCRINE SYNDROMES

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Proteins</th>
<th>Tumors Typically Associated with Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypercalcemia of malignancy</td>
<td>Parathyroid hormone–related peptide (PTHrP)</td>
<td>Non–small cell lung cancer</td>
</tr>
<tr>
<td></td>
<td>Parathyroid hormone (PTH)</td>
<td>Breast cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Renal cell carcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Head and neck cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bladder cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Myeloma</td>
</tr>
<tr>
<td>Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</td>
<td>Arginine vasopressin (AVP)</td>
<td>Small cell lung cancer</td>
</tr>
<tr>
<td></td>
<td>Atrial natriuretic peptide</td>
<td>Head and neck cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non–small cell lung cancer</td>
</tr>
<tr>
<td>Cushing’s syndrome</td>
<td>Adrenocorticotropic hormone (ACTH)</td>
<td>Small cell lung cancer</td>
</tr>
<tr>
<td></td>
<td>Corticotropin-releasing hormone (CRH)</td>
<td>Carcinoid tumors</td>
</tr>
<tr>
<td>Acromegaly</td>
<td>Growth hormone–releasing hormone (GHRH)</td>
<td>Carcinoid</td>
</tr>
<tr>
<td></td>
<td>Growth hormone (GH)</td>
<td>Small cell lung cancer</td>
</tr>
<tr>
<td>Gynecomastia</td>
<td>Human chorionic gonadotropin (hCG)</td>
<td>Testicular cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lung cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carcinoid tumors of the lung and gastrointestinal tract</td>
</tr>
<tr>
<td>Non–islet cell tumor hypoglycemia</td>
<td>Insulin-like growth factor 2 (IGF-2)</td>
<td>Sarcomas</td>
</tr>
</tbody>
</table>
Second, ectopic hormones serve as valuable peripheral markers for neoplasia. Because of the broad spectrum of ectopic hormone secretion, screening measurements of plasma hormone levels for diagnostic purposes are not cost-effective. However, in pts with malignancies that are known to secrete hormones, serial measurements of circulating hormone levels can serve as markers for completeness of tumor excision and for effectiveness of radiation therapy or chemotherapy. Likewise, tumor recurrence may be heralded by reappearance of elevated plasma hormone levels before mass effects of the tumor are evident. However, some tumors at recurrence do not secrete hormones, so hormone measurements cannot be relied on as the sole evidence of tumor activity.

**Paraneoplastic Endocrine Syndromes**

Therapy of ectopic hormone-secreting tumors should be directed when possible toward removal of the tumor. When the tumor cannot be removed or is incurable, specific therapy can be directed toward inhibiting hormone secretion (octreotide for ectopic acromegaly or mitotane to inhibit adrenal steroidogenesis in the ectopic ACTH syndrome) or blocking the action of the hormone at the tissue level (demeclocycline for inappropriate vasopressin secretion).

**HYPERCALCEMIA**

The most common paraneoplastic syndrome, hypercalcemia of malignancy accounts for 40% of all hypercalcemia. Of cancer pts with hypercalcemia, 80% have humoral hypercalcemia mediated by parathyroid hormone–related peptide; 20% have local osteolytic hypercalcemia mediated by cytokines such as interleukin 1 and tumor necrosis factor. Many tumor types may produce hypercalcemia (Table 81-1). Pts may have malaise, fatigue, confusion, anorexia, bone pain, polyuria, weakness, constipation, nausea, and vomiting. At high calcium levels, confusion, lethargy, coma, and death may ensue. Median survival of hypercalcemic cancer pts is 1–3 months. Treatment with saline hydration, furosemide diuresis, and pamidronate (60–90 mg IV) or zoledronate (4–8 mg IV) controls calcium levels within 2 days and suppresses calcium release for several weeks. Oral bisphosphonates can be used for chronic treatment.

**HYPONATREMIA**

Most commonly discovered in asymptomatic individuals as a result of serum electrolyte measurements, hyponatremia is usually due to tumor secretion of arginine vasopressin, a condition called syndrome of inappropriate antidiuretic hormone secretion (SIADH). Atrial natriuretic hormone also may produce hyponatremia. SIADH occurs most commonly in small cell lung cancer (15%) and head and neck cancer (3%). A number of drugs may produce the syndrome. Symptoms of fatigue, poor attention span, nausea, weakness, anorexia, and headache may be controlled by restricting fluid intake to 500 mL/d or blocking the effects of the hormone with 600–1200 mg demeclocycline a day. With severe hyponatremia (<115 meq/L) or in the setting of mental status changes, normal saline infusion plus furosemide may be required; rate of correction should be <1 meq/L per hour to prevent complications.

**ECTOPIC ACTH SYNDROME**

When pro-opiomelanocortin mRNA in the tumor is processed into ACTH, excessive secretion of glucocorticoids and mineralocorticoids may ensue. Pts develop
Cushing’s syndrome with hypokalemic alkalosis, weakness, hypertension, and hyperglycemia. About half the cases occur in small cell lung cancer. ACTH production adversely affects prognosis. Ketoconazole (400–1200 mg/d) or metyrapone (1–4 g/d) may be used to inhibit adrenal steroid synthesis.

Paraneoplastic neurologic disorders (PNDs) are cancer-related syndromes that can affect any part of the nervous system; caused by mechanisms other than metastasis or by complications of cancer such as coagulopathy, stroke, metabolic and nutritional conditions, infections, and side effects of cancer therapy. In 60% of pts the neurologic symptoms precede cancer diagnosis. PNDs occur in 0.5–1% of all cancer pts, but they occur in 2–3% of pts with neuroblastoma or small cell lung cancer (SCLC), and in 30–50% of pts with thymoma or sclerotic myeloma.

**CLINICAL FEATURES**

Recognition of a distinctive paraneoplastic syndrome (Table 82-1); should prompt a search for cancer, as prompt treatment of tumor may improve the course of PNDs; many of these disorders also occur without cancer. Diagnosis is based upon the clinical pattern, exclusion of other cancer-related disorders, confirmatory serum or CSF antibodies (Table 82-2), or electrodiagnostic testing. For any type of PND, if antineuronal antibodies are negative, the diagnosis rests on the demonstration of cancer and the exclusion of other cancer-related or independent disorders. Whole-body positron emission tomographic scans often uncover tumors undetected by other tests.

**PNDs of the Central Nervous System and Dorsal Root Ganglia**  
MRIs and CSF studies are important to rule out neurologic complications due to the direct spread of cancer. In most PNDs the MRI findings are nonspecific. CSF findings typically consist of mild to moderate pleocytosis (<200 mononuclear cells, predominantly lymphocytes), an increase in the protein concentration, intrathecal synthesis of IgG, and a variable presence of oligoclonal bands. A biopsy of affected nervous system tissue may be useful to rule out other disorders (e.g., metastasis, infection); neuropathologic findings are not specific for PNDs.

- *Limbic encephalitis* is characterized by confusion, depression, agitation, anxiety, severe short-term memory deficits, partial complex seizures, and dementia; the MRI usually shows unilateral or bilateral medial temporal lobe abnormalities.

- *Paraneoplastic cerebellar degeneration* begins as dizziness, oscillopsia, blurry or double vision, nausea, and vomiting; a few days or weeks later, dysarthria, gait and limb ataxia, and variable dysphagia can appear.
• **Opsoclonus-myoclonus syndrome** consists of involuntary, chaotic eye movements in all directions of gaze plus myoclonus; it is frequently associated with ataxia.

• **Acute necrotizing myelopathy.** Reports of paraneoplastic spinal cord syndromes have decreased in recent years; it is unclear if this is due to improved oncological interventions or better detection of nonparaneoplastic etiologies.

• **Paraneoplastic retinopathies** involve cone and rod dysfunction characterized by photosensitivity, progressive loss of vision and color perception, central or ring scotomas, night blindness, and attenuation of photopic and scotopic responses in the electroretinogram (ERG).

• **Dorsal root ganglionopathy** (sensory neuronopathy) is characterized by sensory deficits that may be symmetric or asymmetric, painful dysesthesias, radicular pain, and decreased or absent reflexes; all modalities of sensation can be involved.

**PNDs of Nerve and Muscle** These disorders may develop anytime during the course of the neoplastic disease. Serum and urine immunofixation studies
Neurologic Paraneoplastic Syndromes

CHAPTER 82

should be considered in patients with peripheral neuropathy of unknown cause; detection of a monoclonal gammopathy suggests the need for additional studies to uncover a B cell or plasma cell malignancy.

Neuropathies occurring at late stages of cancer or with lymphoma are usually due to axonal degeneration of unclear etiology. These neuropathies are often masked by concurrent neurotoxicity from chemotherapy and other cancer therapies. Neuropathies that develop in the early stages of cancer often show a rapid progression, sometimes with a relapsing and remitting course, and evidence of inflammatory infiltrates and axonal loss or demyelination in biopsy studies. If demyelinating features predominate, IVIg or glucocorticoids may improve

**TABLE 82-2 PARANEOPLASTIC ANTINEURONAL ANTIBODIES, ASSOCIATED SYNDROMES AND CANCERS**

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Syndrome</th>
<th>Associated Cancers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Hu (ANNA-1)</td>
<td>PEM (including cortical, limbic, brainstem encephalitis, cerebellar dysfunction, myelitis), PSN, autonomic dysfunction</td>
<td>SCLC, other neuroendocrine tumors</td>
</tr>
<tr>
<td>Anti-Yo (PCA-1)</td>
<td>PCD</td>
<td>Ovary and other gynecologic cancers, breast</td>
</tr>
<tr>
<td>Anti-Ri (ANNA-2)</td>
<td>PCD, brainstem encephalitis, opsoclonus-myooclonus</td>
<td>Breast, gynecological, SCLC</td>
</tr>
<tr>
<td>Anti-Tr</td>
<td>PCD</td>
<td>Hodgkin's lymphoma</td>
</tr>
<tr>
<td>Anti-Zic</td>
<td>PCD, encephalomyelitis</td>
<td>SCLC and other neuroendocrine tumors</td>
</tr>
<tr>
<td>Anti-CV₂/CRMP5</td>
<td>PEM, PCD, chorea, peripheral neuropathy, uveitis</td>
<td>SCLC, thymoma, other</td>
</tr>
<tr>
<td>Anti-Ma proteins&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Limbic, hypothalamic, brainstem encephalitis (infrequently PCD)</td>
<td>Germ-cell tumors of testis, lung cancer, other solid tumors</td>
</tr>
<tr>
<td>Anti-NR1/NR2 subunits of NMDA receptor</td>
<td>Encephalitis with prominent psychiatric symptoms, seizures, hypoventilation</td>
<td>Ovarian teratoma</td>
</tr>
<tr>
<td>Anti-amphiphysin</td>
<td>Stiff-person syndrome, PEM</td>
<td>Breast, SCLC</td>
</tr>
<tr>
<td>Anti-VGCC&lt;sup&gt;b&lt;/sup&gt;</td>
<td>LEMS, PCD</td>
<td>SCLC, lymphoma</td>
</tr>
<tr>
<td>Anti-AChR&lt;sup&gt;b&lt;/sup&gt;</td>
<td>MG</td>
<td>Thymoma</td>
</tr>
<tr>
<td>Anti-VGKC&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Peripheral nerve hyperexcitability (neuromyotonia), limbic encephalitis</td>
<td>Thymoma, SCLC, others</td>
</tr>
<tr>
<td>Anti-recoverin</td>
<td>Cancer-associated retinopathy (CAR)</td>
<td>SCLC and other</td>
</tr>
<tr>
<td>Anti-bipolar cells of the retina</td>
<td>Melanoma-associated retinopathy (MAR)</td>
<td>Melanoma</td>
</tr>
</tbody>
</table>

<sup>a</sup>Patients with antibodies to Ma2 are usually men with testicular cancer. Patients with additional antibodies to other Ma proteins are men or women with a variety of solid tumors.

<sup>b</sup>These antibodies can occur with or without a cancer association.

Note: PEM: paraneoplastic encephalomylitis; PCD, paraneoplastic cerebellar degeneration; PSN, paraneoplastic sensory neuronopathy; LEMS, Lambert-Eaton myasthenic syndrome; MG, myasthenia gravis; VGCC, voltage-gated calcium channel; AChR, acetylcholine receptor; VGKC, voltage-gated potassium channel; SCLC, small-cell lung cancer; NMDA, N-methyl-D-aspartate.
symptoms. Myasthenia gravis is discussed in Chap. 204, and dermatomyositis in Chap. 205.

**PATHOPHYSIOLOGY**

Most PNDs are mediated by immune responses triggered by neuronal proteins (onconeuronal antigens) expressed by tumors. Many specific antibody-associated immune responses have been identified. Target onconeuronal antigens are usually intracellular proteins with roles in neuronal development and function.

**Paraneoplastic Neurologic Disorders**

These disorders in general respond poorly to therapy. Treatment of PNDs focuses mainly on recognition and control of the underlying malignancy; a stabilization or improvement of symptoms has been reported in some patients with successful tumor control. Variable responses have been described following treatment with glucocorticoids and other immunosuppressive agents as well as IVIg and plasma exchange.

For a more detailed discussion, see Dalmau J, Rosenfeld MR: Paraneoplastic Neurologic Syndromes, Chap. 97, p. 623, in HPIM-17.
The laboratory diagnosis of infection requires the demonstration—either direct or indirect—of viral, bacterial, fungal, or parasitic agents in tissues, fluids, or excreta of the host. The traditional detection methods of microscopy and culture are time-consuming and are increasingly being replaced by nucleic acid probe assays.

**MICROSCOOPY**

- Wet mounts: The examination of wet mounts does not require fixation of the specimen before microscopy. Wet mounts are useful for certain large and/or motile organisms; e.g., with dark-field illumination, *Treponema* can be detected in genital lesions. Fungal elements may be identified in skin scrapings with 10% KOH wet mount preparations. Some wet mounts use staining to enhance detection—e.g., India ink to visualize encapsulated cryptococci in cerebrospinal fluid (CSF).

- Stains: Without staining, bacteria are difficult to visualize. *Gram’s stain* differentiates between organisms with thick peptidoglycan cell walls (gram-positive) and those with thin peptidoglycan cell walls and outer membranes that can be dissolved with alcohol or acetone (gram-negative). This stain is particularly useful for sputum samples that have ≥25 polymorphonuclear leukocytes (PMNs) and <10 epithelial cells. In normally sterile fluids (e.g., CSF), the detection of bacteria suggests the infectious etiology ([Fig. 83-1](#)) and correlates with the presence of >10⁴ bacteria/mL. Sensitivity is increased by centrifugation of the sample. *Acid-fast stains* are useful for organisms that retain carbol fuchsin dye after acid/organic solvation (e.g., *Mycobacterium* spp.). Modification of this procedure permits the detection of weakly acid-fast organisms such as *Nocardia*. *Immunofluorescent stains* (antibody coupled directly or indirectly to a fluorescing compound) can detect viral antigens [e.g., cytomegalovirus (CMV), herpes simplex virus, and respiratory viruses] within cultured cells or can reveal difficult-to-grow bacteria such as *Legionella*.

**MACROSCOPIC ANTIGEN DETECTION**

Latex agglutination assays and enzyme immunoassays (EIAs) are rapid and inexpensive tests that identify bacteria, viruses, or extracellular bacterial toxins by means of their protein or polysaccharide antigens. The assays are performed either directly on clinical specimens or after growth of the organisms in the laboratory.

**CULTURE**

The success of efforts to culture a specific pathogen often depends on the use of appropriate collection and transport procedures in conjunction with a laboratory-
FIGURE 83-1 Interpretation of Gram’s stain.

### Gram-Negative Organisms

<table>
<thead>
<tr>
<th></th>
<th>GRx only</th>
<th>Oxidase +</th>
<th>Oxidase –</th>
<th>Fastidious</th>
<th>Anaerobic</th>
<th>Curved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rod</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pseudomonas</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Aeromonas</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pasteurella</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Enterobacteriaceae</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Others</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Haemophilus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Legionella</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bordetella</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Brucella</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Franciscella</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bacteroides</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prevotella</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fusobacterium</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Others</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Vibrio</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Campylobacter</td>
</tr>
<tr>
<td>Coccus</td>
<td>Neisseria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Veillonella</td>
</tr>
<tr>
<td></td>
<td>Branhamella</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acidaminococcus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Megasphaera</td>
</tr>
</tbody>
</table>

### Gram-Positive Organisms

<table>
<thead>
<tr>
<th></th>
<th>Branching</th>
<th>Spores</th>
<th>Acid-Fast</th>
<th>Catalase +</th>
<th>Catalase –</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rod</td>
<td>Nocardia</td>
<td>Clostridium</td>
<td>Mycobacterium</td>
<td>Corynebacterium</td>
<td>Lactobacillus</td>
</tr>
<tr>
<td></td>
<td>Actinomyces</td>
<td>Bacillus</td>
<td></td>
<td>Listeria</td>
<td>Others</td>
</tr>
<tr>
<td></td>
<td>Bifidobacterium</td>
<td></td>
<td></td>
<td>Others</td>
<td></td>
</tr>
<tr>
<td>Coccus</td>
<td></td>
<td></td>
<td></td>
<td>Staphylococcus</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Micrococcus</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Others</td>
<td></td>
</tr>
</tbody>
</table>
processing algorithm suitable for the specimen. Instructions for collection are listed in Table 83-1. Bacterial isolation relies on the use of artificial media that support bacterial growth in vitro. Once bacteria are isolated, different methods are used to characterize specific isolates (e.g., phenotyping, gas-liquid chromatography, nucleic acid tests). Viruses are grown on a monolayer of cultured cells sensitive to infection with the suspected virus. After proliferation of viral particles, cells are examined for cytopathic effects or immunofluorescent studies are performed to detect viral antigens.

**SEROLOGY**

The measurement of serum antibody provides an indirect marker for past or current infection with a specific viral agent or other pathogen. Quantitative assays detect increases in antibody titers, most often using paired serum samples obtained at illness onset and 10–14 days later (i.e., acute- and convalescent-phase samples). Serology can also be used to document protective levels of antibody, particularly in diseases for which vaccines are available (e.g., rubella, varicella-zoster virus infections).

**NUCLEIC ACID PROBES**

Techniques for the detection and quantitation of specific DNA and RNA base sequences in clinical specimens have become powerful tools for the diagnosis of infection and are useful in four settings:

1. To detect and/or quantify specific pathogens in clinical specimens
2. To identify organisms that are difficult to identify by conventional methods
3. To determine whether two or more isolates are closely related (e.g., belong to the same clone or strain)
4. To predict sensitivity (typically of viruses) to chemotherapeutic agents

Probes are available for directly detecting various pathogens (e.g., *Chlamydia trachomatis*, *Neisseria gonorrhoeae*) in clinical specimens and for confirming the identity of cultured pathogens (e.g., *Mycobacterium* spp., *Streptococcus* spp., and *Staphylococcus aureus*). The sensitivity and specificity of probe assays for direct detection are comparable to those of more traditional assays, including EIA and culture. Hybrid capture, an alternative assay that anneals an RNA probe to a DNA target, is available for *C. trachomatis*, *N. gonorrhoeae*, CMV, and human papillomavirus.

- Amplification strategies [e.g., polymerase chain reaction (PCR), ligase chain reaction] enhance the sensitivity of RNA or DNA assays, but false-positive findings can result from even low levels of contamination.

**SUSCEPTIBILITY TESTING**

Susceptibility testing allows the clinician to choose the optimal antimicrobial agents and to identify potential infection-control problems (e.g., the level of methicillin-resistant *S. aureus* in a hospital). Susceptibility testing for fungi has only recently been standardized; several systems have now been approved.

**PARASITES**

Table 83-2 summarizes the diagnosis of some common parasitic infections. The cornerstone for the diagnosis of parasitic diseases, as for that of many other infections, is the elicitation of a thorough history of the illness and of epidemiologic factors such as travel, recreational activities, and occupation.
<table>
<thead>
<tr>
<th>Type of Culture (Synonyms)</th>
<th>Specimen</th>
<th>Minimum Volume</th>
<th>Container</th>
<th>Other Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood, routine (blood culture for aerobes, anaerobes, and yeasts)</td>
<td>Whole blood</td>
<td>10 mL in each of 2 bottles for adults and children; 5 mL, if possible, in aerobic bottles for infants; less for neonates</td>
<td>See below.</td>
<td>See below.</td>
</tr>
<tr>
<td>Blood for fungi/Mycobacterium spp.</td>
<td>Whole blood</td>
<td>10 mL in each of 2 bottles, as for routine blood cultures, or in Isolator tube requested from laboratory</td>
<td>Same as for routine blood culture</td>
<td>Specify “hold for extended incubation,” since fungal agents may require ≥4 weeks to grow.</td>
</tr>
<tr>
<td>Blood, Isolator (lysis centrifugation)</td>
<td>Whole blood</td>
<td>10 mL</td>
<td>Isolator tubes</td>
<td>Use mainly for isolation of fungi, <em>Mycobacterium</em>, or other fastidious aerobes and for elimination of antibiotics from cultured blood in which organisms are concentrated by centrifugation.</td>
</tr>
<tr>
<td><strong>Respiratory Tract</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nose</td>
<td>Swab from nares</td>
<td>1 swab</td>
<td>Sterile culturette or similar transport system containing holding medium</td>
<td>Swabs made of calcium alginate may be used.</td>
</tr>
<tr>
<td>Throat</td>
<td>Swab of posterior pharynx, ulcerations, or areas of suspected purulence</td>
<td>1 swab</td>
<td>Sterile culturette or similar swab specimen collection system containing holding medium</td>
<td>See below.</td>
</tr>
<tr>
<td>Specimen</td>
<td>Description</td>
<td>Volume</td>
<td>Container</td>
<td>Cause for rejection: Care must be taken to ensure that the specimen is sputum and not saliva. Examination of Gram’s stain, with number of epithelial cells and PMNs noted, can be an important part of the evaluation process. Induced sputum specimens should not be rejected.</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>--------</td>
<td>-----------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Sputum</td>
<td>Fresh sputum (not saliva)</td>
<td>2 mL</td>
<td>Commercially available sputum collection system or similar sterile container with screw cap</td>
<td></td>
</tr>
<tr>
<td>Bronchial aspirates</td>
<td>Transtracheal aspirate, bronchoscopy specimen, or bronchial aspirate</td>
<td>1 mL of aspirate or brush in transport medium</td>
<td>Sterile aspirate or bronchoscopy tube, bronchoscopy brush in a separate sterile container</td>
<td></td>
</tr>
<tr>
<td>Stool</td>
<td>Rectal swab or (preferably) fresh, randomly collected stool</td>
<td>1 g of stool or 2 rectal swabs</td>
<td>Plastic-coated cardboard cup or plastic cup with tight-fitting lid. Other leak-proof containers are also acceptable.</td>
<td>If <em>Vibrio</em> spp. are suspected, the laboratory must be notified, and appropriate collection/transport methods should be used.</td>
</tr>
<tr>
<td>Stool for <em>Yersinia</em>, <em>Escherichia coli</em> O157</td>
<td>Fresh, randomly collected stool</td>
<td>1 g</td>
<td>Plastic-coated cardboard cup or plastic cup with tight-fitting lid</td>
<td>Limitations: Procedure requires enrichment techniques.</td>
</tr>
<tr>
<td>Stool for <em>Aeromonas</em> and <em>Plesiomonas</em></td>
<td>Fresh, randomly collected stool</td>
<td>1 g</td>
<td>Plastic-coated cardboard cup or plastic cup with tight-fitting lid</td>
<td>Limitations: Stool should not be cultured for these organisms unless also cultured for other enteric pathogens.</td>
</tr>
<tr>
<td>Type of Culture (Synonyms)</td>
<td>Specimen</td>
<td>Minimum Volume</td>
<td>Container</td>
<td>Other Considerations</td>
</tr>
<tr>
<td>----------------------------</td>
<td>----------</td>
<td>----------------</td>
<td>-----------</td>
<td>----------------------</td>
</tr>
<tr>
<td><strong>Urogenital Tract</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine</td>
<td>Clean-voided urine specimen or urine collected by catheter</td>
<td>0.5 mL</td>
<td>Sterile, leak-proof container with screw cap or special urine transfer tube</td>
<td>See below. &lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Urogenital secretions</td>
<td>Vaginal or urethral secretions, cervical swabs, uterine fluid, prostatic fluid, etc.</td>
<td>1 swab or 0.5 mL of fluid</td>
<td>Vaginal and rectal swabs transported in Amies transport medium or similar holding medium for group B <em>Streptococcus</em>; direct inoculation preferred for <em>Neisseria gonorrhoeae</em></td>
<td>Vaginal swab samples for “routine culture” should be discouraged whenever possible unless a particular pathogen is suspected. For detection of multiple organisms (e.g., group B <em>Streptococcus</em>, <em>Trichomonas</em>, <em>Chlamydia</em>, or <em>Candida</em> spp.), 1 swab per test should be obtained.</td>
</tr>
<tr>
<td><strong>Body Fluids, Aspirates, and Tissues</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebrospinal fluid (lumbar puncture)</td>
<td>Spinal fluid</td>
<td>1 mL for routine cultures; ≥5 mL for <em>Mycobacterium</em></td>
<td>Sterile tube with tight-fitting cap</td>
<td>Do not refrigerate; transfer to laboratory as soon as possible.</td>
</tr>
<tr>
<td>Body fluids</td>
<td>Aseptically aspirated body fluids</td>
<td>1 mL for routine cultures</td>
<td>Sterile tube with tight-fitting cap. Specimen may be left in syringe used for collection if the syringe is capped before transport.</td>
<td>For some body fluids (e.g., peritoneal lavage samples), increased volumes are helpful for isolation of small numbers of bacteria.</td>
</tr>
<tr>
<td>Biopsy and aspirated materials</td>
<td>Tissue removed at surgery, bone, anticoagulated bone marrow, biopsy samples, or other specimens from normally sterile areas</td>
<td>1 mL of fluid or a 1-g piece of tissue</td>
<td>Sterile culturette-type swab or similar transport system containing holding medium. Sterile bottle or jar should be used for tissue specimens.</td>
<td>Accurate identification of specimen and source is critical. Enough tissue should be collected for both microbiologic and histopathologic evaluations.</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Wounds</td>
<td>Purulent material or abscess contents obtained from wound or abscess without contamination by normal microflora</td>
<td>2 swabs or 0.5 mL of aspirated pus</td>
<td>Culturette swab or similar transport system or sterile tube with tight-fitting screw cap. For simultaneous anaerobic cultures, send specimen in anaerobic transport device or closed syringe.</td>
<td>Collection: Abscess contents or other fluids should be collected in a syringe (rather than with a swab) when possible to provide an adequate sample volume and an anaerobic environment.</td>
</tr>
</tbody>
</table>

**Special Recommendations**

<p>| Fungi                         | Specimen types listed above may be used. When urine or sputum is cultured for fungi, a first morning specimen is usually preferred. | 1 mL or as specified above for individual listing of specimens. Large volumes may be useful for urinary fungi. | Sterile, leak-proof container with tight-fitting cap | Collection: Specimen should be transported to microbiology laboratory within 1 h of collection. Contamination with normal flora from skin, rectum, vaginal tract, or other body surfaces should be avoided. |
| Mycobacterium (acid-fast bacilli) | Sputum, tissue, urine, body fluids | 10 mL of fluid or small piece of tissue. Swabs should not be used. | Sterile container with tight-fitting cap | Detection of Mycobacterium spp. is improved by use of concentration techniques. Smears and cultures of pleural, peritoneal, and pericardial fluids often have low yields. Multiple cultures from the same pt are encouraged. Culturing in liquid media shortens the time to detection. (continued) |</p>
<table>
<thead>
<tr>
<th>Type of Culture (Synonyms)</th>
<th>Specimen</th>
<th>Minimum Volume</th>
<th>Container</th>
<th>Other Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Legionella</td>
<td>Pleural fluid, lung biopsy, bronchoalveolar lavage fluid, bronchial/transbronchial biopsy. Rapid transport to laboratory is critical.</td>
<td>1 mL of fluid; any size tissue sample, although a 0.5-g sample should be obtained when possible</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Anaerobic organisms</td>
<td>Aspirated specimens from abscesses or body fluids</td>
<td>1 mL of aspirated fluid, 1 g of tissue or 2 swabs</td>
<td>An appropriate anaerobic transport device is required.</td>
<td>Specimens cultured for obligate anaerobes should be cultured for facultative bacteria as well. Fluid or tissue is preferred to swabs.</td>
</tr>
<tr>
<td>Viruses¹</td>
<td>Respiratory secretions, wash aspirates from respiratory tract, nasal swabs, blood samples (including buffy coats), vaginal and rectal swabs, swab specimens from suspicious skin lesions, stool samples (in some cases)</td>
<td>1 mL of fluid, 1 swab, or 1 g of stool in each appropriate transport medium</td>
<td>Fluid or stool samples in sterile containers or swab samples in viral culturette devices (kept on ice but not frozen) are generally suitable. Plasma samples and buffy coats in sterile collection tubes should be kept at 4–8°C. If specimens are to be shipped or kept for a long time, freezing at –80°C is usually adequate.</td>
<td>Most samples for culture are transported in holding medium containing antibiotics to prevent bacterial overgrowth and viral inactivation. Many specimens should be kept cool but not frozen, provided they are transported promptly to the laboratory. Procedures and transport media vary with the agent to be cultured and the duration of transport.</td>
</tr>
</tbody>
</table>

*Note: It is absolutely essential that the microbiology laboratory be informed of the site of origin of the sample to be cultured and of the infections that are suspected. This information determines the selection of culture media and the length of culture time.*
a For samples from adults and children, two bottles (smaller for pediatric samples) should be used; one with dextrose phosphate, tryptic soy, or another appropriate broth and the other with thioglycollate or another broth containing reducing agents appropriate for isolation of obligate anaerobes. For children, from whom only limited volumes of blood can be obtained, only an aerobic culture should be done unless there is specific concern about anaerobic sepsis (e.g., with abdominal infections). For special situations (e.g., suspected fungal infection, culture-negative endocarditis, or mycobacteremia), different blood collection systems may be used (Isolator systems; see table).

b Collection: An appropriate disinfecting technique should be used on both the bottle septum and the pt. Do not allow air bubbles to get into anaerobic broth bottles.

c Special considerations: There is no more important clinical microbiology test than the detection of blood-borne pathogens. The rapid identification of bacterial and fungal agents is a major determinant of pts' survival. Bacteria may be present in blood either continuously (as in endocarditis, overwhelming sepsis, and the early stages of salmonellosis and brucellosis) or intermittently (as in most other bacterial infections, in which bacteria are shed into the blood on a sporadic basis). Most blood culture systems employ two separate bottles containing broth medium: one that is ventilated in the laboratory for the growth of facultative and aerobic organisms and a second that is maintained under anaerobic conditions. In cases of suspected continuous bacteremia/fungemia, two or three samples should be drawn before the start of therapy, with additional sets obtained if fastidious organisms are thought to be involved. For intermittent bacteremia, two or three samples should be obtained at least 1 h apart during the first 24 h.

d Normal microflora includes α-hemolytic streptococci, saprophytic Neisseria spp., diphtheroids, and Staphylococcus spp. Aerobic culture of the throat ("routine") includes screening for and identification of β-hemolytic Streptococcus spp. and other potentially pathogenic organisms. Although considered components of the normal microflora, organisms such as Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pneumoniae will be identified by most laboratories, if requested. When Neisseria gonorrhoeae or Corynebacterium diphtheriae is suspected, a special culture request is recommended.

e (1) Clean-voided specimens, midvoid specimens, and Foley or indwelling catheter specimens that yield ≥50,000 organisms/mL and from which no more than three species are isolated should have organisms identified. Neither indwelling catheter tips nor urine from the bag of a catheterized pt should be cultured. (2) Straight-catheterized, bladder-tap, and similar urine specimens should undergo a complete workup (identification and susceptibility testing) for all potentially pathogenic organisms, regardless of colony count. (3) Certain clinical problems (e.g., acute dysuria in women) may warrant identification and susceptibility testing of isolates present at concentrations of <50,000 organisms/mL.

f Aspirated specimens in capped syringes or other transport devices designed to limit oxygen exposure are suitable for the cultivation of obligate anaerobes. A variety of commercially available transport devices may be used. Contamination of specimens with normal microflora from the skin, rectum, vaginal vault, or another body site should be avoided. Collection containers for aerobic culture (such as dry swabs) and inappropriate specimens (such as refrigerated samples; expectorated sputum; stool; gastric aspirates; and vaginal, throat, nose, and rectal swabs) should be rejected as unsuitable.

Laboratories generally use diverse methods to detect viral agents, and the specific requirements for each specimen should be checked before a sample is sent.
## TABLE 83-2  DIAGNOSIS OF SOME COMMON PARASITIC INFECTIONS

<table>
<thead>
<tr>
<th>Parasite</th>
<th>Geographic Distribution</th>
<th>Parasite Stage</th>
<th>Body Fluid or Tissue</th>
<th>Serologic Tests</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood flukes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schistosoma mansoni</td>
<td>Africa, Central and South America, West Indies</td>
<td>Ova, adults</td>
<td>Feces</td>
<td>EIA, WB</td>
<td>Rectal snips, liver biopsy</td>
</tr>
<tr>
<td>S. haematobium</td>
<td>Africa</td>
<td>Ova, adults</td>
<td>Urine</td>
<td>WB</td>
<td>Liver, urine, or bladder biopsy</td>
</tr>
<tr>
<td>S. japonicum</td>
<td>Far East</td>
<td>Ova, adults</td>
<td>Feces</td>
<td>WB</td>
<td>Liver biopsy</td>
</tr>
<tr>
<td>Intestinal roundworms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Strongyloides stercoralis</td>
<td>Moist tropics and subtropics</td>
<td>Larvae</td>
<td>Feces, sputum, duodenal fluid</td>
<td>EIA</td>
<td>Dissemination in immuno-deficiency</td>
</tr>
<tr>
<td>(strongyloidiasis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intestinal protozoans</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Entamoeba histolytica</td>
<td>Worldwide, especially tropics</td>
<td>Troph, cyst</td>
<td>Feces, liver</td>
<td>EIA, antigen detection</td>
<td>Ultrasound, liver CT, PCR</td>
</tr>
<tr>
<td>(amebiasis)</td>
<td>Worldwide</td>
<td>Troph, cyst</td>
<td></td>
<td>Antigen detection</td>
<td>String test, DFA, PCR</td>
</tr>
<tr>
<td>Giardia lamblia (giardiasis)</td>
<td>Worldwide</td>
<td>Oocyst</td>
<td>Feces</td>
<td>—</td>
<td>Acid-fast&lt;sup&gt;a&lt;/sup&gt;, PCR</td>
</tr>
<tr>
<td>Isospora belli</td>
<td>Worldwide</td>
<td>Oocyst</td>
<td>Feces</td>
<td>—</td>
<td>Acid-fast, DFA, biops, PCR</td>
</tr>
<tr>
<td>Cryptosporidium</td>
<td>Worldwide</td>
<td>Oocyst</td>
<td>Feces</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Blood and tissue protozoans</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasmodium spp. (malaria)</td>
<td>Subtropics and tropics U.S., especially New England</td>
<td>Asexual</td>
<td>Blood</td>
<td>Limited use</td>
<td>PCR</td>
</tr>
<tr>
<td>Babesia microti (babesiosis)</td>
<td></td>
<td>Asexual</td>
<td>Blood</td>
<td>IIF</td>
<td>Animal spp.; in asplenia, PCR</td>
</tr>
<tr>
<td>Toxoplasma gondii</td>
<td>Worldwide</td>
<td>Cyst, trop</td>
<td>CNS, eye, muscles, other</td>
<td>EIA, IIF</td>
<td>PCR</td>
</tr>
</tbody>
</table>

<sup>a</sup>Acid-fastness is best demonstrated by auramine fluorescence or modified acid-fast stain.

**Note:** WB, western blot; CT, computed tomography; CNS, central nervous system; EIA, enzyme immunoassay; troph, trophozoite; DFA, direct fluorescent antibody; IIF, indirect immunofluorescence; PCR, polymerase chain reaction.

**Source:** Adapted from Reed SL, Davis CE: Chap. e16, *Harrison’s Online*. 

---

<sup>a</sup>Acid-fastness is best demonstrated by auramine fluorescence or modified acid-fast stain.

**Note:** WB, western blot; CT, computed tomography; CNS, central nervous system; EIA, enzyme immunoassay; troph, trophozoite; DFA, direct fluorescent antibody; IIF, indirect immunofluorescence; PCR, polymerase chain reaction.

**Source:** Adapted from Reed SL, Davis CE: Chap. e16, *Harrison’s Online*. 

---
INTESTINAL PARASITES

Most helminths and protozoa exit the body in the fecal stream. Feces should be collected in a clean cardboard container, with the time of collection recorded. Contamination with urine or water should be avoided. Fecal samples should be collected before the ingestion of barium or other contrast agents and before treatment with antidiarrheal agents or antacids; these substances alter fecal consistency and interfere with microscopic detection of parasites. The collection of three samples on alternate days is recommended because of the cyclic shedding of most parasites in the feces. Macroscopic examination involves a search for adult worms or tapeworm segments. Microscopic examination is not complete until direct wet mounts have been evaluated and concentration techniques as well as permanent stains applied. Sampling of duodenal contents may be needed to detect *Giardia lamblia*, *Cryptosporidium*, and *Strongyloides* larvae. “Cellophane tape” methods may be needed to detect pinworm ova or *Taenia saginata*.

BLOOD AND TISSUE PARASITES

Invasion of tissue by parasites may direct the evaluation of other samples—e.g., examination of urine sediment is the appropriate way to detect *Schistosoma haematobium*. The laboratory procedures for detection of parasites in other body fluids are similar to those used in the examination of feces. Wet mounts, concentration techniques, and permanent stains should all be used. The parasites most commonly detected in Giemsa-stained blood smears are the plasmodia, microfilariae, and African trypanosomes; however, wet mounts may be more sensitive for microfilariae and African trypanosomes. The timing of blood collection is crucial—e.g., to diagnose *Wuchereria bancrofti*, blood must be drawn near midnight, when the nocturnal microfilariae are active. Diagnosis of malaria and distinctions among *Plasmodium* species are made by microscopic examination of thick and thin blood films.

ANTIBODY AND ANTIGEN DETECTION

In addition to direct detection techniques, antibody assays for many of the important tissue parasites are available. PCR is useful for the diagnosis of many protozoan infections but should be used only as an adjunct to conventional techniques for parasite detection.

For a more detailed discussion, see McAdam AJ, Onderdonk AB: Laboratory Diagnosis of Infectious Diseases, Chap. e14; and Reed SL, Davis CE: Laboratory Diagnosis of Parasitic Infections, Chap. e16, in *Harrison’s Online.*
The development of vaccines and drugs that prevent and cure bacterial infections was one of the twentieth century’s major contributions to human longevity and quality of life. Antibacterial agents are among the most commonly prescribed drugs worldwide.

**MECHANISMS OF DRUG ACTION**

Antibacterial agents act on unique targets not found in mammalian cells.

- **Inhibition of cell-wall synthesis:** Drugs that inhibit cell-wall synthesis are almost always bactericidal. Bacterial autolysins (cell-wall recycling enzymes) contribute to cell lysis in the presence of these agents.
  - β-lactam antibiotics
  - Glycopeptides (vancomycin)
- **Inhibition of protein synthesis:** Typically, inhibition takes place through interaction with bacterial ribosomes. Except for aminoglycosides, these drugs are bacteriostatic.
  - Aminoglycosides
  - Macrolides (erythromycin, clarithromycin, azithromycin), ketolides (telithromycin), and lincosamides (clindamycin)
  - Streptogramins [quinupristin/dalfopristin (Synercid)]
  - Oxazolidinone (linezolid)
  - Tetracyclines (tetracycline, doxycycline, minocycline) and glycyclcyclines (tigecycline)
- **Inhibition of bacterial metabolism:** Drugs interfere with bacterial folic acid synthesis.
  - Sulfonamides
  - Trimethoprim
- **Inhibition of nucleic acid synthesis or activity**
  - Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)
  - Rifampin
  - Metronidazole
- **Alteration of cell-membrane permeability**
  - Polymyxins (polymyxin B, colistin)
  - Daptomycin

**MECHANISMS OF ANTIBACTERIAL RESISTANCE**

Bacteria can either be intrinsically resistant to an agent (e.g., anaerobic bacteria are resistant to aminoglycosides) or acquire resistance through mutation of resident genes or acquisition of new genes. The major mechanisms of resistance used by bacteria are drug inactivation, alteration or overproduction of the antibacterial target, acquisition of a new drug-insensitive target, decreased permeability to the agent, failure to convert an inactive prodrug to its active derivative, and active efflux of the agent.
PHARMACOKINETICS OF ANTIBIOTICS

The pharmacokinetic profile refers to drug concentrations in serum and tissue versus time and reflects the processes of absorption, distribution, metabolism, and elimination.

- Absorption: bioavailability after oral, IM, or IV administration. The IM and IV routes offer 100% bioavailability; bioavailability after oral administration ranges from 10% (e.g., penicillin G) to nearly 100% (e.g., amoxicillin, clindamycin, metronidazole, fluoroquinolones).

- Distribution: The concentration of an antibiotic must exceed the minimal inhibitory concentration (MIC) at the site of infection to be effective.

- Metabolism and elimination: Antibacterial agents are disposed of by hepatic elimination (metabolism or biliary elimination), renal excretion of the unchanged or metabolized form, or a combination of the two. The mode of excretion is important in adjusting dosage if elimination is impaired.

PRINCIPLES OF ANTIBACTERIAL CHEMOTHERAPY

- When possible, obtain specimens to identify the etiologic agent prior to treatment.

- Use local susceptibility patterns to help direct empirical treatment.
  Bacteria are considered susceptible to an antibacterial drug if the achievable peak serum concentration exceeds the MIC by ~4-fold.

  The pharmacodynamic profile refers to the quantitative relationships among (1) the time course of antibiotic concentrations in serum and tissue, (2) the MIC, and (3) the microbial response (inhibition of growth or rate of killing). Antibiotic classes are either:
  Concentration dependent (e.g., fluoroquinolones, aminoglycosides):
  Increases in antibiotic concentration lead to a more rapid rate of bacterial death.

  Time dependent (e.g., β-lactam antibiotics): The reduction in bacterial density is proportional to the duration of the period during which concentrations exceed the MIC.

- Once etiology and susceptibility are known, change the therapeutic regimen to one that has the narrowest effective spectrum and (if possible) is least costly. Although combination chemotherapy usually is not indicated, it is used for certain purposes:
  To prevent emergence of resistance
  For synergistic or additive activity
  For therapy directed against multiple potential pathogens

- Choose a therapeutic agent on the basis of:
  Pharmacologic data
  Adverse reaction profile
  Site of infection (e.g., is it a protected site such as CSF or heart valve vegetation?)
  Host immune status (e.g., does the host have impaired humoral or cellular immune function? is the pt pregnant?)
  Evidence of efficacy in clinical trials

- Check for drug interactions and contraindications before prescribing antibiotics.
CHOICE OF ANTIBACTERIAL AGENTS

Table 84-1 lists infections for which specific antibacterial agents are among the drugs of choice as well as common pathogen resistance rates for those agents. For current and practical information regarding antimicrobial drugs and treatment regimens, consult relevant chapters in HPIM-17. In addition, online references such as the Johns Hopkins antibiotic guide (www.Hopkins-abxguide.org) are available. Evidence-based practice guidelines for most infections are available from the Infectious Diseases Society of America (www.idsociety.org).

ADVERSE REACTIONS

Adverse reactions are classified as either dose-related (e.g., aminoglycoside-induced nephrotoxicity) or unpredictable. Unpredictable reactions are idiosyncratic or allergic. The most clinically relevant adverse reactions to common antibacterial drugs are listed below.

β-Lactam Drugs
- Allergies in ~1–4% of treatment courses. Cephalosporins cause allergy in 2–4% of penicillin-allergic pts. Aztreonam is safe in β-lactam–allergic pts. Nonallergic skin reactions: Ampicillin “rash” is common among pts with Epstein-Barr virus infection.
- Diarrhea, including *Clostridium difficile* colitis

Vancomycin
- Anaphylactoid reaction (“red man syndrome”). Avoid by giving vancomycin as a 1- to 2-h infusion.
- Nephrotoxicity, ototoxicity, allergy, neutropenia

Daptomycin
- Distal muscle pain or weakness; weekly creatine phosphokinase measurements, especially in pts also receiving statins

Aminoglycosides
- Nephrotoxicity (generally reversible); greatest with prolonged therapy in the elderly or with preexisting renal insufficiency. Monitor serum creatinine every 2–3 days.
- Otoxicity: often irreversible; risk factors similar to those for nephrotoxicity; both vestibular and hearing toxicities

Macrolides/Ketolides
- GI distress (e.g., erythromycin)
- Otoxicity (e.g., high-dose IV erythromycin)
- Cardiac toxicity (QTc prolongation and torsades de pointes, especially when inhibitors of erythromycin metabolism are given simultaneously)
- Hepatic toxicity (telithromycin)
- Respiratory failure in pts with myasthenia gravis (telithromycin)

Clindamycin
- Diarrhea, including *C. difficile* colitis

Tetracyclines/Glycylcyclines
- GI distress: up to 20% with tigecycline
- Esophageal ulceration: doxycycline (take in the morning with fluids)
<table>
<thead>
<tr>
<th>Agent</th>
<th>Infections</th>
<th>Common Pathogen(s) (Resistance Rate, %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillin G</td>
<td>Syphilis, yaws, leptospirosis, groups A and B streptococcal infections, pneumococcal infections, actinomycosis, oral and periodontal infections, meningococcal meningitis and meningococcemia, viridans streptococcal endocarditis, clostridial myonecrosis, tetanus, anthrax, rat-bite fever, Pasteurella multocida infections, and erysipeloid (Erysipelothrix rhusiopathiae)</td>
<td>Neisseria meningitidis&lt;sup&gt;b&lt;/sup&gt; (intermediate, &lt;sup&gt;c&lt;/sup&gt; 15–30; resistant, 0; geographic variation) Viridans streptococci (intermediate, 15–30; resistant, 5–10) Streptococcus pneumoniae (intermediate, 23; resistant, 17)</td>
</tr>
<tr>
<td>Ampicillin, amoxicillin</td>
<td>Salmonellosis, acute otitis media, Haemophilus influenzae meningitis and epiglottitis, Listeria monocytogenes meningitis, Enterococcus faecalis UTI</td>
<td>Escherichia coli (37) H. influenzae (35) Salmonella spp.&lt;sup&gt;b&lt;/sup&gt; (30–50; geographic variation) Enterococcus spp. (24) S. aureus (46; MRSA) Staphylococcus epidermidis (78; MRSE)</td>
</tr>
<tr>
<td>Nafcillin, oxacillin</td>
<td>Staphylococcus aureus (non-MRSA) bacteremia and endocarditis</td>
<td>P. aeruginosa (6)</td>
</tr>
<tr>
<td>Piperacillin plus tazobactam</td>
<td>Intraabdominal infections (facultative enteric gram-negative bacilli plus obligate anaerobes); infections caused by mixed flora (aspiration pneumonia, diabetic foot ulcers); infections caused by Pseudomonas aeruginosa</td>
<td>E. coli (7) S. aureus (46; MRSA) Bacteroides fragilis (12) S. pneumoniae (intermediate, 16; resistant, 0) E. coli and Klebsiella pneumoniae (1; ESBL producers)</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>E. coli UTI, surgical prophylaxis, S. aureus (non-MRSA) bacteremia and endocarditis</td>
<td>E. coli (7) S. aureus (46; MRSA) Bacteroides fragilis (12) S. pneumoniae (intermediate, 16; resistant, 0) E. coli and Klebsiella pneumoniae (1; ESBL producers)</td>
</tr>
<tr>
<td>Cefoxitin, cefotetan</td>
<td>Intraabdominal infections and pelvic inflammatory disease</td>
<td>S. pneumoniae (intermediate, 16; resistant, 0) E. coli and Klebsiella pneumoniae (1; ESBL producers)</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>Gonococcal infections, pneumococcal meningitis, viridans streptococcal endocarditis, salmonellosis and typhoid fever, hospital-acquired infections caused by non-pseudomonal facultative gram-negative enteric bacilli</td>
<td>S. pneumoniae (intermediate, 16; resistant, 0) E. coli and Klebsiella pneumoniae (1; ESBL producers)</td>
</tr>
<tr>
<td>Ceftazidime, cefepime</td>
<td>Hospital-acquired infections caused by facultative gram-negative enteric bacilli and Pseudomonas</td>
<td>P. aeruginosa (16) (See ceftriaxone for ESBL producers) P. aeruginosa (6) Acinetobacter spp. (35)</td>
</tr>
<tr>
<td>Imipenem, meropenem</td>
<td>Intraabdominal infections, hospital-acquired infections (non-MRSA), infections caused by Enterobacter spp. and ESBL-producing gram-negative bacilli</td>
<td>P. aeruginosa (6) Acinetobacter spp. (35)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Resistance rates vary by geographic location and may be influenced by the use of antibiotics. 
<sup>b</sup> Intermediate resistance is defined as 15–30%, resistant is defined as >30%. 
<sup>c</sup> Geographical variation refers to differences in resistance rates between different regions or countries. 

(continued)
### TABLE 84-1 INFECTIONS FOR WHICH SPECIFIC ANTIBACTERIAL AGENTS ARE AMONG THE DRUGS OF CHOICE (CONTINUED)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Infections</th>
<th>Common Pathogen(s) (Resistance Rate, %)*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aztreonam</strong></td>
<td>Hospital-acquired infections caused by facultative gram-negative bacilli and <em>Pseudomonas</em> in penicillin-allergic patients</td>
<td><em>P. aeruginosa</em> (16)</td>
</tr>
<tr>
<td></td>
<td>Bacteremia, endocarditis, and other serious infections due to MRSA; pneumococcal meningitis; antibiotic-associated pseudomembranous colitis&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td><strong>Vancomycin</strong></td>
<td>Bacteremia, endocarditis, and other serious infections due to MRSA; pneumococcal meningitis; antibiotic-associated pseudomembranous colitis&lt;sup&gt;d&lt;/sup&gt;</td>
<td><em>Enterococcus</em> spp. (24)</td>
</tr>
<tr>
<td><strong>Daptomycin</strong></td>
<td>VRE infections; MRSA bacteremia</td>
<td></td>
</tr>
<tr>
<td><strong>Gentamicin, amikacin, tobramycin</strong></td>
<td>Combined with a penicillin for staphylococcal, enterococcal, or viridans streptococcal endocarditis; combined with a β-lactam antibiotic for gram-negative bacteria; pyelonephritis</td>
<td>UNK</td>
</tr>
<tr>
<td><strong>Erythromycin, clarithromycin, azithromycin</strong></td>
<td><em>Legionella</em>, <em>Campylobacter</em>, and <em>Mycoplasma</em> infections; CAP; group A streptococcal pharyngitis in penicillin-allergic pts; bacillary angiomatosis (<em>Bartonella henselae</em>); gastric infections due to <em>Helicobacter pylori</em>; <em>Mycobacterium avium-intracellulare</em> infections</td>
<td><em>S. pneumoniae</em> (28)</td>
</tr>
<tr>
<td></td>
<td><strong>Erythromycin, clarithromycin, azithromycin</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Clindamycin</strong></td>
<td>Severe, invasive group A streptococcal infections; infections caused by obligate anaerobes; infections caused by susceptible staphylococci</td>
<td><em>S. aureus</em> (nosocomial = 58; CA-MRSA = 10&lt;sup&gt;b&lt;/sup&gt;)</td>
</tr>
<tr>
<td><strong>Doxycycline, minocycline</strong></td>
<td>Acute bacterial exacerbations of chronic bronchitis, granuloma inguinale, brucellosis (with streptomycin), tularemia, glanders, melioidosis, spirochetal infections caused by <em>Borrelia</em> (Lyme disease and relapsing fever; doxycycline), infections caused by <em>Vibrio vulnificus</em>, some <em>Aeromonas</em> infections, infections due to <em>Stenotrophomonas</em> (minocycline), plague, ehrlichiosis, chlamydial infections (doxycycline), granulomatous skin infections due to <em>Mycobacterium marinum</em> (minocycline), rickettsial infections, mild CAP, skin and soft tissue infections caused by gram-positive cocci (CA-MRSA infections, leptospirosis, syphilis, actinomycosis in the penicillin-allergic pt)</td>
<td><em>S. pneumoniae</em> (17)</td>
</tr>
<tr>
<td><strong>Trimethoprim-sulfamethoxazole</strong></td>
<td>Community-acquired UTI; <em>S. aureus</em> skin and soft tissue infections (CA-MRSA)</td>
<td><em>E. coli</em> (19)</td>
</tr>
<tr>
<td><strong>Sulfonamides</strong></td>
<td>Nocardial infections, leprosy (dapsone, a sulfone), and toxoplasmosis (sulfadiazine)</td>
<td>MRSA (3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>UNK</td>
</tr>
<tr>
<td>Drug</td>
<td>Indications</td>
<td>Organisms</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Ciprofloxacin, levofloxacin, moxifloxacin | CAP (levofloxacin and moxifloxacin); UTI; bacterial gastroenteritis; hospital-acquired gram-negative enteric infections; *Pseudomonas* infections (ciprofloxacin and levofloxacin) | *S. pneumoniae* (1)  
*E. coli* (13)  
*P. aeruginosa* (23)  
*Salmonella* spp. (10–50; geographic variation)  
*Neisseria gonorrhoeae*<sup>a</sup> (0–5, non–West Coast U.S.; 10–15, California and Hawaii; 20–70, Asia, England, Wales) |
| Rifampin                    | Staphylococcal foreign body infections, in combination with other antistaphylococcal agents; *Legionella* pneumonia | Staphylococci rapidly develop resistance during rifampin monotherapy. |
| Metronidazole               | Obligate anaerobic gram-negative bacteria (*Bacteroides* spp.): abscess in lung, brain, or abdomen; bacterial vaginosis; antibiotic-associated *Clostridium difficile* disease | UNK                                                                       |
| Linezolid                   | VRE; staphylococcal skin and soft tissue infection (CA-MRSA)              | UNK                                                                       |
| Polymyxin E (colistin)      | Hospital-acquired infection due to gram-negative bacilli resistant to all other chemotherapy: *P. aeruginosa, Acinetobacter* spp., *Stenotrophomonas maltophilia* | UNK                                                                       |
| Quinupristin/ dalfopristin  | VRE                                                                       | Vancomycin-resistant *E. faecalis*<sup>b</sup> (100)                     |
| Mupirocin                   | Topical application to nares to eradicate *S. aureus* carriage             | Vancomycin-resistant *E. faecium* (10)                                    |

<sup>a</sup>Unless otherwise noted, resistance rates are based on all isolates tested in 2005 in the clinical microbiology laboratory at Virginia Commonwealth University Medical Center. The rates are consistent with those reported by the National Nosocomial Infections Surveillance System (Am J Infect Control 32:470, 2004).<sup>b</sup>Data from recent literature sources. Intermediate resistance.

<sup>d</sup>Drug is given orally for this indication.

**Abbreviations:** CA-MRSA, community-acquired methicillin-resistant *S. aureus*; CAP, community-acquired pneumonia; MRSA, methicillin-resistant *S. aureus*; MRSE, methicillin-resistant *S. epidermidis*; UTI, urinary tract infection; VRE, vancomycin-resistant enterococci; ESBL, extended-spectrum β-lactamase; UNK, resistance rates unknown.
Sulfonamides and Trimethoprim
- Allergic reactions: rash (more common in HIV-infected pts), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis
- Hematologic reactions: uncommon; include agranulocytosis and granulocytopenia (more common in HIV-infected pts), hemolytic and megaloblastic anemia, thrombocytopenia
- Renal insufficiency: crystalluria with sulfadiazine

Fluoroquinolones
- Diarrhea, including *C. difficile* colitis
- Contraindicated for general use in pts <18 years old and pregnant women; appear safe in treatment of pulmonary infections in children with cystic fibrosis
- CNS adverse effects (e.g., insomnia)
- Miscellaneous allergies, tendon rupture, dysglycemias, QTc prolongation

Rifampin
- Hepatotoxicity; rare
- Turns secretions such as urine and tears orange
- Intermittent administration can be associated with flulike symptoms, hemolysis, and renal insufficiency.

Metronidazole
- Metallic taste is common.

Linezolid
- Myelosuppression follows long-term treatment.
- Ocular and peripheral neuritis follows long-term treatment.

For a more detailed discussion, see Archer GL, Polk RE: Treatment and Prophylaxis of Bacterial Infections, Chap. 127, p. 851, in HPIM-17. For a discussion of antifungal therapy, see Chap. 114 in this manual; for antimycobacterial therapy, see Chap. 102; for antiviral therapy, see Chaps. 107 through 112; and for antiparasitic therapy, see Chaps. 116 and 117.

Health Care–Associated Infections

Hospital-acquired (nosocomial) infections (defined as those not present or incubating at the time of admission to the hospital) and other health care–associated infections are estimated to affect >2 million pts, cost $4.5 billion, and contribute to 88,000 deaths in U.S. hospitals each year. Efforts to lower infection risks have been challenged by the growing numbers of immunocompromised pts, antibiotic-resistant bacteria, fungal and viral superinfections, and invasive procedures and devices.

**PREVENTION OF HOSPITAL-ACQUIRED INFECTIONS**

Hospital infection-control programs use several mechanisms to prevent nosocomial infections.
• Surveillance: review of microbiology laboratory results, surveys of nursing wards, and use of other mechanisms to keep track of infections acquired after hospital admission. Hospital infection-control programs focus primarily on infections associated with the greatest morbidity or the highest costs.

• Prevention and control measures: Hand hygiene is the single most important measure to prevent cross-infection. Other measures include identifying and eradicating reservoirs of infection and minimizing use of invasive procedures and catheters.

• Isolation techniques to limit the spread of infection
  1. Standard precautions are used for all pts when there is a potential for contact with blood, other body fluids, nonintact skin, or mucous membranes. Hand hygiene and use of gloves are central components of standard precautions; in certain cases, masks, eye protection, and gowns are used as well.
  2. Transmission-based guidelines: Airborne precautions, droplet precautions, and contact precautions are used to prevent transmission of disease from infected pts. More than one precaution can be combined for diseases that have more than one mode of transmission (e.g., varicella). Because antibiotic-resistant bacteria can be present on intact skin of infected pts, any contact with sick pts who may be harboring those bacteria should involve hand hygiene and use of gloves. Gowns are frequently used as well, although their importance in preventing cross-infection is less clear.

NOSOCOMIAL AND DEVICE-RELATED INFECTIONS

Nosocomial infections are due to the combined effect of the pt’s own flora and the presence of invasive devices in 25–50% of cases. Intensive education and “bundling” of evidence-based interventions reduce infection rates (see Table 85-1).

Urinary Tract Infections  Up to 40–45% of nosocomial infections are UTIs. Most nosocomial UTIs are associated with prior instrumentation or indwelling bladder catheterization. The 3–10% risk of infection for each day a catheter remains in place is due to the ascent of bacteria from the periurethral area or via intraluminal contamination of the catheter. The pt should be assessed for symptoms of upper tract disease, such as flank pain, fever, and leukocytosis. Lower tract symptoms, such as dysuria, are unreliable as markers of infection in catheterized pts. If infection is suspected, the catheter should be replaced and a freshly voided urine specimen obtained for culture; repeat cultures should confirm the persistence of infection at the time therapy is initiated. Urinary sediment should be examined for evidence of infection (e.g., pyuria). See Table 85-1 for interventions to prevent catheter-associated UTIs. In men, condom catheters—unless carefully maintained—are as strongly associated with infection as indwelling catheters.

Pneumonia  Accounting for 15–20% of nosocomial infections, pneumonia increases the duration of hospital stay and costs and is associated with more deaths than are infections at any other body site. Pts aspirate endogenous or hospital-acquired flora. Risk factors include events that increase colonization with potential pathogens, such as prior antibiotic use, contaminated ventilator equipment, or increased gastric pH; events that increase risk of aspiration, such as nasogastric or endotracheal intubation or decreased level of consciousness; and conditions that compromise host defense mechanisms in the lung, such as chronic obstructive pulmonary disease. Diagnosis depends on clinical criteria such as fever, leukocytosis, purulent secretions, and new or changing pulmonary infiltrates on chest x-ray. An etiology should be sought by studies of lower
Infectious Diseases

SECTION 7

respiratory tract samples protected from upper-tract contamination; quantitative cultures have diagnostic sensitivities in the range of 80%. Febrile pts with nasogastric tubes should also have sinusitis or otitis media ruled out. Etiologic organisms (some of which are more common among critically ill pts in ICUs) include *Streptococcus pneumoniae* and *Haemophilus influenzae* early during hospitalization and *Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella, Enterobacter, Acinetobacter*, and other gram-negative bacilli later in the hospital stay. Efforts at prevention should focus on meticulous aseptic care of respirator equipment and the interventions listed in Table 85-1.

**Surgical Wound Infections** Making up 20–30% of nosocomial infections, surgical wound infections increase the length of hospital stay as well as costs. These infections often become evident after pts have left the hospital; thus it is difficult to assess the true incidence. Common risk factors include deficits in the

<table>
<thead>
<tr>
<th>TABLE 85-1</th>
<th>EXAMPLES OF “BUNDLED INTERVENTIONS” TO PREVENT COMMON HEALTH CARE–ASSOCIATED INFECTIONS AND OTHER ADVERSE EVENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prevention of Central Venous Catheter Infections</strong></td>
<td>Educate personnel about catheter insertion and care. Use chlorhexidine to prepare the insertion site. Use maximum barrier precautions during catheter insertion. Ask daily: Is the catheter needed?</td>
</tr>
<tr>
<td><strong>Prevention of Ventilator-Associated Pneumonia and Complications</strong></td>
<td>Elevate head of bed to 30–45 degrees. Give “sedation vacation” and assess readiness to extubate daily. Use peptic ulcer disease prophylaxis. Use deep-vein thrombosis prophylaxis (unless contraindicated).</td>
</tr>
<tr>
<td><strong>Prevention of Surgical-Site Infections</strong></td>
<td>Administer prophylactic antibiotics within 1 h before surgery; discontinue within 24 h. Limit any hair removal to the time of surgery; use clippers or do not remove hair at all. Maintain normal perioperative glucose levels (cardiac surgery patients). Maintain perioperative normothermia (colorectal surgery patients).</td>
</tr>
<tr>
<td><strong>Prevention of Urinary Tract Infections</strong></td>
<td>Place bladder catheters only when absolutely needed (e.g., to relieve obstruction), not solely for the provider’s convenience. Use aseptic technique for catheter insertion and urinary tract instrumentation. Minimize manipulation or opening of drainage systems. Remove bladder catheters as soon as is feasible.</td>
</tr>
</tbody>
</table>

* These components of care are supported by clinical trials and experimental evidence in the specified populations; they may prove valuable for other surgical patients as well.

Health Care–Associated Infections

CHAPTER 85

431

surgeon’s technical skill, the pt’s underlying conditions (e.g., diabetes mellitus or obesity), and inappropriate timing of antibiotic prophylaxis. Other factors include the presence of drains, prolonged preoperative hospital stays, shaving of the operative site the day before surgery (rather than just before the procedure), long duration of surgery, and infection at remote sites.

Diagnosis begins with a careful assessment of the surgical site in the febrile postoperative pt. *S. aureus*, coagulase-negative staphylococci, and enteric and anaerobic bacteria are the most common pathogens. In rapidly progressing postoperative infections, group A streptococcal or clostridial etiologies should be considered. Treatment includes administration of appropriate antibiotics and drainage or excision of infected or necrotic material. See Table 85-1 for interventions to prevent surgical wound infections. Other interventions include attention to technical surgical issues, operating room asepsis, and preoperative treatment of active infections.

### Intravascular Device Infections

Infections of intravascular devices cause up to 50% of nosocomial bacteremias; central vascular catheters account for 80–90% of these infections. As many as 200,000 bloodstream infections associated with central vascular catheters occur each year in the United States, with attributable mortality rates of 12–25% and a cost of $25,000 per episode. In pts with vascular catheters, infection is suspected on the basis of the appearance of the catheter site and/or the presence of fever or bacteremia without another source. Coagulase-negative staphylococci, *S. aureus* (including methicillin-resistant isolates), enterococci, nosocomial gram-negative bacilli, and *Candida* are the pathogens most frequently associated with these bacteremias. The diagnosis is confirmed by isolation of the same bacteria from peripheral blood cultures and from semiquantitative or quantitative cultures of samples from the vascular catheter tip. In addition to the initiation of appropriate antibiotic treatment, other considerations include the level of risk for endocarditis (relatively high in pts with *S. aureus* bacteremia) and the decision regarding catheter removal, which is usually necessary to cure infection. If salvage of the catheter is attempted, the “antibiotic lock” technique (instillation of concentrated antibiotic solution into the catheter lumen along with systemic antibiotic administration) may be used. If the catheter is changed over a guidewire and cultures of the removed catheter tip are positive, the catheter should be moved to a new site. See Table 85-1 for interventions that have been highly effective in reducing rates of central venous catheter infections. Femoral insertion sites should be avoided.

### EPIDEMIC AND EMERGING PROBLEMS

- **Influenza**: Vaccination of pts and health care workers, early use of antiviral agents for control of outbreaks, and adherence to surveillance and droplet precautions for symptomatic pts are the main components of infection control.
- **Nosocomial diarrhea**: Infection with *Clostridium difficile* is increasing in frequency and severity. Important infection-control components include judicious antibiotic use; heightened suspicion in cases with atypical presentations; and early diagnosis, treatment, and implementation of contact precautions. Norovirus causes nosocomial outbreaks of diarrheal syndromes in which nausea and vomiting are prominent aspects. Contact precautions may need to be augmented by environmental cleaning and active exclusion of ill staff and visitors.
- **Chickenpox**: If varicella-zoster virus (VZV) exposure occurs, postexposure prophylaxis with varicella-zoster immune globulin (VZIG) is considered for
immunocompromised or pregnant contacts (with preemptive administration of acyclovir an alternative for some susceptible persons), and susceptible employees are furloughed for 8–21 days (or for 28 days if VZIg has been given). Although VZIg is no longer manufactured in the United States, a new product is awaiting FDA approval. Vaccine should be offered routinely to VZV-susceptible employees.

- **Tuberculosis**: Prompt recognition and isolation of cases, use of negative-pressure private rooms with 100% exhaust and 6–12 air changes per hour, use of approved N95 “respirators,” and follow-up skin testing of exposed personnel are required.
- **Aspergillosis**: Linked to hospital renovations and disturbance of dusty surfaces
- **Antibiotic-resistant bacterial infection**: Close laboratory surveillance, strict infection-control practices, and aggressive antibiotic-control policies are the cornerstones of resistance-control efforts.
- **Bioterrorism preparedness**: Education, effective systems of internal and external communication, and risk assessment capabilities are key features.

For a more detailed discussion, see Weinstein RA: Health Care-Associated Infections, Chap. 125, p. 835, in HPIM-17.

### Infections in the Immunocompromised Host

The immunocompromised pt is at increased risk for infection with both common and opportunistic pathogens.

#### INFECTIONS IN CANCER PTS

Table 86-1 lists the normal barriers to infection whose disruption may permit infections in cancer pts. Infection-associated mortality rates among cancer pts have decreased as a result of an evolving approach entailing early use of empirical broad-spectrum antibiotics; empirical antifungal therapy in neutropenic pts who, after 4–7 days of antibiotic treatment, remain febrile without positive cultures; and use of antibiotics for afebrile neutropenic pts as broad-spectrum prophylaxis against infections.

#### System-Specific Syndromes

- **Skin infections**
  1. Cellulitis caused by streptococci, staphylococci, *Escherichia coli*, *Pseudomonas*, or fungi
  2. Macules or papules due to bacteria (e.g., *Pseudomonas aeruginosa* causing ecthyma gangrenosum) or fungi (*Candida*)
  3. Sweet’s syndrome or febrile neutrophilic dermatosis: most often seen in neutropenic leukemic pts; red or bluish-red papules or nodules that form sharply bordered plaques
<table>
<thead>
<tr>
<th>Type of Defense</th>
<th>Specific Lesion</th>
<th>Cells Involved</th>
<th>Organism</th>
<th>Cancer Association</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical barrier</td>
<td>Breaks in skin</td>
<td>Skin epithelial cells</td>
<td>Staphylococci, streptococci</td>
<td>Head and neck, squamous cell carcinoma</td>
<td>Cellulitis, extensive skin infection</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emptying of fluid</td>
<td>Occlusion of orifices: ureters, bile duct,</td>
<td>Luminal epithelial</td>
<td>Gram-negative bacilli</td>
<td>Renal, ovarian, biliary tree, metastatic diseases of</td>
<td>Rapid, overwhelming bacteremia; urinary tract infection</td>
</tr>
<tr>
<td>collections</td>
<td>colon</td>
<td>cells</td>
<td></td>
<td>many cancers</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphatic function</td>
<td>Node dissection</td>
<td>Lymph nodes</td>
<td>Staphylococci, streptococci</td>
<td>Breast cancer surgery</td>
<td>Cellulitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Splenic clearance</td>
<td>Splenectomy</td>
<td>Splenic reticuloendothelial cells</td>
<td><em>Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Babesia, Capnocytophaga canimorsus</em></td>
<td>Hodgkin’s disease, leukemia, idiopathic thrombocytopenic purpura</td>
<td>Rapid, overwhelming sepsis</td>
</tr>
<tr>
<td>of microorganisms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phagocytosis</td>
<td>Lack of granulocytes</td>
<td>Granulocytes (neutrophils)</td>
<td>Staphylococci, streptococci, enteric organisms, fungi</td>
<td>Hairy cell, acute myelocytic, and acute lymphocytic leukemias</td>
<td>Bacteremia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Humoral immunity</td>
<td>Lack of antibody</td>
<td>B cells</td>
<td><em>S. pneumoniae, H. influenzae, N. meningitidis</em></td>
<td>Chronic lymphocytic leukemia, multiple myeloma</td>
<td>Infections with encapsulated organisms, sinusitis, pneumonia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cellular immunity</td>
<td>Lack of T cells</td>
<td>T cells and macrophages</td>
<td>Mycobacterium tuberculosis, Listeria, herpesviruses, fungi, other intracellular parasites</td>
<td>Hodgkin’s disease, leukemia, T cell lymphoma</td>
<td>Infections with intracellular bacteria, fungi, parasites</td>
</tr>
</tbody>
</table>

**TABLE 86-1** DISRUPTION OF NORMAL BARRIERS THAT MAY PREDISPOSE TO INFECTIONS IN PTS WITH CANCER
4. Erythema multiforme with mucous membrane involvement due to herpes simplex virus (HSV)
5. Drug-associated Stevens-Johnson syndrome

- **Catheter-related infections:** If a red streak develops over the SC part of a “tunneled” catheter, the device must be removed to prevent extensive cellulitis and tissue necrosis. Exit-site infections caused by coagulase-negative staphylococci can be treated with vancomycin without catheter removal. Infections caused by other organisms, including *Staphylococcus aureus*, *P. aeruginosa*, *Candida*, *Stenotrophomonas*, or *Bacillus*, usually require catheter removal.

- **Upper GI infections:** mouth ulcerations (viridans streptococci, anaerobic bacteria, and HSV); thrush (*Candida albicans*); and esophagitis (*C. albicans* and HSV)

- **Lower GI infections**
  1. Hepatic candidiasis results from seeding of the liver during neutropenia in pts with hematologic malignancy but presents when neutropenia resolves. Pts have fever, abdominal pain, nausea, and increased alkaline phosphatase levels. CT may reveal bull’s-eye lesions. MRI is also helpful in the diagnosis. Amphotericin B is usually prescribed initially, but fluconazole may be useful for outpatient treatment.

  2. Typhlitis/neutropenic colitis is more common among children than among adults and among pts with acute myelocytic leukemia or acute lymphocytic leukemia (ALL) than among pts with other forms of cancer. Pts have fever, right lower quadrant tenderness, and diarrhea that is often bloody. The diagnosis is confirmed by the documentation of a thickened cecal wall via CT, MRI, or ultrasound. Treatment should be directed against gram-negative bacteria and bowel flora.

- **CNS infections**
  1. Meningitis: Consider *Cryptococcus* or *Listeria*. Splenectomized pts and those with hypogammaglobulinemia are also at risk for infection with encapsulated bacteria such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis*.

  2. Encephalitis can develop in pts receiving high-dose cytotoxic treatment or chemotherapy that affects T cell function. Consider varicella-zoster virus (VZV), JC virus (progressive multifocal leukoencephalopathy), cytomegalovirus (CMV), *Listeria*, HSV, and human herpesvirus 6 (HHV-6).

  3. Brain masses: Consider *Nocardia*, *Cryptococcus*, *Aspergillus*, and *Toxoplasma gondii*. Epstein-Barr virus–associated lymphoproliferative disease (EBV-LPD) may present as a mass lesion.

- **Pulmonary infections**
  1. Localized: Bacterial pneumonia, *Legionella*, mycobacteria

  2. Nodular: Suggests fungal etiology (e.g., *Mucor*, *Aspergillus*). *Aspergillus* causes invasive disease in neutropenic pts, presenting as a thrombotic event due to blood vessel invasion, pleuritic chest pain, and fever. Hemoptysis is an ominous sign. *Nocardia* can also cause nodular lesions.

  3. Diffuse: Consider viruses (e.g., CMV), *Chlamyphilus*, *Pneumocystis*, mycobacteria, and *T. gondii*. Viruses that cause upper respiratory infections in normal hosts (e.g., influenza, respiratory syncytial) may cause fatal pneumonitis.

- **Renal and ureteral infections:** Usually associated with obstructing tumor masses. *Candida* has a predilection for the kidneys, reaching this site via either hematogenous seeding or retrograde spread from the bladder. Adenovirus can cause hemorrhagic cystitis.
Infections in the Immunocompromised Host

CHAPTER 86

Approach to Diagnosis and Treatment of Febrile Neutropenic Pts

Figure 86-1 presents an algorithm for the diagnosis and treatment of febrile neutropenic pts. The initial regimen can be refined on the basis of culture data. Adding antibiotics to the initial regimen is not appropriate unless there is a clinical or microbiologic reason to do so. For antifungal treatment, amphotericin B is being supplanted by newer azoles (e.g., voriconazole or posaconazole) or echinocandins (e.g., caspofungin). Echinocandins are useful against infections with azole-resistant Candida. Antiviral agents may be appropriate, particularly those...
Infectious Diseases

SECTION 7

directed against the herpes group viruses HSV and CMV. Prophylactic antibiotics (e.g., fluoroquinolones) in severely neutropenic pts or antifungal agents (e.g., fluconazole) in pts with hematopoietic stem cell transplants may prevent infections. Pneumocystis prophylaxis is mandatory for pts with ALL and for those receiving glucocorticoid-containing regimens.

INFECTIONS IN TRANSPLANT RECIPIENTS

Evaluation of infections in transplant recipients must involve consideration of both donor and recipient and of the immunosuppressive drugs required to reduce rejection of the transplanted organ.

Hematopoietic Stem Cell Transplantation (HSCT) Infections occur in a predictable time frame after HSCT (Table 86-2).

- **Bacterial infections**: Neutropenia-related infectious complications are most common during the first month. Some centers give prophylactic antibiotics (e.g., levofloxacin) that may decrease the risk of gram-negative bacteremia but increase the risk of *Clostridium difficile* colitis.
- **Fungal infections**: Infections with resistant fungi are more common when pts are given prophylactic fluconazole. Prolonged treatment with glucocorticoids or other immunosuppressive agents increases the risk of infection with

### TABLE 86-2 INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

<table>
<thead>
<tr>
<th>Infection Site</th>
<th>Early (&lt;1 Month)</th>
<th>Middle (1–4 Months)</th>
<th>Late (&gt;6 Months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disseminated</td>
<td>Aerobic gram-negative, gram-positive bacteria</td>
<td><em>Nocardia</em></td>
<td>Encapsulated bacteria</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Candida</em>, <em>Aspergillus</em></td>
<td>(<em>Streptococcus pneumonia, Haemophilus influenzae, Neisseria meningitidis</em>)</td>
</tr>
<tr>
<td>Skin and mucous membranes</td>
<td>HSV</td>
<td>HHV-6</td>
<td>VZV</td>
</tr>
<tr>
<td>Lungs</td>
<td>Aerobic gram-negative, gram-positive bacteria</td>
<td>CMV, seasonal respiratory viruses</td>
<td><em>Pneumocystis</em></td>
</tr>
<tr>
<td></td>
<td><em>Candida</em>, <em>Aspergillus</em></td>
<td><em>Pneumocystis Toxoplasma</em></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td>CMV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>BK virus, adenovirus</td>
<td>BK virus</td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>HHV-6</td>
<td>HHV-6</td>
<td>Toxoplasma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>JC virus</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>HHV-6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note*: CMV, cytomegalovirus; HHV-6, human herpesvirus 6; HSV, herpes simplex virus; VZV, varicella-zoster virus.
Infections in the Immunocompromised Host

CHAPTER 86

Candida or Aspergillus and of reactivation of endemic fungi. Maintenance prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX; 160/800 mg/d starting 1 month after engraftment and continuing for at least 1 year) is recommended to prevent Pneumocystis pneumonia (PCP).

- Parasitic infections: PCP prophylaxis with TMP-SMX is also protective against disease caused by Toxoplasma as well as against infections caused by certain bacteria, including Nocardia, Listeria, S. pneumoniae, and H. influenzae.

- Viral infections: Prophylactic acyclovir or valacyclovir for HSV-seropositive pts reduces rates of mucositis and prevents pneumonia and other HSV manifestations. Zoster is usually managed readily with acyclovir. HHV-6 delays monocyte and platelet engraftment and may be linked to encephalitis or pneumonitis. CMV causes interstitial pneumonia, bone marrow suppression, colitis, and graft failure. The risk is highest with a CMV-seropositive donor and a CMV-seronegative recipient. Severe disease is more common among allogeneic transplant recipients and is often associated with graft-versus-host disease. Many centers give prophylactic IV ganciclovir or oral valganciclovir from engraftment to day 120 after allogeneic HSCT. In addition, preemptive therapy is given when CMV is detected in blood by an antigen or DNA test. EBV-LPD as well as infections caused by respiratory syncytial virus, parainfluenza virus, metapneumovirus, influenza virus, and adenovirus can occur. BK virus (a polyomavirus) has been found in the urine of pts after HSCT.

Solid Organ Transplantation After solid organ transplantation, pts do not go through a stage of neutropenia like that seen after HSCT; thus the infections in these two groups of pts differ. However, solid organ transplant recipients are immunosuppressed for longer periods with agents that chronically impair T cell immunity.

1. Infection risk depends on the interval since transplantation.
   a. Early infections (<1 month): Infections are related to surgery and wounds.
   b. Middle-period infections (1–6 months): Infections are the same as those seen in pts with chronically impaired T cell immunity. CMV causes severe systemic disease or infection of transplanted organs; the latter increases the risk of organ rejection, prompting increased immunosuppression that, in turn, increases CMV replication. Diagnosis, treatment, and prophylaxis of CMV infection are the keys to interrupting this cycle. Late-onset disease may occur when prophylaxis is stopped. However, the transplant recipient is often better equipped to combat late infection as a result of improved graft function and, in many cases, less intense immunosuppression.
   c. Late infections (>6 months): Listeria, Nocardia, various fungi, and other intracellular organisms associated with defects in cell-mediated immunity may pose problems. When EBV-LPD occurs (often within the transplanted organ), immunosuppression should be decreased or discontinued, if possible.

2. Kidney transplantation: TMP-SMX prophylaxis for the first 4 months decreases infection rates. Valacyclovir or valganciclovir may be considered for prophylactic treatment of high-risk pts to prevent primary or reactivation CMV infection and other herpesvirus disease. BK virus replication is associated with ureteral strictures, nephropathy, and vasculopathy. Reduction of the degree of immunosuppression is critical to reduce rates of graft loss.

3. Heart transplantation
   a. Early period: Sternal wound infection and mediastinitis due to common skin organisms, gram-negative bacteria, fungi, and Mycoplasma hominis.
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Intensive Chemotherapy</th>
<th>Hodgkin’s Disease</th>
<th>Hematopoietic Stem Cell Transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphtheria-tetanus&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Primary series and boosters as necessary</td>
<td>No special recommendation</td>
<td>12, 14, and 24 months after transplantation</td>
</tr>
<tr>
<td>Poliomyelitis&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Complete primary series and boosters</td>
<td>No special recommendation</td>
<td>12, 14, and 24 months after transplantation</td>
</tr>
<tr>
<td>Haemophilus influenzae type b conjugate</td>
<td>Primary series and booster for children</td>
<td>Immunization before treatment and booster 3 months afterward</td>
<td>12, 14, and 24 months after transplantation</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>Not routinely recommended</td>
<td>Not routinely recommended</td>
<td>12, 14, and 24 months after transplantation</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>Complete series</td>
<td>No special recommendation</td>
<td></td>
</tr>
<tr>
<td>23-Valent pneumococcal polysaccharide&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Every 5 years</td>
<td>Immunization before treatment and booster 3 months afterward</td>
<td>12 and 24 months after transplantation</td>
</tr>
<tr>
<td>4-Valent meningococcal conjugate&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Should be administered to splenectomized pts and pts living in endemic areas, including college students in dormitories</td>
<td>Should be administered to splenectomized pts and pts living in endemic areas, including college students in dormitories</td>
<td>Should be administered to splenectomized pts and pts living in endemic areas, including college students in dormitories</td>
</tr>
<tr>
<td>Influenza</td>
<td>Seasonal immunization</td>
<td>Seasonal immunization</td>
<td>Seasonal immunization</td>
</tr>
<tr>
<td>Measles/mumps/rubella</td>
<td>Contraindicated</td>
<td>Contraindicated</td>
<td>After 24 months in pts without graft-versus-host disease</td>
</tr>
<tr>
<td>Varicella-zoster virus</td>
<td>Contraindicated&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Contraindicated</td>
<td>Contraindicated</td>
</tr>
</tbody>
</table>

<sup>a</sup>The Td (tetanus-diphteria) combination is currently recommended for adults. Pertussis vaccines have not been recommended for people >6 years of age in the past. However, recent data indicate that the Tdap (tetanus-diphtheria-acellular pertussis) product is both safe and efficacious in adults.

<sup>b</sup>Live-virus vaccine is contraindicated; inactivated vaccine should be used.

<sup>c</sup>The seven-serotype pneumococcal conjugate vaccine is currently recommended only for children. It is anticipated that future vaccines will include more serotypes and will be recommended for adults.

<sup>d</sup>Currently licensed for people 11–55 years of age.

<sup>e</sup>Contact the manufacturer for more information on use in children with acute lymphocytic leukemia.
b. Middle period: The risk of *T. gondii* infection is high. TMP-SMX prophylaxis, which also protects the pt against *Pneumocystis, Nocardia,* and other organisms, is warranted. CMV disease due to reactivation or primary infection is associated with poor outcomes.

c. Late period: EBV-LPD, PcP

4. Lung transplantation

a. Early period: Pneumonia, mediastinitis

b. Middle period: CMV disease is most severe in lung or heart-lung transplant recipients; it is very common if either the donor or the recipient is seropositive. Prophylaxis is indicated.

c. Late period: EBV-LPD, PcP. Prophylaxis is given for 1 year.

5. Liver transplantation

a. Early period: Peritonitis, intraabdominal abscesses. Biliary leaks are particularly common in live-donor liver transplants (LDLTs). Fungal infections are common and correlate with preoperative glucocorticoid use or long-term antimicrobial use.

b. Middle period: Cholangitis, especially in LDLTs; viral hepatitis due to reactivation of hepatitis B and C infections. High-dose IV hepatitis B immune globulin is given; other agents are being studied for hepatitis B and C. CMV infection occurs in seronegative recipients of organs from seropositive donors; disease is not usually as severe as in other types of transplantation.

6. Within the first 12 months after solid organ transplantation, tuberculosis occurs at rates higher than those observed after HSCT. The incidence reflects the prevalence of tuberculosis in local populations.

## Immunizations in Immunosuppressed Pts

Recommendations for vaccination of cancer pts receiving chemotherapy, pts with Hodgkin’s disease, and hematopoietic stem cell transplant recipients are listed in Table 86-3. In solid organ transplant recipients, the usual vaccines and boosters should be given before immunosuppression. Pneumococcal vaccination should be repeated every 5 years; this vaccine can be given with meningococcal vaccine. Solid organ transplant recipients receiving immunosuppressive agents should not receive live vaccines.

For a more detailed discussion, see Finberg R: Infections in Patients with Cancer, Chap. 82, p. 533; Madoff LC, Kasper DL: Introduction to Infectious Diseases: Host-Pathogen Interactions, Chap. 113, p. 749; and Finberg R, Fingeroth J: Infections in Transplant Recipients, Chap. 126, p. 842, in HPIM-17.
Infective Endocarditis

Acute endocarditis is a febrile illness that rapidly damages cardiac structures, seeds extracardiac sites hematogenously, and can progress to death within weeks. Subacute endocarditis follows an indolent course, rarely causes metastatic infection, and progresses gradually unless complicated by a major embolic event or a ruptured mycotic aneurysm.

Epidemiology

In developed countries, the incidence of endocarditis ranges from 2.6 to 7.0 cases per 100,000 population per year. Predisposing conditions include congenital heart disease, illicit IV drug use, degenerative valve disease, intracardiac devices, and health care–associated infections. The incidence of endocarditis is increased among the elderly and among pts with prosthetic heart valves. The risk of endocarditis is greatest during the first 6 months after valve replacement.

Etiology

The causative microorganisms vary, in part because of different portals of entry. In native valve endocarditis (NVE), viridans streptococci, staphylococci, and HACEK organisms (Haemophilus spp., Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae) enter the bloodstream from oral, skin, and upper respiratory tract portals, respectively. Streptococcus bovis originates from the gut and is associated with colon polyps or cancer. Enterococci originate from the genitourinary tract. Nosocomial endocarditis, frequently due to Staphylococcus aureus, arises most often from bactemia related to intravascular devices. Prosthetic valve endocarditis (PVE) developing within 2 months of surgery is due to intraoperative contamination or a bactereemic postoperative complication and is typically caused by coagulase-negative staphylococci (CoNS), S. aureus, facultative gram-negative bacilli, diphtheroids, or fungi. At 1 year after valve surgery, endocarditis is caused by the same organisms that cause community-acquired NVE. IV drug users are particularly prone to tricuspid valve endocarditis caused by S. aureus (often a methicillin-resistant strain); they are also at risk for left-sided endocarditis caused by S. aureus, Pseudomonas aeruginosa, or Candida spp. Fastidious organisms such as the nutritionally variant bacteria Granulicatella and Abiotrophia, HACEK bacteria, Bartonella spp., Coxiella burnetii, Brucella spp., and Tropheryma whippelii can cause culture-negative endocarditis. β-Hemolytic streptococci, S. aureus, and pneumococci typically cause acute endocarditis, while viridans streptococci, enterococci, CoNS, and HACEK organisms usually cause subacute disease.

Pathogenesis

If endothelial injury occurs, direct infection by pathogens such as S. aureus can result, or an uninfected platelet-fibrin thrombus may develop and become infected during transient bacteremia. The vegetation (Fig. 87-1) is the prototypic lesion at the site of infection: a mass of platelets, fibrin, and microcolonies of organisms, with scant inflammatory cells.
Infective Endocarditis

CHAPTER 87

CLINICAL FEATURES

The clinical syndrome is variable and spans a continuum between acute and subacute presentations.

Cardiac Manifestations

- Heart murmurs, particularly new or worsened regurgitant murmurs, are ultimately heard in 85% of pts with acute NVE.
- Congestive heart failure (CHF) develops in 30–40% of pts and is usually due to valvular dysfunction.
- Extension of infection can result in perivalvular abscesses, which in turn may cause fistulae from the aortic root into cardiac chambers or may burrow through epicardium and cause pericarditis.
- Heart block may result when infection extends into the conduction system.
- Emboli to a coronary artery may result in myocardial infarcts.

Noncardiac Manifestations

- Hematogenous bacterial seeding (e.g., to the spleen, kidneys, and meninges) can cause abscesses in noncardiac tissues.
- Arterial emboli of vegetation fragments lead to infection or infarction of remote tissues such as the extremities, spleen, kidneys, bowel, or brain. Emboli most commonly arise from vegetations >10 mm in diameter and from those located on the mitral valve. With antibiotic treatment, the frequency of emboli decreases from 13 per 1000 pt-days during the first week of infection to 1.2 per 1000 pt-days during the third week.
- Neurologic complications are seen in up to 40% of pts and include embolic stroke, aseptic or purulent meningitis, intracranial hemorrhage due to ruptured mycotic aneurysms (focal dilations of arteries at points in the artery wall that have been weakened by infection or where septic emboli have lodged) or hemorrhagic infarcts, seizures, encephalopathy, and microabscesses.
- Renal infarcts cause flank pain and hematuria without renal dysfunction.
- Immune complex deposition causes glomerulonephritis and renal dysfunction.
Peripheral manifestations such as Osler’s nodes, subungual hemorrhages, Janeway lesions, and Roth’s spots are nonsuppurative complications seen in prolonged infection and are now rare because of early diagnosis and treatment.

**Tricuspid Valve Endocarditis** This condition is associated with fever, faint or no heart murmur, and prominent pulmonary findings such as cough, pleuritic chest pain, and nodular pulmonary infiltrates.

**Health Care–Associated Endocarditis** Manifestations depend on the presence or absence of a retained intracardiac device. For example, transvenous pacemaker lead–related endocarditis may be associated with generator pocket infection and results in fever, minimal murmur, and pulmonary symptoms due to septic emboli.

**Paravalvular Infection** This condition is common in PVE, resulting in partial valve dehiscence, regurgitant murmurs, CHF, or disruption of the conduction system.

**DIAGNOSIS**

- The Duke criteria (Table 87-1) constitute a sensitive and specific diagnostic schema. **Definite** endocarditis is defined by 2 major, 1 major plus 3 minor, or 5 minor criteria. **Possible** endocarditis is defined by 1 major plus 1 minor criterion or by 3 minor criteria.
- If blood cultures are negative after 48–72 h, 2 or 3 additional cultures should be performed, and the laboratory should be asked for advice regarding optimal culture techniques.
- Serology is helpful in the diagnosis of *Brucella, Bartonella, Legionella*, or *C. burnetii* endocarditis.
- Echocardiography should be performed to confirm the diagnosis, to verify the size of vegetations, to detect intracardiac complications, and to assess cardiac function. Transthoracic echocardiography (TTE) does not detect vegetations <2 mm in diameter and is not adequate to evaluate prosthetic valves or to detect intracardiac complications; however, TTE may be used in pts with a low pretest likelihood of endocarditis (<5%). In other pts, transesophageal echocardiography (TEE) is indicated. TEE detects vegetations in >90% of cases of definite endocarditis and is optimal for evaluation of prosthetic valves and detection of abscesses, valve perforation, or intracardiac fistulas.
- Other laboratory studies should be performed—e.g., a complete blood count, creatinine measurement, liver function tests, chest radiography, and electrocardiography. The erythrocyte sedimentation rate, C-reactive protein level, and circulating immune complex titer are typically elevated.

**ANTI-MICROBIAL THERAPY**

Antimicrobial therapy must be bactericidal and prolonged. See Table 87-2 for organism-specific regimens. Most pts defervesce within 5–7 days. Blood cultures should be repeated until sterile, and results should be rechecked if there is recrudescent fever and at 4–6 weeks after therapy to document cure. If pts are febrile for 7 days despite antibiotic therapy, an evaluation for paravalvular or extracardiac abscesses should be performed.

- Pts with acute endocarditis require antibiotic treatment as soon as three sets of blood culture samples are obtained, but stable pts with subacute dis-
ease should have antibiotics withheld until a diagnosis is made. Pts treated with vancomycin or an aminoglycoside should have serum drug levels monitored. Tests to detect renal, hepatic, and/or hematologic toxicity should be performed periodically.

- Selection of optimal treatment for streptococcal endocarditis requires determination of the minimal inhibitory concentration (MIC) of penicillin for the causative isolate. Two-week regimens should not be used for compli-
### Antibiotic Treatment for Infective Endocarditis Caused by Common Organisms

<table>
<thead>
<tr>
<th>Organism</th>
<th>Drug, Dose, Duration</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Streptococci</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Penicillin-susceptible<sup>b</sup> streptococci, *S. bovis* | Penicillin G (2–3 mU IV q4h for 4 weeks)  
Ceftriaxone (2 g/d IV as a single dose for 4 weeks)  
Vancomycin<sup>c</sup> (15 mg/kg IV q12h for 4 weeks)  
Penicillin G (2–3 mU IV q4h) or ceftriaxone (2 g IV qd) for 2 weeks  
*plus* gentamicin<sup>d</sup> (3 mg/kg qd IV or IM as a single dose<sup>e</sup> or divided into equal doses q8h for 2 weeks) | —  
Can use ceftriaxone in pts with nonimmediate penicillin allergy  
Use vancomycin in pts with severe or immediate β-lactam allergy  
Avoid 2-week regimen when risk of aminoglycoside toxicity is increased and in prosthetic valve or complicated endocarditis |
| Relatively penicillin-resistant<sup>f</sup> streptococci | Penicillin G (4 mU IV q4h) or ceftriaxone (2 g IV qd) for 4 weeks  
*plus* gentamicin<sup>d</sup> (3 mg/kg qd IV or IM as a single dose<sup>e</sup> or divided into equal doses q8h for 2 weeks) | Penicillin alone at this dose for 6 weeks or with gentamicin during initial 2 weeks preferred for prosthetic valve endocarditis caused by streptococci with penicillin MICs of >0.1 μg/mL |
| Moderately penicillin-resistant<sup>g</sup> streptococci, nutritionally variant organisms, or *Gemella morbillorum* | Penicillin G (4–5 mU IV q4h) or ceftriaxone (2 g IV qd) for 6 weeks  
*plus* gentamicin<sup>d</sup> (3 mg/kg qd IV or IM as a single dose<sup>e</sup> or divided into equal doses q8h for 6 weeks)  
Vancomycin<sup>c</sup> as noted above for 4 weeks | Preferred for prosthetic valve endocarditis caused by streptococci with penicillin MICs of >0.1 μg/mL |
| Enterococci<sup>h</sup> | Penicillin G (4–5 mU IV q4h)  
Ampicillin (2 g IV q4h)  
Vancomycin<sup>c</sup> (15 mg/kg IV q12h)  
*plus* gentamicin<sup>d</sup> (1 mg/kg IV q8h), both for 4–6 weeks | —  
Can use streptomycin (7.5 mg/kg q12h) in lieu of gentamicin if there is not high-level resistance to streptomycin  
Use vancomycin plus gentamicin for penicillin-allergic pts, or desensitize these pts to penicillin |
<table>
<thead>
<tr>
<th>Organism and Characteristics</th>
<th>Treatment Options</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Staphylococci</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Methicillin-susceptible, infecting native valves (no foreign devices)</strong></td>
<td>Nafcillin or oxacillin (2 g IV q4h for 4–6 weeks) plus (optional) gentamicin&lt;sup&gt;d&lt;/sup&gt; (1 mg/kg IM or IV q8h for 3–5 days) Cefazolin (2 g IV q8h for 4–6 weeks) plus (optional) gentamicin&lt;sup&gt;d&lt;/sup&gt; (1 mg/kg IM or IV q8h for 3–5 days) Vancomycin&lt;sup&gt;c&lt;/sup&gt; (15 mg/kg IV q12h for 4–6 weeks)</td>
</tr>
<tr>
<td><strong>Methicillin-resistant, infecting native valves (no foreign devices)</strong></td>
<td>Vancomycin&lt;sup&gt;c&lt;/sup&gt; (15 mg/kg IV q12h for 4–6 weeks)</td>
</tr>
<tr>
<td><strong>Methicillin-susceptible, infecting prosthetic valves</strong></td>
<td>Nafcillin or oxacillin (2 g IV q4h for 6–8 weeks) plus gentamicin&lt;sup&gt;d&lt;/sup&gt; (1 mg/kg IM or IV q8h for 2 weeks) plus rifampin&lt;sup&gt;i&lt;/sup&gt; (300 mg PO q8h for 6–8 weeks)</td>
</tr>
<tr>
<td><strong>Methicillin-resistant, infecting prosthetic valves</strong></td>
<td>Vancomycin&lt;sup&gt;c&lt;/sup&gt; (15 mg/kg IV q12h for 6–8 weeks) plus gentamicin&lt;sup&gt;d&lt;/sup&gt; (1 mg/kg IM or IV q8h for 2 weeks) plus rifampin&lt;sup&gt;i&lt;/sup&gt; (300 mg PO q8h for 6–8 weeks)</td>
</tr>
<tr>
<td><strong>HACEK organisms</strong></td>
<td>Ceftriaxone (2 g/d IV as single dose for 4 weeks) Ampicillin/sulbactam (3 g IV q6h for 4 weeks)</td>
</tr>
<tr>
<td>Can use penicillin (4 mU q4h) if isolate is penicillin-susceptible (does not produce β-lactamase) Can use cefazolin regimen for pts with nonimmediate penicillin allergy Use vancomycin for pts with immediate (urticarial) or severe penicillin allergy No role for routine use of rifampin Use gentamicin during initial 2 weeks; determine susceptibility to gentamicin before initiating rifampin; if pt is highly allergic to penicillin, use regimen for methicillin-resistant staphylococci; if β-lactam allergy is of the minor, nonimmediate type, can substitute cefazolin for oxacillin/nafcillin Use gentamicin during initial 2 weeks; determine gentamicin susceptibility before initiating rifampin Can use another third-generation cephalosporin at comparable dosage</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>Doses are for adults with normal renal function. Doses of gentamicin, streptomycin, and vancomycin must be adjusted for reduced renal function. Ideal body weight is used to calculate doses of gentamicin and streptomycin per kilogram (men = 50 kg + 2.3 kg per inch over 5 feet; women = 45.5 kg + 2.3 kg per inch over 5 feet).  
<sup>b</sup>MIC, ≤0.1 μg/mL.  
<sup>c</sup>Desirable peak vancomycin level 1 h after completion of a 1-h infusion is 30–45 μg/mL.  
<sup>d</sup>Aminoglycosides should not be administered as single daily doses for enterococcal endocarditis and should be introduced as part of the initial treatment. Target peak and trough serum concentrations of divided-dose gentamicin 1 h after a 20- to 30-min infusion or IM injection are ~3–5 μg/mL and ≤1 μg/mL, respectively; target peak and trough serum concentrations of streptomycin (timing as with gentamicin) are 20–35 μg/mL and <10 μg/mL, respectively.  
<sup>e</sup>Neflomycin (4 mg/kg qd, as a single dose) can be used in lieu of gentamicin.  
<sup>f</sup>MIC, >0.1 μg/mL and <0.5 μg/mL.  
<sup>g</sup>MIC, ≥0.5 μg/mL and <8.0 μg/mL.  
<sup>h</sup>Vancomycin is an effective antibiotic for HACEK organisms.  
<sup>i</sup>Rifampin increases warfarin and dicumarol requirements for anticoagulation.  

---

**Antibiotics and Dosages**

- **Nafcillin or oxacillin (2 g IV q4h for 4–6 weeks)**
- **Gentamicin (1 mg/kg IM or IV q8h for 3–5 days)**
- **Vancomycin (15 mg/kg IV q12h for 4–6 weeks)**
- **Cefazolin (2 g IV q8h for 4–6 weeks)**
- **Rifampin (300 mg PO q8h for 6–8 weeks)**
- **Ceftriaxone (2 g/d IV as single dose for 4 weeks)**
- **Ampicillin/sulbactam (3 g IV q6h for 4 weeks)**
- **Gentamicin (1 mg/kg IM or IV q8h for 2 weeks)**
- **Streptomycin (120 mg IM q12h for 2 weeks)**

**Dosing Adjustments**

- **Gentamicin and streptomycin** doses are adjusted for reduced renal function.
- **Vancomycin** dosing is adjusted based on ideal body weight.

**Susceptibility Testing**

- **Determine susceptibility** to antibiotics before administration.

**Adverse Effects**

- **Rifampin** increases the requirement for anticoagulants.

---

**Notes**

- **MIC** values are provided for reference.
- **Dosing Regimens** are designed for specific bacterial strains.
cated NVE or for PVE. Groups B, C, and G streptococcal endocarditis should be treated with the regimen recommended for relatively penicillin-resistant streptococci (Table 87-2).

- Enterococci require the synergistic activity of a cell wall–active agent and an aminoglycoside for killing. Enterococci must be tested for high-level resistance to streptomycin and gentamicin; if resistance is detected, the addition of an aminoglycoside will not produce a synergistic effect, and the cell wall–active agent should be given alone for periods of 8–12 weeks or—for Enterococcus faecalis—high-dose ampicillin plus ceftriaxone can be given. If treatment fails or the isolate is resistant to commonly used agents, surgical therapy is advised (see below and Table 87-3). The aminoglycoside can be discontinued in those pts who have responded satisfactorily to therapy if toxicity develops after 2–3 weeks of treatment.

- Staphylococcal PVE is treated for 6–8 weeks with a multidrug regimen. Rifampin is important because it kills organisms adherent to foreign material. Two other agents in addition to rifampin help prevent the emergence of rifampin resistance in vivo. Susceptibility testing for gentamicin should be performed before rifampin is given; if the strain is resistant, another aminoglycoside or a fluoroquinolone should be substituted.

- Pts with negative blood cultures and without confounding prior antibiotic treatment should receive ceftriaxone plus gentamicin. If the pt has a prosthetic valve, those two drugs plus vancomycin should be given.

**SURGICAL TREATMENT**

Surgery should be considered early in the course of illness in pts with the indications listed in Table 87-3, although most of these indications are not absolute. However, pts who develop acute aortic regurgitation with preclusion of the mitral valve or a sinus of Valsalva abscess rupture into the right heart require emergent surgery. Likewise, surgery should not be delayed when severe valvular dysfunction with progressive CHF or uncontrolled or perivalvular infection is present. Cardiac surgery should be delayed for 2–3 weeks if...

**TABLE 87-3 INDICATIONS FOR CARDIAC SURGICAL INTERVENTION IN PTS WITH ENDOCARDITIS**

<table>
<thead>
<tr>
<th>Surgery required for optimal outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate to severe CHF due to valve dysfunction</td>
</tr>
<tr>
<td>Partially dehisced unstable prosthetic valve</td>
</tr>
<tr>
<td>Persistent bacteremia despite optimal antimicrobial therapy</td>
</tr>
<tr>
<td>Lack of effective microbicidal therapy (e.g., fungal or Brucella endocarditis)</td>
</tr>
<tr>
<td>S. aureus PVE with an intracardiac complication</td>
</tr>
<tr>
<td>Relapse of PVE after optimal antimicrobial therapy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Surgery to be strongly considered for improved outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perivalvular extension of infection</td>
</tr>
<tr>
<td>Poorly responsive S. aureus endocarditis involving the aortic or mitral valve</td>
</tr>
<tr>
<td>Large (&gt;10-mm diameter) hypermobile vegetations with increased risk of embolism</td>
</tr>
<tr>
<td>Persistent unexplained fever (≥10 days) in culture-negative NVE</td>
</tr>
<tr>
<td>Poorly responsive or relapsed endocarditis due to highly antibiotic-resistant enterococci or gram-negative bacilli</td>
</tr>
</tbody>
</table>

*Surgery must be carefully considered; findings are often combined with other indications to prompt surgery.

Note: CHF, congestive heart failure; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis.
possible when the pt has had a nonhemorrhagic embolic stroke and for 4 weeks when the pt has had a hemorrhagic embolic stroke. Ruptured mycotic aneurysms should be clipped and cerebral edema allowed to resolve prior to cardiac surgery.

**ANTIBIOTIC THERAPY AFTER CARDIAC SURGERY**

- Uncomplicated NVE caused by susceptible organisms, with negative valve cultures at surgery: The duration of pre- and postoperative treatment should equal the total duration of recommended therapy, with ~2 weeks of treatment given postoperatively.
- Endocarditis with paravalvular abscess, partially treated PVE, or culture-positive valves: Pts should receive a full course of therapy postoperatively.

**PREVENTION**

The American Heart Association has dramatically restricted recommendations for antibiotic prophylaxis, advising prophylaxis only for pts at highest risk of severe morbidity and death from endocarditis. Prophylaxis is recommended

**TABLE 87-4 HIGH-RISK CARDIAC LESIONS FOR WHICH ENDOCARDITIS PROPHYLAXIS IS ADVISED BEFORE DENTAL PROCEDURES**

<table>
<thead>
<tr>
<th>Lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prosthetic heart valves</td>
</tr>
<tr>
<td>Prior endocarditis</td>
</tr>
<tr>
<td>Unrepaired cyanotic congenital heart disease, including palliative shunts or conduits</td>
</tr>
<tr>
<td>Completely repaired congenital heart defects during the 6 months after repair</td>
</tr>
<tr>
<td>Incompletely repaired congenital heart disease with residual defects adjacent to prosthetic material</td>
</tr>
<tr>
<td>Valvulopathy developing after cardiac transplantation</td>
</tr>
</tbody>
</table>


**TABLE 87-5 ANTIBIOTIC REGIMENS FOR PROPHYLAXIS OF ENDOCARDITIS IN ADULTS WITH HIGH-RISK CARDIAC LESIONS**

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.</td>
<td>Standard oral regimen</td>
</tr>
<tr>
<td>1.</td>
<td>Amoxicillin 2.0 g PO 1 h before procedure</td>
</tr>
<tr>
<td>B.</td>
<td>Inability to take oral medication</td>
</tr>
<tr>
<td>1.</td>
<td>Ampicillin 2.0 g IV or IM within 1 h before procedure</td>
</tr>
<tr>
<td>C.</td>
<td>Penicillin allergy</td>
</tr>
<tr>
<td>1.</td>
<td>Clarithromycin or azithromycin 500 mg PO 1 h before procedure</td>
</tr>
<tr>
<td>2.</td>
<td>Cephalexin 2.0 g PO 1 h before procedure</td>
</tr>
<tr>
<td>3.</td>
<td>Clindamycin 600 mg PO 1 h before procedure</td>
</tr>
<tr>
<td>D.</td>
<td>Penicillin allergy, inability to take oral medication</td>
</tr>
<tr>
<td>1.</td>
<td>Cefazolin or ceftriaxone 1.0 g IV or IM 30 min before procedure</td>
</tr>
<tr>
<td>2.</td>
<td>Clindamycin 600 mg IV or IM 1 h before procedure</td>
</tr>
</tbody>
</table>

*For high-risk lesions, see Table 87-4. Prophylaxis is not advised for other lesions.

*Do not use cephalosporins in pts with immediate hypersensitivity (urticaria, angioedema, anaphylaxis) to penicillin.

only for those dental procedures involving manipulation of gingival tissue or the periapical region of the teeth or perforation of the oral mucosa (including respiratory tract surgery). Table 87-4 lists the high-risk cardiac lesions for which prophylaxis is advised, and Table 87-5 lists the recommended antibiotic regimens for this purpose.

For a more detailed discussion, see Karchmer AW: Infective Endocarditis, Chap. 118, p. 789, in HPIM-17.

## Intraabdominal Infections

Intraperitoneal infections result when normal anatomic barriers are disrupted. Organisms contained within the bowel or an intraabdominal organ enter the sterile peritoneal cavity, causing peritonitis and—if the infection goes untreated and the pt survives—abscesses.

### PERITONITIS

Peritonitis is a life-threatening event that is often accompanied by bacteremia and sepsis. Primary peritonitis has no apparent source, whereas secondary peritonitis is caused by spillage from an intraabdominal viscus.

#### PRIMARY (SPONTANEOUS) BACTERIAL PERITONITIS (PBP)

PBP is most common among pts with cirrhosis (usually due to alcoholism) and preexisting ascites, although it is also described in other settings (e.g., malignancy, hepatitis). PBP is due to hematogenous spread of organisms to ascitic fluid in pts in whom a diseased liver and altered portal circulation compromise the liver’s filtration function.

**Clinical Features**  
Fever is common. Although some pts experience an acute onset of abdominal pain or signs of peritoneal irritation, other pts have only nonspecific and nonlocalizing manifestations (e.g., malaise, fatigue, encephalopathy). PBP is diagnosed if peritoneal fluid is sampled and contains >250 polymorphonuclear leukocytes/μL. Enteric gram-negative bacilli such as *Escherichia coli* or gram-positive organisms such as streptococci, enterococci, and pneumococci are the most common etiologic agents; a single organism is typically isolated. Culture yield is improved if 10 mL of peritoneal fluid is placed directly into blood culture bottles. Blood cultures should be performed because bacteremia is common.

**Primary (Spontaneous) Bacterial Peritonitis**

Ceftriaxone (2 g/d IV) or piperacillin/tazobactam (3.375 g qid IV) constitutes appropriate empirical treatment. The regimen should be narrowed after the etiology is identified. Treatment should continue for 5–14 days, depending on how quickly the pt’s condition improves.
Prevention Up to 70% of pts have a recurrence of PBP within 1 year. Fluoroquinolones (e.g., ciprofloxacin, 750 mg weekly) or trimethoprim-sulfamethoxazole (TMP-SMX; one double-strength tablet daily) provides effective prophylaxis but increases the risk of serious staphylococcal infections over time.

SECONDARY PERITONITIS

Secondary peritonitis develops when bacteria contaminate the peritoneum as a result of spillage from an intraabdominal viscus. Infection almost always involves a mixed aerobic and anaerobic flora, especially when the contaminating source is colonic.

Clinical Features Initial symptoms may be localized or vague and depend on the primary organ involved. Once infection has spread to the peritoneal cavity, pain increases; pts lie motionless, often with knees drawn up to avoid stretching the nerve fibers of the peritoneal cavity. Coughing or sneezing causes severe, sharp pain. There is marked voluntary and involuntary guarding of anterior abdominal musculature, tenderness (often with rebound), and fever.

Diagnosis and Treatment There is marked leukocytosis with a left shift. Studies to find the source of peritonitis are central to treatment. Abdominal taps are done only to exclude hemoperitoneum in trauma cases. The selected antibiotics are aimed at aerobic gram-negative bacilli and anaerobes—e.g., penicillin/β-lactamase inhibitor combinations or, in critically ill pts in the ICU, imipenem (500 mg q6h IV) or drug combinations such as ampicillin plus metronidazole plus ciprofloxacin. Surgical intervention is often needed.

PERITONITIS IN PTS UNDERGOING CHRONIC AMBULATORY PERITONEAL DIALYSIS

Common etiologic agents include *Staphylococcus* spp. such as coagulase-negative staphylococci and *Staphylococcus aureus* (~45% of cases), gram-negative bacilli, and fungi such as *Candida* spp. Several hundred milliliters of removed dialysis fluid should be centrifuged and sent for culture, preferably in blood culture bottles to improve the diagnostic yield. Empirical therapy should be directed against aerobic gram-negative bacilli and anaerobes—e.g., penicillin/β-lactamase inhibitor combinations or, in critically ill pts in the ICU, imipenem (500 mg q6h IV) or drug combinations such as ampicillin plus metronidazole plus ciprofloxacin. Vancomycin should be used instead of cefazolin if methicillin resistance is prevalent, if the pt has an overt exit-site infection, or if the pt appears toxic. Antibiotics are given either continuously (e.g., with each exchange) or intermittently (e.g., once daily with the dose allowed to remain in the peritoneal cavity for 6 h). Severely ill pts should be given the same regimen IV. Catheter removal should be considered if the pt’s condition does not improve within 48 h.

INTRAABDOMINAL ABSCESSES

INTRAPERITONEAL ABSCESSES

Seventy-four percent of intraabdominal abscesses are intraperitoneal or retroperitoneal and not visceral. Most abscesses arise from colonic sources. Abscesses develop in untreated peritonitis as an extension of the disease process and as an attempt by the host’s defenses to contain the infection. *Bacteroides fragilis* accounts for only 0.5% of the normal colonic flora, but it is the anaerobe most frequently isolated from intraabdominal abscesses and from blood. Scanning procedures facilitate the diagnosis; abdominal CT has the highest yield. Ultrasonography is useful for the right upper quadrant (RUQ), the kidneys, and the pelvis. Indium-labeled white blood cells and gallium localize in abscesses; how-
ever, because the bowel takes up gallium, the indium scan may be preferable. Occasionally, exploratory laparotomy is still needed to identify an abscess.

Antimicrobial therapy is adjunctive to drainage and/or surgical correction of an underlying lesion or process, although diverticular abscesses usually wall off locally and surgical intervention is not routinely needed. Antimicrobial agents with activity against gram-negative bacilli and anaerobic organisms are indicated (see “Secondary Peritonitis,” above).

VISCERAL ABSCESSES

Liver Abscess  Liver abscesses account for up to half of visceral intraabdominal abscesses and are caused most commonly by biliary tract disease (due to aerobic gram-negative bacilli, enterococci) and less often by local spread from other contiguous sites of infection (mixed aerobic and anaerobic infection) or hematogenous seeding (infection with a single species, usually staphylococci or streptococci). Pts have fever, anorexia, weight loss, nausea, and vomiting, but only ~50% have signs localized to the RUQ, such as pain, tenderness, hepatomegaly, and jaundice. Serum levels of alkaline phosphatase are elevated in ~70% of pts, and leukocytosis is common. About one-third of pts are bacteremic. Amebic liver abscesses are not uncommon; amebic serology has yielded positive results in >95% of affected pts. Drainage remains the mainstay of treatment, but medical management with long courses of antibiotics can be successful. Percutaneous drainage tends to fail when there are multiple, sizable abscesses; viscous abscess contents that plug the pigtail catheter; associated disease (e.g., of the biliary tract); or lack of response in 4–7 days.

Splenic Abscess  Splenic abscesses usually develop by hematogenous spread of infection (e.g., due to endocarditis). Abdominal pain or splenomegaly occurs in ~50% of cases and pain localized to the left upper quadrant in ~25%. Fever and leukocytosis are common. Chest x-ray may show infiltrates or left-sided pleural effusions. Splenic abscesses are most often caused by streptococci; S. aureus is the next most common cause. Gram-negative bacilli can cause splenic abscess in pts with urinary tract foci, and Salmonella can be responsible in pts with sickle cell disease. The diagnosis is often made only after the pt’s death; the condition is frequently fatal if left untreated. Pts with multiple or complex multilocular abscesses should undergo splenectomy, receive adjunctive antibiotics, and be vaccinated against encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis). Percutaneous drainage has been successful for single, small (<3-cm) abscesses and may also be useful for pts at high surgical risk.

Perinephric and Renal Abscesses  More than 75% of these abscesses are due to ascending infection and are preceded by pyelonephritis. Areas of abscess within the renal parenchyma may rupture into the perinephric space. The most important risk factor is the presence of renal calculi that produce local obstruction to urinary flow. Other risk factors include structural abnormalities of the urinary tract, a history of urologic surgery, trauma, or diabetes. E. coli, Proteus spp. (associated with struvite stones), and Klebsiella spp. are the most common etiologic agents. Clinical signs are nonspecific and include flank pain, abdominal pain, and fever. The diagnosis should be considered if pts with pyelonephritis have persistent fever after 4 or 5 days of treatment, if a urine culture yields a polymicrobial flora in pts with known renal stone disease, or if fever and pyuria occur in conjunction with a sterile urine culture. Treatment includes drainage and the administration of antibiotics active against the organisms recovered. Percutaneous drainage is usually successful.
Psoas Abscess  Psoas abscesses arise from hematogenous seeding or from contiguous spread from an intraabdominal or pelvic source or from nearby bony structures (e.g., vertebral bodies). S. aureus is most common when the source is hematogenous or bony; a mixed enteric flora is likely with an abdominal source. Pts have fever, lower abdominal or back pain, or pain referred to the hip or knee.

For a more detailed discussion, see Baron MJ, Kasper DL: Intraabdominal Infections and Abscesses, Chap. 121, p. 807, in HPIM-17.

Infectious Diarrheas

Infectious diarrheas are the second most common group of diseases worldwide and are a significant cause of morbidity and mortality in developing countries. Disease is mediated by toxins and/or direct invasion of the GI mucosa. The wide range of clinical manifestations is matched by the wide variety of infectious agents involved (Table 89-1).

APPROACH TO THE PATIENT: INFECTIOUS DIARRHEA

The history should include inquiries about fever (which may suggest invasive disease), abdominal pain, nausea, vomiting, frequency and character of stools, duration of diarrhea, food recently ingested (seafood; possible common food sources, such as a picnic), travel (location, duration, and nature of trip), sexual exposures, and general medical history (immunosuppression, treatment with antibiotics or gastric-acid inhibitors). On physical examination, particular attention to signs of dehydration and abdominal findings is warranted. Stool specimens should be examined grossly (e.g., grossly visible blood or mucus in stools suggests an inflammatory process) and microscopically. A fecal leukocyte test can be done but has an unclear predictive value; fecal lactoferrin, a marker for fecal leukocytes, is more sensitive. Whether stool cultures and other tests should be performed depends on the clinical circumstances.

NONINFLAMMATORY DIARRHEA

TRAVELER’S DIARRHEA

Of people traveling to Asia, Africa, or Central or South America, 20–50% experience the sudden onset of abdominal cramps, anorexia, and watery diarrhea. Disease usually begins within 3–5 days of arrival, is associated with ingestion of contaminated food or water, lasts 1–5 days, and is most often due to enterotoxigenic and enteroaggregative Escherichia coli (ETEC). Bismuth subsalicylate [2 tablets (525 mg) every 30–60 min, up to 8 doses] can be used prophylactically. Hydration usually constitutes adequate treatment, but, if desired, a 1- to 3-day course of a fluoroquinolone (or azithromycin in children or
<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Location</th>
<th>Illness</th>
<th>Stool Findings</th>
<th>Examples of Pathogens Involved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noninflammatory</td>
<td>Proximal small bowel</td>
<td>Watery diarrhea</td>
<td>No fecal leukocytes; mild or no increase in fecal lactoferrin</td>
<td><em>Vibrio cholerae</em>, enterotoxigenic <em>Escherichia coli</em> (LT and/or ST), enteroaggregative <em>E. coli</em>, <em>Clostridium perfringens</em>, <em>Bacillus cereus</em>, <em>Staphylococcus aureus</em>, <em>Aeromonas hydrophila</em>, <em>Plesiomonas shigelloides</em>, rotavirus, norovirus, enteric adenoviruses, <em>Giardia lamblia</em>, <em>Cryptosporidium</em> spp., <em>Cyclospora</em> spp., microsporidia</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>Colon or distal small bowel</td>
<td>Dysentery or inflammatory diarrhea</td>
<td>Fecal polymorphonuclear leukocytes; substantial increase in fecal lactoferrin</td>
<td><em>Shigella</em> spp., <em>Salmonella</em> spp., <em>Campylobacter jejuni</em>, enterohemorrhagic <em>E. coli</em>, enteroinvasive <em>E. coli</em>, <em>Yersinia enterocolitica</em>, <em>Vibrio parahaemolyticus</em>, <em>Clostridium difficile</em>, <em>A. hydrophila</em>, <em>P. shigelloides</em>, <em>Entamoeba histolytica</em></td>
</tr>
<tr>
<td>Penetrating</td>
<td>Distal small bowel</td>
<td>Enteric fever</td>
<td>Fecal mononuclear leukocytes</td>
<td><em>Salmonella typhi</em>, <em>Y. enterocolitica</em>, <em>Campylobacter fetus</em></td>
</tr>
</tbody>
</table>

*Abbreviations:* LT, heat-labile enterotoxin; ST, heat-stable enterotoxin.

in travelers to Thailand) can decrease the duration of illness to 24–36 h. Anti-motility agents (e.g., loperamide, 4 mg at onset, then 2 mg after each loose stool, to 16 mg in a 24-h period) can control diarrhea.

**BACTERIAL FOOD POISONING**

Evidence of a common-source outbreak is often found.

1. *Staphylococcus aureus*: Enterotoxin is elaborated in food left at room temperature (e.g., at picnics). The incubation period is 1–6 h. Disease lasts <12 h and consists of diarrhea, nausea, vomiting, and abdominal cramping, usually without fever.

2. *Bacillus cereus*
   a. Emetic form: presents like *S. aureus* food poisoning, is associated with contaminated fried rice
   b. Diarrheal form: incubation period of 8–16 h; diarrhea, cramps, no vomiting

3. *Clostridium perfringens*: Heat-resistant spores in undercooked meat, poultry, or legumes; incubation period, 8–14 h; 24-h illness of diarrhea and abdominal cramps, without vomiting or fever

**CHOLERA**

Cholera is caused by *Vibrio cholerae* serogroups O1 (classic and El Tor biotypes) and O139. It is native to the Ganges delta on the Indian subcontinent, but currently >90% of cases reported to the World Health Organization (WHO) are from Africa. Spread is by fecal contamination of water and food sources. Infection requires ingestion of a relatively large inoculum (compared with other pathogens). Toxin production causes disease manifestations.

**Clinical Manifestations**

- Incubation period of 24–48 h followed by painless watery diarrhea and vomiting that can cause profound, rapidly progressive dehydration and death within hours
- “Rice-water” stool: gray, cloudy fluid with flecks of mucus

**Diagnosis**

Stool cultures on selective medium (e.g., TCBS agar)

**Cholera**

Rapid fluid replacement, preferably with WHO’s oral rehydration solution (ORS), which contains (per liter of water) Na+, 75 mmol; K+, 20 mmol; Cl−, 65 mmol; citrate, 10 mmol; and glucose, 75 mmol. If available, rice-based ORS is considered superior to standard ORS for cholera. Severely dehydrated pts should be managed initially with IV hydration; Ringer’s lactate is the best choice. A single dose of an antibiotic can be used in conjunction: doxycycline (300 mg), ciprofloxacin (30 mg/kg, not to exceed 1 g), or azithromycin (1 g).

**VIBRIO PARAHAEOMOLYTICUS AND NON-O1 V. CHOLERAE**

These infections are linked to ingestion of seawater or contaminated, undercooked seafood. After an incubation period of 4 h to 4 days, watery diarrhea, abdominal cramps, nausea, vomiting, and occasionally fever and chills develop. The disease lasts a median of 3 days. Dysentery is a less common presentation. Pts with comorbid disease (e.g., liver disease) sometimes have extraintestinal infections that require antibiotics.
NOROVIRUSES AND RELATED HUMAN CALICIVIRUSES

These viruses are common causes of traveler’s diarrhea and of viral gastroenteritis in pts of all ages as well as of epidemics worldwide, with a higher prevalence in cold-weather months. In the United States, >90% of outbreaks of nonbacterial gastroenteritis are caused by noroviruses. Very small inocula are required for infection. Thus, although the fecal-oral route is the primary mode of transmission, aerosolization, fomite contact, and person-to-person contact can also result in infection.

Clinical Manifestations  After a 24-h incubation period (range, 12–72 h), pts experience the sudden onset of nausea, vomiting, diarrhea, and/or abdominal cramps with constitutional symptoms. Stools are loose, watery, and without blood, mucus, or leukocytes. Disease lasts 12–60 h.

ONLY SUPPORTIVE MEASURES ARE REQUIRED

ROTAVIRUSES

Most rotavirus infections occur by 3–5 years of age, but adults can become infected if exposed. Reinfections are progressively less severe. Large quantities of virus are shed in the stool during the first week of infection, and transmission takes place both via the fecal-oral route and from person to person. Disease incidence peaks in the cooler fall and winter months. Rotavirus is common in both industrialized and developing nations.

Clinical Manifestations  After an incubation period of 1–3 days, disease onset is abrupt. Vomiting often precedes diarrhea (loose, watery stools without blood or fecal leukocytes), and about one-third of pts are febrile. Symptoms resolve within 3–7 days, but life-threatening dehydration is more common than with most other types of gastroenteritis.

Diagnosis  Enzyme immunoassays (EIAs) or viral RNA detection techniques, such as polymerase chain reaction, can identify rotavirus in stool samples.

ONLY SUPPORTIVE TREATMENT IS NEEDED

Prevention  A rotavirus vaccine was recommended for routine administration to U.S. infants in 2006; an earlier vaccine had been withdrawn by the U.S. Food and Drug Administration (FDA) because it was causally linked to intussusception. Disease in developing countries occurs in younger children and is more severe than in industrialized countries; further study is needed before global recommendations for vaccine use can be issued.

GIARDIASIS

*Giardia lamblia* inhabits the small intestines of humans and other mammals. Cysts are ingested from the environment, excyst in the small intestine, and release flagellated trophozoites. Infection results from as few as 10 cysts. Trans-
mission occurs via the fecal-oral route, by ingestion of contaminated food and water, or from person to person in settings with poor fecal hygiene (e.g., day-care centers, institutional settings) or via sexual contact. Standard chlorination techniques used to control bacteria do not destroy cysts. People at the extremes of age, those newly exposed, and pts with hypogammaglobulinemia are at increased risk—a pattern suggesting a role for humoral immunity in resistance.

**Clinical Manifestations**

- The incubation period lasts 5 days to 3 weeks. Disease ranges from asymptomatic carriage (most common) to fulminant diarrhea and malabsorption.
- Diarrhea, abdominal pain, bloating, belching, flatus, nausea, and vomiting last >1 week. Fever is rare, as is blood or mucus in stool.
- Chronic disease is often dominated by symptoms of malabsorption.

**Diagnosis** Giardiasis can be diagnosed by parasite antigen detection in feces and/or examination of several samples from freshly collected stool specimens, with concentration methods used to identify cysts (oval, with four nuclei) or trophozoites (pear-shaped, flattened parasites with two nuclei and four pairs of flagella).

<table>
<thead>
<tr>
<th><strong>Giardiasis</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Metronidazole (250 mg tid for 5 days) or tinidazole (2 g once)</td>
</tr>
<tr>
<td>2. Nitazoxanide (500 mg bid for 3 days)</td>
</tr>
<tr>
<td>3. In cases of treatment failure, document continued infection before re-treatment, and seek possible sources of reinfection. Repeat therapy for up to 21 days at higher doses (e.g., metronidazole at 750 mg tid).</td>
</tr>
</tbody>
</table>

**CRYSTOSPORIDIOSIS**

Cryptosporidial infection is acquired by ingestion of oocysts that subsequently excyst, enter intestinal cells, and generate oocysts that are excreted in feces. Person-to-person transmission of infectious oocysts can occur among close contacts and in day-care settings. Waterborne transmission is common. Oocysts are not killed by routine chlorination.

**Clinical Manifestations**

- Incubation period: ~1 week
- Asymptomatic infection or watery, nonbloody diarrhea, occasionally with abdominal pain, nausea, anorexia, fever, and/or weight loss lasting 1–2 weeks
- Immunocompromised hosts, especially HIV-infected pts: Disease can be chronic and can cause severe dehydration, weight loss, and wasting, with biliary tract involvement.

**Diagnosis** On multiple days, examine fecal samples for oocysts (4–5 μm in diameter, smaller than most parasites). Modified acid-fast staining, direct immunofluorescent techniques, and EIAs can enhance diagnosis.

<table>
<thead>
<tr>
<th><strong>Cryptosporidiosis</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitazoxanide: FDA-approved in tablet form for adults (500 mg bid for 3 days) and as an elixir for children. However, this drug is not effective in HIV-infected pts; improved immune status due to antiretroviral therapy can alleviate symptoms in those pts.</td>
</tr>
</tbody>
</table>
Infectious Diseases

• Supportive measures include replacement of fluid and electrolytes and use of antidiarrheal agents.

ISOSPORIASIS

*Isospora belli* infection is acquired by oocyst ingestion and is most common in tropical and subtropical countries. Acute infection can begin suddenly with fever, abdominal pain, and watery, nonbloody diarrhea and can last for weeks to months. Eosinophilia may occur. Compromised (e.g., HIV-infected) pts may have chronic disease.

**Diagnosis** Detection of large oocysts in stool by modified acid-fast staining

**Rx Isosporiasis**

Responds to trimethoprim-sulfamethoxazole (TMP-SMX; 160/800 mg qid for 10 days, then tid for 3 weeks). Pyrimethamine (50–75 mg/d) can be given to pts intolerant of TMP-SMX. Pts with AIDS may need suppressive maintenance therapy to prevent relapses.

CYCLOSPORIASIS

*Cyclospora cayetanensis* can be transmitted through water or food (e.g., basil, raspberries). Clinical symptoms include diarrhea, flulike symptoms, flatulence, and burping. Disease can be self-limited or can persist for >1 month.

**Diagnosis** Detection of oocysts in stool (studies must be specifically requested)

**Rx Cyclosporiasis**

TMP-SMX (160/800 mg bid for 1 week). Pts with AIDS may need suppressive maintenance therapy to prevent relapses.

INFLAMMATORY DIARRHEA

SALMONELLOSIS

**Etiology and Pathogenesis** Salmonellae cause infection when 10³–10⁶ organisms are ingested. Conditions that reduce gastric acidity or decrease intestinal integrity increase susceptibility to infection. Organisms penetrate the small-intestinal mucosa and traverse the intestinal layer through cells within Peyer’s patches. *S. typhi* and *S. paratyphi* survive within macrophages, then disseminate throughout the body via lymphatics, and ultimately colonize reticuloendothelial tissues. Nontyphoidal salmonellae most commonly cause gastroenteritis, invading the large- and small-intestinal mucosa and resulting in massive polymorphonuclear leukocyte infiltration.

**Epidemiology and Clinical Manifestations**

1. **Typhoid (enteric) fever:** Humans are the only hosts for *S. typhi* and *S. paratyphi* (enteric fever, typhoid fever). Disease results from ingestion of contaminated food or water and is rare in developed nations. After an incubation period of 3–21 days, prolonged fever is the most prominent symptom. Additional nonspecific symptoms include chills, headache, sweating,
cough, malaise, and arthralgias. GI symptoms are variable and can include anorexia, nausea, vomiting, and diarrhea or, less often, constipation. Abdominal pain occurs in 30–40% of pts. Physical findings include rash ("rose spots"), hepatosplenomegaly, epistaxis, and relative bradycardia. Late complications include intestinal perforation and/or GI hemorrhage due to ulceration and necrosis of infiltrated Peyer’s patches. Long-term *Salmonella* carriage in urine or stool develops in 1–4% of pts, usually in association with disease in the bladder or the biliary and GI tracts.

2. *Nontyphoidal salmonellosis*: The incidence of nontyphoidal salmonellosis in the United States is 14.7 cases per 100,000 persons, with 1.4 million cases and 400 deaths each year. Most disease is caused by *S. typhimurium* or *S. enteritidis*. Disease is acquired from multiple animal reservoirs. The main mode of transmission is from contaminated food products, such as eggs (*S. enteritidis*), poultry, undercooked meat, unpasteurized dairy products, seafood, and fresh produce. Infection is also acquired during exposure to pets, especially reptiles.

   a. *Gastroenteritis*: Nausea, vomiting, diarrhea, abdominal cramping, and fever occur 6–48 h after exposure. Diarrhea is usually loose, nonbloody, and moderate in volume, but stools are sometimes bloody. Diarrhea is usually self-limited, abating within 3–7 days, and fever resolves within 72 h in most cases. Stool cultures may remain positive for ≥4–5 weeks.

   b. *Extraintestinal infections*: Up to 5% of pts are bacteremic, and 5–10% of bacteremic pts may develop localized infections, particularly in vascular sites (e.g., aortic aneurysms). *S. choleraesuis* and *S. dublin* are unusual serotypes that cause high rates of bacteremia and invasive infection. Localized infections caused by nontyphoidal salmonellae are rare and include abscesses, meningitis, pneumonia, UTIs, and osteomyelitis (particularly in pts with sickle cell disease, hemoglobinopathies, or preexisting bone disease).

   c. *Reactive arthritis* (Reiter’s syndrome) can follow *Salmonella* gastroenteritis in persons with the HLA-B27 histocompatibility antigen.

**Diagnosis**  Positive cultures of blood, stool, or other specimens are required for diagnosis. If blood cultures are positive for nontyphoidal salmonellae, high-grade bacteremia should be ruled out by obtaining multiple blood cultures.

### Salmonellosis

1. **Typhoid fever**: A fluoroquinolone (e.g., ciprofloxacin, 500 mg PO bid) or a third-generation cephalosporin (e.g., ceftriaxone, 1–2 g/d IV or IM) for 10–14 days is recommended. For susceptible strains, a fluoroquinolone is more efficacious than a β-lactam. Dexamethasone may be of benefit in severe cases.

2. **Nontyphoidal salmonellosis**: Antibiotic treatment is not recommended in most cases. However, infants, the elderly, the immunosuppressed, and pts with cardiac, valvular, or endovascular abnormalities may require antibiotic treatment. Fluoroquinolones or third-generation cephalosporins are given until defervescence (if the pt is immunocompetent) or for 1–2 weeks (if the pt is immunocompromised). HIV-infected pts are at high risk for *Salmonella* bacteremia and should receive 4 weeks of oral quinolone therapy after 1–2 weeks of IV treatment. In cases of relapse, long-term suppression with a quinolone or TMP-SMX should be considered. Pts with endovascular infections or endocarditis should receive 6 weeks of treatment with a third-generation cephalosporin. Infected aneurysms or endovascular lesions may require surgical resection.
CAMPYLOBACTERIOSIS

Etiology Campylobacters are a common bacterial cause of gastroenteritis in the United States. Most cases are caused by *C. jejuni*.

Epidemiology Campylobacters are common commensals in the GI tract of many food animals and household pets. In the United States, ingestion of contaminated poultry accounts for 30–70% of cases. Transmission to humans occurs via contact with or ingestion of raw or undercooked food products or direct contact with infected animals.

Clinical Manifestations
1. *Gastroenteritis*: An incubation period of 2–4 days (range, 1–7 days) is followed by a prodrome of fever, headache, myalgia, and/or malaise. Within the next 12–48 h, diarrhea (with stools containing blood, mucus, and leukocytes), cramping abdominal pain, and fever develop. Most cases are self-limited, but illness persists for >1 week in 10–20% of pts and may be confused with inflammatory bowel disease.
2. *Extraintestinal infections*: Other species (e.g., *C. fetus*) can cause a similar illness or prolonged relapsing systemic disease without a primary focus in compromised pts. The course may be fulminant, with bacterial seeding of many organs, particularly vascular sites. Fetal death can result from infection in a pregnant pt.
3. Complications
   a. Severe, persistent, disseminated disease in pts with AIDS or hypogammaglobulinemia
   b. Local suppurative complications (e.g., cholecystitis)
   c. Reactive arthritis in persons with the HLA-B27 phenotype
   d. Guillain-Barré syndrome (campylobacters are associated with 20–40% of cases)

Diagnosis Confirmation of diagnosis is based on cultures of stool, blood, or other specimens on special media and/or with selective techniques (e.g., growth at 42°C).

**Campylobacteriosis**
1. Fluid and electrolyte replacement
2. Avoidance of antimotility agents, which may prolong symptoms and are associated with toxic megacolon
3. Antibiotic treatment does not benefit all pts but is indicated in cases with high fever, bloody and/or severe diarrhea, disease persistence for >1 week, or worsening symptoms.
   a. Erythromycin (250 mg qid for 5–7 days) or newer macrolides
   b. Ciprofloxacin (500 mg bid) or another fluoroquinolone for 5–7 days (although resistance is increasing)

SHIGELLOSIS AND INFECTION WITH SHIGA TOXIN-PRODUCING/ENTEROHEMORRHAGIC ESCHERICHIA COLI (STEC/EHEC)

Etiology Shigellae are small, gram-negative, nonmotile bacilli that are very closely related to *E. coli*. The four most common *Shigella* serotypes are *S. dysenteriae* type 1, *S. flexneri*, *S. boydii*, and *S. sonnei* (the cause of most shigellosis cases in the United States). There are no animal reservoirs other than higher primates. These bacteria are transmitted from person to person via the fecal-oral
route and occasionally via intermediate vectors such as food, water, flies, and fomites. Shigellosis is associated with a high rate of secondary household transmission. Shigellae survive the low pH of the gastric acid barrier, and as few as 100 organisms can cause infection. Shiga toxin and Shiga-like toxins produced by some strains of *E. coli* (including O157:H7) are important factors in disease severity. The toxins target endothelial cells and play a significant role in the microangiopathic complications of *Shigella* and *E. coli* infections, such as hemolytic-uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). *Shigella* causes extensive ulceration of the epithelial surface of the colonic mucosa.

**Clinical Manifestations**

1. Pts can remain asymptomatic, develop fever with or without watery diarrhea, or experience a progression to bloody diarrhea and dysentery characterized by small volumes of bloody, mucopurulent stools with associated severe abdominal cramping and tenesmus.

2. Without treatment, most episodes resolve in 1 week.

3. Complications
   a. Severe cases occur most often in children <5 years of age; disease may progress to toxic dilatation, colonic perforation, rectal prolapse, and death.
   b. HUS has been linked to Shiga toxin produced by *S. dysenteriae* type 1 in developing countries but is rare in industrialized countries, where *E. coli* O157:H7 is a more common cause. The syndrome is defined by a triad of microangiopathic, Coombs-negative hemolytic anemia; thrombocytopenia; and acute renal failure due to glomerular capillary thromboses.

**Diagnosis**

- Shigellosis is diagnosed directly by stool culture. STEC/EHEC infection is diagnosed by screening of stool cultures for *E. coli* strains that do not ferment sorbitol, with subsequent serotyping for O157. The yield is increased if stools contain leukocytes or blood. Most cases of bloody diarrhea in the United States are due to *E. coli* O157:H7 or *C. jejuni*.
- Tests to detect Shiga toxins or toxin genes are sensitive, specific, and rapid. This approach detects non-O157 STEC/EHEC and sorbitol-fermenting strains of O157:H7.

**Shigellosis and Infection with STEC/EHEC**

1. In the United States, because of the ready transmissibility of *Shigella*, antibiotics are recommended. Fluoroquinolones are effective (e.g., ciprofloxacin, 500 mg bid), as are ceftriaxone, azithromycin, and pivmecillinam. *S. dysenteriae* infection should be treated for 5 days and non-*dysenteriae* *Shigella* infection for 3 days. Immunocompromised pts should receive 7–10 days of treatment.

2. Antibiotic treatment for STEC/EHEC infections is controversial and may increase the incidence of HUS.

3. Rehydration usually is not needed; *Shigella* infection rarely causes significant dehydration. If required, rehydration should be oral, and nutrition should be started as soon as possible. Use of antimotility agents may prolong fever and increase the risk of HUS and toxic megacolon.

**YERSINIOSIS**

**Etiology and Clinical Manifestations**  
*Y. enterocolitica* and *Y. pseudotuberculosis* are nonmotile gram-negative rods that cause enteritis or enterocolitis with self-limited diarrhea that lasts an average of 2 weeks (especially common with *Y. en-
*Y. pseudotuberculosis* as well as mesenteric adenitis and terminal ileitis that can resemble acute appendicitis (especially common with *Y. pseudotuberculosis*). Septicemia and metastatic focal infections can occur in pts with chronic liver disease, malignancy, diabetes mellitus, and other underlying illnesses. Infection has been linked to reactive arthritis in HLA-B27-positive pts.

**Diagnosis**  
Stool culture studies for *Yersinia* must be specifically requested and require the use of special media.

### AMEBIASIS

Amebiasis is caused by *Entamoeba histolytica* and is the third most common cause of death from parasitic disease worldwide. The incidence is high in developing countries and among travelers, recent immigrants, men who have sex with men, and inmates of institutions in developed nations. Infection follows ingestion of cysts from fecally contaminated water, food, or hands. Motile trophozoites are released from cysts in the small intestine and then cause infection in the large bowel. Trophozoites may be shed in stool (in active dysentery) or encyst. Excreted cysts survive for weeks in a moist environment.

### Clinical Manifestations

- **Asymptomatic infection**: 90% of cases
- **Colitis**: Develops in 10% of pts 2–6 weeks after ingestion of infectious cysts, with lower abdominal pain, mild diarrhea, malaise, weight loss, and diffuse lower abdominal or back pain. Dysentery may develop, with daily passage of 10–12 small stools consisting mostly of blood and mucus. Fewer than 40% of pts have fever. Toxic megacolon is a rare complication.Pts taking glucocorticoids are at greater risk for severe disease. Chronic amebiasis may be confused with inflammatory bowel disease. Amebomas—inflammatory mass lesions—may develop in chronic amebic intestinal disease.
- **Extraintestinal infection**: Liver abscess is the most common type of extraintestinal infection; trophozoites invade veins to reach the liver through the portal venous system. Most pts are febrile and have right upper quadrant pain that can radiate to the shoulder, point tenderness over the liver, and right-sided pleural effusion. Fewer than one-third of pts have active diarrhea. Abscesses can also occur elsewhere (e.g., lung, brain).

**Diagnosis** Barium rapidly kills trophozoites. At least three fresh stool specimens should be examined for amebic cysts or trophozoites. Sigmoidoscopy with biopsy of ulcers (often flask-shaped) may aid in the diagnosis but poses a risk of perforation. Serologic assays (enzyme-linked immunosorbent assay and agar gel diffusion) are positive in >90% of pts with colitis, amebomas, or liver abscess. Serology reverts to negative within 6–12 months after active disease resolves. Imaging of the liver may assist in the diagnosis of liver abscess.

### Amebiasis

Iodoquinol (650 mg tid for 20 days) and paromomycin (500 mg tid for 10 days) are luminal agents that eradicate cysts in pts with colitis or liver abscess
and in asymptomatic carriers. Tissue amebicides include nitroimidazole compounds—e.g., metronidazole (750 mg PO or IV tid for 5–10 days) or tinidazole (2 g PO once)—and should be given with a luminal agent for colitis or liver abscess. A clinical response occurs within 72 h in >90% of pts with liver abscess. Aspiration of liver abscesses usually does not accelerate healing. Indications for aspiration include the need to rule out pyogenic abscess, a lack of response to treatment after 3–5 days, an imminent threat of liver- abscess rupture, or the need to prevent left-lobe abscess rupture into the pericardium.

**Clostridium Difficile-Associated Disease (CDAD)**

CDAD is the diarrheal illness most commonly diagnosed in the hospital. The disease is acquired almost exclusively in association with antimicrobial treatment, but use of proton pump inhibitors may also be a risk factor; virtually all antibiotics carry a risk of CDAD. After *C. difficile* colonizes the gut, its spores vegetate, multiply, and secrete toxin A (an enterotoxin) and toxin B (a cytotoxin), causing diarrhea and pseudomembranous colitis. Spores can persist on environmental hospital surfaces for months and on the hands of hospital personnel who do not practice adequate hand hygiene. Rates and severity of CDAD in the United States, Canada, and Europe have increased markedly in the past decade. An epidemic strain accounts for much of the increase and is characterized by production of 16–23 times as much toxin A and toxin B as is documented for control strains, by the presence of a third toxin (binary toxin), and by high-level resistance to fluoroquinolones.

**Clinical Manifestations**

- Diarrhea, with up to 20 bowel movements per day. Stools usually are not grossly bloody and are soft to watery, with a characteristic odor.
- Fever, abdominal pain, and leukocytosis are common. Pts with unexplained leukocytosis, particularly in the presence of adynamic colon, should be evaluated for CDAD.
- CDAD may become fulminant, and toxic megacolon or sepsis may develop.

**Diagnosis** If clinically suspected, CDAD should be diagnosed by means of stool studies. Stool culture for toxin-producing *C. difficile* is most sensitive; if the isolate tests positive for toxin, this test is also specific. However, the test takes at least 48 h. The cell culture cytotoxin test is specific but less sensitive and also takes 48 h. EIAs for toxin A, toxins A and B, or *C. difficile* common antigen more rapidly yield results that are moderately sensitive and specific.

**C. difficile-Associated Disease**

Primary CDAD
- Discontinue ongoing antimicrobial treatment if possible.
- Promptly initiate specific treatment for CDAD.
  - Mild to moderate CDAD: metronidazole (500 mg tid for 10 days), with extension of therapy if the clinical response is slow
  - Severe CDAD (e.g., >15,000 WBCs/μL) or failure to respond to metronidazole: vancomycin (125 mg qid PO for 10 days)

Recurrent CDAD
- Occurs in 15–30% of pts, especially affecting the elderly, pts who remain hospitalized, and pts who have already had a CDAD relapse. The first recurrence should be re-treated with metronidazole or vancomycin.
For multiple recurrences, consider a course of vancomycin treatment followed by *Saccharomyces boulardii* administration, synthetic fecal bacterial enema, or intentional colonization with a nontoxigenic strain of *C. difficile*. Alternative regimens that are sometimes successful are (1) vancomycin given in tapering doses or with pulsed dosing for 4–6 weeks and (2) sequential treatment with vancomycin followed by rifaximin (400 mg bid for 14 days). IV immunoglobulin has also been used with some success.

**Fulminant CDAD**
- Presentation of acute abdomen: ileus, marked leukocytosis
- Vancomycin, given via nasogastric tube and retention enema, plus IV metronidazole
- Surgical colectomy can be life-saving.

For a more detailed discussion, see Butterton JR, Calderwood SB: Acute Infectious Diarrheal Diseases and Bacterial Food Poisoning, Chap. 122, p. 813; Gerding DN, Johnson S: *Clostridium difficile*-Associated Disease, Including Pseudomembranous Colitis, Chap. 123, p. 818; Russo TA, Johnson JR: Diseases Caused by Gram-Negative Enteric Bacilli, Chap. 143, p. 937; Pegues DA, Miller SI: Salmonellosis, Chap. 146, p. 956; Sansonetti P, Bergounioux J: Shigellosis, Chap. 147, p. 962; Blaser MJ: Infections Due to *Campylobacter* and Related Species, Chap. 148, p. 965; Waldor MK, Keusch GT: Cholera and Other Vibrios, Chap. 149, p. 968; Dennis DT, Campbell GL: Plague and Other *Yersinia* Infections, Chap. 152, p. 980; Parashar UD, Glass RI: Viral Gastroenteritis, Chap. 183, p. 1204; and Weller PF: Protozoal Intestinal Infections and Trichomoniasis, Chap. 208, p. 1311, in HPIM-17.
SPECIFIC SYNDROMES

URETHRITIS IN MEN

Etiology and Epidemiology
• Most cases are caused by either Neisseria gonorrhoeae or Chlamydia trachomatis. Other causative organisms include Ureaplasma urealyticum, Mycoplasma genitalium, Trichomonas vaginalis, and herpes simplex virus (HSV).
• Chlamydia causes 30–40% of nongonococcal urethritis (NGU) cases. M. genitalium is the probable cause in many Chlamydia-negative cases of NGU.

Clinical Considerations
• Pts present with mucopurulent urethral discharge that can usually be expressed by milking the urethra.
• Exclude both local and systemic complications (e.g., epididymitis and disseminated gonorrhea, respectively).
• A Gram’s-stained smear of urethral exudates containing ≥5 polymorphonuclear leukocytes (PMNs)/1000× field is diagnostic of N. gonorrhoeae if positive for intracellular gram-negative diplococci. Centrifuged sediment of the day’s first 20–30 mL of voided urine can be examined instead.
• Perform tests for N. gonorrhoeae and C. trachomatis using “multiplex” nucleic acid amplification tests (NAATs) of early-morning, first-voided urine.
• Treat urethritis while test results are pending.

Urethritis in Men
• Treat gonorrhea (unless excluded) with a single dose of ceftriaxone (125 mg IM), cefpodoxime (400 mg PO), or cefixime (400 mg PO), plus treat Chlamydia with azithromycin (1 g PO once) or doxycycline (100 mg bid for 7 days); azithromycin may be more effective for M. genitalium.
• For recurrent symptoms: With reexposure, re-treat pt and partner. If no reexposure, exclude T. vaginalis (with culture or NAATs of urethral swab and early-morning, first-voided urine). Treat with metronidazole or tinidazole (2 g PO once) plus azithromycin (1 g PO once).

EPIDIDYMITIS

Etiology
• In sexually active young men, epididymitis is caused by C. trachomatis and, less commonly, by N. gonorrhoeae.
• In older men or after urinary tract instrumentation, consider urinary pathogens.
• In men who practice insertive rectal intercourse, consider Enterobacteriaceae.

Clinical Considerations
• Usually unilateral testicular pain of acute onset, intrascrotal swelling, tenderness, and fever.
• Rule out testicular torsion, tumor, and trauma.
• If symptoms persist after treatment, rule out testicular tumor and chronic granulomatous disease.

Epididymitis
• Ceftriaxone (250 mg IM once) followed by doxycycline (100 mg PO bid for 10 days)
• Fluoroquinolones are no longer recommended because of increasing resistance in *N. gonorrhoeae*.

**URETHRITIS (THE URETHRAL SYNDROME) IN WOMEN**

• Caused by *C. trachomatis*, *N. gonorrhoeae*, occasionally HSV
• Internal vs. external dysuria (the latter seen with vulvovaginitis)
• Usually no urinary urgency or frequency, distinct from bacterial cystitis
• Pyuria with culture demonstrating <100 uropathogens/mL of urine supports a diagnosis of urethral syndrome rather than cystitis.
• Evaluate *N. gonorrhoeae* or *C. trachomatis* with specific tests (e.g., NAATs on the first 10 mL of voided urine).

**VULVOVAGINAL INFECTIONS**

• Unsolicited reporting of abnormal vaginal discharge suggests trichomoniasis or bacterial vaginosis (BV).
  
  *Trichomoniasis* is characterized by vulvar irritation and a profuse, yellow, purulent, homogeneous vaginal discharge with a pH typically ≥5.0.
  
  *BV* is characterized by vaginal malodor and a slight to moderate increase in white, homogeneous vaginal discharge with a pH typically >4.5.

  *Genital herpes*, which can cause vulvar pruritus, burning, irritation, and lesions as well as external dysuria and vulvar dyspareunia, must be considered in the diagnosis.

• Vulvovaginal infections are associated with increased risk of HIV acquisition.
• Vaginal trichomoniasis and BV early in pregnancy are associated with premature onset of labor.
• Vulvovaginal candidiasis develops with increased frequency among women with systemic illnesses (e.g., diabetes, HIV disease).
• Examine abnormal vaginal discharge for pH, a fishy odor after mixing with 10% KOH (BV), evidence on microscopy of motile trichomonads and/or clue cells of BV (vaginal epithelial cells coated with coccobacillary organisms) when mixed with saline, or hyphae or pseudohyphae on microscopy when 10% KOH is added (vaginal candidiasis).
• A new DNA probe test (the Affirm test) can detect *T. vaginalis*, *Candida albicans*, and increased concentrations of *Gardnerella vaginalis*.

**Vulvovaginal Infections**

• Vulvovaginal candidiasis: miconazole (100-mg vaginal suppository) or clotrimazole (100-mg vaginal tablet) once daily for 7 days; or fluconazole (150 mg PO once)
• Trichomoniasis: metronidazole or tinidazole (2 g PO once) or metronidazole (500 mg PO bid for 7 days)
• BV: metronidazole (500 mg PO bid for 7 days) or clindamycin 2% cream (one full applicator vaginally each night for 7 days)
• Antenatal treatment of *T. vaginalis* or BV has not reduced rates of perinatal morbidity or preterm delivery.
MUCOPURULENT CERVICITIS

- Inflammation of the columnar epithelium and subepithelium of the endocervix
- “Silent partner” of urethritis in men
- Major etiologies: N. gonorrhoeae, C. trachomatis, M. genitalium. Many cases are idiopathic. HSV cervicitis produces ulcerative lesions on the exocervix.
- Yellow mucopurulent discharge from cervical os, with $\geq 20$ PMNs/1000$\times$ field on Gram’s stain of cervical mucus
- Intracellular gram-negative diplococci on Gram’s stain of cervical mucus are specific but $< 50\%$ sensitive for gonorrhea.

See “Urethritis in Men,” above.

PELVIC INFLAMMATORY DISEASE (PID)

**Definition**  
Infection ascending from the cervix or vagina to the endometrium and/or fallopian tubes (or beyond) to cause peritonitis, perihepatitis, or pelvic abscess

**Etiology**  
N. gonorrhoeae, C. trachomatis, M. genitalium, anaerobic and facultative organisms such as Prevotella spp., group B streptococci

**Epidemiology**

- Each year in the United States, PID accounts for 70,000–100,000 hospitalizations and $\sim 176,000$ visits to physicians’ offices.
- Risk factors: cervicitis, BV, vaginal douching, menstruation, intrauterine contraceptive device (IUD) use. Oral contraceptive pills decrease risk.
- N. gonorrhoeae presentation is usually more acute than that of C. trachomatis.

**Clinical Manifestations**

1. Endometritis: pain and vaginal bleeding; lower quadrant, adnexal, and cervical motion pain not severe if this is the only manifestation of PID
2. Salpingitis: bilateral lower abdominal and pelvic pain, nausea, vomiting, peritoneal signs
   a. Mucopurulent cervicitis with discharge; cervical motion, uterine, and adnexal tenderness or swelling on examination
   b. Fever (one-third of cases), elevated erythrocyte sedimentation rate (75%), elevated peripheral white blood cell count (60%)
3. Perihepatitis and periappendicitis
   a. Fitz-Hugh–Curtis syndrome: perihepatitis associated with salpingitis in 3–10% of PID cases. Chlamydia is the most common etiologic agent, but this syndrome is also caused by N. gonorrhoeae; right or bilateral upper quadrant pain, occasional hepatic friction rub
   b. Periappendicitis in $\sim 5\%$ of pts with PID due to gonococci or chlamydiae

**Diagnosis**

- Predictors of PID: pelvic pain, tenderness, endocervical discharge with increased PMNs, onset with menses, history of abnormal menstrual bleeding preceding or coincident with pain in $\sim 40\%$ of women, presence of an IUD, sexual partner with urethritis
- Perform ultrasonography or MRI if tuboovarian or pelvic abscess is a concern.
- Evaluate for pregnancy with human $\beta$-chorionic gonadotropin test.
- Unilateral pain or a pelvic mass is an indication for laparoscopy, as are atypical clinical findings or poor responses to appropriate treatment.
Section 7 Infectious Diseases

- Gram’s staining of endocervical swabs for PMNs and gram-negative diplococci; NAATs for *N. gonorrhoeae* and *C. trachomatis*; aerobic and anaerobic cultures

**Pelvic Inflammatory Disease**

Initiate empirical treatment for PID in sexually active young women and other women who are at risk for PID and who have pelvic or lower abdominal pain with no other explanation as well as cervical motion, uterine, or adnexal tenderness.

Recommendations per 2006 CDC guidelines:

1. Parenteral regimens
   a. Cefotetan (2 g IV q12h) or cefoxitin (2 g IV q6h) plus doxycycline (100 mg IV or PO q12h) until 48 h after improvement; then doxycycline (100 mg PO bid) to complete a 14-day course
   b. Alternative: clindamycin (900 mg IV q8h) plus gentamicin (2.0 mg/kg IV or IM load followed by 1.5 mg/kg q8h) until 48 h after improvement; then complete a 14-day course with either oral doxycycline (100 mg bid) or oral clindamycin (450 mg qid). Once-daily aminoglycoside dosing may be used instead.

2. Outpatient regimens: (1) ofloxacin (400 mg PO bid for 14 days) or levofloxacin (500 mg PO once daily for 14 days) plus metronidazole (500 mg PO bid for 14 days); or (2) ceftriaxone (250 mg IM once) plus doxycycline (100 mg PO bid) and metronidazole (500 mg PO bid) for 14 days. Regimen 2 is preferred because of increasing fluoroquinolone resistance in *N. gonorrhoeae*.

3. Consider hospitalization if the diagnosis is uncertain, the pt is pregnant, an abscess is suspected, the illness is severe, nausea and vomiting preclude outpatient treatment, or the pt is infected with HIV, is unlikely to follow an outpatient regimen, or has already had an unsuccessful course of outpatient treatment.

4. Evaluate in 72 h for treatment response.

**Prognosis**  
Late sequelae include infertility (11% after one episode of PID, 23% after two, and 54% after three or more); ectopic pregnancy (sevenfold increase in risk); chronic pelvic pain (eightfold increase in rate of hysterectomy); and recurrent salpingitis.

**Prevention**  
Risk-based chlamydial screening of young women can reduce PID incidence.

**Ulcerative Genital Lesions**

- See Table 90-1 and sections on individual pathogens below.
- The most common etiologies in the United States are genital herpes, syphilitic ulcers, and chancroid.
- All pts with genital ulcerations should undergo HIV serologic testing.
- Immediate treatment (before all test results are available) is often appropriate to improve response, reduce transmission, and cover pts who might not return for follow-up visits.

**Proctitis, Proctocolitis, Enterocolitis, Enteritis**

**Definitions**

- *Proctitis*: inflammation limited to rectal mucosa from direct inoculation of typical sexually transmitted disease (STD) pathogens; associated with pain, mucopurulent discharge, tenesmus, and constipation
<table>
<thead>
<tr>
<th>Feature</th>
<th>Syphilis</th>
<th>Herpes</th>
<th>Chancroid</th>
<th>Lymphogranuloma Venereum</th>
<th>Donovanosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incubation period</td>
<td>9–90 days</td>
<td>2–7 days</td>
<td>1–14 days</td>
<td>3 days–6 weeks</td>
<td>1–4 weeks (up to 6 months)</td>
</tr>
<tr>
<td>Early primary lesions</td>
<td>Papule</td>
<td>Vesicle</td>
<td>Pustule</td>
<td>Papule, pustule, or vesicle</td>
<td>Papule</td>
</tr>
<tr>
<td>No. of lesions</td>
<td>Usually one</td>
<td>Multiple</td>
<td>Usually multiple, may coalesce</td>
<td>Usually one; often not detected, despite lymphadenopathy</td>
<td></td>
</tr>
<tr>
<td>Diameter</td>
<td>5–15 mm</td>
<td>1–2 mm</td>
<td>Variable</td>
<td>2–10 mm</td>
<td>Variable</td>
</tr>
<tr>
<td>Edges</td>
<td>Sharply demarcated, elevated, round, or oval</td>
<td>Erythematous</td>
<td>Undermined, ragged, irregular</td>
<td>Elevated, round, or oval</td>
<td>Variable, irregular</td>
</tr>
<tr>
<td>Depth</td>
<td>Superficial or deep</td>
<td>Superficial</td>
<td>Excavated</td>
<td>Superficial or deep</td>
<td>Elevated</td>
</tr>
<tr>
<td>Base</td>
<td>Smooth, nonpurulent, relatively nonvascular</td>
<td>Serous, erythematous, nonvascular</td>
<td>Purulent, bleeds easily</td>
<td>Variable, nonvascular</td>
<td>Red and velvety, bleeds readily</td>
</tr>
<tr>
<td>Induration</td>
<td>Firm</td>
<td>None</td>
<td>Soft</td>
<td>Occasionally firm</td>
<td>Firm</td>
</tr>
<tr>
<td>Pain</td>
<td>Uncommon</td>
<td>Frequently tender</td>
<td>Usually very tender</td>
<td>Variable</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>Firm, nontender, bilateral</td>
<td>Firm, tender, often bilateral with initial episode</td>
<td>Tender, may suppurate, loculated, usually unilateral</td>
<td>None; pseudobuboes</td>
<td></td>
</tr>
</tbody>
</table>
• Ingestion of typical intestinal pathogens through oral-anal exposure during sexual contact can result in the following syndromes, often associated with diarrhea: (1) proctocolitis: inflammation from rectum to colon, (2) entero-colitis: inflammation involving both large and small intestine, and (3) enteritis: inflammation of small intestine alone.

Etiology and Epidemiology

• *N. gonorrhoeae*, HSV, and *C. trachomatis* are the chief causes of proctitis; symptoms are minimal and localized.
• HSV proctitis and lymphogranuloma venereum (LGV) proctocolitis can cause severe pain, fever, and systemic manifestations. Sacral nerve root radiculopathy, with urinary retention or anal sphincter dysfunction, is associated with primary HSV.
• LGV and syphilis can be associated with granulomata and inflammation.
• *Giardia lamblia* is a common cause of enteritis in men who have sex with men (MSM).
• *Campylobacter* or *Shigella* spp. can cause sexually acquired proctocolitis.

INDIVIDUAL PATHOGENS

GONORRHEA

Etiology  *N. gonorrhoeae*: gram-negative, nonmotile, non-spore-forming organisms that grow in pairs and are shaped like coffee beans

Epidemiology

• ~325,000 cases reported in the United States in 2006; actual case numbers higher
• U.S. incidence: 120 cases per 100,000 population—the highest among industrialized nations
• Attack rates are highest among sexually active 15- to 19-year-old women and 20- to 24-year-old men; rates are highest among African Americans.
• Efficient male-to-female transmission; 40–60% rate with a single unprotected encounter; 20% rate to women who practice fellatio with infected partners; chance of HIV acquisition increased if infected person also has gonorrhea
• Drug-resistant strains are widespread. Penicillin, ampicillin, and tetracycline are no longer reliable agents. Third-generation cephalosporins remain effective. Fluoroquinolone-containing regimens are no longer routinely recommended.

Clinical Syndromes

1. *Urethritis* (see above): incubation period, 2–7 days. Uncommon complications include epididymitis, prostatitis, penile edema, abscesses or fistulas, seminal vesiculitis, and balanitis if uncircumcised.
2. *Cervicitis* (see above): incubation period, ~10 days. Co-infection with *N. gonorrhoeae* and *C. trachomatis* is documented in up to 40% of genital gonococcal infections.
3. Anorectal gonorrhea: spreads from cervical exudates in women; rarely the sole site of infection or the cause of symptomatic proctitis; recent resurgence in MSM. Anorectal strains in the latter population tend to be more resistant to antibiotics than isolates from other sites.

4. Pharyngeal gonorrhea: usually asymptomatic infection resulting from oral-genital sexual exposure; transmission from the pharynx rare; almost always coexists with genital infection. Rate may increase during pregnancy because of altered sexual practices. Most cases resolve spontaneously. If symptomatic, pharyngeal gonorrhea is harder to eradicate than genital disease. Follow-up cultures are needed.

5. Ocular gonorrhea: caused by autoinoculation; swollen eyelid, hyperemia, chemosis, profuse purulent discharge, occasional corneal ulceration and perforation. Rule out associated genital infection.

6. Gonorrhea in pregnancy: Salpingitis and PID in the first trimester can cause fetal loss. Other STDs must be ruled out. Third-trimester disease can cause prolonged rupture of membranes, premature delivery, chorioamnionitis, funisitis, neonatal sepsis, and perinatal distress and death. Ophthalmia neonatorum, the most common form of gonorrhea in neonates, is preventable by prophylactic 1% silver nitrate drops, but treatment requires systemic antibiotics.

7. Gonococcal arthritis and disseminated gonococcal infection (DGI)
   a. DGI strains resist bactericidal action of human serum and often do not elicit inflammation at genital sites.
   b. Up to 13% of pts with DGI have terminal complement deficiencies.
   c. Menstruation is a risk factor for dissemination; two-thirds of pts with DGI are women.
   d. A bacteremic phase, often not clinically recognized, precedes arthritis.
   e. Arthritis presents as painful joints in conjunction with tenosynovitis, skin lesions, and polyarthralgias of knees, elbows, and distal joints. Skin lesions develop in 75% of pts and include papules and pustules, often with hemorrhage. Suppurative arthritis affects one or two joints, most often knees, wrists, ankles, and elbows.

Laboratory Diagnosis

- Intracellular gram-negative cocci in urethral discharge collected from a male pt with Dacron or rayon swabs
- Culture on Thayer-Martin or other media selective for gonococci. Process immediately or store in candle extinction jars prior to incubation. Use special transport systems or culture media with CO2-generating systems.
- A single culture of endocervical discharge has a sensitivity of 80–90%.
- A DNA probe that hybridizes gonococcal 16S ribosomal RNA has good sensitivity, particularly in high-risk men, but provides no susceptibility information.

Gonorrhea

See Table 90-2.

INFECTIONS WITH CHLAMYDIA TRACHOMATIS

Etiology

- Obligate intracellular bacteria in their own order, Chlamydiaceae
- Serovars D through K are associated with STDs. Serovars L1, L2, and L3 produce LGV. LGV strains are unique: they are unusually invasive, produce disease in lymphatic tissue, and grow in cell culture systems and macrophages.
# Table 90-2

## Recommended Treatment for Gonococcal Infections: 2006 Guidelines of the Centers for Disease Control and Prevention (Updated in 2007)

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Treatment of Choice</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uncomplicated gonococcal infection of the cervix, urethra, pharynx, or rectum</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td><strong>First-line regimens</strong>&lt;br&gt;Ceftriaxone (125 mg IM, single dose) or Cefixime (400 mg PO, single dose) plus&lt;br&gt;If chlamydial infection is not ruled out: Azithromycin (1 g PO, single dose) or Doxycycline (100 mg PO bid for 7 days)</td>
</tr>
<tr>
<td>Epididymitis</td>
<td>See text and Chap. 124, HPIM-17</td>
</tr>
<tr>
<td>Pelvic inflammatory disease</td>
<td>See text and Chap. 124, HPIM-17</td>
</tr>
<tr>
<td>Gonococcal conjunctivitis in an adult</td>
<td>Ceftriaxone (1 g IM, single dose)&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ophthalmia neonatorum&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Ceftriaxone (25–50 mg/kg IV, single dose, not to exceed 125 mg)</td>
</tr>
<tr>
<td>Disseminated gonococcal infection&lt;sup&gt;f&lt;/sup&gt;</td>
<td><strong>Initial therapy</strong>&lt;br&gt;Patients tolerant of β-lactam drugs&lt;br&gt;Ceftriaxone (1 g IM or IV q24h; recommended) or Cefotaxime (1 g IV q8h) or Cefotizoxime (1 g IV q8h) or Spectinomycin (2 g IM q12h)&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Meningitis or endocarditis</td>
<td>See Chap. 137, HPIM-17&lt;sup&gt;h&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>True failure of treatment with a recommended regimen is rare and should prompt an evaluation for reinfection or consideration of an alternative diagnosis.

<sup>b</sup>Spectinomycin, cefotetan, and cefoxitin, which are alternative agents, currently are unavailable or in short supply in the United States.

<sup>c</sup>Spectinomycin may be ineffective for the treatment of pharyngeal gonorrhea.

<sup>d</sup>Plus lavage of the infected eye with saline solution (once).

<sup>e</sup>Prophylactic regimens are discussed in Chap. 137, HPIM-17.

<sup>f</sup>Hospitalization is indicated if the diagnosis is uncertain, if the pt has frank arthritis with an effusion, or if the pt cannot be relied on to adhere to treatment.

<sup>g</sup>All initial regimens should be continued for 24–48 h after clinical improvement begins, at which time therapy may be switched to one of the continuation regimens to complete a full week of antimicrobial treatment. Treatment for chlamydial infection (as above) should be given if this infection has not been ruled out.

<sup>h</sup>Hospitalization is indicated to exclude suspected meningitis or endocarditis.
Sexually Transmitted Diseases

CHAPTER 90

Epidemiology
- Most common STDs in the United States; ~4 million cases per year
- Clinical spectrum paralleling that of *N. gonorrhoeae* infections
- Asymptomatic or mild clinical disease more common, but morbidity greater with *Chlamydia* than with *N. gonorrhoeae*
- *C. trachomatis* has been identified in the fallopian tubes or endometrium of up to half of women with PID. Infertility due to fallopian tube scarring has been strongly linked to antecedent *C. trachomatis* infection.

Clinical Syndromes
1. Urethritis, epididymitis, cervicitis, salpingitis, PID, and proctitis (discussed above)
2. Associated with Reiter’s syndrome (conjunctivitis, urethritis or cervicitis, arthritis, mucocutaneous lesions). *C. trachomatis* is recovered from the urethra of up to 70% of men with nondiarrheal Reiter’s and associated urethritis. More than 80% of pts have the HLA-B27 phenotype.
3. LGV: The primary genital lesion is noted in about one-third of heterosexual men and occasionally in women. See Table 90-1 for clinical details. LGV is associated with systemic symptoms. Painful adenopathy above and below the inguinal ligament presents with the “sign of the groove.”

Diagnosis
- Four laboratory procedures are available for diagnosis:
  - Direct microscopic examination of tissue scrapings (low sensitivity except in conjunctivitis and frequent false-positive results)
  - Isolation of the organism in cell culture: low sensitivity, high cost
  - Nonculture techniques: direct immunofluorescent antibody (DFA) slide tests; enzyme-linked immunosorbent assay; NAATs using polymerase chain reaction (PCR), ligase chain reaction (LCR), or transcription-mediated amplification (TMA). Tests surpass culture in sensitivity and allow use of urine specimens rather than urethral or cervical swabs.
  - Detection of antibody in serum or in local secretions: of limited usefulness except in LGV

Infections with *Chlamydia trachomatis*
- See “Specific Syndromes,” above.
- LGV: doxycycline (100 mg PO bid) or erythromycin base (500 mg PO qid) for at least 3 weeks

INFECTIONS DUE TO MYCOPLASMAS

Etiology and Epidemiology
- Smallest free-living organisms known; lack a cell wall; resist in vitro cultivation
- *M. genitalium* and ureaplasmas (*U. parvum* and *U. urealyticum*) cause urethritis and other genital conditions; *M. hominis* and ureaplasmas are part of the complex flora of BV.
- Higher colonization rates in disadvantaged populations

Clinical Syndromes and Diagnosis
- Cause NGU and BV; associated with PID and tubal factor infertility
- Can be associated with reactive arthritis and Reiter’s syndrome, which are usually due to *C. trachomatis*
• The ubiquity of the organisms in the lower genital tract makes isolation attempts unnecessary in most cases. Microbiologic diagnosis is beyond the capability of most laboratories. NAATs have been developed.

**Infections Due to Mycoplasmas**

Current recommendations for treatment of NGU and PID are appropriate for genital mycoplasmas.

**SYPHILIS**

**Etiology and Epidemiology**

• Caused by *Treponema pallidum* subspecies *pallidum*, a thin, delicate organism with 6–14 spirals and tapered ends (6–15 μm long, 0.2 μm wide)

• Cases acquired by sexual contact with infectious lesions (chancre, mucous patch, skin rash, condyloma latum); nonsexual acquisition through close personal contact, infection in utero, blood transfusion, organ transplantation

• 33,278 reported cases in the United States in 2005

• High-risk populations include MSM, many of whom are co-infected with HIV. Rates among heterosexual African Americans in urban areas peaked in 1990, are now declining, but remain higher than for other racial/ethnic groups.

• One-half of sexual contacts of persons with infectious syphilis become infected. All recently exposed sexual contacts are treated.

**Pathogenesis** Untreated syphilis penetrates intact mucous membranes or microscopic abrasions, entering lymphatics and blood within hours. Systemic infection and metastatic foci result. The primary lesion appears at the site of inoculation within 4–6 weeks and heals spontaneously. Generalized parenchymal [central nervous system (CNS), liver, lymph node], constitutional, and mucocutaneous manifestations of secondary syphilis appear 6–8 weeks later despite high antibody titers, subsiding in 2–6 weeks. A latent period follows. One-third of pts eventually develop tertiary disease (syphilitic gummas, cardiovascular disease, neurologic disease); one-quarter of those pts die.

**Clinical Manifestations**

1. **Primary**: chancre at site of inoculation (penis, rectum or anal canal, mouth, cervix, labia). See Table 90-1 for clinical details. Adenopathy can persist long after the chancre heals. Serology can be negative; tests should be repeated in 1–2 weeks.

2. **Secondary**: diffuse mucocutaneous lesions of variable morphologies, generalized nontender lymphadenopathy. Primary chancre may still be present. Initial lesions are bilaterally symmetric, pale red or pink, nonpruritic macules that progress to papules and may become necrotic. Lesions are widely distributed over the trunk and extremities, including the palms and soles. In moist intertriginous areas, papules can enlarge and erode to produce broad, highly infectious lesions called *condylomata lata*. Superficial mucosal erosions are called *mucous patches*. Constitutional symptoms are often present. The CNS is seeded by organisms in ≥30% of cases, although no clinical meningitis is evident. Less common findings include hepatitis, nephropathy, arthritis, optic neuritis, and anterior uveitis.

3. **Latent**: positive syphilis serology without clinical manifestations. Early latent syphilis develops within the first year of infection. Late latent syphilis, which develops >1 year after infection, is unlikely to cause infectious relapse. However, women with latent syphilis can infect the fetus in utero.
4. Late
   a. CNS disease: a continuum throughout syphilis. Asymptomatic cerebrospinal fluid (CSF) abnormalities exist in up to 40% of pts with primary or secondary syphilis and in 25% of those with latent disease. Symptomatic neurosyphilis develops only in this subset. Meningeal findings, including headache, nausea, vomiting, change in mental status, and neck stiffness, often with associated uveitis or iritis, present within 1 year of infection. Meningovascular involvement (5–10 years after infection) usually presents as a subacute encephalitic prodrome and is followed by a gradually progressive vascular syndrome. Parenchymatous involvement presents at 20 years for general paresis and 25–30 years for tabes dorsalis. A general mnemonic for paresis is personality, affect, reflexes (hyperactive), eye (Argyll Robertson pupils, which react to accommodation but not to light), sensorium (illusions, delusions, hallucinations), intellect (decrease in recent memory and orientation, judgment, calculations, insight), and speech. Tabes dorsalis is a demyelination of posterior columns, dorsal roots, and dorsal root ganglia, with ataxic, wide-based gait and foot slap; paresthesia; bladder disturbances; impotence; areflexia; and loss of position, deep pain, and temperature sensations. Trophic joint degeneration (Charcot’s joints), optic atrophy, and Argyll Robertson pupils are also present.
   b. Cardiovascular syphilis: About 10% of pts with untreated late latent syphilis develop cardiovascular symptoms 10–40 years later. Endarteritis obliterans of the vasa vasorum providing the blood supply to large vessels results in aortitis, aortic regurgitation, saccular aneurysm, and coronary ostial stenosis.
   c. Late benign syphilis (gumma): usually solitary lesions showing granulomatous inflammation with central necrosis; found most often in the skin and skeletal system, mouth, upper respiratory tract, liver, and stomach

5. Congenital: Syphilis can be transmitted throughout pregnancy. Lesions begin to be manifest in the fetus at ~4 months of gestation. All pregnant women should be tested for syphilis early in pregnancy.

Diagnosis
• Dark-field microscopy or immunofluorescence antibody staining of exudates from most lesions (e.g., chancres or condylomata lata) is rarely available today.
• Nontreponemal serologic tests that measure IgG and IgM directed against a cardiolipin-lecithin-cholesterol antigen complex [e.g., rapid plasma reagin (RPR), Venereal Disease Research Laboratory (VDRL)]
• Treponemal serologic tests: agglutination assay (e.g., the Serodia TP-PA test) and the fluorescent treponemal antibody–absorbed (FTA-ABS) test. Results remain positive even after successful treatment.
• Three uses of serology: screening or diagnosis, quantitation of titers (e.g., with RPR) to monitor response to treatment, and confirmation of the diagnosis in a pt with a positive nontreponemal test
• Lumbar puncture (LP) is recommended for pts with syphilis and neurologic signs or symptoms, other late syphilis manifestations, or suspected treatment failure and for HIV-infected pts with untreated syphilis of unknown or >1 year’s duration. CSF exam demonstrates pleocytosis and increased protein. A positive CSF VDRL test is specific but not sensitive; an unabsorbed FTA test is sensitive but not specific. A negative unabsorbed FTA test excludes neurosyphilis.
• Pts with syphilis should be evaluated for HIV disease.
## Table 90-3: Recommendations for the Treatment of Syphilis

<table>
<thead>
<tr>
<th>Stage of Syphilis</th>
<th>Patients without Penicillin Allergy</th>
<th>Patients with Confirmed Penicillin Allergy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary, secondary, or early latent</td>
<td>Penicillin G benzathine (single dose of 2.4 mU IM)</td>
<td>Tetracycline hydrochloride (500 mg PO qid) or doxycline (100 mg PO bid) for 2 weeks</td>
</tr>
<tr>
<td>Late latent (or latent of uncertain duration), cardiovascular, or benign tertiary</td>
<td>Lumbar puncture CSF normal: Penicillin G benzathine (2.4 mU IM weekly for 3 weeks) CSF abnormal: treat as neurosyphilis</td>
<td>Lumbar puncture CSF normal and pt not infected with HIV: Tetracycline hydrochloride (500 mg PO bid) for 4 weeks CSF normal and pt infected with HIV: Desensitization and treatment with penicillin if compliance cannot be ensured CSF abnormal: treat as neurosyphilis</td>
</tr>
<tr>
<td>Neurosyphilis (asymptomatic or symptomatic)</td>
<td>Aqueous penicillin G (18–24 mU/d IV, given as 3–4 mU q4h or continuous infusion for 10–14 days) or Aqueous penicillin G procaine (2.4 mU/d IM) plus oral probenecid (500 mg qid), both for 10–14 days</td>
<td>Desensitization and treatment with penicillin</td>
</tr>
<tr>
<td>Syphilis in pregnancy</td>
<td>According to stage</td>
<td>Desensitization and treatment with penicillin</td>
</tr>
</tbody>
</table>

*See Chap. 162, HPIM-17, for full discussion of syphilis therapy in HIV-infected individuals. Note: mU, million units; CSF, cerebrospinal fluid. Source: These recommendations are based on those issued by the Centers for Disease Control and Prevention in 2006.*

### Syphilis

See Table 90-3.

- Jarisch-Herxheimer reaction: a dramatic reaction to treatment most commonly seen with initiation of therapy for primary (~50% of pts) or secondary (~90%) syphilis. The reaction is associated with fever, chills, myalgias, tachycardia, headache, tachypnea, and vasodilation. Symptoms subside within 12–24 h without treatment.
- Response to treatment should be monitored with RPR or VDRL titers at 6 and 12 months (every 3 months in HIV-infected persons) in early syphilis and at 6, 12, and 24 months in late or latent syphilis. If the titer rises fourfold or fails to fall fourfold in primary or secondary syphilis or in pts with
latent or late syphilis whose initial titers are $\geq 1:32$, or if symptoms persist or recur, the pt should be re-treated and evaluated with LP to exclude neurosyphilis. In treated neurosyphilis, CSF cell counts should be monitored every 6 months for 2 years or until normal, and quantitative RPR or VDRL should be monitored every 6 months for 2 years.

**HERPES SIMPLEX VIRUS INFECTIONS**

**Etiology and Epidemiology**
- HSV is a linear, double-strand DNA virus.
- More than 90% of adults in the United States have antibodies to HSV-1 by age 50; ~20% of the U.S. population has antibodies to HSV-2.
- Unrecognized carriage of HSV-2 and frequent asymptomatic reactivations of virus from the genital tract foster the continued spread of HSV disease.
- Genital lesions caused by HSV-1 have lower recurrence rates in the first year (~55%) than those caused by HSV-2 (~90%).

**Clinical Manifestations**
See Table 90-1 for clinical details. First episodes of genital herpes can be associated with fever, headache, malaise, and myalgias. More than 80% of women with primary genital herpes have cervical or urethral involvement. Local symptoms include pain, dysuria, vaginal and urethral discharge, and tender inguinal lymphadenopathy.

**Diagnosis**
- Staining of scrapings with Wright’s or Giemsa’s (Tzanck preparation) to detect giant cells or intranuclear inclusions is well described, but most clinicians are not skilled in these techniques, which furthermore do not differentiate between HSV and varicella-zoster virus.
- Isolation of HSV in tissue culture or demonstration of HSV antigens or DNA in scrapings from lesions is the most accurate diagnostic method. PCR is increasingly being used for detection of HSV DNA and is more sensitive than culture at mucosal sites.

**Rx Herpes Simplex Virus Infections**
- **First episodes**: acyclovir (400 mg tid), valacyclovir (1 g bid), or famciclovir (250 mg bid) for 7–14 days
- **Recurrent episodes**: acyclovir (800 mg tid for 2 days), valacyclovir (500 mg bid for 3 days), or famciclovir (750 or 1000 mg bid for 1 day, 1500 mg once, or 500 mg stat followed by 250 mg q12h for 3 days); alternatively, acyclovir (200 mg 5 times per day), valacyclovir (500 mg bid), or famciclovir (125 mg bid) for 5 days
- **Suppression**: acyclovir (400 mg bid or 800 mg qd), famciclovir (250 mg bid), or valacyclovir (500 mg qd for pts with <9 episodes per year; otherwise, 1 g qd or 500 mg bid)
- Once-daily valacyclovir reduces transmission of HSV-2 between sexual partners and is more effective than famciclovir at reducing subclinical shedding.

**CHANCROID (HAEMPHILUS DUCREYI INFECTION)**

**Epidemiology**
Significant problem in developing countries, increasing incidence in the United States, associated with HIV infection because of genital ulcerations.
Infectious Diseases

SECTION 7

Clinical Manifestations  
See Table 90-1 for clinical details.

Diagnosis  
PCR or culture for *H. ducreyi*

**Chancroid (Haemophilus ducreyi Infection)**

Azithromycin (1 g PO once), ciprofloxacin (500 mg PO bid for 3 days), ceftriaxone (250 mg IM once), or erythromycin base (500 mg tid for 1 week)

**Donovanosis (Klebsiella Granulomatis Infection)**

Etiology and Epidemiology  
Also known as *granuloma inguinale* and *granuloma venereum*, donovanosis is caused by *Klebsiella granulomatis*. The infection is endemic in the Caribbean, southern Africa, and southeastern India and among Aborigines in Australia. Fewer than 20 cases are reported annually in the United States.

Clinical Manifestations, Diagnosis, and Treatment  
See Table 90-1 for clinical manifestations. Lesions slowly enlarge, causing genital swelling (especially of the labia), with occasional progression to pseudoelephantiasis. Extragenital lesions occur in 6% of pts. Diagnosis is based on identification of typical intracellular Donovan bodies within large mononuclear cells in smears from lesions or biopsy specimens. PCR and serology are also available. Pts should be treated with azithromycin (500 mg/d or 1 g weekly until healing of lesions—usually 3–5 weeks). Doxycycline (100 mg bid) is an alternative.

**Human Papillomavirus (HPV) Infections**

Etiology  
Papillomaviruses are nonenveloped, double-strand DNA viruses with icosahedral capsids composed of 72 capsomers. HPV-6 and HPV-11 are associated with anogenital warts (condylomata acuminata). HPV types 16, 18, 31, 33, and 45 have been most strongly associated with cervical cancers. Most infections, including those with oncogenic types, are self-limited.

Clinical Manifestations  
• Incubation period of 3–4 months (range, 1 month to 2 years)
• Common warts and plantar warts
• Anogenital warts on the skin and mucosal surfaces of genitalia and perianal areas

Diagnosis  
• Direct visualization (may be aided by application of 3–5% acetic acid solution to lesions)
• Papanicolaou smears from cervical or anal scrapings show cytologic evidence of HPV infection.
• PCR or hybrid-capture assay of lesions

**Human Papillomavirus Infections**

Many lesions resolve spontaneously. Current treatment is not completely effective, and some agents have significant side effects. Provider-administered therapy can include cryotherapy, podophyllin resin (10–25%), trichloroacetic acid or bichloroacetic acid (80–90%), surgical excision, intralesionally administered interferon, or laser surgery. Pt-administered therapy consists of podofilox (0.5% solution or gel) or imiquimod (topically applied interferon inducer; 5% cream).
Prevention  A quadrivalent vaccine containing HPV types 6, 11, 16, and 18 is recommended for administration to girls and young women 9–26 years of age. HPV types 6 and 11 cause 90% of anogenital warts, and HPV types 16 and 18 cause 70% of cervical cancers. Because 30% of cervical cancers are caused by HPV types not included in the vaccine, no changes in clinical cancer-screening programs are currently recommended.


Infections of the Skin, Soft Tissues, Joints, and Bones

SKIN AND SOFT TISSUE INFECTIONS

Skin and soft tissue infections are diagnosed principally by a careful history (e.g., temporal progression, travel, animal exposure, bites, trauma, underlying medical conditions) and physical examination (appearance of lesions and distribution). Types of skin and soft tissue manifestations include the following:

1. Vesicles: Due to proliferation of organisms, usually viruses, within the epidermis (e.g., varicella; herpes simplex; infections with coxsackievirus, poxviruses, Rickettsia akari). Molluscum contagiosum is a poxvirus infection transmitted by close contact, including sexual intercourse. This virus causes distinctive proliferative skin lesions that are 2–5 mm in diameter, pearly, flesh-colored, and umbilicated with a dimple at the center. Lack of inflammation and necrosis distinguishes these lesions from other poxvirus lesions.

2. Bullae: Caused by toxin-producing organisms. Different entities affect different skin levels; for example, staphylococcal scalded-skin syndrome and toxic epidermal necrolysis cause cleavage of the stratum corneum and the stratum germinativum, respectively. Bullae are also seen in necrotizing fasciitis, gas gangrene, and Vibrio vulnificus infection in pts with cirrhosis who have ingested contaminated raw seafood or been exposed to Gulf of Mexico or Atlantic seaboard waters.

3. Crusted lesions: Impetigo caused by either Streptococcus pyogenes (impetigo contagiosa) or Staphylococcus aureus (bullous impetigo) usually starts with a bullous phase before crusting. Epidemics of impetigo caused by methicillin-resistant S. aureus (MRSA) have been reported. It is important to recognize impetigo contagiosa because of its relation to poststreptococcal
glomerulonephritis. Crusted lesions are also seen in some systemic fungal infections, dermatophytic infections, and cutaneous mycobacterial infection.

4. Folliculitis: Localized infection of hair follicles is usually due to *S. aureus*. “Hot-tub folliculitis” is a diffuse condition caused by *Pseudomonas aeruginosa*. Freshwater avian schistosomes cause swimmer’s itch.

5. Papular and nodular lesions: Can be caused by *Bartonella* (cat-scratch disease), *Treponema pallidum*, papillomavirus, mycobacteria, and helminths.

6. Ulcers, with or without eschars: Can be caused by cutaneous anthrax, ulceroglandular tularemia, plague, mycobacterial infection, and (in the case of genital lesions) chancroid or syphilis.

7. Erysipelas: Lymphangitis of the dermis, with abrupt onset of fiery red swelling of the face or extremities, well-defined indurated margins, intense pain, and rapid progression. *S. pyogenes* is the exclusive cause (see Chap. 94).

**CELLULITIS**

**Definition** Cellulitis, an acute inflammatory condition of the skin, is characterized by localized pain, erythema, swelling, and heat.

**Etiology**
- May be caused by indigenous skin flora (e.g., *S. aureus*, *S. pyogenes*). *S. aureus* cellulitis spreads from a central localized infection site. *S. pyogenes* can cause a rapidly spreading, diffuse process, often with fever and lymphangitis; recurrent episodes occur in association with chronic venous stasis and lymphedema. Group B streptococcal cellulitis is associated with older age, diabetes, and peripheral vascular disease.
- May also be caused by exogenous bacteria. A thorough history and epidemiologic data may help identify the cause—e.g., *Pasteurella multocida* after a cat or dog bite; *Capnocytophaga canimorsus* after a dog bite; *Eikenella corrodens* after a human bite; *P. aeruginosa* in association with ecthyma gangrenosum in neutropenic pts, a penetrating injury (stepping on a nail), or “hot-tub” folliculitis; *Aeromonas hydrophila* after a laceration sustained in fresh water; or *Erysipelothrix rhusiopathiae* after contact with domestic swine and fish.

**Diagnosis** If there is a wound or portal of entry, Gram’s staining and culture may identify the etiology. If both a wound and a portal of entry are lacking, aspiration or biopsy of the leading edge of the cellulitis tissue yields a diagnosis in only about one-fifth of cases.

- **Cellulitis**

  See Table 91-1. A typical course is 2 weeks long. IV therapy is usually given until inflammation and systemic signs and symptoms have improved.

**NECROTIZING FASCIITIS**

**Definition** Necrotizing fasciitis is caused by either *S. pyogenes* or mixed aerobic and anaerobic bacteria, usually of GI or genitourinary origin. Strains of MRSA have been implicated as a cause of necrotizing fasciitis. Infection, either apparent or inapparent, results from a breach in integrity of skin or mucous membrane barriers.

**Clinical Features**
- Onset of severe pain and fever, with minimal physical findings; rapid progression to swelling; brawny edema; dark red induration; bullae; friable, necrotic skin.
<table>
<thead>
<tr>
<th>Diagnosis/Condition</th>
<th>Primary Treatment</th>
<th>Alternative Treatment</th>
<th>See Also HPIM-17 Chap(s.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Animal bite (prophylaxis or early infection)</td>
<td>Amoxicillin/clavulanate, 875/125 mg PO bid</td>
<td>Doxycycline, 100 mg PO bid</td>
<td>e15</td>
</tr>
<tr>
<td>Animal bite (established infection)</td>
<td>Ampicillin/sulbactam, 1.5–3.0 g IV q6h</td>
<td>Clindamycin, 600–900 mg IV q8h plus Ciprofloxacin, 400 mg IV q12h or Cefoxitin, 2 g IV q6h</td>
<td>e15</td>
</tr>
<tr>
<td>Bacillary angiomatosis</td>
<td>Erythromycin, 500 mg PO qid</td>
<td>Doxycycline, 100 mg PO bid</td>
<td>153</td>
</tr>
<tr>
<td>Herpes simplex (primary genital)</td>
<td>Acyclovir, 400 mg PO tid for 10 days</td>
<td>Famiciclovir, 250 mg PO tid for 5–10 days or Valacyclovir, 1000 mg PO bid for 10 days</td>
<td>172, 173</td>
</tr>
<tr>
<td>Herpes zoster (immunocompetent host &gt;50 years of age)</td>
<td>Acyclovir, 800 mg PO 5 times daily for 7–10 days</td>
<td>Famiciclovir, 500 mg PO tid for 7–10 days or Valacyclovir, 1000 mg PO bid for 7 days</td>
<td>173</td>
</tr>
<tr>
<td>Cellulitis (staphylococcal or streptococcal b,c)</td>
<td>Nafcillin or oxacillin, 2 g IV q4–6h</td>
<td>Cefazolin, 1–2 g q8h plus Ampicillin/sulbactam, 1.5–3.0 g IV q6h or Erythromycin, 0.5–1.0 g IV q6h or Clindamycin, 600–900 mg IV q8h</td>
<td>129, 130</td>
</tr>
<tr>
<td>MRSA skin infection d</td>
<td>Vancomycin, 1 g IV q12h</td>
<td>Linezolid, 600 mg IV q12h</td>
<td>129</td>
</tr>
<tr>
<td>Necrotizing fasciitis (group A streptococcal b)</td>
<td>Clindamycin, 600–900 mg IV q6–8h plus Penicillin G, 4 million units IV q4h</td>
<td>Clindamycin, 600–900 mg IV q6–8h plus Cefalosporin (first- or second-generation)</td>
<td>130</td>
</tr>
</tbody>
</table>

(continued)
Infectious Diseases

SECTION 7

• Thrombosis of blood vessels in dermal papillae leads to ischemia of peripheral nerves and anesthesia of the affected area.
• Infection spreads to deep fascia and along fascial planes through venous channels and lymphatics.
• Pts are toxic and develop shock and multiorgan failure.

Diagnosis

Diagnosis is based on clinical presentation. Other findings may include (1) renal failure, often preceding shock and hypotension; (2) gas in tissue (in mixed infections but rarely with \textit{S. pyogenes}); and (3) markedly elevated serum creatine phosphokinase levels.

Necrotizing Fasciitis

• Emergent surgical exploration to deep fascia and muscle, with removal of necrotic tissue.
• For antibiotic choices, see Table 91-1.
MYOSITIS/MYONECROSIS

Definitions
- **Myositis**: can be caused by viruses (influenza virus, dengue virus, coxsackievirus), parasites (*Trichinella*, cysticerci, *Toxoplasma*), or bacteria (*clostridia*, streptococci). This condition usually manifests with myalgias, but pain can be severe in coxsackievirus, *Trichinella*, and bacterial infections.
- **Pyomyositis**: localized muscle infection, usually due to *S. aureus*.
- **Myonecrosis**: caused by clostridial species (*C. perfringens*, *C. septicum*, *C. histolyticum*) or by mixed aerobic and anaerobic bacteria. Myonecrosis is usually related to trauma; however, spontaneous gangrene—usually due to *C. septicum*—can occur in pts with neutropenia, GI malignancy, or diverticulosis. Myonecrosis occurs with necrotizing fasciitis in ~50% of cases.

Diagnosis and Treatment
- Emergent surgical intervention to remove necrotic tissue, visualize deep structures, obtain materials for culture and sensitivity testing, and reduce compartment pressure.
- Empirical antibiotic treatment should target likely etiologies—e.g., vancomycin (1 g IV every 12 h) for pyomyositis and ampicillin/sulbactam (2–3 g IV every 6 h) for mixed aerobic-anaerobic infections. For treatment of clostridial myonecrosis (gas gangrene), see Table 91-1.

INFECTION ARTHRITIS

Joints become infected by hematogenous seeding (the most common route), by spread from a contiguous site of infection, or by direct inoculation (e.g., during trauma or surgery).

Etiology and Clinical Features
- **Children <5 years**: *S. aureus*, *S. pyogenes*, *Kingella kingae*
- **Young adults**: *Neisseria gonorrhoeae*, *S. aureus*
- **Adults**: *S. aureus*, *N. gonorrhoeae*, gram-negative bacilli, pneumococci, streptococci (groups A, B, C, F, and G)

**Nongonococcal Bacterial Arthritis**  
Risk is increased in pts with rheumatoid arthritis, diabetes mellitus, glucocorticoid therapy, hemodialysis, malignancy, and IV drug use. An extraarticular focus is found in ~25% of pts. 
In 90% of pts, one joint is involved—most often the knee, which is followed in frequency by the hip, shoulder, wrist, and elbow. IV drug users often have spinal, sacroiliac, or sternoclavicular joint involvement. Pts have moderate to severe pain, effusion, decreased range of motion, and fever. Gram-positive cocci (most commonly *S. aureus*, followed by streptococci of groups A and G) cause 75% of cases.

**Gonococcal Arthritis**  
Women are more likely than men to develop disseminated gonococcal disease, particularly during menses and during pregnancy (see Chap. 90). True gonococcal arthritis usually affects a single joint: hip, knee, ankle, or wrist.

**Prosthetic Joint Infection**
- Complicates 1–4% of joint replacements
- Usually acquired intra- or perioperatively
- Acute presentations are seen in infections caused by *S. aureus*, pyogenic streptococci, and enteric bacilli.
- Indolent presentations are seen in infections caused by coagulase-negative staphylococci and diphtheroids.
Miscellaneous Etiologies  Other causes of septic arthritis include Lyme disease, tuberculosis and other mycobacterial infections, fungal infections (coccidioidomycosis, histoplasmosis), and viral infections (rubella, mumps, hepatitis B, parvovirus infection).

Reiter’s Arthritis  Reiter’s arthritis follows ~1% of cases of nongonococcal urethritis and 2% of enteric infections due to Yersinia enterocolitica, Shigella flexneri, Campylobacter jejuni, and Salmonella species in genetically susceptible pts.

Diagnosis  Infection of the joint is evidenced by clinical signs and symptoms. Examination of synovial fluid from the affected joint is essential. *Normal* synovial fluid contains <180 cells (mostly mononuclear)/μL. Acute bacterial infection of joints results in synovial fluid cell counts averaging 100,000/μL (range, 25,000–250,000/μL), with >90% polymorphonuclear leukocytes (PMNs). Synovial fluid in gonococcal arthritis contains >50,000 cells/μL, but results of Gram’s staining are usually negative, and cultures of synovial fluid are positive in <40% of cases. Other mucosal sites should be cultured to diagnose gonorrhea. Pts with septic arthritis due to mycobacteria or fungi can have 10,000–30,000 cells/μL in synovial fluid, with 50–70% PMNs. Synovial fluid cell counts in noninfectious inflammatory arthritides are typically 30,000–50,000/μL.

Gram’s staining of synovial fluid should be performed, and injection into blood culture bottles can increase the yield of synovial fluid cultures. Fluid should be examined for crystals to rule out gout or pseudogout, and an attempt should be made to identify the extraarticular source of hematogenous seeding.

Blood for cultures should be taken before initiation of antibiotic therapy. Blood cultures are positive in up to 50% of cases due to *S. aureus* but are less commonly positive with other organisms.

Plain radiographs show soft tissue swelling, joint space widening, and displacement of tissue planes by distended capsule. Narrowing of the joint space and bony erosions suggest advanced disease.

**Infectious Arthritis**

Drainage of pus and necrotic debris is needed to cure infection and to prevent destruction of cartilage, postinfectious degenerative arthritis, and joint deformity or instability.

Empirical antibiotics can include oxacillin (2 g every 4 h) if gram-positive cocci are seen in synovial fluid; vancomycin (1 g every 12 h) if MRSA is a concern; or ceftriaxone (1 g q24h) if no organism is evident (to cover community-acquired organisms). In IV drug users, treatment for gram-negative organisms such as *P. aeruginosa* should be considered. After definitive diagnosis, treatment should be adjusted. Treatment for *S. aureus* should be given for 4 weeks, that for enteric gram-negative bacilli for 3–4 weeks, and that for pneumococci or streptococci for 2 weeks. Treatment of gonococcal arthritis should commence with ceftriaxone (1 g/d) until improvement and can be completed with an oral fluoroquinolone (e.g., ciprofloxacin, 500 mg bid). If fluoroquinolone resistance is not prevalent, a fluoroquinolone can be given for the entire course.

Prosthetic joint infections should be treated with surgery and high-dose IV antibiotics for 4–6 weeks. The prosthesis often has to be removed; to avoid joint removal, antibiotic suppression of infection may be tried. A 3- to 6-month course of ciprofloxacin and rifampin has been successful in *S. aureus* prosthetic joint infections of relatively short duration.
OSTEOMYELITIS

Definitions
1. **Osteomyelitis**: infection of bone caused by pyogenic bacteria and mycobacteria that gain access to bone by the hematogenous route (20% of cases, primarily in children), via direct spread from a contiguous focus of infection, or by a penetrating wound
2. **Sequestra**: ischemic necrosis of bone resulting in the separation of large devascularized bone fragments; caused when pus spreads into vascular channels
3. **Involucrum**: elevated periosteal deposits of new bone around a sequestrum

Clinical Features  
**Acute Hematogenous Osteomyelitis**  
This condition usually involves a single bone (long bones in children), presenting as an acute febrile illness with localized pain and tenderness. Restriction of movement or difficulty bearing weight is often evident. Infection may extend to joint spaces. In adults, vertebral bodies are most often involved. Organisms seed the end plate and extend into the disk space and thence to adjacent vertebral bodies. A prior history of degenerative disease or trauma is common. Diabetic pts, pts undergoing hemodialysis, and IV drug users are at increased risk. Bacteremic infections or UTIs are common sources in older men. The lumbar and cervical spine is often involved in pyogenic infections and the thoracic spine in tuberculosis. Pts can present either acutely, with ongoing bacteremia, or indolently, with vague dull pain that increases over weeks and low-grade or no fever.  
Spinal epidural abscess may complicate vertebral osteomyelitis, presenting as spinal pain and progressing to radicular pain and/or weakness; it is best diagnosed by MRI and must be treated urgently to prevent neurologic complications.  
Usually, a single organism causes acute hematogenous osteomyelitis; **S. aureus** accounts for ~50% of cases. Other common pathogens include gram-negative bacilli. Less common causes include **Mycobacterium tuberculosis**, **Brucella**, and fungi.

**Osteomyelitis from a Contiguous Focus of Infection**  
- Accounts for ~80% of all cases  
- Includes osteomyelitis in the setting of bites, puncture wounds, open fractures, peripheral vascular disease (particularly in diabetic adults), and foreign bodies  
- Although **S. aureus** is one of the pathogens in more than half of cases, infections are often polymicrobial and involve gram-negative and anaerobic bacteria as well.

**Chronic Osteomyelitis**  
- More likely to develop after infection from a contiguous source of infection than is acute hematogenous osteomyelitis.  
- The presence of a foreign body also increases risk.  
- The clinical course is prolonged and is characterized by quiescent periods with acute exacerbations, lack of fever, and development of sinus tracts that can occasionally drain pus or bits of necrotic bone.

**Diagnosis**  
Erythrocyte sedimentation rate (ESR) and C-reactive protein levels are usually increased in acute infection and can be used to monitor the response to treatment.

Imaging studies are important in the diagnosis of osteomyelitis, but there is a lack of consensus about their optimal use (see Table 91-2). Conditions due to noninfectious etiologies can be distinguished from osteomyelitis by imaging studies because the former do not usually cross the disk space.
Infectious Diseases

SECTION 7

If at all possible, appropriate samples for microbiologic studies should be obtained before antibiotic treatment. Blood should be cultured in acute hematogenous osteomyelitis. The results of cultures from sinus tracts do not correlate well with organisms infecting the bone; thus bone samples for cultures must be obtained either percutaneously or intraoperatively.

### TABLE 91-2  DIAGNOSTIC IMAGING STUDIES FOR OSTEOMYELITIS

<table>
<thead>
<tr>
<th>Type of Study</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plain radiographs</td>
<td>Insensitive, especially in early osteomyelitis. May show periosteal elevation after 10 days, lytic changes after 2–6 weeks. Useful to look for anatomic abnormalities (e.g., fractures, bony variants, or deformities), foreign bodies, and soft tissue gas.</td>
</tr>
<tr>
<td>Three-phase bone scan (99mTc-MDP)</td>
<td>Characteristic finding in osteomyelitis: increased uptake in all three phases of scan. Highly sensitive (~95%) in acute infection; somewhat less sensitive if blood flow to bone is poor. Specificity moderate if plain films are normal, but poor in presence of neuropathic arthropathy, fractures, tumor, infarction.</td>
</tr>
<tr>
<td>Other radionuclide scans</td>
<td>Examples: $^{67}$Ga-citrate, $^{111}$In-labeled WBCs. $^{111}$In-WBCs more specific than gallium but not always available. Often used in conjunction with bone scan because its greater specificity for inflammation than $^{99m}$Tc-MDP helps to distinguish infectious from noninfectious processes. Lack of consensus over role; often supplanted by MRI when the latter is available.</td>
</tr>
<tr>
<td>Ultrasound</td>
<td>May detect subperiosteal fluid collection or soft tissue abscess adjacent to bone, but largely supplanted by CT and MRI.</td>
</tr>
<tr>
<td>CT</td>
<td>Limited role in acute osteomyelitis. In chronic osteomyelitis, excellent for detection of sequestra, cortical destruction, soft tissue abscesses, and sinus tracts. Use limited in the presence of a metallic foreign body.</td>
</tr>
<tr>
<td>MRI</td>
<td>As sensitive as $^{99m}$Tc-MDP bone scan for acute osteomyelitis (~95%); detects changes in water content of marrow before disruption of cortical bone. High specificity (~87%), with better anatomic detail than nuclear studies. Procedure of choice for vertebral osteomyelitis because of high sensitivity for epidural abscess. Use may be limited by a metallic foreign body.</td>
</tr>
</tbody>
</table>

*Note:* WBCs, white blood cells; MDP, monodiphosphonate.

If at all possible, appropriate samples for microbiologic studies should be obtained before antibiotic treatment. Blood should be cultured in acute hematogenous osteomyelitis. The results of cultures from sinus tracts do not correlate well with organisms infecting the bone; thus bone samples for cultures must be obtained either percutaneously or intraoperatively.

### Osteomyelitis

Antibiotics used for therapy (see Table 91-3) should be bactericidal and given at high doses, usually commencing with IV administration.

1. *Acute hematogenous osteomyelitis in children:* 4–6 weeks of treatment. After 5–10 days, high-dose oral treatment can be used.
2. *Vertebral osteomyelitis:* 6–8 weeks of treatment. Consider a longer course if the ESR does not decline by at least two-thirds. The majority of epidural abscesses require surgical intervention.
<table>
<thead>
<tr>
<th>Organism</th>
<th>Primary</th>
<th>Suggested Regimen&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Staphylococcus aureus</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penicillin-resistant, methicillin-sensitive (MSSA)</td>
<td>Nafcillin or oxacillin, 2 g IV q4h</td>
<td>Cefazolin, 1 g IV q8h; ceftriaxone, 1 g IV q24h; clindamycin, 900 mg IV q8h&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Penicillin-sensitive</td>
<td>Penicillin, 3–4 million U IV q4h</td>
<td>Cefazolin, ceftriaxone, clindamycin (as above)</td>
</tr>
<tr>
<td>Methicillin-resistant (MRSA)</td>
<td>Vancomycin, 15 mg/kg IV q12h; rifampin, 300 mg PO q12h</td>
<td>Clindamycin&lt;sup&gt;c&lt;/sup&gt; (as above); linezolid, 600 mg IV or PO q12h&lt;sup&gt;d&lt;/sup&gt;; daptomycin, 4–6 mg/kg IV q24h&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Streptococci (including <em>S. milleri</em>, β-hemolytic streptococci)</strong></td>
<td>Penicillin (as above)</td>
<td>Cefazolin, ceftriaxone, clindamycin (as above)</td>
</tr>
<tr>
<td><strong>Gram-negative aerobic bacilli</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Escherichia coli</em>, other &quot;sensitive&quot; species</td>
<td>Ampicillin, 2 g IV q4h; cefazolin, 1 g IV q8h</td>
<td>Ceftriaxone, 1 g IV q24h; parenteral or oral fluoroquinolone (e.g., ciprofloxacin, 400 mg IV or 750 mg PO q12h)&lt;sup&gt;c&lt;/sup&gt; May substitute parenteral or oral fluoroquinolone for β-lactam agents (if pt is allergic) or for tobramycin (in relation to nephrotoxicity)</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>Extended-spectrum β-lactam agent (e.g., piperacillin, 3–4 g IV q4–6h; or ceftazidime, 2 g IV q12h) plus tobramycin, 5–7 mg/kg q24h&lt;sup&gt;f&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td><strong>Enterobacter spp., other &quot;resistant&quot; species</strong></td>
<td>Extended-spectrum β-lactam agent IV or fluoroquinolone IV or PO&lt;sup&gt;e&lt;/sup&gt; (as above)</td>
<td></td>
</tr>
<tr>
<td>Mixed infections possibly involving anaerobic bacteria</td>
<td>Ampicillin/sulbactam, 1.5–3 g IV q6h; piperacillin/tazobactam, 3.375 g IV q6h</td>
<td>Carbenem antibiotic or a combination of a fluoroquinolone plus clindamycin (as above) or metronidazole, 500 mg PO tid</td>
</tr>
</tbody>
</table>

<sup>a</sup>Duration of treatment is discussed in the text.

<sup>b</sup>Cephalosporins may be used for the treatment of pts allergic to penicillin whose reaction did not consist of anaphylaxis or urticaria (immediate-type hypersensitivity).

<sup>c</sup>Because of the possibility of inducible resistance, clindamycin must be used with caution for the treatment of strains resistant to erythromycin. Consult clinical microbiology laboratory.

<sup>d</sup>Experience is limited; there are anecdotal reports of efficacy.

<sup>e</sup>Oral fluoroquinolones must not be coadministered with divalent cations (calcium, magnesium, iron, aluminum), which block the drugs' absorption.

<sup>f</sup>Tobramycin levels and renal function must be monitored closely to minimize the risks of nephro- and ototoxicity.
3. **Contiguous-focus osteomyelitis**: surgical debridement and 4–6 weeks of treatment unless only the outer cortex of bone is involved. In the latter situation, a 2-week course of antibiotic treatment after thorough debridement has had excellent success.

4. **Chronic osteomyelitis**: It should be decided whether aggressive treatment is warranted or intermittent antibiotic therapy to suppress exacerbations is adequate. Otherwise, surgery and 4–6 weeks of antibiotic therapy can be tried. The value of further suppressive antibiotic treatment remains unproven.


---

### Pneumococcal Infections

#### Etiology

**Streptococcus pneumoniae** (the pneumococcus) is a gram-positive coccus that grows in chains and causes α-hemolysis on blood agar. Nearly every clinical isolate has a polysaccharide capsule. Ninety distinct capsules have been identified.

#### Epidemiology

*S. pneumoniae* colonizes the nasopharynx of 5–10% of healthy adults and 20–40% of healthy children on any single occasion. Once colonization takes place, pneumococci usually persist in adults for 4–6 weeks but can persist for up to 6 months. The organisms are spread by direct or droplet transmission as a result of close contact, and their spread is enhanced by crowding or poor ventilation. Outbreaks among adults have occurred in military barracks, prisons, homeless shelters, and nursing homes. Rates of bacteremic infection are highest among children <2 years of age and drop to low levels until age 55, when incidence again begins to increase. Pneumococcal pneumonia occurs annually in an estimated 20 young adults per 100,000 and in 280 persons >70 years of age per 100,000. Native Americans, Native Alaskans, and African Americans are unusually susceptible to invasive disease.

#### Pathogenesis

Once the nasopharynx has been colonized, infection can result if pneumococci are carried into contiguous areas (e.g., the sinuses) or are inhaled or aspirated into the bronchioles or alveoli. Spread to meninges, joints, and other sites through the bloodstream usually arises from a respiratory tract focus of infection. Pneumococci cause an inflammatory response, but—in the absence of anticapsular antibodies, which provide the best specific protection against pneumococcal
infection—the polysaccharide capsule renders the organisms resistant to phagocytosis and killing. Many conditions predispose to pneumococcal infection. Risk factors for disease include increased exposure to pneumococci (e.g., in day-care centers, military barracks, prisons, or homeless shelters); antecedent respiratory insult with inflammation (e.g., influenza or upper respiratory viral infection, cigarette smoking, or chronic obstructive pulmonary disease); anatomic disruption (e.g., dural tear); defects in antibody production (e.g., in pts with multiple myeloma or lymphoma); defects in splenic function (e.g., asplenia, sickle cell disease); and other, multifactorial conditions (e.g., infancy or aging, HIV infection, glucocorticoid treatment, cirrhosis, diabetes). The absence of a spleen predisposes to fulminant pneumococcal disease.

SPECIFIC INFECTIONS

Otitis Media and Sinusitis  *S. pneumoniae* is the most common bacterial isolate from middle-ear fluid in acute otitis media and from paranasal sinus fluid during acute sinusitis. See Chap. 62 for more detail.

Pneumonia  Pts usually present with fever, cough, and sputum production. Nausea and vomiting or diarrhea may be prominent. A small subset of pts present with an acute onset of a shaking chill, fever, and cough productive of blood-tinged sputum. On examination, pts usually appear ill and anxious, with fever, tachypnea, and tachycardia. Dullness to percussion, increased vocal fremitus, and bronchial or tubular breath sounds or crackles can be heard on pulmonary examination. Pleural effusions are common and may cause dullness to percussion, decreased breath sounds, and lack of fremitus. Hypoxemia may cause confusion, but meningitis should be considered as well. Empyema complicates ~2% of cases. On chest x-ray, air-space consolidation is the predominant finding; disease is multilobar in about half of pts. Air bronchograms are evident in fewer than half of cases but are more common in bacteremic disease. Leukocytosis [>12,000 white blood cells (WBCs)/μL] is usually present; WBC counts of <6000/μL may be associated with a poor prognosis. Pneumococcal pneumonia is strongly suggested by a sputum Gram’s stain with >25 polymorphonuclear leukocytes (PMNs) and <10 squamous epithelial cells per low-power field along with slightly elongated gram-positive cocci in pairs and chains. When a sputum sample of good quality can be obtained prior to antibiotic treatment (which rapidly clears pneumococci from the sputum), Gram’s stain and culture are >80% and >90% sensitive, respectively. Blood cultures are positive in ~25% of cases.

Meningitis  *S. pneumoniae* is the most common cause of meningitis in adults; the incidence among children has been dramatically reduced by the use of pediatric pneumococcal conjugate vaccine. Infection usually results from hematogenous spread but can also be the result of drainage from colonized nasopharyngeal lymphatics or veins or of contiguous spread (e.g., dural tear). Clinical and laboratory features resemble those of meningitis due to other bacteria. Pts have fever, headache, and neck stiffness, and disease progresses over 24–48 h to confusion and obtundation. On examination, the pt is acutely ill with a rigid neck. Cerebrospinal fluid (CSF) findings consist of pleocytosis with ≥85% PMNs, elevated protein levels (100–500 mg/dL), and decreased glucose content (<30 mg/dL). Organisms can be seen on a gram-stained specimen of CSF if antibiotics have not yet been given.

Other Syndromes  Pneumococcal endocarditis (an acute infection that results in rapid destruction of heart valves), pericarditis, septic arthritis, osteomyelitis, peritonitis, salpingitis, epidural and brain abscesses, and cellulitis have been de-
scribed. Unusual manifestations of pneumococcal infection should prompt consideration of testing for HIV infection.

**Pneumococcal Infections**

Penicillin has been the cornerstone of treatment, but resistance has been slowly increasing. Resistance to other antibiotics is often documented as well. In the United States, ~20% of pneumococcal isolates are intermediately susceptible to penicillin [minimum inhibitory concentration (MIC), 0.1–1.0 μg/mL], and 15% are resistant (MIC, ≥2.0 μg/mL). These definitions are based on levels achievable in the CSF to treat meningitis. Pneumonia caused by a penicillin-resistant strain often still responds to conventional doses of penicillin. Most penicillin-intermediate strains are susceptible to ceftriaxone, cefotaxime, cefepime, and cefpodoxime, but penicillin-resistant pneumococci are often resistant to those cephalosporins as well. One-quarter of pneumococcal isolates in the United States are resistant to macrolides, with particularly high rates among strains that are also resistant to penicillin; doxycycline resistance rates are similar to rates of macrolide resistance. However, >90% of isolates retain sensitivity to clindamycin. The newer quinolones exhibit excellent activity against pneumococci, but resistance is emerging because of the widespread use of these agents.

**Pneumonia**

- **Outpatient treatment:** Amoxicillin (1 g q8h) should be effective except against strains highly resistant to penicillin. In those cases, a newer fluoroquinolone (e.g., levofloxacin, 750 mg/d) can be used.
- **Inpatient treatment:** For strains susceptible or intermediately resistant to penicillin, β-lactam antibiotics are recommended—e.g., penicillin (3–4 mU q4h), ampicillin (1–2 g q6h), or ceftriaxone (1 g q12–24h). Pneumonia that is likely to be due to highly antibiotic-resistant pneumococci should be treated with either vancomycin (1 g q12h) or a quinolone together with a third-generation cephalosporin. Treatment should initially be given by the IV route in most cases, and therapy should continue until at least 5 days after the pt becomes afebrile.

**Meningitis**

Initial treatment should include ceftriaxone (2 g q12h) plus vancomycin (1 g q12h). Both drugs are used because the cephalosporin is likely to be effective in most cases and penetrates well into the CSF, while vancomycin covers all isolates (including those resistant to penicillin and cephalosporins) but displays unpredictable CSF penetration. If the isolate is susceptible or intermediately resistant to ceftriaxone, vancomycin should be discontinued; if it is resistant to ceftriaxone, both agents should be continued. Treatment for 10 days is recommended. Glucocorticoids should be given before or in conjunction with the first dose of antibiotics.

**Endocarditis**

Treatment with ceftriaxone and vancomycin, pending susceptibility testing, is indicated. Aminoglycosides can be used for synergy, but rifampin and fluoroquinolones are antagonistic with β-lactam antibiotics against pneumococci.

**PREVENTION**

Pneumococcal polysaccharide vaccine contains capsular polysaccharide from the 23 most prevalent serotypes of *S. pneumoniae*. One case-control study
showed a protection rate of 85% for ≥5 years among persons <55 years of age, but the level and duration of protection decrease with advancing age. Pts at high risk for pneumococcal disease may not respond well to the vaccine. However, because of the safety and low cost of the vaccine, its administration is still recommended. Candidates for the vaccine include pts >2 years of age who are at risk for a serious complication of pneumococcal infection (e.g., asplenic pts; pts >65 years of age; pts with CSF leak, diabetes, alcoholism, cirrhosis, chronic renal insufficiency, chronic pulmonary disease, or advanced cardiovascular disease); pts who have an immunocompromising condition associated with increased risk of pneumococcal disease, such as multiple myeloma or HIV infection; pts who are at genetically increased risk, such as Native Americans and Native Alaskans; and pts who live in environments where outbreaks are likely, such as nursing homes. Recommendations for revaccination are less clear; most experts recommend at least one revaccination 5 years after initial vaccination. Children <2 years of age should receive the conjugate pneumococcal vaccine, which reduces invasive pneumococcal illness in this age group (and, through a herd effect, in the population as a whole) as well as nasopharyngeal colonization. The conjugate vaccine has also reduced the proportion of cases of pneumococcal disease caused by antibiotic-resistant strains. However, serotypes not contained in the vaccine, which are often antibiotic resistant, have caused an increased number of infections since the commencement of widespread vaccination; this trend is being closely monitored.

For a more detailed discussion, see Musher DM: Pneumococcal Infections, Chap. 128, p. 865, in HPIM-17.

**93 Staphylococcal Infections**

**ETIOLOGY**

Staphylococci are gram-positive cocci that form grapelike clusters on Gram’s stain and are catalase positive (unlike streptococci), nonmotile, aerobic, and facultatively anaerobic. *Staphylococcus aureus*, which is distinguished from other staphylococci by its production of coagulase, is the most virulent species, causing disease through both toxin-mediated and non-toxin-mediated mechanisms.

**S. AUREUS INFECTIONS**

**Epidemiology** *S. aureus* is a component of the normal human flora, most frequently colonizing the anterior nares but also colonizing the skin (particularly damaged skin), vagina, axilla, perineum, and oropharynx. Of healthy persons, 25–50% may be persistently or transiently colonized with *S. aureus*, and the rate is especially high among insulin-dependent diabetics, HIV-infected persons, injection drug users, hemodialysis pts, and pts with skin damage. Sites of colonization are reservoirs for future infection. *S. aureus* is an important cause of nosocomial as well as community-acquired infections. Methicillin-resistant *S. aureus* (MRSA) is common in hospitals, and its prevalence is increasing dramat-
Infectious Diseases

SECTION 7

ically in community settings among individuals without prior medical exposure. In the United States, strain USA300 causes most community-acquired MRSA (CA-MRSA) infections. Outbreaks of CA-MRSA occur among diverse groups, including prisoners, athletes, and drug users. Common risk factors include poor hygienic conditions, close contact, contaminated materials, and damaged skin. CA-MRSA can cause serious disease in immunocompetent individuals.

Pathogenesis Invasive *S. aureus* Disease *S. aureus* is a pyogenic pathogen known for its capacity to induce abscess formation. For invasive *S. aureus* infection to occur, some or all of the following steps are necessary.

• Local colonization of tissue surfaces or inoculation directly into tissue—e.g., as a result of minor abrasions or via IV access catheters. The bacteria adhere to different tissue surfaces and can form a biofilm similar to that formed by coagulase-negative staphylococci.

• Invasion: Bacteria replicate at the site of infection and elaborate enzymes that facilitate survival and local spread. CA-MRSA has been linked with the Panton-Valentine leukocidin toxin, which may contribute to more serious infections.

• Evasion of the host response and metastatic spread: *S. aureus* possesses an antiphagocytic polysaccharide microcapsule that facilitates evasion of host defenses and plays a role in abscess formation. In addition, *S. aureus* can survive intracellularly. Recurrences are relatively frequent because the organisms can survive in a quiescent state in various tissues and then cause recrudescent infections when conditions are suitable.

Host Response to *S. aureus* Infection Polymorphonuclear leukocytes (PMNs) constitute the primary host response to *S. aureus* infection.

Groups at Increased Risk of *S. aureus* Infection Hosts at increased risk for *S. aureus* infection include those with skin abnormalities, congenital or acquired qualitative or quantitative PMN defects (e.g., neutropenia, chronic granulomatous disease), or indwelling foreign bodies. At-risk populations often have multiple factors that increase susceptibility to *S. aureus* infections. For example, diabetic pts have increased rates of colonization; use injectable insulin, which can introduce the organism into tissue; and may have impaired leukocyte function.

Toxin-Mediated Disease *S. aureus* produces three types of toxins: cytotoxins, pyrogenic toxins, and exfoliative toxins. Antitoxin antibodies are protective against toxin-mediated staphylococcal illness. Enterotoxins and toxic shock syndrome toxin 1 (TSST-1) act as “superantigens” or T cell mitogens and cause the release of large amounts of inflammatory mediators, producing multisystem disease that includes fever, rash, and hypotension.

Diagnosis *S. aureus* infections are readily diagnosed by Gram’s stain and microscopic examination of infected tissue. The organisms appear as large gram-positive cocci in pairs or clusters. Routine cultures are usually positive. Polymerase chain reaction assays have been developed for rapid testing.

Clinical Syndromes Skin and Soft Tissue Infections Predisposing factors include skin disease, skin damage, injections, and poor personal hygiene. These infections are characterized by pus-containing blisters.

• *Folliculitis* involves hair follicles.

• *Furuncles* (boils) extend from follicles to cause true abscesses and more extensive, painful lesions.
Carbuncles are often located in the lower neck, are even more severe and painful, and are due to coalesced lesions extending to deeper SC tissue.

Mastitis occurs in nursing mothers.

S. aureus also causes impetigo, cellulitis, hidradenitis suppurativa, and surgical wound infections (see Chap. 91).

Musculoskeletal Infections

S. aureus is the most common cause of osteomyelitis arising from either hematogenous dissemination or contiguous spread from a soft tissue site (e.g., diabetic or vascular ulcers). Hematogenous osteomyelitis in children involves long bones and presents with fever, bone pain, and reluctance to bear weight. Leukocytosis, increased erythrocyte sedimentation rate, and positive blood cultures are typical. Hematogenous osteomyelitis in adults is often vertebral and occurs in pts with endocarditis, pts undergoing hemodialysis, injection drug users, or diabetics. Intense back pain and fever can occur. Epidural abscess is a serious complication that can present as trouble voiding or walking or as radicular pain in addition to symptoms of osteomyelitis; neurologic compromise can develop in the absence of timely treatment. Osteomyelitis from contiguous soft tissue infections is suggested by exposure of bone, a draining fistulous tract, failure to heal, or continued drainage.

S. aureus is also the most common cause of septic arthritis. S. aureus septic arthritis in adults is associated with trauma or surgery or is due to hematogenous dissemination.

Pyomyositis, an infection of skeletal muscles that is seen in tropical climates and in seriously compromised pts (including HIV-infected pts), causes fever, swelling, and pain overlying involved muscle and is usually due to S. aureus.

Respiratory Tract Infections

Infections in newborns and infants: serious infections characterized by fever, dyspnea, and respiratory failure. Pneumatoceles may develop, and pneumothorax and empyema may occur.

Nosocomial pneumonia: occurs primarily in intubated pts in intensive care units. Clinical presentations resemble those of other nosocomial pneumonias. Pts have an increased volume of purulent sputum, fever, and new pulmonary infiltrates and can develop respiratory distress.

Community-acquired pneumonia: usually postviral (e.g., after influenza). Pts may present with fever, bloody sputum production, and midlung-field pneumatoceles or multiple patchy pulmonary infiltrates.

Bacteremia and Sepsis

The incidence of metastatic seeding during bacteremia has been estimated to be as high as 31%. Bones, joints, kidneys, and lungs are most commonly infected. Diabetes, HIV infection, and renal insufficiency are often seen in association with S. aureus bacteremia and increase the risk of complications.

Infective Endocarditis (See also Chap. 87) S. aureus accounts for 25–35% of cases of bacterial endocarditis. The incidence is increasing as a result of injection drug use, hemodialysis, intravascular prosthetic devices, and immunosuppression. Mortality rates range from 20 to 40% despite the availability of effective antibiotics. There are four clinical settings in which S. aureus endocarditis is encountered.

Right-sided endocarditis in association with injection drug use: Pts have high fever, a toxic appearance, and pleuritic chest pain and produce purulent sputum that is sometimes bloody. Chest x-ray can reveal septic emboli: small, peripheral, circular lesions that may cavitate.
• Left-sided native-valve endocarditis: Compared with pts with right-sided disease, those with left-sided native-valve endocarditis tend to be older, to have a worse prognosis, and to have a higher incidence of complications, including peripheral emboli, cardiac decompensation, and metastatic seeding.

• Prosthetic-valve endocarditis: This infection, which is particularly fulminant if it occurs in the early postoperative period, is associated with a high mortality rate. Valve replacement is usually an urgent priority. Pts are prone to develop valvular insufficiency and myocardial abscesses.

• Nosocomial endocarditis: makes up 15–30% of S. aureus endocarditis cases and is related to the increased use of intravascular devices. Pts are often critically ill before the infection, with many comorbid conditions, and the disease can be difficult to recognize.

Urinary Tract Infections (UTIs) UTIs are infrequently caused by S. aureus. Unlike UTIs caused by other urinary pathogens, those caused by S. aureus are most often due to hematogenous dissemination.

Prosthetic Device–Related Infections In contrast with coagulase-negative staphylococci, S. aureus causes more acute disease with localized and systemic manifestations that tend to be rapidly progressive. Successful treatment usually involves removal of the prosthetic device.

Community-Acquired MRSA Infections CA-MRSA infections can have many unusual presentations (e.g., necrotizing fasciitis, necrotic pneumonia, sepsis, purpura fulminans) that reflect the increased virulence of CA-MRSA strains.

Toxin-Mediated Disease
• Toxic shock syndrome (TSS): Pts with staphylococcal TSS may not have a clinically evident staphylococcal infection. TSS results from elaboration of an enterotoxin (many nonmenstrual TSS cases) or TSST-1 (some nonmenstrual cases and >90% of menstrual cases). Menstrual cases occur 2–3 days after menses begin. Diagnosis is based on a constellation of clinical findings. The case definition includes a fever ≥38.9°C (≥102°F); hypotension; a diffuse macular rash that involves the palms and soles, with subsequent desquamation 1–2 weeks after disease onset; multisystem involvement—e.g., hepatic (bilirubin or aminotransferase levels ≥2 times normal), hematologic (platelet count ≤100,000/μL), renal (blood urea nitrogen or creatinine ≥2 times normal), mucous membrane (vaginal, oropharyngeal, or conjunctival hyperemia), GI (vomiting or diarrhea at the onset of illness), muscular (myalgias or serum creatine phosphokinase ≥2 times normal), or central nervous (disorientation or altered consciousness without focal findings); and no evidence of other illnesses.

• Food poisoning: results from inoculation of toxin-producing S. aureus into food by colonized food handlers. Toxin is then elaborated in growth-promoting foods, such as custard, potato salad, or processed meat. The heat-stable toxin is not destroyed even if heating kills the bacteria. Disease onset is rapid and explosive, occurring within 1–6 h of ingestion of contaminated food. The chief signs and symptoms are nausea and vomiting, but diarrhea, hypotension, and dehydration may occur. Fever is absent. Symptoms resolve within 8–10 h.

• Staphylococcal scalded-skin syndrome (SSSS): most often affects newborns and children. Disease ranges from localized blisters to exfoliation of most of the skin surface. The skin is fragile, with tender, thick-walled, fluid-filled bullae. Nikolsky’s sign is diagnosed when gentle pressure of bullae causes rupture of lesions and leaves denuded underlying skin.
Prevention Hand washing and careful attention to appropriate isolation procedures prevent the spread of \emph{S. aureus} infection. Mupirocin treatment to eliminate nasal carriage of \emph{S. aureus} has reduced rates of infection among hemodialysis and peritoneal dialysis pts. Reduction in rates of wound infection among pts undergoing surgery is less evident.

**INFECTIONS CAUSED BY COAGULASE-NEGATIVE STAPHYLOCOCCI (CoNS)**

CoNS are less virulent than \emph{S. aureus} but are important and common causes of prosthetic-device infections. Of CoNS species, \emph{S. epidermidis} most often causes disease. This organism is a normal component of the skin, oropharyngeal, and vaginal flora. \emph{S. saprophyticus} is a cause of UTIs. Two other species of CoNS, \emph{S. lugdunensis} and \emph{S. schleiferi}, are more virulent and cause serious infections such as native-valve endocarditis and osteomyelitis.

**Pathogenesis** CoNS are uniquely adapted to cause prosthetic-device infections because they can elaborate extracellular polysaccharide (glycocalyx or slime) that forms a biofilm on the device surface, protecting bacteria from host defenses as well as from antibiotic treatment while allowing bacterial survival.

**Clinical Syndromes** CoNS cause diverse prosthetic device–related infections. Signs of localized infection are usually subtle, disease progression is slow, and systemic findings are limited. Fever and mild leukocytosis may be documented. Infections not associated with prosthetic devices are infrequent, but up to 5% of native-valve endocarditis cases have been due to CoNS in some series.

**Diagnosis** CoNS are readily detected by standard methods, but distinguishing infection from colonization is often problematic because CoNS are common contaminants of cultures of blood and other sites.

\textbf{Staphylococcal Infections}

Suppurative collections should be surgically drained. The emergence of CA-MRSA has increased the importance of culturing material from all collections to identify the pathogen and determine its antimicrobial susceptibility. In most cases of prosthetic-device infection, the device should be removed, although some CoNS infections can be managed medically. Antibiotic therapy for \emph{S. aureus} infection is generally prolonged (i.e., 4–8 weeks), particularly if blood cultures remain positive 48–96 h after initiation of therapy, if the infection was acquired in the community, if a removable focus of infection is not removed, or if cutaneous or embolic manifestations of infection occur. Antimicrobial therapy for serious \emph{S. aureus} infections is summarized in Table 93-1. Penicillinase-resistant penicillins, such as nafcillin or first-generation cephalosporins, are highly effective against penicillin-resistant strains. The incidence of MRSA is high in hospital settings, and strains immediately or fully resistant to vancomycin have been described. In general, vancomycin is less bactericidal than the \(\beta\)-lactams and should be used only when absolutely indicated. Among newer antistaphylococcal agents, quinupristin/dalfopristin is typically bactericidal but is only bacteriostatic against isolates resistant to erythromycin or clindamycin; linezolid is bacteriostatic and has not yet been established as efficacious in deep-seated infections such as osteomyelitis; and daptomycin is bactericidal. Tigecycline, a broad-spectrum minocycline analogue, has bacteriostatic activity against MRSA. Other alternatives include the quinolones, but resistance to these drugs is increasing, especially among MRSA strains. Trimethoprim-sulfamethoxazole (TMP-SMX) and minocycline have been successfully used to
<table>
<thead>
<tr>
<th>Sensitivity/Resistence of Isolate</th>
<th>Drug of Choice</th>
<th>Alternative(s)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitive to penicillin</td>
<td>Penicillin G (4 mU q4h)</td>
<td>Nafcillin (2 g q4h) or oxacillin (2 g q4h), cefazolin (2 g q8h), vancomycin (1 g q12h&lt;sup&gt;b&lt;/sup&gt;)</td>
<td>Fewer than 5% of isolates are sensitive to penicillin.</td>
</tr>
<tr>
<td>Sensitive to methicillin</td>
<td>Nafcillin or oxacillin (2 g q4h)</td>
<td>Cefazolin (2 g q8h&lt;sup&gt;b&lt;/sup&gt;), vancomycin (1 g q12h&lt;sup&gt;b&lt;/sup&gt;)</td>
<td>Patients with penicillin allergy can be treated with a cephalosporin if the allergy does not involve an anaphylactic or accelerated reaction; vancomycin is the alternative. Desensitization to β-lactams may be indicated in selected cases of serious infection where maximal bactericidal activity is needed (e.g., prosthetic-valve endocarditis&lt;sup&gt;c&lt;/sup&gt;). Type A β-lactamase may rapidly hydrolyze cefazolin and reduce its efficacy in endocarditis.</td>
</tr>
<tr>
<td>Resistant to methicillin</td>
<td>Vancomycin (1 g q12h&lt;sup&gt;b&lt;/sup&gt;)</td>
<td>TMP-SMX (TMP, 5 mg/kg q12h&lt;sup&gt;b&lt;/sup&gt;), minocycline or doxycycline (100 mg PO q12h&lt;sup&gt;b&lt;/sup&gt;), ciprofloxacin (400 mg q12h&lt;sup&gt;b&lt;/sup&gt;), levofloxacin (300 mg q24h&lt;sup&gt;b&lt;/sup&gt;), quinupristin/dalfopristin (7.5 mg/kg q8h), linezolid (600 mg q12h except: 400 mg q12h for uncomplicated skin infections); daptomycin (4-6 mg/kg q24h&lt;sup&gt;b&lt;/sup&gt;/d) for bacteremia, endocarditis, and complicated skin infections; tigecycline (100 mg IV once, then 50 mg q12h) for skin and soft tissue infections; investigational drugs: oritavancin, dalbavancin, telavancin</td>
<td>Sensitivity testing is necessary before an alternative drug is used. Adjunctive drugs (those that should be used only in combination with other antimicrobial agents) include gentamicin (1 mg/kg q8h&lt;sup&gt;b&lt;/sup&gt;), rifampin (300 mg PO q8h), and fusidic acid (500 mg q8h; not readily available in the United States). Quinupristin/dalfopristin is bactericidal against methicillin-resistant isolates unless the strain is resistant to erythromycin or clindamycin. The newer quinolones may retain in vitro activity against ciprofloxacin-resistant isolates; resistance may develop during therapy. The efficacy of adjunctive therapy is not well established in many settings. Both linezolid and quinupristin/dalfopristin have had in vitro activity against most VISA and VRSA strains. See footnote for treatment of prosthetic-valve endocarditis.</td>
</tr>
</tbody>
</table>

<sup>a</sup>TABLE 93-1 ANTIMICROBIAL THERAPY FOR SERIOUS STAPHYLOCOCCAL INFECTIONS<sup>d</sup>

<sup>b</sup>Many isolates are now resistant to penicillin and methicillin. Sensitivity testing is necessary before initiating therapy. Adjunctive drugs (those that should be used only in combination with other antimicrobial agents) include gentamicin (1 mg/kg q8h<sup>b</sup>), rifampin (300 mg PO q8h), and fusidic acid (500 mg q8h; not readily available in the United States). Quinupristin/dalfopristin is bactericidal against methicillin-resistant isolates unless the strain is resistant to erythromycin or clindamycin. The newer quinolones may retain in vitro activity against ciprofloxacin-resistant isolates; resistance may develop during therapy. The efficacy of adjunctive therapy is not well established in many settings. Both linezolid and quinupristin/dalfopristin have had in vitro activity against most VISA and VRSA strains. See footnote for treatment of prosthetic-valve endocarditis.
<table>
<thead>
<tr>
<th>Resistance to Methicillin</th>
<th>Resistance to Vancomycin</th>
<th>Empirical Therapy</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resistant with intermediate or complete resistance to vancomycin</td>
<td>Uncertain</td>
<td>Same as for methicillin-resistant strains; check antibiotic susceptibilities</td>
<td>Same as for methicillin-resistant strains; check antibiotic susceptibilities</td>
</tr>
<tr>
<td>Not yet known (i.e., empirical therapy)</td>
<td>Vancomycin (1 g q12h)</td>
<td>—</td>
<td>Empirical therapy is given when the susceptibility of the isolate is not known. Vancomycin with or without an aminoglycoside is recommended for suspected community- or hospital-acquired <em>S. aureus</em> infections because of the increased frequency of methicillin-resistant strains in the community.</td>
</tr>
</tbody>
</table>

---

- Recommended dosages are for adults with normal renal and hepatic function. The route of administration is IV unless otherwise indicated.
- The dosage must be adjusted in patients with reduced creatinine clearance.
- For the treatment of prosthetic-valve endocarditis, the addition of gentamicin (1 mg/kg q8h) and rifampin (300 mg PO q8h) is recommended, with adjustment of the gentamicin dosage if the creatinine clearance rate is reduced.
- Daptomycin cannot be used for pneumonia.
- Vancomycin-resistant *S. aureus* isolates from clinical infections have been reported.

**Note:** TMP-SMX, trimethoprim-sulfamethoxazole; VISA, vancomycin-intermediate *S. aureus*; VRSA, vancomycin-resistant *S. aureus*.

**Source:** Modified with permission of the *New England Journal of Medicine* (Lowy, 1998). Copyright 1998 Massachusetts Medical Society. All rights reserved.
treat MRSA infections in cases of vancomycin toxicity or intolerance. Synergy has been demonstrated for certain antimicrobial combinations: β-lactams and aminoglycosides; vancomycin and gentamicin; vancomycin, gentamicin, and rifampin (against CoNS); and vancomycin and rifampin.

Special considerations for treatment include:

• Uncomplicated skin and soft tissue infections: Oral agents are usually adequate.
• Native-valve endocarditis: A β-lactam for 6 weeks plus gentamicin (1 mg/kg every 8 h) for 3–5 days. (Addition of gentamicin does not alter clinical outcome but reduces the duration of bacteraemia.) If infection is due to MRSA, vancomycin (1 g every 12 h) is recommended. Treatment should continue for 6 weeks.
• Prosthetic-valve endocarditis: Surgery is often needed in addition to antibiotics. A β-lactam (or vancomycin if MRSA is involved) with gentamicin and rifampin is indicated.
• Hematogenous osteomyelitis or septic arthritis: A 4-week treatment course is adequate for children, but adults require longer courses. Joint infections require repeated aspiration or arthroscopy to prevent damage from inflammatory cells.
• Chronic osteomyelitis: Surgical debridement is needed in most cases.
• Prosthetic-joint infections: Ciprofloxacin and rifampin have been used successfully in combination, particularly when the prosthesis cannot be removed.
• CA-MRSA infections: Initiation of appropriate empirical therapy is important in skin and soft tissue infections due to CA-MRSA. Oral agents effective against these isolates include clindamycin, TMP-SMX, doxycycline, and linezolid. Susceptibility varies in different geographic regions.
• TSS: Supportive therapy and removal of tampons or other packing material or debridement of an infected site are most important. The role of antibiotics is less clear, but a clindamycin/semisynthetic penicillin combination is recommended. Clindamycin is used because it is a protein synthesis inhibitor and has been shown to decrease toxin synthesis in vitro. IV immunoglobulin may be helpful. The role of glucocorticoids is uncertain.

For a more detailed discussion, see Lowy FD: Staphylococcal Infections, Chap. 129, p. 872, in HPIM-17.

Streptococci and enterococci are part of the normal human flora, colonizing the respiratory, GI, and genitourinary tracts. These gram-positive cocci form chains when grown in liquid media. Culture on blood agar reveals three hemolytic patterns.
• β-Hemolysis: complete hemolysis around a colony. This pattern is seen with streptococci of Lancefield groups A, B, C, and G. Lancefield grouping is based on cell-wall carbohydrate antigens.

• α-Hemolysis: partial hemolysis imparting a greenish appearance to agar. This pattern is seen with *S. pneumoniae* and viridans streptococci.

• γ-Hemolysis: no hemolysis. This pattern is typical of enterococci, *S. bovis*, and anaerobic streptococci.

**GROUP A STREPTOCOCCUS (GAS)**

**Etiology and Pathogenesis** GAS causes suppurative infections and is associated with postinfectious syndromes such as acute rheumatic fever (ARF) and poststreptococcal glomerulonephritis (PSGN). Worldwide, GAS contributes to ~500,000 deaths per year. The major surface protein, M protein, and the hyaluronic acid polysaccharide capsule protect against phagocytic ingestion and killing. GAS produces a large number of extracellular products that may contribute to local and systemic toxicity; these include streptolysins S and O, streptokinase, DNases, and pyrogenic toxins that cause the rash of scarlet fever and contribute to the pathogenesis of toxic shock syndrome (TSS) and necrotizing fasciitis.

**Clinical Features**

**Pharyngitis** GAS accounts for 20–40% of all cases of exudative pharyngitis in children >3 years of age. Respiratory droplets spread infection. After an incubation period of 1–4 days, pts develop sore throat, fever, chills, malaise, and GI manifestations. Examination reveals an erythematous pharyngeal mucosa, swelling, purulent exudates over the posterior pharynx and tonsillar pillars, and tender anterior cervical adenopathy. Viral pharyngitis is the more likely diagnosis when patients have coryza, hoarseness, conjunctivitis, or mucosal ulcers. Rapid diagnosis by latex agglutination or enzyme immunoassay is variably sensitive but highly specific. Throat culture is the gold standard for diagnosis. Serologic tests (e.g., antistreptolysin O) confirm past infection in pts with suspected ARF but are not useful for the acute diagnosis of pharyngitis. Symptoms resolve spontaneously in most pts after 3–5 days.

**Group A Streptococcal Pharyngitis**

The primary goal of treatment is to prevent suppurative complications (e.g., lymphadenitis, abscess, sinusitis, bacteremia, pneumonia) and ARF; therapy does not seem to prevent PSGN. See Table 94-1 for recommended treatments. Macrolides such as erythromycin may be used, but resistance to these agents is increasing. Asymptomatic pharyngeal GAS carriage usually is not treated; however, when the pt is the source of infection in others, penicillin V (500 mg qid for 10 days) with rifampin (600 mg bid for the final 4 days) is used.

**Scarlet Fever** Scarlet fever is the designation for GAS pharyngitis associated with a characteristic rash. The rash typically appears in the first 2 days of illness over the upper trunk and spreads to the extremities but not to the palms and soles. The skin has a sandpaper feel. Other findings include strawberry tongue (enlarged papillae on a coated tongue) and Pastia’s lines (accentuation of rash in skin folds). Rash improves in 6–9 days with desquamation on palms and soles. Scarlet fever is much less common than in the past.

**Skin and Soft Tissue Infections** See Chap. 91 for further discussion of clinical manifestations and treatment.
1. **Impetigo**: A superficial skin infection, impetigo is also occasionally caused by *Staphylococcus aureus*. The disease is most often seen in young children in warmer months or climates and under poor hygienic conditions. The facial areas around the nose and mouth and the legs are the sites most commonly involved. Red papular lesions evolve into pustules that crust. Patients are usually afebrile. For treatment, see Table 94-1. Empirical antibiotic therapy should cover GAS and *S. aureus*; thus dicloxacillin or cephalexin (250 mg qid for 10 days) is used. Topical mupirocin ointment is also effective. GAS impetigo is associated with PSGN.

2. **Cellulitis**: GAS cellulitis develops at anatomic sites where normal lymphatic drainage has been disrupted (e.g., areas of prior cellulitis, the ipsilateral arm after mastectomy and axillary node dissection). Organisms may enter at sites distant from the area of cellulitis where there is a breach of skin integrity. *GAS* may cause rapidly developing postoperative wound infection. *Erysipelothrix*, a form of cellulitis that usually involves the malar facial area or the lower extremities, is caused almost exclusively by GAS. Patients experience an acute onset of bright red swelling that is sharply demarcated from normal skin as well as pain and fever. The illness develops over hours, and blebs or bullae may form after 2 or 3 days. Empirical treatment for cellulitis is directed against GAS and *S. aureus*. For treatment of erysipelas or cellulitis known to be due to GAS, see Table 94-1.

3. **Necrotizing fasciitis**: GAS causes ~60% of cases of necrotizing fasciitis. For treatment, see Table 94-1.

**Pneumonia and Empyema**  GAS occasionally causes pneumonia. The onset can be gradual or abrupt. Patients have pleuritic chest pain, fever, chills, and dyspnea; ~50% have accompanying pleural effusions that are almost always infected and should be drained quickly to avoid loculation. For treatment, see Table 94-1.

**Bacteremia**  In most cases of bacteremia, a focus is readily identifiable. Bacteremia occurs occasionally with cellulitis and frequently with necrotizing fasci-
tis. If no focus is evident, a diagnosis of endocarditis, occult abscess, or osteomyelitis should be considered.

Puerperal Sepsis

Common in the preantibiotic era, puerperal sepsis is now rare. Outbreaks are associated with asymptomatic carriage of GAS by delivery room personnel.

Toxic Shock Syndrome

Table 94-2 presents a proposed case definition for streptococcal TSS. Unlike TSS due to *S. aureus*, streptococcal TSS includes bacteremia in most pts, does not usually cause the development of a rash, and commonly includes a soft tissue infection (cellulitis, necrotizing fasciitis, or myositis). The mortality rate for streptococcal TSS is ~30%, with most deaths due to shock and respiratory failure. For treatment, see Table 94-1.

Prevention

Household contacts of individuals with invasive GAS infection are at increased risk of infection; asymptomatic colonization with GAS is detected in up to 25% of persons with >4 h/d of same-room exposure to an index case. However, antibiotic prophylaxis is not routinely recommended.

**STREPTOCOCCI OF GROUPS C AND G**

Streptococci of groups C and G cause infections similar to those caused by GAS. Strains that form small colonies on blood agar (<0.5 mm) are generally of the *S. milleri* group; large-colony group C and G streptococci are now considered a single species. These organisms cause cellulitis, bacteremia, and septic arthritis. Bacteremia occurs more frequently in elderly or chronically ill pts. Some distinct zoonotic group C species can also cause human infection. Treatment is the same as for GAS infection. Bacteremia or septic arthritis should be treated with penicillin (2–4 mU IV every 4 h). Although it has not been shown to be superior, gentamicin (1 mg/kg every 8 h) is recommended by some experts for endocarditis or septic arthritis due to group C or G streptococci because of a poor clinical response to penicillin alone. Joint infections can require repeated aspiration or open drainage for cure.

**GROUP B STREPTOCOCCUS (GBS)**

GBS is a major cause of meningitis and sepsis in neonates and a frequent cause of peripartum fever in women.
**Neonatal Infection**  Early-onset infection occurs within the first week of life (median age, 20 h). The infection is acquired within the maternal genital tract during birth. Neonates have respiratory distress, lethargy, hypotension, bacteremia, pneumonia (one-third to one-half of cases), and meningitis (one-third of cases).

Late-onset infection develops between 1 week and 3 months of age (mean age, 3–4 weeks). Meningitis is the most common manifestation. Infants are lethargic, febrile, and irritable; feed poorly; and may have seizures.

**Group B Streptococcal Infections in Neonates**

Penicillin or ampicillin is the agent of choice for GBS infections and is administered with gentamicin while cultures are pending. Pts with bacteremia or soft tissue infection should receive penicillin at a dosage of 200,000 units/kg per day in divided doses; those with meningitis should receive 400,000 units/kg per day in divided doses for 14 days. Many physicians continue to give gentamicin until the pt improves clinically.

**Prevention**  About half of the infants delivered vaginally to mothers colonized with GBS (5–40% of women) become colonized, but only 1–2% develop infection. With maternal colonization, the risk of neonatal GBS infection is high if delivery is preterm or if the mother has an early rupture of membranes (>24 h before delivery), prolonged labor, fever, or chorioamnionitis. Identification of high-risk mothers and prophylactic administration of ampicillin or penicillin during delivery reduce the risk of neonatal infection. Screening for anogenital colonization with GBS at 35–37 weeks of pregnancy is currently recommended. Women who have previously given birth to an infant with GBS disease, who have a history of GBS bacteriuria during pregnancy, or who have an unknown culture status but risk factors noted above should receive intrapartum prophylaxis (usually 5 mU of penicillin G followed by 2.5 mU every 4 h until delivery). Cefazolin can be used as well. If the mother is at risk for anaphylaxis and the GBS isolate is known to be susceptible, clindamycin or erythromycin can be used; otherwise, vancomycin is indicated.

**Adult Infection**  Most GBS infections in adults are related to pregnancy and parturition. Other GBS infections are seen in the elderly, especially those with underlying conditions such as diabetes mellitus or cancer. Cellulitis and soft tissue infection, urinary tract infection (UTI), pneumonia, endocarditis, and septic arthritis are most common. Penicillin (12 mU/d for localized infections and 18–24 mU/d for endocarditis or meningitis, in divided doses) is recommended. Vancomycin is an acceptable alternative for penicillin-allergic pts. Relapse or recurrent invasive infection occurs in ~4% of cases.

**ENTEROCOCCI AND NONENTEROCOCCAL GROUP D STREPTOCOCCI**

**Enterococci**  Epidemiology  *E. faecalis* and *E. faecium* are significant pathogens that tend to produce infection in elderly or debilitated pts and in those whose mucosal or epithelial barriers are disrupted or whose normal flora is perturbed by antibiotic treatment.

**Clinical Features**  Enterococci cause UTIs, especially in pts who have received antibiotics or have undergone instrumentation; bacteremia related to intravascular catheters; bacterial endocarditis of both native and prosthetic valves (10–20% of cases, usually with a subacute presentation but sometimes with an acute presentation and rapidly progressive valve destruction); biliary tract infections; and mixed infections, including those arising from bowel flora (e.g., abdominal surgical wounds and diabetic foot ulcers).
Streptococcal/Enterococcal Infections

CHAPTER 94

Enterococcal Infections

Therapy is complicated by the fact that penicillin alone does not reliably kill enterococci except in UTIs as well as by increasing drug resistance.

- Endocarditis and meningitis: penicillin (3–4 mU every 4 h) or ampicillin (2 g every 4 h) plus gentamicin (1 mg/kg every 8 h) for 4–6 weeks. Vancomycin may be substituted in penicillin-allergic pts.
- Gentamicin resistance (minimum inhibitory concentration > 2000 μg/mL) is increasingly common. If gentamicin-resistant strains are susceptible to streptomycin, the latter agent should be substituted.
- Penicillin or ampicillin resistance: If resistance is due to β-lactamase production, then β-lactam/β-lactamase inhibitor combinations, carbapenems (e.g., imipenem), or vancomycin may be used along with gentamicin.
- Vancomycin and penicillin resistance: Quinupristin/dalfopristin is effective against *E. faecium* with this resistance pattern. Linezolid, daptomycin, and tigecycline have activity against *E. faecalis* and *E. faecium* with such resistance.

Other Group D Streptococci

*S. bovis* has been associated with GI malignancies and other bowel lesions, which are found in ≥60% of pts presenting with *S. bovis* endocarditis. Penicillin alone constitutes adequate therapy.

VIRIDANS STREPTOCOCCI

Many viridans streptococcal species are part of the normal oral flora, residing in close association with the teeth and gingiva. Minor trauma such as flossing or brushing teeth can cause transient bacteremia. Viridans streptococci have a predilection to cause endocarditis. Moreover, they are often part of a mixed flora in sinus infections and brain and liver abscesses. Bacteremia is common in neutropenic pts, who can develop a sepsis syndrome with high fever and shock. Risk factors in these pts include trimethoprim-sulfamethoxazole (TMP-SMX) or fluoroquinolone prophylaxis, mucositis, or antacid or histamine-antagonist therapy. *S. milleri* (also known as *S. intermedius* or *S. anginosus*) differs from other viridans streptococci in both hemolytic pattern and clinical syndromes; this organism commonly causes suppurative infections, especially abscesses of brain and viscera, as well as respiratory tract infections such as pneumonia, empyema, and lung abscess. Neutropenic pts should receive vancomycin pending susceptibility testing; other pts may be treated with penicillin.

**ABIOTROPHIA SPECIES (NUTRITIONALLY VARIANT STREPTOCOCCI)**

The organisms formerly known as nutritionally variant streptococci are now classified as the separate genus *Abiotrophia*. These fastidious organisms require media that are enriched (e.g., with vitamin B₆) for growth. They are associated with more frequent treatment failure and relapse in cases of endocarditis than are viridans streptococci. Addition of gentamicin (1 mg/kg every 8 h) to the penicillin regimen is recommended when *Abiotrophia* is present.

**DIPHTHERIA**

**Definition** Diphtheria is a nasopharyngeal and skin infection caused by *Corynebacterium diphtheriae*. Some strains produce diphtheria toxin, which can cause myocarditis, polyneuropathy, and other systemic toxicities. The toxin is associated with the formation of pseudomembranes in the pharynx during respiratory infection.
**Etiology**  
*C. diphtheriae* is a club-shaped, gram-positive, unencapsulated, non-motile, nonsporulating rod. The bacteria often form clusters of parallel arrays (palisades) in culture, referred to as Chinese characters.

**Epidemiology**  
*C. diphtheriae* is transmitted via the aerosol route, primarily during close contact. Fewer than five cases due to routine immunization are diagnosed per year in the United States. Disease in the United States occurs in elderly and alcoholic individuals—often those of low socioeconomic status—as well as in Native Americans.

**Clinical Features**  
**Respiratory Diphtheria**  
Upper respiratory tract illness due to *C. diphtheriae* typically has a 2- to 5-day incubation period. Clinical diagnosis is based on the constellation of sore throat; low-grade fever; and a tonsillar, pharyngeal, or nasal pseudomembrane. Unlike that of GAS pharyngitis, the pseudomembrane of diphtheria is tightly adherent; dislodging the membrane usually causes bleeding. Occasionally, weakness, dysphagia, headache, and voice change are the initial manifestations. Massive swelling of the tonsils and “bull-neck” diphtheria resulting from submandibular and paratracheal edema can develop. This illness is further characterized by foul breath, thick speech, and stridorous breathing.

**Complications**
- Respiratory tract obstruction due to swelling and sloughing of pseudomembrane
- Myocarditis (dysrhythmia, dilated cardiomyopathy) is seen in almost one-quarter of hospitalized pts; those who die usually do so within 4 or 5 days.
- Neurologic manifestations may appear during the first 2 weeks of illness. They begin with dysphagia and nasal dysarthria and progress to cranial nerve involvement, including weakness of the tongue and facial numbness. Respiratory and abdominal muscle weakness may follow. Several weeks later, a generalized sensorimotor polyneuropathy with prominent autonomie dysfunction (including hypotension) may occur. Most survivors improve gradually.

**Diagnosis**  
A definitive diagnosis is based on compatible clinical findings and isolation of *C. diphtheriae* from local lesions or its identification by histopathology. Nonselective media and appropriate selective media must be used.

---

**Diphtheria antitoxin** is the most important component of treatment and should be given as soon as possible. Because antitoxin is produced in horses, current protocol includes a test dose to rule out immediate-type hypersensitivity. Pts who exhibit hypersensitivity should be desensitized before receiving a full dose.

To obtain antitoxin, contact the National Immunization Program at the CDC (404-639-8257 during the day; 770-488-7100 at other times). See [www.cdc.gov/nip/vaccine/dat/default.htm](http://www.cdc.gov/nip/vaccine/dat/default.htm) for further information. Treatment to prevent transmission to contacts is administered for 14 days; the recommended options are (1) procaine penicillin G (600,000 U IM every 12 h in adults; 12,500–25,000 U/kg IM every 12 h in children) until the pt can take oral penicillin V (125–250 mg qid); or (2) erythromycin (500 mg IV every 6 h in adults; 40–50 mg/kg per day IV in 2–4 divided doses in children) until the pt can take oral erythromycin (500 mg qid). Rifampin and clindamycin are other options. Cultures should document eradication of the organism 1 and 14 days after completion of antibiotic therapy. Supportive care and isolation should be instituted.
Prognosis  Risk factors for death include bull-neck diphtheria, myocarditis with ventricular tachycardia, atrial fibrillation, complete heart block, an age of >60 years or <6 months, alcoholism, extensive pseudomembrane elongation, and laryngeal, tracheal, or bronchial involvement. The interval between onset of local disease and antitoxin administration also predicts outcome.

Prevention  DTaP (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) is recommended for primary immunization of children up to age 7 years. Tdap (tetanus toxoid with reduced diphtheria toxoid and acellular pertussis) is recommended as the booster vaccine for children 11–12 years old and as the catch-up vaccine for children 7–10 and 13–18 years old. Td (tetanus and diphtheria toxoids) is recommended for routine booster use in adults at 10-year intervals or for tetanus-prone wounds. When >10 years have elapsed since the last Td dose, adults 19–64 years old should receive a single dose of Tdap. Close contacts of pts with respiratory diphtheria should have throat specimens cultured for *C. diphtheriae*, should receive a 7- to 10-day course of oral erythromycin or one dose of benzathine penicillin (1.2 mU for persons ≥6 years old; 600,000 U for children <6 years old), and should receive vaccine if immunization status is uncertain.

INFECTIONS WITH OTHER CORYNEBACTERIA AND RELATED ORGANISMS

Nondiphtherial *Corynebacterium* species and related organisms are common components of the normal human flora. Although frequently considered contaminants, these bacteria are associated with invasive disease in immunocompromised hosts.

- *C. ulcerans* infection is a zoonosis that causes diphtheria-like illness and requires similar treatment.
- *C. jeikeium* colonizes pts with cancer or severe immunodeficiency and can cause severe sepsis, endocarditis, device-related infections, pneumonia, and soft tissue infections. Treatment consists of removal of the source of infection and administration of vancomycin.
- *C. urealyticum* is a cause of nosocomial UTI and sepsis. Vancomycin is an effective therapeutic agent.
- *Rhodococcus* causes tuberculosis-like infections with granulomatous pathology in immunocompromised hosts, often occurring in conjunction with HIV infection. Vancomycin, macrolides, clindamycin, rifampin, and TMP-SMX have been used to treat these infections.
- *Arcanobacterium haemolyticum* can cause pharyngitis and chronic skin ulcers, often in association with a scarlatiniform rash similar to that caused by GAS. The organism is susceptible to β-lactam agents, macrolides, fluoroquinolones, clindamycin, vancomycin, and doxycycline. Penicillin failures have occurred.

For a more detailed discussion, see Wessels MR: Streptococcal and Enterococcal Infections, Chap. 130, p. 881; and Bishai WR, Murphy JR: Diphtheria and Other Infections Caused by Corynebacteria and Related Species, Chap. 131, p. 890, in HPIM-17.
Infectious Diseases

SECTION 7

Meningococcal and Listerial Infections

MENINGOCOCCAL INFECTIONS

Etiology and Epidemiology  
*Neisseria meningitidis* (the meningococcus) causes two life-threatening diseases: meningitis and fulminant meningococcemia. Meningococci are gram-negative aerobic diplococci with a polysaccharide capsule. Five serogroups—A, B, C, Y, and W-135—account for >90% of the 300,000–500,000 cases of meningococcal disease that occur worldwide each year. Serogroup A causes recurrent epidemics in sub-Saharan Africa. In the United States, serogroup B causes most sporadic disease, serogroup C causes most outbreaks, and serogroup Y is becoming more prevalent, particularly among older pts and pts with underlying chronic disease. Rates of meningococcal disease are highest among infants and children; a second peak in teenagers is due to residence in barracks, dormitories, or other crowded situations. Meningococci are transmitted via respiratory secretions. Colonization of the nasopharynx or pharynx can persist asymptomatically for months. In nonepidemic situations, 10% of the population is colonized. Household contact with a meningococcal disease pt or a meningococcal carrier, household or institutional crowding, exposure to tobacco smoke, and a recent viral upper respiratory infection are risk factors for colonization and invasive disease.

Pathogenesis  
Meningococci colonize the upper respiratory tract, are internalized by nonciliated mucosal cells, enter the submucosa, and reach the bloodstream. If bacterial multiplication is slow, the bacteria may seed local sites such as the meninges. If multiplication is rapid, meningococcemia develops. Morbidity and mortality from meningococcemia have been directly correlated with the amount of circulating endotoxin, which can be 10- to 1000-fold higher than levels seen in other gram-negative bacteremias. Deficiencies in antithrombin and proteins C and S can occur during meningococcal disease, and there is a strong negative correlation between protein C activity and mortality risk. Antibodies to serogroup-specific capsular polysaccharide constitute the major host defense. Protective antibodies are induced by colonization with nonpathogenic bacteria possessing cross-reactive antigens. Deficiency of late complement components C5–C9 can result in recurrent infections.

Clinical Features

- Respiratory tract disease that is clinically apparent is most common among adults. Serogroup Y causes pneumonia, particularly often in military populations.
- Meningococcemia without meningitis occurs in ~10–30% of pts with meningococcal disease. Clinical manifestations include the following.
  1. Fever, chills, nausea, vomiting, myalgias, prostration
  2. Rash: erythematous macules, primarily on the trunk and extremities, that become petechial and—in severe cases—purpuric and may coalesce into hemorrhagic bullae that necrose and ulcerate
  3. Fulminant disease is associated with hemorrhagic skin lesions and disseminated intravascular coagulation (DIC) and is perhaps the most rapidly fatal form of septic shock in humans. Waterhouse-Friderichsen syndrome
consists of DIC-induced microthrombosis, hemorrhage, tissue injury, and adrenal insufficiency.

4. Long-term morbidity includes loss of skin, limbs, or digits from ischemic necrosis and infarction.

5. Chronic meningococcemia is a rare syndrome of episodic fever, rash, and arthralgias lasting for weeks to months. If treated with steroids, this condition may become fulminant or evolve into meningitis.

- Meningitis pts usually present after >24 h of illness with headache, nausea and vomiting, neck stiffness, lethargy, and confusion. Petechial or purpuric skin lesions help distinguish this form of bacterial meningitis from other types. Cerebrospinal fluid (CSF) examination reveals an increased protein concentration, a low glucose level, and neutrophilic leukocytosis. Sequelae include mental retardation, deafness, and hemiparesis.

- Arthritis occurs in ~10% of pts with meningococcal disease.

**Diagnosis**

Definitive diagnosis relies on isolation of the organism from normally sterile body fluids. Gram’s staining of CSF yields positive results in ~85% of pts with meningococcal meningitis; if results are positive in the absence of CSF leukocytosis, the prognosis is poor. Polymerase chain reaction tests on buffy coat or CSF are more sensitive than Gram’s staining or latex agglutination tests for meningococcal polysaccharides and are unaffected by prior antibiotic therapy.

**Meningococcal Infections**

See Table 95-1. Glucocorticoid therapy (10 mg IV 15 min before the first antibiotic dose and then q6h for 4 days) is controversial, but many experts recommend it. Pts with fulminant meningococcemia need aggressive supportive therapy that can include vigorous fluid resuscitation, elective ventilation, pressor agents, fresh-frozen plasma (in pts with abnormal clotting parameters), and supplemental glucocorticoid treatment (hydrocortisone, 1 mg/kg every 6 h) for impaired adrenal reserve. Activated protein C (24 μg/kg per hour in a continuous infusion for 96 h) is recommended for pts with severe sepsis of any cause and an APACHE II score of >25; pts with meningococcemia may be one group most likely to benefit from this treatment. If the platelet count is <50,000/μL or if there is active bleeding, activated protein C should not be given.

**Prognosis**

Shock, purpuric or ecchymotic rash, low or normal blood leukocyte count, an age of ≥60 years, coma, absence of meningitis, thrombocytopenia, and low erythrocyte sedimentation rate are all associated with increased mortality risk. Receipt of antibiotics prior to hospital admission has been associated with a better outcome in some studies.

**Prevention**

- Vaccines: A meningococcal conjugate vaccine active against serogroups A, C, Y, and W-135 but not against serogroup B was licensed in 2005 for use in the United States. The conjugate vaccine has increased immunogenicity and probably confers longer-duration protection than the previously available polysaccharide vaccine. The conjugate vaccine is also expected to reduce asymptomatic carriage of *N. meningitidis* and to produce herd immunity. In light of these considerations, the meningococcal conjugate vaccine is now recommended for routine vaccination of all persons 11–18 years old
Infectious Diseases

SECTION 7

and of persons 2–55 years old who are at increased risk for meningococcal disease.

• Antimicrobial chemoprophylaxis: See Table 95-1 for prophylaxis options. Household and other close contacts (e.g., day-care center contacts, persons exposed to a pt’s oral secretions) have a >400-fold higher risk of meningococcal disease than the population as a whole.

• Respiratory isolation of hospitalized pts during the first 24 h of treatment is required.

### TABLE 95-1
**ANTIBIOTIC TREATMENT, CHEMOPROPHYLAXIS, AND VACCINATIONS FOR INVASIVE MENINGOCOCCAL DISEASE**

**Antibiotic Treatment**

1. Ceftriaxone 2 g IV q12h (100 mg/kg per day) or cefotaxime 2 g IV q4h
2. For penicillin-sensitive *N. meningitidis*: Penicillin G 18–24 million units per day in divided doses q4h (250,000 units/kg per day)
3. Chloramphenicol 75–100 mg/kg per day in divided doses q6h
4. Meropenem 1.0 g (children, 40 mg) IV q8h
5. In an outbreak setting in developing countries: Long-acting chloramphenicol in oil suspension (Tifomycin), single dose
   - Adults: 3.0 g (6 mL)
   - Children 1–15 years old: 100 mg/kg
   - Children <1 year old: 50 mg/kg

**Chemoprophylaxis**

- **Rifampin (oral)**
  - Adults: 600 mg bid for 2 days
  - Children ≥1 month old: 10 mg/kg bid for 2 days
  - Children <1 month old: 5 mg/kg bid for 2 days

- **Ciprofloxacin (oral)**
  - Adults: 500 mg, 1 dose

- **Ceftriaxone (IM)**
  - Adults: 250 mg, 1 dose
  - Children <15 years old: 125 mg, 1 dose

- **Azithromycin (oral)**
  - 500 mg, 1 dose

**Vaccination**

- **A, C, Y, W-135 vaccine (Memomune, Aventis Pasteur) or A, C vaccine**
  - Single 0.5-mL subcutaneous injection

- **New C; A, C; and A, C, Y, W-135 meningococcal conjugate vaccines**

*Patients with meningococcal meningitis should receive antimicrobial therapy for at least 5 days.*

*Use is recommended for close contacts of cases or if ceftriaxone is not used for primary treatment.*

*At present, use is generally limited to the control of epidemics and to individuals with increased risk of meningococcal disease. Vaccine efficacy wanes after 3–5 years, and vaccine is not effective in recipients <2 years of age.*

*These vaccines appear to provide immunity in young children, a prolonged immune response, and herd immunity (decreased transmission and colonization); see “Prevention” section of text.*
**Listerial Infections**

**Etiology and Epidemiology** *Listeria monocytogenes* is a foodborne pathogen that can cause serious infections, particularly in pregnant women and immunocompromised individuals. The organism is a nonsporulating, gram-positive rod that demonstrates motility when cultured at low temperatures. Listeriosis can follow the ingestion of contaminated food. *Listeria* can be found in processed and unprocessed foods such as soft cheeses, delicatessen meats, hot dogs, milk, and cold salads.

**Clinical Features** *Listeria* causes several clinical syndromes, of which meningitis and septicemia are most common.

- **Gastroenteritis**: Gastroenteritis can develop within 48 h after the ingestion of contaminated foods containing a large inoculum of bacteria. Listeriosis should be considered in outbreaks of gastroenteritis when cultures for other likely pathogens are negative.
- **Bacteremia**: Pts present with fever, chills, myalgias, and arthralgias. Neurologic findings or meningeal signs may suggest the diagnosis. Endocarditis is uncommon and is associated with fatality rates of 35–50%.
- **Meningitis**: *Listeria* causes ~5–10% of cases of community-acquired meningitis in adults. In the United States, case-fatality rates are 15–26%. Listerial meningitis differs from meningitis of other bacterial etiologies in that its presentation is often subacute and the CSF profile usually reveals <1000 white blood cells/μL with a less marked polymorphonuclear leukocyte predominance. Low glucose levels and a positive Gram’s stain are seen in ~30–40% of cases.
- **Meningoencephalitis and central nervous system (CNS) infection**: *Listeria* can directly invade the brain parenchyma and cause cerebritis or focal abscess. Brainstem invasion can cause severe rhombencephalitis. Pts have fever and headache followed by asymmetric cranial nerve defects, cerebellar signs, and hemiparetic/hemisensory defects.
- **Infection in pregnant women and neonates**: Listeriosis is a serious infection in pregnancy. Pts are usually bacteremic and present with a nonspecific febrile illness that includes myalgias/arthritis, backache, and headache. CNS involvement is rare. Infection develops in 70–90% of fetuses from infected women; almost 50% of infected fetuses die. This risk can be reduced with prepartum treatment. Infected women usually do well after delivery. Overwhelming listerial fetal infection—granulomatosis infantiseptica—is characterized by miliary microabscesses and granulomas, most often in the skin, liver, and spleen.

**Diagnosis** Timely diagnosis requires that the illness be considered in groups at risk: pregnant women, elderly pts, neonates, immunocompromised pts (e.g., transplant recipients, cancer pts, pts being treated with tumor necrosis factor antagonists or glucocorticoids), and pts with chronic underlying medical conditions (e.g., alcoholism, diabetes). Listeriosis is diagnosed when the organism is cultured from a usually sterile site, such as blood, CSF, or amniotic fluid. Listeriae may be confused with “diphtheroids” or pneumococci in gram-stained CSF or may be gram-variable and confused with *Haemophilus* spp.

**Rx** **Listerial Infections**

- Ampicillin is the drug of choice for the treatment of listerial infections; penicillin is also highly active. Adults should receive ampicillin at a dosage
of 2 g IV every 4 h. Most experts recommend gentamicin (1.0–1.7 mg/kg every 8 h) for synergy. For penicillin-allergic pts, trimethoprim-sulfamethoxazole (15–20 mg of TMP/kg IV daily in divided doses every 6–8 h) should be given. These doses cover CNS infection and bacteremia. Cephalosporins are not effective. Neonates should receive ampicillin and gentamicin, dosed by weight.

- The duration of therapy depends on the syndrome: 2 weeks for bacteremia, 3 weeks for meningitis, 6–8 weeks for brain abscess/encephalitis, and 4–6 weeks for endocarditis. Early-onset neonatal disease can be severe and requires >2 weeks of treatment.

**Prognosis** With prompt therapy, 50–70% of pts recover fully unless they have brain abscess or rhombencephalitis. Of live-born treated neonates in one series, 60% recovered fully, 24% died, and 13% were left with sequelae or complications.

**Prevention** Pregnant women and other persons at risk for listeriosis should avoid soft cheeses and should avoid or thoroughly reheat ready-to-eat and deli-catessen foods.


### Infections Caused by *Haemophilus*, *Bordetella*, *Moraxella*, and HACEK Group Organisms

#### HAEMOPHILUS INFLUENZAE

**Etiology and Epidemiology** *H. influenzae* is a small, gram-negative, pleomorphic coccobacillus. Strains with a polysaccharide capsule are serotyped a through f. *H. influenzae* type b (Hib) is most important clinically, causing systemic invasive disease, primarily in infants and children <6 years of age. Use of Hib conjugate vaccine has dramatically decreased rates of Hib colonization and invasive disease. Nontypable strains of *H. influenzae* (NTHi), which are unencapsulated, cause disease by locally invading mucosal surfaces. NTHi strains colonize the upper respiratory tract of up to 75% of healthy adults. *H. influenzae* is spread by airborne droplets or through direct contact with secretions or fomites.

**Clinical Features**

- **Hib**

  1. Meningitis is associated with high morbidity; 6% of pts have sensorineural hearing loss; one-fourth have some significant sequelae; mortality is ~5%.
2. Epiglottitis, which occurs in older children and occasionally in adults, involves cellulitis of the epiglottis and supraglottic tissues that begins with a sore throat and progresses rapidly to dysphagia, drooling, and airway obstruction.

3. Miscellaneous: cellulitis, pneumonia, osteomyelitis

   • NTHi
   1. Community-acquired pneumonia in adults—especially those with chronic obstructive pulmonary disease (COPD) or AIDS—and exacerbations of COPD
   2. Miscellaneous: childhood otitis media, puerperal sepsis, neonatal bacteremia, sinusitis, and—less commonly—invasive infections (e.g., osteomyelitis, endocarditis)

Diagnosis

Gram’s staining and culture of clinical samples

H. influenzae Infections

• Hib meningitis in adults: ceftriaxone (2 g every 12 h for 1–2 weeks)
• Hib meningitis in children: ceftriaxone (75–100 mg/kg per day, split into two doses given every 12 h) plus dexamethasone (0.6 mg/kg per day in four divided doses for 2 days at initiation of antibiotic treatment to prevent hearing loss)
• Epiglottitis: ceftriaxone (50 mg/kg daily for 1–2 weeks)
• NTHi: About 20–35% of clinical isolates produce β-lactamase. Many agents are useful: amoxicillin/clavulanate, extended-spectrum cephalosporins, newer macrolides (azithromycin or clarithromycin), and fluoroquinolones (in nonpregnant adults).
• Ampicillin-resistant strains of H. influenzae in which resistance is due to altered penicillin-binding proteins rather than to β-lactamase production are increasing in prevalence in Europe and Japan.

Prevention

Hib vaccine is recommended for all children; the immunization series should be started at ~2 months of age. Secondary attack rates are high among household contacts of pts with Hib disease. All children and adults (except pregnant women) in households with a case of Hib disease and at least one incompletely immunized contact <4 years of age should receive prophylaxis with oral rifampin.

PERTUSSIS

Etiology

Bordetella pertussis causes pertussis, an acute respiratory tract infection. B. pertussis is a fastidious gram-negative aerobic bacillus that attaches to ciliated epithelial cells of the nasopharynx, multiplies locally, and produces a wide array of toxins and biologically active products.

Epidemiology

Pertussis is highly communicable. In households, attack rates are 80% among unimmunized contacts and 20% among immunized contacts. Pertussis remains an important cause of infant morbidity and death in developing countries. In the United States, the incidence has increased slowly since 1976, particularly among adolescents and adults. Persistent cough of >2 weeks’ duration in an adult may be due to B. pertussis in 12–30% of cases. Severe morbidity and mortality are restricted to infants <6 months of age.
**Clinical Features**  After an incubation period of 7–10 days, a prolonged coughing illness begins. Symptoms are usually more severe in infants and young children.

- The *catarrhal* phase is similar to the common cold and lasts 1–2 weeks.
- The *paroxysmal* phase follows and lasts 2–4 weeks. It is characterized by cough that at times occurs in spasmodic fits of 5–10 coughs each. Episodes are worse at night. Vomiting or a “whoop” may follow a coughing fit. Apnea and cyanosis can occur during spasms. Pts become increasingly fatigued.
- *Convalescent* phase: Symptoms resolve over 1–3 months.

**Diagnosis**

- Cultures of nasopharyngeal secretions remain positive in untreated cases for a mean of 3 weeks after illness onset. Secretions must be inoculated immediately onto selective media. Results become positive by day 5.
- Compared with culture, polymerase chain reaction of nasopharyngeal specimens provides increased sensitivity and longer duration of a positive result in both treated and untreated pts. Results can be available within hours.
- Although serology can be useful in pts with symptoms lasting >4 weeks, diagnostic criteria are not agreed upon, and antibody tests are not widely available.

**Pertussis**

- Macrolides: erythromycin (1–2 g/d for 1–2 weeks); clarithromycin (250 mg bid for 1 week); azithromycin (500-mg load on day 1, then 250 mg/d for 4 days)
- Trimethoprim-sulfamethoxazole (TMP-SMX) in macrolide-intolerant pts
- Respiratory isolation for hospitalized pts until antibiotics have been given for 5 days

**Prevention**

- Chemoprophylaxis with macrolides for household contacts of pts, especially if there are household members at high risk of severe disease (e.g., children <1 year of age)
- Immunization: In the United States, acellular vaccines are safe for older children and adults.

**MORAXELLA CATARRHALIS**

**Etiology**  *M. catarrhalis* is a gram-negative coccus that resembles *Neisseria*. It can retain crystal violet on Gram’s staining and be confused with *Staphylococcus aureus*. Part of the normal flora of the upper airways, *M. catarrhalis* colonizes up to 50% of healthy children and up to 3–7% of healthy adults. Infection rates peak in late winter/early spring.

**Clinical Features**

- Otitis media and sinusitis: *M. catarrhalis* is the third most common cause of otitis media in children and is a prominent isolate from cases of acute and chronic sinusitis.
- Purulent tracheobronchitis and pneumonia: Most pts are >50 years of age and have COPD (often with lung cancer as well).
- Symptoms are mild to moderate; invasive disease (e.g., empyema) is rare.

**Diagnosis**  Gram’s staining and cultures of sputum
**M. catarrhalis Infections**

Moraxellae are susceptible to β-lactam/β-lactamase inhibitor combinations, second- and third-generation cephalosporins, doxycycline, newer macrolides, TMP-SMX, and fluoroquinolones. Respiratory infections should be treated with a 5-day course and sinusitis for longer durations.

---

**THE HACEK GROUP**

**Etiology**  The HACEK group consists of fastidious, slow-growing, gram-negative bacteria whose growth requires carbon dioxide. Normal residents of the oral cavity, HACEK bacteria can cause both local oral infections and severe systemic disease, particularly endocarditis. Several *Haemophilus* species, *Actinobacillus actinomycetemcomitans*, *Cardiobacterium hominis*, *Eikenella corrodens*, and *Kingella kingae* make up this group.

**Clinical Features**

- **HACEK endocarditis:** Up to 3% of cases of infective endocarditis are caused by HACEK organisms; most of these cases are due to *A. actinomycetemcomitans*, *Haemophilus* species, or *C. hominis*. Pts often have underlying valvular disease. Embolization is common, even in subacute presentations. Major emboli are found in 28–71% of pts and vegetations—often very large—in 85%. Cultures can take 30 days to become positive, although most cultures that ultimately yield HACEK bacteria become positive in the first week, especially with newer detection systems such as BACTEC.
- **Haemophilus species:** *H. aphrophilus*, *H. parainfluenzae*, and *H. paraphrophilus* cause more than half of all cases of HACEK endocarditis. Pts usually present within the first 2 months of illness, and 19–50% of pts develop congestive heart failure.
- **A. actinomycetemcomitans:** This organism is isolated from soft tissue infections in association with *Actinomyces israelii*. It is associated with severe destructive periodontal disease, which also is frequently evident in pts with endocarditis.
- **C. hominis:** Unlike other HACEK bacteria, *C. hominis* most often affects the aortic valve. Long-standing infection usually precedes diagnosis.
- **E. corrodens:** Usually a component of mixed infections, *E. corrodens* is common in human bite wounds, head and neck soft-tissue infections, endocarditis, and infections in IV drug users.
- **K. kingae:** *K. kingae* is the third most common cause of septic arthritis in children <2 years old and a common cause of osteomyelitis in the same age group. *K. kingae* bacteremia is seen in association with stomatitis (e.g., due to herpes simplex virus infection). Unlike other *K. kingae* infections, endocarditis due to this organism occurs in older children and adults. Inoculation of clinical specimens (e.g., synovial fluid) into aerobic blood culture bottles enhances recovery of this organism.

---

**HACEK Group Infections**

See Table 96-1 for antibiotic regimens used to treat endocarditis and other serious infections caused by HACEK organisms. Native-valve endocarditis should be treated for 4 weeks and prosthetic-valve endocarditis for 6 weeks. Unlike prosthetic-valve endocarditis caused by other gram-negative organisms, that due to HACEK bacteria can often be cured with antibiotics alone (i.e., without surgery).
<table>
<thead>
<tr>
<th>Organism</th>
<th>Initial Therapy</th>
<th>Alternative Agents</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Haemophilus species</em>, <em>Actinobacillus</em></td>
<td>Ceftriaxone (2 g/d)</td>
<td>Ampicillin/sulbactam (3 g of ampicillin q6h) or fluoroquinolones&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Ampicillin ± an aminoglycoside can be used if the organism does not produce β-lactamase.&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td><em>Actinomycetemcomitans</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Cardiobacterium hominis</em></td>
<td>Penicillin (16–18 mU/d in 6 divided doses) or ampicillin (2 g q4h)</td>
<td>Ceftriaxone (2 g/d) or ampicillin/sulbactam (3 g of ampicillin q6h)</td>
<td>An aminoglycoside (gentamicin, 3 mg/kg per day in 3 divided doses) may be added, but its value has not been proven. The organism is usually pan-sensitive, but high-level penicillin resistance has been reported.</td>
</tr>
<tr>
<td><em>Eikenella corrodens</em></td>
<td>Ampicillin (2 g q4h)</td>
<td>Ceftriaxone (2 g/d) or fluoroquinolones&lt;sup&gt;b&lt;/sup&gt;</td>
<td>The organism is typically resistant to clindamycin, metronidazole, and aminoglycosides.</td>
</tr>
<tr>
<td><em>Kingella kingae</em></td>
<td>Ceftriaxone (2 g/d) or ampicillin/sulbactam (3 g of ampicillin q6h)</td>
<td>Fluoroquinolones&lt;sup&gt;b&lt;/sup&gt;</td>
<td>The prevalence of β-lactamase-producing strains is increasing. Efficacy for invasive infections is best demonstrated for first-line treatments.</td>
</tr>
</tbody>
</table>

<sup>a</sup>Susceptibility testing should be performed in all cases to guide therapy.<br><sup>b</sup>Fluoroquinolones are not recommended for treatment of children <17 years of age.<br><sup>c</sup>European guidelines for endocarditis recommend the addition of gentamicin (3 mg/kg per day in 3 divided doses for 2–4 weeks).
Diseases Caused by Gram-Negative Enteric Bacteria, Pseudomonas, and Legionella

INFECTIONS CAUSED BY GRAM-NEGATIVE ENTERIC BACTERIA

GENERAL CONSIDERATIONS

Gram-negative bacilli (GNB) are normal components of the human colonic flora and can colonize mucosal and skin surfaces of pts in long-term-care and hospital settings. Virtually every organ or body cavity can be infected with GNB. Escherichia coli and, to a lesser degree, Klebsiella and Proteus account for most infections. Isolation of GNB from any sterile site almost always implies infection. Isolation from nonsterile sites requires clinical correlation. Early appropriate antimicrobial therapy improves outcomes. Multidrug resistance in GNB [e.g., due to extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases] is increasing worldwide. Combination empirical antimicrobial therapy may be appropriate pending susceptibility results.

EXTRAINTESTINAL INFECTIONS CAUSED BY PATHOGENIC E. COLI

Most E. coli isolates from symptomatic infections outside the GI tract are distinct from commensal strains and from pathogenic strains that cause intestinal infections.

Clinical Features

• Urinary tract infection (UTI): E. coli is the most prevalent pathogen in all genitourinary syndromes and causes 85–95% of acute uncomplicated UTIs.
• Abdominal and pelvic infection: the second most common site of infection with extraintestinal pathogenic strains of E. coli (ExPEC). Syndromes include peritonitis, intraabdominal abscesses, and cholangitis.
• Pneumonia: In pts with underlying illnesses and antibiotic exposure, rates of colonization with and pneumonia due to GNB increase. ExPEC is a common cause of pneumonia in long-term-care residents and hospitalized pts. E. coli can cause multifocal nodular infiltrates with tissue necrosis. Mortality rates are high.
• Meningitis: occurs mostly in neonates; caused by strains with the K1 capsular serotype
• Cellulitis/musculoskeletal infection: E. coli often contributes to infection of decubitus ulcers and to diabetic lower-extremity ulcers. When close to the
Infectious Diseases

SECTION 7

perineum, cellulitis and burn-site or surgical-site infections can be due to *E. coli*. Osteomyelitis, particularly vertebral, is more common than is generally appreciated; *E. coli* accounts for up to 10% of cases in some series.

- Bacteremia: can arise from primary infection at any site, but originates most commonly from the urinary tract and next most commonly from the bowel and biliary tract. Endovascular infections are rare but have been described.

**Diagnosis**

ExPEC grows readily on standard media. Most strains ferment lactose and are indole-positive.

### Extraintestinal Infections Caused by *E. coli*

Rates of resistance to ampicillin, first-generation cephalosporins, trimethoprim-sulfamethoxazole (TMP-SMX), and fluoroquinolones are increasing. ESBLs are increasingly common in *E. coli*. Currently, cephalosporins (particularly second-, third-, and fourth-generation agents), monobactams, piperacillin-tazobactam, carbapenems, and aminoglycosides retain good activity.

### Intestinal Infections Caused by *E. coli*

At least five “pathotypes” of *E. coli* cause intestinal infections exclusively. (For further discussion, see Chap. 89.)

1. Shiga toxin–producing *E. coli* (STEC)/enterohemorrhagic *E. coli* (EHEC): In contrast to other pathotypes, STEC/EHEC causes infection more frequently in developed countries. *E. coli* O157:H7 belongs to this pathotype. STEC/EHEC is associated with ingestion of contaminated food and water or person-to-person transmission. Ground beef is a common food source.

2. Pathotypes most common in developing countries
   a. Enterotoxigenic *E. coli* (ETEC): the most common agent of traveler’s diarrhea
   b. Enteropathogenic *E. coli* (EPEC): an important cause of diarrhea among infants
   c. Enteroinvasive *E. coli* (EIEC): causes inflammatory colitis similar to that caused by *Shigella*
   d. Enteroaggregative and diffusely adherent *E. coli* (EAEC): causes prolonged watery diarrhea

**Diagnosis**

Specific diagnosis is usually unnecessary except when STEC/EHEC is involved. Bloody diarrhea can be screened for *E. coli* strains that do not ferment sorbitol, and strains can then be typed for *E. coli* O157:H7. However, testing for Shiga toxins or toxin genes is more sensitive, specific, and rapid.

### Intestinal Infections Caused by *E. coli*

Supportive care, replacement of water and electrolytes, and avoidance of antibiotics in STEC/EHEC infection (since antibiotic use may increase the risk of hemolytic-uremic syndrome) are indicated.

### Klebsiella Infections

**Etiology**

*K. pneumoniae* colonizes the colon in 5–35% of healthy individuals and causes most Klebsiella infections. *K. oxytoca* causes infections in long-
Diseases Caused by Gram-Negative Bacteria

CHAPTER 97


**Clinical Features**

- **Pneumonia:** occurs primarily in pts with underlying disease (e.g., alcoholism, diabetes, chronic obstructive pulmonary disease). Long-term-care facility residents and hospitalized pts have higher rates of oropharyngeal colonization and more frequent *K. pneumoniae* pulmonary infections. The presentation is similar to that of pneumonia caused by other enteric GNB, with purulent sputum production and pulmonary infiltrates on chest x-ray (CXR). Infection can progress to pulmonary necrosis, pleural effusion, and empyema.
- **UTI:** *K. pneumoniae* causes 1–2% of cases of uncomplicated cystitis and 5–17% of cases of complicated UTI.
- **Abdominal infections:** spectrum similar to that of *E. coli*, but less frequent occurrence
- **Cellulitis and soft tissue infections:** most often involve devitalized tissues in compromised hosts. *K. pneumoniae* causes some surgical-site infections.
- **Miscellaneous:** Bacteremia can arise from a primary infection at any site.
- **Other infections:** include endophthalmitis, nosocomial sinusitis, osteomyelitis

**Diagnosis**

*Klebsiellae* usually ferment lactose, although the subspecies *rhinoscleromatis* and *ozaenae* are nonfermenters and are indole-negative.

**PROTEUS INFECTIONS**

**Etiology**

*P. mirabilis* is part of the colonic flora in up to half of healthy people and causes 90% of *Proteus* infections. *P. vulgaris* and *P. penneri* are isolated primarily from pts in hospitals and long-term-care facilities.

**Clinical Features**

*Proteus* causes 1–2% of uncomplicated UTIs, 5% of hospital-acquired UTIs, and 10–15% of complicated UTIs, especially those associated with urinary catheters. Pts with long-term catheterization have *Proteus* infection prevalence rates of 20–45%. *Proteus* produces high levels of urease, alkalinizes urine, and causes formation of struvite calculi. Removal of the stones or the urinary catheter is usually required for cure of infection. Infections rarely occur in other sites.

**Diagnosis**

*Proteus* strains are typically lactose-negative and exhibit swarming motility on agar plates. *P. mirabilis* is indole-negative, whereas most other *Proteus* strains are indole-positive.

**Proteus Infections**

*P. mirabilis* is susceptible to most agents. Resistance to ampicillin, first-generation cephalosporins, and quinolones is increasing. *P. vulgaris* and *P. penneri*
are more resistant. Imipenem, fourth-generation cephalosporins, aminoglycosides, and TMP-SMX exhibit excellent activity.

OTHER GRAM-NEGATIVE ENTERIC PATHOGENS

Enterobacter (e.g., *E. cloacae*, *E. aerogenes*), Acinetobacter (e.g., *A. baumannii*), Serratia (e.g., *S. marcescens*), and Citrobacter (e.g., *C. freundii*, *C. koseri*) usually cause nosocomial infections. These organisms are associated with moist environmental foci. Risk factors include immunosuppression, comorbid disease, prior antibiotic use, and intensive care unit (ICU) stays. Infections caused by *Morganella* (e.g., *M. morganii*) and *Providencia* (e.g., *P. stuartii*, *P. rettgeri*) resemble *Proteus* infections in terms of epidemiology, pathogenicity, and clinical manifestations but occur almost exclusively in persons in long-term-care facilities and, to a lesser degree, in hospitalized pts.

Clinical Features

- Pneumonia, particularly ventilator-associated
- UTI, especially catheter-related. *Morganella* and *Providencia* are particularly strongly associated with long-term catheterization (>30 days).
- Intravascular device–related infection, surgical-site infection, and abdominal infection
- Biliary disease is associated with *Enterobacter*.
- *Acinetobacter* has caused soft tissue and bone infections among soldiers with battlefield injuries.

**Other Gram-Negative Enteric Pathogens**

Significant antibiotic resistance makes therapy challenging. Imipenem and aminoglycosides (amikacin > gentamicin) are most reliably active, and fourth-generation cephalosporins often display excellent activity. *Enterobacter* is commonly resistant to third-generation cephalosporins and monobactams. *Acinetobacter* may be susceptible to β-lactam/β-lactamase inhibitor agents, but these agents do not have enhanced activity against *Enterobacter* or *Citrobacter*. Susceptibility testing is essential. Some isolates may retain susceptibility only to colistin and polymyxin B.

AEROMONAS INFECTIONS

*A. hydrophila* is the most common *Aeromonas* species causing infection. *Aeromonas* organisms proliferate in potable and fresh water and are a putative cause of gastroenteritis. *Aeromonas* causes bacteraemia and sepsis in infants and compromised hosts, especially those with cancer, hepatobiliary disease, trauma, or burns. The organisms can produce skin lesions similar to the ecthyma gangrenosum lesions seen with *P. aeruginosa*. *Aeromonas* causes nosocomial infections related to catheters, surgical incisions, and use of leeches.

**Aeromonas Infections**

*Aeromonas* is usually susceptible to fluoroquinolones (e.g., ciprofloxacin at a dose of 500 mg PO q12h or 400 mg IV q12h), TMP-SMX (10 mg of TMP/kg per day in 3 or 4 divided doses), third-generation cephalosporins, and aminoglycosides.
Diseases Caused by Gram-Negative Bacteria

CHAPTER 97

INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA AND RELATED ORGANISMS

PSEUDOMONAS AERUGINOSA

Epidemiology  
*P. aeruginosa* is found in most moist environments. The many factors that predispose to *P. aeruginosa* infection include disruption of cutaneous or mucosal barriers (e.g., due to burns or trauma), immunosuppression (e.g., due to neutropenia, AIDS, or diabetes), and disruption of the normal bacterial flora (e.g., due to broad-spectrum antibiotic therapy).

Laboratory Features  
*P. aeruginosa* is a motile gram-negative rod that commonly produces green or bluish pigment. *P. aeruginosa* differs from enteric GNB in that it has a positive reaction in the oxidase test and does not ferment lactose.

Clinical Features

- **Bacteremia**
  1. *P. aeruginosa* is no longer a major cause of life-threatening bacteremia in neutropenic pts or those with burn injury. *P. aeruginosa* bacteremia is currently most common among pts in the ICU.
  2. Pathognomonic skin lesions, called *ecthyma gangrenosum*, develop in a small minority of pts with *P. aeruginosa* bacteremia, beginning as painful reddish maculopapular lesions that become black and necrotic.
- **Respiratory tract infections:** the most common of all infections caused by *P. aeruginosa*
  1. Acute pneumonia: presents with fever, chills, and cough and can have a fulminant course with cyanosis, tachypnea, and systemic toxicity. CXR shows bilateral pneumonia, often with nodular densities and/or cavitation. This presentation is now uncommon. Community-acquired necrotizing pneumonia can follow inhalation of hot-tub water contaminated with *P. aeruginosa*.
  2. Ventilator-associated pneumonia (VAP): *P. aeruginosa* is considered a major cause of VAP, although colonization may be difficult to distinguish from true infection. Clinically, most pts have a slowly progressive infiltrate, although progression is rapid in some cases. Infiltrates may become necrotic. Bronchoalveolar lavage or protected-brush sampling of distal airways should be done to substantiate *P. aeruginosa* pneumonia.
- **Chronic respiratory infections** in pts with underlying or predisposing conditions (e.g., cystic fibrosis or bronchiectasis)
- **Endocarditis:** occurs mostly in IV drug users and pts with prosthetic valves
- **Bone and joint infections**
  1. Sternoclavicular joint infection: a complication of injection drug use
  2. Vertebral osteomyelitis: associated with UTIs in the elderly and with injection drug use
  3. Osteomyelitis of the foot: follows plantar puncture wounds, typically through sneakers. This infection is most common among children.
- **Central nervous system infections:** rare, almost always secondary to surgical procedures or head trauma
- **Eye infections:** keratitis, corneal ulcer, and endophthalmitis can occur, usually resulting from trauma or surface injury by contact lenses. These infections are rapidly progressing entities that demand immediate therapeutic intervention.
Infectious Diseases

SECTION 7

• Ear infections
  1. External otitis (“swimmer’s ear”)
  2. Malignant external otitis: occurs mostly in elderly diabetic pts. Decreased hearing and severe ear pain are the usual presenting symptoms. If the infection is diagnosed late in the course, pts may present with cranial-nerve palsies or cavernous venous sinus thrombosis. Infection involves ear cartilage and sometimes mastoid and petrous ridge bone. Treatment is the same as for osteomyelitis.

• UTIs: complicated or nosocomial

• Skin and soft tissue infections: folliculitis and other papular or vesicular lesions linked to whirlpools, spas, and swimming pools

• Infections in febrile neutropenic pts: P. aeruginosa is always targeted in empirical treatment of these pts. The most common clinical syndromes are bacteremia, pneumonia, and soft tissue infections, mainly manifesting as ecthyma gangrenosum.

• Infections in AIDS pts: P. aeruginosa infections are more common among AIDS pts. Pneumonia is associated with a high frequency of cavitary disease. Since the advent of antiretroviral therapy, P. aeruginosa infection has declined in incidence among these pts but still occurs, presenting particularly often as sinusitis.

P. aeruginosa Infections

See Table 97-1 for antibiotic options and schedules. Severe or life-threatening infections are generally treated with two antibiotics to which the infecting strain is sensitive, although evidence that this course is more efficacious than monotherapy has been lacking since the introduction of more active \( \beta \)-lactam agents.

BACTERIA RELATED TO PSEUDOMONAS SPECIES

Stenotrophomonas maltophilia and Burkholderia cepacia  

S. maltophilia is a nosocomial pathogen; most cases of infection occur in the setting of prior broad-spectrum antimicrobial therapy that has eradicated the normal flora in immunocompromised pts. S. maltophilia causes pneumonia, especially VAP. Bacteremic S. maltophilia pneumonia can lead to septic shock in ICU pts. Central venous line infection (most often in cancer pts) and ecthyma gangrenosum in neutropenic pts have been described.

B. cepacia is recognized as an antibiotic-resistant nosocomial pathogen in ICU pts. This organism can colonize airways during broad-spectrum antimicrobial treatment and is a cause of VAP, catheter-associated infection, and wound infection. B. cepacia can cause a rapidly fatal syndrome of respiratory distress and septicemia in cystic fibrosis pts.

S. maltophilia and B. cepacia Infections

Intrinsic resistance to many antibiotics limits treatment. TMP-SMX (15–20 mg of TMP/kg per day) is the preferred agent. In addition, S. maltophilia is often susceptible to ticarcillin/clavulanate and levofloxacin, while B. cepacia is often susceptible to meropenem and doxycycline.

Miscellaneous Organisms  

Melioidosis is endemic to Southeast Asia and is caused by Burkholderia pseudomallei. Glanders is associated with close con-
## Table 97-1: Antibiotic Treatment of Infections Due to *Pseudomonas aeruginosa* and Related Organisms

<table>
<thead>
<tr>
<th>Infection</th>
<th>Antibiotics and Dosages</th>
<th>Other Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bacteremia</strong></td>
<td><strong>Nonneutropenic host</strong>&lt;br&gt;Monotherapy: Ceftazidime (2 g q8h IV) or cefepime (2 g q12h IV)&lt;br&gt;Combination therapy: Piperacillin/tazobactam (3.375 g q4h IV) or imipenem (500 mg q6h IV) or meropenem (1 g q8h IV)&lt;br&gt;<strong>Plus</strong> Amikacin (7.5 mg/kg q12h or 15 mg/kg q24h IV) or cefepime (2 g q8h IV) or all other agents in above dosages</td>
<td>Add an aminoglycoside for patients in shock and in regions or hospitals where rates of resistance to the primary β-lactam agents are high. Tobramycin may be used instead of amikacin (susceptibility permitting).</td>
</tr>
<tr>
<td><strong>Neutropenic host</strong></td>
<td>Antibiotic regimens as for bacteremia for 6–8 weeks&lt;br&gt;Drugs and dosages as for bacteremia, except that the available carbapenems should not be the primary drugs because of high rates of resistance during therapy</td>
<td>Resistance during therapy is common. Surgery is required for relapse. IDSA guidelines recommend the addition of an aminoglycoside or ciprofloxacin. The duration of therapy is 10–14 days.</td>
</tr>
<tr>
<td><strong>Endocarditis</strong></td>
<td>Antibiotic regimens as for bacteremia for 6–8 weeks&lt;br&gt;Drugs and dosages as for bacteremia, except that the available carbapenems should not be the primary drugs because of high rates of resistance during therapy</td>
<td>Duration of therapy varies with the drug used (e.g., 6 weeks for a β-lactam agent; at least 3 months for oral therapy except in puncture-wound osteomyelitis, for which the duration should be 2–4 weeks).</td>
</tr>
<tr>
<td><strong>Pneumonia</strong></td>
<td>Ceftazidime or cefepime at the same dosages as for bacteremia; aminoglycosides not a necessary component of therapy; ciprofloxacin (500–750 mg q12h PO) may be used</td>
<td>Duration of therapy is ≥2 weeks. Abscesses or other closed-space infections may require drainage. The duration of therapy is ≥2 weeks.</td>
</tr>
<tr>
<td><strong>Bone infection, malignant otitis externa</strong></td>
<td>Ceftazidime or cefepime (2 g q8h IV) or meropenem (1 g q8h IV)</td>
<td></td>
</tr>
<tr>
<td><strong>Central nervous system infection</strong></td>
<td>Ceftazidime or cefepime (2 g q8h IV) or meropenem (1 g q8h IV)</td>
<td></td>
</tr>
<tr>
<td><strong>Eye infection</strong></td>
<td><strong>Keratitis/ulcer</strong>&lt;br&gt;Topical therapy with tobramycin/ciprofloxacin/levofloxacin eyedrops</td>
<td>Use maximal strengths available or compounded by pharmacy.</td>
</tr>
<tr>
<td><strong>Endophthalmitis</strong></td>
<td>Ceftazidime or cefepime as for central nervous system infection&lt;br&gt;<strong>Plus</strong> Topical therapy</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Infection</th>
<th>Antibiotics and Dosages</th>
<th>Other Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urinary tract infection</td>
<td>Ciprofloxacin (500 mg q12h PO) or levofloxacin (750 mg q24h) or any aminoglycoside (total daily dose given once daily)</td>
<td>Relapse may occur if an obstruction or a foreign body is present.</td>
</tr>
<tr>
<td>Multidrug-resistant <em>P. aeruginosa</em> infection</td>
<td>Colistin (100 mg q12h IV) for the shortest possible period to obtain a clinical response</td>
<td>Doses used have varied. Dosage adjustment is required in renal failure. Inhaled colistin may be added for pneumonia (100 mg q12h).</td>
</tr>
<tr>
<td><em>Stenotrophomonas maltophilia</em> infection</td>
<td>TMP-SMX (1600/320 mg q12h IV for 14 days) Ticarcillin/clavulanate (3.1 g q4h IV for 14 days)</td>
<td>Resistance to all agents is increasing. Levofloxacin may be an alternative, but there is little published clinical experience with this agent.</td>
</tr>
</tbody>
</table>
| *Burkholderia cepacia* infection       | Meropenem (1 g q8h IV for 14 days)  
TMP-SMX (1600/320 mg q12h IV for 14 days) | Resistance to both agents is increasing. Do not use them in combination because of possible antagonism. |
| Melioidosis, glanders                  | Ceftazidime (2 g q6h for 2 weeks) or meropenem (1 g q8h for 2 weeks) or imipenem (500 mg q6h for 2 weeks) followed by TMP-SMX (1600/320 mg q12h PO for 3 months) | See “Further Readings” in HPIM-17, Chap. 145, for more details on therapy and alternative agents. |

*Note:* IDSA, Infectious Diseases Society of America; TMP-SMX, trimethoprim-sulfamethoxazole.
tact with horses or other equines and is caused by *Burkholderia mallei*. These diseases present as acute or chronic pulmonary or extrapulmonary suppurative illnesses or as acute septicemia.

**LEGIONELLA INFECTIONS**

**Microbiology** Legionellaceae are intracellular aerobic gram-negative bacilli that grow on buffered charcoal yeast extract (BCYE) agar. *L. pneumophila* causes 80–90% of cases of human *Legionella* disease; serogroups 1, 4, and 6 are most common. Eighteen other species, including *L. micdadei*, have been linked to human infections.

**Epidemiology** *Legionella* is found in fresh water and human-constructed water sources. Outbreaks have been traced to potable-water supplies and occasionally cooling towers. The organisms are transmitted to individuals primarily via aspiration but can also be transmitted by aerosolization and direct instillation into the lung during respiratory tract manipulations. *Legionella* is the fourth most common cause of community-acquired pneumonia, accounting for 2–9% of cases. It causes 10–50% of cases of nosocomial pneumonia if the hospital’s water system is colonized with the organism. Pts who have chronic lung disease, who smoke, and/or who are elderly or immunosuppressed are at particularly high risk for disease. Cell-mediated immunity is the primary mechanism of host defense.

**Clinical Features**

- Pontiac fever: a flulike illness with a 24- to 48-h incubation period. Pneumonia does not develop, but malaise, fatigue, myalgias, and fever are common. The disease is self-limited, and recovery takes place in a few days.
- Legionnaires’ disease: more severe than other atypical pneumonias and more likely to result in ICU admission
  1. After an incubation period (usually 2–10 days), nonspecific symptoms (e.g., malaise, fatigue, headache, fever) develop and are followed by a cough that is usually mild and nonproductive.
  2. Chest pain (pleuritic or nonpleuritic) can be prominent, and dyspnea is common. Sputum is usually scant and may be blood-streaked.
  3. GI manifestations (pain, nausea, vomiting, diarrhea) may be pronounced.
  4. Diarrhea, confusion, high fevers, hyponatremia, increased values in liver function tests, hematuria, hypophosphatemia, and elevated creatine phosphokinase levels are documented more frequently than in other pneumonias.
  5. The heart is the most common extrapulmonary site of disease (myocarditis, pericarditis, and occasionally prosthetic valve endocarditis).
  6. CXR reveals pulmonary infiltrates, multilobar involvement in many instances, and pleural effusion in up to 63% of cases. In compromised hosts, nodular infiltrates, abscesses, and cavities can be seen.

**Diagnosis**

- Sputum or bronchoalveolar samples are subjected to direct fluorescent antibody (DFA) staining and culture. DFA testing is rapid and specific but less sensitive than culture.
- Cultures on BCYE media require 3–5 days to become positive.
- Diagnosis by antibody testing can take 12 weeks.
- Urinary antigen testing is rapid, inexpensive, easy to perform, second only to culture in terms of sensitivity, and highly specific. It is useful only for *L. pneumophila* serogroup 1, which causes 80% of disease cases. Urinary anti-
gen is detectable 3 days after disease onset and generally disappears over 2 months, although positivity can be prolonged if the pt is receiving glucocorticoid therapy.

**Legionella Infections**

- Newer macrolides (e.g., azithromycin at 500 mg/d or clarithromycin at 500 mg bid, IV or PO) or fluoroquinolones (e.g., levofloxacin at 750 mg IV or 500 mg PO daily or moxifloxacin at 400 mg PO daily) are most effective. Rifampin (100–600 mg bid) combined with either class of drug is recommended in severe cases.
- Tetracyclines (doxycycline at 100 mg bid, IV or PO) or TMP-SMX (160/800 mg IV q8h or PO bid) are alternatives.
- Immunocompetent hosts can receive 10–14 days of therapy, but immunocompromised hosts should receive a 3-week course of treatment. A 5- to 10-day course of azithromycin is adequate because of this drug’s long half-life.

**Prognosis** Mortality approaches 80% among compromised hosts who do not receive timely therapy. Among immunocompetent hosts, mortality can approach 31% without treatment but ranges from 0 to 11% if pts receive appropriate therapy. Fatigue, weakness, and neurologic symptoms can persist for >1 year.

For a more detailed discussion, see Barlam TF, Kasper DL: Infections Due to the HACEK Group and Miscellaneous Gram-Negative Bacteria, Chap. 140, p. 926; Sabria M, Yu VL: Legionella Infection, Chap. 141, p. 929; Russo TA, Johnson JR: Diseases Caused by Gram-Negative Enteric Bacilli, Chap. 143, p. 937; and Ramphal R: Infections Due to Pseudomonas Species and Related Organisms, Chap. 145, p. 949, in HPIM-17.

**BRUCELLOSIS**

**Etiology** Brucellae are facultative intracellular parasites in a genus that includes four major species: *B. melitensis* (acquired by humans most commonly from sheep, goats, and camels), *B. suis* (from swine), *B. abortus* (from cattle or buffalo), and *B. canis* (from dogs). Brucellosis is transmitted via ingestion, inhalation, or mucosal or percutaneous exposure; the disease in humans is usually associated with exposure to infected animals or their products in either occupational settings (e.g., slaughterhouse work, farming,) or domestic settings (e.g., consumption of contaminated foods, especially dairy products).

**Clinical Features** An incubation period of 1 week to several months is followed by the development of undulating fever; sweats; increasing apathy, fa-
tigue, and anorexia; and nonspecific symptoms such as headache, myalgias, and chills. Brucellosis often presents with one of three patterns: a febrile illness similar to but less severe than typhoid fever; fever and acute monarthritis, typically of the hip or knee, in a young child (septic arthritis); or long-lasting fever and low back or hip pain in an older man (vertebral osteomyelitis). Brucella infection can cause lymphadenopathy, hepatosplenomegaly, epididymoorchitis, neurologic involvement, and focal abscess.

**Diagnosis** Laboratory personnel must be alerted to the potential diagnosis to ensure that they take precautions to prevent occupational exposure. The organism is successfully cultured in 50–70% of cases, but culture identification usually takes up to 6 weeks. Cultures using the BACTEC systems can be deemed negative at 3 weeks. Agglutination assays for IgM are positive early in infection. Single titers of $\geq 1:160$ and $1:320$–$1:640$ are diagnostic in nonendemic and endemic areas, respectively. Brucellosis must be distinguished from tuberculosis; if this distinction is not possible, the regimen should be tailored to avoid inadvertent monotherapy for tuberculosis (see below). Brucellosis tends to cause less bone and joint destruction than tuberculosis (Table 98-1).

**Table 98-1** Radiology of the Spine: Differentiation of Brucellosis from Tuberculosis

<table>
<thead>
<tr>
<th></th>
<th>Brucellosis</th>
<th>Tuberculosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Site</strong></td>
<td>Lumbar and others</td>
<td>Dorsolumbar</td>
</tr>
<tr>
<td><strong>Vertebrae</strong></td>
<td>Multiple or contiguous</td>
<td>Contiguous</td>
</tr>
<tr>
<td><strong>Diskitis</strong></td>
<td>Late</td>
<td>Early</td>
</tr>
<tr>
<td><strong>Body</strong></td>
<td>Intact until late</td>
<td>Morphology lost early</td>
</tr>
<tr>
<td><strong>Canal compression</strong></td>
<td>Rare</td>
<td>Common</td>
</tr>
<tr>
<td><strong>Epiphysitis</strong></td>
<td>Anterosuperior (Pom’s sign)</td>
<td>General: upper and lower disk regions, central, subperiosteal</td>
</tr>
<tr>
<td><strong>Osteophyte</strong></td>
<td>Anterolateral (parrot beak)</td>
<td>Unusual</td>
</tr>
<tr>
<td><strong>Deformity</strong></td>
<td>Wedging uncommon</td>
<td>Anterior wedge, gibbus</td>
</tr>
<tr>
<td><strong>Recovery</strong></td>
<td>Sclerosis, whole body</td>
<td>Variable</td>
</tr>
<tr>
<td><strong>Paravertebral abscess</strong></td>
<td>Small, well-localized</td>
<td>Common and discrete loss, transverse process</td>
</tr>
<tr>
<td><strong>Psoas abscess</strong></td>
<td>Rare</td>
<td>More likely</td>
</tr>
</tbody>
</table>

**Rx** Brucellosis

- Streptomycin at a dosage of 750 mg to 1 g daily (or gentamicin at 5–6 mg/kg daily) for 14–21 days plus doxycycline at a dosage of 100 mg bid for 6 weeks is recommended. Complex disease (e.g., significant neurologic disease or endocarditis) requires at least 3–6 months of treatment with multiple agents.
- Alternative: rifampin (600–900 mg/d) plus doxycycline (100 mg bid) for 6 weeks. Trimethoprim-sulfamethoxazole (TMP-SMX) can be given instead of doxycycline—e.g., to children or pregnant women.
- Relapse occurs in ~30% of cases, usually because of poor compliance. Pts should be monitored for at least 2 years.
TULAREMIA

Epidemiology  Human infections caused by *Francisella tularensis* occur via interaction with biting or blood-sucking insects (especially ticks and tabanid flies), wild or domestic animals (e.g., wild rabbits, squirrels), or the environment. The organism can persist for months in mud, water, and decaying animal carcasses. More than half of U.S. cases occur in Arkansas, Oklahoma, and Missouri. The organism gains entry into the skin or mucous membranes through bites or inapparent abrasions or is acquired via inhalation or ingestion. *F. tularensis* is a potential agent of bioterrorism (see Chap. 32).

Clinical Features  The incubation period is 2–10 days long. Tularemia often starts with an acute onset of fever, chills, headache, and myalgias. One of several syndromes can develop:

1. **Ulceroglandular/glandular tularemia** (75–85% of cases)
   a. The hallmark is an indurated, erythematous, nonhealing ulcer lasting 1–3 weeks (ulceroglandular form) that begins as a pruritic papule, ulcerates, has sharply demarcated edges and a yellow exudate, and develops a black base. A primary skin lesion may not be apparent in 5–10% of cases (glandular form).
   b. Lymphadenopathy is related to the location of the tick bite; inguinal/femoral nodes are most often affected in adults because of the frequency of bites on the legs. Lymph nodes can become fluctuant and drain spontaneously.

2. **Oculoglandular tularemia**: Infection of the conjunctiva, usually by contact with contaminated fingers, results in purulent conjunctivitis with regional adenopathy and debilitating pain. Painful preauricular lymphadenopathy is unique to tularemia.

3. **Oropharyngeal and GI tularemia**: Acquired via ingestion, infection can present with pharyngitis and cervical adenopathy, intestinal ulcerations, mesenteric adenopathy, diarrhea, nausea, vomiting, and abdominal pain.

4. **Pulmonary tularemia**: Infection is acquired via inhalation or hematogenous spread. Pts present with a nonproductive cough, dyspnea, pleuritic chest pain, bilateral patchy or lobar infiltrates, cavities, and occasional pleural effusions and empyema on chest x-ray.

5. **Typhoidal tularemia**: Consists of fever and signs of sepsis without focal findings

Diagnosis

- Polychromatic staining of clinical specimens (Gram’s staining of little help)
- Serology via microagglutination or tube agglutination test. A single titer of ≥1:160 or a fourfold increase in titer after 2–3 weeks is considered positive.
- Culture is difficult and poses a significant risk to laboratory personnel. Polymerase chain reaction (PCR) methods have been used to detect *F. tularensis* DNA in clinical specimens.

**Rx**  Tularemia

- Gentamicin is considered the drug of choice for both adults (5 mg/kg daily in 2 divided doses) and children (2.5 mg/kg tid or 5 mg/kg bid) with tularemia. Streptomycin (1 g q12h) is also effective, but tobramycin is not. Defervescence usually occurs within 2 days, but healing of skin lesions and lymph nodes may take 1–2 weeks. Late lymph-node suppuration can occur, with sterile necrotic tissue.
• Rapidly responding mild to moderate disease can be treated for 5–7 days; otherwise, treatment is given for 7–10 days.
• Alternatives include tetracyclines or chloramphenicol (relapse rates of up to 20%).
• Fluoroquinolones have shown promise, but clinical trials are pending.

PLAGUE

**Epidemiology**  *Yersinia pestis* causes plague, one of the most virulent and lethal of all bacterial diseases. Most often seen in Asia, Africa, and the Americas, plague occurs in the United States, primarily in New Mexico, Arizona, Colorado, and California. Wild rodents and rats are the usual hosts; ground squirrels, prairie dogs, and chipmunks are the main epizootic hosts in the United States. Fleabites or direct contact with infected tissues or airborne droplets can cause human infections. *Y. pestis* is a potential agent of bioterrorism (see Chap. 32).

**Clinical Features**  There are three major presentations.
1. **Bubonic plague:** the most common form, caused by the bite of an infected flea
   a. After an incubation period of 2–6 days, the pt develops chills, fever, myalgias and arthralgias, headache, weakness, and signs of toxemia.
   b. Within 24 h, adenopathy proximal to the inoculation site occurs. An enlarging node or bubo becomes painful and tender. Edema and erythema—but not cellulitis or lymphangitis—develop in the surrounding tissue.
   c. The primary inoculation site may have a papule, pustule, ulcer, or eschar.
   d. Disease progresses to lethargy, convulsions, shock, organ failure, and death.
2. **Septicemic plague**
   a. Overwhelming infection (no bubo) with disease progression to multiorgan failure, disseminated intravascular coagulation, hypotension, and death
   b. GI symptoms (diarrhea, nausea and vomiting, abdominal pain) are common.
3. **Pneumonic plague:** the most life-threatening form
   a. After an incubation period of 3–5 days, there is a sudden onset of chills, fever, headache, myalgias, weakness, and dizziness.
   b. Pulmonary signs include tachypnea, dyspnea, cough, sputum production, chest pain, hemoptysis, and circulatory collapse. Auscultatory findings are minimal. Sputum is watery, frothy, and blood-tinted or frankly bloody.
   c. Bronchopneumonia progresses rapidly to involve multiple lobes and both lungs, with liquefaction necrosis and cavitation of consolidated areas.
   d. Secondary pneumonic plague is a diffuse interstitial process and may be less infectious because sputum is tenacious and scant.

**Diagnosis**  A high index of clinical suspicion and a thorough clinical and epidemiologic examination are required for timely diagnosis and treatment. Smear and culture of specimens of blood, lymph node aspirates, pulmonary aspirates, and other sites should be prepared as appropriate. Smears should be examined immediately with Wayson or Giemsa stain (*Y. pestis* has a bipolar appearance resembling closed safety pins) and with Gram’s stain and should be submitted for direct fluorescent antibody testing, enzyme-linked immunosorbent assay, or PCR. Acute-phase—and, if possible, convalescent-phase—serum samples should undergo serologic testing. Either a single titer of >1:128 or seroconversion (as documented by a fourfold or greater rise in titer) is considered diagnos-
tic. Confirm with the F1 antigen hemagglutination-inhibition test, which is positive in most cases by 1–2 weeks.

**Plague**

- Without treatment, >50% of pts with bubonic plague and nearly all pts with septicemic or pneumonic plague die.
- Streptomycin or gentamicin is the drug of choice.
- Doxycycline and chloramphenicol are alternative agents.
- National bioterrorism-response protocols recommend administration of gentamicin, ciprofloxacin, and doxycycline in the event of a *Y. pestis* attack.
- Persons who are exposed to pts with pneumonic plague or who have traveled to an area where a plague outbreak is in progress should receive short-term (5-day) prophylaxis with doxycycline (adult dose, 100–200 mg q12–24h), ciprofloxacin (1 g q12h), or TMP-SMX (320 mg of TMP q12h).
- Pts hospitalized with pneumonic plague should remain on respiratory droplet precautions until treatment has been given for at least 48 h.

**BARTONELLA INFECTIONS**

*Bartonella* species are gram-negative bacteria that cause an array of infectious disease syndromes. Therapy for these syndromes is summarized in Table 98-2.

### Table 98-2: Treatment of Adults with Disease Caused by *Bartonella* Species

<table>
<thead>
<tr>
<th>Disease</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cat-scratch disease</td>
<td></td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>Consider azithromycin (500 mg PO on day 1, then 250 mg PO qd for 4 days)</td>
</tr>
<tr>
<td>Retinitis</td>
<td>Doxycycline (100 mg PO bid for 4–6 weeks) plus Rifampin (300 mg PO bid for 4–6 weeks)</td>
</tr>
<tr>
<td>Bacillary angiomatosis</td>
<td>Erythromycin (500 mg PO qd for 3 months) or Doxycycline (100 mg PO bid for 3 months)</td>
</tr>
<tr>
<td>Bacillary peliosis</td>
<td>Erythromycin (500 mg PO qd for 4 months) or Doxycycline (100 mg PO bid for 4 months)</td>
</tr>
<tr>
<td>Bartonella endocarditis</td>
<td></td>
</tr>
<tr>
<td>Suspected</td>
<td>Gentamicin (3 mg/kg qd IV for 14 days) plus Ceftriaxone (2 g IV qd for 6 weeks) with or without Doxycycline (100 mg PO bid for 6 weeks)</td>
</tr>
<tr>
<td>Confirmed</td>
<td>Gentamicin (3 mg/kg qd IV for 14 days) plus Doxycycline (100 mg PO bid for 6 weeks)</td>
</tr>
<tr>
<td>Trench fever</td>
<td>Doxycycline (200 mg PO qd for 4 weeks) plus Gentamicin (3 mg/kg qd IV for 14 days)</td>
</tr>
<tr>
<td>Bartonellosis</td>
<td></td>
</tr>
<tr>
<td>Oroya fever</td>
<td>Chloramphenicol (500 mg PO or IV qid for 14 days) plus a β-lactam agent or Ciprofloxacin (500 mg bid for 10 days)</td>
</tr>
<tr>
<td>Verruga peruana</td>
<td>Rifampin (10 mg/kg qd PO for 14 days) or Streptomycin (15–20 mg/kg qd IM for 10 days)</td>
</tr>
</tbody>
</table>

This infection is associated with exposure to cats (especially kittens) with asymptomatic *B. henselae* bacteremia. Infection is transmitted by scratch, bite, or lick; ~40% of cases involve adults.

**Clinical Features** Appearance of a localized lesion (papule, vesicle, or nodule) is followed 2–3 weeks later by lymphadenopathy. Unilateral solitary or regional adenopathy develops in >90% of pts. Nodes are tender, firm, and mobile; ~10% suppurate. Systemic symptoms include fever, malaise, headache, myalgias, and anorexia. Lymphadenopathy in untreated pts usually resolves within 3 months. Disseminated disease may occur and most often involves the nervous system (encephalitis, neuroretinitis), visceral organs (granulomatous hepatitis, splenitis), or bone.

**Diagnosis**
- Serologic testing for antibody to *B. henselae*
- Lymph node biopsy or aspiration. PCR analysis of a tissue sample is preferred; cultures are rarely positive.

**BACILLARY ANGIOMATOSIS AND PELIOSIS HEPATIS**

**Clinical Features** These diseases, caused by *B. henselae* and *B. quintana*, occur most often in HIV-infected pts with CD4+ T cell counts of <100/μL. Pts with bacillary angiomatosis present with painless skin lesions, but subcutaneous masses or nodules, ulcerated plaques, and verrucous growths also occur. Lesions may be single or multiple and vary from tan to red to deep purple. They may invade underlying bone. Dissemination may occur, affecting the oropharynx, lungs, heart, intestines, lymph nodes, muscle, or brain. Pts with peliosis hepatis present with nonspecific systemic symptoms, with or without cutaneous involvement.

**Diagnosis**
- Radiographic studies of osseous bacillary angiomatosis demonstrate lytic bone lesions, while imaging of pts with peliosis hepatis reveals hypodense regions in the liver.
- Histopathologic findings (sites of angiogenesis and inflammation) and a positive Warthin-Starry stain

**TRENCH FEVER**

Caused by *B. quintana*, trench fever can occur as any of four patterns: a solitary episode of fever; a febrile illness of <1 week’s duration; quintan fever (febrile episodes of ~5 days interspersed with asymptomatic intervals of ~5 days); and a persistent, febrile, debilitating illness lasting >1 month, with fever, headache, weight loss, and leg pain. The diagnosis is made by blood culture or serologic studies.

**CULTURE-NEGATIVE ENDOCARDITIS**

*Bartonella* species are an important cause of culture-negative endocarditis. Blood cultures are positive in ~25% of cases; yield is enhanced by extended incubation (4–6 weeks). Serologic tests or PCR testing for *Bartonella* in cardiac valve tissue can establish the diagnosis in pts with negative blood cultures.

**OROYA FEVER AND VERRUGA PERUANA**

These infections, caused by *B. bacilliformis*, are transmitted by a sandfly vector found in river valleys of the Andes Mountains. Pts present with fever; profound
anemia follows. Without treatment, mortality is high. During convalescence, cutaneous lesions—verrugas—can develop; these lesions are typically reddish-purple pruritic papules or nodules similar to the skin lesions of bacillary angiomatosis. The diagnosis is based on detection of intraerythrocytic organisms in a Wright-Giemsa-stained thin blood smear and/or blood culture. Biopsy of verrugas reveals formation of new blood vessels and endothelial hyperplasia.

For a more detailed discussion, see Corbel MJ, Beeching NJ: Brucellosis, Chap. 150, p. 973; Jacobs RF, Schutze GE: Tularemia, Chap. 151, p. 976; Dennis DT, Campbell GL: Plague and Other Yersinia Infections, Chap. 152, p. 980; and Spach DH, Darby E: Bartonella Infections, Including Cat-Scratch Disease, Chap. 153, p. 987, in HPIM-17.

# Anaerobic Infections

## DEFINITIONS

- **Anaerobic bacteria:** require reduced oxygen tension for growth; do not grow on the surface of solid media in 10% CO₂ in air
- **Microaerophilic bacteria:** grow in an atmosphere of 10% CO₂ in air or under anaerobic or aerobic conditions, but grow best if only a small amount of atmospheric oxygen is present
- **Facultative bacteria:** grow in the presence or absence of air

## TETANUS

### Etiology, Epidemiology, and Pathogenesis

Tetanus is a neurologic disorder characterized by increased muscle tone and spasms caused by tetanospasmin, a toxin produced by *Clostridium tetani*. *C. tetani* is a drumstick-shaped, spore-forming, anaerobic gram-positive rod that is ubiquitous in soil. In the United States, disease occurs in inadequately immunized persons, primarily nonwhites and the elderly; in developing countries, neonatal tetanus is most common. After contaminating wounds (typically puncture wounds), spores germinate if there is low oxidation-reduction potential (e.g., due to devitalized tissue or foreign bodies) and produce toxin. The toxin blocks release of inhibitory neurotransmitters (glycine and γ-aminobutyric acid) in presynaptic terminals, and rigidity results from an increased resting firing rate of the α-motor neurons.

### Clinical Features

- **Generalized tetanus:** A median of 7 days after injury (range, 3–14 days), pts develop trismus—increased tone of the masseter muscles (lockjaw)—as well as sustained facial muscle contraction (risus sardonicus), dysphagia, neck stiffness or pain, back muscle contraction (opisthotonos), and rigidity of the abdominal wall and proximal limb muscles. Mentation is clear. Pts are often afebrile. Paroxysmal generalized spasms, either entirely spontaneous or pro-
voked by even the slightest stimulation, may result in cyanosis and ventilatory compromise. Autonomic dysfunction can cause labile hypertension, tachycardia, arrhythmias, and sudden cardiac arrest.

- **Local tetanus**: Only muscles near the wound are affected.
- **Neonatal tetanus**: Occurs in children of unimmunized mothers, often after contamination of the umbilical cord stump, and is usually fatal if not treated.

### Diagnosis

The diagnosis is made primarily on clinical grounds. Muscle enzyme levels can be elevated.

### Tetanus

- Monitor and give supportive care in a quiet intensive care unit room.
- Give penicillin (10–12 mU/d IV for 10 days) or metronidazole (500 mg q6h or 1 g q12h) to eliminate vegetative cells and a source of further toxin. Clindamycin and erythromycin are alternatives.
- Give one dose of human tetanus immune globulin (TIG, 3000–6000 units IM) to neutralize unbound toxin; divide the dose because of the large volume.
- Control muscle spasms with benzodiazepines such as diazepam. Therapeutic paralysis with neuromuscular blocking agents may be necessary. However, prolonged paralysis may follow discontinuation of these agents.
- Immunize recovering pts. Natural disease does not induce immunity.

### Prevention

- Primary vaccination: Adults should receive two doses 4–8 weeks apart and a third dose 6–12 months later. Every 10 years, pts >7 years of age should receive a booster dose of adsorbed tetanus and diphtheria toxoid (Td) or tetanus/diphtheria/attenuated pertussis vaccine (Tdap). A single dose of Tdap should be given to adults 19–64 years of age who have not previously received Tdap.
- Wound management: Administer Td or Tdap if the pt’s immune status is unknown, immunization was incomplete, or >10 years have elapsed since the last booster. In contaminated or severe wounds, administer Td if >5 years have elapsed since the last vaccination. Consider TIG (250 units IM) for all but clean or minor wounds if the pt’s immune status is unknown or immunization was incomplete. Vaccine and antibody should be given at separate sites.

### Prognosis

The mortality rate is <10% with optimal management. Recovery is usually complete but extends over 4–6 weeks. Prolonged ventilator support may be needed. Increased muscle tone and minor spasms may last for months.

### Botulism

#### Etiology, Epidemiology, and Pathogenesis

Botulism is a paralytic disease caused by neurotoxins elaborated by *Clostridium botulinum*, an anaerobic spore-forming bacterium. The neurotoxin inhibits the release of the neurotransmitter acetylcholine. *C. botulinum* is found in soil and marine environments worldwide. *C. botulinum* toxin types A, B, E, and rarely F cause human disease. Most U.S. food-borne cases are associated with home-canned food, especially vegetables, fruits, and condiments. Type E is associated with fish products. Disease occurs when (1) spores contaminate food; (2) the food is subsequently preserved in a manner that kills other bacteria but not the spores and provides anaerobic conditions at a pH and temperature permissive for germination and toxin production; and (3) the food is ingested before being heated to a tempera-
ture adequate for toxin destruction. Toxin is heat-labile (inactivated when heated for 10 min at 100°C), and spores are heat-resistant (inactivated at 116°–121°C or with steam sterilizers or pressure cookers).

Clinical Features

- **Food-borne botulism** occurs 18–36 h after ingestion of food contaminated with toxin and ranges in severity from mild to fatal (within 24 h). The characteristic presentation is symmetric descending paralysis with early cranial nerve involvement (diplopia, dysarthria, dysphonia, ptosis, and/or dysphagia) that can progress to paralysis, respiratory failure, and death. Sensory findings are absent. Nausea, abdominal pain, and vomiting may occur. Fever is uncommon. Pts are usually alert and oriented but may be drowsy or agitated.

- **Wound botulism** occurs when spores contaminate a wound and germinate—e.g., in wounds of black-tar heroin users. Wound botulism has a longer incubation period (~10 days) than food-borne botulism and causes no GI symptoms. Otherwise, the two diseases are similar.

- **Intestinal botulism**, spores germinate in the intestine and produce toxin, which is absorbed and causes illness. This form in infants has been associated with contaminated honey; thus honey should not be fed to children <12 months of age.

- **Bioterrorism-related botulism** is the potential result of the intentional dispersal (as an aerosol or as a contaminant in ingested material) of the most potent bacterial toxin known.

Diagnosis

The clinical symptoms should suggest the diagnosis. The definitive test is the demonstration of the toxin in serum with a mouse bioassay, but this test may yield a negative result, particularly in wound and infant intestinal botulism. Demonstration of the organism or the toxin in clinical samples strongly suggests the diagnosis.

**Botulism**

- Supportive care with intubation and mechanical ventilation as needed
- Routine administration of bivalent equine antitoxin to types A and B; use of an investigational monovalent antitoxin if exposure to type E toxin (i.e., through seafood ingestion) is suspected.
- Infants should receive human botulism immune globulin, which can be obtained from the California Department of Health Services (510-231-7600 or www.infantbotulism.org).
- Wound botulism: exploration, debridement, penicillin treatment (to eradicate the organism from the site), and administration of equine antitoxin
- For antitoxin and management advice, contact state health departments or the Centers for Disease Control and Prevention (emergency number: 770-488-7100).

**Prognosis**

The mortality rate has been reduced to ~7.5%. Type A disease tends to be the most severe. Respiratory support may be required for months. Residual weakness and autonomic dysfunction may persist for as long as a year.

**OTHER CLOSTRIDIAL INFECTIONS**

**Etiology and Pathogenesis** Clostridia are gram-positive, spore-forming obligate anaerobes. In humans, they reside in the GI and female genital tracts. *Clostridium botulinum* is a soil-dwelling organism that produces a potent neurotoxin that can be transmitted to humans through food, ingestion, or infected wounds. Other clostridial species, such as *Clostridium tetani* (tetanus), *Clostridium perfringens* (gas gangrene), and *Clostridium welchii* (gas gangrene), also cause significant infections, primarily in wounds or following their ingestion.
Anaerobic Infections

*C. perfringens* is the most common clostridial species isolated from tissue infections and bacteremias; next in frequency are *C. novyi* and *C. septicum*. Tissue necrosis and low oxidation-reduction potential are factors that allow rapid growth and toxin production and are essential for the development of severe disease. *C. perfringens* produces multiple virulence factors and toxins, including α-toxin, which causes hemolysis, destroys platelets and polymorphonuclear leukocytes, causes widespread capillary damage, and is probably important in the initiation of muscle infections that can progress to gas gangrene.

**Clinical Features**

I. Intestinal disorders: food poisoning and antibiotic-associated colitis (see Chap. 89)

II. Suppurative deep-tissue infections: severe local inflammation without systemic signs (e.g., intraabdominal infection, empyema, pelvic abscess). Clostridia can be identified in association with other bacteria or as the sole isolate. These organisms are isolated from two-thirds of pts with intraabdominal infections resulting from intestinal perforation. *C. perfringens* is isolated from 20% of diseased gallbladders at surgery and from at least 50% of pts with emphysematous cholecystitis.

III. Skin and soft tissue infections

A. Localized infection without systemic signs (also called anaerobic cellulitis): An indolent infection that may spread to contiguous areas, it causes little pain or edema and does not involve the muscles. Gas production may be more noticeable than in more severe infections because of the lack of edema. If not treated appropriately, infection may progress to severe systemic toxic illness.

B. The onset of spreading cellulitis and fasciitis with systemic toxicity is abrupt, with rapid spread through fascial planes. On examination, SC crepitus with little localized pain is evident. The infection can be rapidly fatal (within 48 h) despite aggressive treatment. It is associated with malignancy, especially of the sigmoid or cecum. This infection differs from necrotizing fasciitis by its rapid mortality, rapid tissue invasion, and massive hemolysis.

C. Gas gangrene (clostridial myonecrosis) is characterized by rapid and extensive necrosis of muscle accompanied by gas formation and systemic toxicity. It is typically associated with traumatic wounds that are deep, necrotic, and without communication to the surface. *C. perfringens* causes 80% of cases. *C. septicum* can cause spontaneous nontraumatic clostridial myonecrosis, often in the setting of leukemia or solid tumors (especially of the GI tract and in particular the colon).

1. Incubation period: <3 days and often <24 h
2. Sudden onset of pain that is localized to the infected area and increases steadily. Infection progresses with swelling; edema; cool, tense, white skin; and profuse serous discharge with a sweetish, mousy odor. Gram’s stain reveals few white cells and many gram-positive rods. Pts have a heightened sense of awareness.

IV. Bacteremia and clostridial sepsis: Transient clostridial bacteremia can arise from a focus in the GI or biliary tract or the uterus and resolves quickly without treatment. Clostridial sepsis is an uncommon but usually fatal clostridial infection, primarily of the uterus, colon, or biliary tract. The majority of cases follow septic abortion within 1–3 days. Pts are hyperalert and have fever, chills, malaise, headache, severe myalgias, abdominal pain, nausea, vomiting, oliguria, hypotension, hemolysis with jaundice (less common with *C. septicum*), and hemoglobinuria. Death occurs within 12 h.
Isolation of clostridia from clinical sites does not alone indicate severe disease. Clinical findings and presentation must be taken into account.

- Surgical intervention and debridement are the mainstays of treatment.
- Antibiotics: Penicillin (3–4 million units q4h) in conjunction with clindamycin (600 mg q6h) is indicated for severe clostridial disease. Clostridial wound contamination alone does not require antibiotics, and localized skin and soft tissue infections without systemic signs can be treated by debridement alone. Because supplicative infections are often mixed, they require broader-spectrum treatment. Use of hyperbaric oxygen for gas gangrene may be beneficial but is controversial and should not delay surgical treatment.

**MIXED ANAEROBIC INFECTIONS**

**Etiology and Pathogenesis** Nonsporulating anaerobic bacteria are components of the normal flora of mucosal surfaces of the mouth, lower GI tract, skin, and female genital tract. Infection results when reduced tissue redox potentials occur—e.g., from tissue ischemia, trauma, surgery, perforated viscus, shock, or aspiration. Infections often involve multiple species of anaerobes combined with microaerophilic and facultative bacteria. Most anaerobes associated with human infections are relatively aerotolerant and can survive for as long as 72 h in the presence of oxygen. Anaerobic bacteria produce exoproteins that enhance virulence; e.g., *Bacteroides fragilis* has a polysaccharide capsule that promotes abscess formation. Major anaerobic gram-positive cocci include *Peptostreptococcus* spp. Major anaerobic gram-positive rods include spore-forming clostridia and non-spore-forming *Propionibacterium acnes* (a rare cause of foreign-body infections). Major anaerobic gram-negative bacilli include the *B. fragilis* group (normal bowel flora), *Fusobacterium* spp. (oral cavity and GI tract), *Prevotella* spp. (oral cavity and female genital tract), and *Porphyromonas* spp. (oral flora).

**Clinical Features**

**Anaerobic Infections of the Mouth, Head, and Neck**
- Gingivitis and periodontal disease: can progress to involve bone, sinuses, and adjacent soft tissue
- Necrotizing ulcerative gingivitis (trench mouth, Vincent’s angina): The pt has a sudden onset of bleeding tender gums, foul breath, and ulceration with gray exudates; widespread destruction of bone and soft tissue can develop (acute necrotizing ulcerative mucositis; cancrum oris, noma) after a debilitating illness, in malnourished children, or in leukemic pts. Lesions heal but leave disfiguring defects.
- Acute necrotizing infections of the pharynx: associated with ulcerative gingivitis. Pts have sore throat, foul breath, fever, a choking sensation, and tonsillar pillars that are swollen, red, ulcerated, and covered with a gray membrane. Lymphadenopathy and leukocytosis are common. Aspiration, lung abscesses, or soft tissue infection can result.
- Peripharyngeal space infections: Peritonsillar abscess (quinsy) is a complication of acute tonsillitis caused by a mixed flora including anaerobes and group A streptococci. Ludwig’s angina is an infection arising from the second and third molars and associated with submandibular soft tissue infection, swelling, pain, trismus, and displacement of the tongue. Swelling can cause respiratory obstruction.
• Sinusitis and otitis: Anaerobes are important, especially in chronic infections.
• Lemierre syndrome: acute oropharyngeal *F. necrophorum* infection causing septic thrombophlebitis of the internal jugular vein and metastatic infections.
• Other complications of anaerobic mouth, head, and neck infections: osteomyelitis, brain abscess, subdural empyema, mediastinitis or pleuropulmonary infection, hematogenous dissemination.

**Central Nervous System Infections**  Up to 85% of brain abscesses yield anaerobic bacteria, usually *Peptostreptococcus*, *Fusobacterium*, *Bacteroides*, and *Prevotella* spp.

**Pleuropulmonary Infections**
• Aspiration pneumonia: Mendelson’s syndrome is characterized by aspiration of the stomach contents, with consequent destruction of the alveolar lining and rapid transudation of fluid into the alveolar space. This condition initially represents a chemical injury and not an infection, and antibiotics should be withheld unless bacterial infection supervenes.
• Bacterial aspiration pneumonia: due to depressed gag reflex, impaired swallowing, or altered mental status. Illness develops over days with low-grade fevers, malaise, and sputum production. Sputum contains a mixed flora, and cultures are usually unreliable because of contamination by oral flora components.
• Necrotizing pneumonitis: numerous small abscesses throughout the lung. The clinical course can be either indolent or fulminant.
• Anaerobic lung abscess: usually a subacute infection, often from a dental source. Pts have constitutional symptoms and foul-smelling sputum.
• Empyema: usually follows long-standing anaerobic pulmonary infection. Pts have symptoms resembling other anaerobic pulmonary infections but may report pleuritic chest pain and marked chest-wall tenderness.

**Intraabdominal Infections**  See Chap. 88.

**Pelvic Infections**  (Chap. 90) Most infections of the female genital tract and pelvis are mixed infections that include anaerobes and coliforms. Pure anaerobic infections occur more often at pelvic sites than at other intraabdominal sites. Pts may have foul-smelling drainage or pus from the uterus, generalized uterine or local pelvic tenderness, and fever. Suppurative thrombophlebitis of the pelvic veins may complicate the picture and lead to septic pulmonary emboli. Anaerobes are also thought to contribute to bacterial vaginosis.

**Skin and Soft Tissue Infections**  (Chap. 91)
• Trauma, ischemia, or surgery may create a suitable environment for skin or soft tissue infections caused by anaerobic bacteria, usually as part of a mixed etiology. There is a higher frequency of fever, foul-smelling drainage, gas in the tissues, and visible foot ulcer in cases involving anaerobic bacteria.
• Meleney’s gangrene (synergistic gangrene), a rare infection of the superficial fascia, is characterized by exquisite pain, redness, swelling, and induration with erythema around a central zone of necrosis, usually at the site of a surgical wound or an ulcer on an extremity.
• Necrotizing fasciitis is a rapidly destructive disease that is usually due to group A *Streptococcus* but can be a mixed anaerobic-aerobic infection. *Fournier’s gangrene* involves the scrotum, perineum, and anterior abdominal wall.

**Bone and Joint Infections**  Anaerobic bone and joint infections usually occur adjacent to soft tissue infections.
**Bacteremia**  
*B. fragilis* is the most common cause of significant anaerobic bacteremia. The clinical course can resemble septic shock, and pts can become extremely ill.

**Diagnosis** When infections develop in close proximity to mucosal surfaces normally harboring anaerobic flora, the involvement of anaerobes should be considered. The three critical steps in successfully culturing anaerobic bacteria from clinical samples are (1) proper specimen collection, with avoidance of contamination by normal flora; (2) rapid specimen transport to the microbiology laboratory in anaerobic transport media; and (3) proper specimen handling.

**Mixed Anaerobic Infections**  
Appropriate treatment requires antibiotic administration (Table 99-1), surgical resection or debridement of devitalized tissues, and drainage.

1. Infections above the diaphragm: Metronidazole treatment gives unpredictable results in infections caused by peptostreptococci, and penicillin resistance is increasing because of β-lactamase production. Either clindamycin or a penicillin/metronidazole combination is an option.

2. Infections below the diaphragm: must be treated with agents active against *Bacteroides* spp., such as metronidazole, β-lactam/β-lactamase inhibitor combinations, or carbapenems. Aerobic gram-negative flora should also be treated, with coverage for enterococci when indicated.

---

**TABLE 99-1**  
**DOSES AND SCHEDULES FOR TREATMENT OF SERIOUS INFECTIONS DUE TO COMMONLY ENCOUNTERED ANAEROBIC GRAM-NEGATIVE RODS**

<table>
<thead>
<tr>
<th>First-Line Therapy</th>
<th>Dose</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metronidazole(^b)</td>
<td>500 mg</td>
<td>q6h</td>
</tr>
<tr>
<td>Ticarcillin/clavulanic acid</td>
<td>3.1 g</td>
<td>q4h</td>
</tr>
<tr>
<td>Piperacillin/tazobactam</td>
<td>3.375 g</td>
<td>q6h</td>
</tr>
<tr>
<td>Imipenem</td>
<td>0.5 g</td>
<td>q6h</td>
</tr>
<tr>
<td>Meropenem</td>
<td>1.0 g</td>
<td>q8h</td>
</tr>
</tbody>
</table>

\(^a\)See disease-specific chapters in HPIM-17 for recommendations on duration of therapy.  
\(^b\)Should generally be used in conjunction with drugs active against aerobic or facultative organisms.  
**Note:** All drugs are given by the IV route.

---

Nocardiae are saprophytic aerobic actinomycetes common in soil. Several species are associated with human disease. *N. asteroides* is the species most commonly associated with invasive disease. *N. brasiliensis* is most often associated with localized skin lesions.

**Epidemiology** In the United States, ~1100 cases of nocardial infection occur annually, of which 85% are pulmonary or systemic. The risk of disease is greater than usual among persons with deficient cell-mediated immunity—e.g., that associated with lymphoma, transplantation, glucocorticoid therapy, or AIDS.

**Pathology and Pathogenesis** Pneumonia and disseminated disease follow inhalation of bacterial mycelia. Nocardiosis causes abscesses with neutrophilic infiltration and necrosis. Organisms survive within phagocytes.

**Clinical Features**

- **Pulmonary disease** is usually subacute, presenting over days to weeks. Extrapulmonary disease is documented in >50% of cases, and some pulmonary involvement is evident in 80% of pts with extrapulmonary disease. A prominent cough productive of small amounts of thick purulent sputum, fever, anorexia, weight loss, and malaise are common; dyspnea, hemoptysis, and pleuritic chest pain are less common. Chest x-ray (CXR) typically shows single or multiple nodular infiltrates of varying sizes that tend to cavitate. Empyema is noted in one-third of cases. Infection may spread to adjacent tissues, such as pericardium or mediastinum.

- **Extrapulmonary disease** typically manifests as subacute abscesses in brain, skin, kidneys, bone, and/or muscle. Some abscesses form fistulae and discharge small amounts of pus, but not those in the lungs or brain. Brain abscesses are usually supratentorial, are often multiloculated, can be single or multiple, and tend to burrow into ventricles or extend into the subarachnoid space.

- **Disease after transcutaneous inoculation**
  1. **Cellulitis:** Subacute cellulitis may present 1–3 weeks after a break in the skin (often contaminated with soil). The firm, tender, erythematous, warm, and nonfluctuant lesions may involve underlying structures.
  2. **Lymphocutaneous syndrome:** A pyodermatous lesion develops at the inoculation site, with central ulceration and purulent discharge. This lesion is often drained by SC nodules along lymphatics. This form resembles sporotrichosis.
  3. **Actinomycetoma:** A nodular swelling forms at the site of local trauma, typically on the feet or hands. Fistulae form and discharge serous or purulent drainage that can contain granules consisting of masses of mycelia. Lesions, which spread slowly along fascial planes to involve adjacent skin and SC tissue and bone, can cause extensive deformity.

- **Eye infections:** Keratitis usually follows eye trauma. Endophthalmitis can occur after eye surgery or during disseminated disease.
Infectious Diseases

SECTION 7

Diagnosis

- Sputum or pus should be examined for branching, beaded, gram-positive filaments. Nocardiae usually give positive results with modified acid-fast stains. Sputum smears are often negative, and bronchoscopy may be needed to obtain adequate specimens.
- Cultures take 2–4 weeks to yield the organism. The laboratory should be alerted if nocardiosis is being considered. Sputum cultures positive for nocardiae should be assumed to reflect disease in immunocompromised hosts but may represent colonization in immunocompetent pts. Brain imaging should be considered in pts with pulmonary or disseminated disease.

Nocardiosis

Table 100-1 lists the drugs, dosages, and durations used for treatment of nocardiosis.

- Sulfonamides are the drugs of choice. For serious disease, serum sulfonamide levels should be monitored and maintained at 100–150 μg/mL. Once disease is controlled, the trimethoprim-sulfamethoxazole dose may be decreased by 50%.
- Susceptibility testing can guide alternative treatments.
- Therapy for nocardiosis should continue while pts remain immunosuppressed.
- Brain abscesses that are large or unresponsive to antibiotics should be aspirated.
- Relapse is common. Pts should be followed for at least 6 months after therapy is complete. Mortality rates are high among pts with nocardiosis of the brain.

**TABLE 100-1 TREATMENT FOR NOCARDIOSIS**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Duration</th>
<th>Drugs (Daily Dose)a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary or systemic</td>
<td></td>
<td>Systemic therapy</td>
</tr>
<tr>
<td>Intact host defenses</td>
<td>6–12 mo</td>
<td>Oral</td>
</tr>
<tr>
<td>Deficient host defenses</td>
<td>12 mob</td>
<td>1. Trimethoprim (10–20 mg/kg) and sulfamethoxazole (50–100 mg/kg)</td>
</tr>
<tr>
<td>CNS disease</td>
<td>12 mo c</td>
<td>2. Minocycline (200–400 mg)</td>
</tr>
<tr>
<td>Cellulitis, lymphocutaneous</td>
<td>2 mo</td>
<td>3. Linezolid (1200 mg)</td>
</tr>
<tr>
<td>syndrome</td>
<td></td>
<td>Parenteral</td>
</tr>
<tr>
<td>Osteomyelitis, arthritis,</td>
<td>4 mo</td>
<td>1. Amikacin (10–15 mg/kg)</td>
</tr>
<tr>
<td>laryngitis, sinusitis</td>
<td></td>
<td>2. Cefotaxime (6 g), ceftriaxone (1–2 g), or imipenem (2 g)</td>
</tr>
<tr>
<td>Actinomycetoma</td>
<td>6–12 mo after clinical cure</td>
<td></td>
</tr>
<tr>
<td>Keratitis</td>
<td>Topical: Until apparent cure</td>
<td>1. Sulfonamide drops</td>
</tr>
<tr>
<td></td>
<td>Systemic: Until 2–4 mo after apparent cure</td>
<td>2. Amikacin drops</td>
</tr>
</tbody>
</table>

aFor each category, choices are numbered in order of preference.
bIn some patients with AIDS or chronic granulomatous disease, therapy for pulmonary or systemic disease must be continued indefinitely.
cIf all apparent CNS disease has been excised, the duration of therapy may be reduced to 6 months.

*Note: CNS, central nervous system.*
Actinomycosis is caused by anaerobic or microaerophilic bacteria primarily of the genus *Actinomyces* (e.g., *A. israelii*). This diagnosis should be considered when a chronic progressive process with mass-like features crosses tissue boundaries, a sinus tract develops, and/or the pt has evidence of a refractory or relapsing infection despite short courses of antibiotics. Most infections are polymicrobial, but the role of other species in the pathogenesis of the disease is unclear.

**Epidemiology** Actinomycosis is associated with poor dental hygiene, use of intrauterine contraceptive devices (IUCDs), and immunosuppression. Its incidence is decreasing, probably as a result of better dental hygiene and earlier initiation of antibiotic treatment.

**Pathogenesis** The agents of actinomycosis are members of the normal oral flora and are commonly cultured from the GI and female genital tracts. Disease occurs only after disruption of the mucosal barrier. Local infection spreads contiguously in a slow, progressive manner, ignoring tissue planes. In vivo growth produces clumps called *grains* or *sulfur granules*. Central necrosis of lesions with neutrophils and sulfur granules is virtually diagnostic of the disease. The fibrotic walls of the mass are often described as “wooden.”

**Clinical Features**

- **Oral-cervicofacial disease:** Infection starts as a soft tissue swelling, abscess, or mass, often at the angle of the jaw with contiguous extension to the brain, cervical spine, or thorax. Pain, fever, and leukocytosis are variable.
- **Thoracic disease:** The pulmonary parenchyma and/or pleural space is usually involved. Chest pain, fever, and weight loss occur. CXR shows a mass lesion or pneumonia. Cavitary disease or hilar adenopathy may occur, and >50% of pts have pleural thickening, effusion, or empyema. Lesions cross fissures or pleura and may involve the mediastinum, contiguous bone, or the chest wall.
- **Abdominal disease:** The diagnosis is challenging and may not be made until months after the initial event (e.g., diverticulitis, bowel surgery). The disease usually presents as an abscess, mass, or lesion fixed to underlying tissue and is often mistaken for cancer. Sinus tracts to the abdominal wall, perianal region, or other organs may develop and mimic inflammatory bowel disease. Involvement of the urogenital tract can present as pyelonephritis or perinephric abscesses.
- **Pelvic disease:** Pelvic actinomycosis is often associated with IUCDs. The presentation is indolent and may follow removal of the device. Pts have fever, weight loss, abdominal pain, and abnormal vaginal bleeding. Endometritis progresses to pelvic masses or tuboovarian abscesses. When there are no symptoms and actinomycosis-causing organisms are isolated, it is not clear whether an IUCD should be removed, but the pt should be carefully observed over time.
- **Miscellaneous sites:** Actinomycosis can involve musculoskeletal tissue, soft tissue, or the central nervous system and can disseminate hematogenously, most commonly to the lungs and liver.

**Diagnosis** Aspirations, biopsies, or surgical excision may be required to obtain material for diagnosis. Microscopic identification of sulfur granules in pus or tissues establishes the diagnosis. Occasionally, sulfur granules are grossly identified from draining sinus tracts or pus. Cultures usually require 5–7 days but may take 2–4 weeks to become positive; even a single antibiotic dose can affect the yield of cultures.
**Actinomycosis**

Like nocardiosis, actinomycosis requires prolonged treatment. IV therapy for 2–6 weeks (usually with penicillin) followed by oral therapy for 6–12 months (e.g., with penicillin or ampicillin) is suggested for serious infection and bulky disease. Less extensive disease, particularly that involving the oral-cervicofacial region, may be cured with a shorter course. If treatment is extended beyond the point of resolution of measurable disease (as quantified by CT or MRI), relapse is minimized. Suitable alternative agents include the tetracyclines (e.g., minocycline, 200 mg/d given IV or PO q12h) or clindamycin (2.7 g/d given IV q8h or 1.2–1.8 g/d given PO q6–8h).

For a more detailed discussion, see Filice GA: Nocardiosis, Chap. 155, p. 992; and Russo TA: Actinomycosis, Chap. 156, p. 996, in HPIM-17.

---

**Tuberculosis and Other Mycobacterial Infections**

**Tuberculosis**

Tuberculosis (TB) is caused by organisms of the *Mycobacterium tuberculosis* complex. This complex includes *M. tuberculosis* (MTB), the most frequent and important agent of human mycobacterial disease, and *M. bovis*, which is acquired via ingestion of unpasteurized milk. MTB is a thin aerobic bacterium that is neutral on Gram’s staining but that, once stained, is acid-fast—i.e., it cannot be decolorized by acid alcohol because of the cell wall’s high content of mycolic acids and other lipids.

**Epidemiology**

- It is estimated that >8.8 million new cases of TB occurred worldwide in 2005, mostly in developing countries. In 2005, 1.6 million deaths due to TB are estimated to have occurred. In the United States, TB tends to be a disease of elderly persons, HIV-infected young adults, immigrants, and the poor. Rates increased during the late 1980s as a result of disease in these populations and the emergence of multidrug-resistant (MDR) TB but have since decreased as a result of strong TB control programs. TB rates are stable or falling globally as well.
- Disease from a pt with pulmonary TB is spread by droplet nuclei that are aerosolized by coughing, sneezing, or speaking. Droplets may be suspended in air for several hours. Transmission is determined by the intimacy and duration of contact with a pt with TB, the degree of infectiousness of the pt, and the shared environment. Pts with cavitary or laryngeal disease are most infectious, with as many as $10^5$–$10^7$ acid-fast bacilli (AFB)/mL of sputum.
- Risk factors for development of active disease after MTB infection include recent acquisition (within the preceding year), comorbidity (e.g., HIV dis-
Pathogenesis. AFB that reach alveoli are ingested by macrophages. If the bacilli are not contained, they multiply, lyse the macrophages, and spread to regional lymph nodes, from which dissemination throughout the body may occur. About 2–4 weeks after infection, delayed-type hypersensitivity (DTH) destroys nonactivated macrophages that contain multiplying bacilli, and a macrophage-activating response activates cells capable of killing AFB. DTH is the basis for tuberculin skin testing (TST). A granuloma forms at the site of the primary lesion and at sites of dissemination. The lesions can then either heal by fibrosis or undergo further evolution. Despite “healing,” viable bacilli can remain dormant within macrophages or in necrotic material for years. Cell-mediated immunity confers partial protection against TB. Cytokines secreted by alveolar macrophages contribute to disease manifestations, granuloma formation, and mycobacterial killing.

Clinical Features. Pulmonary TB. TB is limited to the lungs in >80% of cases in HIV-negative pts.
1. Primary disease: The initial infection is frequently located in the middle and lower lobes. The primary lesion usually heals spontaneously, and a calcified nodule (Ghon lesion) remains. Hilar and paratracheal lymphadenopathy are common. In immunosuppressed pts and children, primary disease may progress rapidly to clinical disease, with cavitation, pleural effusions, and hematogenous dissemination.
2. Postprimary (adult-type, reactivation, or secondary) disease: usually localized to the apical and posterior segments of the upper lobes and the superior segments of the lower lobes
   a. Early symptoms of fever, night sweats, weight loss, anorexia, malaise, and weakness are nonspecific and insidious.
   b. Cough and purulent sputum production, often with blood streaking, occur. Occasionally, massive hemoptysis follows erosion of a vessel located in the wall of a cavity.
   c. Disease can be limited, or extensive cavitation may develop. Extensive disease may cause dyspnea and respiratory distress.

Extrapulmonary TB. Any site in the body can be involved. Up to two-thirds of HIV-infected pts with TB have extrapulmonary disease.
1. Lymphadenitis occurs in >40% of extrapulmonary TB cases, especially among HIV-infected pts. Painless swelling of cervical and supraclavicular nodes (scrofula) is typical. Early on, nodes are discrete but can be inflamed with a fistulous tract. Fine-needle aspiration or surgical biopsy of the node is required for diagnosis. AFB smears are positive in ~50% of cases and cultures in 70–80%.
2. Pleural involvement is common in primary TB, resulting from penetration of bacilli into the pleural space or contiguous spread of parenchymal inflammation.
   a. DTH in response to these bacilli can result in effusion. Fluid is straw-colored and exudative, with protein levels >50% of those in serum, normal to low glucose levels, a usual pH of ~7.3 (occasionally <7.2), and pleocytosis (500–6000 cells/μL). Mononuclear cells are most common, although neutrophils may be present early in disease, and mesothelial cells are rare or absent. The pleural concentration of adenosine deami-
nase (ADA), if low, virtually excludes TB. Pleural biopsy is often required for diagnosis, with up to 80% of biopsy cultures positive.

b. Empyema is uncommon and results from rupture of a cavity with many bacilli into the pleural space.

3. In \textit{genitourinary} disease, local symptoms predominate (e.g., frequency and dysuria). Calcifications and ureteral strictures can be seen. In >90% of cases, urinalysis shows pyuria and hematuria with negative bacterial cultures; in 90% of cases, culture of three morning urine specimens is diagnostic. Genital TB is more common among women than among men. Fallopian tube and uterine disease can cause infertility.

4. \textit{Skeletal} disease: The spine, hips, and knees are the most common sites. Spinal TB (Pott’s disease) often involves two or more adjacent vertebral bodies; in adults, lower thoracic/upper lumbar vertebrae are usually affected. Disease spreads to adjacent vertebral bodies, later affecting the intervertebral disk and causing collapse of vertebral bodies in advanced disease (kyphosis, gibbus). Paravertebral cold abscesses may form.

5. \textit{Meningitis} occurs most often in young children and HIV-seropositive pts. Disease typically evolves over 1–2 weeks.

a. Cranial nerve involvement (particularly of ocular nerves) is common. Disease progresses to coma, hydrocephalus, and intracranial hypertension.

b. Cerebrospinal fluid (CSF) has a high lymphocyte count, an elevated protein level, and a low glucose concentration. Cultures are positive in 80% of cases. Polymerase chain reaction is ~80% sensitive but gives a false-positive result 10% of the time.

c. Neurologic sequelae are seen in ~25% of treated pts; adjunctive glucocorticoids enhance survival among pts >14 years of age but do not reduce the frequency of neurologic sequelae.

6. \textit{Gastrointestinal} disease affects the terminal ileum and cecum, causing abdominal pain and diarrhea, and can present with a clinical picture similar to that of Crohn’s disease. A palpable mass and bowel obstruction may occur. TB peritonitis presents with fever, abdominal pain, and ascites that is exudative with a high protein content and lymphocytic leukocytosis. Peritoneal biopsy is usually required for diagnosis.

7. \textit{Pericarditis} is characterized by an acute or subacute onset of fever, dull retrosternal pain, and sometimes a friction rub. Effusion is common. Chronic constrictive pericarditis is a potentially fatal complication, even in treated pts. Adjunctive glucocorticoids may help manage acute disease but do not seem to reduce constriction.

8. \textit{Miliary} disease arises from hematogenous spread of MTB throughout the body. Lesions are small (1- to 2-mm) granulomas, and symptoms are nonspecific. Hepatomegaly, splenomegaly, lymphadenopathy, and choroidal tubercles of the eye may occur.

\textbf{HIV-Associated TB} \hspace{1em} The manifestations of TB vary with the stage of HIV infection. When cell-mediated immunity is only partly compromised, pulmonary TB presents as typical upper-lobe cavitary disease. In late HIV infection, a primary TB-like pattern may be evident, with diffuse interstitial or miliary infiltrates, little or no caviation, and intrathoracic lymphadenopathy. Extrapulmonary disease occurs frequently; common forms include lymphadenitis, meningitis, pleuritis, pericarditis, mycobacteremia, and disseminated disease.

\textbf{Diagnosis} 

- Maintain a high index of suspicion, perform appropriate radiographic studies, and obtain appropriate clinical specimens.
• Examine diagnostic specimens for AFB with auramine-rhodamine stain and fluorescence microscopy.
• Isolate and identify MTB on culture; liquid media and speciation by molecular methods have decreased the time required for diagnostic confirmation to 2–3 weeks.
• Nucleic acid amplification is useful for rapid confirmation of TB in AFB-positive specimens.
• The results of drug susceptibility testing are most rapid if liquid medium is used.
• TST is of limited value in active disease because of low sensitivity and specificity but is the most widely used screening test for latent TB infection. Interferon-γ (IFN-γ) release assays (IGRAs) measure the release of IFN-γ by T cells after stimulation with TB-specific antigens. IGRAs are as sensitive as TST in active disease and are more specific; however, further studies must assess their performance in this setting.

DRUGS
First-Line Agents
• Rifampin: the most important and potent antituberculous agent. The standard dosage in adults is 600 mg/d. The drug distributes well throughout body tissues, including inflamed meninges. It turns body fluids (e.g., urine, saliva, tears) red-orange and is excreted through bile and the enterohepatic circulation. Rifampin is usually well tolerated but may cause GI upset. The drug can cause hepatitis when given in combination with isoniazid or pyrazinamide. Rash, anemia, and thrombocytopenia are less common side effects. Of note, rifampin is a potent inducer of hepatic microsomal enzymes and decreases the half-life of many other drugs.
• Isoniazid (INH): the best agent available after rifampin. The usual adult dosage is 300 mg/d or 900 mg 2 or 3 times per week. INH is distributed well throughout the body and infected tissues, including CSF and caseous granulomas. The most important toxicities are hepatotoxicity and peripheral neuropathy. INH-associated hepatitis is idiosyncratic and increases with age, alcohol use, pregnancy or the postpartum period, active hepatitis B infection, and concomitant use of rifampin. Because peripheral neuropathy can result from interference with pyridoxine metabolism, pyridoxine (25–50 mg/d) should be given to pts with other risk factors for neuropathy, such as diabetes, alcohol abuse, or malnutrition.
• Ethambutol: the least potent first-line agent, ethambutol is usually given at a dosage of 15–20 mg/kg daily. It is distributed throughout the body but reaches only low levels in CSF. At higher doses, retrobulbar optic neuritis can occur, causing central scotoma and impairing both visual acuity and the ability to see green.
• Pyrazinamide: the usual dosage is 15–30 mg/kg daily (maximum, 2 g/d). The drug distributes well throughout the body, including the CSF. At current doses, hepatotoxicity is no greater than with INH or rifampin. Hyperuricemia and—in rare instances—gout can occur.

Other Effective Agents
• Streptomycin: the usual adult dose is 0.5–1.0 g IM daily or 5 times per week. Streptomycin causes ototoxicity, affecting both hearing and vestibular function, but is less nephrotoxic than other aminoglycosides.
• Rifabutin: may be as effective as rifampin, eliciting fewer drug interactions, and is active against some rifampin-resistant TB strains. Tissue le-
vels are 5–10 times higher than plasma levels. Most adverse effects are dose-related.

- **Rifapentine**: similar to rifampin but can be given once or twice weekly. This drug is not approved by the U.S. Food and Drug Administration for the treatment of HIV-infected pts because rifampin monoresistance has been documented in pts taking INH and once-weekly rifapentine.

**Second-Line Agents**

- **Fluoroquinolones** (e.g., levofloxacin, ciprofloxacin, and moxifloxacin) have solid, broad antimycobacterial activity. Other agents are used uncommonly but may be needed in disease caused by resistant strains of MTB.

**REGIMENS**

See Table 101-1.

- Nonadherence to the regimen is the most important impediment to cure. Directly observed treatment (especially during the initial 2 months) and fixed-drug-combination products should be used if possible.
- Bacteriologic evaluation is the preferred method of monitoring response to treatment. Virtually all pts should have negative sputum cultures by the end of 2–3 months of treatment. If the culture remains positive, treatment failure and drug resistance should be suspected.
- Drug resistance may be either primary (i.e., infection caused by a strain resistant prior to therapy) or acquired (i.e., resistance arising during treatment because of an inadequate regimen or the pt’s noncompliance). MDR TB is defined as that caused by strains resistant to isoniazid and rifampin.
- Close monitoring for drug toxicity should take place during treatment and should include baseline liver function tests (LFTs) and monthly questioning about possible hepatitis symptoms. High-risk pts (e.g., older pts, pts who use alcohol daily) should have LFT values monitored during treatment.
- HIV-associated TB: Three considerations are important for HIV-infected pts receiving TB treatment.
  1. Immune reconstitution inflammatory syndrome (IRIS) may occur when antiretroviral therapy (ART) is initiated. Symptoms and signs of TB are exacerbated as immune function improves.
  2. ART agents and rifamycin may interact.
  3. Rifampin monoresistance may develop with widely spaced intermittent treatment.

**Prevention**

- Vaccination: An attenuated strain of *M. bovis*, bacille Calmette-Guérin (BCG), protects infants and young children from serious forms of TB. Its efficacy is unclear in other situations.
- Treatment of latent infection: Candidates for chemoprophylaxis are usually identified by TST. Positive skin tests are determined by reaction size and risk group (Table 101-2), and, if the test is positive, drug treatment is considered (Table 101-3). INH should not be given to persons with active liver disease.

**LEPROSY**

**Etiology and Epidemiology** Leprosy, a nonfatal chronic infectious disease caused by *M. leprae*, is a disease of the developing world; its global prevalence is difficult to assess and is variously estimated at 0.6–8 million. Africa has the
Tuberculosis and Other Mycobacterial Infections

CHAPTER 101

highest prevalence, and Asia has the most cases. More than 80% of the world’s cases occur in a few countries: India, China, Myanmar, Indonesia, Nepal, Brazil, Nigeria, and Madagascar. Leprosy is associated with poverty and rural residence. The route of transmission is uncertain but may be via nasal droplets, contact with infected soil, or insect vectors.

<table>
<thead>
<tr>
<th>Indication</th>
<th>Initial Phase</th>
<th>Continuation Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Duration,</td>
<td>Drugs</td>
</tr>
<tr>
<td></td>
<td>Months</td>
<td></td>
</tr>
<tr>
<td>New smear- or culture-</td>
<td>2</td>
<td>HRZE&lt;sup&gt;a,b&lt;/sup&gt;</td>
</tr>
<tr>
<td>positive cases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New culture-negative cases</td>
<td>2</td>
<td>HRZE&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>2</td>
<td>HRE&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td>Failure and relapse&lt;sup&gt;f&lt;/sup&gt; to H</td>
<td>Throughout (6)</td>
<td>RZE&lt;sup&gt;g&lt;/sup&gt;</td>
</tr>
<tr>
<td>Resistance (or intolerance) to H + R</td>
<td>Throughout (12–18)</td>
<td>ZEQ + S (or another injectable agent&lt;sup&gt;b&lt;/sup&gt;)</td>
</tr>
<tr>
<td>Resistance to all first-line drugs</td>
<td>3</td>
<td>HRZES&lt;sup&gt;i&lt;/sup&gt;</td>
</tr>
<tr>
<td>Standardized re-treatment (susceptibility testing unavailable)</td>
<td>Throughout (12)&lt;sup&gt;j&lt;/sup&gt;</td>
<td>HZE&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td>Drug intolerance to R</td>
<td>2</td>
<td>HRE&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td>Drug intolerance to Z</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>All drugs can be given daily or intermittently (three times weekly throughout or twice weekly after 2–8 weeks of daily therapy during the initial phase).

<sup>b</sup>Streptomycin can be used in place of ethambutol but is no longer considered to be a first-line drug by ATS/IDSA/CDC.

<sup>c</sup>The continuation phase should be extended to 7 months for pts with cavitary pulmonary tuberculosis who remain sputum culture-positive after the initial phase of treatment.

<sup>d</sup>HIV-negative pts with noncavitary pulmonary tuberculosis who have negative sputum AFB smears after the initial phase of treatment can be given once-weekly rifapentine/isoniazid in the continuation phase.

<sup>e</sup>The 6-month regimen with pyrazinamide can probably be used safely during pregnancy and is recommended by the WHO and the International Union Against Tuberculosis and Lung Disease. If pyrazinamide is not included in the initial treatment regimen, the minimum duration of therapy is 9 months.

<sup>f</sup>Regimen is tailored according to the results of drug susceptibility tests.

<sup>g</sup>A fluoroquinolone may strengthen the regimen for pts with extensive disease.

<sup>h</sup>Amikacin, kanamycin, or capreomycin. All these agents should be discontinued after 2–6 months, depending on tolerance and response.

<sup>i</sup>Streptomycin should be discontinued after 2 months. This regimen is less effective for pts in whom treatment has failed, who have an increased probability of rifampin-resistant disease. In such cases, the re-treatment regimen might include second-line drugs chosen in light of the likely pattern of drug resistance.

<sup>j</sup>Streptomycin for the initial 2 months or a fluoroquinolone might strengthen the regimen for pts with extensive disease.

Note: H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin; Q, a quinolone antibiotic; PAS, para-aminosalicylic acid.
Clinical, Histologic, and Immunologic Spectrum  The spectrum of clinical and histologic manifestations of leprosy is attributable to variability in the immune response to M. leprae. The spectrum from polar tuberculoid leprosy (TL) to polar lepromatous leprosy (LL) is associated with an evolution from localized to more generalized disease manifestations and an increasing bacterial load. Prognosis, complications, and intensity of antimicrobial therapy depend on where a pt presents on the clinical spectrum. The incubation period ranges from 2 to 40 years but is usually 5–7 years.

Tuberculoid Leprosy  
• Disease is confined to the skin and peripheral nerves. AFB are few or absent.  
• One or several hypopigmented macules or plaques with sharp margins that are hypesthetic and have lost sweat glands and hair follicles are present.  
• There is asymmetric enlargement of one or several peripheral nerves—most often the ulnar, posterior auricular, peroneal, and posterior tibial nerves—associated with hypesthesia and myopathy.

Lepromatous Leprosy  
• Symmetrically distributed skin nodules, raised plaques, and diffuse dermal infiltration that can cause leonine facies, loss of eyebrows and lashes, pendulous earlobes, and dry scaling  
• Numerous bacilli in skin, nerves, and all organs except lungs and central nervous system  
• Nerve enlargement and damage are usually symmetric; symmetric nerve-trunk enlargement and acral distal peripheral neuropathy are seen.

Complications  
• Reactional states: inflammatory conditions at the site of lesions. Erythema nodosum leprosum (ENL) occurs in pts near the LL end of the disease spectrum as they tend toward TL after treatment.

### TABLE 101-2  TUBERCULIN REACTION SIZE AND TREATMENT OF LATENT TB INFECTION

<table>
<thead>
<tr>
<th>Risk Group</th>
<th>Tuberculin Reaction Size, mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-infected persons or persons receiving immuno-suppressive therapy</td>
<td>≥5</td>
</tr>
<tr>
<td>Close contacts of TB pts</td>
<td>≥5&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Persons with fibrotic lesions on chest radiography</td>
<td>≥5</td>
</tr>
<tr>
<td>Recently infected persons (≤2 years)</td>
<td>≥10</td>
</tr>
<tr>
<td>Persons with high-risk medical conditions&lt;sup&gt;b&lt;/sup&gt;</td>
<td>≥10</td>
</tr>
<tr>
<td>Low-risk persons&lt;sup&gt;c&lt;/sup&gt;</td>
<td>≥15</td>
</tr>
</tbody>
</table>

<sup>a</sup>Tuberculin-negative contacts, especially children, should receive prophylaxis for 2–3 months after contact ends and should then undergo repeat TST. Those whose results remain negative should discontinue prophylaxis. HIV-infected contacts should receive a full course of treatment regardless of TST results.

<sup>b</sup>Including diabetes mellitus, some hematologic and reticuloendothelial diseases, injection drug use (with HIV seronegativity), end-stage renal disease, and clinical situations associated with rapid weight loss.

<sup>c</sup>Except for employment purposes where longitudinal TST screening is anticipated, TST is not indicated for these low-risk persons. A decision to treat should be based on individual risk/benefit considerations.
### TABLE 101-3
**REVISED DRUG REGIMENS FOR TREATMENT OF LATENT TB INFECTION (LTBI) IN ADULTS**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Interval and Duration</th>
<th>Comments&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Rating&lt;sup&gt;b&lt;/sup&gt; (Evidence&lt;sup&gt;c&lt;/sup&gt;)</th>
<th>HIV-Negative</th>
<th>HIV-Infected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid</td>
<td>Daily for 9 months&lt;sup&gt;d,e&lt;/sup&gt;</td>
<td>In HIV-infected persons, isoniazid may be administered concomitantly with nucleoside reverse transcriptase inhibitors, protease inhibitors, or nonnucleoside reverse transcriptase inhibitors (NNRTIs).</td>
<td>A (II)</td>
<td>A (II)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Twice weekly for 9 months&lt;sup&gt;d,e&lt;/sup&gt;</td>
<td>Directly observed therapy (DOT) must be used with twice-weekly dosing.</td>
<td>B (II)</td>
<td>B (II)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Daily for 6 months&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Regimen is not indicated for HIV-infected persons, those with fibrotic lesions on chest radiographs, or children.</td>
<td>B (I)</td>
<td>C (I)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Twice weekly for 6 months&lt;sup&gt;e&lt;/sup&gt;</td>
<td>DOT must be used with twice-weekly dosing.</td>
<td>B (II)</td>
<td>C (I)</td>
<td></td>
</tr>
<tr>
<td>Rifampin&lt;sup&gt;f&lt;/sup&gt;</td>
<td>Daily for 4 months</td>
<td>Regimen is used for contacts of pts with isoniazid-resistant, rifampin-susceptible TB. In HIV-infected pts, most protease inhibitors and delavirdine should not be administered concurrently with rifampin. Rifabutin, with appropriate dose adjustments, can be used with protease inhibitors (saquinavir should be augmented with ritonavir) and NNRTIs (except delavirdine). Consult web-based updates for the latest specific recommendations.</td>
<td>B (II)</td>
<td>B (III)</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Comments

<sup>b</sup> Rating

<sup>c</sup> Evidence

(continued)
Infectious Diseases

SECTION 7

Extremities: Neuropathy results in insensitivity and affects fine touch, pain, and heat receptors. Ulcerations, trauma, secondary infections, and (at times) a profound osteolytic process can take place.

Nose: chronic nasal congestion, epistaxis, destruction of cartilage with saddle-nose deformity or anosmia

Eye: trauma, secondary infection, corneal ulcerations, opacities, uveitis, cataracts, glaucoma, blindness

Testes: orchitis, aspermia, impotence, infertility

Diagnosis
In TL, the advancing edge of a skin lesion should be biopsied. In LL, biopsy of even normal-appearing skin often yields positive results.

### DRUGS

- Rifampin (600 mg daily or monthly) is the only agent bactericidal against *M. leprae*.

---

**TABLE 101-3** REVISED DRUG REGIMENS FOR TREATMENT OF LATENT TB INFECTION (LTBI) IN ADULTS (CONTINUED)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Interval and Duration</th>
<th>Comments</th>
<th>HIV-Negative</th>
<th>HIV-Infected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rifampin plus pyrazinamide (RZ)</td>
<td>Daily for 2 months</td>
<td>Regimen generally should not be offered for treatment of LTBI in either HIV-infected or HIV-negative pts.</td>
<td>D (II)</td>
<td>D (II)</td>
</tr>
<tr>
<td></td>
<td>Twice weekly for 2–3 months</td>
<td></td>
<td>D (III)</td>
<td>D (III)</td>
</tr>
</tbody>
</table>

*a* Interactions with HIV-related drugs are updated frequently and are available at [www.aidsinfo.nih.gov/guidelines](http://www.aidsinfo.nih.gov/guidelines).

*b* Strength of the recommendation: A. Both strong evidence of efficacy and substantial clinical benefit support recommendation for use. Should always be offered. B. Moderate evidence for efficacy or strong evidence for efficacy but only limited clinical benefit supports recommendation for use. Should generally be offered. C. Evidence for efficacy is insufficient to support a recommendation for or against use, or evidence for efficacy might not outweigh adverse consequences (e.g., drug toxicity, drug interactions) or cost of the treatment or alternative approaches. Optional. D. Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should generally not be offered. E. Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should never be offered.

*c* Quality of evidence supporting the recommendation: I. Evidence from at least one properly randomized controlled trial. II. Evidence from at least one well-designed clinical trial without randomization, from cohort or case-controlled analytic studies (preferably from more than one center), from multiple time-series studies, or from dramatic results in uncontrolled experiments. III. Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.

*d* Recommended regimen for persons <18 years old.

*e* Recommended regimen for pregnant women.

f The substitution of rifapentine for rifampin is not recommended because rifapentine’s safety and effectiveness have not been established for pts with LTBI.

Source: Adapted from CDC: Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 49(RR-6), 2000.
• Dapsone (50–100 mg/d). Hemolysis and methemoglobinemia are common adverse effects. G6PD deficiency must be ruled out before therapy to avoid hemolytic anemia. GI intolerance, headache, pruritus, peripheral neuropathies, and rash can occur.
• Clofazimine (50–100 mg/d, 100 mg 3 times per week, or 300 mg monthly). A phenazine iminoquinone dye, clofazimine is weakly active against *M. leprae*. Adverse effects include skin discoloration and GI intolerance.

**REGIMENS**
• Paucibacillary disease in adults (<6 skin lesions)
  1. Dapsone (100 mg/d) and rifampin (600 mg monthly, supervised) for 6 months or dapsone (100 mg/d) for 5 years
  2. With a single lesion: a single dose of rifampin (600 mg), ofloxacin (400 mg), and minocycline (100 mg)
• Multibacillary disease in adults (≥6 skin lesions)
  1. Dapsone (100 mg/d) plus clofazimine (50 mg/d) unsupervised as well as rifampin (600 mg monthly) plus clofazimine (300 mg monthly) supervised for 1–2 years
  2. Relapse can occur years later; prolonged follow-up is needed.
  3. Some experts prefer rifampin (600 mg/d for 3 years) and dapsone (100 mg/d) for life.
• Reactional states
  1. Mild reactions: glucocorticoids (40–60 mg/d for at least 3 months)
  2. If ENL is present and persists despite two courses of steroids, thalidomide (100–300 mg nightly) should be given. Because of thalidomide’s teratogenicity, its use is strictly regulated.

**INFECTIONS WITH NONTUBERCULOUS MYCOBACTERIA (NTM)**

Mycobacteria other than MTB and *M. leprae* are distributed widely throughout the environment in water, biofilms, and soil as well as in numerous animal species. Isolation of NTM from a clinical specimen may reflect colonization and requires an assessment of the organism’s significance.

**Microbiology**  *M. abscessus*, *M. fortuitum*, and *M. chelonae* grow rapidly (within 7 days). Other NTM species, such as *M. avium* and *M. intracellulare* (the *M. avium* complex, or MAC), *M. kansasii*, *M. ulcerans*, and *M. marinum*, more typically grow within 2–3 weeks, although newer broth culture systems can isolate these organisms more quickly.

**Clinical Features**

MAC
   a. Pts present with chronic cough, dyspnea, and fatigue but no fever. Two patterns are seen: (1) primary pulmonary disease presenting as nodules or bronchiectasis and (2) secondary disease (sometimes cavitary) in pts with underlying lung disease [e.g., chronic obstructive pulmonary disease (COPD), prior TB, cystic fibrosis]. MAC can also cause hypersensitivity pneumonitis after a pt’s repeated exposure to indoor hot tubs containing MAC-contaminated water.
   b. CT of the chest should be performed to document the extent of disease at baseline.
   c. Most pts with secondary MAC pulmonary disease should be treated. Pts with primary MAC pulmonary disease may not need treatment if there
is no disease progression and the pts’ age or underlying disease is likely to be the critical determinant of survival over the next few years. Agents include clarithromycin (250–500 mg bid) or azithromycin (250 mg daily or three times a week) plus ethambutol (15 mg/kg daily). Some authorities include rifampin or rifabutin. Streptomycin or amikacin can be included in the first 2 months for severe disease, and a fluorquinolone can be considered if one of the first-line agents cannot be tolerated. A macrolide-containing regimen should be given for ≥12 months after sputum cultures become negative.

2. Disseminated disease occurs primarily in immunocompromised pts, including those with advanced HIV disease who are not receiving ART.
   a. Pts present with fever, weakness, wasting, and adenopathy. Laboratory studies reveal anemia, hypoalbuminemia, increased alkaline phosphatase levels, and blood cultures positive for MAC.
   b. Blood cultures yield positive results within 2–3 weeks. AFB staining of bone marrow, intestine, and/or liver can provide the diagnosis.
   c. Pts in whom ART is initiated may experience IRIS 1–12 weeks later and develop localized or generalized culture-positive lymphadenitis.
   d. Treatment should consist of a macrolide—clarithromycin (500 mg bid) or azithromycin (500 mg/d)—plus ethambutol (15 mg/kg daily) and ART. Rifabutin may be included as well. Therapy can be stopped after 12 months if CD4+ T cell counts have been >100/μL for at least 6 months.
   e. Chemoprophylaxis with azithromycin (1200 mg weekly) or clarithromycin (500 mg bid) is indicated to prevent MAC disease in pts with CD4+ T cell counts of <50/μL or when another AIDS-defining illness occurs. Prophylaxis should be continued until the CD4+ T cell count has been >100/μL for at least 3 months.

*M. kansasii*  
*M. kansasii* is the second most common cause of lung disease due to NTM in the United States. The average age of onset is 60 years, and most pts have COPD, lung cancer, silicosis, or prior TB. Clinical features resemble those of pulmonary TB. A sputum culture positive for *M. kansasii* is usually clinically significant, especially in HIV-positive pts. Treatment with rifampin (600 mg/d), isoniazid (300 mg/d), and ethambutol (15 mg/kg daily) should be administered for at least 12 months after the last positive culture. Disseminated disease can occur in pts with advanced AIDS and resembles disseminated MAC infection but has more prominent pulmonary findings. Treatment is the same as for pulmonary disease. Pts should be given an ART regimen compatible with a rifamycin.

*M. abscessus, M. chelonae, and M. fortuitum*  
Disseminated cutaneous disease is the most common clinical manifestation of infection with the rapidly growing NTM species. Lesions are cellulitic or nodular, erythematous, indurated, and tender. They may ulcerate and exude purulent drainage and may spread proximally along lymphatics. These organisms may infect surgical or traumatic wounds, contaminated injection sites, or sites of body piercing. Pulmonary infections, usually due to *M. abscessus*, are the next most common manifestation and occur in pts with an underlying lung disease such as cystic fibrosis. Susceptibility testing should be performed, although all three species are usually susceptible to clarithromycin (500 mg bid) and amikacin (10–15 mg/kg daily). Cefoxitin (3 g q6h) or imipenem (500 mg q6–12h) is effective for most *M. abscessus* and *M. fortuitum* infections. Experts recommend up to 6 months of treatment for bacteremic or disseminated cutaneous disease and 12 months of treatment after sputum cultures are negative for pulmonary disease. Localized
cutaneous lesions may respond to a single agent, such as clarithromycin, administered for 2 weeks.

*M. marinum*  *M. marinum* is widely distributed in water and causes chronic cutaneous infections when open wounds are exposed to a colonized water source, usually via fish tanks, shellfish, or marine settings. *M. marinum* grows best at 30°C, a temperature lower than that at which other mycobacteria thrive. After a median incubation period of 21 days, a granulomatous or ulcerating skin lesion develops, with subsequent proximal spread along lymphatics; extension to deeper structures may occur in pts receiving immunosuppressive therapy, resulting in tenosynovitis or osteomyelitis. Administration of clarithromycin and ethambutol for 1–2 months after lesion resolution (usually a 3- to 4-month course) is recommended.

*M. ulcerans*  *M. ulcerans* causes a cutaneous infection (Buruli ulcer) in endemic regions (e.g., in Central and West Africa and Central and South America). The initial lesion is a painless nodule that progresses to a deep ulcer with sloughing of skin and SC tissue. Osteomyelitis may occur, and deforming scarring and contractures may result from extensive necrosis. Antimycobacterial treatment has not yet been shown to be helpful; surgical treatment is important.

Early Infection, Stage 2: Disseminated Infection

- Hematogenous spread occurs within days to weeks after infection. Secondary annular lesions may develop.
- Pts develop headache, mild neck stiffness, fever, chills, migratory musculoskeletal pain, arthralgias, malaise, and fatigue. These symptoms subside within a few weeks, even in untreated pts.
- Meningeal irritation: CSF is initially normal; however, weeks to months later, ~15% of pts progress to frank neurologic abnormalities (meningitis; encephalitis; cranial neuritis, including bilateral facial palsy; motor or sensory radiculoneuropathy; mononeuritis multiplex; ataxia; and myelitis).
- Cardiac involvement occurs in ~8% of pts. Atrioventricular (AV) block of fluctuating degree is most common, but acute myopericarditis is possible.

Late Infection, Stage 3: Persistent Infection

- Lyme arthritis develops in ~60% of untreated pts in the United States. It usually consists of intermittent attacks of oligoarticular arthritis in large joints (especially the knees) lasting weeks to months. Joint fluid cell counts range from 500 to 110,000/μL. Recurrent attacks decrease yearly, but a few pts have chronic arthritis with bony and cartilage erosion. Arthritis can persist despite eradication of spirochetes.
- Chronic neurologic involvement is less common. Encephalopathy affecting memory, mood, or sleep can be accompanied by axonal polyneuropathy manifested as either distal paresthesia or spinal radicular pain. In Europe, severe encephalomyelitis is seen with B. garinii infection.
- Acrodermatitis chronica atrophicans, a late skin manifestation, is seen in Europe and Asia and is associated with B. afzelii infection.

Diagnosis

- Culture of the organism in Barbour-Stoenner-Kelly medium is largely a research tool. Cultures are positive only early in illness, with the organism isolated primarily from EM skin lesions.
- Polymerase chain reaction (PCR) is most useful for joint fluid, is less sensitive for cerebrospinal fluid (CSF), and has little utility for plasma or urine testing.
- Serology can be problematic because tests do not clearly distinguish between active and inactive infection. Serologic testing should be undertaken when the pt has at least an intermediate pretest likelihood of having Lyme disease.
- Two-step testing: enzyme-linked immunosorbent assay (ELISA) screening with Western blot testing in cases with positive or equivocal results. IgM and IgG testing should be done in the first month of illness, after which IgG testing alone is adequate.

Lyme Borreliosis

Except for neurologic and cardiac disease, most treatment can be oral.

1. Doxycycline (100 mg bid) is the agent of choice for men and nonpregnant women and is also effective against anaplasmosis.
2. Amoxicillin (500 mg tid), cefuroxime (500 mg bid), erythromycin (250 mg qid), and newer macrolides are alternative agents, preferred in that order.
3. More than 90% of pts have good outcomes with a 14-day course of treatment for localized infection or a 21-day course for disseminated infection.
4. Neuroborreliosis: IV treatment with ceftriaxone (2 g/d for 14–28 days) should be given. Cefotaxime or penicillin is an alternative.
5. Pts with high-degree AV block should receive a 28-day course that commences with IV ceftriaxone (or alternative IV drugs) until the high-degree AV block has resolved; oral agents can then be used to complete treatment.

6. Lyme arthritis: 30–60 days of PO antibiotic. For pts who do not respond to oral agents, re-treatment with IV ceftriaxone for 28 days is appropriate. If joint inflammation persists after therapy but PCR testing for *B. burgdorferi* DNA in joint fluid gives negative results, anti-inflammatory agents or synovectomy may be successful.

7. Chronic Lyme disease: Persistent musculoskeletal and neurocognitive symptoms with fatigue occur in a small percentage of pts after antibiotic treatment. Further antibiotic courses are not helpful; treatment consists of symptom-based supportive care.

**Prophylaxis**  If an attached, engorged *I. scapularis* nymph is found or if follow-up will be difficult, a single 200-mg dose of doxycycline, given within 72 h of the tick bite, effectively prevents the disease. This measure is not routinely recommended.

**Prognosis**  Early treatment results in an excellent prognosis. Although convalescence is longer the later antibiotics are given, the overall prognosis remains excellent, with minimal or no residual deficits. Reinfection can occur. No vaccine is commercially available.

### ENDEMIC TREPONEMATOSES

**Etiology and Epidemiology**  The endemic treponematoses—yaws, endemic syphilis, and pinta—are nonvenereal chronic childhood diseases caused by organisms closely related to the agent of syphilis, *Treponema pallidum*. Early skin lesions are infectious; disease is transmitted by direct contact.

**Clinical Features**  Disease is manifest by primary skin lesions that become disseminated with time. After a latency phase, destructive gummas in skin, bone, and joints occur as late manifestations. Pinta causes dyschromic macules but not destructive lesions.

**Diagnosis**  Diagnosis is based on clinical presentation and dark-field microscopy of scrapings from lesions. Serologic tests for syphilis are also used to diagnose endemic treponematoses.

**Endemic Treponematoses**

Benzathine penicillin (1.2 million units for adults, 600,000 units for children <10 years of age) is the treatment of choice. Doxycycline is probably an effective alternative.

### LEPTOSPIROSIS

**Etiology and Epidemiology**  Leptospires are spirochetal organisms that cause an important zoonosis with a broad spectrum of clinical manifestations. Rodents, particularly rats, are the most important disease reservoir, but many mammalian species can harbor the organisms. Transmission can occur during contact with urine, blood, or tissue from infected animals or during exposure to
contaminated environments. Organisms are found in urine and can survive in water for many months. The disease is particularly common in developing tropical nations. Approximately 40–120 cases are reported each year in the United States, but these numbers are likely to represent significant underestimates. Risk factors in the United States include recreational water activities, occupational activities that result in exposure to animals or animal waste (e.g., sewage work), and residence in urban settings with expanding rat populations.

**Pathogenesis** Entry of the organisms via skin abrasions or intact mucous membranes is followed by leptospiremia and widespread dissemination. Organisms can be isolated from blood and CSF for the first 4–10 days of illness. Leptospires damage blood vessel walls and cause vasculitis, leakage, and extravasation, including hemorrhages. Vasculitis is responsible for most manifestations.

**Clinical Features**
- Incubation period, 1–2 weeks (range, 2–20 days)
- Anicteric leptospirosis, a biphasic illness, is the milder form and is found in 90% of symptomatic cases.
  1. Flulike illness: fever, severe headache, nausea, vomiting. Myalgias, especially of the calves, back, and abdomen, are a dominant feature.
  2. Conjunctival suffusion and fever are the most common physical findings; rash develops occasionally. Symptoms subside within 1 week and recur after 1–3 days in conjunction with antibody development.
  3. Symptoms are generally milder in phase 2, but up to 15% of pts can develop clinically evident aseptic meningitis. A higher percentage of pts have asymptomatic CSF pleocytosis. Iritis, chorioretinitis, and uveitis can occur. Symptoms usually subside in days but can persist for weeks to months.
- Icteric leptospirosis (Weil’s syndrome) is severe, with a mortality rate of 5–15%.
  1. After 4–9 days of mild illness, more severe symptoms develop; however, illness is not truly biphasic.
  2. Pts have jaundice, hepatosplenomegaly, and abdominal tenderness.
  3. Renal failure with acute tubular necrosis may develop.
  4. Cough, dyspnea, chest pain, and hemoptysis can occur.
  5. Hemorrhagic manifestations commonly include epistaxis, petechiae, purpura, and ecchymoses.
  6. Rhabdomyolysis, hemolysis, myocarditis, pericarditis, congestive heart failure, shock, adult respiratory distress syndrome, pancreatitis, and multi-organ failure have all been described.
- Laboratory findings
  1. Azotemia, abnormal urinary sediment, proteinuria
  2. Elevated erythrocyte sedimentation rate, marked leukocytosis, thrombocytopenia
  3. Elevated bilirubin and alkaline phosphatase levels, mild aminotransferase increases
  4. Prolonged prothrombin time, elevated creatine phosphokinase level
  5. Patchy alveolar pattern due to hemorrhage on chest x-ray

**Diagnosis**
- Serology: Microscopic agglutination test (MAT) done at Centers for Disease Control and Prevention; ELISA available at reference laboratories
- The organism can be cultured from blood or CSF in the first 10 days of illness or from urine after the first week. Cultures most often become positive within 2–4 weeks (range, 1 week to 4 months).
- Differential: dengue, malaria, viral hepatitis, hantavirus disease, rickettsial disease
Treatment should be started as early as possible but should be given even if delayed. IV agents, including penicillin G (1.5 million units qid), ampicillin (1 g qid), ceftriaxone (1 g once daily), and erythromycin (500 mg qid), are all effective. Milder cases can be treated with oral doxycycline (100 mg bid) or amoxicillin (500 mg qid).

Etiology  
Borrelia recurrentis causes louse-borne relapsing fever (LBRF). LBRF is transmitted from person to person by the body louse. Tick-borne relapsing fever (TBRF), a zoonosis usually transmitted from rodents to humans via the bite of various Ornithodoros ticks, is caused by multiple Borrelia species. DNA rearrangement within vmp genes on linear plasmids results in variation in expression of surface antigens, allowing evasion of host immune responses.

Epidemiology  
Rates of LBRF have decreased markedly with improvements in the standard of living. TBRF still occurs worldwide and often goes unrecognized or underreported. About 35 cases per year are reported in the United States, mostly in forested mountainous areas of far western states and among persons sleeping in rustic mountain cabins and vacation homes. Ticks feed painlessly and quickly (20–45 min).

Clinical Features  
Symptoms are similar in the two types of relapsing fever.
1. Mean incubation period, 7 days; range, 2–18 days
2. Sudden onset of high fever, headache, shaking chills, sweats, dizziness, nausea, vomiting, myalgias, arthralgias (sometimes severe); no arthritis
3. Tachycardia, tachypnea, dehydration, scleral icterus, and petechiae can occur. Conjunctivae are often injected, and photophobia is common.
4. Epistaxis, blood-tinged sputum, and gastrointestinal or central nervous system hemorrhage can occur.
5. Symptoms increase for 2–7 days, then end in a crisis with two phases.
   a. Chill phase: rigors, rising temperature, hypermetabolism
   b. Flush phase: falling temperature, diaphoresis, decreased effective circulating blood volume
6. Spirochetemia and symptoms recur after days to weeks. LBRF is associated with 1 or 2 relapses, TBRF with up to 10. Each episode is less severe and is followed by a longer afebrile interval than the last.

Diagnosis  
Spirochetes can be demonstrated in blood, bone marrow aspirates, or CSF by dark-field microscopy or in thick or thin smears of peripheral blood or buffy-coat preparations treated with Wright, Giemsa, or acridine orange stain. Organisms are most numerous during high fevers before the crisis.

Relapsing Fever  
One dose of doxycycline (100 mg), erythromycin (500 mg), or chloramphenicol (500 mg) is effective for LBRF. A 7-day course is recommended for TBRF. A Jarisch-Herxheimer-like reaction within 1–4 h of the first dose occurs in >50% of TBRF cases but is more severe in LBRF cases or when high numbers of spirochetes are circulating at treatment outset. The reaction can last up to 8 h; pts should be closely monitored.
Infectious Diseases

SECTION 7

Prognosis
Untreated LBRF has a high case-fatality rate, but the mortality rate is <5% with therapy. TBRF is generally a milder disease.

For a more detailed discussion, see Lukehart SA: Endemic Trepomatoses, Chap. 163, p. 1046; Speelman P, Hartskeerl R: Leptospirosis, Chap. 164, p. 1048; Dennis DT: Relapsing Fever, Chap. 165, p. 1052; and Steere AC: Lyme Borreliosis, Chap. 166, p. 1055, in HPIM-17. For a discussion of syphilis, see Chap. 90 in this manual.

Rickettsial Diseases

Rickettsiae are obligate intracellular gram-negative coccobacilli and short bacilli usually transmitted by tick, mite, flea, or louse vectors. Except in the case of louse-born typhus, humans are incidental hosts.

103

Tick- and Mite-Borne Spotted Fevers

Rocky Mountain Spotted Fever (RMSF)

Epidemiology
Caused by R. rickettsii, RMSF is the most severe rickettsial disease. In the United States, the prevalence is highest in the south-central and southeastern states. Most cases occur between May and September. RMSF is transmitted by different ticks in different geographic areas; e.g., the American dog tick (Dermacentor variabilis) transmits RMSF in the eastern two-thirds of the United States and in California.

Pathogenesis
Rickettsiae are inoculated by the tick after ≥6 h of feeding, spread lymphohematogenously, and infect numerous foci of contiguous infected endothelial cells. Increased vascular permeability, with edema, hypovolemia, and ischemia, causes tissue and organ injury.

Clinical Features
The incubation period is ~1 week (range, 2–14 days). Symptoms in the first 3 days of illness are nonspecific and include fever, headache, malaise, myalgias, nausea, vomiting, and anorexia. By day 3, half of pts have a rash. Macules typically appear on the wrists and ankles, subsequently spreading to the rest of the extremities and the trunk. Lesions initially blanch; however, because of vascular damage, central hemorrhage later develops and the lesions become petechial. Such petechiae eventually develop in 41–59% of pts, appearing on or after day 6 of illness in ~74% of all cases that include a rash. The palms and soles become involved after day 5 in 43% of pts but do not become involved at all in 18–64%. Pts develop hypovolemia, prerenal azotemia, hypotension, noncardiogenic pulmonary edema, and cardiac involvement with dysrhythmias. Pulmonary disease is an important factor in fatal cases and develops in 17% of cases overall. Central nervous system (CNS) involvement is the other important determinant of outcome. Encephalitis can progress to stupor or delirium, ataxia, coma, seizures, cranial nerve palsy, hearing loss, severe vertigo, nystagmus, dys-
arthria, aphasia, and other CNS signs. Meningoencephalitis can develop, with cerebrospinal fluid notable for pleocytosis, mononuclear cell predominance, and increased protein and normal glucose levels. Renal and hepatic injury can occur, and bleeding is a rare but potentially life-threatening consequence of severe vascular damage. Other laboratory findings may include increased plasma levels of acute-phase reactants such as C-reactive protein, hyponatremia, and elevated levels of creatine kinase.

**Prognosis**  
Without treatment, the pt usually dies in 8–15 days; a rare fulminating presentation can result in death within 5 days. The mortality rate was 20–25% in the preantibiotic era and remains at 3–5% despite the availability of effective antibiotics, mostly because of delayed diagnosis.

**Diagnosis**  
Within the first 3 days, diagnosis is difficult, since only 3% of pts have the classic triad of fever, rash, and known history of tick exposure. When the rash appears, the diagnosis should be considered. Immunohistologic examination of a cutaneous biopsy sample from a rash lesion is the only diagnostic test of use during acute illness. Serology, most commonly the indirect immunofluorescence assay (IFA), is usually positive 7–10 days after disease onset, and a diagnostic titer of $\geq 1:64$ is usually documented.

---

**Rocky Mountain Spotted Fever**

Doxycycline (100 mg bid PO or IV) is the treatment of choice for both children and adults but not for pregnant women and pts allergic to this drug, who should receive chloramphenicol. Treatment is given until the pt is afebrile and has been improving for 2 or 3 days.

---

**OTHER TICK-BORNE SPOTTED FEVERS**

*R. conorii* causes disease in southern Europe, Africa, and Asia. The name for *R. conorii* infection varies by region (e.g., Mediterranean spotted fever, Kenya tick typhus). Disease is characterized by high fever, rash, and—in most locales—an inoculation eschar (tache noire) at the site of the tick bite. A severe form of disease with ~50% mortality occurs in pts with diabetes, alcoholism, or heart failure. African tick-bite fever, caused by *R. africae*, occurs in sub-Saharan Africa and the Caribbean and is the rickettsiosis most frequently imported into Europe and North America. Tick-borne spotted fever is diagnosed on clinical grounds. Doxycycline (100 mg bid for 1–5 days), ciprofloxacin (750 mg bid for 5 days), or chloramphenicol (500 mg qid for 7–10 days) is effective for treatment.

---

**RICKETTSIALPOX**

**Epidemiology**  
Rickettsialpox is caused by *R. akari* and is maintained by mice and their mites. Recognized principally in New York City, rickettsialpox has been reported in other urban and rural locations in the United States as well as in Ukraine, Croatia, and Turkey. This infection is more common than was previously thought.

**Clinical Features**  
A papule forms at the site of the mite bite and develops a central vesicle that becomes a painless black-crusted eschar surrounded by an erythematous halo. Lymph nodes draining the region of the eschar enlarge. After an incubation period of 10–17 days, malaise, chills, fever, headache, and myalgia mark disease onset. A macular rash appears on day 2–6 of illness and
Infectious Diseases

SECTION 7

RS  Rickettsialpox

Doxycycline is the drug of choice for treatment.

FLEA- AND LOUSE-BORNE TYPHUS GROUP RICKETTSIOSES

ENDEMIC MURINE TYPHUS (FLEA-BORNE)

Epidemiology  Caused by *R. typhi*, endemic murine typhus has a rat reservoir and is transmitted by fleas. Humans become infected when rickettsia-laden flea feces are scratched into pruritic bite lesions; less often, the flea bite itself transmits the organisms. In the United States, endemic typhus occurs mainly in southern Texas and southern California; globally, it occurs in warm (often coastal) areas throughout the tropics and subtropics. Flea bites are not often recalled by pts, but exposure to animals such as cats, opossums, raccoons, skunks, and rats is reported by ~40%.

Clinical Features  The incubation period averages 11 days (range, 8–16 days). Prodromal symptoms 1–3 days before the abrupt onset of chills and fever include headache, myalgia, arthralgia, nausea, and malaise. Nausea and vomiting are common early in illness. The duration of untreated disease averages 12 days (range, 9–18 days). Rash is apparent at presentation (usually ~4 days after symptom onset) in 13% of pts; 2 days later, half of the remaining pts develop a maculopapular rash that involves the trunk more than the extremities, is seldom petechial, and rarely involves the face, palms, or soles. Pulmonary disease is common, causing a hacking, nonproductive cough. Almost one-fourth of pts who undergo chest x-ray (CXR) have pulmonary densities due to interstitial pneumonia, pulmonary edema, and pleural effusions. Abdominal pain, confusion, stupor, seizures, ataxia, coma, and jaundice occur less commonly. Laboratory abnormalities include anemia, leukocytosis, thrombocytopenia, hyponatremia, hypoalbuminemia, increased hepatic aminotransferase levels, and prerenal azotemia. Disease can be severe enough for admission to an intensive care unit, and complications include respiratory failure requiring intubation and mechanical ventilation, hematemesis, cerebral hemorrhage, and hemolysis. The disease is more severe in older pts, those with underlying disease, and those treated with a sulfonamide drug.

Diagnosis  The diagnosis can be based on cultivation, polymerase chain reaction (PCR), cross-adsorption serologic studies of acute- and convalescent-phase sera, or immunohistology.

RX  Endemic Murine Typhus (Flea-Borne)

Doxycycline (100 mg bid for 7–15 days) is effective.

EPIDEMIC TYPHUS (LOUSE-BORNE)

Epidemiology  Epidemic typhus is caused by *R. prowazekii* and is transmitted by the human body louse. The louse lives in clothing under poor hygienic con-
Rickettsial Diseases

CHAPTER 103

557

ditions, particularly in colder climates and classically at times of war or natural
disaster. Eastern flying-squirrel lice and fleas maintain *R. prowazekii* in a
zoonotic cycle. Lice feed on pts with epidemic typhus and then defecate the or-
ganism into the bite at their next meal. The pt autoinoculates the organism
while scratching. Because lice abandon pts with high fevers, they effectively
spread disease. *Brill-Zinsser disease* is a recrudescent and mild form of epi-
demic typhus whose occurrence years after acute illness suggests that *R.
prowazekii* remains dormant in the host, reactivating when immunity wanes.

**Clinical Features** After an incubation period of ~1 week (range, 7–14 days),
there is an abrupt onset of high fevers, prostration, severe headache, cough, and
severe myalgias. Rash appears on the upper trunk around the fifth day of illness
and spreads to involve all body-surface areas except the face, palms, and soles.
Photophobia with conjunctival injection and eye pain is also common. Confu-
sion and coma, skin necrosis, and gangrene of the digits are noted in severe cas-
es. Untreated, the disease is fatal in 7–40% of cases. Pts develop renal failure,
multiorgan involvement, and prominent neurologic manifestations.

**Diagnosis** The diagnosis can be based on serology or immunohistochemistry
or on detection of the organism in a louse found on a pt. Cross-adsorption IFA
can distinguish *R. prowazekii* from *R. typhi*.

**SCRUB TYPHUS**

*Orientia tsutsugamushi*, the agent of scrub typhus, is a member of the family
Rickettsiaceae that is transmitted by larval mites or chiggers in environments of
heavy scrub vegetation. Disease occurs during the wet season. It is endemic in
Asia, northern Australia, and the Pacific islands. Clinical manifestations range
from mild to fatal disease. Pts have an eschar at the site of chigger feeding, re-
gional lymphadenopathy, and maculopapular rash. Severe cases include en-
cephalitis and interstitial pneumonia. Scrub typhus can be diagnosed by
serologic assays (IFA, indirect immunoperoxidase and enzyme immunoassays).
A 7- to 15-day course of doxycycline (100 mg bid) or chloramphenicol (500
mg qid) is effective.

**EHRLICHIOSSES AND ANAPLASMOSIS**

Ehrlichiae are obligately intracellular organisms transmitted by ticks. Two dis-
tinct *Ehrlichia* species and one *Anaplasma* species cause human infections.

**HUMAN MONOCYTOTROPIC EHRLICHIOSIS (HME)**

HME is caused by *Ehrlichia chaffeensis*. Most cases of HME occur in southeast-
ern, south-central, and mid-Atlantic states. Most pts are male; the median age of
pts is 53 years. After a median incubation period of 8 days, pts develop fever,
headache, myalgia, and malaise. Nausea, vomiting, diarrhea, cough, rash, and
confusion may be noted. Disease can be severe: up to 62% of pts are hospitalized.
Complications include a toxic shock-like syndrome, respiratory distress, menin-
goencephalitis, fulminant infection, and hemorrhage. Leukopenia, thrombocyto-

---

**Epidemic Typhus (Louse-Borne)**

Doxycycline (a 200-mg dose once or 100 mg bid until 2–3 days after the pt
has defervesced).
Infectious Diseases

SECTION 7

Penicilliosis and elevated serum aminotransferase levels are common. The diagnosis is usually based on clinical presentation, but PCR testing before initiation of antibiotic therapy or retrospective serodiagnosis to detect increased antibody titers can be performed. Bone marrow examination reveals hypercellular marrow, and non-caseating granulomas may be evident. Morulae are rarely seen in peripheral blood. Treatment with doxycycline (100 mg bid) or tetracycline (250–500 mg q6h) is effective and should be continued for 3–5 days after defervescence.

EHRLICHIOSIS EWINGII

Ehrlichiosis ewingii resembles HME but is less severe. Most cases are diagnosed in immunocompromised pts. Treatment is the same as for HME.

HUMAN GRANULOCYTOTROPIC ANAPLASMOSIS (HGA)

HGA is caused by Anaplasma phagocytophilum. Most cases of human anaplasmosis occur in northeastern and upper midwestern states. After an incubation period of 4–8 days, pts develop fever, myalgia, headache, and malaise. A minority of pts develop nausea, vomiting, diarrhea, cough, or confusion. Severe complications—respiratory insufficiency, a toxic shock-like syndrome, and opportunistic infections—occur most often in the elderly. Although the mortality rate is low, nearly 7% of pts require intensive care. On laboratory examination, pts are found to have leukopenia, thrombocytopenia, and elevated serum aminotransferase levels. HGA is not associated with vasculitis or granulomas. Anaplasmosis should be considered in pts with atypical severe presentations of Lyme disease. Co-infection with either Borrelia burgdorferi (the agent of Lyme disease) or Babesia microti should be considered in all cases because these three agents share the Ixodes scapularis vector and have the same geographic distribution. Peripheral blood films may reveal morulae in neutrophils in 20–75% of infections. PCR testing before antibiotic therapy or retrospective serologic testing for rises in antibody can confirm the diagnosis. Treatment with doxycycline (100 mg bid) is effective, and most pts defervesce within 24–48 h. Pregnant women may be treated with rifampin.

PREVENTION

These diseases are prevented by avoidance of ticks in endemic areas, use of protective clothing and tick repellents, careful tick searches after exposures, and prompt removal of attached ticks.

Q FEVER

Etiology Coxella burnetii causes Q fever. The organism can exist as a highly infectious phase I form within humans or as an avirulent phase II form. C. burnetii can form spores that allow its prolonged survival in harsh environments.

Epidemiology Q fever is a zoonosis that occurs worldwide. The primary sources of human infection are infected cattle, sheep, and goats, but cats, rabbits, pigeons, and dogs can transmit the disease as well. C. burnetii localizes to the uterus and mammary glands of infected female mammals. It is reactivated in pregnancy and is found at high concentrations in the placenta. At parturition, the organism is dispersed as an aerosol, and infection usually follows inhalation. Abattoir workers, veterinarians, and others persons who have contact with infected animals are at risk. Exposure to newborn animals or infected products of conception poses the highest risk. C. burnetii is shed in the milk for weeks to
months after parturition. Ingestion of contaminated milk is believed to be an important route of transmission in some areas, although the evidence on this point is contradictory.

**Clinical Features**

- **Acute Q fever:** The incubation period lasts 3–30 days. Clinical presentations include flulike syndromes, prolonged fever, pneumonia, hepatitis, pericarditis, myocarditis, meningoencephalitis, and infection during pregnancy. Symptoms are often nonspecific (e.g., fever, fatigue, headache, chills, sweats, nausea, vomiting, diarrhea, cough, and occasionally rash). Multiple rounded opacities on CXR are common and are highly suggestive of Q fever pneumonia. The white blood cell count is usually normal, but thrombocytopenia occurs. During recovery, reactive thrombocytosis can develop. Pts with acute Q fever and lesions of native or prosthetic heart valves should be monitored serologically for 2 years. If phase I IgG titers are >1:800, further evaluation is indicated. Some authorities treat pts with acute Q fever and valvulopathy for 1 year with doxycycline and hydroxychloroquine to prevent chronic Q fever.

- **Chronic Q fever:** This uncommon entity almost always implies endocarditis, occurring in pts with prior valvular heart disease, immunosuppression, or chronic renal failure. Fever is absent or low grade; nonspecific symptoms may be present for a year before diagnosis. Vegetations are seen in only 12% of cases and manifest as nodules on the valve. Hepatomegaly and/or splenomegaly in combination with a positive rheumatoid factor, high erythrocyte sedimentation rate, high C-reactive protein level, and/or increased γ-globulin concentration suggests the diagnosis. Although *C. burnetii* can be isolated by a shell-vial technique, most laboratories are not permitted to attempt isolation because of its highly contagious nature. PCR testing of tissue or biopsy specimens can be used, but serology is the most common diagnostic tool; IFA is the method of choice. In chronic Q fever, titers of antibody to phase I antigen are much higher than those to phase II; the reverse is true in acute infection. Acute infection can be diagnosed by a fourfold rise in antibody titer. Chronic infection is associated with an IgG titer of ≥1:800 to phase I antigen.

**RX**  

**Q Fever**

Acute Q fever is treated with doxycycline (100 mg bid for 14 days). Quinolones are also efficacious. If Q fever is diagnosed during pregnancy, trimethoprim-sulfamethoxazole should be administered up to term. The currently recommended treatment for chronic Q fever is doxycycline (100 mg bid) and hydroxychloroquine (200 mg tid; plasma concentrations maintained at 0.8–1.2 μg/mL) for 18 months. In vitro, hydroxychloroquine renders doxycycline bactericidal against *C. burnetii*. The minimal inhibitory concentration (MIC) of doxycycline for the pt’s isolate should be determined and serum levels monitored. Pts should be advised about photosensitivity and retinal toxicity risks with treatment. Pts who cannot receive this regimen should be treated with at least two agents active against *C. burnetii*. The combination of rifampin (300 mg once daily) plus doxycycline (100 mg bid) or ciprofloxacin (750 mg bid) has been used with success. Treatment should be given for at least 3 years and discontinued only if phase I IgA and IgG antibody titers are ≤1:50 and ≤1:200, respectively.

For a more detailed discussion, see Walker DH et al: Rickettsial Diseases, Chap. 167, p. 1059, in HPIM-17.
Mycoplasmas are the smallest free-living organisms. Lacking a cell wall and bounded only by a plasma membrane, they colonize mucosal surfaces of the respiratory and urogenital tracts.

**M. Pneumoniae**

**Epidemiology**  *M. pneumoniae* causes upper and lower respiratory tract disease, with the highest attack rates among persons 5–20 years old. Infection is acquired by inhalation of aerosols. Children <5 years old usually have only upper respiratory tract disease; children ≥5 years old and adults usually have bronchitis and pneumonia. Infection can be severe in pts with sickle cell disease as a result of functional asplenia.

**Clinical Features**  The incubation period is longer than those for other respiratory infections, typically lasting for 2–3 weeks. Pts often have antecedent upper respiratory tract symptoms and then develop fever, sore throat, and prominent headache and cough. Myalgias, arthralgias, and GI symptoms are uncommon. Sputum production is lacking or minimal. If present, sputum is usually white but may be blood-tinged. Pharyngeal injection is common. Bullous myringitis (blisters on the tympanic membrane) is an uncommon but unique manifestation. Physical findings are minimal, and pleural effusion is documented in <20% of pts. Extrapulmonary manifestations suggest *M. pneumoniae* infection because, although unusual in the latter illness, they are even rarer in other respiratory illnesses. These manifestations include erythema multiforme, digital necrosis (due to high titers of cold agglutinins) in pts with sickle cell disease, myocarditis, pericarditis, encephalitis, cerebellar ataxia, Guillain-Barré syndrome, transverse myelitis, peripheral neuropathy, hemolytic anemia, coagulopathies, and arthritis (in pts with hypogammaglobulinemia).

**Diagnosis**  Chest x-ray may show reticulonodular or interstitial infiltrates, primarily in the lower lobes. Most infections are not definitively diagnosed. Gram’s staining gives negative results because mycoplasmas lack a cell wall; culture is possible but very difficult; and serologic tests are not positive early enough to help guide clinical decisions (although they may be helpful retrospectively when acute- and convalescent-phase sera are available). Cold agglutinins are nonspecific but develop within the first 7–10 days in >50% of pts with *M. pneumoniae* pneumonia. A titer of ≥1:32 suggests the diagnosis. Antigen detection tests have been developed but are not yet widely available.

**Rx**  *M. pneumoniae* Infections  Upper respiratory infections due to *M. pneumoniae* do not require antibiotic treatment. Pneumonia is usually self-limited, but effective antibiotics shorten the duration of illness and reduce coughing and therefore may also reduce transmission. If the diagnosis is known, doxycycline (100 mg bid), macrolides (e.g., clarithromycin, 500 mg bid; or azithromycin, 500 mg/d), or fluoroquinolones (e.g., levofloxacin, 750 mg/d) are effective and should be administered for 14–21 days. For empirical treatment of community-acquired
pneumonia, a fluoroquinolone alone or a macrolide plus ceftriaxone (1 g/d) is recommended for better coverage of \textit{Streptococcus pneumoniae} and \textit{Haemophilus influenzae}. 

\textbf{GENITAL MYCOPLASMAS} 
See Chap. 90. 

For a more detailed discussion, see McCormack WM: Infections Due to Mycoplasmas, Chap. 168, p. 1068, in HPIM-17. 

\section*{105 Chlamydial Infections} 

Three chlamydial species infect humans: \textit{Chlamydia trachomatis}, \textit{Chlamydo-philica psittaci}, and \textit{Chlamydophila pneumoniae} (formerly the TWAR agent). Chlamydiae are obligate intracellular bacteria, possess both DNA and RNA, and have a cell wall and ribosomes similar to those of gram-negative bacteria. These organisms have a complex reproductive cycle and exist in two forms. The \textit{elementary body} (the infective form) is adapted for extracellular survival, while the \textit{reticulate body} is adapted for intracellular survival and multiplication. After replication, reticulate bodies condense into elementary bodies that are released to infect other cells or people. \textit{C. trachomatis}, \textit{C. psittaci}, and \textit{C. pneumoniae} share group-specific antigens; the microimmunofluorescence test can differentiate among the three species. 

\section*{C. \textit{TRACHOMATIS} INFECTIONS} 

\textbf{GENITAL INFECTIONS, INCLUDING LYMPHOGRA-NULOMA VENEREUM} 
See Chap. 90. 

\textbf{TRACHOMA AND ADULT INCLUSION CONJUNCTIVITIS (AIC)} 

\textbf{Definitions and Etiology} Trachoma is a chronic conjunctivitis caused by \textit{C. trachomatis} serovars A, B, Ba, and C. AIC is an acute eye infection in adults exposed to infected genital secretions and in their newborns; this infection is caused by sexually transmitted \textit{C. trachomatis} strains, usually serovars D through K. 

\textbf{Epidemiology} Trachoma causes ~20 million cases of blindness worldwide, primarily in northern and sub-Saharan Africa, the Middle East, and parts of Asia. Transmission occurs from eye to eye via hands, flies, towels, and other fomites, particularly among young children in rural communities with limited water supplies. 

\textbf{Clinical Features} Both trachoma and AIC present initially as conjunctivitis, with small lymphoid follicles in the conjunctiva. Trachoma usually starts insid-
Infectious Diseases

SECTION 7

Psittacosis is primarily an infection of birds and mammals. Most avian species can harbor *C. psittaci*, but psittacine birds (e.g., parrots, parakeets) are most often infected. Psittacosis is an occupational disease in pet-shop owners, poultry workers, and other individuals with regular avian contact. Present in nasal secretions, excreta, tissues, and feathers of infected birds, *C. psittaci* is transmitted to humans mainly by the respiratory route, gains access to the upper respiratory tract, spreads hematogenously, and localizes in the pulmonary alveoli and reticuloendothelial cells of the spleen and liver. The pathognomonic histologic finding is the presence of macrophages with typical cytoplasmic inclusion bodies in alveoli filled with fluid, erythrocytes, and lymphocytes.

Clinical Features After an incubation period of 7–14 days or longer, disease onset may be gradual or may be abrupt with shaking chills and fever to 40.6°C (105°F). Headache is prominent, and many pts have a dry, hacking, nonproductive cough. Small amounts of mucoid or bloody sputum may be produced as disease progresses. An increased respiratory rate and dyspnea with cyanosis can develop with extensive pulmonary involvement. Pts also report myalgias, spasm and stiffness of back and neck muscles, lethargy, depression, agitation, insomnia, and disorientation. Occasionally, pts are comatose at presentation. GI symptoms can occur. Physical findings are less prominent than symptoms and x-ray findings would suggest. Splenomegaly is evident in 10–70% of pts.

Diagnosis This diagnosis should be considered in a pt with pneumonia and splenomegaly and is confirmed by serologic studies. A rise in the titer of com-

### Diagnosis

Clinical diagnosis is based on the presence of two of the following signs: lymphoid follicles on the upper tarsal conjunctiva, typical conjunctival scarring, vascular pannus, or limbal follicles. Intracytoplasmic chlamydial inclusions are found in 10–60% of Giemsa-stained conjunctival smears. Chlamydial polymerase chain reaction or ligase chain reaction is more sensitive and often gives positive results when smears or cultures are negative.

### Treatment and Prevention

- AIC responds to azithromycin (a single 1-g dose) or doxycycline (100 mg bid for 7 days); treatment of sexual partners is needed to prevent ocular re-infection and chlamydial genital disease.
- The World Health Organization’s Global Campaign to Eliminate Trachoma promotes surgery for deformed eyelids; periodic mass treatment with azithromycin; face washing; and environmental improvements.
plement-fixing antibody between acute- and convalescent-phase serum samples suggests the diagnosis.

**C. psittaci Infections**

Tetracycline (2–4 g/d in four divided doses) or doxycycline (100 mg bid) is consistently effective, resulting in defervescence and symptom alleviation within 24–48 h. Treatment is continued for 7–14 days after defervescence to avoid relapse. Erythromycin is an alternative agent; azithromycin and some fluoroquinolones are active in vitro and are likely to be effective.

**C. PNEUMONIAE INFECTIONS**

**Epidemiology** Infections are most common among young adults but can occur throughout life, and reinfection is common. Seroprevalence exceeds 40% in the many adult populations tested throughout the world. Epidemics occur in close residential quarters such as military barracks. There is an epidemiologic association between serologic evidence of *C. pneumoniae* infection and atherosclerotic disease. *C. pneumoniae* has been identified in atherosclerotic plaques by electron microscopy, DNA hybridization, immunocytochemistry, and culture. It is hypothesized that the organism's presence accelerates atherosclerosis, especially in the setting of high cholesterol levels.

**Clinical Features** Manifestations of *C. pneumoniae* infection include pharyngitis, sinusitis, bronchitis, and pneumonitis. Primary infection is more severe than reinfection. Pneumonia due to *C. pneumoniae* resembles that due to *Mycoplasma pneumoniae*: pts have antecedent upper respiratory tract symptoms, fever, dry cough, minimal findings on auscultation, small segmental infiltrates on chest x-ray, and no leukocytosis. Elderly pts can have severe disease.

**Diagnosis** Diagnosis is difficult. Serology does not reliably distinguish *C. pneumoniae* from *C. trachomatis* or *C. psittaci*.

**C. pneumoniae Infections**

Erythromycin or tetracycline (2 g/d for 10–14 days) is recommended. Other macrolides (e.g., azithromycin) or quinolones (e.g., levofloxacin) are alternative agents.

For a more detailed discussion, see Stamm WE: Chlamydial Infections, Chap. 169, p. 1070, in HPIM-17.
Infectious Diseases

SECTION 7

Herpesvirus Infections

HERPES SIMPLEX VIRUSES

Etiology and Pathogenesis  The herpes simplex viruses HSV-1 and HSV-2 are linear, double-stranded DNA viruses. There is ~50% sequence homology between HSV-1 and HSV-2. Exposure to HSV at mucosal surfaces or abraded skin sites permits viral entry and replication in cells of the epidermis and dermis. HSV enters sensory or autonomic neuronal cells and is transported to nerve cell bodies in ganglia, where it can cause latency. The virus is maintained in a repressed state compatible with the survival and normal activities of the cell. Reactivation occurs when normal viral gene expression resumes, with reappearance of the virus on mucosal surfaces. Both antibody-mediated and cell-mediated immunity (including type-specific immunity) are clinically important.

Epidemiology  HSV-1 is acquired more frequently and at an earlier age than HSV-2. More than 90% of adults have antibodies to HSV-1 by the fifth decade of life. Antibodies to HSV-2 usually are not detected until adolescence and correlate with sexual activity. In the United States, 15–20% of the population has antibody to HSV-2. Infection with HSV-2 is an independent risk factor for the acquisition and transmission of infection with HIV-1, which can be shed from genital herpes lesions. HSV is transmitted by contact with active lesions or with virus shed from mucocutaneous surfaces by asymptomatic persons. During the first years after primary infection with HSV-1 or HSV-2, viral shedding from mucosal sites of immunocompetent and immunocompromised adults can occur on 30–50% and up to 80% of days, respectively. Pts with long-term infection can shed HSV on as many as 20–30% of days. The large reservoir of unidentified carriers and the frequent asymptomatic reactivation of HSV-2 have fostered the continued spread of HSV throughout the world.

Clinical Spectrum  The incubation period for primary infection is 1–26 days (median, 6–8 days). Reactivation depends on anatomic site and virus type as well as the pt’s age and immune status. Overall, genital HSV-2 is twice as likely to reactivate as genital HSV-1 and recurs 8–10 times more often. In contrast, oral-labial HSV-1 recurs more frequently than oral-labial HSV-2.

Oral-Facial Infections

• Primary HSV-1 infection: seen most often in children and young adults. Pts commonly have gingivostomatitis, pharyngitis, and up to 2 weeks of fever, malaise, myalgia, inability to eat, and cervical adenopathy with lesions on the palate, gingiva, tongue, lip, face, posterior pharynx, and/or tonsillar pillars. Exudative pharyngitis may occur.

• Reactivation: Viral excretion in the saliva, intraoral mucosal ulcerations, or ulcers on the vermilion border of the lip or external facial skin can occur with reactivation of latent virus in the trigeminal ganglia. Pts undergoing trigeminal nerve root decompression or dental extraction can develop oral-labial herpes a median of 3 days after the procedure.

• Infection in compromised hosts: Compromised hosts (e.g., AIDS pts, pts undergoing induction chemotherapy or in the early phases of transplanta-
Herpesvirus Infections

CHAPTER 106

Herpesvirus Infections

Herpesvirus Infections

Primary infection (see Chap. 90): Pts with prior HSV-1 infection have milder cases. About 15% of cases are associated with other clinical syndromes, such as aseptic meningitis, cervicitis, and urethritis.

Reactivation: Reactivation infections are often subclinical or can cause genital lesions or urethritis with dysuria. Even without a history of rectal intercourse, perianal lesions can occur as a result of latency established in the sacral dermatome from prior genital tract infection. Proctitis can cause anorectal pain, discharge, tenesmus, and constipation. Ulcerative lesions can be seen in the distal 10 cm of the rectal mucosa.

Whitlow In HSV infection of the finger, pts experience an abrupt onset of edema, erythema, pain, and vesicular or pustular lesions of the fingertips that are often confused with the lesions of pyogenic bacterial infection. Fever and lymphadenitis are common.

Herpes Gladiatorum HSV infection caused by trauma to the skin during wrestling can occur anywhere on the body but commonly affects the thorax, ears, face, and hands.

Eye Infections HSV is the most frequent cause of corneal blindness in the United States.

Keratitis: acute onset of pain, blurred vision, chemosis, conjunctivitis, and dendritic lesions of the cornea. Topical glucocorticoids may exacerbate disease. Recurrences are common.

Chorioretinitis: usually seen with disseminated HSV infection

Acute necrotizing retinitis: a rare, serious manifestation of HSV or VZV infection

Central and Peripheral Nervous System Infections

Encephalitis: In the United States, HSV causes 10–20% of all cases of sporadic viral encephalitis, and 95% of these cases are due to HSV-1. The estimated incidence is 2.3 cases per 1 million persons per year. Encephalitis can occur during primary infection or in pts already seropositive for HSV-1. Pts present with an acute onset of fever and focal neurologic symptoms and signs, especially in the temporal lobe. Neurologic sequelae are common, especially in pts >50 years of age. Antiviral treatment should be started empirically until the diagnosis is confirmed or an alternative diagnosis is made. IV treatment is recommended until cerebrospinal fluid (CSF) levels of viral DNA are reduced or undetectable.

Aseptic meningitis: HSV DNA is found in CSF from 3–15% of pts with aseptic meningitis, usually in association with primary genital HSV infection. This acute, self-limited disease without sequelae is manifested by head-
Infectious Diseases

SECTION 7

ache, fever, and photophobia. Pts have symptoms for 2–7 days. Lymphocytic pleocytosis in the CSF is documented. HSV is the most common cause of recurrent lymphocytic meningitis (Mollaret’s meningitis).

- Autonomic dysfunction caused by either HSV or VZV most commonly affects the sacral region. Numbness, tingling of the buttocks or perineal areas, urinary retention, constipation, and impotence can occur. Symptoms take days to weeks to resolve. Hypesthesia and/or weakness of the lower extremities may develop and persist for months. Rarely, transverse myelitis or Guillain-Barré syndrome follows HSV infection.

Visceral Infections

- Viremia can cause multiorgan involvement.
- Esophagitis: Pts present with odynophagia, dysphagia, substernal pain, and weight loss. Ulcers are most common in the distal esophagus. Cytologic examination and culture of secretions obtained by endoscopy are indicated to distinguish this entity from esophagitis of other etiologies (e.g., Candida esophagitis).
- Pneumonitis: Rarely, focal necrotizing pneumonitis due to extension of herpetic tracheobronchitis into the lung parenchyma occurs in severely immunocompromised pts. Hematogenous dissemination from other sites can cause bilateral interstitial pneumonitis. Mortality rates exceed 80% in compromised pts.

Neonatal Infections

The frequency of neonatal visceral and/or central nervous system (CNS) infection is highest among pts <6 weeks of age. The mortality rate is 65% without therapy but drops to 25% with IV acyclovir treatment. Fewer than 10% of neonates with CNS disease develop normally. Infection is usually acquired perinatally from contact with infected genital secretions during delivery. More than two-thirds of cases are due to HSV-2. The risk is 10 times higher for infants born to a mother who has recently acquired HSV.

Diagnosis

- Tzanck preparation: This method entails Wright’s, Giemsa’s, or Papanicolaou’s staining of scrapings from the base of lesions to detect giant cells or intranuclear inclusions, which are typical of both HSV and VZV infection. Few clinicians are skilled in the technique, the sensitivity of staining is low, and these cytologic methods do not differentiate between HSV and VZV infections.
- Culture: Positive results are seen within 48–96 h after inoculation. Spin-amplified culture with HSV antigen staining can yield a diagnosis in <24 h.
- Polymerase chain reaction (PCR) detection of HSV DNA: This method is the most sensitive for detection of HSV. Its sensitivity is higher in vesicular rather than ulcerative mucosal lesions, in primary rather than recurrent disease, and in compromised rather than immunocompetent hosts. PCR examination of CSF for viral DNA is the most sensitive noninvasive method for early diagnosis of HSV encephalitis. Examination of tissue obtained by brain biopsy for HSV antigen, DNA, or replication is also highly sensitive and has a low complication rate.
- Serologic assays can identify and distinguish between carriers of HSV-1 and HSV-2.

Table 106-1 details antiviral chemotherapy for HSV infection. Acyclovir and other drugs of its class serve as substrates for the HSV enzyme thymidine kinase. These drugs are phosphorylated to the monophosphate form in herpes-
TABLE 106-1  ANTIVIRAL CHEMOTHERAPY FOR HSV INFECTION

I. Mucocutaneous HSV infections

A. Infections in immunosuppressed pts

1. Acute symptomatic first or recurrent episodes: IV acyclovir (5 mg/kg q8h) or oral acyclovir (400 mg qid), famciclovir (500 mg bid or tid), or valacyclovir (500 mg bid) is effective. Treatment duration may vary from 7 to 14 days.

2. Suppression of reactivation disease (genital or oral-labial): IV acyclovir (5 mg/kg q8h) or oral valacyclovir (500 mg bid) or acyclovir (400–800 mg 3–5 times per day) prevents recurrences during the 30-day period immediately after transplantation. Longer-term HSV suppression is often used for pts with continued immunosuppression. In bone marrow and renal transplant recipients, oral valacyclovir (2 g/d) is also effective in reducing cytomegalovirus infection. Oral valacyclovir at a dose of 4 g/d has been associated with thrombotic thrombocytopenic purpura after extended use in HIV-positive pts. In HIV-infected pts, oral acyclovir (400–800 mg bid), valacyclovir (500 mg bid), or famciclovir (500 mg bid) is effective in reducing clinical and subclinical reactivations of HSV-1 and HSV-2.

B. Infections in immunocompetent pts

1. Genital herpes

a. First episode: Oral acyclovir (200 mg 5 times per day or 400 mg tid), valacyclovir (1 g bid), or famciclovir (250 mg bid) for 7–14 days is effective. IV acyclovir (5 mg/kg q8h for 5 days) is given for severe disease or neurologic complications such as aseptic meningitis.

b. Symptomatic recurrent genital herpes: Short-course (1- to 3-day) regimens are preferred because of low cost and convenience. Oral acyclovir (800 mg tid for 2 days), valacyclovir (500 mg bid for 3 days), or famciclovir (750 or 1000 mg bid for 1 day, a 1500-mg single dose, or 500 mg stat followed by 250 mg q12h for 3 days) effectively shortens lesion duration. Other options include oral acyclovir (200 mg 5 times per day), valacyclovir (500 mg bid), and famciclovir (125 mg bid) for 5 days.

c. Suppression of recurrent genital herpes: Oral acyclovir (200-mg capsules tid or qid, 400 mg bid, or 800 mg qd), famciclovir (250 mg bid), or valacyclovir (500 mg qd) is effective. Pts with >9 episodes per year should take oral valacyclovir at a dosage of 1 g qd or 500 mg bid.

2. Oral-labial HSV infections

a. First episode: Oral acyclovir (200 mg) is given 4 or 5 times per day; an oral acyclovir suspension can be used (600 mg/m² qid). Oral famciclovir (250 mg bid) or valacyclovir (1 g bid) has been used clinically.

b. Recurrent episodes: If initiated at onset of the prodrome, single-dose or 1-day therapy effectively reduces pain and speeds healing. Regimens include oral famciclovir (a 1500-mg single dose or 750 mg bid for 1 day) or valacyclovir (a 2-g single dose or 2 g bid for 1 day). Self-initiated therapy with 6-times-daily topical penciclovir cream effectively speeds healing of oral-labial HSV. Topical acyclovir cream has also been shown to speed healing.

c. Suppression of reactivation of oral-labial HSV: If started before exposure and continued for the duration of exposure (usually 5–10 days), oral acyclovir (400 mg bid) prevents reactivation of recurrent oral-labial HSV infection associated with severe sun exposure.

(continued)
virus-infected cells. Cellular enzymes then convert the monophosphate form into the triphosphate form, which incorporates into the viral DNA chain and inhibits viral DNA polymerase. Acyclovir-resistant strains of HSV have been identified but are uncommon. Almost all resistance—more often to HSV-2 than to HSV-1—has been seen in strains from immunocompromised pts. The

<table>
<thead>
<tr>
<th>TABLE 106-1</th>
<th>ANTIVIRAL CHEMOTHERAPY FOR HSV INFECTION (CONTINUED)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Surgical prophylaxis of oral or genital HSV infection: Several surgical procedures (e.g., laser skin resurfacing, trigeminal nerve-root decompression, and lumbar disk surgery) have been associated with HSV reactivation. IV acyclovir (5 mg/kg q8h) or oral acyclovir (800 mg bid), valacyclovir (500 mg bid), or famciclovir (250 mg bid) effectively reduces reactivation. Therapy should be initiated 48 h before surgery and continued for 3–7 days.</td>
<td></td>
</tr>
<tr>
<td>4. Herpetic whitlow: Oral acyclovir (200 mg) is given 5 times daily for 7–10 days.</td>
<td></td>
</tr>
<tr>
<td>5. HSV proctitis: Oral acyclovir (400 mg 5 times per day) is useful in shortening the course of infection. In immunosuppressed pts or in pts with severe infection, IV acyclovir (5 mg/kg q8h) may be useful.</td>
<td></td>
</tr>
<tr>
<td>6. Herpetic eye infections: In acute keratitis, topical trifluorothymidine, vidarabine, idoxuridine, acyclovir, penciclovir, and interferon are all beneficial. Debridement may be required. Topical steroids may worsen disease.</td>
<td></td>
</tr>
</tbody>
</table>

II. CNS HSV infections

A. HSV encephalitis: IV acyclovir (10 mg/kg q8h; 30 mg/kg per day) is given for 10 days or until HSV DNA is no longer detected in CSF. |
B. HSV aseptic meningitis: No studies of systemic antiviral chemotherapy exist. If therapy is to be given, IV acyclovir (15–30 mg/kg per day) should be used. |
C. Autonomic radiculopathy: No studies are available. Most authorities recommend a trial of IV acyclovir. |

III. Neonatal HSV infections: IV acyclovir (60 mg/kg per day, divided into 3 doses) is given. The recommended duration of treatment is 21 days. Monitoring for relapse should be undertaken, and some authorities recommend continued suppression with oral acyclovir suspension for 3–4 months. |

IV. Visceral HSV infections

A. HSV esophagitis: IV acyclovir (15 mg/kg per day). In some pts with milder forms of immunosuppression, oral therapy with valacyclovir or famciclovir is effective. |
B. HSV pneumonitis: No controlled studies exist. IV acyclovir (15 mg/kg per day) should be considered. |

V. Disseminated HSV infections: No controlled studies exist. IV acyclovir (5 mg/kg q8h) should be tried. Adjustments for renal insufficiency may be needed. No definite evidence indicates that therapy will decrease the risk of death. |

VI. Erythema multiforme associated with HSV: Anecdotal observations suggest that oral acyclovir (400 mg bid or tid) or valacyclovir (500 mg bid) will suppress erythema multiforme. |

VII. Infections due to acyclovir-resistant HSV: IV foscarnet (40 mg/kg q8h) should be given until lesions heal. The optimal duration of therapy and the usefulness of its continuation in suppressing lesions are unclear. Some pts may benefit from cutaneous application of trifluorothymidine or 5% cidoflovir gel. |

Note: HSV, herpes simplex virus; CSF, cerebrospinal fluid.
level of clinical suspicion of resistance should rise if HSV persists despite ade-
quate acyclovir treatment.

- Acyclovir: This agent is available for IV, oral, and topical administration. 
  IV acyclovir can cause transient renal insufficiency due to crystallization 
  of the compound in the renal parenchyma. The drug should be given 
  slowly over 1 h to a well-hydrated pt. CSF levels are 30–50% of plasma 
  levels, so doses are doubled for treatment of CNS infection over those 
  used to treat mucocutaneous disease. Even higher doses are used for neo-
  natal infections.

- Valacyclovir: The L-valyl ester of acyclovir, this agent is converted to acy-
  clovir by intestinal and hepatic hydrolysis after oral administration, with 
  greater bioavailability, higher blood levels, and less frequent administra-
  tion than acyclovir. Thrombotic thrombocytopenic purpura has been re-
  ported in compromised pts who have received high doses (8 g/d) and after 
  extended use in HIV-seropositive pts receiving 4 g daily.

- Famciclovir: This drug offers excellent bioavailability and a twice-daily 
  dosing schedule.

Prevention The use of barrier forms of contraception, especially condoms, 
decreases the likelihood of HSV transmission, particularly during asymptom-
atic viral excretion.

VARICELLA-ZOSTER VIRUS

VZV causes two distinct entities: primary infection (varicella or chickenpox) 
and reactivation infection (herpes zoster or shingles). Primary infection is trans-
mitted by the respiratory route. The virus replicates and causes viremia, which 
is reflected by the diffuse and scattered skin lesions in varicella; it then estab-
ishes latency in the dorsal root ganglia.

Chickenpox

- VZV causes disease only in humans. Chickenpox is highly contagious, with 
an attack rate of 90% among susceptible persons. Household attack rates 
among susceptible siblings are 70–90%. Before vaccine became available, 
children 5–9 years old accounted for half of all cases. With vaccine use, the 
annualized incidence of chickenpox has decreased significantly.

- The incubation period ranges from 10 to 21 days, but most pts evince dis-
  ease within 14–17 days. Pts are infectious for 48 h before onset of rash and 
  remain infectious until all vesicles have crusted.

- Pts present with fever, rash, and malaise. In immunocompetent hosts, the dis-
  ease is benign and lasts 3–5 days. Skin lesions include maculopapules, vesi-
  cles, and scabs in various stages of evolution. Most lesions are small and 
  have an erythematous base of 5–10 mm. Successive crops appear over 2–4 
  days. Lesions can occur on the mucosa of the pharynx or vagina. Severity 
  varies from person to person, but older pts tend to have more severe disease.

- Compromised hosts (e.g., leukemic pts) have numerous lesions (often with a 
hemorrhagic base) that take longer to heal. These pts are more likely than 
immunocompetent pts to have visceral complications that, if not treated, are 
fatal in 15% of cases.

Complications

- Bacterial superinfection is usually caused by Streptococcus pyogenes or 
  Staphylococcus aureus (including methicillin-resistant S. aureus).
• The CNS is the most common extracutaneous site of VZV disease in children. Acute cerebellar ataxia and meningeal irritation usually appear ~21 days after the onset of rash and run a benign course. CSF contains lymphocytes and has elevated protein levels. Aseptic meningitis, encephalitis, transverse myelitis, Guillain-Barré syndrome, or Reye’s syndrome (which mandates the avoidance of aspirin administration to children) can occur. There is no specific therapy other than supportive care.

• The most serious complication of chickenpox, pneumonia develops more frequently among adults (occurring in up to 20% of cases) than among children. The onset comes 3–5 days into illness, with tachypnea, cough, dyspnea, and fever. Cyanosis, pleuritic chest pain, and hemoptysis are common. Chest x-ray shows nodular infiltrates and interstitial pneumonitis.

• Perinatal varicella has a high mortality rate when maternal disease occurs within 5 days before delivery or within 48 h afterward. Congenital varicella causing birth defects is rare.

**Herpes Zoster (Shingles)**  Herpes zoster represents a reactivation of VZV from dorsal root ganglia.

• The incidence is highest among pts ≥60 years of age.
• There is usually a unilateral vesicular eruption within a dermatome, often associated with severe pain. Dermatomes T3 to L3 are most frequently involved. Dermatomal pain may precede lesions by 48–72 h. The usual duration of disease is 7–10 days, but it may take as long as 2–4 weeks for the skin to return to normal.

**Complications**

• Zoster ophthalmicus: Zoster of the ophthalmic division of the trigeminal nerve is a debilitating condition that can cause blindness if not treated.
• Ramsay Hunt syndrome is characterized by pain and vesicles in the external auditory canal, loss of taste in the anterior two-thirds of the tongue, and ipsilateral facial palsy.
• Postherpetic neuralgia (PHN) is a debilitating complication of shingles. Pain persists for months after resolution of cutaneous disease. At least 50% of pts over age 50 report some degree of PHN.
• Abnormal CSF in the absence of symptoms is not uncommon. Symptomatic meningoencephalitis can occur.
• Compromised pts—particularly those with Hodgkin’s disease and non-Hodgkin’s lymphoma—are at greatest risk for severe zoster and progressive disease. Cutaneous dissemination occurs in up to 40% of these pts; among those with cutaneous dissemination, the risk of visceral and other complications (pneumonitis, meningoencephalitis, hepatitis) increases by 5–10%. Bone marrow transplant recipients are also at high risk of VZV infection; these pts can have cutaneous or visceral dissemination. Mortality rates are 10%. PHN, scarring, and bacterial superinfection are common in VZV infection developing within 9 months of transplantation. Concomitant graft-versus-host disease increases the chance of dissemination and/or death.

**Diagnosis**

• Isolation of VZV in tissue culture, detection of VZV DNA by PCR, or direct immunofluorescent staining of cells from the lesion base
• Seroconversion or a fourfold or greater rise in antibody titer between convalescent- and acute-phase serum specimens. The fluorescent antibody to membrane antigen (FAMA) test, immune adherence hemagglutination test, and enzyme-linked immunosorbent assay (ELISA) are the most frequently used techniques.
Varicella-Zoster Virus Infections

- **Chickenpox**
  1. Antiviral therapy: Acyclovir for children <12 years of age (20 mg/kg q6h, if initiated early in disease) and for adolescents and adults (800 mg five times daily for 5–7 days for chickenpox of ≤24 h duration) is recommended. Valacyclovir and famciclovir are probably as efficacious or more so.
  2. Good hygiene, meticulous skin care, and antipruritic drugs are important to relieve symptoms and prevent bacterial superinfection of skin lesions.

- **Zoster**
  - Lesions heal more quickly with antiviral treatment: acyclovir, 800 mg five times daily for 7–10 days; famciclovir, 500 mg tid for 7 days (one study also showed twofold faster resolution of PHN with this agent); or valacyclovir, 1 g tid for 5–7 days.
  - Compromised hosts: Acyclovir (10–12.5 mg/kg q8h for 7 days) should be given IV, at least at the outset, for chickenpox and herpes zoster to reduce the risk of complications, although this regimen does not speed the healing or relieve the pain of skin lesions. Low-risk immunocompromised pts can be treated with oral valacyclovir or famciclovir.
  - Pneumonia: This complication may require ventilatory support in addition to antiviral treatment.
  - Zoster ophthalmicus: Antiviral treatment and consultation with an ophthalmologist are required.
  - PHN: Gabapentin, amitriptyline, lidocaine patches, and fluphenazine may relieve pain and can be given along with routine analgesic agents. Prednisone (administered at a dosage of 60 mg/d for the first week of zoster, tapered over 21 days, and given with antiviral therapy) can accelerate quality-of-life improvements, including a return to usual activity; this treatment is indicated only for healthy elderly persons with moderate or severe pain at presentation.

**Prevention**

- **Vaccine**
  - Varicella: Two doses of a live attenuated vaccine are recommended for all children: the first at 12–15 months of age and the second at ~4–6 years of age. VZV-seronegative pts ≥13 years of age should receive two doses of vaccine at least 1 month apart.
  - Zoster: A vaccine with 18 times the viral content of varicella vaccine, given to pts ≥60 years of age, reduces the incidence of zoster and PHN. Zoster vaccine is recommended for routine use in this age group.
  - Varicella-zoster immune globulin (VZIg): given to VZV-susceptible hosts within 96 h of a significant exposure if the risk of complications from varicella is high (e.g., immunocompromised pts, pregnant women, premature infants, neonates whose mother had chickenpox onset within 5 days before or 2 days after delivery). VZIg is not longer manufactured in the United States; a new product is awaiting FDA approval.
  - Antiviral treatment: Seven days after intense exposure, prophylaxis can be given to high-risk pts who are ineligible for vaccine or for whom the 96-h window after direct contact has passed. This intervention may lessen illness severity.

**HUMAN HERPESVIRUS (HHV) TYPES 6, 7, AND 8**

- HHV-6 causes exanthem subitum (roseola infantum), a common childhood febrile illness with rash, and is a major cause of febrile seizures without rash
in infancy. Older pts can have an infectious mononucleosis syndrome or encephalitis. Compromised hosts can have disseminated disease and pneumonitis. More than 80% of adults are seropositive for HHV-6. This virus has been implicated in graft dysfunction and increased all-cause mortality in transplant recipients and may contribute to the pathogenesis of multiple sclerosis.

- HHV-7 is commonly present in saliva. Manifestations of childhood HHV-7 infection include fever and seizures. HHV-7 may have an association with pityriasis rosea.

- HHV-8 is associated with Kaposi’s sarcoma (KS), body cavity–based lymphoma in AIDS pts, and multicentric Castleman’s disease. The virus appears to be sexually spread and may also be transmitted in saliva, by organ transplantation, and through IV drug use. Primary HHV-8 infection in healthy children can present as fever and rash. In immunocompromised hosts, primary infection may present as fever, splenomegaly, pancytopenia, and rapid-onset KS. Neoplastic disorders develop only after immunocompromise.

For a more detailed discussion, see Baden LR, Dolin R: Antiviral Chemotherapy, Excluding Antiretroviral Drugs, Chap. 171, p. 1087; Corey L: Herpes Simplex Viruses, Chap. 172, p. 1095; Whitley RJ: Varicella-Zoster Virus Infections, Chap. 173, p. 1102; and Hirsch MS: Cytomegalovirus and Human Herpesvirus Types 6, 7, and 8, Chap. 175, p. 1109, in HPIM-17.

**Cytomegalovirus and Epstein-Barr Virus Infections**

**Cytomegalovirus (CMV)**

**Etiology** CMV is a herpesvirus that renders infected cells 2–4 times the size of surrounding cells. These cytomegalic cells contain an eccentrically placed intranuclear inclusion surrounded by a clear halo, with an “owl’s-eye” appearance.

**Epidemiology** CMV disease is found worldwide. In the United States, ~1% of newborns are infected. The virus may be spread in breast milk, saliva, feces, and urine. Transmission requires repeated or prolonged contact. In adolescents and adults, sexual transmission is common, and CMV has been identified in semen and cervical secretions. Latent CMV infection persists throughout life unless reactivation is triggered by depressed cell-mediated immunity (e.g., in transplant recipients or HIV-infected pts).

**Pathogenesis** Primary CMV infection is associated with a vigorous T lymphocyte response; atypical lymphocytes are predominantly activated CD8+ T cells. Latent infection occurs in multiple cell types and various organs. Chronic antigen stimulation in the presence of immunosuppression (e.g., in the transplantation setting) and certain immunosuppressive agents (e.g., antithymocyte globulin) promote CMV reactivation. CMV disease increases the risk of infection with opportunistic pathogens by depressing T lymphocyte responsiveness.
**Clinical Features  Congenital CMV Infection**  
Cytomegalic inclusion disease occurs in ~5% of infected fetuses in the setting of primary maternal CMV infection in pregnancy. Pts have petechiae, hepatosplenomegaly, and jaundice. Other findings include microcephaly with or without cerebral calcifications, intrauterine growth retardation, prematurity, and chorioretinitis. Laboratory findings include abnormal liver function tests (LFTs), thrombocytopenia, hemolysis, and increased cerebrospinal fluid (CSF) protein levels. The mortality rate is 20–30% among infants with severe disease; survivors have intellectual or hearing difficulties.

**Perinatal CMV Infection**  
Perinatal infection with CMV is acquired by breastfeeding or contact with infected maternal secretions. Most pts are asymptomatic, but interstitial pneumonitis and other opportunistic infections can occur, particularly in premature infants.

**CMV Mononucleosis**  
This heterophile antibody-negative illness is the most common CMV syndrome in immunocompetent hosts. The incubation period ranges from 20 to 60 days. Symptoms last 2–6 weeks and include fevers, profound fatigue and malaise, myalgias, headache, and splenomegaly; pharyngitis and cervical lymphadenopathy are rare. Laboratory findings include relative lymphocytosis with >10% atypical lymphocytes. Increased serum levels of aminotransferases and alkaline phosphatase as well as immunologic abnormalities (e.g., the presence of cryoglobulins or cold agglutinins) can be evident. Recovery is complete, but postviral asthenia can persist for months. CMV excretion in urine, genital secretions, and/or saliva can continue for months or years.

**CMV Infection in the Immunocompromised Host**  
CMV is the most common and important viral pathogen complicating organ transplantation; CMV infection is a risk factor for graft loss and death. The risk of infection is greatest 1–4 months after transplantation, but retinitis can occur later. Primary CMV infection is more likely than reactivation to cause severe disease with high viral loads. Seropositive recipients can develop reinfection with a new, donor-derived strain of CMV. Reactivation infection is common but less important clinically. The transplanted organ is at particular risk; e.g., CMV pneumonitis tends to follow lung transplantation. Around 15–20% of bone marrow transplant recipients develop CMV pneumonia 5–13 weeks after transplantation, with a case-fatality rate of 84–88%. The risk of severe disease may be reduced by antiviral prophylaxis or preemptive therapy.

CMV is an important pathogen in pts with HIV infection whose CD4+ cell counts have fallen below 50–100/μL. In this setting, CMV produces retinitis, colitis, and disseminated disease.

Immunocompromised pts with CMV infection develop fever, malaise, anorexia, fatigue, night sweats, and arthralgias or myalgias. Tachypnea, hypoxia, and unproductive cough precede respiratory involvement. Involvement of the GI tract may be localized or extensive, with ulcers that can bleed or perforate developing in any part of the tract. Hepatitis is common. Central nervous system (CNS) disease, most often affecting HIV-infected pts, takes one of two forms: encephalitis with dementia or ventriculoecephalitis with cranial nerve deficits, disorientation, and lethargy. Subacute progressive polyradiculopathy has also been described. CMV retinitis can result in blindness. Lesions begin as small white areas of granular retinal necrosis, with later development of hemorrhages, vessel sheathing, and retinal edema. Fatal infection is associated with persistent viremia and multiorgan involvement. Extensive adrenal necrosis is often seen at autopsy.
Infectious Diseases

SECTION 7

Diagnosis

- Viral culture: A shell-vial assay gives more rapid results from tissue culture; samples are centrifuged, and monoclonal antibodies are used to detect immediate-early CMV antigen.

- Detection of CMV antigens (pp65) in peripheral-blood leukocytes or of CMV DNA in blood, CSF, or tissues [e.g., with polymerase chain reaction (PCR) assays]: Positive results may be obtained days sooner than with culture methods, allowing earlier interventions.

- Antibodies may not be detectable for up to 4 weeks in primary infection, and titers may remain elevated for years. IgM may be useful in diagnosing acute infection.

Cytomegalovirus Infections

- When possible, seronegative donors should be used for seronegative transplant recipients.

- CMV immune or hyperimmune globulin may reduce the risk of CMV disease in seronegative renal transplant recipients and prevent congenital CMV infection in infants of women with primary CMV infection during pregnancy.

- Ganciclovir (or valganciclovir, the oral prodrug of ganciclovir) produces response rates of 70–90% among HIV-infected pts with CMV retinitis or colitis. Induction therapy with ganciclovir (5 mg/kg bid IV) or valganciclovir (900 mg bid PO) is given for 14–21 days. In bone marrow transplant recipients, CMV pneumonia should be treated with both ganciclovir and CMV immune globulin; clinical response rates are 50–70% with combination therapy. Neutropenia is an adverse reaction to ganciclovir treatment that may require administration of colony-stimulating factors. Maintenance therapy (ganciclovir, 5 mg/kg qd IV; or valganciclovir, 900 mg qd PO) is needed for prolonged periods except in AIDS pts receiving antiretroviral treatment who have a sustained (>6-month) increase in CD4+ T cell counts to levels of >100–150/μL. Prophylactic or suppressive ganciclovir or valganciclovir can be given to high-risk transplant recipients (those who are seropositive before transplantation or culture positive afterward).

- Ganciclovir can be administered via a slow-release pellet sutured into the eye, but this intervention does not provide treatment for the contralateral eye or for systemic disease.

- Foscarnet is active against CMV infection but is reserved for cases of ganciclovir failure or intolerance because of its toxicities, which include renal dysfunction, hypomagnesemia, hypokalemia, hypocalcemia, and paresthesia. This drug must be given via an infusion pump, and its administration must be closely monitored. An induction regimen of 60 mg/kg q8h or 90 mg/kg q12h for 2 weeks is followed by maintenance regimens of 90–120 mg/kg daily.

- Cidofovir has a long intracellular half-life. Induction regimens of 5 mg/kg per week for 2 weeks are followed by maintenance regimens of 3–5 mg/kg every 2 weeks. Cidofovir causes severe nephrotoxicity by proximal tubular cell injury. The use of saline hydration and probenecid reduces this adverse effect.

EPSTEIN-BARR VIRUS (EBV)

Epidemiology  EBV is a herpesvirus that infects >90% of persons by adulthood. Infectious mononucleosis (IM) is a disease of young adults and is more
common in areas with higher standards of hygiene; infection occurs at a younger age in poorer areas. EBV is spread by contact with oral secretions (e.g., by transfer of saliva during kissing) and is shed in oropharyngeal secretions by >90% of asymptomatic seropositive individuals.

**Pathogenesis**  
EBV infects the epithelium of the oropharynx and salivary glands as well as B cells in tonsillar crypts. The virus spreads through the bloodstream. Reactive T cells proliferate, and there is polyclonal activation of B cells. Memory B cells are the reservoir for EBV. Cellular immunity is more important than humoral immunity in controlling infection. If T cell immunity is compromised, EBV-infected B cells may proliferate—a step toward neoplastic transformation.

**Clinical Features**

I. Infants and young children: asymptomatic or mild pharyngitis

II. Adolescents and adults: IM, with an incubation period of ~4–6 weeks

A. A prodrome of fatigue, malaise, and myalgia may last for 1–2 weeks before fever onset.

B. Illness lasts for 2–4 weeks and is characterized by fever, sore throat, lymphadenopathy (especially of the posterior cervical nodes), malaise, and headache. Signs include pharyngitis or exudative tonsillitis that can resemble streptococcal infection, splenomegaly (usually in the second or third week), hepatomegaly, rash, and periorbital edema. Ampicillin treatment can cause a rash that does not represent a true penicillin allergy. Erythema nodosum or erythema multiforme can occur.

C. Malaise and difficulty with concentration can persist for months.

D. Laboratory findings: Lymphocytosis occurs in the second or third week, with >10% atypical lymphocytes (enlarged cells with abundant cytoplasm and vacuoles). Most atypical lymphocytes are CD8+ T cells. Neutropenia, thrombocytopenia, and abnormal LFTs are common.

E. Complications

1. CNS: In the first 2 weeks of IM, meningitis or encephalitis can present as headache, meningismus, cerebellar ataxia, acute hemiplegia, or psychosis. The CSF contains lymphocytes. Most cases resolve without sequelae.

2. Autoimmune hemolytic anemia (Coombs-positive, with cold agglutinins directed against the i RBC antigen) can last for 1–2 months. Severe disease (red cell aplasia, severe granulocytopenia or pancytopenia, or hemophagocytic syndrome) can occur.

3. Splenic rupture is more common among males than among females and may manifest as abdominal pain, referred shoulder pain, or hemodynamic compromise.

4. Upper airway obstruction due to hypertrophy of lymphoid tissue may occur.

5. Hepatitis, myocarditis, pericarditis, pneumonia, interstitial nephritis, and vasculitis are rare complications.

III. EBV-associated lymphoproliferative disease occurs in immunodeficient pts (e.g., pts infected with HIV, transplant recipients, pts receiving immunosuppressive therapy). Proliferating EBV-infected B cells infiltrate lymph nodes and multiple organs; there is B cell hyperplasia or lymphoma. Pts have fever and lymphadenopathy or GI symptoms.

IV. Oral hairy leukoplakia consists of white corrugated lesions on the tongue in HIV-infected pts.

V. EBV-associated malignancies include Burkitt’s lymphoma, anaplastic nasopharyngeal carcinoma, Hodgkin’s disease (especially the mixed-cellularity
Infectious Diseases

SECTION 7

**Type**, and CNS lymphoma (especially HIV-related). The risk of Hodgkin’s disease is significantly increased in young adults after EBV-seropositive IM.

**Diagnosis**

- **Heterophile test** ([Table 107-1](#)): The heterophile titer is defined as the highest serum dilution that agglutinates sheep, horse, or cow erythrocytes after adsorption with guinea pig kidney. A titer of ≥40-fold is diagnostic of acute EBV infection. Heterophile titers are positive in 40% of pts during the first week and in 80–90% of pts by the third week. The test remains positive for 3 months—or as long as a year—after the onset of acute infection. The monospot test for heterophile antibodies is ~75% sensitive and ~90% specific compared with EBV-specific serologies.

- **EBV-specific antibody testing** ([Table 107-1](#)): Specific antibody testing can be useful in heterophile-negative pts (a group that includes many young children) and pts with atypical disease. Antibodies to viral capsid antigen occur in >90% of cases. IgM titers are elevated only during the first 2–3 months of disease and are most useful in diagnosing acute infection. Documented seroconversion to Epstein-Barr nuclear antigen (EBNA) is also useful. EBNA antibodies are not detected until 3–6 weeks after symptom onset and then persist for life. Other antibodies may be elevated but are less useful diagnostically.

- **Other studies**: Detection of EBV DNA by PCR is useful in demonstrating the association with various malignancies (e.g., positive EBV DNA of the CSF in HIV-associated CNS lymphoma) and in monitoring EBV DNA levels in the blood of pts with lymphoproliferative disease. High EBV DNA levels in plasma correlate with lower survival rates in anaplastic nasopharyngeal carcinoma.

**Epstein-Barr Virus Infections**

IM is treated with supportive measures. Excessive physical activity should be avoided in the first month of illness to reduce the possibility of splenic rup-

<table>
<thead>
<tr>
<th>Condition</th>
<th>Heterophile</th>
<th>Anti-VCA</th>
<th>Anti-EA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute infectious mononucleosis</td>
<td>+</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Convalescence</td>
<td>±</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>Past infection</td>
<td>–</td>
<td>–</td>
<td>++</td>
</tr>
<tr>
<td>Reactivation with immunodeficiency</td>
<td>–</td>
<td>–</td>
<td>+++</td>
</tr>
<tr>
<td>Burkitt’s lymphoma</td>
<td>–</td>
<td>–</td>
<td>+++</td>
</tr>
<tr>
<td>Nasopharyngeal carcinoma</td>
<td>–</td>
<td>–</td>
<td>+++</td>
</tr>
</tbody>
</table>

**Note**: VCA, viral capsid antigen; EA, early antigen; EA-D antibody, antibody to early antigen in diffuse pattern in nucleus and cytoplasm of infected cells; EA-R antibody, antibody to early antigen restricted to the cytoplasm; EBNA, Epstein-Barr nuclear antigen.

ture. Splenectomy is required if rupture occurs. Administration of glucocorticoids may be indicated for some complications of IM; e.g., these agents may be given to prevent airway obstruction or for autoimmune hemolytic anemia. Antiviral therapy (e.g., with acyclovir) is generally not effective. Treatment of posttransplantation EBV lymphoproliferative syndrome is generally directed toward reduction of immunosuppression, although other treatments—e.g., with interferon α or antibody to CD20 (rituximab)—and donor lymphocyte infusions have been used with varying success.

Influenza and Other Viral Respiratory Diseases

Influenza and Other Viral Respiratory Diseases

INFLUENZA

Etiology  Influenza A, B, and C viruses are RNA viruses and members of the Orthomyxoviridae family. Influenza A viruses are subtyped by surface hemagglutinin (H) and neuraminidase (N) antigens. Influenza A and B viruses are major human pathogens and are morphologically similar. Virus attaches to cell receptors via the hemagglutinin. Neuraminidase degrades the receptor and plays a role in the release of virus from infected cells after replication has occurred. Antibodies to the H antigen are the major determinants of immunity, while antibodies to the N antigen limit viral spread and contribute to reduction of the infection.

Epidemiology  Influenza outbreaks occur each year but vary in extent and severity. Until 30 years ago, there were influenza A epidemics or pandemics every 10–15 years due in part to the propensity of the H and N antigens to undergo periodic antigenic variation. Major changes (which are restricted to influenza A viruses) are called antigenic shifts and are associated with pandemics. Minor variations are called antigenic drifts. The segmented genome of influenza A and B viruses allows reassortment. Prior pandemic strains of influenza A virus have been linked to genetic reassortment between human and avian strains, with adaptation of an avian virus to efficient infection of humans. The avian influenza strain A/H5N1, first detected in 1997, has not resulted in a pandemic because efficient person-to-person transmission has not been observed; infection is linked to direct contact with infected poultry. Thus far, influenza A/H5N1 has caused 261 cases of infection in 10 countries in Asia and the Middle East.

Generally, influenza A epidemics begin abruptly, peak over 2–3 weeks, last 2–3 months, and then subside rapidly. They take place almost exclusively during the winter months in temperate climates but occur year-round in the tropics. The morbidity and mortality associated with influenza outbreaks continue to
be substantial, particularly among persons with comorbid disease. Chronic cardiac and pulmonary disease and old age are prominent risk factors for severe illness. Influenza B viruses have a more restricted host range and do not undergo antigenic shifts, although they do exhibit antigenic drift. Outbreaks are less extensive and less severe than those of influenza A, occurring most commonly in schools and military camps. Influenza C causes subclinical infection.

**Pathogenesis**  Influenza is acquired from respiratory secretions of acutely ill individuals through aerosols generated by coughs and sneezes and possibly by hand-to-hand contact or other personal or fomite contact. Virus then infects the ciliated columnar epithelial cells and spreads quickly to infect other respiratory cells. Cells undergo degenerative changes, become necrotic, and desquamate. Extrapulmonary sites of infection are rare, but cytokine induction causes systemic symptoms. Host defenses include production of humoral antibody, local IgA antibody, cell-mediated immune responses, and interferon. Viral shedding usually stops 2–5 days after disease onset.

**Clinical Features**
- Systemic symptoms: abrupt onset of headache, fever, chills, myalgia, malaise
- Respiratory tract symptoms: cough and sore throat that can become more prominent as systemic symptoms subside
- Physical findings are minimal in uncomplicated disease.
- Pts with uncomplicated influenza improve over 2–5 days and have largely recovered at 1 week, although cough can persist for 1–2 weeks. Postinfluenzal asthenia may persist for weeks.

**Complications** Complications are more common among pts >64 years old, pregnant women, and pts with chronic disorders (e.g., cardiac or pulmonary disease, diabetes, renal diseases, hemoglobinopathies, or immunosuppression).
- Pneumonia: the most significant complication of influenza. Pts can have tachypnea, cyanosis, diffuse rales, and signs of consolidation.
  1. Primary viral: least common but most severe. Acute influenza progresses relentlessly, with persistent fever, dyspnea, cyanosis, and hemoptysis. Chest x-ray (CXR) may show diffuse infiltrates. Acute respiratory distress syndrome (ARDS) can result. Cultures of respiratory secretions yield high viral titers. Primary pneumonia is especially common among pts with cardiac disease, particularly mitral stenosis.
  2. Secondary bacterial: usually due to *Streptococcus pneumoniae*, *Staphylococcus aureus*, or *Haemophilus influenzae*. Pts improve over 2–3 days of illness and then have a recurrence of fever and clinical signs of bacterial pneumonia (e.g., cough, sputum production, and consolidation on CXR).
  3. Pts can have features of both primary and secondary pneumonia.
- Extrapulmonary complications
  1. Reye’s syndrome: associated with influenza B more often than with influenza A; also associated with varicella-zoster virus infection and with aspirin use. Aspirin should not be given to children with acute viral respiratory infections.
  2. Miscellaneous: Myositis, rhabdomyolysis, and myoglobinuria are rare despite the prevalence of severe myalgia. Myocarditis and pericarditis, encephalitis, transverse myelitis, and Guillain-Barré syndrome have been reported.
- Avian influenza (A/H5N1): Infected pts have high rates of pneumonia and extrapulmonary manifestations such as diarrhea and CNS involvement. Deaths are associated with multisystem dysfunction, including cardiac and renal failure. Mortality rates have approached 60%.
Influenza and Other Viral Respiratory Diseases

Laboratory Findings  Tissue culture of virus from throat swabs, nasopharyngeal washes, or sputum usually gives a positive result within 48–72 h. Rapid tests for viral nucleoprotein or neuraminidase are highly sensitive, with a specificity of 60–90%. Serology requires the availability of acute- and convalescent-phase sera and is useful only retrospectively.

**Influenza**

- Symptom-based therapy (e.g., acetaminophen, rest, hydration)
- Antiviral agents ([Table 108-1](#))
  1. Antiviral treatment has been tested in healthy adults with uncomplicated influenza but not in pts with severe disease.
  2. The neuraminidase inhibitors oseltamivir and zanamivir decrease the duration of signs and symptoms by 1–1.5 days if therapy is begun with-

**TABLE 108-1  ANTIVIRAL MEDICATIONS FOR TREATMENT AND PROPHYLAXIS OF INFLUENZA**

<table>
<thead>
<tr>
<th>Antiviral Drug</th>
<th>Age Group (years)</th>
<th>Children (≤12)</th>
<th>13–64</th>
<th>≥65</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oseltamivir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment, influenza A and B</td>
<td>Age 1–12, dose varies by weight(^a)</td>
<td>75 mg PO bid</td>
<td>75 mg PO bid</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Age 1–12, dose varies by weight(^b)</td>
<td>75 mg PO qd</td>
<td>75 mg PO qd</td>
<td></td>
</tr>
<tr>
<td>Zanamivir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment, influenza A and B</td>
<td>Age 7–12, 10 mg bid by inhalation</td>
<td>10 mg bid by inhalation</td>
<td>10 mg bid by inhalation</td>
<td></td>
</tr>
<tr>
<td>Prophylaxis, influenza A and B</td>
<td>Age 5–12, 10 mg qd by inhalation</td>
<td>10 mg qd by inhalation</td>
<td>10 mg qd by inhalation</td>
<td></td>
</tr>
<tr>
<td>Amantadine(^c)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment, influenza A</td>
<td>Age 1–9, 5 mg/kg in 2 divided doses, up to 150 mg/d</td>
<td>Age ≥10, 100 mg PO bid</td>
<td>≤100 mg/d</td>
<td></td>
</tr>
<tr>
<td>Prophylaxis, influenza A</td>
<td>Age 1–9, 5 mg/kg in 2 divided doses, up to 150 mg/d</td>
<td>Age ≥10, 100 mg PO bid</td>
<td>≤100 mg/d</td>
<td></td>
</tr>
<tr>
<td>Rimantadine(^c)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment, influenza A</td>
<td>Not approved</td>
<td>100 mg PO bid</td>
<td>100–200 mg/d</td>
<td></td>
</tr>
<tr>
<td>Prophylaxis, influenza A</td>
<td>Age 1–9, 5 mg/kg in 2 divided doses, up to 150 mg/d</td>
<td>Age ≥10, 100 mg PO bid</td>
<td>100–200 mg/d</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)<15 kg: 30 mg bid; >15–23 kg: 45 mg bid; >23–40 kg: 60 mg bid; >40 kg: 75 mg bid.

\(^b\)<15 kg: 30 mg qd; >15–23 kg: 45 mg qd; >23–40 kg: 60 mg qd; >40 kg: 75 mg qd.

\(^c\)Amantadine and rimantadine are not currently recommended (2006–2007) because of widespread resistance in influenza A/H3N2 viruses. Their use may be reconsidered if viral susceptibility is reestablished.
in 2 days of illness onset. Zanamivir may exacerbate bronchospasm in asthmatic pts, while oseltamivir has been associated with nausea and vomiting (reactions whose incidence is reduced if the drug is given with food) and with neuropsychiatric side effects in children. Antiviral resistance to neuraminidase inhibitors is infrequent but can occur.

3. Amantadine and rimantadine are not recommended at present because of widespread resistance among influenza A/H3N2 viruses. Amantadine causes mild CNS side effects (e.g., jitteriness, anxiety, insomnia, difficulty concentrating) in ~5–10% of pts. Rimantadine has fewer CNS side effects.

**Prophylaxis**

- **Vaccination:** Influenza vaccine is derived from the influenza A and B viruses that have circulated during the previous influenza season. If the currently circulating virus is similar to the vaccine strain, 50–80% protection is expected. Influenza vaccination is recommended for any individual >6 months of age who is at increased risk for complications (Table 108-2). The commercially available vaccines are inactivated and may be given to immunocompromised pts. A live attenuated influenza vaccine given by intranasal spray has been approved and can be used for healthy children and adults up to 49 years of age.

- **Chemoprophylaxis:** Efficacy rates in preventing illness are 84–89% for oseltamivir or zanamivir. Amantadine and rimantadine are not recommended

<table>
<thead>
<tr>
<th>TABLE 108-2</th>
<th>PERSONS FOR WHOM ANNUAL INFLUENZA VACCINATION IS RECOMMENDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children 6–59 months old</td>
<td>Women who will be pregnant during the influenza season</td>
</tr>
<tr>
<td>Persons ≥50 years old</td>
<td>Children and adolescents (6 months to 18 years old) who are receiving long-term aspirin therapy and therefore may be at risk for developing Reye’s syndrome after influenza</td>
</tr>
<tr>
<td>Adults and children who have chronic disorders of the pulmonary or cardiovascular systems, including asthma</td>
<td>Adults and children who have required regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunodeficiency (including immunodeficiency caused by medications or by HIV)</td>
</tr>
<tr>
<td>Adults and children who have any condition (e.g., cognitive dysfunction, spinal cord injuries, seizure disorders, or other neuromuscular disorders) that can compromise respiratory function or the handling of respiratory secretions or can increase the risk of aspiration</td>
<td>Residents of nursing homes and other chronic-care facilities that house persons of any age who have chronic medical conditions</td>
</tr>
<tr>
<td>Persons who live with or care for persons at high risk for influenza-related complications, including healthy household contacts of and caregivers for children from birth through 59 months of age</td>
<td>Health care workers</td>
</tr>
</tbody>
</table>

*Hypertension itself is not considered a chronic disorder for which influenza vaccination is recommended.

at this time. Prophylaxis is useful for high-risk individuals who have not received vaccine and are exposed to influenza; it can be administered simultaneously with inactivated—but not with live—vaccine.

**OTHER COMMON VIRAL RESPIRATORY INFECTIONS**

(See also Chap. 62)

**RHINOVIRUSES**

Rhinoviruses are RNA viruses of the Picornaviridae family.

- Major cause of the “common cold” (up to 50% of cases)
- Spread by direct contact with infected secretions, usually respiratory droplets
- Short incubation period (1–2 days). Pts develop rhinorrhea, sneezing, nasal congestion, and sore throat. Fever and systemic symptoms are unusual.
- Severe disease is rare but is described in bone marrow transplant recipients.
- Diagnosis is not usually attempted. PCR and tissue culture methods are available.

**CORONAVIRUSES**

**General Information** Coronaviruses are RNA viruses that account for 10–35% of common colds and cause typical presentations. A coronavirus was identified as the cause of severe acute respiratory syndrome (SARS).

**The SARS Outbreak** **Epidemiology** SARS began in China in 2002. Although >8000 cases were ultimately identified in 28 countries of Asia, Europe, and North America, ~90% of all cases occurred in China and Hong Kong. Case-fatality rates were ~9.5% overall. Transmission appeared to take place by both large and small aerosols and perhaps also by the fecal-oral route. The last reported cases occurred in 2004.

**Pathogenesis** SARS virus probably enters and infects cells of the respiratory tract but also causes viremia and is found in the urine and in the stool. Viral titers in the respiratory tract peak ~10 days after the onset of illness. Pulmonary pathology consists of hyaline membrane formation, pneumocyte desquamation in alveolar spaces, and an interstitial infiltrate.

**Clinical Features** The incubation period lasts 2–7 days. A systemic illness with fever, malaise, headache, and myalgias is followed in 1–2 days by nonproductive cough, dyspnea, diarrhea, and abnormal CXR. Respiratory function deteriorates in the second week of illness and can progress to ARDS and multiorgan dysfunction. A worse prognosis is associated with an age of >50 years and with comorbidities such as cardiovascular disease, diabetes, and hepatitis. Pregnant women have particularly severe disease.

**Diagnosis** Lymphopenia affecting mostly CD4+ T cells, thrombocytopenia, and increased serum levels of aminotransferases, creatine kinase, and lactate dehydrogenase (LDH) are described. Diagnosis is based on clinical, epidemiologic, and laboratory features. Virus can be isolated from respiratory tract secretions. A rapid diagnosis can be made by reverse-transcriptase polymerase chain reaction (PCR) of respiratory tract samples and plasma early in illness and of urine and stool later in the course. Serum antibodies are detectable by enzyme-linked immunosorbent assay (ELISA) or immunofluorescence and develop within 28 days of illness onset.
**SARS**

Aggressive supportive care is most important. No specific therapy has established efficacy.

**Prevention**  
SARS caused a worldwide public health response; case definitions were established, travel advisories issued, and quarantines imposed in certain locales. Transmission to health care workers was frequent; strict infection control measures were found to be essential.

**HUMAN RESPIRATORY SYNCYTIAL VIRUS**

Human respiratory syncytial virus (HRSV) is so named because its replication in vitro leads to fusion of neighboring cells into large multinucleated syncytia. HRSV is an RNA virus and a member of the Paramyxoviridae family. It is a major respiratory pathogen among young children and the foremost cause of lower respiratory disease among infants. Rates of illness peak at 2–3 months of age, when attack rates among susceptible individuals approach 100%. HRSV accounts for 20–25% of hospital admissions of infants and young children for pneumonia and for up to 75% of cases of bronchiolitis in this age group. The virus is transmitted efficiently via contact with contaminated fingers or fomites and by spread of coarse aerosols. The incubation period is 4–6 days. Viral shedding can last for >2 weeks in children and compromised hosts. HRSV is an important nosocomial pathogen.

**Clinical Features**

- **Infants:** Around 20–40% of infections result in lower tract disease, including pneumonia, bronchiolitis, and tracheobronchitis. Mild disease begins with rhinorrhea, low-grade fever, cough, and wheezing, and recovery comes within 1–2 weeks. Severe disease is marked by tachypnea and dyspnea; hypoxia, cyanosis, and apnea can ensue. Examination reveals wheezing, rhonchi, and rales. CXR may reveal hyperexpansion, peribronchial thickening, and variable infiltrates. Mortality rates can be high, especially among infants with prematurity, bronchopulmonary dysplasia, congenital heart disease, nephrotic syndrome, or immunosuppression.

- **Milder disease results from reinfection among older children and adults.**

- **The common cold is the most common presentation in adults, but HRSV can cause lower respiratory tract disease with fever, including severe pneumonia in elderly pts. HRSV pneumonia can be a significant cause of morbidity and death among transplant recipients, with case-fatality rates of 20–80%.**

**Diagnosis**  
Immunofluorescence, ELISA, and other techniques can identify HRSV isolates in tissue culture. Rapid viral diagnosis is available by immunofluorescence or ELISA of nasopharyngeal washes, aspirates, or swabs. Serologic testing is also available.

**Human Respiratory Syncytial Virus**

For upper tract disease, treatment is symptom-based. For severe lower tract disease, aerosolized ribavirin is beneficial to infants, but its efficacy in older children and adults (including immunocompromised pts) has not been established. Health care workers exposed to the drug have experienced minor toxicity, including eye and respiratory tract irritation. Ribavirin is mutagenic, teratogenic, and embryotoxic; its use is contraindicated in pregnancy, and its
aerosolized administration is a risk to pregnant health care workers. IV immunoglobulin (IVIg), immunoglobulin with high titers of antibody to HRSV (RSVIg), and monoclonal IgG antibody to HRSV (palivizumab) are available but have not been shown to be beneficial.

**Prevention**  Monthly RSVIg or palivizumab is approved for prophylaxis in children <2 years of age who have bronchopulmonary dysplasia or cyanotic heart disease or who were born prematurely.

**METAPNEUMOVIRUS**

Metapneumovirus is an RNA virus of the Paramyxoviridae family. This newly described respiratory pathogen causes disease in a wide variety of age groups, with clinical manifestations similar to those caused by HRSV. Diagnosis is made by PCR or tissue culture of nasal aspirates or respiratory secretions. Treatment is primarily supportive and symptom-based.

**PARAINFLUENZA VIRUS**

This RNA virus of the Paramyxoviridae family ranks second only to HRSV as a cause of lower respiratory tract disease among young children and is the most common cause of croup (laryngotracheobronchitis). Infections are milder among older children and adults, but severe, prolonged, and fatal infection is reported among pts with severe immunosuppression, including transplant recipients. Tissue culture, rapid testing, or PCR of respiratory tract secretions or nasopharyngeal washings can detect the virus. Glucocorticoids are beneficial in severe cases. Ribavirin has been used on occasion, and anecdotal reports indicate some efficacy.

**ADENOVIRUSES**

Adenoviruses are DNA viruses that cause ~10% of acute respiratory infections among children but <2% of respiratory illnesses among civilian adults. Some serotypes are associated with outbreaks among military recruits. Transmission can take place via inhalation of aerosolized virus, through inoculation of the conjunctival sacs, and probably via the fecal-oral route.

- In children, adenovirus causes acute upper and lower respiratory tract infections; upper tract infections are more common. The virus causes outbreaks of pharyngoconjunctival fever (often at summer camps), an illness characterized by bilateral conjunctivitis, granular conjunctivae, rhinitis, sore throat, and cervical adenopathy.
- In adults, adenovirus causes sore throat, fever, cough, coryza, and regional adenopathy.
- Other manifestations include diarrheal illness, hemorrhagic cystitis, and epidemic keratoconjunctivitis.
- Immunocompromised pts, especially transplant recipients, can develop disseminated disease, pneumonia, hepatitis, nephritis, colitis, encephalitis, and hemorrhagic cystitis. Adenovirus may involve the transplanted organ.
- Definitive diagnosis can be made by isolation in tissue culture; by rapid testing (with immunofluorescence or ELISA) of nasopharyngeal aspirates, conjunctival or respiratory secretions, urine, or stool; or by PCR testing.
- Treatment is supportive. Ribavirin and cidofovir exhibit in vitro activity against adenovirus.
MEASLES (RUBEOLA)

Definition and Etiology  Measles is a highly contagious, acute, exanthematic respiratory disease with a characteristic clinical picture and a pathognomonic enanthem (Koplik’s spots). Measles is caused by an RNA virus of the genus *Morbillivirus* and the family Paramyxoviridae.

Epidemiology  Routine administration of the measles vaccine has markedly decreased the number of cases in the United States. Most of the 37 U.S. cases reported in 2004 were attributable to international importation of the virus. The disease is spread by respiratory secretions through exposure to aerosols and through direct contact with larger droplets. Pts are contagious from 1–2 days before symptom onset until 4 days after the rash appears; infectivity peaks during the prodromal phase.

Clinical Features
- Symptoms and rash occur a mean of 10 and 14 days, respectively, after infection.
- Prodrome: 2–4 days of malaise, cough, coryza, conjunctivitis, nasal discharge, and fever. Fever starts to resolve by day 4 or 5 after rash onset.
- Koplik’s spots: 1- to 2-mm blue-white spots on a bright red background; typically occur on the buccal mucosa, alongside the second molars, 1–2 days before rash
- An erythematous, nonpruritic, maculopapular rash begins at the hairline and behind the ears, spreads down the trunk and limbs to include the palms and soles, can become confluent, and begins to fade by day 4. Rash is often more severe in adults.
- Lymphadenopathy, diarrhea and vomiting, and splenomegaly are common.
- Pts with defects in cell-mediated immunity are at risk for severe, protracted, and fatal disease and may have no rash.
- Complications
  - Respiratory tract: otitis media in children, croup in infants. Adults and immunocompromised children can develop primary viral giant cell pneumonia.
  - CNS disease
    - Acute encephalitis: headache, drowsiness, coma, seizures; 10% mortality; retardation, epilepsy, and other sequelae in survivors
    - Risk of progressive fatal encephalitis 1–6 months after illness in immunocompromised pts

For a more detailed discussion, see Baden LR, Dolin R: Antiviral Chemotherapy, Excluding Antiretroviral Drugs, Chap. 171, p. 1087; Dolin R: Common Viral Respiratory Infections and Severe Acute Respiratory Syndrome (SARS), Chap. 179, p. 1120; and Dolin R: Influenza, Chap. 180, p. 1127, in HPIM-17.
Subacute sclerosing panencephalitis: protracted, chronic, rare form of encephalitis with progressive dementia over several months; more common among children who contract measles at <2 years of age; rare in the United States because of widespread vaccination

GI tract: hepatitis, colitis, adenitis, appendicitis
Myocarditis, glomerulonephritis, thrombocytopenic purpura

- Atypical measles occurs in pts who contract measles after receiving inactivated vaccine (in use before 1967). Pts have a peripheral rash that moves centrally, high fevers, edema of the extremities, interstitial pulmonary infiltrates, hepatitis, and occasionally pleural effusions. Full recovery is typical, but convalescence may be prolonged. Inactivated vaccine has not been available for >35 years; atypical measles has virtually disappeared.

**Diagnosis**
Lymphopenia and neutropenia are common. Immunofluorescent staining of respiratory secretions for measles antigen or examination of secretions for multinucleated giant cells can help establish the diagnosis. Virus can be isolated from respiratory secretions or urine. Polymerase chain reaction (PCR) is available as well. IgM antibody appears 1–2 days before rash.

**Measles**
- Supportive care; antibiotics for bacterial superinfections (e.g., otitis or pneumonia)
- Vitamin A for young children hospitalized with measles and for pediatric measles pts with immunodeficiency, vitamin A deficiency, impaired intestinal absorption, malnutrition, or immigration from areas with high measles mortality rates
- Ribavirin may be considered for use in immunocompromised pts.

**Prevention**
Live attenuated vaccine containing measles, mumps, and rubella (MMR) antigens is given routinely at 12–15 months; a second dose is given to school-age children at 4–12 years of age. MMR vaccine is being supplanted by MMRV vaccine, which also covers varicella. Older individuals without prior documented illness or vaccination should be immunized. Asymptomatic HIV-infected children should receive MMR vaccine, but pts with severe immunosuppression, others with impaired cell-mediated immunity, pregnant women, and persons with anaphylaxis to egg protein or neomycin should not receive the vaccine.
Postexposure prophylaxis with immunoglobulin should be considered in susceptible children or adults exposed to measles; a dose of 0.25 mL/kg is given to healthy pts and a dose of 0.5 mL/kg to immunocompromised hosts, with a maximal dose of 15 mL.

**RUBELLA (GERMAN MEASLES)**

**Etiology and Epidemiology**
Rubella is a contagious infectious disease caused by an RNA togavirus of the genus *Rubivirus*. Virus is shed in respiratory secretions during the prodromal phase, and shedding continues for a week after symptom onset. Transmission occurs via droplets or direct contact with nasopharyngeal secretions. Infants with congenital disease can shed virus from the respiratory tract and urine for 2 years. Rubella vaccine, introduced in 1969, has eliminated most disease. In 2001–2004, an average of 14 cases of postnatally acquired rubella were reported annually in the United States; 4 confirmed cases of congenital rubella syndrome were reported to the Centers for Disease Control and Prevention in 2006.
Infectious Diseases

SECTION 7

Control and Prevention during this 4-year period. Young immigrants from Latin America and the Caribbean, where childhood vaccination against the disease is not routine, are at increased risk.

Clinical Features
- Incubation period: average, 18 days; range, 12–23 days
- Usually a mild or subclinical illness; may be more severe in adults
- A prodrome of malaise, fever, and anorexia is followed by posterior auricular, cervical, and suboccipital lymphadenopathy; fever; mild coryza; and conjunctivitis.
- Rash follows, beginning on the face, spreading down the body, and lasting 3–5 days.
- Women are more prone to arthritis of the fingers, wrists, and/or knees; this condition can take weeks to resolve.
- Congenital rubella is the most serious manifestation of rubella infection and can include cataracts, heart disease, deafness, and other deficits. Maternal infection results in fetal infection in ~50% of cases in the first trimester and in about one-third of cases in the second trimester. Fetal disease is more severe the earlier infection occurs.

Diagnosis
- Enzyme-linked immunosorbent assay (ELISA) testing for IgG and IgM antibodies
- Congenital rubella can be diagnosed by isolation of the virus, a positive PCR assay, detection of IgM antibodies in a single serum sample, and/or documentation of either the persistence of antibodies beyond 1 year of age or a rising antibody titer at any time during infancy in an unvaccinated child.
- Biopsy tissue samples or blood or CSF samples can be analyzed for rubella antigen with monoclonal antibodies or for rubella RNA via in situ hybridization or PCR.

Prevention
- See MMR recommendations under “Measles (Rubeola),” above. Pregnancy should be avoided for at least 3 months after vaccination. However, the occurrence of vaccine-related congenital rubella has not been proven in women inadvertently vaccinated during pregnancy.

MUMPS

Definition and Etiology
Mumps is an acute systemic communicable viral infection whose most distinctive feature is swelling of one or both parotid glands. It is caused by the mumps virus, an RNA paramyxovirus with only one antigenic type.

Epidemiology
The introduction of mumps vaccine in 1967 resulted in a marked decline in new mumps cases in the United States. Currently, there are ~231–277 cases annually, a >99% reduction from prevaccine levels. Pts may shed virus before clinical disease onset or during subclinical infection (which occurs in one-third of pts). The virus is transmitted by droplet nuclei, saliva, and fomites. Transmission occurs 1–2 days before parotitis onset and can continue for up to 5 days afterward. Viral replication in the upper respiratory tract leads to viremia, which is followed by infection of glandular tissues and/or the central nervous system.

Clinical Features
- The incubation period is generally 14–18 days (range, 7–23 days).
- A prodrome of fever, malaise, myalgia, and anorexia is followed 1–7 days later by tender parotitis that is bilateral in two-thirds of pts. Pts have trouble
Rubeola, Rubella, Mumps, and Parvovirus

CHAPTER 109

eating, swallowing, or talking. Swelling slowly resolves within a week. Submaxillary and sublingual glands are involved less often.

- After parotitis, orchitis is the most common manifestation among postpubertal males, occurring in about one-fifth of cases. The testes are painful, tender, and enlarged, and atrophy can develop in half of affected men. Orchitis is bilateral in <15% of cases, and sterility is rare. In women, oophoritis can occur but does not lead to sterility.

- Aseptic meningitis: Cerebrospinal fluid (CSF) pleocytosis can occur in half of mumps cases, but clinical meningitis is evident in only 5–25%. CSF glucose levels may be very low, and polymorphonuclear leukocytes may predominate in the first 24 h, leading to a consideration of bacterial meningitis. Disease is self-limited; cranial nerve palsies occasionally lead to permanent sequelae, particularly deafness.

- Pancreatitis, myocarditis, and other unusual manifestations can occur. High serum amylase levels due to parotitis make pancreatitis difficult to diagnose. First-trimester maternal infection can cause spontaneous abortions but not congenital malformations.

Diagnosis  Mumps virus is easily isolated and can be rapidly identified in shell-vial cultures by immunofluorescence. Virus can be recovered from saliva, throat, urine (in which it is shed for up to 2 weeks), and CSF. PCR is also available. ELISA is useful for serologic diagnosis.

Prevention  See MMR recommendations under “Measles (Rubeola),” above.

PARVOVIRUS INFECTION

Etiology  Parvovirus B19, a DNA virus of the family Parvoviridae, is the only member shown definitively to be a human pathogen.

Pathogenesis  B19 replicates in erythroid progenitors. Infection leads to high-titer viremia and arrest of erythropoiesis. When an IgM and IgG antibody response is mounted, normal erythropoiesis resumes. Pts with increased erythropoiesis (especially with hemolytic anemia) can develop a transient crisis with severe anemia, while pts who do not mount an adequate antibody response can develop chronic anemia. At 2–3 weeks after infection, an immune-mediated phase of illness, with rash and/or arthritis, occurs in the healthy host in the presence of rising antibody titers.

Epidemiology  B19 is endemic worldwide and is transmitted via the respiratory route. By the age of 15 years, ≥50% of children have antibody; >90% of elderly pts are antibody-positive.

Clinical Features

- Erythema infectiosum (fifth disease) is a mild viral illness with a facial “slapped-cheek” rash (more common in children) and low-grade fever. A lacy, reticular rash develops primarily on the arms and legs.

- Polyarthropathy syndrome: occurs in ~50% of adults and in women more often than in men. The arthritis is typically symmetric and affects the small joints of the hands and occasionally the ankles, knees, and wrists. Most cases resolve in 3 weeks, but some persist for months.

- Transient aplastic crisis (TAC): Pts with chronic hemolytic conditions (e.g., hemoglobinopathies, autoimmune hemolytic anemia) can develop aplastic crisis with B19 infection that can be life-threatening. Pts display symptoms associated with severe anemia.
Infectious Diseases

SECTION 7

• Pure red cell aplasia/chronic anemia: Pts have persistent anemia, high levels of B19 DNA in serum, and absent or low-level B19 IgG. HIV-infected pts, transplant recipients, and pts with other immunodeiciencies are at risk.

• Hydrops fetalis: B19 infection during pregnancy can lead to hydrops fetalis and/or fetal loss. The risk of transplacental fetal infection is ~30%, and the risk of fetal loss (which occurs predominantly early in the second trimester) is ~9%. The risk of congenital infection is <1%.

Diagnosis Diagnosis relies on measurement of B19-specific IgM and IgG antibodies. Detection of B19 DNA via quantitative PCR should be used to diagnose TAC or chronic anemia. In acute infection, the viremia load can exceed $>10^{12}$ B19 DNA genome equivalents (ge)/mL of serum; pts with TAC or chronic anemia generally have $>10^5$ B19 DNA ge/mL. Bone marrow examination demonstrates characteristic giant pronormoblasts and the absence of erythroid precursors.

**Parovirus Infection**

Aplastic crisis should be treated with transfusions as needed; in pts receiving chemotherapy, this treatment should be temporarily discontinued if possible. Commercial IV immunoglobulin should be given to immunodeficient anemic pts to control and possibly cure B19 infection.

**Prevention** Pts with chronic B19 infection or TAC should be considered infectious. Hospitalized pts with chronic B19 infection or TAC pose a risk of nosocomial transmission and should be placed on contact and respiratory isolation precautions.

For a more detailed discussion, see Brown KE: Parovirus Infections, Chap. 177, p. 1114; Gershon A: Measles (Rubeola), Chap. 185, p. 1214; Rubella (German Measles), Chap. 186, p. 1217; and Mumps, Chap. 187, p. 1220, in HPIM-17.

Enteroviral Infections

**ETIOLOGY**

Enteroviruses are so named because of their ability to multiply in the GI tract, but they do not typically cause gastroenteritis. This group of viruses includes 3 serotypes of poliovirus, 23 serotypes of coxsackievirus A, 6 serotypes of coxsackievirus B, 29 serotypes of echovirus, and enteroviruses 68–71. Enteroviruses 73–102 have recently been identified in humans, but the clinical features of these viruses have not yet been defined. In the United States, echovirus causes most enteroviral infections.
**PATHOGENESIS AND IMMUNITY**

Of the enteroviruses, poliovirus is best characterized. After ingestion, poliovirus infects GI tract mucosal epithelial cells, spreads to regional lymph nodes, causes viremia, and replicates in the reticuloendothelial system; in some cases, a second round of viremia occurs. Virus gains access to the central nervous system (CNS) either via the bloodstream or via direct spread from neural pathways. Virus is present in blood for 3–5 days. It is shed from the oropharynx for up to 3 weeks and from the GI tract for up to 12 weeks after infection. Immunocompromised pts can shed virus for up to 20 years. Infection is controlled by humoral and secretory immunity in the GI tract.

**EPIDEMIOLOGY**

Enteroviruses cause disease worldwide, especially in areas with crowded conditions and poor hygiene. Infants and young children are most often infected and are the most frequent shedders. Transmission takes place mainly by the fecal-oral route, but airborne transmission and placental transmission have been described. Pts are most infectious shortly before or after the onset of symptoms. The incubation period ranges from 2 to 14 days but usually is <1 week in duration.

**CLINICAL FEATURES**

**Poliovirus**

- Most infections are asymptomatic. Mild illness resolves in 3 days and is manifest by fever, malaise, sore throat, myalgias, and headache.
- Aseptic meningitis (nonparalytic) occurs in ~1% of pts. Examination of cerebrospinal fluid (CSF) reveals normal glucose and protein concentrations and lymphocytic pleocytosis [with polymorphonuclear leukocytes (PMNs) sometimes predominating early].
- Paralytic disease is least common. Risk factors include older age, pregnancy, and trauma or strenuous exercise at the onset of CNS symptoms. Aseptic meningitis is followed ≥1 day later by severe back, neck, and muscle pain as well as a gradual development of motor weakness. This weakness is usually asymmetric and proximal and is most common in the legs; the arms and the abdominal, thoracic, and bulbar muscles are other frequently involved sites. Paralysis occurs only during the febrile phase. Physical examination reveals weakness, fasciculations, decreased muscle tone, and reduced or absent reflexes in affected areas; hyperreflexia may precede the loss of reflexes. Bulbar paralysis is associated with dysphagia, difficulty handling secretions, or dysphonia. Respiratory insufficiency due to aspiration or neurologic involvement may develop. Severe medullary infection may lead to circulatory collapse. Most pts recover some function, but around two-thirds have residual neurologic sequelae.
- Live poliovirus vaccine–associated disease: The risk is estimated to be 1 case per 2.5 million doses and is ~2000 times higher among immunodeficient persons.
- Postpolio syndrome: new weakness 20–40 years after poliomyelitis. Onset is insidious, progression is slow, and plateau periods can last 1–10 years.

**Coxsackievirus, Echovirus, and Other Enteroviruses**

In the United States, 5–10 million cases of symptomatic enteroviral disease other than poliomyelitis occur each year.

- Nonspecific febrile illness (summer grippe) occurs during the summer and early fall. Pts experience an acute onset of fever, malaise, and headache;
upper respiratory symptoms; nausea; and vomiting. Disease resolves within a week.

- **Generalized disease of the newborn**: occurs from the first week of life to 3 months of age. The illness resembles bacterial sepsis and has a high associated mortality rate. Myocarditis, hypotension, hepatitis, disseminated intravascular coagulation, meningitis, and pneumonia are complications.

- **Aseptic meningitis and encephalitis**: Enteroviruses cause 90% of aseptic meningitis cases among children and young adults. Pts have an acute onset of fever, chills, headache, photophobia, nausea, and vomiting, with meningismus on examination. Diarrhea, rashes, myalgias, pleurodynia, myocarditis, and herpangina may occur. CSF examination reveals pleocytosis, with PMNs sometimes predominating early but a shift to lymphocyte predominance within 24 h. Total cell counts usually do not exceed 1000/μL. CSF glucose and protein levels are typically normal. Symptoms resolve within a week, but CSF abnormalities persist longer. Encephalitis is much less common and is usually mild, with an excellent prognosis in healthy hosts. However, pts with γ globulin defects can develop chronic meningitis or encephalitis. Pts receiving γ globulin replacement may develop neurologic disease due to echovirus.

- **Pleurodynia (Bornholm disease)**: Pts have an acute onset of fever associated with spasms of pleuritic chest pain (more common among adults) or upper abdominal pain (more common among children). Fever subsides when pain resolves. A pleural rub may be present. Coxsackievirus B is the most common cause. Disease lasts for several days and can be treated with nonsteroidal anti-inflammatory drugs and heat application to the affected muscles.

- **Myocarditis and pericarditis**: Enteroviruses (e.g., coxsackievirus B) cause up to one-third of cases of acute myocarditis. Disease is more common among males and occurs most often in newborns (who have the most severe disease), adolescents, and young adults. Pts have upper respiratory symptoms followed by fever, chest pain, dyspnea, arrhythmias, and occasionally congestive heart failure. A pericardial friction rub, ST-segment and T-wave abnormalities on electrocardiogram, and elevated serum levels of myocardial enzymes can be present. Up to 10% of pts develop chronic dilated cardiomyopathy. Constrictive pericarditis may occur.

- **Exanthems**: Enteroviral infection is a leading cause of exanthems among children in the summer and fall. Echoviruses 9 and 16 are common causes.

- **Hand-foot-and-mouth disease**: Pts present with fever, anorexia, and malaise, followed by sore throat and vesicles on the buccal mucosa, tongue, and dorsum or palms of the hands and occasionally on the palate, uvula, tonsillar pillars, or feet. Lesions can become bullous and ulcerate. The disease is highly infectious, with attack rates of almost 100% among young children. Symptoms resolve within a week. Coxsackievirus A16 and enterovirus 71 are the most common etiologic agents. A Taiwan epidemic of enterovirus 71 infection was associated with CNS disease, myocarditis, and pulmonary hemorrhage. Deaths occurred primarily among children ≤5 years old.

- **Herpangina**: associated with coxsackievirus A infection. Pts have fever, sore throat, and dysphagia and develop grayish-white papulovesicular lesions that ulcerate and are concentrated in the posterior portion of the mouth. Lesions can persist for weeks. In contrast to herpes simplex stomatitis, enteroviral herpangina is not associated with gingivitis.

- **Acute hemorrhagic conjunctivitis**: associated with enterovirus 70 and coxsackievirus A24. Pts experience an acute onset of severe eye pain, blurred vision, photophobia, watery eye discharge, fever, and headache. Edema, chemosis, and subconjunctival hemorrhage are evident. Symptoms resolve within 10 days.
**DIAGNOSIS**

Enterovirus can be isolated from throat or rectal swabs, stool, and/or normally sterile body fluids. Stool and throat cultures may reflect colonization, but throat cultures are more likely to be associated with disease because virus is shed for shorter periods from the throat. Positive results for normally sterile body fluids, such as CSF and serum, reflect disease. Serotyping is not clinically useful. Polymerase chain reaction (PCR) detects >92% of the serotypes that infect humans. PCR of the CSF is sensitive and specific and is more rapid than culture; however, the result of PCR is less likely to be positive if pts present ≥3 days after meningitis onset. In those cases, PCR of fecal specimens, although less specific, should be considered. PCR of the serum is also useful in disseminated disease. Tests are more likely to be positive early in disease.

**PREVENTION**

Hand hygiene, use of gowns and gloves, and enteric precautions (for 7 days after disease onset) prevent nosocomial transmission of enteroviruses during epidemics. The availability of poliovirus vaccines and the implementation of polio eradication programs have largely eliminated disease due to wild-type poliovirus; of 1959 cases in 2006, ~90% were from Nigeria and India. Outbreaks and sporadic disease due to vaccine-derived poliovirus occur. Both oral poliovirus vaccine (OPV) and inactivated poliovirus vaccine (IPV) induce IgG and IgA antibodies that persist for at least 5 years. OPV causes less viral shedding, reduces the risk of community transmission of wild-type virus, costs less, and is easier to administer than IPV. Most developing countries, particularly those with persistent wild-type poliomyelitis, use OPV. Developed countries without wild-type disease but with cases of vaccine-associated polio have adopted all-IPV childhood vaccination programs. Doses are given at 2, 4, and 6–18 months and at 4–6 years of age. Unvaccinated adults in the United States do not need routine poliovirus vaccination but should receive three doses of IPV (the second dose 1–2 months after the first and the final dose 6–12 months later) if they are traveling to polioendemic areas or might be exposed to wild-type poliovirus in their communities or workplaces. Adults at increased risk of exposure who have received their primary vaccination series should receive a single dose of IPV.

For a more detailed discussion, see Cohen JI: Enteroviruses and Reoviruses, Chap. 184, p. 1208, in HPIM-17.
Infectious Diseases

SECTION 7

Insect- and Animal-Borne Viral Infections

RABIES

Rabies is a zoonosis generally transmitted to humans by the bite of a rabid animal and caused by rabies virus: a rodlike, enveloped, single-stranded RNA virus in the family Rhabdoviridae of the genus Lyssavirus. Each animal reservoir harbors distinct rabies virus variants.

Epidemiology Worldwide, canine rabies causes ~55,000 human deaths each year, most in Asia and Africa. In North America, bats, raccoons, skunks, and foxes carry endemic rabies. Bats cause the most human cases in the United States; rabies can be transmitted by minor or unrecognized bat bites.

Pathogenesis The incubation period varies from 2 weeks to >1 year (mean, 1–3 months). During most of this period, rabies virus is present at or close to the site of the bite. Virus replicates at the inoculation site and spreads to peripheral nerves and then to the central nervous system (CNS), dispersing rapidly throughout the gray matter. Establishment of CNS infection is followed by centrifugal spread along peripheral nerves to other tissues, including salivary glands—hence the excretion of virus in the saliva of rabid animals. The most characteristic pathologic CNS finding is the Negri body—an eosinophilic cytoplasmic inclusion that is found within neurons and is composed of rabies virus particles in an amorphous matrix.

Clinical Features Rabies has the highest case-fatality rate of any infectious disease. Clinical rabies can be divided into three phases.

- **Prodrome** (1–7 days): Pts have fever, headache, malaise, nausea, vomiting, and anxiety or agitation. Paresthesia and/or fasciculations at or near the site of viral inoculation are found in 50–80% of cases and are suggestive of rabies.
- **Acute neurologic phase**: presents as the encephalitic (furious) form in 80% of cases and as the paralytic form in 20%
  - **Encephalitic form** (1–7 days): Pts develop fever, confusion, hallucinations, combative ness, muscle spasms, hyperactivity, and seizures. Autonomic dysfunction is common and includes hypersalivation, excessive perspiration, pupillary dilation, gooseflesh, and/or priapism. Prominent early brainstem dysfunction distinguishes rabies from other viral encephalitides. Hydrophobia and aerophobia occur as a consequence of involuntary, painful contraction of the diaphragm and the accessory respiratory, laryngeal, and pharyngeal muscles in response to swallowing liquid or air. Hypersalivation and pharyngeal dysfunction produce characteristic foaming at the mouth.
  - **Paralytic form** (2–10 days): For unknown reasons, muscle weakness predominates but cardinal features of rabies encephalitis are lacking.
- **Coma and death** (1–14 days): Even with aggressive supportive measures, recovery is rare.

Diagnosis

- Examination of cerebrospinal fluid (CSF) can show a mild pleocytosis and a slightly increased protein level.
• Rabies virus–specific antibodies may be detected in serum and CSF a few days after symptom onset, but pts may die without detectable antibodies. Rabies virus–specific antibodies in the CSF suggest rabies regardless of immunization status.

• Reverse-transcription polymerase chain reaction (RT-PCR) can detect virus in fresh saliva, CSF, and tissue. RT-PCR can also distinguish among rabies virus variants and may indicate the likely source of infection.

• Direct fluorescent antibody (DFA) testing: DFA testing is sensitive and specific and can be applied to brain tissue or skin biopsies from the nape of the neck (where virus is found in cutaneous nerves at the base of hair follicles).

• Differential diagnosis: Other viral encephalitides [e.g., those due to herpes simplex virus (HSV) type 1, varicella-zoster virus, and enteroviruses as well as arboviruses] should be considered.

Rabies

Treatment is palliative and supportive. There is no established treatment for rabies.

Prevention

• Rabies is almost uniformly fatal but is nearly always preventable with appropriate postexposure prophylaxis during the incubation period.

• The wound should be thoroughly scrubbed with soap and flushed with water; these measures can reduce the risk of rabies by 90%.

• Postexposure prophylaxis (PEP; Fig. 111-1)

  Passive immunization with rabies immune globulin (RIG): RIG should be given to previously unvaccinated persons as soon as possible but no later than 7 days after the first vaccine dose (see below). If possible, the full dose of RIG (20 IU/kg) should be infused at the bite site; any residual RIG should be given IM at a distant site.

  Inactivated rabies vaccine should be given as soon as possible (1 mL IM in the deltoid region) and repeated on days 3, 7, 14, and 28.

• Preexposure prophylaxis is occasionally given to persons at high risk. A primary vaccine schedule is given on days 0, 7, and 21 or 28. Serum neutralizing antibody titers can be monitored to determine the need for booster doses of vaccine.

INFECTIONS CAUSED BY ARTHROPOD- AND RODENT-BORNE VIRUSES

More than 500 distinct RNA viruses are maintained in arthropods or chronically infected rodents. Arthropod-borne viruses infect their vector after a blood meal from a viremic vertebrate; the viruses penetrate the gut and spread throughout the vector; when in the salivary glands, they can be transmitted to another vertebrate during a blood meal. The rodent-borne viruses cause chronic infections transmitted between rodents. Humans become infected by inhalation of aerosols containing the viruses and through close contact with rodents and their excreta. These infections are most common in the tropics but also occur in temperate and frigid climates.

Clinical Features Infection usually causes one of four major clinical syndromes: fever and myalgia, encephalitis, arthritis and rash, or hemorrhagic fever (HF).
Fever and Myalgia This is the most common syndrome associated with these viruses. Typically, pts have an acute onset of fever, severe myalgia, and headache. Complete recovery is usual. Important examples include the following.

- **Lymphocytic choriomeningitis (LCM):** This infection is transmitted from the common house mouse and pet hamsters via aerosols of excreta and secreta. Unlike other viral infections that cause fever and myalgia, LCM has a gradual onset. Other manifestations include transient alopecia, arthritis, cough, maculopapular rash, and orchitis. About one-fourth of infected pts have a biphasic illness. After a 3- to 6-day febrile phase, there is a remission followed by recurrent fever, headache, nausea, vomiting, and meningeal signs lasting ~1 week. Pregnant women can have mild infection yet pass on the virus to the fetus, who can develop hydrocephalus and chorioretinitis. The diagnosis should be considered in adult pts who have aseptic meningitis in the autumn months and who have had a febrile prodrome. CSF examination reveals
mononuclear cell counts that can exceed 1000/μL and low glucose levels. Marked leukopenia and thrombocytopenia are common. Recovery of LCM virus from blood or CSF is most likely in the initial phase of illness. Diagnosis can be made by IgM-capture enzyme-linked immunosorbent assay (ELISA) of serum or CSF or by RT-PCR of CSF (if this test is available).

- **Dengue fever**: The vector of all four distinct dengue viruses (serotypes 1–4) is *Aedes aegypti*, which is also a vector for yellow fever. A second infection with a different dengue serotype can lead to dengue hemorrhagic fever (DHF; see “Hemorrhagic Fever,” below). Year-round transmission occurs between latitudes 25°N and 25°S. After an incubation period of 2–7 days, pts experience the sudden onset of fever, headache, retroorbital pain, back pain, severe myalgia (break-bone fever), adenopathy, palatal vesicles, and scleral injection. The illness usually lasts 1 week, and a maculopapular rash often appears near the time of defervescence. Epistaxis, petechiae, and GI bleeding may occur. Leukopenia, thrombocytopenia, and increased serum aminotransferase levels may be documented. IgM ELISA, antigen-detection ELISA, or RT-PCR during the acute phase permits the diagnosis. Virus is easily isolated from blood during the acute phase.

**Encephalitis** Depending on the causative virus, there is much variability in the ratio of clinical to subclinical disease, mortality, and residua (Table 111-1). The pt usually presents with a prodrome of nonspecific symptoms followed quickly by headache, meningeal signs, photophobia, and vomiting. Complications include deepening lethargy and ultimately coma, tremors, cranial nerve palsies, and focal neurologic signs and seizures. Acute encephalitis usually lasts from a few days to 2–3 weeks, but recovery may be slow. Treatable causes of encephalitis (e.g., HSV) should be ruled out quickly. Many viruses cause arboviral encephalitis. Some important examples follow.

- **Japanese encephalitis**: This infection is present throughout Asia and is occasionally found in the western Pacific islands. An effective vaccine (given on days 0, 7, and 30) is available and is indicated for summer travelers to rural Asia, where the risk can be as high as 2.1 cases per 10,000 per week. Expatriates have an especially high risk of severe and often fatal disease. There is a 0.1–1% chance of a vaccine reaction (which may be severe but is rarely fatal) beginning 1–9 days after vaccination. Spinal and motor neuron disease can be documented in addition to the encephalitis.

- **West Nile encephalitis**: Usually a mild or asymptomatic disease, West Nile virus infection can cause aseptic meningitis or encephalitis. Introduced into New York City in 1999, it has now spread throughout the United States. Encephalitis, serious sequelae, and death are more common among elderly pts, diabetic pts, and pts with previous CNS disease. Unusual clinical features include chorioretinitis and flaccid paralysis.

- **Eastern equine encephalitis**: This disease is found primarily within endemic swampy foci along the eastern coast of the United States, with inland foci as distant as Michigan. It is most common in the summer and early fall. One of the most severe arboviral conditions, eastern equine encephalitis is characterized by rapid onset, rapid progression, high mortality risk, and frequent residua. Necrotic lesions and polymorphonuclear leukocyte (PMN) infiltrates are found in the brain at autopsy. PMN-predominant pleocytosis of the CSF within the first 3 days of disease is common, as is leukocytosis with a left shift in peripheral blood.

**Arthritis and Rash** Arboviruses are common causes of true arthritis accompanied by a febrile illness and maculopapular rash. Examples include the following:
• *Sindbis virus*: found in northern Europe and the independent states of the former Soviet Union

• *Chikungunya virus*: of African origin. In a massive epidemic in 2004 in the Indian Ocean region, the disease appeared to be spread solely by travelers.

• *Ross River virus*: a cause of epidemic polyarthritis in Australia since the start of the twentieth century

**Hemorrhagic Fever** The viral HF syndrome is a constellation of findings based on vascular instability and decreased vascular integrity. Pts develop local hemorrhage, hypotension, and—in severe cases—shock. All HF syndromes begin with the abrupt onset of fever and myalgia and can progress to severe prostration, headache, dizziness, photophobia, abdominal and/or chest pain, anorexia, and GI disturbances. On initial physical examination, there is conjunctival suffusion, muscle or abdominal tenderness to palpation, hypotension, petechiae, and periorbital edema. Laboratory examination usually reveals elevated serum aminotrans-
Insect- and Animal-Borne Viral Infections

CHAPTER 111

ferase levels, proteinuria, and hemoconcentration. Shock, multifocal bleeding, and CNS involvement (encephalopathy, coma, convulsions) are poor prognostic signs. Early recognition is important; appropriate supportive measures and, in some cases, virus-specific therapy can be instituted.

- **Lassa fever**: Endemic and epidemic in West Africa, Lassa fever virus is spread to humans by aerosols from chronically infected rodents. Transmission by close person-to-person contact can occur. A gradual onset gives way to more severe constitutional symptoms and prostration. Bleeding is evident in 15–30% of cases. CNS dysfunction is marked by confusion, tremors of the upper extremity and tongue, and cerebellar signs; effusions, including pericarditis in men, are common. Pregnant women have higher mortality rates, and the fetal death rate is 92% in the last trimester. Pts who are pregnant should consider termination of the pregnancy. Pts with high-level viremia or a serum aspartate aminotransferase level of >150 IU/mL are at an

<table>
<thead>
<tr>
<th>Case-to-Infection Ratio</th>
<th>Age of Cases</th>
<th>Case-Fatality Rate, %</th>
<th>Residua</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1:1000</td>
<td>&lt;15 years</td>
<td>&lt;0.5</td>
<td>Recurrent seizures in ~10%; severe deficits in rare cases; decreased school performance and behavioral change suspected in small proportion</td>
</tr>
<tr>
<td>&lt;1:200</td>
<td>Milder cases in the young; more severe cases in adults &gt;40 years old, particularly the elderly</td>
<td>7</td>
<td>Common in the elderly</td>
</tr>
<tr>
<td>1:200–300</td>
<td>All ages; children in highly endemic areas</td>
<td>20–50</td>
<td>Common (approximately half of cases); may be severe</td>
</tr>
<tr>
<td>Very low</td>
<td>Mainly the elderly</td>
<td>5–10</td>
<td>Uncommon</td>
</tr>
<tr>
<td>1:12</td>
<td>All ages; milder in children</td>
<td>1–5</td>
<td>20%</td>
</tr>
<tr>
<td>—</td>
<td>All ages; milder in children</td>
<td>20</td>
<td>Approximately half of cases; often severe; limb-girdle paralysis</td>
</tr>
<tr>
<td>—</td>
<td>All ages; some predilection for children</td>
<td>~10</td>
<td>Common (approximately half of cases)</td>
</tr>
<tr>
<td>1:40 adult</td>
<td>All ages; predilection for children</td>
<td>50–75</td>
<td>Common</td>
</tr>
<tr>
<td>1:17 child</td>
<td>All ages; predilection for children &lt;2 years old (increased mortality in elderly)</td>
<td>3–7</td>
<td>Common only among infants &lt;1 year old</td>
</tr>
<tr>
<td>1:1000 adult</td>
<td>All ages; predilection for children</td>
<td>~10</td>
<td>—</td>
</tr>
<tr>
<td>1:50 child</td>
<td>All ages; predilection for children</td>
<td>~10</td>
<td>—</td>
</tr>
<tr>
<td>1:1 infant</td>
<td>All ages; predilection for children</td>
<td>~10</td>
<td>—</td>
</tr>
<tr>
<td>1:250 adult</td>
<td>All ages; predilection for children</td>
<td>~10</td>
<td>—</td>
</tr>
<tr>
<td>1:25 child (approximate)</td>
<td>All ages; predilection for children</td>
<td>~10</td>
<td>—</td>
</tr>
</tbody>
</table>
elevated risk of death, and the administration of ribavirin, which appears to reduce this risk, should be considered. Ribavirin is given by slow IV infusion; an initial dose of 32 mg/kg is followed by 16 mg/kg every 6 h for 4 days and then by 8 mg/kg every 8 h for 6 days.

- **South American HF syndromes** (Argentine, Bolivian, Venezuelan, Brazilian): These syndromes resemble Lassa fever; however, thrombocytopenia and bleeding are common, whereas CNS dysfunction is not. Passive antibody treatment for Argentine HF is effective, and an effective vaccine exists. Ribavirin is likely to be effective in all South American HF syndromes.

- **Rift Valley fever**: Although Rift Valley virus typically causes fever and myalgia, HF can occur with prominent liver involvement, renal failure, and disseminated intravascular coagulation (DIC). Retinal vasculitis can occur in ~10% of infections, and pts’ vision can be permanently impaired. There is no proven therapy for Rift Valley fever.

- **Crimean-Congo HF**: This disease is similar to other HF syndromes but causes extensive liver damage and jaundice. Ribavirin should be given in severe cases.

- **HF with renal syndrome**
  This entity is most often caused in Europe by Puumala virus (rodent reservoir, the bank vole) and in Asia by Hantaan virus (rodent reservoir, the striped field mouse). More than 100,000 cases of severe disease occur annually in endemic areas of Asia. Severe classic Hantaan disease has four stages.
  - **Febrile stage**: abrupt onset of fever, headache, myalgia, thirst
  - **Hypotensive stage**: falling blood pressure; relative bradycardia; laboratory findings including leukocytosis with a left shift, atypical lymphocytosis, proteinuria, vascular leakage causing hemoconcentration, and renal tubular necrosis
  - **Oliguric stage**: continuing hemorrhage; oliguria persisting for 3–10 days before renal function returns
  - **Polyuric stage**: As renal function returns, there is a danger of dehydration and electrolyte abnormalities.

  The diagnosis can be made by IgM-capture ELISA, which should yield a positive result within 48 h of admission. RT-PCR of a blood clot gives a positive result early in the clinical course.

  Treatment: Expectant management of shock and renal failure is crucial. Ribavirin may reduce mortality and morbidity in severe cases if treatment is begun within the first 4 days of illness.

- **Hantavirus pulmonary syndrome** (HPS): The disease is linked to rodent exposure and particularly affects rural residents in dwellings permeable to rodent entry. Sin Nombre virus infects the deer mouse and is the most important virus causing HPS in the United States.
  - **Clinical findings**
    - **Prodrome** (3–4 days; range, 1–11 days): fever, myalgia, dizziness, vertigo, malaise, nausea, vomiting, abdominal pain
    - **Cardiopulmonary phase**: tachycardia, hypotension, tachypnea, early signs of pulmonary edema
    - **Final phase**: rapid decompensation with hypoxemia, respiratory failure, low cardiac output, myocardial depression, increased pulmonary vascular permeability, shock

  Laboratory findings include thrombocytopenia (an important early clue), atypical lymphocytes, and a left shift, often with leukocytosis; hemoconcentration; hypoalbuminemia; and proteinuria. IgM testing of acute-phase serum can yield positive results, even during the prodromal stage.
RT-PCR of blood clots or tissue usually gives a positive result in the first 7–9 days of illness.

Treatment: Intensive respiratory management and other supportive measures are crucial in the first few hours after presentation. Shock should be managed with pressor agents and modest amounts of fluid.

Prognosis: Most pts who survive for 48 h recover without residua. Mortality rates are ~30–40% despite optimal management.

- **Yellow fever**: Yellow fever is a former cause of major epidemics. Hundreds of cases in South America and thousands of cases in Africa still occur. Yellow fever causes a typical HF syndrome with prominent hepatic necrosis. Pts are viremic for 3–4 days and can have jaundice, hemorrhage, black vomit, anuria, and terminal delirium. Vaccination of visitors to endemic areas and control of the mosquito vector *A. aegypti* prevent disease.

- **Dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS)**: Previous infection with a heterologous dengue virus serotype may elicit nonprotective antibodies and enhanced disease if pts are reinfected. The risk decreases considerably after age 12; DHF/DSS is more common among females than among males, more severe among Caucasians than among blacks, and more common among well-nourished than among malnourished persons. DHF is marked by bleeding tendencies. DSS is more serious because of vascular permeability leading to shock. In mild cases, lethargy, thrombocytopenia, and hemoconcentration occur 2–5 days after typical dengue fever, usually at the time of defervescence. In severe cases, frank shock occurs with cyanosis, hepatomegaly, ascites and pleural effusions, and GI bleeding. Shock lasts for 1–2 days and usually responds to supportive measures. With good care, the overall mortality rate is as low as 1%. Control of *A. aegypti*, the mosquito vector, is the key to control of the disease.

## EBOLA AND MARBURG VIRUS INFECTIONS

**Etiology**  
Marburg and Ebola viruses are two distinct single-stranded RNA viruses of the family Filoviridae. Almost all Filoviridae are African viruses that cause severe disease with high mortality rates. Both Marburg virus and Ebola virus are biosafety level 4 pathogens because of the high mortality rate from infection and the aerosol infectivity of the agents.

**Epidemiology**  
The first human cases of Marburg virus infection occurred in laboratory workers exposed to infected African green monkeys from Uganda. In 2004–2005, a massive Marburg virus epidemic occurred in Angola, with a case-fatality rate of 90%. Ebola virus has been associated with epidemics of severe HF. The first two epidemics were due to different subtypes: Zaire, with 90% mortality, and Sudan, with 50% mortality. Interhuman spread was noted. However, epidemiologic studies have failed to yield evidence for an important role (like that documented in Ebola disease in monkeys) of airborne particles in human Ebola disease. The reservoir is unknown, but speculation currently centers on bats.

**Pathogenesis**  
Both viruses replicate well in virtually all cell types, and viral replication is associated with cellular necrosis. Acute infection is associated with high levels of circulating virus and viral antigen until antibody development, evidence of which is usually lacking in fatal cases. Virions are abundant in fibroblasts, interstitium, and SC tissues and may escape through breaks in the skin or through sweat glands—a potential scenario that may be correlated with the risk of transmission through close pt contact or by touching of deceased pts. High levels of circulating proinflammatory cytokines contribute to disease severity.
**Clinical Features**  After a 7- to 10-day incubation period, pts experience an abrupt onset of fever, headache, severe myalgia, nausea, vomiting, diarrhea, prostration, and depressed mentation. A maculopapular rash may appear at day 5–7 and be followed by desquamation. Bleeding can occur from any mucosal site and into the skin. The fever may break after 10–12 days, and the pt may eventually recover. Recrudescence and secondary bacterial infection may occur.

**Laboratory Findings**  Leukopenia is common early on and is followed by neutrophilia. Thrombocytopenia, DIC, and increases in serum aminotransferase and amylase levels can develop. Proteinuria and renal failure are proportional to shock.

**Diagnosis**  High concentrations of virus in blood can be documented by antigen detection ELISA, virus isolation, or RT-PCR. Antibodies can be detected in recovering pts.

---

**Ebola and Marburg Virus Infections**

Supportive measures may not be as useful as had been hoped, but studies in rhesus monkeys suggest that treatment with an inhibitor of factor VIIa/tissue factor or with activated protein C may improve survival rates.

---

**112 HIV Infection and AIDS**

**DEFINITION**

AIDS was originally defined empirically by the Centers for Disease Control and Prevention (CDC) as "the presence of a reliably diagnosed disease that is at least moderately indicative of an underlying defect in cell-mediated immunity." Following the recognition of the causative virus, HIV, and the development of sensitive and specific tests for HIV infection, the definition of AIDS has undergone substantial revision. The current surveillance definition categorizes HIV-infected persons on the basis of clinical conditions associated with HIV infection and CD4+T lymphocyte counts (Tables 182-1 and 182-2, p. 1138, in HPIM-17). From a practical standpoint, the clinician should view HIV disease as a spectrum of disorders ranging from primary infection, with or without the acute HIV syndrome, to the asymptomatic infected state to advanced disease.

**ETIOLOGY**

AIDS is caused by infection with the human retroviruses HIV-1 or -2. HIV-1 is the most common cause worldwide; HIV-2 has about 40% sequence homology
with HIV-1, is more closely related to simian immunodeficiency viruses, and has been identified predominantly in western Africa. HIV-2 infection has also been reported in Europe, South America, Canada, the United States, and elsewhere. These viruses are passed through sexual contact; through transfusion of contaminated blood or blood products, through sharing of contaminated needles and syringes among injection drug abusers; intrapartum or perinatally from mother to infant; or via breast milk. There is no evidence that the virus can be passed through casual or family contact or by insects such as mosquitoes. There is a definite, though small, occupational risk of infection for health care workers and laboratory personnel who work with HIV-infected specimens. The risk of transmission of HIV from an infected health care worker to his or her pts through invasive procedures is extremely low.

**Epidemiology**

Through 2006, an estimated 982,498 cumulative cases of AIDS had been diagnosed in the United States; ~56% of those have died. However, the death rate from AIDS has decreased substantially in the past 10 years primarily due to the increased use of potent antiretroviral drugs. At the end of 2003, an estimated 1.0–1.2 million HIV-infected persons were living in the United States. Major risk groups continue to be men who have had sex with men and men and women injection drug users (IDUs). However, the number of cases that are transmitted heterosexually, particularly to women, is increasing rapidly (see Figs. 182-8, p. 1143; 182-14 through 182-16, pp. 1148 and 1149, in HPIM-17). As the majority of IDU-associated cases are among inner-city minority populations, the burden of HIV infection and AIDS falls increasingly and disproportionately on minorities, especially in the cities of the northeast and southeast United States. Cases of AIDS are still being found among individuals who have received contaminated blood products in the past, although the risk of acquiring new infection through this route is extremely small in the United States. HIV infection/AIDS is a global pandemic, especially in developing countries. The current estimate of the number of cases of HIV infection worldwide is ~33.2 million, two-thirds of whom are in sub-Saharan Africa; ~50% of cases are in women (Figs. 182-7, p. 1142; 182-9, p. 1143; 182-11 through 182-13, pp. 1147 and 1148, in HPIM-17).

**Pathophysiology and Immunopathogenesis**

The hallmark of HIV disease is a profound immunodeficiency resulting from a progressive quantitative and qualitative deficiency of the subset of T lymphocytes referred to as helper or inducer T cells. This subset of T cells is defined phenotypically by the expression on the cell surface of the CD4 molecule, which serves as the primary cellular receptor for HIV. A co-receptor must be present with CD4 for efficient entry of HIV-1 into target cells. The two major co-receptors for HIV-1 are the chemokine receptors CCR5 and CXCR4. Although the CD4+ T lymphocyte and CD4+ monocyte lineage are the principal cellular targets of HIV, virtually any cell that expresses CD4 along with one of the co-receptors can potentially be infected by HIV; however, viral replication is not efficient in these other cell types.

**Primary Infection** Following initial transmission, the virus infects CD4+ cells, probably T lymphocytes, monocytes, or bone marrow-derived dendritic cells. Both during this initial stage and later in infection, the lymphoid system is a major site for the establishment and propagation of HIV infection. The gut-associated lymphoid tissue (GALT) plays a major role in the establishment of infection and in the early depletion of memory CD4+ T cells.
Essentially all pts undergo a viremic stage during primary infection; in some pts this is associated with the "acute retroviral syndrome," a mononucleosis-like illness (see below). This phase is important in disseminating virus to lymphoid and other organs throughout the body, and it is ultimately contained partially by the development of an HIV-specific immune response.

**Establishment of Chronic and Persistent Infection** Despite the robust immune response that is mounted following primary infection, the virus is not cleared from the body. Instead, a chronic infection develops that persists for a median time of 10 years before the untreated patient becomes clinically ill. During this period of clinical latency, the number of CD4+ T cells gradually declines but few, if any, clinical signs and symptoms may be evident; however, active viral replication can almost always be detected by measurable plasma viremia and the demonstration of virus replication in lymphoid tissue. The level of steady-state viremia (referred to as the *viral set point*) at ~6 months to 1 year postinfection has important prognostic implications for the progression of HIV disease; individuals with a low viral set point at 6 months to 1 year after infection progress to AIDS more slowly than those whose set point is very high at this time (see Fig. 182-20, p. 1152, in HPIM-17).

**Advanced HIV Disease** In untreated pts or in pts in whom therapy has not controlled viral replication (see below), after some period of time (often years), CD4+ T cell counts will fall below a critical level (~200/μL) and pts become highly susceptible to opportunistic disease. The presence of a CD4+ T cell count of <200/μL or an AIDS-defining opportunistic disease establishes a diagnosis of AIDS. Control of plasma viremia by effective antiretroviral therapy, particularly maintaining the plasma viral load at <50 copies of RNA per ml, even in individuals with low CD4+ T cell counts, has increased survival in these pts, including those whose CD4+ T cell counts may not increase significantly as a result of therapy.

**IMMUNE ABNORMALITIES IN HIV DISEASE**
A broad range of immune abnormalities has been documented in HIV-infected pts resulting in varying degrees of immunodeficiency. These include both quantitative and qualitative defects in lymphocyte, monocyte/macrophage, and natural killer (NK) cell function. Autoimmune phenomena have also been observed in HIV-infected individuals.

**IMMUNE RESPONSE TO HIV INFECTION**
Both humoral and cellular immune responses to HIV develop soon after primary infection (see summary in Table 182-5, p. 1163, and Fig. 182-24, p. 1163, in HPIM-17). Humoral responses include antibodies with HIV binding and neutralizing activity, as well as antibodies participating in antibody-dependent cellular cytotoxicity (ADCC). Cellular immune responses include the generation of HIV-specific CD4+ and CD8+ T lymphocytes, as well as NK cells and mononuclear cells mediating ADCC. CD8+ T lymphocytes may also suppress HIV replication in a noncytolytic, non-MHC restricted manner. This effect is mediated by soluble factors such as the CC-chemokines RANTES, MIP-1α, and MIP-1β. For the most part, the natural immune response to HIV is not adequate. Broadly reacting neutralizing antibodies against HIV are not easily generated in infected individuals, and eradication of the virus from infected individuals by naturally occurring immune responses has not been reported.
HIV Infection and AIDS

CHAPTER 112

DIAGNOSIS OF HIV INFECTION

Laboratory diagnosis of HIV infection depends on the demonstration of anti-HIV antibodies and/or the detection of HIV or one of its components.

The standard screening test for HIV infection is the detection of anti-HIV antibodies using an enzyme immunoassay (EIA). This test is highly sensitive (>99.5%) and is quite specific. Most commercial EIA kits are able to detect antibodies to both HIV-1 and -2. Western blot is the most commonly used confirmatory test and detects antibodies to HIV antigens of specific molecular weights. Antibodies to HIV begin to appear within 2 weeks of infection, and the period of time between initial infection and the development of detectable antibodies is rarely >3 months. The HIV p24 antigen can be measured using an EIA-type capture assay. Plasma p24 antigen levels rise during the first few weeks following infection, prior to the appearance of anti-HIV antibodies. A guideline for the use of these serologic tests in the diagnosis of HIV infection is depicted in Fig. 112-1.

HIV can be cultured directly from tissue, peripheral blood cells, or plasma, but this is most commonly done in a research setting. HIV genetic material can be detected using reverse transcriptase PCR (RT-PCR), branched DNA (bDNA), or nucleic acid sequence–based assay (NASBA). These tests are useful in pts with a positive or indeterminate EIA and an indeterminate Western blot, as may be seen early in infection, or in pts in whom serologic testing may be unreliable (such as those with hypogammaglobulinemia).

LABORATORY MONITORING OF PATIENTS WITH HIV INFECTION

Measurement of the CD4+ T cell count and level of plasma HIV RNA are important parts of the routine evaluation and monitoring of HIV-infected individuals. The CD4+ T cell count is a generally accepted indicator of the immunologic competence of the pt with HIV infection, and there is a close relationship between the CD4+ T cell count and the clinical manifestations of

![FIGURE 112-1](image-url)
AIDS (Fig. 182-29, p. 1168, in HPIM-17). Pts with CD4+ T cell counts < 200/μL are at higher risk of infection with *Pneumocystis jiroveci*, while pts with CD4+ T cell counts < 50/μL are at higher risk for developing CMV disease and infection with *Mycobacterium avium intracellulare*. Pts should have the CD4+ T cell count measured at the time of diagnosis and every 3–6 months thereafter (measurements may be done more frequently in pts with declining counts). According to most practice guidelines, a CD4+ T cell count < 350/μL is an indication to initiate antiretroviral therapy. While the CD4+ T cell count provides information on the current immunologic status of the pt, the HIV RNA level predicts what will happen to the CD4+ T cell count in the near future and hence reflects the clinical prognosis. Measurements of plasma HIV RNA levels should be made at the time of HIV diagnosis and every 3–4 months thereafter in the untreated pt. Measurement of plasma HIV RNA is also useful in making therapeutic decisions about antiretroviral therapy (see below). Following the initiation of therapy or any change in therapy, HIV RNA levels should be monitored approximately every 4 weeks until the effectiveness of the therapeutic regimen is determined by the development of a new steady-state level of HIV RNA. During therapy, levels of HIV RNA should be monitored every 3–4 months to evaluate the continuing effectiveness of therapy.

The sensitivity of an individual’s HIV virus(es) to different antiretroviral agents can be tested by either genotypic or phenotypic assays. In the hands of experts, the use of resistance testing to select a new antiretroviral regimen in patients failing their current regimen leads to a ~0.5-log greater decline in viral load compared to the efficacy of regimens selected solely on the basis of drug history. HIV resistance testing may also be of value in selecting an initial treatment regimen in geographic areas with a high prevalence of baseline resistance.

### CLINICAL MANIFESTATIONS OF HIV INFECTION

A complete discussion is beyond the scope of this chapter. The major clinical features of the various stages of HIV infection are summarized below (see also Chap. 182, HPIM-17).

**Acute HIV (Retroviral) Syndrome** Approximately 50–70% of infected individuals experience an acute syndrome following primary infection. The acute syndrome follows infection by 3–6 weeks. It can have multiple clinical features (Table 112-1), lasts 1–2 weeks, and resolves spontaneously as an immune response to HIV develops and the viral load diminishes from its peak levels. Most pts will then enter a phase of clinical latency, although an occasional pt will experience rapidly progressive immunologic and clinical deterioration.

### TABLE 112-1 CLINICAL FINDINGS IN THE ACUTE HIV SYNDROME

<table>
<thead>
<tr>
<th>General</th>
<th>Neurologic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>Meningitis</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>Encephalitis</td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>Peripheral neuropathy</td>
</tr>
<tr>
<td>Headache/retroorbital pain</td>
<td>Myelopathy</td>
</tr>
<tr>
<td>Arthralgias/myalgias</td>
<td>Dermatologic</td>
</tr>
<tr>
<td>Lethargy/malaise</td>
<td>Erythematous maculopapular rash</td>
</tr>
<tr>
<td>Anorexia/weight loss</td>
<td>Mucocutaneous ulceration</td>
</tr>
<tr>
<td>Nausea/vomiting/diarrhea</td>
<td></td>
</tr>
</tbody>
</table>

Asymptomatic Infection The length of time between HIV infection and development of disease varies greatly, but the median is estimated to be 10 years in untreated individuals. HIV disease with active viral replication usually progresses during this asymptomatic period, and CD4+ T cell counts fall. The rate of disease progression is directly correlated with plasma HIV RNA levels. Pts with high levels of HIV RNA progress to symptomatic disease faster than do those with low levels of HIV RNA.

Symptomatic Disease Symptoms of HIV disease can develop at any time during the course of HIV infection. In general, the spectrum of illness changes as the CD4+ T cell count declines. The more severe and life-threatening complications of HIV infection occur in patients with a CD4+ T cell count < 200/μl. Overall, the clinical spectrum of HIV disease is constantly changing as pts live longer and new and better approaches to treatment and prophylaxis of opportunistic infections are developed. In addition, a variety of neurologic, cardiovascular, and hepatic problems are increasingly seen in pts with HIV infection and may be a direct consequence of HIV infection. The key element to treating symptomatic complications of HIV disease, whether primary or secondary, is achieving good control of HIV replication through the use of combination antiretroviral therapy and instituting primary and secondary prophylaxis as indicated. Major clinical syndromes seen in the symptomatic stage of HIV infection are summarized below.

- **Persistent generalized lymphadenopathy**: Palpable adenopathy at two or more extranginal sites that persists for >3 months without explanation other than HIV infection. Many pts will go on to disease progression.
- ** Constitutional symptoms**: Fever persisting for >1 month, involuntary weight loss of >10% of baseline, diarrhea for >1 month in absence of explainable cause.
- **Neurologic disease**: Most common is HIV encephalopathy (AIDS dementia complex); other neurologic complications include opportunistic infections, primary CNS lymphoma, CNS Kaposi’s sarcoma, aseptic meningitis, myelopathy, peripheral neuropathy, and myopathy.
- **Secondary infectious diseases**: *P. jiroveci* pneumonia is most common opportunistic infection, occurring in ~80% of untreated individuals during the course of their illness. Other common pathogens include CMV (chorioretinitis, colitis, pneumonitis, adrenalitis), *Candida albicans* (oral thrush, esophagitis), *M. avium intracellulare* (localized or disseminated infection), *M. tuberculosis*, *Cryptococcus neoformans* (meningitis, disseminated disease), *Toxoplasma gondii* (encephalitis, intracerebral mass lesion), herpes simplex virus (severe mucocutaneous lesions, esophagitis), diarrhea due to *Cryptosporidium* spp. or *Isospora belli*, bacterial pathogens (especially in pediatric cases).
- **Secondary neoplasms**: Kaposi’s sarcoma (cutaneous and visceral, more fulminant course than in non-HIV-infected pts), lymphoid neoplasms (especially B cell lymphomas of brain, marrow, GI tract).
- **Other diseases**: A variety of organ-specific syndromes can be seen in HIV-infected pts, either as primary manifestations of the HIV infection or as complications of treatment.

General principles of pt management include counseling, psychosocial support, and screening for infections and other conditions and require comprehensive knowledge of the disease processes associated with HIV infection.
ANTIRETROVIRAL THERAPY  (See Table 112-2)
The cornerstone of medical management of HIV infection is highly active combination antiretroviral therapy, or HAART. Suppression of HIV replication is an important component in prolonging life as well as in improving the quality of life of pts with HIV infection. However, several important questions related to the treatment of HIV disease lack definitive answers. Among them are questions of when antiretroviral therapy should be started, what is the best HAART regimen, when should a given regimen be changed, and what drugs in a regimen should be changed when a change is made. The drugs that are currently licensed for the treatment of HIV infection are listed in Table 112-2. These drugs fall into four main categories: those that inhibit the viral reverse transcriptase enzyme, those that inhibit the viral protease enzyme, those that inhibit viral entry, and those that inhibit the viral integrase. There are numerous drug-drug interactions that must be taken into consideration when using these medications. One of the main problems that has been encountered with the widespread use of HAART regimens has been a syndrome of hyperlipidemia and fat redistribution often referred to as lipodystrophy syndrome (Chap. 182, HPIM-17).

Nucleoside Analogues
These agents act by causing premature DNA-chain termination during the reverse transcription of viral RNA to proviral DNA and should be used in combination with other antiretroviral agents. The most common usage is together with another nucleoside analogue and a nonnucleoside reverse transcriptase inhibitor or a protease inhibitor (see below).

Nonnucleoside Reverse Transcriptase Inhibitors
These agents interfere with the function of HIV-1 reverse transcriptase by binding to regions outside the active site and causing conformational changes in the enzyme that render it inactive. These agents are very potent; however, when they are used as monotherapy, they induce rapid emergence of drug-resistant mutants. Four members of this class, nevirapine, delavirdine, efavirenz, and etravirine are currently available for clinical use. These drugs are licensed for use in combination with other antiretrovirals.

Protease Inhibitors
These drugs are potent and selective inhibitors of the HIV-1 protease enzyme and are active in the nanomolar range. Unfortunately, as in the case of the nonnucleoside reverse transcriptase inhibitors, this potency is accompanied by the rapid emergence of resistant isolates when these drugs are used as monotherapy. Thus, the protease inhibitors should be used only in combination with other antiretroviral drugs.

HIV Entry Inhibitors
These agents act by interfering with the binding of HIV to its receptor or co-receptor or by interfering with the process of fusion. A variety of small molecules that bind to HIV-1 co-receptors are currently in clinical trials. The first drugs in this class to be licensed are the fusion inhibitor enfuvirtide and the entry inhibitor maraviroc.

HIV Integrase Inhibitors
These drugs interfere with the integration of proviral DNA into the host cell genome. The first agent in this class, raltegravir, was approved in 2007 for use in treatment-experienced patients.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Status</th>
<th>Indication</th>
<th>Dose in Combination</th>
<th>Supporting Data</th>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reverse Transcriptase Inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zidovudine (AZT, azidothymidine,</td>
<td>Licensed</td>
<td>Treatment of HIV infection in combination with</td>
<td>200 mg q8h or 300 mg bid</td>
<td>19 vs 1 death in original placebo-controlled trial in 281 patients with AIDS</td>
<td>Anemia, granulocytopenia, myopathy, lactic acidosis, hepatomegaly with</td>
</tr>
<tr>
<td>Retrovir, 3’azido-3’-deoxythymidine)</td>
<td></td>
<td>other antiretroviral agents</td>
<td></td>
<td>or ARC. Decreased progression to AIDS in patients with CD4+ T cell</td>
<td>steatosis, headache, nausea</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prevention of maternal-fetal HIV transmission</td>
<td></td>
<td>counts &lt;500/μL, n = 2051. In pregnant women with CD4+ T cell count ≥200/μL, AZT</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PO beginning at weeks 14–34 of gestation plus IV drug during labor and delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>plus PO AZT to infant for 6 wk decreased transmission of HIV by 67.5% (from</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>25.5% to 8.3%), n = 363</td>
<td></td>
</tr>
<tr>
<td>Didanosine (Videx, Videx EC, ddl,</td>
<td>Licensed</td>
<td>For treatment of HIV infection in combination with</td>
<td>Buffered: Requires 2 tablets to</td>
<td>Clinically superior to AZT as monotherapy in 913 patients with prior AZT therapy.</td>
<td>Pancreatitis, peripheral neuropathy, abnormalities on liver function</td>
</tr>
<tr>
<td>dideoxyinosine, 2’,3’-dideoxyinosine)</td>
<td></td>
<td>other antiretroviral agents</td>
<td>achieve adequate buffering of stomach</td>
<td>Clinically superior to AZT and comparable to AZT + ddl and AZT + ddC in 1067</td>
<td>tests, lactic acidosis, hepatomegaly with steatosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>acid; should be administered on an</td>
<td>AZT-naive patients with CD4+ T cell counts of 200–500/μL.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>empty stomach ≥60 kg: 200 mg bid</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&lt;60 kg: 125 mg bid Enteric coated:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>≥60 kg: 400 mg qd &lt; 60 kg: 250 mg qd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Status</td>
<td>Indication</td>
<td>Dose in Combination</td>
<td>Supporting Data</td>
<td>Toxicity</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>----------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>---------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>Zalcitabine (ddC, HIVID, 2′,3′-dideoxycytidine)</td>
<td>Licensed Discontinued in 2006</td>
<td>In combination with other antiretroviral agents for the treatment of HIV infection</td>
<td>0.75 mg tid</td>
<td>Clinically inferior to AZT monotherapy as initial treatment. Clinically as good as ddi in advanced patients intolerant to AZT. In combination with AZT, was clinically superior to AZT alone in patients with AIDS or CD4+ T cell count &lt;350/µL.</td>
<td>Peripheral neuropathy, pancreatitis, lactic acidosis, hepatomegaly with steatosis, oral ulcers</td>
</tr>
<tr>
<td>Stavudine (d4T, Zerit, 2′,3′-didehydro-3′,3′-dideoxythymidine)</td>
<td>Licensed</td>
<td>Treatment of HIV-infected patients in combination with other antiretroviral agents</td>
<td>≥60 kg: 40 mg bid &lt;60 kg: 30 mg bid</td>
<td>Superior to AZT with respect to changes in CD4+ T cell counts in 359 patients who had received ≥24 wk of AZT. Following 12 wk of randomization, the CD4+ T cell count had decreased in AZT-treated controls by a mean of 22/µL, while in stavudine-treated patients, it had increased by a mean of 22/µL.</td>
<td>Peripheral neuropathy, pancreatitis, lactic acidosis, hepatomegaly with steatosis, ascending neuromuscular weakness, lipodystrophy</td>
</tr>
<tr>
<td>Lamivudine (Epivir, 2′,3′-dideoxy-3′-thiacytidine, 3TC)</td>
<td>Licensed</td>
<td>In combination with other antiretroviral agents for the treatment of HIV infection</td>
<td>150 mg bid</td>
<td>Superior to AZT alone with respect to changes in CD4 counts in 495 patients who were zidovudine-naive and 477 patients who were zidovudine-experienced. Overall CD4+ T cell counts for the zidovudine group were at baseline by 24 wk, while in the group treated with zidovudine plus lamivudine, they were 10–50 cells/µL above baseline. 54% decrease in progression to AIDS/death compared to AZT alone.</td>
<td>Hepatotoxicity</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Status</td>
<td>Dosage</td>
<td>Clinical Effect</td>
<td>Side Effects</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>--------</td>
<td>--------</td>
<td>-----------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>Emtricitabine (FTC, Emtriva)</td>
<td>Licensed</td>
<td>In combination with other antiretroviral agents for the treatment of HIV infection</td>
<td>200 mg qd</td>
<td>Comparable to d4T in combination with ddI and efavirenz in 571 treatment-naive patients. Similar to 3TC in combination with AZT or d4T + NNRTI or PI in 440 patients doing well for at least 12 weeks on a 3TC regimen.</td>
<td>Hepatotoxicity</td>
</tr>
<tr>
<td>Abacavir (Ziagen)</td>
<td>Licensed</td>
<td>For treatment of HIV infection in combination with other antiretroviral agents</td>
<td>300 mg bid</td>
<td>Abacavir + AZT + 3TC equivalent to indinavir + AZT + 3TC with regard to viral load suppression (~60% in each group with &lt;400 HIV RNA copies/mL plasma) and CD4 cell increase (~100/μL in each group) at 24 weeks</td>
<td>Hypersensitivity reaction (can be fatal); fever, rash, nausea, vomiting, malaise or fatigue, and loss of appetite</td>
</tr>
<tr>
<td>Tenofovir (Viread)</td>
<td>Licensed</td>
<td>For use in combination with other antiretroviral agents when treatment is indicated</td>
<td>300 mg qd</td>
<td>Reduction of ~0.6 log in HIV-1 RNA levels when added to background regimen in treatment-experienced patients</td>
<td>Potential for renal toxicity</td>
</tr>
<tr>
<td>Delavirdine (Rescriptor)</td>
<td>Licensed</td>
<td>For use in combination with appropriate antiretrovirals when treatment is warranted</td>
<td>400 mg tid</td>
<td>Delavirdine + AZT superior to AZT alone with regard to viral load suppression at 52 weeks</td>
<td>Skin rash, abnormalities in liver function tests</td>
</tr>
<tr>
<td>Nevirapine (Viramune)</td>
<td>Licensed</td>
<td>In combination with other antiretroviral agents for treatment of progressive HIV infection</td>
<td>200 mg/d × 14 days then 200 mg bid</td>
<td>Increases in CD4+ T cell count, decrease in HIV RNA when used in combination with nucleosides</td>
<td>Skin rash, hepatotoxicity</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Drug</th>
<th>Status</th>
<th>Indication</th>
<th>Dose in Combination</th>
<th>Supporting Data</th>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efavirenz (Sustiva)</td>
<td>Licensed</td>
<td>For treatment of HIV infection in combination with other antiretroviral agents</td>
<td>600 mg qhs</td>
<td>Efavirenz + AZT + 3TC comparable to indinavir + AZT + 3TC with regard to viral load suppression (a higher percentage of the efavirenz group achieved viral load &lt;50 copies/mL; however, the discontinuation rate in the indinavir group was unexpectedly high, accounting for most treatment “failures”); CD4 cell increase (~140/μL in each group) at 24 weeks.</td>
<td>Rash, dysphoria, elevated liver function tests, drowsiness, abnormal dreams, depression</td>
</tr>
<tr>
<td>Etravirine</td>
<td>Licensed</td>
<td>In combination with other antiretroviral agents in treatment-experienced adult pts who have evidence of viral replication and HIV-1 strains resistant to an NNRTI inhibitor and other antiretroviral agents</td>
<td>200 mg bid (or twice daily)</td>
<td>At 24 weeks in treatment-experienced pts with 1 or more NNRTI mutation and 3 or more PI mutations at screening, 74% of pts randomized to etravirine + background had HIV levels &lt;400 copies/mL compared to 51.5% of pts randomized to background regimen + placebo. All subjects received darunavir/ritonavir as part of their background regimen. CD4+ T cell counts increased by 81 cells/mL in the etravirine arm and 64 cells/mL in the placebo arm.</td>
<td>Skin rash</td>
</tr>
</tbody>
</table>
## Protease Inhibitors

<table>
<thead>
<tr>
<th>Medication</th>
<th>Status</th>
<th>Dosage/Use</th>
<th>Efficacy</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saquinavir mesylate (Invirase—hard gel capsule)</td>
<td>Licensed</td>
<td>In combination with other antiretroviral agents when therapy is warranted</td>
<td>1000 mg + 100 mg ritonavir bid</td>
<td>Increases in CD4+ T cell counts, reduction in HIV RNA most pronounced in combination therapy with ddC. 50% reduction in first AIDS-defining event or death in combination with ddC compared to either agent alone.</td>
</tr>
<tr>
<td>(Fortovase—soft gel capsule)</td>
<td>Licensed Discontinued 2006</td>
<td>For use in combination with other antiretroviral agents when treatment is warranted</td>
<td>1200 mg tid</td>
<td>Reduction in the mortality rate and AIDS-defining events for patients who received hard-gel formulation in combination with ddC</td>
</tr>
<tr>
<td>Ritonavir (Norvir)</td>
<td>Licensed</td>
<td>In combination with other antiretroviral agents for treatment of HIV infection when treatment is warranted</td>
<td>600 mg bid</td>
<td>Reduction in the cumulative incidence of clinical progression or death from 34 to 17% in patients with CD4+ T cell count &lt;100/μL treated for a median of 6 months</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Drug</th>
<th>Status</th>
<th>Indication</th>
<th>Dose in Combination</th>
<th>Supporting Data</th>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indinavir sulfate</td>
<td>Licensed</td>
<td>For treatment of HIV infection in combination with other antiretroviral agents when antiretroviral treatment is warranted</td>
<td>800 mg q8h or 800 mg + 100 mg ritonavir bid or 1000 mg q8h when used with efavirenz or nevirapine</td>
<td>Increase in CD4+ T cell count by 100/μL and 2-log decrease in HIV RNA levels when given in combination with zidovudine and lamivudine. Decrease of 50% in risk of progression to AIDS or death when given with zidovudine and lamivudine compared with zidovudine and lamivudine alone.</td>
<td>Nephrolithiasis, indirect hyperbilirubinemia, hyperglycemia, fat redistribution, lipid abnormalities</td>
</tr>
<tr>
<td>Nelfinavir mesylate</td>
<td>Licensed</td>
<td>For treatment of HIV infection in combination with other antiretroviral agents when antiretroviral therapy is warranted</td>
<td>750 mg tid or 1250 mg bid</td>
<td>2.0-log decline in HIV RNA when given in combination with stavudine</td>
<td>Diarrhea, loose stools, hyperglycemia, fat redistribution, lipid abnormalities May contain traces of the potential carcinogen/teratogen ethyl methane sulfonate</td>
</tr>
<tr>
<td>Drug</td>
<td>Status</td>
<td>Dosage/Regimen</td>
<td>Side Effects</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>----------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amprenavir</td>
<td>Licensed</td>
<td>In combination with other antiretroviral agents for treatment of HIV infection 1200 mg bid or 600 mg + 100 mg ritonavir bid or 1200 mg + 200 mg ritonavir qd 1400 mg bid or 700 mg + 100 mg ritonavir bid</td>
<td>In treatment-naive patients, amprenavir + AZT + 3TC superior to AZT + 3TC with regard to viral load suppression (53% vs 11% with &lt;400 HIV RNA copies/mL plasma at 24 weeks). CD4+ T cell responses similar between treatment groups. In treatment-experienced patients, amprenavir + NRTIs similar to indinavir + NRTIs with regard to viral load suppression (43% vs 53% with &lt;400 HIV RNA copies/mL plasma at 24 weeks). CD4+ T cell responses superior in the indinavir + NRTIs group.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fosamprenavir</td>
<td>Licensed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lopinavir/ritonavir</td>
<td>Licensed</td>
<td>For treatment of HIV infection in combination with other antiretroviral agents 400 mg/100 mg bid</td>
<td>In treatment-naive patients, lopinavir/ritonavir + d4T + 3TC superior to nelfinavir+d4T + 3TC with regard to viral load suppression (79% vs 64% with &lt;400 HIV RNA copies/μL at 40 weeks). CD4+ T cell increases similar in both groups.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir</td>
<td>Licensed</td>
<td>For treatment of HIV infection in combination with other antiretroviral agents 400 mg qd or 300 mg qd + ritonavir 100 mg qd when given with efavirenz</td>
<td>Comparable to efavirenz when given in combination with AZT + 3TC in a study of 810 treatment-naive patients. Comparable to nelfinavir when given in combination with d4T + 3TC in a study of 467 treatment-naive patients.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Drug</th>
<th>Status</th>
<th>Indication</th>
<th>Dose in Combination</th>
<th>Supporting Data</th>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tipranavir (Apti-vus)</td>
<td>Licensed</td>
<td>In combination with 200 mg ritonavir for combination therapy in treatment-experienced adults</td>
<td>500 mg + 200 mg ritonavir twice daily</td>
<td>At 24 weeks, patients with prior extensive exposure to ARVs showed a $-0.8$ log change in HIV RNA levels and a 34 cell increase in CD4+ T cells compared to $-0.25$ log and 4 cells in the control arm. Inferior to lopinavir/ritonavir in a randomized, controlled trial in naïve patients.</td>
<td>Diarrhea, nausea, fatigue, headache, skin rash, hepatotoxicity, intracranial hemorrhage</td>
</tr>
<tr>
<td>Darunavir (Prezista)</td>
<td>Licensed</td>
<td>In combination with 100 mg ritonavir for combination therapy in treatment-experienced adults</td>
<td>600 mg + 100 mg ritonavir twice daily with food</td>
<td>At 24 weeks, patients with prior extensive exposure to antiretrovirals treated with a new combination including darunavir showed a $-1.89$ log change in HIV RNA levels and a 92 cell increase in CD4+ T cells compared to $-0.48$ log and 17 cells in the control arm.</td>
<td>Diarrhea, nausea, headache</td>
</tr>
</tbody>
</table>

**Entry Inhibitors**

<p>| Enfuvirtide (Fuzeon) | Licensed | In combination with other agents in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy | 90 mg SC bid | In treatment of experienced patients, superior to placebo when added to new optimized background (37% vs 16% with $&lt;400$ HIV RNA copies/mL at 24 weeks; + 71 vs + 35 CD4+ T cells at 24 weeks) | Local injection reactions, hypersensitivity reactions, increased rate of bacterial pneumonia |</p>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Status</th>
<th>Use</th>
<th>Dose</th>
<th>Outcome</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maraviroc (Selzentry)</td>
<td>Licensed</td>
<td>In combination with other antiretroviral agents in treatment experienced adults infected with only CCR5-tropic HIV-1 that is resistant to multiple antiretroviral agents</td>
<td>150–600 mg bid depending upon concomitant medications (see text)</td>
<td>At 24 weeks, among 635 patients with CCR5-tropic virus and HIV-1 RNA &gt;5000 copies/mL despite at least 6 months of prior therapy with at least one agent from 3 of the 4 antiretroviral drug classes, 61% of patients randomized to maraviroc achieved HIV RNA levels &lt;400 copies/mL compared to 28% of patients randomized to placebo</td>
<td>Hepatotoxicity, nasopharyngitis, fever, cough, rash, abdominal pain, dizziness, fever, musculoskeletal symptoms</td>
</tr>
<tr>
<td>Integrase Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raltegravir (Isentress)</td>
<td>Licensed</td>
<td>In combination with other antiretroviral agents in treatment experienced patients with evidence of ongoing HIV-1 replication</td>
<td>400 mg bid</td>
<td>At 24 weeks, among 436 patients with three-class drug resistance, 76% of patients randomized to receive raltegravir achieved HIV RNA levels &lt;400 copies/mL compared to 41% of patients randomized to receive placebo</td>
<td>Nausea, rash</td>
</tr>
</tbody>
</table>

Note: ARC, AIDS-related complex; NRTIs, nonnucleoside reverse transcriptase inhibitors.
CHOICE OF ANTIRETROVIRAL TREATMENT STRATEGY

The large number of available antiretroviral agents coupled with relatively few clinical end-point studies make the subject of antiretroviral therapy one of the more controversial in the management of HIV-infected pts.

The principles of therapy for HIV infection have been articulated by a panel sponsored by the U.S. Department of Health and Human Services (Table 112-3). Treatment decisions must take into account the fact that one is dealing with a chronic infection and that complete eradication of HIV infection is probably not possible with currently available HAART regimens. Thus, immediate treatment of HIV infection upon diagnosis may not be prudent, and therapeutic decisions must take into account the balance between risks and benefits. At present a reasonable course of action is to initiate antiretroviral therapy in anyone with the acute HIV syndrome; pts with symptomatic disease; pts with evidence of renal disease; pts with asymptomatic infection and CD4+ counts < 350/μL; and pts with hepatitis B infection when hepatitis B treatment is indicated, to avoid development of resistant strains of HIV. In addition, one may wish to administer a 4-week course of therapy to uninfected individuals immediately following a high-risk exposure to HIV (see below).

When the decision to initiate therapy is made, the physician must decide which drugs to use in the initial regimen. The two options for initial therapy most commonly in use today are: two nucleoside analogues (one of which is usually lamivudine or emtricitabine) combined with a protease inhibitor; or

### TABLE 112-3
PRINCIPLES OF THERAPY OF HIV INFECTION

<table>
<thead>
<tr>
<th>Principle</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Ongoing HIV replication leads to immune system damage and progression to AIDS.</td>
</tr>
<tr>
<td>2. Plasma HIV RNA levels indicate the magnitude of HIV replication and the rate of CD4+ T cell destruction. CD4+ T cell counts indicate the current level of competence of the immune system.</td>
</tr>
<tr>
<td>3. Rates of disease progression differ among individuals, and treatment decisions should be individualized based upon plasma HIV RNA levels and CD4+ T cell counts.</td>
</tr>
<tr>
<td>4. Maximal suppression of viral replication is a goal of therapy; the greater the suppression the less likely the appearance of drug-resistant quasispecies.</td>
</tr>
<tr>
<td>5. The most effective therapeutic strategies involve the simultaneous initiation of combinations of effective anti-HIV drugs with which the patient has not been previously treated and that are not cross-resistant with antiretroviral agents that the patient has already received.</td>
</tr>
<tr>
<td>6. The antiretroviral drugs used in combination regimens should be used according to optimum schedules and dosages.</td>
</tr>
<tr>
<td>7. The number of available drugs is limited. Any decisions on antiretroviral therapy have a long-term impact on future options for the patient.</td>
</tr>
<tr>
<td>8. Women should receive optimal antiretroviral therapy regardless of pregnancy status.</td>
</tr>
<tr>
<td>9. The same principles apply to children and adults. The treatment of HIV-infected children involves unique pharmacologic, virologic, and immunologic considerations.</td>
</tr>
<tr>
<td>10. Compliance is an important part of ensuring maximal effect from a given regimen. The simpler the regimen, the easier it is for the patient to be compliant.</td>
</tr>
</tbody>
</table>

*Source: Modified from Principles of Therapy of HIV Infection, USPHS, and the Henry J. Kaiser Family Foundation.*
two nucleoside analogues and a nonnucleoside reverse transcriptase inhibitor. There are no clear data at present on which to base distinctions between these two approaches. Following the initiation of therapy, one should expect a 1-log (tenfold) reduction in plasma HIV RNA within 1–2 months; eventually a decline in plasma HIV RNA to <50 copies/mL; and a rise in CD4+ T cell count of 100–150/μL. Failure to achieve and maintain an HIV RNA level <50 copies/mL is an indication to consider a change in therapy. Other reasons for changing therapy are listed in Table 112-4. When changing therapy because of treatment failure, it is important to attempt to provide a regimen with at least two new drugs. In the pt in whom a change is made for reasons of drug toxicity, a simple replacement of one drug is reasonable.

### Treatment of Secondary Infections and Neoplasms

Specific for each infection and neoplasm (see Chap. 182, in HPIM-17).

#### Prophylaxis Against Secondary Infections

Primary prophylaxis is clearly indicated for *P. jiroveci* pneumonia (especially when CD4+ T cell counts fall to <200 cells/μL), for *M. avium* complex infections in pts with CD4+ T cell counts <50 cells/μL, and for *M. tuberculosis* infections in pts with a positive PPD or anergy if at high risk of TB. Vaccination with the influenza and pneumococcal polysaccharide vaccines is generally recommended for all pts with CD4+ T cell counts >200/μL (see Table 182-8, pp. 1170, 1171, in HPIM-17). Secondary prophylaxis, when available, is indicated for virtually every infection experienced by HIV-infected pts.

### HIV AND THE HEALTH CARE WORKER

There is a small but definite risk to health care workers of acquiring HIV infection via needle stick exposures, large mucosal surface exposures, or exposure of open wounds to HIV-infected secretions or blood products. The risk of HIV transmission after a skin puncture by an object contaminated with blood from a person with documented HIV infection is ~0.3%, compared to 20–30% risk for hepatitis B infection from a similar incident. Postexposure prophylaxis appears to be effective in decreasing the likelihood of acquisition of infection through accidental exposure in the health care setting. In this regard, a U.S. Public Health Service

---

**Table 112-4**

<table>
<thead>
<tr>
<th>INDICATIONS FOR CHANGING ANTIRETROVIRAL THERAPY IN PATIENTS WITH HIV INFECTIONa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than a 1-log drop in plasma HIV RNA by 4 weeks following the initiation of therapy</td>
</tr>
<tr>
<td>A reproducible significant increase (defined as 3-fold or greater) from the nadir of plasma HIV RNA level not attributable to intercurrent infection, vaccination, or test methodology</td>
</tr>
<tr>
<td>Persistently declining CD4+ T cell numbers</td>
</tr>
<tr>
<td>Clinical deterioration</td>
</tr>
<tr>
<td>Side effects</td>
</tr>
</tbody>
</table>

*aGenerally speaking, a change should involve the initiation of at least 2 drugs felt to be effective in the given patient. The exception to this is when change is being made to manage toxicity, in which case a single substitution is reasonable. Source: Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. USPHS.*
working group has recommended that chemoprophylaxis be given as soon as possible after occupational exposure. While the precise regimen remains a subject of debate, the U.S. Public Health Service guidelines recommend (1) a combination of two nucleoside analogue reverse transcriptase inhibitors given for 4 weeks for routine exposures, or (2) a combination of two nucleoside analogue reverse transcriptase inhibitors plus a third drug given for 4 weeks for high-risk or otherwise complicated exposures. Most clinicians administer the latter regimen in all cases in which a decision to treat is made. Regardless of which regimen is used, treatment should be initiated as soon as possible after exposure.

Prevention of exposure is the best strategy and includes following universal precautions and proper handling of needles and other potentially contaminated objects.

Transmission of TB is another potential risk for all health care workers, including those dealing with HIV-infected pts. All workers should know their PPD status, which should be checked yearly.

**VACCINES**

Development of a safe and effective HIV vaccine is the object of active investigation at present. The first series of clinical trials of candidate vaccines in humans have not proven the candidates to be effective in preventing acquisition of infection or in lowering the viral set point after acquisition of infection.

**PREVENTION**

Education, counseling, and behavior modification remain the cornerstones of HIV prevention efforts. While abstinence is an absolute way to prevent sexual transmission, other strategies include “safe sex” practices such as use of condoms. Avoidance of shared needle use by IDUs is critical. If possible, breastfeeding should be avoided by HIV-positive women, as the virus can be transmitted to infants via this route. In societies where withholding of breastfeeding is not feasible, treatment of the mother, if possible, greatly decreases the chances of transmission.

For a more detailed discussion, see Fauci AS, Lane HC: Human Immunodeficiency Virus (HIV) Disease: AIDS and Related Disorders, Chap. 182, p. 1137, in HPIM-17.

**Fungal Infections**

**GENERAL CONSIDERATIONS**

Yeast (e.g., *Candida, Cryptococcus*) appear microscopically as round, budding forms; molds (e.g., *Aspergillus, Rhizopus*) appear as filamentous forms called hyphae; and *dimorphic fungi* (e.g., *Histoplasma*) are spherical in tissue but appear as molds in culture. *Endemic* fungi pathogenic for humans are saprophytic in nature and infect hosts preferentially by inhalation. *Opportunistic* fungi in-
vade the host from normal sites of colonization (e.g., mucous membranes or the GI tract). Definitive diagnosis of any fungal infection requires histopathologic identification of the fungus invading tissue and evidence of an accompanying inflammatory response.

**ANTIFUNGAL AGENTS**

**Amphotericin B (AmB)**
- The broadest-spectrum antifungal agent
- Significant toxicities include nephrotoxicity and fever, chills, and nausea during treatment.
- Lipid formulations are used to circumvent nephrotoxicity and infusion reactions; whether there is truly a clinically significant difference remains controversial. Lipid formulations are expensive.

**Imidazoles and Triazoles** Azoles cause little or no nephrotoxicity. Unlike AmB, which is considered fungicidal, azoles are fungistatic.

**Fluconazole**
- Useful for coccidioidal and cryptococcal meningitis and for candidal infections, including candidemia
- Not effective against aspergillosis or mucormycosis
- Effective as fungal prophylaxis in bone marrow and high-risk liver transplant recipients
- Has oral and IV formulations and a long half-life
- Penetrates into most body fluids, including ocular fluids and cerebrospinal fluid (CSF)
- Toxicity is minimal but includes hepatotoxicity (at high doses), alopecia, muscle weakness, dry mouth, and metallic taste.

**Voriconazole**
- Available in oral and IV preparations
- First-line agent against *Aspergillus*
- Active against *Scedosporium* and *Fusarium*
- Has broader spectrum than fluconazole against *Candida* species
- Multiple drug interactions
- Common side effects include hepatotoxicity, skin rashes (including photosensitivity), and visual disturbances.
- Metabolized completely by the liver; dose adjustments required in pts with hepatic dysfunction
- Because of renal excretion of cyclodextrin after receipt of the IV formulation, oral treatment is indicated for pts with severe renal insufficiency.

**Itraconazole**
- Useful for blastomycosis, histoplasmosis, cutaneous candidiasis, coccidiodomycosis, sporotrichosis, onychomycosis, tinea versicolor, tinea capitis, and indolent aspergillosis
- Absorption is variable after administration in capsule form; blood levels should be monitored during treatment for disseminated mycosis.
- Minimal CSF penetration
- Cyclodextrin is used in both the oral solution and the IV formulation.

**Posaconazole**
- Approved for prophylaxis of aspergillosis and candidiasis in high-risk immunocompromised pts
Infectious Diseases

**Echinocandins**
- Caspofungin, anidulafungin, and micafungin are approved echinocandin agents that are available for IV administration only.
- Among the safest antifungal agents
- Broad-spectrum fungicidal activity against *Candida* species; also efficacious as salvage therapy for aspergillosis
- Cyclosporine increases caspofungin levels, but no dose adjustment is needed with anidulafungin or micafungin.

**Flucytosine** Used in combination with AmB (e.g., for cryptococcal meningitis); has excellent CSF penetration. Adverse effects include bone marrow suppression.

**Flucytosine**

**Candidiasis**

**Etiology** *Candida* is a small, thin-walled ovoid yeast that reproduces by budding and occurs in three forms in tissue: blastospores, pseudohyphae, and hyphae. *Candida* is ubiquitous in nature and inhabits the GI tract, the female genital tract, and the skin. *C. albicans* is common, but non-*albicans* species (e.g., *C. glabrata*, *C. krusei*, *C. parapsilosis*, *C. tropicalis*) now cause ~50% of all cases of candidemia and disseminated candidiasis.

**Pathogenesis**
- *Candida* probably enters the bloodstream from mucosal surfaces after multiplying to large numbers as a result of bacterial suppression by antibacterial drugs.
- Other risk factors for hematogenous dissemination include indwelling intravascular or urinary catheters and hyperalimentation fluids.
- Neonates of low birth weight, neutropenic pts, pts taking high-dose glucocorticoids, and pts with other impairments of host defenses are also susceptible to hematogenous seeding.

**Clinical Features**
1. **Oral thrush**: white, adherent, painless, discrete or confluent patches in the mouth, tongue, or esophagus. **Vulvovaginal thrush**: pruritus, pain, vaginal discharge
2. **Cutaneous candidiasis**: includes paronychia, balanitis, and intertrigo, manifesting as redness, pain, pustules
3. **Chronic mucocutaneous candidiasis**: infection of hair, nails, skin, and mucous membranes that persists despite therapy and is associated with a specific immunologic dysfunction
4. **Esophageal candidiasis**: substernal pain or sense of blockage on swallowing
5. **Urinary tract candidiasis**: Candidal colonization secondary to indwelling catheters is common; if the urinary tract is obstructed, *Candida* causes cystitis and upper tract disease.
6. **Candidemia**: often originating from the GI tract or from skin via an intra-vascular catheter
   a. The brain, chorioretina, heart, and kidneys are most commonly infected. Except in neutropenic pts, the liver and spleen are less often infected. Ocular involvement may require partial vitrectomy to prevent permanent blindness.
   b. Skin involvement manifests as macronodular lesions.
   c. Chorioretinal or skin involvement predicts a high probability of abscess formation in deep organs from generalized hematogenous seeding. Nearly any organ can become infected.

**Diagnosis**
- Demonstration of pseudohyphae on wet mount with culture confirmation
- Recovery of *Candida* from sputum, urine, or peritoneal catheters may reflect colonization rather than deep infection. The most challenging aspect of diagnosis is determining which pts have hematogenously disseminated disease.

**Candidiasis**
- **Cutaneous**: topical azoles or nystatin
- **Vulvovaginal**: vaginal azole suppositories or fluconazole (150 mg PO once)
- **Thrush**: clotrimazole troches or nystatin
- **Esophageal**: fluconazole (100–200 mg/d) or itraconazole (200 mg/d). Caspofungin, micafungin, and AmB are alternatives.
- **Deeply invasive candidiasis**
  1. Foreign materials (e.g., catheters) should be removed or replaced, when possible.
  2. AmB (including lipid formulations), echinocandins, and fluconazole or voriconazole are used; no agent is clearly superior to the others.
  3. Nonneutropenic, hemodynamically stable pts: Unless azole resistance is considered likely, fluconazole is the agent of choice.
  4. Neutropenic or hemodynamically unstable pts: Initial treatment should consist of broader-spectrum agents such as AmB or echinocandins. Once the pt’s condition has stabilized and the infecting strain has been isolated and identified, treatment can be adjusted.
  5. *Candida* endocarditis should be treated with valve removal and long-term antifungal administration.

**Prevention**
- Allogeneic stem-cell and high-risk liver transplant recipients typically receive prophylaxis with fluconazole (400 mg/d).
- Prophylaxis in acute leukemic and other neutropenic pts is controversial. Prophylaxis may be useful in high-risk postoperative pts but should not be given routinely to pts in general surgical or medical intensive care units.
- HIV-infected pts generally should not receive chronic prophylaxis against mucocutaneous disease unless they have frequent recurrences.

**ASPERgillosis**

**Etiology** *Aspergillus* is a mold with septate branching hyphae. It has a worldwide distribution and typically grows in decomposing plant materials. *A. fumigatus* is the most common cause of invasive aspergillosis.
Pathogenesis

- Inhalation is common; only intense exposures cause disease in healthy, immunocompetent individuals.
- The primary risk factors for invasive aspergillosis are profound neutropenia and glucocorticoid use. Risk increases with longer duration of these conditions.Pts with chronic pulmonary aspergillosis have a wide spectrum of underlying pulmonary diseases (e.g., tuberculosis, sarcoidosis).

Clinical Features

1. **Invasive pulmonary aspergillosis**: The frequency of invasive disease and the pace of progression increase with greater degrees of immunocompromise. Acute and subacute forms have courses of ≤1 month and 1–3 months, respectively. Of invasive aspergillosis cases, >80% involve the lungs. Pts can be asymptomatic or can present with fever, cough, chest discomfort, hemoptysis, and shortness of breath. Early diagnosis requires a high index of suspicion, screening for circulating antigen, and urgent CT of the chest.

2. **Invasive sinusitis**: The sinuses are involved in 5–10% of cases of invasive aspergillosis, especially in leukemic pts and hematopoietic stem-cell transplant recipients. Pts have fever, nasal or facial discomfort, and nasal discharge. CT or MRI of the sinuses is essential.

3. **Disseminated aspergillosis**: occurs in the most immunocompromised pts. *Aspergillus* disseminates from lung to brain, skin, thyroid, bone, and other organs. Pts develop skin lesions and deteriorate clinically over 1–3 days, developing fever and signs of mild sepsis with multiple abnormalities in laboratory tests. Blood cultures are usually negative.

4. **Cerebral aspergillosis**: Single or multiple lesions, hemorrhagic infarction, and cerebral abscess are common. The presentation can be acute or subacute, with mood changes, focal signs, seizures, and a decline in mental status. MRI is the most useful investigation.

5. **Chronic pulmonary aspergillosis** is characterized by one or more cavities expanding over months to years, with pulmonary symptoms, fatigue, and weight loss. Pericavitary infiltrates and multiple cavities are typical. Without treatment, pulmonary fibrosis can develop.

6. **Aspergilloma**: fungal ball in residual chest cavities. Life-threatening hemoptysis may occur.

7. **Chronic sinusitis**: three presentations
   a. Fungal ball without invasion in a diseased, chronically infected sinus
   b. Chronic invasive, slowly progressive disease
   c. Chronic granulomatous inflammation

8. **Allergic bronchopulmonary aspergillosis** (ABPA)
   a. Seen in asthmatics and cystic fibrosis pts
   b. Intermittent wheezing, infiltrates due to bronchial plugging, eosinophilia, sputum

Diagnosis

- Histologic examination of affected tissue reveals either infarction, with invasion of blood vessels by fungal hyphae, or acute necrosis.
- Culture is important in confirming the diagnosis but may be falsely positive (e.g., in pts with airway colonization) or falsely negative.
- Galactomannan antigen testing of serum from high-risk pts is best done prospectively, as positive results precede clinical disease; false-positive results can occur.
• Definitive diagnosis requires a positive culture of an ordinarily sterile site or positive results of histologic testing and culture of a sample taken from the affected organ.
• Data suggestive of the diagnosis include a halo sign on high-resolution thoracic CT scan (a localized ground-glass appearance representing hemorrhagic infarction surrounding a nodule).
• IgE antibody to Aspergillus antigens is seen in ABPA.

**Aspergillosis**

- See Table 113-1 for recommended treatments and doses.
- Invasive aspergillosis: Duration of treatment varies from ~3 months to years, depending on the host and the response.
- Chronic and allergic forms of aspergillosis: Voriconazole or posaconazole can be substituted for itraconazole in instances of treatment failure, adverse events, or emergence of resistance. Itraconazole blood levels should be monitored. Chronic cavitary pulmonary aspergillosis probably requires treatment for life.
- Surgical treatment is important for some forms of aspergillosis (e.g., maxillary sinus fungal ball; single aspergilloma; invasive disease of bone, heart valve, brain, or sinuses).

**Outcome**

Invasive aspergillosis is curable if immune reconstitution occurs. Poor outcomes are seen in pts with cerebral aspergillosis, endocarditis, bilateral extensive invasive pulmonary disease, late-stage AIDS, relapsed uncontrolled leukemia, or allogeneic hematopoietic stem cell transplants. The overall mortality rate is ~50% with treatment, but the disease is uniformly fatal without therapy.

**CRYPTOCOCCOSIS**

**Etiology** Cryptococcus is a yeast-like fungus. *C. neoformans* and *C. gattii* are pathogenic for humans and can cause cryptococcosis.

**Epidemiology** *C. neoformans* is found in soil contaminated with pigeon droppings, whereas *C. gattii* is associated with eucalyptus trees. *C. neoformans* infection is strongly associated with advanced HIV disease, treatment with glucocorticoids or immunosuppressive drugs, transplantation, and hematologic malignancy. *C. gattii* infection is not associated with specific immune deficits.

**Pathogenesis** Most cases are acquired via inhalation, with consequent pulmonary infection. Spread to the brain can occur. *C. neoformans* has a polysaccharide capsule that is antiphagocytic and interferes with local immune responses.

**Clinical Features**

1. **Meningoencephalitis**: most common presentation
   a. Early: headache, fever, lethargy, cranial nerve paresis, visual deficits, meningoencephalitis
   b. Symptoms can be of several weeks’ duration.
2. **Pulmonary manifestations**
   a. Usually asymptomatic but can present as cough, increased sputum production, and chest pain
   b. Often runs an indolent course; often is associated with prior disease (e.g., malignancy, diabetes, tuberculosis)
   c. Cryptococcomas: usually seen in immunocompetent pts; associated with *C. gattii* infections
<table>
<thead>
<tr>
<th>Indication</th>
<th>Primary Treatment</th>
<th>Evidence Level</th>
<th>Precautions</th>
<th>Secondary Treatment</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invasive&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Voriconazole</td>
<td>AI</td>
<td>Drug interactions (especially with rifampin), renal failure (IV only)</td>
<td>Amphotericin B, caspofungin, posaconazole, micafungin</td>
<td>As primary therapy, voriconazole carries 20% more responses than amphotericin B. If azole prophylaxis fails, it is unclear whether a class change is required for therapy.</td>
</tr>
<tr>
<td>Prophylaxis</td>
<td>Itraconazole solution, posaconazole</td>
<td>AI</td>
<td>Diarrhea and vomiting with itraconazole, vincristine interaction</td>
<td>Micafungin, aerosolized amphotericin B</td>
<td>Some centers monitor plasma levels of itraconazole.</td>
</tr>
<tr>
<td>ABPA</td>
<td>Itraconazole</td>
<td>AI</td>
<td>Some glucocorticoid interactions, including with inhaled formulations</td>
<td>Voriconazole</td>
<td>Long-term therapy is helpful in most patients. Others can discontinue treatment. No evidence indicates whether or not therapy modifies progression to bronchiectasis/fibrosis.</td>
</tr>
<tr>
<td>Single aspergilloma</td>
<td>Surgery</td>
<td>BII</td>
<td>Multicavity disease: poor outcome of surgery; medical therapy preferable</td>
<td>Itraconazole, voriconazole, intracavity amphotericin B</td>
<td>Single large cavities with an aspergilloma are best resected.</td>
</tr>
<tr>
<td>Chronic pulmonary</td>
<td>Itraconazole</td>
<td>BII</td>
<td>Poor absorption of capsules with proton pump inhibitors or H₂ blockers</td>
<td>Voriconazole, IV amphotericin B</td>
<td>Resistance may emerge during treatment, especially if plasma drug levels are subtherapeutic.</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------</td>
<td>-----</td>
<td>---------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>

**Note:** The oral dose is usually 200 mg bid for voriconazole and itraconazole and 400 mg bid for posaconazole. The IV dose of voriconazole is 6 mg/kg twice at 12-h intervals (loading doses) followed by 4 mg/kg q12h. Plasma monitoring is helpful in optimizing the dosage. Caspofungin is given as a single loading dose of 70 mg, followed by 50 mg/d; some authorities use 70 mg/d for patients weighing >80 kg, and lower doses are required with hepatic dysfunction. Micafungin is given as 50 mg/d for prophylaxis and as at least 150 mg/d for treatment; this drug is not yet approved by the U.S. Food and Drug Administration (FDA) for this indication. Amphotericin B deoxycholate is given at a daily dose of 1 mg/kg if tolerated. Several strategies are available for minimizing renal dysfunction. Lipid-associated amphotericin B is given at 3 mg/kg (AmBisome) or 5 mg/kg (Abelet). Different regimens are available for aerosolized amphotericin B, but none is FDA approved. Other considerations that may alter dose selection or route include age; concomitant medications; renal, hepatic, or intestinal dysfunction; and drug tolerability.

*a Evidence levels are those used in treatment guidelines (Stevens DA et al: Practice guidelines for diseases caused by *Aspergillus*. Clin Infect Dis 30:696, 2000).

*b An infectious disease consultation is appropriate for these patients.
3. **Skin lesions**
   a. Associated with disseminated cryptococcosis
   b. Lesions can be papules, plaques, purpura, vesicles, tumor-like lesions, or rashes.

**Diagnosis**
- Diagnosis requires the demonstration of *C. neoformans* in normally sterile tissue. Positive cultures of CSF and blood are diagnostic.
- India ink smear of CSF is a useful rapid diagnostic technique. Pts have high protein levels in CSF, with mononuclear cell pleocytosis.
- Cryptococcal antigen testing of CSF, serum

### Cryptococcosis

1. Pulmonary cryptococcosis in an immunocompetent pt: fluconazole (200–400 mg/d for 3–6 months)
2. Extrapulmonary cryptococcosis may initially require AmB (0.5–1.0 mg/kg daily for 4–6 weeks).
3. Central nervous system (CNS) cryptococcal disease in HIV-seronegative pts: induction phase with AmB (0.5–1.0 mg/kg daily) followed by prolonged consolidation therapy with fluconazole (400 mg/d)
4. Meningoencephalitis in immunocompetent pts: AmB (0.5–1.0 mg/kg) plus flucytosine (100 mg/kg) daily for 6–10 weeks or the same drugs at the same dosages for 2 weeks followed by fluconazole (400 mg/d) for 10 weeks
5. HIV-infected pts with CNS involvement: AmB (0.7–1.0 mg/kg daily) plus flucytosine for at least 2 weeks followed by fluconazole (400 mg/d) for 10 weeks and then by lifelong maintenance therapy with fluconazole (200 mg/d). If antiretroviral therapy results in immunologic improvement, it may be possible to stop fluconazole.
6. Prognosis depends on the underlying disease process.

### MUCORMYCOSIS

#### Etiology
Mucormycosis is caused by fungi from the order Mucorales, primarily those of the genera *Rhizopus* and *Rhizomucor*. Mucorales appear as broad, usually nonseptate hyphae with branches at right angles; organisms are described as ribbon-like.

#### Epidemiology
Mucorales are ubiquitous in the environment, and spores of these fungi are likely to be inhaled daily. Pts at high risk include those with diabetes, immunocompromise (e.g., after organ transplantation), or iron overload syndromes (e.g., in pts on hemodialysis) and associated use of deferoxamine therapy; in those pts, spores germinate, hyphae develop, and the fungi invade blood vessels and surrounding tissues in the lungs. Dissemination can occur.

#### Clinical Features
1. **Rhinocerebral mucormycosis**
   a. Pts may present with typical symptoms of sinusitis: low-grade fever, dull sinus pain, nasal congestion, and thin bloody nasal discharge.
   b. The disease may progress to hypesthesia or numbness of the face overlying the infection, headache, bloody nasal discharge, and altered mental status.
   c. Hyperemic areas of the palate can progress to a black eschar.
d. Orbit involvement causes double vision, blindness, reduction of ocular motion, proptosis, and ptosis.
e. Cavernous sinus thrombosis is an ominous sign.

2. Pulmonary mucormycosis: Neutropenia is a common predisposing factor.
   a. Progressive, severe, tissue-destructive pneumonia with high fever and toxicity
   b. Rapidly developing cavitation
   c. Hematogenous spread beyond the lungs to the brain and other organs

3. GI and cutaneous infections have been reported.

Diagnosis

Biopsy of sites of infection for histology and culture is critical for an accurate diagnosis; as much tissue as possible should be submitted for examination.

**Mucormycosis**

Three factors are key to successful outcomes: reversal of underlying predisposing condition, if possible; aggressive surgical debridement; and aggressive antifungal treatment.

- AmB dosing is often limited by nephrotoxicity. Use of liposomal AmB (15–20 mg/kg per day of Ambisome or 15 mg/kg per day of Abelcet) maximizes the drug’s delivery to tissues as well as the speed of its delivery, with nephrotoxicity occurring in <50% of pts. Posaconazole may also prove to be efficacious.
- Although the optimal duration is unknown, treatment should continue for at least 3 months after (1) clinical abnormalities resolve or stabilize, leaving no clinical evidence of disease at the involved site(s); and (2) scans, x-rays, and laboratory studies yield normal or stable results.
- Follow-up should continue for at least 1 year to confirm that infection does not recur.

**HISTOPLASMOSIS**

**Etiology**  *Histoplasma capsulatum*, a dimorphic fungus, causes histoplasmosis. Mycelia are infectious and have microconidial and macroconidial forms.

**Epidemiology**  Histoplasmosis is the most prevalent endemic mycosis in North America and is also found in Central and South America, Africa, and Asia. In the United States, histoplasmosis is endemic in the Ohio and Mississippi river valleys. The fungus is found in soil, particularly that enriched by droppings of certain birds and bats.

**Pathogenesis and Pathology**  Microconidia are inhaled, reach the alveoli, and are transformed into yeasts with occasional narrow budding. A granulomatous reaction results, but, in pts with impaired cellular immunity, infection may disseminate.

**Clinical Features**

1. **Acute pulmonary histoplasmosis**
   a. Asymptomatic or mild respiratory disease with cough, fever, hilar adenopathy, pneumonitis
   b. Occasionally associated with arthralgia or arthritis, erythema nodosum, or pericarditis

2. **Progressive disseminated histoplasmosis (PDH)**
   a. Typically seen in immunocompromised pts (e.g., pts with HIV infection, those at the extremes of age, and those using immunosuppressive agents)
b. The clinical spectrum ranges from a rapidly fatal course with diffuse interstitial or reticulonodular lung infiltrates, shock, and multiorgan failure to a subacute course with focal organ involvement, hepatosplenomegaly, fever, and weight loss. Meningitis, oral mucosal ulcerations, GI ulcerations, and adrenal insufficiency can occur.

3. **Chronic cavitary histoplasmosis**
   a. Most often affects smokers with structural lung disease (e.g., emphysema)
   b. Cough, weight loss, night sweats, apical infiltrates, cavitation, pleural thickening similar to that in tuberculosis

4. **Fibrosing mediastinitis associated with histoplasmosis** (rare): progressive fibrosis around hilar and mediastinal nodes resulting in superior vena cava syndrome, obstruction of pulmonary vessels, and recurrent airway obstruction

5. **African histoplasmosis**: distinct clinical presentation with frequent skin and bone involvement

### Diagnosis
- Fungal culture: may take 1 month to become positive. In 75% of cases, pts with PDH and chronic cavitary disease have positive cultures of bronchoalveolar lavage fluid, bone marrow aspirate, and/or blood.
- Fungal stains of cytopathology or biopsy materials
- *Histoplasma* antigen assay of blood or urine is useful in diagnosing PDH or acute disease and in monitoring the response to treatment.
- Serologic tests can diagnose self-limited acute pulmonary and chronic cavitary histoplasmosis.

### Histoplasmosis
See Table 113-2 for treatment recommendations. Fibrosing mediastinitis does not respond to antifungal treatment.

## COCCIDIOIDOMYCOSIS

**Etiology**  Coccidioidomycosis is caused by the two species of the dimorphic soil-dwelling fungus *Coccidioides*: *C. immitis* and *C. posadasii*.

**Epidemiology**  Coccidioidomycosis is highly endemic in California, Arizona, and other areas of the southwestern United States; northern Mexico and localized regions in Central and South America also account for cases of infection. Direct exposure to soil harboring *Coccidioides* increases risk, but infection can occur without overt soil exposure and may be related to other climatic factors (e.g., periods of dryness after rainy seasons). The frequency of cases has recently increased dramatically in south-central Arizona, perhaps because of the influx of older, susceptible persons into the area.

**Pathogenesis and Pathology**  Infection, which results from inhalation of airborne arthroconidia, incites necrotizing granulomas in host tissue.

**Clinical Features**

1. **Primary pulmonary infection**: symptomatic in 40% of cases
   a. Fever, cough, chest pain; also erythema nodosum, erythema multiforme, other hypersensitivity reactions, night sweats, arthralgias
   b. Chest x-ray: infiltrate, hilar and mediastinal adenopathy, pleural effusion in ~10%
<table>
<thead>
<tr>
<th>Type of Histoplasmosis</th>
<th>Treatment Recommendations</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute pulmonary, moderate to severe illness with diffuse infiltrates and/or hypoxemia</td>
<td>Lipid amphotericin B (3–5 mg/kg per day) ± glucocorticoids for 1–2 weeks; then itraconazole (200 mg twice daily) for 12 weeks. Monitor renal and hepatic function.</td>
<td>Patients with mild cases usually recover without therapy, but itraconazole should be considered if the patient's condition has not improved after 1 month.</td>
</tr>
<tr>
<td>Chronic/cavitary pulmonary</td>
<td>Itraconazole (200 mg once or twice daily) for at least 12 months. Monitor hepatic function.</td>
<td>Continue treatment until radiographic findings show no further improvement. Monitor for relapse after treatment is stopped.</td>
</tr>
<tr>
<td>Progressive disseminated</td>
<td>Lipid amphotericin B (3–5 mg/kg per day) for 1–2 weeks; then itraconazole (200 mg twice daily) for at least 12 months. Monitor renal and hepatic function.</td>
<td>Liposomal amphotericin B is preferred, but the amphotericin B lipid complex may be used because of cost. Chronic maintenance therapy may be necessary if the degree of immunosuppression cannot be reduced.</td>
</tr>
<tr>
<td>Central nervous system</td>
<td>Liposomal amphotericin B (5 mg/kg per day) for 4–6 weeks; then itraconazole (200 mg 2 or 3 times daily) for at least 12 months. Monitor renal and hepatic function.</td>
<td>A longer course of lipid amphotericin B is recommended because of the high risk of relapse. Itraconazole should be continued until cerebrospinal fluid or CT abnormalities clear.</td>
</tr>
</tbody>
</table>
c. Occasionally presents as diffuse reticulonodular pulmonary process with dyspnea and fever
d. Mild peripheral-blood eosinophilia

2. Cavitary pulmonary disease: chronic thin-walled cavities. Symptomatic pts have cough, hemoptysis, and pleuritic chest pain.

3. Disseminated infection
a. More likely in pts with cell-mediated immunosuppression (e.g., Hodgkin’s disease, HIV infection), pregnant women, and certain racial and ethnic groups
b. Common sites for dissemination include bone, skin, joint, soft tissue, and meninges
c. Meningitis: fatal if untreated. Pts have persistent headache, lethargy, and confusion. Examination of CSF reveals lymphocytic pleocytosis, elevated protein levels, profound hypoglycorrhachia, and occasional eosinophilia.

Diagnosis
• Serology: Tube-precipitin (TP) and complement-fixation (CF) assays, immuno-diffusion, and enzyme immunoassay (EIA) to detect IgM and IgG antibodies. TP antibody does not gauge disease progression and is not found in CSF. Rising CF titers in serum are associated with clinical progression, and CF antibody in CSF indicates meningitis. EIA frequently yields false-positive results.
• Examine tissue by smear and culture. Alert the laboratory of the possible diagnosis to avoid exposure.

Coccidioidomycosis
• Focal primary pneumonia: no therapy except in pts with underlying cellular immunodeficiency or prolonged symptoms
• Diffuse pulmonary disease: AmB (0.7–1.0 mg/kg daily or three times a week IV) followed by itraconazole or fluconazole (minimum oral dose of 400 mg/d) after clinical improvement occurs
• Pulmonary cavities: Most do not require treatment.
• Chronic pulmonary disease and disseminated infection: prolonged triazole therapy (i.e., for ≥1 year)
• Meningitis: lifelong therapy with a triazole. Fluconazole is the drug of choice (≥400 mg/d). If triazole therapy fails, intrathecal AmB may be used.

Blastomycosis
Blastomyces dermatitidis is a dimorphic fungus that is found in the southeastern and south-central states bordering the Mississippi and Ohio river basins, in areas of the United States and Canada bordering the Great Lakes and the St. Lawrence River, and in Africa. Infection is caused by inhalation of Blastomyces from moist soil rich in organic debris. Acute pulmonary infection can present as an abrupt onset of fever, chills, pleuritic chest pain, and arthralgias. However, most pts have chronic indolent pneumonia with fever, weight loss, productive cough, and hemoptysis. Skin disease is common and can present as verrucous or ulcerative lesions. Osteomyelitis is seen in up to one-fourth of infections.

Diagnosis Smears of clinical samples or cultures of sputum, pus, or tissue are required for diagnosis. Antigen detection in urine and serum may assist in diagnosing infection and in monitoring pts during therapy.
Blastomycosis

Every pt should be treated because of the high risk of dissemination. AmB should be given for rapidly progressive infections or severe illness; when the pt’s condition stabilizes (usually after 2 weeks of AmB therapy in non-CNS disease), the regimen can be switched to itraconazole (200–400 mg/d for 6–12 months). CNS disease is treated initially with AmB; after a total dose of ≥2 g, a switch can be made to fluconazole (800 mg/d for 6–12 months). More indolent infections can be treated with itraconazole (200–400 mg/d for 6–12 months). Among compliant immunocompetent pts, clinical and mycologic response rates are 90–95%.

MALASSEZIA INFECTION

Malassezia species are components of the normal skin flora and can cause tinea (pityriasis) versicolor, the most common superficial skin infection. M. furfur causes catheter-related fungemia in premature neonates and immunocompromised adults receiving IV lipids by central venous catheter.

SPOROTRICHOSIS

Sporothrix schenckii is a dimorphic fungus found in soil, plants, and moss and on animals. Infection, which results from inoculation of the organism into the skin, is seen especially often in florists, gardeners, and nursery workers.

Clinical Features
- **Plaque disease**: Sporotrichosis is limited to the site of inoculation. The lesion enlarges; it may ulcerate and become verrucous.
- **Lymphocutaneous disease**: 80% of cases. Secondary lesions ascend along lymphatics draining the area, producing small painless nodules that erupt, drain, and ulcerate.
- **Osteoarticular disease**: granulomatous tenosynovitis and bursitis, especially in alcoholic pts
- **Pulmonary sporotrichosis and disseminated disease**: can occur in compromised hosts

Diagnosis  
Culture or skin biopsy

Sporotrichosis

Cutaneous sporotrichosis is treated with itraconazole (100–200 mg/d). For extracutaneous disease, itraconazole (200 mg bid) can be given, but AmB is more effective for life-threatening pulmonary disease or disseminated infection.

PARACOCCIDIOIDOMYCOSIS

Paracoccidioidomycosis (South American blastomycosis) is caused by *Paracoccidioides brasiiliensis*, a dimorphic fungus acquired by inhalation from environmental sources. Pulmonary infection follows inhalation of conidia and may disseminate to skin, lymph nodes, and adrenal glands. Diagnosis relies on culture of the organism. Itraconazole is effective, but AmB may be required for seriously ill pts.
Infectious Diseases

SECTION 7

PENICILLIOSIS

Penicillium marneffei is a leading cause of opportunistic infection in pts with immunocompromise (e.g., due to AIDS) in Southeast Asia and is acquired by spore inhalation. Clinical manifestations are similar to those of disseminated histoplasmosis, with fever, weight loss, generalized lymphadenopathy, and hepatomegaly. Diffuse papular lesions are common in pts with AIDS. AmB is the treatment of choice for severely ill pts; less severe disease may be treated with itraconazole. Primary therapy is usually given for 2 months; suppressive therapy with itraconazole may be indicated for pts with HIV infection or AIDS.

FUSARIOSIS

Fusarium species cause necrotic skin lesions in immunocompetent pts at sites of trauma; these fungi cause disseminated disease in immunocompromised pts, especially those who are severely neutropenic. The clinical presentation is generally nonspecific, with fever and skin lesions that become necrotic and resemble ecthyma gangrenosum. Blood cultures are positive in 50% of cases; in contrast, blood cultures are rarely positive in aspergillosis or zygomycosis. Fusarium species are often resistant to antifungal agents; high-dose AmB or voriconazole (6 mg/kg q12h for the first 24 h; then 4 mg/kg q12h) has been successful in some pts.

PSEUDALLESCHERIASIS AND SCEDOSPORIOSIS

Pseudallescheria boydii, Scedosporium apiospermum, and S. prolificans are molds that cause severe pneumonia, invasive sinusitis, and hematogenous dissemination (including brain abscess) in immunocompromised hosts. Most disseminated infections are fatal. AmB is not effective, but some infections have been cured with voriconazole at the doses used to treat fusariosis. Surgical drainage or debridement may be helpful.

DERMATOPHYTOSIS

See Chap. 64.

Pneumocystis, an opportunistic fungal pulmonary pathogen, is an important cause of pneumonia in immunocompromised hosts. *P. jirovecii* infects humans, whereas *P. carinii*—the original species described—infects rats. In contrast to most fungi, *Pneumocystis* lacks ergosterol and is not susceptible to antifungal drugs that inhibit ergosterol synthesis. Developmental stages include the small trophic form, the cyst, and the intermediate precyst stage.

**EPIDEMIOLOGY**

*Pneumocystis* is found worldwide. Most healthy children have been exposed to the organism by 3–4 years of age. Both airborne transmission and person-to-person transmission have been demonstrated.

**PATHOGENESIS**

Defects in cellular and humoral immunity predispose to *Pneumocystis* pneumonia. HIV-infected pts are at particular risk, and the risk rises dramatically when CD4+ T cell counts fall below 200/μL. Other persons at risk include those receiving immunosuppressive therapy (particularly glucocorticoids) for cancer and organ transplantation; those taking biologic agents (e.g., infliximab and etanercept for rheumatoid arthritis and inflammatory bowel disease); malnourished premature infants; and children with primary immunodeficiency disorders. The organisms are inhaled and attach tightly to type I cells in alveoli, although they remain extracellular. On histology, alveoli are seen to be filled with foamy, vacuolated exudates. Severe disease may cause interstitial edema, fibrosis, and hyaline membrane formation.

**CLINICAL AND LABORATORY FEATURES**

Pts develop dyspnea, fever, and nonproductive cough. Pts without HIV infection often become symptomatic after their glucocorticoid dose has been tapered, and symptoms last 1–2 weeks. HIV-infected pts are usually ill for several weeks or longer with more subtle manifestations. On physical examination, pts are found to have tachypnea, tachycardia, and cyanosis, but findings on pulmonary examination are often unremarkable. Reduced arterial oxygen pressure, increased alveolar-arterial oxygen gradient, and respiratory alkalosis are evident. Gallium scans can be positive, with nonspecific uptake in the lungs. Serum lactate dehydrogenase levels can be elevated, but this finding is nonspecific. Chest x-ray classically reveals bilateral diffuse infiltrates beginning in the perihilar regions. Other findings (e.g., nodular densities, cavitary lesions) have been described. Pneumothorax may occur. Rare cases of disseminated infection have been described, mainly in HIV pts taking aerosolized pentamidine. Lymph nodes, spleen, liver, and bone marrow are most often involved.

**DIAGNOSIS**

Histopathologic staining makes the definitive diagnosis. Methenamine silver and other cell wall stains selectively stain the wall of *Pneumocystis* cysts. Wright-Giemsa stains the nuclei of all developmental stages. Immunofluorescence with
monoclonal antibodies increases diagnostic sensitivity. DNA amplification by polymerase chain reaction is most sensitive but may not distinguish colonization from infection. Proper specimens are key. HIV-infected pts have a higher organism burden, and their *Pneumocystis* infections can often be diagnosed by means of sputum induction. However, fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) remains the mainstay of diagnosis. Transbronchial biopsy and open lung biopsy are used only when BAL results are negative.

**COURSE AND PROGNOSIS**

Therapy is most effective if started early, before there is extensive alveolar damage. The mortality rate is 15–20% at 1 month and 50–55% at 1 year among HIV-infected pts. The risk of early death remains high among people who need mechanical ventilation (60%) and among non-HIV-infected pts (40%).

**Pneumocystis** Infections

Pts are classified as having disease that is mild (a PaO2 >70 mmHg or a PAO2 – PaO2 gradient <35 mmHg on room air) or moderate to severe (a PaO2 ≤70 mmHg or a PAO2 – PaO2 gradient ≥35 mmHg). Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice for all pts. For doses and adverse effects of TMP-SMX and alternative regimens, see Table 114-1. For mild to moderate

<table>
<thead>
<tr>
<th>Drug(s), Dose, Route</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First Choice</strong>a</td>
<td></td>
</tr>
<tr>
<td>TMP-SMX (5 mg/kg TMP, 25 mg/kg SMXb) q6–8h PO or IV</td>
<td>Fever, rash, cytopenias, hepatitis, hyperkalemia, GI disturbances</td>
</tr>
<tr>
<td><strong>Other Agents</strong>a</td>
<td></td>
</tr>
<tr>
<td>TMP, 5 mg/kg q6–8h, plus dapsone, 100 mg qd PO</td>
<td>Hemolysis (G6PD deficiency), methemoglobinemia, fever, rash, GI disturbances</td>
</tr>
<tr>
<td>Atovaquone, 750 mg bid PO</td>
<td>Rash, fever, GI and hepatic disturbances</td>
</tr>
<tr>
<td>Clindamycin, 300–450 mg q6h PO or 600 mg q6–8h IV, plus primaquine, 15–30 mg qd PO</td>
<td>Hemolysis (G6PD deficiency), methemoglobinemia, rash, colitis, neutropenia</td>
</tr>
<tr>
<td>Pentamidine, 3–4 mg/kg qd IV</td>
<td>Hypotension, azotemia, cardiac arrhythmias, pancreatitis, dysglycemias, hypocalcemia, neutropenia, hepatitis</td>
</tr>
<tr>
<td>Trimetrexate, 45 mg/m² qd IV, plus leucovorin, c 20 mg/kg q6h PO or IV</td>
<td>Cytopenias, peripheral neuropathy, hepatic disturbances</td>
</tr>
<tr>
<td><strong>Adjunctive Agent</strong></td>
<td></td>
</tr>
<tr>
<td>Prednisone, 40 mg bid × 5 d, 40 mg qd × 5 d, 20 mg qd × 11 d; PO or IV</td>
<td>Immunosuppression, peptic ulcer, hyperglycemia, mood changes, hypertension</td>
</tr>
</tbody>
</table>

aTherapy is administered for 14 days to non-HIV-infected pts and for 21 days to HIV-infected pts.
bEquivalent of 2 double-strength (DS) tablets. (One DS tablet contains 160 mg of TMP and 800 mg of SMX.)
cLeucovorin prevents bone marrow toxicity from trimetrexate.
cases, alternatives include TMP plus dapsone or clindamycin plus primaquine. Atovaquone is less effective than TMP-SMX but is better tolerated. Alternative treatments for moderate to severe infection include parenteral pentamidine, IV clindamycin plus primaquine, or trimetrexate. Clindamycin plus primaquine may be more efficacious than pentamidine. Adjunctive administration of tapering doses of glucocorticoids to HIV-infected pts with moderate to severe disease reduces the risk of respiratory function deterioration shortly after initiation of treatment. The use of glucocorticoids in other pts remains to be evaluated.

PREVENTION

Primary prophylaxis is indicated for HIV-infected pts with CD4+ T cell counts <200/μL or a history of oropharyngeal candidiasis. Guidelines for other compromised hosts are less clear. Secondary prophylaxis is indicated for all pts who have recovered from pneumocystosis. In HIV infection, once CD4+ counts have risen to >200/μL and have remained above that cutoff for ≥3 months, prophylaxis may be stopped. For prophylaxis regimens, see Table 114-2. TMP-SMX is the drug of choice for both primary and secondary prophylaxis and also protects against toxoplasmosis and some bacterial infections.

For a more detailed discussion, see Smulian AG, Walzer PD: Pneumocystis Infection, Chap. 200, p. 1267, in HPIM-17.

### Table 114-2 PROPHYLAXIS OF PNEUMOCYSTOSIS

<table>
<thead>
<tr>
<th>Drug(s), Dose, Route</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First Choice</strong></td>
<td></td>
</tr>
<tr>
<td>TMP-SMX, 1 DS tablet or 1 SS tablet qd PO(^b)</td>
<td>TMP-SMX can be safely reintroduced in some pts who have experienced mild to moderate side effects.</td>
</tr>
<tr>
<td><strong>Other Agents</strong></td>
<td></td>
</tr>
<tr>
<td>Dapsone, 50 mg bid or 100 mg qd PO</td>
<td>—</td>
</tr>
<tr>
<td>Dapsone, 50 mg qd PO, plus pyrimethamine, 50 mg weekly PO, plus leucovorin, 25 mg weekly PO</td>
<td>Leucovorin prevents bone marrow toxicity from pyrimethamine.</td>
</tr>
<tr>
<td>Dapsone, 200 mg weekly PO, plus pyrimethamine, 75 mg weekly PO, plus leucovorin, 25 mg weekly PO</td>
<td>Leucovorin prevents bone marrow toxicity from pyrimethamine.</td>
</tr>
<tr>
<td>Pentamidine, 300 mg monthly via Respigrad II nebulizer</td>
<td>Adverse reactions include cough and bronchospasm.</td>
</tr>
<tr>
<td>Atovaquone, 1500 mg qd PO</td>
<td>—</td>
</tr>
<tr>
<td>TMP-SMX, 1 DS tablet 3 times weekly PO</td>
<td>TMP-SMX can be safely reintroduced in some pts who have experienced mild to moderate side effects.</td>
</tr>
</tbody>
</table>

\(^a\)For list of adverse effects, see Table 114-1.

\(^b\)One DS tablet contains 160 mg of TMP and 800 mg of SMX.

**Note:** DS, double-strength; SS, single-strength.
 Protozoal Infections

MALARIA

Epidemiology  Malaria is the most important parasitic disease in humans, causing 1–3 million deaths each year.

Etiology  Four major species of *Plasmodium* cause nearly all human disease: *P. falciparum*, *P. vivax*, *P. ovale*, and *P. malariae*. *P. falciparum*, the cause of most cases of severe disease and most deaths, predominates in Africa, New Guinea, and Haiti. *P. vivax* is more common in Central America. *P. falciparum* and *P. vivax* are equally prevalent in South America, the Indian subcontinent, eastern Asia, and Oceania. *P. malariae* is less common but is found in most areas (especially throughout sub-Saharan Africa).

Pathogenesis
• Female anopheline mosquitoes inoculate *sporozoites* into humans during a blood meal. Sporozoites are carried to the liver, reproduce asexually, and produce *merozoites* that enter the bloodstream, invade red blood cells (RBCs), and become *trophozoites*. After progressively consuming and degrading intracellular proteins (principally hemoglobin), trophozoites become *schizonts*. When RBCs rupture, the cycle repeats with invasion of new RBCs.
• In *P. vivax* or *P. ovale* infection, dormant forms called *hypnozoites* remain in liver cells and may cause disease 3 weeks to >1 year later.
• Some parasites develop into long-lived sexual forms called *gametocytes*.
• RBCs infected with *P. falciparum* may exhibit *cytoadherence* (attachment to venular and capillary endothelium), *rosetting* (adherence to uninfected RBCs), and *agglutination* (adherence to other infected RBCs). The result is sequestration of *P. falciparum* in vital organs, with consequent underestimation (through parasitemia determinations) of parasite numbers in the body. Sequestration is central to the pathogenesis of falciparum malaria but is not evident in the other three “benign” forms.
• In nonimmune individuals, infection triggers nonspecific host defense mechanisms such as splenic filtration. With repeated exposure to malaria, a specific immune response develops and limits the degree of parasitemia. Over time, pts are rendered immune to disease but remain susceptible to infection. Genetic disorders more common in endemic areas protect against death from malaria (e.g., sickle cell disease, ovalocytosis, thalassemia, and G6PD deficiency).

Clinical Features
• Fever and nonspecific symptoms (headache, fatigue, muscle aches) occur at the onset of disease. Nausea, vomiting, and orthostasis are also common.
• Febrile paroxysms at regular intervals can occur and suggest infection with *P. vivax* or *P. ovale*.
• Splenomegaly may develop along with mild anemia, hepatomegaly, and jaundice.
• Severe falciparum malaria causes multiorgan dysfunction.
  1. Cerebral malaria: coma, obtundation, delirium, diffuse symmetric encephalopathy without focal neurologic signs. Seizures are common in children.
2. Poor prognostic signs: hypoglycemia, especially in children and pregnant women (may be exacerbated by quinine or quinidine treatment); acidosis; noncardiogenic pulmonary edema; renal failure; severe anemia and coagulation abnormalities; severe jaundice and liver dysfunction

- Malaria in pregnancy: Pregnant women have unusually severe illness. Premature labor, stillbirths, delivery of low-birth-weight infants, and fetal distress are common.
- Malaria in children: Most persons who die of malaria are children. Convulsions, coma, hypoglycemia, acidosis, and severe anemia occur at high rates.
- Transfusion malaria: has a shorter incubation period than naturally acquired disease
- Tropical splenomegaly: abnormal response to repeated infections. Pts have massive splenomegaly and, to a lesser degree, hepatomegaly. Pts have a dragging sensation in the abdomen.

**Diagnosis**

- Demonstration of asexual forms of the parasite on peripheral blood smears is required for diagnosis. Giemsa is the preferred stain, but other stains (e.g., Wright’s) can be used. Both thick and thin smears should be examined. Thick smears concentrate parasites by 40- to 100-fold compared with thin smears and increase diagnostic sensitivity. If the level of clinical suspicion is high and smears are initially negative, they should be repeated q12–24h for 2 days.
- Rapid antibody-based diagnostic stick or card tests are available for *P. falciparum*.
- The parasitemia level should be calculated from a thin smear and is expressed as the number of parasitized erythrocytes per 1000 RBCs.
- Other laboratory studies: anemia, elevated erythrocyte sedimentation rate, reduced platelet count (to $10^5/\mu L$)

**Malaria**

See Table 115-1 for treatment options.

- Artemisinin-based combinations are recommended as first-line treatments for falciparum malaria. These agents are not available in the United States for treatment of uncomplicated *P. falciparum* disease, however.
- Severe falciparum malaria: Treatment with parenteral water-soluble artemisinin derivatives reduces mortality rates by 35% from rates obtained with quinine. IV artesunate is available for emergency use in the United States through the Centers for Disease Control and Prevention (CDC) drug service; contact the CDC Malaria Hotline at 770-488-7788 or the CDC Emergency Operations Center at 770-488-7100.
- If falciparum malaria is treated with quinidine, pts should undergo cardiac monitoring; increased QT intervals (>0.6 s) and QRS widening by >25% are indications for slowing the infusion rate.
- Pts with severe falciparum malaria require intensive nursing care and monitoring. Ancillary drugs, including glucocorticoids or heparin, should not be given. Exchange transfusions can be considered for severely ill pts, although indications for their use are not yet agreed upon. Unconscious pts should have blood glucose levels measured q4–6h. Pts with glucose levels of <2.2 mmol/L (<40 mg/dL) and pts treated with IV quinine or quinidine should receive IV dextrose.
- Parasite counts and hematocrits should be measured q6–12h.
### TABLE 115-1 REGIMENS FOR THE TREATMENT OF MALARIA

<table>
<thead>
<tr>
<th>Type of Disease or Treatment</th>
<th>Regimen(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uncomplicated Malaria</strong></td>
<td></td>
</tr>
<tr>
<td>Known chloroquine-sensitive</td>
<td>Chloroquine (10 mg of base/kg stat followed by 5 mg/kg at 12, 24, and 36 h or by 10 mg/kg at 24 h and 5 mg/kg at 48 h) or Amodiaquine (10–12 mg of base/kg qd for 3 days) In addition to chloroquine or amodiaquine as detailed above, primaquine (0.25 mg of base/kg qd; 0.375–0.5 mg of base/kg qd in Southeast Asia and Oceania) should be given for 14 days to prevent relapse. In mild G6PD deficiency, 0.75 mg of base/kg should be given once weekly for 6 weeks. Primaquine should not be given in severe G6PD deficiency.</td>
</tr>
<tr>
<td>strains of <em>Plasmodium vivax, P. malariae, P. ovale, P. falciparum</em>&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Radical treatment for <em>P. vivax</em> or <em>P. ovale</em> infection</td>
<td></td>
</tr>
<tr>
<td>Sensitive <em>P. falciparum</em> malaria&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Artesunate&lt;sup&gt;c&lt;/sup&gt; (4 mg/kg qd for 3 days) plus sulfadoxine (25 mg/kg)/pyrimethamine (1.25 mg/kg) as a single dose or Artesunate&lt;sup&gt;c&lt;/sup&gt; (4 mg/kg qd for 3 days) plus amodiaquine (10 mg of base/kg qd for 3 days)&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Multidrug-resistant <em>P. falciparum</em> malaria</td>
<td>Either artemether-lumefantrine&lt;sup&gt;c&lt;/sup&gt; (1.5/9 mg/kg bid for 3 days with food) or artemunate&lt;sup&gt;c&lt;/sup&gt; (4 mg/kg qd for 3 days) plus Mefloquine (25 mg of base/kg)—either 8 mg/kg qd for 3 days or 15 mg/kg on day 2 and then 10 mg/kg on day 3)&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Second-line treatment/treatment of imported malaria</td>
<td>Either artemunate&lt;sup&gt;c&lt;/sup&gt; (2 mg/kg qd for 7 days) or quinine (10 mg of salt/kg tid for 7 days) plus 1 of the following 3: 1. Tetracycline&lt;sup&gt;e&lt;/sup&gt; (4 mg/kg qid for 7 days) 2. Doxycycline&lt;sup&gt;e&lt;/sup&gt; (3 mg/kg qd for 7 days) 3. Clindamycin (10 mg/kg bid for 7 days) or Atovaquone-proguanil (20/8 mg/kg qd for 3 days with food)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Chloroquine is contraindicated in patients with known or suspected chloroquine-resistant *P. falciparum* malaria. Amodiaquine is contraindicated in patients with known or suspected amodiaquine-resistant *P. falciparum* malaria.

<sup>b</sup> Artesunate is contraindicated in patients with known or suspected artemisinin-resistant *P. falciparum* malaria. Mefloquine is contraindicated in patients with known or suspected mefloquine-resistant *P. falciparum* malaria.

<sup>c</sup> Artemisinin derivatives are contraindicated in patients with known or suspected artemisinin-resistant *P. falciparum* malaria.

<sup>d</sup> Mefloquine is not recommended as a single agent for the treatment of *P. falciparum* malaria.

<sup>e</sup> Tetracycline, doxycycline, and clindamycin are contraindicated in pregnant women and children under 8 years of age.
Protozoal Infections

CHAPTER 115

- Pts should be monitored for vomiting for 1 h after oral malaria treatment, and the dose should be repeated if vomiting occurs.
- Primaquine eradicates persistent liver stages and prevents relapse in *P. vivax* or *P. ovale* infection. G6PD deficiency must be ruled out before treatment.

### Prevention

**Personal Protection Measures**

Measures that can protect persons against infection include avoidance of mosquito exposure at peak feeding times (dusk and dawn) and use of insect repellents containing DEET (10–35%) or (if DEET is unacceptable) picaridin (7%), suitable clothing, and insecticide-impregnated bed nets.

**Chemoprophylaxis**

See Table 115-2 for prophylaxis options.

- Mefloquine is the only drug advised for pregnant women traveling to areas with drug-resistant malaria and is generally considered safe in the second and third trimesters.
- The CDC offers 24-h travel and malaria information at 877-FYI-TRIP.

### TABLE 115-1 REGIMENS FOR THE TREATMENT OF MALARIA (CONTINUED)

<table>
<thead>
<tr>
<th>Type of Disease or Treatment</th>
<th>Regimen(s)</th>
</tr>
</thead>
</table>
| Severe Falciparum Malaria \( ^{f} \) | Artesunate \( ^{c} \) (2.4 mg/kg stat IV followed by 2.4 mg/kg at 12 and 24 h and then daily if necessary) \( ^{g} \)
  or
  Artemether \( ^{c} \) (3.2 mg/kg stat IM followed by 1.6 mg/kg qd)
  or
  Quinine dihydrochloride (20 mg of salt/kg \( ^{h} \) infused over 4 h, followed by 10 mg of salt/kg infused over 2–8 h q8h \( ^{i} \))
  or
  Quinidine (10 mg of base/kg \( ^{h} \) infused over 1–2 h, followed by 1.2 mg of base/kg per hour \( ^{i} \) with electrocardiographic monitoring) |

\( ^{a} \)Very few areas now have chloroquine-sensitive malaria (Fig. 203-2).
\( ^{b} \)In areas where the partner drug to artesunate is known to be effective.
\( ^{c} \)Artemisinin derivatives are not registered in the United States and some other temperate countries.
\( ^{d} \)Fixed-dose coformulated combinations are available.
\( ^{e} \)Tetracycline and doxycycline should not be given to pregnant women or to children <8 years of age.
\( ^{f} \)Oral treatment should be substituted as soon as the patient recovers sufficiently to take fluids by mouth.
\( ^{g} \)Artesunate is the drug of choice when available. The data from large studies in Southeast Asia showed a 35% reduction in mortality rate from that with quinine. Severe malaria in children in high-transmission settings has different characteristics; thus trials are ongoing in Africa comparing artesunate with quinine to determine whether there is a survival benefit in African children.
\( ^{h} \)A loading dose should not be given if therapeutic doses of quinine or quinidine have definitely been administered in the previous 24 h. Some authorities recommend a lower dose of quinidine.
\( ^{i} \)Infusions can be given in 0.9% saline and 5% or 10% dextrose in water. Infusion rates for quinine and quinidine should be carefully controlled.

**Note:** G6PD, glucose-6-phosphate dehydrogenase.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Usage</th>
<th>Adult Dose</th>
<th>Pediatric Dose</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atovaquone/proguanil (Malarone)</td>
<td>Prophylaxis in areas with chloroquine- or mefloquine-resistant <em>Plasmodium falciparum</em></td>
<td>1 adult tablet PO(^a)</td>
<td>5–8 kg: (\frac{1}{2}) pediatric tablet(^b) daily</td>
<td>Begin 1–2 days before travel to malarious areas. Take daily at the same time each day while in the malarious area and for 7 days after leaving such areas. Atovaquone-proguanil is contraindicated in persons with severe renal impairment (creatinine clearance rate &lt;30 mL/min). It is not recommended for children weighing &lt;5 kg, pregnant women, or women breast-feeding infants weighing &lt;5 kg. Atovaquone/proguanil should be taken with food or a milky drink.</td>
</tr>
<tr>
<td>Chloroquine phosphate (Aralen and generic)</td>
<td>Prophylaxis only in areas with chloroquine-sensitive <em>P. falciparum</em>(^c)</td>
<td>300 mg of base (500 mg of salt) PO once weekly</td>
<td>5 mg of base/kg (8.3 mg of salt/kg) PO once weekly, up to a maximum adult dose of 300 mg of base</td>
<td>Begin 1–2 weeks before travel to malarious areas. Take weekly on the same day of the week while in the malarious areas and for 4 weeks after leaving such areas. Chloroquine phosphate may exacerbate psoriasis.</td>
</tr>
<tr>
<td>Doxycycline (many brand names and generic)</td>
<td>Prophylaxis in areas with chloroquine- or mefloquine-resistant <em>P. falciparum</em>(^c)</td>
<td>100 mg PO qd (\geq 8) years of age: 2 mg/kg, up to adult dose</td>
<td>(\geq 8) years of age: 2 mg/kg, up to adult dose</td>
<td>Begin 1–2 days before travel to malarious areas. Take daily at the same time each day while in the malarious areas and for 4 weeks after leaving such areas. Doxycycline is contraindicated in children &lt;8 years of age and in pregnant women.</td>
</tr>
<tr>
<td>Hydroxychloroquine sulfate (Plaquenil)</td>
<td>An alternative to chloroquine for primary prophylaxis only in areas with chloroquine-sensitive <em>P. falciparum</em>(^c)</td>
<td>310 mg of base (400 mg of salt) PO once weekly</td>
<td>5 mg of base/kg (6.5 mg of salt/kg) PO once weekly, up to maximum adult dose of 310 mg of base</td>
<td>Begin 1–2 weeks before travel to malarious areas. Take weekly on the same day of the week while in the malarious areas and for 4 weeks after leaving such areas. Hydroxychloroquine may exacerbate psoriasis.</td>
</tr>
</tbody>
</table>
| **Mefloquine**  
(Lariam and generic) | **Prophylaxis in areas with chloroquine-resistant *P. falciparum*** | 228 mg of base (250 mg of salt) PO once weekly | ≤9 kg: 4.6 mg of base/kg (5 mg of salt/kg) PO once weekly  
10–19 kg: 1/4 tablet once weekly  
20–30 kg: 1/2 tablet once weekly  
31–45 kg: 3/4 tablet once weekly  
≥46 kg: 1 tablet once weekly | Begin 1–2 weeks before travel to malarious areas. Take weekly on the same day of the week while in the malarious areas and for 4 weeks after leaving such areas. Mefloquine is contraindicated in persons allergic to this drug or related compounds (e.g., quinine and quinidine) and in persons with active or recent depression, generalized anxiety disorder, psychosis, schizophrenia, other major psychiatric disorders, or seizures. Use with caution in persons with psychiatric disturbances or a history of depression. Mefloquine is not recommended for persons with cardiac conduction abnormalities. |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primaquine</strong></td>
<td><strong>An option for prophylaxis in special circumstances</strong></td>
<td>30 mg of base (52.6 mg of salt) PO qd</td>
<td>0.5 mg of base/kg (0.8 mg of salt/kg) PO qd, up to adult dose; should be taken with food</td>
<td>Begin 1–2 days before travel to malarious areas. Take daily at the same time each day while in the malarious areas and for 7 days after leaving such areas. Primaquine is contraindicated in persons with G6PD1 deficiency. It is also contraindicated during pregnancy and in lactation unless the infant being breast-fed has a documented normal G6PD level. Use in consultation with malaria experts.</td>
</tr>
<tr>
<td><strong>Primaquine</strong></td>
<td><strong>Used for presumptive antirelapse therapy (terminal prophylaxis) to decrease risk of relapses of <em>P. vivax</em> and <em>P. ovale</em></strong></td>
<td>30 mg of base (52.6 mg of salt) PO qd for 14 days after departure from the malarious area</td>
<td>0.5 mg of base/kg (0.8 mg of salt/kg), up to adult dose, PO qd for 14 days after departure from the malarious area</td>
<td>This therapy is indicated for persons who have had prolonged exposure to <em>P. vivax</em> and/or <em>P. ovale</em>. It is contraindicated in persons with G6PD1 deficiency as well as during pregnancy and in lactation unless the infant being breast-fed has a documented normal G6PD level.</td>
</tr>
</tbody>
</table>

---

*An adult tablet contains 250 mg of atovaquone and 100 mg of proguanil hydrochloride.  
A pediatric tablet contains 62.5 mg of atovaquone and 25 mg of proguanil hydrochloride.  
Very few areas now have chloroquine-sensitive malaria (Fig. 203-2 in HPIM-17).  
**Source:** CDC: [http://wwwn.cdc.gov/travel/contentMalariaDrugsHC.aspx](http://wwwn.cdc.gov/travel/contentMalariaDrugsHC.aspx).
BABESIOSIS

Etiology Babesiosis is caused by intraerythrocytic protozoa of the genus Babesia. B. microti is the most common species in the United States. B. divergens causes disease in Europe.

Epidemiology In the United States, infections occur most frequently along the northeastern coast. Hard-bodied ticks (Ixodes scapularis in the United States and I. ricinus in Europe) transmit the parasite.

Clinical Features
- The incubation period is usually 1–6 weeks. There is a gradual onset of fevers, fatigue, myalgias, arthralgias, and—less often—dyspnea, headache, anorexia, and nausea. Pts have mild hepatosplenomegaly, anemia, thrombocytopenia, and elevated liver enzymes. Parasitemia levels may range from 1 to 10% in immunocompetent pts and up to 85% in asplenic pts.
- Complications include respiratory failure, disseminated intravascular coagulation, congestive heart failure, and renal failure. Immunocompromised pts (e.g., HIV-infected pts, asplenic pts), pts with concurrent Lyme disease, and pts >50 years of age have more severe disease.
- B. divergens causes severe—often fatal—disease in asplenic pts. This illness is characterized by high fevers, hemolytic anemia, jaundice, and renal failure.

Diagnosis Giemsa-stained thin smears identify intraerythrocytic Babesia parasites, which appear annular, oval, or piriform. Ring forms resembling P. falciparum but without pigment are most common. Tetrads (“Maltese crosses”)—formed by four budding merozoites—are pathognomonic for B. microti and other small Babesia species. An indirect immunofluorescence antibody test for B. microti is available from the CDC. Persistent low-grade infection is best diagnosed by polymerase chain reaction (PCR) testing of blood.

Babesiosis
- Mild disease: atovaquone (750 mg q12h PO) plus azithromycin (500–1000 mg/d PO on day 1 followed by 250 mg/d PO for immunocompetent pts or 600–1000 mg/d PO for immunocompromised pts) for 7–10 days
- Severe infections: clindamycin (300–600 mg q6h IV or 600 mg q8h PO) plus quinine (650 mg q6–8h PO). Also consider exchange transfusion.
- B. divergens infection: immediate exchange transfusion; clindamycin (600 mg q6–8h IV) and quinine (650 mg q8h PO)

LEISHMANIASIS

Etiology Leishmania spp. are obligate intracellular protozoa endemic in the tropics, sub tropics, and southern Europe. Organisms of the L. donovani complex usually cause visceral leishmaniasis; L. tropica, L. major, and L. aethiopica cause Old World cutaneous leishmaniasis; and the L. mexicana complex causes New World or American cutaneous leishmaniasis. Leishmaniasis is typically a vector-borne zoonosis caused by the bite of female phlebotomine sandflies. The parasite’s flagellated promastigote is introduced into the mammalian host and transforms into the nonflagellated amastigote within macrophages.
Protozoal Infections

CHAPTER 115

Epidemiology, Prevention, and Control

• Around 90% of visceral leishmaniasis cases occur in southern Asia, the Indian subcontinent, eastern Africa, and the Americas (with particularly high rates in northeastern Brazil). More than 90% of cutaneous cases occur in Afghanistan, the Middle East, Brazil, and Peru.
• Prevention and control measures must be tailored to the specific setting. Personal protective measures include minimizing nocturnal outdoor activities (when sandflies are active) and using protective clothing and insect repellent.

Clinical Features

Visceral Leishmaniasis

• The incubation period can range from weeks to months or even years. Disease manifestations can be acute, subacute, or chronic.
• Kala-azar: The classic picture is of cachectic, febrile pts with massive splenomegaly, hepatomegaly, and life-threatening disease.
• Abnormal laboratory findings include pancytopenia, hypergammaglobulinemia, and hypoalbuminemia.
• The diagnosis should be considered in HIV-infected pts with visceral disease who have been in endemic areas.

Cutaneous Leishmaniasis

• After an incubation period of weeks to months, papular lesions progress to plaques (which can be smooth, scaly, or nodular and can develop central ulceration) and then to atrophic scars. Both active and healed lesions can cause significant morbidity. L. aethiopica and L. mexicana cause chronic, disseminated, nonulcerative skin lesions. Leishmaniasis recidivans, caused by L. tropica, manifests as a chronic solitary cheek lesion that expands slowly with central healing.
• Regional adenopathy, multiple primary and satellite lesions, and bacterial superinfection can occur.

Mucosal Leishmaniasis

This disfiguring sequela of New World cutaneous leishmaniasis results from dissemination of parasites from the skin to the naso-oro-pharyngeal mucosa. Persistent nasal symptoms, such as epistaxis with erythema and edema of the mucosa, are followed by progressive ulcerative destruction.

Diagnosis

• Visceral leishmaniasis: Identification of amastigotes on slides that have been stained (e.g., with Giemsa) or by culture of tissue aspirates or biopsy samples of spleen, liver, bone marrow, or lymph nodes yields the diagnosis. Spleen aspiration poses a high risk of hemorrhage. Seropositivity can be diagnostic in an appropriate setting; the sensitivity of serology is lower in HIV-infected pts.
• Cutaneous and mucosal leishmaniasis: Diagnosis is made by examination of aspirates and biopsy specimens of skin lesions and lymph nodes. Serology is not useful.

Leishmaniasis

• Visceral leishmaniasis: The pentavalent antimonial (Sb⁵⁺) compounds sodium stibogluconate and meglumine antimonate (20 mg/kg per day IV or IM for 28 days) are the first-line therapeutic agents. Amphotericin B (AmB; either deoxycholate or a lipid formulation) is recommended (total dose, 15–20 mg/kg) in areas with Sb⁵⁺ resistance (e.g., northeastern India). The oral agent miltefosine (2.5 mg/kg daily for 28 days) is effective but must be used carefully to prevent the emergence of resistance. Sb⁵⁺ treatment is associated with significant but reversible toxicity (body aches, malaise,
Infectious Diseases

SECTION 7

Infectious Diseases

- Elevated liver function test values, chemical pancreatitis) whose incidence increases as treatment continues.
- Cutaneous leishmaniasis: The decision to treat cutaneous leishmaniasis should be based on therapeutic goals (e.g., accelerating healing, decreasing morbidity), parasite factors (e.g., tissue tropisms and drug sensitivities), and the extent to which the lesions are of concern (e.g., location on the face). Administration of SbV (20 mg/kg daily for 20 days) constitutes the most effective treatment; conventional AmB is likely to be highly effective. The efficacy of oral agents is dependent on species and strain. Local therapies may be considered for cases without demonstrable local dissemination.
- Mucosal leishmaniasis: SbV or conventional AmB is effective. Oral miltefosine shows promise. Glucocorticoid therapy is indicated if respiratory compromise develops after the start of therapy.

TRYPANOSOMIASIS

CHAGAS’ DISEASE

Etiology and Pathology Trypanosoma cruzi causes Chagas’ disease (also known as American trypanosomiasis) and is transmitted among mammalian hosts by hematophagous reduviid bugs. One week after parasitic invasion, an indurated inflammatory lesion appears at the portal of entry, and organisms disseminate through the lymphatics and the bloodstream, often parasitizing muscles particularly heavily.

Epidemiology Chagas’ disease is the most important parasitic disease in Latin America. T. cruzi is found mostly among the poor in rural Mexico and Central and South America. An estimated 12 million persons are infected, with 25,000 deaths annually.

Clinical Features
- Acute disease: An indurated area of erythema and swelling (the chagoma) with local lymphadenopathy may appear. Romaña’s sign—unilateral painless edema of the palpebrae and periocular tissues—occurs when the conjunctiva is the portal of entry.
  1. Malaise, fever, anorexia, rash, lymphadenopathy, and hepatosplenomegaly develop.
  2. After symptoms resolve spontaneously, pts enter an asymptomatic phase.
- Chronic disease: becomes apparent years to decades after initial infection
  1. Heart: rhythm disturbances, dilated cardiomyopathy, thromboembolism. Right bundle branch block and other conduction abnormalities may occur.
  2. Megaesophagus: dysphagia, odynophagia, chest pain, and aspiration. Weight loss, cachexia, or pulmonary infection can cause death.
  3. Megacolon: abdominal pain, chronic constipation. Advanced megacolon can cause obstruction, volvulus, septicemia, and death.

Diagnosis Microscopic examination of fresh anticoagulated blood or theuffy coat may reveal motile organisms. Giemsa-stained thin and thick blood smears can also be used. If attempts to visualize the organism fail, PCR or hemoculture can be performed. Chronic Chagas’ disease is diagnosed by detection of specific antibodies. The assays vary in specificity and sensitivity; false-positive results pose a particular problem. A positive result should be confirmed by at least two assays. The U.S. Food and Drug Administration has approved a test to screen blood and organ donors for T. cruzi.
Protozoal Infections

CHAPTER 115

Chagas’ Disease

Acute Chagas’ disease is treated with nifurtimox, which reduces symptom duration, parasitemia level, and mortality rate but cures only ~70% of pts. Treatment should be initiated as early as possible in acute disease. Adults should receive 8–10 mg/kg daily in four divided oral doses for 90–120 days. Higher doses are given to children and adolescents. Adverse drug effects include abdominal pain, anorexia, nausea, vomiting, weight loss, and neurologic reactions such as restlessness, disorientation, insomnia, paresthesia, and seizures. In Latin America, the drug of choice is benznidazole (5 mg/kg per day for 60 days). Benznidazole is associated with peripheral neuropathy, rash, and granulocytopenia. Treatment of chronic Chagas’ disease is controversial. The current consensus of Latin American authorities is that pts up to 18 years of age should receive treatment.

SLEEPING SICKNESS

Etiology and Epidemiology  Sleeping sickness (human African trypanosomiasis) is caused by parasites of the *T. brucei* complex and is transmitted via tsetse flies. *T. b. rhodesiense* causes the East African form and *T. b. gambiense* the West African form. During stage I of infection, the parasites disseminate through the lymphatics and the bloodstream. Central nervous system (CNS) invasion occurs during stage II. West African infection occurs primarily in rural populations and rarely develops in tourists. East African disease has reservoirs in antelope and cattle; tourists can be infected when visiting areas where infected game and vectors are present.

Clinical Features  A painful chancre sometimes appears at the site of inoculation. Stage I is marked by bouts of high fever alternating with afebrile periods and by lymphadenopathy with discrete, rubbery, nontender nodes. *Winterbottom’s sign*—the enlargement of nodes of the posterior cervical triangle—is a classic sign. Pruritus and maculopapular rashes are common. Malaise, headache, arthralgias, hepatosplenomegaly, and other nonspecific manifestations can develop. In stage II, pts develop progressive indifference and daytime somnolence, a state that sometimes alternates with restlessness and insomnia. Extrapyramidal signs may include choreiform movements, tremors, and fasciculations; ataxia is common. Progressive neurologic impairment may end in coma and death. East African disease is a more acute illness that, without treatment, generally leads to death in weeks or months.

Diagnosis  Examination of fluid from the chancre, thin or thick blood smears, lymph node aspirates, bone marrow biopsy specimens, or cerebrospinal fluid (CSF) samples can reveal the parasite. CSF should be examined whenever the diagnosis is being considered. Increased opening pressure, increased protein level, and increased mononuclear cell counts are common. Parasites can be visualized in the sediment of centrifuged CSF.

Sleeping Sickness

Treatment is toxic and must be closely supervised.

- **Stage I disease**
  - East African: suramin (a test dose of 100–200 mg followed by 20 mg/kg IV on days 1, 5, 12, 18, and 26). Fever, photophobia, pruritus, arthralgias, skin eruptions, and renal damage can occur. Severe reactions (shock, seizures) can be fatal.
Infectious Diseases

**West African**: pentamidine (4 mg/kg daily IM or IV for 10 days). Serious adverse reactions include nephrotoxicity, abnormal liver function, neutropenia, hypoglycemia, and sterile abscesses. Suramin is the alternative treatment.

- **Stage II disease**
  - East African: melarsoprol (2–3.6 mg/kg daily in 3 divided doses for 3 days; 1 week later, 3.6 mg/kg per day in 3 divided doses for 3 days; 1 week later, the latter course repeated). To reduce melarsoprol-induced encephalopathy, administer prednisolone (1 mg/kg up to 40 mg daily, starting 1–2 days before the first dose of melarsoprol and continuing through the last dose).
  - West African: Eflornithine (400 mg/kg per day in 4 divided doses for 2 weeks) is the first-line agent, with melarsoprol as an alternative.

## TOXOPLASMOSIS

**Etiology and Epidemiology**

Toxoplasmosis is caused by the intracellular parasite *Toxoplasma gondii*. In the United States and most European countries, seroconversion rates increase with age and exposure. Cats and their prey are the definitive hosts. Transmission occurs when humans ingest oocysts from contaminated soil or tissue cysts from undercooked meat. Acute infection with *T. gondii* during pregnancy results in transmission to the fetus in about one-third of cases. Congenital infection can occur if the mother is infected <6 months before conception and becomes increasingly likely throughout pregnancy, with a 65% likelihood if the mother is infected in the third trimester.

**Pathogenesis**

Both humoral and cellular immunity are important, but infection commonly persists. Such lifelong infection usually remains subclinical. Compromised hosts do not control infection; progressive focal destruction and organ failure occur.

**Clinical Features**

- Disease in immunocompetent hosts is usually asymptomatic and self-limiting and does not require therapy; 80–90% of cases go unrecognized. Cervical lymphadenopathy is the most common finding; nodes are nontender and discrete. Generalized lymphadenopathy can occur. Fever, headache, malaise, and fatigue are documented in 20–40% of pts with lymphadenopathy.

  - Immunocompromised pts, including those with AIDS and those receiving immunosuppressive treatment for lymphoproliferative disorders, are at greatest risk. Most clinical disease is due to reactivated latent infection.
  1. CNS: principal site of involvement. Findings include encephalopathy, meningoencephalitis, and mass lesions. Pts may exhibit changes in mental status, fever, seizures, headaches, and aphasia. The brainstem, basal ganglia, pituitary gland, and corticomedullary junction are most often involved.
  2. Pneumonia: Dyspnea, fever, and nonproductive cough can progress to respiratory failure. *Toxoplasma* pneumonia is often confused with *Pneumocystis* pneumonia.
  3. Miscellaneous sites: GI tract, pancreas, eyes, heart, liver

- Congenital infection affects 400–4000 infants each year in the United States. Severe disease, manifesting as hydrocephalus, microcephaly, mental retardation, and chorioretinitis, is more common the earlier the infection is contracted.
Protozoal Infections

CHAPTER 115

• Ocular infection: T. gondii is estimated to cause ~35% of all cases of choriotexitis in the United States and Europe. Most cases are associated with congenital infection. Blurred vision, scotoma, photophobia, and eye pain are manifestations of infection; macular involvement can occur with loss of central vision. On examination, yellow-white cotton-like patches with indistinct margins of hyperemia are seen. Older lesions appear as white plaques with distinct borders and black spots.

Diagnosis
• Acute toxoplasmosis can be diagnosed by the demonstration of tachyzoites in tissue or by documentation of the simultaneous presence of serum IgM and IgG antibodies to T. gondii.
• In AIDS pts, the infection is diagnosed presumptively on the basis of clinical presentation and a positive test for IgG antibody to T. gondii. In these pts, CT or MRI of the brain shows lesions that are often multiple and contrast enhancing. A single lesion may prove to be a CNS lymphoma rather than toxoplasmosis.
• Congenital toxoplasmosis is diagnosed by PCR of the amniotic fluid (to detect the B1 gene of the parasite) and by the persistence of IgG antibody or a positive IgM titer after the first week of life; IgG antibody determinations should be repeated every 2 months.
• Ocular toxoplasmosis is diagnosed by the detection of typical lesions on ophthalmologic examination and the demonstration of a positive IgG titer.

PourToxoplasmosis

• Congenital infection: daily pyrimethamine (0.5–1 mg/kg) and sulfadiazine (100 mg/kg) for 1 year. If infection is diagnosed and treated early, up to 70% of children can have normal findings at follow-up evaluations.
• Ocular disease: pyrimethamine and sulfadiazine or clindamycin for 1 month
• Immunocompromised pts: pyrimethamine (200-mg PO loading dose followed by 50–75 mg/d) plus sulfadiazine (4–6 g/d PO, divided into 4 doses) plus leucovorin (10–15 mg/d). Pyrimethamine (75 mg/d) plus clindamycin (450 mg tid) is an alternative. Glucocorticoids are often used to treat intracerebral edema. After 4–6 weeks (or after radiographic improvement), the pt may be switched to chronic suppressive therapy (secondary prophylaxis) with pyrimethamine (25–50 mg/d) plus sulfadiazine (2–4 g/d), pyrimethamine (75 mg/d) plus clindamycin (450 mg tid), or pyrimethamine alone (50–75 mg/d).

Chemoprophylaxis The risk of disease is very high among AIDS pts who are seropositive for T. gondii and have a CD4+ T lymphocyte count of <100/μL. Trimethoprim-sulfamethoxazole (one double-strength tablet daily) should be given to these pts as prophylaxis against both Pneumocystis pneumonia and toxoplasmosis. Primary or secondary prophylaxis can be stopped if, after institution of antiretroviral treatment, the CD4+ T lymphocyte count increases to >200/μL and remains above that cutoff for 3 months.

Personal Protection Measures Toxoplasma infection can be prevented by avoiding undercooked meats and oocyst-contaminated materials (e.g., cats’ litter boxes).
Helminthic Infections and Ectoparasite Infestations

HELMINTHS

NEMATODES

The nematodes, or roundworms, that are of medical significance can be broadly classified as either tissue or intestinal parasites.

Tissue Nematode Infections

Trichinellosis  

**Etiology**  

*T. spiralis* and seven other *Trichinella* species cause human infection.

**Life Cycle and Epidemiology**  

Infection results when humans ingest meat (usually pork) that contains cysts with *Trichinella* larvae. During the first week of infection, the larvae invade the small-bowel mucosa; during the second and third weeks, they mature into adult worms, which release new larvae that migrate to striated muscle via the circulation and encyst.

**Clinical Features**  

Light infections (<10 larvae per gram of muscle) are asymptomatic. A burden of >50 larvae per gram can cause fatal disease.

- Week 1: diarrhea, abdominal pain, constipation, nausea, and/or vomiting
- Week 2: hypersensitivity reactions with fever and hypereosinophilia; periorbital and facial edema; hemorrhages in conjunctivae, retina, and nail beds; maculopapular rash; headache; cough; dyspnea; dysphagia. Deaths are usually due to myocarditis with arrhythmias or congestive heart failure and are less often caused by pneumonitis or encephalitis.
- Weeks 2–3: myositis, myalgias, muscle edema, weakness (especially in extraocular muscles, biceps, neck, lower back, and diaphragm). Symptoms peak at 3 weeks; convalescence is prolonged.

**Diagnosis**

- Eosinophilia in >90% of pts, peaking at a level of >50% at 2–4 weeks
- Elevated IgE and muscle enzyme levels; increase in specific antibody titers by week 3
- A definitive diagnosis is made by the detection of larvae on biopsy of at least 1 g of muscle tissue. Yields are highest near tendon insertions.
**Trichinellosis**

Drugs are ineffective against muscle larvae, but mebendazole (200–400 mg tid for 3 days; then 400 mg tid for 8–14 days) and albendazole (400 mg bid for 8–14 days) may be active against enteric-stage parasites. Glucocorticoids (1 mg/kg daily for 5 days) may reduce severe myositis and myocarditis.

**Prevention**  Cooking pork until it is no longer pink or freezing it at 15˚C for 3 weeks kills larvae and prevents infection.

**Visceral and Ocular Larva Migrans  Etiology**  Most cases of larva migrans are caused by *Toxocara canis*.

**Life Cycle and Epidemiology**  Infection results when humans—most often preschool children—ingest soil contaminated by puppy feces that contain infective *T. canis* eggs. Larvae penetrate the intestinal mucosa and disseminate hematogenously to a wide variety of organs [e.g., liver, lungs, central nervous system (CNS)], provoking intense eosinophilic granulomatous responses.

**Clinical Features**  Heavy infections may cause fever, malaise, anorexia, weight loss, cough, wheezing, rashes, and hepatosplenomegaly. Ocular disease usually develops in older children or young adults and includes endophthalmitis, uveitis, chorioretinitis, and/or an eosinophilic mass that mimics retinoblastoma.

**Diagnosis**  No eggs are found in the stool because larvae do not develop into adult worms. Blood eosinophilia up to 90%, leukocytosis, and hypergamma-globulinemia may be evident. Toxocaral antibodies can be detected by enzyme-linked immunosorbent assay (ELISA).

**Visceral and Ocular Larva Migrans**

Glucocorticoids can reduce inflammatory complications. Ocular infections can be treated with albendazole (800 mg bid for adults and 400 mg bid for children) for 5–20 days in conjunction with glucocorticoids.

**Cutaneous Larva Migrans**  This disease is caused by larvae of animal hookworms, usually the dog and cat hookworm *Ancylostoma braziliense*. Larvae in contaminated soil penetrate human skin; erythematous lesions form along the tracks of their migration and advance several centimeters each day. Pruritus is intense. Vesicles or bullae may form. Ivermectin (a single dose of 200 μg/kg) or albendazole (200 mg bid for 3 days) can relieve the symptoms of this self-limited infestation.

**Intestinal Nematode Infections**  Intestinal nematodes infect >1 billion persons worldwide in regions with poor sanitation, particularly in developing countries in the tropics or subtropics. These parasites contribute to malnutrition and diminished work capacity.

**Ascariasis  Etiology**  Ascariasis is caused by *Ascaris lumbricoides*, the largest intestinal nematode, which reaches lengths up to 40 cm. The parasite is transmitted via fecally contaminated soil.

**Life Cycle**  Swallowed eggs hatch in the intestine, invade the mucosa, migrate to the lungs, break into the alveoli, ascend the bronchial tree, are swallowed, reach the small intestine, mature, and produce up to 240,000 eggs per day that pass in the feces.
**Clinical Features**  Most infections have a low worm burden and are asymptomatic. During lung migration of the parasite, pts may develop a cough and substernal discomfort, occasionally with dyspnea or blood-tinged sputum, fever, and eosinophilia. Eosinophilic pneumonitis (Löffler’s syndrome) may be evident. Heavy infections occasionally cause pain, small-bowel obstruction, perforation, volvulus, biliary obstruction and colic, or pancreatitis.

**Laboratory Findings**  *Ascaris* eggs (65 by 45 μm) can be found in fecal samples. Adult worms can pass in the stool or through the mouth or nose. During the transpulmonary migratory phase, larvae can be found in sputum or gastric aspirates.

**Rx**  

**Ascariasis**

A single dose of albendazole (400 mg), mebendazole (500 mg), or ivermectin (150–200 μg/kg) is effective. Pyrantel pamoate (a single dose of 11 mg/kg, up to 1 g) is safe in pregnancy.

**Hookworm  Etiology**  Two hookworm species, *Ancylostoma duodenale* and *Necator americanus*, cause human infections.

**Life Cycle**  Infectious larvae penetrate the skin, reach the lungs via the bloodstream, invade the alveoli, ascend the airways, are swallowed, reach the small intestine, mature into adult worms, attach to the mucosa, and suck blood and interstitial fluid.

**Clinical Features**  Most infections are asymptomatic. Chronic infection causes iron deficiency and—in marginally nourished persons—progressive anemia and hypoproteinemia, weakness, shortness of breath, and skin depigmentation.

**Laboratory Findings**  Hookworm eggs (40 by 60 μm) can be found in the feces. Stool concentration may be needed for the diagnosis of light infections.

**Rx**  

**Hookworm**

Albendazole (400 mg once), mebendazole (500 mg once), or pyrantel pamoate (11 mg/kg daily for 3 days) is effective. Nutritional support, iron replacement, and deworming are undertaken as needed.

**Strongyloidiasis  Etiology and Epidemiology**  Unlike other helminths, *Strongyloides stercoralis* can replicate in the human host, permitting ongoing cycles of autoinfection from endogenously produced larvae. Autoinfection is most common among immunocompromised hosts, including those receiving glucocorticoids. Hyperinfection and widespread larval dissemination can occur in these pts. However, severe disease due to *Strongyloides* is unusual in HIV-infected pts.

**Life Cycle**  Infection results when filariform larvae in fecally contaminated soil penetrate the skin or mucous membranes. Larvae travel through the bloodstream to the lungs, break through alveolar spaces, ascend the bronchial tree, are swallowed, reach the small intestine, mature into adult worms, and penetrate the mucosa of the proximal small bowel; eggs hatch in the intestinal mucosa. Rhabditiform larvae can pass with the feces into the soil or can develop into filariform larvae that penetrate the colonic wall or perianal skin and enter the circulation to establish ongoing autoinfection.
Clinical Features   Uncomplicated disease is associated with mild cutaneous and/or abdominal manifestations such as urticaria, larva currens (a pathognomonic serpiginous, pruritic, erythematous eruption along the course of larval migration that may advance up to 10 cm/h), abdominal pain, nausea, diarrhea, bleeding, and weight loss. Colitis, enteritis, or malabsorption can develop. Disseminated disease involves extraintestinal tissues, including the CNS, peritoneum, liver, and kidney. Bacteremia can develop when enteric flora components enter the bloodstream through disrupted mucosal barriers. Gram-negative sepsis, pneumonia, or meningitis can complicate the disease.

Diagnosis   Eosinophilia is common, with levels that fluctuate over time. Eggs are rarely found in feces because they hatch in the colon. A single stool examination detects rhabditiform larvae (~250 μm long) in about one-third of uncomplicated infections. Duodenojejunal contents can be sampled if stool examinations are negative. Antibodies can be detected by ELISA. In disseminated infection, filariform larvae can be found in stool or at sites of larval migration.

Strongyloidiasis

Ivermectin (200 μg/kg daily for 2 days) is more effective than albendazole (400 mg daily for 3 days). Disseminated disease should be treated with ivermectin for ≥5–7 days.

Enterobiasis   Etiology   Enterobiasis (pinworm) is caused by Enterobius vermicularis.

Life Cycle   Adult worms in the bowel lumen migrate nocturnally out into the perianal region, releasing immature eggs that become infective within hours. Autoinfection results from perianal scratching and transport of infective eggs to the mouth. Person-to-person spread occurs. Pinworm is common among schoolchildren and their household contacts and among institutionalized populations.

Clinical Features   Perianal pruritus is the cardinal symptom and is often worst at night.

Diagnosis   Eggs in the perianal region are detected by application of cellulose acetate tape in the morning. Eggs measure 55 by 25 μm and are flattened on one side.

Enterobiasis

One dose of mebendazole (100 mg), albendazole (400 mg), or pyrantel pamoate (11 mg/kg; maximum, 1 g) is given, with the same treatment repeated after 2 weeks. Household members should also be treated.

Filarial and Related Infections   Filarial worms are nematodes that dwell in the SC tissue and lymphatics. More than 170 million people are infected worldwide. Infection is established only with repeated and prolonged exposures to infective larvae. Disease tends to be more intense and acute in newly exposed individuals than in natives of endemic areas.

Life Cycle   Insects transmit infective larvae to humans. Adult worms reside in lymphatics or SC tissues; their offspring are microfilariae (200–250 μm long, 5–7 μm wide) that either circulate in the blood or migrate through the skin.
Subperiodic forms are those that are present in peripheral blood at all times and peak in the afternoon. Nocturnally periodic forms are scarce in peripheral blood by day and increase by night. Adult worms live for years; microfilariae live for 3–36 months. A rickettsia-like endosymbiont, Wolbachia, is found in all stages of the four major filarial species that cause human disease and may prove to be a target for future antifilarial chemotherapy.

Lymphatic Filariasis  
**Etiology**  
*Wuchereria bancrofti*, *Brugia malayi*, or *B. timori* can reside in lymphatic channels or lymph nodes. *W. bancrofti* is most common and usually is nocturnally periodic.

**Pathology**  
Adult worms cause inflammatory damage to the lymphatics.

**Clinical Features**  
Asymptomatic microfilaremia, hydrocele, acute adenolymphangitis (ADL), and chronic lymphatic disease are the main clinical presentations. ADL is associated with high fever, lymphatic inflammation, and transient local edema. *W. bancrofti* particularly affects genital lymphatics. ADL may progress to lymphatic obstruction and elephantiasis with brawny edema, thickening of the SC tissues, and hyperkeratosis. Superinfection is a problem.

**Diagnosis**  
Detection of the parasite is difficult, but microfilariae can be found in peripheral blood, hydrocele fluid, and occasionally other body fluids. Timing of blood collection is critical. Two assays are available to detect *W. bancrofti* circulating antigens, and a polymerase chain reaction (PCR) has been developed to detect DNA of both *W. bancrofti* and *B. malayi* in the blood. High-frequency ultrasound of the scrotum or the female breast can identify motile adult worms. Pts have eosinophilia and elevated IgE levels. The presence of antifilarial antibody supports the diagnosis, but cross-reactivity with other helminthic infections makes interpretation difficult.

**Diethylcarbamazine (DEC) given at 6 mg/kg daily for 12 days is the standard regimen, but one dose may be equally efficacious. An alternative is albendazole (400 mg bid for 21 days), but this drug may be less effective than DEC. An 8-week course of daily doxycycline, which targets *Wolbachia* endosymbionts, has significant macrofilaricidal activity and sustained microfilaricidal activity, as does a 7-day course of daily DEC/albendazole.**

**Prevention**  
- Mosquito control or personal protective equipment can minimize bites.
- Mass annual distribution of albendazole with DEC or ivermectin for community-based control reduces microfilaremia and interrupts transmission.

Onchocerciasis  
**Etiology**  
Onchocerciasis (“river blindness”) is caused by *Onchocerca volvulus*, is the second leading cause of infectious blindness worldwide, and is transmitted by the bite of an infected blackfly. The blackfly vector breeds along free-flowing rivers and streams and restricts its flight to an area within several kilometers of these breeding sites.

**Life Cycle**  
Larvae develop into adult worms that are found in SC nodules (*onchocercomata*). After months or years, microfilariae migrate out of the nodules and concentrate in the dermis. Onchocerciasis affects primarily the skin, eyes, and lymph nodes. Microfilariae cause inflammation and fibrosis. Neovascularization and corneal scarring cause corneal opacities and blindness.
**Clinical Features**

- Skin: Pruritus and rash are the most common manifestations.
- Onchocercomata: palpable and/or visible, firm and nontender
- Ocular tissue: Conjunctivitis with photophobia is an early finding. Sclerosing keratitis, anterior uveitis, iridocyclitis, and secondary glaucoma due to anterior uveal tract deformity are complications.
- Lymphadenopathy: especially in the inguinal and femoral areas

**Diagnosis**  
A definitive diagnosis is based on the finding of an adult worm in an excised nodule or of microfilariae in a skin snip. Eosinophilia and elevated serum IgE levels are common. Specific antibody assays and PCR to detect onchocercal DNA are available in some laboratories.

---

**Onchocerciasis**

Nodules on the head should be excised to avoid ocular infection. Ivermectin in a single dose of 150 μg/kg, given yearly or semiannually, is the mainstay of treatment. In regions where *O. volvulus* is co-endemic with *Loa loa*, ivermectin is contraindicated because of the risk of severe posttreatment encephalopathy. Doxycycline therapy for 6 weeks may render adult female worms sterile for long periods and also targets the *Wolbachia* endosymbiont.

---

**Trematodes**

The trematodes, or flatworms, may be classified according to the tissues invaded by the adult flukes. The life cycle involves a definitive mammalian host in which adult worms produce eggs and an intermediate host (e.g., snails) in which larval forms multiply. Worms do not multiply within the definitive host. Human infection results from either direct penetration of intact skin or ingestion.

**Schistosomiasis**

**Etiology**  
Schistosomes are blood flukes that infect 200–300 million persons in South America, the Caribbean, Africa, the Middle East, and Southeast Asia. Five species cause human schistosomiasis: the intestinal species *Schistosoma mansoni*, *S. japonicum*, *S. mekongi*, and *S. intercalatum* and the urinary species *S. haematobium*. Infection is initiated by penetration of intact skin by infective cercariae—the form of the parasite released from snails in freshwater bodies. As they mature into schistosomes, the parasites reach the portal vein; they mate and then migrate to the venules of the bladder and ureters (*S. haematobium*) or the mesentery (*S. mansoni*, *S. japonicum*, *S. mekongi*, *S. intercalatum*) and deposit eggs. Some mature ova are extruded into the intestinal or urinary lumina, from which they may be voided and ultimately may reach water and perpetuate the life cycle. The persistence of other ova in tissues leads to a granulomatous host response and fibrosis. Factors governing disease manifestations include the intensity and duration of infection, the site of egg deposition, and the genetic characteristics of the host.

**Pathogenesis**  
In the liver, granulomata cause presinusoidal portal blockage, hemodynamic changes (including portal hypertension), and periportal fibrosis. Similar processes occur in the bladder.

**Clinical Features**

Clinical manifestations vary by species, intensity of infection, and host factors.

- Cercarial invasion (“swimmers’ itch”): An itchy maculopapular rash develops 2–3 days after parasitic invasion. This condition is most frequently
caused by *S. mansoni* or *S. japonicum* but is most severe if due to avian schistosomes, which invade human skin but then die in SC tissue.

- **Acute schistosomiasis (Katayama fever):** A serum sickness–like illness with fever, generalized lymphadenopathy, hepatosplenomegaly, and peripheral blood eosinophilia may develop during worm maturation and at the start of oviposition. Parasite-specific antibodies may be detected before eggs are seen in excreta.

- **Chronic schistosomiasis causes manifestations that depend primarily on the schistosome species.**
  1. Intestinal species cause colicky abdominal pain, bloody diarrhea, anemia, hepatosplenomegaly, and portal hypertension. Esophageal varices with bleeding, ascites, hypoalbuminemia, and coagulation defects are late complications.
  2. Urinary species cause dysuria, frequency, hematuria, obstruction with hydroureter and hydroureter and hydronephrosis, fibrosis of bladder granulomas, and late development of squamous cell carcinoma of the bladder.
  3. Granulomata and fibrosis at other sites (e.g., in the lungs and the CNS) may occur.

**Diagnosis** Diagnosis is based on clinical presentation, blood eosinophilia, and a positive serologic assay for schistosomal antibodies. Examination of stool or urine can yield positive results. Infection may also be diagnosed by examination of tissue samples (e.g., rectal biopsies).

**Schistosomiasis**

Severe acute schistosomiasis requires hospitalization and supportive measures along with a consideration of glucocorticoid treatments. After the acute critical phase has resolved, praziquantel results in parasitologic cure in ~85% of cases. The recommended doses are 20 mg/kg bid for 1 day for *S. mansoni*, *S. intercalatum*, and *S. haematobium* infections and 20 mg/kg tid for 1 day for *S. japonicum* and *S. mekongi* infections. Late established manifestations, such as fibrosis, do not improve with treatment.

**Prevention** Travelers should avoid contact with all freshwater bodies.

**Liver (Biliary) Flukes** Stool ova and parasite (O & P) examination diagnoses infection with liver flukes.

- Clonorchiasis and opisthorchiasis occur in Southeast Asia. Infection is acquired by ingestion of contaminated raw freshwater fish. Chronic infection causes cholangitis, cholangiohepatitis, and biliary obstruction and is associated with cholangiocarcinoma. Therapy for acute infection consists of praziquantel administration (25 mg/kg tid for 1 day).

- Fascioliasis is endemic in sheep-raising countries. Infection is acquired by ingestion of contaminated aquatic plants (e.g., watercress). Acute disease causes fever, right upper quadrant (RUQ) pain, hepatomegaly, and eosinophilia. Chronic infection is associated with bile duct obstruction and biliary cirrhosis. For treatment, triclabendazole is given as a single dose of 10 mg/kg.

**Lung Flukes** Infection with *Paragonimus* spp. is acquired by ingestion of contaminated crayfish and freshwater crabs. Acute infection causes lung hemorrhage, necrosis with cyst formation, and parenchymal eosinophilic infiltrates. A productive cough, with brownish or bloody sputum, in association with peripheral blood eosinophilia is the usual presentation in pts with heavy infection. In
chronic cases, bronchitis or bronchiectasis may predominate. CNS disease can also occur and can result in seizures. The diagnosis is made by O & P examination of sputum or stool. Praziquantel (25 mg/kg tid for 2 days) is the therapeutic agent of choice.

**CESTODES**

The cestodes, or tapeworms, can be classified into two groups, according to whether humans are the definitive or the intermediate hosts. The tapeworm attaches to intestinal mucosa via sucking cups or hooks located on the scolex. Proglottids (segments) form behind the scolex and constitute the bulk of the tapeworm. Eggs of the various *Taenia* species are identical; thus diagnosis to the species level relies on differences in the morphology of the scolex or proglottids.

**Taeniasis Saginata**  
**Etiology and Pathogenesis**  
Humans are the definitive host for *Taenia saginata*, the beef tapeworm, which inhabits the upper jejunum. Eggs are excreted in feces and ingested by cattle or other herbivores; larvae encyst (cysticerci) in the striated muscles of these animals. When humans ingest raw or undercooked beef, the cysticerci mature into adult worms.

**Clinical Features**  
Pts may experience perianal discomfort, mild abdominal pain, nausea, change in appetite, weakness, and weight loss.

**Diagnosis**  
The diagnosis is made by detection of eggs or proglottids in the stool. Eggs may be found in the perianal area. Eosinophilia may develop, and IgE levels may be elevated.

![Taeniasis Saginata](image)

Praziquantel is given in a single dose of 10 mg/kg.

**Taeniasis Solium and Cysticercosis**  
**Etiology and Pathogenesis**  
Humans are the definitive host and pigs the usual intermediate host for *T. solium*, the pork tapeworm. The disease, which is due to ingestion of pork infected with cysticerci, is similar to taeniasis saginata. If humans ingest *T. solium* eggs (e.g., as a result of close contact with a tapeworm carrier or via autoinfection), they develop cysticercosis. Larvae penetrate the intestinal wall and are carried to many tissues, where cysticerci develop.

**Clinical Features**  
- Intestinal infections: Epigastric discomfort, nausea, a sensation of hunger, weight loss, and diarrhea can occur, but most infections are asymptomatic.
- Cysticercosis: Cysticerci can be found anywhere in the body but most often are detected in the brain, skeletal muscle, SC tissue, or eye. Neurologic manifestations are most common and include seizures due to inflammation surrounding cysticerci in the brain, hydrocephalus (from obstruction of cerebrospinal fluid flow by cysticerci and accompanying inflammation or by arachnoiditis), headache, nausea, vomiting, changes in vision, dizziness, ataxia, and confusion.

**Diagnosis**  
Intestinal infection is diagnosed by detection of eggs or proglottids in stool. A consensus conference has delineated criteria for the diagnosis of cysticercosis (*Table 116-1*). Findings on neuroimaging include cystic lesions with or without enhancement, one or more nodular calcifications, or focal enhancing lesions.
Infectious Diseases

SECTION 7

Taeniasis Solium and Cysticercosis

Intestinal infections respond to a single dose of praziquantel (10 mg/kg). Neurocysticercosis can be treated with albendazole (15 mg/kg per day for 8–28 days) or praziquantel (50–60 mg/kg daily in 3 divided doses for 15–30 days). Pts should be carefully monitored, given the potential for an inflammatory response to treatment, and high-dose glucocorticoids should be used during treatment. Since glucocorticoids induce praziquantel metabolism, cimetidine should be given with praziquantel to inhibit this effect. Supportive measures include antiepileptic administration and treatment of hydrocephalus as indicated.

Echinococcosis  Etiology and Pathogenesis  Echinococcosis is an infection of humans that is caused by Echinococcus larvae. The adult worm of E. granulosus lives in the jejunum of dogs and releases eggs that humans may ingest. Disease is prevalent in areas where livestock is raised in association with dogs. After ingestion, embryos escape from the eggs, penetrate the intestinal mucosa, enter the portal circulation, and are carried to many organs but particularly the liver and lungs. Larvae develop into fluid-filled unilocular hydatid cysts within which daughter cysts develop, as do germinating cystic structures. Cysts expand over years. E. multilocularis, found in arctic or subarctic regions, is simi-
lar, but rodents are the intermediate hosts. The parasite is multilocular, and vesicles progressively invade host tissue by peripheral extension of processes from the germinal layer.

**Clinical Features** Expanding cysts exert the effects of space-occupying lesions, causing symptoms in the affected organ. Pts with hepatic disease most commonly present with abdominal pain or a palpable mass in the RUQ. Compression of a bile duct may cause biliary obstruction or may mimic cholelithiasis. Rupture or leakage from a hydatid cyst may cause fever, pruritus, urticaria, eosinophilia, or anaphylaxis. Pulmonary cysts may rupture into the bronchial tree or the peritoneal cavity and cause cough, chest pain, or hemoptysis. Rupture of cysts may result in multifocal dissemination. *E. multilocularis* disease may present as a hepatic tumor, with destruction of the liver and extension into vital structures.

**Diagnosis** Radiographic imaging is important in evaluating echinococcal cysts. Daughter cysts within a larger cyst are pathognomonic of *E. granulosus*. Eggshell or mural calcification on CT is also indicative of *E. granulosus* infections. Serology may be useful but can be negative in up to half of pts with lung cysts. Serology is usually positive in pts with hepatic disease. Aspiration of cysts usually is not attempted because leakage of cyst fluid can cause dissemination or anaphylactic reactions.

**Echinococcosis** Ultrasound staging is recommended for *E. granulosus* infection. Therapy is based on considerations of the size, location, and manifestations of cysts and the overall health of the pt. For some uncomplicated lesions, percutaneous aspiration, infusion of scolicidal agents, and reaspiration are recommended. Albendazole (15 mg/kg daily in 2 divided doses for 4 days before the procedure and for at least 4 weeks afterward) is given for prophylaxis of secondary peritoneal echinococcosis due to inadvertent spillage of fluid during this treatment. Surgery is the treatment of choice for complicated *E. granulosus* cysts. Albendazole should also be given prophylactically, as just described. Praziquantel (50 mg/kg daily for 2 weeks) may hasten the death of protoscolices. Medical therapy alone with albendazole for 12 weeks to 6 months results in cure in ~30% of cases and in clinical improvement in another 50%. *E. multilocularis* infection is treated surgically, and albendazole is given for at least 2 years after presumptively curative surgery. If surgery is not curative, albendazole should be continued indefinitely.

**Diphyllobothriasis** *Diphyllobothrium latum*, the longest tapeworm (up to 25 cm), attaches to the ileal and occasionally the jejunal mucosa. Humans are infected by eating raw fish. Symptoms are rare and usually mild, but infection can cause vitamin B\textsubscript{12} deficiency because the tapeworm absorbs large amounts of vitamin B\textsubscript{12} and interferes with ileal B\textsubscript{12} absorption. Up to 2% of infected pts, especially the elderly, have megaloblastic anemia resembling pernicious anemia and can suffer neurologic sequelae due to B\textsubscript{12} deficiency. The diagnosis is made by detection of eggs in the stool. Praziquantel (5–10 mg/kg once) is highly effective.

**ECTOPARASITES** Ectoparasites are arthropods or helminths that infest the skin of other animals, from which they derive sustenance. These organisms can incidentally inflict direct injury, elicit hypersensitivity, or inoculate toxins or pathogens.
Scabies  
**Etiology**  
Scabies is caused by the human itch mite *Sarcoptes scabiei*.

**Life Cycle and Epidemiology**  
Gravid female mites burrow beneath the stratum corneum, deposit eggs that mature in 2 weeks, and emerge as adults to reinvoke the same or another host. Scabies transmission is facilitated by intimate contact with an infested person and by crowding, uncleanliness, or contact with multiple sexual partners. The itching and rash are due to a sensitization reaction against excreta of the mite. Immunity and associated scratching limit most infestations to <15 mites per person. Norwegian or crusted scabies—hyperinfection with thousands of mites—is associated with glucocorticoid use and immunodeficiency diseases.

**Clinical Features**  
Itching is worst at night and after a hot shower. Burrows appear as dark wavy lines that end in a pearly bleb containing the female mite. Most lesions are between the fingers or on the volar wrists, elbows, and penis. Bacterial superinfection can occur.

**Diagnosis**  
Scrapings from unroofed burrows reveal the mite, its eggs, or fecal pellets.

---

Scabies  
Permethrin cream (5%) should be applied thinly behind the ears and from the neck down after bathing and removed 8 h later with soap and water. A dose of ivermectin (200 μg/kg) is also effective but is not yet approved by the U.S. Food and Drug Administration for scabies treatment. For crusted scabies, first a keratolytic agent (e.g., 6% salicylic acid) and then scabicides are applied to the scalp, face, and ears in addition to the rest of the body. Two doses of ivermectin, separated by an interval of 1–2 weeks, may be required in pts with crusted scabies. Itching and hypersensitivity may persist for weeks or months in scabies and should be managed with symptom-based treatment. Bedding and clothing should be washed in hot water and dried in a heated dryer, and close contacts should be treated to prevent reinfections.

---

Pediculiasis  
**Etiology and Epidemiology**  
Nymphs and adults of human lice—*Pediculus capitis* (the head louse), *P. humanus* (the body louse), and *Pthirus pubis* (the pubic louse)—feed at least once a day and ingest human blood exclusively. The saliva of these lice produces an irritating rash in sensitized persons. Eggs are cemented firmly to hair or clothing, and empty eggs (nits) remain affixed for months after hatching. Lice are generally transmitted from person to person. Head lice are transmitted among schoolchildren and body lice among persons who do not change their clothes often; pubic lice are usually transmitted sexually. The body louse is a vector for the transmission of diseases such as louse-borne typhus, relapsing fever, and trench fever.

**Diagnosis**  
The diagnosis can be suspected if nits are detected, but confirmatory measures should include the demonstration of a live louse.

---

Pediculiasis  
If live lice are found, treatment with 1% permethrin (two 10-min applications 10 days apart) is usually adequate. If this course fails, treatment for ≤12 h with 0.5% malathion may be indicated. Ivermectin may be useful in cases resistant to permethrin and malathion. Eyelid infestations should be treated with petrolatum applied for 3–4 days. The hair should be combed with a fine-
toothed comb to remove nits. Pediculicides applied from head to foot may be needed in hirsute pts to remove body lice. Clothes and bedding should be de-loused by placement in a hot dryer for 30 minutes or by heat pressing.

**Myiasis**  In this infestation, maggots invade living or necrotic tissue or body cavities and produce clinical syndromes that vary with the species of fly. In wound and body-cavity myiasis, flies are attracted to blood and pus, and newly hatched larvae enter wounds or diseased skin. Treatment consists of maggot removal and tissue debridement.

**Leech Infestations**  Medicinal leeches can reduce venous congestion in surgical flaps or replanted body parts. *Aeromonas hydrophila* colonizes the gullets of commercially available leeches.

This page intentionally left blank
General examination of a pt with suspected heart disease should include vital signs (respiratory rate, pulse, blood pressure), skin color (e.g., cyanosis, pallor), clubbing, edema, evidence of decreased perfusion (cool and sweaty skin), and hypertensive changes in optic fundi. Examine abdomen for evidence of hepatomegaly, ascites, or abdominal aortic aneurysm. An ankle-brachial index (systolic bp at ankle divided by arm systolic bp) <0.9 indicates lower extremity arterial obstructive disease. Important findings on cardiovascular examination include:

**CAROTID ARTERY PULSE**  (Fig. 117-1)

- **Pulsus parvus**: Weak upstroke due to decreased stroke volume (hypovolemia, LV failure, aortic or mitral stenosis).
- **Pulsus tardus**: Delayed upstroke (aortic stenosis).
- **Bounding (hyperkinetic) pulse**: Hyperkinetic circulation, aortic regurgitation, patent ductus arteriosus, marked vasodilatation.
- **Pulsus bisferiens**: Double systolic pulsation in aortic regurgitation, hypertrophic cardiomyopathy.
- **Pulsus alternans**: Regular alteration in pulse pressure amplitude (severe LV dysfunction).
- **Pulsus paradoxus**: Exaggerated inspiratory fall (>10 mmHg) in systolic bp (pericardial tamponade, severe obstructive lung disease).

**JUGULAR VENOUS PULSATION (JVP)**

Jugular venous distention develops in right-sided heart failure, constrictive pericarditis, pericardial tamponade, obstruction of superior vena cava. JVP normally
falls with inspiration but may rise (Kussmaul’s sign) in constrictive pericarditis. Abnormalities in examination include:

- **Large “a” wave**: Tricuspid stenosis (TS), pulmonic stenosis, AV dissociation (right atrium contracts against closed tricuspid valve).
- **Large “v” wave**: Tricuspid regurgitation, atrial septal defect.
- **Steep “y” descent**: Constrictive pericarditis.
- **Slow “y” descent**: Tricuspid stenosis.

### TABLE 117-1 HEART MURMURS

<table>
<thead>
<tr>
<th>Murmurs</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Systolic Murmurs</strong></td>
<td></td>
</tr>
<tr>
<td>Ejection-type</td>
<td>Aortic outflow tract</td>
</tr>
<tr>
<td></td>
<td>Aortic valve stenosis</td>
</tr>
<tr>
<td></td>
<td>Hypertrophic obstructive cardiomyopathy</td>
</tr>
<tr>
<td></td>
<td>Aortic flow murmur</td>
</tr>
<tr>
<td></td>
<td>Pulmonary outflow tract</td>
</tr>
<tr>
<td></td>
<td>Pulmonic valve stenosis</td>
</tr>
<tr>
<td></td>
<td>Pulmonic flow murmur</td>
</tr>
<tr>
<td>Holosystolic</td>
<td>Mitral regurgitation</td>
</tr>
<tr>
<td></td>
<td>Tricuspid regurgitation</td>
</tr>
<tr>
<td></td>
<td>Ventricular septal defect</td>
</tr>
<tr>
<td>Late-systolic</td>
<td>Mitral or tricuspid valve prolapse</td>
</tr>
<tr>
<td><strong>Diastolic Murmurs</strong></td>
<td></td>
</tr>
<tr>
<td>Early diastolic</td>
<td>Aortic valve regurgitation</td>
</tr>
<tr>
<td></td>
<td>Pulmonic valve regurgation</td>
</tr>
<tr>
<td>Mid-to-late diastolic</td>
<td>Mitral or tricuspid stenosis</td>
</tr>
<tr>
<td>Continuous</td>
<td>Flow murmur across mitral or tricuspid valves</td>
</tr>
<tr>
<td></td>
<td>Patent ductus arteriosus</td>
</tr>
<tr>
<td></td>
<td>Coronary AV fistula</td>
</tr>
<tr>
<td></td>
<td>Ruptured sinus of Valsalva aneurysm</td>
</tr>
</tbody>
</table>
PRECORDIAL PALPATION

Cardiac apical impulse is normally localized in the fifth intercostal space, mid-clavicular line (Fig. 117-2). Abnormalities include:

- **Forceful apical thrust**: Left ventricular hypertrophy.
- **Lateral and downward displacement of apex impulse**: Left ventricular dilatation.
- **Prominent presystolic impulse**: Hypertension, aortic stenosis, hypertrophic cardiomyopathy.
- **Double systolic apical impulse**: Hypertrophic cardiomyopathy.
- **Sustained “lift” at lower left sternal border**: Right ventricular hypertrophy.
- **Dyskinetic (outward bulge) impulse**: Ventricular aneurysm, large dyskinetic area post MI, cardiomyopathy.

AUSCULTATION

HEART SOUNDS (Fig. 117-2)

$S_1$ **Loud**: Mitral stenosis, short PR interval, hyperkinetic heart, thin chest wall. **Soft**: Long PR interval, heart failure, mitral regurgitation, thick chest wall, pulmonary emphysema.

TABLE 117-2 EFFECTS OF PHYSIOLOGIC AND PHARMACOLOGIC INTERVENTIONS ON THE INTENSITY OF HEART MURMURS AND SOUNDS

| Respiration | Systolic murmurs due to TR or pulmonic blood flow through a normal or stenotic valve and diastolic murmurs of TS or PR generally increase with inspiration, as do right-sided $S_3$ and $S_4$. Left-sided murmurs and sounds usually are louder during expiration, as is the PES. |
| Valsalva maneuver | Most murmurs decrease in length and intensity. Two exceptions are the systolic murmur of HCM, which usually becomes much louder, and that of MVP, which becomes longer and often louder. Following release of the Valsalva maneuver, right-sided murmurs tend to return to control intensity earlier than left-sided murmurs. |
| After VPB or AF | Murmurs originating at normal or stenotic semilunar valves increase in the cardiac cycle following a VPB or in the cycle after a long cycle length in AF. By contrast, systolic murmurs due to AV valve regurgitation either do not change, diminish (papillary muscle dysfunction), or become shorter (MVP). |
| Positional changes | With standing, most murmurs diminish, two exceptions being the murmur of HCM, which becomes louder, and that of MVP, which lengthens and often is intensified. With squatting, most murmurs become louder, but those of HCM and MVP usually soften and may disappear. Passive leg raising usually produces the same results. |
| Exercise | Murmurs due to blood flow across normal or obstructed valves (e.g., PS, MS) become louder with both isotonic and submaximal isometric (hand-grip) exercise. Murmurs of MR, VSD, and AR also increase with handgrip exercise. However, the murmur of HCM often decreases with near maximum handgrip exercise. Left-sided $S_4$ and $S_3$ are often accentuated by exercise, particularly when due to ischemic heart disease. |

Note: TR, tricuspid regurgitation; TS, tricuspid stenosis; PR, pulmonic regurgitation; HCM, hypertrophic cardiomyopathy; MVP, mitral valve prolapse; PS, pulmonic stenosis; MS, mitral stenosis; MR, mitral regurgitation; PES, pulmonic ejection sound; VSD, ventricular septal defect; AR, aortic regurgitation; VPB, ventricular premature beat; AF, atrial fibrillation.
S₂ Normally A₂ precedes P₂ and splitting increases with inspiration; abnormalities include:

- **Widened** splitting: Right bundle branch block, pulmonic stenosis, mitral regurgitation.
- **Fixed** splitting (no respiratory change in splitting): Atrial septal defect.
- **Narrow** splitting: Pulmonary hypertension.
- **Paradoxical** splitting (splitting narrows with inspiration): Aortic stenosis, left bundle branch block, CHF.
- **Loud** A₂: Systemic hypertension.
- **Soft** A₂: Aortic stenosis (AS).
- **Loud** P₂: Pulmonary arterial hypertension.
- **Soft** P₂: Pulmonic stenosis (PS).

S₃ Low-pitched, heard best with bell of stethoscope at apex, following S₂; normal in children; after age 30–35, indicates LV failure or volume overload.

S₄ Low-pitched, heard best with bell at apex, preceding S₁; reflects atrial contraction into a noncompliant ventricle; found in AS, hypertension, hypertrophic cardiomyopathy, and coronary artery disease (CAD).

**Opening Snap (OS)** High-pitched; follows S₂ (by 0.06–0.12 s), heard at lower left sternal border and apex in mitral stenosis (MS); the more severe the MS, the shorter the S₂–OS interval.

**Ejection Clicks** High-pitched sounds following S₁; observed in dilatation of aortic root or pulmonary artery, congenital AS (loudest at apex) or PS (upper left sternal border); the latter decreases with inspiration.

**Figure 117-3** A. Schematic representation of ECG, aortic pressure (AOP), left ventricular pressure (LVP), and left atrial pressure (LAP). The gray areas indicated a transvalvular pressure difference during systole. HSM, holosystolic murmur; MSM, midsystolic murmur. B. Graphic representation of ECG, aortic pressure (AOP), left ventricular pressure (LVP), and left atrial pressure (LAP) with gray areas indicating transvalvular diastolic pressure difference. EDM, early diastolic murmur; PSM, presystolic murmur; MDM, middiastolic murmur.
Midsystolic Clicks  At lower left sternal border and apex, often followed by late systolic murmur in mitral valve prolapse.

HEART MURMURS  (Tables 117-1 and 117-2, Fig. 117-3)

Systolic Murmurs  May be “crescendo-decrescendo” ejection type, pansystolic, or late systolic; right-sided murmurs (e.g., tricuspid regurgitation) typically increase with inspiration.

Diastolic Murmurs
- Early diastolic murmurs: Begin immediately after S₂, are high-pitched, and are usually caused by aortic or pulmonary regurgitation.
- Mid-to-late diastolic murmurs: Low-pitched, heard best with bell of stethoscope; observed in MS or TS; less commonly due to atrial myxoma.
- Continuous murmurs: Present in systole and diastole (envelops S₂); found in patent ductus arteriosus and sometimes in coarctation of aorta; less common causes are systemic or coronary AV fistula, aortopulmonary septal defect, ruptured aneurysm of sinus of Valsalva.

For a more detailed discussion, see O’Rourke RA, Braunwald E: Physical Examination of the Cardiovascular System, Chap. 220, p. 1382, in HPIM-17.

118  Electrocardiography

STANDARD APPROACH TO THE ECG

Normally, standardization is 1.0 mV per 10 mm, and paper speed is 25 mm/s (each horizontal small box = 0.04 s).

Heart Rate  Beats/min = 300 divided by the number of large boxes (each 5 mm apart) between consecutive QRS complexes. For faster heart rates, divide 1500 by number of small boxes (1 mm apart) between each QRS.

Rhythm  Sinus rhythm is present if every P wave is followed by a QRS, PR interval ≥ 0.12 s, every QRS is preceded by a P wave, and the P wave is upright in leads I, II, and III. Arrhythmias are discussed in Chaps. 129 and 130.

Mean Axis  If QRS is primarily positive in limb leads I and II, then axis is normal. Otherwise, find limb lead in which QRS is most isoelectric (R = S). The mean axis is perpendicular to that lead (Fig. 118-1). If the QRS complex is positive in that perpendicular lead, then mean axis is in the direction of that lead; if negative, then mean axis points directly away from that lead.

Left-axis deviation (more negative than −30°) occurs in diffuse left ventricular disease, inferior MI; also in left anterior hemiblock (small R, deep S in leads II, III, and aVF).
Right-axis deviation (>90°) occurs in right ventricular hypertrophy (R > S in V1) and left posterior hemiblock (small Q and tall R in leads II, III, and aVF). Mild right-axis deviation is seen in thin, healthy individuals (up to 110°).

**Intervals (Normal Values in Parentheses)**

**PR (0.12–0.20 s)**
- **Short:** (1) preexcitation syndrome (look for slurred QRS upstroke due to “delta” wave), (2) nodal rhythm (inverted P in aVF).
- **Long:** first-degree AV block (Chap. 129).

**QRS (0.06–0.10 s)**  
- **Wide:** (1) ventricular premature beats, (2) bundle branch blocks: right (RsR’ in V1, deep S in V6) and left [RR’ in V6 (Fig. 118-2)], (3) toxic levels of certain drugs (e.g., quinidine), (4) severe hypokalemia.

**QT (<50% of RR interval; corrected QT ≤ 0.44 s)**  
- **Prolonged:** congenital, hypokalemia, hypocalcemia, drugs (e.g., quinidine, procainamide, tricyclics).

**Hypertrophy**
- **Right atrium:** P wave ≥ 2.5 mm in lead II.
- **Left atrium:** P biphasic (positive, then negative) in V1, with terminal negative force wider than 0.04 s.
- **Right ventricle:** R > S in V1 and R in V1 > 5 mm; deep S in V6, right-axis deviation.
- **Left ventricle:** S in V1 plus R in V5 or V6 ≥ 35 mm or R in aVL > 11 mm.

**Infarction** (Figs. 118-3 and 118-4)  
- **Q-wave MI:** Pathologic Q waves (≥0.04 s and ≥25% of total QRS height) in leads shown in Table 118-1; acute non-Q-
Electrocardiography

CHAPTER 118

wave MI shows ST-T changes in these leads without Q wave development. A number of conditions (other than acute MI) can cause Q waves (Table 118-2).

ST-T Waves

- **ST elevation**: Acute MI, coronary spasm, pericarditis (concave upward) (see Fig. 123-1 and Table 123-2), LV aneurysm, Brugada pattern (RBBB with ST elevation in V1–V2).
- **ST depression**: Digitalis effect, strain (due to ventricular hypertrophy), ischemia, or nontransmural MI.

![Intraventricular conduction abnormalities](image1)

**FIGURE 118-2** Intraventricular conduction abnormalities. Illustrated are right bundle branch block (RBBB); left bundle branch block (LBBB); left anterior hemiblock (LAH); right bundle branch block with left anterior hemiblock (RBBB + LAH); and right bundle branch block with left posterior hemiblock (RBBB + LPH). (Reproduced from RJ Myerburg: HPIM-12.)

![Sequence of depolarization and repolarization changes](image2)

**FIGURE 118-3** Sequence of depolarization and repolarization changes with (A) acute anterior and (B) acute inferior wall Q-wave infarctions. With anterior infarcts, ST elevation in leads I, aVL, and the precordial leads may be accompanied by reciprocal ST depressions in leads II, III, and aVF. Conversely, acute inferior (or posterior) infarcts may be associated with reciprocal ST depressions in leads V1 to V3. (After AL Goldberger: Clinical Electrocardiography: A Simplified Approach, 7th ed. St. Louis, Mosby/Elsevier, 2006.)
Acute inferior wall myocardial infarction. The ECG of 11/29 shows minor nonspecific ST-segment and T-wave changes. On 12/5 an acute myocardial infarction occurred. There are pathologic Q waves (1), ST-segment elevation (2), and terminal T-wave inversion (3) in leads II, III, and aVF indicating the location of the infarct on the inferior wall. Reciprocal changes in aVL (small arrow). Increasing R-wave voltage with ST depression and increased voltage of the T wave in V₂ are characteristic of true posterior wall extension of the inferior infarction. (*Reproduced from RJ Myerburg: HPIM-12.*)

**TABLE 118-1** LEADS WITH ABNORMAL Q WAVES IN MI

<table>
<thead>
<tr>
<th>Leads with Abnormal Q Waves</th>
<th>Site of Infarction</th>
</tr>
</thead>
<tbody>
<tr>
<td>V₁–V₂</td>
<td>Anteroseptal</td>
</tr>
<tr>
<td>V₃–V₄</td>
<td>Apical</td>
</tr>
<tr>
<td>I, aVL, V₅–V₆</td>
<td>Anterolateral</td>
</tr>
<tr>
<td>II, III, aVF</td>
<td>Inferior</td>
</tr>
<tr>
<td>V₁–V₂ (tall R, not deep Q)</td>
<td>True posterior</td>
</tr>
</tbody>
</table>

**TABLE 118-2** DIFFERENTIAL DIAGNOSIS OF Q WAVES (WITH SELECTED EXAMPLES)

Physiologic or positional factors  
1. Normal variant “septal” Q waves  
2. Normal variant Q waves in V₁ to V₂, aVL, III, and aVF  
3. Left pneumothorax or dextrocardia  
Myocardial injury or infiltration  
1. Acute processes: myocardial ischemia or infarction, myocarditis, hyperkalemia  
2. Chronic processes: myocardial infarction, idiopathic cardiomyopathy, myocarditis, amyloid, tumor, sarcoid, scleroderma  
Ventricular hypertrophy/enlargement  
1. Left ventricular (poor R-wave progression)  
2. Right ventricular (reversed R-wave progression)  
3. Hypertrophic cardiomyopathy  
Conduction abnormalities  
1. Left bundle branch block  
2. Wolff-Parkinson-White patterns

*Small or absent R waves in the right to midprecordial leads.  
• **Tall peaked T**: Hyperkalemia; acute MI (“hyperacute T”).
• **Inverted T**: Non-Q-wave MI, ventricular “strain” pattern, drug effect (e.g., digitalis), hypokalemia, hypocalcemia, increased intracranial pressure (e.g., subarachnoid bleed).

For a more detailed discussion, see Goldberger AL: Electrocardiography, Chap. 221, p. 1398 in HPIM-17.

## 119 Noninvasive Examination of the Heart

### ECHOCARDIOGRAPHY (Table 119-1 and Fig. 119-1)

Visualizes heart in real time with ultrasound; Doppler recordings noninvasively assess hemodynamics and abnormal flow patterns. Imaging may be compromised in patients with chronic obstructive lung disease, thick chest wall, or narrow intercostal spaces.

#### Chamber Size and Ventricular Performance

Size of atria and ventricles can be accurately measured. Global and regional systolic wall motion abnormalities of both ventricles can be assessed; ventricular hypertrophy/infiltration may be visualized; evidence of pulmonary hypertension may be obtained. RV systolic pressure (RVSP) is calculated from maximum velocity of tricuspid regurgitation (TR):

\[
RVSP = 4 \times (TR \text{ velocity})^2 + RA \text{ pressure}
\]

(RA pressure is same as JVP estimated by physical exam). In absence of RV outflow obstruction, RVSP = pulmonary artery systolic pressure.

LV diastolic function is assessed by transmitral Doppler (see Fig. 222-5, page 1399 in HPIM-17) and Doppler tissue imaging, which measures velocity of myocardial relaxation.

### TABLE 119-1 CLINICAL USES OF ECHOCARDIOGRAPHY

<table>
<thead>
<tr>
<th>Method</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-D echo</td>
<td>Cardiac chambers: size, hypertrophy, wall motion abnormalities</td>
</tr>
<tr>
<td></td>
<td>Valves: morphology and motion</td>
</tr>
<tr>
<td></td>
<td>Pericardium: effusion, tamponade</td>
</tr>
<tr>
<td></td>
<td>Aorta: Aneurysm, dissection</td>
</tr>
<tr>
<td></td>
<td>Assess intracardiac masses</td>
</tr>
<tr>
<td>Doppler echocardiography</td>
<td>Valvular stenosis and regurgitation</td>
</tr>
<tr>
<td></td>
<td>Intracardiac shunts</td>
</tr>
<tr>
<td></td>
<td>Diastolic filling/dysfunction</td>
</tr>
<tr>
<td></td>
<td>Approximate intracardiac pressures</td>
</tr>
<tr>
<td>Transesophageal echocardiography</td>
<td>Superior to 2-D echo to identify:</td>
</tr>
<tr>
<td></td>
<td>Infective endocarditis</td>
</tr>
<tr>
<td></td>
<td>Cardiac source of embolism</td>
</tr>
<tr>
<td></td>
<td>Prosthetic valve dysfunction</td>
</tr>
<tr>
<td></td>
<td>Aortic dissection</td>
</tr>
<tr>
<td>Stress echocardiography</td>
<td>Assess myocardial ischemia and viability</td>
</tr>
</tbody>
</table>
Valvular Abnormalities Thickness, mobility, calcification, and regurgitation of each cardiac valve can be assessed. Severity of valvular stenosis is calculated by Doppler \[ \text{peak gradient} = 4 \times (\text{peak velocity})^2 \]. Structural lesions (e.g., flail leaflet, vegetation) resulting in regurgitation may be identified and Doppler estimates severity of regurgitation.

Pericardial Disease Echo is noninvasive modality of choice to rapidly identify pericardial effusion and assess its hemodynamic significance; in tamponade there is diastolic RA and RV collapse, dilatation of IVC, exaggerated respiratory alterations in transvalvular Doppler velocities. Actual thickness of pericardium (e.g., in suspected constrictive pericarditis) is better measured by CT or MRI.

Intracardiac Masses May visualize atrial or ventricular thrombus, intracardiac tumors, and valvular vegetations. Yield of identifying cardiac source of embolism is low in absence of cardiac history or physical findings. Transesophageal echocardiography (TEE) is more sensitive than standard transthoracic study for masses < 1 cm in diameter.

**FIGURE 119-1** Two-dimensional echocardiographic still-frame images of a normal heart. Upper: Parasternal long axis view during systole and diastole (left) and systole (right). During systole, there is thickening of the myocardium and reduction in the size of the left ventricle (LV). The valve leaflets are thin and open widely. Lower: Parasternal short axis view during diastole (left) and systole (right) demonstrating a decrease in the left ventricular cavity size during systole as well as an increase in wall thickness. LA, left atrium; RV, right ventricle; Ao, aorta. (Reproduced from RJ Myerburg in HPIM-12.)
Aortic Disease  Aneurysm and dissection of the aorta may be evaluated and complications (aortic regurgitation, tamponade) assessed (Chap. 132) by standard transthoracic echo. TEE is more sensitive and specific for aortic dissection.

Congenital Heart Disease  (See Chap. 120)
Echo, Doppler, and contrast echo (rapid IV injection of agitated saline) are useful in identifying congenital lesions and shunts.

Stress Echocardiography  Echo performed prior to, and after, treadmill or bicycle exercise identifies regions of prior MI and inducible myocardial ischemia (↓ regional contraction with exercise) Dobutamine pharmacologic stress echo can be substituted for patients who cannot exercise.

NUCLEAR CARDIOLOGY

Uses nuclear isotopes to assess LV perfusion and contractile function.

Ventricular Function Assessment  Blood pool imaging is obtained by injecting intravenous 99mTc-labeled albumin or RBCs to quantify LV ejection fraction. Contractile function can also be assessed during gated single photon emission CT (SPECT) myocardial perfusion exercise test imaging (see below).
<table>
<thead>
<tr>
<th></th>
<th>Echo</th>
<th>Nuclear</th>
<th>CT(^a)</th>
<th>MRI(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LV Size/function</td>
<td>Initial modality of choice</td>
<td>Available from gated SPECT stress imaging</td>
<td>Best resolution</td>
<td>Best resolution</td>
</tr>
<tr>
<td></td>
<td>Low cost, portable</td>
<td></td>
<td>Highest cost</td>
<td>Highest cost</td>
</tr>
<tr>
<td></td>
<td>Provides ancillary structural and hemo-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>dynamic information</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valve disease</td>
<td>Initial modality of choice</td>
<td></td>
<td>Visualize valve motion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Valve motion</td>
<td></td>
<td>Delineate abnormal flow</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Doppler hemodynamics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pericardial disease</td>
<td>Pericardial effusion</td>
<td></td>
<td>Pericardial thickening</td>
<td>Pericardial thickening</td>
</tr>
<tr>
<td></td>
<td>Doppler hemodynamics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aortic disease</td>
<td>TEE rapid diagnosis(^c)</td>
<td></td>
<td>Image entire aorta</td>
<td>Image entire aorta</td>
</tr>
<tr>
<td></td>
<td>Acute dissection</td>
<td></td>
<td>Acute aneurysm</td>
<td>Aortic aneurysm</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Aortic dissection</td>
<td>Chronic dissection</td>
</tr>
<tr>
<td>Cardiac masses</td>
<td>TTE—large intracardiac masses</td>
<td></td>
<td>Extracardiac masses</td>
<td>Extracardiac masses</td>
</tr>
<tr>
<td></td>
<td>TEE—smaller intracardiac masses(^c)</td>
<td></td>
<td>Myocardial masses</td>
<td>Myocardial masses</td>
</tr>
</tbody>
</table>

\(^a\)Contrast required.  
\(^b\)Relative contraindication: pacemakers, metallic objects, claustrophobic.  
\(^c\)When not seen on TTE.

**Note:** Echo, echocardiography; SPECT, single-photon emission CT; TEE, transesophageal echocardiography; TTE, transthoracic echocardiogram.
Nuclear Myocardial Perfusion Assessment  SPECT imaging using $^{201}$Tl or $^{99m}$Tc-labeled compounds (sestamibi or tetrofosmin), obtained at peak exercise and at rest, depicts zones of prior infarction as fixed defects and regions of inducible myocardial ischemia as reversible defects. Nuclear imaging is more sensitive, but less specific, than stress echocardiography for detection of ischemia.

For patients who can’t exercise, pharmacologic perfusion imaging with adenosine, dipyridamole, or dobutamine is used instead (see Chap. 128). For patients with LBBB, perfusion imaging with adenosine or dipyridamole is preferred to avoid artifactual septal defects that are common with exercise imaging.

Pharmacologic positron emission tomography scanning is especially useful in imaging obese patients and to assess myocardial viability.

**MAGNETIC RESONANCE IMAGING (MRI)**

Delineates cardiac structures with high resolution without ionizing radiation. Excellent technique to characterize intracardiac masses, the pericardium, great vessels, and anatomic relationships in congenital heart disease. MRI with delayed gadolinium enhancement (avoid in patients with renal insufficiency) differentiates ischemic from nonischemic cardiomyopathy and is useful in assessing myocardial viability.

**COMPUTED TOMOGRAPHY (CT)**

Provides high-resolution images of cardiac structures and detects coronary calcification in atherosclerosis with high sensitivity (but low specificity). CT angiography delineates abnormalities of the great vessels, including aortic aneurysms and dissection, and pulmonary embolism. Multislice spiral CT is evolving technology that provides high-resolution images of coronary anatomy; it is currently most useful for evaluating suspected coronary anatomic anomalies and to “rule out” high-grade coronary stenoses in patients with chest pain and intermediate pretest probability of coronary artery disease.

*Table 119-2* summarizes key diagnostic features of the noninvasive imaging modalities.

For a more detailed discussion, see Nishimura RA, Gibbons RJ, Glockner JF, Tajik AJ: Noninvasive Cardiac Imaging: Echocardiography, Nuclear Cardiology, and MRI/CT Imaging, Chap. 222, p. 1397 in HPIM-17.
ACyanotic Congenital Heart Lesions
With Left-to-Right Shunt

Atrial Septal Defect (ASD)
Most common is ostium secundum ASD, located at mid interatrial septum. Sinus venosus type ASD involves the high atrial septum and may be associated with anomalous pulmonary venous drainage to the right heart. Ostium primum ASDs (e.g., typical of Down’s syndrome) appear at lower atrial septum, adjacent to atrioventricular (AV) valves.

History   Usually asymptomatic until third or fourth decades when exertional dyspnea, fatigue, and palpitations may occur. Onset of symptoms may be associated with development of pulmonary hypertension (see below).

Physical Examination   Prominent right ventricular (RV) impulse, wide fixed splitting of S2, systolic murmur from flow across pulmonic valve, diastolic flow rumble across tricuspid valve, prominent jugular venous v wave.

ECG   Incomplete RBBB (rSR’ in right precordial leads) common. Left axis deviation frequently present with ostium primum defect.

CXR   Increased pulmonary vascular markings, prominence of right atrium (RA), RV, and main pulmonary artery (LA enlargement not usually present).

Echocardiogram   RA, RV, and pulmonary artery enlargement; Doppler shows abnormal turbulent transatrial flow. Echo contrast (agitated saline injection into peripheral systemic vein) may visualize transatrial shunt. Transesophageal echo usually diagnostic if transthoracic echo is ambiguous.

In the absence of contraindications an ASD with pulmonary-to-systemic flow ratio (PF:SF) > 2.0:1.0 should be repaired surgically or by percutaneous transcatheter closure. Surgery is contraindicated with significant pulmonary hypertension and PF:SF < 1.2:1.0. Medical management includes antiarrhythmic therapy for associated atrial fibrillation or supraventricular tachycardia (Chap. 130) and standard therapy for symptoms of heart failure (Chap. 131).

Ventricular Septal Defect (VSD)
Congenital VSDs may close spontaneously during childhood. Symptoms relate to size of the defect and pulmonary vascular resistance.

History   CHF may develop in infancy. Adults may be asymptomatic or develop fatigue and reduced exercise tolerance.
**Physical Examination**  Systolic thrill and holosystolic murmur at lower left sternal border, loud P₂, S₃; diastolic flow murmur across mitral valve.

**ECG**  Normal with small defects. Large shunts result in LA and LV enlargement.

**CXR**  Enlargement of main pulmonary artery, LA, and LV, with increased pulmonary vascular markings.

**Echocardiogram**  LA and LV enlargement; defect may be directly visualized. Color Doppler demonstrates flow across the defect.

### Ventricular Septal Defect

Fatigue and mild dyspnea are treated with diuretics and afterload reduction (Chap. 131). Surgical closure is indicated if PF:SF > 1.5:1 in absence of very high pulmonary vascular resistance.

### PATENT DUCTUS ARTERIOSUS (PDA)

Abnormal communication between the descending aorta and pulmonary artery; associated with birth at high altitudes and maternal rubella.

**History**  Asymptomatic or fatigue and dyspnea on exertion.

**Physical Examination**  Hyperactive LV impulse; loud continuous “machinery” murmur at upper left sternal border. If pulmonary hypertension develops, diastolic component of the murmur may disappear.

**ECG**  LV hypertrophy is common; RV hypertrophy if pulmonary hypertension develops.

**CXR**  Increased pulmonary vascular markings: enlarged main pulmonary artery, LV, ascending aorta; occasionally, calcification of ductus.

**Echocardiography**  Hyperdynamic, enlarged LV; the PDA can often be visualized on two-dimensional echo; Doppler demonstrates abnormal flow through it.

### Patent Ductus Arteriosus

In absence of pulmonary hypertension, PDA should be surgically ligated or divided to prevent infective endocarditis, LV dysfunction, and pulmonary hypertension. Transcatheter closure is possible in selected pts.

### PROGRESSION TO PULMONARY HYPERTENSION (PHT)

Pts with large, uncorrected left-to-right shunts (e.g., ASD, VSD, or PDA) may develop progressive, irreversible PHT with reverse shunting of desaturated blood into the arterial circulation (right-to-left direction), resulting in Eisenmenger syndrome. Fatigue, lightheadedness, and chest pain due to RV ischemia are common, accompanied by cyanosis, clubbing of digits, loud P₂, murmur of pulmonary valve regurgitation, and signs of RV failure. ECG and echocardiogram show RV hypertrophy. Therapeutic options are limited and include pulmonary artery vasodilators and consideration of single lung transplant with repair of cardiac defect, or heart-lung transplantation.
ACyanotic Congenital Heart Lesions Without a Shunt

Pulmonic Stenosis (PS)
A transpulmonary valve gradient < 50 mmHg rarely causes symptoms, and progression tends not to occur. Higher gradients result in dyspnea, fatigue, light-headedness, chest pain (RV ischemia).

Physical Examination  Jugular venous distention with prominent a wave, RV parasternal impulse, wide splitting of S2 with soft P2, ejection click followed by “diamond-shaped” systolic murmur at upper left sternal border, right-sided S4.

ECG  Normal in mild PS; RA and RV enlargement in advanced PS.

CXR  Often shows poststenotic dilatation of the pulmonary artery and RV enlargement.

Echocardiography  RV hypertrophy and systolic “doming” of the pulmonic valve. Doppler accurately measures transvalvular gradient.

Pulmonic Stenosis
Moderate or severe stenosis (gradient > 50 mmHg) requires surgical (or balloon) valvuloplasty.

Congenitally Bicuspid Aortic Valve
One of the most common congenital heart malformations; rarely results in childhood aortic stenosis (AS), but is a cause of AS and/or regurgitation later in life. May go undetected in early life or suspected by the presence of a systolic ejection click; often identified during echocardiography that was obtained for another reason. See Chap. 121 for typical history, physical findings, and treatment of subsequent clinical aortic valve disease.

Coarctation of the Aorta
Aortic constriction just distal to the origin of the left subclavian artery is a surgically correctable form of hypertension (Chap. 124). Usually asymptomatic, but it may cause headache, fatigue, or claudication of lower extremities. Often accompanied by bicuspid aortic valve.

Physical Examination  Hypertension in upper extremities; delayed femoral pulses with decreased pressure in lower extremities. Pulsatile collateral arteries can be palpated in the intercostal spaces. Systolic (and sometimes also diastolic) murmur is best heard over the mid-upper back at left interscapular space.

ECG  LV hypertrophy.

CXR  Notching of the ribs due to collateral arteries; “figure 3” appearance of distal aortic arch.

Echocardiography  Can delineate site and length of coarctation, and Doppler determines the pressure gradient across it. MR or CT angiography also visualizes the site of coarctation and can identify associated collateral vessel formation.
Coarctation of the Aorta

Surgical correction (or percutaneous transcatheter stent dilation in selected patients), although hypertension may persist. Recoarctation after surgical repair may be amenable to percutaneous balloon dilatation.

COMPLEX CONGENITAL HEART LESIONS

Such lesions are often accompanied by cyanosis. Examples include:

TETRALOGY OF FALLOT

The four main components are: (1) malaligned VSD, (2) obstruction to RV outflow, (3) aorta that overrides the VSD, (4) RV hypertrophy (RVH). Degree of RV outflow obstruction largely determines clinical presentation; when severe, the large right-to-left shunt causes cyanosis and systemic hypoxemia. ECG shows RVH. CXR demonstrates “boot-shaped” heart with prominent RV. Echocardiography delineates VSD, overriding aorta, and RVH and quantitates degree of RV outflow obstruction.

COMPLETE TRANPOSITION OF THE GREAT ARTERIES

Accounts for 10% of patients with cyanotic congenital heart disease. Aorta and pulmonary artery arise abnormally from the right and left ventricles respectively, creating two separate parallel circulations; a communication must exist between the two sides (ASD, PDA, or VSD) to sustain life. Development of RV dysfunction and heart failure are common by the third decade. Echocardiography reveals the aberrant anatomy.

EBSTEIN ANOMALY

Abnormal downward placement of tricuspid valve within the RV; tricuspid regurgitation, hypoplasia of RV, and a right-to-left shunt are common. Echocardiography shows apical displacement of tricuspid septal leaflet, abnormal RV size, and quantitates degree of tricuspid regurgitation.

ENDOCARDITIS PROPHYLAXIS IN CONGENITAL HEART DISEASE

American Heart Association 2007 Guidelines recommend antibiotic prophylaxis only in specific patients with congenital heart disease, i.e., those who are to undergo a dental procedure associated with bacteremia who have:

1. Unrepaired cyanotic congenital heart disease (e.g., tetralogy of Fallot)
2. Repaired congenital heart disease with residual defects adjacent to site of a prosthetic patch or transcatheter device
3. A history of complete repair of congenital defects with prosthetic material or a transcatheter device within the previous 6 months.

For a more detailed discussion, see Child JS: Congenital Heart Disease in the Adult, Chap. 229, p. 1458, in HPIM-17.
MITRAL STENOSIS (MS)

Etiology  Most commonly rheumatic, although history of acute rheumatic fever is now uncommon; congenital MS is an uncommon cause, observed primarily in infants.

History  Symptoms most commonly begin in the fourth decade, but MS often causes severe disability at earlier ages in developing nations. Principal symptoms are dyspnea and pulmonary edema precipitated by exertion, excitement, fever, anemia, paroxysmal tachycardia, pregnancy, sexual intercourse, etc.

Physical Examination  Right ventricular lift; palpable S1; opening snap (OS) follows A2 by 0.06–0.12 s; OS–A2 interval inversely proportional to severity of obstruction. Diastolic rumbling murmur with presystolic accentuation in sinus rhythm. Duration of murmur correlates with severity of obstruction.

Complications  Hemoptysis, pulmonary embolism, pulmonary infection, systemic embolization; endocarditis is uncommon in pure MS.

Laboratory  ECG  Typically shows atrial fibrillation (AF) or left atrial (LA) enlargement when sinus rhythm is present. Right-axis deviation and RV hypertrophy in the presence of pulmonary hypertension.

CXR  Shows LA and RV enlargement and Kerley B lines.

Echocardiogram  Most useful noninvasive test; shows inadequate separation, calcification and thickening of valve leaflets and subvalvular apparatus, and LA enlargement. Doppler flow recordings provide estimation of transvalvular gradient, mitral valve area, and degree of pulmonary hypertension (Chap. 119).

Mitral Stenosis  See Fig. 121-1.

Pts should receive prophylaxis for recurrent rheumatic fever (penicillin V 250–500 mg PO bid or benzathine penicillin G 1–2 M units IM monthly.) In the presence of dyspnea, sodium restriction and oral diuretic therapy; beta blockers; digitalis, or rate-limiting calcium channel antagonists (i.e., verapamil or diltiazem) to slow ventricular rate in AF. Warfarin (with target INR 2.0–3.0) for pts with AF and/or history of systemic and pulmonic emboli. For AF of recent onset, consider reversion (chemical or electrical) to sinus rhythm, ideally after ≥3 weeks of anticoagulation. Mitral valvotomy in the presence of symptoms and mitral orifice ≤~1.5 cm². In uncomplicated MS, percutaneous balloon valvuloplasty is the procedure of choice; if not feasible, then open surgical valvotomy (Fig. 121-1).

MITRAL REGURGITATION (MR)

Etiology  Rheumatic heart disease in ~33% of patients with chronic MR. Other causes: mitral valve prolapse, ischemic heart disease with papillary muscle dysfunction, LV dilatation of any cause, mitral annular calcification, hypertrophic cardiomyopathy, infective endocarditis, congenital.
Valvular Heart Disease

CHAPTER 121

Clinical Manifestations

Fatigue, weakness, and exertional dyspnea. Physical examination: sharp upstroke of arterial pulse, LV lift, S1 diminished; wide splitting of S2; S3; loud holosystolic murmur and often a brief early-mid-diastolic murmur.

Echocardiogram

Enlarged LA, hyperdynamic LV; Doppler echocardiogram helpful in diagnosing and assessing severity of MR and degree of pulmonary hypertension.

Mitral Regurgitation

See Fig. 121-2.

For severe/decompensated MR, treat as for heart failure (Chap. 131), including diuretics, ACE inhibitors, beta blockers, and digoxin. Intravenous vasodilators
Cardiology

SECTION 8

Cardiology

(e.g., IV nitroprusside) are beneficial for acute, severe MR. Anticoagulation is indicated in the presence of atrial fibrillation. Surgical treatment, either valve repair or replacement, is indicated if patient has symptoms or evidence of progressive LV dysfunction [LV ejection fraction (LVEF) < 60% or end-systolic LV diameter by echo >40 mm]. Operation should be carried out before development of severe chronic heart failure.

MITRAL VALVE PROLAPSE (MVP)

Etiology Most commonly idiopathic; may accompany rheumatic fever, ischemic heart disease, atrial septal defect, the Marfan syndrome.

Pathology Redundant mitral valve tissue with myxedematous degeneration and elongated chordae tendineae.

Clinical Manifestations More common in females. Most pts are asymptomatic and remain so. Most common symptoms are atypical chest pain and a variety of
Valvular Heart Disease

CHAPTER 121

**Valvular Heart Disease**

Valvular heart disease includes defects of the heart valves, leading to regurgitation or stenosis of one or more valves. It can be caused by congenital anomalies, rheumatic fever, bacterial endocarditis, and calcific degeneration.

**Supraventricular and Ventricular Arrhythmias.** Most important complication is severe MR resulting in LV failure. Rarely, systemic emboli from platelet-fibrin deposits on valve. Sudden death is a *very rare* complication.

**Physical Examination**

- Mid or late systolic click(s) followed by late systolic murmur at the apex; exaggeration by Valsalva maneuver, reduced by squatting and isometric exercise (Chap. 117).

**Echocardiogram**

- Shows posterior displacement of one or both mitral leaflets late in systole.

---

**Mitral Valve Prolapse**

- Asymptomatic pts should be reassured. Beta blockers may lessen chest discomfort and palpitations. Prophylaxis for infective endocarditis is indicated only if prior history of endocarditis. Valve repair or replacement for pts with severe mitral regurgitation; aspirin or anticoagulants for pts with history of TIA or embolization.

**Aortic Stenosis (AS)**

**Etiology**

- Most common cause in adults is age-related degenerative calcific AS and is usually mild. Other causes are congenital (bicuspid valves) or rheumatic (almost always associated with rheumatic mitral valve disease).

**Symptoms**

- Dyspnea, angina, and syncope are cardinal symptoms; they occur late, after years of obstruction.

**Physical Examination**

- Weak and delayed arterial pulses with carotid thrill.
- Double apical impulse; A₂ soft or absent; S₄ common. Diamond-shaped systolic murmur ≥ grade 3/6, often with systolic thrill. Murmure typically loudest at 2nd right intercostal space, with radiation to carotids.

**Laboratory**

- ECG and CXR: Often show LV hypertrophy, but not useful for predicting gradient.

**Echocardiogram**

- Shows thickening of LV wall, calcification and thickening of aortic valve cusps with reduced systolic opening. Dilatation and reduced contraction of LV indicate poor prognosis. Doppler useful for estimating gradient and calculating valve area.

---

**Aortic Stenosis**

See *Fig. 121-3.*

Avoid strenuous activity in severe AS, even in asymptomatic phase. Treat heart failure in standard fashion (Chap. 131), but use vasodilators with caution in patients with advanced disease. Valve replacement is indicated in adults with symptoms resulting from AS and hemodynamic evidence of severe obstruction. Operation should be carried out *before* frank failure has developed.

---

**Aortic Regurgitation (AR)**

**Etiology**

- Rheumatic etiology is common, especially if rheumatic mitral disease present; may also be due to infective endocarditis, syphilis, aortic dissec-
tion, or aortic dilatation due to cystic medial necrosis; three-fourths of pts are males.

**Clinical Manifestations**  Exertional dyspnea and awareness of heartbeat, angina pectoris, and signs of LV failure. Wide pulse pressure, waterhammer pulse, capillary pulsations (Quincke’s sign), A_{2} soft or absent, S_{3} common. Blowing, decrescendo diastolic murmur along left sternal border (along right sternal border with aortic dilatation). May be accompanied by systolic murmur of augmented blood flow.

**Laboratory**  ECG and CXR  LV enlargement.

**Echocardiogram**  LA enlargement, LV enlargement, high-frequency diastolic fluttering of mitral valve. Failure of coaptation of aortic valve leaflets may be present. Doppler studies useful in detection and quantification of AR.
Aortic Regurgitation

Standard therapy for LV failure (Chap. 131). Vasodilators (long-acting nifedipine or ACE inhibitors) are recommended as antihypertensive agents. Surgical valve replacement should be carried out in pts with severe AR when symptoms develop or in asymptomatic pts with LV dysfunction (LVEF < 50%, LV end-systolic volume > 55 mL/m², end-systolic diameter > 55 mm or LV diastolic dimension > 75 mm) by echocardiography.

TRICUSPID STENOSIS (TS)

Etiology  Usually rheumatic; most common in females; almost invariably associated with MS.

Clinical Manifestations  Hepatomegaly, ascites, edema, jaundice, jugular venous distention with slow y descent (Chap. 117). Diastolic rumbling murmur along left sternal border increased by inspiration with loud presystolic component. Right atrial and superior vena caval enlargement on chest x-ray. Doppler echocardiography demonstrates thickened valve and impaired separation of leaflets and provides estimate of transvalvular gradient.

Tricuspid Stenosis

In severe TS, surgical relief is indicated, with valvular repair or replacement.

TRICUSPID REGURGITATION (TR)

Etiology  Usually functional and secondary to marked RV dilatation of any cause and often associated with pulmonary hypertension.

Clinical Manifestations  Severe RV failure, with edema, hepatomegaly, and prominent v waves in jugular venous pulse with rapid y descent (Chap. 117). Systolic murmur along lower left sternal edge is increased by inspiration. Doppler echocardiography confirms diagnosis and estimates severity.

Tricuspid Regurgitation

Intensive diuretic therapy when right-sided heart failure signs are present. In severe cases (in absence of severe pulmonary hypertension), surgical treatment consists of tricuspid annuloplasty or valve replacement.

For a more detailed discussion, see O’Gara P, Braunwald E: Valvular Heart Disease, Chap. 230, p. 1465, in HPIM-17.
Table 122-1 summarizes distinguishing features of the cardiomyopathies.

**DILATED CARDIOMYOPATHY (CMP)**

Symmetrically dilated left ventricle (LV), with poor systolic contractile function; right ventricle (RV) commonly involved.

### TABLE 122-1  LABORATORY EVALUATION OF THE CARDIOMYOPATHIES

<table>
<thead>
<tr>
<th></th>
<th>Dilated</th>
<th>Restrictive</th>
<th>Hypertrophic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chest roentgenogram</strong></td>
<td>Moderate to marked cardiac silhouette enlargement</td>
<td>Mild cardiac silhouette enlargement</td>
<td>Mild to moderate cardiac silhouette enlargement</td>
</tr>
<tr>
<td></td>
<td>Pulmonary venous hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Electrocardiogram</strong></td>
<td>ST-segment and T-wave abnormalities</td>
<td>Low voltage, conduction defects</td>
<td>ST-segment and T-wave abnormalities</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Left ventricular abnormalities</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hypertrophy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Abnormal Q waves</td>
</tr>
<tr>
<td><strong>Echocardiogram</strong></td>
<td>Left ventricular dilatation and dysfunction</td>
<td>Increased left ventricular wall thickness</td>
<td>Normal or mildly reduced systolic function</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Normal or mildly reduced systolic function (RVG)</td>
</tr>
<tr>
<td><strong>Radionuclide studies</strong></td>
<td>Left ventricular dilatation and dysfunction (RVG)</td>
<td>Normal or mildly reduced systolic function (RVG)</td>
<td>Vigorous systolic function (RVG)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Perfusion defect (201TI or technetium sestamibi)</td>
</tr>
<tr>
<td><strong>Cardiac catheterization</strong></td>
<td>Left ventricular dilatation and dysfunction Elevated left- and often right-sided filling pressures Diminished cardiac output</td>
<td>Normal or mildly reduced systolic function Elevated left- and right-sided filling pressures</td>
<td>Vigorous systolic function Dynamic left ventricular outflow obstruction Elevated left- and right-sided filling pressures</td>
</tr>
</tbody>
</table>

**Note:** RVG, radionuclide ventriculogram; 201TI, thallium 201.

**Source:** J Wynne, E Braunwald, Table 231-3 in HPIM-17.
**Etiology**  Up to \( \frac{1}{3} \) of patients have a familial form, including those cases due to mutations in genes encoding sarcomeric proteins. Other causes include previous myocarditis, toxins [ethanol, certain antineoplastic agents (doxorubicin, trastuzumab, imatinib mesylate)], connective tissue disorders, muscular dystrophies, “peripartum.” Severe coronary disease/infarctions or chronic aortic/mitral regurgitation may behave similarly.

**Symptoms**  Congestive heart failure (Chap. 131); tachyarrhythmias and peripheral emboli from LV mural thrombus occur.

**Physical Examination**  Jugular venous distention (JVD), rales, diffuse and dyskinetic LV apex, S3, hepatomegaly, peripheral edema; murmurs of mitral and tricuspid regurgitation are common.

**Laboratory**  

<table>
<thead>
<tr>
<th>Test</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ECG</strong></td>
<td>Left bundle branch block and ST-T-wave abnormalities common.</td>
</tr>
<tr>
<td><strong>CXR</strong></td>
<td>Cardiomegaly, pulmonary vascular redistribution, pulmonary effusions common.</td>
</tr>
<tr>
<td><strong>Echocardiogram, CT, and Cardiac MRI</strong></td>
<td>LV and RV enlargement with globally impaired contraction. <strong>Regional</strong> wall motion abnormalities suggest coronary artery disease rather than primary cardiomyopathy.</td>
</tr>
<tr>
<td><strong>Brain Natriuretic Peptide (BNP)</strong></td>
<td>Level elevated in heart failure cardiomyopathy but not in patients with dyspnea due to lung disease.</td>
</tr>
</tbody>
</table>

### Dilated Cardiomyopathy

Standard therapy of CHF (Chap. 131); vasodilator therapy with ACE inhibitor (preferred), angiotensin receptor blocker or hydralazine-nitrate combination shown to improve longevity. Add spironolactone for patients with advanced heart failure. Chronic anticoagulation with warfarin, recommended for very low ejection fraction (<25%), if no contraindications. Antiarrhythmic drugs (Chap. 130), e.g., amiodarone, indicated only for symptomatic or sustained arrhythmias as they may cause proarrhythmic side effects; implanted internal defibrillator is often a better alternative. Consider biventricular pacing for persistently symptomatic patients with widened (≥130 ms) QRS complex and ejection fraction <35%. Possible trial of immunosuppressive drugs, if active myocarditis present on RV biopsy (controversial as long-term efficacy has not been demonstrated). In selected pts, consider cardiac transplantation.

### Restrictive Cardiomyopathy

Increased myocardial “stiffness” impairs ventricular relaxation; diastolic ventricular pressures are elevated. Etiologies include infiltrative disease (amyloid, sarcoid, hemochromatosis, eosinophilic disorders), endomyocardial fibrosis, Fabry’s disease, and prior mediastinal irradiation.

**Symptoms**  Are of CHF, although right-sided heart failure often predominates, with peripheral edema and ascites.

**Physical Examination**  Signs of right-sided heart failure: JVD, hepatomegaly, peripheral edema, murmur of tricuspid regurgitation. Left-sided signs may also be present.
Laboratory ECG Low limb lead voltage, sinus tachycardia, ST-T-wave abnormalities.

CXR Mild LV enlargement.

Echocardiogram, CT, Cardiac MRI Bilateral atrial enlargement; increased ventricular thickness (“speckled pattern”) in infiltrative disease, especially amyloidosis. Systolic function is usually normal but may be mildly reduced.

Cardiac Catheterization Increased LV and RV diastolic pressures with “dip and plateau” pattern; RV biopsy useful in detecting infiltrative disease (rectal or fat pad biopsy useful in diagnosis of amyloidosis).

Note: Must distinguish restrictive cardiomyopathy from constrictive pericarditis, which is surgically correctable. Thickening of pericardium in pericarditis usually apparent in CT or MRI.

Restrictive Cardiomyopathy

Salt restriction and diuretics ameliorate pulmonary and systemic congestion; digitalis is not indicated unless systolic function is impaired or atrial arrhythmias are present. Note: Increased sensitivity to digitalis in amyloidosis. Anticoagulation often indicated, particularly in pts with eosinophilic endomyocarditis. For specific therapy of hemochromatosis and sarcoidosis, see Chaps. 351 and 322, respectively, in HPIM-17.

HYPERTROPHIC CARDIOMYOPATHY

Marked LV hypertrophy; often asymmetric, without underlying cause. Systolic function is usually normal; increased LV stiffness results in elevated diastolic filling pressures. Typically results from mutations in sarcomeric proteins (autosomal dominant transmission).

Symptoms Secondary to elevated diastolic pressure, dynamic LV outflow obstruction (if present), and arrhythmias; dyspnea on exertion, angina, and presyncope; sudden death may occur.

Physical Examination Brisk carotid upstroke with pulsus bisferiens; S4, harsh systolic murmur along left sternal border, blowing murmur of mitral regurgitation at apex; murmur changes with Valsalva and other maneuvers (Chap. 117).

Laboratory ECG LV hypertrophy with prominent “septal” Q waves in leads I, aVL, V5–6. Periods of atrial fibrillation or ventricular tachycardia are often detected by Holter monitor.

Echocardiogram LV hypertrophy, often with asymmetric septal hypertrophy (ASH) and ≥1.3 × thickness of LV posterior wall; LV contractile function excellent with small end-systolic volume. If LV outflow tract obstruction is present, systolic anterior motion (SAM) of mitral valve and midsystolic partial closure of aortic valve are present. Doppler shows early systolic accelerated blood flow through LV outflow tract.

Hypertrophic Cardiomyopathy

Strenuous exercise should be avoided. Beta blockers, verapamil, diltiazem, or disopyramide used individually to reduce symptoms. Digoxin, other ino-
tropes, diuretics, and vasodilators are generally contraindicated. Endocarditis antibiotic prophylaxis (Chap. 87) is necessary only in patients with a prior history of endocarditis. Antiarrhythmic agents, especially amiodarone, may suppress atrial and ventricular arrhythmias. In selected pts, LV outflow gradient can be reduced by controlled septal infarction by ethanol injection into the septal artery. Consider implantable automatic defibrillator for pts with high-risk profile, e.g., history of syncope or aborted cardiac arrest, ventricular tachycardia, marked LVH (>3 cm), family history of sudden death. Surgical myectomy may be useful in pts refractory to medical therapy.

### MYOCARDITIS

Inflammation of the myocardium most commonly due to acute viral infection; may progress to chronic dilated cardiomyopathy. Myocarditis may develop in pts with HIV infection or Lyme disease. Chagas disease is a common cause of myocarditis in endemic areas, typically Central and South America.

**History**  Fever, fatigue, palpitations; if LV dysfunction develops, then symptoms of CHF are present. Viral myocarditis may be preceded by URI.

**Physical Examination**  Fever, tachycardia, soft S1; S3 common.

**Laboratory**  CK-MB isoenzyme and cardiac troponins may be elevated in absence of MI. Convalescent antiviral antibody titers may rise.

**ECG**  Transient ST-T-wave abnormalities.

**CXR**  Cardiomegaly

**Echocardiogram, Cardiac MRI**  Depressed LV function; pericardial effusion present if accompanying pericarditis present. MRI demonstrates contrast enhancement.

**Rx**  Myocarditis

Rest; treat as CHF (Chap. 131); immunosuppressive therapy (steroids and azathioprine) may be considered if RV biopsy shows active inflammation, but long-term efficacy has not been demonstrated. In fulminant cases, cardiac transplantation may be indicated.

For a more detailed discussion, see Wynne J, Braunwald E: Cardiomyopathy and Myocarditis, Chap. 231, p. 1481, in HPIM-17.
ACUTE PERICARDITIS

Causes  See Table 123-1

History  Chest pain, which may be intense, mimicking acute MI, but characteristically sharp, pleuritic, and positional (relieved by leaning forward); fever and palpitations are common.

Physical Examination  Rapid or irregular pulse, coarse pericardial friction rub, which may vary in intensity and is loudest with pt sitting forward.

Laboratory  
ECG  (See Table 123-2 and Fig. 123-1)  Diffuse ST elevation (concave upward) usually present in all leads except aVR and V_1; PR-segment depression may be present; days later (unlike acute MI), ST returns to baseline and T-wave inversion develops. Atrial premature beats and atrial fibrillation may appear. Differentiate from ECG of early repolarization variant (ERV) (ST-T ratio <0.25 in ERV, but >0.25 in pericarditis).

CXR  Increased size of cardiac silhouette if large (>250 mL) pericardial effusion is present, with “water bottle” configuration.

Echocardiogram  Most readily available test for detection of pericardial effusion, which commonly accompanies acute pericarditis.

Rx  Acute Pericarditis

Aspirin 650–975 mg qid or other NSAIDs (e.g., ibuprofen 400–800 mg qid or indomethacin 25–75 mg qid); addition of colchicine 0.6 mg bid may be useful. For severe, refractory pain, prednisone 40–80 mg/d is used and tapered over several weeks or months. Intractable, prolonged pain or frequently recurrent episodes may require pericardiectomy. Anticoagulants are relatively contraindicated in acute pericarditis because of risk of pericardial hemorrhage.

| TABLE 123-1  MOST COMMON CAUSES OF PERICARDITIS |
| "Idiopathic" |
| Infections (particularly viral) |
| Acute myocardial infarction |
| Metastatic neoplasm |
| Mediastinal radiation therapy |
| Chronic renal failure |
| Connective tissue disease (e.g., rheumatoid arthritis, SLE) |
| Drug reaction (e.g., procainamide, hydralazine) |
| "Autoimmune" following heart surgery or myocardial infarction (several weeks/months later) |
###CHAPTER 123

####CARDIAC TAMPOONADE

Life-threatening condition resulting from accumulation of pericardial fluid under pressure; impaired filling of cardiac chambers and decreased cardiac output.

**Etiology**  Previous pericarditis (most commonly metastatic tumor, uremia, viral or idiopathic pericarditis), cardiac trauma, or myocardial perforation during catheter or pacemaker placement.

**History**  Hypotension may develop suddenly; subacute symptoms include dyspnea, weakness, confusion.

**Physical Examination**  Tachycardia, hypotension, pulsus paradoxus (inspiratory fall in systolic blood pressure >10 mmHg), jugular venous distention with preserved x descent, but loss of y descent; heart sounds distant. If tamponade develops subacutely, peripheral edema, hepatomegaly, and ascites are frequently present.

**Laboratory**  
- **ECG**  Low limb lead voltage; large effusions may cause electrical alternans (alternating size of QRS complex due to swinging of heart).
- **CXR**  Enlarged cardiac silhouette if large (>250 mL) effusion present.
- **Echocardiogram**  Swinging motion of heart within large effusion; prominent respiratory alteration of RV dimension with RA and RV collapse during diastole. Doppler shows marked respiratory variation of transvalvular flow velocities.
- **Cardiac Catheterization**  Confirms diagnosis; shows equalization of diastolic pressures in all four chambers; pericardial = RA pressure.

###TABLE 123-2  ECG IN ACUTE PERICARDITIS VS. ACUTE (Q-WAVE) MI

<table>
<thead>
<tr>
<th>ST-Segment Elevation</th>
<th>ECG Lead Involvement</th>
<th>Evolution of ST and T Waves</th>
<th>PR-Segment Depression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pericarditis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concave upward</td>
<td>All leads involved except aVR and V₁</td>
<td>ST remains elevated for several days; after ST returns to baseline, T waves invert</td>
<td>Yes, in majority</td>
</tr>
<tr>
<td>Acute ST Elevation MI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Convex upward</td>
<td>ST elevation over infarcted region only; reciprocal ST depression in opposite leads</td>
<td>T waves invert within hours, while ST still elevated; followed by Q wave development</td>
<td>No</td>
</tr>
</tbody>
</table>

**CONSTRUCTIVE PERICARDITIS**

Rigid pericardium leads to impaired cardiac filling, elevation of systemic and pulmonary venous pressures, and decreased cardiac output. Results from healing and
FIGURE 123-1  Electrocardiogram in acute pericarditis. Note diffuse ST-segment elevation and PR-segment depression.
Pericardial Disease

CHAPTER 123

scar formation in some pts with previous pericarditis. Viral, tuberculosis (mostly in developing nations), previous cardiac surgery, collagen vascular disorders, uremia, neoplastic and radiation-associated pericarditis are potential causes.

**History**  Gradual onset of dyspnea, fatigue, pedal edema, abdominal swelling; symptoms of LV failure uncommon.

**Physical Examination**  Tachycardia, jugular venous distention (prominent y descent), which increases further on inspiration (Kussmaul’s sign); hepatomegaly, ascites, peripheral edema are common; sharp diastolic sound, “pericardial knock” following S₂ sometimes present.

**Laboratory**  **ECG**  Low limb lead voltage; atrial arrhythmias are common.

**CXR**  Rim of pericardial calcification is most common in tuberculous pericarditis.

**Echocardiogram**  Thickened pericardium, normal ventricular contraction; abrupt halt in ventricular filling in early diastole. Dilatation of IVC is common. Dramatic effects of respiration are typical: During inspiration the ventricular septum shifts to the left with prominent reduction of blood flow velocity across mitral valve; pattern reverses during expiration (Fig 123-2).

**CT or MRI**  More precise than echocardiogram in demonstrating thickened pericardium.

**Cardiac Catheterization**  Equalization of diastolic pressures in all chambers; ventricular pressure tracings show “dip and plateau” appearance. Differentiate from restrictive cardiomyopathy (Table 123-3).

**R**  **Constrictive Pericarditis**

Surgical stripping of the pericardium. Progressive improvement ensues over several months.

**FIGURE 123-2**  Constrictive pericarditis Doppler schema of respirophasic changes in mitral and tricuspid inflow. Reciprocal patterns of ventricular filling are assessed on pulsed Doppler examination of mitral (MV) and tricuspid (TV) inflow. (Courtesy of Bernard E. Bulwer, MD; with permission.)
If careful history and physical exam do not suggest etiology, the following may lead to diagnosis:

- Skin test and cultures for tuberculosis (Chap. 101)
- Serum albumin and urine protein measurement (nephrotic syndrome)
- Serum creatinine and BUN (renal failure)
- Thyroid function tests (myxedema)
- ANA (SLE and other collagen-vascular disease)
- Search for a primary tumor (especially lung and breast)

For a more detailed discussion, see Braunwald E: Pericardial Disease, Chap. 232, p. 1488, in HPIM-17.

| TABLE 123-3 FEATURES THAT DIFFERENTIATE CONSTRUCTIVE PERICARDITIS FROM RESTRICTIVE CARDIOMYOPATHY |
|-------------------------------------------------|-------------------------------------------------|
| Constrictive Pericarditis | Restrictive Cardiomyopathy |
| **Physical Exam** | **Physical Exam** | **Physical Exam** |
| Kussmaul's sign | Present | Absent |
| Pericardial knock | May be present | Absent |
| **Chest X-ray** | **Chest X-ray** | **Chest X-ray** |
| Pericardial calcification | May be present | Absent |
| **Echocardiography** | **Echocardiography** | **Echocardiography** |
| Thickened pericardium | Present | Absent |
| Thickened myocardium | Absent | Present |
| Exaggerated variation in transvalvular velocities | Present | Absent |
| **CT or MRI** | **CT or MRI** | **CT or MRI** |
| Thickened pericardium | Present | Absent |
| **Cardiac Catheterization** | **Cardiac Catheterization** | **Cardiac Catheterization** |
| Equalized RV and LV diastolic pressures | Yes | Often LV > RV |
| Elevated PA systolic pressure | Uncommon | Usual |
| Effect of inspiration on systolic pressures | Discordant: LV↓, RV↑ | Concordant: LV↓, RV↓ |
| Endomyocardial biopsy | Normal | Usually abnormal (e.g., amyloid) |

*Note: LV, left ventricle; PA, pulmonary artery; RV, right ventricle.*
CHAPTER 124
Hypertension

Definition  Chronic elevation in bp >140/90; etiology unknown in 80–95% of pts (“essential hypertension”). Always consider a secondary correctable form of hypertension, especially in pts under age 30 or those who become hypertensive after 55. Isolated systolic hypertension (systolic ≥ 140, diastolic < 90) most common in elderly pts, due to reduced vascular compliance.

SECONDARY HYPERTENSION

Renal Artery Stenosis (Renovascular Hypertension)  Due either to atherosclerosis (older men) or fibromuscular dysplasia (young women). Presents with recent onset of hypertension, refractory to usual antihypertensive therapy. Abdominal bruit is present in 50% of cases; often audible; mild hypokalemia due to activation of the renin-angiotensin-aldosterone system may be present.

Renal Parenchymal Disease  Elevated serum creatinine and/or abnormal urinalysis, containing protein, cells, or casts.

Coarctation of Aorta  Presents in children or young adults; constriction is usually present in aorta at origin of left subclavian artery. Exam shows diminished, delayed femoral pulsations; late systolic murmur loudest over the midback. CXR shows indentation of the aorta at the level of the coarctation and rib notching (due to development of collateral arterial flow).

Pheochromocytoma  A catecholamine-secreting tumor, typically of the adrenal medulla or extraadrenal paraganglion tissue, that presents as paroxysmal or sustained hypertension in young to middle-aged pts. Sudden episodes of headache, palpitations, and profuse diaphoresis are common. Associated findings include chronic weight loss, orthostatic hypotension, and impaired glucose tolerance. Pheochromocytomas may be localized to the bladder wall and may present with micturition-associated symptoms of catecholamine excess. Diagnosis is suggested by elevated plasma metanephrine level or urinary catecholamine metabolites in a 24-h urine collection (see below); the tumor is then localized by CT scan or MRI.

Hyperaldosteronism  Usually due to aldosterone-secreting adenoma or bilateral adrenal hyperplasia. Should be suspected when hypokalemia is present in a hypertensive pt off diuretics (Chap. 180).

Other Causes  Oral contraceptive usage, obstructive sleep apnea (Chap. 144), Cushing’s and adrenogenital syndromes (Chap. 180), thyroid disease (Chap. 179), hyperparathyroidism (Chap. 179), and acromegaly (Chap. 177). In patients with systolic hypertension and wide pulse pressure, consider thyrotoxicosis, aortic regurgitation (Chap. 121), and systemic AV fistula.

APPROACH TO THE PATIENT

HISTORY  Most pts are asymptomatic. Severe hypertension may lead to headache, dizziness, or blurred vision.
Clues to Specific Forms of Secondary Hypertension

Use of medications (e.g., birth control pills, glucocorticoids, decongestants, erythropoietin, NSAIDs, cyclosporine); paroxysms of headache, sweating, or tachycardia (pheochromocytoma); history of renal disease or abdominal trauma (renal hypertension); daytime somnolence and snoring (sleep apnea).

PHYSICAL EXAMINATION

Measure bp with appropriate-sized cuff (large cuff for large arm). Measure bp in both arms as well as a leg (to evaluate for coarctation). Signs of hypertension include retinal arteriolar changes (narrowing/nicking); left ventricular lift, loud A2, S4. Clues to secondary forms of hypertension include cushingoid appearance, thyromegaly, abdominal bruit (renal artery stenosis), delayed femoral pulses (coarctation of aorta).

LABORATORY WORKUP

Screening Tests for Secondary Hypertension

Should be carried out on all pts with documented hypertension: (1) serum creatinine, BUN, and urinalysis (renal parenchymal disease); (2) serum K measured off diuretics (hypokalemia prompts workup for hyperaldosteronism or renal artery stenosis); (3) CXR (rib notching or indentation of distal aortic arch in coarctation of the aorta); (4) ECG (LV hypertrophy suggests chronicity of hypertension); (5) other useful screening blood tests include CBC, glucose, lipid levels, calcium, uric acid; (6) thyroid-stimulating hormone if thyroid disease suspected.

Further Workup

Indicated for specific diagnoses if screening tests are abnormal or bp is refractory to antihypertensive therapy: (1) renal artery stenosis: magnetic resonance angiography, captopril renogram, renal duplex ultrasound, digital subtraction angiography, renal arteriography, and measurement of renal vein renin; (2) Cushing’s syndrome: dexamethasone suppression test (Chap. 180); (3) pheochromocytoma: 24-h urine collection for catecholamines, metanephrines, and vanillylmandelic acid and/or measurement of plasma metanephrine; (4) primary hyperaldosteronism: depressed plasma renin activity and hypersecretion of aldosterone, both of which fail to change with volume expansion; (5) renal parenchymal disease (Chaps. 147,150,151).

Hypertension

Helpful lifestyle modifications include weight reduction (to attain BMI < 25 kg/m2); sodium restriction; diet rich in fruits, vegetables, and low-fat dairy products; regular exercise; and moderation of alcohol consumption.

DRUG THERAPY OF ESSENTIAL HYPERTENSION  

(See Table 124-1 and Fig. 124-1)

Goal is to control hypertension with minimal side effects. A combination of medications with complementary actions is often required. First-line agents include diuretics, beta blockers, ACE inhibitors, angiotensin receptor antagonists, and calcium antagonists. On-treatment blood pressure goal is <135–140 systolic, <80–85 diastolic (<130/80 in patients with diabetes or chronic kidney disease).

Diuretics

Should be cornerstone of most antihypertensive regimes. Thiazides preferred over loop diuretics because of longer duration of action; however, the latter are more potent when serum creatinine > 2.5 mg/dL. Major side effects include hypokalemia, hyperglycemia, and hyperuricemia, which can be mini-
Diuretics

- **Thiazides**
  - Hydrochlorothiazide
    - Usual Total Daily Dose: 6.25–50 mg (1–2)
    - Potential Adverse Effects: Hypokalemia, hyperuricemia, hyperglycemia, ↑ cholesterol, ↑ triglycerides

- **Thiazide-like**
  - Chlorthalidone
    - Usual Total Daily Dose: 25–50 mg (1)
    - Potential Adverse Effects: Hypokalemia, hyperuricemia

- **Loop diuretics**
  - Furosemide
    - Usual Total Daily Dose: 40–80 mg (2–3)
    - Potential Adverse Effects: Hypokalemia, hyperuricemia

- **K⁺-retaining**
  - Spironolactone
    - Usual Total Daily Dose: 25–100 mg (1–2)
    - Potential Adverse Effects: Hyperkalemia, gynecomastia

- **Eplerenone**
  - Usual Total Daily Dose: 25–100 mg (1–2)
  - Potential Adverse Effects: Hyperkalemia

- **Amiloride**
  - Usual Total Daily Dose: 5–10 mg (1–2)
  - Potential Adverse Effects: Hyperkalemia

- **Triamterene**
  - Usual Total Daily Dose: 50–100 mg (1–2)
  - Potential Adverse Effects: Hyperkalemia

**Beta Blockers**

- **β₁-selective**
  - Atenolol
    - Usual Total Daily Dose: 25–100 mg (1–2)
    - Potential Adverse Effects: Bronchospasm, bradycardia, heart block, fatigue, sexual dysfunction, ↑ triglycerides, ↓ HDL

- **Nonselective**
  - Metoprolol
    - Usual Total Daily Dose: 25–100 mg (1–2)
    - Potential Adverse Effects: Bronchospasm, bradycardia, heart block, fatigue, sexual dysfunction, ↑ triglycerides, ↓ HDL

- **Propranolol**
  - Usual Total Daily Dose: 40–160 mg (2)
  - Potential Adverse Effects: Bronchospasm, bradycardia, heart block, fatigue, sexual dysfunction, ↑ triglycerides, ↓ HDL

- **Propranolol LA**
  - Usual Total Daily Dose: 60–180 mg (1)
  - Potential Adverse Effects: Bronchospasm, bradycardia, heart block, fatigue, sexual dysfunction, ↑ triglycerides, ↓ HDL

**ACE inhibitors**

- **Captopril**
  - Usual Total Daily Dose: 12.5–50 mg (2)
  - Potential Adverse Effects: Cough, hyperkalemia, azotemia, angioedema

- **Lisinopril**
  - Usual Total Daily Dose: 25–200 mg (2)
  - Potential Adverse Effects: Cough, hyperkalemia, azotemia, angioedema

- **Ramipril**
  - Usual Total Daily Dose: 2.5–20 mg (1–2)
  - Potential Adverse Effects: Cough, hyperkalemia, azotemia, angioedema

- **Losartan**
  - Usual Total Daily Dose: 25–100 mg (1–2)
  - Potential Adverse Effects: Hyperkalemia, azotemia

**Angiotensin II receptor blockers**

- **Labetolol**
  - Usual Total Daily Dose: 200–800 mg (2)
  - Potential Adverse Effects: Bronchospasm, bradycardia, heart block, fatigue, sexual dysfunction, ↑ triglycerides, ↓ HDL

**Calcium channel antagonists**

- **Dihydropyridines**
  - Nifedipine
    - Usual Total Daily Dose: 30–60 mg (1)
    - Potential Adverse Effects: Edema, constipation

- **Nondihydropyridines**
  - Verapamil
    - Usual Total Daily Dose: 120–360 mg (1–2)
    - Potential Adverse Effects: Edema, constipation, bradycardia, heart block

- **Diltiazem**
  - Usual Total Daily Dose: 180–420 mg (1)
  - Potential Adverse Effects: Edema, constipation, bradycardia, heart block

Diuretics are particularly effective in elderly and black pts. Prevention of hypokalemia is especially important in pts on digitalis glycosides.

**Beta Blockers**

Particularly useful in young pts with “hyperkinetic” circulation. Begin with low dosage (e.g., metoprolol succinate 25–50 mg daily). Relative contraindications: bronchospasm, CHF, AV block, bradycardia, and “brittle” insulin-dependent diabetes.
ACE Inhibitors and Angiotensin II Receptor Blockers

ACE inhibitors are well tolerated with low frequency of side effects. May be used as monotherapy or in combination with a diuretic, calcium antagonist, or beta blocker. Side effects are uncommon and include angioedema, hyperkalemia and azotemia (particularly in pts with elevated baseline serum creatinine). A nonproductive cough may develop in the course of therapy in up to 15% of patients, requiring an alternative regimen. Note that renal function may deteriorate rapidly as a result of ACE inhibition in pts with bilateral renal artery stenosis.

Potassium supplements and potassium-sparing diuretics should be used cautiously with ACE inhibitors to prevent hyperkalemia. If pt is intravascularly volume depleted, hold diuretics for 2–3 days prior to initiation of ACE inhibitor, which should then be administered at very low dosage (e.g., captopril, 6.25 mg bid).

For pts who do not tolerate an ACE inhibitor because of cough, substitute an angiotensin receptor antagonist.

Calcium Antagonists

Direct arteriolar vasodilators; all have negative inotropic effects (particularly verapamil) and should be used cautiously if LV dysfunction is present. Vera-

FIGURE 124-1 Initiation of therapy in patients with hypertension. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; BB, beta blocker.
<table>
<thead>
<tr>
<th>Class of Drug</th>
<th>Compelling Indications</th>
<th>Possible Indications</th>
<th>Compelling Contraindications</th>
<th>Possible Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diuretics</td>
<td>Heart failure</td>
<td>Diabetes</td>
<td>Gout</td>
<td>Dyslipidemia</td>
</tr>
<tr>
<td></td>
<td>Elderly patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Systolic hypertension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Blockers</td>
<td>Angina</td>
<td>Heart failure</td>
<td>Asthma and COPD</td>
<td>Dyslipidemia</td>
</tr>
<tr>
<td></td>
<td>After myocardial infarct</td>
<td>Pregnancy</td>
<td>Heart block(^a)</td>
<td>Athletes and physically active patients</td>
</tr>
<tr>
<td></td>
<td>Tachyarrhythmias</td>
<td></td>
<td></td>
<td>Peripheral vascular disease</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>Heart failure</td>
<td>Chronic renal parenchymal disease</td>
<td>Pregnancy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Left ventricular dysfunction</td>
<td></td>
<td>Hyperkalemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>After myocardial infarct</td>
<td></td>
<td>Bilateral renal artery stenosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diabetic nephropathy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angiotensin receptor</td>
<td>ACE inhibitor cough</td>
<td>Chronic renal parenchymal disease</td>
<td>Pregnancy</td>
<td></td>
</tr>
<tr>
<td>blockers</td>
<td>Heart failure</td>
<td></td>
<td>Hyperkalemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diabetic nephropathy</td>
<td></td>
<td>Bilateral renal artery stenosis</td>
<td></td>
</tr>
<tr>
<td>Calcium channel</td>
<td>Angina</td>
<td>Peripheral vascular disease</td>
<td>Heart block(^b)</td>
<td>Congestive heart failure(^c)</td>
</tr>
<tr>
<td>blocker</td>
<td>Elderly patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Systolic hypertension</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)Grade 2 or 3 atrioventricular block.
\(^b\)Grade 2 or 3 atrioventricular block with verapamil or diltiazem.
\(^c\)Verapamil or diltiazem.

Note: COPD, chronic obstructive pulmonary disease; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.

Source: Adapted with permission from 1999 WHO.
pamil, and to a lesser extent diltiazem, can result in bradycardia and AV block, so combination with beta blockers is generally avoided. Use sustained-release formulations, as short-acting dihydropyridine calcium channel blockers may increase incidence of coronary events. Common side effects include peripheral edema and constipation.

If bp proves refractory to drug therapy, workup for secondary forms of hypertension, especially renal artery stenosis and pheochromocytoma.

Table 124-2 lists compelling indications for specific initial drug treatment.

### SPECIAL CIRCUMSTANCES

#### Pregnancy
Most commonly used antihypertensives include methyldopa (250–1000 mg PO bid-tid), labetalol (100–200 mg bid), and hydralazine (10–150 mg PO bid-tid). Calcium channel blockers (e.g., nifedipine, long-acting, 30–60 mg daily) also appear to be safe in pregnancy. Beta blockers need to be used cautiously—fetal hypoglycemia and low birth weights have been reported. ACE inhibitors and angiotensin receptor antagonists are contraindicated in pregnancy.

#### Renal Disease
Standard thiazide diuretics may not be effective. Consider metolazone, furosemide, or bumetanide, alone or in combination.

#### Diabetes
Goal bp < 130/80. Consider ACE inhibitors and angiotensin receptor blockers as first-line therapy to control bp and slow renal deterioration.

#### Malignant Hypertension
Defined as an abrupt increase in bp in patient with chronic hypertension or sudden onset of severe hypertension, and is a medical emergency. Immediate therapy is mandatory if there is evidence of cardiac decompensation (CHF, angina), encephalopathy (headache, seizures, visual disturbances), or deterio-
rating renal function. Drugs to treat hypertensive crisis are listed in Table 124-3. Replace with PO antihypertensive as pt becomes asymptomatic and diastolic bp improves.

For a more detailed discussion, see Kotchen TA: Hypertensive Vas-

cular Disease, Chap. 241, p. 1549, in HPIM-17.

**125 Metabolic Syndrome**

The metabolic syndrome (insulin resistance syndrome, syndrome X) is an important risk factor for cardiovascular disease and type 2 diabetes; it consists of a constellation of metabolic abnormalities that includes insulin resistance, hypertension, dyslipidemia, central obesity, and endothelial dysfunction.

**ETIOLOGY**

Overweight/obesity, sedentary lifestyle, increasing age, and lipodystrophy are all risk factors for the metabolic syndrome. The exact cause is not known and may be multifactorial. Insulin resistance is central to the development of the metabolic syndrome. Increased intracellular fatty acid metabolites contribute to insulin resistance by impairing insulin-signaling pathways and accumulating as triglycerides in skeletal and cardiac muscle, while stimulating hepatic glucose and triglyceride production. Excess adipose tissue leads to increased production of proinflammatory cytokines.

**CLINICAL FEATURES**

There are no specific symptoms of the metabolic syndrome. The major features include central obesity, hypertriglyceridemia, low HDL cholesterol, hyperglyce-
mia, and hypertension (Table 125-1). Associated conditions include cardiovas-
cular disease, type 2 diabetes, nonalcoholic fatty liver disease, hyperuricemia, polycystic ovary syndrome, and obstructive sleep apnea.

**DIAGNOSIS**

The diagnosis of the metabolic syndrome relies on satisfying the criteria listed in Table 125-1. Screening for associated conditions should be considered.

**Rx Metabolic Syndrome**

Obesity is the driving force behind the metabolic syndrome. Thus, weight re-
duction is the primary approach to this disorder. In general, recommendations for weight loss include a combination of caloric restriction, increased physical activity, and behavior modification. Weight loss drugs or bariatric surgery are adjuncts that may be considered for obesity management (Chap. 181). Hyper-
tension (Chap. 124), impaired fasting glucose or diabetes (Chap. 182), and lipid
SECTION 8  Cardiology

700

abnormalities (Chap. 187) should be managed according to current guidelines. The antihypertensive regimen should include an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker when possible.

For a more detailed discussion, see Eckel RH: The Metabolic Syndrome, Chap. 236, p. 1509, in HPIM-17.

<table>
<thead>
<tr>
<th>TABLE 125-1</th>
<th>NCEP:ATPIII 2001 AND IDF CRITERIA FOR THE METABOLIC SYNDROME</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCEP:ATPIII 2001</td>
<td>Three or more of the following:</td>
</tr>
<tr>
<td></td>
<td>Central obesity: Waist circumference &gt;102 cm (M), &gt;88 cm (F)</td>
</tr>
<tr>
<td></td>
<td>Hypertriglyceridemia: Triglycerides ≥150 mg/dL or specific medication</td>
</tr>
<tr>
<td></td>
<td>Low HDL cholesterol: &lt;40 mg/dL and &lt;50 mg/dL, respectively, or specific medication</td>
</tr>
<tr>
<td></td>
<td>Hypertension: Blood pressure ≥130 mm systolic or ≥85 mm diastolic or specific medication</td>
</tr>
<tr>
<td></td>
<td>Fasting plasma glucose ≥100 mg/dL or specific medication or previously diagnosed type 2 diabetes</td>
</tr>
</tbody>
</table>

**Abbreviations:** NCEP:ATPIII, National Cholesterol Education Program, Adult Treatment Panel III; HDL, high-density lipoprotein; IDF, International Diabetes Foundation.

ST-Segment Elevation Myocardial Infarction (STEMI)

Early recognition and immediate treatment of acute MI are essential; diagnosis is based on characteristic history, ECG, and serum cardiac markers.

**Symptoms**  Chest pain similar to angina (Chap. 33) but more intense and persistent; not fully relieved by rest or nitroglycerin, often accompanied by nausea, sweating, apprehension. However, ~25% of MIs are clinically silent.

**Physical Examination**  Pallor, diaphoresis, tachycardia, S₄, dyskinetic cardiac impulse may be present. If CHF exists, rales and S₃ are present. Jugular venous distention is common in right ventricular infarction.

**ECG**  ST elevation, followed by T-wave inversion, then Q-wave development over several hours (see Figs. 118-3 and 118-4).

**Non-ST Elevation MI, or NSTEMI**  ST depression followed by persistent ST-T-wave changes without Q-wave development. Comparison with old ECG helpful (see Chap. 127).

**Cardiac Biomarkers**  Cardiac-specific troponins T and I are highly specific for myocardial injury and are the preferred biochemical markers for diagnosis of
ST-Segment Elevation Myocardial Infarction

CHAPTER 126

acute MI. They remain elevated for 7–10 days. Creatine phosphokinase (CK) level rises within 4–8 h, peaks at 24 h, returns to normal by 48–72 h. CK-MB isoenzyme is more specific for MI but may also be elevated with myocarditis or after electrical cardioversion. Total CK (but not CK-MB) rises (two- to three-fold) after IM injection, vigorous exercise, or other skeletal muscle trauma. A ratio of CK-MB mass:CK activity ≥ 2.5 suggests acute MI. CK-MB peaks earlier (about 8 h) following acute reperfusion therapy (see below). Serum cardiac markers should be measured at presentation, 6–9 h later, then at 12–24 h.

**Noninvasive Imaging Techniques** Use when diagnosis of MI is not clear. **Echocardiography** detects infarct-associated regional wall motion abnormalities (but cannot distinguish acute MI from a previous myocardial scar). Echo is also useful in detecting RV infarction, LV aneurysm, and LV thrombus. **Myocardial perfusion imaging** (thallium 201 or technetium 99m-sestamibi) is sensitive for regions of decreased perfusion but is not specific for acute MI. **MRI with delayed gadolinium enhancement** accurately indicates regions of infarction but is technically difficult to obtain in acutely ill patients.

**STEMI**

**Initial Therapy**

Initial goals are to: (1) quickly identify if patient is candidate for reperfusion therapy, (2) relieve pain, and (3) prevent/treat arrhythmias and mechanical complications.

- Aspirin should be administered immediately (162–325 mg chewed at presentation, then 162–325 mg PO qd), unless pt is aspirin-intolerant.
- Perform targeted history, exam, and ECG to identify STEMI (>1 mm ST elevation in two contiguous limb leads, ≥ 2mm ST elevation in two contiguous precordial leads, or new LBBB) and appropriateness of reperfusion therapy [percutaneous coronary intervention (PCI) or intravenous fibrinolytic agent], which reduces infarct size, LV dysfunction, and mortality.
- Primary PCI is generally more effective than fibrinolysis and is preferred at experienced centers capable of performing procedure rapidly (Fig. 126-1), especially when diagnosis is in doubt, cardiogenic shock is present, bleeding risk is increased, or if symptoms have been present for >3 h.
- Proceed with IV fibrinolysis if PCI is not available or if logistics would delay PCI >1 h longer than fibrinolysis could be initiated (Fig. 126-1). Door-to-needle time should be <30 min for maximum benefit. Ensure absence of contraindications (Fig. 126-2) before administering fibrinolytic agent. Those treated within 1–3 h benefit most; can still be useful up to 12 h if chest pain is persistent or ST remains elevated in leads that have not developed new Q waves. Complications include bleeding, reperfusion arrhythmias, and, in case of streptokinase (SK), allergic reactions. Enoxaparin or heparin [60 U/kg (maximum 4000 U), then 12 (U/kg)/h (maximum 1000 U/h)] should be initiated with fibrinolytic agents (Fig. 126-2); maintain activated partial thromboplastin time (aPTT) at 1.5–2.0 × control (~50–70 s).
- If chest pain or ST elevation persists >90 min after fibrinolysis, consider referral for rescue PCI. Later coronary angiography after fibrinolysis generally reserved for pts with recurrent angina or positive stress test.

The initial management of NSTEMI (non-Q MI) is different (Chap. 127). In particular, fibrinolytic therapy should not be administered.
Additional Standard Treatment

(Whether or not reperfusion therapy is undertaken):

- **Hospitalize in CCU** with continuous ECG monitoring.

- **IV line** for emergency arrhythmia treatment.

- **Pain control**: (1) Morphine sulfate 2–4 mg IV q5–10min until pain is relieved or side effects develop [nausea, vomiting, respiratory depression (treat with naloxone 0.4–1.2 mg IV), hypotension (if bradycardic, treat with atropine 0.5 mg IV; otherwise use careful volume infusion)]; (2) nitroglycerin 0.3 mg SL if systolic bp > 100 mmHg; for refractory pain: IV nitroglycerin (begin at 10 μg/min, titrate upward to maximum of 200 μg/min, monitoring bp closely); do not administer nitrates within 24 h of sildenafil or within 48 h of tadalafil (used for erectile dysfunction); (3) β-adrenergic antagonists (see below).

- **Oxygen**: 2–4 L/min by nasal cannula (if needed to maintain O₂ saturation > 90%).

- **Mild sedation** (e.g., diazepam 5 mg, oxazepam 15–30 mg or lorazepam 0.5–2 mg PO three to four times daily).

- **Soft diet** and stool softeners (e.g., docusate sodium 100–200 mg/d).

- **β-Adrenergic blockers** (Chap. 124) reduce myocardial O₂ consumption, limit infarct size, and reduce mortality. Especially useful in pts with hypertension, tachycardia, or persistent ischemic pain; contraindications include active CHF, systolic bp < 95 mmHg, heart rate < 50 beats/min, AV block, or history of bronchospasm. Consider IV (e.g., metoprolol 5 mg q5–10min to total dose of 15 mg), if patient is hypertensive. Otherwise, begin PO regimen (e.g., metoprolol 25–100 mg two times daily).

- **Anticoagulation/antiplatelet agents**: Pts who receive fibrinolytic therapy are begun on heparin and aspirin as indicated above. In absence of fibrinolytic therapy, administer aspirin, 160–325 mg qd, and low-dose heparin (5000 U SC q12h) or enoxaparin (40 mg SC daily) for DVT prevention. Full-dose IV heparin (PTT 2 × control) or low-molecular-weight heparin (e.g., enoxaparin 1 mg/kg SC q12h) followed by oral anticoagulants is rec-
SELECTION CRITERIA
1. Acute chest discomfort characteristic of myocardial infarction
2. ECG criteria for ST-elevation MI (a, b, or c):
   a. ST elevation $\geq 0.1 \text{ mV (1 mm)}$ in at least 2 leads of either:
      Inferior group: II, III, aVF
      Lateral group: I, aVL, V5, V6
   b. ST elevation $\geq 0.2 \text{ mV (1 mm)}$ in at least 2 contiguous anterior
      leads (V1–V4)
   c. New LBBB
3. Primary PCI not available, or delay to PCI would be $>1$ h longer than initiation of fibrinolysis

ASSESS FOR CONTRAINDICATIONS
- Prior intracranial bleeding
- Intracranial malignancy or vascular malformation
- Ischemic stroke or head trauma in previous 3 months
- Aortic dissection
- Active bleeding (with exception of menses)
- Internal bleeding in previous 4 weeks
- Severe hypertension (systolic $>180$ or diastolic $>110$)
- Prolonged (>10 min) CPR chest compressions
- INR $\geq 2.0$ on warfarin, or known bleeding diathesis
- Pregnancy

FIBRINOLYTIC DRUG INTRAVENOUS DOSAGE

<table>
<thead>
<tr>
<th>Fibrinolytic Drug</th>
<th>Intravenous Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Streptokinase</td>
<td>1.5 million U over 60 min</td>
</tr>
<tr>
<td>Alteplase*</td>
<td>15-mg bolus, then 0.75 mg/kg (up to 50 mg) over 30 min, then 0.5 mg/kg (up to 35 mg) over 60 min</td>
</tr>
<tr>
<td>Reteplase*</td>
<td>10 U over 2 min; repeat same dose 30 min later</td>
</tr>
<tr>
<td>Tenecteplase*</td>
<td>Single bolus over 5 s, based on weight: &lt;60 kg: 30 mg 60–69 kg: 35 mg 70–79 kg: 40 mg 80–89 kg: 45 mg $&gt;90$ kg: 50 mg</td>
</tr>
</tbody>
</table>

*If alteplase, reteplase, or tenecteplase used, also administer IV heparin 60-U/kg bolus (maximum 4000 U) followed by 12 (U/kg)/h (maximum 1000 U/h), then adjusted to maintain aPTT at 1.5–2 x control (∼50–70 s) for 48 h

SUBSEQUENT CORONARY ANGIOGRAPHY RESERVED FOR
- Failure of reperfusion (persistent chest pain or ST elevation after 90 min)
- Spontaneous recurrent ischemia during hospitalization
- Positive exercise test prior to or soon after discharge

FIGURE 126-2 Algorithm for fibrinolytic therapy of acute STEMI.
ommended for pts with severe CHF, presence of ventricular thrombus by echocardiogram, or large dyskinetic region in anterior MI. Oral anticoagulants are continued for 3–6 months, then replaced by aspirin.

- **ACE inhibitors** reduce mortality in pts following acute MI and should be prescribed within 24 h of hospitalization for pts with STEMI—e.g., captopril (6.25 mg PO test dose) advanced to 50 mg PO tid. ACE inhibitors should be continued indefinitely after discharge in pts with CHF or those with asymptomatic LV dysfunction [ejection fraction (EF) \(\leq 40\%\)]; if ACE inhibitor intolerant, use angiotensin receptor blocker (ARB; e.g., valsartan or candesartan).

- **Serum magnesium** level should be measured and repleted if necessary to reduce risk of arrhythmias.

### COMPLICATIONS

(For arrhythmias, see also Chaps. 129 and 130)

**Ventricular Arrhythmias** Isolated ventricular premature beats (VPBs) occur frequently. Precipitating factors should be corrected [hypoxemia, acidosis, hypokalemia (maintain serum K\(^+\) \(\approx 4.5\) mmol/L), hypercalcemia, hypomagnesemia, CHF, arrhythmogenic drugs]. Routine beta-blocker administration (see above) diminishes ventricular ectopy. Other in-hospital antiarrhythmic therapy should be reserved for pts with sustained ventricular arrhythmias.

**Ventricular Tachycardia** If hemodynamically unstable, perform immediate electrical countershock (unsynchronized discharge of 200–300 J or 50% less if using biphasic device). If hemodynamically tolerated, use IV amiodarone (bolus of 150 mg over 10 min; infusion of 1.0 mg/min for 6 h, then 0.5 mg/min).

**Ventricular Fibrillation (VF)** VF requires immediate defibrillation (200–400 J). If unsuccessful, initiate cardiopulmonary resuscitation (CPR) and standard resuscitative measures (Chap. 11). Ventricular arrhythmias that appear several days or weeks following MI often reflect pump failure and may warrant invasive electrophysiologic study and use of an implantable cardioverter defibrillator (ICD).

**Accelerated Idioventricular Rhythm** Wide QRS complex, regular rhythm, rate 60–100 beats/min, is common and usually benign; if it causes hypotension, treat with atropine 0.6 mg IV.

**Supraventricular Arrhythmias** Sinus tachycardia may result from CHF, hypoxemia, pain, fever, pericarditis, hypovolemia, administered drugs. If no cause is identified, may treat with beta blocker. Other supraventricular arrhythmias (paroxysmal supraventricular tachycardia, atrial flutter, and fibrillation) are often secondary to CHF, in which case digoxin (Chap. 131) is treatment of choice. In absence of CHF, may use beta blocker, verapamil, or diltiazem (Chap. 130). If hemodynamically unstable, proceed with electrical cardioversion.

**Bradyarrhythmias and AV Block** (See Chap. 129) In inferior MI, usually represent heightened vagal tone or discrete AV nodal ischemia. If hemodynamically compromised (CHF, hypotension, emergence of ventricular arrhythmias), treat with atropine 0.5 mg IV q5min (up to 2 mg). If no response, use temporary external or transvenous pacemaker. Isoproterenol should be avoided. In anterior MI, AV conduction defects usually reflect extensive tissue necrosis. Consider temporary external or transvenous pacemaker for (1) complete heart block, (2) Mobitz type II block (Chap. 129), (3) new bifascicular block (LBBB, RBBB
+ left anterior hemiblock, RBBB + left posterior hemiblock), (4) any bradyarrhythmia associated with hypotension or CHF.

**Congestive Heart Failure**  CHF may result from systolic “pump” dysfunction, increased LV diastolic “stiffness,” and/or acute mechanical complications.

**Symptoms**  Dyspnea, orthopnea, tachycardia.

**Examination**  Jugular venous distention, S₃ and S₄ gallop, pulmonary rales; systolic murmur if acute mitral regurgitation or ventricular septal defect (VSD) has developed.

**Table 126-1**  Intravenous Vasodilators and Inotropic Drugs Used in Acute MI

<table>
<thead>
<tr>
<th>Drug</th>
<th>Usual Dosage Range</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitroglycerin</td>
<td>5–100 μg/min</td>
<td>May improve coronary blood flow to ischemic myocardium</td>
</tr>
<tr>
<td>Nitroprusside</td>
<td>0.5–10 (μg/kg)/min</td>
<td>More potent vasodilator, but improves coronary blood flow less than nitroglycerin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>With therapy &gt;24 h or in renal failure, watch for thiocyanate toxicity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(blurred vision, tinnitus, delirium)</td>
</tr>
<tr>
<td>Dobutamine</td>
<td>2–20 (μg/kg)/min</td>
<td>Results in ↑ cardiac output, ↓ PCW, but does not raise bp</td>
</tr>
<tr>
<td>Dopamine</td>
<td>2–20 (μg/kg)/min</td>
<td>More appropriate than dobutamine if hypertensive</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hemodynamic effect depends on dose:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(&lt;5: ↑ renal blood flow</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.5–10: positive inotrope</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;10: vasoconstriction</td>
</tr>
<tr>
<td>Milrinone</td>
<td>50–μg/kg over 10 min, then 0.375–0.75 (μg/kg)/min</td>
<td>Ventricular arrhythmias may result</td>
</tr>
</tbody>
</table>

**Initial therapy includes diuretics (begin with furosemide 10–20 mg IV), inhaled O₂, and vasodilators, particularly nitrates [PO, topical, or IV (Chap. 131) unless pt is hypotensive (systolic bp < 100 mmHg)]; digitalis is usually of little benefit in acute MI unless supraventricular arrhythmias are present. Diuretic, vasodilator, and inotropic therapy (Table 126-1) may be guided by invasive hemodynamic monitoring (Swan-Ganz pulmonary artery catheter, arterial line), particularly in pts with accompanying hypotension (Table 126-2; Fig. 126-3). In acute MI, optimal pulmonary capillary wedge pressure (PCW) is 15–20 mmHg; in the absence of hypotension, PCW > 20 mmHg is treated with diuretic plus vasodilator therapy [IV nitroglycerin (begin at 10 μg/min) or nitroprusside (begin at 0.5 μg/kg per min)] and titrated to optimize bp, PCW, and systemic vascular resistance (SVR).

\[
SVR = \frac{(\text{mean arterial pressure} - \text{mean RA pressure}) \times 80}{\text{cardiac output}}
\]
Normal SVR = 900 – 1350 dyn • s/cm\(^5\). If PCW > 20 mmHg and pt is hypotensive (Table 126-2 and Fig. 126-3), evaluate for VSD or acute mitral regurgitation, add dobutamine [begin at 1–2 (\(\mu\)g/kg)/min], titrate upward to maximum of 10 (\(\mu\)g/kg)/min; beware of drug-induced tachycardia or ventricular ectopy.

After stabilization on parenteral vasodilator therapy, oral therapy follows with an ACE inhibitor, an ARB, or the combination of nitrates plus hydrala-
zine (Chap. 131). Consider addition of long-term aldosterone antagonist (spironolactone 25–50 mg daily, or eplerenone 25 mg daily) to ACE inhibitor if LV ejection fraction (LVEF) ≤ 40% or symptomatic heart failure or diabetes are present—do not use if renal insufficiency or hyperkalemia are present.

**Cardiogenic Shock** (See Chap. 12) Severe LV failure with hypotension (bp < 90 mmHg) and elevated PCW (>20 mmHg), accompanied by oliguria (<20 mL/h), peripheral vasoconstriction, dulled sensorium, and metabolic acidosis.

**Rx Cardiogenic Shock**

Swan-Ganz catheter and intraarterial bp monitoring are essential; aim for mean PCW of 18–20 mmHg with adjustment of volume (diuretics or infusion) as needed. Vasopressors [e.g. dopamine (Table 126-1)] and/or intraaortic balloon counterpulsation may be necessary to maintain systolic bp > 90 mmHg and reduce PCW. Administer high concentration of O₂ by mask; if pulmonary edema coexists, consider bilateral positive airway pressure (Bi-PAP) or intubation and mechanical ventilation. Acute mechanical complications (see below) should be sought and promptly treated.
If cardiogenic shock develops within 36 h of acute STEMI, reperfusion by PCI or coronary artery bypass grafting (CABG) may markedly improve LV function.

**Hypotension**  May also result from *RV MI*, which should be suspected in inferior or posterior MI, if jugular venous distention and elevation of right-heart pressures predominate (rales are typically absent and PCW may be normal); right-sided ECG leads typically show ST elevation, and echocardiography may confirm diagnosis. *Treatment* consists of volume infusion, gauged by PCW and arterial pressure. Noncardiac causes of hypotension should be considered: hypovolemia, acute arrhythmia, or sepsis.

**Acute Mechanical Complications**  Ventricular septal rupture and acute mitral regurgitation due to papillary muscle ischemia/infarct develop during the first week following MI and are characterized by sudden onset of CHF and new systolic murmur. Echocardiography with Doppler can confirm presence of these complications. PCW tracings may show large v waves in either condition, but an oxygen “step-up” as the catheter is advanced from RA to RV suggests septal rupture.

Acute medical therapy of these conditions includes vasodilator therapy (IV nitroprusside: begin at 10 μg/min and titrate to maintain systolic bp ≈ 100 mm-Hg); intraaortic balloon pump may be required to maintain cardiac output. Surgical correction is the definitive therapy. Acute ventricular free-wall rupture presents with sudden loss of bp, pulse, and consciousness, while ECG shows an intact rhythm (pulseless electrical activity); emergent surgical repair is crucial, and mortality is high.

**Pericarditis**  Characterized by pleuritic, positional pain and pericardial rub (Chap. 123); atrial arrhythmias are common; must be distinguished from recurrent angina. Often responds to aspirin, 650 mg PO qid. Anticoagulants should be avoided when pericarditis is suspected to avoid development of tamponade.

**Ventricular Aneurysm**  Localized “bulge” of LV chamber due to infarcted myocardium. *True aneurysms* consist of scar tissue and do not rupture. However, complications include CHF, ventricular arrhythmias, and thrombus formation. Typically, ECG shows persistent ST-segment elevation, >2 weeks after initial infarct; aneurysm is confirmed by echocardiography and by left ventriculography. The presence of thrombus within the aneurysm, or a large aneurysmal segment due to anterior MI, warrants oral anticoagulation with warfarin for 3–6 months.

*Pseudoaneurysm* is a form of cardiac rupture contained by a local area of pericardium and organized thrombus; direct communication with the LV cavity is present; surgical repair usually necessary to prevent rupture.

**Recurrent Angina**  Usually associated with transient ST-T wave changes; signals high incidence of reinfarction; when it occurs in early post-MI period, proceed directly to coronary arteriography, to identify those who would benefit from percutaneous coronary intervention or coronary artery bypass surgery.

**SECONDARY PREVENTION**

For pts who have not already undergone coronary angiography and PCI, submaximal exercise testing should be performed prior to or soon after discharge. A positive test in certain subgroups (angina at a low workload, a large region of provable ischemia, or provable ischemia with a reduced LVEF) suggests need for cardiac catheterization to evaluate myocardium at risk of recurrent infarction.
Beta blockers (e.g., timolol, 10 mg bid; metoprolol, 25–100 mg bid) should be prescribed routinely for at least 2 years following acute MI (Table 124-1), unless contraindications present (asthma, CHF, bradycardia, “brittle” diabetes). Aspirin (80–325 mg/d) is administered to reduce incidence of subsequent infarction, unless contraindicated (e.g., active peptic ulcer, allergy). In aspirin-intolerant pts, use clopidogrel (75 mg/d) instead. If the LVEF ≤ 40%, an ACE inhibitor (e.g., captopril 6.25 mg PO tid, advanced to target dose of 50 mg PO tid) or ARB (if ACE inhibitor is not tolerated) should be used indefinitely. Consider addition of aldosterone antagonist (see “Congestive Heart Failure” section above).

Modification of cardiac risk factors must be encouraged: discontinue smoking; control hypertension, diabetes, and serum lipids (typically atorvastatin 80 mg daily in immediate post-MI period—see Chap. 187); and pursue graduated exercise.

For a more detailed discussion, see Antman EM, Braunwald E: ST-Segment Elevation Myocardial Infarction, Chap. 239, p. 1532, in HPIM-17.

Unstable Angina and Non-ST-Elevation Myocardial Infarction

Unstable angina (UA) and non-ST-elevation MI (NSTEMI) are acute coronary syndromes with similar mechanisms, clinical presentations, and treatment strategies.

Clinical Presentation  UA includes (1) new onset of severe angina, (2) angina at rest or with minimal activity, and (3) recent increase in frequency and intensity of chronic angina. NSTEMI is diagnosed when symptoms of UA are accompanied by evidence of myocardial necrosis (e.g., elevated cardiac biomarkers). Some patients with NSTEMI present with symptoms identical to STEMI—the two are differentiated by ECG (see Chap. 126).

Physical Examination  May be normal or include diaphoresis, pale cool skin, tachycardia, S₄, basilar rales; if large region of ischemia, may demonstrate S₃, hypotension.

Electrocardiogram  Most commonly ST depression and/or T-wave inversion; unlike STEMI, there is no Q-wave development.

Cardiac Biomarkers  CK-MB and/or cardiac-specific troponins (more specific and sensitive markers of myocardial necrosis) are elevated in NSTEMI. Small troponin elevations may also occur in pts with CHF, myocarditis, or pulmonary embolism.

Unstable Angina and Non-ST-Elevation Myocardial Infarction

First step is appropriate triage based on likelihood of coronary artery disease (CAD) and acute coronary syndrome (Fig. 127-1) as well as identification of
Higher-risk pts (Fig. 127-2). Patients with low likelihood of active ischemia are initially monitored by serial ECGs, serum cardiac biomarkers, and for recurrent chest discomfort; if these are negative, stress testing (or CT angiography if probability of CAD is low) can be used for further therapeutic planning.

Therapy of UA/NSTEMI is directed: (1) against the inciting intracoronary thrombus, and (2) toward restoration of balance between myocardial oxygen supply and demand. Patients with the highest risk scores (Fig. 127-2) benefit the most from aggressive interventions.

**ANTITHROMBOTIC THERAPIES**

- Aspirin (162–325 mg, then 75–325 mg/d)
- Clopidogrel (300 mg PO load, then 75 mg/d) unless excessive risk of bleeding or immediate coronary artery bypass grafting (CABG) likely
• Unfractionated heparin [60 U/kg then 12 (U/kg)/h (maximum 1000 U/h)] to achieve aPTT 1.5–2.5 × control, or low-molecular-weight heparin (e.g., enoxaparin 1 mg/kg SC q12h)
• Add intravenous GP IIb/IIIa antagonist for high-risk pts for whom invasive management is planned [e.g., tirofiban, 0.4 (μg/kg)/min × 30 min, then 0.1 (μg/kg)/min for 48–96 h; or eptifibatide, 180-μg/kg bolus, then 2.0 (μg/kg)/min for 72–96 h].
• Do not administer fibrinolytic therapy to pts with UA/NSTEMI.

ANTI-ISCHEMIC THERAPIES
• Nitroglycerin 0.3–0.6 mg sublingually or by buccal spray. If chest discomfort persists after three doses given 5 min apart, consider IV nitroglycerin (5–10 μg/min, then increase by 10 μg/min every 3–5 min until symptoms relieved or systolic bp < 100 mmHg). Do not use nitrates in pts with recent use of phosphodiesterase-5 inhibitors for erectile dysfunction (e.g., not within 24 h of sildenafil or within 48 h of tadalafil).
• Beta blockers (e.g., metoprolol 5 mg IV q5–10min to total dose of 15 mg, then 25–50 mg PO q6h) targeted to a heart rate of 50–60 beats/min. In pts with contraindications to beta blockers (e.g., bronchospasm), consider long-acting verapamil or diltiazem (Table 124-1).

ADDITIONAL RECOMMENDATIONS
• Admit to unit with continuous ECG monitoring, initially with bed rest.
• Consider morphine sulfate 2–5 mg IV q5–30min for refractory chest discomfort (Chap. 126).
• Add HMG-CoA reductase inhibitor (initially at high dose, e.g., atorvastatin 80 mg daily) and consider ACE inhibitor (Chap. 126).

INVASIVE VS. CONSERVATIVE STRATEGY
In highest risk pts (Table 127-1), an early invasive strategy (coronary arteriography within ~48 h followed by percutaneous intervention or CABG) improves outcomes. In lower-risk pts, angiography can be deferred but should be pursued if myocardial ischemia recurs spontaneously (angina or ST deviations at rest or with minimal activity) or is provoked by stress testing.
LONG-TERM MANAGEMENT

- Stress importance of smoking cessation, achieving optimal weight, diet low in saturated and trans-fats, regular exercise; these principles can be reinforced by encouraging patient to enter cardiac rehabilitation program.
- Continue aspirin, clopidogrel (for at least 9–12 months), beta-blocker, statin, and ACE inhibitor (especially if hypertensive or diabetic or LV ejection fraction is reduced).

For a more detailed discussion, see Cannon CP, Braunwald E: Unstable Angina and Non-ST-Elevation Myocardial Infarction, Chap. 238, p. 1527, in HPIM-17.

Chronic Stable Angina

ANGINA

Angina pectoris, the most common clinical manifestation of coronary artery disease (CAD), results from an imbalance between myocardial O2 supply and demand, most often due to atherosclerotic coronary artery obstruction. Other major conditions that upset this balance and result in angina include aortic valve disease (Chap. 121), hypertrophic cardiomyopathy (Chap. 122), and coronary artery spasm (see below).

Symptoms  Angina is typically associated with exertion or emotional upset; relieved quickly by rest or nitroglycerin (Chap. 33). Major risk factors are cigarette smoking, hypertension, hypercholesterolemia (↑LDL fraction; ↓HDL), diabetes, obesity, and family history of CAD before age 55.

Physical Examination  Often normal; arterial bruits or retinal vascular abnormalities suggest generalized atherosclerosis; S4 is common. During acute angi-
nal episode, other signs may appear: loud $S_3$ or $S_4$, diaphoresis, rales, and a transient murmur of mitral regurgitation due to papillary muscle ischemia.

**Laboratory ECG** May be normal between anginal episodes or show old infarction (Chap. 118). During angina, ST- and T-wave abnormalities typically appear (ST-segment depression reflects subendocardial ischemia; ST-segment elevation may reflect acute infarction or transient coronary artery spasm). Ventricular arrhythmias frequently accompany acute ischemia.

**Stress Testing** Enhances diagnosis of CAD (Fig. 128-1). Exercise is performed on treadmill or bicycle until target heart rate is achieved or pt becomes symptomatic (chest pain, light-headedness, hypotension, marked dyspnea, ventricular tachycardia) or develops diagnostic ST-segment changes. Useful information includes duration of exercise achieved; peak heart rate and bp; depth, morphology, and persistence of ST-segment depression; and whether and at which level of exercise pain, hypotension, or ventricular arrhythmias develop. Exercise testing with radionuclide or echocardiographic imaging increases sensitivity and specificity and is particularly useful if baseline ECG abnormalities prevent interpretation of test. *Note:* Exercise testing should not be performed in pts with acute MI, unstable angina, or severe aortic stenosis. If the pt is unable to exercise, pharmacologic stress with intravenous dipyridamole (or adenosine) or dobutamine can be performed in conjunction

---

**FIGURE 128-1** Role of exercise testing in management of CAD; EF, left ventricular ejection fraction. [Modified from LS Lilly, in Textbook of Primary Care Medicine, 3d ed., J Nobel (ed.) St. Louis, Mosby, 2001, p. 552.]
with radionuclide or echocardiographic imaging. (Table 128-1). Patients with LBBB on baseline ECG should be referred for adenosine or dipyridamole radionuclide imaging, which is most specific for diagnosis of CAD in this setting.

The prognostic utility of coronary calcium detection (by electron-beam or multidetector CT) in the diagnosis of CAD has not yet been fully characterized. Some pts do not experience chest pain during ischemic episodes with exertion (“silent ischemia”) but are identified by transient ST-T-wave abnormalities during stress testing or ambulatory ECG monitoring (see below).

**Coronary Arteriography**  The definitive test for assessing severity of CAD; major indications are (1) angina refractory to medical therapy, (2) markedly positive exercise test (≥2-mm ST-segment depression, onset of ischemia at low workload, or ventricular tachycardia or hypotension with exercise) suggestive of left main or three-vessel disease, (3) recurrent angina or positive exercise test after MI, (4) to assess for coronary artery spasm, and (5) to evaluate pts with perplexing chest pain in whom noninvasive tests are not diagnostic.

The role of new noninvasive coronary imaging techniques (CT and MR angiography) has not yet been defined.

### Chronic Stable Angina

#### GENERAL
- Identify and treat risk factors: mandatory cessation of smoking; treatment of diabetes, hypertension, and lipid disorders (Chap. 187); advocate a diet low in saturated fat and trans-fats.
- Correct exacerbating factors contributing to angina: morbid obesity, CHF, anemia, hyperthyroidism.
- Reassurance and pt education.

#### DRUG THERAPY
Sublingual nitroglycerin (TNG 0.3–0.6 mg); may be repeated at 5-min intervals; warn pts of possible headache or light-headedness; teach prophylactic

### Table 128-1  STRESS TESTING RECOMMENDATIONS

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Recommended Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient able to exercise</td>
<td></td>
</tr>
<tr>
<td>If baseline ST-T on ECG is normal</td>
<td>Standard exercise test (treadmill, bicycle, or arm ergometry)</td>
</tr>
<tr>
<td>If baseline ST-T impairs test</td>
<td>Standard exercise test (above) combined with either</td>
</tr>
<tr>
<td>interpretation (e.g., LVH with strain,</td>
<td>Perfusion scintigraphy (thallium 201, 99mTc-sestamibi or rubidium-82 PET) or</td>
</tr>
<tr>
<td>digoxin)</td>
<td>Echocardiography</td>
</tr>
<tr>
<td>Patient not able to exercise</td>
<td></td>
</tr>
<tr>
<td>(regardless of baseline ST-T abnormality)</td>
<td>Pharmacologic stress test (IV dobutamine, dipyridamole, or adenosine combined</td>
</tr>
<tr>
<td></td>
<td>with either</td>
</tr>
<tr>
<td></td>
<td>Perfusion scintigraphy (thallium 201, 99mTc-sestamibi or rubidium-82 PET) or</td>
</tr>
<tr>
<td></td>
<td>Echocardiography</td>
</tr>
<tr>
<td>LBBB on baseline ECG</td>
<td>Adenosine (or dipyridamole) 99mTc-sestamibi</td>
</tr>
<tr>
<td>Alternative choice (if baseline ST-T</td>
<td>Ambulatory ECG monitor</td>
</tr>
<tr>
<td>normal)</td>
<td></td>
</tr>
</tbody>
</table>
Chronic Stable Angina

CHAPTER 128

use of TNG prior to activity that regularly evokes angina. If chest pain persists for >10 min despite 2–3 TNG, pt should report promptly to nearest medical facility for evaluation of possible unstable angina or acute MI.

LONG-TERM ANGINA SUPPRESSION

Three classes of drugs are used, frequently in combination:

Long-Acting Nitrates

May be administered by many routes (Table 128-2); start at the lowest dose and frequency to limit tolerance and side effects of headache, light-headedness, tachycardia.

Beta Blockers (See Table 128-1)

All have antianginal properties; \( \beta_1 \)-selective agents are less likely to exacerbate airway or peripheral vascular disease. Dosage should be titrated to resting heart rate of 50–60 beats/min. Contraindications to beta blockers include CHF, AV block, bronchospasm, “brittle” diabetes. Side effects include fatigue, bronchospasm, depressed LV function, impotence, depression, and masking of hypoglycemia in diabetics.

Calcium Antagonists (See Table 124-1)

Useful for stable and unstable angina, as well coronary vasospasm. Combination with other antianginal agents is beneficial, but verapamil should be administered very cautiously, or not at all, to pts on beta blockers or disopyramide (additive effects on LV dysfunction). Use sustained-release, not short-acting, calcium antagonists; the latter increase coronary mortality.

Ranolazine

For patients who continue to experience stable angina despite the above standard medications, consider addition of ranolazine (500–1000 mg PO bid), which reduces anginal frequency and improves exercise capacity without af-
fecting blood pressure or heart rate. Ranolazine is contraindicated in hepatic impairment, prolongation of the QT₉ interval, or in combination with drugs that inhibit its metabolism (e.g., ketoconazole, macrolide antibiotics, HIV protease inhibitors, diltiazem and verapamil).

**Aspirin**

80–325 mg/d reduces the incidence of MI in chronic stable angina, following MI, and in asymptomatic men. It is recommended in pts with CAD in the absence of contraindications (GI bleeding or allergy). Consider clopidogrel (75 mg/d) for aspirin-intolerant individuals.

The addition of an ACE inhibitor is recommended in patients with CAD and LV ejection fraction < 40%, hypertension, diabetes, or chronic kidney disease.

**MECHANICAL REVASCULARIZATION**

**Percutaneous Coronary Intervention (PCI)**

Includes percutaneous transluminal angioplasty (PTCA) and/or stenting. Performed on anatomically suitable stenoses of native vessels and bypass grafts; more effective than medical therapy for relief of angina. Has not been shown to reduce risk of MI or death in chronic stable angina; should not be performed on asymptomatic or only mildly symptomatic individuals. With PCI initial relief of angina occurs in 95% of pts; however, with PTCA alone stenosis recurs in 30–45% within 6 months (more commonly in pts with initial unstable angina, incomplete dilation, diabetes, or stenoses containing thrombi). If restenosis occurs, PTCA can be repeated with success and risks like original procedure. Potential complications include dissection or thrombosis of the vessel and uncontrolled ischemia or CHF. Complications are most likely to occur in pts with CHF, long eccentric stenoses, calcified plaque, female gender, and dilation of an artery that perfuses a large segment of myocardium with inadequate collaterals. Placement of a bare metal intracoronary stent in suitable pts reduces the restenosis rate to ~30% at 6 months. Restenosis is nearly abolished when drug-eluting stents are used, but late stent thrombosis can rarely occur. The latter is prevented by prolonged antiplatelet therapy (aspirin indefinitely and clopidogrel for a minimum of 12 months).

**Coronary Artery Bypass Surgery (CABG)**

For angina refractory to medical therapy or when the latter is not tolerated (and when lesions are not amenable to PCI) or if severe CAD is present (e.g., left main, three-vessel disease with impaired LV function). CABG is currently preferred over PCI in diabetics with CAD in ≥2 vessels because of better survival.

The relative advantages of PCI and CABG are summarized in **Table 128-3**.

**PRINZMETAL’S VARIANT ANGINA (CORONARY VASOSPASM)**

Intermittent focal spasm of coronary artery; often associated with atherosclerotic lesion near site of spasm. Chest discomfort is similar to angina but more severe and occurs typically at rest, with transient ST-segment elevation. Acute infarction or malignant arrhythmias may develop during spasm-induced ischemia. Evaluation includes observation of ECG (or ambulatory Holter monitor) for transient ST elevation; diagnosis confirmed at coronary angiography using provocative (e.g., IV acetylcholine) testing. Primary treatment consists of long-acting nitrates and calcium antagonists. Prognosis is better in pts with anatomically normal coronary arteries than in those with fixed coronary stenoses.
Bradyarrhythmias arise from: (1) failure of impulse initiation (sinoatrial node dysfunction) or (2) impaired electrical conduction (e.g., AV conduction blocks).

SINOATRIAL (SA) NODE DYSFUNCTION

Etiologies are either intrinsic [degenerative, ischemic, inflammatory, infiltrative (e.g., senile amyloid), or rare mutations in sodium channel or pacemaker current genes] or extrinsic [e.g., drugs (beta blockers, Ca++ channel blockers, digoxin), autonomic dysfunction, hypothyroidism].

Symptoms are due to bradycardia (fatigue, weakness, lightheadedness, syncope) and/or episodes of associated tachycardia (e.g., rapid palpitations, angina) in patients with sick sinus syndrome (SSS).

Diagnosis  Examine ECG for evidence of sinus bradycardia (sinus rhythm at <60 beats/min) or failure of rate to increase with exercise, sinus pauses, or exit

For a more detailed discussion, see Antman EM, Selwyn AP, Braunwald E, Loscalzo J: Ischemic Heart Disease, Chap. 237, p. 1514, in HPIM-17.

### Table 128-3

COMPARISON OF REVASCULARIZATION PROCEDURES IN MULTIVESSEL DISEASE

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percutaneous coronary revascularization (angioplasty and/or stenting)</td>
<td>Less invasive&lt;br&gt;Shorter hospital stay&lt;br&gt;Lower initial cost&lt;br&gt;Easy repeated&lt;br&gt;Effective in relieving symptoms</td>
<td>Restenosis&lt;br&gt;Possible incomplete revascularization&lt;br&gt;Unknown outcomes in pts with severe left ventricular dysfunction&lt;br&gt;Limited to specific anatomic subsets&lt;br&gt;Less beneficial outcome in diabetics with 2- to 3-vascular coronary disease</td>
</tr>
</tbody>
</table>
block. In patients with SSS, periods of tachycardia (i.e., atrial fibrillation/flutter) occur. Prolonged ECG monitoring (24-h Holter or 30-day loop event monitor) aids in identifying these abnormalities. Invasive electrophysiologic testing is rarely necessary to establish diagnosis.

Sinoatrial Node Dysfunction

Remove or treat extrinsic causes such as contributing drugs or hypothyroidism. Otherwise, symptoms of bradycardia respond to permanent pacemaker placement. In SSS, treat associated atrial fibrillation or flutter as indicated in Chap. 130.

AV BLOCK

Impaired conduction from atria to ventricles may be structural and permanent, or reversible (e.g., autonomic, metabolic, drug-related)—see Table 129-1.

<table>
<thead>
<tr>
<th>TABLE 129-1</th>
<th>ETIOLOGIES OF ATRIOVENTRICULAR BLOCK</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Autonomic</strong></td>
<td>Carotid sinus hypersensitivity</td>
</tr>
<tr>
<td><strong>Metabolic/endocrine</strong></td>
<td>Hyperkalemia</td>
</tr>
<tr>
<td></td>
<td>Hypermagnesemia</td>
</tr>
<tr>
<td><strong>Drug-related</strong></td>
<td>Beta blockers</td>
</tr>
<tr>
<td></td>
<td>Calcium channel blockers</td>
</tr>
<tr>
<td></td>
<td>Digitalis</td>
</tr>
<tr>
<td><strong>Infectious</strong></td>
<td>Endocarditis</td>
</tr>
<tr>
<td></td>
<td>Lyme disease</td>
</tr>
<tr>
<td></td>
<td>Chagas disease</td>
</tr>
<tr>
<td></td>
<td>Syphilis</td>
</tr>
<tr>
<td><strong>Heritable/congenital</strong></td>
<td>Congenital heart disease</td>
</tr>
<tr>
<td></td>
<td>Maternal SLE</td>
</tr>
<tr>
<td><strong>Inflammatory</strong></td>
<td>SLE</td>
</tr>
<tr>
<td></td>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td><strong>Infiltrative</strong></td>
<td>Amyloidosis</td>
</tr>
<tr>
<td></td>
<td>Sarcoidosis</td>
</tr>
<tr>
<td><strong>Neoplastic/traumatic</strong></td>
<td>Lymphoma</td>
</tr>
<tr>
<td></td>
<td>Mesothelioma</td>
</tr>
<tr>
<td></td>
<td>Melanoma</td>
</tr>
<tr>
<td><strong>Degenerative</strong></td>
<td>Lev disease</td>
</tr>
<tr>
<td><strong>Coronary artery disease</strong></td>
<td>Acute MI</td>
</tr>
</tbody>
</table>

*Note: SLE, systemic lupus erythematosus; OMIM, Online Mendelian Inheritance in Man (database); MCTD, mixed connective tissue disease; MI, myocardial infarction.*
Bradyarrhythmias

CHAPTER 129

First Degree

Prolonged, constant PR interval (>0.20 s). May be normal or secondary to increased vagal tone or drugs (e.g., beta-blocker, diltiazem, verapamil, digoxin); treatment not usually required.

Second Degree

Mobitz I (Wenckebach)

Narrow QRS, progressive increase in PR interval until a ventricular beat is dropped, then sequence is repeated (Fig. 129-1D). Seen with drug intoxication (digitalis, beta blockers), increased vagal tone, inferior MI. Usually transient, no therapy required; if symptomatic, use atropine (0.6 mg IV, repeated × 3–4) or temporary pacemaker.

Mobitz II

Fixed PR interval with occasional dropped beats, in 2:1, 3:1, or 4:1 pattern; the QRS complex is usually wide. Seen with MI or degenerative conduction system disease; more serious than Mobitz I—may progress suddenly to complete AV block; permanent pacemaker is indicated.

Third Degree (Complete AV Block)

Complete failure of conduction from atria to ventricles; atria and ventricles depolarize independently. May occur with MI, digitalis toxicity, or degenerative conduction system disease. Permanent pacemaker is usually indicated, except when reversible (e.g., drug-related or appears only transiently in MI without associated bundle branch block).

For a more detailed discussion, see Tomaselli GF: The Bradyarrhythmias, Chap. 225, p. 1416, in HPIM-17.
Tachyarrhythmias may appear in the presence or absence of structural heart disease; they are more serious in the former. Conditions that provoke arrhythmias include (1) myocardial ischemia, (2) CHF, (3) hypoxemia, (4) hypercapnia, (5) hypotension, (6) electrolyte disturbances (e.g., hypokalemia and/or hypomagnesemia), (7) drug toxicity (digoxin, pharmacologic agents that prolong QT interval), (8) caffeine, (9) ethanol.

**Diagnosis** Examine ECG for evidence of ischemic changes (Chap. 118), prolonged or shortened QT interval, characteristics of Wolff-Parkinson-White (WPW) syndrome (see below), or ST elevation in leads V₁–V₃ typical of Brugada syndrome. See Fig. 130-1 and Table 130-1 for diagnosis of tachyarrhythmias; always identify atrial activity and relationship between P waves and QRS complexes. To aid the diagnosis:

- Obtain long rhythm strip of lead II, aVF, or V₁. Double the ECG voltage and increase paper speed to 50 mm/s to help identify P waves.
- Place accessory ECG leads (e.g., right-sided chest leads) to help identify P waves. Record ECG during carotid sinus massage (Table 130-1). Note: Do not massage both carotids simultaneously.
- For intermittent symptoms, consider 24-h Holter monitor (if symptoms occur daily), a patient-activated event monitor, or, if symptoms are very infrequent but severely symptomatic, an implanted loop monitor. A standard exercise test may help provoke arrhythmias for diagnostic purposes.

Tachyarrhythmias with wide QRS complex beats may represent ventricular tachycardia or supraventricular tachycardia with aberrant conduction. Factors favoring ventricular tachycardia include (1) AV dissociation, (2) QRS > 0.14 s, (3) rightward and superior QRS axis, (4) no response to carotid sinus massage, (5) morphology of QRS unlike typical RBBB or LBBB, and similar to that of previous ventricular premature beats (Table 130-2).

**Rx** Tachyarrhythmias (Tables 130-1 and 130-3)

Precipitating causes (listed above) should be corrected. If pt is hemodynamically compromised (angina, hypotension, CHF), proceed to immediate cardioversion.

Do not cardiovert sinus tachycardia; exercise caution if digitalis toxicity is suspected. Initiate drugs as indicated in the tables; follow drug levels and ECG intervals (esp. QRS and QT). Reduce dosage for pts with hepatic or renal dysfunction as indicated in Table 130-3. Drug efficacy is confirmed by ECG (or Holter) monitoring, stress testing, and, in special circumstances, invasive electrophysiologic study.

Antiarrhythmic agents all have potential toxic side effects, including provocation of ventricular arrhythmias, esp. in pts with LV dysfunction or history of sustained ventricular arrhythmias. Drug-induced QT prolongation and associated torsades de pointes ventricular tachycardia (Table 130-1) is most common with group IA and III agents; the drug should be discontinued if the
### Tachyarrhythmias

#### CHAPTER 130

**FIGURE 130-1** Tachyarrhythmias. *(Modified from BE Sobel, E Braunwald: HPIM-9, p. 1052.)*

<table>
<thead>
<tr>
<th>Rhythm &amp; Rate Disturbances</th>
<th>Atrial Rate</th>
<th>Ventricular Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Ectopic atrial contraction</td>
<td>-</td>
<td>N</td>
</tr>
<tr>
<td>B. Sinus tachycardia</td>
<td>100+</td>
<td>100+</td>
</tr>
<tr>
<td>C. Reentrant AV nodal tachycardia</td>
<td>160</td>
<td>160</td>
</tr>
<tr>
<td>D. Atrial tachycardia with block (2:1)</td>
<td>16</td>
<td>80</td>
</tr>
<tr>
<td>E. Atrial flutter (2:1 block)</td>
<td>300</td>
<td>150</td>
</tr>
<tr>
<td>F. Atrial fibrillation</td>
<td>500+</td>
<td>Variable</td>
</tr>
<tr>
<td>G. Ectopic ventricular contractions</td>
<td>-</td>
<td>N</td>
</tr>
<tr>
<td>H. Ventricular tachycardia</td>
<td>70</td>
<td>150</td>
</tr>
<tr>
<td>I. Ventricular fibrillation</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>J. Wolff-Parkinson-White with delta waves</td>
<td>70</td>
<td>70</td>
</tr>
<tr>
<td>K. Wolff-Parkinson-White without delta waves</td>
<td>70</td>
<td>70</td>
</tr>
<tr>
<td>Rhythm</td>
<td>Example (See Fig. 130-1)</td>
<td>Atrial Rate</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Narrow QRS Complex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial premature beats</td>
<td>A</td>
<td>—</td>
</tr>
<tr>
<td>Sinus tachycardia</td>
<td>B</td>
<td>100–160</td>
</tr>
<tr>
<td>AV nodal tachycardia (reentrant)</td>
<td>C</td>
<td>120–250</td>
</tr>
<tr>
<td>Atrial tachycardia</td>
<td>D</td>
<td>130–200</td>
</tr>
<tr>
<td>Heart Arrhythmia</td>
<td>Rate</td>
<td>Description</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Atrial flutter</td>
<td>E</td>
<td>250–350 “Sawtooth” flutter waves; 2:1, 4:1 block</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>F</td>
<td>&gt;350 No discrete P; irregularly spaced QRS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multifocal atrial tachycardia</td>
<td></td>
<td>100–150 More than 3 different P wave shapes with varying PR intervals</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Slow the ventricular rate: beta blocker, verapamil, diltiazem, or digoxin
2. Convert to NSR (after anticoagulation if chronic) electrically (50–100 J for atrial flutter, 100–200 J for atrial fibrillation) or chemically with IV ibutilide or oral group IC, III, or IA* agent. Atrial flutter may respond to rapid atrial pacing, and radio frequency ablation highly effective to prevent recurrences.

Treat underlying lung disease; verapamil may be used to slow ventricular rate; group IC agents or amiodarone may ↓ episodes.

*(continued)*
<table>
<thead>
<tr>
<th>Rhythm</th>
<th>Example (See Fig. 130-1)</th>
<th>Atrial Rate</th>
<th>Features</th>
<th>Carotid Sinus Massage</th>
<th>Precipitating Conditions</th>
<th>Initial Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wide QRS Complex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ventricular premature beats</td>
<td>G</td>
<td></td>
<td>Fully compensatory pause between normal beats</td>
<td>No effect</td>
<td>CAD, MI, CHF, hypoxia, hypokalemia, digitalis toxicity, prolonged QT interval (congenital or drugs: quinidine and other antiarrhythmics, tricyclics, phenothiazines)</td>
<td>May not require therapy; if needed, use beta blocker</td>
</tr>
<tr>
<td>Ventricular tachycardia</td>
<td>H</td>
<td></td>
<td>QRS rate 100–250; slightly irregular rate</td>
<td>No effect</td>
<td>If unstable: electrical conversion/defibrillation (&gt; 200 J); otherwise: Acute (IV): amiodarone, lidocaine, procainamide; chronic management: usually ICD. Patients without structural heart disease (focal outflow tract VT) may respond to beta blockers or verapamil.</td>
<td></td>
</tr>
<tr>
<td>Accelerated idioventricular rhythm (AIVR)</td>
<td></td>
<td></td>
<td>Gradual onset and offset; QRS rate 40–120</td>
<td></td>
<td>Acute MI, cocaine, myocarditis</td>
<td>Usually none; for symptoms, use atropine or atrial pacing</td>
</tr>
<tr>
<td>Ventricular fibrillation</td>
<td>I</td>
<td></td>
<td>Erratic electrical activity only</td>
<td>No effect</td>
<td>Immediate defibrillation</td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td>Symptom</td>
<td>Effect</td>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Torsades de pointes</td>
<td>Ventricular tachycardia with sinusoidal oscillations of QRS height</td>
<td>No effect</td>
<td>Prolonged QT interval (congenital or drugs: quinidine and other anti-arrhythmics, tricyclics, phenothiazines)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IV magnesium (1–2 g bolus); overdrive pacing; isoproterenol (unless CAD present); lidocaine. Drugs that prolong QT interval are contraindicated.</td>
<td>Same as treatment of respective supraventricular rhythm; if ventricular rate rapid (&gt;200), treat as WPW (see text).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Supraventricular tachycardias with aberrant ventricular conduction

<table>
<thead>
<tr>
<th>P wave typical of the supraventricular rhythm; wide QRS complex due to conduction through partially refractory pathways</th>
</tr>
</thead>
</table>

Etiologies of the respective supraventricular rhythms listed above; atrial fibrillation with rapid, wide QRS may be due to preexcitation (WPW)

Same as treatment of respective supraventricular rhythm; if ventricular rate rapid (>200), treat as WPW (see text).

---

*Note:* CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; EtOH, ethyl alcohol; ICD, implantable cardioverter defibrillator; NSR, normal sinus rhythm; WPW, Wolff-Parkinson-White.

*Antiarrhythmic drug groups listed in Table 130-3.*
QTc interval (QT divided by square root of RR interval) increases by >25%. Antiarrhythmic drugs should be avoided in pts with asymptomatic ventricular arrhythmias after MI, since mortality risk increases.

CHRONIC ATRIAL FIBRILLATION
Evaluate potential underlying cause (e.g., thyrotoxicosis, mitral stenosis, excessive ethanol consumption, pulmonary embolism). Pts with risk factors for stroke (e.g., rheumatic mitral valve disease, history of cerebrovascular accident or transient ischemic attack, hypertension, diabetes, CHF, age >75) should receive warfarin anticoagulation (INR 2.0–3.0). Substitute aspirin, 325 mg/d, for pts without these risk factors or if contraindication to warfarin exists.

Control ventricular rate (60–80 beats/min at rest, <100 beats/min with mild exercise) with beta blocker, calcium channel blocker (verapamil, diltiazem), or digoxin.

Consider cardioversion (100–200 J) after ≥3 weeks therapeutic anticoagulation, or acutely if no evidence of left atrial thrombus by transesophageal echo, especially if symptomatic despite rate control. Initiation of group IC, III, or IA agent (usually initiate with inpatient monitoring) prior to electrical cardioversion facilitates maintenance of sinus rhythm after successful procedure. Type IC (Table 130-3) drugs are preferred in pts without structural heart

### TABLE 130-2 WIDE COMPLEX TACHYCARDIA

**ECG Criteria That Favor Ventricular Tachycardia**

1. AV dissociation
2. QRS width: >0.14 s with RBBB configuration
   >0.16 s with LBBB configuration
3. QRS axis: Left axis deviation with RBBB morphology
   Extreme left axis deviation (northwest axis) with LBBB morphology
4. Concordance of QRS in precordial leads
5. Morphologic patterns of the QRS complex
   RBBB: Mono- or biphasic complex in V₁
   RS (only with left axis deviation) or QS in V₆

LBBB: Broad R wave in V₁ or V₂ ≥0.04 s
Onset of QRS to nadir of S wave in V₁ or V₂ of ≥0.07 s
Notched downslope of S wave in V₁ or V₂
Q wave in V₆

**Note:** AV, atrioventricular; BBB, bundle branch block.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Loading Dose</th>
<th>Maintenance Dose</th>
<th>Side Effects</th>
<th>Excretion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group IA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quinidine sulfate</td>
<td>PO: 200–400 mg q6h</td>
<td>Diarrhea, tinnitus,</td>
<td></td>
<td>Hepatic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>QT prolongation,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>hypotension, anemia,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>thrombocytopenia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quinidine gluconate</td>
<td>PO: 324–628 mg q8h</td>
<td>Nausea, lupus-like</td>
<td></td>
<td>Hepatic</td>
</tr>
<tr>
<td>Procainamide</td>
<td>IV: 1–4 mg/min</td>
<td>syndrome, agranulo-</td>
<td></td>
<td>Renal and hepatic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>cytosis, QT prolong-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sustained-release:</td>
<td></td>
<td>Myocardial depression</td>
<td></td>
<td>Renal and hepatic</td>
</tr>
<tr>
<td>Disopyramide</td>
<td>PO: 500–1000 mg q4h</td>
<td>AV block, QT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV: 1000–2500 mg q12h</td>
<td>prolongation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sustained-release:</td>
<td></td>
<td>anticholinergic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group IB</td>
<td></td>
<td>effects</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lidocaine</td>
<td>PO: 200–400 mg q12h</td>
<td>Confusion, seizures,</td>
<td></td>
<td>Hepatic</td>
</tr>
<tr>
<td></td>
<td>IV: 1 mg/kg bolus followed by 0.5</td>
<td>respiratory arrest</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>mg/kg bolus q8–10 min to total 3 mg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexiletine</td>
<td></td>
<td>Nausea, tremor,</td>
<td></td>
<td>Hepatic</td>
</tr>
<tr>
<td><strong>Group IC</strong></td>
<td></td>
<td>gait disturbance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flecainide</td>
<td>PO: 150–300 mg q8–12h</td>
<td>Nausea, exacerbation</td>
<td></td>
<td>Hepatic and renal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>of ventricular arrhythmia, prolongation of PR and QRS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PO: 50–200 mg q12h</td>
<td>intervals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Propafenone</td>
<td>PO: 150–300 mg q8h</td>
<td>CHF, bradycardia,</td>
<td></td>
<td>Hepatic</td>
</tr>
<tr>
<td><strong>Group II</strong></td>
<td></td>
<td>AV block, broncho-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metoprolol</td>
<td>IV: 5–10 mg q5min × 3</td>
<td>Spasm</td>
<td></td>
<td>Hepatic</td>
</tr>
<tr>
<td>Esmolol</td>
<td>IV: 500 μg/kg over 1 min</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Drug</th>
<th>Loading Dose</th>
<th>Maintenance Dose</th>
<th>Side Effects</th>
<th>Excretion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group III</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td>PO: 800–1600 mg qd × 1–2 weeks, then 400–600 mg/d × 3 weeks</td>
<td>PO: 100–400 mg qd</td>
<td>Thyroid abnormalities, pulmonary fibrosis, hepatitis, corneal microdeposits, bluish skin, QT prolongation</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>IV: 150 mg over 10 min</td>
<td>IV: 1 mg/min × 6 h, then 0.5 mg/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ibutilide</td>
<td>IV (≥60 kg): 1 mg over 10 min, can repeat after 10 min</td>
<td>—</td>
<td>Torsades de pointes, hypotension, nausea</td>
<td>Hepatic</td>
</tr>
<tr>
<td>Dofetilide</td>
<td>PO: 125–500 μg bid</td>
<td>—</td>
<td>Torsades de pointes, headache, dizziness</td>
<td>Renal</td>
</tr>
<tr>
<td><strong>Group IV</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verapamil</td>
<td>IV: 2.5–10 mg over 3–5 min</td>
<td>IV: 2.5–10 mg/h PO: 80–120 mg q6–8 h</td>
<td>AV block, CHF, hypotension, constipation</td>
<td>Hepatic</td>
</tr>
<tr>
<td>Diltiazem</td>
<td>IV: 0.25 mg/kg over 3–5 min; can repeat with 0.35 mg/kg after 15 min</td>
<td>IV: 5–15 mg/h PO: 30–60 mg q6h</td>
<td>—</td>
<td>Hepatic</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digoxin</td>
<td>IV, PO: 0.75–1.5 mg over 24 h</td>
<td>IV, PO: 0.125–0.25 mg qd</td>
<td>Nausea, AV block, ventricular and supraventricular arrhythmias</td>
<td>Renal</td>
</tr>
<tr>
<td>Adenosine</td>
<td>IV: 6-mg rapid bolus; if no effect then 12-mg bolus</td>
<td>—</td>
<td>Transient hypotension or atrial standstill</td>
<td>—</td>
</tr>
</tbody>
</table>
disease, and type III drugs are recommended in presence of left ventricular dysfunction or coronary artery disease (Fig. 130-2). Anticoagulation should be continued for a minimum of 3 weeks after successful cardioversion. Catheter-based ablation can be considered for recurrent symptomatic atrial fibrillation (AF) refractory to pharmacologic measures.

PREEXCITATION SYNDROME (WPW)

Conduction occurs through an accessory pathway between atria and ventricles. Baseline ECG typically shows a short PR interval and slurred upstroke of the QRS (“delta” wave) (Fig. 130-1J). Associated tachyarrhythmias are of two types:

- Narrow QRS complex tachycardia (antegrade conduction through AV node). Treat cautiously with IV adenosine or beta blocker, verapamil, or diltiazem (Table 130-2).
- Wide QRS complex tachycardia (antegrade conduction through accessory pathway); may also be associated with AF with a very rapid (>250/min) ventricular rate, which can degenerate into VF. If hemodynamically compromised, immediate cardioversion is indicated; otherwise, treat with IV procainamide or ibutilide (Table 130-3), not digoxin, beta blocker, or verapamil.

Consider catheter ablation of accessory pathway for long-term prevention.

For a more detailed discussion, see Marchlinski F: The Tachyarrhythmias, Chap. 226, p. 1425, in HPIM-17.
HEART FAILURE

Definition
Condition in which heart is unable to pump sufficient blood for metabolizing tissues or can do so only from an abnormally elevated filling pressure.

It is important to identify the underlying nature of the cardiac disease and the factors that precipitate acute CHF. Underlying cardiac disease includes states that depress systolic ventricular function (coronary artery disease, hypertension, dilated cardiomyopathy, valvular disease, congenital heart disease) and states of heart failure with preserved ejection fraction (e.g., restrictive cardiomyopathies, hypertrophic cardiomyopathy, arrhythmias, endomyocardial disorders), also termed diastolic failure.

Acute precipitating factors include increased Na intake, noncompliance with anti-CHF medications, acute MI (may be silent), exacerbation of hypertension, acute arrhythmias, infections and/or fever, pulmonary embolism, anemia, thyrotoxicosis, pregnancy, acute myocarditis or infective endocarditis, and certain drugs (e.g., nonsteroidal anti-inflammatory agents, verapamil).

Symptoms
Due to inadequate perfusion of peripheral tissues (fatigue, dyspnea) and elevated intracardiac filling pressures (orthopnea, paroxysmal nocturnal dyspnea, peripheral edema), patients with diastolic dysfunction may have an S4. Laboratory testing can further assess left ventricular function by echocardiography and brain natriuretic peptide (BNP) measurements.

Conditions That Mimic CHF
Pulmonary Disease
Chronic bronchitis, emphysema, and asthma (Chaps. 136 and 138) should be considered when evaluating patients with respiratory symptoms.

Other Causes of Peripheral Edema
Liver disease, varices, and cyclic edema are conditions that can mimic CHF but do not result in jugular venous distention. Edema due to renal disease can be differentiated from pulmonary causes of dyspnea by elevated serum creatinine and abnormal urinalysis.

Conditions That Mimic CHF
Pulmonary Disease
Chronic bronchitis, emphysema, and asthma (Chaps. 136 and 138) should be considered when evaluating patients with respiratory symptoms.

Other Causes of Peripheral Edema
Liver disease, varices, and cyclic edema are conditions that can mimic CHF but do not result in jugular venous distention. Edema due to renal disease can be differentiated from pulmonary causes of dyspnea by elevated serum creatinine and abnormal urinalysis.
view of treatment shown in Table 131-1: notably, ACE inhibitors and beta blockers are cornerstones of therapy in patients with impaired ejection fraction (EF). Once symptoms develop:

- **Decrease cardiac workload:** Reduce physical activity; include periods of bed rest. Prevent deep venous thrombosis of immobile pts with heparin, 5000 U SC bid, or enoxaparin, 40 mg SC qd.

- **Control excess fluid retention:**
  1. **Dietary sodium restriction** (eliminate salty foods, e.g., potato chips, canned soups, bacon, salt added at table); more stringent requirements (<2 g NaCl/d) in advanced CHF. If dilutional hyponatremia present, restrict fluid intake (<1000 mL/d).
  2. **Diuretics** (see Chap. 49): Loop diuretics [e.g., furosemide (see Table 131-2)] are most potent and unlike thiazides remain effective when GFR < 25 mL/min. Combine loop diuretic with thiazide or metolazone for augmented effect. Potassium-sparing diuretics are useful adjunct to reduce potassium loss; should be used cautiously when combined with ACE inhibitor or angiotensin receptor blocker (ARB) to avoid hyperkalemia.

During diuresis, obtain daily weights, aiming for loss of 1–1.5 kg/d.

- **ACE inhibitors** (Table 131-2): Recommended as standard initial CHF therapy. ACE inhibitors are mixed (arterial and venous) dilators and are particularly effective and well tolerated. They have been shown to prolong life in pts with symptomatic CHF. ACE inhibitors have also been shown to delay the onset of CHF in pts with asymptomatic LV dysfunction and to lower mortality when begun soon after acute MI. ACE inhibitors may result in significant hypotension in pts who are volume depleted, so start at lowest dosage (e.g., captopril 6.25 mg PO tid). ARBs (Table 131-2) may be substituted if pt is intolerant of ACE inhibitor (because of cough or angioedema). Consider hydralazine plus an oral nitrate instead in pts who develop hyperkalemia or renal insufficiency on ACE inhibitor.
• **Beta blockers** (Table 131-2) administered in gradually augmented dosage improve symptoms and prolong survival in pts with moderate (NYHA class II–III) heart failure and reduced EF. After pt stabilized on ACE inhibitor and diuretic, begin at low dosage and increase gradually [e.g., carvedilol 3.125 mg bid, double q2weeks as tolerated to maximum of 25 mg bid (for weight < 85 kg) or 50 mg bid (weight > 85 kg)].

• Aldosterone antagonists, e.g., spironolactone, 25 mg/d, added to standard therapy in patients with advanced heart failure have been shown to reduce mortality. Its diuretic properties may also be beneficial, and it should be considered in patients with class III/IV heart failure symptoms.

• **Digoxin** is useful in heart failure due to (1) marked systolic dysfunction (LV dilatation, low EF, S3) and (2) heart failure associated with atrial fibrillation (AF) and rapid ventricular rate. Unlike ACE inhibitors and beta blockers, digoxin does not prolong survival in heart failure pts but reduces hospitalizations. Not indicated in CHF due to pericardial disease, restrictive cardiomyopathy, or mitral stenosis (unless AF is present). Digoxin is contraindicated in hypertrophic cardiomyopathy and in pts with AV conduction blocks.

---

**TABLE 131-1**  
**THERAPY FOR HEART FAILURE**

1. General measures  
   a. Restrict salt intake  
   b. Avoid antiarrhythmics for asymptomatic arrhythmias  
   c. Avoid NSAIDs  
   d. Immunize against influenza and pneumococcal pneumonia

2. Diuretics  
   a. Use in volume-overloaded pts to achieve normal JVP and relief of edema  
   b. Weigh daily to adjust dose  
   c. For diuretic resistance, administer IV or use 2 diuretics in combination (e.g., furosemide plus metolazone)  
   d. Low-dose dopamine to enhance renal flow

3. ACE inhibitors  
   a. For all patients with LV systolic heart failure or asymptomatic LV dysfunction  
   b. Contraindications: Serum K+ > 5.5, advanced renal failure (e.g., creatinine > 3 mg/dL), bilateral renal artery stenosis, pregnancy

4. Beta blockers  
   a. For patients with class II–III heart failure, combined with ACE inhibitor and diuretics  
   b. Contraindications: Bronchospasm, symptomatic bradycardia or advanced heart block, unstable heart failure or class IV symptoms

5. Digitalis  
   a. For persistently symptomatic pts with systolic heart failure (especially if atrial fibrillation present) added to ACE inhibitor, diuretics, beta blocker

6. Other measures  
   a. Consider angiotensin receptor blocker or combination of hydralazine and oral nitrate if not tolerant of ACE inhibitor  
   b. Consider spironolactone in class III–IV heart failure  
   c. Consider ventricular resynchronization in pts with class III or IV heart failure and QRS > 120 ms  
   d. Consider implantable cardioverter-defibrillator in pts with class III heart failure and ejection fraction <30%

**Source:** Modified from E Braunwald: HPIM-15, p. 1318.
Digoxin loading dose is administered over 24 h (0.5 mg PO/IV, followed by 0.25 mg q6h to achieve total of 1.0–1.5 mg). Subsequent dose (0.125–0.25 mg qd) depends on age, weight, and renal function and is guided by measurement of serum digoxin level (maintain level < 1.0 ng/mL).

Digitalis toxicity may be precipitated by hypokalemia, hypoxemia, hypercalcemia, hypomagnesemia, hypothyroidism, or myocardial ischemia. Early signs of toxicity include anorexia, nausea, and lethargy. Cardiac toxicity includes ventricular extrasystoles and ventricular tachycardia and fibrillation; atrial tachycardia with block; sinus arrest and sinoatrial block; all degrees of AV block. Chronic digitalis intoxication may cause cachexia, gynecomastia, “yellow” vision, or confusion. At first sign of digitalis toxicity, discontinue the drug; maintain serum K concentration between 4.0 and 5.0 mmol/L.

### TABLE 131-2 DRUGS FOR THE TREATMENT OF CHRONIC HEART FAILURE (EF <40%)

<table>
<thead>
<tr>
<th>Diuretics</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Furosemide</td>
<td>20–40 mg qd or bid</td>
<td>400 mg/d&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Torsemide</td>
<td>10–20 mg qd bid</td>
<td>200 mg/d&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Bumetanide</td>
<td>0.5–1.0 mg qd or bid</td>
<td>10 mg/d&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>25 mg qd</td>
<td>100 mg/d&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Metolazone</td>
<td>2.5–5.0 mg qd or bid</td>
<td>20 mg/d&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

### Angiotensin-Converting Enzyme Inhibitors

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Captopril</td>
<td>6.25 mg tid</td>
</tr>
<tr>
<td>Enalapril</td>
<td>2.5 mg bid</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>2.5–5.0 mg qd</td>
</tr>
<tr>
<td>Ramipril</td>
<td>1.25–2.5 mg bid</td>
</tr>
<tr>
<td>Trandolapril</td>
<td>0.5 mg qd</td>
</tr>
</tbody>
</table>

### Angiotensin Receptor Blockers

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Valsartan</td>
<td>40 mg bid</td>
</tr>
<tr>
<td>Candesartan</td>
<td>4 mg qd</td>
</tr>
<tr>
<td>Irbesartan</td>
<td>75 mg qd</td>
</tr>
<tr>
<td>Losartan</td>
<td>12.5 mg qd</td>
</tr>
</tbody>
</table>

### β Receptor Blockers

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Carvedilol</td>
<td>3.125 mg bid</td>
</tr>
<tr>
<td>Bisoprolol</td>
<td>1.25 mg qd</td>
</tr>
<tr>
<td>Metoprolol succinate CR</td>
<td>12.5–25 mg qd</td>
</tr>
</tbody>
</table>

### Additional Therapies

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Spironolactone</td>
<td>12.5–25 mg qd</td>
</tr>
<tr>
<td>Eplerenone</td>
<td>25 mg qd</td>
</tr>
<tr>
<td>Combination of hydralazine/isosorbide dinitrate</td>
<td>10–25 mg/10 mg tid</td>
</tr>
<tr>
<td>Fixed dose of hydralazine/isosorbide dinitrate</td>
<td>37.5 mg/20 mg (one tablet) tid</td>
</tr>
<tr>
<td>Digoxin</td>
<td>0.125 mg qd</td>
</tr>
</tbody>
</table>

<sup>a</sup>Dose must be titrated to reduce the patient’s congestive symptoms.

<sup>b</sup>Target dose not established.
Bradyarrhythmias and AV block may respond to atropine (0.6 mg IV); otherwise, a temporary pacemaker may be required. Digitalis-induced ventricular arrhythmias are usually treated with lidocaine (Chap. 130). Antidigoxin antibodies are available for massive overdose.

- The combination of the oral vasodilators hydralazine and isosorbide dinitrate may be of benefit for chronic administration in pts intolerant of ACE inhibitors and ARBs and is also recommended as part of standard therapy in African Americans with class II–IV heart failure.
- In sicker, hospitalized patients, IV vasodilator therapy (Table 131-2) is monitored by placement of a pulmonary artery catheter and indwelling arterial line. Nitroprusside is a potent mixed vasodilator for pts with markedly elevated systemic vascular resistance. It is metabolized to thiocyanate, then excreted via the kidneys. To avoid thiocyanate toxicity (seizures, altered mental status, nausea), follow thiocyanate levels in pts with renal dysfunction or if administered for >2 days.

IV nesiritide (Table 131-3), a purified preparation of BNP, is a vasodilator that reduces pulmonary capillary wedge pressure and dyspnea in patients with acutely decompensated CHF. It should be used only in patients with refractory heart failure.

- **IV inotropic agents** (see Table 131-3) are administered to hospitalized pts for refractory symptoms or acute exacerbation of CHF to augment cardiac output. They are contraindicated in hypertrophic cardiomyopathy. **Dobutamine** augments cardiac output without significant peripheral vasoconstriction or tachycardia. **Dopamine** at low dosage [1–5 (μg/kg)/min] facilitates diuresis; at higher dosage [5–10 (μg/kg)/min] positive inotropic effects predominate; peripheral vasoconstriction is greatest at dosage >10 (μg/kg)/min. **Milrinone** [0.375 (μg/kg)/min after 50-μg/kg loading dose] is a non-

<table>
<thead>
<tr>
<th>TABLE 131-3</th>
<th>DRUGS FOR TREATMENT OF ACUTE HEART FAILURE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initiating Dose</strong></td>
<td><strong>Maximal Dose</strong></td>
</tr>
<tr>
<td>Vasodilators</td>
<td></td>
</tr>
<tr>
<td>Nitroglycerin</td>
<td>20 μg/min</td>
</tr>
<tr>
<td>Nitroprusside</td>
<td>10 μg/min</td>
</tr>
<tr>
<td>Nesiritide</td>
<td>Bolus 2 μg/kg</td>
</tr>
<tr>
<td>Inotropes</td>
<td></td>
</tr>
<tr>
<td>Dobutamine</td>
<td>1–2 μg/kg per min</td>
</tr>
<tr>
<td>Milrinone</td>
<td>Bolus 50 μg/kg</td>
</tr>
<tr>
<td>Dopamine</td>
<td>1–2 μg/kg per min</td>
</tr>
<tr>
<td>Levosimendan</td>
<td>Bolus 12 μg/kg</td>
</tr>
<tr>
<td>Vasoconstrictors</td>
<td></td>
</tr>
<tr>
<td>Dopamine for hypotension</td>
<td>5 μg/kg per min</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>0.5 μg/kg per min</td>
</tr>
<tr>
<td>Phenylephrine</td>
<td>0.3 μg/kg per min</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>0.05 units/min</td>
</tr>
</tbody>
</table>

aUsually <4 μg/kg/min.
bInotropes will also have vasodilatory properties.
cApproved outside of the United States for the management of acute heart failure.
sympathetic positive inotrope and vasodilator. The above vasodilators and inotropic agents may be used together for additive effect.

Consider implantable cardioverter defibrillator prophylactically for class II–III heart failure and LVEF < 30–35%. Patients with an LVEF <35%, refractory CHF, and QRS > 120 ms may be candidates for biventricular pacing (cardiac resynchronization therapy). Pts with severe disease and <6 months expected survival, who meet stringent criteria, may be candidates for a ventricular assist device or cardiac transplantation.

- Patients with predominantly diastolic heart failure are treated with salt restriction and diuretics. Beta blockers and ACE inhibitors may be of benefit in blunting neurohormonal activation.

### COR PULMONALE

RV enlargement resulting from primary lung disease; leads to RV hypertrophy and eventually to RV failure. Etiologies include:

- **Pulmonary parenchymal or airway disease.** Chronic obstructive lung disease (COPD), interstitial lung diseases, bronchiectasis, cystic fibrosis (Chaps. 138 and 141).
- **Pulmonary vascular disease.** Recurrent pulmonary emboli, primary pulmonary hypertension (PHT) (Chap. 134), vasculitis, sickle cell anemia.
- **Inadequate mechanical ventilation.** Kyphoscoliosis, neuromuscular disorders, marked obesity, sleep apnea.

**Symptoms** Depend on underlying disorder but include dyspnea, cough, fatigue, and sputum production (in parenchymal diseases).

**Physical Examination** Tachypnea, cyanosis, clubbing are common. RV impulse along left sternal border, loud P2, right-sided S4. If RV failure develops, elevated jugular venous pressure, hepatomegaly with ascites, pedal edema. Murmur of tricuspid regurgitation (Chap. 117) may appear.

**Laboratory ECG** RV hypertrophy and RA enlargement (Chap. 118); tachyarhythmias are common.

**Radiologic Studies** CXR shows RV and pulmonary artery enlargement; if PHT present, tapering of the pulmonary artery branches. Chest CT identifies emphysema, interstitial lung disease, and acute pulmonary embolism; V/Q scan more reliable for diagnosis of chronic thromboemboli. Pulmonary function tests and ABGs characterize intrinsic pulmonary disease.

**Echocardiogram** RV hypertrophy; LV function typically normal. RV systolic pressure can be estimated from Doppler measurement of tricuspid regurgitant flow. If imaging is difficult because of air in distended lungs, RV volume and wall thickness can be evaluated by MRI.

**Cor Pulmonale**

Aimed at underlying pulmonary disease and may include bronchodilators, antibiotics, and oxygen administration. If RV failure is present, treat as CHF, instituting low-sodium diet and diuretics; digoxin must be administered cautiously (toxicity increased due to hypoxemia, hypercapnia, acidosis). Loop diuretics must also be used with care to prevent significant metabolic alkalosis.
that blunts respiratory drive. Supraventricular tachyarrhythmias are common and treated with digoxin or verapamil (should typically avoid beta blockers). Chronic anticoagulation with warfarin is indicated when pulmonary hypertension is accompanied by RV failure. See Chap. 140 for treatment of pulmonary embolism, and Chap. 134 for management of pulmonary hypertension.

For a more detailed discussion, see Mann DL: Heart Failure and Cor Pulmonale, Chap. 227, p. 1443, in HPIM-17.

### Aortic Aneurysm

Abnormal dilatation of the abdominal or thoracic aorta; in ascending aorta most commonly secondary to cystic medial necrosis; aneurysms of descending thoracic and abdominal aorta are primarily atherosclerotic. Rare causes of aneurysms are infections (syphilitic, tuberculous, mycotic) and vasculitides (e.g., Takayasu’s arteritis, giant cell arteritis).

**History**  May be clinically silent, but thoracic aortic aneurysms can result in deep, diffuse chest pain, dysphagia, hoarseness, hemoptysis, dry cough; abdominal aneurysms may result in abdominal pain or thromboemboli to the lower extremities.

**Physical Examination**  Abdominal aneurysms are often palpable, most commonly in periumbilical area. Pts with ascending thoracic aneurysms may show features of the Marfan syndrome (HPIM-17, Chap. 357).

**Laboratory**  Suspect thoracic aneurysm by abnormal CXR (enlarged aortic silhouette) and confirm by echocardiography, contrast CT, or MRI. Confirm abdominal aneurysm by abdominal plain film (rim of calcification), ultrasound, CT, MRI, or contrast aortography. If clinically suspected, obtain serologic test for syphilis, especially if ascending thoracic aneurysm shows thin shell of calcification.

**Rx**  Aortic Aneurysm

Control of hypertension (Chap. 124) is essential. Surgical resection of thoracic aortic aneurysms >5.5–6 cm in diameter (abdominal aortic aneurysms >5.5 cm), for persistent pain despite bp control, or for evidence of rapid expansion. In pts with the Marfan syndrome, thoracic aortic aneurysms >5 cm usually warrant repair.

### Aortic Dissection  (Fig. 132-1)

Potentially life-threatening condition in which disruption or aortic intima allows dissection of blood into vessel wall; may involve ascending aorta (type II), descend-
ing aorta (type III), or both (type I). Alternative classification: Type A—dissection involves ascending aorta; type B—limited to descending aorta. Involvement of the ascending aorta is most lethal form. Variant acute aortic syndromes include intramural hematoma without an intimal flap, and penetrating atherosclerotic ulcer.

**Etiology** Ascending aortic dissection associated with hypertension, cystic medial necrosis, the Marfan and Ehlers-Danlos syndromes; descending dissections commonly associated with atherosclerosis or hypertension. Incidence is increased in pts with coarctation of aorta, bicuspid aortic valve, and rarely in third trimester of pregnancy in otherwise normal women.

**Symptoms** Sudden onset of severe anterior or posterior chest pain, with “ripping” quality; maximal pain may travel if dissection propagates. Additional symptoms relate to obstruction of aortic branches (stroke, MI), dyspnea (acute aortic regurgitation), or symptoms of low cardiac output due to cardiac tamponade (dissection into pericardial sac).

**Physical Examination** Sinus tachycardia common; if cardiac tamponade develops, hypotension, pulsus paradoxus, and pericardial rub appear. Asymmetry
of carotid or brachial pulses, aortic regurgitation, and neurologic abnormalities associated with interruption of carotid artery flow are common findings.

**Laboratory**  
**CXR:** Widening of mediastinum; dissection can be confirmed by CT, MRI, or ultrasound (esp. transesophageal echocardiography). Aortography is rarely required, as sensitivity of these noninvasive techniques is >90%.

### Aortic Dissection

Reduce cardiac contractility and treat hypertension to maintain systolic bp between 100 and 120 mmHg using IV agents (Table 132-1), e.g., sodium nitroprusside accompanied by a beta blocker (aiming for heart rate of 60 beats per min), followed by oral therapy. If beta blocker contraindicated, consider IV verapamil or diltiazem (see Table 130-3). Direct vasodilators (hydralazine, diazoxide) are contraindicated because they may increase shear stress. Ascending aortic dissection (type A) requires surgical repair emergently or, if pt can be stabilized with medications, semielectively. Descending aortic dissections are stabilized medically (maintain systolic bp between 110 and 120 mmHg) with oral antihypertensive agents (esp. beta blockers); immediate surgical repair is not necessary unless continued pain or extension of dissection is observed (by serial MRI or CT performed every 6–12 months).

### OTHER ABNORMALITIES OF THE AORTA

#### Atherosclerotic Occlusive Disease of Abdominal Aorta

Particularly common in presence of diabetes mellitus or cigarette smoking. Symptoms include intermittent claudication of the buttocks and thighs and impotence (Leriche syndrome); femoral and other distal pulses are absent. Diagnosis is established by noninvasive leg pressure measurements and Doppler velocity analysis, and confirmed by MRI, CT, or aortography. Catheter-based endovascular treatment or aortic-femoral bypass surgery is required for symptomatic treatment.

#### Takayasu’s (“Pulseless”) Disease

Arteritis of aorta and major branches in young women. Anorexia, weight loss, fever, and night sweats occur. Localized symptoms relate to occlusion of aortic branches (cerebral ischemia, claudication, and loss of pulses in arms). ESR is increased; diagnosis confirmed by aortography. Glucocorticoid and immunosuppressive therapy may be beneficial, but mortality is high.

---

For a more detailed discussion, see Creager MA, Loscalzo J: Diseases of the Aorta, Chap. 242, p. 1563, in HPIM-17.
Occlusive or inflammatory disease that develops within the peripheral arteries, veins, or lymphatics.

**ARTERIOSCLEROSIS OF PERIPHERAL ARTERIES**

**History**  *Intermittent claudication* is muscular cramping with exercise; quickly relieved by rest. Pain in buttocks and thighs suggests aortoiliac disease; calf muscle pain implies femoral or popliteal artery disease. More advanced arteriosclerotic obstruction results in pain at rest; painful ulcers of the feet (painless in diabetics) may result.

**Physical Examination**  Decreased peripheral pulses (ankle:brachial index <1.0), blanching of affected limb with elevation, dependent rubor (redness). Ischemic ulcers or gangrene of toes may be present.

**Laboratory**  Doppler ultrasound of peripheral pulses before and during exercise localizes stenoses; magnetic resonance angiography or contrast arteriography performed only if reconstructive surgery or angioplasty is considered.

---

**Arteriosclerosis**

Most pts can be managed medically with daily exercise program, careful foot care (especially in diabetics), treatment of hypercholesterolemia, and local debridement of ulcerations. Abstinence from cigarettes is mandatory. Some, but not all, pts note symptomatic improvement with drug therapy (pentoxifylline or cilostazol). Pts with severe claudication, rest pain, or gangrene are candidates for arterial reconstructive surgery; percutaneous transluminal angioplasty or stent placement can be performed in selected pts.

---

**OTHER CONDITIONS THAT IMPAIR PERIPHERAL ARTERIAL FLOW**

**Arterial Embolism**  This is due to thrombus or vegetation within the heart or aorta or paradoxically from a venous thrombus through a right-to-left intracardiac shunt.

**History**  Sudden pain or numbness in an extremity in the absence of previous history of claudication.

**Physical Examination**  Absent pulse, pallor, and decreased temperature of limb distal to the occlusion. Lesion is identified by angiography.

---

**Arterial Embolism**

Intravenous heparin is administered to prevent propagation of clot. For acute severe ischemia, immediate endovascular or surgical embolectomy is indicated. Thrombolytic therapy (e.g., tissue plasminogen activator or urokinase) may be effective for thrombus within atherosclerotic vessel or arterial bypass graft.
Atheroembolism  A subset of acute arterial occlusion due to embolization of fibrin, platelets, and cholesterol debris from more proximal atheromas or aneurysm; typically occurs after intraarterial instrumentation. Depending on location, may lead to stroke, renal insufficiency, or pain and tenderness in embolized tissue. Atheroembolism to lower extremities results in blue toe syndrome, which can progress to necrosis and gangrene. Treatment is supportive; for recurrent episodes, surgical intervention in the proximal atherosclerotic vessel or aneurysm may be required.

Vasospastic Disorders  This manifests by Raynaud’s phenomenon in which cold exposure results in triphasic color response: blanching of the fingers, followed by cyanosis, then redness. Usually a benign disorder. However, suspect an underlying disease (Table 133-1) if tissue necrosis occurs, if disease is unilateral, or if it develops after age 50.

Vasospastic Disorders

Keep extremities warm; calcium channel blockers (e.g., nifedipine XL 30–90 mg PO qd) or α-adrenergic antagonists (e.g., prazocin 1–5 mg tid) may be effective.

Thromboangiitis Obliterans (Buerger’s Disease)  Occurs in young men who are heavy smokers and involves both upper and lower extremities; nonatheromatous inflammatory reaction develops in veins and small arteries leading to superficial thrombophlebitis and arterial obstruction with ulceration or gangrene of digits. Abstinence from tobacco is essential.

VENOUS DISEASE

Superficial Thrombophlebitis  A benign disorder characterized by erythema, tenderness, and edema along involved vein. Conservative therapy includes local heat, elevation, and anti-inflammatory drugs such as aspirin. More serious conditions such as cellulitis or lymphangitis may mimic this, but these are associated with fever, chills, lymphadenopathy, and red superficial streaks along inflamed lymphatic channels.

**TABLE 133-1**  CLASSIFICATION OF RAYNAUD’S PHENOMENON

| Primary or idiopathic Raynaud’s phenomenon: Raynaud’s disease |
| Collagen vascular diseases: scleroderma, systemic lupus erythematosus, rheumatoid arthritis, dermatomyositis, polymyositis |
| Arterial occlusive diseases: atherosclerosis of the extremities, thromboangiitis obliterans, acute arterial occlusion, thoracic outlet syndrome |
| Pulmonary hypertension |
| Neurologic disorders: intervertebral disk disease, syringomyelia, spinal cord tumors, stroke, poliomyelitis, carpal tunnel syndrome |
| Blood dyscrasias: cold agglutinins, cryoglobulinemia, cryofibrinogenemia, myeloproliferative disorders, Waldenström’s macroglobulinemia |
| Trauma: vibration injury, hammer hand syndrome, electric shock, cold injury, typing, piano playing |
| Drugs: ergot derivatives, methysergide, β-adrenergic receptor blockers, bleomycin, vinblastine, cisplatin |
Deep Venous Thrombosis (DVT) This is a more serious condition that may lead to pulmonary embolism (Chap. 140). Particularly common in pts on prolonged bed rest, those with chronic debilitating disease, and those with malignancies (Table 133-2).

History Pain or tenderness in calf or thigh, usually unilateral; may be asymptomatic, with pulmonary embolism as primary presentation.

Physical Examination Often normal; local swelling or tenderness to deep palpation may be present over affected vein.

Laboratory D-Dimer testing is sensitive but not specific for diagnosis. Most helpful noninvasive testing is ultrasound imaging of the deep veins with Doppler interrogation. These noninvasive studies are most sensitive for proximal (upper leg) DVT, less sensitive for calf DVT. Invasive venography is used when diagnosis is not clear. MRI may be useful for diagnosis of proximal DVT and DVT within the pelvic veins or in the superior or inferior vena cavae.

Systemic anticoagulation with heparin [5000- to 10,000-U bolus, followed by continuous IV infusion to maintain a PTT at 2 × normal (or using a nomogram: 80 U/kg bolus followed by initial infusion of 18 U/kg/hour)] or low-molecular-weight heparin (e.g., enoxaparin 1 mg/kg SC bid), followed by warfarin PO (overlap with heparin for at least 4–5 days and continue for at least 3 months if proximal deep veins involved). Adjust warfarin dose to maintain prothrombin time at INR 2.0–3.0.

DVT can be prevented by early ambulation following surgery or with low-dose unfractionated heparin during prolonged bed rest (5000 U SC bid-tid) or low-molecular-weight heparin (e.g., enoxaparin 40 mg SC daily), supplemented by pneumatic compression boots. Following knee or hip surgery, warfarin (INR 2.0–3.0) is an effective regimen. Low-molecular-weight heparins are also effective in preventing DVT after general or orthopedic surgery.

Chronic Venous Insufficiency This results from prior DVT or venous valvular incompetence and manifests as chronic dull ache in leg that worsens with prolonged standing, edema, and superficial varicosities. May lead to erythema, hyperpigmentation, and recurrent cellulitis; ulcers may appear at medial and
lateral malleoli. Treatment includes graduated compression stockings and leg elevation.

**LYMPHEDEMA**

Chronic, painless edema, usually of the lower extremities; may be primary (inherited) or secondary to lymphatic damage or obstruction (e.g., recurrent lymphangitis, tumor, filariasis).

**Physical Examination** Marked pitting edema in early stages; limb becomes indurated with nonpitting edema chronically. Differentiate from chronic venous insufficiency, which displays hyperpigmentation, stasis dermatitis, and superficial venous varicosities.

**Laboratory** Abdominal and pelvic ultrasound or CT or MRI to identify obstructing lesions. Lymphangiography or lymphoscintigraphy (rarely done) to confirm diagnosis. If unilateral edema, differentiate from DVT by noninvasive venous studies (above).

**RX Lymphedema**

(1) Meticulous foot hygiene to prevent infection, (2) leg elevation, (3) compression stockings and/or pneumatic compression boots. Diuretics should be avoided to prevent intravascular volume depletion.

For a more detailed discussion, see Creager MA, Loscalzo J: Vascular diseases of the extremities, Chap. 243, in HPIM-17.

**Pulmonary Hypertension**

**Definition** Elevation of pulmonary artery (PA) pressure due to pulmonary vascular or parenchymal disease, increased left heart filling pressure, or a combination. **Table 134-1** lists most common etiologies. Pulmonary hypertension is most common cause of cor pulmonale (Chap. 131).

**Symptoms** Exertional dyspnea, fatigue, angina (due to RV ischemia), syncope, peripheral edema.

**Physical Examination** Jugular venous distention, RV lift, increased P2, rightsided S4. Tricuspid regurgitation appears in advanced stages.

**Laboratory** CXR shows enlarged central PA. **ECG** may demonstrate RV hypertrophy and RA enlargement. **Echocardiogram** shows RV and RA enlargement; RV systolic pressure can be estimated from Doppler recording of tricuspid
Pulmonary Hypertension

CHAPTER 134

regurgitation (Chap. 118). Pulmonary function tests identify underlying obstructive or restrictive lung disease; impaired CO diffusion capacity is common. V/Q nuclear scan or contrast-enhanced high-resolution chest CT can identify thromboembolic pulmonary vascular disease. ANA titer is elevated in collagen vascular diseases. HIV testing should be performed in individuals at risk. Cardiac catheterization accurately measures PA pressures, cardiac output, identifies underlying congenital vascular shunts; during procedure, response to short-acting vasodilators can be assessed.

Figure 134-1 summarizes workup of patient with unexplained pulmonary hypertension.

### PRIMARY PULMONARY HYPERTENSION

Uncommon (2 cases/million), very serious form of pulmonary hypertension. Most pts present in 4th and 5th decades, female >> male predominance; up to 20% of cases are familial. Major symptom is dyspnea, often with insidious onset. Mean survival < 3 years in absence of therapy.

**Physical Examination** Prominent a wave in jugular venous pulse, right ventricular heave, narrowly split S2 with accentuated P2. Terminal course is characterized by signs of right-sided heart failure. CXR: RV and central pulmonary arterial prominence. Pulmonary arteries taper sharply. PFT: usually normal or mild restrictive defect. ECG: RV enlargement, right axis deviation, and RV hypertrophy. Echocardiogram: RA and RV enlargement and tricuspid regurgitation.

**Differential Diagnosis** Other disorders of heart, lungs, and pulmonary vasculature must be excluded. Lung function studies will identify chronic pulmonary disease causing pulmonary hypertension and cor pulmonale. Interstitial diseases (PFTs, CT scan) and hypoxic pulmonary hypertension (ABGs, SaO2) should be excluded. Perfusion lung scan should be performed to exclude chronic pulmo-

<table>
<thead>
<tr>
<th>TABLE 134-1</th>
<th>CAUSES OF PULMONARY HYPERTENSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pulmonary Arterial Hypertension</strong></td>
<td>Primary pulmonary hypertension</td>
</tr>
<tr>
<td></td>
<td>Collagen vascular diseases (e.g., CREST, scleroderma, SLE, RA)</td>
</tr>
<tr>
<td></td>
<td>Congenital systemic to pulmonary shunts (e.g., ventricular septal defect, patent ductus arteriosus, atrial septal defect)</td>
</tr>
<tr>
<td></td>
<td>Portal hypertension</td>
</tr>
<tr>
<td></td>
<td>HIV infection</td>
</tr>
<tr>
<td></td>
<td>Anorexigen use (e.g., fenfluramines)</td>
</tr>
<tr>
<td><strong>Pulmonary Venous Hypertension</strong></td>
<td>LV diastolic dysfunction (e.g., LV hypertrophy, coronary artery disease)</td>
</tr>
<tr>
<td></td>
<td>Mitral stenosis or regurgitation</td>
</tr>
<tr>
<td><strong>Lung Disease and Hypoxemia</strong></td>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td></td>
<td>Interstitial lung disease</td>
</tr>
<tr>
<td></td>
<td>Sleep apnea</td>
</tr>
<tr>
<td></td>
<td>Chronic hypoventilation</td>
</tr>
<tr>
<td><strong>Pulmonary Thromboembolic Disease</strong></td>
<td>Acute pulmonary embolism (Chap. 140)</td>
</tr>
<tr>
<td></td>
<td>Chronic pulmonary embolism</td>
</tr>
</tbody>
</table>

*Note: CREST, calcinosis, Raynaud’s phenomenon, esophageal involvement, sclerodactyly, and telangiectasia (syndrome).*
nary embolism (PE). Spiral CT scan, pulmonary arteriogram, and even open-lung biopsy may be required to distinguish PE from idiopathic pulmonary arterial hypertension. Rarely, pulmonary hypertension is due to parasitic disease (schistosomiasis, filariasis). Cardiac disorders to be excluded include pulmonary artery and pulmonic valve stenosis. Pulmonary artery and ventricular and atrial shunts with pulmonary vascular disease (Eisenmenger reaction) should be sought. Silent mitral stenosis should be excluded by echocardiography.

**FIGURE 134-1** An algorithm for the workup of a patient with unexplained pulmonary hypertension. Note: COPD, chronic obstructive pulmonary disease; PAH, pulmonary arterial hypertension. (Adapted with permission from S Rich: HPIM-17.)
Primary Pulmonary Hypertension

Limit physical activities, use diuretics for peripheral edema, O₂ supplementation if PO₂ reduced, and chronic warfarin anticoagulation (target INR = 2.0–3.0).

If short-acting vasodilators are beneficial during acute testing in catheter laboratory, pt may benefit from high-dose calcium channel blocker (e.g., nifedipine, up to 240 mg/d), but must monitor for hypotension or worsening of right heart failure.

For patients with advanced refractory symptoms, options to improve symptoms and functional class include prostaglandins [epoprostenol (which has been shown to increase survival) via continuous central IV access, or treprostinil via continuous subcutaneous infusion pump] and the orally active endothelin receptor antagonist bosentan.

For selected patients with persistent right heart failure, lung transplantation can be considered.

For a more detailed discussion, see Rich S: Pulmonary Hypertension, Chap. 244, p. 1576, in HPIM-17.
This page intentionally left blank
RESPIRATORY FUNCTION

The respiratory system includes not only the lungs but also the chest wall, pulmonary circulation, and central nervous system. Three major types of respiratory system disturbances will be reviewed: ventilatory function, pulmonary circulation, and gas exchange.

Disturbances in Ventilatory Function

Ventilation involves the delivery of gas to the alveoli. Pulmonary function tests are used to assess ventilatory function. The classification of lung volumes, which are measured with pulmonary function testing, is shown in Fig. 135-1. Spirometry involves forced exhalation from total lung capacity (TLC) to residual volume (RV); key measurements from a spirogram are the forced expiratory volume in 1 s (FEV₁) and the forced vital capacity (FVC). Expiratory flow rates may be plotted against lung volumes to yield a flow-volume curve. Other lung volumes, including TLC and RV, are measured under static conditions using either helium dilution or body plethysmography. Lung volumes and flow rates are typically compared with population-based normal values that adjust for the age, height, sex, and race of the pt.

There are two major patterns of abnormal ventilatory function detected by pulmonary function testing: restrictive and obstructive (Tables 135-1 and 135-2). The presence of obstruction is determined by a reduced ratio of FEV₁/FVC, and...
the severity of airflow obstruction is determined by the level of reduction of FEV1. With airflow obstruction, TLC may be normal or increased, and RV is typically elevated. With severe airflow obstruction, the FVC is often reduced.

The presence of a restrictive pattern is determined by a reduction in lung volumes, especially TLC. When pulmonary parenchymal processes cause restriction, RV is also decreased, but the FEV1/FVC is normal. With extraparenchymal etiologies of restrictive ventilatory defects, such as neuromuscular weakness or chest wall abnormalities, the impact on RV and FEV1/FVC is more variable.

**Disturbances in Pulmonary Circulation** The pulmonary vasculature normally handles the right ventricular output (~5 L/min) at a low pressure. Normal mean pulmonary artery pressure (PAP) is 15 mmHg. When cardiac output increases, pulmonary vascular resistance (PVR) normally falls, leading to only small increases in mean PAP.

Assessment of the pulmonary vasculature requires measuring pulmonary vascular pressures and cardiac output to derive PVR. PVR rises with hypoxemia (due to vasoconstriction), intraluminal thrombi (due to diminished cross-

---

**TABLE 135-1 COMMON RESPIRATORY DISEASES BY DIAGNOSTIC CATEGORIES**

<table>
<thead>
<tr>
<th>Obstructive</th>
<th>Restrictive—Parenchymal</th>
<th>Restrictive—Extraparenchymal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td>Bronchiectasis</td>
<td>Pneumoconiosis</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>Cystic fibrosis</td>
<td>Drug- or radiation-induced interstitial lung disease</td>
</tr>
<tr>
<td></td>
<td>Bronchiolitis</td>
<td></td>
</tr>
</tbody>
</table>

**TABLE 135-2 ALTERATIONS IN VENTILATORY FUNCTION IN DIFFERENT PULMONARY DISEASE CATEGORIES**

<table>
<thead>
<tr>
<th>Obstructive</th>
<th>TLC</th>
<th>RV</th>
<th>VC</th>
<th>FEV1/FVC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restrictive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary parenchymal</td>
<td>N to ↑</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>Extraparenchymal—neuromuscular weakness</td>
<td>↓</td>
<td>↓</td>
<td>Variable</td>
<td>Variable</td>
</tr>
<tr>
<td>Extraparenchymal—chest wall deformity</td>
<td>↓</td>
<td>Variable</td>
<td>↓</td>
<td>N</td>
</tr>
</tbody>
</table>

**Note:** N, normal; for other abbreviations, see text.
sectional area from obstruction), or destruction of small pulmonary vessels (due to scarring or loss of the alveolar walls).

All diseases of the respiratory system causing hypoxemia are capable of causing pulmonary hypertension. However, pts with prolonged hypoxemia related to chronic obstructive pulmonary disease, interstitial lung disease, chest wall disease, and obesity-hypoventilation–sleep apnea are particularly likely to develop pulmonary hypertension. When pulmonary vessels are directly affected, as with recurrent pulmonary emboli, the decrease in cross-sectional area of the pulmonary vasculature is the primary mechanism for increased PVR, rather than hypoxemia.

**Disturbances in Gas Exchange**

The primary functions of the respiratory system are to remove CO₂ from blood entering the pulmonary circulation and to provide O₂ to blood leaving the pulmonary circulation. Normal tidal volume is approximately 500 mL and normal respiratory rate is approximately 15 breaths/min, leading to a total minute ventilation of approximately 7.5 L/min. Because of anatomic dead space, alveolar ventilation is approximately 5 L/min. Gas exchange depends on alveolar ventilation rather than total minute ventilation.

Partial pressure of CO₂ in arterial blood (PₐCO₂) is directly proportional to the amount of CO₂ produced each minute (V̇CO₂) and inversely proportional to alveolar ventilation (V̇A).

\[
PₐCO₂ = 0.863 \times \frac{V̇CO₂}{V̇A}
\]

Adequate movement of gas between alveoli and pulmonary capillaries by diffusion is required for normal gas exchange. Diffusion can be tested by measuring the diffusing capacity of the lung for a low concentration of carbon monoxide (DLCO). DLCO measurement is typically corrected for the pt’s hemoglobin level. Diffusion abnormalities rarely result in arterial hypoxemia at rest but can cause hypoxemia with exercise. Gas exchange is critically dependent on proper matching of ventilation and perfusion.

Assessment of gas exchange is commonly performed with arterial blood gases, which provide measurements of the partial pressures of O₂ and CO₂. The actual content of O₂ in blood is determined by both PₐO₂ and hemoglobin concentration. The alveolar-arterial O₂ difference [(A – a) gradient] can provide useful information when assessing abnormalities in gas exchange. The normal (A – a) gradient is <15 mmHg under age 30 but increases with aging. In order to calculate the (A – a) gradient, the alveolar PO₂ (PₐO₂) must be calculated:

\[
PₐO₂ = FIO₂ \times (PB – PH₂O) – PaCO₂/R
\]

where FIO₂ = fractional concentration of inspired O₂ (0.21 while breathing room air), PB = barometric pressure (760 mmHg at sea level), PH₂O = water vapor pressure (47 mmHg when air is saturated at 37°C), and R = respiratory quotient (the ratio of CO₂ production to O₂ consumption, usually assumed to be 0.8). The (A – a) gradient is calculated by subtracting the measured PaO₂ from the calculated PₐO₂.

Adequacy of CO₂ removal is reflected in the partial pressure of CO₂ measured in an arterial blood gas. Pulse oximetry is a valuable, widely used, and noninvasive tool to assess O₂ saturation, but it provides no information about PₐCO₂. Other limitations of pulse oximetry include relative insensitivity to oxygenation changes when PaO₂ is >60 mmHg, problems with obtaining an adequate signal when cutaneous perfusion is decreased, and inability to distinguish oxyhemoglobin from other forms of hemoglobin, such as carboxyhemoglobin and methemoglobin.
Mechanisms of Abnormal Respiratory Function  

The four basic mechanisms of hypoxemia are (1) decrease in inspired PO₂, (2) hypoventilation, (3) shunt, and (4) ventilation/perfusion mismatch. Decrease in inspired PO₂ (e.g., at high altitude) and hypoventilation (characterized by an increased PaCO₂) both lower alveolar oxygenation; thus, the (A – a) gradient is normal. Shunting (e.g., intracardiac shunt) causes hypoxemia by bypassing the alveolar capillaries. Shunting is characterized by an elevated (A – a) gradient and is relatively refractory to oxygenation improvement with supplemental O₂. Ventilation/perfusion mismatch is the most common cause of hypoxemia; it is associated with an elevated (A – a) gradient, but supplemental O₂ corrects the hypoxemia by raising the O₂ content of blood from regions with low ventilation/perfusion ratios.

An algorithm for approaching the hypoxemic pt is shown in Fig. 135-2.

Hypercapnia is caused by inadequate alveolar ventilation. Potential contributing factors include (1) increased CO₂ production, (2) decreased ventilatory drive, (3) malfunction of the respiratory pump or increased airway resistance, and (4) inefficiency of gas exchange (increased dead space or ventilation/perfusion mismatch).

Although diffusion abnormalities rarely cause hypoxemia at rest, assessment of DLCO can be used to determine the functional integrity of the alveolar-capillary membrane. Diseases that solely affect the airways typically do not reduce the DLCO. DLCO is reduced in interstitial lung disease, emphysema, and pulmonary vascular disease. DLCO can be elevated in alveolar hemorrhage and congestive heart failure.

---

**FIGURE 135-2** Flow diagram outlining the diagnostic approach to the pt with hypoxemia (PaO₂ <80 mmHg). PaO₂ – PaO₂ is usually <15 mmHg for subjects ≤30 years old and increases ~3 mmHg per decade after age 30. COPD, chronic obstructive pulmonary disease. (From SE Weinberger: Principles of Pulmonary Medicine, 4th ed. Philadelphia, Saunders, 2004; with permission.)
Noninvasive Procedures  

Radiographic Studies  The chest x-ray (CXR), generally including both posteroanterior and lateral views, is often the first diagnostic study in pts presenting with respiratory symptoms. With some exceptions (e.g., pneumothorax), the CXR pattern is usually not sufficiently specific to establish a diagnosis; instead, the CXR serves to detect disease, assess magnitude, and guide further diagnostic investigation. CXRs can detect a localized opacification that is classified as a nodule (<3 cm in diameter), a mass (≥3 cm in diameter), or an infiltrate. With diffuse lung disease, CXR can detect an alveolar, interstitial, or nodular pattern. CXR can also detect pleural effusion and pneumothorax, as well as abnormalities in the hila and mediastinum.

Chest CT is widely used to clarify radiographic abnormalities detected by CXR. Advantages of chest CT compared with CXR include (1) ability to distinguish superimposed structures due to cross-sectional imaging; (2) superior assessment of tissue density, permitting accurate assessment of the size and density of pulmonary nodules and improved identification of abnormalities adjacent to the chest wall, such as pleural disease; (3) with the use of IV contrast, ability to distinguish vascular from nonvascular structures; (4) with CT angiography, ability to detect pulmonary emboli; and (5) due to superior visible detail, improved recognition of parenchymal and airway diseases, including emphysema, bronchiectasis, and interstitial lung disease.

A variety of other imaging techniques are used less commonly to assess respiratory disease. MRI is generally less useful than CT but is preferred in the evaluation of intrathoracic cardiovascular pathology and to distinguish vascular and nonvascular structures without IV contrast. Ultrasound is not useful for assessing the pulmonary parenchyma, but it can detect pleural abnormalities and guide thoracentesis of a pleural effusion. Pulmonary angiography can assess the pulmonary arterial system for venous thromboembolism but has largely been replaced by CT angiography.

Nuclear Medicine Imaging  Ventilation-perfusion lung scans can be used to assess for pulmonary thromboembolism but have also largely been replaced by CT angiography. Positron emission tomography (PET) scanning assesses the uptake and metabolism of a radiolabeled glucose analogue. Because malignant lesions have increased metabolic activity, PET scanning is useful to assess pulmonary nodules for potential malignancy and to stage lung cancer.

Sputum Exam  Sputum can be obtained by spontaneous expectoration or induced by inhalation of an irritating aerosol like hypertonic saline. Sputum is distinguished from saliva by the presence of bronchial epithelial cells and alveolar macrophages as opposed to squamous epithelial cells. Sputum exam should include gross inspection for blood, color, and odor, as well as Gram’s stain and routine bacterial culture. Bacterial culture of expectorated sputum may be misleading due to contamination with oropharyngeal flora. Sputum samples can also be assessed for a variety of other pathogens, including mycobacteria, fungi, and viruses. Sputum samples induced by hypertonic saline can be stained for the presence of Pneumocystis jiroveci.

Pulmonary Function Tests  As discussed previously in this chapter, pulmonary function tests (PFTs) may indicate abnormalities of airway function, alterations of lung volume, and disturbances of gas exchange. PFTs may also provide objective measures of therapeutic response, e.g., to bronchodilators.

Invasive Procedures  

Bronchoscopy  Bronchoscopy is a procedure that provides direct visualization of the tracheobronchial tree. The fiberoptic broncho-
scope is used in most cases, but rigid bronchoscopy is valuable in specific circumstances, including massive hemorrhage and foreign body removal. Flexible fiberoptic bronchoscopy allows visualization of the airways; identification of endobronchial abnormalities, including tumors and sites of bleeding; and collection of diagnostic specimens by washing, brushing, biopsy, or lavage. Washing involves instilling sterile saline through the bronchoscope channel onto the surface of a lesion; part of the saline is suctioned back through the bronchoscope and processed for cytology and microorganisms. Bronchial brushings can be obtained from the surface of an endobronchial lesion or from a more distal mass or infiltrate (potentially with fluoroscopic guidance) to obtain transbronchial biopsies of more distal lung tissue. Transbronchial biopsy is particularly useful in diagnosing diffuse infectious processes, lymphangitic spread of cancer, and granulomatous diseases. Complications of transbronchial biopsy include hemorrhage and pneumothorax.

Bronchoalveolar lavage (BAL) is an adjunct to fiberoptic bronchoscopy, permitting collection of cells and liquid from distal air spaces. After wedging the bronchoscope in a subsegmental airway, saline is instilled and then suctioned back through the bronchoscope for analyses, which can include cytology, microbiology, and cell counts. BAL is especially useful in the diagnosis of *P. jiroveci* pneumonia and some other infections.

**Video-Assisted Thoracic Surgery** Video-assisted thoracic surgery (VATS), also known as thoracoscopy, is widely used for the diagnosis of pleural lesions as well as peripheral parenchymal infiltrates and nodules. VATS involves passing a rigid scope with a camera through a trocar and into the pleural space; instruments can be inserted and manipulated through separate intercostal incisions. VATS has largely replaced “open biopsy,” which requires a thoracotomy.

**Percutaneous Needle Aspiration of the Lung** A needle can be inserted through the chest wall and into a pulmonary lesion to aspirate material for cytologic and microbiologic studies. Percutaneous needle aspiration is usually performed under CT guidance. Owing to the small size of the sample obtained, sampling error is a limitation of the procedure.

**Thoracentesis and Pleural Biopsy** Thoracentesis should be performed as an early step in the evaluation of a pleural effusion of uncertain etiology. Analysis of pleural fluid can determine the etiology of the effusion (Chap. 143). Large-volume thoracentesis can be therapeutic by palliating dyspnea. Closed pleural biopsy can also be done when a pleural effusion is present but has largely been replaced by VATS.

**Mediastinoscopy** Tissue biopsy is often required to assess mediastinal masses or lymph nodes. Mediastinoscopy is performed from a suprasternal approach, and a rigid mediastinoscope is inserted—from which biopsies can be obtained. Lymph nodes in the left paratracheal or aortopulmonary locations typically require a parasternal mediastinotomy to provide access for biopsy.

Asthma is a syndrome characterized by airflow obstruction that varies both spontaneously and with specific treatment. Chronic airway inflammation causes airway hyperresponsiveness to a variety of triggers, leading to airflow obstruction and respiratory symptoms including dyspnea and wheezing. Although asthmatics typically have periods of normal lung function with intermittent airflow obstruction, a subset of pts develop chronic airflow obstruction.

The prevalence of asthma has increased markedly over the past 30 years. In developed countries, approximately 10% of adults and 15% of children have asthma. Most asthmatics are atopic, and they often have allergic rhinitis and/or eczema. The majority of asthmatics have childhood-onset disease. A minority of asthmatic pts do not have atopy (negative skin prick tests to common allergens and normal serum total IgE levels). These individuals, occasionally referred to as "intrinsic asthmatics," often have adult-onset disease. Occupational asthma can result from a variety of chemicals, including toluene diisocyanate and trimellitic anhydride, and also can have an adult onset.

Asthmatics can develop increased airflow obstruction and respiratory symptoms in response to a variety of different triggers. Inhaled allergens can be potent asthma triggers for individuals with specific sensitivity to those agents. Viral URIs commonly trigger asthma exacerbations. β-adrenergic blocking medications can markedly worsen asthma symptoms and should typically be avoided in asthmatics. Exercise often triggers increased asthma symptoms, which usually begin after exercise has ended. Other triggers of increased asthma symptoms include air pollution, occupational exposures, and stress.

Clinical Evaluation of the Patient

History

Common respiratory symptoms in asthma include wheezing, dyspnea, and cough. These symptoms often vary widely within a particular individual, and they can change spontaneously or with age, season of the year, and treatment. Symptoms may be worse at night, and nocturnal awakenings are an indicator of inadequate asthma control. The severity of their asthmatic symptoms, as well as their need for systemic steroid treatment, hospitalization, and intensive care treatment, are important to ascertain. Types of asthmatic triggers for the particular pt, and their recent exposure to them, should be determined.

Physical Exam

It is important to assess for signs of respiratory distress, including tachypnea, use of accessory respiratory muscles, and cyanosis. On lung exam, there may be wheezing and rhonchi throughout the chest, typically more prominent in expiration than inspiration. Localized wheezing may indicate an endobronchial lesion. Evidence of allergic nasal, sinus, or skin disease should be assessed. When asthma is adequately controlled, the physical exam may be normal.

Pulmonary Function Tests

Spirometry often shows airflow obstruction, with a reduction in the FEV1 and FEV1/FVC ratio. However, spirometry may be normal, especially if asthma symptoms are adequately treated. Bronchodilator reversibility is demonstrated by an increase in FEV1 by ≥200 mL and ≥12% from baseline FEV1 15–20 min after a short-acting β agonist (often albuterol MDI two puffs or 180 μg). Many but not all asthmatics will demonstrate significant bronchodilator
reversibility; optimal pharmacologic treatment may reduce bronchodilator reversibility. The peak expiratory flow rate (PEF) can be used by the pt to track asthma control objectively at home. Measurement of lung volumes is not typically performed, but increases in total lung capacity and residual volume may be observed. The diffusion capacity for carbon monoxide is usually normal.

Other Laboratory Tests  Blood tests are usually not helpful. CBC may demonstrate eosinophilia. Specific IgE measurements for inhaled allergens (RAST) or allergy skin testing may assist in determining allergic triggers. Total serum IgE is markedly elevated in allergic bronchopulmonary aspergillosis (ABPA).

Radiographic Findings  Chest x-ray is usually normal. In acute exacerbations, pneumothorax may be identified. In ABPA, eosinophilic pulmonary infiltrates may be observed. Chest CT scan is not typically performed in routine asthma but may show central bronchiectasis in ABPA.

Differential Diagnosis  The differential diagnosis of asthma includes other disorders that can cause wheezing and dyspnea. Upper airway obstruction by tumor or laryngeal edema can mimic asthma, but stridor in the large airways is typically noted on physical examination. Localized wheezing in the chest may indicate an endobronchial tumor or foreign body. CHF can cause wheezing but is typically accompanied by bibasilar crackles. Eosinophilic pneumonias and Churg-Strauss syndrome may present with wheezing. Vocal cord dysfunction can mimic severe asthma and may require direct laryngoscopy to assess. When asthma involves chronic airflow obstruction, distinguishing it from chronic obstructive pulmonary disease (COPD) can be very difficult.

Rx Chronic Asthma

If a specific inciting agent for asthmatic symptoms can be identified and eliminated, that is an optimal part of treatment. In most cases, pharmacologic therapy is required. The two major classes of drugs are bronchodilators, which provide rapid symptomatic relief by relaxing airway smooth muscle, and controllers, which limit the airway inflammatory process.

Bronchodilators  The most widely used class of bronchodilators is β₂-adrenergic agonists, which relax airway smooth muscle by activating β₂-adrenergic receptors. Two types of inhaled β₂ agonists are widely used in asthma treatment: short-acting (SABA) and long-acting (LABA). SABAs, which include albuterol, have rapid onset of action and last for up to 6 h. SABAs are effective rescue medications, but excessive use indicates inadequate asthma control. SABAs can prevent exercise-induced asthma if administered before exercise. LABAs, which include salmeterol and formoterol, have a slower onset of action but last for >12 h. Combinations of LABAs with inhaled corticosteroids reduce asthma exacerbations and provide an excellent long-term treatment option for asthma severity of moderate persistent degree or greater.

Common side effects of β₂-adrenergic agonists include muscle tremors and palpitations. These side effects are more prominent with oral formulations, which should not generally be used. There have been ongoing concerns about mortality risks associated with β₂-adrenergic agonists, which have not been completely resolved. LABAs taken without concomitant inhaled steroid treatment may increase this risk.

Other available bronchodilator medications include anticholinergics and theophylline. Anticholinergics, which are available in short-acting and long-acting
inhaled formulations, are commonly used in COPD. They appear to be considerably less effective than β₂-adrenergic agonists in asthma, and they are considered only if other asthma medications do not provide adequate asthma control. Theophylline may have both bronchodilator and anti-inflammatory effects; it is not widely used due to the potential toxicities associated with high plasma levels.

**Controller Therapies**

Inhaled corticosteroids (ICS) are the most effective controller treatments for asthma. ICS are usually given twice daily; a variety of ICS medications are available, including fluticasone, triamcinolone, budesonide, flunisolide, and beclomethasone. Although they do not provide immediate symptom relief, respiratory symptoms and lung function often begin to improve within several days of initiating treatment. ICS reduce exercise-induced symptoms, nocturnal symptoms, and acute exacerbations.

ICS side effects include hoarseness and oral candidiasis; these effects may be minimized by use of a spacer device and by rinsing out the mouth after taking ICS.

Other available controller therapies for asthma include systemic corticosteroids. Although quite helpful in the management of acute asthma exacerbations, oral or IV steroid use should be avoided if at all possible in the chronic management of asthma due to multiple potential side effects. Antileukotrienes, such as montelukast and zafirlukast, may be quite beneficial in some pts. Cromolyn sodium and nedocromil sodium are not widely used due to their brief durations of action and typically modest effects. Omalizumab is an antibody that neutralizes IgE; with SC injection it appears to reduce acute asthma exacerbation frequency in severe asthmatics. However, it is expensive and considered only for highly selected pts with elevated total serum IgE levels and refractory asthma symptoms.

**Overall Treatment Approach**

In addition to limiting exposure to their environmental triggers for asthma, pts should receive stepwise therapy appropriate for their disease severity (Figure 136-1). Asthmatics with mild intermittent symptoms are typically managed adequately with SABAs taken on an as-needed basis. Use of SABAs more than three times a week suggests that controller therapy, typically with an ICS twice per day, is required. If symptoms are not adequately controlled with ICS, LABAs can be added. If symptoms are still not adequately controlled, higher doses of ICS and/or alternative controller therapies should be considered.

**ASTHMA EXACERBATIONS**

**Clinical Features**  Asthma exacerbations are periods of acute worsening of asthma symptoms that may be life-threatening. Exacerbations are commonly triggered by viral URIs, but other triggers also can be involved. Symptoms often include increased dyspnea, wheezing, and chest tightness. Physical examination can reveal pulsus paradoxus as well as tachypnea, tachycardia, and lung hyperinflation. Pulmonary function testing reveals a reduction in FEV₁ and PEF. Hypoxemia can result; P_{CO₂} is usually reduced due to hyperventilation. Normal or rising P_{CO₂} can signal impending respiratory failure.

**Asthma Exacerbations**

The mainstays of asthma exacerbation treatment are high doses of SABAs and systemic corticosteroids. SABAs may be administered by nebulizer or
metered-dose inhaler with a spacer; very frequent dosing (q1h or more) may be required initially. IV corticosteroids, such as methylprednisolone (e.g., 80 mg IV q8h) may be used, although oral corticosteroids also may be used. Supplemental oxygen should be provided to maintain adequate oxygen saturation (>90%). If respiratory failure occurs, mechanical ventilation should be instituted, with care to minimize airway pressures and auto-PEEP. Because bacterial infections rarely trigger asthma exacerbations, antibiotics are not routinely administered.

In an effort to treat asthma exacerbations before they become severe, asthma pts should receive written action plans with instructions for self-initiation of treatment based on respiratory symptoms and reductions in PEF.

For a more detailed discussion, see Barnes PJ: Asthma, Chap. 248, p. 1596 in HPIM-17.

The susceptibility to develop many pulmonary diseases is influenced by environmental factors. This chapter will focus on occupational and toxic chemical exposures. However, a variety of non-occupational indoor exposures such as environmental tobacco smoke exposure (lung cancer), radon gas (lung cancer), and biomass cooking (COPD) also should be considered. Particle size is an important determinant of the impact of environmental exposures on the respiratory system. Particles >10 μm in diameter typically are captured by the upper airway. Particles 2.5–10 μm in diameter will likely deposit in the upper tracheobronchial tree, while smaller particles will reach the alveoli.
APPROACH TO THE PATIENT WITH ENVIRONMENTAL LUNG DISEASES

Because there are many types of occupational lung disease (pneumoconiosis) that can mimic diseases not known to relate to environmental factors, obtaining a careful occupational history is essential. In addition to the types of occupation performed by the pt, the specific environmental exposures, use of protective respiratory devices, and ventilation of the work environment can provide key information. Assessing the temporal development of symptoms relative to the pt’s work schedule also can be very useful.

The chest x-ray is very valuable in the assessment of environmental lung disease, but it may over- or underestimate the functional impact of pneumoconioses. Pulmonary function tests should be used to assess the severity of impairment, but they typically do not suggest a specific diagnosis. Changes in spirometry before and after a work shift can provide strong evidence for bronchoconstriction in suspected occupational asthma. Some radiologic patterns are distinctive for certain occupational lung diseases; chest x-rays are widely used, and chest CT scans can provide more detailed evaluation.

OCCUPATIONAL EXPOSURES AND PULMONARY DISEASE

Inorganic Dusts  Asbestos-Related Diseases

In addition to exposures to asbestos that may occur during the production of asbestos products (from mining to manufacturing), common occupational asbestos exposures occur in shipbuilding and other construction trades (e.g., pipefitting, boilermaking) and in the manufacture of safety garments and friction materials (e.g., brake and clutch linings). Along with worker exposure in these areas, bystander exposure (e.g., spouses) can be responsible for some asbestos-related lung diseases.

A range of respiratory diseases has been associated with asbestos exposure. Pleural plaques indicate that asbestos exposure has occurred, but they are typically not symptomatic. Interstitial lung disease, often referred to as asbestosis, is pathologically and radiologically similar to idiopathic pulmonary fibrosis; it is typically accompanied by a restrictive ventilatory defect on pulmonary function testing. Asbestosis can develop after 10 years of exposure, and no specific therapy is available.

Benign pleural effusions can also occur from asbestos exposure. Lung cancer is clearly associated with asbestos exposure but does not typically present for at least 15 years after initial exposure. The lung cancer risk increases multiplicatively with cigarette smoking. In addition, mesotheliomas (both pleural and peritoneal) are strongly associated with asbestos exposure, but they are not related to smoking. Relatively brief asbestos exposures may lead to mesotheliomas, which typically do not develop for decades after the initial exposure. Biopsy of pleural tissue, typically by thoracoscopic surgery, is required for diagnosing mesothelioma.

Silicosis  Silicosis results from exposure to free silica (crystalline quartz), which occurs in mining, stone cutting, abrasive industries (e.g., stone, clay, glass, and cement manufacturing), foundry work, and quarrying. Heavy exposures over relatively brief time periods (as little as 10 months) can cause acute silicosis—which is pathologically similar to pulmonary alveolar proteinosis and associated with a characteristic chest CT pattern known as “crazy paving.” Acute silicosis can be severe and progressive; whole lung lavage may be of some therapeutic benefit.
Longer-term exposures can result in simple silicosis, with small rounded opacities in the upper lobes of the lungs. Calcification of hilar lymph nodes can give a characteristic “eggshell” appearance. Progressive nodular fibrosis can result in masses >1 cm in diameter in complicated silicosis. When such masses become very large, the term **progressive massive fibrosis** is used to describe the condition. Due to impaired cell-mediated immunity, silicosis pts are at increased risk of tuberculosis, atypical mycobacterial infections, and fungal infections. Silica may also be a lung carcinogen.

**Coal Worker’s Pneumoconiosis**  Occupational exposure to coal dust predisposes to coal worker’s pneumoconiosis (CWP), which is less common among coal workers in the western United States due to a lower risk from the bituminous coal found in that region. Simple CWP is defined radiologically by small nodular opacities and is not typically symptomatic. The development of larger nodules (>1 cm in diameter), usually in the upper lobes, characterizes complicated CWP. Complicated CWP is often symptomatic and is associated with reduced pulmonary function and increased mortality.

**Berylliosis**  Beryllium exposure may occur in the manufacturing of alloys, ceramics, and electronic devices. Although acute beryllium exposure can rarely produce acute pneumonitis, a chronic granulomatous disease very similar to sarcoidosis is much more common. Radiologically, chronic beryllium disease, like sarcoidosis, is characterized by pulmonary nodules along septal lines. As in sarcoidosis, either a restrictive or obstructive ventilatory pattern on pulmonary function testing can be seen. Bronchoscopy with transbronchial biopsy is typically required to diagnose chronic beryllium disease. The most effective way to distinguish chronic beryllium disease from sarcoidosis is to perform a beryllium lymphocyte proliferation test using blood or bronchoalveolar lavage lymphocytes. Removal from further beryllium exposure is required, and corticosteroids may be beneficial.

**Organic Dusts**  **Cotton Dust (Byssinosis)**  Dust exposures occur in the production of yarns for cotton, linen, and rope-making. Flax, hemp, and jute produce a similar syndrome. At the early stages of byssinosis, chest tightness occurs near the end of the first day of the work week. In progressive cases, symptoms are present throughout the work week. After at least 10 years of exposure, chronic airflow obstruction can develop. In symptomatic individuals, limiting further exposure is essential.

**Grain Dust**  Farmers and grain elevator operators are at risk for grain dust–related lung disease, which is similar to COPD. Symptoms include cough, wheezing, and dyspnea. Pulmonary function tests show airflow obstruction.

**Farmer’s Lung**  Exposure to moldy hay containing thermophilic actinomycetes can lead to the development of hypersensitivity pneumonitis. Within 8 h after exposure, the acute presentation of farmer’s lung includes fever, cough, and dyspnea. With repeated exposures, chronic and patchy interstitial lung disease can develop.

**Toxic Chemicals**  Many toxic chemicals can affect the lung in the form of vapors and gases.

Smoke inhalation can be lethal to firefighters and fire victims through a variety of mechanisms. Carbon monoxide poisoning can cause life-threatening hypoxemia. Combustion of plastics and polyurethanes can release toxic agents including cyanide. Occupational asthma can result from exposure to diisocyanates in polyurethanes and acid anhydrides in epoxides.
PRINCIPLES OF MANAGEMENT

Treatment of environmental lung diseases typically involves limiting or avoiding exposures to the toxic substance. Chronic interstitial lung diseases (e.g., asbestosis, CWP) are not responsive to glucocorticoids, but acute organic dust exposures may respond to corticosteroids. Therapy of occupational asthma (e.g., disocyanates) follows usual asthma guidelines (Chap. 136) and therapy of occupational COPD (e.g., byssinosis) follows usual COPD guidelines (Chap 138).

For a more detailed discussion, see Speizer FE and Balmes JR: Environmental Lung Disease, Chap. 250, p. 1611, in HPIM-17.

138 Chronic Obstructive Pulmonary Disease

DEFINITION AND EPIDEMIOLOGY

Chronic obstructive pulmonary disease (COPD) is a disease state characterized by chronic airflow obstruction; thus, pulmonary function testing is central to its diagnosis. The presence of airflow obstruction is determined by a reduced ratio of the forced expiratory volume in 1 s (FEV₁) to the forced vital capacity (FVC). Among individuals with a reduced FEV₁/FVC, the severity of airflow obstruction is determined by the level of reduction in FEV₁ (Table 138-1): ≥80% is stage I, 50–80% is stage II, 30–50% is stage III, and <30% is stage IV. Cigarette smoking is the major environmental risk factor for COPD. The risk of COPD increases with cigarette smoking intensity, which is typically quantified as pack-years. (One pack of cigarettes smoked per day for 1 year equals 1 pack-year.) Individuals with airway hyperresponsiveness and certain occupational exposures (e.g., coal mining, gold mining, and cotton textiles) are likely also at increased risk for COPD. In countries in which biomass combustion with poor ventilation is used for cooking, an increased risk of COPD among women has been reported. COPD is a progressive disorder; however, the rate of loss of lung function often slows markedly if smoking cessation occurs. In normal individuals, FEV₁ reaches a lifetime peak at around age 25 years, enters a plateau phase, and subsequently declines gradually and progressively. Subjects can develop COPD by having reduced maximally attained lung function, shortened plateau phase, or accelerated decline in lung function.

Symptoms often occur only when COPD is advanced; thus, early detection requires spirometric testing. The PaO₂ typically remains near normal until the FEV₁ falls to <50% of the predicted value. Hypercarbia and pulmonary hypertension are most common after FEV₁ has fallen to <25% of predicted. COPD pts with similar FEV₁ values can vary markedly in their respiratory symptoms and functional impairment. COPD often includes periods of increased respiratory symptoms, such as dyspnea, cough, and phlegm production, which are known as exacerbations. Exacerbations are often triggered by bacterial and/or viral respiratory infections. These exacerbations become more common as COPD severity
increases, but some individuals are much more susceptible to developing exacerbations than others with similar degrees of airflow obstruction.

**CLINICAL MANIFESTATIONS**

**History** Subjects with COPD usually have smoked ≥20 pack-years of cigarettes. Common symptoms include cough and phlegm production; individuals with chronic productive cough for 3 months per year for the preceding 2 years have chronic bronchitis. However, chronic bronchitis without airflow obstruction is not included within COPD. Dyspnea, especially with exertion, is a common and potentially disabling symptom in COPD subjects. Exercise involving upper-body activity is especially difficult for severe COPD pts. Weight loss and cachexia are common in advanced disease. Hypoxemia and hypercarbia may result in fluid retention, morning headaches, sleep disruption, erythrocytosis, and cyanosis.

Exacerbations are more frequent as disease progresses and are most often triggered by respiratory infections, often with a bacterial component. Exacerbations may also be precipitated by left ventricular failure, cardiac arrhythmia, pneumothorax, pneumonia, and pulmonary thromboembolism.

**Physical Findings** The physical examination may be normal until COPD is fairly advanced. As disease progresses, signs of hyperinflation may become more prominent. Wheezing is occasionally observed, but it does not predict the severity of obstruction or response to therapy. Persistently localized wheezing raises the possibility of lung cancer.

During COPD exacerbations, signs of respiratory distress may be prominent, including tachycardia, tachypnea, use of accessory muscles of respiration, and cyanosis.

**Radiographic Findings** Plain chest x-ray may show hyperinflation, emphysema, and pulmonary hypertension. It is typically performed to exclude other disease processes during routine evaluation, and to exclude pneumonia during
exacerbations. Chest CT scanning has much greater sensitivity for detecting emphysema but is typically reserved for the evaluation of advanced disease when surgical options such as lung volume reduction and lung transplantation are being considered.

**Pulmonary Function Tests** Objective documentation of airflow obstruction is essential for diagnosing COPD. Standardized staging of COPD is based on post-bronchodilator spirometry. In COPD, the FEV₁/FVC ratio is reduced below 0.7. Despite prolonged expiratory efforts, subjects may not be able to achieve a plateau in their FVC. Increases in total lung capacity and residual volume, as well as reduced diffusing capacity for carbon monoxide, are typically seen in emphysema.

**Laboratory Tests** α₁ antitrypsin (α₁AT) testing, typically by measurement of the protein level in the bloodstream, is recommended to exclude severe α₁AT deficiency. Augmentation therapy (a weekly IV infusion) is available for individuals with severe α₁AT deficiency (e.g., PI Z). Pulse oximetry can determine the O₂ saturation. However, arterial blood gases remain useful to assess the severity of CO₂ retention as well as acid-base disorders. During acute exacerbations, arterial blood gases should be considered in pts with mental status changes, significant respiratory distress, very severe COPD, or a history of hypercarbia. Complete blood counts are useful in advanced disease to assess for erythrocytosis, which can occur secondary to hypoxemia, and anemia, which can worsen dyspnea.

**OUTPATIENT MANAGEMENT**

**Smoking Cessation** Elimination of tobacco smoking has been convincingly shown to reduce decline in pulmonary function and to prolong survival in pts with COPD. Although lung function does not typically improve substantially after smoking cessation, the rate of decline in FEV₁ often reverts to that of nonsmokers. Pharmacologic treatment to assist with smoking cessation is often beneficial. Use of nicotine replacement therapy (available as a patch, gum, nasal spray, and oral inhaler) can increase rates of smoking cessation; oral bupropion (150 mg bid after starting at 150 mg qd for 3 days) also produces significant benefit and can be combined successfully with nicotine replacement. Varenicline, a partial agonist for nicotinic acetylcholine receptors, also can promote smoking cessation. All adult, nonpregnant smokers without specific contraindications should be offered pharmacologic treatment to assist with smoking cessation.

**Nonpharmacologic Treatment** Pulmonary rehabilitation improves functional status and reduces hospitalizations. Annual influenza vaccinations are strongly recommended; in addition, pneumococcal vaccination is recommended.

**Bronchodilators** Although inhaled bronchodilator medications do not increase longevity in COPD, they may significantly reduce respiratory symptoms. Short- and long-acting β-adrenergic agonists, short- and long-acting anticholinergics, and theophylline derivatives all may be used. Although oral medications are associated with greater rates of adherence, inhaled medications generally have fewer side effects.

Pts with mild disease can usually be managed with an inhaled short-acting anticholinergic such as ipratropium or a short-acting β agonist such as al-
buterol. Combination therapy and long-acting β agonists and/or anticholinergics should be added in pts with severe disease. The narrow toxic-therapeutic ratio of theophylline compounds limits their use, and either low doses or regular monitoring of serum levels are required.

**Corticosteroids**

Chronic systemic corticosteroid treatment is not recommended in COPD pts due to the risk of multiple complications, including osteoporosis, weight gain, cataracts, and diabetes mellitus. Although multiple studies have demonstrated that inhaled steroids do not reduce the rate of decline of FEV₁ in COPD, inhaled steroid medications may reduce the frequency of exacerbations in individuals with severe COPD. Combinations of inhaled steroids and long-acting β agonists reduce COPD exacerbations and may reduce mortality—although that has not been conclusively shown.

**Oxygen**

Long-term supplemental oxygen therapy has been shown to reduce symptoms and improve survival in COPD pts who are chronically hypoxemic. Documentation of the need for O₂ requires a measurement of PaO₂ or oxygen saturation (SaO₂) after a period of stability. Pts with a PaO₂ ≤55 mmHg or SaO₂ ≤88% should receive O₂ to raise the SaO₂ to ≥90%. O₂ is also indicated for pts with PaO₂ of 56–59 mmHg or SaO₂ ≤89% if associated with signs and symptoms of pulmonary hypertension or cor pulmonale. For individuals who meet these guidelines, continuous O₂ therapy is recommended because the number of hours per day of oxygen use is directly related to the mortality benefit. Supplemental oxygen may also be prescribed for selected COPD pts who desaturate only with exercise or during sleep, although the evidence for benefit is less compelling.

**Surgical Options for Severe COPD**

Two main types of surgical options are available for end-stage COPD. Lung volume reduction surgery can reduce mortality and improve lung function in selected pts with upper lobe–predominant emphysema and low exercise capacity (after pulmonary rehabilitation). Individuals who meet the criteria for the high-risk group (FEV₁ <20% predicted and either a diffuse distribution of emphysema or lung carbon monoxide diffusing capacity <20% predicted) should not be considered for lung volume reduction surgery. In addition to surgical lung volume reduction, several bronchoscopic lung volume reduction approaches are in clinical trials. Lung transplantation should be considered for COPD pts who have very severe chronic airflow obstruction and disability at a relatively young age despite maximal medical therapy.

**MANAGEMENT OF COPD EXACERBATIONS**

COPD exacerbations are a major cause of morbidity and mortality. Critical decisions in management include whether hospitalization is required. Although there are not definitive guidelines to determine which COPD pts require hospitalization for an exacerbation, the development of respiratory acidosis, significant hypercarbia, worsening hypoxemia, pneumonia, or social situations without adequate home support for the treatment required should prompt consideration of hospitalization.

Key components of exacerbation treatment include bronchodilators, antibiotics, and short courses of systemic glucocorticoids.

**Antibiotics**

Because bacterial infections often trigger COPD exacerbations, antibiotic therapy should be strongly considered, especially with increased sputum volume or change in sputum color. Common pathogens include *Streptococcus*
pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antibiotic choice should depend on the local antibiotic sensitivity patterns, previous sputum culture results for a particular pt, and the severity of disease. Trimethoprim-sulfamethoxazole, doxycycline, and amoxicillin are reasonable choices for subjects with mild to moderate COPD; broader-spectrum antibiotics should be considered for subjects with more severe underlying COPD and/or more severe exacerbations. Outside of the setting of an acute exacerbation, chronic antibiotic therapy is not recommended in COPD.

**Bronchodilators**

Bronchodilator therapy is essential during COPD exacerbations. Short-acting β-adrenergic agonists by inhalation (e.g., albuterol q1–2h) are used; addition of anticholinergics is likely of benefit (e.g., ipratropium q4–6h). Administration of bronchodilators by nebulizer is often used initially because it is easier to administer to pts in respiratory distress. Conversion to metered-dose inhaler administration can be successfully achieved with appropriate training of the pt and staff.

**Glucocorticoids**

Systemic steroids hasten resolution of symptoms and reduce relapses and subsequent exacerbations for up to 6 months. Dosing is not well worked out, but 30–40 mg of prednisone daily (or IV equivalent) is standard, with a total course of 10–14 days. Hyperglycemia is the most commonly reported complication and should be monitored.

**Oxygen**

Hypoxemia often worsens during COPD exacerbations. Supplemental O₂ should be administered to maintain SaO₂ ≥90%. Delivery systems include nasal prongs at 1–2 L/min or 24% Venturi mask. Very high O₂ delivery can worsen hypercapnia, primarily due to increasing ventilation-perfusion mismatch. However, providing adequate O₂ to obtain saturation of ~90% is the key goal. Therefore, supplemental O₂ delivery should be focused on providing adequate oxygenation without providing unnecessarily high O₂ saturations. Pts may require use of supplemental O₂ after hospital discharge until the exacerbation completely resolves.

**Ventilatory Support**

The diagnosis of acute respiratory failure is made on the basis of a decrease in PaO₂ by 10–15 mmHg from baseline or an increase in PaO₂ associated with a pH <7.30. Numerous studies suggest that noninvasive mask ventilation [noninvasive positive pressure ventilation (NPPV)] can improve outcomes in acute COPD exacerbations with respiratory failure (PaCO₂ >45 mmHg). Contraindications to NPPV include cardiovascular instability, impaired mental status, inability to cooperate, copious secretions, craniofacial abnormalities or facial trauma, extreme obesity, or significant burns. Progressive hypercapnia, refractory hypoxemia, or alterations in mental status that compromise ability to comply with NPPV therapy may necessitate endotracheal intubation for mechanical ventilation.

For a more detailed discussion, see Reilly JJ Jr., Silverman EK, Shapiro SD: Chronic Obstructive Pulmonary Disease, Chap. 254, p. 1635, in HPIM-17.
Pneumonia, an infection of the pulmonary parenchyma, is classified as community-acquired (CAP) or health care–associated (HCAP). The HCAP category is subdivided into hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). HCAP is associated with hospitalization for ≥48 h, hospitalization for ≥2 days in the prior 3 months, nursing home or extended-care facility residence, antibiotic therapy in the preceding 3 months, chronic dialysis, home infusion therapy, home wound care, and contact with a family member who has a multidrug-resistant (MDR) infection.

**PATHOPHYSIOLOGY**

- Microorganisms gain access to the lower respiratory tract via microaspiration from the oropharynx (the most common route), inhalation of contaminated droplets, hematogenous spread, or contiguous extension from an infected pleural or mediastinal space.
- Classic pneumonia (typified by that due to *Streptococcus pneumoniae*) presents as a lobar pattern and evolves through four phases.
  - Edema: Proteinaceous exudates are present in the alveoli.
  - Red hepatization: Erythrocytes and neutrophils are present in the intraalveolar exudate.
  - Gray hepatization: Neutrophils predominate, with abundant fibrin deposition. Bacteria are absent.
  - Resolution: Macrophages are the dominant cell type in the alveolar space. Debris and inflammation have cleared.
- In VAP, respiratory bronchiolitis can precede pneumonia. A bronchopneumonia pattern is most common.

**COMMUNITY-ACQUIRED PNEUMONIA**

**Epidemiology and Etiology**  
CAP, which affects ~4 million adults each year in the United States, is more common among pts with severe underlying illness. Many factors (e.g., alcoholism, asthma, age >70 years, immunosuppression, smoking, and HIV infection) influence the types of pathogens that should be considered in identifying the etiologic agent. Relatively few pathogens cause most cases.

- Typical bacterial pathogens: *S. pneumoniae, Haemophilus influenzae, Staphylococcus aureus* [including community-acquired methicillin-resistant *S. aureus* (CA-MRSA)], gram-negative bacteria such as *Klebsiella pneumoniae* and *Pseudomonas aeruginosa*
- Atypical organisms: *Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella* spp., respiratory viruses (e.g., influenza viruses)
- Anaerobes play a significant role in CAP only when aspiration occurs days to weeks before presentation.
Clinical Features

• Typical symptoms are fever, chills, sweats, cough (either nonproductive or productive of mucoid, purulent, or blood-tinged sputum), pleuritic chest pain, and dyspnea.

• Other common symptoms include nausea, vomiting, diarrhea, fatigue, headache, myalgias, and arthralgias. Elderly pts may present atypically with confusion.

• Physical examination: tachypnea, increased or decreased tactile fremitus, dull to flat percussion reflecting consolidation or pleural fluid, crackles, bronchial breath sounds, pleural friction rub

Diagnosis

• Chest x-ray (CXR) is usually adequate for diagnosis, but CT of the chest may be required in some cases. Some patterns suggest an etiology; e.g., pneumatoceles suggest *S. aureus*.

• Sputum stains and culture: The presence of >25 white blood cells and <10 squamous epithelial cells per high-power field suggests that a sample is appropriate for culture. A single, predominant organism on Gram’s stain suggests the etiology. Other stains should be used as indicated (e.g., for *Mycobacterium tuberculosis* or fungi).

• Blood cultures are positive in 5–14% of cases, most commonly yielding *S. pneumoniae*. Blood cultures are optional for most CAP pts but should be performed for high-risk pts (e.g., pts with neutropenia or asplenia).

• Urine antigen tests for *S. pneumoniae* and *Legionella pneumophila* type 1 can be helpful.

• Serology: A fourfold rise in titer of specific IgM antibody can assist in the diagnosis of pneumonia due to some pathogens. The time required to obtain a final result makes serology of limited clinical utility.

Community-Acquired Pneumonia

Site of Care

Two sets of criteria identify pts who will benefit from hospital care. It is not clear which set is superior, and application of each tool should be tempered by a consideration of factors relevant to the individual pt.

• Pneumonia Severity Index (PSI): Points are given for 20 variables, including age, coexisting illness, and abnormal physical and laboratory findings. On this basis, pts are assigned to one of five classes of mortality risk.

• CURB-65: Five variables are included: confusion (C); urea $>$7 mmol/L (U); respiratory rate $\geq$30/min (R); blood pressure, systolic $\leq$90 mmHg or diastolic $\leq$60 mmHg (B); and age $\geq$65 years (65). Pts with a score of 0 can be treated at home, pts with a score of 2 should be hospitalized, and pts with a score of $\geq$3 may require management in the ICU.

Antibiotic Therapy

For recommendations on empirical antibiotic treatment of CAP, see Table 139-1. U.S. guidelines always target *S. pneumoniae* and atypical pathogens. A retrospective review of pts $>$65 years of age suggests that this approach lowers the mortality rate. A pt initially treated with IV antibiotics can be switched to oral agents when he or she can ingest and absorb drugs, is hemodynamically stable, and is showing clinical improvement. CAP is typically treated for 10–14 days, but a 5-day course of a fluoroquinolone is sufficient for cases of uncomplicated CAP. A longer course is required for pts with bacteremia, metastatic infection, or infection with a particularly virulent pathogen and in most cases of severe CAP.
Complications

- Common complications of severe CAP include respiratory failure, shock and multiorgan failure, bleeding diatheses, and exacerbation of comorbid disease.
- Metastatic infection (e.g., brain abscess, endocarditis) may occur and requires immediate attention.

### TABLE 139-1

<table>
<thead>
<tr>
<th>EMPIRICAL ANTIBIOTIC TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outpatients</strong></td>
</tr>
<tr>
<td>Previously healthy and no antibiotics in past 3 months</td>
</tr>
<tr>
<td>- A macrolide [clarithromycin (500 mg PO bid) or azithromycin (500 mg PO once, then 250 mg od)] or</td>
</tr>
<tr>
<td>- Doxycycline (100 mg PO bid)</td>
</tr>
<tr>
<td>Comorbidities or antibiotics in past 3 months: select an alternative from a different class</td>
</tr>
<tr>
<td>- A respiratory fluoroquinolone [moxifloxacin (400 mg PO od), gatifloxacin (320 mg PO od), levofloxacin (750 mg PO od)] or</td>
</tr>
<tr>
<td>- A β-lactam [preferred: high-dose amoxicillin (1 g tid) or amoxicillin/clavulanate (2 g bid); alternatives: ceftriaxone (1–2 g IV od), cefpodoxime (200 mg PO bid), cefuroxime (500 mg PO bid)] plus a macrolide&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>In regions with a high rate of “high-level” pneumococcal macrolide resistance,&lt;sup&gt;b&lt;/sup&gt; consider alternatives listed above for pts with comorbidities.</td>
</tr>
<tr>
<td><strong>Inpatients, non-ICU</strong></td>
</tr>
<tr>
<td>- A respiratory fluoroquinolone [moxifloxacin (400 mg PO or IV od), gatifloxacin (320 mg PO od), levofloxacin (750 mg PO or IV od)]</td>
</tr>
<tr>
<td>- A β-lactam&lt;sup&gt;c&lt;/sup&gt; [cefotaxime (1–2 g IV q8h), ceftriaxone (1–2 g IV od), ampicillin (1–2 g IV q4–6h), eraptemen (1 g IV od in selected pts)] plus a macrolide&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>In regions with a high rate of “high-level” pneumococcal macrolide resistance,&lt;sup&gt;e&lt;/sup&gt; consider alternatives listed above for pts with comorbidities.</td>
</tr>
<tr>
<td><strong>Inpatients, ICU</strong></td>
</tr>
<tr>
<td>- A β-lactam&lt;sup&gt;e&lt;/sup&gt; [cefotaxime (1–2 g IV q8h), ceftriaxone (2 g IV od), ampicillin-sulbactam (2 g IV q8h)] plus</td>
</tr>
<tr>
<td>- Azithromycin or a fluoroquinolone (as listed above for inpatients, non-ICU)</td>
</tr>
<tr>
<td><strong>Special concerns</strong></td>
</tr>
<tr>
<td>If <em>Pseudomonas</em> is a consideration</td>
</tr>
<tr>
<td>- An antipseudomonal β-lactam [pipercillin/tazobactam (4.5 g IV q6h), cefepime (1–2 g IV q12h), imipenem (500 mg IV q6h), meropenem (1 g IV q8h)] plus either ciprofloxacin (400 mg IV q12h) or levofloxacin (750 mg IV od)</td>
</tr>
<tr>
<td>- The above β-lactams plus an aminoglycoside [amikacin (15 mg/kg od) or tobramycin (1.7 mg/kg od) and azithromycin]</td>
</tr>
<tr>
<td>- The above β-lactams/ plus an aminoglycoside plus an antipseudomonal fluoroquinolone</td>
</tr>
<tr>
<td>If CA-MRSA is a consideration</td>
</tr>
<tr>
<td>- Add linezolid (600 mg IV q12h) or vancomycin (1 g IV q12h)</td>
</tr>
</tbody>
</table>

**Note:** CA-MRSA, community-acquired methicillin-resistant *Staphylococcus aureus*; ICU, intensive care unit.

<sup>a</sup>Doxycycline (100 mg PO bid) is an alternative to the macrolide.
<sup>b</sup>MICs of >16 μg/mL in 25% of isolates.
<sup>c</sup>A respiratory fluoroquinolone should be used for penicillin-allergic pts.
<sup>d</sup>Doxycycline (100 mg IV q12h) is an alternative to the macrolide.
<sup>e</sup>For penicillin-allergic pts, use a respiratory fluoroquinolone and aztreonam (2 g IV q8h).
<sup>f</sup>For penicillin-allergic pts, substitute aztreonam.
Pneumonia and Lung Abscess

CHAPTER 139

• Lung abscess may occur in association with aspiration or infection caused by single CAP pathogens (e.g., CA-MRSA or *P. aeruginosa*). Drainage should be established and proper antibiotics administered.

• Pleural effusion should be tapped for diagnostic and therapeutic purposes. If the fluid has a pH <7, a glucose level <2.2 mmol/L, and a lactate dehydrogenase content >1000 U or if bacteria are seen or cultured, fluid should be drained; a chest tube is usually required.

**Follow-Up**

• CXR abnormalities may require 4–12 weeks to clear.

• Pts should receive influenza and pneumococcal vaccines, as appropriate.

### HEALTH CARE–ASSOCIATED PNEUMONIA

(see also Chap. 85)

#### VENTILATOR-ASSOCIATED PNEUMONIA

VAP is a common complication in pts on mechanical ventilation, with prevalence estimates of 6–52 cases per 100 pts. Three factors important in the pathogenesis of VAP are colonization of the oropharynx with pathogenic microorganisms, aspiration of these organisms to the lower respiratory tract, and compromise of normal host defense mechanisms. Potential etiologic agents include MDR and non-MDR pathogens; the prominence of the various pathogens depends on the length of hospital stay at the time of infection. Clinical manifestations are similar to those in other forms of pneumonia.

**Diagnosis** Diagnosis is difficult. Application of clinical criteria consistently results in overdiagnosis of VAP. Use of quantitative cultures to discriminate between colonization and true infection by determining bacterial burden may be helpful; the more distal in the respiratory tree the diagnostic sampling, the more specific the results.

#### TABLE 139-2

**EMPIRICAL ANTIBIOTIC TREATMENT OF HEALTH CARE–ASSOCIATED PNEUMONIA**

<table>
<thead>
<tr>
<th>Patients without Risk Factors for MDR Pathogens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceftriaxone (2 g IV q24h) or Moxifloxacin (400 mg IV q24h), ciprofloxacin (400 mg IV q8h), or levofloxacin (750 mg IV q24h) or Ampicillin/sulbactam (3 g IV q6h) or Ertapenem (1 g IV q24h)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients with Risk Factors for MDR Pathogens</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. A β-lactam: Cefazidime (2 g IV q8h) or cefepime (2 g IV q8–12h) or Piperacillin/tazobactam (4.5 g IV q6h), imipenem (500 mg IV q6h or 1 g IV q8h), or meropenem (1 g IV q8h) plus</td>
</tr>
</tbody>
</table>

| 2. A second agent active against gram-negative bacterial pathogens: Gentamicin or tobramycin (7 mg/kg IV q24h) or amikacin (20 mg/kg IV q24h) or Ciprofloxacin (400 mg IV q8h) or levofloxacin (750 mg IV q24h) plus |

| 3. An agent active against gram-positive bacterial pathogens: Linezolid (600 mg IV q12h) or Vancomycin (15 mg/kg, up to 1 g IV, q12h) |

**Note:** MDR, multidrug-resistant.
Ventilator-Associated Pneumonia

Higher mortality rates are associated with inappropriate initial empirical treatment. See Table 139-2 for recommended options for empirical therapy for HCAP. Broad-spectrum treatment should be modified when a pathogen is identified. Treatment failure in VAP is not uncommon, especially when MDR pathogens are involved; MRSA and *P. aeruginosa* are associated with high failure rates. VAP complications include prolongation of mechanical ventilation, increased length of stay in the ICU, and necrotizing pneumonia with pulmonary hemorrhage or bronchiectasis. VAP is associated with significant mortality risk. Strategies effective for the prevention of VAP are listed in Table 139-3.

### Table 139-3 Pathogenic Mechanisms and Corresponding Prevention Strategies for Ventilator-Associated Pneumonia

<table>
<thead>
<tr>
<th>Pathogenic Mechanism</th>
<th>Prevention Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oropharyngeal colonization with pathogenic bacteria</td>
<td>Avoidance of prolonged antibiotic courses</td>
</tr>
<tr>
<td>Elimination of normal flora</td>
<td>Short course of prophylactic antibiotics for comatose pts&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Large-volume oropharyngeal aspiration around time of intubation</td>
<td>Postpyloric enteral feeding&lt;sup&gt;b&lt;/sup&gt;; avoidance of high gastric residuals, prokinetic agents</td>
</tr>
<tr>
<td>Gastroesophageal reflux</td>
<td>Avoidance of gastrointestinal bleeding due to prophylactic agents that raise gastric pH&lt;sup&gt;b&lt;/sup&gt;; selective decontamination of digestive tract with nonabsorbable antibiotics&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Bacterial overgrowth of stomach</td>
<td>Hand washing, especially with alcohol-based hand rub; intensive infection control education&lt;sup&gt;a&lt;/sup&gt;; isolation; proper cleaning of reusable equipment</td>
</tr>
<tr>
<td>Cross-infection from other colonized patients</td>
<td>Endotracheal intubation; avoidance of sedation; decompression of small-bowel obstruction</td>
</tr>
<tr>
<td>Large-volume aspiration</td>
<td>Noninvasive ventilation&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Microaspiration around endotracheal tube</td>
<td>Daily awakening from sedation&lt;sup&gt;a&lt;/sup&gt;; weaning protocols&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Endotracheal intubation</td>
<td>Early percutaneous tracheostomy&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Prolonged duration of ventilation</td>
<td>Head of bed elevated&lt;sup&gt;a&lt;/sup&gt;; continuous aspiration of subglottic secretions with specialized endotracheal tube&lt;sup&gt;a&lt;/sup&gt;; avoidance of reintubation; minimization of sedation and pt transport</td>
</tr>
<tr>
<td>Abnormal swallowing function</td>
<td>Tight glycemic control&lt;sup&gt;a&lt;/sup&gt;; lowering of hemoglobin transfusion threshold; specialized enteral feeding formula</td>
</tr>
<tr>
<td>Secretions pooled above endotracheal tube</td>
<td></td>
</tr>
<tr>
<td>Altered lower respiratory host defenses</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>Strategies demonstrated to be effective in at least one randomized controlled trial.

<sup>b</sup>Strategies with negative randomized trials or conflicting results.
Pulmonary Thromboembolism and Deep-Vein Thrombosis

DEFINITION AND NATURAL HISTORY
Venous thromboembolism includes both deep-vein thrombosis (DVT) and pulmonary thromboembolism (PE). DVT results from blood clot formation within large veins, usually in the legs. PE results from DVTs that have broken off and traveled to the pulmonary arterial circulation. DVT is approximately three times more common than PE. Although DVTs are typically related to thrombus formation in the legs and/or pelvis, indwelling venous catheters have increased the occurrence of upper extremity DVT. In the absence of PE, the major complication of DVT is postphlebitic syndrome, which causes chronic leg swelling and discomfort due to damage to the venous valves of the affected leg. PE is often fatal, usually due to progressive right ventricular failure. Chronic thromboembolic pulmonary hypertension is another long-term complication of PE.

Some genetic risk factors, including factor V Leiden and the prothrombin G20210A mutation, have been identified, but they account for only a minority of venous thromboembolic disease. A variety of other risk factors have been identified, including immobilization during prolonged travel, obesity, smoking, surgery, trauma, oral contraceptives, and postmenopausal hormone replacement. Medical conditions that increase the risk of venous thromboembolism include cancer and antiphospholipid antibody syndrome.

CLINICAL EVALUATION

History DVTs often present with progressive lower calf discomfort. For PE, dyspnea is the most common presenting symptom. Chest pain can indicate pulmonary infarction with pleural irritation. Syncope can occur with massive PE.

Physical Examination Tachypnea and tachycardia are common in PE. Low-grade fever, neck vein distention, and a loud P2 on cardiac examination can be seen. Hypotension and cyanosis suggest massive PE. Physical examination with DVT may be notable only for mild calf tenderness. However, with massive DVT, marked thigh swelling and inguinal tenderness can be observed.

Laboratory Tests Normal D-dimer level (<500 μg/mL by enzyme-linked immunosorbent assay) essentially rules out PE, although hospitalized pts often have elevated D-dimer levels due to other disease processes. Although hypoxemia and an increased alveolar-arterial O2 gradient may be observed in PE, ar-
aterial blood gases are rarely useful in diagnosing PE. Elevated serum troponin and brain natriuretic peptide levels are associated with increased risk of complications in PE. The electrocardiogram can show an S1Q3T3 sign in PE, but that finding is not frequently observed.

**Imaging Studies** Venous ultrasonography can detect DVT by demonstrating loss of normal venous compressibility. When combined with Doppler imaging of venous flow, the detection of DVT by ultrasonography is excellent. For pts with nondiagnostic venous ultrasound studies, CT or MRI can be used to assess for DVT. Contrast phlebography is very rarely required.

In PE, a normal chest x-ray (CXR) is common. Although not commonly observed, focal oligemia and peripheral wedge-shaped densities on CXR are well-established findings in PE. Chest CT with IV contrast has become the primary diagnostic imaging test for PE. Ventilation/perfusion lung scanning is primarily used for subjects unable to tolerate IV contrast. Transthoracic echocardiography is valuable to assess for RV hypokinesis with moderate to large PE, but it is not typically useful for diagnosing the presence of a PE. With the advent of contrast chest CT scans for PE diagnosis, pulmonary angiography studies are rarely performed.

**Integrated Diagnostic Approach** An integrated diagnostic approach that considers the clinical suspicion for DVT and PE is required. For individuals with a low clinical likelihood of DVT or with a low to moderate clinical likelihood of PE, the d-dimer level can be used to determine if further imaging studies are required. An algorithm for imaging studies in both DVT and PE is shown in Fig. 140-1. The differential diagnosis of DVT includes a ruptured Baker’s cyst and cellulitis. The differential diagnosis of PE is broad and includes pneumonia, acute myocardial infarction, and aortic dissection.

**Anticoagulation**

Although anticoagulants do not dissolve existing clots in DVT or PE directly, they limit further thrombus formation and allow fibrinolysis to occur. In order to provide effective anticoagulation rapidly, parenteral anticoagulation is used for the initial treatment of venous thromboembolism. Traditionally, unfractionated heparin (UFH) has been used, with a target activated partial thromboplastin time (aPTT) of 2–3 times the upper limit of the normal laboratory value. UFH is typically administered with a bolus of 5000–10,000 U followed by a continuous infusion of approximately 1000 U/h. Frequent dosage adjustments are often required to achieve and maintain a therapeutic aPTT with UFH. Heparin-induced thrombocytopenia can occur with UFH. However, the short-half life of UFH remains a significant advantage.

Alternatives to UFH for acute anticoagulation include low-molecular-weight heparins (LMWHs) such as enoxaparin and tinzaparin. Laboratory monitoring is not required, but doses are adjusted for renal impairment or obesity. Fondaparinux, a pentasaccharide, is another parenteral alternative to UFH that does not require laboratory monitoring but does require dose adjustment for renal insufficiency.

After initiating treatment with a parenteral agent, warfarin is typically used for long-term oral anticoagulation. Warfarin can be initiated soon after a parenteral agent is given; however, 5–7 days are typically required for warfarin to achieve therapeutic anticoagulation. Warfarin is given to achieve a therapeutic international normalized ratio (INR) of the prothrombin time, which is typi-
cally an INR of 2–3. Pts vary widely in their required warfarin doses; dosing often begins at 5 mg/d, with adjustment based on the INR.

The most troublesome adverse event from anticoagulation treatment is hemorrhage. For severe hemorrhage while undergoing treatment with UFH or LMWH, protamine can be given to reverse anticoagulation. Severe bleeding while anticoagulated with warfarin can be treated with fresh frozen plasma or cryoprecipitate; milder hemorrhage or markedly elevated INR values can be treated with vitamin K. Warfarin should be avoided in pregnant pts.

The duration of anticoagulation for an initial DVT or PE is at least 3–6 months. Recurrent DVT or PE typically requires lifelong anticoagulation.
Although anticoagulation is the mainstay of therapy for venous thromboembolism, additional therapeutic modalities also can be employed (Fig. 140-2). Inferior vena cava filters can be used if thrombosis recurs despite adequate anticoagulation. Fibrinolytic therapy (often with tissue plasminogen activator) should be considered for massive PE, although the risk of hemorrhage is significant. Surgical embolectomy also can be considered for massive PE.

If PE pts develop chronic thromboembolic pulmonary hypertension, surgical intervention (pulmonary thromboendarterectomy) can be performed.

For a more detailed discussion, see Goldhaber SZ: Deep Venous Thrombosis and Pulmonary Thromboembolism, Chap. 256, p. 1651, in HPIM-17.

### Interstitial Lung Disease

Interstitial lung diseases (ILDs) are a group of >200 disease entities characterized by diffuse parenchymal abnormalities. ILDs can be classified into two major groups: (1) diseases associated with predominant inflammation and fibrosis, and (2) diseases with predominantly granulomatous reaction in interstitial or vascular areas (Table 141-1). ILDs are nonmalignant and noninfectious, and they are typically chronic. The differential diagnosis of ILDs often includes infections (e.g., atypical mycobacteria, fungi) and malignancy (e.g., bronchoalveolar cell carcinoma, lymphangitic carcinomatosis). One of the most common...
Interstitial Lung Disease

CHAPTER 141

ILDs associated with a granulomatous reaction, sarcoidosis, is discussed in Chap. 175. Many ILDs are of unknown etiology; however, some ILDs are known to be associated with specific environmental exposures including asbestos, radiation therapy, and organic dusts.

#### TABLE 141-1

**MAJOR CATEGORIES OF ALVEOLAR AND INTERSTITIAL INFLAMMATORY LUNG DISEASE**

<table>
<thead>
<tr>
<th>Lung Response: Alveolitis, Interstitial Inflammation, and Fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Known Cause</strong></td>
</tr>
<tr>
<td>Asbestos</td>
</tr>
<tr>
<td>Fumes, gases</td>
</tr>
<tr>
<td>Drugs (antibiotics, amiodarone, gold) and chemotherapy drugs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lung Response: Granulomatous</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Known Cause</strong></td>
</tr>
<tr>
<td>Hypersensitivity pneumonitis (organic dusts)</td>
</tr>
<tr>
<td><strong>Unknown Cause</strong></td>
</tr>
<tr>
<td>Sarcoïdosis</td>
</tr>
<tr>
<td>Langerhans cell granulomatosis (eosinophilic granuloma of the lung)</td>
</tr>
<tr>
<td>Granulomatous vasculitides</td>
</tr>
<tr>
<td>Wegener’s granulomatosis, allergic granulomatosis of Churg-Strauss</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lung Response: Alveolitis, Interstitial Inflammation, and Fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Known Cause</strong></td>
</tr>
<tr>
<td>Asbestos</td>
</tr>
<tr>
<td>Fumes, gases</td>
</tr>
<tr>
<td>Drugs (antibiotics, amiodarone, gold) and chemotherapy drugs</td>
</tr>
</tbody>
</table>

### TABLE 141-1

**MAJOR CATEGORIES OF ALVEOLAR AND INTERSTITIAL INFLAMMATORY LUNG DISEASE**

<table>
<thead>
<tr>
<th>Lung Response: Alveolitis, Interstitial Inflammation, and Fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Known Cause</strong></td>
</tr>
<tr>
<td>Asbestos</td>
</tr>
<tr>
<td>Fumes, gases</td>
</tr>
<tr>
<td>Drugs (antibiotics, amiodarone, gold) and chemotherapy drugs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lung Response: Granulomatous</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Known Cause</strong></td>
</tr>
<tr>
<td>Hypersensitivity pneumonitis (organic dusts)</td>
</tr>
<tr>
<td><strong>Unknown Cause</strong></td>
</tr>
<tr>
<td>Sarcoïdosis</td>
</tr>
<tr>
<td>Langerhans cell granulomatosis (eosinophilic granuloma of the lung)</td>
</tr>
<tr>
<td>Granulomatous vasculitides</td>
</tr>
<tr>
<td>Wegener’s granulomatosis, allergic granulomatosis of Churg-Strauss</td>
</tr>
</tbody>
</table>
APPROACH TO THE PATIENT WITH INTERSTITIAL LUNG DISEASE

History
Common presenting symptoms for pts with ILDs include dyspnea and non-productive cough. Symptom onset and duration can assist in the differential diagnosis. Chronic symptoms (over months to years) are typically seen in most ILDs, including idiopathic pulmonary fibrosis (IPF) and pulmonary Langerhans cell histiocytosis (PLCH or eosinophilic granuloma). Subacute symptoms (over weeks to months) can also be observed in most ILDs, especially in sarcoidosis, drug-induced ILDs, and alveolar hemorrhage syndromes. Acute presentations are uncommon for ILDs but are typically observed with acute interstitial pneumonia (AIP), and they can also occur with eosinophilic pneumonia and hypersensitivity pneumonitis. Sudden onset of dyspnea can indicate a pneumothorax, which occurs in PLCH and tuberous sclerosis/lymphangioleiomyomatosis. Episodic presentations also are unusual, but they are more typical for eosinophilic pneumonia, hypersensitivity pneumonitis, and cryptogenic organizing pneumonitis [COP, also known as bronchiolitis obliterans with organizing pneumonia (BOOP)].

Age at presentation also can guide the differential diagnosis. IPF pts typically present at age >50, while PLCH, LAM, and connective tissue disease—related ILD often present between the ages of 20–40. LAM occurs exclusively in women, while ILD in rheumatoid arthritis (RA) typically occurs in men. Cigarette smoking is a risk factor for several ILDs including IPF, PLCH, Goodpasture’s syndrome, and respiratory bronchiolitis. Occupational exposures can be important risk factors for many types of hypersensitivity pneumonitis as well as pneumoconioses. Medical treatment with radiation and drugs also should be assessed.

Physical Examination
Tachypnea and end-inspiratory crackles are commonly observed in inflammatory ILDs, but they are less frequent in granulomatous ILDs. Clubbing of the digits is observed in some pts with advanced ILD.

Laboratory Studies
Antinuclear antibodies and rheumatoid factor at low titers are observed in some IPF pts without a connective tissue disorder. Specific serum antibodies can confirm exposure to relevant antigens in hypersensitivity pneumonitis, but they do not prove causation.

Chest Imaging
Chest x-ray (CXR) does not typically provide a specific diagnosis but often raises the possibility of ILD by demonstrating a bibasilar reticular pattern. Upper-lung-zone predominance of nodular opacities is noted in several ILDs, including PLCH, sarcoidosis, and silicosis. High-resolution chest CT scans provide improved sensitivity for the early detection of ILDs and may be sufficiently specific to allow a diagnosis to be made in ILDs such as IPF, PLCH, and asbestosis. Honeycombing is indicative of advanced fibrosis.

Tissue and Cellular Examination
In order to provide a specific diagnosis and assess disease activity, lung biopsy is often required. Bronchoscopy with transbronchial biopsies can be diagnostic in some ILDs, including sarcoidosis. In addition, bronchoscopy
can assist by excluding chronic infections or lymphangitic carcinomatosis. However, the more extensive tissue samples provided by open lung biopsies, often obtained by video-assisted thoracic surgery, are often required to establish a specific diagnosis. Evidence for diffuse end-stage disease, such as widespread honeycombing, or other major operative risks, are relative contraindications to lung biopsy procedures.

**PRINCIPLES OF MANAGEMENT**

If a causative agent can be identified (e.g., thermophilic actinomyces in hypersensitivity pneumonitis), cessation of exposure to that agent is imperative. Because the response to treatment among different ILDs is so variable, identification of treatable causes is essential. Glucocorticoids can be highly effective for eosinophilic pneumonias, COP, HP, radiation pneumonitis, and drug-induced ILD. Prednisone at 0.5–1.0 mg/kg qd is commonly given for 4–12 weeks, followed by a gradual tapering dose. On the other hand, glucocorticoids are typically not beneficial in IPF. Smoking cessation is essential, especially for smoking-related ILDs such as PLCH and respiratory bronchiolitis.

Supportive therapeutic measures include providing supplemental O2 for pts with significant hypoxemia (PaO2 <55 mmHg at rest). Pulmonary rehabilitation may also be beneficial. For young pts with end-stage ILD, lung transplantation should be considered.

**SELECTED INDIVIDUAL ILDS**

**Idiopathic Pulmonary Fibrosis**  IPF, which is also known as usual interstitial pneumonia (UIP), is the most common idiopathic interstitial pneumonia. Cigarette smoking is a risk factor for IPF. Common respiratory symptoms include dyspnea and a nonproductive cough. Physical examination is notable for inspiratory crackles at the lung bases. Clubbing may occur. High-resolution chest CT scans show subpleural reticular opacities predominantly in the lower lung fields, which are associated with honeycombing in advanced disease. Pulmonary function tests reveal a restrictive ventilatory defect with reduced lung carbon monoxide diffusing capacity (DLCO). Surgical lung biopsy is usually required to confirm the diagnosis, although classic presentations may not require a biopsy. IPF can include acute exacerbations characterized by accelerated clinical deterioration over days to weeks. IPF is poorly responsive to available pharmacologic treatment.

**ILD Associated with Connective Tissue Disorders**  Pulmonary manifestations may precede systemic manifestations of a connective tissue disorder. In addition to direct pulmonary involvement, it is necessary to consider complications of therapy (e.g., opportunistic infections), respiratory muscle weakness, esophageal dysfunction, and associated malignancies as contributors to pulmonary parenchymal abnormalities in pts with connective tissue disorders. Progressive systemic sclerosis (scleroderma) commonly includes ILD as well as pulmonary vascular disease. Lung involvement tends to be highly resistant to available treatment.

In addition to pulmonary fibrosis (ILD), RA can involve a range of pulmonary complications, including pleural effusions, pulmonary nodules, and pulmonary vasculitis. ILD in RA pts is more common in men.
Systemic lupus erythematosus (SLE) also can involve a range of pulmonary complications, including pleural effusions, pulmonary vascular disease, pulmonary hemorrhage, and BOOP. Chronic, progressive ILD is not commonly observed.

**Cryptogenic Organizing Pneumonia**  When the BOOP pathologic pattern occurs without another primary pulmonary disorder, the term *cryptogenic organizing pneumonia* (COP) is used. COP may present with a flu-like illness. Recurrent and migratory pulmonary opacities are common. Glucocorticoid therapy is often effective.

**Pulmonary Alveolar Proteinosis**  Pulmonary alveolar proteinosis (PAP) is a diffuse lung disease that involves the accumulation of lipoproteinaceous material in the distal airspaces, rather than a classic ILD. More common in males, PAP usually presents insidiously, with dyspnea, fatigue, weight loss, and low-grade fever. Whole lung lavage may be of therapeutic benefit.

**Pulmonary Infiltrates with Eosinophilia**  Several disorders are characterized by pulmonary infiltrates and peripheral blood eosinophilia. Tropical eosinophilia relates to parasitic infection; drug-induced eosinophilic pneumonias are more common in the United States. Loeffler’s syndrome typically includes migratory pulmonary infiltrates and minimal clinical symptoms. Acute eosinophilic pneumonia involves pulmonary infiltrates with severe hypoxemia. Chronic eosinophilic pneumonia is often in the differential diagnosis with other ILDs; it includes fever, cough, and weight loss, with a CXR notable for peripheral infiltrates. Eosinophilic pneumonias tend to be rapidly responsive to glucocorticoid therapy.

**Alveolar Hemorrhage Syndromes**  A variety of diseases can cause diffuse alveolar hemorrhage, including systemic vasculitic syndromes (e.g., Wegener’s granulomatosis), connective tissue diseases (e.g., SLE), and Goodpasture’s syndrome. Although typically an acute process, recurrent episodes can lead to pulmonary fibrosis. Hemoptysis may not occur initially in one-third of cases. CXR typically shows patchy or diffuse alveolar opacities. The DLCO may be increased. High doses of IV methylprednisolone are typically required, followed by gradual tapering of systemic steroid doses. Plasmapheresis may be effective for Goodpasture’s Syndrome.

**Pulmonary Langerhans Cell Histiocytosis**  PLCH is a smoking-related diffuse lung disease that typically affects men 20–40 years of age. Presenting symptoms often include cough, dyspnea, chest pain, weight loss, and fever. Pneumothorax occurs in 25% of pts. High-resolution chest CT scan reveals upper-zone-predominant nodular opacities and thin-walled cysts. Smoking cessation is the key therapeutic intervention.

**Hypersensitivity Pneumonitis**  HP is an inflammatory lung disorder caused by repeated inhalation of an organic agent in a susceptible individual. Many organic agents have been implicated. Clinical presentations can be acute, with cough, fever, and dyspnea developing within 6–8 h after exposure; subacute, with cough and dyspnea that can become progressively worse over weeks; and chronic, which can appear similar to IPF. Peripheral blood eosinophilia is not observed. Serum precipitins can be measured as an indicator of an environmental exposure. Although helpful in implicating specific agents, the presence of a specific serum precipitin is not diagnostic since many exposed individuals without HP will have such precipitins; false-negative results can also occur. Diagnosis is made based on symptoms, physical exam, pulmonary function tests, and radiographic studies that are consistent with HP; history of exposure to a recog-
Diseases of the Pleura and Mediastinum

Chapter 142

For a more detailed discussion, see King TE Jr: Interstitial Lung Diseases, Chap. 255 (p. 1643); Kline JN and Hunninghake GW: Hypersensitivity Pneumonitis and Pulmonary Infiltrates with Eosinophilia, Chap. 249 (p. 1607); in HPIM-17.

Diseases of the Pleura and Mediastinum

PLEURAL EFFUSION

Etiology and Diagnostic Approach  Pleural effusion is defined as excess fluid accumulation in the pleural space. It can result from increased pleural fluid formation in the lung interstitium, parietal pleura, or peritoneal cavity, or from decreased pleural fluid removal by the parietal pleural lymphatics.

The two major classes of pleural effusions are transudates, which are caused by systemic influences on pleural fluid formation or resorption, and exudates, which are caused by local influences on pleural fluid formation and resorption. Common causes of transudative effusions are left ventricular heart failure, cirrhosis, and nephrotic syndrome. Common causes of exudative effusions are pneumonia, malignancy, and pulmonary embolism. A more comprehensive list of the etiologies of transudative and exudative pleural effusions is provided in Table 142-1.

Exudates fulfill at least one of the following three criteria: high pleural fluid/serum protein ratio (>0.5), pleural fluid lactate dehydrogenase (LDH) greater than two-thirds of the laboratory normal upper limit for serum LDH, or pleural/serum LDH ratio >0.6. Transudative effusions typically do not meet any of these criteria. For exudative effusions, pleural fluid should also be tested for pH, glucose, white blood cell count with differential, microbiologic studies, cytology, and amylase. An algorithm for determining the etiology of a pleural effusion is presented in Fig. 142-1.

Despite full evaluation, no cause for the pleural effusion will be found in 25% of pts; many of these effusions are likely due to viral infections. A subset of the most common types of pleural effusions is described in the following sections.

Transudative Pleural Effusions  Transudative pleural effusions related to left ventricular failure are often bilateral; if unilateral, right-sided effusions are more common than left-sided effusions. Thoracentesis is not always required to confirm the transudative nature of the pleural effusions if congestive heart failure is present; however, if the effusions are not comparable in size, if the pt is febrile, or if pleuritic chest pain is present, thoracentesis should be strongly considered.

Parapneumonic Effusion/Empyema  Parapneumonic effusions are exudates that are associated with contiguous bacterial lung infections, including pneumo-
and lung abscess. In the setting of pulmonary infections, the presence of free pleural fluid can be demonstrated with a lateral decubitus x-ray, chest CT scan, or ultrasound. If the pleural fluid is grossly purulent, it is referred to as an empyema. Tube thoracostomy (i.e., chest tube) for management of parapneumonic effusions is likely indicated if any of the following applies (in descending order of importance): (1) gross pus is present, (2) Gram’s stain or culture of pleural fluid is positive, (3) pleural fluid glucose is <3.3 mmol/L (<60 mg/dL), (4) pleural fluid pH is <7.20, or (5) there is loculated pleural fluid.

If chest tube drainage does not result in complete removal of pleural fluid, streptokinase (250,000 units) can be instilled through the tube, or thoracoscopy can be performed to lyse adhesions. If these approaches are not effective, surgical decortication may be required.

### Malignant Pleural Effusions
Metastatic cancer is a common cause of exudative pleural effusions. Tumors that frequently cause malignant effusions include lung cancer, breast cancer, and lymphoma. The pleural fluid glucose level may be markedly reduced. Cytologic examination of the pleural fluid is usually diagnostic. If cytologic examination of thoracentesis fluid is negative, thoracosco-
FIGURE 142-1  Approach to the diagnosis of pleural effusions. PF, pleural fluid; PE, pulmonary embolism; CHF, congestive heart failure; TB, tuberculosis; LDH, lactate dehydrogenase; CT, computed tomography.
should be considered. Symptomatic relief of dyspnea can be provided by therapeutic thoracentesis. If the pleural fluid recurs, pleural sclerosis can be performed with pleural abrasion via thoracoscopy or with instillation of a sclerosing agent, such as doxycycline, through a chest tube.

**Effusions Related to Pulmonary Thromboembolism** Pleural effusions in pulmonary thromboembolism are usually exudative but can be transudative. The presence of a pleural effusion does not alter the standard treatment for pulmonary embolism (Chap. 140). If the effusion increases in size during anticoagulation treatment, possible explanations include recurrent embolism, hemothorax, or empyema.

**Tuberculous Pleuritis** Usually associated with primary tuberculosis (Tb) infection, tuberculous pleural effusions are exudative with predominant lymphocytosis. The presence of high levels of Tb markers in the pleural fluid, such as adenosine deaminase, interferon-γ, or positive polymerase chain reaction for Tb DNA, can establish the diagnosis. Mycobacterial cultures obtained from pleural fluid (low positive culture rate) or pleural biopsy (high positive culture rate with needle biopsy or thoracoscopy) can definitively confirm the diagnosis. Although tuberculous pleuritis often resolves without treatment, active tuberculosis can develop years later if antimycobacterial treatment is not given.

**Rheumatoid Arthritis (RA)** RA can cause pleural effusions that are exudative. Effusions may precede articular symptoms. Pleural fluid shows very low glucose and pH. Rheumatoid pleural effusions are usually seen in males.

**Chylothorax** Chylothorax is an exudative pleural effusion with milky fluid and an elevated triglyceride level (>1.2 mmol/L or >110 mg/dL). The most common etiologies are trauma to the thoracic duct and mediastinal tumors. Chest tube placement is often required, and octreotide administration may be beneficial. Prolonged chest tube drainage can lead to malnutrition.

**Hemothorax** Hemothorax commonly results from trauma; blood vessel rupture and tumor are other potential etiologies. When frankly bloody pleural fluid is noted at thoracentesis, the hematocrit should be tested. If the hematocrit of the pleural fluid is >50% of the bloodstream hematocrit, a hemothorax is present. Chest tube placement is typically required. If pleural blood loss is >200 mL/h, thoracic surgical intervention should be pursued.

**PNEUMOTHORAX**

Pneumothorax (Ptx) is defined as gas in the pleural space. Spontaneous Ptx occurs without trauma to the thorax. Primary spontaneous Ptx occurs in the absence of underlying lung disease and typically results from apical pleural blebs. Simple aspiration may be adequate treatment for an initial primary spontaneous Ptx, but recurrence typically requires thoracoscopic intervention. Secondary spontaneous Ptx occurs in the setting of underlying lung disease, most commonly chronic obstructive pulmonary disease. Chest tube placement is typically required for secondary spontaneous Ptx, and pleurodesis (with pleural abrasion or a sclerosing agent) should be considered.

Traumatic Ptx usually requires chest tube placement. Iatrogenic Ptx can occur from transthoracic needle biopsy, thoracentesis, placement of a central venous catheter, or transbronchial biopsy. Treatment with O₂ or aspiration is often adequate for iatrogenic Ptx, but chest tube placement may be required. Tension Ptx can result from trauma or mechanical ventilation. Positive pleural
pressure in mechanical ventilation can rapidly lead to a tension Ptx with reduced cardiac output. Urgent treatment is required, either with a chest tube or, if not immediately available, with a large-bore needle inserted into the pleural space through the second anterior intercostal space.

MEDIASTINAL DISEASE

Mediastinitis  Mediastinitis can be an acute or chronic process. Acute mediastinitis can result from esophageal perforation or after cardiac surgery with median sternotomy. Esophageal perforation can occur spontaneously or iatrogenically; surgical exploration of the mediastinum, repair of the esophageal perforation, and drainage of the pleural space and mediastinum are required. Mediastinitis after median sternotomy typically presents with wound drainage and is diagnosed by mediastinal needle aspiration. Treatment requires drainage, debridement, and IV antibiotics.

Chronic mediastinitis can cause a spectrum of disease ranging from granulomatous inflammation of lymph nodes to fibrosing mediastinitis. Chronic mediastinitis is commonly caused by Tb and histoplasmosis; other etiologies are also possible, including sarcoidosis and silicosis. Granulomatous inflammation is usually asymptomatic. Fibrosing mediastinitis causes symptoms related to compression of mediastinal structures, such as the superior vena cava, esophagus, or large airways. Fibrosing mediastinitis is very difficult to treat.

Mediastinal Masses  Different types of mediastinal masses are found in the anterior, middle, and posterior mediastinal compartments. The most common mass lesions in the anterior mediastinum are thymomas, lymphomas, teratomas, and thyroid lesions. In the middle mediastinum, vascular masses, enlarged lymph nodes (e.g., metastatic cancer or granulomatous disease), and bronchogenic or pleuropericardial cysts are found. Posterior mediastinal masses include neurogenic tumors, gastroenteric cysts, and esophageal diverticula.

CT scans are invaluable for evaluating mediastinal masses. Barium swallow studies can assist in evaluating posterior mediastinal masses. Biopsy procedures are typically required to diagnose mediastinal masses; needle biopsy procedures (e.g., percutaneous or bronchoscopy), mediastinoscopy, and thoracoscopy are potential options.

For a more detailed discussion, see Light RW: Disorders of the Pleura and Mediastinum, Chap. 257, p. 1658, in HPIM-17.

ALVEOLAR HYPOVENTILATION

 Exists when arterial P_{CO_2} increases above the normal 37–43 mmHg. In most clinically important chronic hypoventilation syndromes, P_{aCO_2} is 50–80 mmHg.
Alveolar hypoventilation is always (1) a defect in the metabolic respiratory control system, (2) a defect in the respiratory neuromuscular system, or (3) a defect in the ventilatory apparatus (Table 143-1).

Disorders associated with impaired respiratory drive, defects in respiratory neuromuscular system, and upper airway obstruction produce an increase in PaCO₂, despite normal lungs, because of a decrease in overall minute ventilation.

Disorders of chest wall, lower airways, and lungs produce an increase in PaCO₂, despite a normal or increased minute ventilation.

Increased PaCO₂ leads to respiratory acidosis, compensatory increase in HCO₃⁻, and decrease in PaO₂.

Hypoxemia may induce secondary polycythemia, pulmonary hypertension, right heart failure. Gas exchange worsens during sleep, resulting in morning headache, impaired sleep quality, fatigue, daytime somnolence, mental confusion.
HYPOVENTILATION SYNDROMES

Primary Alveolar  Cause unknown; rare; thought to arise from defect in metabolic respiratory control system; key diagnostic finding is chronic respiratory acidosis without respiratory muscle weakness or impaired ventilatory mechanics. Some pts respond to respiratory stimulants and supplemental O2.

Neuromuscular  Several primary neuromuscular disorders produce chronic hypoventilation (Table 143-1). Hypoventilation usually develops gradually, but acute, superimposed respiratory loads (e.g., viral bronchitis with airways obstruction) may precipitate respiratory failure. Diaphragm weakness is a common feature, with orthopnea and paradoxical abdominal movement in supine posture. Testing reveals low maximum voluntary ventilation and reduced maximal inspiratory and expiratory pressures. Therapy involves treatment of underlying condition. Many pts benefit from mechanical ventilatory assistance at night (often through nasal mask) or the entire day (typically through tracheostomy).

Obesity-Hypoventilation  Massive obesity imposes a mechanical load on the respiratory system. Small percentage of morbidly obese pts develop hypercapnia, hypoxemia, and ultimately polycythemia, pulmonary hypertension, and right heart failure. Most pts have mild to moderate airflow obstruction. Treatment includes weight loss, smoking cessation, and pharmacologic respiratory stimulants such as progesterone. Nocturnal mask ventilation may minimize nocturnal hypoxemia and treats coexisting sleep-disordered breathing.

HYPERVENTILATION

Increased ventilation, causing PaCO2 < 37 mmHg. Causes include lesions of the CNS, metabolic acidosis, anxiety, drugs (e.g., salicylates), hypoxemia, hypoglycemia, hepatic coma, and sepsis. Hyperventilation may also occur with some types of lung disease, particularly interstitial disease and pulmonary edema.

For a more detailed discussion, see Phillipson EA: Disorders of Ventilation, Chap. 258, p. 1661.

Sleep Apnea

By convention, apnea is defined as cessation of airflow for >10 s. Hypopnea is defined as reduction in airflow resulting in arousal from sleep or oxygen desaturation. Minimum number of apneic or hypopneic events per night for diagnosis is uncertain, but most pts have at least 10–15/h of sleep. Prevalence estimates vary depending on threshold for diagnosis (events/h) and on definition of hypopnea (degree of desaturation required), but conservative figures are 10% of working-age men and 4% of women.

Some pts have central apnea with transient loss of neural drive to respiratory muscles during sleep. Vast majority have primarily obstructive apnea with oc-
clusion in the upper airway. Snoring is frequent. Sleep plays a permissive role in collapse of upper airway. Alcohol and sedatives exacerbate the condition.

**SYMPTOMS**

These include snoring, excessive daytime sleepiness, memory loss, depression, and impotence. Sleepiness increases risk of automobile accidents. Nocturnal hypoxia, a consequence of apnea, may contribute to systemic hypertension, arrhythmias, and right ventricular hypertrophy.

Most pts have structural narrowing of upper airway. Obesity is frequent, but many pts have normal body habitus. Most pts have obstruction at nasal or palatal level. Mandibular deformities (retrognathia) also predispose.

**DIAGNOSIS**

This requires overnight observation of the pt. The definitive test for obstructive sleep apnea is overnight polysomnography, including sleep staging and respiratory monitoring.

**Rx Sleep Apnea**  (See Table 144-1)

Therapy is directed at increasing upper airway size, increasing upper airway tone, and minimizing upper airway collapsing pressures. Weight loss often reduces disease severity but infrequently obviates the need for other therapy. Majority of pts with severe sleep apnea require nasal continuous positive airway pressure (nasal C-PAP). Mandibular positioning device (dental) may treat pts with mild or moderate disease. Surgery (uvulopalatopharyngoplasty) is usually reserved for pts who fail other therapies.

For a more detailed discussion, see Douglas, NJ: Sleep Apnea, Chap. 259, p. 1665, in HPIM-17.

### Table 144-1 MANAGEMENT OF OBSTRUCTIVE SLEEP APNEA (OSA)

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Mild to Moderate OSA</th>
<th>Moderate to Severe OSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>↑ Upper airway muscle tone</td>
<td>Avoidance of alcohol, sedatives</td>
<td>Uvulopalatopharyngoplasty</td>
</tr>
<tr>
<td>↑ Upper airway lumen size</td>
<td>Weight reduction, Avoidance of supine posture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral prosthesis</td>
<td></td>
</tr>
<tr>
<td>↓ Upper airway subatmospheric pressure, Bypass occlusion</td>
<td>Improved nasal patency</td>
<td>Nasal continuous positive airway pressure, Tracheostomy</td>
</tr>
</tbody>
</table>

*Source: EA Phillipson: HPIM-16, p. 1575.*
The approach to renal disease begins with recognition of particular syndromes on the basis of findings such as presence or absence of azotemia, proteinuria, hypertension, edema, abnormal urinalysis, electrolyte disorders, abnormal urine volumes, or infection (Table 145-1).

**ACUTE RENAL FAILURE** (See Chap. 146)

Clinical syndrome is characterized by a rapid, severe decrease in glomerular filtration rate (GFR) [rise in serum creatinine and blood urea nitrogen (BUN)], usually with reduced urine output. Extracellular fluid expansion leads to edema, hypertension, and occasionally acute pulmonary edema. Hyperkalemia, hypotension, and acidosis are common. Etiologies include ischemia; nephrotoxic injury due to drugs, toxins, or endogenous pigments; sepsis; severe renovascular disease; glomerulonephritis (GN); interstitial nephritis, particularly allergic interstitial nephritis due to medications; thrombotic microangiopathy; or conditions related to pregnancy. Prerenal and postrenal failure are potentially reversible causes.

**Rapidly Progressive Glomerulonephritis** Defined as a >50% reduction in renal function, occurring over weeks to months. Broadly classified into three major subtypes on the basis of renal biopsy findings and pathophysiology: (1) immune complex–associated, e.g., in systemic lupus erythematosus (SLE); (2) “pauci-immune,” associated with antineutrophil cytoplasmic antibodies (ANCA) specific for myeloperoxidase or proteinase-3; and (3) associated with anti–glomerular basement (anti-GBM) antibodies, e.g., in Goodpasture’s syndrome.

Pts are initially nonoliguric and may have recent flulike symptoms (myalgias, low-grade fevers, etc.); later, oliguric renal failure with uremic symptoms supervenes. Hypertension is common, particularly in poststreptococcal GN. Symptoms of associated disorders may be prominent, e.g., arthritis/arthritis in SLE or vasculitis. Pulmonary manifestations in ANCA- and anti-GBM-associated rapidly progressive GN range from asymptomatic infiltrates to life-threatening pulmonary hemorrhage. Urinalysis typically shows hematuria, proteinuria, and red blood cell (RBC) casts; however, while highly specific for GN, RBC casts are not a particularly sensitive finding.

**Acute Glomerulonephritis** (See Chap. 150) Often called nephritic syndrome, classically caused by poststreptococcal GN. An acute illness with sudden onset of hematuria, edema, hypertension, oliguria, and elevated BUN and creatinine. Mild pulmonary congestion may be present. An antecedent or concurrent infection or multisystem disease may be causative, or glomerular disease may exist alone. Hematuria, proteinuria, and pyuria are usually present, and RBC casts confirm the diagnosis. Serum complement may be decreased in certain conditions.
### TABLE 145-1
INITIAL CLINICAL AND LABORATORY DATABASE FOR DEFINING MAJOR SYNDROMES IN NEPHROLOGY

<table>
<thead>
<tr>
<th>Syndromes</th>
<th>Important Clues to Diagnosis</th>
<th>Common Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute or rapidly progressive renal failure</td>
<td>Anuria</td>
<td>Hypertension, pulmonary edema, peripheral edema, hematuria, proteinuria, pyuria</td>
</tr>
<tr>
<td></td>
<td>Oliguria</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Documented recent decline in GFR</td>
<td></td>
</tr>
<tr>
<td>Acute nephritis</td>
<td>Hematuria, RBC casts</td>
<td>Proteinuria</td>
</tr>
<tr>
<td></td>
<td>Azotemia, oliguria</td>
<td>Pyuria</td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>Edema, hypertension</td>
<td>Circulatory congestion</td>
</tr>
<tr>
<td></td>
<td>Azotemia for &gt;3 months</td>
<td>Hematuria, proteinuria</td>
</tr>
<tr>
<td></td>
<td>Symptoms or signs of uremia</td>
<td>Edema, hypertension</td>
</tr>
<tr>
<td></td>
<td>Shrunken, echogenic kidneys on ultrasound</td>
<td>Hyperkalemia, acidosis, hypocalcemia, anemia</td>
</tr>
<tr>
<td>Nephrotic syndrome</td>
<td>Proteinuria &gt;3.5 g per 1.73 m² per 24 h</td>
<td>Edema</td>
</tr>
<tr>
<td></td>
<td>Hypoalbuminemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hyperlipidemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lipiduria</td>
<td></td>
</tr>
<tr>
<td>Asymptomatic urinary abnormalities</td>
<td>Hematuria</td>
<td>Hematuria</td>
</tr>
<tr>
<td></td>
<td>Proteinuria (below nephrotic range)</td>
<td>Mild azotemia</td>
</tr>
<tr>
<td></td>
<td>Sterile pyuria, casts</td>
<td>Mild proteinuria</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>Bacteriuria &gt;10⁵ colonies per mL</td>
<td>Fever</td>
</tr>
<tr>
<td></td>
<td>Other infectious agent documented in urine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pyuria, leukocyte casts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frequency, urgency</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bladder tenderness, flank tenderness</td>
<td></td>
</tr>
<tr>
<td>Renal tubule defects</td>
<td>Electrolyte (Na⁺, K⁺, Mg²⁺, phosphate, or Ca²⁺) or solute (glucose, uric acid, amino acid) disorders</td>
<td>Hematuria “Tubular” proteinuria \nEnuresis \nElectrolyte or acid-base disorders</td>
</tr>
<tr>
<td></td>
<td>Polyuria, nocturia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symptoms or signs of renal osteodystrophy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Structurally abnormal kidneys, e.g., cysts</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>Systolic/diastolic hypertension</td>
<td>Moderate proteinuria \nAzotemia \nHematuria \nPyuria \nFrequency, urgency</td>
</tr>
<tr>
<td>Nephrolithiasis</td>
<td>Previous history of stone passage or removal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Previous history of stone seen by x-ray</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renal colic</td>
<td></td>
</tr>
<tr>
<td>Urinary tract obstruction</td>
<td>Azotemia, oliguria, anuria</td>
<td>Hematuria</td>
</tr>
<tr>
<td></td>
<td>Polyuria, nocturia, urinary retention</td>
<td>Pyuria</td>
</tr>
<tr>
<td></td>
<td>Slowing of urinary stream</td>
<td>Enuresis, dysuria</td>
</tr>
<tr>
<td></td>
<td>Large prostate, large kidneys</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Flank tenderness, full bladder after voiding</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** GFR, glomerular filtration rate; RBC, red blood cell.  
**Source:** Modified from FL Coe, BM Brenner: HPIM-14.
CHRONIC RENAL FAILURE  (See Chap. 147)

Progressive permanent loss of renal function over months to years does not cause symptoms of uremia until GFR is reduced to about 10–15% of normal. Hypertension may occur early. Later, manifestations include anorexia, nausea, vomiting, dysgeusia, insomnia, weight loss, weakness, paresthesia, bleeding, serositis, anemia, acidosis, hypocalcemia, hyperphosphatemia, and hyperkalemia. Common causes include diabetes mellitus, severe hypertension, glomerular disease, urinary tract obstruction, vascular disease, polycystic kidney disease, and interstitial nephritis. Indications of chronicity include longstanding azotemia, anemia, hyperphosphatemia, hypocalcemia, shrunken kidneys, renal osteodystrophy by x-ray, or findings on renal biopsy (extensive glomerular sclerosis, arteriosclerosis, and/or tubulointerstitial fibrosis).

NEPHROTIC SYNDROME  (See Chap. 150)

Defined as heavy albuminuria (>3.5 g/d in the adult) with or without edema, hypoaalbuminemia, hyperlipidemia, and varying degrees of renal insufficiency. Can be idiopathic or due to drugs, infections, neoplasms, or multisystem or hereditary diseases. Complications include severe edema, thromboembolic events, infection, and protein malnutrition.

ASYMPTOMATIC URINARY ABNORMALITIES

Hematuria may be due to neoplasms, stones, infection at any level of the urinary tract, sickle cell disease, or analgesic abuse. Renal parenchymal causes are suggested by RBC casts, proteinuria, and/or dysmorphic RBCs in urine. Pattern of gross hematuria may be helpful in localizing site. Hematuria with minimal or low-grade proteinuria is most commonly due to thin basement membrane nephropathy or IgA nephropathy. Modest proteinuria may be an isolated finding due to fever, exertion, congestive heart failure (CHF), or upright posture; renal causes include early stages of diabetes nephropathy, amyloidosis, or other causes of glomerular disease. Pyuria can be caused by urinary tract infection (UTI), interstitial nephritis, GN, or renal transplant rejection. “Sterile” pyuria is associated with UTI treated with antibiotics, glucocorticoid therapy, acute febrile episodes, cyclophosphamide therapy, pregnancy, renal transplant rejection, genitourinary trauma, prostatitis, cystourethritis, tuberculosis and other mycobacterial infections, fungal infection, *Haemophilus influenzae*, anaerobic infection, fastidious bacteria, and bacterial L forms.

URINARY TRACT INFECTION  (See Chap. 152)

Generally defined as >10^5 bacteria per mL of urine. Levels between 10^2 and 10^5/mL may indicate infection but are usually due to poor sample collection, especially if mixed flora are present. Adults at risk are sexually active women or anyone with urinary tract obstruction, vesicoureteral reflux, bladder catheterization, neurogenic bladder (associated with diabetes mellitus), or primary neurologic diseases. Prostatitis, urethritis, and vaginitis may be distinguished by quantitative urine culture. Flank pain, nausea, vomiting, fever, and chills indicate kidney infection, i.e., pyelonephritis. UTI is a common cause of sepsis, especially in the elderly and institutionalized.

RENAL TUBULAR DEFECTS  (See Chap. 151)

Generally inherited, these include anatomic defects (polycystic kidneys, medullary cystic disease, medullary sponge kidney) detected in the evaluation of hematuria, flank pain, infection, or renal failure of unknown cause. Isolated or
generalized defects of renal tubular salt, solute, acid, and water transport can also occur. The Fanconi syndrome is characterized by multiple defects in proximal tubular solute transport; cardinal features include generalized aminoaciduria, glycosuria with a normal serum glucose, and phosphaturia. The Fanconi syndrome can also encompass a proximal renal tubular acidosis, hypouricemia, hypokalemia, polyuria, hypovitaminosis D and hypocalemia, and low-molecular-weight proteinuria. This syndrome can be hereditary (e.g., in Dent’s disease and cystinosis) or acquired, the latter due to drugs (ifosfamide, tenofovir, valproic acid), toxins (aristolochic acid), heavy metals, multiple myeloma, or amyloidosis. Hereditary hypokalemic alkalosis is typically caused by defects in ion transport by the thick ascending limb (Bartter’s syndrome) and the distal convoluted tubule (Gitelman’s syndrome); similar acquired defects can occur after exposure to aminoglycosides or cisplatin. Nephrogenic diabetes insipidus and renal tubular acidosis are caused by defects in distal tubular water and acid transport, respectively; these also have both hereditary and acquired forms.

**HYPERTENSION** (See Chap. 124)

Blood pressure >140/90 mmHg affects 20% of the U.S. adult population; when inadequately controlled, it is an important cause of cerebrovascular accident, myocardial infarction, and CHF and can contribute to the development of renal failure. Hypertension is usually asymptomatic until cardiac, renal, or neurologic symptoms appear; retinopathy or left ventricular hypertrophy (S4 heart sound, electrocardiographic or echocardiographic evidence) may be the only clinical sequelae. In most cases hypertension is idiopathic and becomes evident between ages 25 and 45. Secondary hypertension is generally suggested by the following clinical scenarios: (1) severe or refractory hypertension, (2) a sudden increase in blood pressure over prior values, (3) onset prior to puberty, or (4) age <30 in a nonobese, non-African-American patient with a negative family history. Clinical clues may suggest specific causes. Hypokalemia suggests renovascular hypertension or primary hyperaldosteronism; paroxysmal hypertension with headache, diaphoresis, and palpitations can occur in pheochromocytoma.

**NEPHROLITHIASIS** (See Chap. 154)

Causes colicky pain, UTI, hematuria, dysuria, or unexplained pyuria. Stones may be found on routine x-ray of kidneys, ureter, and bladder (KUB); however, noncontrast helical CT, with 5-mm CT cuts, will pick up stones not detected by KUB x-ray and will furthermore assess for the presence of obstruction. Most are radiopaque Ca stones and are associated with high levels of urinary Ca, and/or oxalate excretion, and/or low levels of urinary citrate excretion. Staghorn calculi are large, branching, radiopaque stones within the renal pelvis due to recurrent infection. Uric acid stones are radiolucent. Urinalysis may reveal hematuria, pyuria, or pathologic crystals.

**URINARY TRACT OBSTRUCTION** (See Chap. 155)

Causes variable symptoms depending on the underlying etiology and whether obstruction is acute or chronic, unilateral or bilateral, complete or partial. It is an important, reversible cause of unexplained renal failure. Upper tract obstruction may be silent or produce flank pain, hematuria, and renal infection. Bladder symptoms or prostatism may be present in lower tract obstruction. Functional consequences include polyuria, anuria, nocturia, acidosis, hyperkalemia, and hypertension. A flank or suprapubic mass may be found on physical exam; an obstructed, enlarged bladder is typically dull to percussion.
Acute Renal Failure

**DEFINITION**

Acute renal failure (ARF) or acute kidney injury (AKI), defined as a measurable increase in the serum creatinine (Cr) concentration [usually relative increase of 50% or absolute increase by 44–88 μmol/L (0.5–1.0 mg/dL)], occurs in ~5–7% of hospitalized pts. It is associated with a substantial increase in in-hospital mortality and morbidity. ARF can be anticipated in some clinical circumstances (e.g., after radiocontrast exposure or major surgery), and there are no specific pharmacologic therapies proven helpful at preventing or reversing the condition. Maintaining optimal renal perfusion and intravascular volume appears to be important in most clinical circumstances; important cofactors in ARF include hypovolemia and drugs that interfere with renal perfusion and/or glomerular filtration [nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers].

**DIFFERENTIAL DIAGNOSIS**

The separation into three broad categories (prerenal, intrinsic renal, and postrenal failure) is of considerable clinical utility (Table 146-1). **Prerenal failure** is most common among hospitalized pts. It may result from true volume depletion (e.g., diarrhea, vomiting, GI or other hemorrhage) or “effective circulatory volume” depletion, i.e., reduced renal perfusion in the setting of adequate or excess blood volume. Reduced renal perfusion may be seen in congestive heart failure (CHF) (due to reduced cardiac output and/or potent vasodilator therapy), hepatic cirrhosis (due most likely to peripheral vasodilation and arteriovenous shunting), nephrotic syndrome and other states of severe hypoproteinemia [total serum protein <54 g/L (<5.4 g/dL)], and renovascular disease (because of fixed stenosis at the level of the main renal artery or large branch vessels). Several drugs can reduce renal perfusion, most notably NSAIDs. ACE inhibitors and angiotensin II receptor antagonists may reduce glomerular filtration rate but do not tend to reduce renal perfusion.

**Causes of intrinsic renal failure** depend on the clinical setting. Among hospitalized patients, especially on surgical services or in intensive care units, acute tubular necrosis (ATN) is the most common diagnosis. A well-defined ischemic event or toxic exposure (e.g., aminoglycoside therapy) may lead to in-hospital ATN. Alternatively, patients may be admitted to the hospital with ATN associated with rhabdomyolysis; common predisposing factors include alcoholism, hypokalemia, and various drugs (e.g., statins). Allergic interstitial nephritis, usually due to antibiotics (e.g., penicillins, cephalosporins, sulfa drugs, quinolones, and rifampin), or NSAIDs, may also be responsible. Radiographic contrast dyes may cause ARF in patients with pre-existing kidney disease; the risk is substantially
<table>
<thead>
<tr>
<th>Prerenal</th>
<th>Intrinsic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume depletion</td>
<td>Acute tubular necrosis (ATN)</td>
</tr>
<tr>
<td>Blood loss</td>
<td>Hypotension or shock, prolonged prerenal azotemia, postoperative sepsis syndrome, rhabdomyolysis, hemolysis, drugs</td>
</tr>
<tr>
<td>GI fluid loss (e.g., vomiting, diarrhea)</td>
<td>Radiocontrast, aminoglycosides, cisplatin</td>
</tr>
<tr>
<td>Overzealous diuretic use</td>
<td>Other tubulointerstitial disease</td>
</tr>
<tr>
<td>Volume overload with reduced renal perfusion</td>
<td>Allergic interstitial nephritis</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>Pyelonephritis (bilateral, or unilateral in single functional kidney)</td>
</tr>
<tr>
<td>Low-output with systolic dysfunction</td>
<td>Heavy metal poisoning</td>
</tr>
<tr>
<td>“High-output” (e.g., anemia, thyrotoxicosis)</td>
<td>Atheroembolic disease—after vascular procedures, thrombolysis, or anticoagulation</td>
</tr>
<tr>
<td>Hepatic cirrhosis</td>
<td>Glomerulonephritis</td>
</tr>
<tr>
<td>Severe hypoproteinemia</td>
<td>(1) ANCA-associated: Wegener’s granulomatosis, idiopathic pauci-immune GN, PAN</td>
</tr>
<tr>
<td>Renovascular disease</td>
<td>(2) Anti-GBM disease; isolated or with pulmonary involvement (Goodpasture’s syndrome)</td>
</tr>
<tr>
<td>Drugs</td>
<td>(3) Immune complex–mediated</td>
</tr>
<tr>
<td>NSAIDs, cyclosporine, amphotericin B, ACE inhibitors, ARBs</td>
<td>Subacute bacterial endocarditis, SLE, cryoglobulinemia (with or without hepatitis C infection), postinfectious GN (classically poststreptococcal)</td>
</tr>
<tr>
<td>Other</td>
<td>IgA nephropathy and Henoch-Schönlein purpura</td>
</tr>
<tr>
<td>Hypercalcemia, “third spacing” (e.g., pancreatitis, systemic inflammatory response), hepatorenal syndrome</td>
<td>Glomerular endotheliopathies</td>
</tr>
<tr>
<td></td>
<td>Thrombotic microangiopathy, malignant hypertension, scleroderma, antiphospholipid syndrome, preeclampsia</td>
</tr>
<tr>
<td></td>
<td>Postrenal (Urinary Tract Obstruction)</td>
</tr>
<tr>
<td></td>
<td>Bladder neck obstruction, bladder calculi</td>
</tr>
<tr>
<td></td>
<td>Prostatic hypertrophy</td>
</tr>
<tr>
<td></td>
<td>Ureteral obstruction due to compression</td>
</tr>
<tr>
<td></td>
<td>Pelvic or abdominal malignancy, retroperitoneal fibrosis</td>
</tr>
<tr>
<td></td>
<td>Nephrolithiasis</td>
</tr>
<tr>
<td></td>
<td>Papillary necrosis with obstruction</td>
</tr>
</tbody>
</table>

Note: NSAIDs, nonsteroidal anti-inflammatory drugs; ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockers; ANCA, antineutrophil cytoplasmic antibody; GN, glomerulonephritis; PAN, polyarteritis nodosa; GBM, glomerular basement membrane; SLE, systemic lupus erythematosus.
Acute Renal Failure

CHAPTER 146

higher in diabetics with chronic kidney disease. Coronary angiography, other vascular procedures, thrombolysis, or anticoagulation may lead to atheroemboli, which cause ARF due to both hemodynamic and inflammatory effects; livedo reticularis, embolic phenomena with preserved peripheral pulses, and eosinophilia are important clues to this diagnosis. Acute glomerulonephritis (Chap. 150) and thrombotic microangiopathies (Chap. 153) may also cause ARF. Thrombotic microangiopathies can be clinically subdivided into renal-limited forms [e.g., \textit{E. coli}–associated hemolytic uremic syndrome (HUS)] and systemic forms [e.g., thrombotic thrombocytopenic purpura (TTP)]. A variety of drugs can cause thrombotic microangiopathies, including calcineurin inhibitors (cyclosporine and tacrolimus), quinine, antiplatelet agents (e.g., ticlopidine), and chemotherapeutics (e.g., mitomycin C and gemcitabine). Important associated disorders include HIV infection, bone marrow transplantation, systemic lupus erythematosus (SLE), and antiphospholipid syndrome.

Postrenal failure is due to urinary tract obstruction, which is also more common among ambulatory rather than hospitalized pts. More common in men than women, it is most often caused by ureteral or urethral blockade. Occasionally, stones, sloughed renal papillae, or malignancy (primary or metastatic) may cause more proximal obstruction.

**CHARACTERISTIC FINDINGS AND DIAGNOSTIC WORKUP**

All pts with ARF manifest some degree of azotemia [increased blood urea nitrogen (BUN) and Cr]. Other clinical features depend on the etiology of renal disease. Pts with \textit{prerenal azotemia} due to volume depletion usually demonstrate orthostatic hypotension, tachycardia, low jugular venous pressure, and dry mucous membranes. Pts with prerenal azotemia and CHF may show jugular venous distention, an S₃ gallop, and peripheral and pulmonary edema. Therefore, the physical exam is critical in the workup of pts with prerenal ARF. In general, the BUN/Cr ratio tends to be high (>20:1), more so with volume depletion and CHF than with cirrhosis. The uric acid may also be disproportionately elevated in noncirrhotic prerenal states (due to increased proximal tubular absorption). Urine chemistries tend to show low urine [Na⁺] (<10–20 mmol/L, <10 with hepatorenal syndrome) and a fractional excretion of sodium (FENa) of <1% (\textit{Table 146-2}). The urinalysis (UA) typically shows hyaline and a few granular casts, without cells or cellular casts. Renal ultrasonography is usually normal.

Pts with \textit{intrinsic renal disease} present with varying complaints. Glomerulonephritis (GN) is often accompanied by hypertension and mild to moderate edema (associated with Na retention and proteinuria, and sometimes with hematuria). An antecedent prodromal illness and/or prominent extrarenal symptoms and signs may occur if GN occurs in the context of a systemic illness, e.g., vasculitis or SLE; these may include hemoptysis or pulmonary hemorrhage (vasculitis and Goodpasture’s syndrome), arthralgias/arthritis (vasculitis or SLE), serositis (SLE), and unexplained sinusitis (vasculitis). The urine chemistries may be indistinguishable from those in pts with prerenal failure; in fact, some pts with GN have renal hypoperfusion (due to glomerular inflammation and ischemia) with resultant hyperreninemia leading to acute volume expansion and hypertension. The urine sediment can be very helpful in these cases. Red blood cell (RBC), white blood cell (WBC), and cellular casts are characteristic of GN; RBC casts are rarely seen in other conditions (i.e., they are highly specific). In the setting of inflammatory nephritis (GN or interstitial nephritis, see below), there may be increased renal echogenicity on ultrasonography. Unlike pts with GN, pts with interstitial diseases are less likely to have hypertension or proteinuria; a notable exception is NSAID-associated acute interstitial nephri-
tis, which can be accompanied by proteinuria due to an associated minimal-change glomerular lesion. Hematuria and pyuria may present on UA; the classic sediment finding in allergic interstitial nephritis is a predominance (>10%) of urinary eosinophils with Wright’s or Hansel’s stain. WBC casts may also be seen, particularly in cases of pyelonephritis.

The UA of patients with ischemic or toxic ATN will characteristically contain pigmented “muddy-brown” granular casts and casts containing tubular epithelial cells. The FE\textsubscript{Na} is typically >1% in ATN but may be <1% in patients with milder, nonoliguric ATN (e.g., from rhabdomyolysis) and in patients with underlying “prerenal” disorders such as CHF or cirrhosis.

Pts with postrenal ARF due to urinary tract obstruction are usually less severely ill than pts with prerenal or intrinsic renal disease, and their presentation may be delayed until azotemia is markedly advanced [BUN >54 μmol/L (150 mg/dL), Cr >1060–1325 μmol/L (12–15 mg/dL)]. An associated impairment of urinary concentrating ability often “protects” the pt from complications of volume overload. Urinary electrolytes typically show a FE\textsubscript{Na} >1%, and microscopic examination of the urinary sediment is usually bland. Ultrasonography is the key diagnostic tool. More than 90% of pts with postrenal ARF show obstruction of the urinary collection system on ultrasound (e.g., dilated ureter, calyces); false negatives include hyperacute obstruction and encasement of the ureter and/or kidney by tumor, functionally obstructing urinary outflow without structural dilation.

### Table 146-2

<table>
<thead>
<tr>
<th>Diagnostic Index</th>
<th>Typical Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fractional excretion of sodium (%)\textsuperscript{a}</td>
<td>Prerenal Azotemia</td>
</tr>
<tr>
<td>(U_{Na}/P_{Cr} \times P_{Na} \times U_{Cr} \times 100)</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Urine sodium concentration (mmol/L)</td>
<td>&lt;10</td>
</tr>
<tr>
<td>Urine creatinine to plasma creatinine ratio</td>
<td>&gt;40</td>
</tr>
<tr>
<td>Urine urea nitrogen to plasma urea nitrogen ratio</td>
<td>&gt;8</td>
</tr>
<tr>
<td>Urine specific gravity</td>
<td>&gt;1.018</td>
</tr>
<tr>
<td>Urine osmolality (mosmol/kg H\textsubscript{2}O)</td>
<td>&gt;500</td>
</tr>
<tr>
<td>Plasma BUN/creatinine ratio</td>
<td>&gt;20</td>
</tr>
<tr>
<td>Renal failure index</td>
<td>&lt;1</td>
</tr>
<tr>
<td>(U_{Na}/U_{Cr} \times P_{Cr})</td>
<td>Hyaline casts</td>
</tr>
<tr>
<td>Urinary sediment</td>
<td></td>
</tr>
</tbody>
</table>

\(\textsuperscript{a}\text{Most sensitive indices.}\)

\textit{Note:} \(U_{Na}\), urine sodium concentration; \(P_{Cr}\), plasma creatinine concentration; \(P_{Na}\), Plasma sodium concentration; \(U_{Cr}\), urine creatinine concentration; BUN, blood urea nitrogen.

### Acute Renal Failure

Treatment should focus on providing etiology-specific supportive care. For example, pts with prerenal failure due to GI fluid loss may experience relatively rapid correction of ARF after the administration of IV fluid to expand volume. The same treatment in prerenal pts with CHF would be counterpro-
ductive; in this case, treatment of the underlying disease with vasodilators and/or inotropic agents would more likely be of benefit.

There are relatively few intrinsic renal causes of ARF for which there is safe and effective therapy. GN associated with vasculitis or SLE may respond to high-dose glucocorticoids and cytotoxic agents (e.g., cyclophosphamide); plasmapheresis and plasma exchange may be useful in other selected circumstances (e.g., Goodpasture’s syndrome and HUS/TTP, respectively). Antibiotic therapy may be sufficient for the treatment of ARF associated with pyelonephritis or endocarditis. There are conflicting data regarding the utility of glucocorticoids in allergic interstitial nephritis. Many practitioners advocate their use with clinical evidence of progressive renal insufficiency despite discontinuation of the offending drug, or with biopsy evidence of potentially reversible, severe disease.

The treatment of urinary tract obstruction often involves consultation with a urologist. Interventions as simple as Foley catheter placement or as complicated as multiple ureteral stents and/or nephrostomy tubes may be required.

**DIALYSIS FOR ARF AND RECOVERY OF RENAL FUNCTION**

Most cases of community- and hospital-acquired ARF resolve with conservative supportive measures, time, and patience. If nonprerenal ARF continues to progress, dialysis must be considered. The traditional indications for dialysis—volume overload refractory to diuretic agents; hyperkalemia; encephalopathy not otherwise explained; pericarditis, pleuritis, or other inflammatory serositis; and severe metabolic acidosis, compromising respiratory or circulatory function—can seriously compromise recovery from acute nonrenal illness. Therefore, dialysis should generally be provided in advance of these complications. The inability to provide requisite fluids for antibiotics, inotropes and other drugs, and/or nutrition should also be considered an indication for dialysis.

Dialytic options for ARF include (1) intermittent hemodialysis (IHD), (2) peritoneal dialysis (PD), and (3) continuous renal replacement therapy (CRRT, i.e., continuous arteriovenous or venovenous hemodiafiltration). Most pts are treated with IHD. It is unknown whether conventional thrice-weekly hemodialysis is sufficient or more frequent treatments are required. Few centers rely on PD for management of ARF (risks include infection associated with intraperitoneal catheter insertion and respiratory compromise due to abdominal distention). At some centers, CRRT is prescribed only in pts intolerant of IHD, usually because of hypotension; other centers use it as the modality of choice for pts in intensive care units. Hybrid hemodialysis techniques, such as slow low-efficiency dialysis (SLED), may be used in centers less familiar with CRRT.

For a more detailed discussion, see Liu KD, Chertow GM: Acute Renal Failure, Chap. 273, p. 1752, in HPIM-17.
Chronic Kidney Disease and Uremia

**Epidemiology**

The prevalence of chronic kidney disease (CKD), generally defined as a long-standing, irreversible impairment of kidney function, is substantially greater than the number of pts with end-stage renal disease (ESRD), now ≥300,000 in the United States. There is a spectrum of disease related to decrements in renal function; clinical and therapeutic issues differ greatly depending on whether the glomerular filtration rate (GFR) reduction is moderate (stage 3 CKD, 30–59 mL/min per 1.73 m²) (Table 58-1), severe (stage 4 CKD, 15–29 mL/min per 1.73 m²), or “end-stage renal disease” (stage 5 CKD, <15 mL/min per 1.73 m²). Dialysis is usually required to control symptoms of uremia with GFR < 10 mL/min per 1.73 m². Common causes of CKD are outlined in Table 147-1.

**Differential Diagnosis**

The first step in the differential diagnosis of CKD is establishing its chronicity, i.e., disproving a major acute component. The two most common means of determining disease chronicity are the history and prior laboratory data (if available) and the renal ultrasound, which is used to measure kidney size. In general, kidneys that have shrunk (<10–11.5 cm, depending on body size) are more likely affected by chronic disease. While reasonably specific (few false positives), reduced kidney size is only a moderately sensitive marker for CKD, i.e., there are several relatively common conditions in which kidney disease may be chronic without any reduction in renal size. Diabetic nephropathy, HIV-associated nephropathy, and infiltrative diseases such as multiple myeloma may in fact be associated with relatively large kidneys despite chronicity. Renal biopsy, although rarely performed in patients with CKD, is a more reliable means of proving chronicity; a predominance of glomerulosclerosis or interstitial fibrosis argues strongly for chronic disease. Hyperphosphatemia and other metabolic derangements are not reliable indicators in distinguishing acute from chronic disease.

Once chronicity has been established, clues from the physical exam, laboratory panel, and urine sediment evaluation can be used to determine etiology. A detailed Hx will identify important comorbid conditions, such as diabetes, HIV.

### Table 147-1: Common Causes of Chronic Renal Failure

<table>
<thead>
<tr>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic nephropathy</td>
</tr>
<tr>
<td>Hypertensive nephrosclerosis&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Glomerulonephritis</td>
</tr>
<tr>
<td>Renovascular disease (ischemic nephropathy)</td>
</tr>
<tr>
<td>Polycystic kidney disease</td>
</tr>
<tr>
<td>Reflux nephropathy and other congenital renal diseases</td>
</tr>
<tr>
<td>Interstitial nephritis, including analgesic nephropathy</td>
</tr>
<tr>
<td>HIV-associated nephropathy</td>
</tr>
<tr>
<td>Transplant allograft failure (“chronic rejection”)</td>
</tr>
</tbody>
</table>

<sup>a</sup>Often diagnosis of exclusion; very few pts undergo renal biopsy; may be occult renal disease with hypertension.
seropositivity, or peripheral vascular disease. The family Hx is paramount in the
workup of autosomal dominant polycystic kidney disease or hereditary nephritis
(Alport’s syndrome). An occupational Hx may reveal exposure to environmental
toxins or culprit drugs (including over-the-counter agents, such as analgesics or
Chinese herbs).

Physical exam may demonstrate abdominal masses (i.e., polycystic kid-
nneys), diminished pulses or femoral/carotid bruits (i.e., atherosclerotic periph-
eral vascular disease), or an abdominal bruit (i.e., renovascular disease). The
Hx and exam may also yield important data regarding severity of disease. The
presence of foreshortened fingers (due to resorption of the distal phalangeal
tufts) and/or subcutaneous nodules may be seen with advanced CKD and sec-
ondary hyperparathyroidism. Excoriations (uremic pruritus), pallor (anemia),
muscle wasting, and a nitrogenous fetor are all signs of advanced CKD, as are
pericarditis, pleuritis, and asterixis, complications of particular concern that
usually prompt the initiation of dialysis.

**Laboratory Findings**  Serum and urine laboratory findings typically provide ad-
ditional information useful in determining the etiology and severity of CKD.
Heavy proteinuria (>3.5 g/d), hypoalbuminemia, hypercholesterolemia, and ede-
ma suggest nephrotic syndrome (Chap. 150). Diabetic nephropathy, membra-
nous nephropathy, focal segmental glomerulosclerosis, minimal change disease,
amyloid, and HIV-associated nephropathy are principal causes. Proteinuria may
decrease slightly with decreasing GFR but rarely to normal levels. Hyperkalemia
and metabolic acidosis may complicate all forms of CKD eventually but can be
more prominent in pts with interstitial renal diseases.

**THE UREMIC SYNDROME**
The culprit toxin(s) responsible for the uremic syndrome remain elusive. The se-
rum creatinine (Cr) is the most common laboratory surrogate of renal function.
GFR can be estimated using serum Cr–based equations derived from the Modifi-
cation of Diet in Renal Disease Study. This “eGFR” is now reported with serum
Cr by most clinical laboratories in the United States and is the basis for the Na-
tional Kidney Foundation classification of chronic kidney disease (Table 58-1).

Uremic symptoms tend to develop with serum Cr > 530–710 μmol/L (> 6–8
mg/dL) or CrCl < 10 mL/min, although these values vary widely. Uremia is thus a
diagnostic illness made in patients with CKD. Symptoms of advanced uremia in-
clude anorexia, weight loss, dyspnea, fatigue, pruritus, sleep and taste disturbanc,
and confusion and other forms of encephalopathy. Key findings on physical exam
include hypertension, jugular venous distention, pericardial and/or pleural friction
rub, muscle wasting, asterixis, excoriations, and ecchymoses. Laboratory abnor-
malities may include hyperkalemia, hyperphosphatemia, metabolic acidosis,
hypocalcemia, hyperuricemia, anemia, and hypoalbuminemia. Most of these ab-
normalities eventually resolve with initiation of dialysis or renal transplantation
(Chaps. 148 and 149) or with appropriate drug therapies (see below).

Hypertension complicates many forms of CKD and warrants aggressive treat-
ment to reduce the risk of stroke and potentially to slow the progression of
CKD (see below). Volume overload contributes to hypertension in many cas-
es, and potent diuretic agents are frequently required. Anemia can be reversed
with recombinant human erythropoietin (rHuEPO); 2000–6000 units SC once
or twice weekly can increase Hb concentrations toward the normal range in
most pts. Iron deficiency and/or other causes of anemia can reduce the response to rHuEPO and should be investigated if present. Iron supplementation is often required; many patients require parenteral iron therapy.

Hyperphosphatemia can be controlled with judicious restriction of dietary phosphorus and the use of postprandial phosphate binders, either calcium-based salts (calcium carbonate or acetate) or nonabsorbed agents (e.g., sevelamer). Hyperkalemia should be controlled with dietary potassium restriction. Sodium polystyrene sulfonate (Kayexalate) can be used in refractory cases, although dialysis should be considered if the potassium is >6 mmol/L on repeated occasions. If these conditions cannot be conservatively controlled, dialysis should be instituted (Chap. 148). It is also advisable to begin dialysis if severe anorexia, weight loss, and/or hypoalbuminemia develop, as it has been definitively shown that outcomes for dialysis pts with malnutrition are particularly poor.

SLOWING PROGRESSION OF RENAL DISEASE
Prospective clinical trials have explored the roles of blood pressure control and dietary protein restriction on the rate of progression of renal failure. Control of hypertension is of benefit, although angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) may exert unique beneficial effects, most likely due to their effects on intrarenal hemodynamics. The effects of ACE inhibitors and ARBs are most pronounced in pts with diabetic nephropathy and in those without diabetes but with significant proteinuria (>1 g/d). Diuretics and other antihypertensive agents are often required, in addition to ACE inhibitors and ARBs, to optimize hypertension control and attenuate disease progression; diuretics may also help control serum [K⁺]. Dietary protein restriction may offer an additional benefit, particularly in these same subgroups.

For a more detailed discussion, see Bargman JM, Skorecki K: Chronic Kidney Disease, Chap. 274, p. 1761, in HPIM-17.

Dialysis

OVERVIEW
Initiation of dialysis usually depends on a combination of the pt’s symptoms, comorbid conditions, and laboratory parameters. Unless a living donor is identified, transplantation is deferred by necessity, due to the scarcity of cadaveric donor organs (median waiting time, 3–6 years at most transplant centers). Dialytic options include hemodialysis and peritoneal dialysis (PD). Roughly 85% of U.S. pts are started on hemodialysis.

Absolute indications for dialysis include severe volume overload refractory to diuretic agents, severe hyperkalemia and/or acidosis, encephalopathy not otherwise explained, and pericarditis or other serositis. Additional indications for dialysis include symptomatic uremia (Chap. 147) (e.g., intractable fatigue, anorexia, dysgeusia, nausea, vomiting, pruritus, difficulty maintaining attention
and concentration) and protein-energy malnutrition/failure to thrive without other overt cause. No absolute serum creatinine, blood urea nitrogen, creatinine or urea clearance, or glomerular filtration rate (GFR) is used as an absolute cut-off for requiring dialysis, although most individuals experience, or will soon develop, symptoms and complications when the GFR is below ~10 mL/min.

**HEMODIALYSIS**

This requires direct access to the circulation, either via a native arteriovenous fistula (the preferred method of vascular access), usually at the wrist (a “Brescia-Cimino” fistula); an arteriovenous graft, usually made of polytetrafluoroethylene; a large-bore intravenous catheter; or a subcutaneous device attached to intravascular catheters. Blood is pumped though hollow fibers of an artificial kidney (the “dialyzer”) and bathed with a solution of favorable chemical composition (isotonic, free of urea and other nitrogenous compounds, and generally low in potassium). Dialysate $[K^+]$ is varied from 0 to 4 mM, depending on predialysis $[K^+]$ and the clinical setting. Dialysate $[Ca^{2+}]$ is typically 2.5 mg/dL (1.25 mM), $[HCO_3^-]$ typically 35 meq/L, and dialysate $[Na^+]$ 140 mM; these can also be modified, depending on the clinical situation. Most pts undergo dialysis thrice weekly, usually for 3–4 h. The efficiency of dialysis is largely dependent on the duration of dialysis, blood flow rate, dialysate flow rate, and surface area of the dialyzer.

Complications of hemodialysis are outlined in Table 148-1. Many of these relate to the process of hemodialysis as an intense, intermittent therapy. In contrast to the native kidney or to PD, both major dialytic functions (i.e., clearance of solutes and fluid removal, or “ultrafiltration”) are accomplished over relatively short time periods. The rapid flux of fluid can cause hypotension, even without a pt reaching “dry weight.” Hemodialysis-related hypotension is common in diabetic pts whose neuropathy prevents the compensatory responses (vasoconstriction and tachycardia) to intravascular volume depletion. Occasionally, confusion or other central nervous system symptoms will occur. The dialysis “disequilibrium syndrome” refers to the development of headache, confusion, and rarely seizures, in association with rapid solute removal early in the pt's dialysis history, before adaptation to the procedure; this complication is largely avoided by an incremental induction of chronic dialytic therapy in uremic patients, starting with treatments of short duration, lower blood flows, and lower dialysate flow rates.

**PERITONEAL DIALYSIS**

PD does not require direct access to the circulation; rather, it obligates placement of a peritoneal catheter that allows infusion of a dialysate solution into the abdominal cavity; this allows transfer of solutes (i.e., urea, potassium, other uremic molecules) across the peritoneal membrane, which serves as the “artifi-

<table>
<thead>
<tr>
<th>Complications of Hemodialysis</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypotension</td>
<td>Dialysis-related amyloidosis</td>
</tr>
<tr>
<td>Accelerated vascular disease</td>
<td>Protein-energy malnutrition</td>
</tr>
<tr>
<td>Rapid loss of residual renal function</td>
<td>Hemorrhage</td>
</tr>
<tr>
<td>Access thrombosis</td>
<td>Dyspnea/hypoxemia$^a$</td>
</tr>
<tr>
<td>Access or catheter sepsis</td>
<td>Leukopenia$^a$</td>
</tr>
</tbody>
</table>

$^a$Particularly with first use of conventional modified cellulosic dialyzer.
cial kidney.” This solution is similar to that used for hemodialysis, except that it must be sterile, and it uses lactate, rather than bicarbonate, to provide base equivalents. PD is far less efficient at cleansing the bloodstream than hemodialysis and therefore requires a much longer duration of therapy. Pts generally have the choice of performing their own “exchanges” (2–3 L of dialysate, 4–5 times during daytime hours) or using an automated device at night. Compared with hemodialysis, PD offers the major advantages of (1) independence and flexibility, and (2) a more gentle hemodynamic profile.

Complications are outlined in Table 148-2. Peritonitis is the most important complication. The clinical presentation typically consists of abdominal pain and cloudy dialysate; peritoneal fluid leukocyte count is typically >100/μL, 50% neutrophils. In addition to the negative effects of the systemic inflammatory response, protein loss is magnified severalfold during the peritonitis episode. If severe or prolonged, an episode of peritonitis may prompt removal of the peritoneal catheter or even discontinuation of the modality (i.e., switch to hemodialysis). Gram-positive organisms (especially Staphylococcus aureus and other Staphylococcus spp.) predominate; Pseudomonas or fungal (usually Candida) infections tend to be more resistant to medical therapy and typically obligate catheter removal. Antibiotic administration may be intravenous or intraperitoneal when intensive therapy is required.

For a more detailed discussion, see Liu KD, Chertow GM: Dialysis in the Treatment of Renal Failure: Chap. 275, p. 1772, in HPIM-17.

### Table 148-2: Complications of Peritoneal Dialysis

<table>
<thead>
<tr>
<th>Condition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peritonitis</td>
<td>Dialysis-related amyloidosis</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td>Insufficient clearance due to vascular disease or other factors</td>
</tr>
<tr>
<td>Hypertriglyceridemia</td>
<td>Uremia secondary to loss of residual renal function</td>
</tr>
<tr>
<td>Obesity</td>
<td></td>
</tr>
<tr>
<td>Hypoproteinemia</td>
<td></td>
</tr>
</tbody>
</table>

Renal Transplantation

With the advent of more potent and well-tolerated immunosuppressive regimens and further improvements in short-term graft survival, renal transplantation remains the treatment of choice for most pts with end-stage renal disease. Results are best with living-related transplantation, in part because of optimized tissue matching and in part because waiting time can be minimized; ideally, these patients are transplanted prior to the onset of symptomatic uremia or indications for dialysis. Many centers now perform living-unrelated donor (e.g., spousal) transplants. Graft survival in these cases is far superior to that observed with cadaveric transplants, although less favorable than with living-related transplants. Factors that influence graft survival are outlined in Table 149-1. Contraindications to renal transplantation are outlined in Table 149-2.
Immunologic rejection is the major hazard to the short-term success of renal transplantation. Rejection may be (1) hyperacute (immediate graft dysfunction due to presensitization) or (2) acute (sudden change in renal function occurring within weeks to months). Rejection is usually detected by a rise in serum creatinine but may also lead to hypertension, fever, reduced urine output, and occasionally graft tenderness. A percutaneous renal transplant biopsy confirms the diagnosis. Treatment usually consists of a “pulse” of methylprednisolone (500–1000 mg/d for 3 days). In refractory or particularly severe cases, 7–10 days of a monoclonal antibody directed at human T lymphocytes may be given.

IMMUNOSUPPRESSION

Maintenance immunosuppressive therapy usually consists of a three-drug regimen, with each drug targeted at a different stage in the immune response. The calcineurin inhibitors cyclosporine and tacrolimus are the cornerstones

### Table 149-1

<table>
<thead>
<tr>
<th>SOME FACTORS THAT INFLUENCE GRAFT SURVIVAL IN RENAL TRANSPLANTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA mismatch</td>
</tr>
<tr>
<td>Presensitization (preformed antibodies)</td>
</tr>
<tr>
<td>Pretransplant blood transfusion</td>
</tr>
<tr>
<td>Very young or older donor age</td>
</tr>
<tr>
<td>Female donor sex</td>
</tr>
<tr>
<td>African-American donor race (compared with Caucasian)</td>
</tr>
<tr>
<td>Older recipient age</td>
</tr>
<tr>
<td>African-American recipient race (compared with Caucasian)</td>
</tr>
<tr>
<td>Prolonged cold ischemia time</td>
</tr>
<tr>
<td>Large recipient body size</td>
</tr>
</tbody>
</table>

### Table 149-2

<table>
<thead>
<tr>
<th>CONTRAINDICATIONS TO RENAL TRANSPLANTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Absolute Contraindications</strong></td>
</tr>
<tr>
<td>Active glomerulonephritis</td>
</tr>
<tr>
<td>Active bacterial or other infection</td>
</tr>
<tr>
<td>Active or very recent malignancy</td>
</tr>
<tr>
<td>HIV infection</td>
</tr>
<tr>
<td>Hepatitis B surface antigenemia</td>
</tr>
<tr>
<td>Severe degrees of comorbidity (e.g., advanced atherosclerotic vascular disease)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Relative Contraindications</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt; 70 years</td>
</tr>
<tr>
<td>Severe psychiatric disease</td>
</tr>
<tr>
<td>Moderately severe degrees of comorbidity</td>
</tr>
<tr>
<td>Hepatitis C infection with chronic hepatitis or cirrhosis</td>
</tr>
<tr>
<td>Noncompliance with dialysis or other medical therapy</td>
</tr>
<tr>
<td>Primary renal diseases</td>
</tr>
<tr>
<td>Primary focal sclerosis with prior recurrence in transplant</td>
</tr>
<tr>
<td>Multiple myeloma</td>
</tr>
<tr>
<td>Amyloid</td>
</tr>
<tr>
<td>Oxalosis</td>
</tr>
</tbody>
</table>
of immunosuppressive therapy. The most potent of orally available agents, calcineurin inhibitors have vastly improved short-term graft survival. Side effects of cyclosporine include hypertension, hyperkalemia, resting tremor, hirsutism, gingival hypertrophy, hyperlipidemia, hyperuricemia and gout, and a slowly progressive loss of renal function with characteristic histopathologic patterns (also seen in exposed recipients of heart and liver transplants). While the side effect profile of tacrolimus is generally similar to cyclosporine, there is a higher risk of hyperglycemia, a lower risk of hypertension, and occasional hair loss rather than hirsutism.

Prednisone is frequently used in conjunction with cyclosporine, at least for the first several months following successful graft function. Side effects of prednisone include hypertension, glucose intolerance, Cushingoid features, osteoporosis, hyperlipidemia, acne, and depression and other mood disturbances.

Mycophenolate mofetil has proved more effective than azathioprine in combination therapy with calcineurin inhibitors and prednisone. The major side effects of mycophenolate mofetil are gastrointestinal (diarrhea is most common); leukopenia (and thrombocytopenia to a lesser extent) develops in a fraction of patients.

Sirolimus is a newer immunosuppressive agent often used in combination with other drugs, particularly when calcineurin inhibitors are reduced or eliminated. Side effects include hyperlipidemia and oral ulcers.

OTHER COMPLICATIONS

Infection and neoplasia are important complications of renal transplantation. Infection is common in the heavily immunosuppressed host (e.g., cadaveric transplant recipient with multiple episodes of rejection requiring steroid pulses or monoclonal antibody treatment). The culprit organism depends in part on characteristics of the donor and recipient and timing following transplantation. In the first month, bacterial organisms predominate. After 1 month, there is a significant risk of systemic infection with cytomegalovirus (CMV), particularly in recipients without prior exposure whose donor was CMV positive. Prophylactic use of ganciclovir or valacyclovir can reduce the risk of CMV disease. Later on, there is a substantial risk of fungal and related infections, especially in pts who are unable to taper prednisone to <20–30 mg/d. Daily low-dose trimethoprim-sulfamethoxazole is effective at reducing the risk of *Pneumocystis carinii* infection.

The polyoma group of DNA viruses (BK, JC, SV40) can be activated by immunosuppression. Reactivation of BK is associated with a typical pattern of renal inflammation, BK nephropathy, which can lead to loss of the allograft; therapy typically involves reduction of immunosuppression to aid in clearance of the reactivated virus.

Epstein-Barr virus–associated lymphoproliferative disease is the most important neoplastic complication of renal transplantation, especially in pts who receive polyclonal (antilymphocyte globulin, used at some centers for induction of immunosuppression) or monoclonal antibody therapy. Non-Hodgkin’s lymphoma and squamous cell carcinoma of the skin are also more common in this population.
ACUTE GLOMERULONEPHRITIS (GN)

Often called the “nephritic syndrome.” Characterized by development, over days, of azotemia, hypertension, edema, hematuria, proteinuria, and sometimes oliguria. Salt and water retention are due to reduced glomerular filtration rate (GFR) and may result in circulatory congestion. Red blood cell (RBC) casts on urinalysis confirm Dx. Proteinuria is usually <3 g/d. Most forms of acute GN are mediated by humoral immune mechanisms. Clinical course depends on underlying lesion (Table 150-1).

Acute Poststreptococcal GN This is the prototype and most common cause in childhood. Nephritis develops 1–3 weeks after pharyngeal or cutaneous infection with “nephritogenic” strains of group A β-hemolytic streptococci. Dx depends on a positive pharyngeal or skin culture (if available), positive titers for antistreptococcal antigens (ASO, anti-DNAse, or antihyaluronidase), and hypocomplementemia. Renal biopsy reveals diffuse proliferative GN. Treatment consists of correction of fluid and electrolyte imbalance. In most cases the disease is self-limited, although the prognosis is less favorable and urinary abnormalities are more likely to persist in adults.

Postinfectious GN May follow other bacterial, viral, and parasitic infections. Examples are bacterial endocarditis, sepsis, hepatitis B, and pneumococcal pneumonia. Features are milder than with poststreptococcal GN. Control of primary infection usually produces resolution of GN.

TABLE 150-1 CAUSES OF ACUTE GLOMERULONEPHRITIS

<table>
<thead>
<tr>
<th>I. Infectious diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Poststreptococcal glomerulonephritis&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>B. Nonstreptococcal postinfectious glomerulonephritis</td>
</tr>
<tr>
<td>2. Viral: hepatitis B, infectious mononucleosis, mumps, measles, varicella, vaccinia, echovirus, and coxsackievirus</td>
</tr>
<tr>
<td>3. Parasitic: malaria, toxoplasmosis</td>
</tr>
<tr>
<td>II. Multisystem diseases: SLE, vasculitis, Henoch-Schönlein purpura, Goodpasture’s syndrome</td>
</tr>
<tr>
<td>III. Primary glomerular diseases: mesangiocapillary glomerulonephritis, Berger’s disease (IgA nephropathy), “pure” mesangial proliferative glomerulonephritis</td>
</tr>
<tr>
<td>IV. Miscellaneous: Guillain-Barré syndrome, irradiation of Wilms’ tumor, self-administered diphtheria-pertussis-tetanus vaccine, serum sickness</td>
</tr>
</tbody>
</table>

<sup>a</sup>Most common cause.

Note: SLE, systemic lupus erythematosus.

RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS (GN)

Defined as a subacute reduction in GFR of >50%, with evidence of a proliferative GN; causes overlap with those of acute GN (Table 150-2). Broadly classified into three major subtypes on the basis of renal biopsy findings and pathophysiology: (1) immune complex–associated, e.g., in systemic lupus erythematosus (SLE); (2) “pauci-immune,” associated with antineutrophil cytoplasmic antibodies (ANCA); and (3) associated with anti–glomerular basement (anti-GBM) antibodies, e.g., in Goodpasture’s syndrome. All three forms will typically have a proliferative, crescentic GN by light microscopy but differ in the results of the immunofluorescence and electron microscopy components of the renal biopsy.

TABLE 150-2 CAUSES OF RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS

<table>
<thead>
<tr>
<th>I. Infectious diseases</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Poststreptococcal glomerulonephritis a</td>
<td></td>
</tr>
<tr>
<td>B. Infective endocarditis</td>
<td></td>
</tr>
<tr>
<td>C. Occult visceral sepsis</td>
<td></td>
</tr>
<tr>
<td>D. Hepatitis B infection (with vasculitis and/or cryoglobulinemia)</td>
<td></td>
</tr>
<tr>
<td>E. HIV infection (?)</td>
<td></td>
</tr>
<tr>
<td>F. Hepatitis C infection (with cryoglobulinemia, membranoproliferative glomerulonephritis)</td>
<td></td>
</tr>
<tr>
<td>II. Multisystem diseases</td>
<td></td>
</tr>
<tr>
<td>A. Systemic lupus erythematosus</td>
<td></td>
</tr>
<tr>
<td>B. Henoch-Schönlein purpura</td>
<td></td>
</tr>
<tr>
<td>C. Systemic necrotizing vasculitis (including Wegener’s granulomatosis)</td>
<td></td>
</tr>
<tr>
<td>D. Goodpasture’s syndrome</td>
<td></td>
</tr>
<tr>
<td>E. Essential mixed (IgG/IgM) cryoglobulinemia</td>
<td></td>
</tr>
<tr>
<td>F. Malignancy</td>
<td></td>
</tr>
<tr>
<td>G. Relapsing polychondritis</td>
<td></td>
</tr>
<tr>
<td>H. Rheumatoid arthritis (with vasculitis)</td>
<td></td>
</tr>
<tr>
<td>III. Drugs</td>
<td></td>
</tr>
<tr>
<td>A. Penicillamine</td>
<td></td>
</tr>
<tr>
<td>B. Hydralazine</td>
<td></td>
</tr>
<tr>
<td>C. Allopurinol (with vasculitis)</td>
<td></td>
</tr>
<tr>
<td>D. Rifampin</td>
<td></td>
</tr>
<tr>
<td>IV. Idiopathic or primary glomerular disease</td>
<td></td>
</tr>
<tr>
<td>A. Idiopathic crescentic glomerulonephritis</td>
<td></td>
</tr>
<tr>
<td>1. Type I—with linear deposits of Ig (anti-GBM antibody–mediated)</td>
<td></td>
</tr>
<tr>
<td>2. Type II—with granular deposits of Ig (immune complex–mediated)</td>
<td></td>
</tr>
<tr>
<td>3. Type III—with few or no immune deposits of Ig (“pauci-immune”)</td>
<td></td>
</tr>
<tr>
<td>4. Antineutrophil cytoplasmic antibody–induced,? forme fruste of vasculitis</td>
<td></td>
</tr>
<tr>
<td>5. Immunotactoid glomerulonephritis</td>
<td></td>
</tr>
<tr>
<td>6. Fibrillary glomerulonephritis</td>
<td></td>
</tr>
<tr>
<td>B. Superimposed on another primary glomerular disease</td>
<td></td>
</tr>
<tr>
<td>1. Mesangiocapillary (membranoproliferative) glomerulonephritis (especially type II)</td>
<td></td>
</tr>
<tr>
<td>2. Membranous glomerulonephritis</td>
<td></td>
</tr>
<tr>
<td>3. Berger’s disease (IgA nephropathy)</td>
<td></td>
</tr>
</tbody>
</table>

*aMost common cause.

Note: GBM, glomerular basement membrane.

SLE (Lupus)  Renal involvement is due to deposition of circulating immune complexes. Clinical features of SLE with or without renal involvement include arthralgias, “butterfly” skin rash, serositis, alopecia (hair loss), and central nervous system disease. Nephrotic syndrome with renal insufficiency is common. Renal biopsy reveals mesangial, focal, or diffuse GN and/or membranous nephropathy. Diffuse GN, the most common finding in renal biopsy series, is characterized by an active sediment, severe proteinuria, and progressive renal insufficiency and may have an ominous prognosis. Pts have a positive antinuclear antibody test, anti-dsDNA antibodies, and hypocomplementemia. Treatment includes glucocorticoids and cytotoxic agents. Oral or IV monthly cyclophosphamide is most commonly employed, typically for a period of 6 months. Mycophenolate mofetil or azathioprine may be used for longer-term therapy.

Antineutrophil Cytoplasmic Antibody (ANCA)-Associated, Pauci-Immune GN  May be renal-limited (idiopathic pauci-immune GN) or associated with systemic vasculitis (Wegener’s granulomatosis or microscopic polyarteritis nodosa). Defining characteristic is the presence of circulating ANCA. These are detected by immunofluorescence of alcohol-fixed neutrophils; a “perinuclear” pattern (pANCA) is usually due to antibodies against myeloperoxidase (MPO), whereas a “cytoplasmic” pattern (cANCA) is almost always due to reactivity against proteinase-3 (PR3). Confirmatory enzyme-linked immunosorbent assay testing against the MPO and PR3 antigens is mandatory, since the pANCA pattern can be caused by antibodies against other neutrophil components, e.g., lactoferrin; these do not have the same consistent relationship to vasculitis and pauci-immune GN. The anti-MPO or anti-PR3 titer does not always correlate with disease activity.

Patients typically have a prodromal, “flulike” syndrome, which may encompass myalgias, fever, arthralgias, anorexia, and weight loss. There may be associated cutaneous, pulmonary, upper respiratory (sinusitis), or neurologic (mononeuritis monoplex) complications of associated systemic vasculitis. In particular, pulmonary necrotizing capillaritis can lead to hemoptysis and pulmonary hemorrhage.

Standard therapy for ANCA-associated RPGN should include steroids and cyclophosphamide. Some centers will also utilize plasmapheresis in the initial management of patients with a severe pulmonary-renal syndrome or to stave off dialysis in patients with severe renal impairment.

Anti-Glomerular Basement Membrane Disease  Caused by antibodies against the α3 NCI (noncollagenous) domain of type IV collagen; circulating anti-GBM antibody and linear immunofluorescence on renal biopsy establish the Dx. Patients may have isolated GN; Goodpasture’s syndrome encompasses GN and lung hemorrhage. Plasma exchange may produce remission. Severe lung hemorrhage is treated with IV glucocorticoids (e.g., 1 g/d × 3 days). Approximately 10–15% will also have ANCA against MPO, some with evidence of vasculitis, e.g., leukocytoclastic vasculitis in the skin.

Henoch-Schönlein Purpura  A generalized vasculitis causing IgA nephropathy, purpura, arthralgias, and abdominal pain; occurs mainly in children. Renal involvement is manifested by hematuria and proteinuria. Serum IgA is increased in half of pts. Renal biopsy is useful for prognosis. Treatment is symptomatic.

Nephrotic Syndrome (NS)  Characterized by albuminuria (>3.5 g/d) and hypoalbuminemia (<30 g/L) and accompanied by edema, hyperlipidemia, and lipiduria. Complications include renal
vein thrombosis and other thromboembolic events, infection, vitamin D deficiency, protein malnutrition, and drug toxicities due to decreased protein binding.

In adults, the most common cause of nephritic syndrome is diabetes. A minority of cases are secondary to SLE, amyloidosis, drugs, neoplasia, or other disorders (Table 150-3). By exclusion, the remainder are idiopathic. Renal biopsy is required to make the diagnosis and determine therapy in idiopathic NS.

### Minimally Change Disease
Causes about 10–15% of idiopathic NS in adults, but 70–90% of NS in children. Blood pressure is normal; GFR is normal or slightly reduced; urinary sediment is benign or may show few RBCs. Protein selectivity is variable in adults. Recent upper respiratory infection, allergies, or immunizations are present in some cases; nonsteroidal anti-inflammatory drugs can cause minimal change disease with interstitial nephritis. Acute renal failure may rarely occur, particularly among elderly persons. Renal biopsy shows only foot process fusion on electron microscopy. Remission of proteinuria with glucocorticoids carries a good prognosis; cytotoxic therapy may be required for relapse. Progression to renal failure is uncommon. Focal sclerosis has been suspected in some cases refractory to steroid therapy.

### Membranous GN
Characterized by subepithelial IgG deposits; accounts for ~30% of adult NS. Pts present with edema and nephrotic proteinuria. Blood pressure, GFR, and urine sediment are usually normal at initial presentation. Hypertension, mild renal insufficiency, and abnormal urine sediment develop later. Renal vein thrombosis is relatively common, more so than with other forms of nephrotic syndrome. Underlying diseases such as SLE, hepatitis B, and solid tumors and exposure to such drugs as high-dose captopril or penicillamine should be sought. Some pts progress to end-stage renal disease (ESRD); however, 20–33% may experience a spontaneous remission. Male gender, older age, hypertension, and persistence of significant proteinuria (>6 g/d) are associated with a higher risk of progressive disease. Optimal immunosuppressive therapy is controversial. Glucocorticoids alone are ineffective. Cytotoxic agents may promote complete or partial remission in some pts, as may cyclosporine. Anti-CD20 antibody therapy with rituximab has recently shown considerable promise, consistent with a role for B cells and antibody production in the pathophysiology. Reduction of proteinuria with angiotensin-converting enzyme (ACE)
inhibitors and/or angiotensin receptor blockers (ARBs) is also an important mainstay of therapy.

**Focal Glomerulosclerosis (FGS)** Can be primary or secondary. Primary tends to be more acute, similar to minimal change disease in abruptness of nephrotic syndrome, but with added features of hypertension, renal insufficiency, and hematuria. Involves fibrosis of portions of some (primarily juxtamedullary) glomeruli and is found in ~33% of pts with NS; African Americans are disproportionately affected (causing ~50% of NS). HIV-associated nephropathy (HIVAN) and collapsing nephropathy have similar pathologic features; both tend to be more rapidly progressive than typical cases. The frequency and severity of HIVAN has decreased with highly active antiretroviral therapy (HAART).

Treatment typically begins with an extended course of steroids; fewer than half undergo remission. Cyclosporine is an evolving therapy for maintenance of remission and for steroid-resistant patients. As in other glomerulopathies, reduction of proteinuria with ACE inhibitors and/or ARBs is also an important component of therapy. Finally, primary FGS may recur after renal transplant, when it may lead to loss of the allograft.

Secondary FGS can occur in the late stages of any form of kidney disease associated with nephron loss (e.g., remote GN, pyelonephritis, vesicoureteral reflux). Typically responds to ACE inhibition and blood pressure control. No benefit of glucocorticoids in secondary FGS. Clinical history, kidney size, biopsy findings, and associated conditions usually allow differentiation of primary vs. secondary causes.

**Membranoproliferative Glomerulonephritis (MPGN)** Mesangial expansion and proliferation extend into the capillary loop. Two ultrastructural variants exist. In MPGN I, subendothelial electron-dense deposits are present, C3 is deposited in a granular pattern indicative of immune-complex pathogenesis, and IgG and the early components of complement may or may not be present. In MPGN II, the lamina densa of the GBM is transformed into an electron-dense character, as is the basement membrane in Bowman’s capsule and tubules. C3 is found irregularly in the GBM. Small amounts of Ig (usually IgM) are present, but early components of complement are absent. Serum complement levels are decreased. MPGN affects young adults. Blood pressure and GFR are abnormal, and the urine sediment is active. Some have acute nephritis or hematuria. Similar lesions occur in SLE and hemolytic-uremic syndrome. Infection with hepatitis C virus (HCV) has been linked to MPGN. Treatment with interferon α and ribavirin has resulted in remission of renal disease in some cases, depending on HCV serotype. Glucocorticoids, cytotoxic agents, antiplatelet agents, and plasmapheresis have been used with limited success. MPGN may recur in allografts.

**Diabetic Nephropathy** The most common cause of NS. Pathologic changes include diffuse and/or nodular glomerulosclerosis, nephrosclerosis, chronic pyelonephritis, and papillary necrosis. Clinical features include proteinuria, hypertension, azotemia, and bacteriuria. Although prior duration of diabetes mellitus (DM) is variable, in type 1 DM proteinuria may develop 10–15 years after onset, progress to NS, and then lead to renal failure over 3–5 years. Other complications of DM are common; retinopathy is nearly universal. Treatment with ACE inhibitors delays the onset of nephropathy and should be instituted in all pts tolerant to that class of drug.

If a cough develops in a pt treated with an ACE inhibitor, an ARB is the next best choice; although long-term studies are lacking, many authorities advocate adding ARBs to ACE inhibitors in patients with persistent, significant proteinuria. If hyperkalemia develops and cannot be controlled with (1) optimizing glucose
control, (2) loop diuretics, or (3) occasional polystyrene sulfonate (Kayexalate), then tight control of blood pressure with alternative agents is warranted. Modest restriction of dietary protein may also slow decline of renal function.

Evaluation of NS is shown in Table 150-4.

### ASYMPTOMATIC URINARY ABNORMALITIES

Proteinuria in the nonnephrotic range and/or hematuria unaccompanied by edema, reduced GFR, or hypertension can be due to multiple causes (Table 150-5).

### TABLE 150-4 EVALUATION OF NEPHROTIC SYNDROME

<table>
<thead>
<tr>
<th>Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>24-h urine for protein; creatinine clearance</td>
</tr>
<tr>
<td>Serum albumin, cholesterol, complement</td>
</tr>
<tr>
<td>Urine protein electrophoresis</td>
</tr>
<tr>
<td>Rule out SLE, diabetes mellitus</td>
</tr>
<tr>
<td>Review drug exposure</td>
</tr>
<tr>
<td>Renal biopsy</td>
</tr>
<tr>
<td>Consider malignancy (in elderly pt with membranous GN or minimal change disease)</td>
</tr>
<tr>
<td>Consider renal vein thrombosis (if membranous GN or symptoms of pulmonary embolism are present)</td>
</tr>
</tbody>
</table>

*Note: SLE, systemic lupus erythematosus; GN, glomerulonephritis.*

### TABLE 150-5 GLOMERULAR CAUSES OF ASYMPTOMATIC URINARY ABNORMALITIES

<table>
<thead>
<tr>
<th>Category</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Hematuria with or without proteinuria</td>
<td>Primary glomerular diseases</td>
</tr>
<tr>
<td></td>
<td>1. Berger’s disease (IgA nephropathy)*</td>
</tr>
<tr>
<td></td>
<td>2. Mesangiocapillary glomerulonephritis</td>
</tr>
<tr>
<td></td>
<td>3. Other primary glomerular hematurias accompanied by “pure” mesangial proliferation, focal and segmental proliferative glomerulonephritis, or other lesions</td>
</tr>
<tr>
<td></td>
<td>4. “Thin basement membrane” disease (? forme fruste of Alport’s syndrome)</td>
</tr>
<tr>
<td></td>
<td>Associated with multisystem or hereditary diseases</td>
</tr>
<tr>
<td></td>
<td>1. Alport’s syndrome and other “benign” familial hematurias</td>
</tr>
<tr>
<td></td>
<td>2. Fabry’s disease</td>
</tr>
<tr>
<td></td>
<td>3. Sickle cell disease</td>
</tr>
<tr>
<td></td>
<td>Associated with infections</td>
</tr>
<tr>
<td></td>
<td>1. Resolving poststreptococcal glomerulonephritis</td>
</tr>
<tr>
<td></td>
<td>2. Other postinfectious glomerulonephritides</td>
</tr>
<tr>
<td>II. Isolated nonnephrotic proteinuria</td>
<td>Primary glomerular diseases</td>
</tr>
<tr>
<td></td>
<td>1. “Orthostatic” proteinuria</td>
</tr>
<tr>
<td></td>
<td>2. Focal and segmental glomerulosclerosis</td>
</tr>
<tr>
<td></td>
<td>3. Membranous glomerulonephritis</td>
</tr>
<tr>
<td></td>
<td>Associated with multisystem or heredofamilial diseases</td>
</tr>
<tr>
<td></td>
<td>1. Diabetes mellitus</td>
</tr>
<tr>
<td></td>
<td>2. Amyloidosis</td>
</tr>
<tr>
<td></td>
<td>3. Nail-patella syndrome</td>
</tr>
</tbody>
</table>

*Most common.

*Source: RJ Glassock, BM Brenner: HPIM-13.*
### Table 150-6: Serologic Findings in Selected Multisystem Diseases Causing Glomerular Disease

<table>
<thead>
<tr>
<th>Disease</th>
<th>C3</th>
<th>Ig</th>
<th>FANA</th>
<th>Anti-dsDNA</th>
<th>Anti-GBM</th>
<th>Cryo-Ig</th>
<th>CIC</th>
<th>ANCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLE</td>
<td>↓</td>
<td>↑IgG</td>
<td>+++</td>
<td>++</td>
<td>–</td>
<td>++</td>
<td>+++</td>
<td>±</td>
</tr>
<tr>
<td>Goodpasture’s syndrome</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>±</td>
<td>+ (10–15%)</td>
</tr>
<tr>
<td>Henoch-Schönlein purpura</td>
<td>–</td>
<td>↑IgA</td>
<td>–</td>
<td>–</td>
<td>+++</td>
<td>–</td>
<td>±</td>
<td>++</td>
</tr>
<tr>
<td>Polyarteritis</td>
<td>↓↑</td>
<td>↑IgG</td>
<td>±</td>
<td>–</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>–</td>
</tr>
<tr>
<td>Wegener’s granulomatosis</td>
<td>↓↑</td>
<td>↑IgA, IgE</td>
<td>–</td>
<td>–</td>
<td>±</td>
<td>++</td>
<td>+++</td>
<td>–</td>
</tr>
<tr>
<td>Cryoglobulinemia</td>
<td>↓</td>
<td>±</td>
<td>–</td>
<td>–</td>
<td>++</td>
<td>+++</td>
<td>++</td>
<td>–</td>
</tr>
</tbody>
</table>

| Multiple myeloma                | –  | IgE  | –    | –          | +        | –       | –   | –     |
| Waldenström’s macroglobulinemia | –  | ↑IgM | –    | –          | –        | –       | –   | –     |
| Amyloidosis                     | –  | ± Ig | –    | –          | –        | –       | –   | –     |

**Note:** C3, complement component 3; Ig, immunoglobulin levels; FANA, fluorescent anti-nuclear antibody assay; anti-dsDNA, antibody to double-stranded (native) DNA; anti-GBM, antibody to glomerular basement membrane antigens; cryo-Ig, cryoimmunoglobulin; CIC, circulating immune complexes; ANCA, antineutrophil cytoplasmic antibody; SLE, systemic lupus erythematosus; –, normal; +, occasionally slightly abnormal; ++, often abnormal; ++++, severely abnormal.

**Source:** RJ Glassock, BM Brenner: HPIM-13.
Thin Basement Membrane Nephropathy

Also known as benign familial hematuria, may cause up to 25% of isolated, sustained hematuria without proteinuria. Diffuse thinning of the glomerular basement membrane on renal biopsy, with minimal other changes. May be hereditary, caused in some instances by defects in type IV collagen. Patients have persistent glomerular hematuria, with minimal proteinuria. The renal prognosis is controversial but appears to be relatively benign.

IgA Nephropathy

Another very common cause of recurrent hematuria of glomerular origin; is most frequent in young men. Episodes of macroscopic hematuria are present with flulike symptoms, without skin rash, abdominal pain, or arthritis. Renal biopsy shows diffuse mesangial deposition of IgA, often with lesser amounts of IgG, nearly always by C3 and properdin but not by C1q or C4. Prognosis is variable; 50% develop ESRD within 25 years; men with hypertension and heavy proteinuria are at highest risk. Glucocorticoids and other immunosuppressive agents have not proved successful. A randomized clinical trial of fish oil supplementation suggested a modest therapeutic benefit. Rarely recurs in allografts.

Chronic Glomerulonephritis

Characterized by persistent urinary abnormalities, slow progressive impairment of renal function, symmetrically contracted kidneys, moderate to heavy proteinuria, abnormal urinary sediment (especially RBC casts), and x-ray evidence of normal pyelocalyceal systems. The time to progression to ESRD is variable, hastened by uncontrolled hypertension and infections. Control of blood pressure is of paramount importance and is the most important factor influencing the pace of progression. While ACE inhibitors and ARBs may be the most effective agents, additional agents should be added if blood pressure is not optimally controlled with ACE inhibitors alone. Diuretics, nondihydropyridine calcium antagonists, and \( \beta \)-adrenergic blockers have been successfully used in a variety of clinical settings.

Glomerulopathies Associated with Multisystem Disease

For a more detailed discussion, see Lewis JB, Neilson EG: Glomerular Diseases, Chap. 277, p. 1782, in HPIM-17.

151 Renal Tubular Disease

Tubulointerstitial diseases constitute a diverse group of acute and chronic, hereditary and acquired disorders involving the renal tubules and supporting structures (Table 151-1). Functionally, they may result in a wide variety of physiologic phenotypes, including nephrogenic diabetes insipidus (DI) with polyuria, non-anion-gap metabolic acidosis, salt-wasting, and hypo- or hyperkalemia. Azotemia is common, owing to associated glomerular fibrosis and/or ischemia. Compared with glomerulopathies, proteinuria and hematuria are less dramatic, and hypertension is less common. The functional consequences of tubular dysfunction are outlined in Table 151-2.
# Table 151-1: Principal Causes of Tubulointerstitial Disease of the Kidney

## Toxins

<table>
<thead>
<tr>
<th>Exogenous toxins</th>
<th>Metabolic toxins</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesic nephropathy&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Acute uric acid nephropathy</td>
</tr>
<tr>
<td>Lead nephropathy</td>
<td>Gouty nephropathy&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Chinese herb nephropathy</td>
<td>Hypercalcemic nephropathy</td>
</tr>
<tr>
<td>Balkan endemic nephropathy</td>
<td>Hypokalemic nephropathy</td>
</tr>
<tr>
<td>Miscellaneous nephrotoxins (e.g., antibiotics, cyclosporine, radiographic contrast media, heavy metals)&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>Miscellaneous metabolic toxins (e.g., hyperoxaluria, cystinosis, Fabry’s disease)</td>
</tr>
</tbody>
</table>

## Neoplasia

<table>
<thead>
<tr>
<th>Lymphoma</th>
<th>Transplant rejection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leukemia</td>
<td>HIV-associated nephropathy</td>
</tr>
<tr>
<td>Multiple myeloma (cast nephropathy, AL amyloidosis)</td>
<td></td>
</tr>
</tbody>
</table>

## Immune Disorders

<table>
<thead>
<tr>
<th>Acute (allergic) interstitial nephritis&lt;sup&gt;a,b&lt;/sup&gt;</th>
<th>Sjögren’s syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amyloidosis</td>
<td></td>
</tr>
<tr>
<td>Transplant rejection</td>
<td></td>
</tr>
<tr>
<td>HIV-associated nephropathy</td>
<td></td>
</tr>
</tbody>
</table>

## Vascular Disorders

<table>
<thead>
<tr>
<th>Arteriolar nephrosclerosis&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Sickle cell nephropathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atheroembolic disease</td>
<td>Acute tubular necrosis&lt;sup&gt;a,b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

## Hereditary Renal Diseases

<table>
<thead>
<tr>
<th>Disorders associated with renal failure</th>
<th>Hereditary tubular disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autosomal dominant polycystic kidney disease</td>
<td>Bartter’s syndrome (hereditary hypokalemic alkalosis)</td>
</tr>
<tr>
<td>Autosomal recessive polycystic kidney disease</td>
<td>Gitelman’s syndrome (hereditary hypokalemic alkalosis)</td>
</tr>
<tr>
<td>Medullary cystic kidney disease</td>
<td>Pseudohypoaldosteronism type I (hypotension/salt wasting and hyperkalemia)</td>
</tr>
<tr>
<td>Hereditary nephritis (Alport’s syndrome)</td>
<td>Pseudohypoaldosteronism type II (hereditary hypertension and hyperkalemia)</td>
</tr>
<tr>
<td></td>
<td>Liddle’s syndrome (hypertension and hypokalemia)</td>
</tr>
<tr>
<td></td>
<td>Hereditary hypomagnesemia</td>
</tr>
<tr>
<td></td>
<td>Hereditary nephrogenic diabetes insipidus</td>
</tr>
<tr>
<td></td>
<td>X-linked (AVP receptor dysfunction)</td>
</tr>
<tr>
<td></td>
<td>Autosomal (aquaporin-2 dysfunction)</td>
</tr>
</tbody>
</table>

(continued)
ACUTE INTERSTITIAL NEPHRITIS (AIN)

Drugs are a leading cause of this type of renal failure, usually identified by a gradual rise in the serum creatinine at least several days after the institution of therapy, occasionally accompanied by fever, eosinophilia, rash, and arthralgias. The onset of renal dysfunction may be very rapid in pts who have previously been sensitized to the offending agent; this is particularly true for rifampin, for which intermittent or interrupted therapy appears to be associated with the development of AIN. In addition to azotemia, there may be evidence of tubular dysfunction (e.g., hyperkalemia, metabolic acidosis). Urinalysis may show hematuria, pyuria, white cell casts, and eosinophiluria on Hansel’s or Wright’s stain; notably, however, eosinophiluria is not specific for AIN, occurring in other causes of acute renal failure, including atheroemboli.

TABLE 151-1 PRINCIPAL CAUSES OF TUBULOINTERSTITIAL DISEASE OF THE KIDNEY (CONTINUED)

<table>
<thead>
<tr>
<th>Infectious Injury</th>
<th>Cause(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute pyelonephritis&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>Obliteration of microvasculature and obstruction of tubules</td>
</tr>
<tr>
<td>Chronic pyelonephritis</td>
<td>Damage to proximal tubular reabsorption of solutes, primarily glucose, amino acids, and phosphate; may also exhibit hypouricemia, proximal tubular acidosis, low-molecular-weight proteinuria</td>
</tr>
<tr>
<td>Miscellaneous Disorders</td>
<td></td>
</tr>
<tr>
<td>Chronic urinary tract obstruction&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Vesicoureteral reflux&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Radiation nephritis</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>Typically acute.

TABLE 151-2 TRANSPORT DYSFUNCTION IN TUBULOINTERSTITIAL DISEASE

<table>
<thead>
<tr>
<th>Defect</th>
<th>Cause(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduced GFR&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Obliteration of microvasculature and obstruction of tubules</td>
</tr>
<tr>
<td>Fanconi syndrome</td>
<td>Damage to proximal tubular reabsorption of solutes, primarily glucose, amino acids, and phosphate; may also exhibit hypouricemia, proximal tubular acidosis, low-molecular-weight proteinuria</td>
</tr>
<tr>
<td>Hyperchloremic acidosis&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1. Reduced ammonia production (CKD) or excretion (hyperkalemia)</td>
</tr>
<tr>
<td></td>
<td>2. Inability to acidify the collecting duct fluid (distal renal tubular acidosis)</td>
</tr>
<tr>
<td></td>
<td>3. Proximal bicarbonate wasting (proximal RTA)</td>
</tr>
<tr>
<td>Polyuria, isothenuria&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Damage to medullary tubules (thick ascending limb and/or collecting duct) and vasculature</td>
</tr>
<tr>
<td>Hypokalemic alkalosis</td>
<td>Damage or hereditary dysfunction of the thick ascending limb or distal convoluted tubule (Bartter’s and Gitelman’s syndromes)</td>
</tr>
<tr>
<td>Hyperkalemia&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Potassium secretory defects including aldosterone resistance</td>
</tr>
<tr>
<td>Salt wasting</td>
<td>Distal tubular damage with impaired sodium reabsorption</td>
</tr>
</tbody>
</table>

<sup>a</sup>Typically acute.

<sup>Note</sup>: GFR, glomerular filtration rate; CKD, chronic kidney disease; RTA, renal tubular acidosis.
Drugs that commonly cause AIN are listed in Table 151-3. Some drugs have a particular predilection for causing AIN, e.g., nafcillin; however, less frequent causes may be apparent only from case reports, such that a detailed history and literature review may be required to make the association with AIN. Many drugs, nonsteroidal anti-inflammatory drugs (NSAIDs) in particular, may elicit a glomerular lesion with similarity to minimal change disease, in addition to AIN; these pts typically have nephrotic-range proteinuria, versus the modest proteinuria typically associated with tubulointerstitial disease.

Renal dysfunction in drug-associated AIN usually improves after withdrawal of the offending drug, but complete recovery may be delayed and incomplete. In uncontrolled studies, glucocorticoids have been shown to promote earlier recovery of renal function and reduce fibrosis; this therapy is generally reserved to avoid or reduce the duration of dialytic therapy in pts who fail to respond to medication withdrawal.

AIN may also occur in the context of systemic infections, classically leptospirosis, Legionella infection, and streptococcal bacterial infection. Finally, the tubulointerstitial nephritis and uveitis syndrome (TINU) is another increasingly recognized form of AIN. In addition to uveitis, which may precede or follow the AIN in pts with TINU, systemic symptoms and signs are common, e.g., weight loss, fever, malaise, arthralgias, and an elevated erythrocyte sedimentation rate. The renal disease is typically self-limited; those with progressive disease are often treated with prednisone.

### CHRONIC INTERSTITIAL NEPHRITIS (IN)

Analgesic nephropathy is an important cause of chronic kidney disease that results from the cumulative (in quantity and duration) effects of combination analgesic agents, usually phenacetin and aspirin. It is thought to be a more common cause of end-stage renal disease (ESRD) in Australia/New Zealand than elsewhere owing to the larger per capita ingestion of analgesic agents in that region of the world. Transitional cell carcinoma may develop. Analgesic

#### TABLE 151-3 CAUSES OF ACUTE INTERSTITIAL NEPHRITIS

<table>
<thead>
<tr>
<th>Category</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drugs (70%, antibiotics in one-third)</td>
<td>Methicillin, nafcillin, oxacillin</td>
</tr>
<tr>
<td></td>
<td>Rifampin</td>
</tr>
<tr>
<td></td>
<td>Penicillins, cephalosporins</td>
</tr>
<tr>
<td></td>
<td>Ciprofloxacin</td>
</tr>
<tr>
<td></td>
<td>Sulfamethoxazole and other sulfonamides</td>
</tr>
<tr>
<td></td>
<td>Proton pump inhibitors, e.g., omeprazole</td>
</tr>
<tr>
<td></td>
<td>H₂ blockers, e.g., cimetidine</td>
</tr>
<tr>
<td></td>
<td>Allopurinol</td>
</tr>
<tr>
<td></td>
<td>5-aminosalicylates</td>
</tr>
<tr>
<td></td>
<td>NSAIDS, including COX-2 inhibitors</td>
</tr>
<tr>
<td>Infections (16%)</td>
<td>Leptospirosis, Legionella, streptococcal, tuberculosis</td>
</tr>
<tr>
<td></td>
<td>Tubulointerstitial nephritis and uveitis syndrome (TINU) (5%)</td>
</tr>
<tr>
<td></td>
<td>Idiopathic (8%)</td>
</tr>
<tr>
<td></td>
<td>Sarcoidosis (1%)</td>
</tr>
</tbody>
</table>

*Note:* NSAIDs, nonsteroidal anti-inflammatory drugs; COX-2, cyclooxygenase 2.
nephropathy should be suspected in pts with a history of chronic headache or back pain with chronic kidney disease (CKD) that is otherwise unexplained. Manifestations include papillary necrosis, calculi, sterile pyuria, and azotemia.

A severe form of chronic tubulointerstitial fibrosis has been associated with the ingestion of Chinese herbal medicines, typically employed as part of a dieting regimen; Balkan endemic nephropathy (BEN), geographically restricted to pts from this region of southeastern Europe, shares many similarities with Chinese herbal nephropathy. These disorders are thought to be caused by exposure to aristolochic acid and/or other plant, endemic (in BEN), and medical toxins (the appetite suppressants fenfluramine and diethylpropion, in Chinese herbal nephropathy). Like analgesic nephropathies, these syndromes are both characterized by a high incidence of genitourinary malignancy.

Metabolic causes of chronic IN include hypercalcemia (with nephrocalcinosis), oxalosis (primary or secondary, e.g., with intestinal disease and hyperabsorption of dietary oxalate), hypokalemia, and hyperuricemia or hyperuricosuria. The renal pathology associated with chronic hypokalemia includes a relatively specific proximal tubular vacuolization, interstitial nephritis, and renal cysts; both chronic and acute renal failure have been described. Chronic IN can occur in association with several systemic diseases, including sarcoidosis, Sjögren’s syndrome, and following radiation or chemotherapy exposure (e.g., ifosfamide, cisplatin).

**MONOCLONAL IMMUNOGLOBULINS AND RENAL DISEASE**

Monoclonal immunoglobulins are associated with a wide variety of renal manifestations (Table 151-4), of which myeloma-associated cast nephropathy is the most common. The physiochemical characteristics of the monoclonal immunoglobulin light or heavy chains determine the clinical phenotype in individual pts, most commonly cast nephropathy, light chain deposition disease, and AL amy-

<table>
<thead>
<tr>
<th>Disease</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cast nephropathy</td>
<td>Most common cause of CKD in myeloma</td>
</tr>
<tr>
<td></td>
<td>Tubular obstruction with light chains</td>
</tr>
<tr>
<td></td>
<td>Interstitial inflammation</td>
</tr>
<tr>
<td></td>
<td>Acute or chronic renal failure</td>
</tr>
<tr>
<td>Light chain deposition disease</td>
<td>Nephrotic syndrome, chronic renal failure</td>
</tr>
<tr>
<td>Heavy chain deposition disease</td>
<td>Nephrotic syndrome, chronic renal failure</td>
</tr>
<tr>
<td>AL amyloidosis</td>
<td>Nephrotic syndrome, cardiac/endocrine/neuropathic involvement</td>
</tr>
<tr>
<td></td>
<td>~10% have associated myeloma</td>
</tr>
<tr>
<td>Hypercalcemia</td>
<td>Renal tubular dysfunction (RTA, nephrogenic DI, etc.)</td>
</tr>
<tr>
<td>Hyperviscosity syndrome</td>
<td>With Waldenström’s macroglobulinemia</td>
</tr>
<tr>
<td>Fanconi syndrome</td>
<td>Glucosuria, aminoaciduria, phosphaturia, ± hyperuricemia, proximal RTA, etc.</td>
</tr>
</tbody>
</table>

*Note: CKD, chronic kidney disease; RTA, renal tubular acidosis; DI, diabetes insipidus.*
loidosis. In cast nephropathy, filtered light chains aggregate and cause tubular obstruction, tubular damage, and interstitial inflammation. Pts can present with chronic renal dysfunction or with acute renal failure; important predisposing factors in acute cast nephropathy include hypercalcemia and volume depletion.

Diagnosis of cast nephropathy relies on the detection of monoclonal light chains in serum and/or urine, typically by protein electrophoresis and immunofixation. Dipstick analysis of the urine for protein is classically negative in cast nephropathy, despite the excretion of up to several grams a day of light chain protein; light chains are not detected by this screening test, which tests only for albuminuria. In contrast, the glomerular deposition of light chains in light chain deposition disease or AL amyloidosis can result in nephrotic-range proteinuria (Table 151-4), with strongly positive urine dipstick for protein.

Management of cast nephropathy encompasses aggressive hydration, treatment of hypercalcemia if present, and chemotherapy for the associated multiple myeloma. Some experts advocate the use of plasmapheresis for pts with acute renal failure and high levels of serum or urine monoclonal light chains; however, a recent negative randomized trial has reduced the enthusiasm for the routine employment of plasmapheresis in this setting.

Filtered light chains and multiple other low-molecular-weight proteins are also endocytosed and metabolized by the proximal tubule. Rarely, specific light chains generate crystalline depositions within proximal tubule cells, causing a Fanconi syndrome; again, this property appears to be caused by the specific physicochemical characteristics of the associated light chains. Fanconi syndrome or dysfunction of the distal nephron (hyperkalemic acidosis or nephrogenic DI) may also complicate renal amyloidosis.

POLYCYSTIC KIDNEY DISEASE

Autosomal dominant polycystic kidney disease (ADPKD) is the most common life-threatening monogenic genetic disorder, caused by autosomal dominant mutations in the \textbf{PKD1} and \textbf{PKD2} genes; it is a quantitatively important cause of ESRD. Autosomal recessive polycystic disease is a less much common cause of renal failure, typically presenting in infancy; hepatic involvement is much more prominent. The massive renal cysts in ADPKD can lead to progressive CKD, episodic flank pain, hematuria (often gross), hypertension, and/or urinary tract infection. The kidneys are often palpable and occasionally of very large size. Hepatic cysts and intracranial aneurysms may also be present; pts with ADPKD and a family history of ruptured intracranial aneurysms should undergo presymptomatic screening. Other common extrarenal features include diverticulosis and mitral valve prolapse.

The expression of ADPKD is highly variable, with the age of onset of ESRD ranging from childhood to old age. The renal phenotype is much milder in pts with mutations in \textbf{PKD1}, who on average develop ESRD approximately 15 years earlier than those with \textbf{PKD2} mutations. Indeed, some pts with ADPKD discover the disease incidentally in late adult life, having had mild to moderate hypertension earlier.

The diagnosis is usually made by ultrasonography. In a 15- to 29-year-old at-risk individual from a family with ADPKD, the presence of at least two renal cysts (unilateral or bilateral) is sufficient for diagnosis. Notably, however, renal cysts are a common ultrasound finding in older pts without ADPKD, particularly those with CKD. Therefore, in at-risk individuals 30–59 years of age, the presence of at least two cysts in each kidney is required for the diagnosis; this increases to four cysts in each kidney for those older than 60. Conversely, the
absence of at least two cysts in each kidney excludes the diagnosis of ADPKD in at-risk individuals between the ages of 30 and 59.

Hypertension is common in ADPKD, often in the absence of an apparent reduction in glomerular filtration rate. Activation of the renin-angiotensin system appears to play a dominant role; angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are the recommended antihypertensive agents, with a target bp of 120/80 mmHg. Promising treatment modalities for halting progression of CKD in ADPKD include vasopressin antagonists and inhibitors of CFTR (the transport protein defective in cystic fibrosis), which dramatically reduce cyst enlargement and renal progression in animal models.

Urinary tract infections are also common in ADPKD. In particular, pts may develop cyst infections, often with negative urine cultures and an absence of pyuria. Pts with an infected cyst may have a discrete area of tenderness, as opposed to the more diffuse discomfort of pyelonephritis; however, clinical distinction between these two possibilities can be problematic. Many commonly utilized antibiotics, including penicillins and aminoglycosides, fail to penetrate cysts and are ineffective; therapy of kidney infections in ADPKD should utilize an antibiotic that is known to penetrate cysts (e.g., quinolones), guided initially by local antimicrobial susceptibility patterns.

RENAL TUBULAR ACIDOSIS (RTA)

This describes a number of pathophysiologically distinct entities of tubular function whose common feature is the presence of a non-anion-gap metabolic acidosis. Diarrhea, CKD, and RTA together constitute the vast majority of cases of non-anion-gap metabolic acidosis. Pts with earlier stages of CKD (Table 57-1) typically develop a non-anion-gap acidosis, with a superimposed increase in the anion gap at later stages (Chap. 2). Acidosis may develop at an earlier stage of CKD in those with prominent injury to the distal nephron, as for example in reflux nephropathy.

Distal Hypokalemic (Type 1) RTA Pts are unable to acidify the urine despite systemic acidosis; the urinary anion gap is positive, reflective of a decrease in ammonium excretion (Chap. 2). Distal hypokalemic RTA may be inherited (both autosomal dominant and autosomal recessive) or acquired due to autoimmune and inflammatory diseases (e.g., Sjögren’s syndrome, sarcoidosis), urinary tract obstruction, or amphotericin B therapy. Chronic type I RTA is typically associated with hypercalciuria and osteomalacia, a consequence of the long-term buffering of acidosis by bone.

Proximal (Type II) RTA There is a defect in bicarbonate reabsorption, usually associated with features of Fanconi syndrome: glycosuria, aminoaciduria, phosphaturia, and uricosuria (indicating proximal tubular dysfunction). Isolated proximal RTA is caused by hereditary dysfunction of the basolateral sodium-bicarbonate cotransporter. Fanconi syndrome may be inherited or acquired due to myeloma, chronic IN (e.g., Chinese herbal nephropathy), or drugs (e.g., ifosfamide, tenofovir). Treatment requires large doses of bicarbonate, which may aggravate hypokalemia, and repletion of phosphorus to prevent bone disease.

Type IV RTA This may be due to hyporeninemic hypoaldosteronism or to resistance of the distal nephron to aldosterone. Hyporeninemic hypoaldosteronism is typically associated with volume expansion and most commonly seen in elderly and/or diabetic pts with CKD. The hyperkalemia associated with NSAIDs and cyclosporine is at least partially due to hyporeninemic hypoaldosteronism. Pts with hyporeninemic hypoaldosteronism are typically hyperkalem-
ic; they may also exhibit a mild non-anion-gap acidosis, with urine pH <5.5 and a positive urinary anion gap. Acidosis often improves with reduction in serum [K+], e.g., with Kayexalate therapy; hyperkalemia appears to interfere with medullary concentration of ammonium by the renal countercurrent mechanism. Should reduction in serum [K+] not improve acidosis, pts should be treated with oral bicarbonate or citrate. Finally, various forms of distal tubular injury and tubulointerstitial disease, e.g., interstitial nephritis, are associated with distal insensitivity to aldosterone; urine pH is classically >5.5, again with a positive urinary anion gap.

For a more detailed discussion, see Yu ASL, Brenner BM: Tubulo-interstitial Diseases of the Kidney, Chap. 279, p. 1806, in HPIM-17.

152 Urinary Tract Infections

ACUTE INFECTIONS: URETHRITIS, CYSTITIS, AND PYELONEPHRITIS

Epidemiology Urinary tract infections (UTIs) are classified epidemiologically as catheter-associated (nosocomial) and non-catheter-associated (community-acquired). Community-acquired UTIs result in >7 million office visits annually in the United States. Most cases involve sexually active young women. UTIs are rare among men <50 years of age. Asymptomatic bacteriuria is common among young women but is most frequently documented in elderly men and women, with rates up to 50% in some studies.

Etiology Uncomplicated community-acquired UTIs—defined as those not associated with calculi, obstruction, or urologic manipulation—are caused by Escherichia coli in ~80% of cases; other gram-negative rods, including Proteus, Klebsiella, and occasionally Enterobacter species, cause smaller proportions of cases. Gram-positive etiologic agents of UTI include Staphylococcus saprophyticus, which causes 10–15% of acute UTIs in young women, and entero cocci. E. coli, Proteus, Klebsiella, Enterobacter, Serratia, and Pseudomonas cause recurrent infections and UTIs associated with urologic manipulation, calculi, or obstruction. Proteus and Klebsiella predispose to stone formation and are isolated more often from pts with calculi. Staphylococcus epidermidis is a common cause of catheter-associated UTI.

Pathogenesis Most UTIs result when bacteria gain access to the bladder via the urethra. Some strains of bacteria (e.g., E. coli, Proteus) are uropathogenic. These strains have virulence genes that increase the likelihood of UTI (e.g., genes encoding fimbriae that mediate attachment to uroepithelial cells). Upper tract disease occurs when bacteria ascend from the bladder. Women prone to infections are colonized with enteric gram-negative bacilli in the periurethral area and distal urethra prior to bacteriuria. Alterations of the normal vaginal flora (e.g., due to antibiotic treatment, other genital infections, or contraceptive use)
contribute to UTIs. Other risk factors include female gender, sexual activity, pregnancy, genitourinary obstruction, neurogenic bladder dysfunction, and vesicoureteral reflux. Hematogenous infection of the kidney is less common and occurs most often in debilitated pts or in the setting of staphylococcal bacteremia or candidemia.

**Clinical Presentations**

- **Cystitis**: Pts have dysuria, frequency, urgency, and suprapubic pain. Urine is cloudy, malodorous, and sometimes bloody. Systemic signs are usually absent. Approximately one-third of pts may have silent upper tract disease.
- **Acute pyelonephritis**: Symptoms develop quickly over an interval lasting from hours to a day. Pts are febrile with shaking chills and can have nausea, vomiting, and diarrhea. Symptoms of cystitis may be absent. Marked tenderness may be evident on deep pressure in one or both costovertebral angles or on deep abdominal palpation.
- **Urethritis**: Women with dysuria, frequency, and pyuria but no growth on bacterial urine cultures may have urethritis due to sexually transmitted pathogens such as *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, or herpes simplex virus (Chap. 90). Pts with hematuria, suprapubic pain, an abrupt onset of illness, an illness duration of <3 days, and a history of UTIs along with a urine culture yielding low counts of *E. coli* or *S. saprophyticus* usually have cystitis.
- **Catheter-associated UTIs** (Chap. 85): Most of these infections cause minimal symptoms and no fever; they often resolve after catheter removal. Treatment without catheter removal usually fails. Bacteriuria should be ignored unless the pt develops symptoms or is at high risk for bacteremia.

**Diagnosis**

- **Urine cultures** should be performed for all pts with suspected upper tract infections, for those with complicating factors, and when the diagnosis of cystitis is in question. Most symptomatic pts have ≥10^5 bacteria/mL of urine. Bacteriuria from suprapubic aspirates or ≥10^2 bacteria/mL of urine obtained via catheterization is significant.
- **The presence of bacteria in Gram-stained uncentrifuged urine** indicates infection and correlates with ≥10^5 bacteria/mL in urine cultures.
- **Urinalysis**: Pyuria is a highly sensitive indicator of infection. Leukocyte esterase “dipstick” positivity is useful when microscopy is not available. Pyuria without bacteriuria may indicate infection with unusual organisms such as *C. trachomatis* or *Mycobacterium tuberculosis* or may be due to noninfectious causes such as calculi. Leukocyte casts are pathognomonic of acute pyelonephritis.

**Acute Infections: Urethritis, Cystitis, and Pyelonephritis**

**Underlying Principles**

- Except in acute uncomplicated cystitis in women, a quantitative urine culture with susceptibility testing should precede empirical treatment.
- Factors predisposing to infection should be identified and corrected if possible.
- Relief of clinical symptoms does not always indicate bacteriologic cure.
- Each course of treatment should be classified as a cure or a failure, and recurrent infections should be classified as early (developing within 2 weeks of the end of therapy) or late and as same-strain or different-strain.
Lower-tract infections usually require only short courses of treatment. Early recurrences may be due to upper-tract foci of infection, while late infections usually represent reinfection.

Most community-acquired infections are due to antibiotic-sensitive strains, despite increasing antibiotic resistance.

Antibiotic-resistant infections should be suspected in pts with recurrent infections, instrumentation, or recent hospitalization.

**Specific Recommendations**

See Table 152-1 for antibiotic choices. Asymptomatic bacteriuria in non-catheterized pts should not be treated unless the pt is pregnant or has other medical conditions such as neutropenia, renal transplantation, or obstruction. Pregnant women should be screened for asymptomatic bacteriuria in the first trimester. Acute pyelonephritis in pregnancy should be managed with hospitalization and parenteral antibiotic therapy. Urologic evaluation should be considered in pts with relapsing infection, a history of childhood infection, stones, or painless hematuria and in women with recurrent pyelonephritis. Most men with UTIs should have a urologic evaluation. Anyone with signs or symptoms of obstruction or stones should undergo prompt urologic evaluation.

**Prognosis** Repeated symptomatic UTIs with obstructive uropathy, neurogenic bladder, structural renal disease, or diabetes progress to chronic renal disease with high frequency.

**Prevention** Women experiencing symptomatic UTIs ≥3 times a year are candidates for long-term administration of low-dose antibiotics. These women should avoid spermicide use and should void after intercourse. Trimethoprim-sulfamethoxazole (TMP-SMX; 80/400 mg), trimethoprim (100 mg), or nitrofurantoin (50 mg) daily or thrice weekly is effective. Alternatively, if UTIs are temporally related to sexual intercourse, the same regimens prevent infection if given only after intercourse.

**PAPILLARY NECROSIS**

- Papillary necrosis is an infection of the renal pyramids in association with vascular disease of the kidney or urinary tract obstruction. Acute renal failure with oliguria or anuria can occur.
- Risk factors include diabetes, sickle cell disease, alcoholism, and vascular disease.
- Hematuria, flank or abdominal pain, chills, and fever are common symptoms.

**EMPHYSEMATOUS PYELONEPHRITIS**

- Emphysematous pyelonephritis is seen in diabetic pts in concert with urinary obstruction and chronic infection.
- This disease is characterized by a rapidly progressive course, fever, leukocytosis, renal parenchymal necrosis, and the accumulation of fermentative gases in kidney and perinephric tissues.
- The syndrome is caused most often by *E. coli* and less commonly by other Enterobacteriaceae.
<table>
<thead>
<tr>
<th>Condition</th>
<th>Characteristic Pathogens</th>
<th>Mitigating Circumstances</th>
<th>Recommended Empirical Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute uncomplicated cystitis in women</td>
<td><em>Escherichia coli</em>, <em>Staphylococcus saprophyticus</em>, <em>Proteus mirabilis</em>, <em>Klebsiella pneumoniae</em></td>
<td>None</td>
<td>3-Day regimens: oral TMP-SMX, TMP, quinolone; 7-day regimen: macrocrystalline nitrofurantoin&lt;sup&gt;b&lt;/sup&gt; Consider 7-day regimen: oral TMP-SMX, TMP, quinolone&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diabetes, symptoms for &gt;7 d, recent UTI, use of diaphragm, age &gt;65 years</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pregnancy</td>
<td></td>
</tr>
<tr>
<td>Acute uncomplicated pyelonephritis in</td>
<td><em>E. coli</em>, <em>P. mirabilis</em>, <em>S. saprophyticus</em></td>
<td>Mild to moderate illness, no nausea or vomiting: outpt therapy</td>
<td>Consider 7-day regimen: oral amoxicillin, macrocrystalline nitrofurantoin, cefpodoxime proxetil, or TMP-SMX&lt;sup&gt;b&lt;/sup&gt; Oral&lt;sup&gt;c&lt;/sup&gt; quinolone for 7–14 d (initial dose given IV if desired); or single-dose ceftriaxone (1 g) or gentamicin (3–5 mg/kg) IV followed by oral TMP-SMX&lt;sup&gt;b&lt;/sup&gt; for 14 d Parenteral&lt;sup&gt;d&lt;/sup&gt; quinolone, gentamicin (± ampicillin), ceftriaxone, or aztreonam until defervescence; then oral&lt;sup&gt;c&lt;/sup&gt; quinolone, cephalexin, or TMP-SMX for 14 d</td>
</tr>
<tr>
<td>women</td>
<td></td>
<td>Severe illness or possible urosepsis: hospitalization required</td>
<td></td>
</tr>
</tbody>
</table>
### Complicated UTI in men and women

| E. coli, Proteus, Klebsiella, Pseudomonas, Serratia, enterococci, staphylococci | Mild to moderate illness, no nausea or vomiting: outpt therapy |
| Severe illness or possible urosepsis: hospitalization required |
| Oral<sup>6</sup> quinolone for 10–14 d |
| Parenteral<sup>4</sup> ampicillin and gentamicin, quinolone, ceftriaxone, aztreonam, ticarcillin/clavulanate, or imipenem-cilastatin until defervescence; then oral<sup>6</sup> quinolone or TMP-SMX for 10–21 d |

<sup>a</sup>Treatments listed are those to be prescribed before the etiologic agent is known; Gram’s staining can be helpful in the selection of empirical therapy. Such therapy can be modified once the infecting agent has been identified. Fluoroquinolones should not be used in pregnancy. TMP-SMX, although not approved for use in pregnancy, has been widely used. Gentamicin should be used with caution in pregnancy because of its possible toxicity to eighth-nerve development in the fetus.

<sup>b</sup>Multiday oral regimens for cystitis are as follows: TMP-SMX, 160/800 mg q12h; TMP, 100 mg q12h; norfloxacin, 400 mg q12h; ciprofloxacin, 250 mg q12h; ofloxacin, 200 mg q12h; levofloxacin, 250 mg q12h; macrocrystalline nitrofurantoin, 100 mg qid; amoxicillin, 250 mg q8h; cefpodoxime proxetil, 100 mg q12h.

<sup>c</sup>Oral regimens for pyelonephritis and complicated UTI are as follows: TMP-SMX, 160/800 mg q12h; ciprofloxacin, 500 mg q12h; ofloxacin, 200–300 mg q12h; lomefloxacin, 400 mg/d; enoxacin, 400 mg q12h; levofloxacin, 250 mg q12h; amoxicillin, 500 mg q8h; cefpodoxime proxetil, 200 mg q12h.

<sup>d</sup>Parenteral regimens are as follows: ciprofloxacin, 400 mg q12h; ofloxacin, 400 mg q12h; levofloxacin, 500 mg/d; gentamicin, 1 mg/kg q8h; ceftriaxone, 1–2 g/d; ampicillin, 1 g q6h; imipenem-cilastatin, 250–500 mg q6–8h; ticarcillin/clavulanate, 3.2 g q8h; aztreonam, 1 g q8–12h.

<sup>6</sup>Note: TMP-SMX, trimethoprim-sulfamethoxazole.
PROSTATITIS

ACUTE BACTERIAL PROSTATITIS

Acute bacterial prostatitis occurs spontaneously in young men but is associated with indwelling catheters in older men. Pts have fever, chills, dysuria, and a tense or boggy, tender prostate. Prostatic massage can cause bacteremia and should be avoided. Gram’s staining and culture of urine identify the etiologic agent. *E. coli* or *Klebsiella* causes most non-catheter-associated cases, while catheter-associated cases are caused by a broader spectrum of pathogens. Third-generation cephalosporins, fluoroquinolones, or aminoglycosides are efficacious.

CHRONIC BACTERIAL PROSTATITIS

Chronic bacterial prostatitis is an uncommon entity. The diagnosis is suggested by a pattern of relapsing UTI in middle-aged men. Symptoms are lacking between episodes, and the prostate feels normal on examination. Some pts have obstructive symptoms or perineal pain. *E. coli, Klebsiella, Proteus,* or other uropathogenic bacteria can be cultured from expressed prostatic secretions or postmassage urine. Antibiotics relieve acute symptoms, but antibiotic penetration into an uninflamed prostate is poor, and relapse is common. Fluoroquinolones are the most effective agents but must be given for at least 12 weeks. Prolonged courses of low-dose antimicrobial agents may suppress symptoms and keep bladder urine sterile.

CHRONIC PELVIC PAIN SYNDROME

Chronic pelvic pain syndrome is characterized by the symptoms of prostatitis with few clinical signs and no bacterial growth in cultures. In sexually active young men, a sexually transmitted disease is likely. Some pts improve with 4–6 weeks of treatment with erythromycin, doxycycline, TMP-SMX, or a fluoroquinolone, but controlled trials are lacking.

For a more detailed discussion, see Stamm WE: Urinary Tract Infections, Pyelonephritis, and Prostatitis, Chap. 282, p. 1820, in HPIM-17.

Renovascular Disease

Ischemic injury to the kidney depends on the rate, site, severity, and duration of vascular compromise. Manifestations range from painful infarction to acute renal failure (ARF), impaired glomerular filtration rate (GFR), hematuria, or tubular dysfunction. Renal ischemia of any etiology may cause renin-mediated hypertension.

ACUTE OCCLUSION OF A RENAL ARTERY

Can be due to thrombosis or embolism (from valvular disease, endocarditis, mural thrombi, or atrial arrhythmias) or to intraoperative occlusion, e.g., during endovascular repair of abdominal aortic aneurysms.
Thrombosis of Renal Arteries  
Large renal infarcts cause pain, vomiting, nausea, hypertension, fever, proteinuria, hematuria, and elevated lactate dehydrogenase (LDH) and aspartate aminotransferase. In unilateral lesion, renal functional loss depends on contralateral function. IV pyelogram or radionuclide scan shows unilateral hypofunction; ultrasound is typically normal until scarring develops. Renal arteriography establishes diagnosis. With occlusions of large arteries, surgery may be the initial therapy; anticoagulation should be used for occlusions of small arteries. Pts should be evaluated for a thrombotic diathesis, e.g., antiphospholipid syndrome.

Renal Atheroembolism  
Usually arises when aortic or coronary angiography or surgery causes cholesterol embolization of small renal vessels in a pt with diffuse atherosclerosis. May also be spontaneous or associated with thrombolytic or rarely may occur after the initiation of anticoagulation (e.g., with warfarin). Renal insufficiency may develop suddenly, a few days or weeks after a procedure or intervention, or gradually; the pace may alternatively be progressive or “stuttering,” with punctuated drops in GFR. Associated findings can include retinal ischemia with cholesterol emboli visible on funduscopic examination, pancreatitis, neurologic deficits (especially confusion), livedo reticularis, peripheral embolic phenomena (e.g., gangrenous toes with palpable pedal pulses), abdominal pain from mesenteric emboli, and hypertension (sometimes malignant). Systemic symptoms may also occur, including fever, myalgias, headache, and weight loss. Peripheral eosinophilia, eosinophiluria, and hypocomplementemia may be observed, mimicking other forms of acute and subacute renal injury. Indeed, atheroembolic renal disease is the “great imitator” of clinical nephrology, presenting in rare instances with malignant hypertension, with nephrotic syndrome, or with what looks like rapidly progressive glomerulonephritis with an “active” urinary sediment; the diagnosis is made by history, clinical findings, and/or the renal biopsy.

Renal biopsy is usually successful in detecting the cholesterol emboli in the renal microvasculature, which are seen as needle-shaped clefts after solvent fixation of the biopsy specimen; these emboli are typically associated with an exuberant intravascular inflammatory response.

There is no specific therapy, and pts have a poor overall prognosis due to the associated burden of atherosclerotic vascular disease. However, there is often a partial improvement in renal function several months after the onset of renal impairment.

RENAL VEIN THROMBOSIS

This occurs in a variety of settings, including pregnancy, oral contraceptive use, trauma, nephrotic syndrome (especially membranous nephropathy; see Chap. 150), dehydration (in infants), extrinsic compression of the renal vein (lymph nodes, aortic aneurysm, tumor), and invasion of the renal vein by renal cell carcinoma. Definitive Dx is established by selective renal renography. Thrombolytic therapy may be effective. Oral anticoagulants (warfarin) are usually prescribed for longer–term therapy.

RENAL ARTERY STENOSIS AND ISCHEMIC NEPHROPATHY  
Main cause of renovascular hypertension. Due to (1) atherosclerosis (two-thirds of cases; usually men age >60 years, advanced retinopathy, history or findings of generalized atherosclerosis, e.g., femoral bruits) or (2) fibromuscular dysplasia (one-third of cases; usually white women age <45 years, brief history of hypertension). Renal hypoperfusion due to renal artery stenosis (RAS) activates
the renin-angiotensin-aldosterone (RAA) axis. Suggestive clinical features include onset of hypertension <30 or >50 years of age, abdominal or femoral bruits, hypokalemic alkalosis, moderate to severe retinopathy, acute onset of hypertension or malignant hypertension, recurrent episodes of acute, otherwise unexplained pulmonary edema (typically with bilateral RAS or RAS in a solitary kidney), and hypertension resistant to medical therapy. Malignant hypertension (Chap. 124) may also be caused by renal vascular occlusion. Pts, particularly those with bilateral atherosclerotic disease, may develop chronic kidney disease (ischemic nephropathy). Although the incidence is difficult to assess, ischemic nephropathy is clearly a major cause of end-stage renal disease (ESRD) in those over 50.

Nitroprusside, labetalol, or calcium antagonists are generally effective in lowering bp acutely; inhibitors of the RAA axis [e.g., angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers] are the most effective long-term treatment.

The “gold standard” in diagnosis of renal artery stenosis is conventional arteriography. Magnetic resonance angiography (MRA) has been used in many centers, given the risk of radiographic contrast nephropathy in pts with renal insufficiency; however, the newly appreciated risk of nephrogenic systemic fibrosis (NSF) in pts with renal insufficiency, attributed to gadolinium-containing MRI contrast agents, has dramatically restricted this practice in most institutions. In pts with normal renal function and hypertension, the captopril (or enalaprilat) renogram may be used as a screening test. Lateralization of renal function [accentuation of the difference between affected and unaffected (or “less affected”) sides] is suggestive of significant vascular disease. Test results may be falsely negative in the presence of bilateral disease.

Medical therapy is advocated for most pts with renal artery stenosis, such that investigation of suspected RAS should be reserved for those in whom an intervention is anticipated. Medical management of atherosclerotic RAS should include lifestyle modification and management of dyslipidemia (Fig. 153-1). Intervention should be reserved for the following scenarios: (1) progressive, un-

<table>
<thead>
<tr>
<th>TABLE 153-1</th>
<th>CLINICAL FINDINGS ASSOCIATED WITH RENAL ARTERY STENOSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>Abrupt onset of hypertension before the age of 50 years (suggestive of fibromuscular dysplasia)</td>
</tr>
<tr>
<td></td>
<td>Abrupt onset of hypertension at or after the age of 50 years (suggestive of atherosclerotic renal artery stenosis)</td>
</tr>
<tr>
<td></td>
<td>Accelerated or malignant hypertension; can sometimes be associated with polydipsia and hyponatremia</td>
</tr>
<tr>
<td></td>
<td>Refractory hypertension (not responsive to therapy with ≥3 drugs)</td>
</tr>
<tr>
<td>Renal abnormalities</td>
<td>Unexplained azotemia (suggestive of atherosclerotic renal artery stenosis)</td>
</tr>
<tr>
<td></td>
<td>Azotemia induced by treatment with an angiotensin-converting enzyme inhibitor</td>
</tr>
<tr>
<td></td>
<td>Unilateral small kidney</td>
</tr>
<tr>
<td></td>
<td>Unexplained hypokalemia</td>
</tr>
<tr>
<td>Other findings</td>
<td>Abdominal bruit, flank bruit, or both</td>
</tr>
<tr>
<td></td>
<td>Severe retinopathy</td>
</tr>
<tr>
<td></td>
<td>Carotid, coronary, or peripheral vascular disease</td>
</tr>
<tr>
<td></td>
<td>Unexplained congestive heart failure or acute pulmonary edema</td>
</tr>
</tbody>
</table>

explained renal failure, particularly in the setting of improved blood pressure control (i.e., with reduced renal perfusion); (2) poorly controlled hypertension despite multiple agents; (3) malignant hypertension; and/or (4) recurrent episodes of acute, otherwise unexplained pulmonary edema. Notably, pts should
always be re-evaluated frequently (every 3–6 months) for the progression of RAS and the development of an indication for revascularization (Fig. 153-1).

The choice of nonmedical management options depends on the type of lesion (atherosclerotic versus fibromuscular), the location of the lesion (ostial versus nonostial), localized surgical and/or interventional expertise, and the presence of other localized comorbidities (i.e., aortic aneurysm or severe aortoiliac disease). Thus fibromuscular lesions, typically located at a distance away from the renal artery ostium, are generally amenable to percutaneous angioplasty; ostial atherosclerotic lesions require stenting. Surgery is more commonly reserved for those who require aortic surgery, but it may be appropriate for those with severe bilateral disease. Again, periodic re-evaluation is needed to follow the response to intervention and, if necessary, investigate for restenosis (Fig. 153-1).

Pts who respond to vascularization will typically have a reduction in bp of 25–30 mmHg systolic, generally within the first 48 h or so after the procedure. For those with renal dysfunction, only ~25% are expected to demonstrate renal improvement, with deterioration in renal function in another 25% and stable function in ~50%. Small kidneys (<8 cm by ultrasound) are much less likely to respond favorably to revascularization.

SCLERODERMA

Scleroderma renal crisis can cause sudden oliguric renal failure and severe hypertension due to small-vessel occlusion in previously stable pts. Aggressive control of bp with ACE inhibitors and dialysis, if necessary, improve survival and may restore renal function.

ARTERIOLAR NEPHROSCLEROSIS

Persistent hypertension causes arteriosclerosis of the renal arterioles and loss of renal function (nephrosclerosis). “Benign” nephrosclerosis is associated with loss of cortical kidney mass and thickened afferent arterioles and mild to moderate impairment of renal function. Renal biopsy will also demonstrate glomerulosclerosis and interstitial nephritis; pts will typically exhibit moderate proteinuria, i.e., <1 g/d. Malignant nephrosclerosis is characterized by accelerated rise in bp and the clinical features of malignant hypertension, including renal failure (Chap. 124). Malignant nephrosclerosis may be seen in association with cocaine use, which also increases the risk of renal progression in pts with “benign” arteriolar nephrosclerosis.

Aggressive control of bp can usually but not always halt or reverse the deterioration of renal function, and some pts have a return of renal function to near normal. Risk factors for progressive renal injury include a history of severe, longstanding hypertension; however, African Americans are at particularly high risk of progressive renal injury. The African American Study of Kidney Disease and Hypertension (AASK) established the superiority of ACE inhibitors over beta blockers or calcium channel blockers, with respect to progression of kidney disease.

THROMBOTIC MICROANGIOPATHIES

The thrombotic microangiopathies (TMAs) are classically subdivided into two general syndromes: thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). TMAs are thus broadly characterized by the presence of ARF, microangiopathic hemolytic anemia, thrombocytopenia, and neurologic dysfunction. Pts with TTP may suffer from the classic pentad of microangiopathic hemolytic anemia, fever, thrombocytopenia, neurologic symp-
toms and signs, and renal dysfunction. Extrarenal symptoms are in contrast less prominent or common, but not unheard of, in postdiarrheal HUS.

The major causes of TMA are listed in Table 153-2; the common pathogenic pathway is endothelial injury. In idiopathic and familial TTP, pts have a marked deficiency in the ADAMTS13 protease, leading to accumulation of ultra-large, unprocessed von Willebrand Factor (vWF) polymers, platelet aggregation, and TMA. In contrast, postdiarrheal HUS is associated with presence of a bacterial toxin (Shiga toxin or verotoxin) that causes endothelial injury; children and the elderly are particularly susceptible. Pts with atypical or nondiarrheal HUS may in turn have inherited or acquired deficiencies in membrane-associated regulatory proteins of the alternative complement pathway, enhancing endothelial sensitivity to complement.

Laboratory evaluation will usually reveal evidence of a microangiopathic hemolytic anemia, although this may be absent in certain causes, e.g., antiphospholipid antibody syndrome. The reticulocyte count should be elevated, along with an increase in the red cell distribution width. Hemolysis should increase levels of LDH and decrease circulating haptoglobin, with a negative Coomb’s test. Examination of the peripheral smear is key, since the presence of schistocytes will help establish the diagnosis. Specific diagnostic tests—e.g., HIV testing, antiphospholipid antibody screens—may be useful in the differential diagnosis. Measurement of vWF protease activity promises considerable diagnostic and therapeutic utility; however, at this point, this is not routinely available in a time

### Table 153-2 Causes of Thrombotic Microangiopathy

<table>
<thead>
<tr>
<th>Genetic</th>
<th>TTP: deficiency of ADAMTS13 (vWF protease)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HUS: deficiency of complement factor H, complement factor I, membrane cofactor protein</td>
</tr>
<tr>
<td>Idiopathic</td>
<td>TTP: acquired antibodies to ADAMTS13 (vWF protease)</td>
</tr>
<tr>
<td></td>
<td>HUS: acquired antibodies to complement factor H, complement factor I, membrane cofactor protein</td>
</tr>
<tr>
<td>Infectious</td>
<td>Bacterial: <em>Escherichia coli</em> O157:H7, <em>Shigella</em>, <em>Salmonella</em>, <em>Campylobacter</em>, etc.</td>
</tr>
<tr>
<td></td>
<td>Viral: HIV, CMV, EBV, etc.</td>
</tr>
<tr>
<td>Drug-related</td>
<td>Calcineurin inhibitors: tacrolimus and cyclosporine</td>
</tr>
<tr>
<td></td>
<td>Antiplatelet agents: ticlopidine, clopidogrel</td>
</tr>
<tr>
<td></td>
<td>Quinine</td>
</tr>
<tr>
<td></td>
<td>Chemotherapy: mitomycin C, gemcitabine, cisplatin</td>
</tr>
<tr>
<td></td>
<td>OKT3 monoclonal antibody</td>
</tr>
<tr>
<td></td>
<td>Angiogenesis/VEGF inhibitors: bevacizumab, sunitinib, sorafenib</td>
</tr>
<tr>
<td>Autoimmune</td>
<td>Anti-phospholipid antibody syndrome</td>
</tr>
<tr>
<td></td>
<td>SLE, vasculitis</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Post–bone marrow transplantation</td>
</tr>
<tr>
<td></td>
<td>Disseminated malignancy</td>
</tr>
<tr>
<td></td>
<td>Pregnancy</td>
</tr>
</tbody>
</table>

_Note:_ TTP, thrombotic thrombocytopenic purpura; ADAMTS13, a disintegrin-like and metalloprotease with thrombospondin type I motif-13; vWF, von Willebrand factor; HUS, hemolytic uremic syndrome; CMV, cytomegalovirus; EBV, Epstein-Barr virus; VEGF, vascular endothelial growth factor; SLE, systemic lupus erythematosus.
Nephrology

SECTION 10

frame suitable for routine clinical use. Renal biopsy will classically demonstrate fibrin- and/or vWF-positive thrombi in arterioles and glomeruli, endothelial injury, and widening of the subendothelial space leading to a “double contour” appearance of the glomerular capillaries.

Treatment of TMA depends on the underlying pathogenesis. Idiopathic TTP is due to the presence of circulating antibody inhibitors of ADAMTS13 and thus responds to plasma exchange, combining plasmapheresis (removal of antibody) and infusion of fresh-frozen plasma (repletion with native ADAMTS13/vWF protease).

TOXEMIAS OF PREGNANCY

Preeclampsia is characterized by hypertension, proteinuria, edema, consumptive coagulopathy, sodium retention, hyperuricemia, and hyperreflexia; eclampsia is the further development of seizures. Glomerular swelling and/or ischemia causes renal insufficiency. Coagulation abnormalities and ARF may occur. Treatment consists of bed rest, sedation, control of neurologic manifestations with magnesium sulfate, control of hypertension with vasodilators and other antihypertensive agents proven safe in pregnancy, and delivery of the infant.

VASculitis

Renal complications are frequent and severe in polyarteritis nodosa, hypersensitivity angiitis, Wegener’s granulomatosis, and other forms of vasculitis (Chap. 168). Therapy is directed toward the underlying disease.

SICKLE CELL NEPHROPATHY

The hypertonic and relatively hypoxic renal medulla coupled with slow blood flow in the vasa recta favors sickling. Papillary necrosis, cortical infarcts, functional tubule abnormalities (nephrogenic diabetes insipidus), glomerulopathy, nephrotic syndrome, and, rarely, ESRD may be complications.

For a more detailed discussion, see Badr KF, Brenner BM: Vascular Injury to the Kidney, Chap. 280, p. 1811, in HPIM-17.

154 Nephrolithiasis

Renal calculi are common, affecting ~1% of the population, and recurrent in more than half of pts. Stone formation begins when urine becomes supersaturated with insoluble components due to (1) low urinary volume, (2) excessive or insufficient excretion of selected compounds, or (3) other factors (e.g., urinary pH) that diminish solubility. Approximately 75% of stones are Ca-based (the majority Ca oxalate; also Ca phosphate and other mixed stones), 15% struvite (magnesium-ammonium-phosphate), 5% uric acid, and 1% cystine, reflecting the metabolic disturbance(s) from which they arise.
Stones in the renal pelvis may be asymptomatic or cause hematuria alone; with passage, obstruction may occur at any site along the collecting system. Obstruction related to the passage of a stone leads to severe pain, often radiating to the groin, sometimes accompanied by intense visceral symptoms (i.e., nausea, vomiting, diaphoresis, light-headedness), hematuria, pyuria, urinary tract infection (UTI), and, rarely, hydronephrosis. In contrast, staghorn calculi, associated with recurrent UTI with urea-splitting organisms (Proteus, Klebsiella, Providencia, Morganella, and others), may be completely asymptomatic, presenting with loss of renal function.

**STONE COMPOSITION**

Most stones are composed of Ca oxalate. These may be associated with hypercalciuria and/or hyperoxaluria. Hypercalciuria can be seen in association with a very high-Na diet, loop diuretic therapy, distal (type I) renal tubular acidosis (RTA), sarcoidosis, Cushing’s syndrome, aldosterone excess, or conditions associated with hypercalcemia (e.g., primary hyperparathyroidism, vitamin D excess, milk-alkali syndrome), or it may be idiopathic. Hyperoxaluria may be seen with intestinal (especially ileal) malabsorption syndromes (e.g., inflammatory bowel disease, pancreatitis), due to reduced intestinal secretion of oxalate and/or the binding of intestinal Ca by fatty acids within the bowel lumen, with enhanced absorption of free oxalate and hyperoxaluria. Ca oxalate stones may also form due to (1) a deficiency of urinary citrate, an inhibitor of stone formation that is underexcreted with metabolic acidosis; and (2) hyperuricosuria (see below). Ca phosphate stones are much less common and tend to occur in the setting of an abnormally high urinary pH (7–8), usually in association with a complete or partial distal RTA.

Struvite stones form in the collecting system when infection with urea-splitting organisms is present. Struvite is the most common component of staghorn calculi and obstruction. Risk factors include previous UTI, nonstruvite stone disease, urinary catheters, neurogenic bladder (e.g., with diabetes or multiple sclerosis), and instrumentation.

Uric acid stones develop when the urine is saturated with uric acid in the presence of an acid urine pH; pts typically have underlying metabolic syndrome and insulin resistance, associated with a relative defect in ammoniagenesis and urine pH that is <5.4 and often <5.0. Pts with myeloproliferative disorders (esp. after treatment with chemotherapy), gout, acute and chronic renal failure, and following cyclosporine therapy often develop hyperuricemia and hyperuricosuria and are at risk for stones if the urine volume diminishes. Hyperuricosuria without hyperuricemia may be seen in association with certain drugs (e.g., probenecid, high-dose salicylates).

Cystine stones are the result of a rare inherited defect in renal and intestinal transport of several dibasic amino acids; the overexcretion of cystine (cysteine disulfide), which is relatively insoluble, leads to nephrolithiasis. Stones begin in childhood and are a rare cause of staghorn calculi; they occasionally lead to end-stage renal disease. Cystine stones are more likely to form in acidic urinary pH.

**WORKUP**

Although some have advocated a complete workup after a first stone episode, others would defer that evaluation until there has been evidence of recurrence or if there is no obvious cause (e.g., low fluid intake during the summer months with obvious dehydration). Table 154-1 outlines a reasonable workup for an outpatient with an uncomplicated kidney stone. On occasion, a stone is recov-
Nephrology

SECTION 10

Nephrology

1. Dietary and fluid intake history
2. Careful medical history and physical examination, focusing on systemic diseases
3. Noncontrast helical CT, with 5-mm CT cuts
4. Routine UA; presence of crystals, hematuria, measurement of urine pH
5. Serum chemistries: BUN, Cr, uric acid, calcium, phosphate, chloride, bicarbonate, PTH
6. Timed urine collections (at least 1 day during week, 1 day on weekend): Cr, Na, K, urea nitrogen, uric acid, calcium, phosphate, oxalate, citrate, pH

Table 154-2 outlines stone-specific therapies for pts with complex or recurrent nephrolithiasis.

**Table 154-1**

**WORKUP FOR AN OUTPATIENT WITH A RENAL STONE**

<table>
<thead>
<tr>
<th>Step</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Dietary and fluid intake history</td>
</tr>
<tr>
<td>2.</td>
<td>Careful medical history and physical examination, focusing on systemic diseases</td>
</tr>
<tr>
<td>3.</td>
<td>Noncontrast helical CT, with 5-mm CT cuts</td>
</tr>
<tr>
<td>4.</td>
<td>Routine UA; presence of crystals, hematuria, measurement of urine pH</td>
</tr>
<tr>
<td>5.</td>
<td>Serum chemistries: BUN, Cr, uric acid, calcium, phosphate, chloride, bicarbonate, PTH</td>
</tr>
<tr>
<td>6.</td>
<td>Timed urine collections (at least 1 day during week, 1 day on weekend): Cr, Na, K, urea nitrogen, uric acid, calcium, phosphate, oxalate, citrate, pH</td>
</tr>
</tbody>
</table>

**Table 154-2**

**SPECIFIC THERAPIES FOR NEPHROLITHIASIS**

<table>
<thead>
<tr>
<th>Stone Type</th>
<th>Dietary Modifications</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium oxalate</td>
<td>Increase fluid intake</td>
<td>Citrate supplementation (calcium or potassium salts &gt; sodium)</td>
</tr>
<tr>
<td></td>
<td>Moderate sodium intake</td>
<td>Cholestyramine or other therapy for fat malabsorption</td>
</tr>
<tr>
<td></td>
<td>Moderate oxalate intake</td>
<td>Thiazides if hypercalciuric</td>
</tr>
<tr>
<td></td>
<td>Moderate protein intake</td>
<td>Allopurinol if hyperuricosuric</td>
</tr>
<tr>
<td></td>
<td>Moderate fat intake</td>
<td></td>
</tr>
<tr>
<td>Calcium phosphate</td>
<td>Increase fluid intake</td>
<td>Thiazides if hypercalciuric</td>
</tr>
<tr>
<td></td>
<td>Moderate sodium intake</td>
<td>Treat hyperparathyroidism if present</td>
</tr>
<tr>
<td>Struvite</td>
<td>Increase fluid intake; same as calcium oxalate if evidence of calcium oxalate nidus for struvite</td>
<td>Methenamine and vitamin C or daily suppressive antibiotic therapy (e.g., trimethoprim-sulfamethoxazole)</td>
</tr>
<tr>
<td>Uric acid</td>
<td>Increase fluid intake</td>
<td>Allopurinol</td>
</tr>
<tr>
<td></td>
<td>Moderate dietary protein intake</td>
<td>Alkali therapy (K⁺ citrate) to raise urine pH to 6.0–6.5</td>
</tr>
<tr>
<td>Cystine</td>
<td>Increase fluid intake</td>
<td>Alkali therapy</td>
</tr>
</tbody>
</table>

Note: Sodium excretion correlates with calcium excretion.
Urinary tract obstruction (UTO), a potentially reversible cause of renal failure (RF), should be considered in all cases of acute or abrupt worsening of chronic RF. Consequences depend on duration and severity and whether the obstruction is unilateral or bilateral. UTO may occur at any level from collecting tubule to urethra. It is preponderant in women (pelvic tumors), elderly men (prostatic disease), diabetic pts (papillary necrosis), pts with neurologic diseases (spinal cord injury or multiple sclerosis, with neurogenic bladder), and individuals with retroperitoneal lymphadenopathy or fibrosis, vesicoureteral reflux, nephrolithiasis, or other causes of functional urinary retention (e.g., anticholinergic drugs).

**CLINICAL MANIFESTATIONS**

Pain can occur in some settings (obstruction due to stones) but is not common. In men, there is frequently a history of prostatism. Physical exam may reveal an enlarged bladder by percussion over the lower abdominal wall. Other findings depend on the clinical scenario. Prostatic hypertrophy can be determined by digital rectal examination. A bimanual examination in women may show a pelvic or rectal mass. The workup of pts with RF suspected of having UTO is shown in Fig. 155-1. Laboratory studies may show marked elevations of blood urea nitrogen and creatinine; if the obstruction has been of sufficient duration, there may be evidence of tubulointerstitial disease (e.g., hyperkalemia, non-anion-gap metabolic acidosis, mild hypernatremia). Urinalysis is most often benign or with a small number of cells; heavy proteinuria is rare. An obstructing stone may be visualized on abdominal radiography or helical noncontrast CT with 5-mm cuts.

Ultrasonography can be used to assess the degree of hydroureter and the integrity of the renal parenchyma; CT or IV urography may be required to localize the level of obstruction. Calyceal dilation is commonly seen; it may be absent with hyperacute obstruction, upper tract encasement by tumor or retroperitoneal fibrosis, or indwelling staghorn calculi. Kidney size may indicate the duration of obstruction. It should be noted that unilateral obstruction may be prolonged and severe (ultimately leading to loss of renal function in the obstructed kidney), with no hint of abnormality on physical exam and laboratory survey.

**Treatment**

Management of acute RF associated with UTO is dictated by (1) the level of obstruction (upper vs. lower tract), and (2) the acuity of the obstruction and its clinical consequences, including renal dysfunction and infection. Benign causes of UTO, including bladder outlet obstruction and nephrolithiasis, should be ruled out because conservative management, including Foley cathe-
ter placement and IV fluids, respectively, will usually relieve the obstruction in most cases.

Among more seriously ill pts, ureteral obstruction due to tumor is the most common and concerning cause of UTO. If technically feasible, ureteral obstruction due to tumor is best managed by cystoscopic placement of a ureteral stent. Otherwise, the placement of nephrostomy tubes with external drainage may be required. IV antibiotics should also be given if there are signs of pyelonephritis or urosepsis. Fluid and electrolyte status should be carefully monitored after obstruction is relieved. There may be a physiologic natriuresis/diuresis related to volume overload. However, there may be an “inappropriate” natriuresis/diuresis related to (1) elevated urea nitrogen, leading to an osmotic diuresis; and (2) acquired nephrogenic diabetes insipidus. Hypernatremia, sometimes of a severe degree, may develop.

For a more detailed discussion, see Seifter JL, Brenner BM: Urinary Tract Obstruction, Chap. 283, p. 1827, in HPIM-17.
Peptic Ulcer and Related Disorders

PEPTIC ULCER DISEASE (PUD)

PUD occurs most commonly in duodenal bulb (duodenal ulcer, DU) and stomach (gastric ulcer, GU). It may also occur in esophagus, pyloric channel, duodenal loop, jejunum, Meckel’s diverticulum. PUD results when “aggressive” factors (gastric acid, pepsin) overwhelm “defensive” factors involved in mucosal resistance (gastric mucus, bicarbonate, microcirculation, prostaglandins, mucosal “barrier”), and from effects of Helicobacter pylori.

Causes and Risk Factors

General  H. pylori is a spiral urease-producing organism that colonizes gastric antral mucosa in up to 100% of persons with DU and 80% with GU. It is also found in normals (increasing prevalence with age) and in those of low socioeconomic status. H. pylori is invariably associated with histologic evidence of active chronic gastritis, which over years can lead to atrophic gastritis and gastric cancer. The other major cause of ulcers (those not due to H. pylori) is nonsteroidal anti-inflammatory drugs (NSAIDs). Fewer than 1% are due to gastrinoma (Zollinger-Ellison syndrome). Other risk factors and associations: hereditary (? increased parietal cell number), smoking, hypercalcemia, mastocytosis, blood group O (antigens may bind H. pylori). Unproven: stress, coffee, alcohol.

Duodenal Ulcer  Mild gastric acid hypersecretion resulting from (1) increased release of gastrin, presumably due to (a) stimulation of antral G cells by cytokines released by inflammatory cells and (b) diminished production of somatostatin by D cells, both resulting from H. pylori infection; and (2) an exaggerated acid response to gastrin due to an increased parietal cell mass resulting from gastrin stimulation. These abnormalities reverse rapidly with eradication of H. pylori. However, a mildly elevated maximum gastric acid output in response to exogenous gastrin persists in some pts long after eradication of H. pylori, suggesting that gastric acid hypersecretion may be, in part, genetically determined. H. pylori may also result in elevated serum pepsinogen levels. Mucosal defense in duodenum is compromised by toxic effects of H. pylori infection on patches of gastric metaplasia that result from gastric acid hypersecretion or rapid gastric emptying. Other risk factors include glucocorticoids, NSAIDs, chronic renal failure, renal transplantation, cirrhosis, chronic lung disease.

Gastric Ulcer  H. pylori is also principal cause. Gastric acid secretory rates are usually normal or reduced, possibly reflecting earlier age of infection by H. pylori than in DU pts. Gastritis due to reflux of duodenal contents (including bile) may play a role. Chronic salicylate or NSAID use may account for 15–30% of GUs and increase risk of associated bleeding, perforation.

Clinical Features  Duodenal Ulcer  Burning epigastric pain 90 min to 3 h after meals, often nocturnal, relieved by food.
**Gastric Ulcer**  Burning epigastric pain made worse by or unrelated to food; anorexia, food aversion, weight loss (in 40%). Great individual variation. Similar symptoms may occur in persons without demonstrated peptic ulcers (“nonulcer dyspepsia”); less responsive to standard therapy.

**Complications**  Bleeding, obstruction, penetration causing acute pancreatitis, perforation, intractability.

**Diagnosis Duodenal Ulcer**  Upper endoscopy or upper GI barium radiography.

**Gastric Ulcer**  Upper endoscopy preferable to exclude possibility that ulcer is malignant (brush cytology, ≥6 pinch biopsies of ulcer margin). Radiographic features suggesting malignancy: ulcer within a mass, folds that do not radiate from ulcer margin, a large ulcer (>2.5–3 cm).

**Detection of *H. pylori***  Detection of antibodies in serum (inexpensive, preferred when endoscopy is not required); rapid urease test of antral biopsy (when endoscopy is required). Urea breath test generally used to confirm eradication of *H. pylori* if necessary. The fecal antigen test is sensitive, specific, and inexpensive (Table 156-1).

---

**Peptic Ulcer Disease**

**MEDICAL**

Objectives: pain relief, healing, prevention of complications, prevention of recurrences. For GU, exclude malignancy (follow endoscopically to healing). Dietary restriction unnecessary with contemporary drugs; discontinue NSAIDs; smoking may prevent healing and should be stopped. Eradication of *H. pylori* markedly reduces rate of ulcer relapse and is indicated for all DUs and GUs associated with *H. pylori* (Table 156-2). Sequential therapy is most effective in...

---

**TABLE 156-1 TESTS FOR DETECTION OF *H. PYLORI***

<table>
<thead>
<tr>
<th>Test</th>
<th>Sensitivity/Specificity, %</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Invasive (Endoscopy/Biopsy Required)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rapid urease</td>
<td>80–95/95/100</td>
<td>Simple; false negative with recent use of PPIs, antibiotics, or bismuth compounds</td>
</tr>
<tr>
<td>Histology</td>
<td>80–90/&gt;95</td>
<td>Requires pathology processing and staining; provides histologic information</td>
</tr>
<tr>
<td>Culture</td>
<td>−/−</td>
<td>Time-consuming, expensive, dependent on experience; allows determination of antibiotic susceptibility</td>
</tr>
<tr>
<td><strong>Noninvasive</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serology</td>
<td>&gt;80/&gt;90</td>
<td>Inexpensive, convenient; not useful for early follow-up</td>
</tr>
<tr>
<td>Urea breath test</td>
<td>&gt;90/&gt;90</td>
<td>Simple, rapid; useful for early follow-up; false negative with recent therapy (see rapid urease test); exposure to low-dose radiation with 14-C test</td>
</tr>
<tr>
<td>Stool antigen</td>
<td>&gt;90/&gt;90</td>
<td>Inexpensive, convenient; not established for eradication but promising</td>
</tr>
</tbody>
</table>

*Note: PPI, proton pump inhibitor.*
the treatment-naïve patient. Acid suppression is generally included in regimen. Standard drugs (H₂ receptor blockers, sucralfate, antacids) heal 80–90% of DUs and 60% of GUs in 6 weeks; healing is more rapid with omeprazole (20 mg/d).

**SURGERY**

Used for complications (persistent or recurrent bleeding, obstruction, perforation) or, uncommonly, intractability (first screen for surreptitious NSAID use and gastrinoma). For DU, see Table 156-3. For GU, perform subtotal gastrectomy.

**TABLE 156-2**

**REGIMENS RECOMMENDED FOR ERADICATION OF *H. PYLORI* INFECTION**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Triple Therapy</strong></td>
<td></td>
</tr>
<tr>
<td>1. Bismuth subsalicylate</td>
<td>2 tablets qid</td>
</tr>
<tr>
<td>plus Metronidazole plus</td>
<td>250 mg qid</td>
</tr>
<tr>
<td>Tetracycline⁵</td>
<td>500 mg qid</td>
</tr>
<tr>
<td>2. Ranitidine bismuth citrate plus</td>
<td>400 mg bid</td>
</tr>
<tr>
<td>Tetracycline plus</td>
<td>500 mg bid</td>
</tr>
<tr>
<td>Clarithromycin or metronidazole</td>
<td>500 mg bid</td>
</tr>
<tr>
<td>3. Omeprazole (lansoprazole) plus</td>
<td>20 mg bid (30 mg bid)</td>
</tr>
<tr>
<td>Clarithromycin plus</td>
<td>250 or 500 mg bid</td>
</tr>
<tr>
<td>Metronidazole or Amoxicillin</td>
<td>500 mg bid</td>
</tr>
<tr>
<td>Amoxicillin⁶</td>
<td>1 g bid</td>
</tr>
<tr>
<td><strong>Quadruple Therapy</strong></td>
<td></td>
</tr>
<tr>
<td>Omeprazole (lansoprazole)</td>
<td>20 mg (30 mg) daily</td>
</tr>
<tr>
<td>Bismuth subsalicylate</td>
<td>2 tablets qid</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>250 mg qid</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>500 mg qid</td>
</tr>
<tr>
<td><strong>Sequential Therapy</strong></td>
<td></td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>40 mg bid days 1–10</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>1 g bid days 1–5</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>500 mg bid days 6–10</td>
</tr>
<tr>
<td>Tinidazole</td>
<td>500 mg bid days 6–10</td>
</tr>
</tbody>
</table>

³Alternative: use prepacked Helidac.
⁵Alternative: use prepacked Prevpac.
⁶Use either metronidazole or amoxicillin, but not both.

**TABLE 156-3**

**SURGICAL TREATMENT OF DUODENAL ULCER**

<table>
<thead>
<tr>
<th>Operation</th>
<th>Recurrence Rate</th>
<th>Complication Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vagotomy + antrectomy (Billroth I or II)⁴</td>
<td>1%</td>
<td>Highest</td>
</tr>
<tr>
<td>Vagotomy and pyloroplasty</td>
<td>10%</td>
<td>Intermediate</td>
</tr>
<tr>
<td>Parietal cell (proximal gastric, superselective) vagotomy</td>
<td>≥10%</td>
<td>Lowest</td>
</tr>
</tbody>
</table>

⁴Billroth I, gastroduodenostomy; Billroth II, gastrojejunostomy.
Complications of Surgery

(1) Obstructed afferent loop (Billroth II), (2) bile reflux gastritis, (3) dumping syndrome (rapid gastric emptying with abdominal distress + postprandial vasomotor symptoms), (4) postvagotomy diarrhea, (5) bezoar, (6) anemia (iron, B₁₂, folate malabsorption), (7) malabsorption (poor mixing of gastric contents, pancreatic juices, bile; bacterial overgrowth), (8) osteomalacia and osteoporosis (vitamin D and Ca malabsorption), (9) gastric remnant carcinoma.

Approach to the Patient with Peptic Ulcer Disease

Optimal approach is uncertain. Serologic testing for *H. pylori* and treating, if present, may be cost-effective. Other options include trial of acid-suppressive therapy, endoscopy only in treatment failures, or initial endoscopy in all cases.

Gastropathies

Erosive Gastropathies

Hemorrhagic gastritis, multiple gastric erosions may be caused by aspirin and other NSAIDs (lower risk with newer agents, e.g., nabumetone and etodolac, which do not inhibit gastric mucosal prostaglandins) or severe stress (burns, sepsis, trauma, surgery, shock, or respiratory, renal, or liver failure). Pt may be asymptomatic or experience epigastric discomfort, nausea, hematemesis, or melena. Diagnosis is made by upper endoscopy.

Removal of offending agent and maintenance of O₂ and blood volume as required. For prevention of stress ulcers in critically ill pts, hourly oral administration of liquid antacids (e.g., Maalox 30 mL), IV H₂ receptor antagonist (e.g., cimetidine, 300-mg bolus + 37.5–50 mg/h IV), or both is recommended to maintain gastric pH > 4. Alternatively, sucralfate slurry, 1 g PO q6h, can be given; does not raise gastric pH and may thus avoid increased risk of aspiration pneumonia associated with liquid antacids. Pantoprazole can be administered IV to suppress gastric acid in the critically ill. Misoprostol, 200 μg PO qid, or profound acid suppression (e.g., famotidine, 40 mg PO bid) can be used with NSAIDs to prevent NSAID-induced ulcers.

Chronic Gastritis

Identified histologically by an inflammatory cell infiltrate dominated by lymphocytes and plasma cells with scant neutrophils. In its early stage, the changes are limited to the lamina propria (*superficial gastritis*). When the disease progresses to destroy glands, it becomes *atrophy gastritis*. The final stage is *gastric atrophy*, in which the mucosa is thin and the infiltrate sparse. Chronic gastritis can be classified based on predominant site of involvement.

Type A Gastritis

This is the body-predominant and less common form. Generally asymptomatic, common in elderly; autoimmune mechanism may be associated with achlorhydria, pernicious anemia, and increased risk of gastric cancer (value of screening endoscopy uncertain). Antibodies to parietal cells present in >90%.

Type B Gastritis

This is antral-predominant disease and caused by *H. pylori*. Often asymptomatic but may be associated with dyspepsia. Atrophic gastritis, gastric atrophy, gastric lymphoid follicles, and gastric B cell lymphomas may occur. Infection early in life or in setting of malnutrition or low gastric acid out-
put is associated with gastritis of entire stomach (including body) and increased risk of gastric cancer. Eradication of *H. pylori* (Table 156-2) not routinely recommended unless PUD or gastric mucosa-associated lymphoid tissue (MALT) lymphoma is present.

**Specific Types of Gastropathy or Gastritis**  Alcoholic gastropathy (submucosal hemorrhages), Ménétrier’s disease (hypertrophic gastropathy), eosinophilic gastritis, granulomatous gastritis, Crohn’s disease, sarcoidosis, infections (tuberculosis, syphilis, fungi, viruses, parasites), pseudolymphoma, radiation, corrosive gastritis.

### ZOLLINGER-ELLISON (Z-E) SYNDROME (GASTRINOMA)

Consider when ulcer disease is severe, refractory to therapy, associated with ulcers in atypical locations, or associated with diarrhea. Tumors are usually pancreatic or in duodenum (submucosal, often small), may be multiple, slowly growing; >60% malignant; 25% associated with MEN 1, i.e., multiple endocrine neoplasia type 1 (gastrinoma, hyperparathyroidism, pituitary neoplasm), often duodenal, small, multicentric, less likely to metastasize to liver than pancreatic gastrinomas but often metastasize to local lymph nodes.

**Diagnosis**  
**Suggestive**  Basal acid output > 15 mmol/h; basal/maximal acid output > 60%; large mucosal folds on endoscopy or upper GI radiograph.

**Confirmatory**  Serum gastrin > 1000 ng/L or rise in gastrin of 200 ng/L following IV secretin and, if necessary, rise of 400 ng/L following IV calcium (Table 156-4).

**Differential Diagnosis**  
**Increased Gastric Acid Secretion**  Z-E syndrome, antral G cell hyperplasia or hyperfunction (? due to *H. pylori*), postgastrectomy retained antrum, renal failure, massive small bowel resection, chronic gastric outlet obstruction.

**Normal or Decreased Gastric Acid Secretion**  Pernicious anemia, chronic gastritis, gastric cancer, vagotomy, pheochromocytoma.

**Omeprazole, beginning at 60 mg PO q A.M. and increasing until maximal gastric acid output is <10 mmol/h before next dose, is drug of choice during evaluation and in pts who are not surgical candidates; dose can often be reduced over time. Radiolabeled octreotide scanning has emerged as the most sensitive test for detecting primary tumors and metastases; may be supplemented with surgery if primary tumor is confirmed.**

<table>
<thead>
<tr>
<th>Table 156-4</th>
<th>DIFFERENTIAL DIAGNOSTIC TESTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Condition</strong></td>
<td><strong>Fasting Gastrin</strong></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>DU</td>
<td>N (≤150 ng/L)</td>
</tr>
<tr>
<td>Z-E</td>
<td>↑↑↑</td>
</tr>
<tr>
<td>Antral G (gastrin) cell hyperplasia</td>
<td>↑</td>
</tr>
</tbody>
</table>

*Note: DU, duodenal ulcer; N, normal; NC, no change; Z-E, Zollinger-Ellison syndrome.*
by endoscopic ultrasonography. Exploratory laparotomy with resection of primary tumor and solitary metastases is done when possible. In pts with MEN 1, tumor is often multifocal and unresectable; treat hyperparathyroidism first (hypergastrinemia may improve). For unresectable tumors, parietal cell vagotomy may enhance control of ulcer disease by drugs. Chemotherapy is used for metastatic tumor to control symptoms (e.g., streptozocin, 5-fluorouracil, doxorubicin, or interferon α); 40% partial response rate.

For a more detailed discussion, see Del Valle J: Peptic Ulcer Disease and Related Disorders, Chap. 287, p. 1855, in HPIM-17.

Inflammatory Bowel Diseases

Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of unknown etiology involving the GI tract. Peak occurrence is between ages 15 and 30 and between ages 60 and 80, but onset may occur at any age. Epidemiologic features are shown in Table 157-1. Pathogenesis of IBD involves activation of immune cells by unknown inciting agent (? microorganism, dietary component, bacterial or self-antigen) leading to release of cytokines and inflammatory mediators. Genetic component suggested by increased risk in first-degree relatives of pts with IBD and concurrence of type of IBD, location of Crohn’s disease, and clinical course. Reported associations include HLA-DR2 in Japanese patients with ulcerative colitis and a Crohn’s disease–related gene called CARD15 on chromosome 16p. CARD15 mutations may account for 10% of CD risk. Other potential pathogenic factors include serum antineutrophil cytoplasmic antibodies (ANCA) in 70% of pts with ulcerative colitis (also in 5–10% of Crohn’s disease pts) and antibodies to *Saccharomyces cerevisiae* (ASCA) in 60–70% of Crohn’s disease pts (also in 10–15% of ulcerative colitis pts and 5% of normal controls). Granulomatous angiitis (vasculitis) may occur in Crohn’s disease. Acute flares may be pre-

### Table 157-1: Epidemiology of IBD

<table>
<thead>
<tr>
<th></th>
<th>Ulcerative Colitis</th>
<th>Crohn’s Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence (North America) per person-years</td>
<td>2.2–14.3/100,000</td>
<td>3.1–14.6/100,000</td>
</tr>
<tr>
<td>Age of onset</td>
<td>15–30 &amp; 60–80</td>
<td>15–30 &amp; 60–80</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Jewish &gt; Non-Jewish Caucasian &gt; African American &gt; Hispanic &gt; Asian</td>
<td></td>
</tr>
<tr>
<td>Male:female ratio</td>
<td>1:1</td>
<td>1.1–1.8:1</td>
</tr>
<tr>
<td>Smoking</td>
<td>May prevent disease</td>
<td>May cause disease</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>No increased risk</td>
<td>Odds ratio 1.4</td>
</tr>
<tr>
<td>Appendectomy</td>
<td>Protective</td>
<td>Not protective</td>
</tr>
<tr>
<td>Monozygotic twins</td>
<td>6% concordance</td>
<td>58% concordance</td>
</tr>
<tr>
<td>Dizygotic twins</td>
<td>0% concordance</td>
<td>4% concordance</td>
</tr>
</tbody>
</table>
cipitated by infections, nonsteroidal anti-inflammatory drugs (NSAIDs), stress. Onset of ulcerative colitis often follows cessation of smoking.

**ULCERATIVE COLITIS (UC)**

**Pathology**  Colonic mucosal inflammation; rectum almost always involved, with inflammation extending continuously (no skip areas) proximally for a variable extent; histologic features include epithelial damage, inflammation, crypt abscesses, loss of goblet cells.

**Clinical Manifestations**  Bloody diarrhea, mucus, fever, abdominal pain, tenesmus, weight loss; spectrum of severity (majority of cases are mild, limited to rectosigmoid). In severe cases dehydration, anemia, hypokalemia, hypoalbuminemia.

**Complications**  Toxic megacolon, colonic perforation; cancer risk related to extent and duration of colitis; often preceded by or coincident with dysplasia, which may be detected on surveillance colonoscopic biopsies.

**Diagnosis**  Sigmoidoscopy/colonoscopy: mucosal erythema, granularity, friability, exudate, hemorrhage, ulcers, inflammatory polyps (pseudopolyps). Barium enema: loss of haustrations, mucosal irregularity, ulcerations.

**CROHN’S DISEASE (CD)**

**Pathology**  Any part of GI tract, usually terminal ileum and/or colon; transmural inflammation, bowel wall thickening, linear ulcerations, and submucosal thickening leading to cobblestone pattern; discontinuous (skip areas); histologic features include transmural inflammation, granulomas (often absent), fissures, fistulas.

**Clinical Manifestations**  Fever, abdominal pain, diarrhea (often without blood), fatigue, weight loss, growth retardation in children; acute ileitis mimicking appendicitis; anorectal fissures, fistulas, abscesses. Clinical course falls into three broad patterns: (1) inflammatory, (2) stricturing, and (3) fistulizing.

**Complications**  Intestinal obstruction (edema vs. fibrosis); rarely toxic megacolon or perforation; intestinal fistulas to bowel, bladder, vagina, skin, soft tissue, often with abscess formation; bile salt malabsorption leading to cholesterol gallstones and/or oxalate kidney stones; intestinal malignancy; amyloidosis.

**Diagnosis**  Sigmoidoscopy/colonoscopy, barium enema, upper GI and small-bowel series: nodularity, rigidity, ulcers that may be deep or longitudinal, cobblestoning, skip areas, strictures, fistulas. CT may show thickened, matted bowel loops or an abscess.

**DIFFERENTIAL DIAGNOSIS**

**Infectious Enterocolitis**  *Shigella*, *Salmonella*, *Campylobacter*, *Yersinia* (acute ileitis), *Plesiomonas shigelloides*, *Aeromonas hydrophila*, *Escherichia coli* serotype O157:H7, *Gonorrhea*, *Lymphogranuloma venereum*, *Clostridium difficile* (pseudomembranous colitis), tuberculosis, amebiasis, cytomegalovirus, AIDS.

**Others**  Ischemic bowel disease, appendicitis, diverticulitis, radiation enterocolitis, bile salt–induced diarrhea (ileal resection), drug-induced colitis (e.g., NSAIDs), bleeding colonic lesion (e.g., neoplasm), irritable bowel syndrome (no bleeding), microscopic (lymphocytic) or collagenous colitis (chronic watery
diarrhea)—normal colonoscopy, but biopsies show superficial colonic epithelial inflammation and, in collagenous colitis, a thick subepithelial layer of collagen; response to aminosalicylates and glucocorticoids variable.

### EXTRAINTESTINAL MANIFESTATIONS OF UC AND CD

1. **Joint**: Peripheral arthritis—parallels activity of bowel disease; ankylosing spondylitis and sacroiliitis (associated with HLA-B27)—activity independent of bowel disease.
2. **Skin**: Erythema nodosum, aphthous ulcers, pyoderma gangrenosum, cutaneous Crohn’s disease.
3. **Eye**: Episcleritis, iritis, uveitis.
4. **Liver**: Fatty liver, “pericholangitis” (intrahepatic sclerosing cholangitis), primary sclerosing cholangitis, cholangiocarcinoma, chronic hepatitis.
5. **Others**: Autoimmune hemolytic anemia, phlebitis, pulmonary embolus (hypercoagulable state).

---

**Inflammatory Bowel Diseases**  
See Fig. 157-1

### Supportive

Antidiarrheal agents (diphenoxylate and atropine, loperamide) in mild disease; IV hydration and blood transfusions in severe disease; parenteral nutrition or defined enteral formulas—effective as primary therapy in CD, although high relapse rate when oral feeding is resumed; should not replace drug therapy; important role in preoperative preparation of malnourished pt; emotional support.

### Sulfasalazine and Aminosalicylates

Active component of sulfasalazine is 5-aminosalicylic acid (5-ASA) linked to sulfapyridine carrier; useful in colonic disease of mild to moderate severity (1–1.5 g PO qid); efficacy in maintaining remission demonstrated only for UC (500 mg PO qid). Toxicity (generally due to sulfapyridine component): dose-related—nausea, headache, rarely hemolytic anemia—may resolve when drug dose is lowered; idiosyncratic—fever, rash, neutropenia, pancreatitis, hepatitis, etc.; miscellaneous—oligospermia. Newer aminosalicylates are as effective as sulfasalazine but with fewer side effects. Enemas containing 4 g of 5-ASA (mesalamine) may be used in distal UC, 1 nightly retained qhs until remission, then q2hs or q3hs. Suppositories containing 500 mg of 5-ASA may be used in proctitis.

### Glucocorticoids

Useful in severe disease and ileal or ileocolonic CD. Prednisone, 40–60 mg PO qd, then taper; IV hydrocortisone, 100 mg tid or equivalent, in hospitalized pts; IV adrenocorticotropic hormone drip (120 U qd) may be preferable in first attacks of UC. Nightly hydrocortisone retention enemas in proctosigmoiditis. Numerous side effects make long-term use problematic.

### Immunosuppressive Agents

Azathioprine, 6-mercaptopurine—50 mg PO qd up to 2.0 or 1.5 mg/kg qd, respectively. Useful as steroid-sparing agents and in intractable or fistulous CD (may require 2- to 6-month trial before efficacy seen). Toxicity—immunosuppression, pancreatitis, ? carcinogenicity. Avoid in pregnancy.

### Metronidazole

Appears effective in colonic CD (500 mg PO bid) and refractory perineal CD (10–20 mg/kg PO qd). Toxicity—peripheral neuropathy, metallic taste, ? car-
FIGURE 157-1 Medical management of IBD.
Cinogenicity. Avoid in pregnancy. Other antibiotics (e.g., ciprofloxacin 500 mg PO bid) may be of value in terminal ileal and perianal CD, and broad-spectrum IV antibiotics are indicated for fulminant colitis and abscesses.

**Others**

Cyclosporine [potential value in a dose of 4 (mg/kg)/d IV for 7–14 days in severe UC and possibly intractable Crohn’s fistulas]; experimental—methotrexate, chloroquine, fish oil, nicotine, others. Infliximab [monoclonal antibody to tumor necrosis factor (TNF)] 5 mg/kg IV induces responses in 65% (complete in 33%) of CD pts refractory to 5-ASA, glucocorticoids, and 6-mercaptopurine. In UC, 27–49% of patients respond.

Adalimumab is a humanized version of the anti-TNF antibody that is less likely to elicit neutralizing antibodies in the pt. Pegylated versions of anti-TNF antibody may be used once monthly.

**Surgery**

UC: Colectomy (curative) for intractability, toxic megacolon (if no improvement with aggressive medical therapy in 24–48 h), cancer, dysplasia. Ileal pouch—anal anastomosis is operation of choice in UC but contraindicated in CD and in elderly. CD: Resection for fixed obstruction (or stricturoplasty), abscesses, persistent symptomatic fistulas, intractability.

---

For a more detailed discussion, see Friedman S, Blumberg RS: Inflammatory Bowel Disease, Chap. 289, p. 1886, in HPIM-17.

---

## Colonic and Anorectal Diseases

### Irritable Bowel Syndrome (IBS)

Characterized by altered bowel habits, abdominal pain, and absence of detectable organic pathology. Most common GI disease in clinical practice. Three types of clinical presentations: (1) spastic colon (chronic abdominal pain and constipation), (2) alternating constipation and diarrhea, or (3) chronic, painless diarrhea.

**Pathophysiology** Visceral hyperalgesia to mechanoreceptor stimuli is common. Reported abnormalities include altered colonic motility at rest and in response to stress, cholinergic drugs, cholecystokinin; altered small-intestinal motility; enhanced visceral sensation (lower pain threshold in response to gut distention); and abnormal extrinsic innervation of the gut. Pts presenting with IBS to a physician have an increased frequency of psychological disturbances—depression, hysteria, obsessive-compulsive disorder. Specific food intolerances and malabsorption of bile acids by the terminal ileum may account for a few cases.

**Clinical Manifestations** Onset often before age 30; females:males = 2:1. Abdominal pain and irregular bowel habits. Additional symptoms often include abdominal distention, relief of abdominal pain with bowel movement, increased
Irritable Bowel Syndrome (Table 158-2)

Reassurance and supportive physician-pt relationship, avoidance of stress or precipitating factors, dietary bulk (fiber, psyllium extract, e.g., Metamucil 1 tbsp daily or bid); for diarrhea, trials of loperamide (2-mg tabs PO q A.M. then 1 PO after each loose stool to a maximum of 8/d, then titrate), diphenoxylate (Lomotil) (up to 2-mg tabs PO qid), or cholestyramine (up to 1-gram packet mixed in water PO qid); for pain, anticholinergics (e.g., dicyclomine HCl 10–40 mg PO qid) or hyoscyamine as Levsin 1–2 PO q4h prn. Amitriptyline 25–50 mg PO qhs or other antidepressants in low doses may relieve pain. Selective serotonin reuptake inhibitors such as paroxetine are being evaluated in constipation-dominant pts, and serotonin receptor antagonists such as alosetron are being evaluated in diarrhea-dominant pts. Psychotherapy, hypnotherapy of possible benefit in severe refractory cases.

DIVERTICULAR DISEASE

Herniations or saclike protrusions of the mucosa through the muscularis at points of nutrient artery penetration; possibly due to increased intraluminal pressure, low-fiber diet; most common in sigmoid colon.

Clinical Presentation
1. Asymptomatic (detected by barium enema or colonoscopy).
2. Pain: Recurrent left lower quadrant pain relieved by defecation; alternating constipation and diarrhea. Diagnosis by barium enema.
3. Diverticulitis: Pain, fever, altered bowel habits, tender colon, leukocytosis. Best confirmed and staged by CT after opacification of bowel. (In pts who recover with medical therapy, perform elective barium enema or colonoscopy in 4–6 weeks to exclude cancer.) Complications: pericolonic abscess, perfo-
4. **Hemorrhage**: Usually in absence of diverticulitis, often from ascending colon and self-limited. If persistent, manage with mesenteric arteriography and intraarterial infusion of vasopressin, or surgery (Chap. 55).

### Diverticular Disease

#### Pain

High-fiber diet, psyllium extract (e.g., Metamucil 1 tbsp PO qd or bid), anticholinergics (e.g., dicyclomine HCl 10–40 mg PO qid).

#### Diverticulitis

NPO, IV fluids, antibiotics for 7–10 d (e.g., trimethoprim/sulfamethoxazole or ciprofloxacin and metronidazole; add ampicillin to cover enterococci in nonresponders); for ambulatory pts, ampicillin/clavulanate (clear liquid diet); surgical resection in refractory or frequently recurrent cases, young persons (<age 50), immunosuppressed pts, or when there is inability to exclude cancer.

Pts who have had at least two documented episodes and those who respond slowly to medical therapy should be offered surgical options to achieve removal of the diseased colonic segment, controlling sepsis, eliminating obstructions or fistulas, and restoring intestinal continuity.

### INTESTINAL PSEUDOObSTRUCTION

Recurrent attacks of nausea, vomiting, and abdominal pain and distention mimicking mechanical obstruction; may be complicated by steatorrhea due to bacterial overgrowth.

### TABLE 158-2 POSSIBLE DRUGS FOR A DOMINANT SYMPTOM IN IBS

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Drug</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>Loperamide</td>
<td>2–4 mg when necessary/maximum 12 g/d</td>
</tr>
<tr>
<td></td>
<td>Cholestyramine resin</td>
<td>4 g with meals</td>
</tr>
<tr>
<td></td>
<td>Alosetron&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.5–1 mg bid (for severe IBS, women)</td>
</tr>
<tr>
<td>Constipation</td>
<td>Psyllium husk</td>
<td>3–4 g bid with meals, then adjust</td>
</tr>
<tr>
<td></td>
<td>Methylcellulose</td>
<td>2 g bid with meals, then adjust</td>
</tr>
<tr>
<td></td>
<td>Calcium polycarbophil</td>
<td>1 g qd to qid</td>
</tr>
<tr>
<td></td>
<td>Lactulose syrup</td>
<td>10–20 g bid</td>
</tr>
<tr>
<td></td>
<td>70% sorbitol</td>
<td>15 mL bid</td>
</tr>
<tr>
<td></td>
<td>Polyethylene glycol 3350</td>
<td>17 g in 250 mL water qd</td>
</tr>
<tr>
<td></td>
<td>Lubiprostone (Amitiza)</td>
<td>24 mg bid</td>
</tr>
<tr>
<td></td>
<td>Magnesium hydroxide</td>
<td>30–60 mL qd</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>Smooth-muscle relaxant</td>
<td>qd to qid ac</td>
</tr>
<tr>
<td></td>
<td>Tricyclic antidepressants</td>
<td>Start 25–50 mg hs, then adjust</td>
</tr>
<tr>
<td></td>
<td>Selective serotonin</td>
<td>Begin small dose, increase as needed</td>
</tr>
<tr>
<td></td>
<td>reuptake inhibitors</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>Available only in the United States.

Source: Adapted from Longstreth GF et al: Functional bowel disorders. Gastroenterology 130:1480, 2006; with permission.
Causes  

**Intestinal Pseudoobstruction**

For acute attacks: intestinal decompression with long tube. Oral antibiotics for bacterial overgrowth (e.g., metronidazole 250 mg PO tid, tetracycline 500 mg PO qid, or ciprofloxacin 500 mg bid 1 week out of each month, usually in an alternating rotation of at least two antibiotics). Avoid surgery. In refractory cases, consider long-term parenteral hyperalimentation.

**VASCULAR DISORDERS (SMALL AND LARGE INTESTINE)**

Mechanisms of Mesenteric Ischemia  
(1) Occlusive: embolus (atrial fibrillation, valvular heart disease); arterial thrombus (atherosclerosis); venous thrombosis (trauma, neoplasm, infection, cirrhosis, oral contraceptives, antithrombin-III deficiency, protein S or C deficiency, lupus anticoagulant, factor V Leiden mutation, idiopathic); vasculitis (systemic lupus erythematosus, polyarteritis, rheumatoid arthritis, Henoch-Schönlein purpura); (2) nonocclusive: hypotension, heart failure, arrhythmia, digitalis (vasoconstrictor).

Acute Mesenteric Ischemia  
Periumbilical pain out of proportion to tenderness; nausea, vomiting, distention, GI bleeding, altered bowel habits. Abdominal x-ray shows bowel distention, air-fluid levels, thumbprinting (submucosal edema) but may be normal early in course. Peritoneal signs indicate infarcted bowel requiring surgical resection. Early celiac and mesenteric arteriography is recommended in all cases following hemodynamic resuscitation (avoid vasopressors, digitalis). Intrarterial vasodilators (e.g., papaverine) can be administered to reverse vasoconstriction. Laparotomy indicated to restore intestinal blood flow obstructed by embolus or thrombosis or to resect necrotic bowel. Postoperative anticoagulation indicated in mesenteric venous thrombosis, controversial in arterial occlusion.

Chronic Mesenteric Insufficiency  
“Abdominal angina”: dull, crampy periumbilical pain 15–30 min after a meal and lasting for several hours; weight loss; occasionally diarrhea. Evaluate with mesenteric angiography for possible bypass graft surgery.

Ischemic Colitis  
Usually due to nonocclusive disease in pts with atherosclerosis. Severe lower abdominal pain, rectal bleeding, hypotension. Abdominal x-ray shows colonic dilatation, thumbprinting. Sigmoidoscopy shows submucosal hemorrhage, friability, ulcerations; rectum often spared. Conservative management (NPO, IV fluids); surgical resection for infarction or postischemic stricture.

**COLONIC ANGIODYSPLASIA**

In persons over age 60, vascular ectasias, usually in right colon, account for up to 40% of cases of chronic or recurrent lower GI bleeding. May be associated with aortic stenosis. Diagnosis is by arteriography (clusters of small vessels, early and prolonged opacification of draining vein) or colonoscopy (flat, bright red, fern-like lesions). For bleeding, treat by colonoscopic electro- or laser coagulation, band ligation, arteriographic embolization, or, if necessary, right hemicolectomy (Chap. 55).
ANORECTAL DISEASES

Hemorrhoids  Due to increased hydrostatic pressure in hemorrhoidal venous plexus (associated with straining at stool, pregnancy). May be external, internal, thrombosed, acute (prolapsed or strangulated), or bleeding. Treat pain with bulk laxative and stool softeners (psyllium extract, dioctyl sodium sulfosuccinate 100–200 mg/d), sitz baths 1–4 per day, witch hazel compresses, analgesics as needed. Bleeding may require rubber band ligation or injection sclerotherapy. Operative hemorrhoidectomy in severe or refractory cases.

Anal Fissures  Medical therapy as for hemorrhoids. Relaxation of the anal canal with nitroglycerin ointment (0.2%) applied tid or botulinum toxin type A up to 20 U injected into the internal sphincter on each side of the fissure. Internal anal sphincterotomy in refractory cases.

Pruritus Ani  Often of unclear cause; may be due to poor hygiene, fungal or parasitic infection. Treat with thorough cleansing after bowel movement, topical glucocorticoid, antifungal agent if indicated.

Anal Condylomas (Genital Warts)  Wartlike papillomas due to sexually transmitted papillomavirus. Treat with cautious application of liquid nitrogen or podophyllotoxin or with intralesional interferon-α. Tend to recur. May be prevented by vaccination with Gardasil.

For a more detailed discussion, see Owyang C: Irritable Bowel Syndrome, Chap. 290, p. 1899; Gearhart SL: Diverticular Disease and Common Anorectal Disorders, Chap. 291, p. 1903; and Gearhart SL: Mesenteric Vascular Insufficiency, Chap. 292, p. 1910, in HPIM-17.

CHOLELITHIASIS

Cholelithiasis, Cholecystitis, and Cholangitis

There are two major types of gallstones: cholesterol and pigment stones. Cholesterol gallstones contain >50% cholesterol monohydrate. Pigment stones have <20% cholesterol and are composed primarily of calcium bilirubinate. In the United States, 80% of stones are cholesterol and 20% pigment.

Epidemiology  One million new cases of cholelithiasis per year in the United States. Predisposing factors include demographic/genetics (increased prevalence in North American Indians), obesity, weight loss, female sex hormones, age, ileal disease, pregnancy, type IV hyperlipidemia, and cirrhosis.

Symptoms and Signs  Many gallstones are “silent,” i.e., present in asymptomatic patients. Symptoms occur when stones produce inflammation or obstruction of the cystic or common bile ducts. Major symptoms: (1) biliary colic—a
severe steady ache in the RUQ or epigastrium that begins suddenly; often occurs 30–90 min after meals, lasts for several hours, and occasionally radiates to the right scapula or back; (2) nausea, vomiting. Physical exam may be normal or show epigastric or RUQ tenderness.

**Laboratory** Occasionally, mild and transient elevations in bilirubin [<85 μmol/L (<5 mg/dL)] accompany biliary colic.

**Imaging** Only 10% of cholesterol gallstones are radiopaque. Ultrasonography is best diagnostic test. The oral cholecystogram has been largely replaced by ultrasound but may be used to assess the patency of the cystic duct and gallbladder emptying function (Table 159-1).

**Differential Diagnosis** Includes peptic ulcer disease (PUD), gastroesophageal reflux, irritable bowel syndrome, and hepatitis.

**Complications** Cholecystitis, pancreatitis, cholangitis.

**Cholelithiasis**

In asymptomatic patients, risk of developing complications requiring surgery is small. Elective cholecystectomy should be reserved for: (1) symptomatic patients (i.e., biliary colic despite low-fat diet); (2) persons with previous complications of cholelithiasis (see below); and (3) presence of an underlying condition predisposing to an increased risk of complications (calcified or porcelain gallbladder). Patients with gallstones > 3 cm or with an anomalous gallbladder containing stones should also be considered for surgery. Laparoscopic cholecystectomy is minimally invasive and is the procedure of choice for most patients undergoing elective cholecystectomy. Oral dissolution agents (ursodeoxycholic acid) partially or completely dissolve small radiolucent stones in 50% of selected patients within 6–24 months. Because of the frequency of stone recurrence and the effectiveness of laparoscopic surgery, the role of oral dissolution therapy has been reduced to selected patients who are not candidates for elective cholecystectomy.

**ACUTE CHOLECYSTITIS**

Acute inflammation of the gallbladder is usually caused by cystic duct obstruction by an impacted stone. Inflammatory response is evoked by: (1) mechanical inflammation from increased intraluminal pressure; (2) chemical inflammation from release of lysolecithin; (3) bacterial inflammation, which plays a role in 50–85% of patients with acute cholecystitis.

**Etiology** 90% calculous; 10% acalculous. Acalculous cholecystitis associated with higher complication rate and associated with acute illness (i.e., burns, trauma, major surgery), fasting, hyperalimentation leading to gallbladder stasis, vasculitis, carcinoma of gallbladder or common bile duct, some gallbladder infections (Leptospira, Streptococcus, Salmonella, or Vibrio cholerae), but in >50% of cases an underlying explanation is not found.

**Symptoms and Signs** (1) Attack of biliary colic (RUQ or epigastric pain) that progressively worsens; (2) nausea, vomiting, anorexia; and (3) fever. Examination typically reveals RUQ tenderness; palpable RUQ mass found in 20% of pts. Murphy’s sign is present when deep inspiration or cough during palpation of the RUQ produces increased pain or inspiratory arrest.
<table>
<thead>
<tr>
<th><strong>TABLE 159-1</strong> DIAGNOSTIC EVALUATION OF THE BILE DUCTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnostic Advantages</strong></td>
<td><strong>Diagnostic Limitations</strong></td>
</tr>
<tr>
<td><strong>Hepatobiliary Ultrasound</strong></td>
<td></td>
</tr>
<tr>
<td>Rapid</td>
<td>Bowel gas</td>
</tr>
<tr>
<td>Simultaneous scanning of GB, liver, bile ducts, pancreas</td>
<td>Massive obesity</td>
</tr>
<tr>
<td>Accurate identification of dilated bile ducts</td>
<td>Ascites</td>
</tr>
<tr>
<td>Not limited by jaundice, pregnancy</td>
<td>Barium</td>
</tr>
<tr>
<td>Guidance for fine-needle biopsy</td>
<td>Partial bile duct obstruction</td>
</tr>
<tr>
<td></td>
<td>Poor visualization of distal CBD</td>
</tr>
<tr>
<td><strong>Computed Tomography</strong></td>
<td></td>
</tr>
<tr>
<td>Simultaneous scanning of GB, liver, bile ducts, pancreas</td>
<td>Extreme cachexia</td>
</tr>
<tr>
<td>Accurate identification of dilated bile ducts, masses</td>
<td>Movement artifact</td>
</tr>
<tr>
<td>Not limited by jaundice, gas, obesity, ascites</td>
<td>Ileus</td>
</tr>
<tr>
<td>High-resolution image</td>
<td>Partial bile duct obstruction</td>
</tr>
<tr>
<td>Guidance for fine-needle biopsy</td>
<td></td>
</tr>
<tr>
<td><strong>Magnetic Resonance Cholangiopancreatography</strong></td>
<td></td>
</tr>
<tr>
<td>Useful modality for visualizing pancreatic and biliary ducts</td>
<td>Cannot offer therapeutic intervention</td>
</tr>
<tr>
<td>Has excellent sensitivity for bile duct dilatation, biliary stricture, and intraductal abnormalities</td>
<td>High cost</td>
</tr>
<tr>
<td>Can identify pancreatic duct dilatation or stricture, pancreatic duct stenosis, and pancreas divisum</td>
<td></td>
</tr>
<tr>
<td><strong>Endoscopic Retrograde Cholangiopancreatography</strong></td>
<td></td>
</tr>
<tr>
<td>Simultaneous pancreatography</td>
<td>Gastroduodenal obstruction</td>
</tr>
<tr>
<td>Best visualization of distal biliary tract</td>
<td>? Roux en Y biliary-enteric anastomosis</td>
</tr>
<tr>
<td>Bile or pancreatic cytology</td>
<td></td>
</tr>
<tr>
<td>Endoscopic sphincterotomy and stone removal</td>
<td></td>
</tr>
<tr>
<td>Biliary manometry</td>
<td></td>
</tr>
<tr>
<td><strong>Percutaneous Transhepatic Cholangiogram</strong></td>
<td></td>
</tr>
<tr>
<td>Extremely successful when bile ducts dilated</td>
<td>Nondilated or sclerosed ducts</td>
</tr>
<tr>
<td>Best visualization of proximal biliary tract</td>
<td></td>
</tr>
<tr>
<td>Bile cytology/culture</td>
<td></td>
</tr>
<tr>
<td>Percutaneous transhepatic drainage</td>
<td></td>
</tr>
<tr>
<td><strong>Endoscopic Ultrasound</strong></td>
<td></td>
</tr>
<tr>
<td>Most sensitive method to detect ampullary stones</td>
<td></td>
</tr>
</tbody>
</table>
Cholelithiasis, Cholecystitis, and Cholangitis

**Laboratory**  Mild leukocytosis; serum bilirubin, alkaline phosphatase, and AST may be mildly elevated.

**Imaging**  Ultrasonography is useful for demonstrating gallstones and occasionally a phlegmonous mass surrounding the gallbladder. Radionuclide scans (HIDA, DIDA, DISIDA, etc.) may identify cystic duct obstruction.

**Differential Diagnosis**  Includes acute pancreatitis, appendicitis, pyelonephritis, peptic ulcer disease, hepatitis, and hepatic abscess.

**Complications**  Empyema, hydrops, gangrene, perforation, fistulization, gallstone ileus, porcelain gallbladder.

---

**Acute Cholecystitis**

No oral intake, nasogastric suction, IV fluids and electrolytes, analgesia (meperidine or NSAIDS), and antibiotics (ureidopenicillins, ampicillin sulbactam, ciprofloxacin, third-generation cephalosporins; anaerobic coverage should be added if gangrenous or emphysematous cholecystitis is suspected; imipenem/meropenem cover the spectrum of bacteria causing ascending cholangitis but should be reserved for the most life-threatening infections when other antibiotics have failed). Acute symptoms will resolve in 70% of patients. Optimal timing of surgery depends on patient stabilization and should be performed as soon as feasible. Urgent cholecystectomy is appropriate in most patients with a suspected or confirmed complication. Delayed surgery is reserved for patients with high risk of emergent surgery and where the diagnosis is in doubt.

---

**Chronic Cholecystitis**

**Etiology**  Chronic inflammation of the gallbladder; almost always associated with gallstones. Results from repeated acute/subacute cholecystitis or prolonged mechanical irritation of gallbladder wall.

**Symptoms and Signs**  May be asymptomatic for years, may progress to symptomatic gallbladder disease or to acute cholecystitis, or present with complications.

**Laboratory**  Tests are usually normal.

**Imaging**  Ultrasonography preferred; usually shows gallstones within a contracted gallbladder (Table 159-1).

**Differential Diagnosis**  Peptic ulcer disease, esophagitis, irritable bowel syndrome.

---

**Chronic Cholecystitis**

Surgery indicated if patient is symptomatic.

---

**Choledocholithiasis/Cholangitis**

**Etiology**  In patients with cholelithiasis, passage of gallstones into common bile duct (CBD) occurs in 10–15%; increases with age. At cholecystectomy, undetected stones are left behind in 1–5% of pts.
**Symptoms and Signs** Choledocholithiasis may present as an incidental finding, biliary colic, obstructive jaundice, cholangitis, or pancreatitis. Cholangitis usually presents as fever, RUQ pain, and jaundice (*Charcot’s triad*).

**Laboratory** Elevations in serum bilirubin, alkaline phosphatase, and amino- transferases. Leukocytosis usually accompanies cholangitis; blood cultures are frequently positive. Amylase is elevated in 15% of cases.

**Imaging** Diagnosis usually made by cholangiography either preoperatively by endoscopic retrograde cholangiopancreatography (ERCP) or intraoperatively at the time of cholecystectomy. Ultrasonography may reveal dilated bile ducts but is not sensitive for detecting CBD stones (*Table 159-1*).

**Differential Diagnosis** Acute cholecystitis, renal colic, perforated viscus, pancreatitis.

**Complications** Cholangitis, obstructive jaundice, gallstone-induced pancreatitis, and secondary biliary cirrhosis.

---

**Choledocholithiasis/Cholangitis**

Laparoscopic cholecystectomy and ERCP have decreased the need for choledocholithotomy and T-tube drainage of the bile ducts. When CBD stones are suspected prior to laparoscopic cholecystectomy, preoperative ERCP with endoscopic palplillation and stone extraction is the preferred approach. CBD stones should be suspected in gallstone pts with (1) history of jaundice or pancreatitis, (2) abnormal LFT, and (3) ultrasound evidence of a dilated common bile duct or stones in the duct. Cholangitis treated like acute cholecystitis; no oral intake, hydration, analgesia, and antibiotics are the mainstays; stones should be removed surgically or endoscopically.

---

**PRIMARY SCLEROSING CHOLANGITIS (PSC)**

PSC is a sclerosing, inflammatory, and obliterative process involving the biliary tree.

**Etiology** Associations: inflammatory bowel disease (75% of cases of PSC—especially ulcerative colitis), AIDS, rarely retroperitoneal fibrosis.

**Symptoms and Signs** Pruritus, RUQ pain, jaundice, fever, weight loss, and malaise. 44% may be asymptomatic at diagnosis. May progress to cirrhosis with portal hypertension.

**Laboratory** Evidence of cholestasis (elevated bilirubin and alkaline phosphatase) common.

**Radiology/Endoscopy** Transhepatic or endoscopic cholangiograms reveal stenosis and dilation of the intra- and extrahepatic bile ducts.

**Differential Diagnosis** Cholangiocarcinoma, Caroli’s disease (cystic dilation of bile ducts), *Fasciola hepatica* infection, echinococcosis, and ascariasis.

---

**Primary Sclerosing Cholangitis**

No satisfactory therapy. Cholangitis should be treated as outlined above. Cholestyramine may control pruritus. Supplemental vitamin D and calcium may
retard bone loss. Glucocorticoids, methotrexate, and cyclosporine have not been shown to be effective. Urodeoxycholic acid improves liver tests, but has not been shown to affect survival. Surgical relief of biliary obstruction may be appropriate but has a high complication rate. Liver transplantation should be considered in pts with end-stage cirrhosis. Median survival: 9–12 years after diagnosis, with age, bilirubin level, histologic stage, and splenomegaly being predictors of survival.


ACUTE PANCREATITIS

The pathologic spectrum of acute pancreatitis varies from interstitial pancreatitis, which is usually a mild and self-limited disorder, to necrotizing pancreatitis, in which the degree of pancreatic necrosis correlates with the severity of the attack and its systemic manifestations.

Etiology Most common causes in the United States are cholelithiasis and alcohol. Others are listed in Table 160-1.

Clinical Features Can vary from mild abdominal pain to shock. Common symptoms: (1) steady, boring midepigastric pain radiating to the back that is frequently increased in the supine position; (2) nausea, vomiting.

Physical exam: (1) low-grade fever, tachycardia, hypotension; (2) erythematous skin nodules due to subcutaneous fat necrosis; (3) basilar rales, pleural effusion (often on the left); (4) abdominal tenderness and rigidity, diminished bowel sounds, palpable upper abdominal mass; (5) Cullen’s sign: blue discoloration in the periumbilical area due to hemoperitoneum; (6) Turner’s sign: blue-red-purple or green-brown discoloration of the flanks due to tissue catabolism of hemoglobin.

Laboratory 1. Serum amylase: Large elevations (>3 × normal) virtually assure the diagnosis if salivary gland disease and intestinal perforation/infarction are excluded. However, normal serum amylase does not exclude the diagnosis of acute pancreatitis, and the degree of elevation does not predict severity of pancreatitis. Amylase levels typically return to normal in 48–72 h.

2. Urinary amylase–creatinine clearance ratio: no more sensitive or specific than blood amylase levels.

3. Serum lipase level: increases in parallel with amylase level and measurement of both tests increases the diagnostic yield.

4. Other tests: Hypocalcemia occurs in ~25% of patients. Leukocytosis (15,000–20,000/μL) occurs frequently. Hypertriglyceridermia occurs in 15–20% of cas-
es and can cause a spuriously normal serum amylase level. Hyperglycemia is common. Serum bilirubin, alkaline phosphatase, and aspartate aminotransferase can be transiently elevated. Hypoalbuminemia and marked elevations of serum lactic dehydrogenase (LDH) are associated with an increased mortality rate. Hypoxemia is present in 25% of patients. Arterial pH < 7.32 may spuriously elevate serum amylase.

**Imaging**

1. Abdominal radiographs are abnormal in 30–50% of patients but are not specific for pancreatitis. Common findings include total or partial ileus (“sentinel loop”) and the “colon cut-off sign,” which results from isolated distention of the transverse colon. Useful for excluding diagnoses such as intestinal perforation with free air.
2. **Ultrasound** often fails to visualize the pancreas because of overlying intestinal gas but may detect gallstones, pseudocysts, mass lesions, or edema or enlargement of the pancreas.

3. **CT** can confirm diagnosis of pancreatitis (edematous pancreas) and is useful for predicting and identifying late complications. Contrast-enhanced dynamic CT is indicated for clinical deterioration, the presence of risk factors that adversely affect survival (Table 160-2), or other features of serious illness.

**Differential Diagnosis** Intestinal perforation (especially peptic ulcer), cholecystitis, acute intestinal obstruction, mesenteric ischemia, renal colic, myocardial ischemia, aortic dissection, connective tissue disorders, pneumonia, and diabetic ketoacidosis.

**Acute Pancreatitis**

Most (90%) cases subside over a period of 3–7 days. Conventional measures: (1) analgesics, such as meperidine; (2) IV fluids and colloids; (3) no oral alimentation. The benefit of antibiotic prophylaxis in necrotizing acute pancreatitis remains controversial. Current recommendation is use of an antibiotic such as imipenem–cilastatin, 500 mg tid for 2 weeks. Not effective: cimetidine (or related agents), H2 blockers, protease inhibitors, glucocorticoids, nasogastric suction, glucagon, peritoneal lavage, and anticholinergic medications. Precipitating factors (alcohol, medications) must be eliminated. In mild or moderate pancreatitis, a clear liquid diet can usually be started after 3–6 days. Patients with severe gallstone-induced pancreatitis often benefit from early (<3 days) papillotomy.

**Complications** It is important to identify patients who are at risk of poor outcome. Risk factors that adversely affect survival in acute pancreatitis are listed in Table 160-2. Fulminant pancreatitis requires aggressive fluid support and meticulous management. Mortality is largely due to infection.

**Systemic** Shock, GI bleeding, common duct obstruction, ileus, splenic infarction or rupture, DIC, subcutaneous fat necrosis, ARDS, pleural effusion, acute renal failure, sudden blindness.
Local

1. Sterile or infected pancreatic necrosis—necrosis may become secondarily infected in 40–60% of patients, typically within 1–2 weeks after the onset of pancreatitis. Most frequent organisms: gram-negative bacteria of alimentary origin, but intraabdominal Candida infection increasing in frequency. Necrosis can be visualized by contrast-enhanced dynamic CT, with infection diagnosed by CT-guided needle aspiration. Laparotomy with removal of necrotic material and adequate drainage should be considered for patients with sterile acute necrotic pancreatitis, if patient continues to deteriorate despite conventional therapy. Infected pancreatic necrosis requires aggressive surgical debridement and antibiotics.

2. Pancreatic pseudocysts develop over 1–4 weeks in 15% of patients. Abdominal pain is the usual complaint, and a tender upper abdominal mass may be present. Can be detected by abdominal ultrasound or CT. In patients who are stable and uncomplicated, treatment is supportive; pseudocysts that are >5 cm in diameter and persist for >6 weeks should be considered for drainage. In patients with an expanding pseudocyst or one complicated by hemorrhage, rupture, or abscess, surgery should be performed.

3. Pancreatic abscess—ill-defined liquid collection of pus that evolves over 4–6 weeks. Can be treated surgically or in selected cases by percutaneous drainage.

4. Pancreatic ascites and pleural effusions are usually due to disruption of the main pancreatic duct. Treatment involves nasogastric suction and parenteral alimentation for 2–3 weeks. If medical management fails, pancreateography followed by surgery should be performed.

CHRONIC PANCREATITIS

Chronic pancreatitis may occur as recurrent episodes of acute inflammation superimposed upon a previously injured pancreas or as chronic damage with pain and malabsorption.

Etiology Chronic alcoholism is most frequent cause of pancreatic exocrine insufficiency in U.S. adults; in 25% of adults, etiology is unknown. Other causes are listed in Table 160-3.

Symptoms and Signs Pain is cardinal symptom. Weight loss, steatorrhea, and other signs and symptoms of malabsorption common. Physical exam often unremarkable.

Laboratory No specific laboratory test for chronic pancreatitis. Serum amylase and lipase levels are often normal. Serum bilirubin and alkaline phosphatase may be elevated. Steatorrhea (fecal fat concentration ≥ 9.5%) late in the course. The bentiromide test, a simple, effective test of pancreatic exocrine function, may be helpful. D-Xylose urinary excretion test is usually normal. Impaired glucose tolerance is present in >50% of pts. Secretin stimulation test is a relatively sensitive test for pancreatic exocrine deficiency.

Imaging Plain films of the abdomen reveal pancreatic calcifications in 30–60%. Ultrasound and CT scans may show dilation of the pancreatic duct. ERCP and endoscopic ultrasound (EUS) provide information about the main pancreatic and smaller ducts.

Differential Diagnosis Important to distinguish from pancreatic carcinoma; may require radiographically guided biopsy.
**Chronic Pancreatitis**

Aimed at controlling pain and malabsorption. Intermittent attacks treated like acute pancreatitis. Alcohol and large, fatty meals must be avoided. Narcotics for severe pain, but subsequent addiction is common. Patients unable to maintain adequate hydration should be hospitalized, while those with milder symptoms can be managed on an ambulatory basis. Surgery may control pain if there is a ductal stricture. Subtotal pancreatectomy may also control pain but at the cost of exocrine insufficiency and diabetes. Malabsorption is managed with a low-fat diet and pancreatic enzyme replacement. Because pancreatic enzymes are inactivated by acid, agents that reduce acid production (e.g., omeprazole or sodium bicarbonate) may improve their efficacy (but should not be given with enteric-coated preparations). Insulin may be necessary to control serum glucose.

**Complications**  
Vitamin B$_12$ malabsorption in 40% of alcohol-induced and all cystic fibrosis cases. Impaired glucose tolerance. Nondiabetic retinopathy due to vitamin A and/or zinc deficiency. GI bleeding, icterus, effusions, subcutaneous fat necrosis, and bone pain occasionally occur. Increased risk for pancreatic carcinoma. Narcotic addiction common.

---

**TABLE 160-3 CHRONIC PANCREATITIS AND PANCREATIC EXOCRINE INSUFFICIENCY: TIGAR-O CLASSIFICATION SYSTEM**

<table>
<thead>
<tr>
<th>Toxic-metabolic</th>
<th>Autoimmune</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcoholic</td>
<td>Isolated autoimmune CP</td>
</tr>
<tr>
<td>Tobacco smoking</td>
<td>Autoimmune CP associated with</td>
</tr>
<tr>
<td>Hypercalcemia</td>
<td>Sjögren’s syndrome</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>Inflammatory bowel disease</td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>Primary biliary cirrhosis</td>
</tr>
<tr>
<td>Medications—phenacetin abuse</td>
<td></td>
</tr>
<tr>
<td>Toxins—organotin compounds (e.g., DBTC)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Idiopathic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early onset</td>
</tr>
<tr>
<td>Late onset</td>
</tr>
<tr>
<td>Tropical</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genetic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hereditary pancreatitis</td>
</tr>
<tr>
<td>Cationic trypsinogen</td>
</tr>
<tr>
<td>CFTR mutations</td>
</tr>
<tr>
<td>SPINK1 mutations</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recurrent and severe acute pancreatitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postnecrotic (severe acute pancreatitis)</td>
</tr>
<tr>
<td>Recurrent acute pancreatitis</td>
</tr>
<tr>
<td>Vascular diseases/ischemia</td>
</tr>
<tr>
<td>Postirradiation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Obstructive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancreas divisum</td>
</tr>
<tr>
<td>Sphincter of Oddi disorders</td>
</tr>
<tr>
<td>(controversial)</td>
</tr>
<tr>
<td>Duct obstruction (e.g., tumor)</td>
</tr>
<tr>
<td>Preampullary duodenal wall cysts</td>
</tr>
<tr>
<td>Posttraumatic pancreatic duct scars</td>
</tr>
</tbody>
</table>

CP, chronic pancreatitis; TIGAR-O, toxic-metabolic, idiopathic, genetic, autoimmune, recurrent and severe acute pancreatitis, obstructive.
Acute viral hepatitis is a systemic infection affecting the liver predominantly. Clinically characterized by malaise, nausea, vomiting, diarrhea, and low-grade fever followed by dark urine, jaundice, and tender hepatomegaly; may be subclinical and detected on basis of elevated aspartate and alanine aminotransferase (AST and ALT) levels. Hepatitis B may be associated with immune-complex phenomena, including arthritis, serum sickness–like illness, glomerulonephritis, and a polyarteritis nodosa–like vasculitis. Hepatitis-like illnesses may be caused not only by hepatotropic viruses (A, B, C, D, E) but also by other viruses (Epstein-Barr, CMV, coxsackievirus, etc.), alcohol, drugs, hypotension and ischemia, and biliary tract disease (Table 161-1).

**Hepatitis A (HAV)**

- **27-nm picornavirus (hepatovirus) with single-stranded RNA genome.**
- **Clinical Course**
  - See Fig. 161-1.
  - **Outcome**
    - Recovery within 6–12 months, usually with no clinical sequelae; a small proportion will have one or two apparent clinical and serologic relapses; in some cases, pronounced cholestasis suggesting biliary obstruction may occur; rare fatalities (fulminant hepatitis), no chronic carrier state.
  - **Diagnosis**
    - IgM anti-HAV in acute or early convalescent serum sample.
  - **Epidemiology**
    - Fecal-oral transmission; endemic in underdeveloped countries; food-borne and waterborne epidemics; outbreaks in day-care centers, residential institutions.
  - **Prevention**
    - After exposure: immune globulin 0.02 mL/kg IM within 2 weeks to household and institutional contacts (not casual contacts at work). Before exposure: inactivated HAV vaccine 1 mL IM (unit dose depends on formulation); half dose to children; repeat at 6–12 months; target travelers, military recruits, animal handlers, day-care personnel, laboratory workers, patients with chronic liver disease, especially hepatitis C.

**Hepatitis B (HBV)**

- **42-nm hepadnavirus with outer surface coat (HBsAg), inner nucleocapsid core (HBcAg), DNA polymerase, and partially double-stranded DNA genome of 3200 nucleotides. Circulating form of HBcAg is HBeAg, a marker of viral replication and infectivity. Multiple serotypes and genetic heterogeneity.**
  - **Clinical Course**
    - See Fig. 161-2.
    - **Outcome**
      - Recovery >90%, fulminant hepatitis (<1%), chronic hepatitis or carrier state (only 1–2% of immunocompetent adults; higher in neonates, elderly, immunocompromised), cirrhosis, and hepatocellular carcinoma (especially following chronic infection beginning in infancy or early childhood) (see Chap. 163).
    - **Diagnosis**
      - HBsAg in serum (acute or chronic infection); IgM anti-HBc (early anti-HBc indicative of acute or recent infection). Most sensitive test is detection of HBV DNA in serum; not generally required for routine diagnosis.
<table>
<thead>
<tr>
<th>Viral Properties</th>
<th>HAV</th>
<th>HBV</th>
<th>HCV</th>
<th>HDV</th>
<th>HEV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size, nm</td>
<td>27</td>
<td>42</td>
<td>~55</td>
<td>~36</td>
<td>~32</td>
</tr>
<tr>
<td>Nucleic acid</td>
<td>RNA</td>
<td>DNA</td>
<td>RNA</td>
<td>RNA</td>
<td>RNA</td>
</tr>
<tr>
<td>Genome length, kb</td>
<td>7.5</td>
<td>3.2</td>
<td>9.4</td>
<td>1.7</td>
<td>7.5</td>
</tr>
<tr>
<td>Classification</td>
<td>Picornavirus</td>
<td>Hepadnavirus</td>
<td>Flavivirus-like</td>
<td>—</td>
<td>Calicivirus-like or alphavirus-like</td>
</tr>
<tr>
<td>Incubation, days</td>
<td>15–45</td>
<td>30–180</td>
<td>15–160</td>
<td>21–140</td>
<td>14–63</td>
</tr>
<tr>
<td>Transmission</td>
<td>Fecal-oral</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>Percutaneous</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Sexual</td>
<td>?</td>
<td>++</td>
<td>Uncommon</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>Perinatal</td>
<td>—</td>
<td>+++</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Clinical Features</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severity</td>
<td>Usually mild</td>
<td>Moderate</td>
<td>Mild</td>
<td>May be severe</td>
<td>Usually mild</td>
</tr>
<tr>
<td>Chronic infection</td>
<td>No</td>
<td>1–10%; up to 90% in neonates</td>
<td>80–90%</td>
<td>Common</td>
<td>No</td>
</tr>
<tr>
<td>Carrier state</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Fulminant hepatitis</td>
<td>0.1%</td>
<td>1%</td>
<td>Rare</td>
<td>Up to 20% in superinfection</td>
<td>10–20% in pregnant women</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>?</td>
<td>No</td>
</tr>
<tr>
<td>Prophylaxis</td>
<td>Ig; vaccine</td>
<td>HBlg; vaccine</td>
<td>None</td>
<td>None (HBV vaccine for susceptibles)</td>
<td>None</td>
</tr>
</tbody>
</table>

**Note:** HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; HEV, hepatitis E virus; Ig, immune globulin; + +, sometimes; + + +, often; ?, possibly.
Epidemiology  Percutaneous (needle stick), sexual, or perinatal transmission. Endemic in sub-Saharan Africa and Southeast Asia, where up to 20% of population acquire infection, usually early in life.

Prevention  After exposure in unvaccinated persons: hepatitis B immune globulin (HBIg) 0.06 mL/kg IM immediately after needle stick to within 14 days of sexual exposure in combination with vaccine series. For perinatal exposure (HbsAg+ mother) HBIg 0.05 mL in the thigh immediately after birth with the vaccine series started within the first 12 h of life. Before exposure: recombinant hepatitis B vaccine IM (dose depends on formulation as well as adult or pediatric and hemodialysis); at 0, 1, and 6 months; deltoid, not gluteal injection. Has been targeted to high-risk groups (e.g., health workers, persons with multiple sexual partners, IV drug users, hemodialysis pts, hemophiliacs, household and sexual contacts of HBsAg carriers, persons travelling in endemic areas, unvaccinated children < 18). Universal vaccination of all children is now recommended in the United States.
Hepatitis C (HCV)  Caused by flavi-like virus with RNA genome of >9000 nucleotides (similar to yellow fever virus, dengue virus); genetic heterogeneity. Incubation period 7–8 weeks.

Clinical Course  Often clinically mild and marked by fluctuating elevations of serum aminotransferase levels; >50% likelihood of chronicity, leading to cirrhosis in >20%.

Diagnosis  Anti-HCV in serum. Current third-generation immunoassay incorporates proteins from the core, NS3, and NS5 regions. The most sensitive indicator of HCV infection is HCV RNA (Fig. 161-3).

Epidemiology  HCV accounts for >90% of transfusion-associated hepatitis cases. IV drug use accounts >50% of reported cases of hepatitis C. Little evidence for frequent sexual or perinatal transmission.

Prevention  Exclusion of paid blood donors, testing of donated blood for anti-HCV. Anti-HCV detected by enzyme immunoassay in blood donors with normal ALT is often falsely positive (30%); result should be confirmed by HCV RNA in serum.

Hepatitis D (HDV, Delta Agent)  Defective 37-nm RNA virus that requires HBV for its replication; either co-infects with HBV or superinfects a chronic HBV carrier. Enhances severity of HBV infection (acceleration of chronic hepatitis to cirrhosis, occasionally fulminant acute hepatitis).

Diagnosis  Anti-HDV in serum (acute hepatitis D—often in low titer, is transient; chronic hepatitis D—in higher titer, is sustained).

Epidemiology  Endemic among HBV carriers in Mediterranean Basin, where it is spread predominantly by nonpercutaneous means. In nonendemic areas (e.g., northern Europe, United States) HDV is spread percutaneously among HbsAg+ IV drug users or by transfusion in hemophiliacs and to a lesser extent among HbsAg+ men who have sex with men.

Prevention  Hepatitis B vaccine (noncarriers only).

Hepatitis E (HEV)  Caused by 29- to 32-nm agent thought to be related to caliciviruses. Enterically transmitted and responsible for waterborne epidemics of
hepatitis in India, parts of Asia and Africa, and Central America. Self-limited illness with high (10–20%) mortality rate in pregnant women.

**Viral Hepatitis**

Activity as tolerated, high-calorie diet (often tolerated best in morning), IV hydration for severe vomiting, cholestyramine up to 4 g PO four times daily for severe pruritus, avoid hepatically metabolized drugs; no role for glucocorticoids. Liver transplantation for fulminant hepatic failure and grades III–IV encephalopathy. In rare instances of severe acute HBV, lamivudine has been used successfully. Most authorities would recommend antiviral therapy for severe acute HBV (see Chap. 162). Meta-analysis of small clinical trials suggests that treatment of acute HCV infection with α-interferon may be effective at reducing the rate of chronicity. Based on these data, many experts feel that acute HCV infection should be treated with a 24-week course of the best available regimens currently used to treat chronic HCV infection (see Chap. 162).

**TOXIC AND DRUG-INDUCED HEPATITIS**

*Dose-Dependent (Direct Hepatotoxins)* Onset is within 48 h, predictable, necrosis around terminal hepatic venule—e.g., carbon tetrachloride, benzene derivatives, mushroom poisoning, acetaminophen, or microvesicular steatosis (e.g., tetracyclines, valproic acid).

*Idiosyncratic* Variable dose and time of onset; small number of exposed persons affected; may be associated with fever, rash, arthralgias, eosinophilia. In many cases, mechanism may actually involve toxic metabolite, possibly determined on genetic basis—e.g., isoniazid, halothane, phenytoin, methyldopa, carbamazepine, diclofenac, oxacillin, sulfonamides.

**Toxic and Drug-Induced Hepatitis**

Supportive as for viral hepatitis; withdraw suspected agent, and include use of gastric lavage and oral administration of charcoal or cholestyramine. Liver transplantation if necessary. In acetaminophen overdose, more specific therapy is available in the form of sulffhydryl compounds (e.g., N-acetylcysteine). These agents appear to act by providing a reservoir of sulffhydryl groups to bind the toxic metabolites or by stimulating synthesis of hepatic glutathione. Therapy should be begun within 8 h of ingestion, but may be effective even if given as late as 24–36 h after overdose.

**ACUTE HEPATIC FAILURE**

Massive hepatic necrosis with impaired consciousness occurring within 8 weeks of the onset of illness.

*Causes* Infections [viral, including HAV, HBV, HCV (rarely), HDV, HEV; bacterial, rickettsial, parasitic], drugs and toxins, ischemia (shock), Budd-Chiari syndrome, idiopathic chronic active hepatitis, acute Wilson’s disease, microvesicular fat syndromes (Rye’s syndrome, acute fatty liver of pregnancy).

*Clinical Manifestations* Neuropsychiatric changes—delirium, personality change, stupor, coma; cerebral edema—suggested by profuse sweating, hemodynamic...
instability, tachyarrhythmias, tachypnea, fever, papilledema, decerebrate rigidity (though all may be absent); deep jaundice, coagulopathy, bleeding, renal failure, acid-base disturbance, hypoglycemia, acute pancreatitis, cardiorespiratory failure, infections (bacterial, fungal).

**Adverse Prognostic Indicators** Age <10 or >40, certain causes (e.g., halothane, hepatitis C), duration of jaundice >7 d before onset of encephalopathy, serum bilirubin > 300 μmol/L (>18 mg/dL), coma (survival <20%), rapid reduction in liver size, respiratory failure, marked prolongation of PT, factor V level <20%. In acetaminophen overdose, adverse prognosis is suggested by blood pH < 7.30, serum creatinine > 266 μmol/L (>3 mg/dL), markedly prolonged PT.

**Acute Hepatic Failure**

Endotracheal intubation often required. Monitor serum glucose—IV D10 or D20 as necessary. Prevent GI bleeding with H2-receptor antagonists and antacids (maintain gastric pH ≥ 3.5). In many centers intracranial pressure is monitored—more sensitive than CT in detecting cerebral edema. Value of dexamethasone for cerebral edema unclear; IV mannitol may be beneficial. Liver transplantation should be considered in pts with grades III–IV encephalopathy and other adverse prognostic indicators.

For a more detailed discussion, see Dienstag JL: Acute Viral Hepatitis, Chap. 298, p. 1932, and Dienstag JL: Toxic and Drug-Induced Hepatitis, Chap. 299, p. 1949, in HPIM-17.

### Chronic Hepatitis

A group of disorders characterized by a chronic inflammatory reaction in the liver for at least 6 months.

**OVERVIEW**

**Etiology** Hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV, delta agent), drugs (methyldopa, nitrofurantoin, isoniazid, dantrolene), autoimmune hepatitis, Wilson’s disease, hemochromatosis, α1-antitrypsin deficiency.

**Histologic Classification** Chronic hepatitis can be classified by grade and stage. The grade is a histologic assessment of necrosis and inflammatory activity and is based on examination of the liver biopsy. The stage of chronic hepatitis reflects the level of disease progression and is based on the degree of fibrosis (see Table 300-2, p. 1956, HPIM-17).

**Presentation** Wide clinical spectrum ranging from asymptomatic serum amino- transferase elevations to apparently acute, even fulminant, hepatitis. Common
symptoms include fatigue, malaise, anorexia, low-grade fever; jaundice is frequent in severe disease. Some pts may present with complications of cirrhosis: ascites, variceal bleeding, encephalopathy, coagulopathy, and hypersplenism. In chronic HBV or HCV and autoimmune hepatitis, extrahepatic features may predominate.

### TABLE 162-1
**COMPARISON OF INTERFERON (PEG IFN), LAMIVUDINE, ADEFOVIR, AND ENTECAVIR THERAPY FOR CHRONIC HEPATITIS B**

<table>
<thead>
<tr>
<th>Feature</th>
<th>PEG IFN&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of administration</td>
<td>Subcutaneous injection</td>
</tr>
<tr>
<td>Duration of therapy&lt;sup&gt;c&lt;/sup&gt;</td>
<td>48–52 weeks</td>
</tr>
<tr>
<td>Tolerability</td>
<td>Poorly tolerated</td>
</tr>
<tr>
<td>HBeAg loss 1 year</td>
<td>29–30%</td>
</tr>
<tr>
<td>HBeAg seroconversion</td>
<td></td>
</tr>
<tr>
<td>1 year Rx</td>
<td>18–20%</td>
</tr>
<tr>
<td>&gt;1 year Rx</td>
<td>NA</td>
</tr>
<tr>
<td>HBeAg seroconversion if ALT &gt;5 × normal</td>
<td>Not reported</td>
</tr>
<tr>
<td>Log&lt;sub&gt;10&lt;/sub&gt; HBV DNA reduction (mean copies/mL)</td>
<td></td>
</tr>
<tr>
<td>HBeAg-reactive</td>
<td>4.5</td>
</tr>
<tr>
<td>HBeAg-negative</td>
<td>4.1</td>
</tr>
<tr>
<td>HBV DNA PCR negative (&lt;300–400 copies/mL; &lt;1,000 copies/mL for adefovir) end of year 1</td>
<td></td>
</tr>
<tr>
<td>HBeAg-reactive</td>
<td>10–25%</td>
</tr>
<tr>
<td>HBeAg-negative</td>
<td>63%</td>
</tr>
<tr>
<td>ALT normalization at end of year 1</td>
<td></td>
</tr>
<tr>
<td>HBeAg-reactive</td>
<td>39%</td>
</tr>
<tr>
<td>HBeAg-negative</td>
<td>34–38%</td>
</tr>
<tr>
<td>HBsAg loss during year 1</td>
<td>0–7%</td>
</tr>
<tr>
<td>HBsAg loss after therapy</td>
<td>3–7% after 6 months</td>
</tr>
<tr>
<td>Histologic improvement (≥2 point reduction in HAI) at year 1</td>
<td></td>
</tr>
<tr>
<td>HBeAg-reactive</td>
<td>38% 6 months after</td>
</tr>
<tr>
<td>HBeAg-negative</td>
<td>48% 6 months after</td>
</tr>
<tr>
<td>Viral resistance</td>
<td>None</td>
</tr>
<tr>
<td>Durability of response 4–6 months after therapy&lt;sup&gt;f&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>HBeAg-reactive</td>
<td>Limited data</td>
</tr>
<tr>
<td>HBeAg-negative</td>
<td>36%</td>
</tr>
<tr>
<td>Cost (U.S. $) for 1 year</td>
<td>$18,000</td>
</tr>
</tbody>
</table>

<sup>a</sup>Generally, these comparisons are based on data on each drug tested individually versus placebo in registration clinical trials. With rare exception, these comparisons are not based on head-to-head testing of these drugs, hence relative advantages and disadvantages should be interpreted cautiously.

<sup>b</sup>Although standard interferon α administered daily or three times a week is approved as therapy for chronic hepatitis B, it has been supplanted by pegylated interferon (PEG IFN), which is administered once a week and is more effective. Standard interferon has no advantages over PEG IFN.

<sup>c</sup>Duration of therapy in clinical efficacy trials; use in clinical practice may vary.

<sup>d</sup>Because of a computer-generated randomization error that resulted in misallocation of drug versus placebo during the second year of clinical-trial treatment, the frequency of HBeAg seroconversion beyond the first year is an estimate (Kaplan-Meier analysis) based on the small subset in whom adefovir was administered correctly.
# CHRONIC HEPATITIS B

Follows up to 1–2% of cases of acute hepatitis B in immunocompetent hosts; more frequent in immunocompromised hosts. Spectrum of disease: asymptomatic antigenemia, chronic hepatitis, cirrhosis, hepatocellular cancer; early phase

<table>
<thead>
<tr>
<th>Lamivudine</th>
<th>Adefovir</th>
<th>Entecavir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td>≥52 weeks</td>
<td>≥48 weeks</td>
<td>≥48 weeks</td>
</tr>
<tr>
<td>Well tolerated</td>
<td>Well tolerated; creatinine monitoring recommended</td>
<td>Well tolerated</td>
</tr>
<tr>
<td>20–33%</td>
<td>23%</td>
<td>22%</td>
</tr>
<tr>
<td>16–21%</td>
<td>12%</td>
<td>21%</td>
</tr>
<tr>
<td>Up to 50% @ 5 years &gt;50%</td>
<td>43% @ 3 years</td>
<td>31% @ 2 years</td>
</tr>
<tr>
<td>5.5</td>
<td>Median 3.5–5</td>
<td>6.9</td>
</tr>
<tr>
<td>4.4–4.7</td>
<td>Median 3.5–3.9</td>
<td>5.0</td>
</tr>
<tr>
<td>36–40%</td>
<td>12–21%</td>
<td>69% (80% @ 2 years)</td>
</tr>
<tr>
<td>39–73%</td>
<td>51% (79% @ 3 years)</td>
<td>90%</td>
</tr>
<tr>
<td>41–75%</td>
<td>58% (81% @ year 3)</td>
<td>78%</td>
</tr>
<tr>
<td>62–79%</td>
<td>48% (69% @ year 3)</td>
<td>78%</td>
</tr>
<tr>
<td>0–4%</td>
<td>0% (1–2% @ 2 years)</td>
<td>2% (5% @ 2 years)</td>
</tr>
<tr>
<td>23% after 2 years</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
<tr>
<td>51–62%</td>
<td>53%</td>
<td>62%</td>
</tr>
<tr>
<td>61–66%</td>
<td>64%</td>
<td>70%</td>
</tr>
<tr>
<td>15–30% @ 1 year</td>
<td>None @ 1 year</td>
<td>None @ 2 years</td>
</tr>
<tr>
<td>70% @ 5 years</td>
<td>29% @ 5 years</td>
<td></td>
</tr>
<tr>
<td>70–80%</td>
<td>91%</td>
<td>82%</td>
</tr>
<tr>
<td>23–35%</td>
<td>Low</td>
<td>48%</td>
</tr>
<tr>
<td>&lt;$2,500</td>
<td>&lt;$6,500</td>
<td>&lt;$8,700</td>
</tr>
</tbody>
</table>

7% during a year of therapy (9% during two years) in lamivudine-resistant patients.

In HBeAg-reactive patients, durability of HBeAg seroconversion; in HBeAg-negative patients, durability of virologic (HBV DNA undetectable by PCR) and biochemical (normal ALT) response.

~17,400 for lamivudine-refractory patients.

Note: ALT, alanine aminotransferase; HAI, histologic activity index; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NA, not applicable; Rx, therapy; PCR, polymerase chain reaction.
<table>
<thead>
<tr>
<th>HBeAg Status</th>
<th>Clinical</th>
<th>HBV DNA (copies/mL)</th>
<th>ALT</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBeAg-reactive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic hepatitis</td>
<td>≥10^5</td>
<td>Normal (≤2 × ULN)_b</td>
<td>No treatment; monitor</td>
<td></td>
</tr>
<tr>
<td>Chronic hepatitis</td>
<td>≥10^5</td>
<td>Normal (≤2 × ULN)_b</td>
<td>No treatment; current treatment of limited benefit (Some suggest liver biopsy and treating if abnormal)</td>
<td>Treat_d</td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>≥10^5</td>
<td>Elevated (&gt;2 × ULN)_b</td>
<td>Treat with oral agents, not PEG IFN</td>
<td></td>
</tr>
<tr>
<td>compensated</td>
<td>+ or –_e</td>
<td>Normal or elevated</td>
<td>Refer for liver transplantation</td>
<td></td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>+ or –_e</td>
<td>Normal or elevated</td>
<td>Inactive carrier; treatment not necessary</td>
<td></td>
</tr>
<tr>
<td>decompensated</td>
<td></td>
<td></td>
<td>Consider liver biopsy; treat if biopsy abnormal</td>
<td></td>
</tr>
<tr>
<td>HBeAg-negative</td>
<td>≤10^4 or 10^5^h</td>
<td>Normal (≤2 × ULN)_b</td>
<td>Treat with oral agents, not PEG IFN</td>
<td></td>
</tr>
<tr>
<td>Chronic hepatitis</td>
<td>≥10^4 or 10^5^h</td>
<td>Normal</td>
<td>Treat with oral agents, not PEG IFN</td>
<td></td>
</tr>
<tr>
<td>Chronic hepatitis</td>
<td>≥10^4 or 10^5^h (&gt;2 × ULN)_b</td>
<td>Elevated</td>
<td>Consider liver biopsy; treat if biopsy abnormal</td>
<td></td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>+ or –_e</td>
<td>Elevated or normal</td>
<td>Treat with oral agents, not PEG IFN (some authors recommend either following or treating for HBV DNA &lt;10^4 copies/mL)</td>
<td></td>
</tr>
</tbody>
</table>
Cirrhosis decompensated  + or – Elevated or normal  Treat with oral agents, not PEG IFN (some authorities would follow without therapy for undetectable HBV DNA; refer for liver transplantation)

4 Liver disease tends to be mild or inactive clinically; most such patients do not undergo liver biopsy.
4 In some guidelines, ALT categories are normal or elevated; in others, ALT categories are ≤ or > 2 times the upper limit of normal.
4 Typical pattern in childhood-acquired infection, common in Asian populations.
4 Any of the oral drugs (lamivudine, adefovir, entecavir) or PEG IFN can be used as first-line therapy (see text); although still used extensively in some parts of the world, lamivudine has been supplanted in some countries as first-line therapy because of its resistance profile. The oral agents, but not PEG IFN, should be used for interferon-refractory/intolerant and immunocompromised patients. PEG IFN is administered weekly by subcutaneous injection for a year; the oral agents are administered daily for at least a year and continued indefinitely or until at least 6 months after HBeAg seroconversion.
4 Treating or monitoring without therapy are options for patients with HBV DNA <10⁴ or <10⁵ copies/mL.
4 Some authorities would observe without treatment if HBV DNA is undetectable (<10⁴ copies/mL), while others would treat regardless of the HBV DNA status. Lamivudine monotherapy is not an attractive choice because of its resistance profile.
4 Some authorities recommend treating regardless of HBV DNA status, while others suggest referring for liver transplantation, without treatment, for those with undetectable HBV DNA (<10⁵ copies/mL). Lamivudine is a less attractive choice because of its resistance profile. Because the emergence of resistance can lead to loss of antiviral benefit and further deterioration in decompensated cirrhosis, some authorities recommend combination therapy (e.g., lamivudine or entecavir plus adefovir) for patients with decompensated cirrhosis.
4 Some authorities rely on a cutoff of 10⁴ copies/mL, while others choose 10⁵ copies/mL.
4 Because HBeAg seroconversion is not an option, the goal of therapy is to suppress HBV DNA and maintain a normal ALT. Although any of the oral agents or PEG IFN can be used as first-line therapy, lamivudine is less favored because of its resistance profile and the need, in the vast majority of cases, for long-term therapy. PEG IFN is administered by subcutaneous injection weekly for a year (caution is warranted in relying on a 6-month posttreatment interval to define a sustained response; the majority of such responses are lost thereafter). Adefovir and entecavir are administered daily, usually indefinitely or, until, as occurs very rarely, virologic and biochemical responses are accompanied by an HBeAg seroconversion.
4 Low-resistance regimen favored (i.e., adefovir or entecavir, not lamivudine) indefinitely. Note: ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; ULN, upper limits of normal; PEG IFN, pegylated interferon.
often associated with continued symptoms of hepatitis, elevated aminotransferase levels, presence in serum of HBeAg and HBV DNA, and presence in liver of replicative form of HBV; later phase in some pts may be associated with clinical and biochemical improvement, disappearance of HBeAg and HBV DNA and appearance of anti-HBeAg in serum, and integration of HBV DNA into host hepatocyte genome. In Mediterranean and European countries as well as in Asia, a frequent variant is characterized by readily detectable HBV DNA, but without HBeAg (anti-HBeAg-reactive). Most of these cases are due to a mutation in the pre-C region of the HBV genome that prevents HBeAg synthesis (may appear during course of chronic wild-type HBV infection as a result of immune pressure and may also account for some cases of fulminant hepatitis B). Chronic hepatitis B ultimately leads to cirrhosis in 25–40% of cases (particularly in pts with HDV superinfection or the pre-C mutation) and hepatocellular carcinoma in many of these pts (particularly when chronic infection is acquired early in life).

**Extrahepatic Manifestations (Immune Complex–Mediated)** Rash, urticaria, arthritis, polyarteritis nodosa–like vasculitis, polyneuropathy, glomerulonephritis.

### Chronic Hepatitis B

There are currently five approved drugs for the treatment of chronic HBV: interferon-α, pegylated interferon, lamivudine, adefovir dipivoxil, and entecavir (see Table 162-1). Table 162-2 summarizes recommendations for treatment of chronic HBV.

### CHRONIC HEPATITIS C

Follows 50–70% of cases of transfusion-associated and sporadic hepatitis C. Clinically mild, often waxing and waning aminotransferase elevations; mild chronic hepatitis on liver biopsy. Extrahepatic manifestations include cryoglobulinemia, porphyria cutanea tarda, membranoproliferative glomerulonephritis, and lymphocytic sialadenitis. Diagnosis confirmed by detecting anti-HCV in serum. May lead to cirrhosis in ≥20% of cases after 20 years.

### Chronic Hepatitis C

Therapy should be considered in pts with biopsy evidence of at least moderate chronic hepatitis (portal or bridging fibrosis) and HCV RNA in serum. The current therapy of choice for chronic HCV infection is a combination of pegylated interferon-α and the guanosine nucleoside analogue ribavirin (see Table 162-3). The dosage and duration of therapy depend on viral genotype (see Table 162-4). Monitoring of HCV plasma RNA is useful in assessing response to therapy. The failure to achieve a 2-log drop in HCV RNA by week 12 of therapy (“early virologic response”) makes it unlikely that further therapy will result in a sustained virologic response. Thus, it is recommended that HCV RNA be measured at baseline and after 12 weeks of therapy. The current consensus view is that therapy can be stopped if an early virologic response is not achieved; however, some experts feel that histologic benefit may occur even in the absence of a virologic response.
Although hepatitis A rarely causes fulminant hepatic failure, it may do so more frequently in pts with chronic liver disease—especially those with chronic hepatitis B or C. The hepatitis A vaccine is immunogenic and well tolerated in pts with chronic hepatitis. Thus, pts with chronic liver disease, especially those with chronic hepatitis B or C, should be vaccinated against hepatitis A.

**AUTOIMMUNE HEPATITIS**

**Classification**  
Type I: classic autoimmune hepatitis, anti-smooth-muscle and/or antinuclear antibodies (ANA). Type II: associated with anti-liver/kidney mi-
### TABLE 162-4
**INDICATIONS AND RECOMMENDATIONS FOR ANTIVIRAL THERAPY OF CHRONIC HEPATITIS C**

**Standard Indications for Therapy**
- Detectable HCV RNA (with or without elevated ALT)
- Portal/bridging fibrosis or moderate to severe hepatitis on liver biopsy

**Retreatment Recommended**
- Relapers after a previous course of standard interferon monotherapy or combination standard interferon/ribavirin therapy
  - A course of PEG IFN plus ribavirin
- Nonresponders to a previous course of standard IFN monotherapy or combination standard IFN/ribavirin therapy
  - A course of PEG IFN plus ribavirin—more likely to achieve a sustained virologic response in Caucasian patients without previous ribavirin therapy, with low baseline HCV RNA levels, with a 2-log₁₀ reduction in HCV RNA during previous therapy, with genotypes 2 and 3, and without reduction in ribavirin dose.

**Antiviral Therapy Not Recommended Routinely but Management Decisions Made on an Individual Basis**
- Children (age <18 years)
- Age >60
- Mild hepatitis on liver biopsy

**Long-Term Maintenance Therapy Recommended**
- Cutaneous vasculitis and glomerulonephritis associated with chronic hepatitis C

**Long-Term Maintenance Therapy Being Assessed in Clinical Trials**
- Relapers
- Nonresponders

**Antiviral Therapy Not Recommended**
- Decompensated cirrhosis
- Pregnancy (teratogenicity of ribavirin)

**Therapeutic Regimens**

**First-line treatment:** PEG IFN subcutaneously once a week plus daily ribavirin orally
- HCV genotypes 1 and 4–48 weeks of therapy
- PEG IFN-α2a 180 µg weekly plus ribavirin 1,000 mg/d (weight <75 kg) to 1200 mg/d (weight ≥75 kg) or
- PEG IFN-α2b 1.5 µg/kg weekly plus ribavirin 800 mg/d (the dose used in registration clinical trials, but the higher, weight-based ribavirin doses above are recommended for both types of PEG IFN)
- HCV genotypes 2 and 3–24 weeks of therapy
- PEG IFN-α2a 180 µg weekly plus ribavirin 800 mg/d or
- PEG IFN-α2b 1.5 µg/kg weekly plus ribavirin 800 mg/d (for patients with genotype 3 who have advanced fibrosis and/or high-level HCV RNA, a full 48 weeks of therapy may be preferable)

**Alternative regimen:** PEG IFN (α2a 180 µg or α2b 1.0 µg/kg) subcutaneously once a week (primarily for patients in whom ribavirin is contraindicated or not tolerated) for 24 (genotypes 2 and 3) or 48 (genotypes 1 and 4) weeks

For HCV-HIV co-infected patients: 48 weeks, regardless of genotype, of weekly PEG IFN-α2a (180 µg) or PEG IFN-α2b (1.5 µg/kg) plus a daily ribavirin dose of at least 600–800 mg, up to full weight-based 1000–1200 mg dosing if tolerated

(continued)
crosomal (anti-LKM) antibodies, which are directed against cytochrome P450IID6 (seen primarily in southern Europe). Type III patients lack ANA and anti-LKM, have antibodies reactive with hepatocyte cytokeratins; clinically similar to type I. Criteria have been suggested by an international group for establishing a diagnosis of autoimmune hepatitis.

Clinical Manifestations  Classic autoimmune hepatitis (type I): 80% women, third to fifth decades. Abrupt onset (acute hepatitis) in a third. Insidious onset in two-thirds: progressive jaundice, anorexia, hepatomegaly, abdominal pain, epistaxis, fever, fatigue, amenorrhea. Leads to cirrhosis; >50% 5-year mortality if untreated.

Extrahepatic Manifestations  Rash, arthralgias, keratoconjunctivitis sicca, thyroiditis, hemolytic anemia, nephritis.

Serologic Abnormalities  Hypergammaglobulinemia, positive rheumatoid factor, smooth-muscle antibody (40–80%), ANA (20–50%), antimitochondrial antibody (10–20%), false-positive anti-HCV enzyme immunoassay but usually not HCV RNA, atypical pANCA. Type II: anti-LKM antibody.

Autoimmune Hepatitis

Indicated for symptomatic disease with biopsy evidence of severe chronic hepatitis (bridging necrosis), marked aminotransferase elevations (5- to 10-fold), and hypergammaglobulinemia. Prednisone or prednisolone 30–60 mg/d PO tapered to 10–15 mg/d over several weeks; often azathioprine 50 mg/d PO is also administered to permit lower glucocorticoid doses and avoid steroid side effects. Monitor liver function tests (LFTs) monthly. Symptoms may improve rapidly, but biochemical improvement may take weeks or months and subsequent histologic improvement (to lesion of mild chronic hepatitis or normal biopsy) up to 18–24 months. Therapy should be continued for at least 12–18 months. Relapse occurs in at least 50% of cases (re-treat). For frequent relapses, consider maintenance therapy with low-dose glucocorticoids or azathioprine 2 (mg/kg)/d.

For a more detailed discussion, see Dienstag JL: Chronic Hepatitis, Chap. 300, p. 1955, in HPIM-17.
**CIRRHOSIS**

*Cirrhosis* is defined histopathologically and has a variety of causes, clinical features, and complications. In cirrhosis, there is the development of liver fibrosis to the point that there is architectural distortion with the formation of regenerative nodules, which results in decreased liver function.

**Causes**  
(See Table 163-1)

**Clinical Manifestations**  
May be absent, with cirrhosis being incidentally found at surgery.

**Symptoms**  
Anorexia, nausea, vomiting, diarrhea, vague RUQ pain, fatigue, weakness, fever, jaundice, amenorrhea, impotence, infertility.

**Signs**  
Spider telangiectases, palmar erythema, jaundice, scleral icterus, parotid and lacrimal gland enlargement, clubbing, Dupuytren’s contracture, gynecomastia, testicular atrophy, hepatosplenomegaly, ascites, gastrointestinal bleeding (e.g., varices), hepatic encephalopathy.

**Laboratory Findings**  
Anemia (microcytic due to blood loss, macrocytic due to folate deficiency; hemolytic called *Zieve’s syndrome*), pancytopenia (hypersplenism), prolonged PT, rarely overt DIC; hyponatremia, hypokalemic alkalo sis, glucose disturbances, hypoalbuminemia.

**Diagnostic Studies**  
Depend on clinical setting. Serum: HBsAg, anti-HBc, anti-HBs, anti-HCV, anti-HDV, Fe, total iron-binding capacity, ferritin, anti-mitochondrial antibody (AMA), smooth-muscle antibody (SMA), anti-liver/kidney microsomal (anti-LKM) antibody, ANA, ceruloplasmin, α₁ antitrypsin (and pi typing); abdominal ultrasound with doppler study, CT or MRI (may show cirrhotic liver, splenomegaly, collaterals, venous thrombosis). Definitive diagnosis often depends on liver biopsy (percutaneous, transjugular, or open).

**Complications**  
(See Table 163-2 and Chaps. 55, 56, and 164)  
The Child-Pugh scoring system has been used to predict the severity of cirrhosis and the risk of complications (see Table 163-3).

<table>
<thead>
<tr>
<th>TABLE 163-1 CAUSES OF CIRRHOSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcoholism</td>
</tr>
<tr>
<td>Chronic viral hepatitis</td>
</tr>
<tr>
<td>Hepatitis B</td>
</tr>
<tr>
<td>Hepatitis C</td>
</tr>
<tr>
<td>Autoimmune hepatitis</td>
</tr>
<tr>
<td>Nonalcoholic steatohepatitis</td>
</tr>
<tr>
<td>Biliary cirrhosis</td>
</tr>
<tr>
<td>Primary biliary cirrhosis</td>
</tr>
<tr>
<td>Primary sclerosing cholangitis</td>
</tr>
<tr>
<td>Autoimmune cholangiopathy</td>
</tr>
</tbody>
</table>
Cirrhosis and Alcoholic Liver Disease

CHAPTER 163

ALCOHOLIC LIVER DISEASE

Excessive alcohol use can cause: fatty liver, alcoholic hepatitis, cirrhosis. Alcoholic cirrhosis accounts for about 40% of the deaths due to cirrhosis. History of excessive alcohol use often denied. Severe forms (hepatitis, cirrhosis) associated with ingestion of 160 g/d for 10–20 years; women more susceptible than men and develop advanced liver disease with less alcohol intake. Hepatitis B and C may be cofactors in the development of liver disease. Malnutrition may contribute to development of cirrhosis.

Fatty Liver  Often presents as asymptomatic hepatomegaly and mild elevations in biochemical liver tests. Reverses on withdrawal of ethanol; does not lead to cirrhosis.

Alcoholic Hepatitis  Clinical presentation ranges from asymptomatic to severe liver failure with jaundice, ascites, GI bleeding, and encephalopathy. Typically anorexia, nausea, vomiting, fever, jaundice, tender hepatomegaly. Occasional

<table>
<thead>
<tr>
<th>TABLE 163-2</th>
<th>COMPLICATIONS OF CIRRHOSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Portal hypertension</td>
<td>Coagulopathy</td>
</tr>
<tr>
<td>Gastroesophageal varices</td>
<td>Factor deficiency</td>
</tr>
<tr>
<td>Portal hypertensive gastropathy</td>
<td>Fibrinolysis</td>
</tr>
<tr>
<td>Splenomegaly, hypersplenism</td>
<td>Thrombocytopenia</td>
</tr>
<tr>
<td>Ascites</td>
<td>Bone disease</td>
</tr>
<tr>
<td></td>
<td>Osteopenia</td>
</tr>
<tr>
<td></td>
<td>Osteoporosis</td>
</tr>
<tr>
<td></td>
<td>Osteomalacia</td>
</tr>
<tr>
<td></td>
<td>Hematologic abnormalities</td>
</tr>
<tr>
<td>Hepatorenal syndrome</td>
<td>Anemia</td>
</tr>
<tr>
<td>Type 1</td>
<td>Hemolysis</td>
</tr>
<tr>
<td>Type 2</td>
<td>Thrombocytopenia</td>
</tr>
<tr>
<td>Hepatic encephalopathy</td>
<td>Neutropenia</td>
</tr>
<tr>
<td>Hepatopulmonary syndrome</td>
<td></td>
</tr>
<tr>
<td>Portopulmonary hypertension</td>
<td></td>
</tr>
<tr>
<td>Malnutrition</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TABLE 163-3</th>
<th>CHILD-PUGH CLASSIFICATION OF CIRRHOSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor</td>
<td>Units</td>
</tr>
<tr>
<td>Serum bilirubin</td>
<td>μmol/L mg/dL</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum albumin</td>
<td>g/L g/dL</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Prothrombin time</td>
<td>Seconds</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascites</td>
<td>None</td>
</tr>
<tr>
<td>Hepatic encephalopathy</td>
<td>None</td>
</tr>
</tbody>
</table>

Note: The Child-Pugh score is calculated by adding the scores of the five factors and can range from 5–15. Child-Pugh class is either A (a score of 5–6), B (7–9), or C (10 or above). Decompensation indicates cirrhosis with a Child-Pugh score of 7 or more (class B). This level has been the accepted criterion for listing for liver transplantation.
cholestatic picture mimicking biliary obstruction. Aspartate aminotransferase (AST) usually <400 U/L and more than twofold higher than alanine aminotransferase (ALT). Bilirubin and WBC may be elevated. Diagnosis defined by liver biopsy findings: hepatocyte swelling, alcoholic hyaline (Mallory bodies), infiltration of PMNs, necrosis of hepatocytes, pericentral venular fibrosis.

Other Metabolic Consequences of Alcoholism Increased NADH/NAD ratio leads to lactic acidemia, ketoacidosis, hyperuricemia, hypoglycemia. Hypomagnesemia, hypophosphatemia. Also mitochondrial dysfunction, induction of microsomal enzymes resulting in altered drug metabolism, lipid peroxidation leading to membrane damage, hypermetabolic state; many features of alcoholic hepatitis are attributable to toxic effects of acetaldehyde and cytokines (interleukins 1 and 6, and TNF, released because of impaired detoxification of endotoxin).

Adverse Prognostic Factors Critically ill patients with alcoholic hepatitis have 30-day mortality rates >50%. Severe alcoholic hepatitis characterized by: PT > 5 × above control, bilirubin > 137 μmol/L (>8 mg/dL), hypoalbuminemia, azotemia. A discriminant function can be calculated as 4.6 × (patient’s PT in seconds) (control PT in seconds) + serum bilirubin (mg/dL). Values ≥32 are associated with poor prognosis. Ascites, variceal hemorrhage, encephalopathy, hepatorenal syndrome predict a poor prognosis.

Alcoholic Liver Disease

Abstinence is essential; 8500–12,500 kJ (2000–3000 kcal) diet with 1 g/kg protein (less if encephalopathy). Daily multivitamin, thiamine 100 mg, folic acid 1 mg. Correct potassium, magnesium, and phosphate deficiencies. Transfusions of packed red cells, plasma as necessary. Monitor glucose (hypoglycemia in severe liver disease). Prednisone 40 mg/d or prednisolone 32 mg/d PO for 1 month may be beneficial in severe alcoholic hepatitis with encephalopathy (in absence of GI bleeding, renal failure, infection). Pentoxifylline demonstrated improved survival and led to the inclusion of this agent as an alternative to glucocorticoids in the treatment of severe alcoholic hepatitis. Liver transplantation may be an option in carefully selected cirrhotic pts who have been abstinent >6 months.

PRIMARY BILIARY CIRRHOSIS

PBC is a progressive nonsuppurative destructive intrahepatic cholangitis. Strong female predominance, median age of 50 years. Presents as asymptomatic elevation in alkaline phosphatase (better prognosis) or with pruritus, progressive jaundice, consequences of impaired bile excretion, and ultimately cirrhosis and liver failure.

Clinical Manifestations Pruritus, fatigue, jaundice, xanthelasma, xanthomata, osteoporosis, steatorrhea, skin pigmentation, hepatosplenomegaly, portal hypertension; elevations in serum alkaline phosphatase, bilirubin, cholesterol, and IgM levels.

Associated Diseases Sjögren’s syndrome, collagen vascular diseases, thyroiditis, glomerulonephritis, pernicious anemia, renal tubular acidosis.

Diagnosis Antimitochondrial antibodies (AMA) in 90% (directed against enzymes of the pyruvate dehydrogenase complex and other 2-oxo-acid dehydrogenase mitochondrial enzymes). Liver biopsy most important in AMA-negative PBC.
Biopsies identify 4 stages: stage 1—destruction of interlobular bile ducts, granulomas; stage 2—ductular proliferation; stage 3—fibrosis; stage 4—cirrhosis.

**Prognosis** Correlates with age, serum bilirubin, serum albumin, prothrombin time, edema.

**Primary Biliary Cirrhosis**

Urodeoxycholic acid 13–15 mg/kg per day has been shown to improve the biochemical and histologic features of disease. Response is greatest when given early. Cholestyramine 4 g PO with meals for pruritus; in refractory cases consider rifampin, naltrexone, plasmapheresis. Calcium, vitamin D, and bisphosphonates are given for osteoporosis. Liver transplantation for end-stage disease.

**LIVER TRANSPLANTATION**

Consider in the absence of contraindications for chronic, irreversible, progressive liver disease or fulminant hepatic failure when no alternative therapy is available (see Table 163-4).

**Contraindications** (See Table 163-5)

**Selection of Donor** Matched for ABO blood group compatibility and liver size (reduced-size grafts may be used, esp. in children). Should be negative for HIV, HBV, and HCV. Living-donor transplant has gained increased popularity with transplantation of the right hepatic lobe from a healthy adult donor to an adult. Living-donor transplant of the left lobe accounts for one-third of all liver transplants in children.

**TABLE 163-4** INDICATIONS FOR LIVER TRANSPLANTATION

<table>
<thead>
<tr>
<th>Children</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biliary atresia</td>
<td>Primary biliary cirrhosis</td>
</tr>
<tr>
<td>Neonatal hepatitis</td>
<td>Secondary biliary cirrhosis</td>
</tr>
<tr>
<td>Congenital hepatic fibrosis</td>
<td>Primary sclerosing cholangitis</td>
</tr>
<tr>
<td>Alagille’s disease&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Autoimmune cholangitis</td>
</tr>
<tr>
<td>Byler’s disease&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Caroli’s disease&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>$\alpha_1$-Antitrypsin deficiency</td>
<td>Cryptogenic cirrhosis</td>
</tr>
<tr>
<td>Inherited disorders of metabolism</td>
<td>Chronic hepatitis with cirrhosis</td>
</tr>
<tr>
<td>Wilson’s disease</td>
<td>Hepatic vein thrombosis</td>
</tr>
<tr>
<td>Tyrosinemia</td>
<td>Fulminant hepatitis</td>
</tr>
<tr>
<td>Glycogen storage diseases</td>
<td>Alcoholic cirrhosis</td>
</tr>
<tr>
<td>Lysosomal storage diseases</td>
<td>Chronic viral hepatitis</td>
</tr>
<tr>
<td>Protoporphyria</td>
<td>Primary hepatocellular maligancies</td>
</tr>
<tr>
<td>Crigler-Najjar disease type I</td>
<td>Hepatic adenomas</td>
</tr>
<tr>
<td>Familial hypercholesterolemia</td>
<td>Nonalcoholic steatohepatitis</td>
</tr>
<tr>
<td>Primary hyperoxaluria type I</td>
<td>Familial amyloid polyneuropathy</td>
</tr>
<tr>
<td>Hemophilia</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>Arteriohepatic dysplasia, with paucity of bile ducts, and congenital malformations, including pulmonary stenosis.

<sup>b</sup>Intrahepatic cholestasis, progressive liver failure, mental and growth retardation.

<sup>c</sup>Multiple cystic dilatations of the intrahepatic biliary tree.
**Immunosuppression**  Various combinations of tacrolimus or cyclosporine and glucocorticoids, sirolimus, mycophenolate mofetil, or OKT3 (monoclonal anti-thymocyte globulin).

**Medical Complications after Transplantation**  Liver graft dysfunction (primary nonfunction, acute or chronic rejection, ischemia, hepatic artery thrombosis, biliary obstruction or leak, recurrence of primary disease); infections (bacterial, viral, fungal, opportunistic); renal dysfunction; neuropsychiatric disorders, cardiovascular instability, pulmonary compromise.

**Success Rate**  Currently, 5-year survival rates exceed 60%; less for certain conditions (e.g., chronic hepatitis B, hepatocellular carcinoma).

---

**TABLE 163-5 CONTRAINDICATIONS TO LIVER TRANSPLANTATION**

<table>
<thead>
<tr>
<th>Absolute</th>
<th>Relative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncontrolled extrahepatic infection</td>
<td>Age &gt;70</td>
</tr>
<tr>
<td>Active, untreated sepsis</td>
<td>Prior extensive hepatobiliary surgery</td>
</tr>
<tr>
<td>Uncorrectable, life-limiting congenital anomalies</td>
<td>Portal vein thrombosis</td>
</tr>
<tr>
<td>Active substance or alcohol abuse</td>
<td>Renal failure</td>
</tr>
<tr>
<td>Advanced cardiopulmonary disease</td>
<td>Previous extrahepatic malignancy (not including nonmelanoma skin cancer)</td>
</tr>
<tr>
<td>Extrahepatic malignancy (not including nonmelanoma skin cancer)</td>
<td>Severe obesity</td>
</tr>
<tr>
<td>Metastatic malignancy to the liver</td>
<td>Severe malnutrition/wasting</td>
</tr>
<tr>
<td>Cholangiocarcinoma</td>
<td>Medical noncompliance</td>
</tr>
<tr>
<td>AIDS</td>
<td>HIV seropositivity</td>
</tr>
<tr>
<td>Life-threatening systemic diseases</td>
<td>Intrahepatic sepsis</td>
</tr>
<tr>
<td></td>
<td>Severe hypoxemia secondary to right-to-left intrapulmonary shunts ($P_{O_2} &lt; 50 \text{ mmHg}$)</td>
</tr>
<tr>
<td></td>
<td>Severe pulmonary hypertension (mean PA pressure &gt;35 mmHg)</td>
</tr>
<tr>
<td></td>
<td>Uncontrolled psychiatric disorder</td>
</tr>
</tbody>
</table>

**Portal Hypertension**

Portal hypertension is defined as elevation of the hepatic venous pressure gradient to >5 mmHg, which occurs as a consequence of cirrhosis (see Chap. 163). It is caused by increased intrahepatic resistance to the passage of blood flow through the liver due to cirrhosis together with increased splanchnic blood flow due to vasodilatation within the splanchnic vascular bed.
Classification  See Table 164-1.

Consequences  The three primary complications of portal hypertension are (1) gastroesophageal varices with hemorrhage, (2) ascites (see Chap. 56), (3) hypersplenism.

ESOPHAGOGRASTIC VARICES

About one-third of patients with cirrhosis have varices, and one-third of patients with varices will develop bleeding. Bleeding is a life-threatening complication; risk of bleeding correlates with: variceal size and location, the degree of portal hypertension (portal venous pressure >12 mmHg), and the severity of cirrhosis, e.g., Child-Pugh classification (see Table 163-3).

Diagnosis  Esophagogastroscopy: procedure of choice for evaluation of upper GI hemorrhage in pts with known or suspected portal hypertension. Celiac and mesenteric arteriography are alternatives when massive bleeding prevents endoscopy and to evaluate portal vein patency (portal vein may also be studied by ultrasound with Doppler and MRI).

RX  Esophagogastric Varices

See Chap. 54 for general measures to treat GI bleeding.

CONTROL OF ACUTE BLEEDING

Choice of approach depends on clinical setting and availability.

1. Endoscopic intervention is employed as first-line treatment to control bleeding acutely. Endoscopic variceal ligation (EVL) is used to control acute bleeding in >90% of cases. EVL is less successful when varices extend into proximal stomach. Some endoscopists will use variceal injection (sclerotherapy) as initial therapy, particularly when bleeding is vigorous.
2. Vasoconstricting agents: somatostatin or octreotide (50–100 μg/h by continuous infusion).
3. Balloon tamponade (Blakemore-Sengstaken or Minnesota tube). Can be used when endoscopic therapy is not immediately available or in pts who need stabilization prior to endoscopic therapy. Complications—obstruction of pharynx, asphyxiation, aspiration, esophageal ulceration. Generally reserved for massive bleeding, failure of vasopressin and/or endoscopic therapy.
4. Transjugular intrahepatic portosystemic shunt (TIPS)—portacaval shunt placed by interventional radiologic technique, reserved for failure of other approaches; risk of hepatic encephalopathy (20–30%), shunt stenosis or occlusion (30–60%), infection.

PREVENTION OF RECURRENT BLEEDING
1. EVL should be repeated until obliteration of all varices is accomplished.
2. Propranolol or nadolol—nonselective beta blockers that act as portal venous antihypertensives; may decrease the risk of variceal hemorrhage and mortality due to hemorrhage.
3. TIPS—regarded as useful “bridge” to liver transplantation in pt who has failed pharmacologic therapy and is awaiting a donor liver.
4. Portosystemic shunt surgery used less commonly with the advent of TIPS; could be considered for pts with good hepatic synthetic function.

PREVENTION OF INITIAL BLEED
For pts at high risk of variceal bleeding, consider prophylaxis with EVL and/or nonselective beta blockers.

HEPATIC ENCEPHALOPATHY
An alteration in mental status and cognitive function occurring in the presence of liver failure; may be acute and reversible or chronic and progressive.

Clinical Features Confusion, slurred speech, change in personality that can include being violent and hard to manage to being sleepy and difficult to arouse, asterixis (flapping tremor). Can progress to coma; initially responsive to noxious stimuli, later unresponsive.

Pathophysiology Gut-derived neurotoxins that are not removed by the liver because of vascular shunting and decreased hepatic mass reach the brain and cause the symptoms of hepatic encephalopathy. Ammonia levels are typically elevated in encephalopathy, but the correlation between the severity of liver disease and height of ammonia levels is often poor. Other compounds that may contribute include false neurotransmitters and mercaptans.

Precipitants GI bleeding, azotemia, constipation, high-protein meal, hypokalemic alkalosis, CNS depressant drugs (e.g., benzodiazepines and barbiturates), hypoxia, hypercarbia, sepsis.

Hepatic Encephalopathy
Remove precipitants; correct electrolyte imbalances. Lactulose (nonabsorbable disaccharide) results in colonic acidification and diarrhea and is the mainstay of treatment; goal is to produce 2–3 soft stools per day. Poorly absorbed antibiotics are often used in patients who do not tolerate lactulose, with alternating administration of neomycin and metronidazole being used to
reduce the individual side effects of each. Rifaximin has recently also been
used; zinc supplementation is sometimes helpful. Liver transplantation when
otherwise indicated.

For a more detailed discussion, see Bacon BR: Cirrhosis and Its
Complications, Chap. 302, p.1971; in HPIM-17.
Diseases of Immediate Type Hypersensitivity

**Definition** These diseases result from IgE-dependent release of mediators from sensitized basophils and mast cells on contact with appropriate antigen (allergen). Associated disorders include anaphylaxis, allergic rhinitis, urticaria, asthma, and eczematous (atopic) dermatitis. Atopic allergy implies a familial tendency to the development of these disorders singly or in combination.

**Pathophysiology** IgE binds to the surface of mast cells and basophils through a high-affinity receptor. Cross-linking of this IgE by antigen causes cellular activation with subsequent release of preformed and newly synthesized mediators including histamine, prostaglandins, leukotrienes (C4, D4, and E4, collectively known as slow-reacting substance of anaphylaxis—SRS-A), acid hydrolases, neutral proteases, proteoglycans, and cytokines (Fig. 165-1). The mediators have been implicated in many pathophysiologic events associated with immmedi-

**FIGURE 165-1** Bioactive mediators of three categories generated by IgE-dependent activation of murine mast cells can elicit common but sequential target cell effects leading to acute and sustained inflammatory responses. LT, leukotriene; PAF, platelet-activating factor; PGD2, prostaglandin D2; IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating factor; INF, interferon; TNF, tumor necrosis factor.
ate type hypersensitivity, such as vasodilatation, increased vasopermeability, smooth-muscle contraction, and chemotactic attraction of neutrophils and other inflammatory cells. The clinical manifestations of each allergic reaction depend largely on the anatomic site(s) and time course of mediator release.

**URTICARIA AND ANGIOEDEMA**

**Definition** May occur together or separately. *Urticaria* involves only the superficial dermis and presents as circumscribed wheals with raised serpiginous borders and blanched centers; wheals may coalesce. *Angioedema* involves deeper layers of skin and may include subcutaneous tissue. The classification of urticaria-angioedema focuses on mechanisms that elicit clinical disease and can be useful for differential diagnosis (see Table 165-1).

**Pathophysiology** Characterized by massive edema formation in the dermis (and subcutaneous tissue in angioedema). Presumably the edema is due to increased vasopermeability caused by mediator release from mast cells or other cell populations.

**Diagnosis** History, with special attention to possible offending exposures and/or ingestion as well as the duration of lesions. Vasculitic urticaria typically persists >72 h, whereas conventional urticaria often has a duration <48 h.

- Skin testing to food and/or inhalant antigens.
- Physical provocation, e.g., challenge with vibratory or cold stimuli.
- Laboratory exam: complement levels, ESR (neither an elevated ESR nor hypocomplementemia is observed in IgE-mediated urticaria or angioedema); C1 inhibitor (C1INH) testing for deficiency of C1INH antigen (type 1) or a non-functional protein (type 2) if history suggests hereditary angioedema; cryoglobulins, hepatitis B antigen, and antibody studies; autoantibody screen.
- Skin biopsy may be necessary.

**TABLE 165-1** CLASSIFICATION OF URTICARIA AND/OR ANGIOEDEMA

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. IgE-dependent</td>
<td>a. Specific antigen sensitivity (pollens, foods, drugs, fungi, molds, Hymenoptera venom, helminths) b. Physical: dermographism, cold, solar c. Autoimmune</td>
</tr>
<tr>
<td>2. Bradykinin-mediated</td>
<td>a. Hereditary angioedema: C1 inhibitor deficiency: null (type 1) and dysfunctional (type 2) b. Acquired angioedema: C1 inhibitor deficiency: anti-idiotype and anti-C1 inhibitor c. Angiotensin-converting enzyme inhibitors</td>
</tr>
<tr>
<td>5. Idiopathic</td>
<td></td>
</tr>
</tbody>
</table>
Differential Diagnosis  Atopic dermatitis, contact sensitivity, cutaneous mastocytosis (urticaria pigmentosa), systemic mastocytosis.

Prevention  Identification and avoidance of offending agent(s), if possible.

### Urticaria and Angioedema

- **H**₁ antihistamines may be helpful: e.g., chlorpheniramine up to 24 mg PO daily; diphenhydramine 25–50 mg PO qid; hydroxyzine 40–200 mg PO daily; cyproheptadine 8–32 mg PO daily; or the non-sedating class, e.g., loratidine 10 mg PO daily; fexofenadine up to 180 mg PO daily; cetirizine 5–10 mg PO daily.
- **H**₂ antihistamines: e.g., ranitidine 150 mg PO bid may add benefit.
- Leukotriene receptor antagonists can be add-on therapy: e.g., montelukast 10 mg daily or zafirlukast 20 mg bid.
- Topical glucocorticoids are of no value in the management of urticaria and/or angioedema. Because of their long-term toxicity, systemic glucocorticoids should not be used in the treatment of idiopathic, allergen-induced, or physical urticaria.

### ALLERGIC RHINITIS

**Definition**  An inflammatory condition of the nose characterized by sneezing, rhinorrhea, and obstruction of nasal passages; may be associated with conjunctival and pharyngeal itching, lacrimation, and sinusitis. Seasonal allergic rhinitis is commonly caused by exposure to pollens, especially from grasses, trees, weeds, and molds. Perennial allergic rhinitis is frequently due to contact with house dust (containing dust mite antigens) and animal danders.

**Pathophysiology**  Deposition of pollens and other allergens on nasal mucosa of sensitized individuals results in IgE-dependent triggering of mast cells with subsequent release of mediators that cause development of mucosal hyperemia, swelling, and fluid transudation. Inflammation of nasal mucosal surface probably allows penetration of allergens deeper into tissue, where they contact peri-venular mast cells. Obstruction of sinus ostia may result in development of secondary sinusitis, with or without bacterial infection.

**Diagnosis**  Accurate history of symptoms correlated with time of seasonal pollination of plants in a given locale; special attention must be paid to other potentially sensitizing antigens such as pets.

- Physical examination: nasal mucosa may be boggy or erythematous; nasal polyps may be present; conjunctivae may be inflamed or edematous; manifestations of other allergic conditions (e.g., asthma, eczema) may be present.
- Skin tests to inhalant and/or food antigens.
- Nasal smear may reveal large numbers of eosinophils; presence of neutrophils may suggest infection.
- Total and specific serum IgE (as assessed by immunoassay) may be elevated.

**Differential Diagnosis**  Vasomotor rhinitis, URI, irritant exposure, pregnancy with nasal mucosal edema, rhinitis medicamentosa, nonallergic rhinitis with eosinophilia, rhinitis due to use of α-adrenergic agents.

**Prevention**  Identification and avoidance of offending antigen(s).
Allergic Rhinitis

- Older antihistamines (e.g., chlorpheniramine, diphenhydramine) are effective but cause sedation and psychomotor impairment including reduced hand-eye coordination and impaired automobile driving skills. Newer antihistamines (e.g., fexofenadine, loratadine, desloradine, cetirizine, and azelastine) are equally effective but are less sedating and more H1 specific.
- Oral sympathomimetics, e.g., pseudoephedrine 30–60 mg PO qid; may aggravate hypertension; combination antihistamine/decongestant preparations may balance side effects and provide improved pt convenience.
- Topical vasoconstrictors—should be used sparingly due to rebound congestion and chronic rhinitis associated with prolonged use.
- Topical nasal glucocorticoids, e.g., beclomethasone, 2 sprays in each nostril bid, or fluticasone, 2 sprays in each nostril once daily.
- Topical nasal cromolyn sodium, 1–2 sprays in each nostril qid.
- Montelukast 10 mg PO daily is approved for seasonal and perennial rhinitis.
- Hyposensitization therapy, if more conservative therapy is unsuccessful.

SYSTEMIC MASTOCYTOSIS

Definition
A systemic disorder characterized by mast cell hyperplasia; generally recognized in bone marrow, skin, GI mucosa, liver, and spleen. Classified as (1) indolent, (2) associated with concomitant hematologic disorder, (3) aggressive, (4) mastocytic leukemia, and (5) mast cell sarcoma.

Pathophysiology and Clinical Manifestations
The clinical manifestations of systemic mastocytosis are due to tissue occupancy by the mast cell mass, the tissue response to that mass (fibrosis), and the release of bioactive substances acting both locally (urticaria pigmentosa, crampy abdominal pain, gastritis, peptic ulcer) and at distal sites (headache, pruritus, flushing, vascular collapse). Clinical manifestations may be aggravated by alcohol, use of narcotics (e.g., codeine), ingestion of NSAIDs.

Diagnosis
Although the diagnosis of mastocytosis may be suspected on the basis of clinical and laboratory findings, it can be established only by tissue biopsy (usually bone marrow biopsy). The diagnostic criteria for systemic mastocytosis are shown in Table 165-2. Laboratory studies that can help support a diagnosis of systemic mastocytosis include measurement of urinary or blood le-

TABLE 165-2 | DIAGNOSTIC CRITERIA FOR SYSTEMIC MASTOCYTOSIS a

| Major: Multifocal dense infiltrates of mast cells in bone marrow or other extracutaneous tissues with confirmation by immunodetection of tryptase or metachromasia |
| Minor: Abnormal mast cell morphology with a spindle shape and/or multilobed or eccentric nucleus |
| Aberrant mast cell surface phenotype with expression of CD25 and CD2 (IL-2 receptor) in addition to C117 (c-kit) |
| Detection of codon 816 mutation in peripheral blood cells, bone marrow cells, or lesional tissue |
| Total serum tryptase (mostly alpha) >20 ng/mL |

aDiagnosis requires either major and one minor or three minor criteria.
vels of mast cell products such as histamine, histamine metabolites, prostaglandin D₂ (PGD₂) metabolites, or mast cell tryptase. Other studies including bone scan, skeletal survey, GI contrast studies may be helpful. Other flushing disorders (e.g., carcinoid syndrome, pheochromocytoma) should be excluded.

**Systemic Mastocystosis**

- H₁ and H₂ antihistamines.
- Proton pump inhibitors for gastric hypersecretion.
- Oral cromolyn sodium for diarrhea and abdominal pain.
- NSAIDs (in nonsensitive pts) may help by blocking PGD₂ production.
- Systemic glucocorticoids may help but frequently are associated with complications.
- Hydroxyurea to reduce mast cell lineage progenitors may have merit in aggressive systemic mastocystosis.
- Chemotherapy for frank leukemias.

For a more detailed discussion, see Austen KF: Allergies, Anaphylaxis, and Systemic Mastocytosis, Chap. 311, p. 2061, in HPIM-17.

---

**Primary Immune Deficiency Diseases**

**DEFINITION**

Disorders involving the cell-mediated (T cell) or antibody-mediated (B cell) pathways of the immune system; some disorders may manifest abnormalities of both pathways. Pts are prone to development of recurrent infections and, in certain disorders, lymphoproliferative neoplasms. Primary disorders may be congenital or acquired; some are familial in nature. Secondary disorders are not caused by intrinsic abnormalities of immune cells but may be due to infection (such as in AIDS; see HPIM-17, Chap. 182), treatment with cytotoxic drugs, radiation therapy, or lymphoreticular malignancies. Pts with disorders of antibody formation are chiefly prone to infection caused by pyogenic bacteria such as Streptococcus pneumoniae, Haemophilus, Staphylococcus aureus, and Giardia. Individuals with T cell defects are generally susceptible to infections with viruses, fungi, and protozoa.

**DIAGNOSIS**

See Table 166-1

**CLASSIFICATION**

**SEVERE COMBINED IMMUNODEFICIENCY (SCID)**

Congenital (autosomal recessive or X-linked); affected infants rarely survive beyond 1 year without treatment. Dysfunction of both cell-mediated and humoral immunity.
Genetic deficiencies in Orail and CD45 may lead to a T-B+NK+ SCID phenotype.

Recombinase activating gene (RAG) deficiency: Autosomal recessive; severe lymphopenia involving B and T cells. Some cases due to mutations in the RAG-1 or RAG-2 genes, the combined activities of which are needed for V(D)J recombination of the T and B cell antigen receptors.

Function-loss mutations in the DNA-dependent tyrosine kinase, Artemis, ligase IV, or Cernnunos genes may cause SCID as they encode essential enzymes for the V(D)J rearrangement process.

Adenosine deaminase (ADA) deficiency: About half of pts with autosomal recessive SCID are deficient in ADA, due to mutations in the ADA gene.

X-linked SCID: Characterized by an absence of peripheral T cells and natural killer (NK) cells. B lymphocytes are present in normal numbers but are functionally defective. These pts have a mutation in the gene that encodes the gamma chain common to the interleukin (IL) -2, -4, -7, -9, -15 receptors, thus disrupting...
the action of these important lymphokines. The same phenotype seen in X-linked SCID can be inherited as an autosomal recessive disease due to mutations in the JAK3 protein kinase gene. This enzyme associates with the common gamma chain of the receptors for IL-2, -4, -9, and -15 and is a key element in the signal transduction pathways used by these receptors.

**Severe Combined Immunodeficiency**

Bone marrow transplantation is useful in some SCID pts.

---

**T CELL IMMUNODEFICIENCY**

**DiGeorge’s syndrome:** Maldevelopment of organs derived embryologically from third and fourth pharyngeal pouches (including thymus); associated with congenital cardiac defects, parathyroid hypoplasia with hypocalcemic tetany, abnormal facies, thymic aplasia; serum Ig levels may be normal, but specific IgG and IgA antibody responses are impaired.

**T cell receptor (TCR) complex deficiency:** Immunodeficiencies due to inherited mutations of the CD3γ and CD3ε components of the TCR complex have been identified. CD3γ mutations result in a selective defect in CD8 T cells, whereas CD3ε mutations lead to a preferential reduction in CD4 T cells.

**MHC class II deficiency:** Antigen-presenting cells from pts with this rare disorder fail to express the class II molecules DP, DQ, and DR on their surface, which results in limited development of CD4+ T cells in the thymus and defective interaction of CD4 T cells and antigen-presenting cells in the periphery. Affected pts experience recurrent bronchopulmonary infections, chronic diarrhea, and severe viral infections.

**Inherited deficiency of purine nucleoside phosphorylase:** Functions in same salvage pathway as ADA; cellular dysfunction may be related to intracellular accumulation of purine metabolites.

**Ataxia-telangiectasia:** Autosomal recessive disorder caused by mutation in the ATM gene (gene product involved in DNA repair). Clinical manifestations include cerebellar ataxia, oculocutaneous telangiectasia, immunodeficiency; not all pts have immunodeficiency; lymphomas common; IgG subclasses may be abnormal.

**The nude syndrome:** This is the counterpart to the nude mouse and is caused by a mutation in the whn gene resulting in impairment of hair follicle and epithelial thymic development. The phenotype is characterized by congenital baldness, nail dystrophy, and severe T cell immunodeficiency.

**Zap70 kinase deficiency:** This tyrosine kinase is a pivotal component of the T cell receptor complex. Mutations in this gene result in a T cell immunodeficiency manifested by recurrent opportunistic infections that begin in the first year of life.

---

**IMMUNOGLOBULIN DEFICIENCY SYNDROMES**

**X-linked agammaglobulinemia:** Due to a mutation in the Bruton’s tyrosine kinase (Btk) gene. Marked deficiency of circulating B lymphocytes; all Ig classes low;
recurrent sinopulmonary infections are the most frequent clinical problem. Mycoplasma infections can cause arthritis in some patients and chronic viral encephalitis sometimes associated with dermatomyositis can be a fatal complication.

**Autosomal agammaglobulinemia:** This can result from mutations in a variety of genes required for B lineage differentiation.

**Transient hypogammaglobulinemia of infancy:** This occurs between 3 and 6 months of age as maternally derived IgG levels decline.

**Isolated IgA deficiency:** Most common immunodeficiency; the majority of affected individuals do not have increased infections; antibodies against IgA may lead to anaphylaxis during transfusion of blood or plasma; may be associated with deficiencies of IgG subclasses; often familial.

**IgG subclass deficiencies:** Total serum IgG may be normal, yet some individuals may be prone to recurrent sinopulmonary infections due to selective deficiencies of certain IgG subclasses.

**Common variable immunodeficiency:** Heterogeneous group of syndromes characterized by panhypogammaglobulinemia, deficiency of IgG and IgA, or selective IgG deficiency and recurrent sinopulmonary infections; associated conditions include chronic giardiasis, intestinal malabsorption, atrophic gastritis with pernicious anemia, benign lymphoid hyperplasia, lymphoreticular neoplasms, arthritis, and autoimmune diseases.

**X-linked immunodeficiency with hyper IgM:** In most pts this syndrome results from genetic mutation in the gene encoding CD40 ligand, a transmembrane protein expressed by activated T cells and necessary for normal T and B cell cooperation, germinal center formation, and immunoglobulin isotype switching. Pts exhibit normal or increased serum IgM with low or absent IgG and IgA and recurrent sinopulmonary infections; pts also exhibit T lymphocyte abnormalities with increased susceptibility to infection with opportunistic pathogens (*P. jiroveci, Cryptosporidium*). Associated conditions include neutropenia and hepatobiliary tract disease.

### Immunoglobulin Deficiency Syndromes

Intravenous immunoglobulin administration (only for pts who have recurrent bacterial infections and are deficient in IgG):

- Starting dose 400–500 mg/kg given every 3–4 weeks
- Adjust dose to keep trough IgG level > 500 mg/dL
- Usually done in outpatient setting
- Decision to treat based on severity of clinical symptoms and response to antigenic challenge

### MISCELLANEOUS IMMUNODEFICIENCY SYNDROMES

- Mucocutaneous candidiasis
- Interferon gamma receptor deficiency
- Interleukin 12 receptor deficiency
- X-linked lymphoproliferative syndrome
- Immunodeficiency with thymoma
- Wiskott-Aldrich syndrome
- Hyper-IgE syndrome
- Metabolic abnormalities associated with immunodeficiency

For a more detailed discussion, see Cooper MD, Schroeder HW Jr: Primary Immune Deficiency Diseases, Chap. 310, p. 2053, in HPIM-17.
Definition  Heterogeneous disorders that share certain common features, including inflammation of skin, joints, and other structures rich in connective tissue; as well as altered patterns of immunoregulation, including production of autoantibodies and abnormalities of cell-mediated immunity. While distinct clinical entities can be defined, manifestations may vary considerably from one patient (pt) to the next, and overlap of clinical features between and among specific diseases can occur.

**SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)**

**Definition and Pathogenesis**  Disease of unknown etiology in which tissues and cells undergo damage mediated by tissue-binding autoantibodies and immune complexes. Genetic, environmental, and sex hormonal factors are likely of pathogenic importance. T and B cell hyperactivity, production of autoantibodies with specificity for nuclear antigenic determinants, and abnormalities of T cell function occur.

**Clinical Manifestations**  90% of pts are women, usually of child-bearing age; more common in blacks than whites. Course of disease is often characterized by periods of exacerbation and relative quiescence. May involve virtually any organ system and have a wide range of disease severity. Common features include:

- **Constitutional**—fatigue, fever, malaise, weight loss
- **Cutaneous**—rashes (especially malar “butterfly” rash), photosensitivity, vasculitis, alopecia, oral ulcers
- **Arthritis**—inflammatory, symmetric, nonerosive
- **Hematologic**—anemia (may be hemolytic), neutropenia, thrombocytopenia, lymphadenopathy, splenomegaly, venous or arterial thrombosis
- **Cardiopulmonary**—pleuritis, pericarditis, myocarditis, endocarditis
- **Nephritis**—classification is primarily histologic (see Table 313-2, p. 2077, in HPIM-17)
- **GI**—peritonitis, vasculitis
- **Neurologic**—organic brain syndromes, seizures, psychosis, cerebritis

**Drug-Induced Lupus**  A clinical and immunologic picture similar to spontaneous SLE may be induced by drugs; in particular: procainamide, hydralazine, isoniazid, chlorpromazine, methyldopa, minocycline, anti-TNF agents. Features are predominantly constitutional, joint, and pleuropericardial; CNS and renal disease are rare. All pts have antinuclear antibodies (ANA); antihistone antibodies may be present, but antibodies to dsDNA and hypocomplementemia are uncommon. Most pts improve following withdrawal of offending drug.

**Evaluation**

- Hx and physical exam
- Presence of ANA is a cardinal feature, but a (+) ANA is not specific for SLE. Laboratory assessment should include: CBC, ESR, ANA and ANA
subtypes (antibodies to dsDNA, ssDNA, Sm, Ro, La, histone), complement levels (C3, C4, CH50), serum immunoglobulins, VDRL, PT, PTT, antinuclear antibody, lupus anticoagulant, UA.

- Appropriate radiographic studies
- ECG
- Consideration of renal biopsy if evidence of glomerulonephritis

**Diagnosis**  Made in the presence of four or more published criteria (Table 313-3, p. 2077, in HPIM-17).

### Systemic Lupus Erythematosus

Choice of therapy is based on type and severity of disease manifestations. Goals are to control acute, severe flares and to develop maintenance strategies where symptoms are suppressed to an acceptable level. Treatment choices depend on (1) whether disease is life-threatening or likely to cause organ damage; (2) whether manifestations are reversible; and (3) the best approach to prevent complications of disease and treatment (see Fig. 313-2, p. 2078, and Table 313-5, p. 2080, in HPIM-17).

#### CONSERVATIVE THERAPIES FOR NON-LIFE-THREATENING DISEASE

- **NSAIDs** (e.g., ibuprofen 400–800 mg three to four times a day). Must consider renal, GI, and cardiovascular complications.
- **Antimalarials** (hydroxychloroquine 400 mg/d)—may improve constitutional, cutaneous, articular manifestations. Ophthalmologic evaluation required before and during Rx to rule out ocular toxicity.

#### TREATMENTS FOR LIFE-THREATENING SLE

- **Systemic glucocorticoids**.
- **Cytotoxic/immunosuppressive agents**—added to glucocorticoids to treat serious SLE.
  1. Cyclophosphamide—administered as IV pulse 7–25 mg/kg every 4 weeks. Daily oral dosing 1.5–3.0 mg/kg per day can also be used but has a greater risk of urinary bladder toxicity.
  2. Mycophenolate mofetil—2–3g/d; efficacy data limited to nephritis.
  3. Azathioprine—may be effective but is slower in inducing therapeutic response.
- **Anticoagulation**—may be indicated in pts with thrombotic complications.

### Rheumatoid Arthritis (RA)

#### Definition and Pathogenesis

A chronic multisystem disease of unknown etiology characterized by persistent inflammatory synovitis, usually involving peripheral joints in a symmetric fashion. Although cartilaginous destruction, bony erosions, and joint deformity are hallmarks, the course of RA can be quite variable. An association with HLA-DR4 has been noted; both genetic and environmental factors may play a role in initiating disease. The propagation of RA is an immunologically mediated event in which joint injury occurs from synovial hyperplasia; lymphocytic infiltration of synovium; and local production of cytokines and chemokines by activated lymphocytes, macrophages, and fibroblasts.

#### Clinical Manifestations

RA occurs in ~0.8% of the population; women affected 3 times more often than men; prevalence increases with age, onset most frequent in fourth and fifth decades.
Articular manifestations—typically a symmetric polyarthritis of peripheral joints with pain, tenderness, and swelling of affected joints; morning stiffness is common; PIP and MCP joints frequently involved; joint deformities may develop after persistent inflammation.

Extraarticular manifestations:
- Cutaneous—rheumatoid nodules, vasculitis
- Pulmonary—nodules, interstitial disease, bronchiolitis obliterans—organizing pneumonia (BOOP), pleural disease, Caplan’s syndrome [sero (+) RA associated with pneumoconiosis]
- Ocular—keratoconjunctivitis sicca, episcleritis, scleritis
- Hematologic—anemia, Felty’s syndrome (splenomegaly and neutropenia)
- Cardiac—pericarditis, myocarditis
- Neurologic—myelopathies secondary to cervical spine disease, entrapment, vasculitis.

Evaluation
- Hx and physical exam with careful examination of all joints.
- Rheumatoid factor (RF) is present in >66% of pts; its presence correlates with severe disease, nodules, extraarticular features.
- Antibodies to cyclic citrullinated protein (anti-CCP) have similar sensitivity but higher specificity than RF; may be most useful in early RA; presence most common in pts with aggressive disease with a tendency for developing bone erosions.
- Other laboratory data: CBC, ESR.
- Synovial fluid analysis—useful to rule out crystalline disease, infection.
- Radiographs—juxtaarticular osteopenia, joint space narrowing, marginal erosions. Chest x-ray should be obtained.

Diagnosis Not difficult in pts with typical established disease. May be confusing early. Classification criteria were developed for investigational purposes, but may be useful (Table 314-1, p. 2089, in HPIM-17).

Differential Diagnosis Gout, SLE, psoriatic arthritis, infectious arthritis, osteoarthritis, sarcoid.

Rheumatoid Arthritis

Goals: lessen pain, reduce inflammation, improve/maintain function, prevent long-term joint damage, control of systemic involvement. Increasing trend to treat RA more aggressively earlier in disease course (Fig. 167-1).
- Pt education on disease, joint protection
- Physical and occupational therapy—strengthen periarticular muscles, consider assistive devices.
- Aspirin or NSAIDs.
- Intraarticular glucocorticoids.
- Systemic glucocorticoids.
- Disease-modifying antirheumatic drugs (DMARDs)—e.g., methotrexate; IM gold compounds; hydroxychloroquine; sulfasalazine; D-penicillamine. Each agent has individual toxicities—pt education and monitoring required. Have been used in combination but with increased toxicity.
- Biologic therapy—TNF modulatory agents (etanercept, infliximab, adalimumab) effective at controlling RA in many pts and can slow the rate of progression of radiographic joint damage and decrease disability; carries potential for serious infection and individual toxicities. IL-1 receptor an-
tagonist (anakinra) can improve the signs and symptoms of RA. Rituximab, a chimeric antibody directed to CD20 that depletes mature B cells, has been approved for RA patients who have failed anti-TNF therapy. Abatacept (CTLA4-Ig)—inhibits T cell activation, can be given with or without methotrexate, and is usually given in those who have failed or have contraindications to anti-TNF therapy.

- **Immunosuppressive therapy**—e.g., azathioprine, leflunomide, cyclosporine, and cyclophosphamide. Generally reserved for pts who have failed DMARDs and biologics.
- **Surgery**—may be considered for severe functional impairment due to deformity.

**SYSTEMIC SCLEROSIS (SCLERODERMA, SSC)**

**Definition and Pathogenesis** Systemic sclerosis (SSc) is a multisystem disorder characterized by thickening of the skin (scleroderma) and distinctive in-
volvement of multiple internal organs (chiefly GI tract, lungs, heart, and kidney). Pathogenesis unclear; involves immunologic mechanisms leading to vascular endothelial damage and activation of fibroblasts.

**Clinical Manifestations**

- **Cutaneous**—edema followed by fibrosis of the skin (chiefly extremities, face, trunk); telangiectasia; calcinosis; Raynaud’s phenomenon
- **Arthralgias and/or arthritis**
- **GI**—esophageal hypomotility; intestinal hypofunction
- **Pulmonary**—fibrosis, pulmonary hypertension, alveolitis
- **Cardiac**—pericarditis, cardiomyopathy, conduction abnormalities
- **Renal**—hypertension; renal crisis/failure

Two distinct subsets can be identified:

1. **Diffuse cutaneous SSc**—rapid development of symmetric skin thickening of proximal and distal extremity, face, and trunk. At high risk for development of visceral disease early in course.
2. **Limited cutaneous SSc**—often have long-standing Raynaud’s phenomenon before other features appear; skin involvement limited to fingers (sclerodactyly), extremity distal to elbows, and face; associated with better prognosis; a subset of limited SSc has features of **CREST syndrome** (calcinosis, Raynaud’s, esophageal dysmotility, sclerodactyly, telangiectasias).

**Evaluation**

- Hx and physical exam with particular attention to blood pressure (heralding feature of renal disease).
- Laboratories: ESR, ANA (anticentromere pattern associated with limited SSc), specific antibodies may include antitopoisomerase I (Scl-70), UA
- Radiographs: CXR, barium swallow if indicated, hand x-rays may show distal tuft resorption and calcinosis.
- Additional studies: ECG, echo, PFT, consider skin biopsy.

**Systemic Sclerosis**

- Education regarding warm clothing, smoking cessation, antireflux measures
- Calcium channel blockers (e.g., nifedipine) useful for Raynaud’s phenomenon. Other agents with potential benefit include sildenafil, losartan, nitroglycerin paste, fluoxetine, bosantan, digital sympathectomy.
- ACE inhibitors—particularly important for controlling hypertension and limiting progression of renal disease.
- Antacids, H2 antagonists, omeprazole, and metoclopramide may be useful for esophageal reflux.
- D-Penicillamine—controversial benefit to reduce skin thickening and prevent organ involvement; no advantages to using doses >125 mg every other day.
- Glucocorticoids—no efficacy in slowing progression of SSc; indicated for inflammatory myositis or pericarditis; high doses early in disease may be associated with development of renal crisis.
- Cyclophosphamide—improves lung function and survival in pts with alveolitis.
- Epoprostenol (prostacyclin) and bosentan (endothelin-1 receptor antagonist)—may improve cardiopulmonary hemodynamics in pts with pulmonary hypertension.
MIXED CONNECTIVE TISSUE DISEASE (MCTD)

**Definition**  Syndrome characterized by a combination of clinical features similar to those of SLE, SSc, polymyositis, and RA; unusually high titers of circulating antibodies to a nuclear ribonucleoprotein (RNP) are found. It is controversial whether MCTD is a truly distinct entity or a subset of SLE or SSc.

**Clinical Manifestations**  Raynaud’s phenomenon, polyarthritis, swollen hands or sclerodactyly, esophageal dysfunction, pulmonary fibrosis, inflammatory myopathy. Renal involvement occurs in about 25%. Laboratory abnormalities include high-titer ANAs, very high titers of antibody to RNP, positive rheumatoid factor in 50% of pts.

**Evaluation**  Similar to that for SLE and SSc.

Mixed Connective Tissue Disease

Few published data. Treat based upon manifestations with similar approach to that used if feature occurred in SLE/SSc/polymyositis/RA.

SJÖGREN’S SYNDROME

**Definition**  An immunologic disorder characterized by progressive lymphocytic destruction of exocrine glands most frequently resulting in symptomatic eye and mouth dryness; can be associated with extraglandular manifestations; predominantly affects middle-age females; may be primary or secondary when it occurs in association with other autoimmune diseases.

**Clinical Manifestations**

- **Constitutional**—fatigue
- **Sicca symptoms**—keratoconjunctivitis sicca (KCS) and xerostomia
- **Dryness of other surfaces**—nose, vagina, trachea, skin
- **Extraglandular features**—arthralgia/arthritis, Raynaud’s, lymphadenopathy, interstitial pneumonitis, vasculitis (usually cutaneous), nephritis, lymphoma.

**Evaluation**

- Hx and physical exam—with special attention to oral, ocular, lymphatic exam and presence of other autoimmune disorders.
- Presence of autoantibodies is a hallmark of disease (ANA, RF, anti-Ro, anti-La)
- Other laboratories—ESR; CBC; renal, liver, and thyroid function tests; serum protein electrophoresis (SPEP) (hypergammaglobulinemia or monoclonal gammopathy common); UA.
- Ocular studies—to diagnose and quantitate KCS; Schirmer’s test, Rose Bengal staining.
- Oral exam—unstimulated salivary flow, dental exam.
- Labial salivary gland biopsy—demonstrates lymphocytic infiltration and destruction of glandular tissue.

**Diagnosis**  Criteria often include: KCS, xerostomia, (+) serologic features of autoimmunity. Positive lip biopsy considered necessary in some series—should be performed in setting of objective KCS/xerostomia with negative serologies.
Sjögren’s Syndrome

- Regular follow-up with dentist and ophthalmologist.
- Dry eyes—artificial tears, ophthalmic lubricating ointments, local stimulation with cyclic adenosine monophosphate or cyclosporine drops.
- Xerostomia—frequent sips of water, sugarless candy.
- Pilocarpine or cevimeline—may help sicca manifestations.
- Hydroxychloroquine—may help arthralgias.
- Glucocorticoids—not effective for sicca Sx but may have role in treatment of extraglandular manifestations.

For a more detailed discussion, see Hahn BH: Systemic Lupus Erythematosus, Chap. 313, p. 2075; Lipsky PE: Rheumatoid Arthritis, Chap. 314, p. 2083; Varga J: Systemic Sclerosis (Scleroderma) and Related Disorders, Chap. 316, p. 2096; Moutsopoulos HM: Sjögren’s Syndrome, Chap. 317, p. 2107, in HPIM-17.

168 Vasculitis

DEFINITION AND PATHOGENESIS

A clinicopathologic process characterized by inflammation of and damage to blood vessels, compromise of vessel lumen, and resulting ischemia. Clinical manifestations depend on size and location of affected vessel. Most vasculitic syndromes appear to be mediated by immune mechanisms. May be primary or sole manifestation of a disease or secondary to another disease process. Unique vasculitic syndromes can differ greatly with regards to clinical features, disease severity, histology, and treatment.

PRIMARY VASCULITIS SYNDROMES

Wegener’s Granulomatosis  Granulomatous vasculitis of upper and lower respiratory tracts together with glomerulonephritis; upper airway lesions affecting the nose and sinuses can cause purulent or bloody nasal discharge, mucosal ulceration, septal perforation, and cartilaginous destruction (saddlenose deformity). Lung involvement may be asymptomatic or cause cough, hemoptysis, dyspnea; eye involvement may occur; glomerulonephritis can be rapidly progressive, asymptomatic, and lead to renal failure.

Churg-Strauss Syndrome (Allergic Angiitis and Granulomatosis)  Granulomatous vasculitis of multiple organ systems, particularly the lung; characterized by asthma, peripheral eosinophilia, eosinophilic tissue infiltration; glomerulonephritis can occur.

Polyarteritis Nodosa (PAN)  Medium-sized muscular arteries involved; frequently associated with arteriographic aneurysms; commonly affects renal arteries, liver, GI tract, peripheral nerves, skin, heart; can be associated with hepatitis B.
Microscopic Polyangiitis  Small-vessel vasculitis that can affect the glomerulus and lungs; medium-sized vessels may also be affected.

Giant Cell Arteritis (Temporal Arteritis)  Inflammation of medium- and large-sized arteries; primarily involves temporal artery but systemic and large vessel involvement may occur; symptoms include headache, jaw/tongue claudication, scalp tenderness, fever, musculoskeletal symptoms (polymyalgia rheumatica); sudden blindness from involvement of optic vessels is a dreaded complication.

Takayasu’s Arteritis  Vasculitis of the large arteries with strong predilection for aortic arch and its branches; most common in young women; presents with inflammatory or ischemic symptoms in arms and neck, systemic inflammatory symptoms, aortic regurgitation.

Henoch-Schönlein Purpura  Characterized by involvement of skin, GI tract, kidneys; more common in children; may recur after initial remission.

Essential Mixed Cryoglobulinemia  Majority of cases are associated with hepatitis C where an aberrant immune response leads to formation of cryoglobulin; characterized by cutaneous vasculitis, arthritis, peripheral neuropathy, and glomerulonephritis.

Idiopathic Cutaneous Vasculitis  Cutaneous vasculitis is defined broadly as inflammation of the blood vessels of the dermis; due to underlying disease in >70% of cases (see “Secondary Vasculitis Syndromes,” below) with 30% occurring idiopathically.

Miscellaneous Vasculitic Syndromes
• Kawasaki disease (mucocutaneous lymph node syndrome)
• Isolated vasculitis of the central nervous system
• Behçet’s syndrome
• Cogan’s syndrome
• Polyangiitis overlap syndrome

SECONDARY VASCULITIS SYNDROMES
• Drug-induced vasculitis
• Serum sickness
• Vasculitis associated with infection, malignancy, rheumatic disease

EVALUATION  (See Fig. 168-1)
• Thorough Hx and physical exam—special reference to ischemic manifestations and systemic inflammatory signs/symptoms.
• Laboratories—important in assessing organ involvement: CBC with differential, ESR, renal function tests, UA. Should also be obtained to rule out other diseases: ANA, rheumatoid factor, anti-GBM, hepatitis B/C serologies, HIV.
• Antineutrophil cytoplasmic autoantibodies (ANCA)—associated with Wegener’s granulomatosis, microscopic polyangiitis, and some patients with Churg-Strauss syndrome; presence of ANCA is adjunctive and should not be used in place of biopsy as a means of diagnosis or to guide treatment decisions.
• Radiographs—CXR should be performed even in the absence of symptoms.
• Diagnosis—can usually be made only by arteriogram or biopsy of affected organ(s).
DIFFERENTIAL DIAGNOSIS

Guided by organ manifestations. In many instances includes infections and neoplasms, which must be ruled out prior to beginning immunosuppressive therapy. Consideration must also be given for diseases that can mimic vasculitis (Table 168-1).

**Vasculitis**

Therapy is based on the specific vasculitic syndrome and the severity of its manifestations. Immunosuppressive therapy should be avoided in disease that rarely results in irreversible organ system dysfunction or that usually does not respond to such agents (e.g., isolated cutaneous vasculitis). Antiviral agents play an important role in treating vasculitis occurring with hepatitis B or C. Glucocorticoids alone may control giant cell arteritis and Takayasu’s arteritis. Cytotoxic agents are particularly important in syndromes with life-threatening organ system involvement, especially active glomerulonephritis. Frequently used agents:
• Prednisone 1 (mg/kg)/d initially, then tapered; convert to alternate-day regimen and discontinue.
• Cyclophosphamide 2 (mg/kg)/d, adjusted to avoid severe leukopenia. Morning administration with a large amount of fluid is important in minimizing bladder toxicity. Treatment should be limited to 3–6 months followed by transition to maintenance therapy with methotrexate or azathioprine. Pulsed intravenous cyclophosphamide (1 g/m² per month) is less effective but may be considered in selected pts who cannot tolerate daily dosing.
• Methotrexate in weekly doses up to 25 mg/week may be used to induce remission in Wegener’s granulomatosis pts who do not have immediately life-threatening disease or cannot tolerate cyclophosphamide. It may also be used for maintaining remission after induction with cyclophosphamide. Cannot be used in renal insufficiency or chronic liver disease.
• Azathioprine 2 (mg/kg)/d. Less effective in treating active disease but useful in maintaining remission after induction with cyclophosphamide.
• Plasmapheresis may have an adjunctive role in rapidly progressive glomerulonephritis.

For a more detailed discussion, see Langford CA, Fauci AS: The Vasculitis Syndromes, Chap. 319, p. 2119; in HPIM-17.

### TABLE 168-1 CONDITIONS THAT CAN MIMIC VASCULITIS

<table>
<thead>
<tr>
<th>Infectious diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial endocarditis</td>
</tr>
<tr>
<td>Disseminated gonococcal infection</td>
</tr>
<tr>
<td>Pulmonary histoplasmosis</td>
</tr>
<tr>
<td>Coccidioidomycosis</td>
</tr>
<tr>
<td>Syphilis</td>
</tr>
<tr>
<td>Lyme disease</td>
</tr>
<tr>
<td>Rocky Mountain spotted fever</td>
</tr>
<tr>
<td>Whipple’s disease</td>
</tr>
<tr>
<td>Coagulopathies/thrombotic microangiopathies</td>
</tr>
<tr>
<td>Antiphospholipid antibody syndrome</td>
</tr>
<tr>
<td>Thrombotic thrombocytopenic purpura</td>
</tr>
<tr>
<td>Neoplasms</td>
</tr>
<tr>
<td>Atrial myxoma</td>
</tr>
<tr>
<td>Lymphoma</td>
</tr>
<tr>
<td>Carcinomatosis</td>
</tr>
<tr>
<td>Drug toxicity</td>
</tr>
<tr>
<td>Cocaine</td>
</tr>
<tr>
<td>Amphetamines</td>
</tr>
<tr>
<td>Ergot alkaloids</td>
</tr>
<tr>
<td>Methysergide</td>
</tr>
<tr>
<td>Arsenic</td>
</tr>
<tr>
<td>Sarcoidosis</td>
</tr>
<tr>
<td>Atheroembolic disease</td>
</tr>
<tr>
<td>Goodpasture’s syndrome</td>
</tr>
<tr>
<td>Amyloidosis</td>
</tr>
<tr>
<td>Migraine</td>
</tr>
<tr>
<td>Cryofibrinogenemia</td>
</tr>
</tbody>
</table>

For a more detailed discussion, see Langford CA, Fauci AS: The Vasculitis Syndromes, Chap. 319, p. 2119; in HPIM-17.
Ankylosing Spondylitis

DEFINITION
Chronic and progressive inflammatory disease of the axial skeleton with sacroiliitis (usually bilateral) as its hallmark. Peripheral joints and extraarticular structures may also be affected. Most frequently presents in young men in second or third decade; strong association with histocompatibility antigen HLA-B27. In Europe, also known as Marie-Strumpell or Bechterew’s disease.

CLINICAL MANIFESTATIONS
- **Back pain and stiffness**—not relieved by lying down, often present at night forcing pt to leave bed, worse in the morning, improves with activity, insidious onset, duration >3 months (often called symptoms of “inflammatory” back pain).
- **Extraaxial arthritis**—hip and shoulders 25–35%, other peripheral joint involvement up to 30%, usually asymmetric.
- **Chest pain**—from involvement of thoracic skeleton and muscular insertions.
- **Extra/juxtaarticular pain**—due to “enthesitis”: inflammation at insertion of tendons and ligaments into bone; frequently affects greater trochanter, iliac crests, ischial tuberosities, tibial tubercles, heels.
- **Extraarticular findings**—include acute anterior uveitis in about 20% of pts, aortitis, aortic insufficiency, GI inflammation, cardiac conduction defects, amyloidosis, bilateral upper lobe pulmonary fibrosis.
- **Constitutional symptoms**—fever, fatigue, weight loss may occur.
- **Neurologic complications**—related to spinal fracture/dislocation (can occur with even minor trauma), atlantoaxial subluxation, cauda equina syndrome.

PHYSICAL EXAMINATION
- Tenderness over involved joints
- Diminished chest expansion
- Diminished anterior flexion of lumbar spine (Schober test)

EVALUATION
- Erythrocyte sedimentation rate (ESR) and C-reactive protein elevated in majority.
- Mild anemia.
- Rheumatoid factor and ANA negative.
- HLA-B27 may be helpful in pts with inflammatory back Sx but negative x-rays.
- Radiographs: early may be normal. Sacroiliac joints: usually symmetric; bony erosions with “pseudowidening” followed by fibrosis and ankylosis. Spine: squaring of vertebrae; syndesmophytes; ossification of annulus fibrosis and anterior longitudinal ligament causing “bamboo spine.” Sites of enthesitis may ossify and be visible on x-ray. MRI is procedure of choice when plain radiographs do not reveal sacroiliac abnormalities and can show early intraarticular inflammation, cartilage changes, and bone marrow edema.
**FIGURE 169-1** Algorithm for diagnosis of the spondyloarthritides.

**DIAGNOSIS OF SPONDYLOARTHRITIDES**

Is there **inflammatory back pain**? ≥ 2 of 4 of the following:
- Causes awakening during second half of the night only
- Morning stiffness ≥ 30 min
- Improves with exercise but not rest
- Alternating buttock pain

Are there criteria for ankylosing spondylitis?
- Sacroiliitis on plain film or MRI plus one or more of
  - Inflammatory back pain
  - Limitation of spinal motion in sagittal and frontal planes
  - Limited chest expansion

Is there evidence of **psoriasis or inflammatory bowel disease**?

Is there evidence of an antecedent infection with an agent likely to trigger ReA?
- One or more of the following:
  - Nongonococcal urethritis or cervicitis
  - Acute diarrhea within 1 month before onset of arthritis
  - Positive stool or genital analysis or serology for *Shigella*, *Salmonella*, *Yersinia*, *Chlamydia*, or *Campylobacter* spp. or *C. difficile*

Is there evidence of **psoriatic spondyloarthritis**?

Is there evidence of **enteropathic spondyloarthritis**?

Is there at least one or more of the following? Specificity increases with increasing number:
- Sacroiliitis by imaging
- Enthesopathy (axial or peripheral)
- Dactylitis
- Buttock pain (unilateral or alternating)
- Iritis
- Family history of IBD, psoriasis, iritis, or any spondyloarthritis
- HLA-B27

Consider other diagnoses
- Observe for evolving symptoms

Unlikely to be spondyloarthritis

Enteropathic or psoriatic spondyloarthritis

Ankylosing spondylitis

Reactive arthritis

Undifferentiated spondyloarthritis

Enteropathic or psoriatic spondyloarthritis
Psoriatic Arthritis

CHAPTER 170

DIAGNOSIS

Modified New York criteria widely used: radiographic evidence of sacroiliitis plus one of: (1) Hx of inflammatory back pain symptoms, (2) lumbar motion limitation, (3) limited chest expansion.

Differential Diagnosis  Spondyloarthropathy associated with reactive arthritis, psoriatic arthritis, enteropathic arthritis (Fig. 169-1). Diffuse idiopathic skeletal hyperostosis.

Ankylosing Spondylitis

- Exercise program to maintain posture and mobility is important.
- TNF modulatory agents (etanercept, infliximab, adalimumab) have been found to suppress disease activity and improve function.
- NSAIDs (e.g., indomethacin 75 mg slow-release daily or bid) useful in most pts.
- Sulfasalazine 2–3 g/d is of modest benefit, primarily for peripheral arthritis.
- Methotrexate, widely used but has not been of proven benefit.
- No documented therapeutic role for systemic glucocorticoids.
- Intraarticular glucocorticoids for persistent enthesitis or peripheral synovitis; ocular glucocorticoids for uveitis with systemic immunosuppression required in some cases; surgery for severely affected or deformed joints.

For a more detailed discussion, see Taurog JD: The Spondyloarthritides, Chap. 318, p. 2109, in HPIM-17.

Psoriatic Arthritis

DEFINITION

Psoriatic arthritis is a chronic inflammatory arthritis that affects 5–30% of persons with psoriasis. Some pts, especially those with spondylitis, will carry the HLA-B27 histocompatibility antigen. Onset of psoriasis usually precedes development of joint disease; approximately 15–20% of pts develop arthritis prior to onset of skin disease. Nail changes are seen in 90% of patients with psoriatic arthritis.

 PATTERNS OF JOINT INVOLVEMENT

There are 5 patterns of joint involvement in psoriatic arthritis (Table 170-1).

EVALUATION

- Negative tests for rheumatoid factor.
- Hypoproliferative anemia, elevated erythrocyte sedimentation rate (ESR).
- Hyperuricemia may be present.
- HIV should be suspected in fulminant disease.
Inflammatory synovial fluid and biopsy without specific findings.

Radiographic features include erosion at joint margin, bony ankylosis, tuft resorption of terminal phalanges, “pencil-in-cup” deformity (bone proliferation at base of distal phalanx with tapering of proximal phalanx), axial skeleton with asymmetric sacroiliitis, asymmetric nonmarginal syndesmophytes.

**DIAGNOSIS**

Suggested by: pattern of arthritis and inflammatory nature, absence of rheumatoid factor, radiographic characteristics, presence of skin and nail changes of psoriasis (see Fig. 169-1).

**Psoriatic Arthritis**

- Coordinated therapy is directed at the skin and joints.
- Pt education, physical and occupational therapy.
- TNF modulatory agents (etanercept, infliximab, adalimumab) can improve skin and joint disease and delay radiographic progression.
- Alefacept in combination with methotrexate can benefit skin and joint disease.
- NSAIDs.
- Intraarticular steroid injections—useful in some settings. Systemic glucocorticoids should rarely be used as may induce rebound flare of skin disease upon tapering.
- Efficacy of gold salts and antimalarials controversial.
- Methotrexate 15–25 mg/week and sulfasalazine 2–3 g/d have clinical efficacy but do not halt joint erosion.
- Leflunomide may be of benefit for skin and joint disease.

For a more detailed discussion, see Taurog JD: The Spondyloarthritides, Chap. 318, p. 2109, in HPIM-17.


**DEFINITION**

*Reactive arthritis* refers to acute nonpurulent arthritis complicating an infection elsewhere in the body. The term has been used primarily to refer to spondyloarthritides following enteric or urogenital infections occurring predominantly in HLA-B27-positive individuals. The triad of arthritis, conjunctivitis, and nongonococcal urethritis was once known by the eponym of *Fiessenger-Leroy-Reiter syndrome*, which is now of historic interest only.

**PATHOGENESIS**

Up to 85% of pts possess the HLA-B27 alloantigen. It is thought that in individuals with appropriate genetic background, reactive arthritis may be triggered by an enteric infection with any of several *Shigella*, *Salmonella*, *Yersinia*, and *Campylobacter* species; by genitourinary infection with *Chlamydia trachomatis*; and possibly by other agents.

**CLINICAL MANIFESTATIONS**

The sex ratio following enteric infection is 1:1; however, genitourinary-acquired reactive arthritis is predominantly seen in young males. In a majority of cases Hx will elicit Sx of genitourinary or enteric infection 1–4 weeks prior to onset of other features.

- **Constitutional**—fatigue, malaise, fever, weight loss.
- **Arthritis**—usually acute, asymmetric, oligoarticular, involving predominantly lower extremities; sacroiliitis may occur.
- **Enthesitis**—inflammation at insertion of tendons and ligaments into bone; dactylitis or “sausage digit,” plantar fasciitis, and Achilles tendinitis common.
- **Ocular features**—conjunctivitis, usually minimal; uveitis, keratitis, and optic neuritis rarely present.
- **Urethritis**—discharge intermittent and may be asymptomatic.
- **Other urogenital manifestations**—prostatitis, cervicitis, salpingitis.
- **Mucocutaneous lesions**—painless lesions on glans penis (*circinate balanitis*) and oral mucosa in approximately a third of pts; *keratoderma blenorrhagica*: cutaneous vesicles that become hyperkerotic, most common on soles and palms.
- **Uncommon manifestations**—pleuropericarditis, aortic regurgitation, neurological manifestations, secondary amyloidosis.

Reactive arthritis is associated with and may be the presenting sign and Sx of HIV.

**EVALUATION**

- Pursuit of triggering infection by culture, serology, or molecular methods as clinically suggested.
- Rheumatoid factor and ANA negative.
- Mild anemia, leukocytosis, elevated ESR may be seen.
- HLA-B27 may be helpful in atypical cases.
- HIV screening should be performed in all pts.
• Synovial fluid analysis—often very inflammatory; negative for crystals or infection.
• Radiographs—erosions may be seen with new periosteal bone formation, ossification of entheses, sacroiliitis (often unilateral).

DIFFERENTIAL DIAGNOSIS
Includes septic arthritis (gram +/–), gonococcal arthritis, crystalline arthritis, psoriatic arthritis (see Fig. 169-1).

RX Reactive Arthritis
• Controlled trials have failed to demonstrate any benefit of antibiotics in reactive arthritis. Prompt antibiotic treatment of acute chlamydial urethritis may prevent subsequent reactive arthritis.
• NSAIDs (e.g., indomethacin 25–50 mg PO tid) benefit most pts.
• Intraarticular glucocorticoids.
• Sulfasalazine up to 3 g/d in divided doses may help some pts with persistent arthritis.
• Cytotoxic therapy, such as azathioprine [1–2 (mg/kg)/d] or methotrexate (7.5–15 mg/week) may be considered for debilitating disease refractory to other modalities; contraindicated in HIV disease.
• Uveitis may require therapy with ocular or systemic glucocorticoids

OUTCOME
Prognosis is variable; 30–60% will have recurrent or sustained disease, with 15–25% developing permanent disability.

For a more detailed discussion, see Taurog JD: The Spondyloarthritides, Chap. 318, p. 2109, in HPIM-17.

Osteoarthritis

DEFINITION
Osteoarthritis (OA) is a disorder characterized by progressive joint failure in which all structures of the joint have undergone pathologic change. The pathologic sine qua non of OA is hyaline articular cartilage loss accompanied by increasing thickness and sclerosis of the subchondral bone plate, outgrowth of osteophytes at the joint margin, stretching of the articular capsule, and weakness of the muscles bridging the joint. There are numerous pathways that lead to OA, but the initial step is often joint injury in the setting of a failure of protective mechanisms.
**EPIDEMIOLOGY**

OA is the most common type of arthritis. The prevalence of OA correlates strikingly with age and it is much more common in women than in men. Joint vulnerability and joint loading are the two major risk factors contributing to OA. These are influenced by factors that include age, female sex, race, genetic factors, nutritional factors, joint trauma, previous damage, malalignment, proprioceptive deficiencies, and obesity.

**PATHOGENESIS**

The earliest changes of OA may begin in cartilage. The 2 major components of cartilage are type 2 collagen, which provides tensile strength, and aggrecan, a proteoglycan. OA cartilage is characterized by gradual depletion of aggrecan, unfurling of the collagen matrix, and loss of type 2 collagen, which leads to increased vulnerability.

**CLINICAL MANIFESTATIONS**

OA can affect almost any joint, but usually occurs in weight-bearing and frequently used joints such as the knee, hip, spine, and hands. The hand joints that are typically affected are the DIP, PIP, or first carpometacarpal (thumb base); metacarpophalangeal joint involvement is rare.

**Symptoms**

- Use-related pain affecting one or a few joints (rest and nocturnal pain less common)
- Stiffness after rest or in morning may occur but is usually brief (<30 min)
- Loss of joint movement or functional limitation
- Joint instability
- Joint deformity
- Joint crepitation (“crackling”)

**Physical Examination**

- Chronic monarthritus or asymmetric oligo/polyarthritus
- Firm or “bony” swellings of the joint margins, e.g., Heberden’s nodes (hand DIP) or Bouchard’s nodes (hand PIP)
- Mild synovitis with a cool effusion can occur but is uncommon
- Crepitance—audible creaking or crackling of joint on passive or active movement
- Deformity, e.g., OA of knee may involve medial, lateral, or patellofemoral compartments resulting in varus or valgus deformities
- Restriction of movement, e.g., limitation of internal rotation of hip
- Objective neurologic abnormalities may be seen with spine involvement (may affect intervertebral disks, apophyseal joints, and paraspinal ligaments)

**EVALUATION**

- Routine lab work usually normal.
- ESR usually normal but may be elevated in patients who have synovitis.
- Rheumatoid factor, ANA studies negative.
- Joint fluid is straw-colored with good viscosity; fluid WBCs < 1000/μL; of value in ruling out crystal-induced arthritis, inflammatory arthritis, or infection.
- Radiographs may be normal at first but as disease progresses may show joint space narrowing, subchondral bone sclerosis, subchondral cysts, and osteophytes. Erosions are distinct from those of rheumatoid and psoriatic
arthritis as they occur subchondrally along the central portion of the joint surface.

**DIAGNOSIS**

Usually established on basis of pattern of joint involvement. Radiographic features, normal laboratory tests, and synovial fluid findings can be helpful if signs suggest an inflammatory arthritis.

**Differential Diagnosis** Osteonecrosis, Charcot joint, rheumatoid arthritis, psoriatic arthritis, crystal-induced arthritides.

### Osteoarthritis

- Treatment goal—alleviate pain and minimize loss of physical function.
- Nonpharmacotherapy strategies aimed at altering loading across the painful joint—includes patient education, weight reduction, appropriate use of cane and other supports, isometric exercises to strengthen muscles around affected joints, bracing/orthotics to correct malalignment.
- Topical capsaicin cream may help relieve hand or knee pain.
- Acetaminophen, salicylates, NSAIDs, COX-2 inhibitors—must weigh individual risks and benefits.
- Tramadol—may be considered in patients whose symptoms are inadequately controlled with NSAIDs; as it is a synthetic opioid agonist, habituation is a potential concern.
- Intraarticular glucocorticoids—may provide symptomatic relief but typically short-lived.
- Intraarticular hyaluronin—can be given for symptomatic knee and hip OA but it is controversial whether they have efficacy beyond placebo.
- Glucosamine and chondroitin—although widely sold, is not FDA approved for use in OA. Proof of efficacy has not been established.
- Systemic glucocorticoids have no place in the treatment of OA.
- Arthroscopic debridement and lavage—can be helpful in the subgroup of patients with knee OA in whom disruption of the meniscus causes mechanical symptoms such as locking or buckling. In patients who do not have mechanical symptoms, this modality appears to be of no greater benefit than placebo.
- Joint replacement surgery may be considered in patients with advanced OA who have intractable pain and loss of function in whom aggressive medical management has failed.

For a more detailed discussion, see Felson DT: Osteoarthritis, Chap. 326, p. 2158, in HPIM-17.
DEFINITION

Gout is a metabolic disease most often affecting middle-aged to elderly men and postmenopausal women. Hyperuricemia is the biologic hallmark of gout. When present, plasma and extracellular fluids become supersaturated with uric acid, which, under the right conditions, may crystallize and result in a spectrum of clinical manifestations that may occur singly or in combination.

PATHOGENESIS

Uric acid is the end product of purine nucleotide degradation; its production is closely linked to pathways of purine metabolism, with the intracellular concentration of 5-phosphoribosyl-1-pyrophosphate (PRPP) being the major determinant of the rate of uric acid biosynthesis. Uric acid is excreted primarily by the kidney through mechanisms of glomerular filtration, tubular secretion, and reabsorption. Hyperuricemia may thus arise in a wide range of settings that cause overproduction or reduced excretion of uric acid or a combination of the two (see Table 353-2, p. 2445; HPIM-17).

Acute Gouty Arthritis

Monosodium urate (MSU) crystals present in the joint are phagocytosed by leukocytes; release of inflammatory mediators and lysosomal enzymes leads to recruitment of additional phagocytes into the joint and to synovial inflammation.

CLINICAL MANIFESTATIONS

Acute arthritis—most frequent early clinical manifestation of gout. Usually initially affects one joint, but may be polyarticular in later episodes. The first metatarsophalangeal joint (podagra) is often involved. Acute gout frequently begins at night with dramatic pain, swelling, warmth, and tenderness. Attack will generally subside spontaneously after 3–10 days. Although some patients may have a single attack, most patients have recurrent episodes with intervals of varying length with no symptoms between attacks. Acute gout may be precipitated by: dietary excess, trauma, surgery, excessive ethanol ingestion, hypouricemic therapy, and serious medical illnesses such as myocardial infarction and stroke.

Chronic arthritis—a proportion of gout patients may have a chronic nonsymmetric synovitis; may rarely be the only manifestation. Can also present with periarticular tophi (aggregates of MSU crystals surrounded by a giant cell inflammatory reaction). Occurs in the setting of long-standing gout.

Extraarticular tophi—often occur in olecranon bursa, helix and anthelix of ears, ulnar surface of forearm, Achilles tendon.

Tenosynovitis

Urate nephropathy—deposition of MSU crystals in interstitium and pyramids. Can cause chronic renal insufficiency.
Acute uric acid nephropathy—reversible cause of acute renal failure due to precipitation of urate in the tubules; patients receiving cytotoxic treatment for neoplastic disease are at risk.

Uric acid nephrolithiasis—responsible for 10% of renal stones in the United States.

**DIAGNOSIS**

- Synovial fluid analysis—should be performed to confirm gout even when clinical appearance is strongly suggestive; joint aspiration and demonstration of both intracellular and extracellular needle-shaped negatively birefringent MSU crystals by polarizing microscopy. Gram stain and culture should be performed on all fluid to rule out infection. MSU crystals can also be demonstrated in chronically involved joints or tophaceous deposits.
- Serum uric acid—normal levels do not rule out gout.
- Urine uric acid—excretion of >800 mg/d on regular diet in the absence of drugs suggests overproduction.
- Screening for risk factors or sequelae—urinalysis; serum creatinine, liver function tests, glucose and lipids; complete blood counts.
- If overproduction is suspected, measurement of erythrocyte hypoxanthine guanine phosphoribosyl transferase (HGPRT) and PRPP levels may be indicated.
- Joint x-rays—may demonstrate cystic changes, erosions with sclerotic margins in advanced chronic arthritis.
- If renal stones suggested, abdominal flat plate (stones often radiolucent), possibly IVP.
- Chemical analysis of renal stones.

**Differential Diagnosis**  Septic arthritis, reactive arthritis, calcium pyrophosphate deposition disease (CPPD), rheumatoid arthritis.

---

**Gout**

**Asymptomatic Hyperuricemia**

As only ~5% of hyperuricemic pts develop gout, treatment of asymptomatic hyperuricemia is not indicated. Exceptions are patients about to receive cytotoxic therapy for neoplasms.

**Acute Gouty Arthritis**

Treatment is given for symptomatic relief only since attacks are self-limited and will resolve spontaneously. Toxicity of therapy must be considered in each pt.

- Analgesia
- NSAIDs—Rx of choice when not contraindicated.
- Colchicine—generally only effective within first 24 h of attack; overdose has potentially life-threatening side effects; use is contraindicated in pts with renal insufficiency, cytopenias, LFTs > 2 × normal, sepsis. PO—0.6 mg qh until patient improves, has GI side effects, or maximal dose of 4 mg is reached. IV administration—dangerous and best avoided; if used, give no more than 2 mg over 24 h and no further drug for 7 days following; IV must never be given in a patient who has received PO colchicine.
- Intraarticular glucocorticoids—septic arthritis must be ruled out prior to injection.
- Systemic glucocorticoids—brief taper may be considered in patients with a polyarticular gouty attack for whom other modalities are contraindicated and where articular or systemic infection has been ruled out.
**Uric Acid-Lowering Agents**

Indications for initiating uric acid–lowering therapy include recurrent frequent acute gouty arthritis, polyarticular gouty arthritis, tophaceous gout, renal stones, prophylaxis during cytotoxic therapy. Should not start during an acute attack. Initiation can precipitate an acute flare; consider concomitant PO colchicine 0.6 mg qd until uric acid < 5.0 mg/dL, then discontinue.

1. **Allopurinol**: Decreases uric acid synthesis by inhibiting xanthine oxidase. Must be dose-reduced in renal insufficiency. Has significant side effects and drug interactions.

2. **Uricosuric drugs** (probenecid, sulfinpyrazone): Increases uric acid excretion by inhibiting its tubular reabsorption; ineffective in renal insufficiency; should not be used in these settings: age > 60, renal stones, tophi, increased urinary uric acid excretion, cytotoxic therapy prophylaxis.

---

**CPPD DEPOSITION DISEASE (PSEUDOGOUT)**

**DEFINITION AND PATHOGENESIS**

CPPD disease is characterized by acute and chronic inflammatory joint disease, usually affecting older individuals. The knee and other large joints most commonly affected. Calcium deposits in articular cartilage (chondrocalcinosis) may be seen radiographically; these are not always associated with symptoms.

CPPD is most often idiopathic but can be associated with other conditions (Table 173-1). Crystals are thought not to form in synovial fluid but are probably shed from articular cartilage into joint space, where they are phagocyted by neutrophils and incite an inflammatory response.

**CLINICAL MANIFESTATIONS**

- **Acute CCPD arthritis** ("pseudogout")—knee is most frequently involved, but polyarticular in 2/3 of cases; involved joint is erythematos, swollen, warm, and painful. Most patients have evidence of chondrocalcinosis.

---

**TABLE 173-1 CONDITIONS ASSOCIATED WITH CALCIUM PYROPHOSPHATE DIHYDRATE DISEASE**

<table>
<thead>
<tr>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aging</td>
</tr>
<tr>
<td>Disease-associated</td>
</tr>
<tr>
<td>Primary hyperparathyroidism</td>
</tr>
<tr>
<td>Hemochromatosis</td>
</tr>
<tr>
<td>Hypophosphatasia</td>
</tr>
<tr>
<td>Hypomagnesemia</td>
</tr>
<tr>
<td>Chronic gout</td>
</tr>
<tr>
<td>Postmeniscectomy</td>
</tr>
<tr>
<td>Epiphyseal dysplasias</td>
</tr>
<tr>
<td>Hereditary: Slovakian-Hungarian, Spanish, Spanish-American (Argentinian, Colombian, and Chilean), French, Swedish, Dutch, Canadian, Mexican-American, Italian-American, German-American, Japanese, Tunisian, Jewish, English</td>
</tr>
</tbody>
</table>

---

*Mutations in the ANKH gene.
• **Chronic arthropathy**—progressive degenerative changes in multiple joints; can resemble osteoarthritis (OA). Joint distribution may suggest CPPD with common sites including knee, wrist, MCP, hips, and shoulders.

• **Symmetric proliferative synovitis**—seen in familial forms with early onset; clinically similar to RA.

• **Intervertebral disk and ligament calcification**

• **Spinal stenosis**

**DIAGNOSIS**

• Synovial fluid analysis—demonstration of calcium pyrophosphate dihydrate crystals that appear as short blunt rods, rhomboids, and cuboids with weak positive birefringence by polarizing microscopy

• Radiographs may demonstrate chondrocalcinosis and degenerative changes (joint space narrowing, subchondral sclerosis/cysts).

• Secondary causes of CPPD should be considered in patients <50 years old.

**Differential Diagnosis**  
OA, RA, gout, septic arthritis.

**Pseudogout**

- NSAIDs
- Intraarticular injection of glucocorticoids
- Colchicine is variably effective.

**CALCIUM APATITE DEPOSITION DISEASE**

Apatite is the primary mineral of normal bone and teeth. Abnormal accumulation can occur in a wide range of clinical settings (Table 173-2). Apatite is an important factor in **Milwaukee shoulder**, a destructive arthropathy of the elderly that occurs in the shoulders and knees. Apatite crystals are small; clumps may stain purplish on Wright’s stain and bright red with alizarin red S. Definitive

**TABLE 173-2  CONDITIONS ASSOCIATED WITH APATITE DEPOSITION DISEASE**

<table>
<thead>
<tr>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aging</td>
</tr>
<tr>
<td>Osteoarthritis</td>
</tr>
<tr>
<td>Hemorrhagic shoulder effusions in the elderly</td>
</tr>
<tr>
<td>Destructive arthropathy</td>
</tr>
<tr>
<td>Tendinitis, bursitis</td>
</tr>
<tr>
<td>Tumoral calcinosis (sporadic cases)</td>
</tr>
<tr>
<td>Disease-associated</td>
</tr>
<tr>
<td>Hyperparathyroidism</td>
</tr>
<tr>
<td>Milk-alkali syndrome</td>
</tr>
<tr>
<td>Renal failure/long-term dialysis</td>
</tr>
<tr>
<td>Connective tissue diseases (e.g., systemic sclerosis, idiopathic myositis, SLE)</td>
</tr>
<tr>
<td>Heterotopic calcification following neurologic catastrophes (e.g., stroke, spinal cord injury)</td>
</tr>
<tr>
<td>Heredity</td>
</tr>
<tr>
<td>Bursitis, arthritis</td>
</tr>
<tr>
<td>Tumoral calcinosis</td>
</tr>
<tr>
<td>Fibrodysplasia ossificans progressiva</td>
</tr>
</tbody>
</table>

*Note: SLE, systemic lupus erythematosus.*
identification requires electron microscopy or x-ray diffraction studies. Radiographic appearance resembles CPPD disease. Treatment: NSAIDs, repeated aspiration, and rest of affected joint.

**CALCIUM OXALATE DEPOSITION DISEASE**

CaOx crystals may be deposited in joints in primary oxalosis (rare) or secondary oxalosis (a complication of end-stage renal disease). Clinical syndrome similar to gout and CPPD disease. Treatment: marginally effective.

For a more detailed discussion, see Wortmann RL: Disorders of Purine and Pyrimidine Metabolism, Chap. 353, p. 2444; and Schumacher HR, Chen LX: Gout and Other Crystal-Associated Arthropathies, Chap. 327, p. 2165, in HPIM-17.

**ENTEROPATHIC ARTHRITIS**

Both peripheral and axial arthritis may be associated with the inflammatory bowel diseases (IBD) of ulcerative colitis or Crohn’s disease. The arthritis can occur after or before the onset of intestinal symptoms. Peripheral arthritis is episodic, asymmetric, and most frequently affects knee and ankle. Attacks usually subside within several weeks and characteristically resolve completely without residual joint damage. Enthesitis (inflammation at insertion of tendons and ligaments into bone) can occur with manifestations of “sausage digit,” Achilles tendinitis, plantar fasciitis. Axial involvement can manifest as spondylitis and/or sacroiliitis (often symmetric). Laboratory findings are nonspecific; rheumatoid factor (RF) absent; only 30–70% HLA-B27 positive; radiographs of peripheral joints usually normal; axial involvement is often indistinguishable from ankylosing spondylitis (see Fig. 169-1).

Directed at underlying IBD; NSAIDs may alleviate joint symptoms but can precipitate flares of IBD; sulfasalazine may benefit peripheral arthritis; treatment of Crohn’s disease with infliximab or adalimumab has improved arthritis.

**Whipple’s Disease** Characterized by arthritis in up to 75% of patients that usually precedes appearance of other symptoms. Usually oligo- or polyarticular, symmetric, transient but may become chronic. Joint manifestations respond to antibiotic therapy.
NEUROPATHIC JOINT DISEASE

Also known as Charcot’s joint, this is a severe destructive arthropathy that occurs in joints deprived of pain and position sense; may occur in diabetic neuropathy, tabes dorsalis, syringomyelia, amyloidosis, spinal cord or peripheral nerve injury. Distribution depends on the underlying joint disease. Joint effusions are usually noninflammatory but can be hemorrhagic. Radiographs can reveal either bone resorption or new bone formation with bone dislocation and fragmentation.

Neuropathic Joint Disease

Stabilization of joint; surgical fusion may improve function.

RELAPSING POLYCHONDRIITIS

An idiopathic disorder characterized by recurrent inflammation of cartilaginous structures. Cardinal manifestations include ear and nose involvement with floppy ear and saddlenose deformities, inflammation and collapse of tracheal and bronchial cartilaginous rings, asymmetric episodic nondeforming polyarthritis. Other features can include scleritis, conjunctivitis, iritis, keratitis, aortic regurgitation, glomerulonephritis, and other features of systemic vasculitis. Onset is frequently abrupt, with the appearance of 1–2 sites of cartilaginous inflammation. Diagnosis is made clinically and may be confirmed by biopsy of affected cartilage.

Relapsing Polychondritis

Glucocorticoids (prednisone 40–60 mg/d with subsequent taper) may suppress acute features and reduce the severity/frequency of recurrences. Cytoxic agents should be reserved for unresponsive disease or for patients who require high glucocorticoid doses. When airway obstruction is severe, tracheostomy is required.

HYPERTROPHIC OSTEOARTHROPATHY

Syndrome consisting of periosteal new bone formation, digital clubbing, and arthritis. Most commonly seen in association with lung carcinoma but also occurs with chronic lung or liver disease; congenital heart, lung, or liver disease in children; and idiopathic and familial forms. Symptoms include burning and aching pain most pronounced in distal extremities. Radiographs show periosteal thickening with new bone formation of distal ends of long bones.

Hypertrophic Osteoarthropathy

Identify and treat associated disorder; aspirin, NSAIDs, other analgesics, vagotomy, or percutaneous nerve block may help to relieve symptoms.

FIBROMYALGIA

A common disorder characterized by chronic widespread musculoskeletal pain, aching, stiffness, paresthesia, disturbed sleep, and easy fatigability along with
multiple tender points. More common in women than men. Diagnosis is made clinically; evaluation reveals soft tissue tender points but no objective joint abnormalities by exam, laboratory, or radiograph.

**Fibromyalgia**

Benzodiazepines or tricyclics for sleep disorder, local measures (heat, massage, injection of tender points), NSAIDs.

**POLYMYALGIA RHEUMATICA (PMR)**

Clinical syndrome characterized by aching and morning stiffness in the shoulder girdle, hip girdle, or neck for >1 month, elevated ESR, and rapid response to low-dose prednisone (15 mg qd). Rarely occurs before age 50; more common in women. PMR can occur in association with giant cell (temporal) arteritis, which requires treatment with higher doses of prednisone. Evaluation should include a careful history to elicit Sx suggestive of giant cell arteritis (Chap. 169); ESR; labs to rule out other processes usually include RF, ANA, CBC, CPK, serum protein electrophoresis; and renal, hepatic, and thyroid function tests.

**Osteonecrosis**

Caused by death of cellular elements of bone, believed to be due to impairment in blood supply. Frequent associations include glucocorticoid treatment, connective tissue disease, trauma, sickle cell disease, embolization, alcohol use. Commonly involved sites include femoral and humeral heads, femoral condyles, proximal tibia. Hip disease is bilateral in >50% of cases. Clinical presentation is usually the abrupt onset of articular pain. Early changes are not visible on plain radiograph and are best seen by MRI; later stages demonstrate bone collapse (“crescent sign”), flattening of articular surface with joint space loss.

**Osteonecrosis**

Limited weight-bearing of unclear benefit; NSAIDs for Sx. Surgical procedures to enhance blood flow may be considered in early-stage disease but are of controversial efficacy; joint replacement may be necessary in late-stage disease for pain unresponsive to other measures.

**PERIARTICULAR DISORDERS**

**Bursitis** Inflammation of the thin-walled bursal sac surrounding tendons and muscles over bony prominences. The subacromial and greater trochanteric bursae are most commonly involved.
**Bursitis**

Prevention of aggravating conditions, rest, NSAIDs, and local glucocorticoid injections.

**Tendinitis**

May involve virtually any tendon but frequently affects tendons of the rotator cuff around shoulder, especially the supraspinatus. Pain is dull and aching but becomes acute and sharp when tendon is squeezed below acromion.

**Calcific Tendinitis**

Results from deposition of calcium salts in tendon, usually supraspinatus. The resulting pain may be sudden and severe.

**Adhesive Capsulitis (“Frozen Shoulder”)**

Results from conditions that enforce prolonged immobility of shoulder joint. Shoulder is painful and tender to palpation, and both active and passive range of motion is restricted.

**Adhesive Capsulitis**

Spontaneous improvement may occur; NSAIDs, local injections of glucocorticoids, and physical therapy may be helpful.

---

**Sarcoidosis**

**DEFINITION**

An inflammatory multisystem disease characterized by the presence of non-caseating granulomas of unknown etiology.

**PATHOPHYSIOLOGY**

The cause of sarcoid is unknown, and current evidence suggests that the triggering of an inflammatory response by an unidentified antigen in a genetically
susceptible host is involved. The granuloma is the pathologic hallmark of sarcoidosis. The initial inflammatory response is an influx of T helper cells and an accumulation of activated monocytes. This leads to an increased release of cytokines and the formation of a granuloma. The granuloma may resolve or lead to chronic disease, including fibrosis.

**CLINICAL MANIFESTATIONS**

In 10–20% of cases, sarcoidosis may first be detected as asymptomatic hilar adenopathy. Sarcoid manifests clinically in organs where it affects function or where it is readily observed. **Löfgren’s syndrome** consists of hilar adenopathy, erythema nodosum, acute arthritis presenting in one or both ankles spreading to involve other joints, and uveitis.

Disease manifestations of sarcoid include:

- **Lung**—most commonly involved organ; 90% of patients with sarcoidosis will have abnormal CXR some time during course. Features include: hilar adenopathy, alveolitis, interstitial pneumonitis; airways may be involved and cause obstruction to airflow; pleural disease and hemoptysis are uncommon.
- **Lymph nodes**—intrathoracic nodes enlarged in 75–90% of patients. Extrathoracic lymph nodes affected in 15%.
- **Skin**—25% will have skin involvement; lesions include erythema nodosum, plaques, maculopapular eruptions, subcutaneous nodules, and *lupus pernio* (indurated blue-purple shiny lesions on face, fingers, and knees).
- **Eye**—uveitis in 30%; may progress to blindness.
- **Upper respiratory tract**—nasal mucosa involved in up to 20%, larynx 5%.
- **Bone marrow and spleen**—mild anemia and thrombocytopenia may occur.
- **Liver**—involved on biopsy in 60–90%; rarely important clinically.
- **Kidney**—parenchymal disease <5%, nephrolithiasis secondary to abnormalities of calcium metabolism.
- **Nervous system**—occurs in 5–10%; cranial/peripheral neuropathy, chronic meningitis, pituitary involvement, space-occupying lesions, seizures.
- **Heart**—disturbances of rhythm and/or contractility, pericarditis.
- **Musculoskeletal**—bone lesions involving cortical bone seen in 3–13%, consisting of cysts in areas of expanded bone or lattice-like changes; dactylitis; joint involvement occurs in 25–50% with chronic mono- or oligoarthritis of knee, ankle, proximal interphalangeal joints.
- **Constitutional symptoms**—fever, weight loss, anorexia, fatigue.
- **Other organ systems**—endocrine/reproductive, exocrine glands, GI.

**EVALUATION**

- Hx and physical exam to rule out exposures and other causes of interstitial lung disease.
- CBC, Ca^{2+}, LFTs, ACE, PPD and control skin tests.
- CXR and/or chest CT, ECG, PFTs.
- Biopsy of lung or other affected organ.
- Bronchoalveolar lavage and gallium scan of lungs may help decide when treatment is indicated and may help to follow therapy; however, these are not uniformly accepted.

**DIAGNOSIS**

Made on basis of clinical, radiographic, and histologic findings. Biopsy of lung or other affected organs is mandatory to establish diagnosis before starting ther-
apy. Transbronchial lung biopsy usually adequate to make the diagnosis. No blood findings are diagnostic. Differential diagnosis includes neoplasms, infections, HIV, other granulomatous processes.

**Sarcoidosis**

As sarcoidosis may remit spontaneously, treatment is largely based upon the level of symptoms and extent of organ involvement (Figs. 175-1 and 175-2). When systemic therapy is indicated, glucocorticoids are the mainstay of therapy. Other immunomodulatory agents have been used in refractory or severe cases or when prednisone cannot be tapered.

---

**FIGURE 175-1** The management of acute sarcoidosis is based on level of symptoms and extent of organ involvement. In patients with mild symptoms, no therapy may be needed unless specified manifestations are noted.

**FIGURE 175-2** Approach to chronic disease is based on whether glucocorticoid therapy is tolerated or not.
OUTCOME

Sarcoidosis is usually a self-limited, non-life-threatening disease. Overall, 50% of pts with sarcoid have some permanent organ dysfunction; death directly due to disease occurs in 5% of cases usually related to lung, cardiac, neurologic, or liver involvement. Respiratory tract abnormalities cause most of the morbidity and mortality related to sarcoid.

For a more detailed discussion, see Baughman RP, Lower EE: Sarcoidosis, Chap. 322, p. 2135, in HPIM-17.

Amyloidosis

DEFINITION

Amyloidosis is a term for a group of diseases that are due to the extracellular deposition of insoluble polymeric protein fibrils in organs and tissues. Clinical manifestations depend on anatomic distribution and intensity of amyloid protein deposition and range from local deposition with little significance to involvement of virtually any organ system with severe pathophysiologic consequences.

CLASSIFICATION

Amyloid diseases are defined by the biochemical nature of the protein in the fibril deposits and are classified according to whether they are systemic or localized, acquired or inherited, and by their clinical patterns. The accepted nomenclature is AX where A indicates amyloidosis and X is the protein in the fibril (see Table 324-1, p. 2145, in HPIM-17):

- AL (immunoglobulin light chains): Primary amyloidosis; most common form of systemic amyloidosis; arises from a clonal B cell disorder, usually multiple myeloma.
- AA (serum amyloid A): Secondary amyloidosis; can occur in association with almost any chronic inflammatory state [e.g., RA, SLE, familial Mediterranean fever (FMF), Crohn’s disease] or chronic infections.
- AF (familial amyloidoses): number of different types that are dominantly transmitted in association with a mutation that enhances protein misfolding and fibril formation; most commonly due to transthyretin.
- Aβ2M: composed of β2 microglobulin; occurs in end-stage renal disease of long duration.
- Localized or organ-limited amyloidoses: most common form is Aβ found in Alzheimer’s disease derived from abnormal proteolytic processing of the amyloid precursor protein.

CLINICAL MANIFESTATIONS

Clinical features are varied and depend entirely on biochemical nature of the fibril protein. Frequent sites of involvement:
• **Kidney**—seen with AA and AL; proteinuria, nephrosis, azotemia.
• **Liver**—occurs in AA, AL, and AF; hepatomegaly.
• **Skin**—characteristic of AL but can be seen in AA; raised waxy papules.
• **Heart**—common in AL and AF; CHF, cardiomegaly, arrhythmias.
• **GI**—common in all types; GI obstruction or ulceration, hemorrhage, protein loss, diarrhea, macroglossia, disordered esophageal motility.
• **Joints**—usually AL, frequently with myeloma; periarticular amyloid deposits, “shoulder pad sign”: firm amyloid deposits in soft tissue around the shoulder, symmetric arthritis of shoulders, wrists, knees, hands.
• **Nervous system**—prominent in AF; peripheral neuropathy, postural hypotension, dementia. Carpal tunnel syndrome may occur in AL and A2M.
• **Respiratory**—lower airways can be affected in AL; localized amyloid can cause obstruction along upper airways.

## DIAGNOSIS

Diagnosis relies on the identification of fibrillar deposits in tissues and typing of the amyloid (Fig. 176-1). Congo red staining of abdominal fat will demonstrate amyloid deposits in >80% of patients with systemic amyloid.
PROGNOSIS

Outcome is variable and depends on type of amyloidosis and organ involvement. Average survival of AL amyloid is ~12 months; prognosis is poor when associated with myeloma. Cardiac dysfunction associated with death in 75% of patients.

For AL most effective treatment is high-dose intravenous melphalan followed by autologous stem-cell transplantation. Only 50% are eligible for such aggressive treatment and peritransplant mortality is higher than for other hematologic diseases because of impaired organ function. In patients who are not candidates for hematopoietic cell transplant, cyclic melphalan and glucocorticoids can decrease the plasma cell burden, but produces remission in only a few percent of patients with a minimal improvement in survival (median 2 years). Treatment of AA is directed towards controlling the underlying inflammatory condition. Colchicine (1–2 mg/d) may prevent acute attacks in FMF and thus may block amyloid deposition. One study found that eprodisate slowed the decline of renal function in AA, but had no significant effect on progression to end-stage renal disease or risk of death. In certain of the forms of AF, genetic counseling is important and liver transplantation is a successful form of therapy.

For a more detailed discussion, see Seldin DC, Skinner M: Amyloidosis, Chap. 324, p. 2145, in HPIM-17.
This page intentionally left blank
The anterior pituitary is often referred to as the “master gland” because, together with the hypothalamus, it orchestrates the complex regulatory functions of multiple other glands (Fig. 177-1). The anterior pituitary produces six major hormones: (1) prolactin (PRL); (2) growth hormone (GH); (3) adrenocorticotropic hormone (ACTH); (4) luteinizing hormone (LH); (5) follicle-stimulating hormone (FSH); and (6) thyroid-stimulating hormone (TSH). Pituitary hormones are secreted in a pulsatile manner, reflecting intermittent stimulation by specific hypothalamic-releasing factors. Each of these pituitary hormones elicits specific responses in peripheral target glands. The hormonal products of these peripheral glands, in turn, exert feedback control at the level of the hypothalamus and pituitary to modulate pituitary function. Disorders of the pituitary include neoplasms that lead to mass effects and clinical syndromes due to excess or deficiency of one or more pituitary hormones.

PITUITARY TUMORS

Pituitary adenomas are benign monoclonal tumors that arise from one of the five anterior pituitary cell types and may cause clinical effects from either overproduction of a pituitary hormone or compressive effects on surrounding structures, including the hypothalamus, pituitary, or both. Tumors secreting prolactin are most common and have a greater prevalence in women than in men. GH- and ACTH-secreting tumors each account for about 10–15% of pituitary tumors. About one-third of all adenomas are clinically nonfunctioning and produce no distinct clinical hypersecretory syndrome. Adenomas are classified as microadenomas (<10 mm) or macroadenomas (≥10 mm). Other entities that can present as a sellar mass include craniopharyngiomas, Rathke’s cleft cysts, sella chordomas, meningiomas, pituitary metastases, and gliomas.

Clinical Features Symptoms from mass effects include headache; visual loss through compression of the optic chiasm superiorly (classically a bitemporal hemianopsia); and diplopia, ptosis, ophthalmoplegia, and decreased facial sensation from cranial nerve compression laterally. Pituitary stalk compression from the tumor may also result in mild hyperprolactinemia. Symptoms of hypopituitarism or hormonal excess may be present as well (see below).

Pituitary apoplexy is an endocrine emergency that typically presents with features that include severe headache, bilateral visual changes, ophthalmoplegia, and, in severe cases, cardiovascular collapse and loss of consciousness. It may result in hypotension, severe hypoglycemia, CNS hemorrhage, and death. Patients with no evident visual loss or impaired consciousness can usually be observed and managed conservatively with high-dose glucocorticoids; surgical decompression should be considered when these features are present.
Sagittal and coronal T1-weighted MRI images with specific pituitary cuts should be obtained before and after administration of gadolinium. In patients with lesions close to the optic chiasm, visual field assessment that uses perimetry techniques should be performed. Initial hormonal evaluation is listed in Table 177-1.

**FIGURE 177-1** Diagram of pituitary axes. Hypothalamic hormones regulate anterior pituitary tropic hormones that, in turn, determine target gland secretion. Peripheral hormones feed back to regulate hypothalamic and pituitary hormones. TRH, thyrotropin-releasing hormone; for other abbreviations, see text.

**Diagnosis** Sagittal and coronal T1-weighted MRI images with specific pituitary cuts should be obtained before and after administration of gadolinium. In patients with lesions close to the optic chiasm, visual field assessment that uses perimetry techniques should be performed. Initial hormonal evaluation is listed in Table 177-1.
Anterior Pituitary and Hypothalamus Disorders

CHAPTER 177

In pituitary apoplexy, CT or MRI of the pituitary may reveal signs of sellar hemorrhage, with deviation of the pituitary stalk and compression of pituitary tissue.

Pituitary Tumors

Pituitary surgery is indicated for mass lesions that impinge on surrounding structures or to correct hormonal hypersecretion (see below). Transsphenoidal surgery, rather than transfrontal resection, is the desired surgical approach for most patients. The goal is selective resection of the pituitary mass lesion without damage to the normal pituitary tissue, to decrease the likelihood of hypopituitarism. Transient or permanent diabetes insipidus, hypopituitarism, CSF rhinorrhea, visual loss, and oculomotor palsy may occur postoperatively. Tumor invasion outside of the sella is rarely amenable to surgical cure, but debulking procedures may relieve tumor mass effects and reduce hormonal hypersecretion. Radiation may be used as an adjunct to surgery, but >50% of patients develop hormonal deficiencies within 10 years, usually due to hypothalamic damage. Prolactin-, GH-, and TSH-secreting tumors may also be amenable to medical therapy.

PITUITARY HORMONE HYPERSECRETION SYNDROMES

HYPERPROLACTINEMIA

Prolactin is unique among the pituitary hormones in that the predominant central control mechanism is inhibitory, reflecting dopamine-mediated suppression of prolactin release. Prolactin acts to induce and maintain lactation and decrease reproductive function and drive [via suppression of gonadotropin-releasing hormone (GnRH), gonadotropins, and gonadal steroidogenesis].

Etiology  Physiologic elevation of prolactin occurs in pregnancy and lactation. Otherwise, prolactin-secreting pituitary adenomas (prolactinomas) are the most common cause of prolactin levels > 100 μg/L. Less pronounced hyperprolactinemia is commonly caused by medications [chlorpromazine, perphenazine, haloperidol, metoclopramide, opiates, H2 antagonists, amitriptyline, selective serotonin reuptake inhibitors (SSRIs), verapamil, estrogens], pituitary stalk damage (tumors,
lymphocytic hypophysitis, granulomas, trauma, irradiation), primary hypothyroid-
ism, or renal failure. Nipple stimulation may also cause acute prolactin increases.

**Clinical Features**  In women, amenorrhea, galactorrhea, and infertility are the hallmarks of hyperprolactinemia. In men, symptoms of hypogonadism (Chap. 183) or mass effects are the usual presenting symptoms, and galactorrhea is uncommon.

**Diagnosis**  Fasting, morning prolactin levels should be measured; when clinical suspicion is high, measurement of levels on several different occasions may be required. If hyperprolactinemia is present, non-neoplastic causes should be excluded (e.g., pregnancy test, hypothyroidism, medications).

---

**Hyperprolactinemia**

If the patient is taking a medication that is known to cause hyperprolactinemia, the drug should be withdrawn, if possible. A pituitary MRI should be performed if the underlying cause of prolactin elevation is unknown. Resection of hypothalamic or sellar mass lesions can reverse hyperprolactinemia due to stalk compression. Medical therapy with a dopamine agonist is indicated in microprolactinomas for control of symptomatic galactorrhea, restoration of gonadal function, or when fertility is desired. Alternatively, estrogen replacement may be indicated if fertility is not desired. Dopamine agonist therapy for macroprolactinomas generally results in both adenoma shrinkage and reduction of prolactin levels. Cabergoline (initial dose 0.5 mg a week, usual dose 0.5–1 mg twice a week) or bromocriptine (initial dose 0.625–1.25 mg qhs, usual dose 2.5 PO three times a day) are the two most frequently used dopamine agonists. These medications should initially be taken at bedtime with food, followed by gradual dose increases, to reduce the side effects of nausea and postural hypotension. Other side effects include constipation, nasal stuffiness, dry mouth, nightmares, insomnia, or vertigo; decreasing the dose usually alleviates these symptoms. Dopamine agonists may also precipitate or worsen underlying psychiatric conditions. Spontaneous remission of microadenomas, presumably caused by infarction, occurs in up to 30% of patients. Surgical debulking may be required for macroprolactinomas that do not respond to medical therapy.

Women with microprolactinomas who become pregnant should discontinue bromocriptine therapy, as the risk for significant tumor growth during pregnancy is low. In those with macroprolactinomas, visual field testing should be performed at each trimester. A pituitary MRI should be performed if severe headache and/or visual defects occur.

---

**ACROMEGALY**

**Etiology**  GH hypersecretion is primarily the result of pituitary adenomas; extrapituitary causes of acromegaly are rare.

**Clinical Features**  In children, GH hypersecretion prior to long bone epiphyseal closure results in gigantism. The presentation of acromegaly in adults is usually indolent. Patients may note a change in facial features, widened teeth spacing, deepening of the voice, snoring, increased shoe or glove size, ring tightening, hyperhidrosis, oily skin, arthropathy, and carpal tunnel syndrome. Frontal bossing, mandibular enlargement with prognathism, macroglossia, an enlarged thyroid, skin tags, thick heel pads, and hypertension may be present on examination. Asso-
associated conditions include cardiomyopathy, left ventricular hypertrophy, diastolic dysfunction, sleep apnea, diabetes mellitus, colon polyps, and colonic malignancy. Overall mortality is increased approximately threefold.

**Diagnosis**  Insulin-like growth factor type I (IGF-I) levels are a useful screening measure, with elevation suggesting acromegaly. Due to the pulsatility of GH, measurement of a single random GH level is not useful for screening. The diagnosis of acromegaly is confirmed by demonstrating the failure of GH suppression to <1 μg/L within 1–2 h of a 75-g oral glucose load.

**Acromegaly**

GH levels are not normalized by surgery alone in many patients with macroadenomas; somatostatin analogues provide adjunctive medical therapy that suppresses GH secretion with modest effects on tumor size. Octreotide (50 μg SC three times a day) is used for initial therapy. Once tolerance of side effects (nausea, abdominal discomfort, diarrhea, flatulence) is established, patients may be changed to long-acting depot formulations (20–30 mg IM every 2–4 weeks). The GH receptor antagonist pegvisomant can be added in patients who do not respond to somatostatin analogues. Pituitary irradiation may also be required as adjuvant therapy but has a high rate of late hypopituitarism.

**CUSHING’S DISEASE**  See Chap. 180

**NONFUNCTIONING AND GONADOTROPIN-PRODUCING ADENOMAS**

These tumors usually present with symptoms of one or more hormonal deficiencies or mass effect. They typically produce small amounts of intact gonadotropins (usually FSH) as well as uncombined and LHβ and FSHβ subunits. Surgery is indicated for mass effects or hypopituitarism; asymptomatic small adenomas may be followed with regular MRI and visual field testing. Diagnosis is based on immunohistochemical analysis of resected tumor tissue.

**TSH-SECRETING ADENOMAS**

TSH-producing adenomas are rare but often large and locally invasive when they occur. Patients present with goiter and hyperthyroidism, and/or sella mass effects. Diagnosis is based on elevated serum free T4 levels in the setting of inappropriately normal or high TSH secretion and MRI evidence of pituitary adenoma. Surgery is indicated and is usually followed by somatostatin analogue therapy to treat residual tumor. Thyroid ablation or antithyroid drugs can be used to reduce thyroid hormone levels.

**HYPOPITUITARISM**

**Etiology**  A variety of disorders may cause deficiencies of one or more pituitary hormones. These disorders may be congenital, traumatic (pituitary surgery, cranial irradiation, head injury), neoplastic (large pituitary adenoma, parasellar mass, craniopharyngioma, metastases, meningioma), infiltrative (hemochromatosis, lymphocytic hypophysitis, sarcoidosis, histiocytosis X), vascular (pituitary apoplexy, postpartum necrosis, sickle cell disease), or infectious (tuberculous, fungal, parasitic).
Clinical Features Hormonal abnormalities after cranial irradiation may occur 5–15 years later, with GH deficiency occurring first, followed sequentially by gonadotropin, TSH, and ACTH deficiency.

Each hormone deficiency is associated with specific findings:

- **GH**: growth disorders in children; increased intraabdominal fat, reduced lean body mass, hyperlipidemia, reduced bone mineral density, and social isolation in adults
- **FSH/LH**: menstrual disorders and infertility in women (Chap. 184); hypogonadism in men (Chap. 183)
- **ACTH**: features of hypocortisolism (Chap. 180) without mineralocorticoid deficiency
- **TSH**: growth retardation in children, features of hypothyroidism in children and adults (Chap. 179)

Diagnosis Biochemical diagnosis of pituitary insufficiency is made by demonstrating low or inappropriately normal levels of pituitary hormones in the setting of low target hormone levels. Initial testing should include an 8 A.M. cortisol level, TSH and free T₄, IGF-I, testosterone in men, assessment of menstrual cycles in women, and prolactin level. Provocative tests may be required to assess pituitary reserve for individual hormones. Adult GH deficiency is diagnosed by demonstrating a subnormal GH response to a standard provocative test (insulin tolerance test, L-arginine + GHRH). Acute ACTH deficiency may be diagnosed by a subnormal response in an insulin tolerance test, metyrapone test, or corticotropin-releasing hormone (CRH) stimulation test. Standard ACTH (cosyntropin) stimulation tests may be normal in acute ACTH deficiency; with adrenal atrophy, the cortisol response to cosyntropin is blunted.

<table>
<thead>
<tr>
<th>Trophic Hormone Deficit</th>
<th>Hormone Replacement</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTH</td>
<td>Hydrocortisone (10–20 mg A.M.; 5–10 mg P.M.)</td>
</tr>
<tr>
<td></td>
<td>Cortisone acetate (25 mg A.M.; 12.5 mg P.M.)</td>
</tr>
<tr>
<td></td>
<td>Prednisone (5 mg A.M.; 2.5 mg P.M.)</td>
</tr>
<tr>
<td>TSH, FSH/LH</td>
<td>L-Thyroxine (0.075–0.15 mg daily)</td>
</tr>
<tr>
<td>Males</td>
<td>Testosterone enanthate (200 mg IM every 2 weeks)</td>
</tr>
<tr>
<td></td>
<td>Testosterone gel (5–10 g/d)</td>
</tr>
<tr>
<td>Females</td>
<td>Conjugated estrogen (0.625–1.25 mg qd for 25 days)</td>
</tr>
<tr>
<td></td>
<td>Progesterone (5–10 mg qd) on days 16–25</td>
</tr>
<tr>
<td></td>
<td>Estradiol skin patch (0.5 mg, every other day)</td>
</tr>
<tr>
<td></td>
<td>For fertility: Menopausal gonadotropins, human choriionic gonadotropins</td>
</tr>
<tr>
<td>GH</td>
<td>Adults: Somatotropin (0.1–1.25 mg SC qd)</td>
</tr>
<tr>
<td></td>
<td>Children: Somatotropin [0.02–0.05 (mg/kg per day)]</td>
</tr>
<tr>
<td>GH</td>
<td>Intranasal desmopressin (5–20 µg twice daily)</td>
</tr>
<tr>
<td></td>
<td>Oral 300–600 µg qd</td>
</tr>
</tbody>
</table>

*(a)*All doses shown should be individualized for specific patients and should be reassessed during stress, surgery, or pregnancy. Male and female fertility requirements should be managed as discussed in Chaps. 183 and 184.

**Note:** For abbreviations, see text.
Hormonal replacement should aim to mimic physiologic hormone production. Effective dose schedules are outlined in Table 177-2. GH therapy, particularly when excessive, may be associated with fluid retention, joint pain, and carpal tunnel syndrome. Glucocorticoid replacement should always precede levothyroxine therapy to avoid precipitation of adrenal crisis. Patients requiring glucocorticoid replacement should wear a medical alert bracelet and should be instructed to take additional doses during stressful events such as acute illness, dental procedures, trauma, and acute hospitalization.

For a more detailed discussion, see Melmed S, Jameson JL: Disorders of the Anterior Pituitary and Hypothalamus, Chap. 333, p. 2195, in HPIM-17.

Diabetes Insipidus and SIADH

The neurohypophysis, or posterior pituitary gland, produces two hormones: (1) arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), and (2) oxytocin. AVP acts on the renal tubules to induce water retention, leading to concentration of the urine. Oxytocin stimulates postpartum milk letdown in response to suckling. Clinical syndromes may result from deficiency or excess of AVP.

DIABETES INSIPIDUS

Etiology Diabetes insipidus (DI) results from abnormalities of AVP production from the hypothalamus or AVP action in the kidney. AVP deficiency is characterized by production of large amounts of dilute urine. In central DI, insufficient AVP is released in response to physiologic stimuli. Causes include acquired (head trauma; neoplastic or inflammatory conditions affecting the posterior pituitary), congenital, and genetic disorders, but almost half of cases are idiopathic. In gestational DI, increased metabolism of plasma AVP by an aminopeptidase produced by the placenta leads to a deficiency of AVP during pregnancy. Primary polydipsia results in secondary insufficiencies of AVP due to inhibition of AVP secretion by excessive fluid intake. Nephrogenic DI can be genetic or acquired from drug exposure (lithium, demeclocycline, amphotericin B), metabolic conditions (hypercalcemia), or renal damage.

Clinical Features Symptoms include polyuria, excessive thirst, and polydipsia, with a 24-h urine output of >50 (mL/kg)/day and a urine osmolality that is less than that of serum (<300 mosmol/kg; specific gravity <1.010). Clinical or laboratory signs of dehydration, including hypernatremia, occur only if the pt simultaneously has a thirst defect or does not have access to water. Other etiologies of hypernatremia are described in Chap. 2.
Diagnosis  
DI must be differentiated from other etiologies of polyuria (Chap. 57). Unless an inappropriately dilute urine is present in the setting of serum hyperosmolality, a fluid deprivation test is used to make the diagnosis of DI. This test should be started in the morning, and body weight, plasma osmolality, sodium concentration, and urine volume and osmolality should be measured hourly. The test should be stopped when body weight decreases by 5% or plasma osmolality/sodium exceed the upper limit of normal. If the urine osmolality is <300 mosmol/kg with serum hyperosmolality, desmopressin (0.03 μg/kg SC) should be administered with repeat measurement of urine osmolality 1–2 h later. An increase of >50% indicates severe pituitary DI, whereas a smaller or absent response suggests nephrogenic DI. Measurement of AVP levels before and after fluid deprivation may be required to diagnose partial DI. Occasionally, hypertonic saline infusion may be required if fluid deprivation does not achieve the requisite level of hypertonic dehydration.

Diabetes Insipidus

Pituitary DI can be treated with desmopressin (DDAVP) subcutaneously (1–2 μg once or twice per day), via nasal spray (10–20 μg two or three times a day), or orally (100–400 μg two or three times a day), with recommendations

<table>
<thead>
<tr>
<th>TABLE 178-1 CAUSES OF SYNDROME OF INAPPROPRIATE ANTI DIURETIC HORMONE (SIADH)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoplasms</td>
</tr>
<tr>
<td>Carcinomas</td>
</tr>
<tr>
<td>Lung</td>
</tr>
<tr>
<td>Duodenum</td>
</tr>
<tr>
<td>Pancreas</td>
</tr>
<tr>
<td>Ovary</td>
</tr>
<tr>
<td>Bladder, ureter</td>
</tr>
<tr>
<td>Other neoplasms</td>
</tr>
<tr>
<td>Thymoma</td>
</tr>
<tr>
<td>Mesothelioma</td>
</tr>
<tr>
<td>Bronchial adenoma</td>
</tr>
<tr>
<td>Carcinoid</td>
</tr>
<tr>
<td>Gangliocytoma</td>
</tr>
<tr>
<td>Ewing’s sarcoma</td>
</tr>
<tr>
<td>Head trauma</td>
</tr>
<tr>
<td>Infections</td>
</tr>
<tr>
<td>Pneumonia, bacterial or viral</td>
</tr>
<tr>
<td>Abscess, lung or brain</td>
</tr>
<tr>
<td>Cavitation (aspergilosis)</td>
</tr>
<tr>
<td>Tuberculosis, lung or brain</td>
</tr>
<tr>
<td>Meningitis, bacterial or viral</td>
</tr>
<tr>
<td>Encephalitis</td>
</tr>
<tr>
<td>AIDS</td>
</tr>
<tr>
<td>Vascular</td>
</tr>
<tr>
<td>Cerebrovascular occlusions, hemorrhage</td>
</tr>
<tr>
<td>Cavernous sinus thrombosis</td>
</tr>
<tr>
<td>Neurologic</td>
</tr>
<tr>
<td>Guillain-Barré syndrome</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
</tr>
<tr>
<td>Delirium tremens</td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis</td>
</tr>
<tr>
<td>Hydrocephalus</td>
</tr>
<tr>
<td>Psychosis</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
</tr>
<tr>
<td>Congenital malformations</td>
</tr>
<tr>
<td>Agenesis corpus callosum</td>
</tr>
<tr>
<td>Cleft lip/palate</td>
</tr>
<tr>
<td>Other midline defects</td>
</tr>
<tr>
<td>Metabolic</td>
</tr>
<tr>
<td>Acute intermittent porphyria</td>
</tr>
<tr>
<td>Pulmonary</td>
</tr>
<tr>
<td>Asthma</td>
</tr>
<tr>
<td>Pneumothorax</td>
</tr>
<tr>
<td>Positive-pressure respiration</td>
</tr>
<tr>
<td>Drugs</td>
</tr>
<tr>
<td>Vasopressin or DDAVP</td>
</tr>
<tr>
<td>Chlorpropamide</td>
</tr>
<tr>
<td>Oxytocin, high dose</td>
</tr>
<tr>
<td>Vincristine</td>
</tr>
<tr>
<td>Carbamazepine</td>
</tr>
<tr>
<td>Nicotine</td>
</tr>
<tr>
<td>Phenothiazines</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
</tr>
<tr>
<td>Monoamine oxidase inhibitors</td>
</tr>
<tr>
<td>Serotonin reuptake inhibitors</td>
</tr>
</tbody>
</table>
to drink to thirst. Symptoms of nephrogenic DI may be ameliorated by treatment with a thiazide diuretic and/or amiloride in conjunction with a low-sodium diet, or with prostaglandin synthesis inhibitors (e.g., indomethacin).

**SYNDROME OF INAPPROPRIATE ANTI DIURETIC HORMONE (SIADH)**

**Etiology** Excessive or inappropriate production of AVP predisposes to hyponatremia, reflecting water retention. The evaluation of hyponatremia is described in Chap. 2. Etiologies of SIADH include neoplasms, lung infections, CNS disorders, and drugs (Table 178-1).

**Clinical Features** If hyponatremia develops gradually, it may be asymptomatic. However, if it develops acutely, symptoms of water intoxication may include mild headache, confusion, anorexia, nausea, vomiting, coma, and convulsions. Laboratory findings include low BUN, creatinine, uric acid, and albumin; serum Na < 130 mmol/L and plasma osmolality < 270 mmol/kg; urine is almost always hypertonic to plasma, and urinary Na+ is usually >20 mmol/L.

**Rx SIADH**

Fluid intake should be restricted to 500 mL less than urinary output. In patients with severe symptoms or signs, hypertonic (3%) saline can be infused at ≤0.05 mL/kg body weight IV per minute, with hourly sodium levels measured until Na increases by 12 mmol/L or to 130 mmol/L, whichever occurs first. However, if the hyponatremia has been present for >24–48 h and is corrected too rapidly, saline infusion has the potential to produce central pontine myelinolysis. Demeclocycline (150–300 mg PO three or four times a day) or fludrocortisone (0.05–0.2 mg PO twice a day) may be required to manage chronic SIADH.

For a more detailed discussion, see Robertson GL: Disorders of the Neurohypophysis, Chap. 334, p. 2217, in HPIM-17.

**Thyroid Gland Disorders**

Disorders of the thyroid gland result primarily from autoimmune processes that stimulate the overproduction of thyroid hormones (thyrotoxicosis) or cause glandular destruction and underproduction of thyroid hormones (hypothyroidism). Neoplastic processes in the thyroid gland can lead to benign nodules or thyroid cancer.

Thyroidal production of the hormones thyroxine (T4) and triiodothyronine (T3) is controlled via a classic endocrine feedback loop (see Fig. 177-1). Some T3 is secreted by the thyroid, but most is produced by deiodination of T4 in peripheral tissues. Both T4 and T3 are bound to carrier proteins [thyroid-binding globulin
(TBG), transthyretin, and albumin] in the circulation. Increased levels of total T₄ and T₃ with normal free levels are seen in states of increased carrier proteins (pregnancy, estrogens, cirrhosis, hepatitis, and inherited disorders). Conversely, decreased total T₄ and T₃ levels with normal free levels are seen in severe systemic illness, chronic liver disease, and nephrosis.

**HYPOTHYROIDISM**

**Etiology** Deficient thyroid hormone secretion can be due to thyroid failure (primary hypothyroidism) or, less commonly, pituitary or hypothalamic disease (secondary hypothyroidism) (Table 179-1). Transient hypothyroidism may occur in silent or subacute thyroiditis. Subclinical (or mild) hypothyroidism is a state of normal thyroid hormone levels and mild elevation of TSH; despite the name, some pts may have minor symptoms. With higher TSH levels and low free T₄ levels, symptoms become more readily apparent in clinical (or overt) hypothyroidism. In areas of iodine sufficiency, autoimmune disease and iatrogenic causes are most common.

**Clinical Features** Symptoms of hypothyroidism include lethargy, dry hair and skin, cold intolerance, hair loss, difficulty concentrating, poor memory, constipation, mild weight gain with poor appetite, dyspnea, hoarse voice, muscle cramping, and menorrhagia. Cardinal features on examination include bradycardia, mild diastolic hypertension, prolongation of the relaxation phase of deep tendon reflexes, and cool peripheral extremities. Goiter may be palpated, or the thyroid may be atrophic and nonpalpable. Carpal tunnel syndrome may

<table>
<thead>
<tr>
<th>TABLE 179-1 CAUSES OF HYPOTHYROIDISM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary</strong></td>
</tr>
<tr>
<td>Autoimmune hypothyroidism: Hashimoto’s thyroiditis, atrophic thyroiditis</td>
</tr>
<tr>
<td>Iatrogenic: ¹³¹I treatment, subtotal or total thyroidectomy, external irradiation of neck for lymphoma or cancer</td>
</tr>
<tr>
<td>Drugs: iodine excess (including iodine-containing contrast media and amiodarone), lithium, antithyroid drugs, p-aminosalicylic acid, interferon-α and other cytokines, aminoglutethimide</td>
</tr>
<tr>
<td>Congenital hypothyroidism: absent or ectopic thyroid gland, dyshormonogenesis, TSH-R mutation</td>
</tr>
<tr>
<td>Iodine deficiency</td>
</tr>
<tr>
<td>Infiltrative disorders: amyloidosis, sarcoidosis, hemochromatosis, scleroderma, cystinosis, Riedel’s thyroiditis</td>
</tr>
<tr>
<td><strong>Transient</strong></td>
</tr>
<tr>
<td>Silent thyroiditis, including postpartum thyroiditis</td>
</tr>
<tr>
<td>Subacute thyroiditis</td>
</tr>
<tr>
<td>Withdrawal of thyroxine treatment in individuals with an intact thyroid</td>
</tr>
<tr>
<td>After ¹³¹I treatment or subtotal thyroidectomy for Graves’ disease</td>
</tr>
<tr>
<td><strong>Secondary</strong></td>
</tr>
<tr>
<td>Hypopituitarism: tumors, pituitary surgery or irradiation, infiltrative disorders, Sheehan’s syndrome, trauma, genetic forms of combined pituitary hormone deficiencies</td>
</tr>
<tr>
<td>Isolated TSH deficiency or inactivity</td>
</tr>
<tr>
<td>Bexarotene treatment</td>
</tr>
<tr>
<td>Hypothalamic disease: tumors, trauma, infiltrative disorders, idiopathic</td>
</tr>
</tbody>
</table>

*Note: TSH, thyroid-stimulating hormone; TSH-R, TSH receptor.*
be present. Cardiomegaly may be present due to pericardial effusion. The most extreme presentation is a dull, expressionless face, sparse hair, periorbital puffiness, large tongue, and pale, doughy, cool skin. The condition may progress into a hypothermic, stuporous state (myxedema coma) with respiratory depression. Factors that predispose to myxedema coma include cold exposure, trauma, infection, and administration of narcotics.

**Diagnosis** Decreased serum T₄ is common to all varieties of hypothyroidism. An elevated TSH is a sensitive marker of primary hypothyroidism. A summary of the investigations used to determine the existence and cause of hypothyroidism is provided in Fig. 179-1. Thyroid peroxidase (TPO) antibodies are increased in >90% of pts with autoimmune-mediated hypothyroidism. Elevated cholesterol, increased creatine phosphokinase, and anemia may be present; bradycardia, low-amplitude QRS complexes, and flattened or inverted T waves may be present on ECG.

**Hypothyroidism**

Adult pts <60 years without evidence of heart disease may be started on 50–100 μg of levothyroxine (T₄) daily. In the elderly or in pts with known coronary artery disease, the starting dose of levothyroxine is 12.5–25 μg/d. The dose should be adjusted in 12.5- to 25-μg increments every 6–8 weeks on the basis of TSH levels, until a normal TSH level is achieved. The usual daily replacement
dose is 1.6 (μg/kg)/d. Women on levothyroxine replacement should have a TSH level checked as soon as pregnancy is diagnosed, as the replacement dose typically increases by 30–50% during pregnancy. Failure to recognize and treat maternal hypothyroidism may adversely affect fetal neural development. Therapy for myxedema coma should include levothyroxine (500 μg) as a single IV bolus followed by daily treatment with levothyroxine (50–100 μg/d), along with hydrocortisone (50 mg every 6 h) for impaired adrenal reserve, ventilatory support, space blankets, and therapy of precipitating factors.

**THYROTOXICOSIS**

**Etiology** Causes of thyroid hormone excess include primary hyperthyroidism (Graves’ disease, toxic multinodular goiter, toxic adenoma, iodine excess); thyroid destruction (subacute thyroiditis, silent thyroiditis, amiodarone, radiation); extrathyroidal sources of thyroid hormone (thyrotoxicosis factitia, struma ovarii, functioning follicular carcinoma); and secondary hyperthyroidism [TSH-secreting pituitary adenoma, thyroid hormone resistance syndrome, human chorionic gonadotropin (hCG)-secreting tumors, gestational thyrotoxicosis].

**Clinical Features** Symptoms include nervousness, irritability, heat intolerance, excessive sweating, palpitations, fatigue and weakness, weight loss with increased appetite, frequent bowel movements, and oligomenorrhea. Pts are anxious, restless, and fidgety. Skin is warm and moist, and fingernails may separate from the nail bed (Plummer’s nails). Eyelid retraction and lid lag may be present. Cardiovascular findings include tachycardia, systolic hypertension, systolic murmur, and atrial fibrillation. A fine tremor, hyperreflexia, and proximal muscle weakness may also be present. Long-standing thyrotoxicosis may lead to osteopenia.

In Graves’ disease, the thyroid is usually diffusely enlarged to two to three times its normal size, and a bruit or thrill may be present. Infiltrative ophthalmopathy (with variable degrees of proptosis, periorbital swelling, and ophthalmoplegia) and dermopathy (pretibial myxedema) may also be found. In subacute thyroiditis, the thyroid is exquisitely tender and enlarged with referred pain to the jaw or ear, and sometimes accompanied by fever and preceded by an upper respiratory tract infection. Solitary or multiple nodules may be present in toxic adenoma or toxic multinodular goiter.

**Thyrotoxic crisis**, or thyroid storm, is rare, presents as a life-threatening exacerbation of hyperthyroidism, and can be accompanied by fever, delirium, seizures, arrhythmias, coma, vomiting, diarrhea, and jaundice.

**Diagnosis** Investigations used to determine the existence and causes of thyrotoxicosis are summarized in Fig. 179-2. Serum TSH is a sensitive marker of thyrotoxicosis caused by Graves’ disease, autonomous thyroid nodules, thyroiditis, and exogenous levothyroxine treatment. Associated laboratory abnormalities include elevation of bilirubin, liver enzymes, and ferritin. Radionuclide uptake may be required to distinguish the various etiologies: high uptake in Graves’ disease and nodular disease vs. low uptake in thyroid destruction, iodine excess, and extrathyroidal sources of thyroid hormone. The ESR is elevated in subacute thyroiditis.

**Thyrotoxicosis**

Graves’ disease may be treated with antithyroid drugs or radioiodine; subtotal thyroidectomy is rarely indicated. The main antithyroid drugs are methima-
Thyroid Gland Disorders

CHAPTER 179

zole or carbimazole (10–20 mg two to three times a day initially, titrated to 2.5–10 mg/d) and propylthiouracil (100–200 mg every 8 h initially, titrated to 50 mg once or twice a day). Thyroid function tests should be checked 3–4 weeks after initiation of treatment, with adjustments to maintain a normal free $T_4$ level. The common side effects are rash, urticaria, fever, and arthralgia (1–5% of pts). Rare but major side effects include hepatitis, an SLE-like syndrome, and agranulocytosis (<1%). All pts should be given written instructions regarding the symptoms of possible agranulocytosis (sore throat, fever, mouth ulcers) and the need to stop treatment pending a complete blood count to confirm that agranulocytosis is not present. Propranolol (20–40 mg every 6 h) or longer acting beta blockers such as atenolol (50 mg/d) may be useful to control adrenergic symptoms. Anticoagulation with warfarin should be considered in all pts with atrial fibrillation. Radioiodine can also be used as initial treatment or in pts who do not undergo remission after a 1- to 2-year trial of antithyroid drugs. Antecedent treatment with antithyroid drugs should be con-

FIGURE 179-2 Evaluation of thyrotoxicosis. aDiffuse goiter, positive TPO antibodies, ophthalmopathy, dermopathy; bcan be confirmed by radionuclide scan.
sidered in elderly pts and those with cardiac problems, with cessation of anti-thyroid drugs 3–5 days prior to radioiodine administration. Radioiodine treatment is contraindicated in pregnancy; instead, symptoms should be controlled with the lowest effective dose of propylthiouracil (PTU). Corneal drying may be relieved with artificial tears and taping the eyelids shut during sleep. Progressive exophthalmos with chemosis, ophthalmoplegia, or vision loss is treated with large doses of prednisone (40–80 mg/d) and ophthalmologic referral; orbital decompression may be required.

In thyroid storm, large doses of PTU (600-mg loading dose) should be administered orally, per nasogastric tube, or per rectum, followed 1 h later by 5 drops saturated solution of KI (SSKI) q6h. PTU (200–300 mg every 6 h) should be continued, along with propranolol (40–60 mg PO q4h or 2 mg IV every 4 h) and dexamethasone (2 mg every 6 h). Any underlying precipitating cause should be identified and treated.

Radioiodine is the treatment of choice for toxic nodules. Subacute thyroiditis should be treated with NSAIDs and beta blockade to control symptoms, with monitoring of the TSH and free T₄ levels every 4 weeks. The clinical course of subacute thyroiditis is summarized in Fig. 179-3. Transient levothyroxine replacement (50–100 μg/d) may be required if the hypothyroid phase is prolonged. Silent thyroiditis (or postpartum thyroiditis if within 3–6 months of delivery) should be treated with beta blockade during the thyrotoxic phase and levothyroxine in the hypothyroid phase, with withdrawal after 6–9 months to assess recovery.

**SICK EUTHYROID SYNDROME**

Any acute, severe illness can cause abnormalities of circulating thyroid hormone levels or TSH, even in the absence of underlying thyroid disease. There-
fore, the routine testing of thyroid function should be avoided in acutely ill pts unless a thyroid disorder is strongly suspected. The most common pattern in sick euthyroid syndrome is a decrease in total and free T₃ levels, with normal levels of TSH and T₄. More ill pts may additionally have a fall in total T₄ levels, with normal free T₃ levels. TSH levels may range from <0.1 to >20 mU/L, with normalization after recovery from illness. Unless there is historic or clinical ev-idence of hypothyroidism, thyroid hormone should not be administered and thyroid function tests should be repeated after recovery.

**AMIODARONE**

Amiodarone treatment is associated with (1) acute, transient changes in thyroid function, (2) hypothyroidism, or (3) thyrotoxicosis. There are two major forms of amiodarone-induced thyrotoxicosis (AIT). Type 1 AIT is associated with an underlying thyroid abnormality (preclinical Graves’ disease or nodular goiter). Thyroid hormone synthesis becomes excessive as a result of increased iodine exposure. Type 2 AIT occurs in pts with no intrinsic thyroid abnormalities and is the result of destructive thyroiditis. Differentiation between type 1 and type 2 AIT may be difficult as the high iodine load interferes with thyroid scans. The drug should be stopped, if possible, with administration of high-dose antithyroid drugs in type 1 AIT or potassium perchlorate (200 mg every 6 h) in type 1 and glucocorticoids in type 2 AIT.

**NONTOXIC GOITER**

*Goiter* refers to an enlarged thyroid gland (>20–25 g) and is more common in women than men. Biosynthetic defects, iodine deficiency, autoimmune disease, and nodular diseases can lead to goiter. If thyroid function is preserved, most goiters are asymptomatic. Substernal goiter may obstruct the thoracic inlet and should be evaluated with respiratory flow measurements and CT or MRI in pts with obstructive signs or symptoms (difficulty swallowing, tracheal compression, or plethora). Thyroid function tests should be performed in all pts with goiter to exclude thyrotoxicosis or hypothyroidism. Ultrasound is not generally indicated in the evaluation of diffuse goiter, unless a nodule is palpable on physical exam.

Iodine or thyroid hormone replacement induces variable regression of goiter in iodine deficiency. Radioiodine reduces goiter size by about 50% in the majority of pts. Surgery is rarely indicated for diffuse goiter but may be required to alleviate compression in pts with nontoxic multinodular goiter.

**TOXIC MULTINODULAR GOITER AND TOXIC ADENOMA**

**TOXIC MULTINODULAR GOITER (MNG)**

In addition to features of goiter, the clinical presentation of toxic MNG includes subclinical hyperthyroidism or mild thyrotoxicosis. The pt is usually elderly and may present with atrial fibrillation or palpitations, tachycardia, nervousness, tremor, or weight loss. Recent exposure to iodine, from contrast dyes or other sources, may precipitate or exacerbate thyrotoxicosis; this may be prevented by prior administration of an antithyroid drug. The TSH level is low. T₄ may be normal or minimally increased; T₃ is often elevated to a greater degree than T₄. Thyroid scan shows heterogeneous uptake with multiple regions of increased and decreased uptake; 24-h uptake of radioiodine may not be increased.
Cold nodules in a multinodular goiter should be evaluated in the same way as solitary nodules (see below). Antithyroid drugs, often in combination with beta blockers, can normalize thyroid function and improve clinical features of thyrotoxicosis but do not induce remission. A trial of radioiodine should be considered before subjecting pts, many of whom are elderly, to surgery.

TOXIC ADENOMA

A solitary, autonomously functioning thyroid nodule is referred to as toxic adenoma. A thyroid scan provides a definitive diagnostic test, demonstrating focal uptake in the hyperfunctioning nodule and diminished uptake in the remainder of the gland, as activity of the normal thyroid is suppressed. Radioiodine ablation (e.g., 10–29.9 mCi $^{131}$I) is usually the treatment of choice.

THYROID NEOPLASMS

Etiology Thyroid neoplasms may be benign (adenomas) or malignant (carcinomas). Carcinomas of the follicular epithelium include papillary, follicular, and anaplastic thyroid cancer. Papillary thyroid cancer is the most common type of thyroid cancer. It tends to be multifocal and to invade locally. Follicular thyroid cancer is difficult to diagnose via fine-needle aspiration (FNA) because the distinction between benign and malignant follicular neoplasms rests largely on evidence of invasion into vessels, nerves, or adjacent structures. It tends to spread hematogenously, leading to bone, lung, and CNS metastases. Anaplastic carcinoma is rare, highly malignant, and rapidly fatal. Thyroid lymphoma often arises in the background of Hashimoto’s thyroiditis and occurs in the setting of a rapidly expanding thyroid mass. Medullary thyroid carcinoma arises from parafollicular (C) cells and may occur sporadically or as a familial disorder, sometimes in association with multiple endocrine neoplasia type 2.

Clinical Features Features suggesting carcinoma include recent or rapid growth of a nodule or mass, history of neck irradiation, lymph node involvement, hoarseness, and fixation to surrounding tissues. Glandular enlargement may result in compression and displacement of the trachea or esophagus and obstructive symptoms. Age <20 or >45, male sex, and larger nodule size are associated with a worse prognosis.

Diagnosis An approach to the evaluation of a solitary nodule is outlined in Fig. 179-4.

Rx Thyroid Neoplasms

Benign nodules should be monitored via serial examination.

Follicular adenomas cannot be distinguished from follicular carcinomas on the basis of cytologic analysis of FNA specimens. The extent of surgical resection (lobectomy vs. near-total thyroidectomy) should be discussed prior to surgery.

Near-total thyroidectomy is required for papillary and follicular carcinoma and should be performed by a surgeon who is highly experienced in the procedure. If risk factors and pathologic features indicate the need for radioiodine treatment, the pt should be treated for several weeks postoperatively with liothyronine (25 μg two to three times a day), followed by withdrawal for an additional 2 weeks, in preparation for postsurgical radioablation of remnant tissue. A therapeutic dose of $^{131}$I is administered when the TSH level > 50 IU/L. Subsequent levothyroxine suppression of TSH to a low, but detectable, level
should be attempted in pts with a high risk of recurrence, and to 0.1–0.5 IU/L in those with a low risk of recurrence. Follow-up scans and thyroglobulin levels should be performed at regular intervals after either thyroid hormone withdrawal or administration of recombinant human TSH.

The management of medullary thyroid carcinoma is surgical, as these tumors do not take up radioiodine. Testing for the \textit{RET} mutation should be performed. Elevated serum calcitonin provides a marker of residual or recurrent disease.

For a more detailed discussion, see Jameson JL, Weetman AP: Disorders of the Thyroid Gland, Chap. 335, p. 2244, in HPIM-17.
HYPERFUNCTION OF THE ADRENAL GLAND

CUSHING’S SYNDROME

Etiology The most common cause of Cushing’s syndrome is iatrogenic, due to administration of glucocorticoids for therapeutic reasons. Endogenous Cushing’s syndrome results from production of excess cortisol (and other steroid hormones) by the adrenal cortex. The major cause is bilateral adrenal hyperplasia secondary to hypersecretion of adrenocorticotropic hormone (ACTH) by the pituitary (Cushing’s disease) or from ectopic sources such as small cell carcinoma of the lung; medullary carcinoma of the thyroid; or tumors of the thymus, pancreas, or ovary. Adenomas or carcinoma of the adrenal gland account for about 25% of Cushing’s syndrome cases.

Clinical Features Some common manifestations (central obesity, hypertension, osteoporosis, psychological disturbances, acne, amenorrhea, and diabetes mellitus) are relatively nonspecific. More specific findings include easy bruising, purple striae, proximal myopathy, fat deposition in the face and interscapular areas (moon facies and buffalo hump), and virilization. Thin, fragile skin and plethoric moon facies may also be found. Hypokalemia and metabolic alkalosis are prominent, particularly with ectopic production of ACTH.

Diagnosis The diagnosis of Cushing’s syndrome requires demonstration of increased cortisol production and abnormal cortisol suppression in response to dexamethasone. For initial screening, measurement of 24-h urinary free cortisol, the 1-mg overnight dexamethasone test [8 A.M. plasma cortisol < 1.8 μg/dL (50 nmol/L)] or late night salivary cortisol measurement is appropriate. Repeat testing or performance of more than one screening test may be required. Definitive diagnosis is established in equivocal cases by inadequate suppression of urinary [<10 μg/d (25 nmol/d)] or plasma cortisol [<5 μg/dL (140 nmol/L)] after 0.5 mg dexamethasone every 6 h for 48 h. This test may also be combined with corticotropin-releasing hormone (CRH) testing to rule out pseudo-Cushing’s states. Once the diagnosis of Cushing’s syndrome is established, further biochemical testing is required to localize the source. Low levels of plasma ACTH levels suggest an adrenal adenoma or carcinoma; inappropriately normal or high plasma ACTH levels suggest a pituitary or ectopic source. In 95% of ACTH-producing pituitary microadenomas, cortisol production is suppressed by high-dose dexamethasone (2 mg every 6 h for 48 h), and MRI of the pituitary should be obtained. However, because up to 10% of ectopic sources of ACTH may also suppress after high-dose dexamethasone testing, inferior petrosal sinus sampling may be required to distinguish pituitary from peripheral sources of ACTH. Imaging of the chest and abdomen is required to localize the source of ectopic ACTH production. Pts with chronic alcoholism and depression may have false-positive results in testing for Cushing’s syndrome. Similarly, pts with acute illness may have abnormal laboratory test results, since major stress disrupts the normal regulation of ACTH secretion.

Rx Cushing’s Syndrome

Therapy of adrenal adenoma or carcinoma requires surgical excision; stress doses of glucocorticoids must be given pre- and postoperatively. Metastatic and unresectable adrenal carcinomas are treated with mitotane in doses gradually increased to 6 g/d in three or four divided doses. Transsphenoidal surgery can be curative for pituitary microadenomas that secrete ACTH, though
radiation may be used when cure is not achieved (see Chap. 177). On occasion, debulking of lung carcinoma or resection of carcinoid tumors can result in remission of ectopic Cushing’s syndrome. If the source of ACTH cannot be resected, bilateral total adrenalectomy or medical management with ketoconazole (600–1200 mg/d), metyrapone (2–3 g/d), or mitotane (2–3 mg/d) may relieve manifestations of cortisol excess. Patients with unresectable pituitary adenomas who have bilateral adrenalectomy are at risk for Nelson’s syndrome (pituitary adenoma enlargement).

ALDOSTERONISM

**Etiology** Aldosteronism is caused by hypersecretion of the adrenal mineralocorticoid aldosterone. Primary aldosteronism refers to an adrenal cause and can be due to either an adrenal adenoma or bilateral adrenal hyperplasia. The term secondary aldosteronism is used when an extraadrenal stimulus is present, as in renal artery stenosis or diuretic therapy.

**Clinical Features** Most pts with primary hyperaldosteronism have headaches and diastolic hypertension. Edema is characteristically absent, unless congestive heart failure or renal disease is present. Hypokalemia, caused by urinary potassium losses, may cause muscle weakness and fatigue, though potassium levels may be normal in mild primary aldosteronism. Hypernatremia and metabolic alkalosis may also occur.

**Diagnosis** The diagnosis is suggested by hypertension that is associated with persistent hypokalemia in a nonedematous pt who is not receiving potassium-wasting diuretics. In pts receiving potassium-wasting diuretics, the diuretic should be discontinued and potassium supplements should be administered for 1–2 weeks. If hypokalemia persists after supplementation, screening using a serum aldosterone and plasma renin activity should be performed. A ratio of serum aldosterone (in ng/dL) to plasma renin activity (in ng/mL per hour) >30 and an absolute level of aldosterone >15 ng/dL suggest primary aldosteronism. Failure to suppress plasma aldosterone (to <5 ng/dL after 500 mL/h of normal saline × 4 h) or urinary aldosterone after saline or sodium loading (to <10 μg/d on day 3 of 200 mmol/d Na PO + fludrocortisone 0.2 mg twice daily × 3 days) confirms primary hyperaldosteronism. Localization should then be undertaken with a high-resolution CT scan of the adrenal glands. If the CT scan is negative, bilateral adrenal vein sampling may be required to diagnose a unilateral aldosterone-producing adenoma. Secondary hyperaldosteronism is associated with elevated plasma renin activity.

RX **Aldosteronism**

Surgery can be curative in pts with adrenal adenoma but is not effective for adrenal hyperplasia, which is managed with sodium restriction and spironolactone (25–100 mg twice daily) or eplerenone (25–50 mg twice daily). Secondary aldosteronism is treated with salt restriction and correction of the underlying cause.

**SYNDROMES OF ADRENAL ANDROGEN EXCESS**

See Chap. 184 for discussion of hirsutism and virilization.
HYPOFUNCTION OF THE ADRENAL GLAND

Primary adrenal insufficiency is due to failure of the adrenal gland, whereas secondary adrenal insufficiency is due to failure of ACTH production or release.

ADDISON’S DISEASE

Etiology  Addison’s disease occurs when >90% of adrenal tissue is destroyed surgically, by granulomatous disease (tuberculosis, histoplasmosis, coccidiomycosis, cryptocoecosis), or via autoimmune mechanisms (alone, or in type I or type II polyglandular autoimmune syndromes). Bilateral tumor metastases, bilateral hemorrhage, CMV, HIV, amyloidosis, sarcoidosis, and adrenoleukodystrophy are rare causes.

Clinical Features  Manifestations include fatigue, weakness, anorexia, nausea and vomiting, weight loss, abdominal pain, cutaneous and mucosal pigmentation, salt craving, hypotension, and, occasionally, hypoglycemia. Routine laboratory parameters may be normal, or serum Na can be reduced and serum K increased. Extracellular fluid depletion accentuates hypotension.

Diagnosis  The best screening test is the cortisol response 60 min after 250 μg ACTH (cosyntropin) IV or IM. Cortisol levels should exceed 18 μg/dL 30–60 min after the ACTH. If the response is abnormal, then primary and secondary deficiency may be distinguished by measurement of aldosterone from the same blood samples. In secondary, but not primary, adrenal insufficiency, the aldosterone increment from baseline will be normal (≥5 ng/dL). Furthermore, in primary adrenal insufficiency, plasma ACTH is elevated, whereas in secondary adrenal insufficiency, plasma ACTH values are low or inappropriately normal. Pts with recent onset or partial pituitary insufficiency may have a normal response to the rapid ACTH stimulation test. In these pts, alternative testing (metyrapone test or insulin tolerance testing) may be used for diagnosis.

Hydrocortisone, at 20–30 mg/d divided into 2/3 in the morning and 1/3 in the afternoon, is the mainstay of glucocorticoid replacement. Some pts benefit from doses administered three times daily, and other glucocorticoids may be given at equivalent doses. Mineralocorticoid supplementation is usually needed for primary adrenal insufficiency, with administration of 0.05–0.1 mg fludrocortisone PO qd and maintenance of adequate Na intake. Doses should be titrated to normalize Na and K levels and to maintain normal bp without postural changes. Measurement of plasma renin levels may also be useful in titrating the dose. All pts with adrenal insufficiency should be instructed in the parenteral self-administration of steroids and should be registered with a medical alert system. During periods of intercurrent illness, the dose of hydrocortisone should be doubled. During adrenal crisis, high-dose hydrocortisone (10 mg/h continuous IV or 100-mg bolus IV three times a day) should be administered along with normal saline. Thereafter, if the patient is improving and is afebrile, the dose can be tapered by 20–30% daily to usual replacement doses.

HYPOALDOSTERONISM

Isolated aldosterone deficiency accompanied by normal cortisol production occurs with hyporeninism, as an inherited biosynthetic defect, postoperatively fol-
following removal of aldosterone-secreting adenomas, and during protracted heparin therapy. Hyporeninemic hypoaldosteronism is seen most commonly in adults with mild renal failure and diabetes mellitus in association with disproportionate hyperkalemia. Oral fludrocortisone (0.05–0.15 mg/d PO) restores electrolyte balance if salt intake is adequate. In pts with hypertension, mild renal insufficiency, or congestive heart failure, an alternative approach is to reduce salt intake and to administer furosemide.
INCIDENTAL ADRENAL MASSES

Adrenal masses are common findings on abdominal CT or MRI scans. The majority (70–80%) of such “incidentalomas” are nonfunctional, and the probability of an adrenal carcinoma is low (<0.01%). The first step in evaluation is to determine the functional status by measurement of plasma free metanephrines to screen for pheochromocytoma. In a pt with a known extraadrenal malignancy, there is a 30–50% chance that the incidentaloma is a metastasis. Additional hormonal evaluation should include overnight 1-mg dexamethasone suppression testing in all pts, plasma renin activity/aldosterone ratio in hypertensives, DHEAS in women with signs of androgen excess, and estradiol in males with feminization. Adrenocortical cancer is suggested by large size (>4–6 cm), irregular margins, tumor inhomogeneity, soft tissue calcifications, and high unenhanced CT attenuation values (>10 HU).

CLINICAL USES OF GLUCOCORTICOIDS

Glucocorticoids are pharmacologic agents used for a variety of disorders such as asthma, rheumatoid arthritis, and psoriasis. The almost certain development of complications (weight gain, hypertension, Cushingoid facies, diabetes mellitus, osteoporosis, myopathy, increased intraocular pressure, ischemic bone necrosis, infection, and hypercholesterolemia) must be weighed against the potential therapeutic benefits of glucocorticoid therapy. These side effects can

### TABLE 180-1 GLUCOCORTICOID PREPARATIONS

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Glucocorticoid</th>
<th>Mineralocorticoid</th>
<th>Dose Equivalent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-acting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>1.0</td>
<td>1.0</td>
<td>20.0</td>
</tr>
<tr>
<td>Cortisone</td>
<td>0.8</td>
<td>0.8</td>
<td>25.0</td>
</tr>
<tr>
<td>Intermediate-acting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednisone</td>
<td>4.0</td>
<td>0.25</td>
<td>5.0</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>5.0</td>
<td>0</td>
<td>4.0</td>
</tr>
<tr>
<td>Triamcinolone</td>
<td>5.0</td>
<td>0</td>
<td>4.0</td>
</tr>
<tr>
<td>Long-acting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>30.0</td>
<td>0</td>
<td>0.75</td>
</tr>
<tr>
<td>Betamethasone</td>
<td>25.0</td>
<td>0</td>
<td>0.6</td>
</tr>
</tbody>
</table>

### TABLE 180-2 A CHECKLIST FOR USE PRIOR TO THE ADMINISTRATION OF GLUCOCORTICOIDS IN PHARMACOLOGIC DOSES

- Presence of tuberculosis or other chronic infection (chest x-ray, tuberculin test)
- Evidence of glucose intolerance, history of gestational diabetes mellitus, or high risk for type 2 diabetes mellitus
- Evidence of preexisting osteoporosis (bone density assessment in organ transplant recipients or postmenopausal patients)
- History of peptic ulcer, gastritis, or esophagitis (stool guaiac test)
- Evidence of hypertension, cardiovascular disease, or hypertriglyceridemia
- History of psychological disorders
be minimized by a careful choice of steroid preparations (Table 180-1), alternate-day or interrupted therapy; the use of topical steroids, i.e., inhaled, intranasal, or dermal whenever possible; the judicious use of non-steroid therapies; monitoring of caloric intake; and instituting measures to minimize bone loss. Pts should be evaluated for the risk of complications before the initiation of glucocorticoid therapy (Table 180-2). Higher doses of glucocorticoids may be required during periods of stress, since the adrenal gland may atrophy in the setting of exogenous glucocorticoids. In addition, following long-term use, glucocorticoids should be tapered with the dual goals of allowing the pituitary-adrenal axis to recover and the avoidance of underlying disease flare.

For a more detailed discussion, see Williams GH, Dluhy RG: Disorders of the Adrenal Cortex, Chap. 336, p. 2247, in HPIM-17.

Obesity

Obesity is a state of excess adipose tissue mass. Obesity should not be defined by body weight alone, as muscular individuals may be overweight by arbitrary standards without having increased adiposity. The most widely used method to classify weight status and risk of disease is the body mass index (BMI), which is equal to weight/height\(^2\) in kg/m\(^2\) (Table 181-1). At a similar BMI, women have more body fat than men. Furthermore, regional fat distribution may influence the risks associated with obesity. Central obesity (high ratio of the circumference of the waist to the circumference of the hips, >0.9 in women and 1.0 in men) is independently associated with a higher risk for diabetes mellitus and cardiovascular disease.

**ETIOLOGY**

Obesity can result from increased energy intake, decreased energy expenditure, or a combination of the two. Excess accumulation of body fat is the consequence of environmental and genetic factors; social factors and economic conditions also

<table>
<thead>
<tr>
<th>BMI (kg/m(^2))</th>
<th>Obesity Class</th>
<th>Risk of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underweight</td>
<td>&lt;18.5</td>
<td>Healthy weight</td>
</tr>
<tr>
<td>Healthy weight</td>
<td>18.5–24.9</td>
<td>Increased</td>
</tr>
<tr>
<td>Overweight</td>
<td>25.0–29.9</td>
<td>I</td>
</tr>
<tr>
<td>Obesity</td>
<td>30.0–34.9</td>
<td>High</td>
</tr>
<tr>
<td>Obesity</td>
<td>35.0–39.9</td>
<td>II</td>
</tr>
<tr>
<td>Extreme obesity</td>
<td>≥40</td>
<td>III</td>
</tr>
</tbody>
</table>

**TABLE 181-1 CLASSIFICATION OF WEIGHT STATUS AND RISK OF DISEASE**

represent important influences. The susceptibility to obesity is polygenic in nature, and 30–50% of the variability in total fat stores is believed to be genetically determined. Secondary causes of obesity include hypothalamic injury, hypothyroidism, Cushing’s syndrome, and hypogonadism. Drug-induced weight gain is also common in those who use antidiabetes agents (insulin, sulfonylureas, thiazolidinediones), glucocorticoids, psychotropic agents, mood stabilizers (lithium), antidepressants (tricyclics, monoamine oxidase inhibitors, paroxetine, mirtazapine), or antiepileptic drugs (valproate, gabapentin, carbamazepine). Insulin-secreting tumors can cause overeating.

**CLINICAL FEATURES**

Obesity has major adverse effects on health. Increased mortality from obesity is primarily due to cardiovascular disease, hypertension, gall bladder disease, diabetes mellitus, and certain forms of cancer. The incidence of endometrial cancer and postmenopausal breast cancer, prostate cancer, and colorectal cancer in both men and women is increased with obesity. Sleep apnea in severely obese individuals poses serious health risks. Obesity is also associated with an increased incidence of steatohepatitis, osteoarthritis, and gout.

**Rx Obesity**

Obesity is a chronic medical condition that requires ongoing treatment and lifestyle modifications. Treatment is important because of the associated health risks but is made difficult by a limited repertoire of effective therapeutic options. Weight regain after weight loss is common with all forms of nonsurgical therapy. The urgency and selection of treatment modalities should be based on the BMI and a risk assessment.

Diet, exercise, and behavior therapy are recommended for all pts with a BMI $\geq 25$ kg/m$^2$. Behavior modification including group counseling, diet diaries, and changes in eating patterns should be initiated. Food-related behaviors should be monitored carefully (avoid cafeteria-style settings, eat small and frequent meals, eat breakfast). A deficit of 7500 kcal will produce a weight loss of approximately 1 kg. Therefore, eating 100 kcal/d less for a year should cause a 5-kg weight loss, and a deficit of 1000 kcal/d should cause a loss of $\sim$1 kg per week. Physical activity should be increased to a minimum of 150 min of moderate intensity physical activity per wk.

Pharmacotherapy may be added to a lifestyle program for pts with a BMI $\geq 30$ kg/m$^2$ or $\geq 27$ kg/m$^2$ with concomitant obesity-related diseases. Sibutramine is a central reuptake inhibitor of both norepinephrine and serotonin that produces a 5–9% weight loss at 12 months, though it increases heart rate and bp in some pts. Orlistat is an inhibitor of intestinal lipase that causes modest weight loss (9–10% at 12 months with lifestyle measures) due to drug-induced fat malabsorption. Metformin tends to decrease body weight in pts with obesity and type 2 diabetes mellitus.

Surgery should be considered for pts with severe obesity (BMI $\geq 40$ kg/m$^2$) or moderate obesity (BMI $\geq 35$ kg/m$^2$) associated with a serious medical condition, repeated failures of other therapeutic approaches, at eligible weight for $>3$ years, capable of tolerating surgery, without addictions or major psychopathology. Weight-loss surgeries are either restrictive (limiting the amount of food the stomach can hold and slowing gastric emptying), such as laparoscopic adjustable silicone gastric banding, or restrictive-malabsorptive, such as Roux-en-Y
gastric bypass (Fig. 181-1). These procedures generally produce a 30–35% weight loss that is maintained in nearly 60% of pts at 5 yrs. Procedures with a malabsorptive component require lifelong supplementation of micronutrients (iron, folate, calcium, vitamins B₁₂ and D) and are associated with a risk of islet cell hyperplasia and hypoglycemia.
ETIOLOGY

Diabetes mellitus (DM) comprises a group of metabolic disorders that share the common phenotype of hyperglycemia. DM is currently classified on the basis of the pathogenic process that leads to hyperglycemia. Type 1 DM is characterized by insulin deficiency and a tendency to develop ketosis, whereas type 2 DM is a heterogeneous group of disorders characterized by variable degrees of insulin resistance, impaired insulin secretion, and excessive hepatic glucose production. Other specific types include DM caused by genetic defects [maturity-onset diabetes of the young (MODY)], diseases of the exocrine pancreas (chronic pancreatitis, cystic fibrosis, hemochromatosis), endocrinopathies (acromegaly, Cushing’s syndrome, glucagonoma, pheochromocytoma, hyperthyroidism), drugs (nicotinic acid, glucocorticoids, thiazides, protease inhibitors), and pregnancy (gestational DM).

DIAGNOSIS

Criteria for the diagnosis of DM include one of the following:

- Fasting plasma glucose $\geq 7.0$ mmol/L ($\geq 126$ mg/dL)
- Symptoms of diabetes plus a random blood glucose concentration $\geq 11.1$ mmol/L ($\geq 200$ mg/dL)
- 2-h plasma glucose $\geq 11.1$ mmol/L ($\geq 200$ mg/dL) during a 75-g oral glucose tolerance test.

These criteria should be confirmed by repeat testing on a different day, unless unequivocal hyperglycemia is present.

Two intermediate categories have also been designated:

- Impaired fasting glucose (IFG) for a fasting plasma glucose level of 5.6–6.9 mmol/L (100–125 mg/dL)
- Impaired glucose tolerance (IGT) for plasma glucose levels of 7.8–11.1 mmol/L (140–199 mg/dL) 2 h after a 75-g oral glucose load

Individuals with IFG or IGT do not have DM but are at substantial risk for developing type 2 DM and cardiovascular disease in the future. The hemoglobin A1c ($\text{HbA1c}$) level is useful for monitoring responses to therapy but is not recommended for screening or diagnosis of DM.

Screening with a fasting plasma glucose level is recommended every 3 years for individuals over the age of 45, as well as for younger individuals who are overweight (body mass index $\geq 25$ kg/m$^2$) and have one or more additional risk factors (Table 182-1).

The metabolic syndrome, the insulin resistance syndrome, and syndrome X are terms used to describe a commonly found constellation of metabolic derangements that includes insulin resistance (with or without diabetes), hypertension, dyslipidemia, central or visceral obesity, and endothelial dysfunction and is associated with accelerated cardiovascular disease (Chap. 125).

CLINICAL FEATURES

Common presenting symptoms of DM include polyuria, polydipsia, weight loss, fatigue, weakness, blurred vision, frequent superficial infections, and poor
wound healing. A complete medical history should be obtained with special emphasis on weight, exercise, smoking, ethanol use, family history of DM, and risk factors for cardiovascular disease. In a patient with established DM, assessment of prior diabetes care, HbA1c levels, self-monitoring blood glucose results, frequency of hypoglycemia, and pt’s knowledge about DM should be obtained. Special attention should be given on physical exam to retinal exam, orthostatic bp, foot exam (including vibratory sensation and monofilament testing), peripheral pulses, and insulin injection sites. Acute complications of DM that may be seen on presentation include diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (Chap. 25).

The chronic complications of DM are listed below:

- Ophthalmologic: nonproliferative or proliferative diabetic retinopathy, macular edema
- Renal: proteinuria, end-stage renal disease (ESRD), type IV renal tubular acidosis
- Neurologic: distal symmetric polyneuropathy, polyradiculopathy, mononeuropathy, autonomic neuropathy
- Gastrointestinal: gastroparesis, diarrhea, constipation
- Genitourinary: cystopathy, erectile dysfunction, female sexual dysfunction
- Cardiovascular: coronary artery disease, congestive heart failure, peripheral vascular disease, stroke
- Lower extremity: foot deformity (hammer toe, claw toe, Charcot foot), ulceration, amputation

**TABLE 182-1 CRITERIA FOR TESTING FOR PRE-DIABETES AND DIABETES IN ASYMPTOMATIC INDIVIDUALS**

<table>
<thead>
<tr>
<th>Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>- First-degree relative with diabetes</td>
</tr>
<tr>
<td>- Physical inactivity</td>
</tr>
<tr>
<td>- Race/ethnicity (e.g., African American, Latino, Native American, Asian American, Pacific Islander)</td>
</tr>
<tr>
<td>- Previously identified IFG or IGT</td>
</tr>
<tr>
<td>- History of GDM or delivery of baby &gt;4 kg (&gt;9 lb)</td>
</tr>
<tr>
<td>- Hypertension (blood pressure ≥ 140/90 mmHg)</td>
</tr>
<tr>
<td>- HDL cholesterol level ≤ 0.90 mmol/L (35 mg/dL) and/or a triglyceride level ≥ 2.82 mmol/L (250 mg/dL)</td>
</tr>
<tr>
<td>- Polycystic ovary syndrome or acanthosis nigricans</td>
</tr>
<tr>
<td>- History of vascular disease</td>
</tr>
</tbody>
</table>

Tests should be considered in all adults at age 45 and adults <45 y with BMI ≥ 25 kg/m2 and one or more of the following risk factors for diabetes.

**Note:** BMI, body mass index; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; GDM, gestational diabetes mellitus; HDL, high-density lipoprotein.

**Source:** Adapted from American Diabetes Association, 2008.

Optimal treatment of DM requires more than plasma glucose management. Comprehensive diabetes care should also detect and manage DM-specific complications and modify risk factors for DM-associated diseases. The pt with type 1 or type 2 DM should receive education about nutrition, exercise, care of diabetes during illness, and medications to lower the plasma glucose.
In general, the target HbA1c level should be <7.0%, though individual considerations (age, ability to implement a complex treatment regimen, and presence of other medical conditions) should also be taken into account. Intensive therapy reduces long-term complications but is associated with more frequent and more severe hypoglycemic episodes. Goal preprandial capillary plasma glucose levels should be 5.0–7.2 mmol/L (90–130 mg/dL) and postprandial levels should be <10.0 mmol/L (<180 mg/dL) 1–2 hr after a meal.

In general, pts with type 1 DM require 0.5–1.0 U/kg per day of insulin divided into multiple doses. Combinations of insulin preparations with different times of onset and duration of action should be used (Table 182-2). Preferred regimens include injection of glargine at bedtime with preprandial lispro, glulisine, or insulin aspart or continuous subcutaneous insulin using an infusion device.

Table 182-2: Pharmacokinetics of Insulin Preparations

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Onset, h</th>
<th>Peak, h</th>
<th>Effective Duration, h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-acting, subcutaneous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lispro</td>
<td>&lt;0.25</td>
<td>0.5–1.5</td>
<td>3–4</td>
</tr>
<tr>
<td>Aspart</td>
<td>&lt;0.25</td>
<td>0.5–1.5</td>
<td>3–4</td>
</tr>
<tr>
<td>Glulisine</td>
<td>&lt;0.25</td>
<td>0.5–1.5</td>
<td>3–4</td>
</tr>
<tr>
<td>Regular</td>
<td>0.5–1.0</td>
<td>2–3</td>
<td>4–6</td>
</tr>
<tr>
<td>Short-acting, inhaled</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhaled regular insulin</td>
<td>&lt;0.25</td>
<td>0.5–1.5</td>
<td>4–6</td>
</tr>
<tr>
<td>Long-acting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPH</td>
<td>1–4</td>
<td>6–10</td>
<td>10–16</td>
</tr>
<tr>
<td>Detemir</td>
<td>1–4</td>
<td>—</td>
<td>12–20</td>
</tr>
<tr>
<td>Glargine</td>
<td>1–4</td>
<td>—</td>
<td>24</td>
</tr>
<tr>
<td>Insulin Combinations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75/25–75% protamine lispro, 25% lispro</td>
<td>&lt;0.25</td>
<td>1.5 h</td>
<td>Up to 10–16</td>
</tr>
<tr>
<td>70/30–70% protamine aspart, 30% aspart</td>
<td>&lt;0.25</td>
<td>1.5 h</td>
<td>Up to 10–16</td>
</tr>
<tr>
<td>50/50–50% protamine lispro, 50% lispro</td>
<td>&lt;0.25</td>
<td>1.5 h</td>
<td>Up to 10–16</td>
</tr>
<tr>
<td>70/30–70% NPH, 30% regular insulin</td>
<td>0.5–1</td>
<td>Dual</td>
<td>10–16</td>
</tr>
<tr>
<td>50/50–50% NPH, 50% regular insulin</td>
<td>0.5–1</td>
<td>Dual</td>
<td>10–16</td>
</tr>
</tbody>
</table>

*aGlargine has minimal peak activity; detemir has some peak activity at 6–14 h.
*bDual: two peaks; one at 2–3 h; the second several hours later.


In general, the target HbA1c level should be <7.0%, though individual considerations (age, ability to implement a complex treatment regimen, and presence of other medical conditions) should also be taken into account. Intensive therapy reduces long-term complications but is associated with more frequent and more severe hypoglycemic episodes. Goal preprandial capillary plasma glucose levels should be 5.0–7.2 mmol/L (90–130 mg/dL) and postprandial levels should be <10.0 mmol/L (<180 mg/dL) 1–2 hr after a meal.

In general, pts with type 1 DM require 0.5–1.0 U/kg per day of insulin divided into multiple doses. Combinations of insulin preparations with different times of onset and duration of action should be used (Table 182-2). Preferred regimens include injection of glargine at bedtime with preprandial lispro, glulisine, or insulin aspart or continuous subcutaneous insulin using an infusion device.

Pts with type 2 DM may be managed with diet and exercise alone or in conjunction with oral glucose-lowering agents, insulin, or a combination of oral agents and insulin. The classes of oral glucose-lowering agents and dosing regimens are listed in Table 182-3. In addition, exenatide is an injectable DPP-IV inhibitor that may be used in combination with metformin or sulfonylureas. A reasonable treatment algorithm for initial therapy proposes metformin as initial therapy because of its efficacy (1–2% decrease in HbA1c), known side-effect profile, and relatively low cost (Fig. 182-1). Metformin has
the advantage that it promotes mild weight loss, lowers insulin levels, improves the lipid profile slightly, and does not cause hypoglycemia when used as monotherapy, though it is contraindicated in renal insufficiency, congestive heart failure, any form of acidosis, liver disease, or severe hypoxia, and should be temporarily discontinued in pts who are seriously ill or receiving radiographic contrast material. Combinations of two oral agents may be used with additive effects, with stepwise addition of bedtime insulin or a third oral agent if adequate control is not achieved. As endogenous insulin production falls, multiple injections of long-acting and short-acting insulin may be required, as in type 1 DM. Individuals who require >1 U/kg per day of long-acting insulin should be considered for combination therapy with an insulin-sensitizing agent such as metformin or a thiazolidinedione.

The morbidity and mortality of DM-related complications can be greatly reduced by timely and consistent surveillance procedures (Table 182-4). A routine urinalysis may be performed as an initial screen for diabetic nephropathy. If it is positive for protein, quantification of protein on a 24-h urine collection should be performed. If the urinalysis is negative for protein, a spot collection for microalbuminuria should be performed (present if 30–300 μg/mg creatinine on two of three tests within a 3- to 6-month period). A resting ECG should be performed in adults, with more extensive cardiac testing for high-risk pts. Therapeutic goals to prevent complications of DM include management of proteinuria with ACE inhibitor therapy, bp control (<130/80 mmHg if no proteinuria, <125/75 if proteinuria), and dyslipidemia manage-

<table>
<thead>
<tr>
<th>TABLE 182-3</th>
<th>ORAL GLUCOSE-LOWERING AGENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agent</td>
<td>Daily Dose, mg</td>
</tr>
<tr>
<td>-------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Biguanide</td>
<td></td>
</tr>
<tr>
<td>Metformin</td>
<td>500–2500</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td></td>
</tr>
<tr>
<td>Glimepiride</td>
<td>1–8</td>
</tr>
<tr>
<td>Glipizide</td>
<td>2.5–40</td>
</tr>
<tr>
<td>Glipizide (ext. release)</td>
<td></td>
</tr>
<tr>
<td>Glyburide</td>
<td>1.25–20</td>
</tr>
<tr>
<td>Glyburide (micronized)</td>
<td></td>
</tr>
<tr>
<td>Non-sulfonylurea secretagogue</td>
<td></td>
</tr>
<tr>
<td>Repaglinide</td>
<td>0.5–16</td>
</tr>
<tr>
<td>Netaglenide</td>
<td>180–360</td>
</tr>
<tr>
<td>α-Glucosidase inhibitor</td>
<td></td>
</tr>
<tr>
<td>Acarbose</td>
<td>25–300</td>
</tr>
<tr>
<td>Miglitol</td>
<td>25–300</td>
</tr>
<tr>
<td>Thiazolidinedione</td>
<td></td>
</tr>
<tr>
<td>Rosiglitazone</td>
<td>2–8</td>
</tr>
<tr>
<td>Pioglitazone</td>
<td>15–45</td>
</tr>
<tr>
<td>DPP-IV inhibitor</td>
<td></td>
</tr>
<tr>
<td>Sitagliptin</td>
<td>100</td>
</tr>
</tbody>
</table>

The morbidity and mortality of DM-related complications can be greatly reduced by timely and consistent surveillance procedures (Table 182-4). A routine urinalysis may be performed as an initial screen for diabetic nephropathy. If it is positive for protein, quantification of protein on a 24-h urine collection should be performed. If the urinalysis is negative for protein, a spot collection for microalbuminuria should be performed (present if 30–300 μg/mg creatinine on two of three tests within a 3- to 6-month period). A resting ECG should be performed in adults, with more extensive cardiac testing for high-risk pts. Therapeutic goals to prevent complications of DM include management of proteinuria with ACE inhibitor therapy, bp control (<130/80 mmHg if no proteinuria, <125/75 if proteinuria), and dyslipidemia manage-
ment [LDL < 2.6 mmol/L (<100 mg/dL) HDL > 1.1 mmol/L (>40 mg/dL) in men and >1.38 mmol/L (50 mg/dL) in women, triglycerides < 1.7 mmol/L (<150 mg/dL)]. In addition, any diabetic over 40 yrs should take a statin, regardless of the LDL cholesterol, and in those with existing cardiovascular disease, the LDL target should be <1.8 mmol/L (70 mg/dL).

**MANAGEMENT OF THE HOSPITALIZED PATIENT**

The goals of diabetes management during hospitalization are near-normal glycemic control, avoidance of hypoglycemia, and transition back to the outpatient setting.

**TABLE 182-4 GUIDELINES FOR ONGOING MEDICAL CARE FOR PATIENTS WITH DIABETES**

- Self-monitoring of blood glucose (individualized frequency)
- HbA1c testing (2–4 times/year)
- Patient education in diabetes management (annual)
- Medical nutrition therapy and education (annual)
- Eye examination (annual)
- Foot examination (1–2 times/year by physician; daily by patient)
- Screening for diabetic nephropathy (annual urine microalbumin)
- Blood pressure measurement (quarterly)
- Lipid profile and serum creatinine (annual)
- Influenza/pneumococcal immunizations
- Consider antiplatelet therapy
diabetes treatment regimen. Pts with type 1 DM undergoing general anesthesia and surgery, or with serious illness, should receive continuous insulin, either through an IV insulin infusion or by SC administration of a reduced dose of long-acting insulin. Short-acting insulin alone is insufficient to prevent the onset of diabetic ketoacidosis. Oral hypoglycemic agents should be discontinued in pts with type 2 DM at the time of hospitalization. Either regular insulin infusion (0.05–0.15 U/kg per hour) or a reduced dose (by 30–50%) of long-acting insulin and short-acting insulin (held, or reduced by 30–50%), with infusion of a solution of 5% dextrose, should be administered when pts are NPO for a procedure. A regimen of long- and short-acting SC insulin should be used in type 2 pts who are eating. Those with DM undergoing radiographic procedures with contrast dye should be well hydrated before and after dye exposure, and the serum creatinine should be monitored after the procedure.

For a more detailed discussion, see Powers AC: Diabetes Mellitus, Chap. 338, p. 2275, in HPIM-17.

Disorders of the Male Reproductive System

The testes produce sperm and testosterone. Inadequate production of sperm can occur in isolation or in the presence of androgen deficiency, which impairs spermatogenesis secondarily.

ANDROGEN DEFICIENCY

Etiology  Androgen deficiency can be due to either testicular failure (primary hypogonadism) or hypothalamic-pituitary defects (secondary hypogonadism). Primary hypogonadism is diagnosed when testosterone levels are low and gonadotropin levels [luteinizing hormone (LH) and follicle-stimulating hormone (FSH)] are high. Klinefelter’s syndrome is the most common cause and is due to the presence of one or more extra X chromosomes, usually a 47,XXY karyotype. Acquired primary testicular failure usually results from viral orchitis but may be due to trauma, cryptorchidism, radiation damage, or systemic diseases such as amyloidosis, Hodgkin’s disease, sickle cell disease, or granulomatous diseases. Testicular failure can occur as a part of a polyglandular autoimmune failure syndrome in which multiple primary endocrine deficiencies coexist. Malnutrition, AIDS, renal failure, liver disease, myotonic dystrophy, paraplegia, and toxins such as alcohol, marijuana, heroin, methadone, lead, and antineoplastic and chemotherapeutic agents can also cause testicular failure. Testosterone synthesis may be blocked by ketoconazole, and testosterone action may be diminished by competition at the androgen receptor by spironolactone and cimetidine.

Secondary hypogonadism is diagnosed when levels of both testosterone and gonadotropins are low (hypogonadotropic hypogonadism). Kallmann’s syn-
drome is due to impairment of the synthesis and/or release of gonadotropin-releasing hormone (GnRH) and is characterized by low levels of LH and FSH, and anosmia. Other individuals present with idiopathic congenital GnRH deficiency without anosmia. Critical illness, Cushing’s syndrome, adrenal hypoplasia congenita, hemochromatosis, and hyperprolactinemia (due to pituitary adenomas or drugs such as phenothiazines) are other causes of isolated hypogonadotropic hypogonadism. Destruction of the pituitary gland by tumors, infection, trauma, or metastatic disease causes hypogonadism in conjunction with disturbances in the production of other pituitary hormones (see Chap. 177).

**Clinical Features**  The history should focus on developmental stages such as puberty and growth spurts, as well as androgen-dependent events such as early morning erections, frequency and intensity of sexual thoughts, and frequency of masturbation or intercourse. The physical examination should focus on secondary sex characteristics such as hair growth in the face, axilla, chest, and pubic regions; gynecomastia; testicular volume; prostate; and height and body proportions. Eunuchoidal proportions are defined as an arm span >2 cm greater than height and suggest that androgen deficiency occurred prior to epiphyseal fusion. Normal testicular size ranges from 3.5–5.5 cm in length, which corresponds to a volume of 12–25 mL. The presence of varicocele should be sought by palpation of the testicular veins with the patient standing. Patients with Klinefelter’s syndrome have small (1–2 mL), firm testes.

A morning total testosterone level <6.93 nmol/L (<200 ng/dL), in association with symptoms, suggests testosterone deficiency. A level of >12.13 nmol/L (>350 ng/dL) makes the diagnosis of androgen deficiency unlikely. In men with testosterone levels between 6.93 and 12.13 nmol/L (200 and 350 ng/dL), the total testosterone level should be repeated and a free testosterone level should be measured. In older men and in patients with other clinical states that are associated with alterations in sex hormone–binding globulin levels, a direct measurement of free testosterone by equilibrium dialysis can be useful in unmasking testosterone deficiency. When androgen deficiency has been confirmed by low testosterone concentrations, LH should be measured to classify the patient as having primary (high LH) or secondary (low or inappropriately normal LH) hypogonadism. In men with primary hypogonadism of unknown cause, a karyotype should be performed to exclude Klinefelter’s syndrome. Measurement of a prolactin level and MRI scan of the hypothalamic-pituitary region should be considered in men with secondary hypogonadism. Gynecomastia in the absence of androgen deficiency should be further evaluated (Fig. 183-1).

**Treatment of hypogonadal men with androgens restores normal male secondary sexual characteristics (beard, body hair, external genitalia), male sexual drive, and masculine somatic development (hemoglobin, muscle mass). Administration of gradually increasing doses of testosterone is recommended for disorders in which hypogonadism occurred prior to puberty. Testosterone levels in the normal range may be achieved through daily application of transdermal testosterone patches (5–10 mg/d) or gel (50–100 mg/d) or parenteral administration of a long-acting testosterone ester (100–200 mg testosterone enanthate at 1- to 3-week intervals). Prostate cancer, severe symptoms of lower urinary tract obstruction, baseline hematocrit > 50%, severe sleep apnea, and class IV congestive heart failure are contraindications for androgen replacement.**
Male infertility plays a role in 25% of infertile couples (couples who fail to conceive after 1 year of unprotected intercourse). Known causes of male infertility include primary hypogonadism (30–40%), disorders of sperm transport (10–20%), and secondary hypogonadism (2%), with an unknown etiology in up to half of men with suspected male factor infertility (see Fig. 184-3). Impaired spermatogenesis occurs with testosterone deficiency but may also be present without testosterone deficiency. Y chromosome microdeletions and substitutions, viral orchitis, tuberculosis, STDs, radiation, chemotherapeutic agents, and environmental toxins have all been associated with isolated impaired spermatogenesis. Pro-

**MALE INFERTILITY**

**Etiology** Male infertility plays a role in 25% of infertile couples (couples who fail to conceive after 1 year of unprotected intercourse). Known causes of male infertility include primary hypogonadism (30–40%), disorders of sperm transport (10–20%), and secondary hypogonadism (2%), with an unknown etiology in up to half of men with suspected male factor infertility (see Fig. 184-3). Impaired spermatogenesis occurs with testosterone deficiency but may also be present without testosterone deficiency. Y chromosome microdeletions and substitutions, viral orchitis, tuberculosis, STDs, radiation, chemotherapeutic agents, and environmental toxins have all been associated with isolated impaired spermatogenesis. Pro-

**FIGURE 183-1** Evaluation of gynecomastia. T, testosterone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; hCGβ, human chorionic gonadotropin β; E2, 17β-estradiol.
longed elevations of testicular temperature, as in varicocele, cryptorchidism, or after an acute febrile illness, may impair spermatogenesis. Ejaculatory obstruction can be a congenital (cystic fibrosis, in utero diethylstilbestrol exposure, or idiopathic) or acquired (vasectomy, accidental ligation of the vas deferens, or obstruction of the epididymis) etiology of male infertility. Androgen abuse by male athletes can lead to testicular atrophy and a low sperm count.

**Clinical Features** Evidence of hypogonadism may be present. Testicular size and consistency may be abnormal, and a varicocele may be apparent on palpation. When the seminiferous tubules are damaged prior to puberty, the testes are small (usually <12 mL) and firm, whereas postpubertal damage causes the testes to be soft (the capsule, once enlarged, does not contract to its previous size). The key diagnostic test is a *semen analysis*. Sperm counts of <13 million/mL, motility of <32%, and <9% normal morphology are associated with subfertility. Testosterone levels should be measured if the sperm count is low on repeated exam or if there is clinical evidence of hypogonadism.

**Male Infertility**

Men with primary hypogonadism occasionally respond to androgen therapy if there is minimal damage to the seminiferous tubules, whereas those with secondary hypogonadism require gonadotropin therapy to achieve fertility. Fertility occurs in about half of men with varicocele who undergo surgical repair. In vitro fertilization is an option for men with mild to moderate defects in sperm quality; intracytoplasmic sperm injection (ICSI) has been a major advance for men with severe defects in sperm quality.

**ERECTILE DYSFUNCTION**

**Etiology** Erectile dysfunction (ED) is the failure to achieve erection, ejaculation, or both. It affects 10–25% of middle-aged and elderly men. ED may result from three basic mechanisms: (1) failure to initiate (psychogenic, endocrinologic, or neurogenic); (2) failure to fill (arteriogenic); or (3) failure to store adequate blood volume within the lacunar network (venoocclusive dysfunction). Diabetic, atherosclerotic, and drug-related causes account for >80% of cases of ED in older men. Among the antihypertensive agents, the thiazide diuretics and beta blockers have been implicated most frequently. Estrogens, GnRH agonists, H₂ antagonists, and spironolactone suppress gonadotropin production or block androgen action. Antidepressant and antipsychotic agents—particularly neuroleptics, tricyclics, and selective serotonin reuptake inhibitors—are associated with erectile, ejaculatory, orgasmic, and sexual desire difficulties. Recreational drugs, including ethanol, cocaine, and marijuana, may also cause ED. Any disorder that affects the sacral spinal cord or the autonomic fibers to the penis may lead to ED.

**Clinical Features** Men with sexual dysfunction may complain of loss of libido, inability to initiate or maintain an erection, ejaculatory failure, premature ejaculation, or inability to achieve orgasm. Initial questions should focus on the onset of symptoms, the presence and duration of partial erections, and the progression of ED. A history of nocturnal or early morning erections is useful for distinguishing physiologic from psychogenic ED. Relevant risk factors should be identified, such as diabetes mellitus, coronary artery disease, lipid disorders, hypertension, peripheral vascular disease, smoking, alcoholism, and endocrine or
neurologic disorders. The patient’s surgical history should be explored, with an emphasis on bowel, bladder, prostate, or vascular procedures. Evaluation includes a detailed general as well as genital physical exam. Penile abnormalities (Peyronie’s disease), testicular size, and gynecomastia should be noted. Peripheral pulses should be palpated, and bruits should be sought. Neurologic exam should assess anal sphincter tone, perineal sensation, and bulbocavernosus reflex. Serum testosterone and prolactin should be measured. Penile arteriography, electromyography, or penile Doppler ultrasound is occasionally performed.

Erectile Dysfunction

An approach to the evaluation and treatment of ED is summarized in Fig. 183-2. Correction of the underlying disorders or discontinuation of responsible medications should be attempted. Oral inhibitors of PDE-5 (sildenafil, tadalafil, and vardenafil) enhance erections after sexual stimulation, with an onset of approximately 60–120 min. They are contraindicated in men receiving any form of nitrate therapy and should be avoided in those with congestive heart failure. Vacuum constriction devices or injection of alprostadil into the urethra or corpora cavernosa may also be effective. The insertion of penile prosthesis is rarely indicated.
The pituitary hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), stimulate ovarian follicular development and result in ovulation at about day 14 of the 28-day menstrual cycle.

**Amenorrhea**

**Etiology** Amenorrhea refers to the absence of menstrual periods. It is classified as primary, if menstrual bleeding has never occurred by age 15 in the absence of hormonal treatment, or secondary, if menstrual periods are absent for >3 months in a woman with previous periodic menses. Pregnancy should be excluded in women of childbearing age with amenorrhea, even when history and physical exam are not suggestive. Oligoamenorrhea is defined as a cycle length of >35 days or <10 menses per year. Both the frequency and amount of bleeding are irregular in oligoamenorrhea. Frequent or heavy irregular bleeding is termed dysfunctional uterine bleeding if anatomic uterine lesions or a bleeding diathesis have been excluded.

The causes of primary and secondary amenorrhea overlap, and it is generally more useful to classify disorders of menstrual function into disorders of the uterus and outflow tract and disorders of ovulation (Fig. 184-1).
Anatomic defects of the outflow tract that prevent vaginal bleeding include absence of vagina or uterus, imperforate hymen, transverse vaginal septae, and cervical stenosis.

Women with amenorrhea and low FSH levels usually have hypogonadotropic hypogonadism due to disease of either the hypothalamus or the pituitary. Hypothalamic causes include Kallmann’s syndrome or Sheehan’s syndrome, hypothalamic lesions (craniopharyngiomas and other tumors, tuberculosis, sarcoidosis, metastatic tumors), hypothalamic trauma or irradiation, rigorous exercise, eating disorders, stressful events, and chronic debilitating diseases (end-stage renal disease, malignancy, malabsorption). Disorders of the pituitary can lead to amenorrhea by two mechanisms: direct interference with gonadotropin secretion or inhibition of gonadotropin secretion via excess prolactin (Chap. 177).

Women with amenorrhea and high FSH levels have ovarian failure, which may be due to Turner’s syndrome, pure gonadal dysgenesis, premature ovarian failure, the resistant-ovary syndrome, and chemotherapy or radiation therapy for malignancy. The diagnosis of premature ovarian failure is applied to women who cease menstruating before age 40.

**Polycystic ovarian syndrome (PCOS)** is characterized by the presence of clinical or biochemical hyperandrogenism (hirsutism, acne, male pattern baldness) in association with amenorrhea or oligomenorrhea. Metabolic changes, including insulin resistance, and infertility are often present; these features are worsened with coexistent obesity. Additional disorders with a similar presentation include excess androgen production from adrenal or ovarian tumors, adult-onset congenital adrenal hyperplasia, and thyroid disorders.

**Diagnosis**  The initial evaluation involves careful physical exam including assessment of hyperandrogenism, serum or urine human chorionic gonadotropin (hCG), and serum FSH levels (Fig. 184-1). Anatomic defects are usually diagnosed by physical exam, though hysterosalpingography or direct visual examination by hysteroscopy may be required. Chromosomal analysis should be performed when gonadal dysgenesis is suspected. The diagnosis of PCOS is based on the coexistence of chronic anovulation and androgen excess, after ruling out other etiologies for these features. The evaluation of hyperprolactinemia is described in Chap. 177. In the absence of a known etiology for hypogonadotropic hypogonadism, MRI of the pituitary-hypothalamic region should be performed when gonadotropins are low or inappropriately normal.

**Amenorrhea**

Disorders of the outflow tract are managed surgically. Decreased estrogen production, whether from ovarian failure or hypothalamic/pituitary disease, should be treated with cyclic estrogens, either in the form of oral contraceptives or conjugated estrogens (0.625–1.25 mg/d PO) and medroxyprogesterone acetate (2.5 mg/d PO or 5–10 mg during the last 5 days of the month). PCOS may be treated with medications to induce periodic withdrawal menses (medroxyprogesterone acetate 5–10 mg or promestrium 200 mg daily for 10–14 days of each month, or oral contraceptive agents) and weight reduction, along with treatment of hirsutism (see below). Individuals with PCOS may benefit from insulin-sensitizing drugs and should be screened for diabetes mellitus.

**PELVIC PAIN**

**Etiology**  Pelvic pain may be associated with normal or abnormal menstrual cycles and may originate in the pelvis or be referred from another region of
the body. A high index of suspicion must be entertained for extrapelvic disorders that refer to the pelvis, such as appendicitis, diverticulitis, cholecystitis, intestinal obstruction, and urinary tract infections. A thorough history including the type, location, radiation, and status with respect to increasing or decreasing severity can help to identify the cause of acute pelvic pain. Associations with vaginal bleeding, sexual activity, defecation, urination, movement, or eating should be sought. Determination of whether the pain is acute versus chronic and cyclic versus noncyclic will direct further investigation (Table 184-1).

**Acute Pelvic Pain** Pelvic inflammatory disease most commonly presents with bilateral lower abdominal pain. Unilateral pain suggests adnexal pathology from rupture, bleeding, or torsion of ovarian cysts, or, less commonly, neoplasms of the ovary, fallopian tubes, or paraovarian areas. Ectopic pregnancy is associated with right- or left-sided lower abdominal pain, vaginal bleeding, and menstrual cycle abnormalities, with clinical signs appearing 6–8 weeks after the last normal menstrual period. Orthostatic signs and fever may be present. Uterine pathology includes endometritis and degenerating leiomyomas.

**Chronic Pelvic Pain** Many women experience lower abdominal discomfort with ovulation (*mittelschmerz*), characterized as a dull, aching pain at midcycle that lasts minutes to hours. In addition, ovulatory women may experience somatic symptoms during the few days prior to menses, including edema, breast engorgement, and abdominal bloating or discomfort. A symptom complex of cyclic irritability, depression, and lethargy is known as *premenstrual syndrome* (PMS). Severe or incapacitating cramping with ovulatory menses in the absence of demonstrable disorders of the pelvis is termed *primary dysmenorrhea*. Secondary dysmenorrhea is caused by underlying pelvic pathology such as endometriosis, adenomyosis, or cervical stenosis.

**Diagnosis** Evaluation includes a history, pelvic exam, hCG measurement, tests for chlamydial and gonococcal infections, and pelvic ultrasound. Laparoscopy or laparotomy is indicated in some cases of pelvic pain of undetermined cause.

<table>
<thead>
<tr>
<th>TABLE 184-1 CAUSES OF PELVIC PAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute</strong></td>
</tr>
<tr>
<td>Cyclic pelvic pain</td>
</tr>
<tr>
<td>Pelvic inflammatory disease</td>
</tr>
<tr>
<td>Ruptured or hemorrhagic ovarian</td>
</tr>
<tr>
<td>cyst or ovarian torsion</td>
</tr>
<tr>
<td>Ectopic pregnancy</td>
</tr>
<tr>
<td>Endometritis</td>
</tr>
<tr>
<td>Acute growth or degeneration of</td>
</tr>
<tr>
<td>uterine myoma</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
Primary dysmenorrhea is best treated with NSAIDs or oral contraceptive agents. Infections should be treated with the appropriate antibiotics. Symptoms from PMS may improve with selective serotonin reuptake inhibitor (SSRI) therapy. The majority of unruptured ectopic pregnancies are treated with methotrexate. Surgery may be required for structural abnormalities.

**HIRSUTISM**

**Etiology**  *Hirsutism*, defined as excessive male-pattern hair growth, affects ~10% of women. It may be familial or caused by PCOS, ovarian or adrenal neoplasms, congenital adrenal hyperplasia, Cushing’s syndrome, hyperprolactinemia, acromegaly, pregnancy, and drugs (androgens, oral contraceptives containing androgenic progestins). Other drugs, such as minoxidil, phenytoin, diazoxide, and cyclosporine, can cause excessive growth of non-androgen-dependent vellus hair, leading to hypertrichosis.

**Clinical Features** An objective clinical assessment of hair distribution and quantity is central to the evaluation. A commonly used method to grade hair growth is the Ferriman-Gallwey score (see Fig. 50-1, p. 302, in HPIM-17). Associated manifestations of androgen excess include acne and male-pattern balding (androgenic alopecia). *Virilization*, on the other hand, refers to the state in which androgen levels are sufficiently high to cause deepening of the voice, breast atrophy, increased muscle bulk, clitoromegaly, and increased libido. Historic elements include menstrual history and the age of onset, rate of progression, and distribution of hair growth. Sudden development of hirsutism, rapid progression, and virilization suggest an ovarian or adrenal neoplasm.

**Diagnosis** An approach to testing for androgen excess is depicted in Fig. 184-2. PCOS is a relatively common cause of hirsutism. The dexamethasone androgen-suppression test (0.5 mg PO every 6 h × 4 days, with free testosterone levels obtained before and after administration of dexamethasone) may distinguish ovarian from adrenal overproduction. Incomplete suppression suggests ovarian androgen excess. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency can be excluded by a 17-hydroxyprogesterone level that is <6 nmol/L (<2 μg/L) either in the morning during the follicular phase or 1 h after administration of 250 μg of cosyntropin. CT may localize an adrenal mass, and ultrasound will identify an ovarian mass, if evaluation suggests these possibilities.

**Hirsutism**

Nonpharmacologic treatments include (1) bleaching; (2) depilatory such as shaving and chemical treatments; and (3) epilatory such as plucking, waxing, electrolysis, and laser therapy. Pharmacologic therapy includes oral contraceptives with a low androgenic progestin and spironolactone (100–200 mg/d PO), often in combination. Glucocorticoids (dexamethasone, 0.25–0.5 mg at bedtime, or prednisone, 5–10 mg at bedtime) are the mainstay of treatment in pts with congenital adrenal hyperplasia. Attenuation of hair growth with pharmacologic therapy is typically not evident until 6 months after initiation of medical treatment and therefore should be used in conjunction with nonpharmacologic treatments.
Menopause

**Etiology**  
*Menopause* is defined as the final episode of menstrual bleeding and occurs at a median age of 51 years. It is the consequence of depletion of ovarian follicles or of oophorectomy. The onset of *perimenopause*, when fertility wanes and menstrual irregularity increases, precedes the final menses by 2–8 years.

**Clinical Features**  
The most common menopausal symptoms are vasomotor instability (hot flashes and night sweats), mood changes (nervousness, anxiety, irritability, and depression), insomnia, and atrophy of the urogenital epithelium and skin. FSH levels are elevated to ≥40 IU/L with estradiol levels that are <30 pg/mL.

---

**Menopause**

During the perimenopause, low-dose combined oral contraceptives may be of benefit. The rational use of postmenopausal hormone therapy requires balancing the potential benefits and risks. Short-term therapy (<5 years) may be beneficial in controlling symptoms of menopause, as long as no contraindications exist. These include unexplained vaginal bleeding, active liver disease, venous thromboembolism, history of endometrial cancer (except stage I with-
CHAPTER 184

Disorders of the Female Reproductive System

out deep invasion), breast cancer, preexisting cardiovascular disease, and diabetes. Hypertriglyceridemia (>400 mg/dL) and active gallbladder disease are relative contraindications. Alternative therapies for symptoms include venlafaxine, fluoxetine, paroxetine, gabapentin, clonidine, vitamin E, or soy-based products. Vaginal estradiol tablets may be used for genitourinary symptoms. Long-term therapy (≥5 years) should be carefully considered, particularly in light of alternative therapies for osteoporosis (bisphosphonates, raloxifene) and of the risks of venous thromboembolism and breast cancer. Estrogens should be given in the minimal effective doses (conjugated estrogen, 0.625 mg/d PO; micronized estradiol, 1.0 mg/d PO; or transdermal estradiol, 0.05–1.0 mg once or twice a week). Women with an intact uterus should be given estrogen in combination with a progestin (medroxyprogesterone either cyclically, 5–10 mg/d PO for days 15–25 each month, or continuously, 2.5 mg/d PO) to avoid the increased risk of endometrial carcinoma seen with unopposed estrogen use.

CONTRACEPTION

The most widely used methods for fertility control include (1) barrier methods, (2) oral contraceptives, (3) intrauterine devices, (4) long-acting progestins, (5) sterilization, and (6) abortion.

Oral contraceptive agents are widely used for both prevention of pregnancy and control of dysmenorrhea and anovulatory bleeding. Combination oral contraceptive agents contain synthetic estrogen (ethinyl estradiol or mestranol) and synthetic progestins. Low-dose norgestimate and third-generation progestins (desogestrel, gestodene, drospirenone) have a less androgenic profile; levonorgestrel appears to be the most androgenic of the progestins and should be avoided in pts with hyperandrogenic symptoms. The three major formulation types include fixed-dose estrogen-progestin, phasic estrogen-progestin, and progestin only.

Despite overall safety, oral contraceptive users are at risk for venous thromboembolism, hypertension, and cholelithiasis. Risks for myocardial infarction and stroke are increased with smoking and aging. Side effects, including breakthrough bleeding, amenorrhea, breast tenderness, and weight gain, are often responsive to a change in formulation.

Absolute contraindications to the use of oral contraceptives include previous thromboembolic disorders, cerebrovascular or coronary artery disease, carcinoma of the breasts or other estrogen-dependent neoplasia, liver disease, hypertriglyceridemia, heavy smoking with age over 35, undiagnosed uterine bleeding, or known or suspected pregnancy. Relative contraindications include hypertension and anticonvulsant drug therapy.

New methods include a weekly contraceptive patch, a monthly contraceptive injection, and a monthly vaginal ring. Long-term progestins may be administered in the form of Depo-Provera.

Emergency contraceptive pills, containing progestin only or estrogen and progestin, can be used within 72 h of unprotected intercourse for prevention of pregnancy. Both Plan B and Preven are emergency contraceptive kits specifically designed for postcoital contraception. In addition, certain oral contraceptive pills may be dosed within 72 h for emergency contraception (Ovral, 2 tabs, 12 h apart; Lo/Ovral, 4 tabs, 12 h apart). Side effects include nausea, vomiting, and breast soreness. Mifepristone (RU486) may also be used, with fewer side effects.
Etiology Infertility is defined as the inability to conceive after 12 months of unprotected sexual intercourse. The causes of infertility are outlined in Fig. 184-3. Male infertility is discussed in Chap. 183.

Clinical Features The initial evaluation includes discussion of the appropriate timing of intercourse, semen analysis in the male, confirmation of ovulation in the female, and, in the majority of situations, documentation of tubal patency in the female. Abnormalities in menstrual function constitute the most common cause of female infertility (Fig. 184-1). A history of regular, cyclic, predictable, spontaneous menses usually indicates ovulatory cycles, which may be confirmed by urinary ovulation predictor kits, basal body temperature graphs, or plasma progesterone measurements during the luteal phase of the cycle. An FSH level < 10 IU/mL on day 3 of the cycle predicts adequate ovarian oocyte reserve. Tubal disease can be evaluated by obtaining a hysterosalpingogram or by diagnostic laparoscopy. Endometriosis may be suggested by history and exam but is often clinically silent and can only be excluded definitively by laparoscopy.

Infertility The treatment of infertility should be tailored to the problems unique to each couple. Treatment options include expectant management, clomiphene citrate with or without intrauterine insemination (IUI), gonadotropins with or without IUI, and in vitro fertilization (IVF). In specific situations, surgery, pulsatile GnRH therapy, intracytoplasmic sperm injection (ICSI), or assisted reproductive technologies with donor egg or sperm may be required.

**FIGURE 184-3** Causes of infertility. FSH, follicle-stimulating hormone; LH, luteinizing hormone.
Hypercalcemia and Hypocalcemia

HYPERCALCEMIA

Hypercalcemia from any cause can result in fatigue, depression, mental confusion, anorexia, nausea, constipation, renal tubular defects, polyuria, a short QT interval, and arrhythmias. CNS and GI symptoms can occur at levels of serum calcium >2.9 mmol/L (>11.5 mg/dL), and nephrocalcinosis and impairment of renal function occur when serum calcium is >3.2 mmol/L (>13 mg/dL). Severe hypercalcemia, usually defined as >3.7 mmol/L (>15 mg/dL), can be a medical emergency, leading to coma and cardiac arrest.

Etiology

The regulation of the calcium homeostasis is depicted in Fig. 185-1. The causes of hypercalcemia are listed in Table 185-1. Hyperparathyroidism and malignancy account for 90% of cases.

Primary hyperparathyroidism is a generalized disorder of bone metabolism due to increased secretion of parathyroid hormone (PTH) by an adenoma (81%) or carcinoma (4%) in a single gland, or by parathyroid hyperplasia (15%). Familial hyperparathyroidism may be part of multiple endocrine neoplasia type 1 (MEN 1), which also includes pituitary and pancreatic islet tumors, or of MEN 2A, in which hyperparathyroidism occurs with pheochromocytoma and medullary carcinoma of the thyroid.

Hypercalcemia associated with malignancy is often severe and difficult to manage. Mechanisms for this include release of PTH-related protein (PTHrP) in lung, kidney, and squamous cell carcinoma; local bone destruction in myeloma and breast carcinoma; activation of lymphocytes leading to release of IL-1 and TNF in myeloma and lymphoma; or an increased synthesis of 1,25(OH)\(_2\)D in lymphoma.

Several other conditions have been associated with hypercalcemia. These include: sarcoidosis and other granulomatous diseases, which lead to increased synthesis of 1,25(OH)\(_2\)D; vitamin D intoxication from chronic ingestion of large vitamin doses (50–100 × physiologic requirements); lithium therapy, which results in hyperfunctioning of the parathyroid glands; and familial hypercalcemic hypercalciuria (FHH) due to autosomal dominant inheritance of a mutation in the calcium-sensing receptor, which results in inappropriate secretion of PTH and enhanced renal calcium resorption. Severe secondary hyperparathyroidism may also complicate end-stage renal disease. Progression to tertiary hyperthyroidism occurs when PTH hypersecretion becomes autonomous and is no longer responsive to medical therapy.
Clinical Features  Most pts with hyperparathyroidism are asymptomatic, even when the disease involves the kidneys and the skeletal system. Pts frequently have hypercalciuria and polyuria, and calcium can be deposited in the renal parenchyma or form calcium oxalate stones. The characteristic skeletal lesion is osteopenia or, rarely, the more severe disorder osteitis fibrosa cystica. Increased bone resorption primarily involves cortical rather than trabecular bone. Hypercalcemia may be intermittent or sustained, and serum phosphate is usually low but may be normal.

Diagnosis  Primary hyperparathyroidism is confirmed by demonstration of an inappropriately high PTH level for the degree of hypercalcemia. Hypercalciuria helps to distinguish this disorder from FHH, in which PTH levels are usually in the normal range and the urine calcium level is low. Levels of PTH are low in hypercalcemia of malignancy (Table 185-2).
Hypercalcemia and Hypocalcemia

CHAPTER 185

Hypercalcemia

The type of treatment is based on the severity of the hypercalcemia and the nature of the associated symptoms. Table 185-3 shows general recommendations that apply to therapy of severe hypercalcemia [levels of >3.2 mmol/L (>13 mg/dL)] from any cause.

TABLE 185-1 CLASSIFICATION OF CAUSES OF HYPERCALCEMIA

<table>
<thead>
<tr>
<th>I. Parathyroid-related</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Primary hyperparathyroidism</td>
</tr>
<tr>
<td>1. Solitary adenomas</td>
</tr>
<tr>
<td>2. Multiple endocrine neoplasia</td>
</tr>
<tr>
<td>B. Lithium therapy</td>
</tr>
<tr>
<td>C. Familial hypocalciuric hypercalcemia</td>
</tr>
<tr>
<td>II. Malignancy-related</td>
</tr>
<tr>
<td>A. Solid tumor with humoral mediation of hypercalcemia (lung, kidney)</td>
</tr>
<tr>
<td>B. Solid tumor with metastases (breast)</td>
</tr>
<tr>
<td>C. Hematologic malignancies (multiple myeloma, lymphoma, leukemia)</td>
</tr>
<tr>
<td>III. Vitamin D-related</td>
</tr>
<tr>
<td>A. Vitamin D intoxication</td>
</tr>
<tr>
<td>B. ↑ 1,25(OH)2D; sarcoidosis and other granulomatous diseases</td>
</tr>
<tr>
<td>C. Idiopathic hypercalcemia of infancy</td>
</tr>
<tr>
<td>IV. Associated with high bone turnover</td>
</tr>
<tr>
<td>A. Hyperthyroidism</td>
</tr>
<tr>
<td>B. Immobilization</td>
</tr>
<tr>
<td>C. Thiazides</td>
</tr>
<tr>
<td>D. Vitamin A intoxication</td>
</tr>
<tr>
<td>V. Associated with renal failure</td>
</tr>
<tr>
<td>A. Severe secondary hyperparathyroidism</td>
</tr>
<tr>
<td>B. Aluminum intoxication</td>
</tr>
<tr>
<td>C. Milk-alkali syndrome</td>
</tr>
</tbody>
</table>

Source: JT Potts Jr: HPIM-16, p. 2252.

TABLE 185-2 DIFFERENTIAL DIAGNOSIS OF HYPERCALCEMIA: LABORATORY CRITERIA

<table>
<thead>
<tr>
<th>Blooda</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ca</td>
</tr>
<tr>
<td>Primary hyperparathyroidism</td>
</tr>
<tr>
<td>Malignancy-associated hypercalcemia:</td>
</tr>
<tr>
<td>Humoral hypercalcemia</td>
</tr>
<tr>
<td>Local destruction (osteolytic metastases)</td>
</tr>
</tbody>
</table>

Symbols in parentheses refer to values rarely seen in the particular disease.
Note: P; inorganic phosphate; iPTH, immunoreactive parathyroid hormone.
Source: JT Potts Jr: HPIM-12, p. 1911.
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Onset of Action</th>
<th>Duration of Action</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydration with saline (≤6 L/d)</td>
<td>Hours</td>
<td>During infusion</td>
<td>Rehydrates; rapid action</td>
<td>Volume overload; electrolyte disturbance</td>
</tr>
<tr>
<td>Forced diuresis (furosemide q1–2h along with aggressive hydration)</td>
<td>Hours</td>
<td>During treatment</td>
<td>Rapid action</td>
<td>Monitoring required to avoid dehydration</td>
</tr>
<tr>
<td>Pamidronate 30–90 mg IV over 4 h</td>
<td>1–2 days</td>
<td>10–14 days</td>
<td>High potency; prolonged action</td>
<td>Fever in 20%</td>
</tr>
<tr>
<td>Zolendronate 4–8 mg IV over 15 min</td>
<td>1–2 days</td>
<td>&gt;3 weeks</td>
<td>High potency; prolonged action; rapid infusion</td>
<td>↓ Ca, ↓ phosphate, ↓ Mg</td>
</tr>
<tr>
<td>Calcitonin (2–8 U/kg SC 6–12 h)</td>
<td>Hours</td>
<td>1–2 days</td>
<td>Rapid onset</td>
<td>Minor: Fever; rare ↓ Ca, ↓ phosphate</td>
</tr>
<tr>
<td>Glucocorticoids (prednisone 10–25 mg PO qid)</td>
<td>Days</td>
<td>Days-weeks</td>
<td>Useful in myeloma, lymphoma, breast CA, sarcoid, vitamin D intox</td>
<td>Limited effect; tachyphylaxis</td>
</tr>
<tr>
<td>Dialysis</td>
<td>Hours</td>
<td>During use–2 days</td>
<td>Useful in renal failure; immediate effect</td>
<td>Effects limited to certain disorders; glucocorticoid side effects</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Complex procedure</td>
</tr>
</tbody>
</table>
In pts with severe primary hyperparathyroidism, surgical parathyroidectomy should be performed promptly. Asymptomatic disease may not require surgery; usual surgical indications include age <50, nephrolithiasis, urine Ca > 400 mg/d, reduced creatinine clearance, reduction in bone mass (T score < -2.5), or serum calcium > 0.25 mmol/L (>1 mg/dL) above the normal range. A minimally invasive approach may be used if preoperative localization via sestamibi scans with SPECT or neck ultrasound demonstrates a solitary adenoma and intraoperative PTH assays are available. Otherwise, neck exploration is required. Postoperative management requires close monitoring of calcium and phosphorus. Calcium supplementation is given for symptomatic hypocalcemia.

Hyperparathyroidism of malignancy is managed by treating the underlying tumor. Adequate hydration and parenteral bisphosphonates can be used to reduce calcium levels.

No therapy is recommended for FHH. Secondary hyperparathyroidism should be treated with phosphate restriction, the use of nonabsorbable antacids or sevelamer, and calcitriol. Tertiary hyperparathyroidism requires parathyroidectomy.

### HYPOCALCEMIA

Chronic hypocalcemia is less common than hypercalcemia but is usually symptomatic and requires treatment. Symptoms include peripheral and perioral paresthesia, muscle spasms, carpopedal spasm, laryngeal spasm, seizure, and respiratory arrest. Increased intracranial pressure and papilledema may occur with long-standing hypocalcemia, and other manifestations may include irritability, depression, psychosis, intestinal cramps, and chronic malabsorption. Chvostek’s and Trousseau’s signs are frequently positive, and the QT interval is prolonged. Both hypomagnesemia and alkalosis lower the threshold for tetany.

**Etiology**  
Transient hypocalcemia often occurs in critically ill pts with burns, sepsis, and acute renal failure; following transfusion with citrated blood; or with medications such as protamine and heparin. Hypoalbuminemia can reduce serum calcium below normal, although ionized calcium levels remain normal. A simplified correction is sometimes used to assess whether the serum calcium concentration is abnormal when serum proteins are low. The correction is to add 0.2 mmol/L (0.8 mg/dL) to the serum calcium level for every 10 g/L (1 g/dL) by which the serum albumin level is below 40 g/L (4.0 g/dL). Alkalosis increases calcium binding to proteins, and in this setting direct measurements of ionized calcium should be used.

The causes of hypocalcemia can be divided into those in which PTH is absent (hereditary or acquired hypoparathyroidism, hypomagnesemia), PTH is ineffective (chronic renal failure, vitamin D deficiency, intestinal malabsorption, pseudohypoparathyroidism), or PTH is overwhelmed (severe, acute hyperphosphatemia in tumor lysis, acute renal failure, or rhabdomyolysis; hungry bone syndrome postparathyroidectomy). The cause of hypocalcemia associated with acute pancreatitis is unclear.

**Hypocalcemia**

Symptomatic hypocalcemia may be treated with intravenous calcium gluconate (bolus of 1–2 g IV over 10–20 minutes followed by infusion of 10 ampules of 10% calcium gluconate diluted in 1 L D5W infused at 30–100 mL/h). Management of chronic hypocalcemia requires an oral calcium preparation,
usually with a vitamin D preparation (Chap. 186). Hypoparathyroidism requires administration of calcium (1–3 g/d) and calcitriol (0.25–1 μg/d), adjusted according to serum calcium levels and urinary excretion. Restoration of magnesium stores may be required to reverse hypocalcemia in the setting of severe hypomagnesemia.

**HYPOPHOSPHATEMIA**

Mild hypophosphatemia is not usually associated with clinical symptoms. In severe hypophosphatemia, pts may have muscle weakness, numbness, paresthesia, and confusion. Rhabdomyolysis may develop during rapidly progressive hypophosphatemia. Respiratory insufficiency can result from diaphragm muscle weakness.

**Etiology** The causes of hypophosphatemia include: decreased intestinal absorption (vitamin D deficiency, phosphorus-binding antacids, malabsorption); urinary losses (hyperparathyroidism, vitamin D deficiency, hyperglycemic states, X-linked hypophosphatemic rickets, oncogenic osteomalacia, alcoholism, or certain toxins); and shifts of phosphorus from extracellular to intracellular compartments (administration of insulin in diabetic ketoacidosis or by hyperalimentation or refeeding in a malnourished pt).

**Hypophosphatemia**

Mild hypophosphatemia can be replaced orally with milk, carbonated beverages, or Neutraphos or K-phos (up to 2 g/d in divided doses). For severe hypophosphatemia [0.5 mmol/L; (<1.5 mg/dL)], IV phosphate may be administered at initial doses of 0.4–0.8 mmol/kg of elemental phosphorus over 6 h. Hypocalcemia should be corrected first, and the dose reduced 50% in hypercalcemia. Serum calcium and phosphate levels should be measured every 6–12 h; a serum calcium × phosphate level >50 must be avoided.

**HYPERPHOSPHATEMIA**

In adults, hyperphosphatemia is defined as a level >1.8 mmol/L (>5.5 mg/dL). The most common causes are acute and chronic renal failure, but it may also be seen in hypoparathyroidism, vitamin D intoxication, acidosis, rhabdomyolysis, and hemolysis. In addition to treating the underlying disorder, dietary phosphorus intake should be limited. Oral aluminum phosphate binders or sevalamer may be used, and hemodialysis should be considered in severe cases.

**HYPOMAGNESEMIA**

Muscle weakness, prolonged PR and QT intervals, and cardiac arrhythmias are the most common manifestations of hypomagnesemia. Magnesium is important for effective PTH secretion as well as the renal and skeletal responsiveness to PTH. Therefore, hypomagnesemia is often associated with hypocalcemia.

**Etiology** Hypomagnesemia generally results from a derangement in renal or intestinal handling of magnesium and is classified as primary (hereditary) or secondary (acquired). Secondary causes are much more common, with renal losses being due to volume expansion, hypercalcemia, osmotic diuresis, loop diuretics,
alcohol, aminoglycosides, cisplatin, cyclosporine, and amphotericin B, and gastrointestinal losses most commonly resulting from vomiting and diarrhea.

**Hypomagnesemia**

For mild deficiency, oral replacement in divided doses totaling 20–30 mmol/d (40–60 meq/d) is effective, though diarrhea may result. Parenteral magnesium administration is usually needed for serum levels <0.5 mmol/L (<1.2 mg/dL), with a continuous infusion of magnesium chloride IV to deliver 50 mmol/d over a 24-h period (dose reduced by 50–75% in renal failure). Therapy may be required for several days. Other electrolyte disturbances should be treated simultaneously. Patients with associated seizures or acute arrhythmias can be given 1–2 g of magnesium sulfate IV over 5–10 min.

**HYPERMAGNESEMIA**

Hypermagnesemia is rare but can be seen in renal failure when pts are taking magnesium-containing antacids, laxatives, enemas, or infusions, or in acute rhabdomyolysis. The most readily detectable clinical sign of hypermagnesemia is the disappearance of deep tendon reflexes, but hypotension, paralysis of respiratory muscles, complete heart block, and cardiac arrest can occur. Treatment includes stopping the preparation, dialysis against a low magnesium bath, or, if associated with life-threatening complications, 100–200 mg of elemental calcium IV over 1–2 h.

For a more detailed discussion, see Bringhurst FR, Demay MB, Krane SM, Kronenberg HM: Bone and Mineral Metabolism in Health and Disease, Chap. 346, p. 2365; Khosla S: Hypercalcemia and Hypocalcemia, Chap. 47, p. 285-287; and Potts JT Jr: Diseases of the Parathyroid Gland and Other Hyper- and Hypocalcemic Disorders, Chap. 347, p. 2377, in HPIM-17.

**OSTEOPOROSIS**

Osteoporosis is defined as a reduction in bone mass (or density) or the presence of fragility fracture. It is defined operationally as a bone density that falls 2.5 SD below the mean for a young normal individual (a T-score of <–2.5). Those with a T-score of <1.0 have low bone density and are at increased risk for osteoporosis. The most common sites for osteoporosis-related fractures are the vertebrae, hip, and distal radius.

**Etiology** Low bone density may result from low peak bone mass or increased bone loss. Risk factors for an osteoporotic fracture are listed in Table 186-1.
and diseases associated with osteoporosis are listed in Table 186-2. Certain drugs, primarily glucocorticoids, cyclosporine, cytotoxic drugs, anticonvulsants, aluminum, and heparin, also have detrimental effects on the skeleton.

**Clinical Features**  Pts with multiple vertebral crush fractures may have height loss, kyphosis, and secondary pain from altered biomechanics of the back. Thoracic fractures can be associated with restrictive lung disease, whereas lumbar fractures are sometimes associated with abdominal symptoms or nerve compres-

---

**TABLE 186-1**  RISK FACTORS FOR OSTEOPOROSIS FRACTURE

<table>
<thead>
<tr>
<th>Nonmodifiable</th>
<th>Modifiable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal history of fracture as an</td>
<td>Estrogen deficiency</td>
</tr>
<tr>
<td>adult</td>
<td>Early menopause (&lt;45 years)</td>
</tr>
<tr>
<td>History of fracture in first-degree</td>
<td>Prolonged premenopausal</td>
</tr>
<tr>
<td>relative</td>
<td>amenorrhea (&gt;1 year)</td>
</tr>
<tr>
<td>Female sex</td>
<td>Low calcium intake</td>
</tr>
<tr>
<td>Advanced age</td>
<td>Alcoholism</td>
</tr>
<tr>
<td>Caucasian race</td>
<td>Impaired eyesight despite</td>
</tr>
<tr>
<td>Dementia</td>
<td>adequate correction</td>
</tr>
<tr>
<td>Potentially modifiable</td>
<td>Recurrent falls</td>
</tr>
<tr>
<td>Current cigarette smoking</td>
<td>Inadequate physical activity</td>
</tr>
<tr>
<td>Low body weight (&lt;58 kg (127 lb)]</td>
<td>Poor health/frailty</td>
</tr>
</tbody>
</table>

---

**TABLE 186-2**  DISEASES ASSOCIATED WITH AN INCREASED RISK OF GENERALIZED OSTEOPOROSIS IN ADULTS

<table>
<thead>
<tr>
<th>Hypogonadal states</th>
<th>Hematologic disorders/malignancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Turner’s syndrome</td>
<td>Multiple myeloma</td>
</tr>
<tr>
<td>Klinefelter’s syndrome</td>
<td>Lymphoma and leukemia</td>
</tr>
<tr>
<td>Anorexia nervosa</td>
<td>Malignancy-associated parathyroid hormone–related (PTHrP) production</td>
</tr>
<tr>
<td>Hypothalamic amenorrhea</td>
<td>Mastocytosis</td>
</tr>
<tr>
<td>Hyperprolactinemia</td>
<td>Hemophilia</td>
</tr>
<tr>
<td>Other primary or secondary</td>
<td>Thalassemia</td>
</tr>
<tr>
<td>hypogonadal states</td>
<td></td>
</tr>
<tr>
<td>Endocrine disorders</td>
<td></td>
</tr>
<tr>
<td>Cushing’s syndrome</td>
<td>Selected inherited disorders</td>
</tr>
<tr>
<td>Hyperparathyroidism</td>
<td>Osteogenesis imperfecta</td>
</tr>
<tr>
<td>Thyrotoxicosis</td>
<td>Marfan’s syndrome</td>
</tr>
<tr>
<td>Type 1 diabetes mellitus</td>
<td>Hemochromatosis</td>
</tr>
<tr>
<td>Acromegaly</td>
<td>Hypophosphatasia</td>
</tr>
<tr>
<td>Adrenal insufficiency</td>
<td>Glycogen storage diseases</td>
</tr>
<tr>
<td>Nutritional and gastrointestinal</td>
<td>Homocystinuria</td>
</tr>
<tr>
<td>disorders</td>
<td></td>
</tr>
<tr>
<td>Malnutrition</td>
<td>Ehlers-Danlos syndrome</td>
</tr>
<tr>
<td>Parenteral nutrition</td>
<td>Porphyria</td>
</tr>
<tr>
<td>Malabsorption syndromes</td>
<td>Menkes’ syndrome</td>
</tr>
<tr>
<td>Gastrectomy</td>
<td>Epidermolysis bullosa</td>
</tr>
<tr>
<td>Severe liver disease, especially</td>
<td>Other disorders</td>
</tr>
<tr>
<td>biliary cirrhosis</td>
<td>Immobilization</td>
</tr>
<tr>
<td>Pernicious anemia</td>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>Rheumatologic disorders</td>
<td>Pregnancy and lactation</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>Scoliosis</td>
</tr>
<tr>
<td>Ankylosing spondylitis</td>
<td>Multiple sclerosis</td>
</tr>
<tr>
<td></td>
<td>Sarcoidosis</td>
</tr>
<tr>
<td></td>
<td>Amyloidosis</td>
</tr>
</tbody>
</table>
Osteoporosis and Osteomalacia

CHAPTER 186

sion leading to sciatica. Dual-energy x-ray absorptiometry has become the standard for measuring bone density. The U.S. Preventive Health Services Task Force recommends that women aged 65 and older be screened routinely for osteoporosis, and at age 60 for women with increased risk. Criteria approved for Medicare reimbursement of bone mass measurement are summarized in Table 186-3. A general laboratory evaluation includes complete blood count, serum and 24-h urine calcium, 25(OH)D level, and renal and hepatic function tests. Further testing is based on clinical suspicion and may include thyroid-stimulating hormone (TSH), urinary free cortisol, parathyroid hormone (PTH), serum and urine electrophoresis, and testosterone levels (in men). Transglutaminase Ab testing may identify asymptomatic celiac disease. Markers of bone resorption (e.g., urine cross-linked N-telopeptide) may be helpful in detecting an early response to anti-resorptive therapy if measured prior to and 4–6 months after initiating therapy.

OSTEOPOROSIS

Treatment involves the management of acute fractures, modifying risk factors, and treating any underlying disorders that lead to reduced bone mass. Treatment decisions are based on an individual’s risk factors, but active treatment is generally recommended if the T-score is ≤2.5. Oral calcium (1–1.5 g/d of elemental calcium in divided doses), vitamin D (400–800 IU/d), exercise, and smoking cessation should be initiated in all patients with osteoporosis. Bisphosphonates (alendronate, 70 mg PO weekly; rispronate, 35 mg PO weekly; ibandronate, 150 mg PO monthly or 3 mg IV every 3 mo; zoledronic acid, 5 mg IV annually) augment bone density and decrease fracture rates. Oral bisphosphonates are poorly absorbed and should be taken in the morning on an empty stomach with 0.25 L (8 oz) of tap water. Estrogen decreases the rate of bone reabsorption, but therapy should be considered carefully in the context of increased risks of cardiovascular disease and breast cancer. Raloxifene (60 mg/d PO), a selective estrogen receptor modulator, increases bone density and decreases total and LDL cholesterol without stimulating endometrial hyperplasia, though it may precipitate hot flashes. PTH(1-34) induces bone formation and may be administered as a daily injection for a maximum of 2 years.

OSTEOMALACIA

Etiology Defective mineralization of the organic matrix of bone results in osteomalacia. Osteomalacia is caused by inadequate intake or malabsorption of vi-

---

**TABLE 186-3** | FDA-APPROVED INDICATIONS FOR BMD TESTS
---|---
Estrogen-deficient women at clinical risk of osteoporosis
Vertebral abnormalities on x-ray suggestive of osteoporosis (osteopenia, vertebral fracture)
Glucocorticoid treatment equivalent to ≥7.5 mg of prednisone, or duration of therapy >3 months
Primary hyperparathyroidism
Monitoring response to an FDA-approved medication for osteoporosis
Repeat BMD evaluations at >23-month intervals, or more frequently, if medically justified

*aCriteria adapted from the 1998 Bone Mass Measurement Act.
Note: BMD, bone mineral density.*
Vitamin D (chronic pancreatic insufficiency, gastrectomy, malabsorption) and disorders of vitamin D metabolism (anticonvulsant therapy, chronic renal failure).

**Clinical Features** Skeletal deformities may be overlooked until fractures occur after minimal trauma. Symptoms include diffuse skeletal pain and bony tenderness and may be subtle. Proximal muscle weakness may mimic primary muscle disorders. A decrease in bone density is usually associated with loss of trabeculae and thinning of the cortices. Characteristic x-ray findings are radiolucent bands (Looser’s zones or pseudofractures) ranging from a few millimeters to several centimeters in length, usually perpendicular to the surface of the femur, pelvis, and scapula. Changes in serum calcium, phosphorus, 25(OH)D, and 1,25(OH)2D levels vary depending on the cause. However, modest vitamin D deficiency leads to compensatory secondary hyperparathyroidism characterized by increased levels of PTH and alkaline phosphatase and relatively low levels of ionized calcium. 1,25-Dihydroxyvitamin D levels may be preserved, reflecting upregulation of 1α-hydroxylase activity.

### Osteomalacia

In osteomalacia due to vitamin D deficiency [serum 25(OH)D < 50 nmol/L (<20 ng/mL)], vitamin D2 (ergocalciferol) is given orally in doses of 50,000 IU weekly for 8 weeks, followed by maintenance therapy with 800 IU daily. Osteomalacia due to malabsorption requires larger doses of vitamin D (up to 100,000 IU/d or 250,000 IU IM biannually). In pts taking anticonvulsants, concurrent vitamin D should be administered in doses that maintain the serum calcium and 25(OH)D levels in the normal range. Calcitriol (0.25–0.5 μg/d PO) is effective in treating hypocalcemia or osteodystrophy caused by chronic renal failure. Vitamin D deficiency should always be repleted in conjunction with calcium supplementation (1.5–2.0 g of elemental calcium daily). Serum and urinary calcium measurements are efficacious for monitoring resolution of vitamin D deficiency, with a goal 24-h urinary calcium excretion of 100–250 mg/24 h.

For a more detailed discussion, see Bringhurst FR, Demay MB, Krane SM, Kronenberg HM: Bone and Mineral Metabolism in Health and Disease, Chap. 346, p. 2365; and Lindsay R, Cosman F: Osteoporosis, Chap. 333, p. 2397, in HPIM-17.

### Hypercholesterolemia and Hypertriglyceridemia

Hyperlipoproteinemia may be characterized by hypercholesterolemia, isolated hypertriglyceridemia, or both (Table 187-1). Diabetes mellitus, obesity, ethanol consumption, oral contraceptives, glucocorticoids, renal disease, hepatic disease, and hypothyroidism can cause secondary hyperlipoproteinemias or worsen underlying hyperlipoproteinemic states.

Standard lipoprotein analysis assesses total cholesterol, HDL, and triglycerides with a calculation of LDL levels using the equation: LDL = total choles-
<table>
<thead>
<tr>
<th>Lipid Phenotype</th>
<th>Plasma Lipid Levels, mmol/L (mg/dL)</th>
<th>Lipoproteins</th>
<th>Elevated</th>
<th>Phenotype</th>
<th>Clinical Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Isolated Hypercholesterolemia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Familial hypercholesterolemia</td>
<td>Heterozygotes: total chol = 7–13 (275–500)</td>
<td>LDL</td>
<td>IIa</td>
<td></td>
<td>Usually develop xanthomas in adulthood and vascular disease at 30–50 years</td>
</tr>
<tr>
<td></td>
<td>Homozygotes: total chol &gt; 13 (&gt;500)</td>
<td>LDL</td>
<td>IIa</td>
<td></td>
<td>Usually develop xanthomas and vascular disease in childhood</td>
</tr>
<tr>
<td>Familial defective apo B100</td>
<td>Heterozygotes: total chol = 7–13 (275–500)</td>
<td>LDL</td>
<td>IIa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polygenic hypercholesterolemia</td>
<td>Total chol = 6.5–9.0 (250–350)</td>
<td>LDL</td>
<td>IIa</td>
<td></td>
<td>Usually asymptomatic until vascular disease develops; no xanthomas</td>
</tr>
<tr>
<td><strong>Isolated Hypertriglyceridemia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Familial hypertriglyceridemia</td>
<td>TG = 2.8–8.5 (250–750) (plasma may be cloudy)</td>
<td>VLDL</td>
<td>IV</td>
<td></td>
<td>Asymptomatic; may be associated with increased risk of vascular disease</td>
</tr>
<tr>
<td>Familial lipoprotein lipase deficiency</td>
<td>TG &gt; 8.5 (&gt;750) (plasma may be milky)</td>
<td>Chylomicrons</td>
<td>I, V</td>
<td></td>
<td>May be asymptomatic; may be associated with pancreatitis, abdominal pain, hepatosplenomegaly</td>
</tr>
<tr>
<td>Familial apo CII deficiency</td>
<td>TG &gt; 8.5 (&gt;750) (plasma may be milky)</td>
<td>Chylomicrons</td>
<td>I, V</td>
<td></td>
<td>As above</td>
</tr>
<tr>
<td><strong>Hypertriglyceridemia and Hypercholesterolemia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined hyperlipidemia</td>
<td>TG = 2.8–8.5 (250–750)</td>
<td>VLDL, LDL</td>
<td>IIb</td>
<td></td>
<td>Usually asymptomatic until vascular disease develops; familial form may also present as isolated high TG or an isolated high LDL cholesterol</td>
</tr>
<tr>
<td></td>
<td>Total chol = 6.5–13.0 (250–500)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysbetalipoproteinemia</td>
<td>TG = 2.8–5.6 (250–500)</td>
<td>VLDL, IDL;</td>
<td>III</td>
<td></td>
<td>Usually asymptomatic until vascular disease develops; may have palmar or tuboeruptive xanthomas</td>
</tr>
<tr>
<td></td>
<td>Total chol = 6.5–13.0 (250–500)</td>
<td>LDL normal</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Total chol, the sum of free and esterified cholesterol; LDL, low-density lipoprotein; TG, triglycerides; VLDL, very low density lipoproteins; IDL, intermediate-density lipoprotein.  
**Source:** From HN Ginsberg, IJ Goldberg: HPIM-15, p. 2250.
terol HDL triglycerides/5. The LDL cholesterol concentration can be estimated using this method only if triglycerides are <4.0 mmol/L (<350 mg/dL). Both LDL and HDL cholesterol levels are temporarily decreased for several weeks after myocardial infarction or acute inflammatory states but can be accurately measured if blood is obtained within 8 h of the event.

**ISOLATED HYPERCHOLESTEROLEMIA**

Elevated levels of fasting plasma total cholesterol [>5.2 mmol/L (>200 mg/dL)] in the presence of normal levels of triglycerides are almost always associated with increased concentrations of plasma LDL cholesterol. A rare individual with markedly elevated HDL cholesterol may also have increased plasma total cholesterol levels. Elevations of LDL cholesterol can result from single-gene defects, polygenic disorders, or from the secondary effects of other disease states.

**FAMILIAL HYPERCHOLESTEROLEMIA (FH)**

FH is a codominant genetic disorder that is due to mutations in the gene for the LDL receptor. Plasma LDL levels are elevated at birth and remain so throughout life. In untreated heterozygous adults, total cholesterol levels range from 7.1–12.9 mmol/L (275–500 mg/dL). Plasma triglyceride levels are typically normal, and HDL cholesterol levels are normal or reduced. Heterozygotes, especially men, are prone to accelerated atherosclerosis and premature coronary artery disease (CAD). Tendon xanthomas (most commonly of the Achilles tendons and the extensor tendons of the knuckles), tuberous xanthomas (softer, painless nodules on the ankles and buttocks), and xanthelasmas (deposits on the eyelids) are common.

**FAMILIAL DEFECTIVE APO B-100**

This autosomal dominant disorder impairs the synthesis and/or function of apo B-100, thereby reducing the affinity for the LDL receptor, slowing LDL catabolism, and causing a phenocopy of FH.

**POLYGENIC HYPERCHOLESTEROLEMIA**

Most moderate hypercholesterolemia [<9.1 mmol/L (<350 mg/dL)] arises from an interaction of multiple genetic defects and environmental factors such as diet, age, and exercise. Plasma HDL and triglyceride levels are normal, and xanthomas are not present.

**Isolated Hypercholesterolemia**

An algorithm for the evaluation and treatment of hypercholesterolemia is displayed in Fig. 187-1. Therapy for all of these disorders includes restriction of dietary cholesterol and HMG-CoA reductase inhibitors. Cholesterol absorption inhibitors and bile acid sequestrants or nicotinic acid may also be required (Table 187-2).

**ISOLATED HYPERTRIGLYCERIDEMIA**

The diagnosis of hypertriglyceridemia is made by measuring plasma lipid levels after an overnight fast. Hypertriglyceridemia in adults is defined as a triglyceride level > 2.3 mmol/L (> 200 mg/dL). An isolated increase in plasma
Hypercholesterolemia and Hypertriglyceridemia

CHAPTER 187

FIGURE 187-1

Algorithms for the evaluation and treatment of hypercholesterolemia (A) and hypertriglyceridemia (B). Statin, HMG-CoA reductase inhibitor; Chol, cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; TSH, thyroid-stimulating hormone; CHD, coronary heart disease.

**Evaluation**
- Lipoprotein profile (Chol, TG, HDL, LDL)
- Risk factor assessment (family, personal history)

**Treatment**

A

- LDL ≥ 130 mg/dL
- Exclude secondary causes
  - Glucose, TSH
  - Liver and renal function tests

- Low risk (0 or 1 risk factors)
  - LDL ≥ 160 → Diet therapy
  - LDL ≥ 190 → Diet therapy + drug therapy

- High risk (existing CHD or atherosclerosis ≥ 2 risk factors and 10-y risk ≥ 20%, or diabetes mellitus)
  - LDL ≥ 100 → Diet therapy
  - Drug therapy

- Moderate risk (≥ 2 risk factors and 10-y risk 20%)
  - LDL ≥ 130 → Diet therapy + drug therapy
  - For 10-y risk 10–20%
  - LDL ≥ 130 → Diet therapy
  - LDL ≥ 160 → Drug therapy for 10-y risk < 10%

B

- History of eruptive xanthomas or abdominal pain (pancreatitis)
- Exercise, weight gain, estrogen treatment, alcohol intake, diabetes
- Lipoprotein profile, (Chol, TG, HDL, LDL)
- Blood sugar, TSH, liver and renal function tests
- Consider dysbetalipoproteinemia if LDL and TG
- Risk factor assessment (family, personal history)

**Treatment**

- Diet therapy and

- LDL ≥ 160 → Drug therapy for 10-y risk < 10%

- Lifestyle modification
  - Diet
  - Exercise
  - Reduce alcohol intake
  - Control diabetes, if present

- <2 risk factors → follow
- ≥ 2 risk factors

- High-dose statin
  - Add Chol absorption inhibitor, niacin, or fibrate if needed

- 200–500 mg/dL
  - without CHD

- 200–500 mg/dL
  - with CHD

- >500 mg/dL
  - Fibrin acid or fish oils
  - Add niacin if needed to lower TG < 500
<table>
<thead>
<tr>
<th>Drugs</th>
<th>Lipoprotein Class Affected</th>
<th>Common Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>HMG-CoA reductase inhibitors</td>
<td>↓ LDL 18–55%</td>
<td>Myalgias, arthralgias, ↑ transaminases,</td>
<td>Acute or chronic liver disease of myositis increased by impaired renal function</td>
</tr>
<tr>
<td>Lovastatin 20–80 mg/d</td>
<td>↓ TG 7–30%</td>
<td>dyspepsia</td>
<td>and in combination with a fibrate</td>
</tr>
<tr>
<td>Pravastatin 40–80 mg qhs</td>
<td>↑ HDL 5–15%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simvastatin 20–80 mg qhs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluvastatin 20–80 mg qhs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atorvastatin 10–80 mg qhs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosuvastatin 10–40 mg qhs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholesterol absorption inhibitors</td>
<td>↓ LDL 18%</td>
<td>↑ Transaminases</td>
<td></td>
</tr>
<tr>
<td>Ezetimibe 10 mg qd</td>
<td>↓ TG 8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bile acid sequestrant</td>
<td>↓ LDL 15–30%</td>
<td>Constipation, gastric discomfort, nausea</td>
<td>Biliary tract obstruction, gastric outlet obstruction</td>
</tr>
<tr>
<td>Cholestyramine 4–32 g qd</td>
<td>↑ TG 10%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colestipol 5–40 g qd</td>
<td>↑ HDL 3–5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colesevelam 3750–4375 mg qd</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicotinic acid</td>
<td>↓ LDL 5–25%</td>
<td>Flushing (may be relieved by aspirin),</td>
<td>Peptic ulcer disease, hepatic disease, gout</td>
</tr>
<tr>
<td></td>
<td>↓ TG 20–50%</td>
<td>hepatic dysfunction, nausea, diarrhea,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>↑ HDL 15–35%</td>
<td>glucose intolerance, hyperuricemia</td>
<td></td>
</tr>
<tr>
<td>Immediate release 100 mg tid,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gradual increase to 1 g tid</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sustained release 250 mg–1.5 g bid</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extended release 500 mg–2 g qhs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibric acid derivatives</td>
<td>↑ or ↓ LDL</td>
<td>↓ Absorption of other drugs</td>
<td>Hepatic or biliary disease, renal insufficiency associated with ↑ risk of myosi-</td>
</tr>
<tr>
<td>Gemfibrozil 600 mg bid</td>
<td>↑ TG 20–50%</td>
<td>↑ Gallstones, dyspepsia, hepatic dysfunc-</td>
<td>tis</td>
</tr>
<tr>
<td>Fenofibrate 145 mg qd</td>
<td>↑ HDL 10–20%</td>
<td>tion, myalgia</td>
<td></td>
</tr>
<tr>
<td>Fish oils 3–6 g qd</td>
<td>↓ TG 5–10%</td>
<td>Dyspepsia, diarrhea, fishy odor to breath</td>
<td></td>
</tr>
</tbody>
</table>

*Note: LDL, low-density lipoprotein; VLDL, very low density lipoprotein; TG, triglycerides; HDL, high-density lipoprotein; LPL, lipoprotein lipase; CPK, creative phosphokinase.*
triglycerides indicates that chylomicrons and/or very low density lipoprotein (VLDL) are increased. Plasma is usually clear when triglyceride levels are <4.5 mmol/L (<400 mg/dL) and cloudy when levels are higher due to VLDL (and/or chylomicron) particles becoming large enough to scatter light. When chylomicrons are present, a creamy layer floats to the top of plasma after refrigeration for several hours. Tendon xanthomas and xanthelasmas do not occur with isolated hypertriglyceridemia, but eruptive xanthomas (small orange-red papules) can appear on the trunk and extremities and lipemia retinalis (orange-yellow retinal vessels) may be seen when the triglyceride levels are >11.3 mmol/L (>1000 mg/dL). Pancreatitis is associated with these high concentrations.

**FAMILIAL HYPERTRIGLYCERIDEMIA**

In this autosomal dominant disorder, increased plasma VLDL causes elevated plasma triglyceride concentrations. Obesity, hyperglycemia, and hyperinsulinemia are characteristic, and diabetes mellitus, ethanol consumption, oral contraceptives, and hypothyroidism may exacerbate the condition. The diagnosis is suggested by the triad of elevated plasma triglycerides [2.8–11.3 mmol/L (250–1000 mg/dL)], normal or only mildly increased cholesterol levels [<6.5 mmol/L (<250 mg/dL)], and reduced plasma HDL. The identification of other first-degree relatives with hypertriglyceridemia is useful in making the diagnosis. Familial dysbetalipoproteinemia and familial combined hyperlipidemia should be ruled out, as these two conditions are associated with accelerated atherosclerosis.

**LIPOPROTEIN LIPASE DEFICIENCY**

This rare autosomal recessive disorder results from the absence or deficiency of lipoprotein lipase, which in turn impairs the metabolism of chylomicrons. Accumulation of chylomicrons in plasma causes recurrent bouts of pancreatitis, usually beginning in childhood, and hepatosplenomegaly is present. Accelerated atherosclerosis is not a feature.

**APO CII DEFICIENCY**

This rare autosomal recessive disorder is due to the absence of apo CII, an essential cofactor for lipoprotein lipase. As a result, chylomicrons and triglycerides accumulate and cause manifestations similar to those in lipoprotein lipase deficiency.

---

**Isolated Hypertriglyceridemia**

An algorithm for the evaluation and treatment of hypertriglyceridemia is displayed in Fig. 187-1. All pts with hypertriglyceridemia should be placed on a fat-free diet with fat-soluble vitamin supplementation. In those with familial hypertriglyceridemia, fibric acid derivatives should be administered if dietary measures fail (Table 187-2).

**HYPERCHOLESTEROLEMIA AND HYPERTRIGLYCERIDEMIA**

Elevations of both triglycerides and cholesterol are caused by elevations in both VLDL and LDL or in VLDL remnant particles.

**FAMILIAL COMBINED HYPERLIPIDEMIA (FCHL)**

This inherited disorder, present in 1/200 persons, can cause different lipoprotein abnormalities in affected individuals, including hypercholesterolemia (ele-
vated LDL), hypertriglyceridemia (elevated triglycerides and VLDL), or both. Atherosclerosis is accelerated. A mixed dyslipidemia [plasma triglycerides 2.3–9.0 mmol/L (200–800 mg/dL), cholesterol levels 5.2–10.3 mmol/L (200–400 mg/dL) and HDL levels <10.3 mmol/L (<40 mg/dL) in men and <12.9 mmol/L (<50 mg/dL) in women] and a family history of hyperlipidemia and/or premature cardiovascular disease suggests the diagnosis of FCHL. Many of these patients also have the metabolic syndrome (Chap. 125). All pts should restrict dietary cholesterol and fat and avoid alcohol and oral contraceptives; patients with diabetes should be treated aggressively. An HMG-CoA reductase inhibitor is usually required, and many patients will require a second drug (cholesterol absorption inhibitor, niacin, or fibrate) for optimal control.

**DYSBETALIPOPROTEINEMIA**

This rare disorder is associated with homozygosity for apo E2, but the development of disease requires additional environmental and/or genetic factors. Plasma cholesterol [6.5–13.0 mmol/L (250–500 mg/dL)] and triglycerides [2.8–5.6 mmol/L (250–500 mg/dL)] are increased due to accumulation of VLDL and chylomicron remnant particles. Patients usually present in adulthood with xanthomas and premature coronary and peripheral vascular disease. Cutaneous xanthomas are distinctive, in the form of palmar and tuberoeruptive xanthomas. Triglycerides and cholesterol are both elevated. Diagnosis is established by lipoprotein electrophoresis or a ratio of VLDL (by centrifugation) to total plasma triglycerides of >0.3. If present, hypothyroidism and diabetes mellitus should be treated, dietary modifications should be instituted, and HMG-CoA reductase inhibitors, fibrates, and/or niacin may be necessary.

**PREVENTION OF THE COMPLICATIONS OF ATHEROSCLEROSIS**

The National Cholesterol Education Program guidelines (Fig. 187-1) are based on plasma LDL levels and estimations of other risk factors. The goal in pts with the highest risk (known coronary heart or other atherosclerotic disease, 10-year Framingham Heart Study risk for coronary heart disease >20%, or diabetes mellitus) is to lower LDL cholesterol to <2.6 mmol/L (<100 mg/dL). In pts with very high risk, clinical trials suggest additional benefit by reducing LDL cholesterol to <1.8 mmol/L (<70 mg/dL). The goal is an LDL cholesterol <3.4 mmol/L (<130 mg/dL) in pts with two or more risk factors for atherosclerotic heart disease and a 10-year absolute risk of 10–20%, though a treatment goal of <2.6 mmol/L (<100 mg/dL) can be considered. The intensity of LDL-lowering drug treatment in high- and moderately high-risk pts should achieve at least a 30% reduction in LDL levels. Risk factors include (1) men > age 45, women > age 55 or after menopause; (2) family history of early CAD (<55 years in a male parent or sibling and <65 years in a female parent or sibling); (3) hypertension (even if it is controlled with medications); (4) cigarette smoking (>10 cigarettes/day); and (5) HDL cholesterol < 1.0 mmol/L (<40 mg/dL). Therapy begins with a low-fat diet, but pharmacologic intervention is often required (Table 187-2).
Hemochromatosis, Porphyrias, and Wilson’s Disease

HEMOCHROMATOSIS

Hemochromatosis is a disorder of iron storage that results in increased intestinal iron absorption with Fe deposition and damage to many tissues. The classic clinical constellation of hemochromatosis is a patient presenting with bronze skin, diabetes, cardiac conduction abnormalities, and liver disease. Two major causes of hemochromatosis exist: hereditary (due to inheritance of mutant \( HFE \) genes) and secondary iron overload (usually the result of disordered erythropoiesis). Alcoholic liver disease and chronic excessive Fe ingestion may also be associated with a moderate increase in hepatic Fe and elevated body Fe stores.

Clinical Features Early symptoms include weakness, lassitude, weight loss, a bronze pigmentation or darkening of skin, abdominal pain, and loss of libido. Hepatomegaly occurs in 95% of pts, sometimes in the presence of normal LFTs. Other signs include spider angiomas, splenomegaly, arthropathy, ascites, cardiac arrhythmias, CHF, loss of body hair, palmar erythema, gynecomastia, and testicular atrophy. Diabetes mellitus occurs in about 65%, usually in pts with family history of diabetes. Adrenal insufficiency, hypothyroidism, and hypoparathyroidism rarely occur.

Diagnosis Serum Fe, percent transferrin saturation, and serum ferritin levels are increased. In an otherwise-healthy person, a fasting serum transferrin saturation > 50% is abnormal and suggests homozygosity for hemochromatosis. In most untreated pts with hemochromatosis, the serum ferritin level is also greatly increased. If either the percent transferrin saturation or the serum ferritin level is abnormal, genetic testing for hemochromatosis should be performed. All first-degree relatives of pts with hemochromatosis should be tested for the C282Y and H63D mutations. Liver biopsy may be required in affected individuals to evaluate possible cirrhosis or to quantify tissue iron. An algorithm for evaluating pts with possible hemochromatosis is shown in Fig. 188-1. Death in untreated pts results from cardiac failure (30%), cirrhosis (25%), and hepatocellular carcinoma (30%); the latter may develop despite adequate Fe removal.

Rx Hemochromatosis Therapy involves removal of excess body Fe, usually by intermittent phlebotomy, and supportive treatment of damaged organs. Since 1 unit of blood contains ~250 mg Fe, and since ≥25 g of Fe must be removed, phlebotomy is performed weekly for 1–2 years. Less frequent phlebotomy is then used to maintain serum Fe at <27 \( \mu \)mol/L (<150 \( \mu \)g/dL). Chelating agents such as deferoxamine (infused SC using a portable pump) remove 10–20 mg iron per day, a fraction of that mobilized by weekly phlebotomy. Chelation therapy is indicated, however, when phlebotomy is inappropriate, such as with anemia or hypoproteinemia. Alcohol consumption should be eliminated.
The porphyrias are inherited or acquired disturbances in heme biosynthesis. Each disorder causes a unique pattern of overproduction, accumulation, and excretion of intermediates of heme synthesis. These disorders are classified as either hepatic or erythropoietic, depending on the primary site of overproduction and accumulation of the porphyrin precursor or porphyrin. The major manifestations of the hepatic porphyrias are neurologic (neuropathic abdominal pain, neuropathy, and mental disturbances), whereas the erythropoietic porphyrias characteristically cause cutaneous photosensitivity. Laboratory testing is required to confirm or exclude the various types of porphyria. However, a definite diagnosis requires demonstration of the specific enzyme deficiency or gene defect.

**ACUTE INTERMITTENT PORPHYRIA**

This is an autosomal dominant disorder with variable expressivity. Manifestations include colicky abdominal pain, vomiting, constipation, port-wine colored urine, and neurologic and psychiatric disturbances. Acute attacks rarely occur before puberty and may last from days to months. Photosensitivity does not occur. Clinical and biochemical manifestations may be precipitated by barbiturates, anticonvulsants, estrogens, oral contraceptives, alcohol, or low-calorie diets. Diagnosis is
established by demonstrating elevation of urinary porphobilinogen (PBG) and γ-aminolevulinic acid (ALA) during an acute attack.

### Acute Intermittent Porphyria

As soon as possible after the onset of an attack, 3–4 mg of heme, in the form of heme arginate, heme albumin, or hematin, should be infused daily for 4 days. Administration of IV glucose at rates up to 20 g/h or parenteral nutrition, if oral feeding is not possible for long periods, can be effective in acute attacks. Narcotic analgesics may be required during acute attacks for abdominal pain, and phenothiazines are useful for nausea, vomiting, anxiety, and restlessness. Treatment between attacks involves adequate nutritional intake, avoidance of drugs known to exacerbate the disease, and prompt treatment of other intercurrent diseases or infections.

### PORPHYRIA CUTANEA TARDA

This is the most common porphyria and is characterized by cutaneous photosensitivity and, usually, hepatic disease. It is due to deficiency (inherited or acquired) of hepatic uroporphyrinogen decarboxylase. Photosensitivity causes facial pigmentation, increased fragility of skin, erythema, and vesicular and ulcerative lesions, typically involving face, forehead, and forearms. Neurologic manifestations are not observed. Contributing factors include excess alcohol, iron, and estrogens. Pts with liver disease are at risk for hepatocellular carcinoma. Plasma and urine uroporphyrin and 7-carboxylate porphyrin are increased.

### Porphyria Cutanea Tarda

Avoidance of precipitating factors, including abstinence from alcohol, estrogens, iron supplements, and other exacerbating drugs, is the first line of therapy. A complete response can almost always be achieved by repeated phlebotomy (every 1–2 weeks) until hepatic iron is reduced. Chloroquine or hydroxychloroquine may be used in low doses (e.g., 125 mg chloroquine phosphate twice weekly) to promote porphyrin excretion in pts unable to undergo or unresponsive to phlebotomy.

### ERYTHROPOIETIC PORPHYRIA

In erythropoietic porphyria, porphyrins from bone marrow erythrocytes and plasma are deposited in the skin and lead to cutaneous photosensitivity. Skin photosensitivity usually begins in childhood. The skin manifestations differ from those of other porphyrias, in that vesicular lesions are uncommon. Redness, swelling, burning, and itching can develop within minutes of sun exposure and resemble angioedema. Symptoms may seem out of proportion to the visible skin lesions. Chronic skin changes may include lichenification, leathery pseudovesicles, labial grooving, and nail changes. Liver function is usually normal, but liver disease and gallstones may occur. Protoporphyrin levels are increased in bone marrow, circulating erythrocytes, plasma, bile, and feces. Urinary levels are normal. Diagnosis is confirmed by identifying a mutation in the ferrochelatase gene.
**Erythropoietic Porphyria**

Oral β-carotene (120–180 mg/d) improves tolerance to sunlight in many patients. The dosage may be adjusted to maintain serum carotene levels between 10 and 15 μmol/L (600–800 μg/dL). Cholestyramine or activated charcoal may promote fecal excretion of protoporphyrin. Transfusions or intravenous heme therapy may be beneficial.

**Wilson’s Disease**

Wilson’s disease is an inherited disorder of copper metabolism, resulting in the toxic accumulation of copper in the liver, brain, and other organs. Individuals with Wilson’s disease have mutations in the ATP7B gene.

**Clinical Features**  
Hepatic disease may present as hepatitis, cirrhosis, or hepatic decompensation. In other pts, neurologic or psychiatric disturbances are the first clinical sign and are always accompanied by Kayser-Fleischer rings (corneal deposits of copper). Dystonia, incoordination, or tremor may be present, and dysarthria and dysphagia are common. Autonomic disturbances may also be present. Microscopic hematuria is common. In about 5% of pts, the first manifestation may be primary or secondary amenorrhea or repeated spontaneous abortions.

**Diagnosis**  
Serum ceruloplasmin levels are often low, and urine copper levels are elevated. The “gold standard” for diagnosis is an elevated copper level on liver biopsy.

**Wilson’s Disease**

Hepatitis or cirrhosis without decompensation should be treated with zinc (50 mg PO three times a day). For pts with hepatic decompensation, trientine (500 mg PO twice a day) plus zinc (separated by at least 1 h) is recommended, though liver transplantation should be considered for severe hepatic decompensation. For initial neurologic therapy, trientine and zinc are recommended for 8 weeks, followed by therapy with zinc alone. Tetrathiomolybdate is an alternative therapeutic option available in the future. Penicillamine is no longer first-line therapy. Zinc treatment does not require monitoring for toxicity, and 24-h urine copper can be followed for a therapeutic response. Trientine may induce bone marrow suppression and proteinuria, and free serum copper levels (adjusting total serum copper for ceruloplasmin copper) must be followed for a therapeutic response. Anticopper therapy must be lifelong.

For a more detailed discussion, see Powell LW: Hemochromatosis, Chap. 351, p. 2429; Desnick RJ and Astrin KH: The Porphyrias, Chap. 352, p. 2434; Brewer GJ: Wilson Disease, Chap. 354, p. 2449; in HPIM-17.
MENTAL STATUS EXAM

- The bare minimum: During the interview, look for difficulties with communication and determine whether the pt has recall and insight into recent and past events.

The goal of the mental status exam is to evaluate attention, orientation, memory, insight, judgment, and grasp of general information. Attention is tested by asking the pt to respond every time a specific item recurs in a list. Orientation is evaluated by asking about the day, date, and location. Memory can be tested by asking pt to immediately recall a sequence of numbers and by testing recall of a series of objects after defined times (e.g., 5 and 15 min). More remote memory is evaluated by assessing pt’s ability to provide a cogent chronologic history of the illness or personal life events. Recall of historic events or dates of current events can be used to assess knowledge. Evaluation of language function should include assessment of spontaneous speech, naming, repetition, reading, writing, and comprehension. Additional tests such as ability to draw

### TABLE 189-1 THE MINI-MENTAL STATUS EXAMINATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Orientation</strong></td>
<td></td>
</tr>
<tr>
<td>Name: season/date/month/year</td>
<td>5 (1 for each name)</td>
</tr>
<tr>
<td>Name: hospital floor/town/state/country</td>
<td>5 (1 for each name)</td>
</tr>
<tr>
<td><strong>Registration</strong></td>
<td></td>
</tr>
<tr>
<td>Identify three objects by name and ask patient to repeat</td>
<td>3 (1 for each object)</td>
</tr>
<tr>
<td><strong>Attention and calculation</strong></td>
<td></td>
</tr>
<tr>
<td>Serial 7s; subtract from 100 (e.g., 93–86–79–72–65)</td>
<td>5 (1 for each subtraction)</td>
</tr>
<tr>
<td>Recall of the three objects presented earlier</td>
<td>3 (1 for each object)</td>
</tr>
<tr>
<td><strong>Language</strong></td>
<td></td>
</tr>
<tr>
<td>Name pencil and watch</td>
<td>2 (1 for each object)</td>
</tr>
<tr>
<td>Repeat “No ifs, ands, or buts”</td>
<td>1</td>
</tr>
<tr>
<td>Follow a 3-step command (e.g., “Take this paper, fold it in half, and place it on the table”)</td>
<td>3 (1 for each command)</td>
</tr>
<tr>
<td>Write “close your eyes” and ask patient to obey written command</td>
<td>1</td>
</tr>
<tr>
<td>Ask patient to write a sentence</td>
<td>1</td>
</tr>
<tr>
<td>Ask patient to copy a design (e.g., intersecting pentagons)</td>
<td>1</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>30</td>
</tr>
</tbody>
</table>
and copy, perform calculations, interpret proverbs or logic problems, identify right vs. left, name and identify body parts, etc., are also important.

A useful screening examination of cognitive function is the mini-mental status examination (MMSE) (Table 189-1).

## CRANIAL NERVE (CN) EXAM

- **The bare minimum:** Check the fundi, visual fields, pupil size and reactivity, extraocular movements, and facial movements.

  **CN I** Occlude each nostril sequentially and ask pt to gently sniff and identify a mild test stimulus, such as soap, toothpaste, coffee, or lemon oil.

  **CN II** Check visual acuity with and without correction using a Snellen chart (distance) and Jaeger’s test type (near). Map visual fields (VFs) by confrontation testing in each quadrant of visual field for each eye individually. The best method is to sit facing pt (2–3 ft apart), have pt cover one eye gently and fix uncov-
A small white object (e.g., a cotton-tipped applicator) is then moved slowly from periphery of field toward center until seen. Pt’s VF should be mapped against examiner’s for comparison. Formal perimetry and tangent screen exam are essential to identify and delineate small defects. Optic fundi should be examined with an ophthalmoscope, and the color, size, and degree of swelling or elevation of the optic disc recorded. The retinal vessels should be checked for size, regularity, AV nicking at crossing points, hemorrhage, exudates, and aneurysms. The retina, including the macula, should be examined for abnormal pigmentation and other lesions.

**CNS III, IV, VI** Describe size, regularity, and shape of pupils; reaction (direct and consensual) to light; and convergence (pt follows an object as it moves closer). Check for lid drooping, lag, or retraction. Ask pt to follow your finger as you move it horizontally to left and right and vertically with each eye first fully adducted then fully abducted. Check for failure to move fully in particular directions and for presence of regular, rhythmic, involuntary oscillations of eyes.
(nystagmus). Test quick voluntary eye movements (saccades) as well as pursuit (e.g., follow the finger).

**CN V**  Feel the masseter and temporalis muscles as pt bites down and test jaw opening, protrusion, and lateral motion against resistance. Examine sensation over entire face as well as response to touching each cornea lightly with a small wisp of cotton.

**CN VII**  Look for asymmetry of face at rest and with spontaneous as well as emotion-induced (e.g., laughing) movements. Test eyebrow elevation, forehead...

*FIGURE 189-1*  Anterior view of dermatomes (left) and cutaneous areas (right) supplied by individual peripheral nerves. (Modified from MB Carpenter and J Sutin, in Human Neuroanatomy, 8th ed, Baltimore, Williams & Wilkins, 1983.)
The Neurologic Examination
CHAPTER 189

wrinkling, eye closure, smiling, frowning; check puff, whistle, lip pursing, and chin muscle contraction. Observe for differences in strength of lower and upper facial muscles. Taste on the anterior two-thirds of tongue can be affected by lesions of the seventh CN proximal to the chorda tympani. Test taste for sweet (sugar), salt, sour (lemon), and bitter (quinine) using a cotton-tipped applicator moistened in appropriate solution and placed on lateral margin of protruded tongue halfway back from tip.

CN VIII Check ability to hear tuning fork, finger rub, watch tick, and whispered voice at specified distances with each ear. Check for air vs. mastoid bone con-
duction (Rinne) and lateralization of a tuning fork placed on center of forehead (Weber). Accurate, quantitative testing of hearing requires formal audiometry. Remember to examine tympanic membranes.

**CNs IX, X** Check for symmetric elevation of palate-uvula with phonation (“ahh”), as well as position of uvula and palatal arch at rest. Sensation in region of tonsils, posterior pharynx, and tongue may also require testing. Pharyngeal (“gag”) reflex is evaluated by stimulating posterior pharyngeal wall on each side with a blunt object (e.g., tongue blade). Direct examination of vocal cords by laryngoscopy is necessary in some situations.

**CN XI** Check shoulder shrug (trapezius muscle) and head rotation to each side (sternocleidomastoid muscle) against resistance.

**CN XII** Examine bulk and power of tongue. Look for atrophy, deviation from midline with protrusion, tremor, and small flickering or twitching movements (fibrillations, fasciculations).

### MOTOR EXAM

- **The bare minimum:** Look for muscle atrophy and check limb tone. Assess upper limb strength by checking for pronator drift and strength of wrist or finger reflexes. Test for lower limb strength by asking pt to walk normally and on heels and toes.

Power should be systematically tested for major movements at each joint (Table 189-2). Strength should be recorded using a reproducible scale (e.g., 0 = no movement, 1 = flicker or trace of contraction with no associated movement at a joint, 2 = movement present but cannot be sustained against gravity, 3 = movement against gravity but not against applied resistance, 4 = movement against some degree of resistance, and 5 = full power; values can be supplemented with + and – signs to provide additional gradations). Speed of movement, ability to relax contractions promptly, and fatigue with repetition should all be noted. Loss in bulk and size of muscle (atrophy) should be noted, as well as the presence of irregular involuntary contraction (twitching) of groups of muscle fibers (fasciculations). Any involuntary movements should be noted at rest, during maintained posture, and with voluntary action.

### REFLEXES

- **The bare minimum:** Tap the biceps, patellar, and Achilles reflexes.

Important muscle-stretch reflexes to test routinely and the spinal cord segments involved in their reflex arcs include biceps (C5, 6); brachioradialis (C5, 6); triceps (C7, 8); patellar (L3, 4); and Achilles (S1, 2). A common grading scale is 0 = absent, 1 = present but diminished, 2 = normal, 3 = hyperactive, and 4 = hyperactive with clonus (repetitive rhythmic contractions with maintained stretch). The plantar reflex should be tested by using a blunt-ended object such as the point of a key to stroke the outer border of the sole of the foot from the heel toward the base of the great toe. An abnormal response (Babinski sign) is extension (dorsiflexion) of the great toe at the metatarsophalangeal joint. In some cases this may be associated with abduction (fanning) of other toes and variable degrees of flexion at ankle, knee, and hip. Normal response is plantar flexion of the toes. Superficial abdominal and anal reflexes are important in certain situations; unlike muscle stretch reflexes, these cutaneous reflexes disappear with CNS lesions.
The bare minimum: Ask whether the pt can feel light touch and the temperature of a cool object in each distal extremity. Check double simultaneous stimulation using light touch on the hands.

For most purposes it is sufficient to test sensation to pinprick, touch, position, and vibration in each of the four extremities (Figs. 189-1 and 189-2). Specific problems often require more thorough evaluation. Patients with cerebral lesions may have abnormalities in “discriminative sensation” such as the ability to perceive double simultaneous stimuli, to localize stimuli accurately, to identify closely approximated stimuli as separate (two-point discrimination), to identify objects by touch alone (stereognosis), or to judge weights, evaluate texture, or identify letters or numbers written on the skin surface (graphesthesia).
COORDINATION AND GAIT

• The bare minimum: Test rapid alternating movements of the fingers and feet, and the finger-to-nose maneuver. Observe the patient while he or she is walking along a straight line.

The ability to move the index finger accurately from the nose to the examiner’s outstretched finger and the ability to slide the heel of each foot from the knee down the shin are tests of coordination. Additional tests (drawing objects in the air, following a moving finger, tapping with index finger against thumb or alternately against each individual finger) may also be useful. The ability to stand with feet together and eyes closed (Romberg test), to walk a straight line (tandem walk), and to turn should all be observed.

THE NEUROLOGIC METHOD AND LOCALIZATION

The clinical data obtained from the neurologic examination coupled with a careful history are interpreted to arrive at an anatomic localization that best explains the clinical findings (Table 189-3) and to select the diagnostic tests most likely to be informative in order to define the pathophysiology of the anatomic lesion.

For a more detailed discussion, see Lowenstein DH, Martin JB, Hauser SL: Approach to the Patient with Neurologic Disease, Chap. 361, p. 2484, in HPIM-17

190 Neuroimaging

The clinician caring for pts with neurologic symptoms is faced with an expanding number of imaging options. MRI is more sensitive than CT for detection of many lesions affecting the nervous system, particularly those of the spinal cord, cranial nerves, and posterior fossa structures. Diffusion MR, a sequence that detects reduction of microscopic motion of water, is the most sensitive technique for detecting acute ischemic stroke and is useful in the detection of encephalitis, abscesses, and prion diseases. CT, however, can be quickly obtained and is widely available, making it a pragmatic choice for initial evaluation of pts with suspected acute stroke (especially when coupled with CT angiography and perfusion CT), hemorrhage, and intracranial or spinal trauma. CT is also more sensitive than MRI for visualizing fine osseous detail and is indicated in the initial evaluation of conductive hearing loss as well as lesions affecting the skull base and calvarium. MRI and CT-myelography have replaced conventional myelography for evaluation of disease of the spinal cord and canal. An increasing number of interventional neuroradiologic techniques are available including embolization, coiling, and stenting of vascular structures as well as spine interventions such as discography, selective nerve root injection, and epidural injection. Conventional angiography is now reserved for patients in whom small-
vessel detail is essential for diagnosis or for whom interventional therapies are planned. Guidelines for initial selection of neuroimaging studies are shown in Table 190-1.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Recommended Technique</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hemorrhage</strong></td>
<td></td>
</tr>
<tr>
<td>Acute parenchymal</td>
<td>CT, MR</td>
</tr>
<tr>
<td>Subacute/chronic</td>
<td>MRI</td>
</tr>
<tr>
<td>Subarachnoid hemorrhage</td>
<td>CT, CTA, lumbar puncture → angiography</td>
</tr>
<tr>
<td><strong>Aneurysm</strong></td>
<td></td>
</tr>
<tr>
<td>Ischemic infarction</td>
<td></td>
</tr>
<tr>
<td>Hemorrhagic infarction</td>
<td>CT or MRI</td>
</tr>
<tr>
<td>Bland infarction</td>
<td>MRI &gt; CT, CTA, angiography</td>
</tr>
<tr>
<td>Carotid or vertebral dissection</td>
<td>MRI/MRA</td>
</tr>
<tr>
<td>Vertebral basilar insufficiency</td>
<td>CTA, MRI/MRA</td>
</tr>
<tr>
<td>Carotid stenosis</td>
<td>CTA &gt; Doppler ultrasound, MRA</td>
</tr>
<tr>
<td><strong>Suspected mass lesion</strong></td>
<td></td>
</tr>
<tr>
<td>Neoplasm, primary or metastatic</td>
<td>MRI + contrast</td>
</tr>
<tr>
<td>Infection/abscess</td>
<td>MRI + contrast</td>
</tr>
<tr>
<td>Immunosuppressed with focal findings</td>
<td>MRI + contrast</td>
</tr>
<tr>
<td><strong>Vascular malformation</strong></td>
<td></td>
</tr>
<tr>
<td>White matter disorders</td>
<td>MRI</td>
</tr>
<tr>
<td>Demyelinating disease</td>
<td>MRI +/– contrast</td>
</tr>
<tr>
<td><strong>Dementia</strong></td>
<td></td>
</tr>
<tr>
<td>Trauma</td>
<td></td>
</tr>
<tr>
<td>Acute trauma</td>
<td>CT (noncontrast)</td>
</tr>
<tr>
<td>Shear injury/chronic hemorrhage</td>
<td>MRI</td>
</tr>
<tr>
<td><strong>Headache/migraine</strong></td>
<td></td>
</tr>
<tr>
<td>First time, no focal neurologic deficits</td>
<td>?CT as screen +/– contrast</td>
</tr>
<tr>
<td>Partial complex/refractory</td>
<td>MRI with coronal T2W imaging</td>
</tr>
<tr>
<td><strong>Seizure</strong></td>
<td></td>
</tr>
<tr>
<td>Cranial neuropathy</td>
<td>MRI with contrast</td>
</tr>
<tr>
<td>Meningeal disease</td>
<td>MRI with contrast</td>
</tr>
<tr>
<td><strong>Spine</strong></td>
<td></td>
</tr>
<tr>
<td>Low back pain</td>
<td></td>
</tr>
<tr>
<td>No neurologic deficits</td>
<td>MRI or CT after 4 weeks</td>
</tr>
<tr>
<td>With focal deficits</td>
<td>MRI &gt; CT</td>
</tr>
<tr>
<td>Spinal stenosis</td>
<td>MRI or CT</td>
</tr>
<tr>
<td>Cervical spondylosis</td>
<td>MRI or CT myelography</td>
</tr>
<tr>
<td>Infection</td>
<td>MRI + contrast, CT</td>
</tr>
<tr>
<td>Myelopathy</td>
<td>MRI + contrast/myelography</td>
</tr>
<tr>
<td>Arteriovenous malformation</td>
<td>MRI, myelography/angiography</td>
</tr>
</tbody>
</table>

*Note: MRA, MR angiography; CTA, CT angiography; T2W, T2-weighted.*

For a more detailed discussion, see Dillon WP: Neuroimaging in Neurologic Disorders, Chap. 362, p. 2489, in HPIM-17.
A seizure is a paroxysmal event due to abnormal, excessive, hypersynchronous discharges from an aggregate of CNS neurons. Epilepsy is diagnosed when there are recurrent seizures due to a chronic, underlying process.

**Seizure Classification**
This is essential for diagnosis, therapy, and prognosis (Table 191-1). Seizures are partial (or focal) or generalized: partial seizures originate in a localized area of cortex and generalized seizures involve diffuse regions of the brain in a bilaterally symmetric fashion. Simple-partial seizures do not affect consciousness and may have motor, sensory, autonomic, or psychic symptoms. Complex-partial seizures include alteration in consciousness coupled with automatisms (e.g., lip smacking, chewing, aimless walking, or other complex motor activities).

Generalized seizures may occur as a primary disorder or result from secondary generalization of a partial seizure. Tonic-clonic seizures (grand mal) cause sudden loss of consciousness, loss of postural control, tonic muscular contraction producing teeth-clenching and rigidity in extension (tonic phase), followed by rhythmic muscular jerking (clonic phase). Tongue-biting and incontinence may occur during the seizure. Recovery of consciousness is typically gradual over many minutes to hours. Headache and confusion are common postictal phenomena. In absence seizures (petit mal) there is sudden, brief impairment of consciousness without loss of postural control. Events rarely last longer than 5–10 s but can recur many times per day. Minor motor symptoms are common, while complex automatisms and clonic activity are not. Other types of generalized seizures include tonic, atonic, and myoclonic seizures.

**Etiology**
Seizure type and age of pt provide important clues to etiology (Table 191-2).
Seizures and Epilepsy

CHAPTER 191

CLINICAL EVALUATION

Careful history is essential since diagnosis of seizures and epilepsy is often based solely on clinical grounds. Differential diagnosis (Table 191-3) includes syncope or psychogenic seizures (pseudoseizures). General exam includes search for infection, trauma, toxins, systemic illness, neurocutaneous abnormalities, and vascular disease. A number of drugs lower the seizure threshold (Table 191-4). Asymmetries in neurologic exam suggest brain tumor, stroke, trauma, or other focal lesions. An algorithmic approach is shown in Fig. 191-1.

LABORATORY EVALUATION

Routine blood studies are indicated to identify the more common metabolic causes of seizures such as abnormalities in electrolytes, glucose, calcium, or magnesium, and hepatic or renal disease. A screen for toxins in blood and urine should be obtained. A lumbar puncture is indicated if there is any suspicion of CNS infection such as meningitis or encephalitis; it is mandatory in HIV-infected patients even in the absence of symptoms or signs suggesting infection.

TABLE 191-2 CAUSES OF SEIZURES

<table>
<thead>
<tr>
<th>Neonates (&lt;1 month)</th>
<th>Perinatal hypoxia and ischemia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intracranial hemorrhage and trauma</td>
</tr>
<tr>
<td></td>
<td>Acute CNS infection</td>
</tr>
<tr>
<td></td>
<td>Metabolic disturbances (hypoglycemia, hypocalemia, hypomagnesemia, pyridoxine deficiency)</td>
</tr>
<tr>
<td></td>
<td>Drug withdrawal</td>
</tr>
<tr>
<td></td>
<td>Developmental disorders</td>
</tr>
<tr>
<td></td>
<td>Genetic disorders</td>
</tr>
<tr>
<td>Infants and children (&gt;1 mo and &lt;12 years)</td>
<td>Febrile seizures</td>
</tr>
<tr>
<td></td>
<td>Genetic disorders (metabolic, degenerative, primary epilepsy syndromes)</td>
</tr>
<tr>
<td></td>
<td>CNS infection</td>
</tr>
<tr>
<td></td>
<td>Developmental disorders</td>
</tr>
<tr>
<td></td>
<td>Trauma</td>
</tr>
<tr>
<td></td>
<td>Idiopathic</td>
</tr>
<tr>
<td>Adolescents (12–18 years)</td>
<td>Trauma</td>
</tr>
<tr>
<td></td>
<td>Genetic disorders</td>
</tr>
<tr>
<td></td>
<td>Infection</td>
</tr>
<tr>
<td></td>
<td>Brain tumor</td>
</tr>
<tr>
<td></td>
<td>Illicit drug use</td>
</tr>
<tr>
<td></td>
<td>Idiopathic</td>
</tr>
<tr>
<td>Young adults (18–35 years)</td>
<td>Trauma</td>
</tr>
<tr>
<td></td>
<td>Alcohol withdrawal</td>
</tr>
<tr>
<td></td>
<td>Illicit drug use</td>
</tr>
<tr>
<td></td>
<td>Brain tumor</td>
</tr>
<tr>
<td></td>
<td>Idiopathic</td>
</tr>
<tr>
<td>Older adults (&gt;35 years)</td>
<td>Cerebrovascular disease</td>
</tr>
<tr>
<td></td>
<td>Brain tumor</td>
</tr>
<tr>
<td></td>
<td>Alcohol withdrawal</td>
</tr>
<tr>
<td></td>
<td>Metabolic disorders (uremia, hepatic failure, electrolyte abnormalities, hypoglycemia)</td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease and other degenerative CNS diseases</td>
</tr>
<tr>
<td></td>
<td>Idiopathic</td>
</tr>
</tbody>
</table>

Note: CNS, central nervous system.
All pts should be evaluated as soon as possible with an EEG, which measures electrical activity of the brain by recording from electrodes placed on the scalp. The presence of electrographic seizure activity during the clinically evident event, i.e., abnormal, repetitive, rhythmic activity, is diagnostic of seizure activity. Table 191-3 lists common causes of seizures and Table 191-4 lists drugs and other substances that can cause seizures.

**TABLE 191-3 DIFFERENTIAL DIAGNOSIS OF SEIZURES**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Electroencephalography (EEG)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Syncope</td>
<td>Transient ischemic attack (TIA)</td>
</tr>
<tr>
<td>Vasovagal syncope</td>
<td>Basilar artery TIA</td>
</tr>
<tr>
<td>Cardiac arrhythmia</td>
<td>Sleep disorders</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>Narcolepsy/cataplex</td>
</tr>
<tr>
<td>Cardiac failure</td>
<td>Benign sleep myoclonus</td>
</tr>
<tr>
<td>Orthostatic hypotension</td>
<td>Movement disorders</td>
</tr>
<tr>
<td>Psychological disorders</td>
<td>Tics</td>
</tr>
<tr>
<td>Psychogenic seizure</td>
<td>Nonepileptic myoclonus</td>
</tr>
<tr>
<td>Hyperventilation</td>
<td>Paroxysmal choreoathetosis</td>
</tr>
<tr>
<td>Panic attack</td>
<td>Special considerations in children</td>
</tr>
<tr>
<td>Metabolic disturbances</td>
<td>Breath-holding spells</td>
</tr>
<tr>
<td>Alcoholic blackouts</td>
<td>Migraine with recurrent abdominal pain and cyclic vomiting</td>
</tr>
<tr>
<td>Delirium tremens</td>
<td>Benign paroxysmal vertigo</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>Apnea</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>Night terrors</td>
</tr>
<tr>
<td>Psychoactive drugs (e.g.,</td>
<td>Sleepwalking</td>
</tr>
<tr>
<td>hallucinogens)</td>
<td></td>
</tr>
<tr>
<td>Migraine</td>
<td></td>
</tr>
<tr>
<td>Confusional migraine</td>
<td></td>
</tr>
<tr>
<td>Basilar migraine</td>
<td></td>
</tr>
</tbody>
</table>

**TABLE 191-4 DRUGS AND OTHER SUBSTANCES THAT CAN CAUSE SEIZURES**

<table>
<thead>
<tr>
<th>Category</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkylating agents (e.g., busulfan, chlorambucil)</td>
<td>Psychotropics</td>
</tr>
<tr>
<td>Antimalarials (chloroquine, mefloquine)</td>
<td>Antidepressants</td>
</tr>
<tr>
<td>Antimicrobials/antivirals</td>
<td>Antipsychotics</td>
</tr>
<tr>
<td>β-Lactam and related compounds</td>
<td>Lithium</td>
</tr>
<tr>
<td>Quinolones</td>
<td>Radiographic contrast agents</td>
</tr>
<tr>
<td>Acyclovir</td>
<td>Theophylline</td>
</tr>
<tr>
<td>Isoniazid</td>
<td>Sedative-hypnotic drug withdrawal</td>
</tr>
<tr>
<td>Ganciclovir</td>
<td>Alcohol</td>
</tr>
<tr>
<td>Anesthetics and analgesics</td>
<td>Barbiturates (short-acting)</td>
</tr>
<tr>
<td>Meperidine</td>
<td>Benzodiazepines (short-acting)</td>
</tr>
<tr>
<td>Tramadol</td>
<td>Drugs of abuse</td>
</tr>
<tr>
<td>Local anesthetics</td>
<td>Amphetamine</td>
</tr>
<tr>
<td>Dietary supplements</td>
<td>Cocaine</td>
</tr>
<tr>
<td>Ephedra (ma huang)</td>
<td>Phencyclidine</td>
</tr>
<tr>
<td>Ginsko</td>
<td>Methylphenidate</td>
</tr>
<tr>
<td>Immunomodulatory drugs</td>
<td>Flumazenil*</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td></td>
</tr>
<tr>
<td>OKT3 (monoclonal antibodies to T cells)</td>
<td></td>
</tr>
<tr>
<td>Tacrolimus</td>
<td></td>
</tr>
<tr>
<td>Interferons</td>
<td></td>
</tr>
</tbody>
</table>

*In benzodiazepine-dependent patients.*
having an abrupt onset and termination, establishes the diagnosis. The absence of electrographic seizure activity does not exclude a seizure disorder, however. The EEG is always abnormal during generalized tonic-clonic seizures. Continuous monitoring for prolonged periods may be required to capture the EEG abnormalities. The EEG can show abnormal discharges during the interictal period that support the diagnosis of epilepsy, and is useful for classifying seizure disorders and determining prognosis.
<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Principal Uses</th>
<th>Typical Dosage and Dosing Intervals</th>
<th>Half-Life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenytoin (diphenylhydantoin)</td>
<td>Dilantin</td>
<td>Tonic-clonic (grand mal) Focal-onset</td>
<td>300–400 mg/d (3–6 mg/kg, adult; 4–8 mg/kg, child) qd-bid</td>
<td>24 h (wide variation, dose-dependent)</td>
</tr>
<tr>
<td>Carbonazepine</td>
<td>Tegretol</td>
<td>Tonic-clonic Focal-onset</td>
<td>600–1800 mg/d (15–35 mg/kg, child) bid-qid</td>
<td>10–17 h</td>
</tr>
<tr>
<td>Valproic acid</td>
<td>Depakene</td>
<td>Tonic-clonic Absence</td>
<td>750–2000 mg/d (20–60 mg/kg) bid-qid</td>
<td>15 h</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>Lamictal</td>
<td>Focal-onset Tonic-clonic</td>
<td>150–500 mg/d bid</td>
<td>25 h (with enzyme-inducers)</td>
</tr>
<tr>
<td>Ethosuximide</td>
<td>Zarontin</td>
<td>Absence (petit mal)</td>
<td>750–1250 mg/d (20–40 mg/kg) qd-bid</td>
<td>60 h, adult 30 h, child</td>
</tr>
<tr>
<td>Topiramate</td>
<td>Topamax</td>
<td>Focal-onset Tonic-clonic</td>
<td>200–400 mg/d; bid</td>
<td>20–30 h</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>Trileptal</td>
<td>Focal-onset</td>
<td>900–2400 mg/d (30–45 mg/kg, child) bid</td>
<td>10–17 h (for active metabolite)</td>
</tr>
</tbody>
</table>

*Phenytoin, carbamazepine, phenobarbital.*
<table>
<thead>
<tr>
<th>Therapeutic Range</th>
<th>Neurologic</th>
<th>Systemic</th>
<th>Drug Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>10–20 μg/mL</td>
<td>Dizziness</td>
<td>Gum hyperplasia</td>
<td>Level increased by isoniazid, sulfonamides, fluoxetine</td>
</tr>
<tr>
<td></td>
<td>Diplopia</td>
<td>Lymphadenopathy</td>
<td>Level decreased by enzyme-inducing drugs&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Ataxia</td>
<td>Hirsutism</td>
<td>Altered folate metabolism</td>
</tr>
<tr>
<td></td>
<td>Incoordination</td>
<td>Osteomalacia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Confusion</td>
<td>Facial coarsening</td>
<td></td>
</tr>
<tr>
<td>6–12 μg/μL</td>
<td>Ataxia</td>
<td>Aplastic anemia</td>
<td>Level decreased by enzyme-inducing drugs&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>Leukopenia</td>
<td>Level increased by erythromycin proponxyphene, isoniazid, cimetidine, fluoxetine</td>
</tr>
<tr>
<td></td>
<td>Diplopia</td>
<td>Gastrointestinal irritation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vertigo</td>
<td>Hepatotoxicity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hyponatremia</td>
<td></td>
</tr>
<tr>
<td>50–150 μg/μL</td>
<td>Ataxia</td>
<td>Hepatotoxicity</td>
<td>Level decreased by enzyme-inducing drugs&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Sedation</td>
<td>Thrombocytopenia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tremor</td>
<td>Gastrointestinal irritation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weight gain</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transient alopecia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hyperammonemia</td>
<td></td>
</tr>
<tr>
<td>Not established</td>
<td>Dizziness</td>
<td>Skin rash</td>
<td>Level decreased by enzyme-inducing drugs&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Diplopia</td>
<td>Stevens-Johnson syndrome</td>
<td>Level increased by valproic acid</td>
</tr>
<tr>
<td></td>
<td>Sedation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ataxia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40–100 μg/μL</td>
<td>Ataxia</td>
<td>Gastrointestinal irritation</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Lethargy</td>
<td>Skin rash</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>Bone marrow suppression</td>
<td></td>
</tr>
<tr>
<td>Not established</td>
<td>Psychomotor slowing</td>
<td>Renal stones (avoid use with other carbonic anhydrase inhibitors)</td>
<td>Level decreased by enzyme-inducing drugs&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Sedation</td>
<td>Speech or language problems</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speech or language problems</td>
<td>Glaucoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fatigue</td>
<td>Weight loss</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paresthesias</td>
<td>Hypohydrosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fatigue</td>
<td>See carbamazepine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ataxia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diplopia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vertigo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> May increase phenytoin.
All patients with unexplained new-onset seizures should have a brain imaging study (MRI or CT) to search for an underlying structural abnormality; the only exception may be children who have an unambiguous history and examination suggestive of a benign, generalized seizure disorder such as absence epilepsy. Newer MRI methods, such as fluid-attenuated inversion recovery (FLAIR), have increased the sensitivity for detection of abnormalities of cortical architecture, including hippocampal atrophy associated with mesial temporal sclerosis, and abnormalities of neuronal migration.

Seizures and Epilepsy

Acutely, the pt should be placed in semiprone position with head to the side to avoid aspiration. Tongue blades or other objects should not be forced between clenched teeth. Oxygen should be given via face mask. Reversible metabolic disorders (e.g., hypoglycemia, hyponatremia, hypocalcemia, drug or alcohol withdrawal) should be promptly corrected. Treatment of status epilepticus is discussed in Chap. 23.

Longer-term therapy includes treatment of underlying conditions, avoidance of precipitating factors, prophylactic therapy with antiepileptic medications or surgery, and addressing various psychological and social issues. Choice of antiepileptic drug therapy depends on a variety of factors including seizure type, dosing schedule, and potential side effects (Tables 191-5 and 191-6). Therapeutic goal is complete cessation of seizures without side effects using a single drug (monotherapy) and a dosing schedule that is easy for the pt to follow. If ineffective, medication should be increased to maximal tolerated dose based primarily on clinical response rather than serum levels. If unsuccessful, a second drug should be added, and when control is obtained, the first drug can be slowly tapered. Some pts will require polytherapy with two

<table>
<thead>
<tr>
<th>Primary Generalized Tonic-Clonic</th>
<th>Partial&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Absence</th>
<th>Atypical Absence, Myoclonic, Atonic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valproic acid</td>
<td>Carbamazepine</td>
<td>Valproic acid</td>
<td>Valproic acid</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>Phenytoin</td>
<td>Ethosuximide</td>
<td>Lamotrigine</td>
</tr>
<tr>
<td>Topiramate</td>
<td>Lamotrigine</td>
<td></td>
<td>Topiramate</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>Oxcarbazepine</td>
<td></td>
<td>Oxcarbazepine</td>
</tr>
<tr>
<td>Valproic acid</td>
<td>Valproic acid</td>
<td></td>
<td>Valproic acid</td>
</tr>
</tbody>
</table>

**Alternatives**

<table>
<thead>
<tr>
<th>Zonisamide&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Levetiracetam&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Lamotrigine</th>
<th>Clonazepam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenytoin</td>
<td>Topiramate</td>
<td>Clonazepam</td>
<td></td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>Tiagabine&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Lamotrigine</td>
<td>Felbamate</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>Zonisamide&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Oxcarbazepine</td>
<td></td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>Gabapentin&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Topiramate</td>
<td>Felbamate</td>
</tr>
<tr>
<td>Primidone</td>
<td>Primidone</td>
<td>Clonazepam</td>
<td></td>
</tr>
<tr>
<td>Felbamate</td>
<td>Felbamate</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>Includes simple partial, complex partial, and secondarily generalized seizures.

<sup>b</sup>As adjunctive therapy.
or more drugs, although monotherapy should be the goal. Pts with certain epilepsy syndromes (e.g., temporal lobe epilepsy) are often refractory to medical therapy and benefit from surgical excision of the seizure focus.

For a more detailed discussion, see Lowenstein DH: Seizures and Epilepsy, Chap. 363, p. 2498, in HPIM-17.

192 Alzheimer’s Disease and Other Dementias

DEMENTIA

Dementia is an acquired deterioration in cognitive ability that impairs the successful performance of activities of daily living. Memory is the most common cognitive ability lost with dementia; 10% of persons over age 70 and 20–40% of individuals over age 85 have clinically identifiable memory loss. Other mental faculties are also affected in dementia, such as language, visuospatial ability, calculation, judgment, and problem solving. Neuropsychiatric and social deficits develop in many dementia syndromes, resulting in depression, withdrawal, hallucinations, delusions, agitation, insomnia, and disinhibition. Dementia is chronic and usually progressive.

Diagnosis The mini-mental status examination (MMSE) is a useful screening test for dementia (Table 189-1). A score of <24 points (out of 30) indicates a need for more detailed cognitive and physical assessment. In some patients with early cognitive disorders, the MMSE may be normal and more detailed neuropsychologic testing will be required.

APPROACH TO THE PATIENT WITH DEMENTIA

Differential Diagnosis Dementia has many causes (Table 192-1). It is essential to exclude treatable etiologies; in one study, the most common potentially reversible diagnoses were depression, hydrocephalus, and alcohol dependence. The major degenerative dementias can usually be distinguished by distinctive symptoms, signs, and neuroimaging features (Table 192-2).

History A subacute onset of confusion may represent delirium and should trigger the search for intoxication, infection, or metabolic derangement (Chap. 17). An elderly person with slowly progressive memory loss over several years is likely to have Alzheimer’s disease (AD). A change in personality, disinhibition, gain of weight, or food obsession suggests frontotemporal dementia (FTD), not AD; apathy, loss of executive function, progressive abnormalities in speech, or relative sparing of memory also suggests FTD. Dementia with
### TABLE 192-1 DIFFERENTIAL DIAGNOSIS OF DEMENTIA

#### Most Common Causes of Dementia

<table>
<thead>
<tr>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s disease</td>
</tr>
<tr>
<td>Vascular dementia</td>
</tr>
<tr>
<td>Multi-infarct</td>
</tr>
<tr>
<td>Diffuse white matter disease</td>
</tr>
<tr>
<td>(Binswanger’s)</td>
</tr>
<tr>
<td>MUlti-infarct</td>
</tr>
<tr>
<td>Diffuse white matter disease</td>
</tr>
<tr>
<td>(Binswanger’s)</td>
</tr>
<tr>
<td>Alcoholism</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
</tr>
<tr>
<td>Drug/medication intoxication</td>
</tr>
</tbody>
</table>

#### Less Common Causes of Dementia

<table>
<thead>
<tr>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin deficiencies</td>
</tr>
<tr>
<td>Thiamine (B1): Wernicke’s encephalopathy</td>
</tr>
<tr>
<td>B12 (pernicious anemia)</td>
</tr>
<tr>
<td>Nicotinic acid (pellagra)</td>
</tr>
<tr>
<td>Endocrine and other organ failure</td>
</tr>
<tr>
<td>Hypothyroidism</td>
</tr>
<tr>
<td>Adrenal insufficiency and Cushing’s syndrome</td>
</tr>
<tr>
<td>Hypo- and hyperparathyroidism</td>
</tr>
<tr>
<td>Renal failure</td>
</tr>
<tr>
<td>Liver failure</td>
</tr>
<tr>
<td>Pulmonary failure</td>
</tr>
<tr>
<td>Chronic infections</td>
</tr>
<tr>
<td>HIV</td>
</tr>
<tr>
<td>Neurophils</td>
</tr>
<tr>
<td>Papovirus (progressive multifocal leukoencephalopathy)</td>
</tr>
<tr>
<td>Prion (Creutzfeldt-Jakob and Gerstmann-Sträussler-Scheinker diseases)</td>
</tr>
<tr>
<td>Tuberculosis, fungal, and protozoal disease</td>
</tr>
<tr>
<td>Whipple’s disease</td>
</tr>
<tr>
<td>Head trauma and diffuse brain damage</td>
</tr>
<tr>
<td>Dementia pugilistica</td>
</tr>
<tr>
<td>Chronic subdural hematoma</td>
</tr>
<tr>
<td>Postanoxia</td>
</tr>
<tr>
<td>Postencephalitis</td>
</tr>
<tr>
<td>Normal-pressure hydrocephalus</td>
</tr>
<tr>
<td>Neoplastic</td>
</tr>
<tr>
<td>Primary brain tumor</td>
</tr>
<tr>
<td>Metastatic brain tumor</td>
</tr>
<tr>
<td>Paraneoplastic limbic encephalitis</td>
</tr>
</tbody>
</table>

#### Toxic disorders

<table>
<thead>
<tr>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug, medication, and narcotic poisoning</td>
</tr>
<tr>
<td>Heavy metal intoxication</td>
</tr>
<tr>
<td>Dialysis dementia (aluminum)</td>
</tr>
<tr>
<td>Organic toxins</td>
</tr>
</tbody>
</table>

#### Psychiatric

<table>
<thead>
<tr>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression (pseudodementia)</td>
</tr>
<tr>
<td>Schizophrenia</td>
</tr>
<tr>
<td>Conversion reaction</td>
</tr>
</tbody>
</table>

#### Degenerative disorders

<table>
<thead>
<tr>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huntington’s disease</td>
</tr>
<tr>
<td>Pick’s disease</td>
</tr>
<tr>
<td>Dementia with Lewy bodies</td>
</tr>
<tr>
<td>Progressive supranuclear palsy (Steel-Richardson syndrome)</td>
</tr>
<tr>
<td>Multisystem degeneration (Shy-Drager syndrome)</td>
</tr>
<tr>
<td>Hereditary ataxias (some forms)</td>
</tr>
<tr>
<td>Motor neuron disease [amyotrophic lateral sclerosis (ALS); some forms]</td>
</tr>
<tr>
<td>Frontotemporal dementia</td>
</tr>
<tr>
<td>Cortical basal degeneration</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
</tr>
<tr>
<td>Adult Down’s syndrome with Alzheimer’s</td>
</tr>
<tr>
<td>ALS–Parkinson’s–Dementia complex of Guam</td>
</tr>
</tbody>
</table>

#### Miscellaneous

<table>
<thead>
<tr>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarcoidosis</td>
</tr>
<tr>
<td>Vasculitis</td>
</tr>
<tr>
<td>CADASIL etc</td>
</tr>
<tr>
<td>Acute intermittent porphyria</td>
</tr>
<tr>
<td>Recurrent nonconvulsive seizures</td>
</tr>
<tr>
<td>Additional conditions in children or adolescents</td>
</tr>
<tr>
<td>Hallervorden-Spatz disease</td>
</tr>
<tr>
<td>Subacute sclerosing panencephalitis</td>
</tr>
<tr>
<td>Metabolic disorders (e.g., Wilson’s and Leigh’s diseases, leukodystrophies, lipid storage diseases, mitochondrial mutations)</td>
</tr>
</tbody>
</table>

*Note: Potentially reversible dementia.*
<table>
<thead>
<tr>
<th>Disease</th>
<th>First Symptom</th>
<th>Mental Status</th>
<th>Neuropsychiatry</th>
<th>Neurology</th>
<th>Imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD</td>
<td>Memory loss</td>
<td>Episodic memory loss</td>
<td>Initially normal</td>
<td>Initially normal</td>
<td>Entorhinal cortex and hippocampal atrophy</td>
</tr>
<tr>
<td>FTD</td>
<td>Apathy; poor judgment/in-sight, speech/language; hyperorality</td>
<td>Frontal/executive, language; spares drawing</td>
<td>Apathy, disinhibition, hyperorality, euphoria, depression</td>
<td>Due to PSP/CBD overlap; vertical gaze palsy, axial rigidity, dystonia, alien hand</td>
<td>Frontal and/or temporal atrophy; spares posterior parietal lobe</td>
</tr>
<tr>
<td>DLB</td>
<td>Visual hallucinations, REM sleep disorder, delirium, Capgras’ syndrome, parkinsonism</td>
<td>Drawing and frontal/executive; spares memory; delirium prone</td>
<td>Visual hallucinations, depression, sleep disorder, delusions</td>
<td>Parkinsonism</td>
<td>Posterior parietal atrophy; hippocampi larger than in AD</td>
</tr>
<tr>
<td>CJD</td>
<td>Dementia, mood, anxiety, movement disorders</td>
<td>Variable, frontal/executive, focal cortical, memory</td>
<td>Depression, anxiety</td>
<td>Myoclonus, rigidity, parkinsonism</td>
<td>Cortical ribboning and basal ganglia or thalamus hyper-intensity on diffusion/flare MRI</td>
</tr>
<tr>
<td>Vascular</td>
<td>Often but not always sudden; variable; apathy, falls, focal weakness</td>
<td>Frontal/executive, cognitive slowing; can spare memory</td>
<td>Apathy, delusions, anxiety</td>
<td>Usually motor slowing, spasticity; can be normal</td>
<td>Cortical and/or subcortical infarctions, confluent white matter disease</td>
</tr>
</tbody>
</table>

Note: AD, Alzheimer’s disease; FTD, frontotemporal dementia; PSP, progressive supranuclear palsy; CBD, cortical basal degeneration; DLB, dementia with Lewy bodies; CJD, Creutzfeldt-Jakob disease.
Lewy bodies (DLB) is suggested by the early presence of visual hallucinations, parkinsonism, delirium, or a sleep disorder. A history of stroke suggests vascular dementia, which may also occur with hypertension, atrial fibrillation, peripheral vascular disease, and diabetes. Rapid progression of dementia with myoclonus suggests a prion disease such as Creutzfeldt-Jakob disease. Gait disturbance is prominent with vascular dementia, Parkinson’s disease, or normal-pressure hydrocephalus. Multiple sex partners or intravenous drug use should trigger search for an infection, especially in persons with HIV. A history of head trauma could indicate chronic subdural hematoma, dementia pugilistica, or normal-pressure hydrocephalus. Alcoholism may suggest malnutrition and thiamine deficiency. A history of gastric surgery may result in loss of intrinsic factor and vitamin B12 deficiency. A careful review of medications, especially of sedatives and tranquilizers, may raise the issue of drug intoxication. A family history of dementia is found in Huntington’s disease, familial AD, or familial FTD. Insomnia or weight loss is often seen with pseudodementia due to depression, which can also be caused by the recent death of a loved one.

Examination
It is essential to document the dementia, look for other signs of nervous system involvement, and search for clues of a systemic disease that might be responsible for the cognitive disorder. AD does not affect motor systems until late in the course. In contrast, FTD patients often develop axial rigidity, supranuclear gaze palsy, or features of amyotrophic lateral sclerosis. In DLB, initial symptoms may be the new onset of a parkinsonian syndrome (resting tremor, cogwheel rigidity, bradykinesia, and festinating gait). Unexplained falls, axial rigidity, and gaze deficits suggest progressive supranuclear palsy (PSP).

Focal neurologic deficits may occur in vascular dementia or brain tumor. Dementia with a myelopathy and peripheral neuropathy suggests vitamin B12 deficiency. A peripheral neuropathy could also indicate an underlying vitamin deficiency or metal intoxication. Dry cool skin, hair loss, and bradycardia suggest hypothyroidism. Confusion associated with repetitive stereotyped movements may indicate ongoing seizure activity. Hearing impairment or visual loss may produce confusion and disorientation misinterpreted as dementia. Such sensory deficits are common in the elderly.

Choice of Diagnostic Studies
A reversible or treatable cause must not be missed, yet no single etiology is common; thus a screen must employ multiple tests, each of which has a low yield. Table 192-3 lists most screening tests for dementia. Guidelines recommend the routine measurement of thyroid function, a vitamin B12 level, and a neuroimaging study (CT or MRI). Lumbar puncture need not be done routinely but is indicated if infection is a consideration. An EEG is rarely helpful except to suggest a prion disease or an underlying nonconvulsive seizure disorder. Brain biopsy is not advised except to diagnose vasculitis, potentially treatable neoplasms, unusual infections, or systemic disorders such as sarcoid.

ALZHEIMER’S DISEASE
Most common cause of dementia; affects 4 million persons in the United States. Cost > $50 billion/year.
Clinical Manifestations  Pts present with subtle recent memory loss, then develop slowly progressive dementia with impairment spreading to language and visuospatial deficits. Memory loss is often not recognized initially, in part due to preservation of social graces until later phases; impaired activities of daily living (keeping track of finances, appointments) draw attention of friends/family. Disorientation, poor judgment, poor concentration, aphasia, and apraxia are increasingly evident as the disease progresses. Pts may be frustrated or unaware of deficit. In end-stage AD, pts become rigid, mute, incontinent, and bedridden. Help may be needed with the simplest tasks, such as eating, dressing, and toilet function. Often, death results from malnutrition, secondary infections, pulmonary emboli, or heart disease. Typical duration is 8–10 years, but the course can range from 1 to 25 years.

Pathogenesis  Risk factors for AD are old age, positive family history. Pathology: neuritic plaques composed in part of Aβ amyloid, derived from amyloid precursor protein (APP); neurofibrillary tangles composed of abnormally phosphorylated tau protein. The apolipoprotein E (apo E) ε4 allele accelerates age of

### TABLE 192-3  EVALUATION OF THE PATIENT WITH DEMENTIA

<table>
<thead>
<tr>
<th>Routine Evaluation</th>
<th>Optional Focused Tests</th>
<th>Occasionally Helpful Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>History</td>
<td>Psychometric testing</td>
<td>EEG</td>
</tr>
<tr>
<td>Physical examination</td>
<td>Chest x-ray</td>
<td>Parathyroid function</td>
</tr>
<tr>
<td>Laboratory tests</td>
<td>Lumbar puncture</td>
<td>Adrenal function</td>
</tr>
<tr>
<td>Thyroid function (TSH)</td>
<td>Liver function</td>
<td>Urine heavy metals</td>
</tr>
<tr>
<td>Vitamin B₁₂</td>
<td>Renal function</td>
<td>RBC sedimentation rate</td>
</tr>
<tr>
<td>Complete blood count</td>
<td>Urine toxin screen</td>
<td>Angiogram</td>
</tr>
<tr>
<td>Electrolytes</td>
<td>HIV</td>
<td>Brain biopsy</td>
</tr>
<tr>
<td>CT/MRI</td>
<td>Apolipoprotein E</td>
<td>SPECT</td>
</tr>
<tr>
<td></td>
<td>RPR or VDRL</td>
<td>PET</td>
</tr>
</tbody>
</table>

### Diagnostic Categories

#### Reversible Causes

<table>
<thead>
<tr>
<th>Examples</th>
<th>Examples</th>
<th>Psychiatric Disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypothyroidism</td>
<td>Alzheimer’s</td>
<td>Depression</td>
</tr>
<tr>
<td>Thiamine deficiency</td>
<td>Frontotemporal dementia</td>
<td>Schizophrenia</td>
</tr>
<tr>
<td>Vitamin B₁₂ deficiency</td>
<td>Huntington’s</td>
<td>Conversion reaction</td>
</tr>
<tr>
<td>Normal-pressure hydrocephalus</td>
<td>Dementia with Lewy bodies</td>
<td></td>
</tr>
<tr>
<td>Subdural hematoma</td>
<td>Vascular</td>
<td></td>
</tr>
<tr>
<td>Chronic infection</td>
<td>Leukoencephalopathies</td>
<td></td>
</tr>
<tr>
<td>Brain tumor</td>
<td>Parkinson’s</td>
<td></td>
</tr>
<tr>
<td>Drug intoxication</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Irreversible/Degenerative Dementias

<table>
<thead>
<tr>
<th>Examples</th>
<th>Examples</th>
<th>Psychiatric Disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Associated Treatable Conditions

| Depreciation | Agitation |
| Seizures     | Caregiver “burnout” |
| Insomnia     | Drug side effects |

**Note:** PET, positron emission tomography; RPR, rapid plasma reagin (test); SPECT, single photon emission CT; VDRL, Venereal Disease Research Laboratory (test for syphilis).
onset of AD and is associated with sporadic and late-onset familial cases. Apo E testing is not indicated as a predictive test. Rare genetic causes of AD are Down’s syndrome and mutations in APP, presenilin I, and presenilin II genes; all appear to increase production of Aβ amyloid. Genetic testing available for presenilin mutations.

Alzheimer’s Disease

AD cannot be cured, and no highly effective drug exists. The focus is on judicious use of cholinesterase inhibitor drugs; symptomatic management of behavioral problems; and building rapport with the pt, family members, and other caregivers.

Donepezil, rivastigmine, galantamine, tacrine (tetrahydroaminoacridine), and memantine are approved by the FDA for treatment of AD. With the exception of memantine, their action is inhibition of cholinesterase, with a resulting increase in cerebral levels of acetylcholine. Memantine appears to act by blocking overexcited N-methyl-D-aspartate (NMDA) channels. These compounds are only modestly efficacious and offer little or no benefit in the late stages of AD; they are associated with improved caregiver ratings of patients’ functioning and with an apparent decreased rate of decline in cognitive test scores over periods of up to 3 years. Donepezil (Aricept), 5–10 mg/d PO, has the advantages of few side effects and single daily dosage. Dosing of memantine begins at 5mg/d with gradual increases (over 1 month) to 10 mg twice a day.

The antioxidants selegiline, α-tocopherol (vitamin E), or both slowed institutionalization and progression to death of AD in one study. Because vitamin E is less toxic than selegiline and is inexpensive; the dose is 1000 IU twice a day. However, its beneficial effects are likely to be small; these high doses of vitamin E have potential cardiovascular complications, dampening enthusiasm for this treatment. There is no role for hormone replacement therapy in prevention of AD in women, and no benefit has been found in the treatment of established AD with estrogen. Prospective studies are examining the role of NSAIDs, statins, insulin regulation, and lowering of serum homocysteine. Other experimental approaches target amyloid either through diminishing its production or promoting clearance by passive immunization with monoclonal antibodies.

Depression, common in early stages of AD, may respond to antidepressant or cholinesterase inhibitors. Selective serotonin reuptake inhibitors (SSRIs) are often used due to their low anticholinergic side effects. Management of behavioral problems in conjunction with family and caregivers is essential. Mild sedation may help insomnia. Control of agitation usually involves antipsychotic medications, but recent trials have questioned the efficacy of this approach; in addition, all of the antipsychotics carry a black box warning in the elderly and should be used with caution. Notebooks and posted daily reminders can function as memory aids in early stages. Kitchens, bathrooms, and bedrooms need evaluation for safety. Pts must eventually stop driving. Caregiver burnout is common; nursing home placement may be necessary. Local and national support groups (Alzheimer’s Disease and Related Disorders Association) are valuable resources.

OTHER CAUSES OF DEMENTIA

Vascular Dementia Typically follows a pattern of either multiple stroke-like episodes (multi-infarct dementia) or diffuse white matter disease (leukoaraiosis,
subcortical arteriosclerotic encephalopathy, Binswanger’s disease) (Fig. 192-1). Unlike AD, focal neurologic signs (e.g., hemiparesis) may be apparent at presentation. Treatment focuses on underlying causes of atherosclerosis; anticholinesterase compounds are being studied for treatment of the dementia.

**Frontotemporal Dementia** Responsible for 10% of all cases of dementia. Extremely heterogeneous; presents with combinations of disinhibition, dementia, apraxia, parkinsonism, and motor neuron disease. May be sporadic or inherited; some familial cases due to mutations of tau or progranulin genes. Treatment is symptomatic; no therapies known to slow progression or improve cognitive symptoms. Many of the behaviors that accompany FTD such as depression, hyperorality, compulsions, and irritability can be helped with SSRIs.

**Dementia with Lewy Bodies** Characterized by visual hallucinations, parkinsonism, fluctuating alertness, and falls. Dementia can precede or follow the appearance of parkinsonism. Lewy bodies are intraneuronal cytoplasmic inclusions. Anticholinesterase compounds, exercise programs to maximize motor function, antidepressants to treat depressive syndromes, and possibly antipsychotics in low doses to alleviate psychosis may be helpful.

**Normal-Pressure Hydrocephalus (NPH)** Uncommon; presents as a gait disorder (ataxic or apractic), dementia, and urinary incontinence. Gait improves in some pts following ventricular shunting; dementia and incontinence do not im-
prove. The diagnosis is difficult to make, and the clinical picture may overlap with several other causes of dementia including AD; historically many individuals treated for NPH have suffered from other dementias.

**Huntington’s Disease**  Chorea, behavioral disturbance, and a frontal/executive disorder (Chap. 43). Typical onset fourth to fifth decade but can present at almost any age. Autosomal dominant inheritance due to expanded trinucleotide repeat in gene encoding the protein huntingtin. Diagnosis confirmed with genetic testing coupled with genetic counseling. Symptomatic treatment of movements and behaviors; SSRIs may help depression.

**Creutzfeldt-Jakob Disease (CJD)**  Prion disorders such as CJD are rare (~1 per million). CJD is a rapidly progressive disorder with dementia, focal cortical signs, rigidity, and myoclonus; death in <1 year from first symptom. The markedly abnormal periodic discharges on EEG and cortical and basal ganglia abnormalities on diffusion-weighted MR are unique diagnostic features. No proven treatments exist.

For a more detailed discussion, see Bird TD, Miller BL: Dementia, Chap. 365, p. 2536, in HPIM-17.

---

### Parkinson’s Disease

**CLINICAL FEATURES**

Parkinsonism consists of tremor, rigidity, bradykinesia, and characteristic abnormalities of gait and posture; may occur with many disorders. Parkinson’s disease (PD) is idiopathic parkinsonism without evidence of more widespread neurologic involvement. PD afflicts >1 million individuals in the United States (~1% of those >55 years). Peak age of onset in the 60s (range is 35–85); course progressive over 10–25 years. Tremor (“pill rolling” of hands) at rest (4–6 Hz); worsens with stress. A faster (7–8 Hz) “action tremor” may also occur when the hands are held against gravity. Presentation with tremor confined to one limb or side of body is common. Other findings: rigidity (“cogwheeling”—increased ratchet-like resistance to passive limb movements), bradykinesia (slowness of voluntary movements), fixed expressionless face (facial masking) with reduced frequency of blinking, hypophonic voice, drooling, impaired rapid alternating movements, micrographia (small handwriting), reduced arm swing, and flexed “stooped” posture with walking, shuffling gait, difficulty initiating or stopping walking, en-bloc turning (multiple small steps required to turn), retropulsion (tendency to fall backwards). Non-motor aspects of PD include depression and anxiety, cognitive impairment, sleep disturbances, sensation of inner restlessness, loss of smell (*anosmia*), and disturbances of autonomic function. In advanced PD, intellectual and behavioral deterioration, aspiration pneumonia, and bedsores (due to immobility) common. Normal muscular strength, deep tendon reflexes, and sensory exam. Diagnosis based upon history and examination; neuroimaging, EEG, and CSF studies usually normal for age.
**PATHOPHYSIOLOGY**

Degeneration of pigmented pars compacta neurons of the substantia nigra in the midbrain resulting in lack of dopaminergic input to striatum; accumulation of eosinophilic intraneural inclusion granules (Lewy bodies). Cause of cell death is unknown, but it may result from generation of free radicals and oxidative stress. Rare genetic forms of parkinsonism exist (~5% of cases); most common are mutations in \( \alpha \)-synuclein or parkin genes. Early age of onset suggests a possible genetic cause of PD, although one genetic form (\( LLRK2 \)) causes PD in the same age range as sporadic PD.

**DIFFERENTIAL DIAGNOSIS**  
(See Table 193-1)

Features of parkinsonism may occur with: depression (paucity of vocal inflection and facial movement); essential tremor (high-frequency tremor with limbs held against gravity, head tremor, improves with alcohol, often family history); normal-pressure hydrocephalus (apraxic gait, urinary incontinence, dementia); Wilson’s disease (early age of onset, Kayser-Fleischer rings, low serum ceruloplasmin); Huntington’s disease (early age of onset, Kayser-Fleischer rings, low serum ceruloplasmin); Huntington’s disease (family history, chorea, dementia); multiple system atrophy (early urinary incontinence, orthostatic hypotension, dysarthria); dementia with Lewy bodies (early hallucinations, behavioral disturbances); progressive supranuclear palsy (early imbalance and falls, vertical gaze paresis).

### Table 193-1  
**HISTORY AND EXAMINATION FEATURES SUGGESTING DIAGNOSES OTHER THAN PARKINSON’S DISEASE**

<table>
<thead>
<tr>
<th>Symptoms/Signs</th>
<th>Alternative Diagnosis to Consider</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History</strong></td>
<td></td>
</tr>
<tr>
<td>Falls as the first symptom</td>
<td>PSP</td>
</tr>
<tr>
<td>Exposure to neuroleptics</td>
<td>Drug-induced parkinsonism</td>
</tr>
<tr>
<td>Onset prior to age 40</td>
<td>If PD, think genetic causes</td>
</tr>
<tr>
<td>Associated unexplained liver disease</td>
<td>Wilson’s disease</td>
</tr>
<tr>
<td>Early hallucinations</td>
<td>Lewy body dementia</td>
</tr>
<tr>
<td>Sudden onset of parkinsonian</td>
<td>Vascular parkinsonism</td>
</tr>
<tr>
<td>symptoms</td>
<td></td>
</tr>
<tr>
<td><strong>Physical Exam</strong></td>
<td></td>
</tr>
<tr>
<td>Dementia as first symptom</td>
<td>Dementia with Lewy bodies</td>
</tr>
<tr>
<td>Prominent orthostasis</td>
<td>MSA-p</td>
</tr>
<tr>
<td>Early dysarthria</td>
<td>MSA-c</td>
</tr>
<tr>
<td>Lack of tremor</td>
<td>Various Parkinson’s-plus syndromes</td>
</tr>
<tr>
<td>High frequency (8–10 Hz) symmetric tremor</td>
<td>Essential tremor</td>
</tr>
</tbody>
</table>

**Note:** PSP, progressive supranuclear palsy; MSA, multiple system atrophy.

---

### Parkinson’s Disease

**Goals** are to maintain function and avoid drug-induced complications. Bradykinesia, tremor, rigidity, and abnormal posture respond early in illness; cognitive symptoms, hypophonia, autonomic dysfunction, and balance difficulties respond poorly.

**Initiation of Therapy**

Dopaminomimetic therapy initiated when symptoms interfere with quality of life. The ideal first-line agent depends on the age and cognitive status of the patient. In early PD, dopamine agonist monotherapy is well tolerated and re-

---
duces risk of later treatment-related complications such as motor fluctuations and dyskinesias (which occur in 50% of pts treated >5 years with levodopa); agonists often lead to cognitive sideeffects (hallucinations) in the elderly and therefore levodopa may be a better initial choice in these patients. Dopamine agonist monotherapy requires higher doses than needed when agonist is used to supplement levodopa (Table 193-2); slow titration necessary to avoid side effects. Most pts require addition of levodopa or another agent within 1–3 years of initiating dopamine agonist monotherapy.

Motor fluctuations are the exaggerated ebb and flow of parkinsonian signs between doses of medications. Dyskinesias refer to choreiform and dystonic movements that can occur as a peak dose effect or at the beginning or end of the dose.

Dopamine Agonists
Compared to levodopa, they are longer acting and thus provide a more uniform stimulation of dopamine receptors. They are effective as monotherapy and as adjuncts to carbidopa/levodopa therapy. They can also be used in combination with anticholinergics and amantadine. Side effects include nausea, postural hypotension, psychiatric symptoms, daytime sedation, and occasional sleep attacks. Pergolide is a dopamine agonist removed from the U.S. market due to its association with asymptomatic valvular heart disease. Table 193-2 provides a guide to the doses and uses of these agents.

Carbidopa/Levodopa Formulations
Available in regular, immediate release (IR) formulations (Sinemet, Atamet and others; 10/100 mg, 25/100 mg, and 25/250 mg), controlled release (CR) formulations (Sinemet CR 25/100 mg, 50/200 mg), and more recently as Stalevo (Table 193-2). The latter combines IR carbidopa/levodopa with 200 mg of entacapone (see below). Carbidopa blocks peripheral levodopa decarboxylation into dopamine and thus symptoms of nausea and orthostasis often associated with the initiation of levodopa. Initial target doses of these medications are summarized in table. Gradual dose escalation recommended; initiation of dosing at mealtimes will reduce nausea.

Levodopa Augmentation
Selegiline is a selective and irreversible monoamine oxidase (MAO) B inhibitor with a modest symptomatic effect when used as monotherapy or as an adjunct to carbidopa/levodopa. Typically, selegiline is used as initial therapy (5 mg with breakfast and lunch) or is added to alleviate tremor or levodopa-associated wearing off; a side effect is insomnia. Two more potent MAO-B inhibitors with once-daily dosing were recently introduced, rasagiline (0.5–1 mg/d) and zydis selegiline (1.25–2.5 mg/d in the morning). The potential role of these drugs as neuroprotective therapies remains controversial.

The catechol O-methyltransferase (COMT) inhibitors entacapone and tolcapone offer yet another strategy to augment the effects of levodopa by blocking the enzymatic degradation of levodopa and dopamine. Entacapone is preferred to tolcapone (hepatic and hematologic side effects). When used with carbidopa/levodopa, these agents alleviate wearing-off symptoms and increase time a pt remains “on” (i.e., well medicated) during the day. Common side effects are GI and hyperdopaminergic, including increased dyskinesias. The dose of entacapone is 200 mg coadministered with each dose of carbidopa/levodopa.

Anticholinergics and amantadine are useful adjuncts. Anticholinergics (trihexyphenidyl, 2–5 mg three times a day; benztropine, 0.5–2 mg three times a day) are particularly useful for controlling rest tremor and dystonia, and amantadine can reduce drug-induced dyskinesias by up to 70%. The mecha-
<table>
<thead>
<tr>
<th>Agents</th>
<th>LD Dose Equivalency</th>
<th>Available Strengths (mg)</th>
<th>Initial Dosing</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbidopa/levodopa (Typical Initial Strength)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbidopa/levodopa IR 25/100</td>
<td>100 mg (levodopa anchor dose)</td>
<td>10/100 25/100 25/250</td>
<td>25/100; 0.5–1 tab tid</td>
<td>Usual range = 300–800 mg/d with typical schedules being q8h to q3h.</td>
</tr>
<tr>
<td>Carbidopa/levodopa CR 50/200</td>
<td>150 mg</td>
<td>25/100 50/200</td>
<td>50/200; 1 tab bid to tid</td>
<td>Increased bioavailability with food. Splitting the tablet negates the CR properties. Usual schedule is q8h to q4h.</td>
</tr>
<tr>
<td>Carbidopa/levodopa/entacapone 25/100/200</td>
<td>120 mg</td>
<td>12.5/50/200 25/100/200</td>
<td>25/100/200; 1 tab bid to tid</td>
<td>Do not split tablets. May combine with Sinemet IR. Usual schedule is q8h to q4h.</td>
</tr>
<tr>
<td>Parcopa 25/100</td>
<td>100 mg</td>
<td>25/100 25/250</td>
<td>25/100; 1 tab tid</td>
<td>Can be used as regular or supplemental rescue doses in cases of regular dose failure. Orally dissolved without water.</td>
</tr>
</tbody>
</table>
### LEVODOPA FORMULATIONS AND DOPAMINE AGONISTS USED IN PARKINSON’S DISEASE (CONTINUED)

<table>
<thead>
<tr>
<th>Dopamine Agonists</th>
<th>DA Equivalent to Above LD Anchor Dose</th>
<th>Available Strengths (mg)</th>
<th>Initial Dosing</th>
<th>Monotherapy</th>
<th>As Adjuncts to LD</th>
<th>Other Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-ergot alkaloids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pramipexole</td>
<td>1 mg</td>
<td>0.125, 0.25, 1, 1.5</td>
<td>0.125 mg tid</td>
<td>1.5–4.5 mg/d</td>
<td>0.375–3.0 mg/d</td>
<td>Renal metabolism; dose adjustments needed in renal insufficiency. Occasionally associated with “sleep attacks.”</td>
</tr>
<tr>
<td>Ropinirole</td>
<td>5 mg</td>
<td>0.25, 0.5, 1, 2, 3, 4, 5</td>
<td>0.25 mg tid</td>
<td>12–24 mg/d</td>
<td>6–16 mg/d</td>
<td>Hepatic metabolism; potential drug-drug interactions. Occasionally associated with “sleep attacks.”</td>
</tr>
<tr>
<td>Ropinirole extended release</td>
<td>Availability pending.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotigotine</td>
<td></td>
<td>2, 4, 6</td>
<td>2 mg/24 h</td>
<td>6 mg/d</td>
<td>2–6 mg/d</td>
<td>Available as transdermal patch.</td>
</tr>
<tr>
<td>Ergot alkaloids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bromocriptine</td>
<td>2 mg</td>
<td>2.5, 5.0</td>
<td>1.25 mg bid to tid</td>
<td>7.5–15 mg/d</td>
<td>3.75–7.5 mg/d</td>
<td>Rare reports of pulmonary and retroperitoneal fibrosis. Relative incidence of sleep attacks not well studied.</td>
</tr>
<tr>
<td>Pergolide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cabergoline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Removed from U.S. market in 2007. See text.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Used in select cases of PD in Europe. Not approved for the treatment of PD in the U.S.</td>
</tr>
</tbody>
</table>

**Note:** Equivalency doses are approximations based on clinical experience, may not be accurate in individual patients, and are not intended to correlate with the in vitro binding affinities of these compounds.

**Abbreviations:** DA, dopamine agonist; IR, immediate release; CR, controlled release; LD, levodopa (with carbidopa). Carbidopa/levodopa/entacapone = Stalevo.
nism of action of amantadine (100 mg twice daily) is unknown; it has anticho-
linergic, dopaminomimetic, and glutamate antagonist properties. In older
patients, it may aggravate confusion and psychosis.

**Surgical Treatments**

In refractory cases, surgical treatment of PD should be considered. The use of
ablation (e.g., pallidotomy or thalamotomy) has decreased greatly since the in-
troduction of deep-brain stimulation. The selection of suitable patients for sur-
gery is most important, since in general patients with atypical Parkinson’s do
not have a favorable response. The indications for surgery are (1) a diagnosis
of idiopathic PD, (2) a clear response to levodopa, (3) significant intractable
tremor, and/or (4) drug-induced dyskinesias and wearing off. Contraindica-
tions to surgery include atypical PD, cognitive impairment, major psychiatric
illness, substantial medical comorbidities, and advanced age (a relative factor).
Symptoms not responding to levodopa are unlikely to benefit from surgery.

For a more detailed discussion, see Delong MR, Juncos JL: Parkin-
son’s Disease and Other Extrapyramidal Movement Disorders,
Chap. 366, p. 2549, in HPIM-17.

---

**CLINICAL PRESENTATION**

Symptoms and signs may include gait impairment, nystagmus, dysarthria (scan-
ning speech), impaired limb coordination, intention tremor (i.e., with move-
ment), hypotonia. **Differential diagnosis:** Unsteady gait associated with vertigo
can resemble gait instability of cerebellar disease but produces a sensation of
movement, dizziness, or light-headedness. Sensory disturbances can also simu-
late cerebellar disease; with sensory ataxia, imbalance dramatically worsens
when visual input is removed (Romberg sign). Bilateral proximal leg weakness
can also rarely mimic cerebellar ataxia.

**APPROACH TO THE PATIENT WITH ATAXIA**

Causes are best grouped by determining whether ataxia is symmetric or fo-
cal and by the time course (Table 194-1). Also important to distinguish
whether ataxia is present in isolation or is part of a multisystem neurologic
disorder. Acute symmetric ataxia is usually due to medications, toxins, viral
infection, or a postinfectious syndrome (especially varicella). Subacute or
chronic symmetric ataxia can result from hypothyroidism, vitamin deficien-
cies, infections (Lyme disease, tabes dorsalis, prions), alcohol, other toxins,
or an inherited condition (see below). An immune-mediated progressive
ataxia is associated with antigliadin antibodies; biopsy of the small intestine
may reveal villous atrophy of gluten enteropathy. Progressive nonfamilial
cerebellar ataxia after age 45 suggests a paraneoplastic syndrome, either
<table>
<thead>
<tr>
<th>Symmetric and Progressive Signs</th>
<th>Focal and Ipsilateral Cerebellar Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute</strong> (Hours to Days)</td>
<td><strong>Acute</strong> (Hours to Days)</td>
</tr>
<tr>
<td>Intoxication: alcohol, lithium, diphenyl-hydantoin, barbiturates (positive history and toxicology screen)</td>
<td>Vascular: cerebellar infarction, hemorrhage, or subdural hematoma</td>
</tr>
<tr>
<td>Acute viral cerebellitis (CSF supportive of acute viral infection)</td>
<td>Infectious: cerebellar abscess (mass lesion on MRI/CT, history in support of lesion)</td>
</tr>
<tr>
<td>Postinfection syndrome</td>
<td><strong>Subacute</strong> (Days to Weeks)</td>
</tr>
<tr>
<td>Intoxication: mercury, solvents, gasoline, glue; cytotoxic chemotherapeutic drugs</td>
<td>Neoplastic: cerebellar glioma or metastatic tumor (positive for neoplasm on MRI/CT)</td>
</tr>
<tr>
<td>Alcoholic-nutritional (vitamin B₁ and B₁₂ deficiency)</td>
<td>Demyelinating: multiple sclerosis (history, CSF, and MRI are consistent)</td>
</tr>
<tr>
<td>Lyme disease</td>
<td>AIDS-related multifocal leukoencephalopathy (positive HIV test and CD4+ cell count for AIDS)</td>
</tr>
<tr>
<td><strong>Chronic</strong> (Months to Years)</td>
<td><strong>Chronic</strong> (Months to Years)</td>
</tr>
<tr>
<td>Paraneoplastic syndrome</td>
<td>Stable gliosis secondary to vascular lesion or demyelinating plaque (stable lesion on MRI/CT older than several months)</td>
</tr>
<tr>
<td>Anti-gliadin antibody syndrome</td>
<td>Congenital lesion: Chiari or Dandy-Walker malformations (malformation noted on MRI/CT)</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td></td>
</tr>
<tr>
<td>Inherited diseases</td>
<td></td>
</tr>
<tr>
<td>Demyelinating: multiple sclerosis (history, CSF, and MRI are consistent)</td>
<td></td>
</tr>
<tr>
<td>Stable gliosis secondary to vascular lesion or demyelinating plaque (stable lesion on MRI/CT older than several months)</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** CSF, cerebrospinal fluid; CT, computed tomography; MRI, magnetic resonance imaging.
subacute cortical cerebellar degeneration (ovarian, breast, lung, Hodgkin’s) or opsoclonus-myoclonus (neuroblastoma, breast, lung).

Unilateral ataxia suggests a focal lesion in the ipsilateral cerebellar hemisphere or its connections. An important cause of acute unilateral ataxia is stroke. Mass effect from cerebellar hemorrhage or swelling from cerebellar infarction can compress brainstem structures, producing altered consciousness and ipsilateral pontine signs (small pupils, lateral gaze or sixth nerve paresis, facial weakness); limb ataxia may not be prominent. Other diseases producing asymmetric or unilateral ataxia include tumors, multiple sclerosis, progressive multifocal leukoencephalopathy (immunodeficiency states), and congenital malformations.

**INHERITED ATAXIAS**

May be autosomal dominant, autosomal recessive, or mitochondrial (maternal inheritance); more than 30 disorders recognized (see Table 368-2, HPIM-17). Friedreich’s ataxia is most common; autosomal recessive, onset before age 25; ataxia with areflexia, upgoing toes, vibration and position sense deficits, cardiomyopathy, hammer toes, scoliosis; linked to expanded trinucleotide repeat in the intron of gene encoding frataxin; a second form of hereditary ataxia is associated with vitamin E deficiency. Common dominantly inherited ataxias are spinocerebellar ataxia (SCA) 1 (olivopontocerebellar atrophy; “ataxin-1” gene) (Fig. 194-1) and SCA3 (Machado-Joseph disease); both may manifest as ataxia with brainstem and/or extrapyramidal signs; SCA3 may also have dystonia and amyotrophy; genes for each disorder contain unstable trinucleotide repeats in coding region.

**EVALUATION**

Diagnostic approach is determined by the nature of the ataxia (Table 194-1). For symmetric ataxias, drug and toxicology screens; vitamin B1, B12, and E levels;
thyroid function tests; antibody tests for syphilis and Lyme infection; anti-glia-
din antibodies; paraneoplastic antibodies (see Chap. 82); and CSF studies often
indicated. Genetic testing is available for many inherited ataxias. For unilateral
or asymmetric ataxias, brain MRI or CT scan is the initial test of choice.

The most important goal is to identify treatable entities including hypothy-
roidism, vitamin deficiency, and infectious causes. Parainfectious ataxia can
be treated with glucocorticoids. Ataxia with anti-gliadin antibodies and gluten
enteropathy may improve with a gluten-free diet. Paraneoplastic disorders are
often refractory to therapy, but some pts improve following removal of the tu-
mor or immunotherapy (Chap. 82). Vitamins B\textsubscript{1} and B\textsubscript{12} should be adminis-
tered to pts with deficient levels. The deleterious effects of diphenylhydantoin
and alcohol on the cerebellum are well known, and these exposures should be
avoided in pts with ataxia of any cause. There is no proven therapy for any of
the autosomal dominant ataxias; family and genetic counseling are important.
There is preliminary evidence that idebenone, a free-radical scavenger, can
improve myocardial hypertrophy in Friedreich’s ataxia; there is no evidence
that it improves neurologic function. Iron chelators and antioxidant drugs are
potentially harmful in Friedreich pts as they may increase heart muscle injury.
Cerebellar hemorrhage and other mass lesions of the posterior fossa may re-
quire emergent surgical treatment to prevent fatal brainstem compression.

For a more detailed discussion, see Rosenberg RN: Ataxic Disor-
ders, Chap. 368, p. 2565, in HPIM-17.

Amyotrophic lateral sclerosis (ALS) is the most important of the motor neuron
diseases (Table 195-1). ALS is caused by degeneration of motor neurons at all
levels of the CNS, including anterior horns of the spinal cord, brainstem motor
nuclei, and motor cortex. Familial ALS (FALS) represents 5–10% of the total
and is inherited usually as an autosomal dominant disorder.

CLINICAL FEATURES
Onset is usually midlife, with most cases progressing to death in 3–5 years. Pre-
sentation is variable depending on whether upper motor or lower motor neurons
are more prominently involved initially.

Common initial symptoms are weakness, muscle wasting, stiffness and cramping, and twitching in muscles of hands and arms, often first in the intrinsic hand muscles. Legs are less severely involved than arms, with complaints of leg stiffness, cramping, and weakness common. Symptoms of brainstem involve-
ment include dysphagia, which may lead to aspiration pneumonia and compro-
mised energy intake; there may be prominent wasting of the tongue leading to
difficulty in articulation (dysarthria), phonation, and deglutition. Weakness of ventilatory muscles leads to respiratory insufficiency. Additional features that characterize ALS are preservation of intellect, lack of sensory abnormalities, pseudobulbar palsy (e.g., involuntary laughter, crying), and absence of bowel or bladder dysfunction.

**PATHOPHYSIOLOGY**

Pathologic hallmark is death of lower motor neurons (consisting of anterior horn cells in the spinal cord and their brainstem homologues innervating bulbar muscles) and upper, or corticospinal, motor neurons (originating in layer five of the motor cortex and descending via the pyramidal tract to synapse with lower motor neurons). Although at onset ALS may involve selective loss of function of only upper or lower motor neurons, it ultimately causes progressive loss of both; the absence of clear involvement of both motor neuron types should call into question the diagnosis of ALS.

**LABORATORY EVALUATION**

EMG provides objective evidence of extensive muscle denervation not confined to the territory of individual peripheral nerves and nerve roots. CSF is usually normal. Muscle enzymes (e.g., CK) may be elevated.

Several types of secondary motor neuron disorders that resemble ALS are treatable (Table 195-2); therefore all pts should have a careful search for these disorders.

MRI or CT-myelography is often required to exclude compressive lesions of the foramen magnum or cervical spine. When involvement is restricted to lower motor neurons only, another important entity is multifocal motor neuropathy with conduction block (MMCB). A diffuse, lower motor axonal neuropathy mimicking ALS sometimes evolves in association with hematopoietic disorders such as lymphoma or multiple myeloma; an M-component in serum should prompt consideration of a bone marrow biopsy. Lyme disease may also cause an axonal, lower motor neuropathy. Other treatable disorders that occasionally mimic ALS are chronic lead poisoning and thyrotoxicosis.
Pulmonary function studies may aid in management of ventilation. Swallowing evaluation identifies those at risk for aspiration. Genetic testing is available for superoxide dismutase 1 (SOD1) (20% of FALS) and for rare mutations in other genes.

**TABLE 195-2 ETIOLOGY AND INVESTIGATION OF MOTOR NEURON DISORDERS**

<table>
<thead>
<tr>
<th>Diagnostic Category</th>
<th>Investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Structural lesions</td>
<td>MRI scan of head (including foramen magnum), cervical spine&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Parasagittal or foramen magnum tumors</td>
<td></td>
</tr>
<tr>
<td>Cervical spondylosis</td>
<td></td>
</tr>
<tr>
<td>Chiari malformation or syrinx</td>
<td></td>
</tr>
<tr>
<td>Spinal cord arteriovenous malformation</td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td></td>
</tr>
<tr>
<td>Bacterial—tetenus, Lyme</td>
<td>CSF exam, culture&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Viral—poliomyelitis, herpes zoster</td>
<td>Lyme antibody titer&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Retroviral myelopathy</td>
<td>Antiviral antibody titers</td>
</tr>
<tr>
<td>Intoxications, physical agents</td>
<td>HTLV-I titers</td>
</tr>
<tr>
<td>Toxins—lead, aluminum, others</td>
<td></td>
</tr>
<tr>
<td>Drugs—strychnine, phenytoin</td>
<td>24-h urine for heavy metals&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Electric shock, x-irradiation</td>
<td>Serum for lead level&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Immunologic mechanisms</td>
<td></td>
</tr>
<tr>
<td>Plasma cell dyscrasias</td>
<td>Complete blood count&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Autoimmune polyradiculoneuropathy</td>
<td>Sedimentation rate&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Motor neuropathy with conduction block</td>
<td>Protein immunoelectrophoresis&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Paraneoplastic</td>
<td>Anti-GM1 antibodies</td>
</tr>
<tr>
<td>Paracarcinomatous/lymphoma</td>
<td>MRI scan, bone marrow biopsy</td>
</tr>
<tr>
<td>Metabolic</td>
<td></td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>Fasting blood sugar (FBS), routine chemistries including calcium&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hyperparathyroidism</td>
<td>PTH, calcium, phosphate</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>Thyroid function&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Deficiency of folate, vitamin B&lt;sub&gt;12&lt;/sub&gt;, vitamin E</td>
<td>Vitamin B&lt;sub&gt;12&lt;/sub&gt;, vitamin E, folate levels&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Malabsorption</td>
<td>24-h stool fat, carotene, prothrombin time</td>
</tr>
<tr>
<td>Mitochondrial dysfunction</td>
<td></td>
</tr>
<tr>
<td>Hereditary biochemical disorders</td>
<td>Fasting lactate, pyruvate, ammonia</td>
</tr>
<tr>
<td>Superoxide dismutase 1 gene mutation</td>
<td>Consider mtDNA analysis</td>
</tr>
<tr>
<td>Androgen receptor defect (Kennedy’s disease)</td>
<td></td>
</tr>
<tr>
<td>Hexosaminidase deficiency</td>
<td>White blood cell DNA analysis</td>
</tr>
<tr>
<td>Infantile (α-glucosidase deficiency/ Pompe’s disease)</td>
<td>Abnormal CAG insert in androgen receptor gene</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>Lysosomal enzyme screen</td>
</tr>
<tr>
<td>Hyperglycinuria</td>
<td>α-Glucosidase level</td>
</tr>
<tr>
<td>Methylcrotonylglycinuria</td>
<td>Lipid electrophoresis</td>
</tr>
<tr>
<td></td>
<td>Urine and serum amino acids</td>
</tr>
<tr>
<td></td>
<td>CSF amino acids</td>
</tr>
</tbody>
</table>

<sup>a</sup>Denotes studies that should be obtained in all cases.

**Note:** CSF, cerebrospinal fluid; HTLV, human T cell lymphotropic virus; PTH, parathyroid hormone.
There is no treatment capable of arresting the underlying pathologic process in ALS. The drug riluzole produces modest lengthening of survival; in one trial the survival rate at 18 months with riluzole (100 mg/d) was similar to placebo at 15 months. It may act by diminishing glutamate release and thereby decreasing excitotoxic neuronal cell death. Side effects of riluzole include nausea, dizziness, weight loss, and elevation of liver enzymes. Clinical trials of several other agents are in progress, including insulin-like growth factor (IGF-1), ceftriaxone, and antisense oligonucleotides (ASO) that diminish expression of mutant SOD1 protein in transgenic ALS mice and rats.

A variety of rehabilitative aids may substantially assist ALS patients. Footdrop splints facilitate ambulation, and finger extension splints can potentiate grip. Respiratory support may be life-sustaining. For pts electing against long-term ventilation by tracheostomy, positive-pressure ventilation by mouth or nose provides transient (several weeks) relief from hypercarbia and hypoxia. Also beneficial are respiratory devices that produce an artificial cough; these help to clear airways and prevent aspiration pneumonia. When bulbar disease prevents normal chewing and swallowing, gastrostomy is helpful in restoring normal nutrition and hydration. Speech synthesizers can augment speech when there is advanced bulbar palsy.

Web-based information on ALS is offered by the Muscular Dystrophy Association (www.mdausa.org) and the Amyotrophic Lateral Sclerosis Association (www.alsa.org).

For a more detailed discussion, see Brown RH Jr: Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases, Chap. 369, p. 2572, in HPIM-17.

The autonomic nervous system (ANS) (Fig. 196-1) innervates the entire neuraxis and permeates all organ systems. It regulates blood pressure (bp), heart rate, sleep, and bladder and bowel function. It operates automatically, so that its full importance becomes recognized only when ANS function is compromised, resulting in dysautonomia.

Key features of the ANS are summarized in Table 196-1. Responses to sympathetic or parasympathetic activation often have opposite effects; partial activation of both systems allows for simultaneous integration of multiple body functions.

Consider disorders of autonomic function in the differential diagnosis of pts with impotence, bladder dysfunction (urinary frequency, hesitancy, or incontinence), diarrhea, constipation, impaired lacrimation, or altered sweating (hyperhidrosis or hypohidrosis).
FIGURE 196-1 Schematic representation of the autonomic nervous system. (From M. Moskowitz: Clin Endocrinol Metab 6:77, 1977.)

**Parasympathetic system** from cranial nerves III, VII, IX, X and from sacral nerves 2 and 3

- **A** Ciliary ganglion
- **B** Sphenopalatine (pterygopalatine) ganglion
- **C** Submandibular ganglion
- **D** Otic ganglion
- **E** Vagal ganglion cells in the heart wall
- **F** Vagal ganglion cells in bowel wall
- **G** Pelvic ganglia

**Sympathetic system** from T1-L2

- **H** Superior cervical ganglion
- **J** Middle cervical ganglion and inferior cervical (stellate) ganglion including T1 ganglion
- **K** Coeliac and other abdominal ganglia
- **L** Lower abdominal sympathetic ganglia

**Preganglionic fibers**

**Postganglionic fibers**
Orthostatic hypotension (OH) is perhaps the most disabling feature of autonomic dysfunction. Syncope results when the drop in bp impairs cerebral perfusion (Chap. 39). Other manifestations of impaired baroreflexes are supine hypertension, a heart rate that is fixed regardless of posture, postprandial hypotension, and an excessively high nocturnal bp. Many patients with OH have a preceding diagnosis of hypertension. The most common causes of OH are not neurologic in origin; these must be distinguished from the neurogenic causes.

**APPROACH TO THE PATIENT WITH AUTONOMIC NERVOUS SYSTEM DISORDERS**

The first step in the evaluation of symptomatic OH is the exclusion of treatable causes. The history should include a review of medications that may cause OH (e.g., diuretics, antihypertensives, antidepressants, phenothiazines, ethanol, narcotics, insulin, dopamine agonists, barbiturates, and calcium channel blocking agents); the precipitation of OH by medications may also be the first sign of an underlying autonomic disorder. The history may reveal an underlying cause for symptoms (e.g., diabetes, Parkinson’s disease) or specific underlying mechanisms (e.g., cardiac pump failure, reduced intravascular volume). The relationship of symptoms to meals (splanchnic pooling), standing on awakening in the morning (intravascular volume depletion), ambient warming (vasodilatation), or exercise (muscle arteriolar vasodilatation) should be sought.

Physical exam includes measurement of supine and standing pulse and bp. OH is defined as a sustained drop in systolic (≥20 mmHg) or diastolic (≥10 mmHg) bp within 3 min of standing up. In nonneurogenic causes of OH (such as hypovolemia), the bp drop is accompanied by a compensatory increase in heart rate of >15 beats/min. A clue to neurogenic OH is aggravation or precipitation of OH by autonomic stressors (such as a meal, hot tub/hot bath, and exercise). Neurologic evaluation should include a mental status exam (to exclude neurodegenerative disorders), cranial nerve exam (impaired downgaze in progressive supranuclear palsy), pupils (Hörner’s or Adie’s pupils), motor tone (Parkinson’s), and sensory exam (polyneuropathies). In pts without a clear initial diagnosis, follow-up exams and laboratory evaluations over 1 to 2 years may reveal the underlying cause.

**TABLE 196-1 FUNCTIONAL CONSEQUENCES OF NORMAL ANS ACTIVATION**

<table>
<thead>
<tr>
<th></th>
<th>Sympathetic</th>
<th>Parasympathetic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate</td>
<td>Increased</td>
<td>Decreased</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Increased</td>
<td>Mildly decreased</td>
</tr>
<tr>
<td>Bladder</td>
<td>Increased sphincter tone</td>
<td>Voiding (decreased tone)</td>
</tr>
<tr>
<td>Bowel motility</td>
<td>Decreased motility</td>
<td>Increased</td>
</tr>
<tr>
<td>Lung</td>
<td>Bronchodilation</td>
<td>Bronchoconstriction</td>
</tr>
<tr>
<td>Sweat glands</td>
<td>Sweating</td>
<td>—</td>
</tr>
<tr>
<td>Pupils</td>
<td>Dilation</td>
<td>Constriction</td>
</tr>
<tr>
<td>Adrenal glands</td>
<td>Catecholamine release</td>
<td>—</td>
</tr>
<tr>
<td>Sexual function</td>
<td>Ejaculation, orgasm</td>
<td>Erection</td>
</tr>
<tr>
<td>Lacrimal glands</td>
<td>—</td>
<td>Tearing</td>
</tr>
<tr>
<td>Parotid glands</td>
<td>—</td>
<td>Salivation</td>
</tr>
</tbody>
</table>
Autonomic function tests are helpful when the history and physical exam findings are inconclusive. Heart rate variation with deep breathing is a measure of vagal function. The Valsalva maneuver measures changes in heart rate and bp while a constant expiratory pressure of 40 mmHg is maintained for 15 s. The Valsalva ratio is the maximum heart rate during the maneuver divided by the minimum heart rate following the maneuver; the ratio reflects cardiovascular function. Tilt-table beat-to-beat bp measurements in the supine, 70° tilt, and tilt-back positions can be used to evaluate orthostatic failure in bp control in pts with unexplained syncope. Most pts with syncope do not have autonomic failure; the tilt-table test can be used to diagnose vasovagal syncope with high sensitivity, specificity, and reproducibility.

Other tests of autonomic function include the quantitative sudomotor axon reflex test (QSART) and the thermoregulatory sweat test (TST). The QSART provides quantitative measure of regional autonomic function mediated by ACh-induced sweating. The TST provides a qualitative measure of sweating in response to a standardized elevation of body temperature. For a more complete discussion of autonomic function tests, see Chap. 370, HPIM-17.

Disorders of the Autonomic Nervous System

Autonomic disorders may occur with a large number of disorders of the central and/or peripheral nervous systems (Table 196-2). Diseases of the CNS may cause ANS dysfunction at many levels, including hypothalamus, brainstem, or spinal cord.

Multiple system atrophy (MSA) is a progressive neurodegenerative disorder comprising autonomic failure (OH and/or a neurogenic bladder are required for diagnosis) combined with either parkinsonism (MSA-p) or cerebellar signs (MSA-c), often along with progressive cognitive dysfunction. Dysautonomia is also common in advanced Parkinson’s disease (Chap. 193).

Spinal cord injury may be accompanied by autonomic hyperreflexia affecting bowel, bladder, sexual, temperature-regulation, or cardiovascular functions. Dangerous increases or decreases in body temperature may result from the inability to experience the sensory accompaniments of heat or cold exposure below the level of the injury. Markedly increased autonomic discharge (autonomic dysreflexia) can be elicited by stimulation of the bladder, skin, or muscles. Bladder distention from palpation, catheter insertion, catheter obstruction, or urinary infection is a common and correctable trigger of autonomic dysreflexia.

Peripheral neuropathies affecting the small myelinated and unmyelinated fibers of the sympathetic and parasympathetic nerves are the most common cause of chronic autonomic insufficiency (Chap. 203). Autonomic involvement in diabetes mellitus typically begins ~10 years after the onset of diabetes and slowly progresses. Diabetic enteric neuropathy may result in gastroparesis, nausea and vomiting, malnutrition, achlorhydria, and bowel incontinence. Impotence, urinary incontinence, pupillary abnormalities, and OH may occur as well. Prolongation of the QT interval increases the risk of sudden death. Autonomic neuropathy occurs in both sporadic and familial forms of amyloidosis. Pts typically present with distal, painful polyneuropathy. Alcoholic polyneuropathy produces symptoms of autonomic failure only when the neuropathy is severe. Attacks of acute intermittent porphyria (AIP) are associated with tachycardia, sweating, urinary retention, and hypertension. Blood pressure fluctuation and cardiac arrhythmias can be severe in Guillain-Barré syndrome. Autoimmune au-
### TABLE 196-2 CLASSIFICATION OF CLINICAL AUTONOMIC DISORDERS

#### I. Autonomic disorders with brain involvement

A. Associated with multisystem degeneration
   1. Multisystem degeneration: autonomic failure clinically prominent
      a. Multiple system atrophy (MSA)
      b. Parkinson’s disease with autonomic failure
      c. Diffuse Lewy body disease (some cases)
   2. Multisystem degeneration: autonomic failure clinically not usually prominent
      a. Parkinson’s disease
      b. Other extrapyramidal disorders (inherited spinocerebellar atrophies, progressive supranuclear palsy, corticobasal degeneration, Machado-Joseph disease)

B. Unassociated with multisystem degeneration
   1. Disorders mainly due to cerebral cortex involvement
      a. Frontal cortex lesions causing urinary/bowel incontinence
      b. Partial complex seizures
   2. Disorders of the limbic and paralimbic circuits
      a. Shapiro’s syndrome (agenesis of corpus callosum, hyperhidrosis, hypothermia)
      b. Autonomic seizures
   3. Disorders of the hypothalamus
      a. Wernicke-Korsakoff syndrome
      b. Diencephalic syndrome
      c. Neuroleptic malignant syndrome
      d. Serotonin syndrome
      e. Fatal familial insomnia
      f. Antidiuretic hormone (ADH) syndromes (diabetes insipidus, inappropriate ADH)
      g. Disturbances of temperature regulation (hyperthermia, hypothermia)
      h. Disturbances of sexual function
      i. Disturbances of appetite
      j. Disturbances of BP/HR and gastric function
      k. Horner’s syndrome
   4. Disorders of the brainstem and cerebellum
      a. Posterior fossa tumors
      b. Syringobulbia and Arnold-Chiari malformation
      c. Disorders of BP control (hypertension, hypotension)
      d. Cardiac arrhythmias
      e. Central sleep apnea
      f. Baroreflex failure
      g. Horner’s syndrome

#### II. Autonomic disorders with spinal cord involvement

A. Traumatic quadriplegia
B. Syringomyelia
C. Subacute combined degeneration
D. Multiple sclerosis
E. Amyotrophic lateral sclerosis
F. Tetanus
G. Stiff-man syndrome
H. Spinal cord tumors

(continued)
tonomic neuropathy presents as the subacute development of autonomic failure featuring OH, enteric neuropathy (gastroparesis, ileus, constipation/diarrhea), loss of sweating, sicca complex, and a tonic pupil. Onset may follow a viral infection; serum antibodies to the ganglionic ACh receptor (A3 AChR) are diagnostic, and some pts appear to respond to immunotherapy. Rare patients develop dysautonomia as a paraneoplastic disorder (Chap. 82). There are five known hereditary sensory and autonomic neuropathies (HSAN I–V).

**Botulism** is associated with blurred vision, dry mouth, nausea, unreactive pupils, urinary retention, and constipation. Postural orthostatic tachycardia syndrome (POTS) presents with symptoms of orthostatic intolerance (not OH), including shortness of breath, light-headedness, and exercise intolerance accompanied by an increase in heart rate but no drop in bp. Primary hyperhidrosis affects 0.6–1.0% of the population; the usual symptoms are excessive sweating of the palms and soles. Onset is in adolescence, and symptoms tend to improve with age. Although not dangerous, this condition is socially embarrassing; treatment with either sympathectomy or local injection of botulinum toxin is often effective.

**COMPLEX REGIONAL PAIN SYNDROME (REFLEX SYMPATHETIC DYSTROPHY—RSD)**

Complex regional pain syndrome (CRPS) type I is a regional pain syndrome that usually develops after tissue trauma. Allodynia (the perception of a nonpainful stimulus as painful), hyperpathia (an exaggerated pain response to a painful stimulus), and spontaneous pain occur. The symptoms are unrelated to the severity of the initial trauma and are not confined to the distribution of a single peripheral nerve. CRPS type II is a regional pain syndrome that develops after injury to a peripheral nerve, usually a major nerve trunk. Spontaneous pain initially develops within the territory of the affected nerve but eventually may spread outside the nerve distribution.
Early mobilization with physical therapy or a brief course of glucocorticoids may be helpful for CRPS type I. Other treatments include the use of adrenergic blockers, NSAIDs, calcium channel blockers, phenytoin, opioids, and calcitonin. Stellate ganglion blockade is a commonly used invasive therapeutic technique that often provides temporary pain relief, but the efficacy of repetitive blocks is uncertain.

Of particular importance is the removal of drugs or amelioration of underlying conditions that cause or aggravate the autonomic symptom. For instance, OH can be related to angiotensin-converting enzyme inhibitors, calcium channel blocking agents, tricyclic antidepressants, levodopa, alcohol, or insulin. Nonpharmacologic approaches are summarized in Table 196-3. Adequate intake of salt and fluids to produce a voiding volume between 1.5 and 2.5 L of urine (containing >170 meq of Na+) each 24 h is essential. Sleeping with the head of the bed elevated will minimize the effects of supine nocturnal hypertension. Prolonged recumbency should be avoided. Pts are advised to sit with legs dangling over the edge of the bed for several minutes before attempting to stand in the morning. Compressive garments such as compression stockings and abdominal binders may be helpful if they can be tolerated. Anemia should be corrected, if necessary, with erythropoietin; the increased intravascular volume that accompanies the rise in hematocrit can exacerbate supine hypertension. Postprandial OH may respond to frequent, small, low-carbohydrate meals.

If these measures are not sufficient, drug treatment might be necessary. Midodrine is a directly acting $\alpha_1$ agonist that does not cross the blood-brain barrier. The dose is 5–10 mg orally three times a day, but some pts respond best to a decremental dose (e.g., 15 mg on awakening, 10 mg at noon, and 5 mg in the afternoon). Midodrine should not be taken after 6 P.M. Side effects include pruritus, uncomfortable piloerection, and supine hypertension. Pyridostigmine appears to improve OH without aggravating supine hypertension by enhancing ganglionic transmission (maximal when orthostatic, minimal supine). Fludrocortisone (0.1–0.3 mg PO twice daily) will reduce OH, but it aggravates supine hypertension. Susceptible patients may develop fluid overload, congestive heart failure, supine hypertension, or hypokalemia.

For a more detailed discussion, see Low PA, Engstrom JW: Disorders of the Autonomic Nervous System, Chap. 370, p. 2576, in HPIM-17.
Disorders of vision and ocular movement are discussed in Chaps. 41 and 61; dizziness and vertigo in Chap. 40; and disorders of hearing in Chap. 61.

**FACIAL PAIN OR NUMBNESS [TRIGEMINAL NERVE (V)]**

(See Fig. 197-1)

**Trigeminal Neuralgia (Tic Douloureux)** Frequent, excruciating paroxysms of pain in lips, gums, cheek, or chin (rarely in ophthalmic division of fifth nerve) lasting seconds to minutes. Typically presents in middle or old age. Pain is often stimulated at trigger points. Sensory deficit cannot be demonstrated. Must be distinguished from other forms of facial pain arising from diseases of jaw, teeth, or sinuses. Rare causes are herpes zoster or a tumor. Onset in young adulthood or if bilateral raises the possibility of multiple sclerosis (Chap. 200).

**Rx Trigeminal Neuralgia**

Carbamazepine is effective in 50–75% of cases. Begin at 100 mg single daily dose taken with food and advance by 100 mg every 1–2 days until substantial (50%) pain relief occurs. Most pts require 200 mg four times a day; doses > 1200 mg daily usually provide no additional benefit. For nonresponders, phenytoin (300–400 mg/d) or baclofen (5–20 mg three to four times a day) can be tried. When medications fail, surgical lesions (heat or gamma energy) can be considered.

**FIGURE 197-1** The three major sensory divisions of the trigeminal nerve consist of the ophthalmic, maxillary, and mandibular nerves.
Trigeminal Neuropathy  Usually presents as facial sensory loss or weakness of jaw muscles. Causes are varied (Table 197-1), including tumors of middle cranial fossa or trigeminal nerve, metastases to base of skull, or lesions in cavernous sinus (affecting first and second divisions of fifth nerve) or superior orbital fissure (affecting first division of fifth nerve).

**FACIAL WEAKNESS [FACIAL NERVE (VII)]**  (See Figure 197-2)

Look for hemifacial weakness that includes muscles of forehead and orbicularis oculi. If lesion is in middle ear portion, taste is lost over the anterior two-thirds of tongue and there may be hyperacusis; if lesion is at internal auditory meatus, there may be involvement of auditory and vestibular nerves; pontine lesions usually affect abducens nerve and often corticospinal tract. Peripheral nerve lesions with incomplete recovery may produce continuous contractions of affected musculature (*facial myokymia*); contraction of all facial muscles on attempts to move one group selectively (*synkinesis*); hemifacial spasms; or anomalous tears when facial muscles activated as in eating (*crocodile tears*).

**Bell’s Palsy**  Most common form of idiopathic facial paralysis; affects 1 in 60 persons over a lifetime. Association with herpes simplex virus type 1. Weakness evolves over 12–48 h, sometimes preceded by retroaural pain. Hyperacusis may be present. Full recovery within several weeks or months in 80%; incomplete paralysis in first week is the most favorable prognostic sign.

Diagnosis can be made clinically in pts with (1) a typical presentation, (2) no risk factors or preexisting symptoms for other causes of facial paralysis, (3) no lesions of herpes zoster in the external ear canal, and (4) a normal neurologic examination with the exception of the facial nerve. In uncertain cases, an ESR, testing for diabetes mellitus, a Lyme titer, angiotensin-converting enzyme level, and chest x-ray for possible sarcoidosis, a lumbar puncture for possible Guillain-Barré syndrome, or MRI scanning may be indicated.

<table>
<thead>
<tr>
<th>TABLE 197-1  TRIGEMINAL NERVE DISORDERS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nuclear (brainstem) lesions</strong></td>
</tr>
<tr>
<td>Multiple sclerosis</td>
</tr>
<tr>
<td>Stroke</td>
</tr>
<tr>
<td>Syringobulbia</td>
</tr>
<tr>
<td>Glioma</td>
</tr>
<tr>
<td>Lymphoma</td>
</tr>
<tr>
<td><strong>Preganglionic lesions</strong></td>
</tr>
<tr>
<td>Acoustic neuroma</td>
</tr>
<tr>
<td>Meningioma</td>
</tr>
<tr>
<td>Metastasis</td>
</tr>
<tr>
<td>Chronic meningitis</td>
</tr>
<tr>
<td>Cavernous carotid aneurysm</td>
</tr>
<tr>
<td>Gasserian ganglion lesions</td>
</tr>
<tr>
<td>Trigeminal neroma</td>
</tr>
<tr>
<td>Herpes zoster</td>
</tr>
<tr>
<td>Infection (spread from otitis media or</td>
</tr>
<tr>
<td>mastoiditis)</td>
</tr>
</tbody>
</table>
Bell’s Palsy

Protect the eye with paper tape to depress the upper eyelid during sleep. Prednisone (60–80 mg/d over 5 days, tapered off over the next 5 days) when started early appears to shorten the recovery period and modestly improve functional outcome. A recently published trial found no added benefit of acyclovir compared to prednisolone alone; the value of valacyclovir (usual dose 1000 mg/d for 5–7 days) is not known.

Other Facial Nerve Disorders  Ramsay Hunt syndrome is caused by herpes zoster infection of geniculate ganglion; distinguished from Bell’s palsy by a vesicular eruption in pharynx and external auditory canal, and by frequent involvement of eighth cranial nerve. Acoustic neuromas often compress the seventh nerve. Infarcts, demyelinating lesions of multiple sclerosis, and tumors are common pontine causes. Bilateral facial weakness may occur in Guillain-Barré syndrome, sarcoidosis, Lyme disease, and leprosy. Hemifacial spasm may occur with Bell’s palsy, irritative lesions (e.g., acoustic neuroma, basilar artery aneurysm, an aberrant vessel compressing the nerve), or as an idiopathic disorder. Blepharospasm consists of involuntary recurrent spasms of both eyelids, usually occurring in the elderly and sometimes with associated facial spasm. May sub-
side spontaneously. Hemifacial spasm or blepharospasm can be treated by injection of botulinum toxin into the orbicularis oculi.

**OTHER CRANIAL NERVE DISORDERS**

**Disorders of the Sense of Smell**  Olfactory nerve (I) disorders are due to interference with access of the odorant to the olfactory neuroepithelium (transport loss), injury to receptor region (sensory loss), or damage to central olfactory pathways (neural loss). The causes of olfactory disorders are summarized in Table 197-2; most common are head trauma in young adults and viral infections in older adults. More than half of people over age 60 suffer from olfactory dysfunction that is idiopathic (*presbyosmia*). Patients often present with a complaint of loss of the sense of taste even though their taste thresholds may be within normal limits.

**Glossopharyngeal Neuralgia**  This form of neuralgia involves the ninth (glossopharyngeal) and sometimes portions of the tenth (vagus) cranial nerves. Paroxysmal, intense pain in tonsillar fossa of throat that may be precipitated by swallowing. There is no demonstrable sensory and motor deficit. Other diseases affecting this nerve include herpes zoster or compressive neuropathy due to tumor or aneurysm in region of jugular foramen (when associated with vagus and accessory nerve palsies).

<table>
<thead>
<tr>
<th>Transport Losses</th>
<th>Neural Losses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergic rhinitis</td>
<td>AIDS</td>
</tr>
<tr>
<td>Bacterial rhinitis and sinusitis</td>
<td>Alcoholism</td>
</tr>
<tr>
<td>Congenital abnormalities</td>
<td>Alzheimer’s disease</td>
</tr>
<tr>
<td>Nasal neoplasms</td>
<td>Cigarette smoke</td>
</tr>
<tr>
<td>Nasal polyps</td>
<td>Depression</td>
</tr>
<tr>
<td>Nasal septal deviation</td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>Nasal surgery</td>
<td>Drugs/toxins</td>
</tr>
<tr>
<td>Viral infections</td>
<td>Huntington’s chorea</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sensory Losses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drugs</td>
</tr>
<tr>
<td>Neoplasms</td>
</tr>
<tr>
<td>Radiation therapy</td>
</tr>
<tr>
<td>Toxin exposure</td>
</tr>
<tr>
<td>Viral infections</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Causes of Olfactory Dysfunction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport Losses</td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td>Allergic rhinitis</td>
</tr>
<tr>
<td>Bacterial rhinitis and sinusitis</td>
</tr>
<tr>
<td>Congenital abnormalities</td>
</tr>
<tr>
<td>Nasal neoplasms</td>
</tr>
<tr>
<td>Nasal polyps</td>
</tr>
<tr>
<td>Nasal septal deviation</td>
</tr>
<tr>
<td>Nasal surgery</td>
</tr>
<tr>
<td>Viral infections</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sensory Losses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drugs</td>
</tr>
<tr>
<td>Neoplasms</td>
</tr>
<tr>
<td>Radiation therapy</td>
</tr>
<tr>
<td>Toxin exposure</td>
</tr>
<tr>
<td>Viral infections</td>
</tr>
</tbody>
</table>
Glossopharyngeal Neuralgia

Medical therapy is similar to that for trigeminal neuralgia, and carbamazepine is generally the first choice. If drug therapy is unsuccessful, surgical procedures (including microvascular decompression, if vascular compression is evident, or rhizotomy of glossopharyngeal and vagal fibers in the jugular bulb) are frequently successful.

Dysphagia and Dysphonia

Lesions of the vagus nerve (X) may be responsible. Unilateral lesions produce drooping of soft palate, loss of gag reflex, and “curtain movement” of lateral wall of pharynx with hoarse, nasal voice. Etiologies include neoplastic and infectious processes of the meninges, tumors and vascular lesions in the medulla, motor neuron disease (e.g., ALS), or compression of the recurrent laryngeal nerve by intrathoracic processes. Aneurysm of the aortic arch, an enlarged left atrium, and tumors of the mediastinum and bronchi are much more frequent causes of an isolated vocal cord palsy than are intracranial disorders. A substantial number of cases of recurrent laryngeal palsy remain idiopathic.

With laryngeal palsy, first determine the site of the lesion. If intramedullary, there are usually other brainstem signs. If extramedullary, the glossopharyngeal (IX) and spinal accessory (XI) nerves are frequently involved (jugular foramen syndrome). If extracranial in the retroparotid space, there may be combinations of ninth, tenth, eleventh, and twelfth cranial nerve palsies and a Horner syndrome. If there is no sensory loss over the palate and pharynx and no palatal weakness or dysphagia, lesion is below the origin of the pharyngeal branches, which leave the vagus nerve high in the cervical region; the usual site of disease is then the mediastinum.

Neck Weakness

Isolated involvement of the accessory (XI) nerve can occur anywhere along its route, resulting in paralysis of the sternocleidomastoid and trapezius muscles. More commonly, involvement occurs in combination with deficits of the ninth and tenth cranial nerves in the jugular foramen or after exit from the skull. An idiopathic form of accessory neuropathy, akin to Bell’s palsy, has been described; most pts recover.

Tongue Paralysis

The hypoglossal (XII) nerve supplies the ipsilateral muscles of the tongue. The nucleus of the nerve or its fibers of exit may be involved by intramedullary lesions such as tumor, poliomyelitis, or most often motor neuron disease. Lesions of the basal meninges and the occipital bones (platybasia, invagination of occipital condyles, Paget’s disease) may compress the nerve in its extramedullary course or in the hypoglossal canal. Isolated lesions of unknown cause can occur. Atrophy and fasciculation of the tongue develop weeks to months after interruption of the nerve.

MULTIPLE CRANIAL NERVE PALSY

Approach to the Patient with Multiple Cranial Nerve Palsies

First determine whether the process is within the brainstem or outside it. Lesions on the surface of the brainstem tend to involve adjacent cranial nerves in succession with only late and slight involvement of long sensory and motor pathways. The opposite is true of processes within the brainstem. In-
volvement of multiple cranial nerves outside of the brainstem may be due to diabetes, trauma, infectious and noninfectious (especially carcinomatous) causes of meningitis; granulomatous diseases including sarcoidosis, tuberculosis, and Wegener’s granulomatosis; tumors; and enlarging saccular aneurysms. A purely motor disorder without atrophy raises a question of myasthenia gravis. Facial diplegia is common in Guillain-Barré syndrome. Ophthalmoplegia may occur with Guillain-Barré syndrome (Fisher variant) or Wernicke’s disease. The cavernous sinus syndrome (Fig. 197-3) is frequently life-threatening. It often presents as orbital or facial pain; orbital swelling and chemosis; fever; oculomotor neuropathy; and trigeminal neuropathy affecting the ophthalmic (V1) and occasionally maxillary (V2) divisions. Cavernous sinus thrombosis, often secondary to infection from orbital cellulitis or sinusitis, is the most frequent cause; other etiologies include aneurysm of the carotid artery, a carotid-cavernous fistula (orbital bruit may be present), meningioma, nasopharyngeal carcinoma, other tumors, or an idiopathic granulomatous disorder (Tolosa-Hunt syndrome). In infectious cases, prompt administration of broad-spectrum antibiotics, drainage of any abscess cavities, and identification of the offending organism is essential. Anticoagulant therapy may benefit cases of primary thrombosis. Repair or occlusion of the carotid artery may be required for treatment of fistulas or aneurysms. The Tolosa-Hunt syndrome generally responds to glucocorticoids.

For a more detailed discussion, see Beal MF, Hauser SL: Trigeminal Neuralgia, Bell’s Palsy, and Other Cranial Nerve Disorders, Chap. 371, p. 2583; and Lalwani AK: Disorders of Smell, Taste, and Hearing, Chap. 30, p. 196, in HPIM-17.
Spinal cord disorders can be devastating, but many are treatable if recognized early (Table 198-1). Knowledge of relevant spinal cord anatomy is often the key to correct diagnosis (Fig. 198-1).

**SYMPTOMS AND SIGNS**

Sensory symptoms often include paresthesias; may begin in one or both feet and ascend. Sensory level to pin sensation or vibration often correlates well with location of transverse lesions. May have isolated pain/temperature sensation loss over the shoulders (“cape” or “syringomyelic” pattern) or loss of sensation to vibration/position on one side of the body and pain/temperature loss on the other (Brown-Séquard hemicord syndrome).

Motor symptoms are caused by disruption of corticospinal tracts that leads to quadriplegia or paraplegia with increased muscle tone, hyperactive deep ten-

### Table 198-1  Treatable Spinal Cord Disorders

<table>
<thead>
<tr>
<th>Compressive</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidural, intradural, or intramedullary neoplasm</td>
<td></td>
</tr>
<tr>
<td>Epidural abscess</td>
<td></td>
</tr>
<tr>
<td>Epidural hemorrhage</td>
<td></td>
</tr>
<tr>
<td>Cervical spondylisis</td>
<td></td>
</tr>
<tr>
<td>Herniated disc</td>
<td></td>
</tr>
<tr>
<td>Posttraumatic compression by fractured or displaced vertebra or hemorrhage</td>
<td></td>
</tr>
<tr>
<td>Vascular</td>
<td></td>
</tr>
<tr>
<td>Arteriovenous malformation</td>
<td></td>
</tr>
<tr>
<td>Antiphospholipid syndrome and other hypercoagulable states</td>
<td></td>
</tr>
<tr>
<td>Inflammatory</td>
<td></td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td></td>
</tr>
<tr>
<td>Neuromyelitis optica</td>
<td></td>
</tr>
<tr>
<td>Transverse myelitis</td>
<td></td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td></td>
</tr>
<tr>
<td>Vasculitis</td>
<td></td>
</tr>
<tr>
<td>Infectious</td>
<td></td>
</tr>
<tr>
<td>Viral: VZV, HSV-1 and -2, CMV, HIV, HTLV-I, others</td>
<td></td>
</tr>
<tr>
<td>Bacterial and mycobacterial: Borrelia, Listeria, syphilis, others</td>
<td></td>
</tr>
<tr>
<td>Mycoplasma pneumoniaiae</td>
<td></td>
</tr>
<tr>
<td>Parasitic: schistosomiasis, toxoplasmosis</td>
<td></td>
</tr>
<tr>
<td>Developmental</td>
<td></td>
</tr>
<tr>
<td>Syringomyelia</td>
<td></td>
</tr>
<tr>
<td>Meningomyelocoele</td>
<td></td>
</tr>
<tr>
<td>Tethered cord syndrome</td>
<td></td>
</tr>
<tr>
<td>Metabolic</td>
<td></td>
</tr>
<tr>
<td>Vitamin B₁₂ deficiency (subacute combined degeneration)</td>
<td></td>
</tr>
<tr>
<td>Copper deficiency</td>
<td></td>
</tr>
</tbody>
</table>

*Note: VZV, varicella-zoster virus; HSV, herpes simplex virus; CMV, cytomegalovirus; HTLV, human T cell lymphotropic virus.*
Spinal Cord Diseases

CHAPTER 198

Don reflexes, and extensor plantar responses. With acute severe lesions there may be initial flaccidity and areflexia (spinal shock).

Autonomic dysfunction includes primarily urinary retention; should raise suspicion of spinal cord disease when associated with back or neck pain, weakness, and/or a sensory level.

Pain may be present. Midline back pain is of localizing value; interscapular pain may be first sign of midthoracic cord compression; radicular pain may mark site of more laterally placed spinal lesion; pain from lower cord (conus medullaris) lesion may be referred to low back.

SPECIFIC SIGNS BY SPINAL CORD LEVEL

Approximate indicators of level of lesion include the location of a sensory level, a band of hyperalgesia/hyperpathia at the upper end of the sensory disturbance, identification of isolated atrophy or fasciculations, or lost tendon reflex at a specific spinal cord segment.

Lesions Near the Foramen Magnum  Weakness of the ipsilateral shoulder and arm, followed by weakness of ipsilateral leg, then contralateral leg, then contralateral arm, with respiratory paralysis.

Cervical Cord  Best localized by noting pattern of motor weakness and areflexia; shoulder (C5), biceps (C5-6), brachioradialis (C6), triceps/finger and wrist extensors (C7), finger flexors (C8).
Thoracic Cord  Localized by identification of a sensory level on the trunk.

Lumbar Cord  Upper lumbar cord lesions paralyze hip flexion and knee extension, whereas lower lumbar lesions affect foot and ankle movements, knee flexion, and thigh extension.

Sacral Cord (Conus Medullaris)  Saddle anesthesia, early bladder/bowel dysfunction, impotence; muscle strength is largely preserved.

Cauda Equina (Cluster of Nerve Roots Derived from Lower Cord)  Lesions below spinal cord termination at the L1 vertebral level produce a flaccid, areflexic, asymmetric paraparesis with bladder/bowel dysfunction and sensory loss below L1; pain is common and projected to perineum or thighs.

INTRAMEDULLARY AND EXTRAMEDULLARY SYNDROMES

Spinal cord disorders may be intramedullary (arising from within the substance of the cord) or extramedullary (compressing the cord or its blood supply). Extramedullary lesions often produce radicular pain, early corticospinal signs, and sacral sensory loss. Intramedullary lesions produce poorly localized burning pain, less prominent corticospinal signs, and often spare perineal/sacral sensation.

ACUTE AND SUBACUTE SPINAL CORD DISEASES  (See Chap. 21)

1. Neoplastic spinal cord compression (see Chap. 21): Most are epidural in origin, resulting from metastases to the adjacent spinal bones (Fig. 198-2). Almost any tumor can be responsible: breast, lung, prostate, lymphoma, and plasma cell dyscrasias most frequent. Thoracic cord most commonly involved. Initial symptom is usually back pain, worse when recumbent, with local tenderness preceding other symptoms by many weeks. Spinal cord compression due to metastases is a medical emergency; in general, therapy will not reverse paralysis of >48 h duration.

**FIGURE 198-2** Epidural spinal cord compression due to breast carcinoma. Sagittal T1-weighted (A) and T2-weighted (B) MRI scans through the cervicothoracic junction reveal an infiltrated and collapsed second thoracic vertebral body with posterior displacement and compression of the upper thoracic spinal cord. The low-intensity bone marrow signal in A signifies replacement by tumor.
2. **Spinal epidural abscess**: Triad of fever, localized spinal pain, and myelopathy (progressive weakness and bladder symptoms); once neurologic signs appear, cord compression rapidly progresses.

3. **Spinal epidural hematoma**: Presents as focal or radicular pain followed by variable signs of a spinal cord or cauda equina disorder.

4. **Acute disk herniation**: Cervical and thoracic disk herniations are less common than lumbar.

5. **Spinal cord infarction**: Anterior spinal artery infarction produces paraplegia or quadriplegia, sensory loss affecting pain/temperature but sparing vibration/position sensation (supplied by posterior spinal arteries), and loss of sphincter control. Onset sudden or evolving over minutes or a few hours. Associated conditions: aortic atherosclerosis, dissecting aortic aneurysm, hypotension. Therapy is directed at the predisposing condition.

6. **Immune-mediated myelopathies**: Acute transverse myelopathy (ATM) occurs in 1% of pts with SLE; associated with antiphospholipid antibodies. Sjögren’s and Behçet’s syndromes, mixed connective tissue disease, and p-ANCA vasculitis are other causes. Sarcoid can produce ATM with large edematous swelling of the spinal cord. Demyelinating diseases, either neumomyelitis optica (NMO) or multiple sclerosis, can also present as ATM; glucocorticoids, consisting of IV methylprednisolone followed by oral prednisone, are indicated for moderate to severe symptoms and refractory cases may respond to plasma exchange (Chap. 200). Treatment with anti-CD20 monoclonal Ab may protect against relapses in NMO. Other cases of ATM are idiopathic.

7. **Infectious myelopathies**: Herpes zoster is the most common viral agent, but herpes simplex virus types 1 and 2, EBV, CMV, and rabies virus are also well-described; in cases of suspected viral myelitis, antivirals may be appropriately started pending laboratory confirmation. Bacterial and mycobacterial causes are less common. Schistosomiasis is an important cause worldwide.

**CHRONIC MYELOPATHIES**

1. **Spondylitic myelopathies**: One of the most common causes of gait difficulty in the elderly. Presents as neck and shoulder pain with stiffness, radicular arm pain, and progressive spastic paraparesis with paresthesias and loss of vibration sense; in advanced cases, urinary incontinence may occur. A tendon reflex in the arms is often diminished at some level. Diagnosis is best made by MRI. Treatment is surgical (Chap. 36).

2. **Vascular malformations**: An important treatable cause of progressive or episodic myelopathy. May occur at any level; diagnosis is made by contrast-enhanced MRI (Fig 198-3) confirmed by selective spinal angiography. Treatment is embolization with occlusion of the major feeding vessels.

3. **Retrovirus-associated myelopathies**: Infection with HTLV-I may produce a slowly progressive spastic paraparesis with variable pain, sensory loss, and bladder disturbance; diagnosis is made by demonstration of specific serum antibody. Treatment is symptomatic. A progressive vacuolar myelopathy may also result from HIV infection.

4. **Syringomyelia**: Cavitary expansion of the spinal cord resulting in progressive myelopathy; may be an isolated finding or associated with protrusion of cerebellar tonsils into cervical spinal canal (Chiari type 1). Classic presentation is loss of pain/temperature sensation in the neck, shoulders, forearms, or hands with areflexic weakness in the upper limbs and progressive spastic paraparesis; cough headache, facial numbness, or thoracic kyphoscoliosis may occur. Diagnosis is made by MRI; treatment is surgical and often unsatisfactory.
5. **Multiple sclerosis**: Spinal cord involvement is common, and is a major cause of disability in progressive forms of MS (Chap. 200).

6. **Subacute combined degeneration (vitamin B₁₂ deficiency)**: Paresthesias in hands and feet, early loss of vibration/position sense, progressive spastic/ataxic weakness, and areflexia due to associated peripheral neuropathy; mental changes ("megaloblastic madness") and optic atrophy may be present along with a serum macrocytic anemia. Diagnosis is confirmed by a low serum B₁₂ level, elevated levels of homocysteine and methylmalonic acid, and in uncertain cases, a positive Schilling test. Treatment is vitamin replacement.

7. **Hypocuric myelopathy**: Clinically nearly identical to subacute combined degeneration (above). Low levels of serum copper and usually ceruloplasmin make the diagnosis. Some cases idiopathic and others follow GI procedures that hinder absorption. Treatment is oral copper supplementation.

8. **Tabes dorsalis (tertiary syphilis)**: May present as lancinating pains, gait ataxia, bladder disturbances, and visceral crises. Cardinal signs are areflexia in the legs, impaired vibration/position sense, Romberg sign, and Argyll Robertson pupils, which fail to constrict to light but react to accommodation.

9. **Familial spastic paraplegia**: Progressive spasticity and weakness in the legs occurring on a familial basis; may be autosomal dominant, recessive, or X-linked. Over 20 different loci identified.

10. **Adrenomyeloneuropathy**: X-linked disorder that is a variant of adrenoleukodystrophy. Usually affected males have a history of adrenal insufficiency and then develop a progressive spastic paraparesis. Female heterozygotes may develop a slower progressive myelopathy without adrenal insufficiency. Diagnosis made by elevated very long chain fatty acids in serum. No
therapy is clearly effective although bone marrow transplantation and nutritional supplements have been tried.

**COMPLICATIONS**

Bladder dysfunction with risk of urinary tract infection; bowel dysmotility; pressure sores; in high cervical cord lesions, mechanical respiratory failure; paroxysmal hypertension or hypotension with volume changes; severe hypertension and bradycardia in response to noxious stimuli or bladder or bowel distention; venous thrombosis and pulmonary embolism.

For a more detailed discussion, see Hauser SL, Ropper AH: Diseases of the Spinal Cord, Chap. 372, p. 2588, in HPIM-17.
although no good data support this practice. Low-dose subcutaneous heparin for immobile pts.

PRINCIPAL INTRACRANIAL TUMORS

Astrocytomas  Most common primary intracranial neoplasm. Only known risk factors are ionizing radiation and uncommon hereditary syndromes (neurofibromatosis, tuberous sclerosis). Prognosis poor if age >65 years, poor baseline functional status, high-grade tumor. Difficult to treat; infiltration along white matter pathways prevents total resection. Imaging studies (Fig. 199-1) fail to indicate full tumor extent. Surgery for tissue diagnosis and to control mass effect; aggressive resection may correlate with survival, especially in younger pts. Mean survival ranges from 93 months for low-grade tumors to 5 months for high-grade tumors. Radiation therapy (RT) prolongs survival and improves quality of life. Systemic chemotherapy with temozolomide, an orally administered alkylating agent, is marginally effective, often employed as adjunct to RT for high-grade gliomas. An alternative approach to chemotherapy of high-grade gliomas is direct implantation of chemotherapy wafers into the resection cavity at the time of surgery. Role of stereotactic radiosurgery (single dose, highly focused radiation—gamma knife) unclear; most useful for tumors <4 cm in diameter. Interstitial brachytherapy (stereotactic implantation of radioactive beads) reserved for tumor recurrence; associated with necrosis of normal brain tissue. For low-grade astrocytoma, optimal management is uncertain; resection with or without RT most often employed.

FIGURE 199-1  Malignant astrocytoma (glioblastoma). Coronal proton density–weighted MR scan through the temporal lobes demonstrates a heterogeneous right temporal lobe mass (arrows) compressing the third and lateral ventricles. The area of hypointense signal (double arrows) indicates either hemorrhage or calcification. Heterogeneous MR signal intensity is typical of glioblastoma.
Oligodendrogliomas  Supratentorial, often with areas of calcification; some have a mixture of astrocytic and oligodendroglial cells. As oligodendroglial component increases in these mixed tumors, so does long-term survival. For low-grade, median survival is 7-8 years with a substantial number of pts with prolonged survival (>10 years). For high-grade tumors, median survival ~5 years. Total surgical resection often possible; chemotherapy response improved when deletions of chromosomes 1p and 19q present.

Ependymomas  Derived from ependymal cells; highly cellular. Location—spinal canal more than intracranial in adults. If total excision possible, 5-year disease-free survival >80%; postoperative RT used if complete excision not possible.

Primitive Neuro-Ectodermal Tumors (PNET)  Half in posterior fossa; highly cellular; derived from neural precursor cells. Treat with surgery and RT. Aggressive treatment can result in prolonged survival, although half of adult pts will relapse within 5 years of treatment.

Primary CNS Lymphomas  B cell malignancy; most occur in immunosuppressed pts (organ transplantation, AIDS). May present as a single mass lesion (immunocompetent pts) or as multiple mass lesions or meningeal disease (immunosuppressed pts). Slit-lamp exam necessary to exclude ocular involvement. Prognosis generally poor. Dramatic, transient responses occur with glucocorticoids. In immunocompetent pts, chemotherapy (rituximab, high-dose methotrexate often along with other agents such as vincristine and procarbazine), and RT may increase survival to ≥3 years; AIDS-related cases survive ≤3 months.

Meningiomas  Extraaxial mass attached to dura; dense and uniform contrast enhancement is diagnostic (Fig. 199-2). Total surgical resection of benign meningiomas is curative. With subtotal resection, local RT reduces recurrence to <10%. Small, asymptomatic meningiomas may be followed radiologically without surgery. Treat rare aggressive meningiomas with excision and RT.

Schwannomas  Vestibular schwannomas present as progressive, unexplained unilateral hearing loss. MRI reveals dense, uniformly enhancing tumor at the cerebellopontine angle. Surgical excision may preserve hearing.

TUMORS METASTATIC TO THE NERVOUS SYSTEM

Hematogenous spread most common. Skull metastases rarely invade CNS; may compress adjacent brain or cranial nerves or obstruct intracranial venous sinuses. Primary tumors that commonly metastasize to the nervous system are listed in Table 199-1. Brain metastases are well demarcated by MRI and enhance with gadolinium. Ring enhancement is nonspecific; differential diagnosis includes brain abscess, radiation necrosis, toxoplasmoma, granulomas, tuberculosis, sarcoidosis, demyelinating lesions, primary brain tumors, CNS lymphoma, stroke, hemorrhage, and trauma. CSF cytology is unnecessary—intraparenchymal metastases rarely shed cells into CSF. One-third of pts presenting with brain metastasis have unknown primary (ultimately small cell lung cancer, melanoma most frequent); primary tumor never identified in 30%. Screen for occult cancer: examine skin and thyroid gland; blood carcinoembryonic antigen (CEA) and liver function tests; CT of chest, abdomen, and pelvis. Further imaging studies unhelpful if above studies negative. Biopsy of primary tumor or accessible brain metastasis is needed to plan treatment. Treatment is palliative—glucocorticoids, anticonvulsants, RT, or surgery may improve quality of life. Whole-brain RT is often given, because multiple microscopic tumor deposits are likely throughout the brain; stereotaxic radiosurgery is of benefit in pts with four or fewer metas-
tases demonstrated by MRI. If a single metastasis is found, it may be surgically excised followed by whole-brain RT. Systemic chemotherapy may produce dramatic responses in isolated cases.

**Leptomeningeal Metastases**  Presents as headache, encephalopathy, cranial nerve or polyradicular symptoms. Diagnosis by CSF cytology, MRI (nodular meningeal tumor deposits or diffuse meningeal enhancement), or meningeal biopsy. Associated with hydrocephalus due to CSF pathway obstruction. Aggressive treatment (intrathecal methotrexate, focal external beam RT) produces sustained response (≥ 6 months) in 20% of pts.

**Spinal Cord Compression from Metastases**  (See Chap. 21) Expansion of vertebral body metastasis posteriorly into epidural space compresses cord. Most

<table>
<thead>
<tr>
<th>Site of Primary Tumor</th>
<th>Brain Metastases, %</th>
<th>Leptomeningeal Metastases, %</th>
<th>Spinal Cord Compression, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung</td>
<td>40</td>
<td>24</td>
<td>18</td>
</tr>
<tr>
<td>Breast</td>
<td>19</td>
<td>41</td>
<td>24</td>
</tr>
<tr>
<td>Melanoma</td>
<td>10</td>
<td>12</td>
<td>4</td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td>7</td>
<td>13</td>
<td>6</td>
</tr>
<tr>
<td>Genitourinary tract</td>
<td>7</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>Other</td>
<td>17</td>
<td>10</td>
<td>30</td>
</tr>
</tbody>
</table>

**FIGURE 199-2** Meningioma. Coronal postcontrast T1-weighted MR image demonstrates an enhancing extraaxial mass arising from the falx cerebri (arrows). There is a “dural tail” of contrast enhancement extending superiorly along the intrahemispheric septum.
common primary tumors are lung, breast, or prostate primary. Back pain (>90%) precedes development of weakness, sensory level, or incontinence. Medical emergency; early recognition of impending spinal cord compression essential to avoid devastating sequelae. Diagnosis is by spine MRI.

COMPLICATIONS OF RADIATION THERAPY

Three patterns of radiation injury after CNS RT:

1. Acute—headache, sleepiness, worse neurologic deficits during or immediately after RT. Rarely seen with current protocols. Self-limited and improves with glucocorticoids.

2. Early delayed—somnolence (children), Lhermitte's sign; within 4 months of RT. Increased T2 signal on MRI. Also self-limited and improves with glucocorticoids.

3. Late delayed—dementia or other progressive neurologic deficits; typically 8–24 months after RT. White matter abnormalities on MRI; ring-enhancing mass due to radiation necrosis. Positron emission tomography (PET) can distinguish delayed necrosis from tumor recurrence. Progressive radiation necrosis is best treated palliatively with surgical resection. Radiation injury of large arteries accelerates the development of atherosclerosis, increasing the risk of stroke years after RT. Endocrine dysfunction due to hypothalamus or pituitary gland injury can be due to delayed effects of RT. Development of a second neoplasm after RT also is a risk years after exposure.

For a more detailed discussion, see Sagar SM, Israel MA: Primary and Metastatic Tumors of the Nervous System, Chap. 374, p. 2601, in HPIM-17.

Multiple Sclerosis (MS)

Characterized by chronic inflammation and selective destruction of CNS myelin; peripheral nervous system is spared. Pathologically, the multifocal scarred lesions of MS are termed plaques. Etiology is thought to be autoimmune, with susceptibility determined by genetic and environmental factors. MS affects 350,000 Americans; onset is most often in early to middle adulthood, and women are affected approximately three times as often as men.

CLINICAL FEATURES

Onset may be abrupt or insidious. Some pts have symptoms that are so trivial that they may not seek medical attention for months or years. Most common are recurrent attacks of focal neurologic dysfunction, typically lasting weeks or months, and followed by variable recovery; some pts initially present with slowly progressive neurologic deterioration. Symptoms often transiently worsen with fatigue, stress, exercise, or heat. Manifestations of MS are protean but commonly include weakness and/or sensory symptoms involving a limb, visual dif-
Neurology

SECTION 14

ficulties, abnormalities of gait and coordination, urinary urgency or frequency, and abnormal fatigue. Motor involvement can present as a heavy, stiff, weak, or clumsy limb. Localized tingling, “pins and needles,” and “dead” sensations are common. Optic neuritis can result in blurring of vision, especially in the central visual field, often with associated retroorbital pain accentuated by eye movement. Involvement of the brainstem may result in diplopia, nystagmus, vertigo, or facial pain, numbness, weakness, hemispasm, or myokymia (rippling muscular contractions). Ataxia, tremor, and dysarthria may reflect disease of cerebellar pathways. Lhermitte’s symptom, a momentary electric shock-like sensation evoked by neck flexion, indicates disease in the cervical spinal cord. Diagnostic criteria are listed in Table 200-1; MS mimics are summarized in Table 200-2.

PHYSICAL EXAMINATION

Abnormal signs usually more widespread than expected from the history. Check for abnormalities in visual fields, loss of visual acuity, disturbed color perception, optic pallor or papillitis, afferent pupillary defect (paradoxical dilation to direct light following constriction to consensual light), nystagmus, internuclear

<table>
<thead>
<tr>
<th>TABLE 200-1</th>
<th>DIAGNOSTIC CRITERIA FOR MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Examination must reveal objective abnormalities of the CNS.</td>
<td></td>
</tr>
<tr>
<td>2. Involvement must reflect predominantly disease of white matter long tracts, usually including (a) pyramidal pathways, (b) cerebellar pathways, (c) medial longitudinal fasciculus, (d) optic nerve, and (e) posterior columns.</td>
<td></td>
</tr>
<tr>
<td>3. Examination or history must implicate involvement of two or more areas of the CNS.</td>
<td></td>
</tr>
<tr>
<td>a. MRI may be used to document a second lesion when only one site of abnormality has been demonstrable on examination. A confirmatory MRI must have either four lesions involving the white matter or three lesions if one is periventricular in location. Acceptable lesions must be &gt;3 mm in diameter. For patients older than 30 years, two of the following criteria must also be met: (a) lesion size &gt;5 mm, (b) lesions adjacent to the bodies of the lateral ventricles, and (c) lesion(s) present in the posterior fossa.</td>
<td></td>
</tr>
<tr>
<td>b. Evoked response testing may be used to document a second lesion not evident on clinical examination.</td>
<td></td>
</tr>
<tr>
<td>4. The clinical pattern must consist of (a) two or more separate episodes of worsening involving different sites of the CNS, each lasting at least 24 h and occurring at least 1 month apart, or (b) gradual or stepwise progression over at least 6 months if accompanied by increased IgG synthesis or two or more oligoclonal bands. MRI may be used to document dissemination in time if a new T2 lesion or a Gd-enhancing lesion is seen 3 or more months after a clinically isolated syndrome.</td>
<td></td>
</tr>
<tr>
<td>5. The patient’s neurologic condition could not better be attributed to another disease.</td>
<td></td>
</tr>
</tbody>
</table>

**Diagnostic Categories**

1. **Definite MS**: All five criteria fulfilled.
2. **Probable MS**: All five criteria fulfilled except (a) only one objective abnormality despite two symptomatic episodes or (b) only one symptomatic episode despite two or more objective abnormalities.
3. **At risk for MS**: Criteria 1, 2, 3, and 5 fulfilled; patient has only one symptomatic episode and one objective abnormality.

**Note:** CNS, central nervous system; MRI, magnetic resonance imaging; Gd, gadolinium.
ophthalmoplegia (slowness or loss of adduction in one eye with nystagmus in the abducting eye on lateral gaze), facial numbness or weakness, dysarthria, weakness and spasticity, hyperreflexia, ankle clonus, upgoing toes, ataxia, sensory abnormalities.

DISEASE COURSE

Four general categories:

- **Relapsing-remitting MS (RRMS)** is characterized by recurrent attacks of neurologic dysfunction usually with or without recovery; between attacks, no progression of neurologic impairment is noted. Accounts for 85% of new-onset MS cases.
- **Secondary progressive MS (SPMS)** always initially presents as RRMS but evolves to be gradually progressive. The majority of RRMS eventually evolves into SPMS.
- **Primary progressive MS (PPMS)** is characterized by gradual progression of disability from onset without discrete attacks; 15% of new-onset MS cases.
- **Progressive-relapsing MS (PRMS)** is a rare form that begins with a primary progressive course, but later superimposed relapses occur.

MS is a chronic illness; 15 years after diagnosis, only 20% of pts have no functional limitation; one-third to one-half will have progressed to SPMS and will require assistance with ambulation.

LABORATORY EVALUATION

MRI reveals multifocal bright areas on T2-weighted sequences in >95% of pts, often in periventricular location; gadolinium enhancement indicates acute lesions with disruption of blood-brain barrier (Fig. 200-1). MRI also useful to ex-
include MS mimics, although findings in MS are not completely specific for the disorder. CSF findings include mild lymphocytic pleocytosis (5–75 cells in 25%), oligoclonal bands (75–90%), elevated IgG (80%), and normal total protein level. Visual, auditory, and somatosensory evoked response tests can identify lesions that are clinically silent; one or more evoked response tests abnormal in 80–90% of pts. Urodynamic studies aid in management of bladder symptoms.

FIGURE 200-1 MRI findings in MS. A. Axial first-echo image from T2-weighted sequence demonstrates multiple bright signal abnormalities in white matter, typical for MS. B. Sagittal T2-weighted FLAIR (fluid attenuated inversion recovery) image in which the high signal of CSF has been suppressed. CSF appears dark, while areas of brain edema or demyelination appear high in signal as shown here in the corpus callosum (arrows). Lesions in the anterior corpus callosum are frequent in MS and rare in vascular disease. C. Sagittal T2-weighted fast spin echo image of the thoracic spine demonstrates a fusiform high-signal-intensity lesion in the mid thoracic spinal cord. D. Sagittal T1-weighted image obtained after the intravenous administration of gadolinium DPTA reveals focal areas of blood-brain barrier disruption, identified as high-signal-intensity regions (arrows).
DISEASE-MODIFYING THERAPIES FOR RELAPSING FORMS OF MS (RRMS, SPMS WITH EXACERBATIONS)

Five treatments are available: interferon (IFN)-β1a (Avonex; 30 μg IM once a week), IFN-β1a (Rebif; 44 μg SC thrice weekly), IFN-β1b (Betaseron; 250 μg SC every other day), glatiramer acetate (Copaxone; 12 mg/d SC), and natalizumab (Tysabri; 300 mg IV every 4 weeks). Each of the first four therapies reduces annual exacerbation rates by ~30% and also reduces the development of new MRI lesions. IFN preparations that are given multiple times weekly (e.g., Rebif or Betaseron) appear to have slightly greater efficacy compared with once-weekly agents (e.g., Avonex) but are also more likely to induce neutralizing antibodies, which may reduce the clinical benefit. Natalizumab is the most effective MS agent available. It dramatically reduces the attack rate and significantly improves all measures of disease severity in MS; however, because of the development of progressive multifocal leukoencephalopathy (PML) in rare patients, it is currently used only for patients who have failed other therapies or who have particularly aggressive presentations. Regardless of which agent is chosen first, treatment should probably be altered in pts who continue to have frequent attacks (Fig. 200-2).

Side effects of IFN include flulike symptoms, local injection site reactions (with SC dosing), and mild abnormalities on routine laboratory evaluation (e.g., elevated liver function tests or lymphopenia). Rarely, more severe hepatotoxicity may occur. Side effects to IFN usually subside with time. Injection site reactions also occur with glatiramer acetate but are less severe than with IFN. Approximately 15% of pts receiving glatiramer acetate experience one or more episodes of flushing, chest tightness, dyspnea, palpitations, and anxiety.

Early treatment with a disease-modifying drug is appropriate for most MS patients. It is reasonable to delay initiating treatment in pts with (1) normal neurologic exams, (2) a single attack or a low attack frequency, and (3) a low “burden of disease” as assessed by brain MRI. Untreated pts need to be followed closely with periodic brain MRI scans; the need for therapy is reassessed if the scans reveal evidence of ongoing disease.

ACUTE RELAPSES

Acute relapses that produce functional impairment may be treated with a short course of IV methylprednisolone (1 g IV qA.M. × 3–5 days) followed by oral prednisone (60 mg qA.M. × 4; 40 mg qA.M. × 4; 20 mg qA.M. × 3). This regimen modestly reduces the severity and shortens the duration of attacks. Plasma exchange (7 exchanges: 40–60 mL/kg, every other day for 14 days) may benefit patients with fulminant attacks of demyelination (not only MS) that are unresponsive to glucocorticoids; cost is high and evidence of efficacy is only preliminary.

PROGRESSIVE SYMPTOMS

For pts with secondary progressive MS who continue to experience relapses, treatment with one of the IFNs is reasonable; however, the IFNs are ineffective against purely progressive MS symptoms. The immunosuppressant/immunomodulator drug mitoxantrone (12 mg/m² by IV infusion every 3 months) is approved in the United States for treatment of secondary progressive MS; however, the evidence for efficacy is relatively weak, and dose-related cardiac toxicity is an important concern. Methotrexate (7.5–20 mg PO once each week) or azathioprine (2–3 mg/kg per day PO) is sometimes tried, but efficacy is modest. Pulse therapy with cyclophosphamide is employed in some centers for young adults with aggressive forms of MS. Other smaller studies have examined monthly
FIGURE 200-2 Therapeutic decision-making for MS.

A

Relapsing-Remitting MS

Acute neurologic change

Exacerbation

Functional impairment

Methylprednisolone/prednisone

Identify and treat any underlying infection or trauma

Prophylaxis
1. IFN-β1a, or
2. IFN-β1b, or
3. Glatiramer acetate

Symptomatic therapy

No functional impairment

Continue periodic clinical/MRI assessments

Intolerant or poor response

Natalizumab

Good response

Continue therapy

Stable

?- Low attack frequency or single attack
?- Normal neurologic exam
?- Low disease burden by MRI

Pseudoexacerbation

No change

Intolerant or poor response

Successive trials of alternatives

B

Progressive MS

Secondary progressive MS

With relapses

1. IFN-β1a, or
2. IFN-β1b

Intolerant or poor response

No proven treatment

Consider Rx with one of the following:
1. Mitoxantrone
2. Azathioprine
3. Methotrexate
4. Pulse cyclophosphamide
5. IVIg
6. Pulse methylprednisolone

Without relapses

Primary progressive MS

Symptomatic therapy

Consider Rx with one of the following:
1. IFN-β1a, or
2. IFN-β1b

Intolerant or poor response

Clinical or MRI change

Repeat clinical exam and MRI in 6 months

Continue periodic clinical/MRI assessments

No change

Identify and treat any underlying infection or trauma

Prophylaxis
1. IFN-β1a, or
2. IFN-β1b, or
3. Glatiramer acetate

Symptomatic therapy

No change

Intolerant or poor response

Successive trials of alternatives

Exacerbation

Acute neurologic change

Yes

No

Functional impairment

Methylprednisolone/prednisone

Identify and treat any underlying infection or trauma

Prophylaxis
1. IFN-β1a, or
2. IFN-β1b, or
3. Glatiramer acetate

Symptomatic therapy

No functional impairment

Continue periodic clinical/MRI assessments

Intolerant or poor response

Natalizumab

Good response

Continue therapy

Stable

?- Low attack frequency or single attack
?- Normal neurologic exam
?- Low disease burden by MRI

Pseudoexacerbation

No change

Intolerant or poor response

Successive trials of alternatives

Intolerant or poor response

Natalizumab
pulses of intravenous immunoglobulin (IVIg) or intravenous methylprednisolone. For patients with PPMS, symptomatic therapy only is recommended.

**SYMPTOMATIC THERAPY**

Spasticity may respond to physical therapy, floresal (20–120 mg/d), diazepam (2–40 mg/d), tizanidine (8–32 mg/d), dantrolene (25–400 mg/d), and cyclobenzaprine hydrochloride (10–60 mg/d). Dysesthesia may respond to carbamazepine (100–1200 mg/d in divided doses), phenytoin (300 mg/d), gabapentin (300–3600 mg/d), pregabalin (50–300 mg/d), or amitriptyline (50–200 mg/d). Treatment of bladder symptoms is based on the underlying pathophysiology investigated with urodynamic testing: bladder hyperreflexia is treated with evening fluid restriction and frequent voiding; if this fails, anticholinergics such as oxybutinin (5–15 mg/d) may be tried; hyporeflexia is treated with the cholinergic drug Bethanechol (10–50 mg three to four times a day), and dyssynergia due to loss of coordination between bladder wall and sphincter muscles is treated with anticholinergics and intermittent catheterization. Depression should be treated aggressively.

**CLINICAL VARIANTS OF MS**

Neuromyelitis optica (NMO), or Devic’s syndrome, consists of separate attacks of acute optic neuritis (bilateral or unilateral) and myelitis. In contrast to MS, the brain MRI is typically, but not always, normal. A focal enhancing region of swelling and cavitation, extending over three or more spinal cord segments, is typically seen on spinal MRI. A highly specific autoantibody directed against the water channel aquaporin-4 is present in the sera of more than half of patients with a clinical diagnosis of NMO. Acute attacks are usually treated with high-dose glucocorticoids as for MS exacerbations. Plasma exchange has also been used empirically for acute episodes that fail to respond to glucocorticoids. Immunosuppressants or IFNs are sometimes used in the hope that further relapses will be prevented; preliminary evidence indicates that B cell depletion with anti-CD20 monoclonal antibody (rituximab) holds promise in preventing NMO relapses.

Acute MS (Marburg’s variant) is a fulminant demyelinating process that progresses to death within 1–2 years. No controlled trials of therapy exist; high-dose glucocorticoids, plasma exchange, and cyclophosphamide have been tried, with uncertain benefit.

**ACUTE DISSEMINATED ENCEPHALOMYELITIS (ADEM)**

A fulminant, often devastating, demyelinating disease that has a monophasic course and may be associated with antecedent immunization or infection. Signs of disseminated neurologic disease are consistently present (e.g., hemiparesis or quadriplegia, extensor plantar responses, lost or hyperactive tendon reflexes, sensory loss, and brainstem involvement). Fever, headache, meningeal response, lethargy progressing to coma, and seizures may occur. CSF pleocytosis, generally 200 cells/μl, is common. MRI may reveal extensive Gadolinium enhancement of white matter in brain and spinal cord. Initial treatment is with high-dose glucocorticoids. Patients who fail to respond may benefit from a course of plasma exchange or IVIg.

For a more detailed discussion, see Hauser SL, Goodin DS: Multiple Sclerosis and Other Demyelinating Diseases, Chap. 375, p. 2611, in HPIM-17.
Acute infections of the nervous system include bacterial meningitis, viral meningitis, encephalitis, focal infections such as brain abscess and subdural empyema, and infectious thrombophlebitis. Key goals: emergently distinguish between these conditions, identify the pathogen, and initiate appropriate antimicrobial therapy.

**APPRAOCH TO THE PATIENT WITH ACUTE INFECTION OF THE NERVOUS SYSTEM**

(Fig. 201-1A) First identify whether infection predominantly involves the subarachnoid space (meningitis) or brain tissue (termed encephalitis when viral, cerebritis or abscess if bacterial, fungal, or parasitic). Nuchal rigidity is the pathognomonic sign of meningeal irritation and is present when the neck resists passive flexion.

Principles of management:
- Initiate empirical therapy whenever bacterial meningitis is considered.
- All pts with head trauma, immunocompromised states, known malignancies, or focal neurologic findings (including papilledema or stupor/coma) should undergo a neuroimaging study of the brain prior to LP. If bacterial meningitis is suspected, begin empirical antibiotic therapy prior to neuroimaging and LP.
- Stupor/coma, seizures, or focal neurologic deficits only rarely occur in viral (“aseptic”) meningitis; pts with these symptoms should be hospitalized and treated empirically for bacterial and viral meningoencephalitis.
- Immunocompetent pts with a normal level of consciousness, no prior antimicrobial treatment, and a CSF profile consistent with viral meningitis (lymphocytic pleocytosis and a normal glucose concentration) can often be treated as outpatients. Failure of a pt with suspected viral meningitis to improve within 48 h should prompt a reevaluation including follow-up exam, repeat imaging and laboratory studies, often including a second LP.

**ACUTE BACTERIAL MENINGITIS**

Pathogens most frequently involved in immunocompetent adults are *Streptococcus pneumoniae* (“pneumococcus,” ~50%) and *Neisseria meningitidis* (“meningococcus,” ~25%). Predisposing factors for pneumococcal meningitis include infection (pneumonia, otitis, sinusitis), asplenia, hypogammaglobulinemia, complement deficiency, alcoholism, diabetes, and head trauma with CSF leak. *Listeria monocytogenes* is an important consideration in pregnant women, individuals >60 years, alcoholics, and immunocompromised individuals of all ages. Enteric gram-negative bacilli and group B streptococcus are increasingly common causes of meningitis in individuals with chronic medical conditions. *Staphylococcus aureus* and coagulase-negative staphylococci are important causes following invasive neurosurgical procedures, especially shunting procedures for hydrocephalus.
Acute Meningitis and Encephalitis

CHAPTER 201

FIGURE 201-1  The management of patients with suspected CNS infection. ADEM, acute disseminated encephalomyelitis; CT, computed tomography; MRI, magnetic resonance imaging; PMNs, polymorphonuclear leukocytes; MNCs, mononuclear cells; CSF, cerebrospinal fluid; PCR, polymerase chain reaction; HSV, herpes simplex virus; VZV, varicella-zoster virus; WNV, West Nile virus; DFA, direct fluorescent antibody; Ag, antigen; VDRL, Venereal Disease Research Laboratory; AFB, acid-fast bacillus; TB, tuberculosis; CXR, chest x-ray; PPD, purified protein derivative; EBV, Epstein-Barr virus; CTFV, Colorado tick fever virus; HHV, human herpesvirus; LCMV, lymphocytic choriomeningitis virus. (Continued)
Clinical Features  Presents as an acute fulminant illness that progresses rapidly in a few hours or as a subacute infection that progressively worsens over several days. The classic clinical triad of meningitis is fever, headache, and nuchal rigidity (“stiff neck”). Alteration in mental status occurs in >75% of pts and can vary from lethargy to coma. Nausea, vomiting, and photophobia are also common. Seizures occur in 20–40% of pts. Raised intracranial pressure (ICP) is the major cause of obtundation and coma. The rash of meningococcemia begins as a diffuse maculopapular rash resembling a viral exanthem but rapidly becomes petechial on trunk and lower extremities, mucous membranes and conjunctiva, and occasionally palms and soles.

Laboratory Evaluation  The CSF profile is shown in Table 201-1. CSF bacterial cultures are positive in >80% of pts, and CSF Gram stain demonstrates organisms in >60%. The latex agglutination (LA) test for detection of bacterial antigens of *S. pneumoniae*, *N. meningitidis*, *Haemophilus influenzae* type b, group B streptococcus, and *Escherichia coli* K1 strains in the CSF is very useful for rapid diagnosis, especially in pts pretreated with antibiotics and when the CSF Gram stain and culture are negative; CSF bacterial PCR assays are replacing this technique. The Limulus amebocyte lysate assay rapidly detects gram-negative endotoxin in CSF and thus is useful in diagnosis of gram-negative bac-
Acute Meningitis and Encephalitis

**CHAPTER 201**

Acute bacterial meningitis; false-positives may occur but sensitivity approaches 100%. Petechial skin lesions, if present, should be biopsied. Blood cultures should always be obtained.

**Differential Diagnosis** Includes viral meningoencephalitis, especially herpes simplex virus (HSV) encephalitis (see below); rickettsial diseases such as Rocky Mountain spotted fever (immunofluorescent staining of skin lesions); focal suppurative CNS infections including subdural and epidural empyema and brain abscess (see below); subarachnoid hemorrhage (Chap. 19); and the demyelinating disease acute disseminated encephalomyelitis (ADEM, Chap. 200).

**Acute Bacterial Meningitis**

Recommendations for empirical therapy are summarized in [Table 201-2](#). Therapy is then modified based on results of CSF culture ([Table 201-3](#)). In general, the treatment course is 7 days for meningococcus, 14 days for pneumococcus, 21 days for gram-negative meningitis, and at least 21 days for *L. monocytogenes*.

Adjunctive therapy with dexamethasone (10 mg IV), administered 15–20 min before the first dose of an antimicrobial agent and repeated every 6 h for 4 days, improves outcome from bacterial meningitis; benefits most striking in pneumococcal meningitis. Dexamethasone may decrease the penetration of vancomycin into CSF, and thus its potential benefit should be carefully weighed when vancomycin is the antibiotic of choice.

In meningococcal meningitis, all close contacts should receive prophylaxis with rifampin [600 mg in adults (10 mg/kg in children > 1 year)] every 12 h for 2 days; rifampin is not recommended in pregnant women. Alternatively, adults can be treated with one dose of ciprofloxacin (750 mg), one dose of azithromycin (500 mg), or one IM dose of ceftriaxone (250 mg).

**Prognosis** Moderate or severe sequelae occur in ~25% of survivors; outcome varies with the infecting organism. Common sequelae include decreased intellectual function, memory impairment, seizures, hearing loss and dizziness, and gait disturbances.

### Table 201-1
cerebrospinal fluid (CSF) abnormalities in bacterial meningitis

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening pressure</td>
<td>&gt;180 mmH2O</td>
</tr>
<tr>
<td>White blood cells</td>
<td>10/μL to 10,000/μL; neutrophils predominate</td>
</tr>
<tr>
<td>Red blood cells</td>
<td>Absent in nontraumatic tap</td>
</tr>
<tr>
<td>Glucose</td>
<td>&lt;2.2 mmol/L (&lt;40 mg/dL)</td>
</tr>
<tr>
<td>CSF/serum glucose</td>
<td>&lt;0.4</td>
</tr>
<tr>
<td>Protein</td>
<td>&gt;0.45 g/L (&gt;45 mg/dL)</td>
</tr>
<tr>
<td>Gram's stain</td>
<td>Positive in &gt;60%</td>
</tr>
<tr>
<td>Culture</td>
<td>Positive in &gt;80%</td>
</tr>
<tr>
<td>Latex agglutination</td>
<td>May be positive in patients with meningitis due to <em>S. pneumoniae</em>, <em>N. meningitidis</em>, <em>H. influenzae</em> type b, <em>E. coli</em>, group B streptococci</td>
</tr>
<tr>
<td>Limulus lysate</td>
<td>Positive in cases of gram-negative meningitis</td>
</tr>
<tr>
<td>PCR</td>
<td>Detects bacterial DNA</td>
</tr>
</tbody>
</table>

*Note:* PCR, polymerase chain reaction.
**VIRAL MENINGITIS**

Presents as fever, headache, and meningeal irritation associated with a CSF lymphocytic pleocytosis. Fever may be accompanied by malaise, myalgia, anorexia, nausea and vomiting, abdominal pain, and/or diarrhea. A mild degree of lethargy or drowsiness may occur; however, a more profound alteration in consciousness should prompt consideration of alternative diagnoses, including encephalitis.

**Etiology**

Using a variety of diagnostic techniques, including CSF PCR, culture, and serology, a specific viral cause can be found in 75–90% of cases. The most important agents are enteroviruses, HSV type 2, and arboviruses (Table 201-4). The incidence of enteroviral and arboviral infections is greatly increased during the summer.

**Diagnosis**

Most important test is examination of the CSF. The typical profile is a lymphocytic pleocytosis (25–500 cells/μL), a normal or slightly elevated protein concentration [0.2–0.8 g/L (20–80 mg/dL)], a normal glucose concentration,
### TABLE 201-3  
**ANTIMICROBIAL THERAPY OF CNS BACTERIAL INFECTIONS BASED ON PATHOGEN**

<table>
<thead>
<tr>
<th>Organism</th>
<th>Antibiotic</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Neisseria meningitides</em></td>
<td></td>
</tr>
<tr>
<td>Penicillin-sensitive</td>
<td>Penicillin G or ampicillin</td>
</tr>
<tr>
<td>Penicillin-resistant</td>
<td>Ceftriaxone or cefotaxime</td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em></td>
<td></td>
</tr>
<tr>
<td>Penicillin-sensitive</td>
<td>Penicillin G</td>
</tr>
<tr>
<td>Penicillin-intermediate</td>
<td>Ceftriaxone or cefotaxime</td>
</tr>
<tr>
<td>Penicillin-resistant</td>
<td>(Ceftriaxone or cefotaxime) + vancomycin</td>
</tr>
<tr>
<td>Gram-negative bacilli (except <em>Pseudomonas</em> spp.)</td>
<td>Ceftriaxone or cefotaxime</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>Nafcillin</td>
</tr>
<tr>
<td><em>Staphylococci</em></td>
<td></td>
</tr>
<tr>
<td>Methicillin-sensitive</td>
<td>Nafcillin</td>
</tr>
<tr>
<td>Methicillin-resistant</td>
<td>Vancomycin</td>
</tr>
<tr>
<td><em>Listeria monocytogenes</em></td>
<td>Amoxicillin + gentamicin</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em></td>
<td>Ceftriaxone or cefotaxime</td>
</tr>
<tr>
<td><em>Streptococcus agalactiae</em></td>
<td>Penicillin G or ampicillin</td>
</tr>
<tr>
<td><em>Bacteroides fragilis</em></td>
<td>Metronidazole</td>
</tr>
<tr>
<td><em>Fusobacterium</em></td>
<td>Metronidazole</td>
</tr>
</tbody>
</table>

*a*Doses are as indicated in Table 201-2.

### TABLE 201-4  
**VIRUSES CAUSING ACUTE MENINGITIS AND ENCEPHALITIS IN NORTH AMERICA**

#### Acute Meningitis

<table>
<thead>
<tr>
<th>Common</th>
<th>Less Common</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enteroviruses (coxsackieviruses, echoviruses, and human enteroviruses 68–71)</td>
<td>Varicella zoster virus</td>
</tr>
<tr>
<td>Herpes simplex virus 2</td>
<td>Epstein-Barr virus</td>
</tr>
<tr>
<td>Arthropod-borne viruses</td>
<td>Lymphocytic choriomeningitis virus</td>
</tr>
<tr>
<td>HIV</td>
<td></td>
</tr>
</tbody>
</table>

#### Acute Encephalitis

<table>
<thead>
<tr>
<th>Common</th>
<th>Less Common</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herpesviruses</td>
<td>Rabies</td>
</tr>
<tr>
<td>Herpes simplex virus 1</td>
<td>Eastern equine encephalitis virus</td>
</tr>
<tr>
<td>Varicella zoster virus</td>
<td>Western equine encephalitis virus</td>
</tr>
<tr>
<td>Epstein-Barr virus</td>
<td>Powassan virus</td>
</tr>
<tr>
<td>Arthropod-borne viruses</td>
<td>Cytomegalovirus*</td>
</tr>
<tr>
<td>La Crosse virus</td>
<td>Enteroviruses*</td>
</tr>
<tr>
<td>West Nile virus</td>
<td>Colorado tick fever</td>
</tr>
<tr>
<td>St. Louis encephalitis virus</td>
<td>Mumps</td>
</tr>
</tbody>
</table>

*a*Immunocompromised host.
and a normal or mildly elevated opening pressure (100–350 mmH₂O). Organisms are not seen on Gram or acid-fast stained smears or India ink preparations of CSF. Rarely, polymorphonuclear leukocytes (PMN) predominate in the first 48 h of illness, especially with echovirus 9, West Nile virus (WNV), eastern equine encephalitis virus, or mumps. The total CSF cell count in viral meningitis is typically 25–500/μL. As a general rule, a lymphocytic pleocytosis with a low glucose concentration should suggest fungal, listerial, or tuberculous meningitis or noninfectious disorders (e.g., sarcoid, neoplastic meningitis).

CSF PCR testing is the procedure of choice for rapid, sensitive, and specific identification of enteroviruses, HSV, EBV, varicella zoster virus (VZV), human herpes virus 6 (HHV-6), and CMV. Attempts should also be made to culture virus from CSF and other sites and body fluids including blood, throat swabs, stool, and urine. Serologic studies, including those utilizing paired CSF and serum specimens, may be helpful for retrospective diagnosis; they are particularly important for diagnosis of WNV and other arbovirus etiologies.

**Differential Diagnosis**  Consider bacterial, fungal, tuberculous, spirochetal, and other infectious causes of meningitis; parameningeal infections; partially treated bacterial meningitis; neoplastic meningitis; noninfectious inflammatory diseases including sarcoid and Behçet’s disease.

---

**Viral Meningitis**

Supportive or symptomatic therapy is usually sufficient, and hospitalization is not required. The elderly and immunocompromised pts should be hospitalized, as should individuals in whom the diagnosis is uncertain or those with significant alterations in consciousness, seizures, or focal neurologic signs or symptoms. Severe cases of meningitis due to HSV, EBV, and VZV can be treated with IV acyclovir (10 mg/kg every 8 h for 7–14 days); for mildly affected pts, a 1-week course of oral antivirals may be appropriate. Additional supportive or symptomatic therapy can include analgesics and antipyretics. Prognosis for full recovery is excellent. Vaccination is an effective method of preventing the development of meningitis and other neurologic complications associated with poliovirus, mumps, measles, and VZV infection.

---

**VIRAL ENCEPHALITIS**

An infection of the brain parenchyma commonly associated with meningitis (“meningoencephalitis”). Clinical features are those of viral meningitis plus evidence of brain tissue involvement, commonly including altered consciousness such as behavioral changes and hallucinations; seizures; and focal neurologic findings such as aphasia, hemiparesis, involuntary movements, and cranial nerve deficits.

**Etiology**  The same organisms responsible for aseptic meningitis are also responsible for encephalitis, although relative frequencies differ. The most common causes of sporadic encephalitis in immunocompetent adults are herpesviruses (HSV, VZV, EBV) (Table 201-4). HSV encephalitis should be considered when focal findings are present and when involvement of the inferomedial frontotemporal regions of the brain is likely (olfactory hallucinations, anosmia, bizarre behavior, or memory disturbance). Epidemics of encephalitis are usually caused by arboviruses. WNV has been responsible for the majority of arbovirus meningitis and encephalitis cases in the United States since 2002; prominent motor manifestations, including acute poliomyelitis-like paralysis, may occur with WNV.
Diagnosis  CSF studies are essential; typical CSF profile is similar to viral meningitis. CSF PCR tests allow for rapid and reliable diagnosis of HSV, EBV, VZV, CMV, HHV-6, and enteroviruses. CSF virus cultures are generally negative. Serologic studies also have a role for some viruses. Demonstration of WNV IgM antibodies is diagnostic of WNV encephalitis.

MRI is the neuroimaging procedure of choice and demonstrates areas of increased T2 signal. Bitemporal and orbitofrontal areas of increased signal are seen in HSV encephalitis but are not diagnostic (Fig. 201-2). The EEG may suggest seizures or show temporally predominant periodic spikes on a slow, low-amplitude background suggestive of HSV encephalitis.

Brain biopsy is now used only when CSF PCR studies fail to identify the cause, focal abnormalities on MRI are present, and progressive clinical deterioration occurs despite treatment with acyclovir and supportive therapy.

Differential Diagnosis  Includes both infectious and noninfectious causes of encephalitis, including vascular diseases; abscess and empyema; fungal (Cryptococcus and Mucor), spirochetal (Leptospira), rickettsial, bacterial (Listeria), tuberculous, and mycoplasma infections; tumors; toxic encephalopathy; SLE; and acute disseminated encephalomyelitis.

**Viral Encephalitis**

All pts with suspected HSV encephalitis should be treated with IV acyclovir (10 mg/kg every 8 h) while awaiting diagnostic studies. Pts with a PCR-confirmed diagnosis of HSV encephalitis should receive a minimum 14-day course of therapy. Consider repeat CSF PCR after completion of acyclovir
therapy; pts with a persistently positive CSF PCR for HSV after completing a standard course of acyclovir therapy should be treated for an additional 7 days, followed by a repeat CSF PCR test. Acyclovir treatment may also benefit encephalitis due to EBV and VZV. No therapy currently available for enteroviral, mumps, or measles encephalitis. Intravenous ribavirin (15–25 mg/kg per day given in 3 divided doses) may benefit severe arbovirus encephalitis due to California encephalitis (LaCrosse) virus. CMV encephalitis should be treated with ganciclovir, foscarnet, or a combination of the two drugs; cidofovir may provide an alternative for nonresponders. No proven therapy is available for WNV encephalitis; small groups of pts have been treated with interferon, ribavirin, WNV-specific antisense oligonucleotides, and intravenous immunoglobulin preparations of Israeli origin containing high titer anti-WNV antibody.

Prognosis  In HSV encephalitis treated with acyclovir, 81% survival in one series; neurologic sequelae were mild or absent in 46%, moderate in 12%, and severe in 42%.

BRAIN ABSCESS

A focal, suppurative infection within the brain parenchyma, typically surrounded by a vascularized capsule. The term cerebritis is used to describe a nonencapsulated brain abscess. Predisposing conditions include otitis media and mastoiditis, paranasal sinusitis, pyogenic infections in the chest or other body sites, head trauma, neurosurgical procedures, and dental infections. Many brain abscesses occur in immunocompromised hosts and are caused less often by bacteria than by fungi and parasites including Toxoplasma gondii, Aspergillus spp., Nocardia spp., Candida spp., and Cryptococcus neoformans. In Latin America and in immigrants from Latin America, the most common cause of brain abscess is Taenia solium (neurocysticercosis). In India and the Far East, mycobacterial infection (tuberculoma) remains a major cause of focal CNS mass lesions.

Clinical Features  Brain abscess typically presents as an expanding intracranial mass lesion, rather than as an infectious process. The classic triad of headache, fever, and a focal neurologic deficit is present in <50% of cases.

Diagnosis  MRI is better than CT for demonstrating abscesses in the early (cerebritis) stages and is superior to CT for identifying abscesses in the posterior fossa. A mature brain abscess appears on CT as a focal area of hypodensity surrounded by ring enhancement. The CT and MRI appearance, particularly of the capsule, may be altered by treatment with glucocorticoids. The distinction between a brain abscess and other focal lesions such as tumors may be facilitated with diffusion-weighted imaging (DWI) sequences in which brain abscesses typically show increased signal and low apparent diffusion coefficient.

Microbiologic diagnosis best determined by Gram stain and culture of abscess material obtained by stereotactic needle aspiration. Up to 10% of patients will also have positive blood cultures. CSF analysis contributes nothing to diagnosis or therapy, and LP increases the risk of herniation.

Optimal therapy involves a combination of high-dose parenteral antibiotics and neurosurgical drainage. Empirical therapy of community-acquired brain
Abscess in an immunocompetent patient typically includes a third-generation cephalosporin (e.g., cefotaxime or ceftriaxone) and metronidazole (see Table 201-2 for antibiotic dosages). In pts with penetrating head trauma or recent neurosurgical procedures, treatment should include ceftazidime as the third-generation cephalosporin to enhance coverage of *Pseudomonas* spp. and vancomycin for coverage of resistant staphylococci. Meropenem plus vancomycin also provides good coverage in this setting.

Aspiration and drainage essential in most cases. Empirical antibiotic coverage is modified based on the results of Gram stain and culture of the abscess contents. Medical therapy alone is reserved for pts whose abscesses are neurosurgically inaccessible and for cerebritis. All pts should receive a minimum of 6–8 weeks of parenteral antibiotic therapy. Pts should receive prophylactic anticonvulsant therapy. Glucocorticoids should not be given routinely.

**Prognosis**  
In modern series the mortality is typically <15%. Significant sequelae including seizures, persisting weakness, aphasia, or mental impairment occur in ≥20% of survivors.

**PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)**

**Clinical Features**  
A progressive disorder due to infection with the JC virus, a human polyoma virus; characterized pathologically by multifocal areas of demyelination of varying size distributed throughout the CNS but sparing the spinal cord and optic nerves. In addition, there are characteristic cytologic alterations in both astrocytes and oligodendrocytes. Pts often present with visual deficits (45%), typically a homonymous hemianopia, and mental impairment (38%) (dementia, confusion, personality change), weakness, and ataxia. Almost all pts have an underlying immunosuppressive disorder. More than 80% of currently diagnosed PML cases occur in patients with AIDS; it has been estimated that nearly 5% of AIDS patients will develop PML.

**Diagnostic Studies**  
MRI reveals multifocal asymmetric, coalescing white matter lesions located periventricularly, in the centrum semiovale, in the parietal-occipital region, and in the cerebellum. These lesions have increased T2 and decreased T1 signal, are generally nonenhancing (rarely they may show ring enhancement), and are not associated with edema or mass effect. CT scans, which are less sensitive than MRI for the diagnosis of PML, often show hypodense nonenhancing white matter lesions.

The CSF is typically normal, although mild elevation in protein and/or IgG may be found. Pleocytosis occurs in <25% of cases, is predominantly mononuclear, and rarely exceeds 25 cells/μL. PCR amplification of JC virus DNA from CSF has become an important diagnostic tool. A positive CSF PCR for JC virus DNA in association with typical MRI lesions in the appropriate clinical setting is diagnostic of PML. Pts with negative CSF PCR studies may require brain biopsy for definitive diagnosis as sensitivity of this test is variable; JC virus antigen and nucleic acid can be detected by immunocytochemistry, in situ hybridization, or PCR amplification on tissue. Detection of JC virus antigen or genomic material should be considered diagnostic of PML only if accompanied by characteristic pathologic changes, since both antigen and genomic material have been found in the brains of normal pts. Serologic studies are of no utility given high basal seroprevalence level (>80%).
Progressive Multifocal Leukoencephalopathy

No effective therapy is available. Some pts with HIV-associated PML have shown dramatic clinical gains associated with improvement in immune status following institution of highly active antiretroviral therapy (HAART).

For a more detailed discussion, see Roos KL, Tyler KL: Meningitis, Encephalitis, Brain Abscess, and Empyema, Chap. 376, p. 2621, in HPIM-17; and HPIM-17 chapters covering specific organisms or infections.

Chronic Meningitis

Chronic inflammation of the meninges (pia, arachnoid, and dura) can produce profound neurologic disability and may be fatal if not successfully treated. The causes are varied. Five categories of disease account for most cases of chronic meningitis:

- Meningeal infections
- Malignancy
- Noninfectious inflammatory disorders
- Chemical meningitis
- Parameningeal infections

CLINICAL FEATURES

Neurologic manifestations consist of persistent headache with or without stiff neck and hydrocephalus; cranial neuropathies; radiculopathies; and/or cognitive or personality changes *(Table 202-1)*. The diagnosis is usually made when clinical presentation leads the physician to examine CSF for signs of inflammation; on occasion the diagnosis is made when a neuroimaging study shows contrast enhancement of the meninges.

Two clinical forms of chronic meningitis exist. In the first, symptoms are chronic and persistent, whereas in the second there are recurrent, discrete episodes with complete resolution of meningeal inflammation between episodes without specific therapy. In the latter group, likely etiologies are herpes simplex virus type 2, chemical meningitis due to leakage from a tumor, a primary inflammatory condition, or drug hypersensitivity.

APPROACH TO THE PATIENT WITH CHRONIC MENINGITIS

Once chronic meningitis is confirmed by CSF examination, effort is focused on identifying the cause *(Tables 202-2 and 202-3)* by (1) further analysis of the CSF, (2) diagnosis of an underlying systemic infection or noninfectious inflammatory condition, or (3) examination of meningeal biopsy tissue.
Proper analysis of the CSF is essential; if the possibility of raised intracranial pressure (ICP) exists, a brain imaging study should be performed before LP. In pts with communicating hydrocephalus caused by impaired resorption of CSF, LP is safe and may lead to temporary improvement. However, if ICP is elevated because of a mass lesion, brain swelling, or a block in ventricular CSF outflow (obstructive hydrocephalus), then LP carries the potential risk of brain herniation. Obstructive hydrocephalus usually requires direct ventricular drainage of CSF.

Contrast-enhanced MRI or CT studies of the brain and spinal cord can identify meningeal enhancement, parameningeal infections (including brain abscess), encasement of the spinal cord (malignancy or inflammation and infection), or nodular deposits on the meninges or nerve roots (malignancy or sarcoidosis). Imaging studies are also useful to localize areas of meningeal disease prior to meningeal biopsy. Cerebral angiography may identify arteritis.

A meningeal biopsy should be considered in pts who are disabled, who need chronic ventricular decompression, or whose illness is progressing rapidly. The diagnostic yield of meningeal biopsy can be increased by targeting regions that enhance with contrast on MRI or CT; in one series, diagnostic biopsies most often identified sarcoid (31%) or metastatic adenocarcinoma (25%). Tuberculosis is the most common condition identified in many reports outside of the United States.

In approximately one-third of cases, the diagnosis is not known despite careful evaluation. A number of the organisms that cause chronic meningitis may take weeks to be identified by culture. It is reasonable to wait until cultures are finalized if symptoms are mild and not progressive. However, in many cases progressive neurologic deterioration occurs, and rapid treatment is required. Empirical therapy in the United States consists of antimycobacterial agents, amphotericin for fungal infection, or glucocorticoids for noninfectious inflammatory causes (most common). It is important to direct empirical therapy of lymphocytic meningitis at tuberculosis, particularly if the condition is associated with hypoglycorrhachia and sixth and other cranial nerve palsies, since untreated disease can be fatal in 4–8 weeks. Carcinomatous or lymphomatous meningitis may be difficult to diagnose initially,
<table>
<thead>
<tr>
<th>Infectious Causes of Chronic Meningitis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common Bacterial Causes</strong></td>
</tr>
<tr>
<td>Partially treated suppurative meningitis</td>
</tr>
<tr>
<td>Parameningeal infection</td>
</tr>
<tr>
<td><em>Mycobacterium tuberculosis</em></td>
</tr>
<tr>
<td>Lyme disease (Bannwarth’s syndrome): <em>Borrelia burgdorferi</em></td>
</tr>
<tr>
<td>Syphilis (secondary, tertiary): <em>Treponema pallidum</em></td>
</tr>
<tr>
<td><strong>Uncommon Bacterial Causes</strong></td>
</tr>
<tr>
<td><em>Actinomyces</em></td>
</tr>
<tr>
<td><em>Nocardia</em></td>
</tr>
<tr>
<td><em>Brucella</em></td>
</tr>
<tr>
<td>Whipple’s disease: <em>Tropheraema whippelii</em></td>
</tr>
<tr>
<td><strong>Rare Bacterial Causes</strong></td>
</tr>
<tr>
<td><em>Leptospirosis; Pseudoallescheria boydii</em></td>
</tr>
<tr>
<td><strong>Fungal Causes</strong></td>
</tr>
<tr>
<td><em>Cryptococcus neoformans</em></td>
</tr>
<tr>
<td><em>Coccidioides immitis</em></td>
</tr>
<tr>
<td><em>Candida sp.</em></td>
</tr>
<tr>
<td><em>Histoplasma capsulatum</em></td>
</tr>
<tr>
<td><em>Blastomyces dermatitidis</em></td>
</tr>
<tr>
<td><em>Aspergillus sp.</em></td>
</tr>
<tr>
<td><em>Sporothrix schenckii</em></td>
</tr>
<tr>
<td><strong>Rare Fungal Causes</strong></td>
</tr>
<tr>
<td><em>Xylohypha</em> (formerly <em>Cladosporium</em> trichoides) and other dark-walled (demataceous) fungi such as <em>Curvularia, Drechslera; Mucor, Pseudoallescheria boydii</em></td>
</tr>
<tr>
<td><strong>Protozoal Causes</strong></td>
</tr>
<tr>
<td><em>Toxoplasma gondii</em></td>
</tr>
<tr>
<td>Trypanosomiasis <em>Trypanosoma gambiense, Trypanosoma rhodesiense</em></td>
</tr>
<tr>
<td><strong>Rare Protozoal Causes</strong></td>
</tr>
<tr>
<td><em>Acanthamoeba sp.</em></td>
</tr>
<tr>
<td><strong>Helminthic Causes</strong></td>
</tr>
<tr>
<td>Cysticercosis (infection with cysts of <em>Taenia solium</em>)</td>
</tr>
<tr>
<td><em>Gnathostoma spinigerum</em></td>
</tr>
<tr>
<td><em>Angiostrongylus cantonensis</em></td>
</tr>
<tr>
<td><em>Baylisascaris procyonis</em> (raccoon ascarid)</td>
</tr>
<tr>
<td><strong>Rare Helminthic Causes</strong></td>
</tr>
<tr>
<td><em>Trichinella spiralis</em> (trichinosis); <em>Echinococcus</em> cysts; <em>Schistosoma</em> sp.</td>
</tr>
<tr>
<td><strong>Viral Causes</strong></td>
</tr>
<tr>
<td>Mumps</td>
</tr>
<tr>
<td>Lymphocytic choriomeningitis</td>
</tr>
<tr>
<td>Echovirus</td>
</tr>
<tr>
<td>Obstructive hydrocephalus usually requires direct ventricular drainage of CSF.</td>
</tr>
<tr>
<td>HIV (acute retroviral syndrome)</td>
</tr>
<tr>
<td>Herpes simplex (HSV)</td>
</tr>
</tbody>
</table>
Peripheral Neuropathies

CHAPTER 203

Peripheral Neuropathies Including Guillain-Barré Syndrome (GBS)

APPROACH TO THE PATIENT WITH PERIPHERAL NEUROPATHY

Peripheral neuropathy (PN) refers to a peripheral nerve disorder of any cause. Nerve involvement may be single (mononeuropathy) or multiple (polyneuropathy); pathology may be axonal or demyelinating. An approach to pts with suspected neuropathy appears in Fig. 203-1.

Address the following initial questions:

1. Is this a peripheral neuropathy? Initial symptoms may be intermittent and examination can be normal. Patients may present with positive (e.g., paresthesias) and/or negative (e.g., numbness) symptoms (Table 203-1). In most cases polyneuropathy begins distally in the toes or feet and then spreads proximally in a stocking distribution. Ankle reflexes are lost. Only once sensory loss reaches the knees or thighs does numbness of fingers appear. Paresthesias that begin in one hand only suggest an entrapment neuropathy such as carpal tunnel syndrome. Motor symptoms usually have a
FIGURE 203-1 Approach to evaluation of peripheral neuropathies. CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; EDX, electrodiagnostic studies; GBS, Guillain-Barré syndrome; IVIg, intravenous immunoglobulin.
Peripheral Neuropathies

CHAPTER 203

later onset than sensory, but when pure motor symptoms are present, it may be difficult to distinguish neuropathy from muscle or neuromuscular junction disorders (which usually feature a more symmetric proximal pattern of weakness). Weakness and atrophy evolve from distal to proximal—initial toe dorsiflexion weakness may progress to bilateral foot drop, intrinsic hand muscle weakness, or (in extreme cases) impairment of muscles needed for ventilation and sphincter function.

2. What is its distribution? Polyneuropathy involves widespread and symmetric dysfunction of the peripheral nerves; mononeuropathy involves a single nerve usually due to trauma or compression; multiple mononeuropathies (mononeuropathy multiplex) can be a result of multiple entrapments, vasculitis, or infiltration.

3. Which fibers are affected? Can be classified as small-fiber sensory, large-fiber sensory, motor, and/or autonomic (Table 203-2).

4. What is the anatomic pattern? Clinical evaluation categorizes neuropathy as axonal, demyelinating, or neuronal (dorsal root ganglion, DRG) (Table 203-3). Electrodiagnostic tests (nerve conduction studies and electromyography, NCS-EMG) can confirm or clarify this clinical categorization.

5. What is the time course? Rapidly evolving neuropathies are often inflammatory; subacute evolution suggests an inflammatory, toxic, or nutritional cause; chronic neuropathies that are long-standing over years may be hereditary (Table 203-4).

6. What is the likely etiology? Categories of polyneuropathy include metabolic (diabetes mellitus, renal failure); infectious (HIV, Lyme disease,

---

**TABLE 203-1 SYMPTOMS, SIGNS, AND TESTS IN PERIPHERAL NEUROPATHY**

<table>
<thead>
<tr>
<th>Large Fiber</th>
<th>Small Fiber</th>
<th>Motor</th>
<th>Autonomic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numbness</td>
<td>Pain: burning, shock-like, stabbing, prickling, shooting, lancinating Alldynia</td>
<td>Cramps Weak grip Footdrop Twitching</td>
<td>Decreased or increased sweating Dry eyes, mouth, Erectile dysfunction Gastroparesis/diarrhea Faintness, light-headedness</td>
</tr>
<tr>
<td>“Pins and needles”</td>
<td>Tingling</td>
<td>Tingling</td>
<td>Tingling</td>
</tr>
<tr>
<td>Tingling</td>
<td>Tingling</td>
<td>Tingling</td>
<td>Tingling</td>
</tr>
<tr>
<td>Poor balance</td>
<td>Poor balance</td>
<td>Poor balance</td>
<td>Poor balance</td>
</tr>
</tbody>
</table>

**Signs**

<table>
<thead>
<tr>
<th>Decreased Vibration</th>
<th>Decreased Pin prick</th>
<th>Reduced Strength Reflexes</th>
<th>Orthostasis Unequal pupil size</th>
</tr>
</thead>
</table>

**Tests**

<table>
<thead>
<tr>
<th>NCS-EMG</th>
<th>Skin biopsy</th>
<th>NCS-EMG</th>
<th>QSART</th>
<th>Tilt table</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nerve biopsy</td>
<td>QST</td>
<td>Nerve biopsy</td>
<td>R-R interval</td>
<td>Valsalva</td>
</tr>
<tr>
<td>LP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** NCS-EMG, nerve conduction studies/electromyography; QSART, quantitative sudomotor axon reflex testing; QST, quantitative sensory test; LP, lumbar puncture.
syphilis); immune-mediated (GBS); hereditary (Charcot-Marie-Tooth disease, CMT); toxic (medications, alcohol); vasculitic (polyarteritis nodosa, cryoglobulinemia); paraneoplastic (especially lung); nutritional (B vitamin deficiencies); and miscellaneous (celiac disease) (Table 203-5).

### POLYNEUROPATHY

**Diagnostic Evaluation**  Screening laboratory studies in a distal, symmetric polyneuropathy may include fasting blood glucose, HbA1C, serum vitamin B12, tests for systemic vasculitis or collagen vascular disease, serum immunoelectrophoresis, measurement of neuropathy-associated antibodies (against gangliosides such as GM1 and MAG or paraneoplastic antigens such as Hu), tests of kidney and thyroid function, and urine screen for heavy metals. Other studies are suggested by the differential diagnosis.
Diagnostic tests to further characterize the neuropathy include NCS-EMG, sural nerve biopsy, muscle biopsy, and quantitative sensory testing. Diagnostic tests are more likely to be informative in pts with asymmetric, motor-predominant, rapid-onset, or demyelinating neuropathies.

**Electrodiagnosis (NCS-EMG)** NCSs are carried out by stimulating motor or sensory nerves electrically at two or more sites. Electrodiagnostic (EDX) features of

**TABLE 203-3** CLASSIFICATION OF NEUROPATHY BY HISTOPATHOLOGY

<table>
<thead>
<tr>
<th>Pattern</th>
<th>Demyelinating</th>
<th>Axonal</th>
<th>Neuronal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset</td>
<td>Acute/subacute</td>
<td>Distal &gt; proximal; length-dependent</td>
<td>Non-length-dependent; UE, LE, face</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Paresthesia and weakness</td>
<td>Slow evolution</td>
<td>Paresthesias, gait ataxia</td>
</tr>
<tr>
<td>Sensory signs</td>
<td>Vibration and proprioception &gt; pain and temperature</td>
<td>Pain and temperature affected &gt; vibration and proprioception</td>
<td>Vibration and proprioception &gt; pain and temperature</td>
</tr>
<tr>
<td>Motor</td>
<td>Distal and proximal weakness</td>
<td>Distal weakness</td>
<td>Proprioceptive weakness</td>
</tr>
<tr>
<td>DTRs</td>
<td>Areflexia</td>
<td>Distal areflexia</td>
<td>Areflexia</td>
</tr>
<tr>
<td>NCS</td>
<td>Velocity affected &gt; amplitude</td>
<td>Amplitudes affected &gt; velocity</td>
<td>Sensory amplitudes affected; radial &gt; sural</td>
</tr>
<tr>
<td>Nerve biopsy</td>
<td>Demyelination and remyelination</td>
<td>Axonal degeneration and regeneration</td>
<td>Axonal degeneration but no regeneration</td>
</tr>
<tr>
<td>Prognosis</td>
<td>Rapid recovery</td>
<td>Slow recovery</td>
<td>Poor recovery</td>
</tr>
<tr>
<td>Causes</td>
<td>GBS, diphtheria, CIDP, DM, MMN</td>
<td>Toxic, metabolic, HIV, CMT2, DM</td>
<td>Sjögren’s, cisplatin, pyridoxine</td>
</tr>
</tbody>
</table>

*Note:* UE, LE, upper, lower extremities; DTRs, deep tendon reflexes; NCS, nerve conduction studies; GBS, Guillain-Barré syndrome; CIDP, chronic inflammatory demyelinating neuropathy; DM, diabetes mellitus; MMN, multifocal motor neuropathy; CMT, Charcot-Marie-Tooth.

**TABLE 203-4** CLASSIFICATION OF NEUROPATHY BY TIME COURSE

<table>
<thead>
<tr>
<th>Type</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute</td>
<td>GBS, porphyria, toxic (triorthocresyl phosphate, vacor, thallium), diphtheria, brachial neuritis</td>
</tr>
<tr>
<td>Subacute</td>
<td>Toxic (hexacarbon, acrylamid), angiopathic, nutritional, alcoholic</td>
</tr>
<tr>
<td>Chronic</td>
<td>Diabetic, CIDP, paraneoplastic, paraprotein</td>
</tr>
<tr>
<td>Longstanding heritable</td>
<td>CMT, Friedreich’s ataxia</td>
</tr>
<tr>
<td>Recurrent</td>
<td>Relapsing CIDP, porphyria, Refsum’s disease, HNPP</td>
</tr>
</tbody>
</table>

*Note:* GBS, Guillain-Barré syndrome; CIDP, chronic inflammatory demyelinating neuropathy; CMT, Charcot-Marie- Tooth (disease); HNPP, hereditary neuropathy with pressure palsies.
demyelination are slowing of nerve conduction velocity (NCV), dispersion of evoked compound action potentials, conduction block (major decrease in amplitude of muscle compound action potentials on proximal stimulation of the nerve, as compared to distal stimulation), and marked prolongation of distal latencies. In contrast, axonal neuropathies are characterized by a reduced amplitude of evoked compound action potentials with relative preservation of NCV. EMG involves recording for electrical potentials from a needle electrode in muscle at rest and during voluntary contraction. EMG is most useful for distinguishing between and among myopathic and neuropathic disorders. Myopathic disorders are marked by small, short-duration, polyphasic muscle action potentials; by contrast, neuropathic disorders are characterized by muscle denervation. Denervation features a decrease in the number of motor units (e.g., an anterior horn cell, its axon, and the motor end plates and muscle fibers it innervates). In long-standing muscle denervation, motor unit potentials become large and polyphasic. This occurs as a result of collateral reinnervation of denervated muscle fibers by axonal sprouts from surviving motor axons. Other EMG features that favor denervation include fibrillations (random, unregulated firing of individual denervated muscle fibers) and fasciculations (random, spontaneous firing of motor units).

<table>
<thead>
<tr>
<th>TABLE 203-5 POLYNEUROPATHIES (PN)(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axonal</td>
</tr>
<tr>
<td>Acquired</td>
</tr>
<tr>
<td>Diabetes</td>
</tr>
<tr>
<td>Uremia</td>
</tr>
<tr>
<td>B(_12) deficiency</td>
</tr>
<tr>
<td>Critical illness</td>
</tr>
<tr>
<td>HIV infection</td>
</tr>
<tr>
<td>Lyme disease</td>
</tr>
<tr>
<td>Lymphoma</td>
</tr>
<tr>
<td>Multiple myeloma</td>
</tr>
<tr>
<td>Acute motor axonal neuropathy</td>
</tr>
<tr>
<td>Drugs: cisplatin, hydralazine, isoniazid, metronidazole, nitrofurantoin, phenytoin, pyridoxine, vincristine</td>
</tr>
<tr>
<td>Toxins: arsenic, thallium, inorganic lead, organophosphates</td>
</tr>
<tr>
<td>Benign monoclonal gammopathy (IgA, IgG)</td>
</tr>
<tr>
<td>Idiopathic</td>
</tr>
<tr>
<td>Hereditary</td>
</tr>
<tr>
<td>HMSN II(^b)</td>
</tr>
<tr>
<td>Amyloid</td>
</tr>
<tr>
<td>Porphyria</td>
</tr>
<tr>
<td>Fabry’s disease</td>
</tr>
<tr>
<td>Abetalipoproteinemia</td>
</tr>
<tr>
<td>Friedreich’s ataxia</td>
</tr>
<tr>
<td>Adrenomyeloneuropathy</td>
</tr>
<tr>
<td>Ataxia telangiectasia</td>
</tr>
</tbody>
</table>

\(^a\)Does not include rare causes

\(^b\)Hereditary motor and sensory neuropathy
Polyneuropathy

Treatment of the underlying disorder, pain management, and supportive care to protect and rehabilitate damaged tissue all need to be considered. Examples of specific therapies include tight glycemic control in diabetic neuropathy, vitamin replacement for B₁₂ deficiency, and immunosuppression for vasculitis.

Pain management usually begins with tricyclic antidepressants (TCAs), duloxetine hydrochloride, or anticonvulsants such as gabapentin. Topical anesthetic agents including lidocaine and capsaicin cream can provide additional relief.

Physical and occupational therapy is important. Proper care of denervated areas prevents skin ulceration, which can lead to poor wound healing, tissue resorption, arthropathy, and ultimately amputation.

Specific Polyneuropathies

1. **Acute inflammatory demyelinating polyneuropathy (AIDP) or Guillain-Barre syndrome (GBS):** an ascending, usually demyelinating, motor > sensory polyneuropathy accompanied by areflexia, motor paralysis, and elevated CSF total protein without pleocytosis. Over two-thirds are preceded by an acute respiratory or gastrointestinal infection. Maximum weakness is usually reached within 2 weeks; demyelination by EMG. Most pts are hospitalized; one-third require ventilatory assistance. 85% make a complete or near-complete recovery with supportive care. Intravenous immune globulin (IVIg) (2 g/kg divided over 5 days) or plasmapheresis (40–50 mL/kg daily for 4–5 days) significantly shortens the course. Glucocorticoids are ineffective. Variants of GBS include Fisher syndrome (ophthalmoparesis, facial diplegia, ataxia, areflexia; associated with serum antibodies to ganglioside GQ1b) and acute motor axonal neuropathy (more severe course than demyelinating GBS; antibodies to GM₁ in some cases).

2. **Chronic inflammatory demyelinating polyneuropathy (CIDP):** a slowly progressive or relapsing polyneuropathy characterized by diffuse hyporeflexia or areflexia, diffuse weakness, elevated CSF protein without pleocytosis, and demyelination by EMG. Begin treatment when progression is rapid or walking is compromised. Initial treatment is usually IVIg; most pts require periodic retreatment at 6-week intervals. Other treatment options include plasmapheresis or glucocorticoids; immunosuppressants (azathioprine, methotrexate, cyclosporine, cyclophosphamide) used in refractory cases.

3. **Diabetic neuropathy:** typically a distal symmetric, sensorimotor, axonal polyneuropathy. A mixture of demyelination and axonal loss is frequent. Other variants include: isolated sixth or third cranial nerve palsies, asymmetric proximal motor neuropathy in the legs, truncal neuropathy, autonomic neuropathy, and an increased frequency of entrapment neuropathy (see below). The lifetime prevalence is ~55% for type 1 and 45% for type 2 diabetes.

4. **Mononeuropathy multiplex (MM):** defined as involvement of multiple individual peripheral nerves. When an inflammatory disorder is the cause, mononeuritis multiplex is the term used. Both systemic (67%) and non-systemic (33%) vasculitis may present as MM. Immunosuppressive treatment of the underlying disease (usually with glucocorticoids and cyclophosphamide) is indicated. A tissue diagnosis of vasculitis should be obtained before initiating treatment; a positive biopsy helps to justify the necessary long-term treatment with immunosuppressive medications, and pathologic confirmation is difficult after treatment has commenced.
<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Precipitating Activities</th>
<th>Examination</th>
<th>Electro-Diagnosis</th>
<th>Differential Diagnosis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Carpal tunnel syndrome</strong></td>
<td>Numbness, pain or paresthesias in fingers</td>
<td>Sleep or repetitive hand activity</td>
<td>Sensory loss in thumb, second, and third fingers; weakness in thenar muscles; inability to make a circle with thumb and index finger</td>
<td>Slowing of sensory and motor conduction across carpal tunnel</td>
<td>C6 radiculopathy</td>
</tr>
<tr>
<td><strong>Ulnar nerve entrapment at the elbow (UNE)</strong></td>
<td>Numbness or paresthesias in ulnar aspect of hand</td>
<td>Elbow flexion during sleep; elbow resting on desk</td>
<td>Sensory loss in the little finger and ulnar half of ring finger; weakness of the interossei and thumb adductor; claw-hand</td>
<td>Focal slowing of nerve conduction velocity at the elbow</td>
<td>Thoracic outlet syndrome C8-T1 radiculopathy</td>
</tr>
<tr>
<td><strong>Ulnar nerve entrapment at the wrist</strong></td>
<td>Numbness or weakness in the ulnar distribution in the hand</td>
<td>Unusual hand activities with tools, bicycling</td>
<td>Like UNE but sensory examination spares dorsum of the hand, and selected hand muscles affected</td>
<td>Prolongation of distal motor latency in the hand</td>
<td>UNE</td>
</tr>
<tr>
<td>Radial neuropathy at the spiral groove</td>
<td>Wrist drop</td>
<td>Sleeping on arm after inebriation with alcohol—&quot;Saturday night palsy&quot;</td>
<td>Wrist drop with sparing of elbow extension (triceps sparing); finger and thumb extensors paralyzed; sensory loss in radial region of wrist</td>
<td>Early—conduction block along the spiral groove</td>
<td>Posterior cord lesion; deltoid also weak</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Thoracic outlet syndrome</td>
<td>Numbness, paresthesias in medial arm, forearm, hand, and fingers</td>
<td>Lifting heavy objects with the hand</td>
<td>Sensory loss resembles ulnar nerve and motor loss resembles median nerve</td>
<td>Absent ulnar sensory response and reduced median motor response</td>
<td>UNE</td>
</tr>
<tr>
<td>Femoral neuropathy</td>
<td>Buckling of knee, numbness or tingling in thigh/medial leg</td>
<td>Abdominal hysterectomy; lithotomy position; hematoma, diabetes</td>
<td>Wasting and weakness of quadriceps; absent knee jerk; sensory loss in medial thigh and lower leg</td>
<td>EMG of quadriceps, iliopsoas, paraspinal muscles, adductor muscles</td>
<td>L2-4 radiculopathy Lumbar plexopathy</td>
</tr>
<tr>
<td>Obturator neuropathy</td>
<td>Weakness of the leg, thigh numbness</td>
<td>Stretch during hip surgery; pelvic fracture; childbirth</td>
<td>Weakness of hip adductors; sensory loss in upper medial thigh</td>
<td>EMG—denervation limited to hip adductors sparing the quadriceps</td>
<td>L3-4 radiculopathy Lumbar plexopathy</td>
</tr>
<tr>
<td>Meralgia paresthetica</td>
<td>Pain or numbness in the anterior lateral thigh</td>
<td>Standing or walking Recent weight gain</td>
<td>Sensory loss in the pocket of the pant distribution</td>
<td>Sometimes slowing of sensory response can be demonstrated across the inguinal ligament</td>
<td>L2 radiculopathy</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>MONONEUROPATHIES (CONTINUED)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Table 203-6</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Precipitating Activities</th>
<th>Examination</th>
<th>Electro-Diagnosis</th>
<th>Differential Diagnosis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Peroneal nerve entrapment at the fibular head</strong></td>
<td>Footdrop</td>
<td>Usually an acute compressive episode identifiable; weight loss</td>
<td>Weak dorsiflexion, eversion of the foot Sensory loss in the anterolateral leg and dorsum of the foot</td>
<td>Focal slowing of nerve conduction across fibular head Denervation in tibialis anterior and peroneus longus muscles</td>
<td>L5 radiculopathy</td>
</tr>
<tr>
<td><strong>Sciatic neuropathy</strong></td>
<td>Flail foot and numbness in foot</td>
<td>Injection injury; fracture/dislocation of hip; prolonged pressure on hip (comatose patient)</td>
<td>Weakness of hamstring, plantar and dorsiflexion of foot; sensory loss in tibial and peroneal nerve distribution</td>
<td>NCS—abnormal sural, peroneal, and tibial amplitudes EMG—denervation in sciatic nerve distribution sparing glutei and paraspinal</td>
<td>L5-S1 radiculopathies</td>
</tr>
<tr>
<td><strong>Tarsal tunnel syndrome</strong></td>
<td>Pain and paresthesias in the sole of the foot but not in the heel</td>
<td>At the end of the day after standing or walking; nocturnal</td>
<td>Sensory loss in the sole of the foot Tinel's sign at tarsal tunnel</td>
<td>Reduced amplitude in sensory or motor components of medial and planter nerves</td>
<td>Polyneuropathy, foot deformity, poor circulation</td>
</tr>
</tbody>
</table>
An autoimmune neuromuscular disorder resulting in weakness and fatigability of skeletal muscles, due to autoantibodies directed against acetylcholine receptors (AChRs) at neuromuscular junctions (NMJs).

**CLINICAL FEATURES**

May present at any age. Symptoms fluctuate throughout the day and are provoked by exertion. Characteristic distribution: cranial muscles (eyelids, extraocular muscles, facial weakness, “nasal” or slurred speech, dysphagia); in 85%, limb muscles (often proximal and asymmetric) become involved. Reflexes and sensation normal. May be limited to extraocular muscles only. Complications: aspiration pneumonia (weak bulbar muscles), respiratory failure (weak chest wall muscles), exacerbation of myasthenia due to administration of drugs with neuromuscular junction blocking effects (quinolones, macrolides, aminoglycosides, procainamide, propranolol, nondepolarizing muscle relaxants).

**PATHOPHYSIOLOGY**

Anti-AChR antibodies reduce the number of available AChRs at the NMJ. Postsynaptic folds are flattened or “simplified,” with resulting inefficient neuromuscular transmission. During repeated or sustained muscle contraction, decrease in amount of ACh released per nerve impulse (“presynaptic rundown,” a normal occurrence), combined with disease-specific decrease in postsynaptic AChRs, results in pathologic fatigue. Thymus is abnormal in 75% of pts (65%...
hyperplasia, 10% thymoma). Other autoimmune diseases may coexist: Hashimoto's thyroiditis, Graves' disease, rheumatoid arthritis, lupus erythematosus.

**DIFFERENTIAL DIAGNOSIS**

1. Lambert-Eaton syndrome (autoantibodies to calcium channels in presynaptic motor nerve terminals)—reduced ACh release; may be associated with malignancy
2. Neurasthenia—weakness/fatigue without underlying organic disorder
3. Penicillamine may cause MG; resolves weeks to months after discontinuing drug
4. Botulism—toxin inhibits presynaptic ACh release; most common form is food-borne.
5. Diplopia from an intracranial mass lesion—compression of nerves to extraocular muscles or brainstem lesions affecting cranial nerve nuclei
6. Hyperthyroidism
7. Progressive external ophthalmoplegia—seen in rare mitochondrial disorders that can be detected with muscle biopsy

**LABORATORY EVALUATION**

- AChR antibodies—levels do not correlate with disease severity; 85% of all MG patients positive; only 50% with pure ocular findings are positive; positive antibodies are diagnostic. Muscle-specific kinase (MuSK) antibodies present in 40% of AChR antibody-negative pts with generalized MG.
- Tensilon (edrophonium) test—a short-acting anticholinesterase—look for rapid and transient improvement of strength; false-positive (placebo response, motor neuron disease) and false-negative tests occur. Atropine IV should be on hand if symptoms such as bradycardia occur.
- EMG—low-frequency (2–4 Hz) repetitive stimulation produces rapid decrement in amplitude (>10–15%) of evoked motor responses.
- chest CT/MRI—search for thymoma.
- Consider thyroid and other studies (e.g., ANA) for associated autoimmune disease.
- Measurements of baseline respiratory function are useful.

**Myasthenia Gravis**

The anticholinesterase drug pyridostigmine (Mestinon) titrated to assist pt with functional activities (chewing, swallowing, strength during exertion); usual initial dose of 30–60 mg 3–4 times daily; long-acting tablets help at night but have variable absorption so are not reliable during the day. Muscarinic side effects (diarrhea, abdominal cramps, salivation, nausea) blocked with atropine/diphenoxylate or loperamide if required. Plasmapheresis or IV immune globulin (IVIg; 400 mg/kg per day for 5 days) provides temporary boost for seriously ill pts; used to improve condition prior to surgery or during myasthenic crisis (severe exacerbation of weakness with respiratory compromise). Thymectomy improves likelihood of long-term remission in adult pts; whether it helps those with pure ocular disease or those age >55 remains unclear. Glucocorticoids are a mainstay of treatment; begin prednisone at low dose (15–25 mg/d), increase by 5 mg/d every 2–3 days until marked clinical improvement or dose of 50–60 mg/d is reached. Maintain high dose for 1–3 months, then decrease to alternate-day regimen. Immunosuppressive drugs (azathioprine, cyclosporine, mycophenolate mofetil, cyclophosphamide) may spare dose of prednisone required long-term to control symptoms. Myasthenic crisis is de-
Myasthenia Gravis (MG)

CHAPTER 204

Myasthenia Gravis (MG) defined as an exacerbation of weakness, usually with respiratory failure, sufficient to endanger life; expert management in an intensive care setting essential as is prompt treatment with IVIg or plasmapheresis to hasten recovery.

For a more detailed discussion, see Drachman DB: Myasthenia Gravis and Other Diseases of the Neuromuscular Junction, Chap. 381, p. 2672, in HPIM-17.
Muscle diseases (myopathies) may be intermittent or persistent and usually present with proximal, symmetric weakness with preserved reflexes and sensation. An associated sensory loss suggests injury to peripheral nerve or the central nervous system rather than myopathy; on occasion, disorders affecting the anterior horn cells, the neuromuscular junction, or peripheral nerves can mimic myopathy. Any disorder causing muscle weakness may be accompanied by fatiguе, referring to an inability to maintain or sustain a force; this must be distinguished from asthenia, a type of fatigue caused by excess tiredness or lack of energy. Fatigue without abnormal clinical or laboratory findings almost never indicates a true myopathy.

Muscle disorders are usually painless; however, myalgias, or muscle pains, may occur. Myalgias must be distinguished from muscle cramps, i.e., painful muscle contractions, usually due to neurogenic disorders. A muscle contracture due to an inability to relax after an active muscle contraction is associated with energy failure in glycolytic disorders. Myotonia is a condition of prolonged muscle contraction followed by slow muscle relaxation.

A limited battery of tests can be used to evaluate a suspected myopathy. CK is the preferred muscle enzyme to measure in the evaluation of myopathies. Electrodiagnostic studies (nerve conduction studies and electromyography, NCS-EMG) are usually necessary to distinguish myopathies from neuropathies and neuromuscular junction disorders. An approach to muscle weakness is presented in Figs. 205-1 and 205-2.

MUSCULAR DYSTROPHIES

A varied group of inherited, progressive degenerations of muscle each with unique features.

DUCHEENNE DYSTROPHY

X-linked recessive mutation of the dystrophin gene that affects males almost exclusively. Progressive weakness in hip and shoulder girdle muscles beginning by age 5; by age 12, the majority are nonambulatory. Survival beyond age 25 is rare. Associated problems include tendon and muscle contractures, progressive kyphoscoliosis, impaired pulmonary function, cardiomyopathy, and intellectual impairment. Palpable enlargement and firmness of some muscles. Becker dystrophy is a less severe form, with a slower course and later age of onset (5–15) but similar clinical, laboratory, and genetic features.

Laboratory findings include massive elevations (20–100 × normal) of serum CK, a myopathic pattern on EMG testing, and evidence of groups of necrotic muscle fibers with regeneration, phagocytosis, and fatty replacement of muscle on biopsy. Diagnosis is established by determination of dystrophin deficiency in muscle tissue or mutation analysis on peripheral blood leukocytes. Testing available for detecting carriers and prenatal diagnosis.
Persistent Weakness

Patterns of Weakness on Neurologic Exam

**Proximal > distal**
- PM; DM; muscular dystrophies

**Ptosis, EOM**
- OPMD; mitochondrial myopathy; myotubular myopathy

**Facial and scapular winging**
- FSHD

**Facial, distal, quadriceps; handgrip myotonia**
- Myotonic muscular dystrophy

**Proximal & distal (hand grip), & quadriceps**
- IBM

**Distal**
- Distal myopathy

**Dropped head**
- MG; PM; ALS

Myopathic EMG confirms muscle disease and excludes ALS
- Repetitive nerve stimulation indicates MG
- CK elevation supports myopathy

May need DNA testing for further distinction of inherited myopathies

Muscle biopsy will help distinguish many disorders

FIGURE 205-1 Diagnostic evaluation of persistent weakness. EOM, extraocular muscle; OPMD, oculopharyngeal muscular dystrophy; FSHD, facioscapulohumeral muscular dystrophy; IBM, inclusion body myositis; DM, dermatomyositis; PM, polymyositis; MG, myasthenia gravis; ALS, amyotrophic lateral sclerosis; CK, creatinine kinase.
Intermittent weakness

Myoglobinuria

No

Variable weakness includes EOMs, ptosis, bulbar and limb muscles

Repetitive nerve stimulation decrement

AChR AB positive
Acquired MG

AChR AB negative
Congenital MG

Acquired MG

Exam normal between attacks
Proximal > distal weakness during attacks

Paradoxical myotonia on exam

Low potassium level

Hypokalemic PP
(myotonia confined to eyelids)

DNA test confirms diagnosis

Normal or elevated potassium level

Hyperkalemic PP
Paramyotonia congenita

Yes

Exam usually normal between attacks
Proximal > distal weakness during attacks

Forearm exercise

Reduced lactic acid:
Consider glycolytic defect

Normal lactic acid:
Consider CPT deficiency

Muscle biopsy defines specific defect

Reduced lactic acid:
Consider glycolytic defect

Normal lactic acid:
Consider CPT deficiency

Hypokalemic PP
(hypokalemic periodic paralysis)

Hyperkalemic PP
(paramyotonia congenita)

Normal lactic acid:
Consider CPT deficiency

Reduced lactic acid:
Consider glycolytic defect

FIGURE 205-2 Diagnostic evaluation for intermittent weakness. EOMs, extraocular muscles; AChR AB, acetylcholine receptor antibody; PP, periodic paralysis; CPT, carnitine palmityl transferase; MG, myasthenia gravis.
Muscular Dystrophy

Treatment is with glucocorticoids [prednisone (0.75 mg/kg)/d]. These slow progression of disease for up to 3 years; some patients cannot tolerate this therapy due to weight gain and increased risk of fractures.

**Limb-Girdle Dystrophy**

A constellation of diseases with proximal muscle weakness involving the pelvic and shoulder girdle musculature. Age of onset, rate of progression, severity of manifestations, inheritance pattern (autosomal dominant or autosomal recessive), and associated complications (e.g., cardiac, respiratory) vary with the specific subtype of disease.

**Myotonic Dystrophy**

Autosomal dominant disorder with genetic anticipation. Weakness typically becomes obvious in the second to third decade and initially involves the muscles of the face, neck, and distal extremities. This results in a distinctive facial appearance (“hatchet face”) characterized by ptosis, temporal wasting, drooping of the lower lip, and sagging of the jaw. Myotonia manifests as a peculiar inability to relax muscles rapidly following a strong exertion (e.g., after tight hand grip) usually by the age of 5, as well as by sustained contraction of muscles following percussion (e.g., of tongue or thenar eminence).

Associated problems can include frontal baldness, posterior subcapsular cataracts, gonadal atrophy, respiratory and cardiac problems, endocrine abnormalities, intellectual impairment, and hypersomnia. Cardiac disturbances, including complete heart block, may be life-threatening. Respiratory function should be carefully followed, as chronic hypoxia may lead to cor pulmonale.

Laboratory studies show normal or mildly elevated CK, characteristic myotonia and myopathic features on EMG, and a typical pattern of muscle fiber injury on biopsy, including selective type I fiber atrophy in 50% of cases. Pts with myotonic dystrophy type 1 have an unstable region of DNA with an increased number of trinucleotide CTG repeats on chromosome 19q13.3 in a protein kinase gene. Genetic testing for early detection and prenatal diagnosis is possible.

**Myotonic Dystrophy**

Phenytoin or mexiletine may help alleviate myotonia, although patients are rarely bothered by this symptom. Pacemaker insertion may be required for syncope or heart block. Orthoses may control foot drop, stabilize the ankle, and decrease falling. Excessive daytime somnolence with or without sleep apnea is not uncommon; sleep studies, noninvasive respiratory support (BiPAP), and treatment with modafinil may be beneficial.

**Facioscapulohumeral (FSH) Dystrophy**

An autosomal dominant, slowly progressive disorder with onset in childhood or young adulthood. Weakness involves facial (usually the initial manifestation), shoulder girdle, and proximal arm muscles and can result in atrophy of biceps, triceps, and scapular winging. Facial weakness results in inability to smile, whistle, or fully close the eyes with loss of facial expressivity. Foot drop and leg weakness may cause falls and progressive difficulty with ambulation.
Laboratory studies reveal normal or slightly elevated CK and usually myopathic features on EMG and muscle biopsy. Pts have deletions at chromosome 4q35. Genetic testing available for carrier detection and prenatal diagnosis.

**Facioscapulohumeral Dystrophy**

Ankle-foot orthoses are helpful for foot drop. Scapular stabilization procedures may help scapular winging but may not improve function.

**OCULOPHARYNGEAL DYSTROPHY (PROGRESSIVE EXTERNAL OPHTHALMOPLEgia)**

Onset in the fourth to sixth decade of ptosis, limitation of extraocular movements, and facial and cricopharyngeal weakness. Dysphagia may be life-threatening. Most pts are of French-Canadian or Spanish-American descent. Mutation in a poly-RNA binding protein responsible.

**INFLAMMATORY MYOPATHIES**

The most common group of acquired and potentially treatable skeletal muscle disorders. Three major forms: polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM). Usually present as progressive and symmetric muscle weakness; extraocular muscles spared but pharyngeal weakness (dysphagia) and head drop from neck muscle weakness common. Respiratory muscles may be affected in advanced cases. IBM is characterized by early involvement of quadriceps (leading to falls) and distal muscles; IBM may have an asymmetric pattern. Progression is over weeks or months in PM and DM, but typically over years in IBM. Skin involvement in DM may consist of a heliotrope rash (blue-purple discoloration) on the upper eyelids with edema, a flat red rash on the face and upper trunk, or erythema over knuckles *(Gottron’s sign)*. A variety of cancers are associated with DM. Features of each disorder are summarized in Table 205-1.

**Inflammatory Myopathies**

Often effective for PM and DM but not for IBM.

- Step 1: Glucocorticoids (prednisone, 1 mg/kg per day for 3–4 weeks, then tapered very gradually)
- Step 2: Approximately 75% of pts require additional therapy with other immunosuppressive drugs. Azathioprine up to 3 mg/kg per day, methotrexate (7.5 mg/week gradually increasing to 25 mg/week), or mycophenolate mofetil commonly used.
- Step 3: Intravenous immunoglobulin (2 g/kg divided over 2–5 days)
- Step 4: A trial of one of the following agents: rituximab, cyclosporine, cyclophosphamide, or tacrolimus.

**DISORDERS OF MUSCLE ENERGY METABOLISM**

There are two principal sources of energy for skeletal muscle: fatty acids and glucose. Abnormalities in either glucose or lipid utilization can be associated with distinct clinical presentations that can range from an acute, painful syndrome that mimics polymyositis to a chronic, progressive muscle weakness simulating muscular dystrophy. Definitive diagnosis usually requires biochemical-
Muscle Diseases

CHAPTER 205

enzymatic studies of biopsied muscle. However, muscle enzymes, EMG, and muscle biopsy all might be abnormal and may suggest specific disorders.

Progressive muscle weakness beginning usually in the third or fourth decade can be due to the adult form of acid maltase deficiency. Respiratory failure is often the initial manifestation; treatment with enzyme replacement may be of benefit. Progressive weakness beginning after puberty occurs with debranching enzyme deficiency. Glycolytic defects, including myophosphorylase deficiency (McArdle’s disease) or phosphofructokinase deficiency, present as exercise intolerance with myalgias. Disorders of fatty acid metabolism present with a similar picture. In adults, the most common cause is carnitine palmitoyltransferase deficiency. Exercise-induced cramps and myoglobinuria are common; strength is normal between the attacks. Dietary approaches (frequent meals and a low-fat high-carbohydrate diet, or a diet rich in medium-chain triglycerides) are of uncertain value.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Polymyositis</th>
<th>Dermatomyositis</th>
<th>Inclusion Body Myositis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at onset</td>
<td>&gt;18 yr</td>
<td>Adulthood and childhood</td>
<td>&gt;50 yr</td>
</tr>
<tr>
<td>Familial association</td>
<td>No</td>
<td>No</td>
<td>Yes, in some cases</td>
</tr>
<tr>
<td>Extramuscular manifestations</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Associated conditions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Connective tissue diseases</td>
<td>Yes&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Scleroderma and mixed connective tissue disease (overlap syndromes)</td>
<td>Yes, in up to 20% of cases&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Systemic autoimmune diseases&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Frequent</td>
<td>Infrequent</td>
<td>Infrequent</td>
</tr>
<tr>
<td>Malignancy</td>
<td>No</td>
<td>Yes, in up to 15% of cases</td>
<td>No</td>
</tr>
<tr>
<td>Viruses</td>
<td>Yes&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Unproven</td>
<td>Yes&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Drugs&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Yes</td>
<td>Yes, rarely</td>
<td>No</td>
</tr>
<tr>
<td>Parasites and bacteria&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

<sup>a</sup>Systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome, systemic sclerosis, mixed connective tissue disease.

<sup>b</sup>Crohn’s disease, vasculitis, sarcoidosis, primary biliary cirrhosis, adult celiac disease, chronic graft-versus-host disease, discoid lupus, ankylosing spondylitis, Behçet’s syndrome, myasthenia gravis, acne fulminans, dermatitis herpetiformis, psoriasis, Hashimoto’s disease, granulomatous diseases, agammaglobulinemia, monoclonal gammopathy, hypereosinophilic syndrome, Lyme disease, Kawasaki disease, autoimmune thrombocytopenia, hypergammaglobulinemic purpura, hereditary complement deficiency, IgA deficiency.

<sup>c</sup>HIV (human immunodeficiency virus) and HTLV-I (human T cell lymphotropic virus type I).

<sup>d</sup>Drugs include penicillamine (dermatomyositis and polymyositis), zidovudine (polymyositis), and contaminated tryptophan (dermatomyositis-like illness). Other myotoxic drugs may cause myopathy but not an inflammatory myopathy (see text for details).

<sup>e</sup>Parasites (protozoa, cestodes, nematodes), tropical and bacterial myositis (pyomyositis).
MITOCHONDRIAL MYOPATHIES

More accurately referred to as mitochondrial cytopathies because multiple tissues are usually affected, these disorders result from defects in mitochondrial DNA. The clinical presentations vary greatly: muscle symptoms may include weakness, ophthalmoparesis, pain, stiffness, or may even be absent; age of onset ranges from infancy to adulthood; associated clinical presentations include ataxia, encephalopathy, seizures, stroke-like episodes, and recurrent vomiting. Three groups: chronic progressive external ophthalmoplegia (CPEO), skeletal muscle–central nervous system syndromes, and pure myopathy syndromes simulating muscular dystrophy. The characteristic finding on muscle biopsy is “ragged red fibers,” which are muscle fibers with accumulations of abnormal mitochondria. Genetics often show a maternal pattern of inheritance because mitochondrial genes are inherited almost exclusively from the oocyte.

PERIODIC PARALYSES

Muscle membrane excitability is affected in a group of disorders referred to as channelopathies. Onset is usually in childhood or adolescence. Episodes typically occur after rest or sleep, often following earlier exercise. May be due to genetic disorders of calcium [hypokalemic periodic paralysis (hypoKPP)], sodium (hyperkalemic periodic paralysis), chloride, or potassium channels. Attacks of hypoKPP are treated with potassium chloride (usually oral), and prophylaxis with acetazolamide (125–1000 mg/d in divided doses) is usually effective. Attacks of thyrotoxic periodic paralysis (usually in Asian men) resemble those of hypoKPP; attacks abate with treatment of the underlying thyroid condition.

ENDOCRINE AND METABOLIC MYOPATHIES

Abnormalities of thyroid function can cause a wide array of muscle disorders. Hypothyroidism is associated with muscle cramps, pain, and stiffness, and proximal muscle weakness occurs in one-third of pts; the relaxation phase of muscle stretch reflexes is characteristically prolonged, and serum CK is often elevated (up to 10 times normal).

Hyperthyroidism can produce proximal muscle weakness and atrophy; bulbar, respiratory, and even esophageal muscles are occasionally involved, causing dysphagia, dysphonia, and aspiration. Other neuromuscular disorders associated with hyperthyroidism include hypoKPP, myasthenia gravis, and a progressive ocular myopathy associated with proptosis (Graves’ ophthalmopathy). Other endocrine conditions, including parathyroid, adrenal, and pituitary disorders, as well as diabetes mellitus, can also produce myopathy. Deficiencies of vitamins D and E are additional causes of muscle weakness.

DRUG-INDUCED MYOPATHIES

Drugs (including glucocorticoids, statins and other lipid-lowering agents) and toxins (e.g., alcohol) are commonly associated with myopathies (Table 205-2). In most cases, weakness is symmetric and involves proximal limb girdle muscles. Weakness, myalgia, and cramps are common symptoms. An elevated CK is often an important indication of toxicity. Diagnosis often depends on resolution of signs and symptoms with removal of offending agent.
### TABLE 205-2 DRUG-INDUCED MYOPATHIES

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Major Toxic Reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipid-lowering agents</td>
<td>Drugs belonging to all three of the major classes of lipid-lowering agents can produce a spectrum of toxicity: asymptomatic serum creatine kinase elevation, myalgias, exercised-induced pain, rhabdomyolysis, and myoglobinuria.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipid-lowering agents</td>
<td>Acute quadriplegic myopathy can occur with or without concomitant glucocorticoids.</td>
</tr>
<tr>
<td>Fibric acid derivatives</td>
<td>Mitochondrial myopathy with ragged red fibers.</td>
</tr>
<tr>
<td>HMG-CoA reductase inhibitors</td>
<td>All drugs in this group can lead to widespread muscle breakdown, rhabdomyolysis, and myoglobinuria.</td>
</tr>
<tr>
<td>Niacin (nicotinic acid)</td>
<td>Local injections cause muscle necrosis, skin induration, and limb contractures.</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>Use of this drug may cause polymyositis and myasthenia gravis.</td>
</tr>
<tr>
<td>Nondepolarizing neuromuscular blocking</td>
<td>All amphiphilic drugs have the potential to produce painless, proximal weakness associated with autophagic vacuoles in the muscle biopsy.</td>
</tr>
<tr>
<td>agents</td>
<td>This drug produces painless, proximal weakness especially in the setting of renal failure. Muscle biopsy shows autophagic vacuoles.</td>
</tr>
<tr>
<td>Zidovudine</td>
<td></td>
</tr>
<tr>
<td>Drugs of abuse</td>
<td></td>
</tr>
<tr>
<td>Alcoholic beverages</td>
<td></td>
</tr>
<tr>
<td>Cocaine</td>
<td></td>
</tr>
<tr>
<td>Heroin</td>
<td></td>
</tr>
<tr>
<td>Phencyclidine</td>
<td></td>
</tr>
<tr>
<td>Meperidine</td>
<td></td>
</tr>
<tr>
<td>Autoimmune toxic myopathy</td>
<td></td>
</tr>
<tr>
<td>D-Penicillamine</td>
<td></td>
</tr>
<tr>
<td>Amphophilic cationic drugs</td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td></td>
</tr>
<tr>
<td>Chloroquine</td>
<td></td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td></td>
</tr>
<tr>
<td>Antimicrotubular drugs</td>
<td></td>
</tr>
<tr>
<td>Colchicine</td>
<td></td>
</tr>
</tbody>
</table>
This page intentionally left blank
Mental disorders are common in medical practice and may present either as a primary disorder or as a comorbid condition. The prevalence of mental or substance use disorders in the United States is ~30%, but only one-third of those individuals are currently receiving treatment.

Disorders of mood, thinking, and behavior may be due to a primary psychiatric diagnosis [DSM-IV (Diagnostic and Statistical Manual, 4th edition, American Psychiatric Association) Axis I major psychiatric disorders] or a personality disorder (DSM-IV Axis II disorders) or may be secondary to metabolic abnormalities, drug toxicities, focal cerebral lesions, seizure disorders, or degenerative neurologic disease. Any pt presenting with new onset of psychiatric symptoms must be evaluated for underlying psychoactive substance abuse and/or medical or neurologic illness. Psychiatric medications are discussed in Chap. 207. The DSM-IV-PC (Primary Care) Manual provides a synopsis of mental disorders commonly seen in medical practice.

MAJOR PSYCHIATRIC DISORDERS (AXIS I DIAGNOSES)

MOOD DISORDERS (MAJOR AFFECTIVE DISORDERS)

Mood disorders are characterized by a disturbance in the regulation of mood, behavior, and affect; subdivided into (1) depressive disorders, (2) bipolar disorders (depression plus manic or hypomanic episodes), and (3) depression in association with medical illness or alcohol and substance abuse (see Chaps. 209 and 210).

Major Depression  Clinical Features  Affects 15% of the general population at some point in life; 6–8% of all outpatients in primary care settings satisfy diagnostic criteria. Diagnosis is made when five (or more) of the following symptoms have been present for 2 weeks (at least one of the symptoms must be #1 or #2 below):

1. Depressed mood
2. Loss of interest or pleasure
3. Change in appetite or weight
4. Insomnia or hypersomnia
5. Fatigue or loss of energy
6. Psychomotor agitation or retardation
7. Feelings of worthlessness or inappropriate guilt
8. Decreased ability to concentrate and make decisions
9. Recurrent thoughts of death or suicide.

A small number of pts with major depression will have psychotic symptoms (hallucinations and delusions) with their depressed mood. Negative life events
can precipitate depression, but genetic factors influence the sensitivity to these events.

Onset of a first depressive episode is typically in early adulthood, although major depression can occur at any age. Untreated episodes generally resolve spontaneously in a few months to a year; however, a sizable number of pts suffer from chronic, unremitting depression or from partial treatment response. Half of all pts experiencing a first depressive episode will go on to a recurrent course. Untreated or partially treated episodes put the pt at risk for future problems with mood disorders. Within an individual, the nature of episodes may be similar over time. A family history of mood disorder is common and tends to predict a recurrent course. Major depression can also be the initial presentation of bipolar disorder (manic depressive illness).

Suicide  Approximately 4–5% of all depressed pts will commit suicide, and most will have sought help from a physician within 1 month of their death. Physicians must always inquire about suicide when evaluating a pt with depression.

Depression with Medical Illness Virtually every class of medication can potentially induce or worsen depression. Antihypertensive drugs, anticholesterolemic agents, and antiarrhythmic agents are common triggers of depressive symptoms. Among the antihypertensive agents, β-adrenergic blockers and, to a lesser extent, calcium channel blockers are the most likely to cause depressed mood. Iatrogenic depression should also be considered in pts receiving glucocorticoids, antimicrobials, systemic analgesics, antiparkinsonian medications, and anticonvulsants.

Between 20 and 30% of cardiac pts manifest a depressive disorder. Tricyclic antidepressants (TCAs) are contraindicated in patients with bundle branch block, and TCA-induced tachycardia is an additional concern in pts with congestive heart failure. Selective serotonin reuptake inhibitors (SSRIs) appear not to induce ECG changes or adverse cardiac events and thus are reasonable first-line drugs for patients at risk for TCA-related complications. SSRIs may interfere with hepatic metabolism of anticoagulants, however, causing increased anticoagulation.

In cancer, the prevalence of depression is 25%, but it occurs in 40–50% of pts with cancers of the pancreas or oropharynx. Extreme cachexia from cancer may be misinterpreted as depression. Antidepressant medications in cancer pts improve quality of life as well as mood.

Diabetes mellitus is another consideration; the severity of the mood state correlates with the level of hyperglycemia and the presence of diabetic complications. Monoamine oxidase inhibitors (MAOIs) can induce hypoglycemia and weight gain. TCAs can produce hyperglycemia and carbohydrate craving. SSRIs, like MAOIs, may reduce fasting plasma glucose, but they are easier to use and may also improve dietary and medication compliance.

Depression may also occur with hypothyroidism or hyperthyroidism, neurologic disorders, in HIV-positive individuals, and in chronic hepatitis C infection (depression worsens with interferon treatment). Some chronic disorders of uncertain etiology, such as chronic fatigue syndrome and fibromyalgia, are strongly associated with depression.

Rk Major Depression

Pts with suicidal ideation require treatment by a psychiatrist and may require hospitalization. Most other pts with an uncomplicated unipolar major depression (a major depression that is not part of a cyclical mood disorder, such as a bipolar disorder) can be successfully treated by a nonpsychiatric physician.
Vigorous intervention and successful treatment appear to decrease the risk of future relapse. Pts who do not respond fully to standard treatment should be referred to a psychiatrist.

Antidepressant medications are the mainstay of treatment, although combined treatment with psychotherapy improves outcome. Symptoms are ameliorated after 6–8 weeks at a therapeutic dose in 60–70% of pts. A guideline for the medical management of depression is shown in Fig. 206-1. Once remission is achieved, antidepressants should be continued for 6–9 months. Pts must be monitored carefully after termination of treatment since relapse is common. Pts with two or more episodes of depression should be considered for indefinite maintenance treatment. Electroconvulsive therapy is generally reserved for life-threatening depression unresponsive to medication or for pts in whom the use of antidepressants is medically contraindicated. Vagus nerve stimulation (VNS) has been approved for treatment-resistant depression as well, but its degree of efficacy is controversial.

**Bipolar Disorder (Manic Depressive Illness)  Clinical Features** A cyclical mood disorder in which episodes of major depression are interspersed with episodes of mania or hypomania; 1.5% of the population is affected. Most pts initially
present with a manic episode in adolescence or young adulthood. Antidepressant therapy in pts with a cyclical mood disorder may provoke a manic episode; pts with a major depressive episode and a prior history of “highs” (mania or hypomania—which can be pleasant/euphoric or irritable/impulsive) and/or a family history of bipolar disorder should not be treated with antidepressants but must be referred promptly to a psychiatrist.

With mania, an elevated, expansive mood, irritability, angry outbursts, and impulsivity are characteristic. Specific symptoms include: (1) increased motor activity and restlessness; (2) unusual talkativeness; (3) flight of ideas and racing thoughts; (4) inflated self-esteem that can become delusional; (5) decreased need for sleep (often the first feature of an incipient manic episode); (6) decreased appetite; (7) distractability; (8) excessive involvement in risky activities (buying sprees, sexual indiscretions). Pts with full-blown mania can become psychotic. Hypomania is characterized by attenuated manic symptoms and is greatly underdiagnosed, as are “mixed episodes,” where both depressive and manic or hypomanic symptoms coexist simultaneously.

Untreated, a manic or depressive episode typically lasts for several weeks but can last as long as 8–12 months. Variants of bipolar disorder include rapid and ultrarapid cycling (manic and depressed episodes occurring at cycles of weeks, days, or hours). In many pts, especially females, antidepressants trigger rapid cycling and worsen the course of illness. Pts with bipolar disorder are at risk for substance use, especially alcohol abuse, and for medical consequences of risky sexual behavior (STDs). Bipolar disorder has a strong genetic component; the concordance rate for monozygotic twins approaches 80%.

**Bipolar Disorder**

Bipolar disorder is a serious, chronic illness that requires lifelong monitoring by a psychiatrist. Acutely manic pts often require hospitalization to reduce environmental stimulation and to protect themselves and others from the consequences of their reckless behavior. The recurrent nature of bipolar disorder necessitates maintenance treatment. Mood stabilizers (lithium, valproic acid, carbamazepine, lamotrigine) are effective for the resolution of acute episodes and for prophylaxis of future episodes.

**SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS**

**Schizophrenia**  
**Clinical Features**  
Occurs in 0.85% of the population worldwide; lifetime prevalence is ~1–1.5%. Characterized by perturbations of language, perception, thinking, social activity, affect, and volition. Pts usually present in late adolescence, often after an insidious premorbid course of subtle psychosocial difficulties. Core psychotic features last ≥6 months and include positive symptoms (such as conceptual disorganization, delusions, or hallucinations) and negative symptoms (loss of function, anhedonia, decreased emotional expression, impaired concentration, and diminished social engagement). Negative symptoms predominate in one-third and are associated with a poor long-term outcome and poor response to treatment.

Prognosis depends not on symptom severity but on the response to antipsychotic medication. A permanent remission without recurrence does occasionally occur. About 10% of schizophrenic patients commit suicide. Comorbid substance abuse is common.
Schizophrenia

Hospitalization is required for acutely psychotic pts who may be dangerous to themselves or others. Conventional antipsychotic medications are effective against hallucinations, delusions, and thought disorder. The novel antipsychotic medications—clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole—are helpful in pts unresponsive to conventional neuroleptics and may also be more useful for negative and cognitive symptoms. Drug treatment by itself is insufficient, and educational efforts directed toward families and relevant community resources are necessary to maintain stability and optimize outcomes.

Other Psychotic Disorders

These include schizoaffective disorder (where symptoms of schizophrenia are interspersed with major mood episodes) and schizophreniform disorder (pts who meet the symptom requirements but not the duration requirements for schizophrenia).

ANXIETY DISORDERS

Characterized by severe, persistent anxiety or sense of dread or foreboding. Most prevalent group of psychiatric illnesses seen in the community; present in 15–20% of medical clinic patients.

Panic Disorder

Occurs in 1–3% of the population; familial aggregation may occur. Onset in late adolescence or early adulthood. Initial presentation is almost always to a nonpsychiatric physician, frequently in the ER, as a possible heart attack or serious respiratory problem. The disorder is often initially unrecognized or misdiagnosed. Three quarters of pts with panic disorder will also satisfy criteria for major depression at some point.

Clinical Features

Characterized by panic attacks, which are sudden, unexpected, overwhelming paroxysms of terror and apprehension with multiple associated somatic symptoms. Attacks usually reach a peak within 10 min, then slowly resolve spontaneously, occurring in an unexpected fashion. Diagnostic criteria for panic disorder include recurrent panic attacks and at least 1 month of concern or worry about the attacks or a change in behavior related to them. Panic attacks must be accompanied by at least four of the following: palpitations, sweating, trembling or shaking, dyspnea, choking, chest pain, nausea or abdominal distress, dizziness or faintness, derealization or depersonalization, fear of losing control, fear of death, paresthesias, and chills or hot flashes.

When the disorder goes unrecognized and untreated, pts often experience significant morbidity: they become afraid of leaving home and may develop anticipatory anxiety, agoraphobia, and other spreading phobias; many turn to self-medication with alcohol or benzodiazepines.

Panic disorder must be differentiated from cardiovascular and respiratory disorders. Conditions that may mimic or worsen panic attacks include hyperthyroidism, pheochromocytoma, hypoglycemia, drug ingestions (amphetamines, cocaine, caffeine, sympathomimetic nasal decongestants), and drug withdrawal (alcohol, barbiturates, opiates, minor tranquilizers).

Panic Disorder

The cornerstone of drug therapy is antidepressant medication. SSRIs benefit the majority of panic disorder patients and do not have the adverse effects of
the TCAs. Benzodiazepines may be used in the short term while waiting for antidepressants to take effect.

Early psychotherapeutic intervention and education aimed at symptom control enhances the effectiveness of drug treatment. Cognitive-behavioral psychotherapy (CBP) (identifying and aborting panic attacks through relaxation and breathing techniques) can be effective.

**Generalized Anxiety Disorder (GAD)** Characterized by persistent, chronic anxiety; occurs in 5–6% of the population.

**Clinical Features** Pts experience persistent, excessive, and/or unrealistic worry associated with muscle tension, impaired concentration, autonomic arousal, feeling “on edge” or restless, and insomnia. Pts worry excessively over minor matters, with life-disrupting effects; unlike panic disorder, complaints of shortness of breath, palpitations, and tachycardia are relatively rare. Secondary depression is common, as is social phobia and comorbid substance abuse.

**Generalized Anxiety Disorder**

A combination of pharmacologic and psychotherapeutic interventions is most effective; complete symptom relief is rare. Benzodiazepines are the initial agents of choice when generalized anxiety is severe and acute enough to warrant drug therapy; physicians must be alert to psychological and physical dependence on benzodiazepines. Some SSRIs are also effective. A subgroup of pts respond to buspirone, a nonbenzodiazepine anxiolytic. Anticonvulsants with GABA-ergic properties (gabapentin, oxcarbazepine, tiagabine, pregabalin, divalproex) may also be effective against anxiety.

**Obsessive-Compulsive Disorder (OCD)** A severe disorder present in 2–3% of the population and characterized by recurrent obsessions (persistent intrusive thoughts) and compulsions (repetitive behaviors) that impair everyday functioning. Pts are often ashamed of their symptoms; physicians must ask specific questions to screen for this disorder including asking about recurrent thoughts and behaviors.

**Clinical Features** Common obsessions include thoughts of violence (such as killing a loved one), obsessive slowness for fear of making a mistake, fears of germs or contamination, and excessive doubt or uncertainty. Examples of compulsions include repeated checking to be assured that something was done properly, hand washing, extreme neatness and ordering behavior, and counting rituals, such as numbering one’s steps while walking.

Onset is usually in adolescence (childhood onset is not rare); more common in males and first-born children. Comorbid conditions are common, the most frequent being depression, other anxiety disorders, eating disorders, and tics. The course of OCD is usually episodic with periods of incomplete remission; some cases may show a steady deterioration in psychosocial functioning.

**Obsessive-Compulsive Disorder**

Clomipramine and the SSRIs (fluoxetine, fluvoxamine) are effective, but only 50–60% of pts show adequate improvement with pharmacotherapy alone. A combination of drug therapy and CBP is most effective for the majority of pts.
Posttraumatic Stress Disorder (PTSD)  Occurs in a subgroup of individuals exposed to a severe life-threatening trauma. If the reaction occurs shortly after the event, it is termed acute stress disorder, but if the reaction is delayed and subject to recurrence, PTSD is diagnosed. Predisposing factors include a past psychiatric history and personality characteristics of extroversion and high neuroticism.

Clinical Features  Individuals experience associated symptoms of detachment and loss of emotional responsivity. The pt may feel depersonalized and unable to recall specific events of the trauma, although it is reexperienced through intrusions in thought, dreams, or flashbacks. Comorbid substance abuse and other mood and anxiety disorders are common. This disorder is extremely debilitating; most pts require referral to a psychiatrist for ongoing care.

Phobic Disorders  Clinical Features  Recurring, irrational fears of specific objects, activities, or situations, with subsequent avoidance behavior of the phobic stimulus. Diagnosis is made only when the avoidance behavior interferes with social or occupational functioning. Affects ~10% of the population.

1. Agoraphobia: Fear of being in public places. May occur in absence of panic disorder, but is almost invariably preceded by that condition.
2. Social phobia: Persistent irrational fear of, and need to avoid, any situation where there is risk of scrutiny by others, with potential for embarrassment or humiliation. Common examples include excessive fear of public speaking and excessive fear of social engagements.
3. Simple phobias: Persistent irrational fears and avoidance of specific objects. Examples include fear of heights (acrophobia), blood, and closed spaces (claustrophobia).

Somatoform Disorders  Clinical Features  Pts with multiple somatic complaints that cannot be explained by a known medical condition or by the effects of substances; seen commonly in primary care practice (prevalence of 5%). In somatization disorder, the pt presents with multiple physical complaints referable to different organ systems. Onset is before age 30, and the disorder is persistent; pts with somatization disorder can be impulsive and demanding. In conversion disorder, the symptoms involve voluntary motor or sensory function. In hypochondriasis, the pt believes there is a serious medical illness, despite reassurance and appropriate medical evaluation. As with somatization disorder, these pts have a history of poor relationships with physicians due to their sense that they have not received adequate evaluation. Hypochondriasis can be disabling and show a
waxing and waning course. In *factitious illnesses*, the pt consciously and voluntarily produces physical symptoms; the sick role is gratifying. *Munchausen’s syndrome* refers to individuals with dramatic, chronic, or severe factitious illness. A variety of signs, symptoms, and diseases have been simulated in factitious illnesses; most common are chronic diarrhea, fever of unknown origin, intestinal bleeding, hematuria, seizures, hypoglycemia. In *malingering*, the fabrication of illness derives from a desire for an external gain (narcotics, disability).

**Somatoform Disorders**

Pts with somatoform disorders are usually subjected to multiple diagnostic tests and exploratory surgeries in an attempt to find their “real” illness. This approach is doomed to failure. Successful treatment is achieved through behavior modification, in which access to the physician is adjusted to provide a consistent, sustained, and predictable level of support that is not contingent on the pt’s level of presenting symptoms or distress. Visits are brief, supportive, and structured and are not associated with a need for diagnostic or treatment action. Pts may benefit from antidepressant treatment. Consultation with a psychiatrist is essential.

**PERSONALITY DISORDERS (AXIS II DIAGNOSES)**

Characteristic patterns of thinking, feeling, and interpersonal behavior that are relatively inflexible and cause significant functional impairment or subjective distress for the individual. Individuals with personality disorders are often regarded as “difficult patients.”

DSM-IV describes three major categories of personality disorders; pts usually present with a combination of features.

**CLUSTER A PERSONALITY DISORDERS**

Includes individuals who are odd and eccentric and who maintain an emotional distance from others. The *paranoid* personality pt has pervasive mistrust and suspiciousness of others. The *schizoid* personality is interpersonally isolated, cold, and indifferent, while the *schizotypal* personality is eccentric and superstitious, with magical thinking and unusual perceptual experiences.

**CLUSTER B PERSONALITY DISORDERS**

Describes individuals whose behavior is impulsive, excessively emotional, and erratic. The *borderline* personality is impulsive and manipulative, with unpredictable and fluctuating intense moods and unstable relationships, a fear of abandonment, and occasional rage episodes. The *histrionic* pt is dramatic, engaging, seductive, and attention-seeking. The *narcissistic* pt is self-centered and has an inflated sense of self-importance combined with a tendency to devalue or demean others, while pts with *antisocial* personality disorder use other people to achieve their own ends and engage in exploitative and manipulative behavior with no sense of remorse.

**CLUSTER C PERSONALITY DISORDERS**

Enduring traits are anxiety and fear. The *dependent* pt fears separation, tries to engage others to assume responsibility, and often has a help-rejecting style. Pts with *compulsive* personality disorder are meticulous and perfectionistic but also
inflexible and indecisive. *Avoidant* pts are anxious about social contact and have difficulty assuming responsibility for their isolation.

For a more detailed discussion, see Reus VI: Mental Disorders, Chap. 386, p. 2710, in HPIM-17.

### Psychiatric Medications

Four major classes are commonly used in adults: (1) antidepressants, (2) anxiolytics, (3) antipsychotics, and (4) mood stabilizing agents. Nonpsychiatric physicians should become familiar with one or two drugs in each of the first three classes so that the indications, dose range, efficacy, potential side effects, and interactions with other medications are well known.

#### GENERAL PRINCIPLES OF USE

1. Most treatment failures are due to undermedication and impatience. For a proper medication trial to take place, an effective dose must be taken for an adequate amount of time. For antidepressants, antipsychotics, and mood stabilizers, full effects may take weeks or months to occur.
2. History of a positive response to a medication usually indicates that a response to the same drug will occur again. A family history of a positive response to a specific medication is also useful.
3.Pts who fail to respond to one drug will often respond to another in the same class; one should attempt another trial with a drug that has a different mechanism of action or a different chemical structure. Treatment failures should be referred to a psychiatrist, as should all pts with psychotic symptoms or who require mood stabilizers.
4. Avoid polypharmacy; a pt who is not responding to standard monotherapy requires referral to a psychiatrist.
5. Pharmacokinetics may be altered in the elderly, with smaller volumes of distribution, reduced renal and hepatic clearance, longer biologic half-lives, and greater potential for CNS toxicity. The rule with elderly pts is to “start low and go slow.”
6. Never stop treatment abruptly; especially true for antidepressants and anxiolytics. In general, medications should be slowly tapered and discontinued over 2–4 weeks.
7. Review possible side effects each time a drug is prescribed; educate pts and family members about side effects and need for patience in awaiting a response.

#### ANTIDEPRESSANTS (ADS)

Useful to group according to known actions on CNS monoaminergic systems (Table 207-1). The selective serotonin reuptake inhibitors (SSRIs) have predominant effects on serotonergic neurotransmission, also reflected in side effect profile.
### TABLE 207-1 ANTIDEPRESSANTS

<table>
<thead>
<tr>
<th>Name</th>
<th>Usual Daily Dose, mg</th>
<th>Side Effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SSRIs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoxetine (Prozac)</td>
<td>10–80</td>
<td>Headache; nausea and other GI effects; jitterseness; insomnia; sexual dysfunction; can affect plasma levels of other meds (except sertraline); akathisia rare</td>
<td>Once daily dosing, usually in A.M.; fluoxetine has very long half-life; must not be combined with MAOIs</td>
</tr>
<tr>
<td>Sertraline (Zoloft)</td>
<td>50–200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paroxetine (Paxil)</td>
<td>20–60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluvoxamine (Luvox)</td>
<td>100–300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Citalopram (Celexa)</td>
<td>20–60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Escitalopram (Lexapro)</td>
<td>10–30</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TCAs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline (Elavil)</td>
<td>150–300</td>
<td>Anticholinergic (dry mouth, tachycardia, constipation, urinary retention, blurred vision); sweating; tremor; postural hypotension; cardiac conduction delay; sedation; weight gain</td>
<td>Once daily dosing, usually qhs; blood levels of most TCAs available; can be lethal in O.D. (lethal dose = 2 g); nortriptyline best tolerated, especially by elderly</td>
</tr>
<tr>
<td>Nortriptyline (Pamelor)</td>
<td>50–200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imipramine (Tofranil)</td>
<td>150–300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Desipramine (Norpramin)</td>
<td>150–300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doxepin (Sinequan)</td>
<td>150–300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clomipramine (Anafranil)</td>
<td>150–300</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mixed norepinephrine/serotonin reuptake inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venlafaxine (Effexor)</td>
<td>75–375</td>
<td>Nausea; dizziness; dry mouth; headaches; increased blood pressure; anxiety and insomnia</td>
<td>Bid-tid dosing (extended release available); lower potential for drug interactions than SSRIs; contraindicated with MAOI</td>
</tr>
<tr>
<td>Duloxetine (Cymbalta)</td>
<td>40–60</td>
<td>Nausea, dizziness, headache, insomnia, constipation</td>
<td>May have utility in treatment of neuropathic pain and stress incontinence</td>
</tr>
<tr>
<td>Mirtazapine (Remeron)</td>
<td>15–45</td>
<td>Somnolence; weight gain; neutropenia rare</td>
<td>Once daily dosing</td>
</tr>
<tr>
<td><strong>Mixed-action drugs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bupropion (Wellbutrin)</td>
<td>250–450</td>
<td>Jitteriness; flushing; seizures in at-risk patients; anorexia; tachycardia; psychosis</td>
<td>Tid dosing, but sustained release also available; fewer sexual side effects than SSRIs or TCAs; may be useful for adult ADD</td>
</tr>
<tr>
<td>Antidepressant</td>
<td>Dose (mg)</td>
<td>Side Effects</td>
<td>Additional Information</td>
</tr>
<tr>
<td>---------------</td>
<td>----------</td>
<td>--------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Trazodone (Desyrel)</td>
<td>200–600</td>
<td>Sedation; dry mouth; ventricular irritability; postural hypotension; priapism rare</td>
<td>Useful in low doses for sleep because of sedating effects with no anticholinergic side effects</td>
</tr>
<tr>
<td>Nefazodone (Serzone)</td>
<td>300–600</td>
<td>Sedation; headache; dry mouth; nausea; constipation</td>
<td>Discontinued sale in United States and several other countries due to risk of liver failure; Lethality in overdose; EPS possible</td>
</tr>
<tr>
<td>Amoxapine (Asendin)</td>
<td>200–600</td>
<td>Sexual dysfunction</td>
<td></td>
</tr>
<tr>
<td><strong>MAOIs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenelzine (Nardil)</td>
<td>45–90</td>
<td>Insomnia; hypotension; anorgasmia; weight gain; hypertensive crisis; toxic reactions with SSRIs</td>
<td>May be more effective in patients with atypical features or treatment-refractory depression</td>
</tr>
<tr>
<td>Tranylcypromine (Parnate)</td>
<td>20–50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isocarboxazid (Marplan)</td>
<td>20–60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transdermal selegiline (Emsam)</td>
<td>6–12</td>
<td>Local skin reaction; hypertension</td>
<td>No dietary restrictions with 6-mg dose</td>
</tr>
</tbody>
</table>

**Note:** ADD, attention deficit disorder; MAOI, monoamine oxidase inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; EPS, extrapyramidal symptoms.
The TCAs, or tricyclic antidepressants, affect noradrenergic and, to a lesser extent, serotonergic neurotransmission but also have anticholinergic and antihistaminic effects. Venlafaxine, duloxetine, and mirtazapine have mixed noradrenergic and serotonergic effects. Bupropion is a novel antidepressant that enhances noradrenergic function. Trazodone and nefazodone have mixed effects on serotonin receptors and on other neurotransmitter systems. The MAOIs inhibit monoamine oxidase, the primary enzyme responsible for the degradation of monoamines in the synaptic cleft.

ADs are effective against major depression, particularly when neurovegetative symptoms and signs are present. Despite the widespread use of SSRIs, there is no convincing evidence that they are more efficacious than TCAs, although their safety profile in overdose is more favorable than that of the TCAs. ADs are also useful in treatment of panic disorder, posttraumatic stress disorder, chronic pain syndromes, and generalized anxiety disorder. The TCA clomipramine and the SSRIs successfully treat obsessive-compulsive disorder.

All ADs require at least 2 weeks at a therapeutic dose before clinical improvement is observed. All ADs also have the potential to trigger a manic episode or rapid cycling when given to a pt with bipolar disorder. The MAOIs must not be prescribed concurrently with other ADs or with narcotics, as potentially fatal reactions may occur. “Withdrawal syndromes” usually consisting of malaise can occur when ADs are stopped abruptly.

**ANXIOLYTICS**

Benzodiazepines bind to sites on the γ-aminobutyric acid receptor and are cross-tolerant with alcohol and with barbiturates. Four clinical properties: (1) sedative, (2) anxiolytic, (3) skeletal muscle relaxant, and (4) antiepileptic. Individual drugs differ in terms of potency, onset of action, duration of action (related to half-life and presence of active metabolites), and metabolism (Table 207-2). Benzodiazepines have additive effects with alcohol; like alcohol, they can produce tolerance and physiologic dependence, with serious withdrawal syndromes (tremors, seizures, delirium, and autonomic hyperactivity) if discontinued too quickly, especially for those with short half-lives.

Buspirone is a nonbenzodiazepine anxiolytic that is nonsedating, is not cross-tolerant with alcohol, and does not induce tolerance or dependence. It requires at least 2 weeks at therapeutic doses to achieve full effects.

**ANTIPSYCHOTIC MEDICATIONS**

These include the typical neuroleptics, which act by blocking dopamine D₂ receptors, and the atypical neuroleptics, which act on dopamine, serotonin, and other neurotransmitter systems. Some antipsychotic effect may occur within hours or days of initiating treatment, but full effects usually require 6 weeks to several months of daily, therapeutic dosing.

**Conventional Antipsychotics** Useful to group into high-, mid-, and low-potency neuroleptics (Table 207-3). High-potency neuroleptics are least sedating, have almost no anticholinergic side effects, and have a strong tendency to induce extrapyramidal side effects (EPSEs). The EPSEs occur within several hours to several weeks of beginning treatment and include acute dystonias, akathisia, and pseudoparkinsonism. Extrapyramidal symptoms respond well to trihexyphenidyl, 2 mg twice daily, or benzotropine mesylate, 1 to 2 mg twice daily. Akathisia may respond to beta blockers. Low-potency neuroleptics are very sedating, may cause orthostatic hypotension, are anticholinergic, and tend not to induce EPSEs frequently.
<table>
<thead>
<tr>
<th>Name</th>
<th>Equivalent PO dose, mg</th>
<th>Onset of Action</th>
<th>Half-life, h</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzodiazepines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diazepam (Valium)</td>
<td>5</td>
<td>Fast</td>
<td>20–70</td>
<td>Active metabolites; quite sedating</td>
</tr>
<tr>
<td>Flurazepam (Dalmane)</td>
<td>15</td>
<td>Fast</td>
<td>30–100</td>
<td>Flurazepam is a pro-drug; metabolites are active; quite sedating</td>
</tr>
<tr>
<td>Triazolam (Halcion)</td>
<td>0.25</td>
<td>Intermediate</td>
<td>1.5–5</td>
<td>No active metabolites; can induce confusion and delirium, especially in elderly</td>
</tr>
<tr>
<td>Lorazepam (Ativan)</td>
<td>1</td>
<td>Intermediate</td>
<td>10–20</td>
<td>No active metabolites; direct hepatic glucuronide conjugation; quite sedating</td>
</tr>
<tr>
<td>Alprazolam (Xanax)</td>
<td>0.5</td>
<td>Intermediate</td>
<td>12–15</td>
<td>Active metabolites; not too sedating; may have specific antidepressant and antipanic activity; tolerance and dependence develop easily</td>
</tr>
<tr>
<td>Chlordiazepoxide (Librium)</td>
<td>10</td>
<td>Intermediate</td>
<td>5–30</td>
<td>Active metabolites; moderately sedating</td>
</tr>
<tr>
<td>Oxazepam (Serax)</td>
<td>15</td>
<td>Slow</td>
<td>5–15</td>
<td>No active metabolites; direct glucuronide conjugation; not too sedating</td>
</tr>
<tr>
<td>Temazepam (Restoril)</td>
<td>15</td>
<td>Slow</td>
<td>9–12</td>
<td>No active metabolites; moderately sedating</td>
</tr>
<tr>
<td>Clonazepam (Klonopin)</td>
<td>0.5</td>
<td>Slow</td>
<td>18–50</td>
<td>No active metabolites; moderately sedating</td>
</tr>
<tr>
<td>Non-benzodiazepines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buspirone (BuSpar)</td>
<td>7.5</td>
<td>2 weeks</td>
<td>2–3</td>
<td>Active metabolites; tid dosing—usual daily dose 10–20 mg tid; nonsedating; no additive effects with alcohol; useful for agitation in demented or brain-injured patients</td>
</tr>
<tr>
<td>Name</td>
<td>Usual PO Daily Dose, mg</td>
<td>Side Effects</td>
<td>Sedation</td>
<td>Comments</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------</td>
<td>---------------------------------------------------</td>
<td>----------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anticholinergic effects; orthostasis; photosensitivity; cholestasis; QT prolongation</td>
<td>+ + +</td>
<td>EPSEs usually not prominent; can cause anticholinergic delirium in elderly patients</td>
</tr>
<tr>
<td>Chlorpromazine (Thorazine)</td>
<td>100–1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thioridazine (Mellaril)</td>
<td>100–600</td>
<td>Agranulocytosis (1%); weight gain; seizures; drooling; hyperthermia</td>
<td>+ +</td>
<td>Requires weekly WBC for first 6 months, then biweekly if stable</td>
</tr>
<tr>
<td>Clozapine (Clozaril)</td>
<td>150–600</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low-potency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trifluoperazine (Stelazine)</td>
<td>2–50</td>
<td>Fewer anticholinergic side effects; fewer EPSEs than with higher potency agents.</td>
<td>+ +</td>
<td>Well tolerated by most patients</td>
</tr>
<tr>
<td>Perphenazine (Trilafon)</td>
<td>4–64</td>
<td></td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>Clozapine (Clozaril)</td>
<td>30–100</td>
<td>Frequent EPSEs</td>
<td>+ +</td>
<td></td>
</tr>
<tr>
<td>Loxapine (Loxitane)</td>
<td>30–100</td>
<td>Frequent EPSEs</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Molveinedone (Moban)</td>
<td>30–100</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High-potency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haloperidol (Haldol)</td>
<td>.5–20</td>
<td>No anticholinergic side effects; EPSEs often prominent</td>
<td>0/+</td>
<td>Often prescribed in doses that are too high; long-acting injectable forms of haloperidol and fluphenazine available</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluphenazine (Prolixin)</td>
<td>1–20</td>
<td>Frequent EPSEs</td>
<td>0/+</td>
<td></td>
</tr>
<tr>
<td>Thiothixene (Navane)</td>
<td>2–50</td>
<td>Frequent EPSEs</td>
<td>0/+</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dosage Range</td>
<td>Side Effects</td>
<td>Notes</td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>--------------</td>
<td>---------------------------------------------------</td>
<td>--------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Risperidone (Risperdal)</td>
<td>2–8 mg</td>
<td>Orthostasis</td>
<td>Requires slow titration; EPSEs observed with doses &gt;6 mg qd</td>
<td></td>
</tr>
<tr>
<td>Olanzapine (Zyprexa)</td>
<td>10–30 mg</td>
<td>Weight gain</td>
<td>+ + Mild prolactin elevation</td>
<td></td>
</tr>
<tr>
<td>Quetiapine (Seroquel)</td>
<td>350–800 mg</td>
<td>Sedation; weight gain; anxiety</td>
<td>+ + + Bid dosing</td>
<td></td>
</tr>
<tr>
<td>Ziprasidone (Geodon)</td>
<td>120–200 mg</td>
<td>Orthostatic hypotension</td>
<td>+/+ Minimal weight gain; increases QT interval</td>
<td></td>
</tr>
<tr>
<td>Aripiprazole (Abilify)</td>
<td>10–30 mg</td>
<td>Nausea, anxiety, insomnia</td>
<td>0/+ Mixed agonist/antagonist</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** EPSEs, extrapyramidal side effects; WBC, white blood count.
Up to 20% of pts treated with conventional antipsychotic agents for >1 year develop tardive dyskinesia (probably due to dopamine receptor supersensitivity), an abnormal involuntary movement disorder most often observed in the face and distal extremities. Treatment includes gradual withdrawal of the neuroleptic, with possible switch to a novel neuroleptic; anticholinergic agents can worsen the disorder.

Rarely, pts exposed to neuroleptics develop neuroleptic malignant syndrome (NMS), a life-threatening complication with a mortality rate as high as 25%; hyperpyrexia, autonomic hyperactivity, muscle rigidity, obtundation, and agitation are characteristic, associated with increased WBC, increased CPK, and myoglobinuria. Treatment involves immediate discontinuation of neuroleptics, supportive care, and use of dantrolene and bromocriptine.

**Novel Antipsychotics** A new class of agents that has become the first line of treatment (Table 207-3); efficacious in treatment-resistant pts, tend not to induce EPSEs or tardive dyskinesia, and appear to have uniquely beneficial properties on negative symptoms and cognitive dysfunction. Main problem is side effect of weight gain (most prominent in clozapine and in olanzapine; can induce diabetes). The CATIE study, a large-scale investigation of antipsychotic agents in the “real world,” revealed a high rate of discontinuation of all medications over 18 months; olanzapine was modestly more effective than other agents but with a higher discontinuation rate due to side effects.

### TABLE 207-4 CLINICAL PHARMACOLOGY OF MOOD STABILIZERS

<table>
<thead>
<tr>
<th>Agent and Dosing</th>
<th>Side Effects and Other Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lithium</td>
<td>Common side effects: Nausea/anorexia/diarrhea, fine tremor, thirst, polyuria, fatigue, weight gain, acne, folliculitis, neutrophilia, hypothyroidism</td>
</tr>
<tr>
<td>Starting dose: 300 mg bid or tid</td>
<td></td>
</tr>
<tr>
<td>Therapeutic blood level: 0.8–1.2 meq/L</td>
<td></td>
</tr>
<tr>
<td>Valproic acid</td>
<td>Common side effects: Nausea/anorexia, weight gain, sedation, tremor, rash, alopecia</td>
</tr>
<tr>
<td>Starting dose: 250 mg tid</td>
<td></td>
</tr>
<tr>
<td>Therapeutic blood level: 50–125 μg/mL</td>
<td></td>
</tr>
<tr>
<td>Carbamazepine/oxtcarbazepine</td>
<td>Common side effects: Nausea/anorexia, sedation, rash, dizziness/ataxia</td>
</tr>
<tr>
<td>Starting dose: 200 mg bid for carbamazepine, 150 bid for oxtcarbazepine</td>
<td></td>
</tr>
<tr>
<td>Therapeutic blood level: 4–12 μg/mL for carbamazepine</td>
<td></td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>Common side effects: Rash, dizziness, headache, tremor, sedation, nausea</td>
</tr>
<tr>
<td>Starting dose: 25 mg/d</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** NSAID, nonsteroidal anti-inflammatory drug; ECG, electrocardiogram.
MOOD-STABILIZING AGENTS

Four mood stabilizers in common use: lithium, carbamazepine, valproic acid, and lamotrigine (Table 207-4). Lithium is the “gold standard” and the best studied, and along with carbamazepine and valproic acid, is used for treatment of acute manic episodes; 1–2 weeks to reach full effect. As prophylaxis, the mood stabilizers reduce frequency and severity of both manic and depressed episodes in cyclical mood disorders. In refractory bipolar disorder, combinations of mood stabilizers may be beneficial.

For a more detailed discussion, see Reus VI: Mental Disorders, Chap. 386, p. 2710, in HPIM-17.

Eating Disorders

DEFINITIONS
Anorexia nervosa is characterized by refusal to maintain normal body weight, resulting in a body weight < 85% of the expected weight for age and height. Bulimia nervosa is characterized by recurrent episodes of binge eating followed by abnormal compensatory behaviors, such as self-induced vomiting, laxative abuse, or excessive exercise. Weight is in the normal range or above.

Both anorexia nervosa and bulimia nervosa occur primarily among previously healthy young women who become overly concerned with body shape and weight. Binge eating and purging behavior may be present in both conditions, with the critical distinction between the two resting on the weight of the individual. The diagnostic features of each of these disorders are shown in Tables 208-1 and 208-2.

CLINICAL FEATURES
Anorexia Nervosa
• General: feeling cold
• Skin, hair, nails: alopecia, lanugo, acrocyanosis, edema

TABLE 208-1 DIAGNOSTIC FEATURES OF ANOREXIA NERVOSA

<table>
<thead>
<tr>
<th>Feature</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refusal to maintain body weight at or above a minimally normal weight</td>
<td>(This includes a failure to achieve weight gain expected during a period of growth leading to an abnormally low body weight.)</td>
</tr>
<tr>
<td>Intense fear of weight gain or becoming fat.</td>
<td></td>
</tr>
<tr>
<td>Distortion of body image (e.g., feeling fat despite an objectively low weight or minimizing the seriousness of low weight).</td>
<td></td>
</tr>
<tr>
<td>Amenorrhea. (This criterion is met if menstrual periods occur only following hormone—e.g., estrogen—administration.)</td>
<td></td>
</tr>
</tbody>
</table>
• Cardiovascular: bradycardia, hypotension
• Gastrointestinal: salivary gland enlargement, slow gastric emptying, constipation, elevated liver enzymes
• Hematopoietic: normochromic, normocytic anemia; leukopenia
• Fluid/electrolyte: increased blood urea nitrogen, increased creatinine, hyponatremia, hypokalemia
• Endocrine: low luteinizing hormone and follicle-stimulating hormone with secondary amenorrhea, hypoglycemia, normal thyroid-stimulating hormone with low normal thyroxine, increased plasma cortisol, osteopenia

Bulimia Nervosa
• Gastrointestinal: salivary gland enlargement, dental erosion
• Fluid/electrolyte: hypokalemia, hypochloremia, alkalosis (from vomiting) or acidosis (from laxative abuse)
• Other: loss callus on dorsum of hand

<table>
<thead>
<tr>
<th>TABLE 208-2</th>
<th>DIAGNOSTIC FEATURES OF BULIMIA NERVOSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrent episodes of binge eating, which is characterized by the consumption of a large amount of food in a short period of time and a feeling that the eating is out of control.</td>
<td></td>
</tr>
<tr>
<td>Recurrent inappropriate behavior to compensate for the binge eating, such as self-induced vomiting.</td>
<td></td>
</tr>
<tr>
<td>The occurrence of both the binge eating and the inappropriate compensatory behavior at least twice weekly, on average, for 3 months.</td>
<td></td>
</tr>
<tr>
<td>Overconcern with body shape and weight.</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** If the diagnostic criteria for anorexia nervosa are simultaneously met, only the diagnosis of anorexia nervosa is given.

Anorexia Nervosa
Weight restoration to 90% of predicted weight is the primary goal in the treatment of anorexia nervosa. The intensity of the initial treatment, including the need for hospitalization, is determined by the pt’s current weight, the rapidity of recent weight loss, and the severity of medical and psychological complications (**Fig. 208-1**). Severe electrolyte imbalances should be identified and corrected. Nutritional restoration can almost always be successfully accomplished by oral feeding. For severely underweight pts, sufficient calories should be provided initially in divided meals as food or liquid supplements to maintain weight and to permit stabilization of fluid and electrolyte balance (1200–1800 kcal/d intake). Calories can be gradually increased to achieve a weight gain of 1–2 kg per week (3000–4000 kcal/d intake). Meals must be supervised. Intake of vitamin D (400 IU/d) and calcium (1500 mg/d) should be sufficient to minimize bone loss. The assistance of psychiatrists or psychologists experienced in the treatment of anorexia nervosa is usually necessary. No psychotropic medications are of established value in the treatment of anorexia nervosa. Medical complications occasionally occur during refeeding; most patients transiently retain excess fluid, occasionally resulting in peripheral edema. Congestive heart failure and acute gastric dilatation have been described when refeeding is rapid. Transient modest elevations in serum levels of liver enzymes occasionally occur. Low levels of magnesium and phosphate should be replaced. Mortality is 5% per decade, from either chronic starvation or suicide.
Bulimia Nervosa

Bulimia nervosa can usually be treated on an outpatient basis (Fig. 208-1). Cognitive behavioral therapy and fluoxetine (Prozac) are first-line therapies. The recommended treatment dose for fluoxetine (60 mg/d) is higher than that typically used to treat depression.

For a more detailed discussion, see Walsh TB: Eating Disorders, Chap. 76, p. 473, in HPIM-17.

Alcoholism

Alcoholism is a multifactorial disorder in which genetic, biologic, and sociocultural factors interact.
• Alcohol dependence: defined in DSM-IV as repeated alcohol-related difficulties in at least three of seven areas of functioning that cluster together over a 12-month period; physiologic tolerance and withdrawal are two of these seven areas and are associated with a more severe course.

• Alcohol abuse: defined as repetitive problems with alcohol in any one of four life areas—social, interpersonal, legal, and occupational—or repeated use in hazardous situations such as driving while intoxicated. A person who is not alcohol dependent may still be given a diagnosis of alcohol abuse.

**CLINICAL FEATURES**

Lifetime risk for alcohol dependence is 10–15% for men and 5–8% for women. Typically, the first major life problem from excessive alcohol use appears in early adulthood, followed by periods of exacerbation and remission. The course is not hopeless; following treatment, between half and two-thirds of patients maintain abstinence for years and often permanently. If the alcoholic continues to drink, life span is shortened by an average of 10–15 years due to increased risk of death from heart disease, cancer, accidents, or suicide.

Screening for alcoholism is important given its high prevalence. A positive answer to any of the “CAGE questions” indicates a high probability of alcoholism: Are you… Cutting down, or feel the need to? Annoyed when people criticize your drinking? Guilty about your drinking? Eye-opening with a drink in the morning? Other standardized questionnaires can be helpful in busy clinical practices including the 10-item Alcohol Use Disorders Identification Test (AUDIT) (see Table 209-1)

Routine medical care requires attention to potential alcohol-related illness and to alcoholism itself:

1. Neurologic—blackouts, seizures, delirium tremens, cerebellar degeneration, neuropathy, myopathy
2. Gastrointestinal—esophagitis, gastritis, pancreatitis, hepatitis, cirrhosis, GI hemorrhage
3. Cardiovascular—hypertension, cardiomyopathy
4. Hematologic—macrocytosis, folate deficiency, thrombocytopenia, leukopenia
5. Endocrine—gynecomastia, testicular atrophy, amenorrhea, infertility
6. Skeletal—fractures, osteonecrosis
7. Cancer—breast cancer, oral and esophageal cancers, rectal cancers

**Alcohol Intoxication** Alcohol is a CNS depressant that acts on receptors for \( \gamma \)-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the nervous system. Behavioral, cognitive, and psychomotor changes can occur at blood alcohol levels as low as 4–7 mmol/L (20–30 mg/dL), a level achieved after the ingestion of one or two typical drinks. Mild to moderate intoxication occurs at 17–43 mmol/L (80–200 mg/dL). Incoordination, tremor, ataxia, confusion, stupor, coma, and even death occur at progressively higher blood alcohol levels.

**Alcohol Withdrawal** Chronic alcohol use produces CNS dependence, and the earliest sign of alcohol withdrawal is tremulousness (“shakes” or “jitters”), occurring 5–10 h after the last drink. This may be followed by generalized seizures in the first 24–48 h; these do not require initiation of antiseizure medications. With severe withdrawal, autonomic hyperactivity ensues (sweating, hypertension, tachycardia, tachypnea, fever), accompanied by insomnia, nightmares, anxiety, and GI symptoms.

**Delirium Tremens (DTs)** A very severe withdrawal syndrome characterized by profound autonomic hyperactivity, extreme confusion, agitation, vivid delu-
Alcoholism

CHAPTER 209

CONDITIONS, and hallucinations (often visual and tactile) that begins 3–5 days after the last drink. Mortality is 5–15%.

**Wernicke’s Encephalopathy** An alcohol-related syndrome characterized by ataxia, ophthalmoplegia, and confusion, often with associated nystagmus, peripheral neuropathy, cerebellar signs, and hypotension; there is impaired short-term memory, inattention, and emotional lability. Korsakoff’s syndrome follows, characterized by anterograde and retrograde amnesia and confabulation. Wernicke-Korsakoff’s syndrome is caused by chronic thiamine deficiency, resulting in damage to thalamic nuclei, mamillary bodies, and brainstem and cerebellar structures.

**LABORATORY FINDINGS**

Include mild anemia with macrocytosis, folate deficiency, thrombocytopenia, granulocytopenia, abnormal liver function tests, hyperuricemia, and elevated triglycerides. Two blood tests with between 70% and 80% sensitivity and specificity are γ-glutamyl transferase (GGT) (>35 U) and carbohydrate-deficient transferrin (CDT) (>20 U/L); the combination of the two is likely to be more accurate than either alone when screening pts for high levels of alcohol intake. Decreases in serum K, Mg, Zn, and PO₄ levels are common. A variety of diagnostic studies may show evidence of alcohol-related organ dysfunction.

---

**TABLE 209-1 **

<table>
<thead>
<tr>
<th>Item</th>
<th>5-Point Scale (Least to Most)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. How often do you have a drink containing alcohol?</td>
<td>Never (0) to 4+ per week (4)</td>
</tr>
<tr>
<td>2. How many drinks containing alcohol do you have on a typical day?</td>
<td>1 or 2 (0) to 10+ (4)</td>
</tr>
<tr>
<td>3. How often do you have six or more drinks on one occasion?</td>
<td>Never (0) to daily or almost daily (4)</td>
</tr>
<tr>
<td>4. How often during the last year have you found that you were not able to stop drinking once you had started?</td>
<td>Never (0) to daily or almost daily (4)</td>
</tr>
<tr>
<td>5. How often during the last year have you failed to do what was normally expected from you because of drinking?</td>
<td>Never (0) to daily or almost daily (4)</td>
</tr>
<tr>
<td>6. How often during the last year have you needed a first drink in the morning to get yourself going after a heavy drinking session?</td>
<td>Never (0) to daily or almost daily (4)</td>
</tr>
<tr>
<td>7. How often during the last year have you had a feeling of guilt or remorse after drinking?</td>
<td>Never (0) to daily or almost daily (4)</td>
</tr>
<tr>
<td>8. How often during the last year have you been unable to remember what happened the night before because you had been drinking?</td>
<td>No (0) to yes, during the last year (4)</td>
</tr>
<tr>
<td>9. Have you or someone else been injured as a result of your drinking?</td>
<td>No (0) to yes, during the last year (4)</td>
</tr>
<tr>
<td>10. Has a relative, friend, doctor or other health worker been concerned about your drinking or suggested that you should cut down?</td>
<td>No (0) to yes, during the last year (4)</td>
</tr>
</tbody>
</table>

*Total score ≥ 8 indicates harmful alcohol use and possible alcohol dependence.**

Acute alcohol withdrawal is treated with multiple B vitamins including thiamine (50–100 mg IV or PO daily for ≥1 week) to replenish depleted stores; use the IV route if Wernicke-Korsakoff's syndrome is suspected since intestinal absorption is unreliable in alcoholics. CNS depressant drugs are used when seizures or autonomic hyperactivity is present to halt the rapid state of withdrawal in the CNS and allow for a slower, more controlled reduction of the substance. Low-potency benzodiazepines with long half-lives are the medication of choice (e.g., diazepam, chlordiazepoxide), because they produce fairly steady blood levels of drug with a wide dose range within which to work. Risks include overmedication and oversedation, which occur less commonly with shorter-acting agents (e.g., oxazepam, lorazepam). Typical doses are diazepam 10 mg or chlordiazepoxide 25–50 mg PO every 4–6 h as needed for objective signs of alcohol withdrawal (such as pulse < 90).

In severe withdrawal or DTs, high doses of benzodiazepines are usually required. Fluid and electrolyte status and blood glucose levels should be closely followed. Cardiovascular and hemodynamic monitoring are crucial, as hemodynamic collapse and cardiac arrhythmia are not uncommon. Generalized withdrawal seizures rarely require aggressive pharmacologic intervention beyond that given to the usual pt undergoing withdrawal, i.e., adequate doses of benzodiazepines.

**RECOVERY AND SOBRIETY**

**Counseling, Education, and Cognitive Approaches**

First, attempts should be made to help the alcoholic achieve and maintain a high level of motivation toward abstinence. These include education about alcoholism and instructing family and/or friends to stop protecting the person from the problems caused by alcohol. A second goal is to help the pt to readjust to life without alcohol and to reestablish a functional lifestyle through counseling, vocational rehabilitation, and self-help groups such as Alcoholics Anonymous (AA). A third component, called relapse prevention, helps the person to identify situations in which a return to drinking is likely, formulate ways of managing these risks, and develop coping strategies that increase the chances of a return to abstinence if a slip occurs. There is no convincing evidence that inpatient rehabilitation is more effective than outpatient care.

**Drug Therapy**

Several medications may be useful in alcoholic rehabilitation; usually medications are continued for 6–12 months if a positive response is seen.

- The opioid-antagonist drug naltrexone, (50–150 mg/d) decreases the probability of a return to drinking and shortens periods of relapse; a once-a-month injectable form of this drug (380 mg) has recently been developed to help improve compliance.

- A second medication, acamprosate (2 g/d), an N-methyl-D-aspartate receptor inhibitor, may be used; efficacy appears to be similar to naltrexone.

- Disulfiram (250 mg/d), an aldehyde dehydrogenase inhibitor, produces an unpleasant and potentially dangerous reaction in the presence of alcohol. Few controlled trials demonstrate a clear superiority over placebo.

For a more detailed discussion, see Schuckit MA: Alcohol and Alcoholism, Chap. 387, p. 2724, in HPIM-17.
Narcotics, or opiates, bind to specific opioid receptors in the CNS and elsewhere in the body. These receptors mediate the opiate effects of analgesia, euphoria, respiratory depression, and constipation. Endogenous opiate peptides (enkephalins and endorphins) are natural ligands for the opioid receptors and play a role in analgesia, memory, learning, reward, mood regulation, and stress tolerance.

The prototypic opiates, morphine and codeine, are derived from the juice of the opium poppy, *Papaver somniferum*. The semisynthetic drugs produced from morphine include hydromorphone (Dilaudid), diacetylmorphine (heroin), and oxycodone. The purely synthetic opioids and their cousins include meperidine, propoxyphene, diphenoxylate, fentanyl, buprenorphine, tramadol, methadone, and pentazocine. All of these substances produce analgesia and euphoria as well as physical dependence when taken in high enough doses for prolonged periods of time.

**CLINICAL FEATURES**

Close to 1 million individuals in the United States are opioid-dependent. A 2005 survey of young adults revealed that 13.5% of high school seniors had tried opioid drugs outside of a doctor’s prescription. Three groups of abusers can be identified:

- **“Medical” abusers.** Pts with chronic pain syndromes who misuse their prescribed analgesics
- **Physicians, nurses, dentists, and pharmacists** with easy access to narcotics
- **“Street” abusers.** Typically a higher functioning individual who began by using tobacco, alcohol, marijuana, and brain depressants or stimulants and then moved on to opiates

**Acute Effects** All opiates have the following CNS effects: sedation, euphoria, decreased pain perception, decreased respiratory drive, and vomiting. In larger doses, markedly decreased respirations, bradycardia, pupillary miosis, stupor, and coma ensue. Additionally, the adulterants used to “cut” street drugs (quinine, phenacetin, strychnine, antipyrine, caffeine, powdered milk) can produce permanent neurologic damage, including peripheral neuropathy, amblyopia, myelopathy, and leukoencephalopathy; adulterants can also produce an “allergic-like” reaction characterized by decreased alertness, frothy pulmonary edema, and an elevation in blood eosinophil count.

**Chronic Effects** Chronic use of opiates will result in tolerance (requiring higher doses to achieve psychotropic effects) and physical dependence. At least 25% of street abusers die within 10–20 years of starting active opiate abuse from suicide, homicide, accidents, or infections such as hepatitis or AIDS; the latter is epidemic among injection drug users, with HIV+ rates as high as 60% in some locales.

**Withdrawal** Withdrawal produces nausea and diarrhea, coughing, lacrimation, mydriasis, rhinorrhea, diaphoresis, twitching muscles, piloerection, fever, tachypnea, hypertension, diffuse body pain, insomnia, and yawning. Relief of these exceedingly unpleasant symptoms by narcotic administration leads to more frequent narcotic use.
With shorter-acting opiates such as heroin, morphine, or oxycodone, withdrawal signs begin 8–16 h after the last dose, peak at 36–72 h, and subside over 5–8 days. With longer-acting opiates such as methadone, withdrawal begins several days after the last dose, peaks at 7–10 days in some cases, and lasts several weeks.

**Narcotic Abuse**

**Overdose**
High doses of opiates, whether taken in a suicide attempt or accidentally when its potency is misjudged, are potentially lethal. Toxicity occurs immediately after IV administration and with a variable delay after oral ingestion. Symptoms include miosis, shallow respirations, bradycardia, hypothermia, and stupor or coma. Treatment requires cardiorespiratory support, using intubation if needed, and administration of the opiate antagonist naloxone (0.4–2 mg IV or IM repeated every 2–3 min up to 10 mg, if no or only partial response). Because the effects of naloxone diminish in 2–3 h compared with longer-lasting effects of heroin (up to 24 h) or methadone (up to 72 h), pts must be observed for at least 1–3 days for reappearance of the toxic state.

**Withdrawal**
One treatment approach to withdrawal is the administration of any opioid (e.g., 10–25 mg of methadone twice a day) on day 1 to decrease symptoms. After several days of a stabilized drug dose, the opioid is then decreased by 10–20% of the original day's dose each day. However, detoxification with opioids is proscribed or limited in most states. Thus, pharmacologic treatments often center on relief of symptoms of diarrhea with loperamide, of “sniffles” with decongestants, and pain with nonopioid analgesics (e.g., ibuprofen). Comfort can be enhanced with administration of the ɑ₂-adrenergic agonist clonidine in doses up to 0.3 mg given two to four times a day to decrease sympathetic nervous system overactivity. Blood pressure must be closely monitored. Some clinicians augment this regimen with low to moderate doses of benzodiazepines for 2–5 days to decrease agitation. An ultrarapid detoxification procedure using deep sedation and withdrawal precipitated by naltrexone has many inherent dangers and few, if any, advantages.

**Opioid Maintenance**
Methadone maintenance is a widely used treatment strategy in the management of opiate addiction. Methadone is a long-acting opioid optimally dosed at 80–120 mg/d (gradually increased over time). This level is optimally effective in blocking heroin-induced euphoria, decreasing craving, and maintaining abstinence from illegal opioids. Over three-quarters of patients in well-supervised methadone clinics are likely to remain heroin-free for ≥6 months. Methadone is administered as an oral liquid given once a day at the program, with weekend doses taken at home. After a period of maintenance (usually 6 months to ≥1 year), the clinician can work to slowly decrease the dose by about 5% per week. An additional medication that has been used for maintenance treatment involves the μ opioid agonist and antagonist buprenorphine; it has several advantages, including low overdose danger, potentially easier detoxification than with methadone, and a probable ceiling effect in which higher doses do not increase euphoria.

**Opiate Antagonists**
The opiate antagonists (e.g., naltrexone) compete with heroin and other opioids at receptors, reducing the effects of the opioid agonists. Administered over long periods with the intention of blocking the opioid “high,” these drugs...
can be useful as part of an overall treatment approach that includes counseling and support. Naltrexone doses of 50 mg/d antagonize 15 mg of heroin for 24 h, and the possibly more effective higher doses (125–150 mg) block the effects of 25 mg of IV heroin for up to 3 days. To avoid precipitating a withdrawal syndrome, patients must be free of opioids for a minimum of 5 days before beginning treatment with naltrexone and should first be challenged with 0.4 or 0.8 mg of the shorter-acting agent naloxone to be certain they can tolerate the long-acting antagonist.

**Drug-Free Programs**

Most opioid treatment programs focus primarily on cognitive-behavioral approaches of enhancing commitment to abstinence, helping individuals to rebuild their lives without substances, and preventing relapse. Whether carried out in inpatient or outpatient settings, patients do not receive maintenance medications.

**PREVENTION**

Except for the terminally ill, physicians should carefully monitor opioid drug use in their patients, keeping doses as low as is practical and administering them over as short a period as the level of pain would warrant in the average person. Physicians must be vigilant regarding their own risk for opioid abuse and dependence, never prescribing these drugs for themselves. For the nonmedical intravenous drug–dependent person, all possible efforts must be made to prevent the infectious consequences of contaminated needles both through methadone maintenance and by considering needle-exchange programs.

For a more detailed discussion, see Shuckit MA: Opioid Drug Abuse and Dependence, Chap. 388, p. 2729, in HPIM-17.
This page intentionally left blank
SECTION 16 DISEASE PREVENTION AND HEALTH MAINTENANCE

211 Routine Disease Screening

A primary goal of health care is to prevent disease or to detect it early enough that interventions will be more effective. In general, screening is most effective when applied to relatively common disorders that carry a large disease burden and have a long latency period. Early detection of disease has the potential to reduce both morbidity and mortality; however, screening asymptomatic individuals carries some risk. False-positive results can lead to unnecessary lab tests and invasive procedures and can increase pt anxiety. Several measurements have been derived to better assess the potential gain from screening and prevention interventions:

- Number of subjects needed to be screened to alter the outcome in one individual
- Absolute impact of screening on disease (e.g., lives saved per thousand screened)
- Relative impact of screening on disease outcome (e.g., the % reduction in deaths)
- The cost per year of life saved
- The increase in average life expectancy for a population

Current recommendations include performance of a routine health care examination every 1–3 years before age 50 and every year thereafter. History should include medication use, allergies, dietary history, use of alcohol and tobacco, sexual practices, safety practices (seat belt and helmet use, gun possession), and a thorough family history. Routine measurements should include assessments of height, weight, body-mass index, and blood pressure. Screening should also be considered for domestic violence and depression.

Counseling by health care providers should be performed at health care visits. Tobacco and alcohol use, diet, and exercise represent the vast majority of factors that influence preventable deaths. While behavioral changes are frequently difficult to achieve, it should be emphasized that studies show even brief (<5 min) tobacco counseling by physicians results in a significant rate of long-term smoking cessation. Instruction about self-examination (e.g., skin, breast, testicular) should also be provided during preventative visits.

The top causes of age-specific mortality and corresponding preventative strategies are listed in Table 211-1. Formal recommendations from the U.S. Preventive Services Task Force are listed in Table 211-2.

Specific recommendations for disease prevention can also be found in subsequent chapters on Immunization and Advice to Travelers (Chap. 212), Cardiovascular Disease Prevention (Chap. 213), Prevention and Early Detection of Cancer (Chap. 214), Smoking Cessation (Chap. 215), and Women’s Health (Chap. 216).
<table>
<thead>
<tr>
<th>Age Group</th>
<th>Leading Causes of Age-Specific Mortality</th>
<th>Screening Prevention Interventions to Consider for Each Specific Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>15–24</td>
<td>1. Accident</td>
<td>• Counseling on routine seat belt use, bicycle/motorcycle/ATV helmets (1)</td>
</tr>
<tr>
<td></td>
<td>2. Homicide</td>
<td>• Counseling on diet and exercise (5)</td>
</tr>
<tr>
<td></td>
<td>3. Suicide</td>
<td>• Discuss dangers of alcohol use while driving, swimming, boating (1)</td>
</tr>
<tr>
<td></td>
<td>4. Malignancy</td>
<td>• Ask about vaccination status (tetanus, diphtheria, hepatitis B, MMR, rubella, varicella, meningitis, HPV)</td>
</tr>
<tr>
<td></td>
<td>5. Heart disease</td>
<td>• Ask about gun use and/or gun possession (2,3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Assess for substance abuse history including alcohol (2,3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Screen for domestic violence (2,3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Screen for depression and/or suicidal/homicidal ideation (2,3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pap smear for cervical cancer screening, discuss STD prevention (4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Recommend skin, breast, and testicular self-exams (4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Recommend UV light avoidance and regular sun screen use (4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Measurement of blood pressure, height, weight and body mass index (5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Discuss health risks of tobacco use, consider emphasis of cosmetic and economic issues to improve quit rates for younger smokers (4,5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• <em>Chlamydia</em> screening and contraceptive counseling for sexually active females</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• HIV, hepatitis B, and syphilis testing if there is high-risk sexual behavior(s) or any prior history of sexually transmitted disease</td>
</tr>
<tr>
<td>25–44</td>
<td>1. Accident</td>
<td>As above plus consider the following:</td>
</tr>
<tr>
<td></td>
<td>2. Malignancy</td>
<td>• Redress smoking status, encourage cessation at every visit (2,3)</td>
</tr>
<tr>
<td></td>
<td>3. Heart disease</td>
<td>• Obtain detailed family history of malignancies and begin early screening/prevention program if patient is at significant increased risk (2)</td>
</tr>
<tr>
<td></td>
<td>4. Suicide</td>
<td>• Assess all cardiac risk factors (including screening for diabetes and hyperlipidemia) and consider primary prevention with aspirin for patients at &gt;3% 5-year risk of a vascular event (3)</td>
</tr>
<tr>
<td></td>
<td>5. Homicide</td>
<td>• Assess for chronic alcohol abuse, risk factors for viral hepatitis, or other risks for development of chronic liver disease</td>
</tr>
<tr>
<td></td>
<td>6. HIV</td>
<td>• Begin breast cancer screening with mammography at age 40 (2)</td>
</tr>
</tbody>
</table>

(continued)
### TABLE 211-1  
**AGE-SPECIFIC CAUSES OF MORTALITY AND CORRESPONDING PREVENTATIVE OPTIONS (CONTINUED)**

<table>
<thead>
<tr>
<th>Age Range</th>
<th>Causes</th>
<th>Preventative Options</th>
</tr>
</thead>
<tbody>
<tr>
<td>45–64</td>
<td>1. Malignancy</td>
<td>- Consider prostate cancer screen with annual PSA and digital rectal exam at age 50 (or possibly earlier in African Americans or patients with family history)</td>
</tr>
<tr>
<td></td>
<td>2. Heart disease</td>
<td>- Begin colorectal cancer screening at age 50 with either fecal occult blood testing, flexible sigmoidoscopy, or colonoscopy</td>
</tr>
<tr>
<td></td>
<td>3. Accident</td>
<td>- Reassess vaccination status at age 50 and give special consideration to vaccines against Streptococcus pneumoniae, influenza, tetanus, and viral hepatitis</td>
</tr>
<tr>
<td></td>
<td>4. Diabetes mellitus</td>
<td>- Consider screening for coronary disease in higher risk patients</td>
</tr>
<tr>
<td></td>
<td>5. Cerebrovascular disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6. Chronic lower respiratory disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7. Chronic liver disease and cirrhosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8. Suicide</td>
<td></td>
</tr>
<tr>
<td>≥65</td>
<td>1. Heart disease</td>
<td>- Readdress smoking status, encourage cessation at every visit</td>
</tr>
<tr>
<td></td>
<td>2. Malignancy</td>
<td>- One-time ultrasound for AAA in men 65–75 who have ever smoked</td>
</tr>
<tr>
<td></td>
<td>3. Cerebrovascular disease</td>
<td>- Consider pulmonary function testing for all long-term smokers to assess for development of chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td></td>
<td>4. Chronic lower respiratory disease</td>
<td>- Vaccinate all smokers against influenza and S. pneumoniae at age 50</td>
</tr>
<tr>
<td></td>
<td>5. Alzheimer’s disease</td>
<td>- Screen all postmenopausal women (and all men with risk factors) for osteoporosis</td>
</tr>
<tr>
<td></td>
<td>6. Influenza and pneumonia</td>
<td>- Reassess vaccination status at age 65, emphasis on influenza and S. pneumoniae</td>
</tr>
<tr>
<td></td>
<td>7. Diabetes mellitus</td>
<td>- Screen for dementia and depression</td>
</tr>
<tr>
<td></td>
<td>8. Kidney disease</td>
<td>- Screen for visual and hearing problems, home safety issues, and elder abuse</td>
</tr>
<tr>
<td></td>
<td>9. Accidents</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10. Septicemia</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** The numbers in parentheses refer to areas of risk in the mortality column affected by the specified intervention.  
**Abbreviations:** MMR, measles-mumps-rubella; HPV, human papilloma virus; STD, sexually transmitted disease; UV, ultraviolet; PSA, prostate-specific antigen; AAA, abdominal aortic aneurysm.
TABLE 211-2
CLINICAL PREVENTIVE SERVICES FOR NORMAL-RISK ADULTS RECOMMENDED BY THE U.S. PREVENTIVE SERVICES TASK FORCE

<table>
<thead>
<tr>
<th>Test or Disorder</th>
<th>Population, a Years</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure, height and weight</td>
<td>&gt;18</td>
<td>Periodically</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>Men &gt; 35</td>
<td>Every 5 years</td>
</tr>
<tr>
<td></td>
<td>Women &gt; 45</td>
<td>Every 5 years</td>
</tr>
<tr>
<td>Diabetes</td>
<td>&gt;45 or earlier, if there are additional risk factors</td>
<td>Every 3 years</td>
</tr>
<tr>
<td>Pap smear b</td>
<td>Within 3 years of onset of sexual activity or 21–65</td>
<td>Every 1–3 years</td>
</tr>
<tr>
<td>Chlamydia</td>
<td>Women 18–25</td>
<td>Every 1–2 years</td>
</tr>
<tr>
<td>Mammography a</td>
<td>Women 18–25</td>
<td>Every 1–2 years</td>
</tr>
<tr>
<td>Colorectal cancer d</td>
<td>Men &gt; 35</td>
<td>Every year</td>
</tr>
<tr>
<td></td>
<td>Women &gt; 40</td>
<td>Every 5 years</td>
</tr>
<tr>
<td></td>
<td>&gt;50</td>
<td>Every 10 years</td>
</tr>
<tr>
<td>Colorectal cancer d</td>
<td>Women &gt; 65</td>
<td>Periodically</td>
</tr>
<tr>
<td></td>
<td>&gt;60 at risk</td>
<td></td>
</tr>
<tr>
<td>Abdominal aortic aneurysm (ultrasound)</td>
<td>Men 65–75 who have ever smoked</td>
<td>Once</td>
</tr>
<tr>
<td>Alcohol use</td>
<td>&gt;18</td>
<td>Periodically</td>
</tr>
<tr>
<td>Vision, hearing</td>
<td>&gt;65</td>
<td>Periodically</td>
</tr>
<tr>
<td>Adult immunization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus-diphtheria (Td)</td>
<td>&gt;18</td>
<td>Every 10 years</td>
</tr>
<tr>
<td>Varicella (VZV)</td>
<td>Susceptibles only, &gt;18</td>
<td>Two doses</td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)</td>
<td>Women, childbearing age</td>
<td>One dose</td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>&gt;65</td>
<td>One dose</td>
</tr>
<tr>
<td>Influenza</td>
<td>&gt;50</td>
<td>Yearly</td>
</tr>
<tr>
<td>Human papillomavirus (HPV)</td>
<td>Up to age 26</td>
<td>If not done prior</td>
</tr>
</tbody>
</table>

aScreening is performed earlier and more frequently when there is a strong family history. Randomized, controlled trials have documented that fecal occult blood testing (FOBT) confers a 15 to 30% reduction in colon cancer mortality. Although randomized trials have not been performed for sigmoidoscopy or colonoscopy, well-designed case-control studies suggest similar or greater efficacy relative to FOBT.

bIn the future, Pap smear frequency may be influenced by HPV testing and the HPV vaccine. Note: Prostate-specific antigen (PSA) testing is capable of enhancing the detection of early-stage prostate cancer, but evidence is inconclusive that it improves health outcomes. PSA testing is recommended by several professional organizations and is widely used in clinical practice, but it is not currently recommended by the U.S. Preventive Services Task Force (Chap. 81).


For a more detailed discussion, see Martin GJ: Screening and Prevention of Disease, Chap. 4, p. 24, in HPIM-17.
Vaccination is one of the greatest public health achievements of the twentieth century and among the most cost-effective health interventions available.

DEFINITIONS

- Immunization: induction or provision of immunity by any means

  Active immunization: administration of a vaccine consisting of either (1) live, attenuated agents (e.g., measles virus); or (2) inactivated agents (e.g., influenza virus), their constituents (e.g., Bordetella pertussis), or their products (e.g., hepatitis B virus)

  Passive immunization: provision of temporary immunity in a person exposed to an infectious disease who has not been actively immunized. Products used for this purpose are standard human immune serum globulin, special immune serum globulins with a known content of antibody to specific agents (e.g., hepatitis B virus or varicella-zoster immune globulin), and specific animal-derived antisera and antitoxins.

VACCINES FOR ROUTINE USE

For the recommended immunization schedule for persons age 0–6 years, see Fig. 212-1; for persons age 7–18 years, see Fig. 212-2; and for adults, see Fig. 212-3. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance in obtaining and completing a VAERS form is available online at www.vaers.hhs.gov or by telephone at 800-822-7967.

ADVICE FOR TRAVELERS

Travelers should be aware of various health risks that might be associated with given destinations. Information regarding country-specific risks can be obtained from the CDC publication Health Information for International Travel, which is available at www.cdc.gov/travel.

IMMUNIZATIONS FOR TRAVEL

There are three categories of immunization for travel.

- **Routine** immunizations (see Figs. 212-1, 212-2, and 212-3) are needed regardless of travel. However, travelers should be certain that their routine immunizations are up to date because certain diseases (e.g., diphtheria, tetanus, polio, measles) are more likely to be acquired outside the United States than at home.

- **Required** immunizations are mandated by international regulations for entry into certain areas.

- **Recommended** immunizations are advisable because they protect against illnesses acquisition of which the traveler is at increased risk. Table 212-1 lists vaccines required or recommended for travel.
### Recommended Immunization Schedule for Persons Aged 0–6 Years

**UNITED STATES • 2007**

<table>
<thead>
<tr>
<th>Vaccine (약)</th>
<th>Age</th>
<th>Birth</th>
<th>1 month</th>
<th>2 months</th>
<th>4 months</th>
<th>6 months</th>
<th>12 months</th>
<th>15 months</th>
<th>18 months</th>
<th>19–23 months</th>
<th>2–3 years</th>
<th>4–6 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B¹</td>
<td>HepB</td>
<td>HepB</td>
<td>see footnote 1</td>
<td>HepB</td>
<td>HepB Series</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus²</td>
<td>Rota</td>
<td>Rota</td>
<td>Rota</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria, Tetanus, Pertussis³</td>
<td>DTaP</td>
<td>DTaP</td>
<td>DTaP</td>
<td>DTaP</td>
<td>DTaP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b⁴</td>
<td>Hib</td>
<td>Hib</td>
<td>Hib</td>
<td>Hib</td>
<td>Hib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal⁵</td>
<td>PCV</td>
<td>PCV</td>
<td>PCV</td>
<td>PCV</td>
<td>PCV</td>
<td>PCV</td>
<td>PPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated Poliovirus</td>
<td>IPV</td>
<td>IPV</td>
<td>IPV</td>
<td>IPV</td>
<td>IPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza⁶</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, Mumps, Rubella⁷</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella⁸</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A⁹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal¹⁰</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **HepB Series**: HepB
- **DTaP**: Diphtheria, Tetanus, Pertussis
- **Rotavirus**: Rotavirus
- **Hib**: Haemophilus influenzae type b
- **PCV**: Pneumococcal
- **IPV**: Inactivated Poliovirus
- **MMR**: Measles, Mumps, Rubella
- **Varicella**: Varicella
- **HepA Series**: Hepatitis A
- **MPSV4**: Meningococcal

**Range of recommended ages**, **Catch-up immunization**, **Certain high-risk groups**
**FIGURE 212-1** Recommended immunization schedule for persons aged 0–6 years—United States, 2006–2007. 1. **Hepatitis B vaccine (HepB).** (Minimum age: birth) **At birth:** Administer monovalent HepB to all newborns before hospital discharge. If mother is hepatitis B surface antigen (HBsAg)-positive, administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth. If mother’s HBsAg status is unknown, administer HepB within 12 hours of birth. Determine the HBsAg status as soon as possible and if HBsAg-positive, administer HBIG (no later than age 1 week). If mother is HBsAg-negative, the birth dose can only be delayed with physician’s order and mother’s negative HBsAg laboratory report documented in the infant’s medical record. **After the birth dose:** The HepB series should be completed with either monovalent HepB or a combination vaccine containing HepB. The second dose should be administered at age 1–2 months. The final dose should be administered at age ≥24 weeks. Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg after completion of ≥3 doses of a licensed HepB series, at age 9–18 months (generally at the next well-child visit). **4-month dose:** It is permissible to administer 4 doses of HepB when combination vaccines are administered after the birth dose. If monovalent HepB is used for doses after the birth dose, a dose at age 4 months is not needed. 2. **Rotavirus vaccine (Rota).** (Minimum age: 6 weeks) **Administer** the first dose at age 6–12 weeks. Do not start the series later than age 12 weeks. Administer the final dose in the series by age 32 weeks. Do not administer a dose later than age 32 weeks. Data on safety and efficacy outside of these age ranges are insufficient. 3. **Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP).** (Minimum age: 6 weeks) The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose. Administer the final dose in the series at age 4–6 years. 4. **Haemophilus influenzae type b conjugate vaccine (Hib).** (Minimum age: 6 weeks) If PRP-OMP (Pedvax-Hib or ComVax [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required. TriHiBit (DTaP/Hib) combination products should not be used for primary immunization but can be used as boosters following any Hib vaccine in children aged ≥12 months. 5. **Pneumococcal vaccine.** (Minimum age: 6 weeks for pneumococcal conjugate vaccine [PCV]; 2 years for pneumococcal polysaccharide vaccine [PPV]). Administer PCV at ages 24–59 months in certain high-risk groups. Administer PPV to children aged ≥2 years in certain high-risk groups. See MMWR 2000;49(No. RR-9):1–35. 6. **Influenza vaccine.** (Minimum age: 6 months for trivalent inactivated influenza vaccine [TIV]; 5 years for live, attenuated influenza vaccine [LAIV]). All children aged 6–59 months and close contacts of all children aged 0–59 months are recommended to receive influenza vaccine. Influenza vaccine is recommended annually for children aged ≥59 months with certain risk factors, health-care workers, and other persons (including household members) in close contact with persons in groups at high risk. See MMWR 2006;55(No. RR-10):1–41. For healthy persons aged 5–49 years, LAIV may be used as an alternative to TIV. Children receiving TIV should receive 0.25 mL if aged 6–35 months or 0.5 mL if aged ≥36 months. Children aged <9 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by ≥4 weeks for TIV and ≥6 weeks for LAIV). 7. **Measles, mumps, and rubella vaccine (MMR).** (Minimum age: 12 months) Administer the second dose of MMR at age 4–6 years. MMR may be administered before age 4–6 years, provided 24 weeks have elapsed since the first dose and both doses are administered at age ≥12 months. 8. **Varicella vaccine.** (Minimum age: 12 months) Administer the second dose of varicella vaccine at age 4–6 years. Varicella vaccine may be administered before age 4–6 years, provided that ≥2 months have elapsed since the first dose and both doses are administered at age ≥12 months. If the second dose was administered ≥28 days following the first dose, the second dose does not need to be repeated. 9. **Hepatitis A vaccine (HepA).** (Minimum age: 12 months) HepA is recommended for all children aged 1 year (i.e., aged 12–23 months). The 2 doses in the series should be administered at least 6 months apart. Children not fully vaccinated by age 2 years can be vaccinated at subsequent visits. HepA is recommended for certain other groups of children, including in areas where vaccination programs target older children. See MMWR 2006;55(No. RR-7):1–23. 10. **Meningococcal polysaccharide vaccine (MPSV4).** (Minimum age: 2 years) Administer MPSV4 to children aged 2–10 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See MMWR 2005;54(No. RR-7):1–21.
### Recommended Immunization Schedule for Persons Aged 7–18 Years

**UNITED STATES • 2007**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Age</th>
<th>7–10 years</th>
<th>11–12 years</th>
<th>13–14 years</th>
<th>15 years</th>
<th>16–18 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetanus, Diphtheria, Pertussis</td>
<td>see footnote 1</td>
<td>Tdap</td>
<td>Tdap</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Papillomavirus</td>
<td>see footnote 2</td>
<td>HPV (3 doses)</td>
<td>HPV Series</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal</td>
<td>MPSV4</td>
<td>MCV4</td>
<td>MCV4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>PPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td>Influenza (Yearly)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td></td>
<td>HepA Series</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td></td>
<td>HepB Series</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated Poliovirus</td>
<td></td>
<td>IPV Series</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, Mumps, Rubella</td>
<td></td>
<td>MMR Series</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td></td>
<td>Varicella Series</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Footnotes:**
1. See footnote 1
2. See footnote 2
3. MCV4
4. PPV
5. Influenza (Yearly)
6. HepA Series
7. HepB Series
8. IPV Series
9. MMR Series
10. Varicella Series

**Legend:**
- Range of recommended ages
- Catch-up immunization
- Certain high-risk groups
1. Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap). (Minimum age: 10 years for BOOSTRIX and 11 years for ADACEL) Administer at age 11–12 years for those who have completed the recommended childhood DTP/DTaP vaccination series and have not received a tetanus and diphtheria toxoids vaccine (Td) booster dose. Adolescents aged 13–18 years who missed the 11–12 year Td/Tdap booster dose should also receive a single dose of Tdap if they have completed the recommended childhood DTP/DTaP vaccination series. 2. Human papillomavirus vaccine (HPV). (Minimum age: 9 years) Administer the first dose of the HPV vaccine series to females at age 11–12 years. Administer the second dose 2 months after the first dose and the third dose 6 months after the first dose. Administer the HPV vaccine series to females at age 13–18 years if not previously vaccinated. 3. Meningococcal vaccine. (Minimum age: 11 years for meningococcal conjugate vaccine [MCV4]; 2 years for meningococcal polysaccharide vaccine [MPSV4]). Administer MCV4 at age 11–12 years and to previously unvaccinated adolescents at high school entry (at approximately age 15 years). Administer MCV4 to previously unvaccinated college freshmen living in dormitories; MPSV4 is an acceptable alternative. Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See MMWR 2005;54(No. RR-7):1–21. Use MPSV4 for children aged 2–10 years and MCV4 or MPSV4 for older children. 4. Pneumococcal polysaccharide vaccine (PPV). (Minimum age: 2 years) Administer for certain high-risk groups. See MMWR 1997;46(No. RR-8):1–24, and MMWR 2000;49(No. RR-9):1–35. 5. Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza vaccine [TIV]; 5 years for live, attenuated influenza vaccine [LAIV]). Influenza vaccine is recommended annually for persons with certain risk factors, health-care workers, and other persons (including household members) in close contact with persons in groups at high risk. See MMWR 2006;55 (No. RR-10):1–41. For healthy persons aged 5–49 years, LAIV may be used as an alternative to TIV. Children aged <9 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by ≥4 weeks for TIV and ≥6 weeks for LAIV). 6. Hepatitis A vaccine (HepA). (Minimum age: 12 months) The 2 doses in the series should be administered at least 6 months apart. HepA is recommended for certain other groups of children, including in areas where vaccination programs target older children. See MMWR 2006;55 (No. RR-7):1–23. 7. Hepatitis B vaccine (HepB). (Minimum age: birth) Administer the 3-dose series to those who were not previously vaccinated. A 2-dose series of Recombivax HB is licensed for children aged 11–15 years. 8. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks) For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if the third dose was administered at age ≥4 years. If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child’s current age. 9. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months) If not previously vaccinated, administer 2 doses of MMR during any visit, with ≥4 weeks between the doses. 10. Varicella vaccine. (Minimum age: 12 months) Administer 2 doses of varicella vaccine to persons without evidence of immunity. Administer 2 doses of varicella vaccine to persons aged <13 years at least 3 months apart. Do not repeat the second dose, if administered ≥28 days after the first dose. Administer 2 doses of varicella vaccine to persons aged ≥13 years at least 4 weeks apart.
# Recommended Adult Immunization Schedule

**United States, October 2006–September 2007**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>19–49 years</th>
<th>50–64 years</th>
<th>≥65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tetanus, diphtheria, pertussis (Td/Tdap)</strong>&lt;sup&gt;1&lt;/sup&gt;</td>
<td>1-dose Td booster every 10 yrs</td>
<td>Substitute 1 dose of Tdap for Td</td>
<td></td>
</tr>
<tr>
<td><strong>Human papillomavirus (HPV)</strong>&lt;sup&gt;2&lt;/sup&gt;</td>
<td>3 doses (females)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Measles, mumps, rubella (MMR)</strong>&lt;sup&gt;3&lt;/sup&gt;</td>
<td>1 or 2 doses</td>
<td>1 dose</td>
<td></td>
</tr>
<tr>
<td><strong>Varicella</strong>&lt;sup&gt;4&lt;/sup&gt;</td>
<td>2 doses (0, 4–8 wks)</td>
<td>2 doses (0, 4–8 wks)</td>
<td></td>
</tr>
<tr>
<td><strong>Influenza</strong>&lt;sup&gt;5&lt;/sup&gt;</td>
<td>1 dose annually</td>
<td></td>
<td>1 dose annually</td>
</tr>
<tr>
<td><strong>Pneumococcal (polysaccharide)</strong>&lt;sup&gt;6,7&lt;/sup&gt;</td>
<td>1–2 doses</td>
<td></td>
<td>1 dose</td>
</tr>
<tr>
<td><strong>Hepatitis A</strong>&lt;sup&gt;8&lt;/sup&gt;</td>
<td>2 doses (0, 6–12 mos, or 0, 6–18 mos)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis B</strong>&lt;sup&gt;9&lt;/sup&gt;</td>
<td></td>
<td>3 doses (0, 1–2, 4–6 mos)</td>
<td></td>
</tr>
<tr>
<td><strong>Meningococcal</strong>&lt;sup&gt;10&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>1 or more doses</td>
</tr>
</tbody>
</table>

---

<sup>1</sup> For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection).

<sup>2</sup> Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications).

---

**Footnotes:**

1. ...10.

---

**Notes:**

- Tdap: Tetanus, diphtheria, pertussis.
- HPV: Human papillomavirus.
- MMR: Measles, mumps, rubella.
- Influenza: Influenza.
- Pneumococcal: Pneumococcal.
- Hepatitis A: Hepatitis A.
- Hepatitis B: Hepatitis B.
- Meningococcal: Meningococcal.
Measles, mumps, rubella (MMR) vaccination. Measles component: adults born before 1957 can be considered immune to measles. Adults born during or after 1957 should receive ≥1 dose of MMR unless they have a medical contraindication, documentation of ≥1 dose, history of measles based on healthcare provider diagnosis, or laboratory evidence of immunity. A second dose of MMR is recommended for adults who have already been infected with any of the HPV vaccine types receive the full benefit of the vaccination. Vaccination is less beneficial for women who have not completed the vaccine series. Ideally, vaccine should be administered before potential exposure to HPV through sexual activity; however, women who are sexually active should still be vaccinated. Sexually active women who have not been infected with any of the HPV vaccine types receive the full benefit of the vaccination. Vaccination is less beneficial for women who have already been infected with one or more of the four HPV vaccine types. A complete series consists of 3 doses. The second dose should be administered 2 months after the first dose; the third dose should be administered 6 months after the first dose. Vaccination is not recommended during pregnancy. If a woman is found to be pregnant after initiating the vaccination series, the remainder of the 3-dose regimen should be delayed until after completion of the pregnancy. 3. Measles, mumps, rubella (MMR) vaccination. Measles component: adults born before 1957 can be considered immune to measles. Adults born during or after 1957 should receive ≥1 dose of MMR unless they have a medical contraindication, documentation of ≥1 dose, history of measles based on healthcare provider diagnosis, or laboratory evidence of immunity. A second dose of MMR is recommended for adults who have already been infected with measles or in an outbreak setting; (2) have been previously vaccinated with killed measles vaccine; (3) have been vaccinated with an unknown type of measles vaccine during 1963–1967; (4) are students in postsecondary educational institutions; (5) work in a healthcare facility; or (6) plan to travel internationally. Withhold MMR or other measles-containing vaccines from HIV-infected persons with severe immunosuppression. (Continued)
Disease Prevention and Health Maintenance

SECTION 16

Figure 212-3 (Continued) (Mumps component: adults born before 1957 can generally be considered immune to mumps. Adults born during or after 1957 should receive 1 dose of MMR unless they have a medical contraindication, history of mumps based on healthcare provider diagnosis, or laboratory evidence of immunity. A second dose of MMR is recommended for adults who (1) are in an age group that is affected during a mumps outbreak; (2) are students in postsecondary educational institutions; (3) work in a healthcare facility; or (4) plan to travel internationally. For unvaccinated healthcare workers born before 1957 who do not have other evidence of mumps immunity, consider giving 1 dose on a routine basis and strongly consider giving a second dose during an outbreak. Rubella component: administer 1 dose of MMR vaccine to women whose rubella vaccination history is unreliable or who lack laboratory evidence of immunity. For women of childbearing age, regardless of birth year, routinely determine rubella immunity and counsel women regarding congenital rubella syndrome. Do not vaccinate women who are pregnant or who might become pregnant within 4 weeks of receiving vaccine. Women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility. 4. Varicella vaccination. All adults without evidence of immunity to varicella should receive 2 doses of varicella vaccine. Special consideration should be given to those who (1) have close contact with persons at high risk for severe disease (e.g., healthcare workers and family contacts of immunocompromised persons) or (2) are at high risk for exposure or transmission (e.g., teachers of young children; child care employees; residents and staff members of institutional settings, including correctional institutions; college students; military personnel; adolescents and adults living in households with children; nonpregnant women of childbearing age; and international travelers). Evidence of immunity to varicella in adults includes any of the following: (1) documentation of 2 doses of varicella vaccine at least 4 weeks apart; (2) U.S.-born before 1980 (although for healthcare workers and pregnant women, birth before 1980 should not be considered evidence of immunity); (3) history of varicella based on diagnosis or verification of varicella by a healthcare provider (for a patient reporting a history of or presenting with an atypical case, a mild case, or both, healthcare providers should seek either an epidemiologic link with a typical varicella case or evidence of laboratory confirmation, if it was performed at the time of acute disease); (4) history of herpes zoster based on healthcare provider diagnosis; or (5) laboratory evidence of immunity or laboratory confirmation of disease. Do not vaccinate women who are pregnant or might become pregnant within 4 weeks of receiving the vaccine. Assess pregnant women for evidence of varicella immunity. Women who do not have evidence of immunity should receive dose 1 of varicella vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility. Dose 2 should be administered 4–8 weeks after dose 1. 5. Influenza vaccination. Medical indications: chronic disorders of the cardiovascular or pulmonary systems, including asthma; chronic metabolic diseases, including diabetes mellitus, renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or HIV); any condition that compromises respiratory function or the handling of respiratory secretions or that can increase the risk of aspiration (e.g., cognitive dysfunction, spinal cord injury, or seizure disorder or other neuromuscular disorder); and pregnancy during the influenza season. No data exist on the risk for severe or complicated influenza disease among persons with asplenia; however, influenza is a risk factor for secondary bacterial infections that can cause severe disease among persons with asplenia. Occupational indications: healthcare workers and employees of long-term–care and assisted living facilities. Other indications: residents of nursing homes and other long-term–care and assisted living facilities; persons likely to transmit influenza to persons at high risk (e.g., in-home household contacts and caregivers of children aged 0–59 months, or persons of all ages with high-risk conditions); and anyone who would like to be vaccinated. Healthy, nonpregnant persons aged 5–49 years without high-risk medical conditions who are not contacts of severely immunocompromised persons in special care units can receive either intranasally administered influenza vaccine (Flumist) or inactivated vaccine. Other persons should receive the inactivated vaccine. (Continued)
6. Pneumococcal polysaccharide vaccination. Medical indications: chronic disorders of the pulmonary system (excluding asthma); cardiovascular diseases; diabetes mellitus; chronic liver diseases, including liver disease as a result of alcohol abuse (e.g., cirrhosis); chronic renal failure or nephrotic syndrome; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy); immunosuppressive conditions (e.g., congenital immunodeficiency, HIV infection [vaccinate as close to diagnosis as possible when CD4 cell counts are highest], leukemia, lymphoma, multiple myeloma, Hodgkin disease, generalized malignancy, or organ or bone marrow transplantation); chemotherapy with alkylating agents, antimitabolites, or high-dose, long-term corticosteroids; and cochlear implants. Other indications: Alaska Natives and certain American Indian populations and residents of nursing homes or other long-term–care facilities. 7. Revaccination with pneumococcal polysaccharide vaccine. One-time revaccination after 5 years for persons with chronic renal failure or nephrotic syndrome; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy); immunosuppressive conditions (e.g., congenital immunodeficiency, HIV infection, leukemia, lymphoma, multiple myeloma, Hodgkin disease, generalized malignancy, or organ or bone marrow transplantation); or chemotherapy with alkylating agents, antimitabolites, or high-dose, long-term corticosteroids. For persons aged ≥65 years, one-time revaccination if they were vaccinated ≥5 years previously and were aged <65 years at the time of primary vaccination. 8. Hepatitis A vaccination. Medical indications: persons with chronic liver disease and persons who receive clotting factor concentrates. Behavioral indications: men who have sex with men and persons who use illegal drugs. Occupational indications: persons working with hepatitis A virus (HAV)–infected primates or with HAV in a research laboratory setting. Other indications: persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A (a list of countries is available at www.cdc.gov/travel/diseases.htm) and any person who would like to obtain immunity. Current vaccines should be administered in a 2-dose schedule at either 0 and 6–12 months, or 0 and 6–18 months. If the combined hepatitis A and hepatitis B vaccine is used, administer 3 doses at 0, 1, and 6 months. 9. Hepatitis B vaccination. Medical indications: persons with end-stage renal disease, including patients receiving hemodialysis; persons seeking evaluation or treatment for a sexually transmitted disease (STD); persons with HIV infection; persons with chronic liver disease; and persons who receive clotting factor concentrates. Occupational indications: healthcare workers and public-safety workers who are exposed to blood or other potentially infectious body fluids. Behavioral indications: sexually active persons who are not in a long-term, mutually monogamous relationship (i.e., persons with >1 sex partner during the previous 6 months); current or recent injection-drug users; and men who have sex with men. Other indications: household contacts and sex partners of persons with chronic hepatitis B virus (HBV) infection; clients and staff members of institutions for persons with developmental disabilities; all clients of STD clinics; international travelers to countries with high or intermediate prevalence of chronic HBV infection (a list of countries is available at www.cdc.gov/travel/diseases.htm); and any adult seeking protection from HBV infection. Settings where hepatitis B vaccination is recommended for all adults: STD treatment facilities; HIV testing and treatment facilities; facilities providing drug-abuse treatment and prevention services; healthcare settings providing services for injection-drug users or men who have sex with men; correctional facilities; end-stage renal disease programs and facilities for chronic hemodialysis patients; and institutions and nonresidential daycare facilities for persons with developmental disabilities. Special formulation indications: for adult patients receiving hemodialysis and other immunocompromised adults, 1 dose of 40 μg/mL (Recombivax HB) or 2 doses of 20 μg/mL (Engerix-B). 10. Meningococcal vaccination. Medical indications: adults with anatomic or functional asplenia, or terminal complement component deficiencies. Other indications: first-year college students living in dormitories; microbiologists who are routinely exposed to isolates of Neisseria meningitidis; military recruits; and persons who travel to or live in countries in which meningococcal disease is hyperendemic or epidemic (e.g., the “meningitis belt” of sub-Saharan Africa during the dry season [December–June]), particularly if their contact with local populations will be prolonged. Vaccination is required by the government of Saudi Arabia for all travelers to Mecca during the annual Haj. Meningococcal conjugate vaccine is preferred for adults with any of the preceding indications who are aged ≤55 years, although meningococcal polysaccharide vaccine (MPSV4) is an acceptable alternative. Revaccination after 5 years might be indicated for adults previously vaccinated with MPSV4 who remain at high risk for infection (e.g., persons residing in areas in which disease is epidemic).
SECTION 16
Disease Prevention and Health Maintenance

PREVENTION OF MALARIA AND OTHER INSECT-BORNE DISEASES

Chemoprophylaxis against malaria and other measures may be recommended for travel. In the United States, 90% of cases of *Plasmodium falciparum* infection occur in persons returning or immigrating from Africa and Oceania. The destination helps determine the particular medication chosen (e.g., whether chloroquine-resistant *P. falciparum* is present), as does the traveler’s preference and medical history. In addition, personal protective measures against mosquito bites, especially between dusk and dawn (e.g., the use of DEET-containing insect repellents, permethrin-impregnated bed nets, and screened sleeping areas), can prevent malaria and other insect-borne diseases (e.g., dengue fever).

### TABLE 212-1 VACCINES COMMONLY USED FOR TRAVEL

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Primary Series</th>
<th>Booster Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholera, live oral (CVD 103-HgR)</td>
<td>1 dose</td>
<td>6 months</td>
</tr>
<tr>
<td>Hepatitis A (Havrix), 1440 enzyme immunoassay U/mL</td>
<td>2 doses, 6–12 months apart, IM</td>
<td>None required</td>
</tr>
<tr>
<td>Hepatitis A (VAQTA, AVAXIM, EPIAXAL)</td>
<td>2 doses, 6–12 months apart, IM</td>
<td>None required</td>
</tr>
<tr>
<td>Hepatitis A/B combined (Twinrix)</td>
<td>3 doses at 0, 1, and 6–12 months or 0, 7, and 21 days plus booster at 1 year, IM</td>
<td>None required except 12 months (once only, for accelerated schedule)</td>
</tr>
<tr>
<td>Hepatitis B (Engerix B): accelerated schedule</td>
<td>3 doses at 0, 1, and 2 months or 0, 7, and 21 days plus booster at 1 year, IM</td>
<td>12 months, once only</td>
</tr>
<tr>
<td>Hepatitis B (Engerix B or Recombivax): standard schedule</td>
<td>3 doses at 0, 1, and 6 months, IM</td>
<td>None required</td>
</tr>
<tr>
<td>Immune globulin (hepatitis A prevention)</td>
<td>1 dose IM</td>
<td>Intervals of 3–5 months, depending on initial dose</td>
</tr>
<tr>
<td>Japanese encephalitis (JEV, Biken)</td>
<td>3 doses, 1 week apart, SC</td>
<td>12–18 months (first booster), then 4 years</td>
</tr>
<tr>
<td>Meningococcus, quadrivalent [Menimmune (polysaccharide), Menactra (conjugate)]</td>
<td>1 dose SC</td>
<td>&gt;3 years (optimal booster schedule not yet determined)</td>
</tr>
<tr>
<td>Rabies (HDCV), rabies vaccine absorbed (RVA), or purified chick embryo cell vaccine (PCEC)</td>
<td>3 doses at 0, 7, and 21 or 28 days, IM</td>
<td>None required except with exposure</td>
</tr>
<tr>
<td>Typhoid Ty21a, oral live attenuated (Vivotif)</td>
<td>1 capsule every other day × 4 doses</td>
<td>5 years</td>
</tr>
<tr>
<td>Typhoid Vi capsular polysaccharide, injectable (Typhim Vi)</td>
<td>1 dose IM</td>
<td>2 years</td>
</tr>
<tr>
<td>Yellow fever</td>
<td>1 dose SC</td>
<td>10 years</td>
</tr>
</tbody>
</table>

PREVENTION OF MALARIA AND OTHER INSECT-BORNE DISEASES
PREVENTION OF GASTROINTESTINAL ILLNESS

Diarrhea is the leading cause of illness in travelers. The incidence is highest in parts of Africa, Central and South America, and Southeast Asia. Travelers should eat only well-cooked hot foods, peeled or cooked fruits and vegetables, and bottled or boiled liquids. Although self-limited, diarrheal illness alters travel plans and confines 20% of pts to bed. Travelers should carry medications for self-treatment. Mild to moderate diarrhea can be treated with loperamide and fluids. Moderate to severe diarrhea should be treated with a 3-day course or a single double dose of a fluoroquinolone. High rates of quinolone-resistant *Campylobacter* in Thailand make azithromycin a better choice for that country. Rifaximin, a poorly absorbed rifampin derivative, is highly effective against noninvasive bacterial pathogens such as toxigenic and enteroaggregative *E. coli*. Prophylaxis with bismuth subsalicylate is ~60% effective; a single daily dose of a quinolone or azithromycin or a once-daily rifaximin regimen during travel of <1 month's duration is 75–90% effective; however, preventive treatment usually is not recommended.

OTHER INFECTIONS

Travelers are at high risk for (1) sexually transmitted diseases preventable by condom use; (2) schistosomiasis preventable by avoidance of swimming or bathing in freshwater lakes, streams, or rivers in endemic areas; and (3) hookworm and *Strongyloides* infections preventable by the avoidance of walking barefoot outside.

TRAVEL DURING PREGNANCY

The safest part of pregnancy in which to travel is between 18 and 24 weeks. Relative contraindications to international travel during pregnancy include a history of miscarriage, premature labor, incompetent cervix, or toxemia or the presence of other general medical problems (e.g., diabetes). Areas of excessive risk (e.g., where live virus vaccines are required for travel or where multidrug-resistant malaria is endemic) should be avoided throughout pregnancy.

THE HIV-INFECTED TRAVELER

HIV-seropositive persons with depressed CD4+ T cell counts should seek counseling from a travel medicine practitioner before departure, particularly when traveling to the developing world. This consultation should include a discussion of the appropriate use of vaccines (e.g., live yellow fever vaccine is not recommended for HIV-infected persons) and prophylactic medications, potential drug interactions (e.g., between some antimalarial agents and antiretroviral treatments), and risks for certain infections. Several countries routinely deny entry to HIV-positive persons.

PROBLEMS AFTER RETURN FROM TRAVEL

- Diarrhea: After traveler’s diarrhea, symptoms may persist because of the continued presence of pathogens (e.g., *Giardia lamblia*) or, more often, because of postinfectious sequelae such as lactose intolerance or irritable bowel syndrome. A trial of metronidazole for giardiasis, a lactose-free diet, or a trial of high-dose hydrophilic muciloid (plus lactulose for constipation) may relieve symptoms.
- Fever: Malaria is the first diagnosis that should be considered when a traveler returns from an endemic area with fever. Malaria is acquired most often in Africa, dengue in Southeast Asia and the Caribbean, typhoid fever in southern Asia, and rickettsial infections in southern Africa.
Skin conditions: Pyodermas, sunburn, insect bites, skin ulcers, and cutaneous larva migrans are the most common skin conditions in returning travelers.

For a more detailed discussion, see Keusch GT et al: Immunization Principles and Vaccine Use, Chap. 116, p. 767; and Keystone JS, Kozarsky PE: Health Advice for International Travel, Chap. 117, p. 782, in HPIM-17.

Cardiovascular Disease Prevention

Cardiovascular disease is the leading cause of death in developed nations; prevention is targeted at modifiable atherosclerosis risk factors (Table 213-1). Identification and control of these attributes reduce subsequent cardiovascular event rates.

**ESTABLISHED RISK FACTORS**

**Cigarette Smoking** Cigarette smoking increases the incidence of, and mortality associated with, coronary heart disease (CHD). Observational studies show that smoking cessation reduces excess risk of coronary events within months; after 3–5 years, the risk falls to that of individuals who never smoked. Patients should be asked regularly about tobacco use, followed by counseling and, as needed, antismoking pharmacologic therapy to assist cessation.

**Lipid Disorders** (See Chap. 187) Both elevated LDL and low HDL cholesterol are associated with cardiovascular events. Each 1-mg/dL increase in serum LDL correlates with a 2–3% rise in CHD risk; each 1-mg/dL decrease in HDL heightens risk by 3–4%. ATP III guidelines advise a fasting lipid profile [total cholesterol, triglycerides, HDL, LDL (calculated or directly measured)] in all adults, repeated every 5 years. Recommended dietary and/or pharmacologic approach depends on presence or risk of coronary artery disease (CAD) and the LDL level (Table 213-2); treatment should be most aggressive in patients with established

<table>
<thead>
<tr>
<th>Table 213-1 ESTABLISHED RISK FACTORS FOR ATHEROSCLEROSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Modifiable Risk Factors</strong></td>
</tr>
<tr>
<td>Cigarette smoking</td>
</tr>
<tr>
<td>Dyslipidemias (↑LDL or ↓HDL)</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>Obesity</td>
</tr>
<tr>
<td>Sedentary lifestyle</td>
</tr>
<tr>
<td><strong>Unmodifiable Risk Factors</strong></td>
</tr>
<tr>
<td>Family history of premature coronary heart disease</td>
</tr>
<tr>
<td>Age (men ≥ 45 years; women ≥ 55 years)</td>
</tr>
<tr>
<td>Male gender</td>
</tr>
</tbody>
</table>
CAD and in those with “equivalent risk” (e.g., presence of peripheral arterial disease or diabetes mellitus). Drug therapy is indicated when LDL level exceeds goal in Table 213-2 by 30 mg/dL (0.8 mmol/L). If elevated triglyceride level (>200 mg/dL [>2.6 mmol/L]) persists after control of LDL, secondary goal is to achieve non-HDL level (calculated as total cholesterol minus HDL) ≤30 mg/dL (0.8 mmol/L) above the target values listed in Table 213-2. In patients with isolated low HDL, encourage beneficial lifestyle measures: smoking cessation, weight loss, and increased physical activity. Consider addition of fibric acid derivative or niacin to raise HDL in patients with established CAD (see Chap. 187).

### Table 213-2: LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories

<table>
<thead>
<tr>
<th>Risk Category</th>
<th>LDL Level, mmol/L (mg/dL)</th>
<th>Goal</th>
<th>Initiate TLC</th>
<th>Consider Drug Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Very high</strong></td>
<td></td>
<td>&lt;1.8 (&lt;70)</td>
<td>≥1.8 (≥70)</td>
<td>≥1.8 (≥70)</td>
</tr>
<tr>
<td>ACS, or CHD w/ DM, or mult CRF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>High</strong></td>
<td></td>
<td>&lt;2.6 (&lt;100) [optional goal: &lt;1.8 (&lt;70)]</td>
<td>≥2.6 (≥100)</td>
<td>≥2.6 (≥100) [&lt;2.6 (&lt;100); consider drug Rx]</td>
</tr>
<tr>
<td>CHD or CHD risk equivalents (10-year risk &gt; 20%)</td>
<td>If LDL &lt; 2.6 (&lt;100)</td>
<td>&lt;1.8 (&lt;70)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Moderately high</strong></td>
<td></td>
<td>&lt;2.6 (&lt;100)</td>
<td>≥3.4 (≥130)</td>
<td>≥3.4 (≥130) [2.6–3.3 (100–129); consider drug Rx]</td>
</tr>
<tr>
<td>2+ risk factors (10-year risk, 10–20%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Moderate</strong></td>
<td></td>
<td>&lt;3.4 (&lt;130)</td>
<td>≥3.4 (≥130)</td>
<td>≥4.1 (≥160)</td>
</tr>
<tr>
<td>2+ risk factors (risk &lt; 10%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lower</strong></td>
<td></td>
<td>&lt;4.1 (&lt;160)</td>
<td>≥4.1 (≥160)</td>
<td>≥4.9 (≥190)</td>
</tr>
<tr>
<td>0–1 risk factor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** LDL, low-density lipoprotein; ACS, acute coronary syndrome; CHD, coronary heart disease; DM, diabetes mellitus; CRF, coronary risk factors.

**Source:** Adapted from S Grundy et al: Circulation 110:227, 2004.

### Hypertension

(See Chap. 124) Systolic or diastolic bp > “optimal” level of 115/75 mmHg is associated with increased risk of cardiovascular disease; each augmentation of 20 mmHg systolic, or 10 mmHg diastolic, above this value doubles the risk. Treatment of elevated blood pressure reduces the rate of stroke, congestive heart failure, and CHD events, with general goal of bp < 140/90 mmHg or <130/80 in patients with diabetes or chronic kidney disease. Cardiovascular event rates in elderly patients with isolated systolic hypertension (systolic > 160 but diastolic < 90) are also reduced by antihypertensive therapy.

See Chap. 124 for antihypertensive treatment recommendations. Patients with “prehypertension” (systolic bp 120–139 mmHg or diastolic bp 80–89 mmHg) should receive counseling about beneficial lifestyle modifications such
as those listed below (e.g., low-fat diet replete with vegetables and fruit, weight loss if overweight, increased physical activity, reduction of excessive alcohol consumption).

**Diabetes Mellitus/Insulin Resistance/Metabolic Syndrome** (See Chaps. 125 and 182) Patients with diabetes most often succumb to cardiovascular disease. LDL levels are typically near average in diabetic pts, but LDL particles are smaller, denser, and more atherogenic; low HDL and elevated triglyceride levels are common. Tight control of serum glucose reduces microvascular diabetic complications (retinopathy, renal disease), but a decrease in macrovascular events (CAD, stroke) has not been definitively shown. Conversely, successful management of associated risk factors in diabetics (e.g., dyslipidemia and hypertension) does reduce cardiovascular events and should be vigorously pursued. As needed, antilipidemic (especially statin) therapy should be used to lower LDL to <100 mg/dL in diabetics, even if patient has no symptoms of CAD.

Individuals without overt diabetes but who have “metabolic syndrome” (constellation of insulin resistance, central obesity, hypertension, hypertriglyceridemia, low HDL—see Chap. 125) are also at high risk of cardiovascular events. Dietary counseling, weight loss, and increased physical activity are important in reducing the prevalence of this syndrome.

**Male Gender/Postmenopausal State** Coronary risk is greater in men compared to that of premenopausal women of same age, but female risk accelerates after menopause. Estrogen-replacement therapy lowers LDL and raises HDL in postmenopausal women and in observational studies has been associated with reduced coronary events. However, prospective clinical trials do not support such a benefit and hormone-replacement therapy should not be prescribed for the purpose of cardiovascular risk reduction, especially in older women.

**EMERGING RISK FACTORS**

May be assessed selectively in patients without above traditional risk factors who have premature vascular disease or strong family history of premature vascular disease.

**Homocysteine** There is a graded correlation between serum homocysteine levels and risk of cardiovascular events and stroke. Supplemental folic acid and other B vitamins lower serum levels, but prospective clinical trials have not shown that such therapy reduces cardiac events.

**Inflammation** Inflammatory serum markers, such as high-sensitivity C-reactive protein (CRP), correlate with the risk of coronary events. CRP prospectively predicts risk of MI and outcomes after acute coronary syndromes; its usefulness and role in prevention as an independent risk factor is currently being defined. Potential benefits of assessing other emerging risk factors [e.g., lipoprotein(a), fibrinogen, infections by *Chlamydia* or CMV] remain unproven and controversial.

**PREVENTION**

**Antithrombotic Therapy in Primary Prevention** Thrombosis at the site of disrupted atherosclerotic plaque is the most common cause of acute coronary events. In primary prevention trials, chronic low-dose aspirin therapy has reduced the risk of a first MI in men and the risk of stroke in women. The American Heart Association recommends aspirin (75–160 mg daily) for men and women who are at high cardiovascular risk (i.e., by Framingham Study criteria, for men with ≥10% 10-year risk, or women with ≥ 20% 10-year risk).
Lifestyle Modifications  Encourage beneficial exercise habits (> 30 min moderate intensity physical activity daily) and sensible diet (low in saturated and trans fat; 2–3 servings of fish/week to ensure adequate intake of omega-3 fatty acids; balance caloric consumption with energy expenditure). Advise moderation in ethanol intake (no more than 1–2 drinks/day).

For a more detailed discussion, see Libby P: The Pathogenesis, Prevention, and Treatment of Atherosclerosis, Chap. 235, p. 1501-1509; Gaziano TA and Gaziano JM: Epidemiology of Cardiovascular Disease, Chap. 218, p. 1375-1379; and Martin GJ: Screening and Prevention of Disease, Chap. 4, p. 24; in HPIM-17.

Prevention and Early Detection of Cancer

One of the most important functions of medical care is to prevent disease or discover it early enough that treatment might be more effective. All risk factors for cancer have not yet been defined. However, a substantial number of factors that elevate risk are within a person’s control. Some of these factors are listed in Table 214-1. Every physician visit is an opportunity to teach and reinforce the elements of a healthy lifestyle.

Cancer screening in the asymptomatic population at average risk is a complicated issue. To be of value, screening must detect disease at a stage that is more readily curable than disease that is treated after symptoms appear. For cervix cancer and colon cancer, screening has been shown to save lives. For other tumors, benefit is less clear. Screening can cause harm; complications may ensue from the screening test or the tests done to validate a positive screening test or from treatments for the underlying disease. Furthermore, quality of life can be adversely affected by false-positive tests. Evaluation of screening tools can be biased and needs to rely on prospective randomized studies. Lead-time bias occurs when the natural history of disease is unaffected by the diagnosis, but the pt is diagnosed earlier in the course of disease than normal; thus, the pt spends more of his/her life span knowing the diagnosis. Length bias occurs when slow-growing cancers that might never have come to medical attention are detected during screening. Overdiagnosis is a form of length bias in which a

### TABLE 214-1 LIFESTYLE FACTORS THAT REDUCE CANCER RISK

<table>
<thead>
<tr>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not use any tobacco products</td>
</tr>
<tr>
<td>Maintain a healthy weight; eat a well-balanced diet; maintain caloric balance</td>
</tr>
<tr>
<td>Exercise at least 3 times a week</td>
</tr>
<tr>
<td>Prevent sun exposure</td>
</tr>
<tr>
<td>Avoid excessive alcohol intake</td>
</tr>
<tr>
<td>Practice safe sex; use condoms</td>
</tr>
</tbody>
</table>

*Not precisely defined, but current recommendations include 5 servings of fruits and vegetables per day, 25 g fiber, and <30% of calories coming from fat.*
cancer is detected when it is not growing and is not an influence on length of survival. Selection bias is the term for the fact that people who volunteer for screening trials may be different from the general population. Volunteers might have family history concerns that actually elevate their risk or they may be generally more health-conscious, which can affect outcome.

The various groups that evaluate and recommend screening practice guidelines have used varying criteria to make their recommendations (Table 214-2). The absence of data on survival for a number of diseases has led to a lack of consensus. In particular, four areas are worth noting.

1. **Prostate cancer**: Prostate-specific antigen (PSA) levels are elevated in prostate cancer, but a substantial number of the cancers detected appear to be non-life-threatening. PSA screening has not been shown to improve survival. Efforts are underway to develop better tests (predominantly using bound vs. free and rate of increase of PSA) to distinguish lethal and nonlethal cancers.

2. **Breast cancer**: The data on annual mammography support its use in women over age 50 years. However, the benefit for women age 40–49 years is quite small. One study shows some advantage for women who are screened starting at age 40 that appears 15 years later; however, it is unclear if this benefit would not have also been derived by starting screening at age 50 years. Women age 40–49 years have a much lower incidence of breast cancer and a higher false-positive rate on mammography. Nearly half of women screened during their forties will have a false-positive test. Refined methods of screening are in development.

3. **Colon cancer**: Annual fecal occult blood testing after age 50 years is felt to be useful. However, colonoscopy is the gold standard in colorectal cancer detection, but it is expensive and has not been shown to be cost-effective in asymptomatic people.

4. **Lung cancer**: Chest radiographs and sputum cytology in smokers appear to identify more early-stage tumors, but paradoxically, the screened pts do not have improved survival. Spiral CT scanning is being evaluated, but it is known to have more false-positive tests.

## CANCER PREVENTION IN HIGH-RISK GROUPS

### BREAST CANCER

Risk factors include age, early menarche, nulliparity or late first pregnancy, high body-mass index, radiation exposure before age 30 years, hormone-replacement therapy (HRT), alcohol consumption, family history, presence of mutations in **BRCA1** or **BRCA2**, and prior history of breast neoplasia. Risk assessment models have been developed to predict an individual’s likelihood of developing breast cancer (see [www.nci.nih.gov/cancertopics/pdq/genetics/breast-and-ovarian/healthprofessional#Section_66](http://www.nci.nih.gov/cancertopics/pdq/genetics/breast-and-ovarian/healthprofessional#Section_66)).

**Diagnosis**  MRI scanning is a more effective screening tool than mammography in women with a familial breast cancer risk.

**Interventions**  Women whose risk exceeds 1.66% in the next 5 years have been shown to have a 50% reduction in breast cancer from taking tamoxifen.Raloxifene also appears to reduce the risk and may have less toxicity. Aromatase inhibitors have generally been superior to tamoxifen in the adjuvant treatment of hormone-sensitive breast cancer but are still being evaluated as preventive agents. Women with strong family histories should undergo testing for mutations in **BRCA1** and **BRCA2**. Mutations in these genes carry a lifetime probabil-
<table>
<thead>
<tr>
<th>Test or Procedure</th>
<th>USPSTF</th>
<th>ACS</th>
<th>CTFPHC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sigmoidoscopy</td>
<td>Fair evidence to recommend</td>
<td>≥50, every 5 years</td>
<td>Fair evidence to consider</td>
</tr>
<tr>
<td>Fecal occult blood testing</td>
<td>≥50, good evidence for every 1–2 years</td>
<td>≥50, every year</td>
<td>Good evidence, age ≥50</td>
</tr>
<tr>
<td>Colonoscopy</td>
<td>No direct evidence</td>
<td>≥50, every 10 years</td>
<td>No direct evidence</td>
</tr>
<tr>
<td>Digital rectal examination</td>
<td>No recommendation</td>
<td>No recommendation</td>
<td>No recommendation</td>
</tr>
<tr>
<td>Prostate-specific antigen</td>
<td>Insufficient evidence to recommend</td>
<td>M: ≥50, every year</td>
<td>Recommendation against</td>
</tr>
<tr>
<td>Pap test</td>
<td>F: 18–65, every 1–3 years</td>
<td>F: with uterine cervix, beginning 3 years after first intercourse or by age 21. Yearly for standard Pap; every 2 years with liquid test.</td>
<td>Fair evidence to include in examination of sexually active women</td>
</tr>
<tr>
<td>Pelvic examination</td>
<td>No recommendation, advise adnexal palpation during exam for other reasons</td>
<td>F: 18–40, every 1–3 years with Pap test; &gt;40, every year</td>
<td>Not considered</td>
</tr>
<tr>
<td>Breast self-examination</td>
<td>No recommendation</td>
<td>≥20, monthly</td>
<td>Fair evidence to exclude</td>
</tr>
<tr>
<td>Breast clinical examination</td>
<td>Insufficient evidence as a stand-alone without mammography</td>
<td>F: 20–40, every 3 years; &gt;40, yearly</td>
<td>F: 50–69, every 1–2 years</td>
</tr>
<tr>
<td>Mammography</td>
<td>F: 40–75, every 1–2 years (fair evidence)</td>
<td>F: ≥40, every year</td>
<td>F: 50–69, every 1–2 years</td>
</tr>
<tr>
<td>Complete skin examination</td>
<td>Insufficient evidence for or against</td>
<td>Periodic exam</td>
<td>Poor evidence to include or exclude</td>
</tr>
</tbody>
</table>

*Summary of the screening procedures recommended for the general population by U.S. Preventive Services Task Force (USPSTF), the American Cancer Society (ACS), and the Canadian Task Force on Prevention Health Care (CTFPHC). These recommendations refer to asymptomatic persons who have no risk factors, other than age or gender, for the targeted condition.

*Note: F, female; M, male.*
Risk factors include diets high in saturated fats and low in fruits and vegetables, smoking, and alcohol consumption. Stronger but less prevalent risk factors are the presence of inflammatory bowel disease or genetic disorders such as familial polyposis (autosomal dominant germ-line mutation in \textit{APC}) and hereditary non-polyposis colorectal cancer (mutations in DNA mismatch repair genes \textit{hMSH2} and \textit{hMLH1}).

\textbf{Interventions}  
Pts with ulcerative colitis and familial polyposis generally undergo total colectomy. In familial polyposis, nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the number and size of polyps. Celecoxib, sulindac, and even aspirin appear to be effective, and celecoxib is approved by the U.S. Food and Drug Administration for this indication. Calcium supplementation can lead to a decrease in the recurrence of adenomas, but it is not yet clear that the risk of colorectal cancer is decreased and survival increased. The Women’s Health Study noted a significant reduction in the risk of colorectal cancer in women taking HRT, but the increase in thrombotic events and breast cancers counterbalanced this benefit. Studies are underway to assess NSAIDs with and without inhibitors of the epidermal growth factor (EGF) receptor in other risk groups.

\textbf{LUNG CANCER}  
Risk factors include smoking, exposure to radiation, asbestos, radon.

\textbf{Interventions}  
Smoking cessation is the only effective prevention. NSAIDs and EGF receptor inhibitors are being evaluated. Carotenoids, selenium, retinoids, and \textit{α}-tocopherol do not work.

\textbf{PROSTATE CANCER}  
Risk factors include age, family history, and possibly dietary fat intake. African Americans are at increased risk. The disease is highly prevalent, with autopsy studies finding prostate cancer in 70–80% of men over age 70.

\textbf{Interventions}  
In a group of men age \textgreater{}55 years with normal rectal examinations and PSA levels <3 ng/mL, daily finasteride reduced the incidence of prostate cancer by 25%. Finasteride also prevents the progression of benign prostate hyperplasia. However, some men experience decreased libido as a side effect. The Gleason grade of tumors seen in men taking finasteride prevention was somewhat higher than the controls; however, androgen deprivation alters the morphology of the cells and it is not yet clear that the Gleason grade is a reliable indicator of tumor aggressiveness in the setting of androgen deprivation. Some data suggest that selenium and \textit{α}-tocopherol may lower risk of prostate cancer. In a lung cancer prevention trial, men taking vitamin E had a 34% lower incidence of prostate cancer during the 6-year study period.

\textbf{CERVICAL CANCER}  
Risk factors include early age at first intercourse, multiple sexual partners, smoking, and infection with human papillomavirus (HPV) types 16, 18, 45, and 56.
Interventions  Regular Pap testing can detect nearly all cases of the premalignant lesion called cervical intraepithelial neoplasia. Untreated, the lesion can progress to carcinoma in situ and invasive cervical cancer. Surgical removal, cryotherapy, or laser therapy is used to treat the disease and is effective in 80%. Risk of recurrence is highest in women over age 30, those with prior HPV infection, and those who have had prior treatment for the same condition. A vaccine (Gardasil) containing antigens of strains 6, 11, 16, and 18 has been shown to be 100% effective in preventing HPV infections from those strains. The vaccine is recommended for all females age 9–16 years and could prevent up to 70% of all cervical cancer.

HEAD AND NECK CANCER

Risk factors include smoking, alcohol consumption, and possibly HPV infection.

Interventions  Oral leukoplakia, white lesions of the oral mucosa, occur in 1–2 persons in 1000, and 2–3% of these pts go on to develop head and neck cancer. Spontaneous regression of oral leukoplakia is seen in 30–40% of pts. Retinoid treatment (13-cis retinoid acid) can increase the regression rate. Vitamin A induces complete remission in ~50% of pts. The use of retinoids in pts who have been diagnosed with head and neck cancer and received definitive local therapy has not produced consistent results. Initial studies claimed that retinoids prevented the development of second primary tumors, a common feature of head and neck cancer. However, large randomized studies did not confirm this benefit. Other studies are underway combining retinoids and NSAIDs with and without EGF receptor inhibitors.

PATIENT EDUCATION IN EARLY DETECTION

Pts can be taught to look for early warning signals. The American Cancer Society has identified seven major warning signs of cancer:

• A change in bowel or bladder habits
• A sore that does not heal
• Unusual bleeding or discharge
• A lump in the breast or other parts of the body
• Chronic indigestion or difficulty in swallowing
• Obvious changes in a wart or mole
• Persistent coughing or hoarseness

For a more detailed discussion, see Brawley OW, Kramer BS: Prevention and Early Detection of Cancer, Chap. 78, p. 486, in HPIM-17.
Disease Prevention and Health Maintenance

SECTION 16

Smoking Cessation

Over 400,000 individuals die each year in the United States from cigarette use: one out of every five deaths nationwide. Approximately 40% of smokers will die prematurely unless they are able to quit; major diseases caused by cigarette smoking are listed in Table 215-1.

**APPROACH TO THE PATIENT WITH NICOTINE ADDICTION**

All pts should be asked whether they smoke, their past experience with quitting, and whether they are currently interested in quitting; those who are not interested should be encouraged and motivated to quit. Provide a clear, strong, and personalized physician message that smoking is an important health concern. A quit date should be negotiated within a few weeks of the visit, and a follow-up contact by office staff around the time of the quit date should be provided. Incorporation of cessation assistance into a practice requires a change of the care delivery infrastructure. Simple changes include:

- Adding questions about smoking and interest in cessation on patient-intake questionnaires

**TABLE 215-1 RELATIVE RISKS FOR CURRENT SMOKERS OF CIGARETTES**

<table>
<thead>
<tr>
<th>Disease or Condition</th>
<th>Current Smokers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Males</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td></td>
</tr>
<tr>
<td>Age 35–64</td>
<td>2.8</td>
</tr>
<tr>
<td>Age ≥65</td>
<td>1.5</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td></td>
</tr>
<tr>
<td>Age 35–64</td>
<td>3.3</td>
</tr>
<tr>
<td>Age ≥65</td>
<td>1.6</td>
</tr>
<tr>
<td>Aortic aneurysm</td>
<td>6.2</td>
</tr>
<tr>
<td>Chronic airway obstruction</td>
<td>10.6</td>
</tr>
<tr>
<td>Cancer</td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>23.3</td>
</tr>
<tr>
<td>Larynx</td>
<td>14.6</td>
</tr>
<tr>
<td>Lip, oral cavity, pharynx</td>
<td>10.9</td>
</tr>
<tr>
<td>Esophagus</td>
<td>6.8</td>
</tr>
<tr>
<td>Bladder, other urinary organs</td>
<td>3.3</td>
</tr>
<tr>
<td>Kidney</td>
<td>2.7</td>
</tr>
<tr>
<td>Pancreas</td>
<td>2.3</td>
</tr>
<tr>
<td>Stomach</td>
<td>2</td>
</tr>
<tr>
<td>Cervix</td>
<td>1.6</td>
</tr>
<tr>
<td>Acute myeloid leukemia</td>
<td>1.4</td>
</tr>
<tr>
<td>Sudden infant death syndrome</td>
<td>2.3</td>
</tr>
<tr>
<td>Infant respiratory distress syndrome</td>
<td>1.3</td>
</tr>
<tr>
<td>Low birth weight at delivery</td>
<td>1.8</td>
</tr>
</tbody>
</table>
Clinical practice guidelines suggest a variety of pharmacologic and non-pharmacologic interventions to aid in smoking cessation (Table 215-2). There are a variety of nicotine-replacement products, including over-the-counter nicotine patches, gum, and lozenges, as well as nicotine nasal and oral inhalers available by prescription; these products can be used for 3–6 months with a gradual step-down in dosage with increasing duration of abstinence. Prescription medications that have been shown to be effective include antidepressants such as bupropion (300 mg/d in divided doses for up to 6 months) and varenicline, a partial agonist for the nicotinic acetylcholine receptor (initial dose 0.5 mg daily increasing to 1 mg twice daily at day 8; treatment duration up to 6 months). Clonidine or nortriptyline may be useful for pts who have failed first-line therapies. Antidepressants are more effective in pts with a history of depressive symptoms. Current recommendations are to offer pharmacologic treatment, usually with nicotine replacement therapy and bupropion, to all who will accept it and to provide counseling and other support as a part of the cessation attempt.

### TABLE 215-2  CLINICAL PRACTICE GUIDELINES

**Physician actions**
- Ask: Systematically identify all tobacco users at every visit
- Advise: Strongly urge all smokers to quit
- Identify smokers willing to quit
- Assist the patient in quitting
- Arrange follow-up contact

**Effective pharmacologic interventions**

**First-line therapies**
- Nicotine gum (1.5)
- Nicotine patch (1.9)
- Nicotine nasal inhaler (2.7)
- Nicotine oral inhaler (2.5)
- Nicotine lozenge (2.0)
- Bupropion (2.1)
- Varenicline (2.7)

**Second-line therapies**
- Clonidine (2.1)
- Nortriptyline (3.2)

**Other Effective Interventions**
- Physician or other medical personnel counseling (10 min) (1.3)
- Intensive smoking cessation programs (at least 4–7 sessions of 20–30 min duration lasting at least 2 and preferably 8 weeks) (2.3)
- Clinic-based smoking status identification system (3.1)
- Counseling by nonclinicians and social support by family and friends
- Telephone counseling (1.2)

* Numerical value following the intervention is the multiple for cessation success compared to no intervention.
Approximately 90% of individuals who will become cigarette smokers initiate the behavior during adolescence; prevention must begin early, preferably in the elementary school years. Physicians who treat adolescents should be sensitive to the prevalence of this problem and screen for tobacco use, reinforcing the fact that most adolescents and adults do not smoke, and explaining that all forms of tobacco are both addictive and harmful.

For a more detailed discussion, see Burns DM: Nicotine Addiction, Chap. 390, p. 2736, in HPIM-17.

The most common causes of death in both men and women are heart disease and cancer, with lung cancer the top cause of cancer death, despite common misperceptions that breast cancer is the most common cause of death in women. These misconceptions perpetuate inadequate attention to modifiable risk factors in women, such as dyslipidemia, hypertension, and cigarette smoking. Furthermore, since women in the Unites States live on average 5.2 years longer than men, the majority of the disease burden for many age-related disorders rests in women. For a discussion of the menopause transition and postmenopausal hormone therapy, see Chap. 184.

Alzheimer’s disease (AD) affects approximately twice as many women as men, due to larger numbers of women surviving to older ages and to sex differences in brain size, structure, and functional organization. Postmenopausal hormone therapy may worsen cognitive function and the development of AD.

Coronary heart disease (CHD) presents differently in women, who are usually 10–15 years older than men with CHD and are more likely to have comorbidities, such as hypertension, congestive heart failure, and diabetes. Women more often have atypical symptoms, such as nausea, vomiting, indigestion, and upper back pain. Physicians are less likely to suspect heart disease in women with chest pain and are less likely to perform diagnostic and therapeutic cardiac procedures in women. The conventional risk factors for CHD are the same in both men and women, though women receive fewer interventions for modifiable risk factors than do men.
DIABETES MELLITUS  (See also Chap. 182)

The prevalence of type 2 diabetes mellitus (DM) is similar between men and women. Polycystic ovary syndrome and gestational diabetes mellitus are both common conditions in premenopausal women that carry an increased risk for type 2 DM. Premenopausal women with DM have identical rates of CHD to those of males.

HYPERTENSION  (See also Chap. 124)

Hypertension, as an age-related disorder, is more common in women than in men after age 60. Antihypertensive drugs appear to be equally effective in women and men; however, women may experience more side effects.

AUTOIMMUNE DISORDERS  (See also Chap. 167)

Most autoimmune disorders occur more commonly in women than in men; these include autoimmune thyroid and liver diseases, lupus, rheumatoid arthritis, scleroderma, multiple sclerosis, and idiopathic thrombocytopenic purpura. The mechanism for these sex differences remains obscure.

HIV INFECTION  (See also Chap. 112)

Heterosexual contact with an at-risk partner is the fastest-growing transmission category of HIV. Women with HIV have more rapid decreases in their CD4 cell counts than men do. Other sexually transmitted diseases, such as chlamydial infection and gonorrhea, are important causes of infertility in women, and papilloma virus infection predisposes to cervical cancer.

OBESITY  (See also Chap. 181)

The prevalence of obesity is higher in women than in men, in part due to the unique risk factors of pregnancy and menopause. In addition, the distribution of body fat differs by sex, with a gluteal and femoral pattern in women and a central pattern in men. Obesity increases a woman’s risk for postmenopausal breast and endometrial cancer, in part because of adipose tissue aromatization of androgens to estrone.

OSTEOPOROSIS  (See also Chap. 186)

Osteoporosis is much more prevalent in postmenopausal women than in age-matched men, since men accumulate more bone mass and lose bone more slowly than do women. In addition, differences in calcium intake, vitamin D, and estrogen levels contribute to sex differences in bone formation and bone loss.

PHARMACOLOGY

On average, women have lower body weights, smaller organs, higher percent body fat, and lower total-body water than men do. Gonadal steroids, menstrual cycle phase, and pregnancy can all affect drug action. Women also take more medications than men do, including over-the-counter formulations and supplements. The greater use of medications, combined with biologic differences, may account for the reported higher frequency of adverse drug reactions in women.

PSYCHOLOGICAL DISORDERS  (See also Chaps. 206 & 208)

Depression, anxiety, and eating disorders (bulimia and anorexia nervosa) are more common in women than in men. Depression occurs in 10% of women during pregnancy and 10–15% of women during the postpartum period.
SLEEP DISORDERS  (See also Chap. 45)
During sleep, women have an increased amount of slow-wave activity, differences in timing of delta activity, and an increase in the number of sleep spindles. They have a decreased prevalence of sleep apnea.

SUBSTANCE ABUSE AND TOBACCO  (See also Chap. 209)
Substance abuse is more common in men than women. However, women alcoholics are less likely to be diagnosed than men and are less likely to seek help. When they do seek help, it is more likely to be from a physician than from a treatment facility. Alcoholic women drink less than alcoholic men but exhibit the same degree of impairment. More men than women smoke tobacco, but the prevalence of smoking is declining faster in men than women.

VIOLENCE AGAINST WOMEN
Domestic violence is the most common cause of physical injury in women. Women may present with symptoms of chronic abdominal pain, headaches, substance abuse, and eating disorders, in addition to obvious manifestations such as trauma. Sexual assault is one of the most common crimes against women and is more likely by a spouse, ex-spouse, or acquaintance than by a stranger.

For a more detailed discussion, see Dunaif A: Women’s Health, Chap. 6, p. 39, HPIM-17.
Adverse drug reactions are among the most frequent problems encountered clinically and represent a common cause for hospitalization. They occur most frequently in pts receiving multiple drugs and are caused by:

- Errors in self-administration of prescribed drugs (quite common in the elderly).
- Exaggeration of intended pharmacologic effect (e.g., hypotension in a pt given antihypertensive drugs).
- Concomitant administration of drugs with synergistic effects (e.g., aspirin and warfarin).
- Cytotoxic reactions (e.g., hepatic necrosis due to acetaminophen).
- Immunologic mechanisms (e.g., quinidine-induced thrombocytopenia, hydralazine-induced SLE).
- Genetically determined enzymatic defects (e.g., primaquine-induced hemolytic anemia in G6PD deficiency).
- Idiosyncratic reactions (e.g., chloramphenicol-induced aplastic anemia).

**Recognition**  
History is of prime importance. Consider the following:

- Nonprescription drugs and topical agents as potential offenders
- Previous reaction to identical drugs
- Temporal association between drug administration and development of clinical manifestations
- Subsidence of manifestations when the agent is discontinued or reduced in dose
- Recurrence of manifestations with cautious readministration (for less hazardous reactions)
- Rare: (1) biochemical abnormalities, e.g., red cell G6PD deficiency as cause of drug-induced hemolytic anemia; (2) abnormal serum antibody in pts with agranulocytosis, thrombocytopenia, hemolytic anemia.

**Table 217-1** lists a number of clinical manifestations of adverse effects of drugs. It is not designed to be complete or exhaustive.

**TABLE 217-1**  
CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS

<table>
<thead>
<tr>
<th>Multisystem Manifestations</th>
<th>Angioedema</th>
<th>Drug-induced lupus erythematosus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaphylaxis</td>
<td>ACE inhibitors</td>
<td>Cephalosporins</td>
</tr>
<tr>
<td>Cephalosporins</td>
<td>Hydralazine</td>
<td></td>
</tr>
<tr>
<td>Dextran</td>
<td>Iodides</td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td>Isoniazid</td>
<td></td>
</tr>
<tr>
<td>Iodinated drugs or contrast media</td>
<td>Methyldopa</td>
<td></td>
</tr>
<tr>
<td>Lidocaine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penicillins</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procaine</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
### Table 217-1: Clinical Manifestations of Adverse Reactions to Drugs (Continued)

#### Multisystem Manifestations (Continued)

<table>
<thead>
<tr>
<th>Multisystem Manifestations</th>
<th>Hyperpyrexia</th>
<th>Hyperkalemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>Antipsychotics</td>
<td>ACE inhibitors</td>
</tr>
<tr>
<td>Aminosalicylic acid</td>
<td></td>
<td>Amiloride</td>
</tr>
<tr>
<td>Amphotericin B</td>
<td></td>
<td>Cytotoxics</td>
</tr>
<tr>
<td>Antihistamines</td>
<td></td>
<td>Digitalis overdose</td>
</tr>
<tr>
<td>Penicillins</td>
<td></td>
<td>Heparin</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>Serum sickness</td>
<td>Heparin</td>
</tr>
<tr>
<td>Procainamide</td>
<td>Aspirin</td>
<td>Lithium</td>
</tr>
<tr>
<td>Quinidine</td>
<td>Penicillins</td>
<td>Lithium</td>
</tr>
<tr>
<td>Sulfonamides</td>
<td>Propylthiouracil</td>
<td>Oral hypoglycemics</td>
</tr>
<tr>
<td>Thiouracil</td>
<td>Sulfonamides</td>
<td>Quinine</td>
</tr>
</tbody>
</table>

#### Endocrine Manifestations

- Addisonian-like syndrome
  - Guanethidine
  - Lithium
  - Major tranquilizers
- Galactorrhea (may also cause amenorrhea)
  - Guanethidine
  - Lithium
  - Major tranquilizers
- Gynecomastia
  - Calcitonin
  - Digitalis
  - Estrogens
  - Griseofulvin
  - Isoniazid
  - Methyldopa
  - Methyldopa
  - Mifepristone
  - Metformin
  - Phenytoin
  - Spironolactone
  - Testosterone
- Sexual dysfunction
  - Beta blockers
  - Clonidine
  - Diuretics
  - Estrogens
  - Methyldopa
  - Methyldopa
  - Mifepristone
  - Phenytoin
  - Sulfonamides
  - Tolbutamide
- Thyroid function tests, disorders of
  - Acetazolamide
  - Amiodarone
  - Chlorpropamide
  - Clofibrate
  - Colestipol and nicotinic acid
  - Gold salts
  - Iodides
  - Lithium
  - Oral contraceptives
  - Phenothiazines
  - Phenylbutazone
  - Phenytoin
  - Sulfonamides
  - Tolbutamide

#### Metabolic Manifestations

<table>
<thead>
<tr>
<th>Metabolic Manifestations</th>
<th>Oral contraceptives</th>
<th>Thiazides</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperbilirubinemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rifampin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypercalcemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antacids with absorbable alkali</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiazides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorothalidone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diazoxide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Encairnide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethacrynic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furosemide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Growth hormone</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
**Metabolic Manifestations (Continued)**

| Potassium preparations including salt substitute | Ethacrynic acid |
| Potassium salts of drugs | Furosemide |
| Spironolactone | Hyperalimentation |
| Succinylcholine | Thiazides |
| Triamterene |

**Hypokalemia**
- Alkali-induced alkalosis
- Amphotericin B
- Diuretics
- Gentamicin
- Insulin
- Laxative abuse
- Mineralocorticoids, some glucocorticoids
- Osmotic diuretics
- Sympathomimetics
- Tetracycline
- Theophylline
- Vitamin B₁₂

**Hyperuricemia**
- Aspirin
- Cytotoxics

**Dermatologic Manifestations**

| Acne | Salicylates |
| Anabolic and androgenic steroids | Sulfonamides |
| Bromides | Sulfothiones |
| Glucocorticoids | Tetracyclines |
| Iodides | Thiazides |
| Isoniazid | |
| Oral contraceptives | |

| Alopecia | |
| Cytotoxics | |
| Ethionamide | |
| Heparin | |
| Oral contraceptives (withdrawal) | |

| Eczema | |
| Captopril | |
| Cream and lotion preservatives | |
| Lanolin | |
| Topical antihistamines | |
| Topical antimicrobials | |
| Topical local anesthetics | |

**Erythema multiforme or Stevens-Johnson syndrome**

| Barbiturates | |
| Chlorpromazine | |
| Codeine | |
| Penicillins | |
| Phenylbutazone | |
| Phenytoin | |

**Erythema nodosum**
- Oral contraceptives
- Penicillins
- Sulfonamides

**Exfoliative dermatitis**
- Barbiturates
- Gold salts
- Penicillins
- Phenylbutazone
- Phenytoin
- Quinidine
- Sulfonamides

**Fixed drug eruptions**
- Barbiturates
- Captopril
- Phenylbutazone
- Quinine
- Salicylates
- Sulfonamides

**Hyperpigmentation**
- Bleomycin
- Busulfan

(continued)
### TABLE 217-1

**CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS**

(Continued)

<table>
<thead>
<tr>
<th>Dermatologic Manifestations (Continued)</th>
<th>Aspirin</th>
<th>Glucocorticoids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chloroquine and other antimalarials</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corticotropin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gold salts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypervitaminosis A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenothiazines</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lichenoid eruptions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aminosalicylic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antimalarials</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorpropamide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gold salts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenothiazines</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Photodermatitis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Captopril</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlor Diazepoxide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furosemide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Griseofulvin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nalidixic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenothiazines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfonamides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetracyclines, particularly demeclocycline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiazides</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Purpura</strong> (see also Thrombocytopenia)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allopurinol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ampicillin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hematologic Manifestations</th>
<th>Clotting abnormalities/ hypothrombinemia</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Agranulocytosis</strong> (see also Pancytopenia)</td>
<td>Cefamandole</td>
<td>Cefoperazone</td>
</tr>
<tr>
<td>Captopril</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbimazole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytotoxics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gold salts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indomethacin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methimazole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxyprenbutazone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenothiazines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Propylthiouracil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfonamides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tolbutamide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Eosinophilia</strong></td>
<td>Aminosalicylic acid</td>
<td>Chlorpropamide</td>
</tr>
<tr>
<td></td>
<td>Erythromycin estolate</td>
<td>Imipramine</td>
</tr>
<tr>
<td></td>
<td>I-Tryptophan</td>
<td>Methotrexate</td>
</tr>
<tr>
<td></td>
<td>Nitrofurantoin</td>
<td>Procarbazine</td>
</tr>
<tr>
<td></td>
<td>Sulfonamides</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
Hematologic Manifestations (Continued)

<table>
<thead>
<tr>
<th>Hemolytic anemia</th>
<th>Cytotoxics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminosalicylic acid</td>
<td>Gold salts</td>
</tr>
<tr>
<td>Cephalosporins</td>
<td>Mephenytoin</td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>Phenylbutazone</td>
</tr>
<tr>
<td>Dapsone</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Insulin</td>
<td>Quinacrine</td>
</tr>
<tr>
<td>Isoniazid</td>
<td>Sulfonamides</td>
</tr>
<tr>
<td>Levodopa</td>
<td>Trimethadione</td>
</tr>
<tr>
<td>Mefenamic acid</td>
<td>Zidovudine (AZT)</td>
</tr>
<tr>
<td>Melphalan</td>
<td></td>
</tr>
<tr>
<td>Methyldopa</td>
<td></td>
</tr>
<tr>
<td>Penicillins</td>
<td></td>
</tr>
<tr>
<td>Phenacetin</td>
<td></td>
</tr>
<tr>
<td>Procainamide</td>
<td></td>
</tr>
<tr>
<td>Quinidine</td>
<td></td>
</tr>
<tr>
<td>Rifampin</td>
<td></td>
</tr>
<tr>
<td>Sulfonamides</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pure red cell aplasia</th>
<th>Azathioprine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chloropropamide</td>
</tr>
<tr>
<td></td>
<td>Isoniazid</td>
</tr>
<tr>
<td></td>
<td>Phenytoin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hemolytic anemias in G6PD deficiency</th>
<th>Aspirin</th>
</tr>
</thead>
<tbody>
<tr>
<td>See Table 66-3</td>
<td>Carbamazepine</td>
</tr>
<tr>
<td></td>
<td>Carbenicillin</td>
</tr>
<tr>
<td></td>
<td>Chloropropamide</td>
</tr>
<tr>
<td></td>
<td>Chlorthalidone</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Leukocytosis</th>
<th>Furosemide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucocorticoids</td>
<td></td>
</tr>
<tr>
<td>Lithium</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lymphadenopathy</th>
<th>Gold salts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenytin</td>
<td></td>
</tr>
<tr>
<td>Primidone</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Megaloblastic anemia</th>
<th>Indomethacin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Folate antagonists</td>
<td>Isoniazid</td>
</tr>
<tr>
<td>Nitrous oxide</td>
<td>Methyldopa</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>Moxalactam</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>Phenylbutazone</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>Phenytoin and other hydantoins</td>
</tr>
<tr>
<td>Primidone</td>
<td>Quinidine</td>
</tr>
<tr>
<td>Triamterene</td>
<td>Quinine</td>
</tr>
<tr>
<td>Trimethroprim</td>
<td>Thiazides</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pancytopenia (aplastic anemia)</th>
<th>Ticarcillin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbamazepine</td>
<td></td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td></td>
</tr>
</tbody>
</table>

Cardiovascular Manifestations

<table>
<thead>
<tr>
<th>Angina exacerbation</th>
<th>Arrhythmias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha blockers</td>
<td>Adriamycin</td>
</tr>
<tr>
<td>Beta blocker withdrawal</td>
<td>Antiarrhythmic drugs</td>
</tr>
<tr>
<td>Ergotamine</td>
<td>Atropine</td>
</tr>
<tr>
<td>Excessive thyroxine</td>
<td>Anticholinesterases</td>
</tr>
<tr>
<td>Hydralazine</td>
<td>Beta blockers</td>
</tr>
<tr>
<td>Methysergid</td>
<td>Digitalis</td>
</tr>
<tr>
<td>Minoxidil</td>
<td>Emetine</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>Lithium</td>
</tr>
<tr>
<td>Oxytocin</td>
<td>Phenothiazines</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>Sympathomimetics</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Cardiovascular Manifestations (Continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyroid hormone</td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
</tr>
<tr>
<td>Verapamil</td>
</tr>
<tr>
<td><strong>AV block</strong></td>
</tr>
<tr>
<td>Clonidine</td>
</tr>
<tr>
<td>Methyldopa</td>
</tr>
<tr>
<td>Verapamil</td>
</tr>
<tr>
<td><strong>Cardiomyopathy</strong></td>
</tr>
<tr>
<td>Adriamycin</td>
</tr>
<tr>
<td>Daunorubicin</td>
</tr>
<tr>
<td>Emetine</td>
</tr>
<tr>
<td>Lithium</td>
</tr>
<tr>
<td>Phenothiazines</td>
</tr>
<tr>
<td>Sulfonamides</td>
</tr>
<tr>
<td>Sympathomimetics</td>
</tr>
<tr>
<td><strong>Fluid retention or congestive heart failure</strong></td>
</tr>
<tr>
<td>Beta blockers</td>
</tr>
<tr>
<td>Calcium antagonists</td>
</tr>
<tr>
<td>Estrogens</td>
</tr>
<tr>
<td>Indomethacin</td>
</tr>
<tr>
<td>Mannitol</td>
</tr>
<tr>
<td>Minoxidil</td>
</tr>
<tr>
<td>Phenylbutazone</td>
</tr>
<tr>
<td>Steroids</td>
</tr>
<tr>
<td><strong>Hypotension</strong></td>
</tr>
<tr>
<td>Calcium antagonists</td>
</tr>
<tr>
<td>Citrated blood</td>
</tr>
<tr>
<td><strong>Respiratory Manifestations</strong></td>
</tr>
<tr>
<td><strong>Airway obstruction</strong></td>
</tr>
<tr>
<td>Beta blockers</td>
</tr>
<tr>
<td>Cephalosporins</td>
</tr>
<tr>
<td>Cholinergic drugs</td>
</tr>
<tr>
<td>NSAIDs</td>
</tr>
<tr>
<td>Penicillins</td>
</tr>
<tr>
<td>Pentazocine</td>
</tr>
<tr>
<td>Streptomycin</td>
</tr>
<tr>
<td>Tartrazine (drugs with yellow dye)</td>
</tr>
<tr>
<td><strong>Cough</strong></td>
</tr>
<tr>
<td>ACE inhibitors</td>
</tr>
<tr>
<td><strong>Pulmonary edema</strong></td>
</tr>
<tr>
<td>Contrast media</td>
</tr>
<tr>
<td>Heroin</td>
</tr>
<tr>
<td>Methadone</td>
</tr>
<tr>
<td>Propoxyphene</td>
</tr>
<tr>
<td><strong>Pulmonary infiltrates</strong></td>
</tr>
<tr>
<td>Acyclovir</td>
</tr>
<tr>
<td>Amiodarone</td>
</tr>
<tr>
<td>Azathioprine</td>
</tr>
<tr>
<td>Bleomycin</td>
</tr>
<tr>
<td>Busulfan</td>
</tr>
<tr>
<td>Carmustine (BCNU)</td>
</tr>
<tr>
<td>Chlorambucil</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
</tr>
<tr>
<td>Melphalan</td>
</tr>
<tr>
<td>Methotrexate</td>
</tr>
<tr>
<td>Methysergide</td>
</tr>
<tr>
<td>Mitomycin C</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
</tr>
<tr>
<td>Procarbazine</td>
</tr>
<tr>
<td>Sulfonamides</td>
</tr>
</tbody>
</table>

(continued)
### Gastrointestinal Manifestations

<table>
<thead>
<tr>
<th>Cholestatic jaundice</th>
<th>Sodium valproate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anabolic steroids</td>
<td>Sulfonamides</td>
</tr>
<tr>
<td>Androgens</td>
<td>Tetracyclines</td>
</tr>
<tr>
<td>Chlorpropamide</td>
<td>Verapamil</td>
</tr>
<tr>
<td>Erythromycin estolate</td>
<td>Zidovudine (AZT)</td>
</tr>
<tr>
<td>Gold salts</td>
<td></td>
</tr>
<tr>
<td>Methimazole</td>
<td></td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td></td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td></td>
</tr>
<tr>
<td>Phenothiazines</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Constipation or ileus</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aluminum hydroxide</td>
<td></td>
</tr>
<tr>
<td>Barium sulfate</td>
<td></td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td></td>
</tr>
<tr>
<td>Ferrous sulfate</td>
<td></td>
</tr>
<tr>
<td>Ion exchange resins</td>
<td></td>
</tr>
<tr>
<td>Opiates</td>
<td></td>
</tr>
<tr>
<td>Phenothiazines</td>
<td></td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
<td></td>
</tr>
<tr>
<td>Verapamil</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diarrhea or colitis</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics (broad-spectrum)</td>
<td></td>
</tr>
<tr>
<td>Colchicine</td>
<td></td>
</tr>
<tr>
<td>Digitalis</td>
<td></td>
</tr>
<tr>
<td>Magnesium in antacids</td>
<td></td>
</tr>
<tr>
<td>Methyldopa</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diffuse hepatocellular damage</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen (paracetamol)</td>
<td></td>
</tr>
<tr>
<td>Allopurinol</td>
<td></td>
</tr>
<tr>
<td>Aminosalicylic acid</td>
<td></td>
</tr>
<tr>
<td>Dapsone</td>
<td></td>
</tr>
<tr>
<td>Erythromycin estolate</td>
<td></td>
</tr>
<tr>
<td>Ethionamide</td>
<td></td>
</tr>
<tr>
<td>Glyburide</td>
<td></td>
</tr>
<tr>
<td>Halothane</td>
<td></td>
</tr>
<tr>
<td>Isoniazid</td>
<td></td>
</tr>
<tr>
<td>Ketoconazole</td>
<td></td>
</tr>
<tr>
<td>Methimazole</td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td></td>
</tr>
<tr>
<td>Methoxyflurane</td>
<td></td>
</tr>
<tr>
<td>Methyldopa</td>
<td></td>
</tr>
<tr>
<td>Monoamine oxidase inhibitors</td>
<td></td>
</tr>
<tr>
<td>Niacin</td>
<td></td>
</tr>
<tr>
<td>Nifedipine</td>
<td></td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td></td>
</tr>
<tr>
<td>Phenytoin</td>
<td></td>
</tr>
<tr>
<td>Propoxyphene</td>
<td></td>
</tr>
<tr>
<td>Propylthiouracil</td>
<td></td>
</tr>
<tr>
<td>Pyridium</td>
<td></td>
</tr>
<tr>
<td>Rifampin</td>
<td></td>
</tr>
<tr>
<td>Salicylates</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intestinal ulceration</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Solid KCl preparations</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Malabsorption</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminosalicylic acid</td>
<td></td>
</tr>
<tr>
<td>Antibiotics (broad-spectrum)</td>
<td></td>
</tr>
<tr>
<td>Cholesterylamine</td>
<td></td>
</tr>
<tr>
<td>Colchicine</td>
<td></td>
</tr>
<tr>
<td>Colestipol</td>
<td></td>
</tr>
<tr>
<td>Cytotoxics</td>
<td></td>
</tr>
<tr>
<td>Neomycin</td>
<td></td>
</tr>
<tr>
<td>Phenobarbital</td>
<td></td>
</tr>
<tr>
<td>Phenytoin</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nausea or vomiting</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Digitalis</td>
<td></td>
</tr>
<tr>
<td>Estrogens</td>
<td></td>
</tr>
<tr>
<td>Ferrous sulfate</td>
<td></td>
</tr>
<tr>
<td>Levodopa</td>
<td></td>
</tr>
<tr>
<td>Opiates</td>
<td></td>
</tr>
<tr>
<td>Potassium chloride</td>
<td></td>
</tr>
<tr>
<td>Tetracyclines</td>
<td></td>
</tr>
<tr>
<td>Theophylline</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Oral conditions</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Gingival hyperplasia</td>
<td></td>
</tr>
<tr>
<td>Calcium antagonists</td>
<td></td>
</tr>
<tr>
<td>Cyclosporine</td>
<td></td>
</tr>
<tr>
<td>Phenytoin</td>
<td></td>
</tr>
<tr>
<td>2. Salivary gland swelling</td>
<td></td>
</tr>
<tr>
<td>Bretylium</td>
<td></td>
</tr>
<tr>
<td>Clonidine</td>
<td></td>
</tr>
<tr>
<td>Guanethidine</td>
<td></td>
</tr>
<tr>
<td>Iodides</td>
<td></td>
</tr>
<tr>
<td>Phenylbutazone</td>
<td></td>
</tr>
<tr>
<td>3. Taste disturbances</td>
<td></td>
</tr>
<tr>
<td>Biguanides</td>
<td></td>
</tr>
<tr>
<td>Captopril</td>
<td></td>
</tr>
<tr>
<td>Griseofulvin</td>
<td></td>
</tr>
<tr>
<td>Lithium</td>
<td></td>
</tr>
<tr>
<td>Metronidazole</td>
<td></td>
</tr>
<tr>
<td>Penicillamine</td>
<td></td>
</tr>
<tr>
<td>Rifampin</td>
<td></td>
</tr>
<tr>
<td>4. Ulceration</td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td></td>
</tr>
<tr>
<td>Cytotoxics</td>
<td></td>
</tr>
<tr>
<td>Gentian violet</td>
<td></td>
</tr>
<tr>
<td>Isoproterenol (sublingual)</td>
<td></td>
</tr>
<tr>
<td>Pancreatin</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
### TABLE 217-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS (CONTINUED)

<table>
<thead>
<tr>
<th>Gastrointestinal Manifestations (Continued)</th>
<th>Renal/Urinary Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal Manifestations (Continued)</td>
<td>Renal/Urinary Manifestations</td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>Sulfonamides</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>Thiazides</td>
</tr>
<tr>
<td>Ethacrynic acid</td>
<td>Peptic ulceration or hemorrhage</td>
</tr>
<tr>
<td>Furosemide</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>Ethacrynic acid</td>
</tr>
<tr>
<td>Opiates</td>
<td>Glucocorticoids</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>NSAIDs</td>
</tr>
<tr>
<td>Renal/Urinary Manifestations</td>
<td></td>
</tr>
<tr>
<td>Bladder dysfunction</td>
<td>Nephrotic syndrome</td>
</tr>
<tr>
<td>Anticholinergics</td>
<td>Captopril</td>
</tr>
<tr>
<td>Disopyramide</td>
<td>Gold salts</td>
</tr>
<tr>
<td>Monoamine oxidase inhibitors</td>
<td>Penicillamine</td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
<td>Phenindione</td>
</tr>
<tr>
<td>Calculi</td>
<td>Probenecid</td>
</tr>
<tr>
<td>Acetazolamide</td>
<td>Obstructive uropathy</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Extrarenal: methysergide</td>
</tr>
<tr>
<td>Concentrating defect with polyuria (or nephrogenic diabetes insipidus)</td>
<td>Intrarenal: cytotoxins</td>
</tr>
<tr>
<td>Demeclocycline</td>
<td>Renal dysfunction</td>
</tr>
<tr>
<td>Lithium</td>
<td>Cyclosporine</td>
</tr>
<tr>
<td>Methoxyflurane</td>
<td>NSAIDS</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Triamterene</td>
</tr>
<tr>
<td>Hemorrhagic cystitis</td>
<td>Renal tubular acidosis</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>Acetazolamide</td>
</tr>
<tr>
<td>Interstitial nephritis</td>
<td>Amphotericin B</td>
</tr>
<tr>
<td>Allopurinol</td>
<td>Degraded tetracycline</td>
</tr>
<tr>
<td>Furosemide</td>
<td>Tubular necrosis</td>
</tr>
<tr>
<td>Penicillins, esp. methicillin</td>
<td>Aminoglycosides</td>
</tr>
<tr>
<td>Phenindione</td>
<td>Amphotericin B</td>
</tr>
<tr>
<td>Sulfonamides</td>
<td>Colistin</td>
</tr>
<tr>
<td>Thiazides</td>
<td>Cyclosporine</td>
</tr>
<tr>
<td>Nephropathies</td>
<td>Methoxyflurane</td>
</tr>
<tr>
<td>Due to analgesics (e.g., phenacetin)</td>
<td>Polymyxins</td>
</tr>
<tr>
<td>Neurologic Manifestations</td>
<td>Radioiodinated contrast medium</td>
</tr>
<tr>
<td>Exacerbation of myasthenia</td>
<td>Sulfonamides</td>
</tr>
<tr>
<td>Aminoglycosides</td>
<td>Tetracyclines</td>
</tr>
<tr>
<td>Extrapyramidal effects</td>
<td>Headache</td>
</tr>
<tr>
<td>Butyrophenones, e.g., haloperidol</td>
<td>Ergotamine (withdrawal)</td>
</tr>
<tr>
<td>Levodopa</td>
<td>Glyceryl trinitrate</td>
</tr>
<tr>
<td>Methyldopa</td>
<td>Hydralazine</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>Indomethacin</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>Peripheral neuropathy</td>
</tr>
<tr>
<td>Phenothiazines</td>
<td>Amiodarone</td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
<td>Chloramphenicol</td>
</tr>
<tr>
<td>Neurologic Manifestations</td>
<td>Chloroquine</td>
</tr>
<tr>
<td>Exacerbation of myasthenia</td>
<td>Chlorpropamide</td>
</tr>
<tr>
<td>Aminoglycosides</td>
<td>Clofibrate</td>
</tr>
<tr>
<td>Polymyxins</td>
<td>Demeclrocycline</td>
</tr>
<tr>
<td>Extrapyramidal effects</td>
<td></td>
</tr>
<tr>
<td>Butyrophenones, e.g., haloperidol</td>
<td>(continued)</td>
</tr>
<tr>
<td>Levodopa</td>
<td></td>
</tr>
</tbody>
</table>
### Neurologic Manifestations (Continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Side Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disopyramide</td>
<td>Hypervitaminosis A</td>
</tr>
<tr>
<td>Ethambutol</td>
<td>Oral contraceptives</td>
</tr>
<tr>
<td>Ethionamide</td>
<td>Tetracyclines</td>
</tr>
<tr>
<td>Glutethimide</td>
<td></td>
</tr>
<tr>
<td>Hydralazine</td>
<td></td>
</tr>
<tr>
<td>Isoniazid</td>
<td></td>
</tr>
<tr>
<td>Methysergide</td>
<td></td>
</tr>
<tr>
<td>Metronidazole</td>
<td></td>
</tr>
<tr>
<td>Nalidixic acid</td>
<td></td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td></td>
</tr>
<tr>
<td>Phenytoin</td>
<td></td>
</tr>
<tr>
<td>Polymyxin, colistin</td>
<td></td>
</tr>
<tr>
<td>Procarbazine</td>
<td></td>
</tr>
<tr>
<td>Streptomycin</td>
<td></td>
</tr>
<tr>
<td>Tolbutamide</td>
<td></td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
<td></td>
</tr>
<tr>
<td>Vincristine</td>
<td></td>
</tr>
<tr>
<td><strong>Pseudotumor cerebri</strong> (or intracranial hypertension)**</td>
<td>Oral contraceptives</td>
</tr>
<tr>
<td>Amiodarone</td>
<td></td>
</tr>
<tr>
<td>Glucocorticoids, mineralocorticoids</td>
<td></td>
</tr>
</tbody>
</table>

### Ocular Manifestations

<table>
<thead>
<tr>
<th>Condition</th>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cataracts</td>
<td>Busulfan, Chlorambucil, Glucocorticoids, Phenothiazines</td>
</tr>
<tr>
<td>Color vision alteration</td>
<td>Barbiturates, Digitalis, Methaqualone, Streptomycin, Thiazides</td>
</tr>
<tr>
<td>Corneal edema</td>
<td>Oral contraceptives</td>
</tr>
<tr>
<td>Corneal opacities</td>
<td>Chloroquine, Indomethacin, Vitamin D</td>
</tr>
<tr>
<td>Ear Manifestations</td>
<td>Furosemide, Nortriptyline, Quinine</td>
</tr>
</tbody>
</table>

### Glaucoma
- Mydriatics
- Sympathomimetics

### Optic neuritis
- Aminosalicylic acid
- Chloramphenicol
- Ethambutol
- Isoniazid
- Penicillamine
- Phenothiazines
- Phenybutazone
- Quinine
- Streptomycin

### Retinopathy
- Chloroquine
- Phenothiazines

### Deafness
- Aminoglycosides
- Aspirin
- Bleomycin
- Chloroquine
- Erythromycin
- Ethacrynic acid

### Vestibular disorders
- Aminoglycosides
- Quinine

(continued)
### TABLE 217-1 CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS (CONTINUED)

<table>
<thead>
<tr>
<th>Musculoskeletal Manifestations</th>
<th>Psychiatric Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bone disorders</strong></td>
<td><strong>Hallucinatory states</strong></td>
</tr>
<tr>
<td>1. Osteoporosis</td>
<td>Amantadine</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>Aminophylline</td>
</tr>
<tr>
<td>Heparin</td>
<td>Anticholinergics</td>
</tr>
<tr>
<td>2. Osteomalacia</td>
<td>Antidepressants</td>
</tr>
<tr>
<td>Aluminum hydroxide</td>
<td>Cimetidine</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>Digitalis</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>Glucocorticoids</td>
</tr>
<tr>
<td>Myopathy or myalgia</td>
<td>Isoniazid</td>
</tr>
<tr>
<td>Amphotericin B</td>
<td>Levodopa</td>
</tr>
<tr>
<td>Clofibrate</td>
<td>Methyldopa</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>Penicillins</td>
</tr>
<tr>
<td>Myopathy or myalgia</td>
<td>Phenothiazines</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>Sedatives and hypnotics</td>
</tr>
<tr>
<td>Myopathy or myalgia</td>
<td><strong>Depression</strong></td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>Amphetamine withdrawal</td>
</tr>
<tr>
<td>Myopathy or myalgia</td>
<td>Beta blockers</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>Centrally acting antihypertensives</td>
</tr>
<tr>
<td>Myopathy or myalgia</td>
<td>(reserpine, methyldopa, clonidine)</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>Glucocorticoids</td>
</tr>
<tr>
<td>Myopathy or myalgia</td>
<td>Levodopa</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>Lysergic acid</td>
</tr>
<tr>
<td>Myopathy or myalgia</td>
<td>Monoamine oxidase inhibitors</td>
</tr>
<tr>
<td>Myopathy or myalgia</td>
<td>Tricyclic antidepressants</td>
</tr>
<tr>
<td>Depression</td>
<td><strong>Schizophrenic-like or paranoid reactions</strong></td>
</tr>
<tr>
<td>Amphetamine withdrawal</td>
<td>Amphetamines</td>
</tr>
<tr>
<td>Beta blockers</td>
<td>Bromides</td>
</tr>
<tr>
<td>Centrally acting antihypertensives</td>
<td>Glucocorticoids</td>
</tr>
<tr>
<td>Depression</td>
<td>Levodopa</td>
</tr>
<tr>
<td>(reserpine, methyldopa, clonidine)</td>
<td>Lysergic acid</td>
</tr>
<tr>
<td>Depression</td>
<td>Monoamine oxidase inhibitors</td>
</tr>
<tr>
<td>Depression</td>
<td>Tricyclic antidepressants</td>
</tr>
<tr>
<td>Depression</td>
<td><strong>Sleep disturbances</strong></td>
</tr>
<tr>
<td>Depression</td>
<td>Anorexiants</td>
</tr>
<tr>
<td>Depression</td>
<td>Levodopa</td>
</tr>
<tr>
<td>Depression</td>
<td>Monoamine oxidase inhibitors</td>
</tr>
<tr>
<td>Depression</td>
<td>Sympathomimetics</td>
</tr>
<tr>
<td>Depression</td>
<td>Tricyclic antidepressants</td>
</tr>
</tbody>
</table>

**Source:** Adapted from AJJ Wood: HPIM-15, pp. 432–436.
INTRODUCTORY COMMENTS

In preparing for the Appendix, the authors have taken into account the fact that the system of international units (SI, système international d’unités) is used in most countries and in some medical journals. However, clinical laboratories may continue to report values in “conventional” units. Therefore, both systems are provided in the Appendix.

REFERENCE VALUES FOR LABORATORY TESTS

(Tables 218-1 through 218-5)
<table>
<thead>
<tr>
<th>Analyte</th>
<th>Specimen&lt;sup&gt;a&lt;/sup&gt;</th>
<th>SI Units</th>
<th>Conventional Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>D-Dimer</td>
<td>P</td>
<td>0.22–0.74 μg/mL</td>
<td>0.22–0.74 μg/mL</td>
</tr>
<tr>
<td>Differential blood count</td>
<td>WB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>WB</td>
<td>0.40–0.70</td>
<td>40–70%</td>
</tr>
<tr>
<td>Bands</td>
<td>WB</td>
<td>0.0–0.05</td>
<td>0–5%</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>WB</td>
<td>0.20–0.50</td>
<td>20–50%</td>
</tr>
<tr>
<td>Monocytes</td>
<td>WB</td>
<td>0.04–0.08</td>
<td>4–8%</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>WB</td>
<td>0.0–0.6</td>
<td>0–6%</td>
</tr>
<tr>
<td>Basophils</td>
<td>WB</td>
<td>0.0–0.02</td>
<td>0–2%</td>
</tr>
<tr>
<td>Eosinophil count</td>
<td>WB</td>
<td>150–300/μL</td>
<td>150–300/mm&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Erythrocyte count</td>
<td>WB</td>
<td>4.30–5.60 × 10&lt;sup&gt;12&lt;/sup&gt;/L</td>
<td>4.30–5.60 × 10&lt;sup&gt;6&lt;/sup&gt;/mm&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Erythrocyte life span</td>
<td>WB</td>
<td>Normal survival 120 days</td>
<td>120 days</td>
</tr>
<tr>
<td>Chromium labeled, half life (t&lt;sub&gt;1/2&lt;/sub&gt;)</td>
<td>WB</td>
<td>25–35 days</td>
<td>25–35 days</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate</td>
<td>WB</td>
<td>Females 0–20 mm/h</td>
<td>0–20 mm/h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Males 0–15 mm/h</td>
<td>0–15 mm/h</td>
</tr>
<tr>
<td>Fibrinogen degradation products</td>
<td>P</td>
<td>0–1 mg/L</td>
<td>0–1 μg/mL</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>P</td>
<td>2.33–4.96 g/L</td>
<td>233–496 mg/dL</td>
</tr>
<tr>
<td>Glucose-6-phosphate dehydrogenase (erythrocyte)</td>
<td>WB</td>
<td>&lt; 2400 s</td>
<td>&lt;40 min</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>WB</td>
<td>Adult males 0.388–0.464</td>
<td>38.8–46.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adult females 0.354–0.444</td>
<td>35.4–44.4</td>
</tr>
</tbody>
</table>

<sup>a</sup> SI = International System of Units; WB = whole blood.
<table>
<thead>
<tr>
<th>Test Description</th>
<th>Units</th>
<th>Reference Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma</td>
<td></td>
<td>6–50 mg/L</td>
</tr>
<tr>
<td>Whole blood</td>
<td></td>
<td>0.6–5.0 mg/dL</td>
</tr>
<tr>
<td>Adult males</td>
<td></td>
<td>133–162 g/L</td>
</tr>
<tr>
<td>Adult females</td>
<td></td>
<td>13.3–16.2 g/dL</td>
</tr>
<tr>
<td>Adult females</td>
<td></td>
<td>120–158 g/L</td>
</tr>
<tr>
<td>Adult males</td>
<td></td>
<td>12.0–15.8 g/dL</td>
</tr>
<tr>
<td>Hemoglobin electrophoresis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin A</td>
<td></td>
<td>0.95–0.98</td>
</tr>
<tr>
<td>Hemoglobin A2</td>
<td></td>
<td>0.015–0.031</td>
</tr>
<tr>
<td>Hemoglobin F</td>
<td></td>
<td>0–0.02</td>
</tr>
<tr>
<td>Hemoglobins other than A, A2, or F</td>
<td></td>
<td>Absent</td>
</tr>
<tr>
<td>Leukocytes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alkaline phosphatase (LAP)</td>
<td></td>
<td>0.2–1.6 μkat/L</td>
</tr>
<tr>
<td>Alkaline phosphatase (LAP)</td>
<td></td>
<td>13–100 μ/L</td>
</tr>
<tr>
<td>Count (WBC)</td>
<td></td>
<td>3.54–9.06 × 10^9/L</td>
</tr>
<tr>
<td>Count (WBC)</td>
<td></td>
<td>3.54–9.06 × 10^3/mm^3</td>
</tr>
<tr>
<td>Mean corpuscular hemoglobin (MCH)</td>
<td></td>
<td>26.7–31.9 pg/cell</td>
</tr>
<tr>
<td>Mean corpuscular hemoglobin concentration (MCHC)</td>
<td></td>
<td>26.7–31.9 pg/cell</td>
</tr>
<tr>
<td>Mean corpuscular hemoglobin of reticulocytes (CH)</td>
<td></td>
<td>24–36 pg</td>
</tr>
<tr>
<td>Mean corpuscular volume (MCV)</td>
<td></td>
<td>79–93.3 fl</td>
</tr>
<tr>
<td>Mean platelet volume (MPV)</td>
<td></td>
<td>9.00–12.95 fl</td>
</tr>
<tr>
<td>Osmotic fragility of erythrocytes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct</td>
<td></td>
<td>0.0035–0.0045</td>
</tr>
<tr>
<td>Index</td>
<td></td>
<td>0.35–0.45%</td>
</tr>
<tr>
<td>Partial thromboplastin time, activated</td>
<td></td>
<td>26.3–39.4 s</td>
</tr>
<tr>
<td>Plasminogen</td>
<td></td>
<td>26.3–39.4 s</td>
</tr>
<tr>
<td>Antigen</td>
<td></td>
<td>84–140 mg/L</td>
</tr>
<tr>
<td>Functional</td>
<td></td>
<td>8.4–14.0 mg/dL</td>
</tr>
<tr>
<td>Plasminogen activator inhibitor 1</td>
<td></td>
<td>4–43 μg/L</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4–43 ng/mL</td>
</tr>
<tr>
<td>Analyte</td>
<td>Specimen&lt;sup&gt;a&lt;/sup&gt;</td>
<td>SI Units</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Platelet aggregation</td>
<td>PRP</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Platelet count</td>
<td>WB</td>
<td>165–415 × 10&lt;sup&gt;9&lt;/sup&gt;/L</td>
</tr>
<tr>
<td>Platelet, mean volume</td>
<td>WB</td>
<td>6.4–11 μm&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Protein C</td>
<td>P</td>
<td>0.70–1.40</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.70–1.30</td>
</tr>
<tr>
<td>Protein S</td>
<td>P</td>
<td>0.70–1.40</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.65–1.40</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.70–1.40</td>
</tr>
<tr>
<td>Prothrombin time</td>
<td>P</td>
<td>12.7–15.4 s</td>
</tr>
<tr>
<td>Reticulocyte count</td>
<td>WB</td>
<td>0.008–0.023 red cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.008–0.020 red cells</td>
</tr>
<tr>
<td>Sickle cell test</td>
<td>WB</td>
<td>Negative</td>
</tr>
<tr>
<td>Thrombin time</td>
<td>P</td>
<td>15.3–18.5 s</td>
</tr>
<tr>
<td>Total eosinophils</td>
<td>WB</td>
<td>150–300 × 10&lt;sup&gt;6&lt;/sup&gt;/L</td>
</tr>
<tr>
<td>Viscosity</td>
<td>P</td>
<td>1.7–2.1</td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>1.4–1.8</td>
</tr>
</tbody>
</table>

<sup>a</sup>P, plasma; JF, joint fluid; PRP, platelet-rich plasma; S, serum; WB, whole blood.
<table>
<thead>
<tr>
<th>Analyte</th>
<th>Specimen&lt;sup&gt;a&lt;/sup&gt;</th>
<th>SI Units</th>
<th>Conventional Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetoacetate</td>
<td>P</td>
<td>20–99 μmol/L</td>
<td>0.2–1.0 mg/dL</td>
</tr>
<tr>
<td>Adrenocorticotropic (ACTH)</td>
<td>P</td>
<td>1.3–16.7 pmol/L</td>
<td>6.0–76.0 pg/mL</td>
</tr>
<tr>
<td>Alanine aminotransferase (AST, SGPT)</td>
<td>S</td>
<td>0.12–0.70 μkat/L</td>
<td>7–41 U/L</td>
</tr>
<tr>
<td>Albumin</td>
<td>S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td>41–53 g/L</td>
<td>4.1–5.3 g/dL</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>40–50 g/L</td>
<td>4.0–5.0 g/L</td>
</tr>
<tr>
<td>Aldolase</td>
<td>S</td>
<td>26–138 nkat/L</td>
<td>1.5–8.1 U/L</td>
</tr>
<tr>
<td>Aldosterone (adult)</td>
<td>S, P</td>
<td>55–250 pmol/L</td>
<td>2–9 ng/dL</td>
</tr>
<tr>
<td>Supine, normal sodium diet</td>
<td>S, P</td>
<td></td>
<td>2–5-fold increase over supine value</td>
</tr>
<tr>
<td>Upright, normal sodium diet</td>
<td>S, P</td>
<td></td>
<td>2–5-fold increase over normal sodium diet level</td>
</tr>
<tr>
<td>Supine, low-sodium diet</td>
<td>S, P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>U</td>
<td></td>
<td>6.38–58.25 nmol/d</td>
<td>2.3–21.0 μg/24 h</td>
</tr>
<tr>
<td>Alpha fetoprotein (adult)</td>
<td>S</td>
<td>0–8.5 μg/L</td>
<td>0–8.5 ng/mL</td>
</tr>
<tr>
<td>Alpha&lt;sub&gt;1&lt;/sub&gt; antitrypsin</td>
<td>S</td>
<td>1.0–2.0 g/L</td>
<td>100–200 mg/dL</td>
</tr>
<tr>
<td>Ammonia, as NH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>P</td>
<td>11–35 μmol/L</td>
<td>19–60 μg/dL</td>
</tr>
<tr>
<td>Amylase (method dependent)</td>
<td>S</td>
<td>0.34–1.6 μkat/L</td>
<td>20–96 U/L</td>
</tr>
<tr>
<td>Androstenedione (adult)</td>
<td>S</td>
<td>1.75–8.73 nmol/L</td>
<td>50–250 ng/dL</td>
</tr>
<tr>
<td>Angiotensin-converting enzyme (ACE)</td>
<td>S</td>
<td>0.15–1.1 μkat/L</td>
<td>9–67 U/L</td>
</tr>
<tr>
<td>Anion gap</td>
<td>S</td>
<td>7–16 mmol/L</td>
<td>7–16 mmol/L</td>
</tr>
<tr>
<td>Arterial blood gases</td>
<td>[HCO&lt;sub&gt;3&lt;/sub&gt;⁻]</td>
<td>22–30 mmol/L</td>
<td>22–30 meq/L</td>
</tr>
<tr>
<td>P&lt;sub&gt;CO₂&lt;/sub&gt;</td>
<td></td>
<td>4.3–6.0 kPa</td>
<td>32–45 mmHg</td>
</tr>
<tr>
<td>pH</td>
<td></td>
<td>7.35–7.45</td>
<td>7.35–7.45</td>
</tr>
<tr>
<td>P&lt;sub&gt;0₂&lt;/sub&gt;</td>
<td></td>
<td>9.6–13.8 kPa</td>
<td>72–104 mmHg</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Analyte</th>
<th>Specimen&lt;sup&gt;a&lt;/sup&gt;</th>
<th>SI Units</th>
<th>Conventional Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspartate aminotransferase (AST, SGOT)</td>
<td>S</td>
<td>0.20–0.65 μkat/L</td>
<td>12–38 U/L</td>
</tr>
<tr>
<td>B type natriuretic peptide (BNP)</td>
<td>P</td>
<td>Age and gender specific: &lt; 167 ng/L</td>
<td>Age and gender specific: &lt; 167 pg/mL</td>
</tr>
<tr>
<td>Bence Jones Protein, urine, quantitative</td>
<td>U</td>
<td>Kappa &lt;25 mg/L</td>
<td>&lt;2.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lambda &lt;50 mg/L</td>
<td>&lt;5.0 mg/dL</td>
</tr>
<tr>
<td>β&lt;sub&gt;2&lt;/sub&gt;-Microglobulin</td>
<td>S</td>
<td>&lt;2.7 mg/L</td>
<td>&lt;0.27 mg/dL</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>&lt;120 μg/d</td>
<td>&lt;120 μg/day</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>S</td>
<td>Total 5.1–22 μmol/L</td>
<td>0.3–1.3 mg/dL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct 1.7–6.8 μmol/L</td>
<td>0.1–0.4 mg/dL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Indirect 3.4–15.2 μmol/L</td>
<td>0.2–0.9 mg/dL</td>
</tr>
<tr>
<td>C peptide (adult)</td>
<td>S, P</td>
<td>0.17–0.66 nmol/L</td>
<td>0.5–2.0 ng/mL</td>
</tr>
<tr>
<td>C1-esterase-inhibitor protein</td>
<td>S</td>
<td>124–250 mg/L</td>
<td>12.4–24.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antigenic Present</td>
<td>Present</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Functional</td>
<td>Present</td>
</tr>
<tr>
<td>CA 125</td>
<td>S</td>
<td>0–35 kU/L</td>
<td>0–35 U/mL</td>
</tr>
<tr>
<td>CA 19-9</td>
<td>S</td>
<td>0–37 kU/L</td>
<td>0–37 U/mL</td>
</tr>
<tr>
<td>CA-15-3</td>
<td>S</td>
<td>0–34 kU/L</td>
<td>0–34 U/mL</td>
</tr>
<tr>
<td>CA27-29</td>
<td>S</td>
<td>0–40 kU/L</td>
<td>0–40 U/mL</td>
</tr>
<tr>
<td>Calcitonin</td>
<td>S</td>
<td>Male 3–26 ng/L</td>
<td>3–26 pg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female 2–17 ng/L</td>
<td>2–17 pg/mL</td>
</tr>
<tr>
<td>Calcium</td>
<td>S</td>
<td>2.2–2.6 mmol/L</td>
<td>8.7–10.2 mg/dL</td>
</tr>
<tr>
<td>Calcium, ionized</td>
<td>WB</td>
<td>1.12–1.32 mmol/L</td>
<td>4.5–5.3 mg/dL</td>
</tr>
<tr>
<td>Parameter</td>
<td>Range</td>
<td>Unit</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>----------------</td>
<td>---------------</td>
<td></td>
</tr>
<tr>
<td>Carbon dioxide content (TCO₂)</td>
<td>22–30 mmol/L</td>
<td>22–30 meq/L</td>
<td></td>
</tr>
<tr>
<td>Carboxyhemoglobin (carbon monoxide content)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonsmokers</td>
<td>0–0.04</td>
<td>0–4%</td>
<td></td>
</tr>
<tr>
<td>Smokers</td>
<td>0.04–0.09</td>
<td>4–9%</td>
<td></td>
</tr>
<tr>
<td>Onset of symptoms</td>
<td>0.15–0.20</td>
<td>15–20%</td>
<td></td>
</tr>
<tr>
<td>Loss of consciousness and death</td>
<td>&gt;0.50</td>
<td>&gt;50%</td>
<td></td>
</tr>
<tr>
<td>Carcinoembryonic antigen (CEA)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonsmokers</td>
<td>0.0–3.0 µg/L</td>
<td>0.0–3.0 ng/mL</td>
<td></td>
</tr>
<tr>
<td>Smokers</td>
<td>0.0–5.0 µg/L</td>
<td>0.0–5.0 ng/mL</td>
<td></td>
</tr>
<tr>
<td>Ceruloplasmin</td>
<td>250–630 mg/L</td>
<td>25–63 mg/dL</td>
<td></td>
</tr>
<tr>
<td>Chloride</td>
<td>102–109 mmol/L</td>
<td>102–109 meq/L</td>
<td></td>
</tr>
<tr>
<td>Cholesterol: see Table 218-5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C3</td>
<td>0.83–1.77 g/L</td>
<td>83–177 mg/dL</td>
<td></td>
</tr>
<tr>
<td>C4</td>
<td>0.16–0.47 g/L</td>
<td>16–47 mg/dL</td>
<td></td>
</tr>
<tr>
<td>Total hemolytic complement (CH50)</td>
<td>50–150%</td>
<td>50–150%</td>
<td></td>
</tr>
<tr>
<td>Factor B</td>
<td>0.17–0.42 g/L</td>
<td>17–42 mg/dL</td>
<td></td>
</tr>
<tr>
<td>Coproporphyrins (types I and III)</td>
<td>150–470 µmol/d</td>
<td>100–300 µg/d</td>
<td></td>
</tr>
<tr>
<td>Cortisol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting, 8 A.M.–12 noon</td>
<td>138–690 nmol/L</td>
<td>5–25 µg/dL</td>
<td></td>
</tr>
<tr>
<td>12 noon–8 P.M.</td>
<td>138–414 nmol/L</td>
<td>5–15 µg/dL</td>
<td></td>
</tr>
<tr>
<td>8 P.M.–8 A.M.</td>
<td>0–276 nmol/L</td>
<td>0–10 µg/dL</td>
<td></td>
</tr>
<tr>
<td>Cortisol, free</td>
<td>55–193 nmol/24 h</td>
<td>20–70 µg/24 h</td>
<td></td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>0.2–3.0 mg/L</td>
<td>0.2–3.0 mg/L</td>
<td></td>
</tr>
<tr>
<td>Creatine kinase (total)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>0.66–4.0 µkat/L</td>
<td>39–238 U/L</td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>0.87–5.0 µkat/L</td>
<td>51–294 U/L</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Analyte</th>
<th>Specimen</th>
<th>SI Units</th>
<th>Conventional Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatine kinase-MB</td>
<td>S</td>
<td>0.0–5.5 μg/L</td>
<td>0.0–5.5 ng/mL</td>
</tr>
<tr>
<td>Mass</td>
<td></td>
<td>0–0.04</td>
<td>0–4.0%</td>
</tr>
<tr>
<td>Fraction of total activity (by electrophoresis)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>S</td>
<td>44–80 μmol/L</td>
<td>0.5–0.9 ng/mL</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td>53–106 μmol/L</td>
<td>0.6–1.2 ng/mL</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dehydroepiandrosterone (DHEA) (adult)</td>
<td>S</td>
<td>6.2–43.4 nmol/L</td>
<td>180–1250 ng/dL</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>4.5–34.0 nmol/L</td>
<td>130–980 ng/dL</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dehydroepiandrosterone (DHEA) sulfate</td>
<td>S</td>
<td>100–6190 μg/L</td>
<td>10–619 μg/dL</td>
</tr>
<tr>
<td>Male (adult)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female (adult, premenopausal)</td>
<td></td>
<td>120–5350 μg/L</td>
<td>12–535 μg/dL</td>
</tr>
<tr>
<td>Female (adult, postmenopausal)</td>
<td></td>
<td>300–2600 μg/L</td>
<td>30–260 μg/dL</td>
</tr>
<tr>
<td>Deoxycorticosterone (DOC) (adult)</td>
<td>S</td>
<td>61–576 nmol/L</td>
<td>2–19 ng/dL</td>
</tr>
<tr>
<td>11-Deoxycortisol (adult) (compound S) (8:00 A.M.)</td>
<td>S</td>
<td>0.34–4.56 nmol/L</td>
<td>12–158 ng/dL</td>
</tr>
<tr>
<td>Dihydrotestosterone</td>
<td>S, P</td>
<td>1.03–2.92 nmol/L</td>
<td>30–85 ng/dL</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>0.14–0.76 nmol/L</td>
<td>4–22 ng/dL</td>
</tr>
<tr>
<td>Female</td>
<td>P</td>
<td>&lt; 475 pmol/L</td>
<td>&lt; 87 pg/mL</td>
</tr>
<tr>
<td>Dopamine</td>
<td>U</td>
<td>425–2610 nmol/d</td>
<td>65–400 μg/d</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>P</td>
<td>Supine (30 min) &lt; 273 pmol/L</td>
<td>&lt; 50 pg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sitting &lt; 328 pmol/L</td>
<td>&lt; 60 pg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Standing (30 min) &lt; 491 pmol/L</td>
<td>&lt; 90 pg/mL</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>0–109 nmol/d</td>
<td>0–20 μg/d</td>
</tr>
<tr>
<td>Test</td>
<td>Normal Range</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythropoietin</td>
<td>S, P 4–27 U/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estradiol</td>
<td>S, P 4–27 U/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Menstruating:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follicular phase</td>
<td>74–532 pmol/L &lt;20–145 pg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mid-cycle peak</td>
<td>411–1626 pmol/L 112–443 pg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luteal phase</td>
<td>74–885 pmol/L 20–241 pg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>217 pmol/L 59 pg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>74 pmol/L 20 pg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estrone</td>
<td>S, P</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Menstruating:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follicular phase</td>
<td>55–555 pmol/L 15–150 pg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luteal phase</td>
<td>55–740 pmol/L 15–200 pg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>55–204 pmol/L 15–55 pg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>55–240 pmol/L 15–65 pg/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatty acids, free (nonesterified)</td>
<td>P &lt;0.28–0.89 mmol/L &lt;8–25 mg/dL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferritin</td>
<td>S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>10–150 μg/L 10–150 ng/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>29–248 μg/L 29–248 ng/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follicle stimulating hormone (FSH)</td>
<td>S, P</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Menstruating:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follicular phase</td>
<td>3.0–20.0 IU/L 3.0–20.0 mIU/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovulatory phase</td>
<td>9.0–26.0 IU/L 9.0–26.0 mIU/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luteal phase</td>
<td>1.0–12.0 IU/L 1.0–12.0 mIU/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>18.0–153.0 IU/L 18.0–153.0 mIU/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1.0–12.0 IU/L 1.0–12.0 mIU/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analyte</td>
<td>Specimen</td>
<td>SI Units</td>
<td>Conventional Units</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>----------</td>
<td>---------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Free testosterone, adult</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>S</td>
<td>2.1–23.6 pmol/L</td>
<td>0.6–6.8 pg/mL</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>163–847 pmol/L</td>
<td>47–244 pg/mL</td>
</tr>
<tr>
<td>Fructosamine</td>
<td>S</td>
<td>&lt;285 μmol/L</td>
<td>&lt;285 μmol/L</td>
</tr>
<tr>
<td>Gamma glutamyltransferase</td>
<td>S</td>
<td>0.15–0.99 μkat/L</td>
<td>9–58 U/L</td>
</tr>
<tr>
<td>Gastrin</td>
<td>S</td>
<td>&lt;100 ng/L</td>
<td>&lt;100 pg/mL</td>
</tr>
<tr>
<td>Glucagon</td>
<td>P</td>
<td>20–100 ng/L</td>
<td>20–100 pg/mL</td>
</tr>
<tr>
<td>Glucose (fasting)</td>
<td>P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td>4.2–6.1 mmol/L</td>
<td>75–110 mg/dL</td>
</tr>
<tr>
<td>Impaired glucose tolerance</td>
<td></td>
<td>6.2–6.9 mmol/L</td>
<td>111–125 mg/dL</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td></td>
<td>&gt;7.0 mmol/L</td>
<td>&gt;125 mg/dL</td>
</tr>
<tr>
<td>Glucose, 2 h postprandial</td>
<td>P</td>
<td>3.9–6.7 mmol/L</td>
<td>70–120 mg/dL</td>
</tr>
<tr>
<td>Growth hormone (resting)</td>
<td>S</td>
<td>0.5–17.0 μg/L</td>
<td>0.5–17.0 ng/mL</td>
</tr>
<tr>
<td>Hemoglobin Alc</td>
<td>WB</td>
<td>0.04–0.06 Hb fraction</td>
<td>4.0–6.0%</td>
</tr>
<tr>
<td>High-density lipoprotein (HDL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homocysteine</td>
<td>P</td>
<td>4.4–10.8 μmol/L</td>
<td>4.4–10.8 μmol/L</td>
</tr>
<tr>
<td>Human chorionic gonadotropin (hCG)</td>
<td>S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-pregnant female</td>
<td></td>
<td>&lt; 5 IU/L</td>
<td>&lt; 5 mIU/mL</td>
</tr>
<tr>
<td>1–2 weeks postconception</td>
<td></td>
<td>9–130 IU/L</td>
<td>9–130 mIU/mL</td>
</tr>
<tr>
<td>2–3 weeks postconception</td>
<td></td>
<td>75–2600 IU/L</td>
<td>75–2600 mIU/mL</td>
</tr>
<tr>
<td>3–4 weeks postconception</td>
<td></td>
<td>850–20,800 IU/L</td>
<td>850–20,800 mIU/mL</td>
</tr>
<tr>
<td>4–5 weeks postconception</td>
<td></td>
<td>4000–100,200 IU/L</td>
<td>4000–100,200 mIU/mL</td>
</tr>
<tr>
<td>5–10 weeks postconception</td>
<td></td>
<td>11,500–289,000 IU/L</td>
<td>11,500–289,000 mIU/mL</td>
</tr>
<tr>
<td>10–14 weeks postconception</td>
<td></td>
<td>18,300–137,000 IU/L</td>
<td>18,300–137,000 mIU/mL</td>
</tr>
<tr>
<td>Second trimester</td>
<td></td>
<td>1400–53,000 IU/L</td>
<td>1400–53,000 mIU/mL</td>
</tr>
<tr>
<td>Third trimester</td>
<td></td>
<td>940–60,000 IU/L</td>
<td>940–60,000 mIU/mL</td>
</tr>
<tr>
<td><strong>β-Hydroxybutyrate</strong></td>
<td><strong>P</strong></td>
<td>0–290 μmol/L</td>
<td>0–3 mg/dL</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------</td>
<td>---------------</td>
<td>-----------</td>
</tr>
<tr>
<td><strong>5-Hydroindoleacetic acid [5-HIAA]</strong></td>
<td><strong>U</strong></td>
<td>10.5–36.6 μmol/d</td>
<td>2–7 mg/d</td>
</tr>
<tr>
<td><strong>17-Hydroxyprogesterone (adult)</strong></td>
<td><strong>S</strong></td>
<td>0.15–7.5 nmol/L</td>
<td>5–250 ng/dL</td>
</tr>
<tr>
<td><strong>Male</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Female</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follicular phase</td>
<td></td>
<td>0.6–3.0 nmol/L</td>
<td>20–100 ng/dL</td>
</tr>
<tr>
<td>Midcycle peak</td>
<td></td>
<td>3–7.5 nmol/L</td>
<td>100–250 ng/dL</td>
</tr>
<tr>
<td>Luteal phase</td>
<td></td>
<td>3–15 nmol/L</td>
<td>100–500 ng/dL</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td></td>
<td>≤ 2.1 nmol/L</td>
<td>≤ 70 ng/dL</td>
</tr>
<tr>
<td><strong>Hydroxyproline</strong></td>
<td><strong>U, 24 hour</strong></td>
<td>38–500 μmol/d</td>
<td>38–500 μmol/d</td>
</tr>
<tr>
<td><strong>Immunofixation</strong></td>
<td><strong>S</strong></td>
<td>Not applicable</td>
<td>No bands detected</td>
</tr>
<tr>
<td><strong>Immunoglobulin, quantitation (adult)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgA</td>
<td><strong>S</strong></td>
<td>0.70–3.50 g/L</td>
<td>70–350 mg/dL</td>
</tr>
<tr>
<td>IgD</td>
<td><strong>S</strong></td>
<td>0–140 mg/L</td>
<td>0–14 mg/dL</td>
</tr>
<tr>
<td>IgE</td>
<td><strong>S</strong></td>
<td>24–430 μg/L</td>
<td>10–179 IU/mL</td>
</tr>
<tr>
<td>IgG</td>
<td><strong>S</strong></td>
<td>7.0–17.0 g/L</td>
<td>700–1700 mg/dL</td>
</tr>
<tr>
<td>IgG1</td>
<td><strong>S</strong></td>
<td>2.7–17.4 g/L</td>
<td>270–1740 mg/dL</td>
</tr>
<tr>
<td>IgG2</td>
<td><strong>S</strong></td>
<td>0.3–6.3 g/L</td>
<td>30–630 mg/dL</td>
</tr>
<tr>
<td>IgG3</td>
<td><strong>S</strong></td>
<td>0.13–3.2 g/L</td>
<td>13–320 mg/dL</td>
</tr>
<tr>
<td>IgG4</td>
<td><strong>S</strong></td>
<td>0.11–6.2 g/L</td>
<td>11–620 mg/dL</td>
</tr>
<tr>
<td>IgM</td>
<td><strong>S</strong></td>
<td>0.50–3.0 g/L</td>
<td>50–300 mg/dL</td>
</tr>
<tr>
<td><strong>Insulin</strong></td>
<td><strong>S, P</strong></td>
<td>14.35–143.5 pmol/L</td>
<td>2–20 μU/mL</td>
</tr>
<tr>
<td><strong>Iron</strong></td>
<td><strong>S</strong></td>
<td>7–25 μmol/L</td>
<td>41–141 μg/dL</td>
</tr>
<tr>
<td><strong>Iron-binding capacity</strong></td>
<td><strong>S</strong></td>
<td>45–73 μmol/L</td>
<td>251–406 μg/dL</td>
</tr>
<tr>
<td><strong>Iron-binding capacity saturation</strong></td>
<td><strong>S</strong></td>
<td>0.16–0.35</td>
<td>16–35%</td>
</tr>
<tr>
<td><strong>Ketone (acetone)</strong></td>
<td><strong>S, U</strong></td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td><strong>17 Ketosteroids</strong></td>
<td><strong>U</strong></td>
<td>0.003–0.012 g/d</td>
<td>3–12 mg/d</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Analyte</th>
<th>Specimen</th>
<th>SI Units</th>
<th>Conventional Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactate</td>
<td>P, arterial</td>
<td>0.5–1.6 mmol/L</td>
<td>4.5–14.4 mg/dL</td>
</tr>
<tr>
<td>Lactate</td>
<td>P, venous</td>
<td>0.5–2.2 mmol/L</td>
<td>4.5–19.8 mg/dL</td>
</tr>
<tr>
<td>Lactate dehydrogenase</td>
<td>S</td>
<td>2.0–3.8 μkat/L</td>
<td>115–221 U/L</td>
</tr>
<tr>
<td>Lactate dehydrogenase isoenzymes</td>
<td>S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fraction 1 (of total)</td>
<td></td>
<td>0.14–0.26</td>
<td>14–26%</td>
</tr>
<tr>
<td>Fraction 2</td>
<td></td>
<td>0.29–0.39</td>
<td>29–39%</td>
</tr>
<tr>
<td>Fraction 3</td>
<td></td>
<td>0.20–0.25</td>
<td>20–26%</td>
</tr>
<tr>
<td>Fraction 4</td>
<td></td>
<td>0.08–0.16</td>
<td>8–16%</td>
</tr>
<tr>
<td>Fraction 5</td>
<td></td>
<td>0.06–0.16</td>
<td>6–16%</td>
</tr>
<tr>
<td>Lipase (method dependent)</td>
<td>S</td>
<td>0.51–0.73 μkat/L</td>
<td>3–43 U/L</td>
</tr>
<tr>
<td>Lipids: see Table 218-5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipoprotein (a)</td>
<td>S</td>
<td>0–300 mg/L</td>
<td>0–30 mg/dL</td>
</tr>
<tr>
<td>Low-density lipoprotein (LDL) (see Table 218-5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luteinizing hormone (LH)</td>
<td>S, P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Menstruating</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follicular phase</td>
<td></td>
<td>2.0–15.0 U/L</td>
<td>2.0–15.0 U/L</td>
</tr>
<tr>
<td>Ovulatory phase</td>
<td></td>
<td>22.0–105.0 U/L</td>
<td>22.0–105.0 U/L</td>
</tr>
<tr>
<td>Luteal phase</td>
<td></td>
<td>0.6–19.0 U/L</td>
<td>0.6–19.0 U/L</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td></td>
<td>16.0–64.0 U/L</td>
<td>16.0–64.0 U/L</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>2.0–12.0 U/L</td>
<td>2.0–12.0 U/L</td>
</tr>
<tr>
<td>Magnesium</td>
<td>S</td>
<td>0.62–0.95 mmol/L</td>
<td>1.5–2.3 mg/dL</td>
</tr>
<tr>
<td>Metanephrine</td>
<td>P</td>
<td>&lt;0.5 nmol/L</td>
<td>&lt;100 pg/mL</td>
</tr>
<tr>
<td>Metanephrine</td>
<td>U</td>
<td>30–211 mmol/mol creatinine</td>
<td>53–367 μg/g creatinine</td>
</tr>
<tr>
<td>Methemoglobin</td>
<td>WB</td>
<td>0.0–0.01</td>
<td>0–1%</td>
</tr>
<tr>
<td>Test</td>
<td>Measurement</td>
<td>Normal Range</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>-------------</td>
<td>--------------------------</td>
<td></td>
</tr>
<tr>
<td>Microalbumin urine</td>
<td>U</td>
<td>0.0–0.03 g/d</td>
<td></td>
</tr>
<tr>
<td>24-h urine</td>
<td></td>
<td>0.0–0.03 g/g creatinine</td>
<td></td>
</tr>
<tr>
<td>Spot urine</td>
<td></td>
<td>0–30 mg/24 h</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0–30 µg/mg creatinine</td>
<td></td>
</tr>
<tr>
<td>Myoglobin</td>
<td>S</td>
<td>Male: 19–92 µg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female: 12–76 µg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>19–92 µg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>12–76 µg/L</td>
<td></td>
</tr>
<tr>
<td>Norepinephrine</td>
<td>U</td>
<td>Male: 89–473 nmol/d</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>15–80 µg/d</td>
<td></td>
</tr>
<tr>
<td>Norepinephrine</td>
<td>P</td>
<td>Supine (30 min): 650–2423 pmol/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sitting: 709–4019 pmol/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Standing (30 min): 739–4137 pmol/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>110–410 pg/mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>120–680 pg/mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>125–700 pg/mL</td>
<td></td>
</tr>
<tr>
<td>N-telopeptide (cross linked), NTx</td>
<td>S</td>
<td>Female, premenopausal: 6.2–19.0 nmol BCE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Male: 5.4–24.2 nmol BCE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6.2–19.0 nmol BCE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5.4–24.2 nmol BCE</td>
<td></td>
</tr>
<tr>
<td>N-telopeptide (cross linked), NTx</td>
<td>U</td>
<td>Female, premenopausal: 17–94 nmol BCE/mmol creatinine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Male: 26–124 nmol BCE/mmol creatinine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>21–83 nmol BCE/mmol creatinine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>17–94 nmol BCE/mmol creatinine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>26–124 nmol BCE/mmol creatinine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>21–83 nmol BCE/mmol creatinine</td>
<td></td>
</tr>
<tr>
<td>5′ Nucleotidase</td>
<td>S</td>
<td>Male: 0.02–0.19 µkat/L</td>
<td></td>
</tr>
<tr>
<td>Osmolality</td>
<td>P</td>
<td>275–295 mOsmol/kg serum water</td>
<td></td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>500–800 mOsmol/kg water</td>
<td></td>
</tr>
<tr>
<td>Osteocalcin</td>
<td>S</td>
<td>11–50 µg/L</td>
<td></td>
</tr>
<tr>
<td>Oxygen content</td>
<td>WB</td>
<td>17–21</td>
<td></td>
</tr>
<tr>
<td>Arterial (sea level)</td>
<td></td>
<td>17–21 vol%</td>
<td></td>
</tr>
<tr>
<td>Venous (sea level)</td>
<td></td>
<td>10–16</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10–16 vol%</td>
<td></td>
</tr>
<tr>
<td>Analyte</td>
<td>Specimen</td>
<td>SI Units</td>
<td>Conventional Units</td>
</tr>
<tr>
<td>----------------------------------------------------</td>
<td>----------</td>
<td>-------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Oxygen percent saturation (sea level)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial</td>
<td>WB</td>
<td>0.97</td>
<td>94–100%</td>
</tr>
<tr>
<td>Venous, arm</td>
<td></td>
<td>0.60–0.85</td>
<td>60–85%</td>
</tr>
<tr>
<td>Parathyroid hormone (intact)</td>
<td>S</td>
<td>8–51 ng/L</td>
<td>8–51 pg/mL</td>
</tr>
<tr>
<td>Phosphatase, alkaline</td>
<td>S</td>
<td>0.56–1.63 μkat/L</td>
<td>33–96 U/L</td>
</tr>
<tr>
<td>Phosphorus, inorganic</td>
<td>S</td>
<td>0.81–1.4 mmol/L</td>
<td>2.5–4.3 mg/dL</td>
</tr>
<tr>
<td>Forphobilinogen</td>
<td>U</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Potassium</td>
<td>S</td>
<td>3.5–5.0 mmol/L</td>
<td>3.5–5.0 meq/L</td>
</tr>
<tr>
<td>Prealbumin</td>
<td>S</td>
<td>170–340 mg/L</td>
<td>17–34 mg/dL</td>
</tr>
<tr>
<td>Progesterone</td>
<td>S, P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follicular</td>
<td></td>
<td>&lt;3.18 nmol/L</td>
<td>&lt;1.0 ng/mL</td>
</tr>
<tr>
<td>Midluteal</td>
<td></td>
<td>9.54–63.6 nmol/L</td>
<td>3–20 ng/mL</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>&lt;3.18 nmol/L</td>
<td>&lt;1.0 ng/mL</td>
</tr>
<tr>
<td>Prolactin</td>
<td>S</td>
<td>0–20 μg/L</td>
<td>0–20 ng/mL</td>
</tr>
<tr>
<td>Prostate-specific antigen (PSA)</td>
<td>S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;40 years</td>
<td></td>
<td>0.0–2.0 μg/L</td>
<td>0.0–2.0 ng/mL</td>
</tr>
<tr>
<td>&gt;40 years</td>
<td></td>
<td>0.0–4.0 μg/L</td>
<td>0.0–4.0 ng/mL</td>
</tr>
<tr>
<td>PSA, free; in males 45–75 years, with PSA values between 4 and 20 μg/mL</td>
<td>S</td>
<td>&gt;0.25 associated with benign prostatic hyperplasia</td>
<td>&gt;25% associated with benign prostatic hyperplasia</td>
</tr>
<tr>
<td>Protein fractions</td>
<td>S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td></td>
<td>35–55 g/L</td>
<td>3.5–5.5 g/dL (50–60%)</td>
</tr>
<tr>
<td>Globulin</td>
<td></td>
<td>20–35 g/L</td>
<td>2.0–3.5 g/dL (40–50%)</td>
</tr>
<tr>
<td>Alpha₁</td>
<td></td>
<td>2–4 g/L</td>
<td>0.2–0.4 g/dL (4.2–7.2%)</td>
</tr>
<tr>
<td>Parameter</td>
<td>Unit</td>
<td>Normal Range</td>
<td>Reference Range</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------</td>
<td>--------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td><strong>Alpha2</strong></td>
<td></td>
<td>5–9 g/L</td>
<td>0.5–0.9 g/dL (6.8–12%)</td>
</tr>
<tr>
<td><strong>Beta</strong></td>
<td></td>
<td>6–11 g/L</td>
<td>0.6–1.1 g/dL (9.3–15%)</td>
</tr>
<tr>
<td><strong>Gamma</strong></td>
<td></td>
<td>7–17 g/L</td>
<td>0.7–1.7 g/dL (13–23%)</td>
</tr>
<tr>
<td><strong>Protein, total</strong></td>
<td>S</td>
<td>67–86 g/L</td>
<td>6.7–8.6 g/dL</td>
</tr>
<tr>
<td><strong>Pyruvate</strong></td>
<td>P, arterial</td>
<td>40–130 μmol/L</td>
<td>0.35–1.14 mg/dL</td>
</tr>
<tr>
<td><strong>Rheumatoid factor</strong></td>
<td>S, JF</td>
<td>&lt;30 kIU/L</td>
<td>&lt;30 IU/mL</td>
</tr>
<tr>
<td><strong>Serotonin</strong></td>
<td>WB</td>
<td>0.28–1.14 μmol/L</td>
<td>50–200 ng/mL</td>
</tr>
<tr>
<td><strong>Sex hormone binding globulin (adult)</strong></td>
<td></td>
<td>Male: 13–71 nmol/L</td>
<td>13–71 nmol/L</td>
</tr>
<tr>
<td><strong>Sodium</strong></td>
<td></td>
<td>Female: 18–114 nmol/L</td>
<td>18–114 nmol/L</td>
</tr>
<tr>
<td><strong>Somatomedin-C (IGF-1) (adult)</strong></td>
<td></td>
<td>Male: 136–146 mmol/L</td>
<td>136–146 meq/L</td>
</tr>
<tr>
<td><strong>Somatostatin</strong></td>
<td>P</td>
<td>&lt;25 ng/L</td>
<td>&lt;25 pg/mL</td>
</tr>
<tr>
<td><strong>Testosterone, total, morning sample</strong></td>
<td>S</td>
<td>Female: 0.21–2.98 nmol/L</td>
<td>6–86 ng/dL</td>
</tr>
<tr>
<td><strong>Thyroglobulin</strong></td>
<td>S</td>
<td>Male: 9.36–37.10 nmol/L</td>
<td>270–1070 ng/dL</td>
</tr>
<tr>
<td><strong>Thyroid-binding globulin</strong></td>
<td>S</td>
<td>0.5–53 μg/L</td>
<td>0.5–53 mg/mL</td>
</tr>
<tr>
<td><strong>Thyroid-stimulating hormone</strong></td>
<td></td>
<td>13–30 mg/L</td>
<td>1.3–3.0 mg/dL</td>
</tr>
<tr>
<td><strong>Thyroxine, free (FT3)</strong></td>
<td>S</td>
<td>0.34–4.25 mIU/L</td>
<td>0.34–4.25 μIU/mL</td>
</tr>
<tr>
<td><strong>Thyroxine, total (T4)</strong></td>
<td>S</td>
<td>10.3–21.9 pmol/L</td>
<td>0.8–1.7 ng/dL</td>
</tr>
<tr>
<td><strong>(Free) thyroxine index</strong></td>
<td>S</td>
<td>70–151 nmol/L</td>
<td>5.4–11.7 μg/dL</td>
</tr>
<tr>
<td><strong>Transferrin</strong></td>
<td>S</td>
<td>6.7–10.9</td>
<td>6.7–10.9</td>
</tr>
<tr>
<td><strong>Thyroxine, total (T4)</strong></td>
<td>S</td>
<td>2.0–4.0 g/L</td>
<td>200–400 mg/dL</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Analyte</th>
<th>Specimen</th>
<th>SI Units</th>
<th>Conventional Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triglycerides (see Table 218-5)</td>
<td>S</td>
<td>0.34–2.26 mmol/L</td>
<td>30–200 mg/dL</td>
</tr>
<tr>
<td>Triiodothyronine, free (fT3)</td>
<td>S</td>
<td>3.7–6.5 pmol/L</td>
<td>2.4–4.2 pg/mL</td>
</tr>
<tr>
<td>Triiodothyronine, total (T3)</td>
<td>S</td>
<td>1.2–2.1 nmol/L</td>
<td>77–135 ng/dL</td>
</tr>
<tr>
<td>Troponin I</td>
<td>S</td>
<td>Normal population, 99 %tile 0–0.08 μg/L</td>
<td>0–0.08 ng/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cut-off for MI  &gt;0.4 μg/L.</td>
<td>&gt;0.4 ng/mL</td>
</tr>
<tr>
<td>Troponin T</td>
<td>S</td>
<td>Normal population, 99 %tile 0–0.1 μg/L.</td>
<td>0–0.01 ng/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cut-off for MI  &gt;0.1 μg/L.</td>
<td>0–0.1 ng/mL</td>
</tr>
<tr>
<td>Urea nitrogen</td>
<td>S</td>
<td>2.5–7.1 mmol/L</td>
<td>7–20 mg/dL</td>
</tr>
<tr>
<td>Uric acid</td>
<td>S</td>
<td>Females 0.15–0.33 μmol/L</td>
<td>2.5–5.6 mg/dL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Males 0.18–0.41 μmol/L</td>
<td>3.1–7.0 mg/dL</td>
</tr>
<tr>
<td>Urobilinogen</td>
<td>U</td>
<td>0.09–4.2 μmol/d</td>
<td>0.05–25 mg/24 h</td>
</tr>
<tr>
<td>Vanillylmandelic acid (VMA)</td>
<td>U, 24h</td>
<td>&lt;30 μmol/d</td>
<td>&lt;6 mg/d</td>
</tr>
<tr>
<td>Vasoactive intestinal polypeptide</td>
<td>P</td>
<td>0–60 ng/L</td>
<td>0–60 pg/mL</td>
</tr>
</tbody>
</table>

*aP, plasma; S, serum; U, urine; WB, whole blood; JF, joint fluid.*
<table>
<thead>
<tr>
<th>Drug</th>
<th>Therapeutic Range</th>
<th>Toxic Level</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SI Units</td>
<td>Conventional Units</td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>66–199 μmol/L</td>
<td>10–30 μg/mL</td>
</tr>
<tr>
<td>Amikacin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peak</td>
<td>34–51 μmol/L</td>
<td>20–30 μg/mL</td>
</tr>
<tr>
<td>Trough</td>
<td>0–17 μmol/L</td>
<td>0–10 μg/mL</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>17–42 μmol/L</td>
<td>4–10 μg/mL</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal transplant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–6 months</td>
<td>208–312 nmol/L</td>
<td>250–375 ng/mL</td>
</tr>
<tr>
<td>6–12 months</td>
<td>166–250 nmol/L</td>
<td>200–300 ng/mL</td>
</tr>
<tr>
<td>&gt;12 months</td>
<td>83–125 nmol/L</td>
<td>100–150 ng/mL</td>
</tr>
<tr>
<td>Cardiac transplant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–6 months</td>
<td>208–291 nmol/L</td>
<td>250–350 ng/mL</td>
</tr>
<tr>
<td>6–12 months</td>
<td>125–208 nmol/L</td>
<td>150–250 ng/mL</td>
</tr>
<tr>
<td>&gt;12 months</td>
<td>83–125 nmol/L</td>
<td>100–150 ng/mL</td>
</tr>
<tr>
<td>Lung transplant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–6 months</td>
<td>250–374 nmol/L</td>
<td>300–450 ng/mL</td>
</tr>
<tr>
<td>Liver transplant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–7 days</td>
<td>249–333 nmol/L</td>
<td>300–400 ng/mL</td>
</tr>
<tr>
<td>2–4 weeks</td>
<td>208–291 nmol/L</td>
<td>250–350 ng/mL</td>
</tr>
<tr>
<td>5–8 weeks</td>
<td>166–249 nmol/L</td>
<td>200–300 ng/mL</td>
</tr>
<tr>
<td>9–52 weeks</td>
<td>125–208 nmol/L</td>
<td>150–250 ng/mL</td>
</tr>
<tr>
<td>&gt;1 year</td>
<td>83–166 nmol/L</td>
<td>100–200 ng/mL</td>
</tr>
<tr>
<td>Digoxin</td>
<td>0.64–2.6 nmol/L</td>
<td>0.5–2.0 ng/mL</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Drug</th>
<th>Therapeutic Range</th>
<th>Toxic Level</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ethanol</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Behavioral changes</td>
<td>SI Units</td>
<td>Conventional Units</td>
</tr>
<tr>
<td></td>
<td>&gt;4.3 mmol/L</td>
<td>&gt;20 mg/dL</td>
</tr>
<tr>
<td>Legal limit</td>
<td>≥17 mmol/L</td>
<td>≥80 mg/dL</td>
</tr>
<tr>
<td>Critical with acute exposure</td>
<td>&gt;54 mmol/L</td>
<td>&gt;250 mg/dL</td>
</tr>
<tr>
<td><strong>Ethylene glycol</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toxic</td>
<td>SI Units</td>
<td>Conventional Units</td>
</tr>
<tr>
<td></td>
<td>&gt;2 mmol/L</td>
<td>&gt;12 mg/dL</td>
</tr>
<tr>
<td>Lethal</td>
<td>&gt;20 mmol/L</td>
<td>&gt;120 mg/dL</td>
</tr>
<tr>
<td><strong>Gentamicin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peak</td>
<td>SI Units</td>
<td>Conventional Units</td>
</tr>
<tr>
<td></td>
<td>10–21 μmol/mL</td>
<td>5–10 μg/mL</td>
</tr>
<tr>
<td>Trough</td>
<td>0–4.2 μmol/mL</td>
<td>0–2 μg/mL</td>
</tr>
<tr>
<td>Lithium</td>
<td>SI Units</td>
<td>Conventional Units</td>
</tr>
<tr>
<td></td>
<td>0.5–1.3 mmol/L</td>
<td>0.5–1.3 meq/L</td>
</tr>
<tr>
<td>Methadone</td>
<td>SI Units</td>
<td>Conventional Units</td>
</tr>
<tr>
<td></td>
<td>1.3–3.2 μmol/L</td>
<td>0.4–1.0 μg/mL</td>
</tr>
<tr>
<td>Methamphetamine</td>
<td>SI Units</td>
<td>Conventional Units</td>
</tr>
<tr>
<td></td>
<td>1.3–4.0 μmol/L</td>
<td>2–6 μg/dL</td>
</tr>
<tr>
<td></td>
<td>4.0–33.5 μmol/L</td>
<td>60–500–1.0 μg/dL, toxic</td>
</tr>
<tr>
<td></td>
<td>67.0–268.0 μmol/L</td>
<td>1000–4000 μg/dL, lethal</td>
</tr>
<tr>
<td><strong>Methanol</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toxic</td>
<td>SI Units</td>
<td>Conventional Units</td>
</tr>
<tr>
<td></td>
<td>&gt;6 mmol/L</td>
<td>&gt;20 mg/dL, toxic</td>
</tr>
<tr>
<td></td>
<td>&gt;16 mmol/L</td>
<td>&gt;50 mg/dL, severe toxicity</td>
</tr>
<tr>
<td></td>
<td>&gt;28 mmol/L</td>
<td>&gt;89 mg/dL, lethal</td>
</tr>
<tr>
<td><strong>Phenobarbital</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SI Units</td>
<td>65–172 μmol/L</td>
<td>15–40 μg/mL</td>
</tr>
<tr>
<td></td>
<td>40–79 μmol/L</td>
<td>10–20 μg/mL</td>
</tr>
<tr>
<td>Phenyoitoin</td>
<td>SI Units</td>
<td>Conventional Units</td>
</tr>
<tr>
<td></td>
<td>&gt;215 μmol/L</td>
<td>&gt;50 μg/mL</td>
</tr>
<tr>
<td></td>
<td>&gt;118 μmol/L</td>
<td>&gt;30 μg/mL</td>
</tr>
<tr>
<td>Phenyoitoin, free %</td>
<td>SI Units</td>
<td>Conventional Units</td>
</tr>
<tr>
<td></td>
<td>&gt;13.9 μmol/L</td>
<td>&gt;3.5 μg/mL</td>
</tr>
<tr>
<td>% Free</td>
<td>4.0–7.9 μmol/L</td>
<td>1–2 μg/mL</td>
</tr>
<tr>
<td></td>
<td>0.08–0.14</td>
<td>8–14%</td>
</tr>
<tr>
<td>Salicylates</td>
<td>SI Units</td>
<td>Conventional Units</td>
</tr>
<tr>
<td></td>
<td>145–2100 μmol/L</td>
<td>2–29 mg/dL</td>
</tr>
<tr>
<td></td>
<td>&gt;2172 μmol/L</td>
<td>&gt;30 mg/dL</td>
</tr>
<tr>
<td></td>
<td>&gt;1.3 mmol/L</td>
<td>0.5–1.3 meq/L</td>
</tr>
<tr>
<td>Drug</td>
<td>Concentration</td>
<td>Kidney transplant</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td><strong>Sirolimus (trough level)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney transplant</td>
<td>4.4–13.1 nmol/L</td>
<td>4–12 ng/mL</td>
</tr>
<tr>
<td><strong>Tacrolimus (FK506) (trough)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney and liver</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–2 months posttransplant</td>
<td>12–19 nmol/L</td>
<td>10–15 ng/mL</td>
</tr>
<tr>
<td>&gt; 2 months posttransplant</td>
<td>6–12 nmol/L</td>
<td>5–10 ng/mL</td>
</tr>
<tr>
<td><strong>Heart</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–2 months posttransplant</td>
<td>19–25 nmol/L</td>
<td>15–20 ng/mL</td>
</tr>
<tr>
<td>3–6 months posttransplant</td>
<td>12–19 nmol/L</td>
<td>10–15 ng/mL</td>
</tr>
<tr>
<td>&gt;6 months posttransplant</td>
<td>10–12 nmol/L</td>
<td>8–10 ng/mL</td>
</tr>
<tr>
<td><strong>Theophylline</strong></td>
<td>56–111 μmol/L</td>
<td>10–20 μg/mL</td>
</tr>
<tr>
<td><strong>Tobramycin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peak</td>
<td>11–22 μmol/L</td>
<td>5–10 μg/mL</td>
</tr>
<tr>
<td>Trough</td>
<td>0–4.3 μmol/L</td>
<td>0–2 μg/mL</td>
</tr>
<tr>
<td><strong>Valproic acid</strong></td>
<td>350–700 μmol/L</td>
<td>50–100 μg/mL</td>
</tr>
<tr>
<td><strong>Vancomycin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peak</td>
<td>14–28 μmol/L</td>
<td>20–40 μg/mL</td>
</tr>
<tr>
<td>Trough</td>
<td>3.5–10.4 μmol/L</td>
<td>5–15 μg/mL</td>
</tr>
<tr>
<td>Specimen</td>
<td>Analyte</td>
<td>SI Units</td>
</tr>
<tr>
<td>---------------</td>
<td>---------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Aluminum</td>
<td>S</td>
<td>&lt;0.2 μmol/L</td>
</tr>
<tr>
<td></td>
<td>U, random</td>
<td>0.19–1.11 μmol/L</td>
</tr>
<tr>
<td>Arsenic</td>
<td>WB</td>
<td>0.03–0.31 μmol/L</td>
</tr>
<tr>
<td></td>
<td>U, 24 h</td>
<td>0.07–0.67 μmol/d</td>
</tr>
<tr>
<td>Cadmium</td>
<td>WB</td>
<td>&lt;44.5 nmol/L</td>
</tr>
<tr>
<td>Coenzyme Q10</td>
<td>P</td>
<td>433–1532 μg/L</td>
</tr>
<tr>
<td>β carotene</td>
<td>S</td>
<td>0.07–1.43 μmol/L</td>
</tr>
<tr>
<td>Copper</td>
<td>S</td>
<td>11–22 μmol/L</td>
</tr>
<tr>
<td></td>
<td>U, 24 h</td>
<td>&lt;0.95 μmol/d</td>
</tr>
<tr>
<td>Folic acid</td>
<td>RC</td>
<td>340–1020 nmol/L</td>
</tr>
<tr>
<td></td>
<td></td>
<td>cells</td>
</tr>
<tr>
<td>Folic acid</td>
<td>S</td>
<td>12.2–40.8 nmol/L</td>
</tr>
<tr>
<td>Lead (adult)</td>
<td>S</td>
<td>&lt;0.5 μmol/L</td>
</tr>
<tr>
<td>Mercury</td>
<td>WB</td>
<td>3.0–294 nmol/L</td>
</tr>
<tr>
<td></td>
<td>U, 24 h</td>
<td>&lt;99.8 nmol/L</td>
</tr>
<tr>
<td>Selenium</td>
<td>S</td>
<td>0.8–2.0 μmol/L</td>
</tr>
<tr>
<td>Vitamin A</td>
<td>S</td>
<td>0.7–3.5 μmol/L</td>
</tr>
<tr>
<td>Vitamin B₁</td>
<td>S</td>
<td>0–75 nmol/L</td>
</tr>
<tr>
<td>Vitamin B₂</td>
<td>S</td>
<td>106–638 nmol/L</td>
</tr>
<tr>
<td>(riboflavin)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin B₆</td>
<td>P</td>
<td>20–121 nmol/L</td>
</tr>
<tr>
<td>Vitamin B₁₂</td>
<td>S</td>
<td>206–735 pmol/L</td>
</tr>
<tr>
<td>Vitamin C (ascor-</td>
<td>S</td>
<td>23–57 μmol/L</td>
</tr>
<tr>
<td>bic acid)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin D₃,</td>
<td>S</td>
<td>60–108 pmol/L</td>
</tr>
<tr>
<td>1,25-dihydroxy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin D₃, 25-</td>
<td>P</td>
<td>37.4–200 nmol/L</td>
</tr>
<tr>
<td>hydroxy</td>
<td></td>
<td>34.9–105 nmol/L</td>
</tr>
<tr>
<td></td>
<td>Summer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Winter</td>
<td></td>
</tr>
<tr>
<td>Vitamin E</td>
<td>S</td>
<td>12–42 μmol/L</td>
</tr>
<tr>
<td>Vitamin K</td>
<td>S</td>
<td>0.29–2.64 nmol/L</td>
</tr>
<tr>
<td>Zinc</td>
<td>S</td>
<td>11.5–18.4 μmol/L</td>
</tr>
</tbody>
</table>

*P, plasma; RC, red cells; S, serum; WB, whole blood; U, urine.*
**TABLE 218-5**  CLASSIFICATION OF LDL, TOTAL, AND HDL CHOLESTEROL

<table>
<thead>
<tr>
<th></th>
<th>LDL cholesterol, mg/dL (mmol/L)</th>
<th>Total cholesterol, mg/dL (mmol/L)</th>
<th>HDL cholesterol, mg/dL (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;70 (&lt;1.81)</td>
<td>&lt;200 (&lt;5.17)</td>
<td>&lt;40 (&lt;1.03)</td>
</tr>
<tr>
<td></td>
<td>&lt;100 (&lt;2.59)</td>
<td>200–239 (5.17–6.18)</td>
<td>≥40 (≥1.03)</td>
</tr>
<tr>
<td></td>
<td>100–129 (2.59–3.34)</td>
<td></td>
<td>≥60 (≥1.55)</td>
</tr>
<tr>
<td></td>
<td>130–159 (3.36–4.11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>160–189 (4.14–4.89)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥190 (≥4.91)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LDL cholesterol, mg/dL (mmol/L)</th>
<th>Therapeutic option for very high risk patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol, mg/dL (mmol/L)</td>
<td>Optimal</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL (mmol/L)</td>
<td>Near optimal/above optimal</td>
</tr>
<tr>
<td></td>
<td>Borderline high</td>
</tr>
<tr>
<td></td>
<td>High</td>
</tr>
<tr>
<td></td>
<td>Very high</td>
</tr>
<tr>
<td></td>
<td>Desirable</td>
</tr>
<tr>
<td></td>
<td>Borderline high</td>
</tr>
<tr>
<td></td>
<td>High</td>
</tr>
<tr>
<td>Note: LDL, low-density lipoprotein; HDL, high-density lipoprotein.</td>
<td></td>
</tr>
</tbody>
</table>
# REFERENCE VALUES FOR SPECIFIC ANALYTES

(Tables 218-6 through 218-9)

## TABLE 218-6 CEREBROSPINAL FLUID (CSF)

<table>
<thead>
<tr>
<th>Constituent</th>
<th>Reference Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osmolarity</td>
<td>292–297 mmol/kg water</td>
</tr>
<tr>
<td>(P_{CO_2})</td>
<td>6–7 kPa</td>
</tr>
<tr>
<td>(C_{O_2})</td>
<td>7.31–7.34</td>
</tr>
<tr>
<td>Glucose</td>
<td>2.22–3.89 mmol/L</td>
</tr>
<tr>
<td>Lactate</td>
<td>1–2 mmol/L</td>
</tr>
<tr>
<td>Total protein, Lumbar</td>
<td>0.15–0.5 g/L</td>
</tr>
<tr>
<td>(IgG)</td>
<td>0.009–0.057 g/L</td>
</tr>
<tr>
<td>(IgG) index(^b)</td>
<td>0.29–0.59</td>
</tr>
<tr>
<td>Oligoclonal bands</td>
<td>&lt;2 bands not present in matched serum sample</td>
</tr>
<tr>
<td>CSF pressure</td>
<td>50–180 mmH(_2)O</td>
</tr>
<tr>
<td>Red blood cells</td>
<td>0</td>
</tr>
<tr>
<td>Leukocytes</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>0–5 mononuclear cells per (\mu)L</td>
</tr>
<tr>
<td>Differential</td>
<td></td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>60–70%</td>
</tr>
<tr>
<td>Monocytes</td>
<td>30–50%</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>None</td>
</tr>
</tbody>
</table>

\(^a\)Since cerebrospinal fluid concentrations are equilibrium values, measurements of the same parameters in blood plasma obtained at the same time are recommended. However, there is a time lag in attainment of equilibrium, and cerebrospinal levels of plasma constituents that can fluctuate rapidly (such as plasma glucose) may not achieve stable values until after a significant lag phase.

\(^b\)IgG index = \(\frac{CSF\ IgG(\text{mg/dL}) \times \text{serum albumin (g/dL)} / \text{Serum IgG(g/dL)}}{\text{CSF albumin (mg/dL)}}\).
<table>
<thead>
<tr>
<th>Table 218-7</th>
<th>Urine Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reference Range</strong></td>
<td><strong>SI Units</strong></td>
</tr>
<tr>
<td>Acidity, titratable</td>
<td>20–40 mmol/d</td>
</tr>
<tr>
<td>Ammonia</td>
<td>30–50 mmol/d</td>
</tr>
<tr>
<td>Amylase</td>
<td>4–400 U/L</td>
</tr>
<tr>
<td>Amylase/creatinine clearance ratio ([[(\text{Cl}<em>{\text{am}}/\text{Cl}</em>{\text{cr}}) \times 100])</td>
<td>1–5</td>
</tr>
<tr>
<td>Calcium (10 meq/d or 200 mg/d dietary calcium)</td>
<td>&lt;7.5 mmol/d</td>
</tr>
<tr>
<td>Creatine, as creatinine</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>&lt;760 μmol/d</td>
</tr>
<tr>
<td>Male</td>
<td>&lt;380 μmol/d</td>
</tr>
<tr>
<td>Creatinine</td>
<td>8.8–14 mmol/d</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>&lt;100,000 eosinophils/L</td>
</tr>
<tr>
<td>Glucose (glucose oxidase method)</td>
<td>0.3–1.7 mmol/d</td>
</tr>
<tr>
<td>5-Hydroxyindoleacetic acid (5-HIAA)</td>
<td>10–47 μmol/d</td>
</tr>
<tr>
<td>Iodine, spot urine</td>
<td></td>
</tr>
<tr>
<td>WHO classification of iodine deficiency</td>
<td></td>
</tr>
<tr>
<td>Not iodine deficient</td>
<td>&gt;100 μg/L</td>
</tr>
<tr>
<td>Mild iodine deficiency</td>
<td>50–100 μg/L</td>
</tr>
<tr>
<td>Moderate iodine deficiency</td>
<td>20–49 μg/L</td>
</tr>
<tr>
<td>Severe iodine deficiency</td>
<td>&lt;20 μg/L</td>
</tr>
<tr>
<td>Microalbumin</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>0.0–0.03 g/d</td>
</tr>
<tr>
<td>Microalbuminuria</td>
<td>0.03–0.30 g/d</td>
</tr>
<tr>
<td>Clinical albuminuria</td>
<td>&gt;0.3 g/d</td>
</tr>
<tr>
<td>Microalbumin/creatinine ratio</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>0–3.4 g/mol creatinine</td>
</tr>
<tr>
<td>Microalbuminuria</td>
<td>3.4–34 g/mol creatinine</td>
</tr>
<tr>
<td>Clinical albuminuria</td>
<td>&gt;34 g/mol creatinine</td>
</tr>
<tr>
<td>Oxalate</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>80–500 μmol/d</td>
</tr>
<tr>
<td>Female</td>
<td>45–350 μmol/d</td>
</tr>
<tr>
<td>pH</td>
<td>5.0–9.0</td>
</tr>
<tr>
<td>Phosphate (phosphorus) (varies with intake)</td>
<td>12.9–42.0 mmol/d</td>
</tr>
<tr>
<td>Potassium (varies with intake)</td>
<td>25–100 mmol/d</td>
</tr>
<tr>
<td>Protein</td>
<td>&lt;0.15 g/d</td>
</tr>
<tr>
<td>Sediment</td>
<td></td>
</tr>
<tr>
<td>Red blood cells</td>
<td>0–2/high power field</td>
</tr>
<tr>
<td>White blood cells</td>
<td>0–2/high power field</td>
</tr>
<tr>
<td>Sodium (varies with intake)</td>
<td>100–260 mmol/d</td>
</tr>
<tr>
<td>Specific gravity</td>
<td>1.001–1.035</td>
</tr>
<tr>
<td>Urea nitrogen</td>
<td>214–607 mmol/d</td>
</tr>
<tr>
<td>Uric acid (normal diet)</td>
<td>1.49–4.76 mmol/d</td>
</tr>
</tbody>
</table>

*Note: WHO, World Health Organization.*
### TABLE 218-8 DIFFERENTIAL NUCLEATED CELL COUNTS OF BONE MARROW ASPIRATES\(^a\)

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Observed Range, %</th>
<th>95% Confidence Intervals, %</th>
<th>Mean, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blast cells</td>
<td>0–3.2</td>
<td>0–3.0</td>
<td>1.4</td>
</tr>
<tr>
<td>Promyelocytes</td>
<td>3.6–13.2</td>
<td>3.2–12.4</td>
<td>7.8</td>
</tr>
<tr>
<td>Neutrophil myelocytes</td>
<td>4–21.4</td>
<td>3.7–10.0</td>
<td>7.6</td>
</tr>
<tr>
<td>Eosinophil myelocytes</td>
<td>0–5.0</td>
<td>0–2.8</td>
<td>1.3</td>
</tr>
<tr>
<td>Metamyelocytes</td>
<td>1–7.0</td>
<td>2.3–5.9</td>
<td>4.1</td>
</tr>
<tr>
<td>Neutrophils</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>21.0–45.6</td>
<td>21.9–42.3</td>
<td>32.1</td>
</tr>
<tr>
<td>Females</td>
<td>29.6–46.6</td>
<td>28.8–45.9</td>
<td>37.4</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>0.4–4.2</td>
<td>0.3–4.2</td>
<td>2.2</td>
</tr>
<tr>
<td>Eosinophils plus eosinophil myelocytes</td>
<td>0.9–7.4</td>
<td>0.7–6.3</td>
<td>3.5</td>
</tr>
<tr>
<td>Basophils</td>
<td>0–0.8</td>
<td>0–0.4</td>
<td>0.1</td>
</tr>
<tr>
<td>Erythroblasts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>18.0–39.4</td>
<td>16.2–40.1</td>
<td>28.1</td>
</tr>
<tr>
<td>Female</td>
<td>14.0–31.8</td>
<td>13.0–32.0</td>
<td>22.5</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>4.6–22.6</td>
<td>6.0–20.0</td>
<td>13.1</td>
</tr>
<tr>
<td>Plasma cells</td>
<td>0–1.4</td>
<td>0–1.2</td>
<td>0.6</td>
</tr>
<tr>
<td>Monocytes</td>
<td>0–3.2</td>
<td>0–2.6</td>
<td>1.3</td>
</tr>
<tr>
<td>Macrophages</td>
<td>0–1.8</td>
<td>0–1.3</td>
<td>0.4</td>
</tr>
<tr>
<td>M:E ratio</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1.1–4.0</td>
<td>1.1–4.1</td>
<td>2.1</td>
</tr>
<tr>
<td>Female</td>
<td>1.6–5.4</td>
<td>1.6–5.2</td>
<td>2.8</td>
</tr>
</tbody>
</table>

\(^a\)Based on bone marrow aspirate from 50 healthy volunteers (30 men, 20 women).


### TABLE 218-9 STOOL ANALYSIS

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Reference Range</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SI Units</td>
</tr>
<tr>
<td>Amount</td>
<td>0.1–0.2 kg/d</td>
</tr>
<tr>
<td>Coproporphyrin Fat Adult</td>
<td>611–1832 nmol/d</td>
</tr>
<tr>
<td>Adult on fat-free diet</td>
<td>&lt;7 g/d</td>
</tr>
<tr>
<td>Fatty acids</td>
<td>0–21 mmol/d</td>
</tr>
<tr>
<td>Leukocytes</td>
<td>None</td>
</tr>
<tr>
<td>Nitrogen</td>
<td>&lt;178 mmol/d</td>
</tr>
<tr>
<td>pH</td>
<td>7.0–7.5</td>
</tr>
<tr>
<td>Occult blood</td>
<td>Negative</td>
</tr>
<tr>
<td>Trypsin</td>
<td>85–510 μmol/d</td>
</tr>
<tr>
<td>Urobilinogen</td>
<td>12–48 nmol/d</td>
</tr>
<tr>
<td>Water</td>
<td>&lt;0.75</td>
</tr>
</tbody>
</table>

### TABLE 218-10  
RENAL FUNCTION TESTS

<table>
<thead>
<tr>
<th>Reference Range</th>
<th>SI Units</th>
<th>Conventional Units</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clearances (corrected to 1.72 m² body surface area)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measures of glomerular filtration rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inulin clearance (CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males (mean ± 1 SD)</td>
<td>2.1 ± 0.4 mL/s</td>
<td>124 ± 25.8 mL/min</td>
</tr>
<tr>
<td>Females (mean ± 1 SD)</td>
<td>2.0 ± 0.2 mL/s</td>
<td>119 ± 12.8 mL/min</td>
</tr>
<tr>
<td>Endogenous creatinine clearance</td>
<td>1.5–2.2 mL/s</td>
<td>91–130 mL/min</td>
</tr>
<tr>
<td><strong>Measures of effective renal plasma flow and tubular function</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>p</em>-Aminohippuric acid clearance (Cl&lt;sub&gt;&lt;span style=&quot;font-variant: small-caps&quot;&gt;PAH&lt;/span&gt;&lt;/sub&gt;)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males (mean ± 1 SD)</td>
<td>10.9 ± 2.7 mL/s</td>
<td>654 ± 163 mL/min</td>
</tr>
<tr>
<td>Females (mean ± 1 SD)</td>
<td>9.9 ± 1.7 mL/s</td>
<td>594 ± 102 mL/min</td>
</tr>
<tr>
<td><strong>Concentration and dilution test</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specific gravity of urine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>After 12-h fluid restriction</td>
<td>&gt;1.025</td>
<td>&gt;1.025</td>
</tr>
<tr>
<td>After 12-h deliberate water intake</td>
<td>≤1.003</td>
<td>≤1.003</td>
</tr>
<tr>
<td>Protein excretion, urine</td>
<td>&lt;0.15 g/d</td>
<td>&lt;150 mg/d</td>
</tr>
<tr>
<td>Specific gravity, maximal range</td>
<td>1.002–1.028</td>
<td>1.002–1.028</td>
</tr>
<tr>
<td>Tubular reabsorption, phosphorus</td>
<td>0.79–0.94 of filtered load</td>
<td>79–94% of filtered load</td>
</tr>
</tbody>
</table>

**Notes:**
- All values are approximations. Differences may occur due to variations in methodologies and equipment.
- SI units are preferred over conventional units for consistency and accuracy in scientific research.
<table>
<thead>
<tr>
<th>Test</th>
<th>SI Units (Range)</th>
<th>Conventional Units (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arteriovenous oxygen difference</td>
<td>30–50 mL/L</td>
<td>30–50 mL/L</td>
</tr>
<tr>
<td>Cardiac output (Fick)</td>
<td>2.5–3.6 L/m² of body surface area per min</td>
<td>2.5–3.6 L/m² of body surface area per min</td>
</tr>
<tr>
<td>Contractility indexes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max. left ventricular $\frac{dp}{dt}$ when $DP = 5.3$ kPa (40 mmHg)</td>
<td>$220$ kPa/s (176–250 kPa/s) ($37.6 \pm 12.2$)/s</td>
<td>$1650$ mmHg/s (1320–1880 mmHg/s) ($37.6 \pm 12.2$)/s</td>
</tr>
<tr>
<td>Mean normalized systolic ejection rate (angiography)</td>
<td>$3.32 \pm 0.84$ end-diastolic volumes per second</td>
<td>$3.32 \pm 0.84$ end-diastolic volumes per second</td>
</tr>
<tr>
<td>Mean velocity of circumferential fiber shortening (angiography)</td>
<td>$1.83 \pm 0.56$ circumferences per second</td>
<td>$1.83 \pm 0.56$ circumferences per second</td>
</tr>
<tr>
<td>Ejection fraction: stroke volume/end-diastolic volume (SV/EDV)</td>
<td>$0.67 \pm 0.08$ (0.55–0.78)</td>
<td>$0.67 \pm 0.08$ (0.55–0.78)</td>
</tr>
<tr>
<td>End-diastolic volume</td>
<td>$70 \pm 20.0$ mL/m² ($60–88$ mL/m²)</td>
<td>$70 \pm 20.0$ mL/m² ($60–88$ mL/m²)</td>
</tr>
<tr>
<td>End-systolic volume</td>
<td>$25 \pm 5.0$ mL/m² ($20–33$ mL/m²)</td>
<td>$25 \pm 5.0$ mL/m² ($20–33$ mL/m²)</td>
</tr>
<tr>
<td>Left ventricular work</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke work index</td>
<td>$50 \pm 20.0$ $(g•m)/m²$ ($30–110$)</td>
<td>$50 \pm 20.0$ $(g•m)/m²$ ($30–110$)</td>
</tr>
<tr>
<td>Left ventricular minute work index</td>
<td>$1.8–6.6$ $[(kg•m)/m²]/min$</td>
<td>$1.8–6.6$ $[(kg•m)/m²]/min$</td>
</tr>
<tr>
<td>Oxygen consumption index</td>
<td>$110–150$ mL</td>
<td>$110–150$ mL</td>
</tr>
<tr>
<td>Maximum oxygen uptake</td>
<td>$35$ mL/min ($20–60$ mL/min)</td>
<td>$35$ mL/min ($20–60$ mL/min)</td>
</tr>
<tr>
<td>Pulmonary vascular resistance</td>
<td>$2–12$ (kPa*s)/L</td>
<td>$20–130$ (dyn*s)/cm²</td>
</tr>
<tr>
<td>Systemic vascular resistance</td>
<td>$77–150$ (kPa*s)/L</td>
<td>$770–1600$ (dyn*s)/cm²</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test</th>
<th>SI Units</th>
<th>Conventional Units</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Absorption tests</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-Xylose: after overnight fast, 25 g xylose given in oral aqueous solution</td>
<td>25% of ingested dose 2.0–3.5 mmol/L</td>
<td>25% of ingested dose 30–52 mg/dL</td>
</tr>
<tr>
<td>Urine, collected for following 5 h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum, 2 h after dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vitamin A:</strong> a fasting blood specimen is obtained and 200,000 units of vitamin A in oil is given orally</td>
<td>Serum level should rise to twice fasting level in 3–5 h</td>
<td>Serum level should rise to twice fasting level in 3–5 h</td>
</tr>
<tr>
<td><strong>Bentiromide test (pancreatic function):</strong> 500 mg bentiromide (chymex) orally; p-aminobenzoic acid (PABA) measured</td>
<td>Plasma &gt;3.6 (±1.1) μg/mL at 90 min</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Urine &gt;50% recovered in 6 h</td>
<td>&gt;50% recovered in 6 h</td>
</tr>
<tr>
<td><strong>Gastric juice</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Volume</strong></td>
<td>2–3 L</td>
<td>2–3 L</td>
</tr>
<tr>
<td>24 h</td>
<td>600–700 mL</td>
<td>600–700 mL</td>
</tr>
<tr>
<td>Nocturnal</td>
<td>30–70 mL/h</td>
<td>30–70 mL/h</td>
</tr>
<tr>
<td>Basal, fasting</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Reaction</strong></td>
<td>1.6–1.8</td>
<td>1.6–1.8</td>
</tr>
<tr>
<td>pH</td>
<td>4–9 μmol/s</td>
<td>15–35 meq/h</td>
</tr>
<tr>
<td><strong>Titratable acidity of fasting juice</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Acid output</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Basal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females (mean ± 1 SD)</td>
<td>0.6 ± 0.5 μmol/s</td>
<td>2.0 ± 1.8 meq/h</td>
</tr>
<tr>
<td>Males (mean ± 1 SD)</td>
<td>0.8 ± 0.6 μmol/s</td>
<td>3.0 ± 2.0 meq/h</td>
</tr>
<tr>
<td><strong>Maximal (after SC histamine acid phosphate, 0.004 mg/kg body weight, and preceded by 50 mg promethazine, or after betazole, 1.7 mg/kg body weight, or pentagastrin, 6 μg/kg body weight)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females (mean ± 1 SD)</td>
<td>4.4 ± 1.4 μmol/s</td>
<td>16 ± 5 meq/h</td>
</tr>
<tr>
<td>Males (mean ± 1 SD)</td>
<td>6.4 ± 1.4 μmol/s</td>
<td>23 ± 5 meq/h</td>
</tr>
<tr>
<td>Basal acid output/maximal acid output ratio</td>
<td>≤0.6</td>
<td>≤0.6</td>
</tr>
<tr>
<td><strong>Gastrin, serum</strong></td>
<td>0–200 μg/L</td>
<td>0–200 pg/mL</td>
</tr>
<tr>
<td><strong>Secretin test (pancreatic exocrine function):</strong> 1 unit/kg body weight, IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Volume (pancreatic juice) in 80 min</strong></td>
<td>&gt;2.0 mL/kg</td>
<td>&gt;2.0 mL/kg</td>
</tr>
<tr>
<td><strong>Bicarbonate concentration</strong></td>
<td>&gt;80 mmol/L</td>
<td>&gt;80 meq/L</td>
</tr>
<tr>
<td><strong>Bicarbonate output in 30 min</strong></td>
<td>&gt;10 mmol</td>
<td>&gt;10 meq</td>
</tr>
</tbody>
</table>
### Table 218-13: Normal Values of Doppler Echocardiographic Measurements in Adults

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Range</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>RVD (cm), measured at the base in apical 4-chamber view</td>
<td>2.6–4.3</td>
<td>3.5 ± 0.4</td>
</tr>
<tr>
<td>LVID (cm), measured in the parasternal long axis view</td>
<td>3.6–5.4</td>
<td>4.7 ± 0.4</td>
</tr>
<tr>
<td>Posterior LV wall thickness (cm)</td>
<td>0.6–1.1</td>
<td>0.9 ± 0.4</td>
</tr>
<tr>
<td>IVS wall thickness (cm)</td>
<td>0.6–1.1</td>
<td>0.9 ± 0.4</td>
</tr>
<tr>
<td>Left atrial dimension (cm), antero-posterior dimension</td>
<td>2.3–3.8</td>
<td>3.0 ± 0.3</td>
</tr>
<tr>
<td>Aortic root dimension (cm)</td>
<td>2.0–3.5</td>
<td>2.4 ± 0.4</td>
</tr>
<tr>
<td>Aortic cusps separation (cm)</td>
<td>1.5–2.6</td>
<td>1.9 ± 0.4</td>
</tr>
<tr>
<td>Percentage of fractional shortening</td>
<td>34–44%</td>
<td>36%</td>
</tr>
<tr>
<td>Mitral flow (m/s)</td>
<td>0.6–1.3</td>
<td>0.9</td>
</tr>
<tr>
<td>Tricuspid flow (m/s)</td>
<td>0.3–0.7</td>
<td>0.5</td>
</tr>
<tr>
<td>Pulmonary artery (m/s)</td>
<td>0.6–0.9</td>
<td>0.75</td>
</tr>
<tr>
<td>Aorta (m/s)</td>
<td>1.0–1.7</td>
<td>1.35</td>
</tr>
</tbody>
</table>

**Note:** RVD, right ventricular dimension; LVID, left ventricular internal dimension; LV, left ventricle; IVS, interventricular septum.

**TABLE 218-14 SUMMARY OF VALUES USEFUL IN PULMONARY PHYSIOLOGY**

<table>
<thead>
<tr>
<th>Pulmonary Mechanics</th>
<th>Symbol</th>
<th>Typical Values</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Man, Age 40, 75 kg, 175 cm Tall</td>
<td>Woman, Age 40, 60 kg, 160 cm Tall</td>
</tr>
<tr>
<td><strong>Spirometry—volume-time curves</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forced vital capacity</td>
<td>FVC</td>
<td>4.8 L</td>
</tr>
<tr>
<td>Forced expiratory volume in 1 s</td>
<td>FEV₁</td>
<td>3.8 L</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
<td>FEV₁%</td>
<td>76%</td>
</tr>
<tr>
<td>Maximal midexpiratory flow</td>
<td>MMF (FEF 25–27)</td>
<td>4.8 L/s</td>
</tr>
<tr>
<td>Maximal expiratory flow rate</td>
<td>MEFR (FEF 200–1200)</td>
<td>9.4 L/s</td>
</tr>
<tr>
<td><strong>Spirometry—flow-volume curves</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximal expiratory flow at 50% of expired vital capacity</td>
<td>V&lt;sub&gt;max&lt;/sub&gt; 50 (FEF 50%)</td>
<td>6.1 L/s</td>
</tr>
<tr>
<td>Maximal expiratory flow at 75% of expired vital capacity</td>
<td>V&lt;sub&gt;max&lt;/sub&gt; 75 (FEF 75%)</td>
<td>3.1 L/s</td>
</tr>
<tr>
<td><strong>Resistance to airflow</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary resistance</td>
<td>RL (R&lt;sub&gt;L&lt;/sub&gt;)</td>
<td>&lt;3.0 (cmH₂O/s)/L</td>
</tr>
<tr>
<td>Airway resistance</td>
<td>Raw</td>
<td>&lt;2.5 (cmH₂O/s)/L</td>
</tr>
<tr>
<td>Specific conductance</td>
<td>SGaw</td>
<td>&gt;0.13 cmH₂O/s</td>
</tr>
<tr>
<td><strong>Pulmonary compliance</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Static recoil pressure at total lung capacity</td>
<td>Pst TLC</td>
<td>25 ± 5 cmH₂O</td>
</tr>
<tr>
<td>Compliance of lungs (static)</td>
<td>CL</td>
<td>0.2 L cmH₂O</td>
</tr>
<tr>
<td>Compliance of lungs and thorax</td>
<td>C(L + T)</td>
<td>0.1 L cmH₂O</td>
</tr>
<tr>
<td>Dynamic compliance of 20 breaths per minute</td>
<td>C&lt;sub&gt;dy&lt;/sub&gt;n 20</td>
<td>0.25 ± 0.05 L/cmH₂O</td>
</tr>
<tr>
<td><strong>Maximal static respiratory pressures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximal inspiratory pressure</td>
<td>MIP</td>
<td>&gt;90 cmH₂O</td>
</tr>
<tr>
<td>Maximal expiratory pressure</td>
<td>MEP</td>
<td>&gt;150 cmH₂O</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th><strong>Lung Volumes</strong></th>
<th><strong>TABLE 218-14</strong></th>
<th><strong>SUMMARY OF VALUES USEFUL IN PULMONARY PHYSIOLOGY (CONTINUED)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total lung capacity</strong></td>
<td>TLC</td>
<td>6.4 L</td>
</tr>
<tr>
<td><strong>Functional residual capacity</strong></td>
<td>FRC</td>
<td>2.2 L</td>
</tr>
<tr>
<td><strong>Residual volume</strong></td>
<td>RV</td>
<td>1.5 L</td>
</tr>
<tr>
<td><strong>Inspiratory capacity</strong></td>
<td>IC</td>
<td>4.8 L</td>
</tr>
<tr>
<td><strong>Expiratory reserve volume</strong></td>
<td>ERV</td>
<td>3.2 L</td>
</tr>
<tr>
<td><strong>Vital capacity</strong></td>
<td>VC</td>
<td>1.7 L</td>
</tr>
<tr>
<td><strong>Gas Exchange (Sea Level)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Arterial O₂ tension</strong></td>
<td>PaO₂</td>
<td>12.7 ± 0.7 kPa (95 ± 5 mmHg)</td>
</tr>
<tr>
<td><strong>Arterial CO₂ tension</strong></td>
<td>PaCO₂</td>
<td>5.3 ± 0.3 kPa (40 ± 2 mmHg)</td>
</tr>
<tr>
<td><strong>Arterial O₂ saturation</strong></td>
<td>SaO₂</td>
<td>0.97 ± 0.02 (97 ± 2%)</td>
</tr>
<tr>
<td><strong>Arterial blood pH</strong></td>
<td>pH</td>
<td>7.40 ± 0.02</td>
</tr>
<tr>
<td><strong>Arterial bicarbonate</strong></td>
<td>HCO₃⁻</td>
<td>24 ± 2 meq/L</td>
</tr>
<tr>
<td><strong>Base excess</strong></td>
<td>BE</td>
<td>0 ± 2 meq/L</td>
</tr>
<tr>
<td><strong>Diffusing capacity for carbon monoxide (single breath)</strong></td>
<td>DLCO</td>
<td>0.42 mL CO/s/mmHg (25 mL CO/min/mmHg)</td>
</tr>
<tr>
<td><strong>Dead space volume</strong></td>
<td>V_D</td>
<td>2 mL/kg body wt</td>
</tr>
<tr>
<td><strong>Physiologic dead space; dead space-tidal volume ratio</strong></td>
<td>V_D/V_T</td>
<td>≤35% V_T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≤20% V_T</td>
</tr>
<tr>
<td><strong>Alveolar-arterial difference for O₂</strong></td>
<td>P(A – a)O₂</td>
<td>≤2.7 kPa ≤20 kPa (≤20 mmHg)</td>
</tr>
</tbody>
</table>
## MISCELLANEOUS (Table 218-15)

### TABLE 218-15  BODY FLUIDS AND OTHER MASS DATA

<table>
<thead>
<tr>
<th>Reference Range</th>
<th>SI Units</th>
<th>Conventional Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascitic fluid: See Table 44-1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body fluid, Total volume (lean) of body weight</td>
<td>50% (in obese) to 70%</td>
<td></td>
</tr>
<tr>
<td>Intracellular</td>
<td>0.3–0.4 of body weight</td>
<td></td>
</tr>
<tr>
<td>Extracellular</td>
<td>0.2–0.3 of body weight</td>
<td></td>
</tr>
<tr>
<td>Body fluid, Total volume (of body weight)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracellular</td>
<td>0.3–0.4 of body weight</td>
<td></td>
</tr>
<tr>
<td>Extracellular</td>
<td>0.2–0.3 of body weight</td>
<td></td>
</tr>
<tr>
<td>Blood</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total volume</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>69 mL per kg body weight</td>
<td>1.15–1.21 L/m² of body surface area</td>
</tr>
<tr>
<td>Females</td>
<td>65 mL per kg body weight</td>
<td>0.95–1.00 L/m² of body surface area</td>
</tr>
<tr>
<td>Plasma volume</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>39 mL per kg body weight</td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>40 mL per kg body weight</td>
<td></td>
</tr>
<tr>
<td>Red blood cell volume</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>30 mL per kg body weight</td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>25 mL per kg body weight</td>
<td></td>
</tr>
<tr>
<td>Body mass index</td>
<td>18.5–24.9 kg/m²</td>
<td>18.5–24.9 kg/m²</td>
</tr>
</tbody>
</table>
This page intentionally left blank
INDEX

Bold number indicates the start of the main discussion of the topic; numbers with “f” and “t” refer to figure and table pages.

A
Abacavir, for HIV/AIDS, 609t
Abatacept, for rheumatoid arthritis, 888
Abciximab, for thrombotic disorders, 338
Abdominal angina, 843
Abdominal pain, 179
acute, catastrophic, 181
causes of, 179t
features of, 180–181
Abdominal radiography, 22
in pancreatitis, 850, 852
Abdominal wall disorders, pain in, 179t
Abiotrophia infection, 501
Abortion, 957
Abscess. See specific sites
ABVD regimen, for Hodgkin’s disease, 363–364
Acamprosate, for alcoholic rehabilitation, 1098
Acanthocytes, 280, 321
Acarbose, for diabetes mellitus, 945t
Accelerated idioventricular rhythm
clinical and ECG features of, 724t
in myocardial infarction, 704
Accessory nerve, 983
disorders of, 1024
Accident prevention, 1104t–1105t
Acebutolol poisoning, 140t
ACE inhibitors
for aortic regurgitation, 683
for coronary artery disease, 716
for diabetic nephropathy, 805
for dilated cardiomyopathy, 685
for glomerulonephritis, 804–805, 808
for heart failure, 731, 732t, 733t, 735
for hypertension, 695t, 696, 697t, 698, 796, 822, 824
for mitral regurgitation, 679
for myocardial infarction, 704, 706, 711–712
preventive treatment, 709
for systemic sclerosis, 889
for unstable angina, 711
Acetaminophen
for back pain, 196
for fever, 201
for migraine, 186t
for osteoarthritis, 902
for pain, 36t–37t, 38
for tension headache, 186
toxicity of, 130, 858
Acetazolamide
for glaucoma, 294
for periodic paralysis, 1074
N-Acetylcysteine, for acetaminophen over-dose, 858
Acetylsalicylic acid, for pain, 36t–37t
Achalasia, 251
Acid-base balance, 3
Acid-base disorders, 14
metabolic acidosis, 16
metabolic alkalosis, 19
mixed disorders, 21
nomogram for, 16f
respiratory acidosis, 21
respiratory alkalosis, 21
Acid-fast bacilli, 538
Acid malase deficiency, 1073
Acidosis, 14
Acinetobacter infection, 516
Acitretin, for psoriasis, 314
Acne, 317
drug-induced, 1133t
Acne rosacea, 318
Acne vulgaris, 310f, 317–318
Acoustic neuroma, 213, 1022
Acrodermatitis chronica atrophicans, 550
Acromegaly, 920
paraneoplastic, 405t, 406
Acrophobia, 1083
ACTH, 917, 918f
deficiency of, 919t, 922, 922t, 936
ectopic ACTH syndrome, 405, 405t, 906
hypersecretion of, 919t, 934–935
therapy for inflammatory bowel disease, 838
Actinic keratosis, 311f
Actinobacillus actinomycetemcomitans infection. See HACEK group infection
Actinomycetoma, 535, 536t
Actinomycosis, 537
abdominal, 537
oral-cervicofacial, 537–538
pelvic, 537
thoracic, 537
Action tremor, 1002
Activated charcoal
for erythropoietic porphyria, 978
for heavy metal poisoning, 155t
for methylxanthine poisoning, 137t
for paralytic shellfish poisoning, 124
for poisoning, 135
for toxic and drug-induced hepatitis, 858
Activated protein C therapy
for Ebola and Marburg virus infections, 600
for meningococcal infections, 505
for sepsis/septic shock, 66
Acute coronary syndrome, 709, 710f
Acute disseminated encephalomyelitis (ADEM), 1041
Acute motor axonal neuropathy, 1061
Acute respiratory distress syndrome (ARDS), 69
clinical course and pathophysiology of, 69–70
definition and etiology of, 69
outcomes of, 71
Acute stress disorder, 1083
Acyclovir
for Bell’s palsy, 1022
for HSV infections, 475, 479t, 566, 567t–568t, 569
for viral encephalitis, 1049–1050
Acidosis, 14
for viral esophagitis, 252
for viral meningitis, 1048
Adalimumab
for ankylosing spondylitis, 897
for inflammatory bowel disease, 840, 907
for psoriatic arthritis, 898
for rheumatoid arthritis, 887
Addison’s disease, 936
drug-induced, 1132t
Adefovir, for chronic hepatitis B, 860t–861t, 864
Adenoma
adrenal, 934–935
colonic, 383
gastric, 381
hepatocellular, 388
pituitary. See Pituitary adenoma
small-bowel, 382
thyroid, 932
Adenosine
for arrhythmias, 728t
for tachyarrhythmias, 722t
for Wolff-Parkinson-White syndrome, 729
Adenosine deaminase deficiency, 882
Adenovirus infection
pharyngoconjunctival fever, 583
respiratory disease, 583
Admission orders, 1
ADMIT VITALS AND PHYSICAL EXAM
(admissions mnemonic), 1–2
Adnexal mass, 395
Adrenal adenoma, 934–935
Adrenal carcinoma, 934–935
Adrenal gland disease, 933
hyperfunction, 934
hypofunction, 936
Adrenal insufficiency
paraneoplastic, 115
primary, 936
secondary, 936
Adrenal mass, incidental, 937f, 938
Adrenomyeloneuropathy, 1030–1031
Adult T cell leukemia/lymphoma, 360
Advance directives, 47
Advanced sleep phase syndrome, 230
Adverse drug reactions, 1131, 1131t–1140t.
See also Drug-induced illness
Aeromonas infection, 478, 516
Affective disorder, major, 1077
African tick-bite fever, 555
Agammaglobulinemia
autosomal, 884
X-linked, 883
Agglutination, 636
Agitation, in terminally ill patient, 53t
AGMA inducers, poisoning, 147t
Agoraphobia, 1081, 1083
Agranulocytosis, drug-induced, 1134t
AIDS. See also HIV/AIDS
definition of, 600
Airborne precautions, 429
Airway obstruction
drug-induced, 1136t
dyspnea in, 231, 233
Alanine aminotransferase (ALT), 268, 268t
Albendazole
for ascariasis, 650
for echinococcosis, 657
for enterobiasis, 651
for hookworm infection, 650
for larva migrans, 649
for lymphatic filariasis, 652
for strongyloidiasis, 651
for taeniasis solium and cysticercosis, 656
for trichinellosis, 649
Albumin
intra venous, for hepatorenal syndrome, 274
serum, in liver disease, 269, 269t
serum-ascites gradient, 273t
urine, 278
Albuterol
for COPD, 761–763
for hyperkalemia, 15t
poisoning, 136t
Alcohol abuse, 1096
Alcohol dependence, 1096
Alcoholic ketoacidosis, 17t, 18
Alcoholic liver disease, 869
Alcohol polynuropathy, 1016
Alcohol intoxication, 1096
Alcoholism, 1095, 1104t
chronic, 852
dementia in, 996t
metabolic consequences of, 870
treatment of
acute withdrawal, 1098
drug therapy, 1098
recovery and sobriety, 1098
relapse prevention, 1098
Alcohol Use Disorder Screening Test
(AUDIT), 1096, 1097t
Alcohol withdrawal, 1096, 1098
Aldosteronism, 935
primary, 935
secondary, 935
Alefacept
for psoriasis, 314
for psoriatic arthritis, 898
Alemtuzumab, for CLL, 356
Alendronate, for osteoporosis, 967
Alendronate, for osteoporosis, 967
Alkaline diuresis, for poisoning, 149t, 160
Alkaline phosphatase, 268, 269, 850
Alkali therapy, for nephrolithiasis, 828t
Alkalosis, 14
Alkylating agents, toxicities of, 341t
Allergic angiitis and granulomatosis, 891
Allergic bronchopulmonary aspergillosis, 622, 624t
Allergic disease, immediate type hypersensitivity, 877
Allergy
anaphylaxis, 116
to insect sting, 127
leukocytosis in, 330
Alopecia, 34, 1018
Alosetron, for irritable bowel syndrome, 841, 842t
Alopecia, 34, 1018
Alosetron, for irritable bowel syndrome, 841, 842t
for irritable bowel syndrome, 841, 842t
Alpha-adrenergic antagonists, for vasospastic disorders, 740
Alpha radiation, 171
Alpha-tocopherol, for prostate cancer prevention, 1124
Alprazolam
dosage and action of, 1089t
poisoning, 143t
Alprostadil injection, for erectile dysfunction, 951
Alteplase, for thrombotic disorders, 338
Aluminum phosphate binders, for hyperphosphatemia, 964
Alveolar-arterial oxygen gradient, 749–750
Alveolar hemorrhage syndrome, 774, 776
Alveolar hypoventilation, 781, 782t
Alveolar ventilation, 749
Alzheimer’s disease, 995, 996t, 998
differentiation of major dementias, 997t
familial, 998
in women, 1128
Aminoglycosides, adverse reactions to, 424
Amikacin
for gram-negative enteric bacterial infections, 516
indications for, 426t
for Klebsiella infections, 515
for nocardiosis, 536t
for nontuberculous mycobacterial infections, 548
for P. aeruginosa infections, 519t
for pneumonia, 766t, 767t
resistance to, 426t
Amiloride
for diabetes insipidus, 8
for edema, 243t
for hypertension, 695
for Liddle’s syndrome, 20
Aminoglycosides, adverse reactions to, 424
Aminophylline, for anaphylaxis, 117
Aminosalicylates, for inflammatory bowel disease, 838
Aminotransferases, 268, 268t
Amoxicillin
dosage and action of, 1089t
poisoning, 143t
indications for, 425t
for H. pylori eradication, 833t
for leptospirosis, 553
for Lyme borreliosis, 550
for otitis media, 303t, 305
for pharyngitis, 304t
for pneumococcal infections, 488
for pneumonia, 766t
for pyelonephritis, 818t
resistance to, 425t
for sinusitis, 303t
Amoxicillin-clavulanate
for animal bite infections, 119t, 479t
for H. influenzae infections, 509
for otitis media, 303t
for pneumonia, 766t
for sinusitis, 303t
Amphetamine poisoning, 136t, 152t
Amphotericin B, 619
for blastomycosis, 631
for candidiasis, 252, 621
for coccidioidomycosis, 630
for cryptococcosis, 626
for febrile neutropenia in cancer patient, 115
for fusariosis, 632
for histoplasmosis, 629t
for leishmaniasis, 643–644
for mucormycosis, 627
for penicilliosis, 632
for sporotrichosis, 631
Ampicillin
for actinomycosis, 538
for bacterial meningitis, 1046t, 1047t
for diverticulitis, 842
for enterococcal infections, 501
for HACEK group infections, 512t
indications for, 425t
for infective endocarditis, 444t, 446
for leptospirosis, 553
for listerial infections, 507
for necrotizing fasciitis, 480t
for osteomyelitis, 485t
for pneumonia, 766t
for Proteus infections, 515
resistance to, 425t
for urinary tract infections, 819t
Ampicillin-clavulanate, for diverticulitis, 842
Ampicillin-sulbactam
for animal bite infections, 119t
for cellulitis, 479t
for cholecystitis, 847
for epiglottitis, 306
for HACEK group infections, 512t
for human bite infections, 119t
for infective endocarditis, 445t
for myositis/myonecrosis, 481
for osteomyelitis, 485t
for pneumonia, 767t
for snakebite, 120t
Amprenavir, for HIV/AIDS, 613t
Amrinone
for beta blocker poisoning, 140t
for calcium channel blocker poisoning, 140t
Amylase, serum, 849
Amylase-creatinine clearance ratio, urinary, 849
Amyl nitrite, for cytochrome oxidase inhibitor poisoning, 145t
Amyloid angiopathy, 82t
Amyloidosis, 913
Amyloidosis, AA (secondary), 913–915, 914f
Amyloidosis, AL (primary), 812t, 813, 913–915, 914f
Amyloidosis, autonomic involvement in, 1016
Amyloidosis, clinical features of, 913–914
Amyloidosis, familial, 913–915, 914f
Amyloidosis, glomerular disease in, 807t
Amyotrophic lateral sclerosis (ALS), familial, 1010
Amyotrophic lateral sclerosis (ALS), treatment of, 1013
Anaerobic bacteria, 528
Anaerobic infection, bacteremia, 534
Anaerobic infection, bone and joint, 533
Anaerobic infection, brain abscess, 533
Anaerobic infection, botulism, 529
Anaerobic infection, brain abscess, 533
Anaerobic infection, treatment of, 534, 534t
Anaerobic infection, of mouth, head, and neck, 533
Anaerobic infection, osteomyelitis, 485t
Anaerobic infection, pelvic, 533
Anaerobic infection, skin/soft tissue, 533
Anakinra, for rheumatoid arthritis, 888
Anaplasma (secondary), 913–915, 914f
Anastrozole, for breast cancer, 378–379
Anastrozole, toxicity of, 342t
Ancylostoma braziliense infection, 649
Ancylostoma duodenale infection. See Hookworm infection
Anidulafungin, 620
Anilines, 146t
Animal bite, rabies, 592
Animal bite, treatment of, 479t
Animal bite, treatment of, 479t
Animal bite, treatment of, 479t
Animal bite, treatment of, 479t
Animal bite, treatment of, 479t
Animal-borne viral infection, 592
Anion gap, 16, 17t, 21
Anion-gap metabolic alkalosis (AGMA) inducers, 131t
Anisocytosis, 321
Anorectal disease, 844
Anorexia, in terminally ill patient, 52t
Anorexia nervosa, 247, 1093, 1093t, 1095f
Anosmia, 1002
Anosognosia, 80
Antacids, for erosive gastropathies, 834
Antacids, for indigestion, 247
Antacids, for peptic ulcer disease, 833
Antacids, for systemic sclerosis, 889
Anterior ischemic optic neuropathy (AION), 216f, 217
Anthrax, 162, 201
Angiography, hepatobiliary, 270–271
Angiotensin receptor blockers, for diabetic nephropathy, 805–806
Angiotensin receptor blockers, for dilated cardiomyopathy, 685
Angiotensin receptor blockers, for glomerulonephritis, 805, 808
Angiotensin receptor blockers, for heart failure, 709
Angiography, hepatobiliary, 270–271
Angiography, hepatobiliary, 270–271
Angiography, hepatobiliary, 270–271
Angiography, hepatobiliary, 270–271
Angiography, hepatobiliary, 270–271
Angiography, hepatobiliary, 270–271
Ankylosing spondylitis, 895, 896f, 897
Ankylosing spondylitis, 895, 896f, 897
Ann Arbor staging system, for Hodgkin’s disease, 363, 363t
Annular skin lesion, 309
Anosmia, 1002
Anosognosia, 80
Anosognosia, 80
Antacids, for erosive gastropathies, 834
Antacids, for indigestion, 247
Antacids, for peptic ulcer disease, 833
Antacids, for systemic sclerosis, 889
Anterior ischemic optic neuropathy (AION), 216f, 217
Anthrax, 162, 201
As bioWeapon, 162, 164t
Antacids, for erosive gastropathies, 834
Antacids, for indigestion, 247
Antacids, for peptic ulcer disease, 833
Antacids, for systemic sclerosis, 889
Anterior ischemic optic neuropathy (AION), 216f, 217
Antibacterial resistance, 422
emerging problems, 432
Antibacterial therapy, 422
adverse reactions to, 424
choice of antibacterial agents, 424, 425t–427t
mechanisms of drug action, 422
pharmacokinetics of antibiotics, 423
principles of, 423
susceptibility testing, 413
toxicity of, 342t
Antibody detection, tissue parasites, 421
Anticholinergics
for asthma, 754–755
for COPD, 761–763
for diverticular disease, 842
for irritable bowel syndrome, 841
for Parkinson’s disease, 1004
poisoning, 131t
Anticholinesterase drugs
for myasthenia gravis, 1066
poisoning, 142t
Anticoagulants
for deep venous thrombosis, 770–771
for myocardial infarction, 702
for pulmonary embolism, 770–771
for SLE, 886
for stroke, 84
preventive treatment, 85
for thrombotic disorders, 336–337, 337t
Anticonvulsants
for pain, 36t–37t, 38
poisoning, 143t
for polyneuropathy, 1061
for subarachnoid hemorrhage, 89
Antidepressants, 1085
for Alzheimer’s disease, 1000
for chronic fatigue syndrome, 291
for depression, 1079
for fibromyalgia, 909
for insomnia, 228
for irritable bowel syndrome, 842t
for pain, 36t–37t, 38
for panic disorder, 1081
poisoning, 138t
for smoking cessation, 1127
Withdrawal syndromes, 1088
Antidiabetics, 133
Antifungal agents, 619
topical, 620
Antigen detection
bacterial and viral infections, 411
tissue parasites, 421
Antigenic drift, 577
Antigenic shift, 577
Anti-glomerular basement membrane disease, 802, 803
Antihistamines
for allergic rhinitis, 880
for antivenom reaction, 122
for chronic fatigue syndrome, 291
for erythema multiforme, 318
for hymenoptera sting, 126
for nausea and vomiting, 245
for pityriasis rosea, 314
poisoning, 138t, 149t, 153t
for scombroid poisoning, 124
for systemic mastocytosis, 881
for urticaria/angioedema, 879
Anti-LKM antibodies, 867
Antimarial, 638t, 639t
poisoning, 146t, 153t
for SLE, 886
Antimetabolites, toxicities of, 341t
Antimonial compounds, for leishmaniasis, 643–644
Antineuronal antibodies, paraneoplastic, 407, 409t
Antineutrophil cytoplasmic autoantibodies (ANCA), 892
glomerulonephritis, 803
Antinuclear antibodies, 743, 774, 865, 867
Antipleatlet agents
for stroke, 84
preventive treatment, 85
for thrombotic disorders, 338
Antiplatelet agents
for stroke, 84
preventive treatment, 85
for thrombotic disorders, 338
Antipsychotics, 1090t–1091t
conventional, 1081, 1088–1092, 1090t
for ergot alkaloid poisoning, 137t
novel, 1081, 1091t, 1092
poisoning, 138t, 149t, 153t
for schizophrenia, 1081
Antipyrretics, 201
Antiretroviral therapy, 606–617, 607t–615t, 617t
Antisocial personality disorder, 1084
Antithrombotic drugs
for myocardial infarction, 710–711
for unstable angina, 710–711
Antithymocyte globulin, for aplastic anemia, 329
α1-Antitrypsin deficiency, 761
Antitussive agents, 235
Antivenom
for snakebite, 121–122
sources of, 123
Antrectomy, 833t
Anuria, 276
Anxiety attack, 210
Anxiety disorder, 1081
Anxiolytics, 1088, 1089t
Aorta
abdominal, occlusive disease of, 738
correction of, 676, 693
Aortography, 736
echocardiography in, 671, 672t
Aortic aneurysm, 736
Aortic dissection, 736, 738t
chest pain in, 176, 177f
classification of, 736–737, 737f
Aortic regurgitation, 662t, 681
echocardiography in, 671f
Aortic stenosis, 662t, 681, 682f
echocardiography in, 671f
Aortography, 736
Aphasia, 224, 225t
Aplastic anemia, 323, 329, 331
Aplastic crisis, parvovirus infections, 587–588
Apnea, in terminally ill patient, 53t
Apo B-100, familial defective, 969t, 970
Apo CII deficiency, 969t, 973
Aprepitant, for nausea and vomiting, 48, 246, 344
Arachnoiditis, lumbar, pain in, 193
Arbovirus infection, 595, 596t–597t
Arcanobacterium haemolyticum infection, 503
Argatroban
for heparin-induced thrombocytopenia, 334
for thrombotic disorders, 337
Arginine
for schizophrenia, 1081
Aripiprazole
dosage and adverse effects of, 1091t
for schizophrenia, 1081
Aromatase inhibitors, for breast cancer, 376, 378–379
Arrhythmia
bradyarrhythmia, 717
drug-induced, 1135t
in myocardial infarction, 704
serum magnesium and, 704
syncope in, 208, 209t
tachyarrhythmias, 720
Arsenic poisoning, 154t–155t
Arsenic trioxide, for AML, 346
Artemether, for malaria, 639t
Artemether-lumefantrine, for malaria, 638t
Artemis gene, 882
Artemisinin derivatives, for malaria, 637, 638t
Arterial blood gases (ABG), 749
in acid-base disorders, 16, 20
Arterial embolism, 739
Arteriosclerosis, of peripheral arteries, 739
Arteriovenous fistula, dural, 82t
Arteriovenous malformation, 1030
intracranial hemorrhage in, 82t
subarachnoid hemorrhage in, 88
Arteritis, 891–892
Artemis gene, 882
Arthritis. See also specific types
gonococcal, 469, 481–482
infectious, 481
HACEK group, 511
S. aureus, 491, 496
streptococcal, 499–500
treatment of, 482
mycoplasmal, 471
nongonococcal bacterial, 481
noninfectious inflammatory, 482
rash and, arboviral disease, 595–596
synovial fluid analysis in, 482
Arthritis mutilans, 898t
Arthropod bite/sting, 124
Arthropod-borne disease protozoan infections, 636
viral infections, 593
Arthropod ectoparasites, 657
Arthroscopic therapy, for osteoarthritis, 902
Asbestosis, 757
Asbestos-related disease, 757
Ascaris, 649
Ascites, 241, 271
chylous, 272, 273t
cirrhotic, 272, 273t
complications of, 272–274
fluid characteristics, 273t
pancreatic, 852
paracentesis, 28–29
primary bacterial peritonitis and, 448
refractory, 272
serum-ascites albumin gradient, 273t
L-Asparaginase, for acute lymphoblastic leukemia and lymphoblastic lymphoma, 359
Aspartate aminotransferase (AST), 268, 268t, 850
Aspergilloma, 622–623, 624t
Aspergillosis, 432, 621
allergic bronchopulmonary, 622, 624t
cerebral, 622
disseminated, 622
pulmonary
chronic, 622–623, 625t
invasive, 622, 624t
sinusitis, 622–623
treatment of, 623, 624t–625t
Asphyxiants, poisoning, 131t, 145t
Aspirin
for angina pectoris, 716
for atrial fibrillation, 726
for cardiovascular disease prevention, 1120
for colon cancer prevention, 1124
for fever, 201
low-dose, 1120
for migraine, 185t
for myocardial infarction, 701–702, 710, 712
preventive treatment, 709
for pain, 36–37, 38
for pericarditis, 688
for rheumatoid arthritis, 887
for stroke, 84
preventive treatment, 86, 87t
for superficial thrombophlebitis, 740
for tension headache, 186
for thrombotic disorders, 338
for unstable angina, 710
Assist-control ventilation, 72, 73t
Assisted reproductive technology, 958
Asterixis, 224
Asthma, 753
chronic, 754–755
dyspnea in, 233
intrinsic, 753
occupational, 753, 758
pulmonary function tests in, 753–754
sleep disorders in, 227, 229t
Asthma exacerbations, 755
Astrocytoma, 1032, 1032f
Asystole, 57, 58f
Ataxia, 1007
acute, 1008t
approach to, 1007–1009, 1008t, 1009f
chronic, 1008t
inherited, 1009
subacute, 1008t
Ataxia-telangiectasia, 883
Atazanavir, for HIV/AIDS, 613t
Atenolol
for hypertension, 695t
poisoning, 140t
for thyrotoxicosis, 929
for vasovagal syncope, 210
Atheroembolism, 740
renal, 821
Atherosclerosis
C. pneumoniae infection and, 563
prevention of complications of, 974
risk factors for, 1118, 1118t
Athetosis, 223
Atorvastatin
for hyperlipidemia, 972t
for myocardial infarction, 711
preventive treatment, 709
for unstable angina, 711
Atovaquone
for babesiosis, 107t, 642
for Pneumocystis infections, 634t, 635
preventive treatment, 635t
Atovaquone-proguanil for malaria, 638t
preventive treatment, 640t
Atrial fibrillation, 721f, 723t
antithrombotic prophylaxis in, 85–86, 87t
chronic, 726
Atrial flutter, 721f, 723t
Atrial premature beats, 722t
Atrial septal defect, 674
ostium primum, 674
ostium secundum, 674
Atrial tachycardia, 722t
with block, 721f
multifocal, 723t
Atrioventricular (AV) block, 718
causes of, 718t
drug-induced, 718t, 1136t
first degree, 719, 719f
in myocardial infarction, 704
second degree
Mobitz I, 719, 719f
Mobitz II, 719, 719f
third degree (complete), 719, 719f
Atrophy (skin lesion), 313t
Atropine
for beta blocker poisoning, 140t
for bradycardia, 702
for calcium channel blocker poisoning, 140t
for cardiac glycoside poisoning, 141t
for cholimergic poisoning, 142t
for inflammatory bowel disease, 838
for nerve agent exposure, 169–171, 170t
poisoning, 138t
for sympatholytic poisoning, 139t
for tachyarrhythmias, 724t
Audiologic assessment, 298
Auer rods, 322
Auscultation, 663
Autoimmune disease
leukopenia in, 331
thrombocytopenia in, 332
in women, 1129
Autoimmune hemolysis, 329
Autologous transfusion, 45
Automated external defibrillator, 55–56
Autonomic nervous system (ANS)
activation of, 1015t
anatomy of, 1014f
function tests, 1016
Autonomic nervous system (ANS) disease, 1013
approach to, 1015
autoimmune, 1016–1018
with brain involvement, 1017t
classification of, 1017t–1018t
drug-induced, 1015
with multisystem degeneration, 1017t
with spinal cord involvement, 1017t
treatment of, 1019
Avascular necrosis, 909
Avoidant personality disorder, 1085
Axillary lymph node, carcinoma in, 402
5-Azacytidine, for myelodysplastic syndromes, 350
Azathioprine
for autoimmune hepatitis, 867
for inflammatory bowel disease, 838
for inflammatory myopathy, 1072
for multiple sclerosis, 1039
for myasthenia gravis, 1066
for myocarditis, 687
for polyneuropathy, 1061
for reactive arthritis, 900
for rheumatoid arthritis, 888
for SLE, 803, 886
toxicity of, 341t
for vasculitis, 894
Azelastine, for allergic rhinitis, 880
Azithromycin
for babesiosis, 107t, 642
for Bartonella infections, 526t
for chancroid, 476
for choler, 453
for C. pneumoniae infections, 563
for C. trachomatis infections, 562
for diarrhea, 1117
for donovanosis, 476
for H. influenzae infections, 1072
indications for, 426t
for Legionella infections, 522
for meningococcal disease prevention, 506t
for M. pneumoniae infections, 560
for nontuberculous mycobacterial infections, 548
for otitis media, 303t
for pertussis, 510
for pneumonia, 766t
resistance to, 426t
for shigellosis, 459
for traveler’s diarrhea, 451
for urethritis in men, 463
Azotemia, 274, 275f
intrinsic renal, 792t
prerenal, 276, 791, 792t
Aztreonam
indications for, 426t
for pyelonephritis, 818t
resistance to, 426t
for sepsis/septic shock, 65t
for urinary tract infections, 819t
B
Babesiosis, 106, 107t, 125, 420t, 642
Babinski sign, 219t, 984
Bacillary angiomatosis, 479t, 526t, 527
Bacillary peliosis, 526t, 527
Bacille Calmette-Guérin, intravesical instillation of, 392
Bacillus anthracis infection. See Anthrax
Bacillus cereus infection, 453
Back pain, 189. See also Low back pain
approach to, 114f
cancer patient with, 114f
Baclofen
for dystonia, 223
poisoning, 144t
for trigeminal neuralgia, 1020
Bacteremia
Aeromonas, 516
anaerobic, 534
clostridial, 531
E. coli, 514
Klebsiella, 515
listerial, 507
P. aeruginosa, 517, 519t
S. aureus, 491
streptococcal, 498–499
Bacterial infection
anaerobic. See Anaerobic infection
diagnosis of, 411
Bacterial vaginosis, 464, 471, 533
Bacteriuria, asymptomatic, 815, 817
Bacteroides fragilis
infection, 532
Balanitis, circinate, 899
Balkan endemic nephropathy, 812
Balloon dilatation, for esophageal disorders,
251
Balloon tamponade, for esophageal varices,
874
Barbiturate(s)
for isoniazid poisoning, 150t
poisoning, 143t
for sedative-hypnotic poisoning, 143t
Barbiturate coma, 92t
Bariatric surgery, 940–941, 941f
Barium contrast x-ray study, 256
Barium enema, air-contrast, 387
Barium radiography, for GI bleeding, 260
Barium swallow, 250–251, 380–381
Barotrauma, 74
Barrett’s esophagus, 246, 379
Barrier contraception, 957
Bartonella
infection, 526, 526t
Bartter’s syndrome, 788
Basil cell carcinoma, 366
keratotic, 366
morphoeform, 366
nodoulcerative, 366
pigmented, 366
superficial, 366
Basal energy expenditure, 39, 39f
Basic life support, 55–57, 56f–58f
Basophilia, 330
Basophilic stippling, 321
Bechterew’s disease. See Ankylosing
spondylitis
Beclomethasone
for allergic rhinitis, 880
for asthma, 755
Bed nets, 1116
Beer poismania, 3
Bee sting, 126
Belladonna alkaloid poisoning, 138t
Bell’s palsy, 565, 1021
Belsey procedure, 247
Benign paroxysmal positional vertigo, 213,
213t, 214t
Bentzonemide test, 852

Benzathine penicillin
for diphtheria prevention, 503
for endemic treponematosis, 551
for pharyngitis, 304t
for rheumatic fever prevention, 678
for streptococcal infections, 498t
for syphilis, 474t
Benzene derivative poisoning, 858
Benznidazole, for Chagas’ disease, 645
Benzodiazepines, 1088
for alcohol withdrawal, 1098
dosage and action of, 1089t
for dystonia, 223
generalized anxiety disorder, 1082
for panic disorder, 1082
poisoning, 143t
sedative-hypnotic poisoning, 143t
for sympathomimetic poisoning, 136t
Benzoyl peroxide, for acne, 318
Benztropine
for extrapyramidal reactions, 149t
for Parkinson’s disease, 1004
Berylliosis, 758
Beta agonists
for asthma, 754
for COPD, 761–762
Beta blockers
for angina pectoris, 715
for aortic dissection, 738, 738t
for cardiomyopathy, 685–686
for glaucoma, 295
for heart failure, 731–732, 732t, 733t,
735
for hypertension, 695, 695t, 697t
for mitral regurgitation, 679
for mitral stenosis, 678
for mitral valve prolapse, 681
for myocardial infarction, 702, 711–712
preventive treatment, 709
poisoning, 140t, 153t
for sinus tachycardia, 704
tachyarrhythmias, 722t–724t
for thyrotoxicosis, 929–930
for unstable angina, 711
for Wolff-Parkinson-White syndrome,
729
Beta-carotene, for erythropoietic porphyria,
978
Betamethasone, 938–939, 938t
Betamethasone, 938–939, 938t
Beta radiation, 171
Bethanecholel
for multiple sclerosis, 1041
poisoning, 142t
Bevacizumab
for colorectal cancer, 387
for kidney cancer, 393
toxicity of, 342t
Bicarbonate, renal retention of, 19
Bicarbonate therapy
for metabolic acidosis, 19, 62
for renal tubular acidosis, 814–815
for tumor lysis syndrome, 116
Bichloroacetic acid, for HPV infection, 476
Bicuspid aortic valve, congenital, 696
Bile ducts, diagnostic evaluation of, 846t
Bile salt deficiency, 259t
Biliary colic, 844–845
Biliary disease
gram-negative enteric bacteria, 516
infections in cancer patients, 433t
Bilirubin, serum,
conjugated fraction (direct), 264, 264t, 267
unconjugated fraction (indirect), 264, 264t, 267
Binge eating, 1093
Biopsy. See also specific organs
collection and transport of, 417t
Bioterrorism
chemical, 168
microbial, 160
radiation, 171
Bipolar disorder, 1079
Bisacodyl, for constipation, 48t
Bismuth subsalicylate
for diarrhea, 1117
for H. pylori eradication, 833t
Bisoprolol, for heart failure, 733t
Bisphosphonates
for breast cancer, 379
for hypercalcemia, 406
for osteoporosis, 967
Bite
arthropod, 124
mammalian, 117
treatment of, 121
management of wound infections, 119t–120t
snakebite, 121
Bladder cancer, 391
Blastomycosis, 630
South American, 631
Bleeding disorders, 332
blood vessel wall defects, 334
cogulation disorders, 334
gastrointestinal, 259
platelet disorders, 332
treatment of, 334–335
Bleomycin
for germ cell tumor, 402
for testicular cancer, 394
toxicity of, 342t
Blepharoconjunctivitis, 294
Blepharospasm, 1022–1023
Blocking agents, for radionuclide contamination, 174
Blood
reference values for laboratory tests, 1141
specimen collection and transport, 414t
toxicologic analysis of, 133, 1157t–1159t
Blood loss
anemia in, 280, 326
symptoms of, 260
Blood smear, 321
erthrocyte abnormalities, 321–322
leukocyte abnormalities, 322
platelet abnormalities, 322
Blood urea nitrogen, 274
Blood vessel wall defects, 334
Blood volume, disorders of, 209t
Blue toe syndrome, 740
Body fluids
reference ranges for volumes of, 1171t
specimen collection and transport, 416t
Body louse, 658–659
Body mass index (BMI), 39, 939, 1171t
Body temperature, 199
Body weight. See Weight entries
Bolivian hemorrhagic fever, 598
Bone density, 967
Bone disease
anaerobic infections, 533
drug-induced, 1140t
neck pain in, 198
ostemalacia, 967
osteoporosis, 965
P. aeruginosa infections, 517, 519t
Bone marrow
cellularity of, 323
damage causing anemia, 323–324
erthroid:granulocytic ratio, 323
examination of, 282, 322
Bone marrow aspirate, 322
reference values for specific analytes, 1164t
Bone marrow failure, 331
Bone marrow transplant, 883
for acute lymphoblastic leukemia and lymphoblastic lymphoma, 359
for AML, 346–347
for CML, 347
for myelodysplastic syndromes, 350
Bone metastasis, osteoblastic, in men, 404
Borderline personality disorder, 1084
Borrelia burgdorferi infection. See Pertussis
Borrelia recurrentis infection, 553
Botulinum toxin
for achalasia, 251
for anal fissures, 844
as bioweapon, 165t, 167
for dystonia, 223
for hemifacial spasm or blepharospasm, 1023
Botulism, 529, 1018
as bioweapon, 530
food-borne, 530
intestinal, 530
treatment of, 165t, 530
wound, 530
Botulism antitoxin, 530
Botulism immune globulin, 530
Bounding pulse, 661, 661f
Bowen’s disease, 360
BPM regimen, for Burkitt’s lymphoma/leukemia, 360
Brachial neuritis, acute, 198
Brachial plexus, injury to, 198
Brachytherapy, interstitial, 1032
Bradycardia, 717
Bradykinesia, 218, 222
Brain abscess, 109t, 111, 1042, 1050
anaerobic, 533
nocardiosis, 535–536
streptococcal, 501
Calcium oxalate deposition disease, 907
Calcium oxalate stones, 827, 828t
Calcium phosphate stones, 827, 828t
Calcium polycarbophil, for irritable bowel syndrome, 842t
Calcium therapy for beta blocker poisoning, 140t
for calcium channel blocker poisoning, 140t
for colon cancer prevention, 1124
for hyperkalemia, 15t
for hypermagnesemia, 965
for hypocalcemia, 963–964
for hypoparathyroidism, 964
for osteoporosis, 967
for primary sclerosing cholangitis, 848
Calicivirus infection, diarrhea, 454
Calorics, 211
Calvert formula, 397
Campylobacteriosis, 458
proctocolitis, 468
Cancer. See also specific types and sites
depression in, 1078
detection of, 1121
fatigue in, 289t
infections in cancer patients, 432, 433t
leukocytosis in, 330
lifestyle factors that reduce risk of, 1121t
oncologic emergencies, 112
paraneoplastic syndromes
endocrine, 405
neurologic, 407, 408t
prevention of, 1104t–1105t, 1121
in high-risk groups, 1122
screening for, 1104t–1105t, 1121
lead-time bias, 1121
overdiagnosis, 1121–1122
selection bias, 1122
spinal cord compression in, 94
tumor growth, 339
vaccination of cancer patients, 438t
warning signs of, 1125
Cancer chemotherapy, 339
categories of agents, 339
complications of, 340–343
curability of cancers with, 340t
development of drug resistance, 339
leukopenia in, 331
nausea and vomiting in, 245t, 246
toxicities of agents, 339, 341t–342t
management of, 343–344
Cancer of unknown primary site, 401
cytogenetics in, 403t
cytokeratin markers, 402, 404f
histology of, 402, 403t
pathologic evaluation of biopsy specimens from, 403t–404t
prognosis for, 402
Carcinosarcoma, 532
Candesartan for heart failure, 733t
for hypertension, 695t
for myocardial infarction, 704
Candidemia, 621
Candidiasis, 317, 620
cutaneous, 311, 620–621
depthly invasive, 621
disseminated, 201
esophageal, 252, 620–621
mucocutaneous, 620, 884
thrush, 620–621
urinary tract, 620
vulvovaginal, 317, 464, 620–621
Capcetabine for breast cancer, 379
for pancreatic cancer, 389
toxicity of, 341t
Capillar telangiectasia, 82t
Captopril for ergot alkaloid poisoning, 137t
for heart failure, 731, 733t
for hypertension, 695t, 696
for myocardial infarction, 704
preventive treatment, 709
Carbamazepine for bipolar disorder, 1080
dosage and adverse effects of, 143t, 153t, 1092t
for glosopharyngeal neuralgia, 1024
for multiple sclerosis, 1041
for pain, 36t–37t
for seizures, 992t–993t, 994t
for trigeminal neuralgia, 1020
Carboplatin for engogt alkaloid poisoning, 137t
for heart failure, 731, 733t
for hypertension, 695t
for myocardial infarction, 704
for seizures, 992t–993t, 994t
for trigeminal neuralgia, 1020
Carpinazole, for thyrotoxicosis, 929
Carbon monoxide poisoning, 98, 130, 145t, 758
Carbon tetrachloride poisoning, 858
Carboplatin for bladder cancer, 392
for head and neck cancer, 368
for ovarian cancer, 397
for toxicity of, 341t
Carcinob, 491
Carcinoid syndrome, 389, 390t
Carcinoid tumor, 389
paraneoplastic syndromes in, 405t
Carcinomatosis, peritoneal, in women, 402
Cardiac arrest, 55
follow-up of, 57–58
management of, 55–57, 56f–58f
Cardiac biomarkers, in myocardial infarction, 700–701, 709
Cardiac catheterization in cardiac tamponade, 689
in cardiomyopathy, 684t, 686
in constrictive pericarditis, 691
in pulmonary hypertension, 743–744
Cardiac disease, See Heart disease
Cardiac glycoside poisoning, 141t
Cardiac tamponade, 60t, 689
Cardiac toxicity, 733
Cardiobacterium hominis infection. See HACEK group infection
Cardiogenic shock, 30, 31f, 59t, 60t, 62, 706t, 707
Cardiomyopathy, 684
dilated, 684
laboratory evaluation of, 684t, 685
drug-induced, 1136t
hypertrophic, 662t, 686
ECG in, 666, 668t
laboratory evaluation of, 684t, 686
restrictive, 685, 692t
laboratory evaluation of, 684t, 686
Cardiopulmonary resuscitation, 55–57, 56f
for hypothermia, 128
Cardiovascular collapse, 55, 55t
Cardiovascular disease. See also Heart disease
drug-induced, 1135t–1136t
prevention of, 1118
antithrombotic therapy, 1120
lifestyle modifications, 1121
risk factors for, 1118–1120
syncpe in, 208, 209t
syphilis, 473
Carisoprodol poisoning, 144t
Carnitine palmitoyltransferase deficiency, 1073
Carotene, serum, 264
Carotene supplementation, for macular degeneration, 296
Carotid artery pulse, 661, 661f
Carotid endarterectomy, 86
Carotid sinus hypersensitivity, 209t
Carotid sinus hypersensitivity, 209t
for heart failure, 732, 733t
for hypertension, 695t
poisoning, 140t
Casposfungin, 620
for candidiasis, 621
Castleman’s disease, multicentric, 572
Cast nephropathy, 812t, 813
Cataplexy, 228, 229t, 230, 230t
Carvedilol
for heart failure, 732, 733t
for hypertension, 695t
poisoning, 140t
Ceftizoxime
for gonococcal infections, 470t
for pelvic inflammatory disease, 466
resistance to, 425t
Cefotaxime
for bacterial meningitis, 1046t, 1047t
for brain abscess, 1051
for gonococcal infections, 470t
for meningococcal infections, 506t
for nocardiosis, 536t
for pneumococcal infections, 488
for pneumonia, 766t
for sepsis/septic shock, 65t, 107t
Cefotaxime
for gonococcal infections, 470t
for urethritis in men, 463
Ceftriaxone
for arthritis, infectious, 482
for bacterial meningitis, 108t, 1046t, 1047t
for Bartonella infections, 526t
for brain abscess, 109t, 1051
for chancroid, 476
for epidemic typhus, 463
for epidural abscess, 109t
for gonococcal infections, 470t
for HACEK group infections, 512t
for H. influenzae infections, 509
indications for, 425t
for infectious endocarditis, 109t, 444t–445t, 446
for leptospirosis, 553
for Lyme borreliosis, 550–551
for meningococcal infections, 506t
preventive treatment, 506t, 1045
for meningococcemia, 107t
for nocardiosis, 536t
for osteomyelitis, 485t
for otitis media, 303t
for pelvic inflammatory disease, 466
for peritonitis, 448
for pneumococcal infections, 488
for pneumonia, 766t, 767t
for post-splenectomy sepsis, 107t
for purpura fulminans, 108t
for pyelonephritis, 818t
for resistance to, 425t
for sepsis/septic shock, 65t
for shigellosis, 459
for typhoid fever, 457
for urethritis in men, 463
for urinary tract infections, 819t

Cefuroxime
for otitis media, 303t
for pneumonia, 766t

Celecoxib
for colon cancer prevention, 1124
for pain, 36t–37t, 38

Celiac arteriography, 873

Cellophane tape methods, 421

Cellulitis, 478, 479t
anaerobic, 531
auricular, 304
clostridial, 531
E. coli, 513–514
Klebsiella, 515

nocardiosis, 535, 536t
streptococcal, 513–514

for for streptococcal infections, 498

Cerebellar degeneration, paraneoplastic, 407, 408t, 409t

Cerebral angiography, 88
Cerebral edema, 859
Cerebral herniation, 90, 91f
Cerebral palsy, 223
Cerebral perfusion pressure (CPP), 90
Cerebral salt wasting, 89
Cerebritis, 1042, 1050

Cerebrospinal fluid analysis
in bacterial meningitis, 1044–1045, 1045t
in chronic meningitis, 1052–1053
lumbar puncture, 27–28, 28f
reference values for specific analytes, 1162t
specimen collection and transport, 416t
in viral meningitis, 1046–1047
Cernunnos gene, 882

Ceruloplasmin, serum, 978
Cerumen impaction, 297–300
Cervical angina syndrome, 198
Cervical cancer, 397
prevention of, 398, 477, 1124–1125
risk factors for, 1124
screening for, 398, 1123t
staging and prognosis in, 396t, 398
Cervical intraepithelial neoplasia, 1125
Cervical lymph node metastasis, 404
Cervical spine disease, pain in, 176f, 178, 196
Cervicitis
chlamydial, 471
gonococcal, 465, 468
mucopeulent, 465
Cestode infection, 655

Cetirizine
for allergic rhinitis, 880
for urticaria/angioedema, 879

Cetuximab
for colorectal cancer, 387
for head and neck cancer, 368
toxicity of, 342t

Cevimeline, for Sjögren’s syndrome, 891

Chagas’ disease, 644
acute, 644–645
chronic, 644–645
Chagoma, 644
Chancroid, 475, 478
features of genital ulcers, 467t

Channelopathy, 1074

Charcoal, activated. See Activated charcoal
Charcot’s joint, 473, 908
Charcot’s triad, 848

Chelation therapy
for heavy metal poisoning, 157t, 159t
for hemochromatosis, 975
for radionuclide contamination, 174

Chemical bioterrorism, 168

Chemotherapy, cancer. See Cancer chemotherapy

Chest pain, 175
approach to, 177f, 178
causes of, 175–178, 175t
differential diagnosis of, 176f
in myocardial infarction, 700
noncardiac, 250

Chest tube, 778, 780

Chest wall disease, 231, 748t, 782
Chest wall pain, 175t, 176f, 178
Chest x-ray
in cardiomyopathy, 684, 684t
in congenital heart disease, 674
in cor pulmonale, 735
in hemoptysis, 237
indications for, 22
in interstitial lung disease, 774
in myocarditis, 687
normal radiograph, 23f
in pericardial disease, 688
in pneumonia, 765
in pulmonary embolism, 770
in respiratory disease, 751
in superior vena cava syndrome, 112
utility of, 22
in valvular heart disease, 678
Cheyne-Stokes respiration, 53t
Chickenpox, 569. See also Varicella-zoster virus infection
Chikungunya virus infection, 596
Child-Pugh classification, of cirrhosis, 869t
Chinese herbal nephropathy, 812
Chlamydial infection, 469, 561
cervicitis, 465, 471
epididymitis, 463, 471
pelvic inflammatory disease, 465, 471
proctitis, 468, 471
salpingitis, 471
urethritis, 463–464, 471
Chlamydia pneumoniae infection, 563
atherosclerosis and, 563
Chlamydia psittaci infection, 562
Chlamydia trachomatis infection, 469, 561
Chloral hydrate poisoning, 144t
Chlorambucil, 341t
Chloramphenicol for Bartonella infections, 526t
for meningococcal infections, 506t
for plague, 164t, 526
for relapsing fever, 553
to Rocky Mountain spotted fever, 555
for scrub typhus, 557
for tick-borne spotted fevers, 555
tularemia, 165t, 524
Chlordiazepoxide dosage and action of, 1089t
poisoning, 143t
Chloroquine for inflammatory bowel disease, 840
for malaria, 638t
preventive treatment, 640t
poisoning, 153t
for porphyria cutanea tarda, 977
Chlorpheniramine for allergic rhinitis, 880
for urticaria/angioedema, 879
Chlorpromazine for delirium, 50t
dosage and adverse effects of, 138t, 139t, 1091t
for migraine, 186t
for serotonin syndrome, 152t
Chlorthalidone for edema, 243t
for hypertension, 695t
Cholangiography, 270
Cholangiopancreatography, 846t, 848
Cholangitis, 847
E. coli, 513
primary sclerosing, 848
Cholecystectomy, 845, 847–848
Cholecystitis acute, 845
chronic, 847
Cholechocholiathiasis, 847
Cholelithiasis, 844, 846t
Cholera, 453
Cholera vaccine, 1116t
Cholestasis, liver function tests in, 268t
Cholesteatoma, 298
Cholesterol blood cardiovascular disease and, 1118–1119, 1119t
goals and cutpoints for therapeutic intervention, 1119t
reference values for laboratory tests, 1116t
HDL, 968–970, 969t
LDL, 968–970, 969t
total, 968–970, 969t
Cholesterol emboli, 821
Cholesterol gallstones, 844
Cholestyramine for erythropoietic porphyria, 978
for hyperlipidemia, 972t
for irritable bowel syndrome, 841, 842t
for nephrolithiasis, 828t
for primary biliary cirrhosis, 871
for primary sclerosing cholangitis, 848
toxic and drug-induced hepatitis, 858
for viral hepatitis, 858
Cholnorganic crisis, 169
Cholinergic poisoning, 131t, 142t
Cholinesterase inhibitors, for Alzheimer’s disease, 1000
CHOP regimen, for follicular lymphoma, 357
Choreaathetosis, 223
Choriocarcinoma, 393
Chronic fatigue syndrome, 290, 1078
CDC criteria for diagnosis of, 290t
Chronic kidney disease, 794
Chronic obstructive pulmonary disease (COPD), 759
dyspnea in, 231, 233
pulmonary function tests in, 759, 760t, 761
sleep disorders in, 228
treatment of exacerbations of, 762–763
outpatient therapy, 761–762
surgery, 762
Chronic progressive external ophthalmoplegia (CPEO), 1074
Churg-Strauss syndrome, 891
Chvostek’s sign, 963
Chylolothorax, 780
Ciclopirox olamine, 620
dermatophyte infections, 317
Cidofovir for adenovirus infections, 583
for cytomegalovirus infections, 574
Ciguatera poisoning, 123
Cilostazol, for arteriosclerosis, 739
Cimetidine for antivenom reaction, 122
erosive gastropathies, 834
Ciprofloxacin for Aeromonas infections, 516
for animal bite infections, 119t, 479t
for anthrax, 164t
for arthritis, infectious, 482
for Bartonella infections, 526t
campylobacteriosis, 458
for chancroid, 476
for cholecytisitis, 847
for cholera, 453
diverticulitis, 842
indications for, 427t
inflammatory bowel disease, 840
intestinal pseudoobstruction, 843
for meningococcal disease prevention, 506t, 1045
for necrotizing fasciitis, 480t
for osteomyelitis, 485t
for P. aeruginosa infections, 519t–520t
for perichondritis, 304
for peritonitis prevention, 449
for plague, 526
for pneumonia, 766t, 767t
for Q fever, 559
for sepsis/septic shock, 65t
for shigellosis, 459
for staphylococcal infections, 494t, 496
for tick-borne spotted fevers, 555
for tuberculosis, 542
for tularemia, 165t
for typhoid fever, 457
Circadian rhythm disorder, 226, 230
Circulatory function tests, reference values for, 1166t
Cirrhotic function tests, reference values for, 1166t
Cirrhosis, 868
ascites in, 272, 273t
causes of, 868t
Child-Pugh classification of, 869t
complications of, 868, 869t
edema in, 241, 243
liver function tests in, 268t
primary bacterial peritonitis in, 448
primary biliary, 870
Claspin
for bladder cancer, 392
for cervical cancer, 398
for endometrial cancer, 397
for extravascular germ cell tumor, 402
for gastric cancer, 381
for head and neck cancer, 368
for lung cancer, 371
for ovarian cancer, 397
for testicular cancer, 394
for toxicity of, 341t
Citalopram
for depression, 50
dosage and adverse effects of, 1086t
Clonazepam
for dyspnea, 49t
for myoclonus, 224
for pain, 37t
for poisoning, 143t
for posthypoxic myoclonus, 98
for seizures, 994t
for vertigo, 214t
Clomipramine
for daytime sleepiness, 230
dosage and adverse effects of, 1086t
for OCD, 1082
Clonazepam
for action of, 1089t
for dyspnea, 49t
for myoclonus, 224
for poisoning, 143t
for posthypoxic myoclonus, 98
for seizures, 994t
for vertigo, 214t
Clonidine
for menopausal symptoms, 957
for narcotic withdrawal, 1100
poisoning, 139t
for smoking cessation, 1127
for tics, 224
Clonorchiasis, 654
Clotidogrel
for angina pectoris, 716
for myocardial infarction, 710, 712
for preventive treatment, 709
for stroke prevention, 85
for thrombotic disorders, 338
for unstable angina, 710
Clostridial infection, 530
bacteremia and sepsis, 531
food poisoning, 453
myonecrosis. See Gas gangrene
skin/soft tissue, 531
Clostridium botulinum infection. See Botulinism
Clostridium difficile-associated disease (CDAD), 431, 461
Clostridium tetani infection. See Tetanus
Clostrimazole, 620
for candidiasis, 252, 464
Clozapine
  dosage and adverse effects of, 139t, 1091t
  for schizophrenia, 1081
Clubbing, 239, 369
Cluster headache, 183–184, 183t
CMV regimen, for bladder cancer, 392
Coagulase-negative staphylococci, 493
Coagulation disorders, 334
  dilutional, 334
  drug-induced, 1134t
  intracranial hemorrhage in, 82t
  in liver disease, 269
  reference values for laboratory tests, 1142t–1144t
Coal tar shampoo, 315
Coal worker’s pneumoconiosis, 758
  hypertension in, 693
Cocaine, 136t, 152t, 153t
Coccidioidomycosis,
  cavitary pulmonary, 630
  disseminated, 630
  primary pulmonary, 629–630
  meningitis, 630
  pericarditis, 688
  in SLE, 885
Cochlear implant, 300
Cockcroft-Gault formula, 276
Codeine
  for cough, 235
  for dyspnea, 49t
  for hemoptysis, 238
  for pain, 36t–37t
  narcotic abuse, 1099
CODOX-M regimen, for Burkitt’s lymphoma, 360
Cognitive-behavioral psychotherapy, 1082
Colognino,
  for cough, 235
  for dyspnea, 49t
  for hemoptysis, 238
  for pain, 36t–37t
  narcotic abuse, 1099
  for pain, 36t–37t
COMIPLA-M regimen, for Burkitt’s lymphoma, 360
Cognitive-behavioral psychotherapy, 1082
Colchicine
  for cough, 235
  for dyspnea, 49t
  for hemoptysis, 238
  narcotic abuse, 1099
  for pain, 36t–37t
  narcotic abuse, 1099
Colonic angiodysplasia, 843
Colonic disease, 840
Colonic polyps, 383
  hereditary syndromes, 383, 384t
Colonic polyps, 383
  hereditary syndromes, 383, 384t
Colono scopy, 387, 1122, 1123t
  for colonic polyps, 383
  in diarrhea, 256
  for GI bleeding, 261
  virtual, 387
Color vision, drug-induced abnormalities, 1139t
Colorectal cancer, 385
  advanced tumor, 387
  local disease, 387
  pathology of, 385, 386f
  prevention of, 387, 1124
  risk factors for, 1124
  screening for, 387, 1105t, 1122, 1123t
  staging and prognosis for, 386f
Coma, 74
  approach to, 77–79
  differential diagnosis of, 76t
  eye movements in, 78–79
  in head trauma, 93
  hyperosmolar, 100
  myxedema, 927–928
  pupillary signs in, 78
  respiratory patterns in, 79
  responsiveness in, 78
Common cold, 301
  coronavirus, 581
  human RSV, 582
  rhinovirus, 581
Common variable immunodeficiency, 884
Complete transposition of the great arteries, 677
Complex regional pain syndrome, 1018
Compulsive personality disorder, 1084
Computed tomography (CT)
  in coma, 79
  in heart disease, 672t, 673
  hepato biliary, 270, 846t
  in increased intracranial pressure, 91
  indications for, 24
  neuroimaging, 986, 987t
  in osteomyelitis, 484t
  in poisoning, 133
  in respiratory disease, 751
  in stroke, 80, 85
  in subarachnoid hemorrhage, 88
  utility of, 24
Concussion, 91, 93
Conduction aphasia, 225–226
Condyloma acuminatum, 310f
Condylomata lata, 472
Confusion, 74
Congenital heart disease, 674
  cyanotic lesions with left-to-right shunt, 674
  cyanotic lesions without shunt, 676
  complex heart lesions, 676
  echocardiography in, 671
  endocarditis prophylaxis in, 677
  pulmonary hypertension in, 675
Congenital rubella syndrome, 585–586
Conjunctivitis
  acute hemorrhagic, 561
  enterovirus, 590
  adult inclusion, 561
  infectious, 887
  interstitial lung disease in, 775–776
  mixed, 890
  rheumatoid arthritis, 886
  Sjögren’s syndrome, 890
  SLÉ, 885
  systemic sclerosis, 888
Consciousness, disorders of, 74, 91
Constipation, 257
  causes of, 257–258
  drug-induced, 257, 1137t–1138t
  irritable bowel syndrome, 840, 842t
  in terminally ill patient, 48
  treatment of, 48, 48t, 258–259
Contact precautions, 429
Continuous renal replacement therapy, 793
Contraception, 957
Controller therapy, for asthma, 755
Conversion disorder, 1083
Coordination, testing of, 986
Copper metabolism, 978
Coprolalia, 223
Corneal abrasion, 294
Coronary arteriography, 711, 714
Coronary artery bypass surgery, 711, 716, 717
Coronary artery disease (CAD), 709, 710, 712
Coronary artery spasm, 714
Coronary vasospasm, 716
Coronavirus infection, 581
Cor pulmonale, 735
Corrosive ingestion, 135
Corticosteroid therapy for asthma, 754–756
for COPD, 762
Cortisol, excess of, 934
Cortisone for hypopituitarism, 922
steroid preparations, 938–939, 938
Corynebacterium diphtheriae infection. See Diphtheria
Corynebacterium infection, nondiphtherial species, 503
Costochondral pain, 178
Cough, 233
approach to, 234–235, 234f
drug-induced, 1136
for COPD, 762
Cough spasm, 714
Creutzfeldt-Jakob disease, 997
for allergic rhinitis, 880
for asthma, 755
for systemic mastocytosis, 881
Crossed SLR sign, 190
Croup, 306, 583–584
cranial nerves
CN I. See Olfactory nerve
CN II, 979–980
CN III, 981–982
CN IV, 981–982
CN V. See Trigeminal nerve
CN VI, 981–982
CN VII. See Facial nerve
CN VIII, 982–984
CN IX, 984
CN X. See Vagus nerve
CN XI. See Accessory nerve
CN XII. See Hypoglossal nerve
disorders of. 1020
multiple cranial nerve palsies, 1024
C-reactive protein, 1120
Creatinine, serum, 795
Creatinine clearance, 274, 276
Crest syndrome, 889
Creutzfeldt-Jakob disease, 997, 998, 1002
Crimean-Congo hemorrhagic fever, 598
Critical care medicine, 30
Critically ill patient, 30
initial evaluation of, 30
limitation or withdrawal of care, 33
mechanical ventilation, 30
monitoring in ICU, 32
multiorgan system failure, 32
neurologic dysfunction, 33
prevention of complications, 33
shock, 30
Crocodile tears, 1021
Crohn’s disease, 837
epidemiology of, 836, 836t
extraintestinal manifestations of, 838
treatment of, 838, 839f, 840
Cromolyn sodium for allergic rhinitis, 880
for asthma, 755
Cyanide poisoning, 145
Cyanosis, 239
causes of, 240t
central, 239, 240t
peripheral, 239, 240t
Cyclic adenosine monophosphate eyedrops, 891
Cyclic vomiting syndrome, 245
Cyclobenzaprine for back pain, 196
for multiple sclerosis, 1041
poisoning, 138t, 144t
Cyclopentolate, for corneal abrasion, 294
Cyclophosphamide for acute renal failure, 793
for breast cancer, 376, 378
for Burkitt’s lymphoma/leukemia, 359
for CLL, 356
for gastric cancer, 381
for idiopathic thrombocytopenic purpura, 335
for inflammatory myopathy, 1072
for multiple sclerosis, 1039
for myasthenia gravis, 1066
for polyneuropathy, 1061
for rheumatoid arthritis, 888
for SLE, 803, 886
Cyclophosphamide (Cont.):
for systemic sclerosis, 889
for vasculitis, 894
Cyclosarin, 169–171
Cyclosporiasis, 456
Cyclosporine
for aplastic anemia, 329
for inflammatory bowel disease, 840
for membranous glomerulonephritis, 804
for myasthenia gravis, 1066
for polyneuropathy, 1061
for primary sclerosing cholangitis, 849
for psoriasis, 314
for rheumatoid arthritis, 888
Cyclosporine eyedrops, 890–891
Cyproheptadine
for ergot alkaloid poisoning, 137t
for serotonin syndrome, 152t
for urticaria/angioedema, 879
Cystectomy, 392
Cysticercosis, 655, 656t
Cystine stones, 827, 828t
Cystitis, 815, 818t
hemorrhagic, drug-induced, 341t, 1138t
Cytarabine
for acute lymphoblastic leukemia and lym-
phoblastic lymphoma, 359
for AML, 346
toxicity of, 341t
Cytoadherence, 636
Cytokeratin, in cancer of unknown primary,
402, 404f
Cytomegalic inclusion disease, 573
Cytomegalovirus immune globulin, 574
Cytomegalovirus infection,
congenital, 573
in HIV/AIDS, 573–574
in immunocompromised host, 573, 800
mononucleosis, 573
neurologic disease, 573
perinatal, 573
pneumonia, 573–574
reinitis, 573
Cytarabine
for AML, 346
toxicity of, 341t
Cytotoxicity, 636
Cytokinetin, in cancer of unknown primary,
402, 404f
Cytomegalovirus infection, 572
congenital, 573
in HIV/AIDS, 573–574
in immunocompromised host, 573, 800
mononucleosis, 573
perinatal, 573
pneumonia, 573–574
reinitis, 573
D
Dacarbazine
for melanoma, 365
toxicity of, 341t
Dactinomycin, 342t
Dalbavancin, for staphylococcal infections,
494t
Dalteparin, for thrombotic disorders, 336
Danazol, for autoimmune hemolysis, 329
Dantrolene
for malignant hyperthermia, 203
for multiple sclerosis, 1041
Dapsone
for leprosy, 547
for Pneumocystis infections, 634t, 635
preventive treatment, 635t
poisoning, 460t
for recluse spider bite, 125
Daptomycin
adverse reactions to, 424
for enterococcal infections, 501
indications for, 426t
resistance to, 426t
for staphylococcal infections, 493, 494t
Darunavir, for HIV/AIDS, 614t
Dasatinib
for CML, 349
toxicity of, 342t
Daunorubicin
for acute lymphoblastic leukemia and lymph-
oblastic lymphoma, 350
for AML, 346
toxicity of, 341t
Daytime sleepiness, excessive, 226, 228,
229t, 784
DDAVP
for hyponatremia, 7
for hypovolemia, 7
for von Willebrand disease, 335
Death and dying,
brain death, 79
leading causes of death by age, 1103,
1104t–1105t
Death rattle, 52t
Debranching enzyme deficiency, 1073
Decerebration, 78
Decitabine, for myelodysplastic syndromes,
350
Decongestants
for chronic fatigue syndrome, 291
poisoning, 136t, 139t
for sinusitis, 302
Decontamination, after nerve agent exposure,
169
Decortication, 78
Deep-brain stimulation, 223, 1007
Deep venous thrombosis, 741, 769
causes of, 741, 741t
prevention of, 731, 741
thrombotic disorders, 336
factors contributing, 741–743
factors increasing, 741
factors decreasing, 741
Treatment of, 336–338, 337t, 741, 770–772
Defecation, 253
Deferasirox, for thalassemia, 328
Deferoxamine
for hemochromatosis, 975
for iron poisoning, 147t
for thalassemia, 328
Dehydration, in terminally ill patient, 52t
Delavirdine, for HIV/AIDS, 606, 609t
Delayed sleep phase syndrome, 226, 230
Delirium, 74, 75t
drug-induced, 75t, 1140t
step-wise evaluation of, 75–76, 77t
in terminally ill patient, 50, 53t
in terminal illness, 50, 50t
in terminal illness, 76
Delirium tremens, 1096–1098
Dexamethasone
for hypothyroidism, 406
for SIADH, 114, 406, 925
Dementia, 995. See also specific types
diagnosis of, 995, 996t, 997t, 999t
differentiation of major types, 997t
sleep disorders in, 227
Dementia with Lewy bodies, 995–998, 997t,
1001
Dengue fever, 595, 1116
Dengue hemorrhagic fever/dengue toxic
shock syndrome, 110, 599
Denileukin diftitox, 342t
Dental procedures, endocarditis prophylaxis before, 447t, 448
Dependent personality disorder, 1084
Depression
drug-induced, 1078, 1140t
major, 1077
with medical illness, 1078
in terminally ill patient, 49–50
treatment of, 50, 1078–1079, 1079f, 1088
weight loss in, 247
Dermatitis, 315
allergic contact, 315
atopic, 310f, 311f, 315
drug-induced, 1133t
irritant contact, 315
seborrheic, 315
stasis, 311f
Dermatofibroma, 311f
Dermatomes, 982f–983f
Dermatomyositis, 1072, 1073t
Dermatophyte infections, 311, 317
Desipramine
dosage and adverse effects of, 1086t
for pain, 36t–37t
Desloradine, for allergic rhinitis, 880
Desmopressin
for diabetes insipidus, 924–925
for hypopituitarism, 922t
Device-related infections, 429
Devic’s syndrome, 1041
Dexamethasone
for bacterial meningitis, 1045
for brain tumor, 1031
for H. influenzae infections, 509
for hirsutism, 955
for increased intracranial pressure, 92t
for multiple myeloma, 361
for nausea and vomiting, 343–344
for spinal cord compression, 95, 113
steroid preparations, 938–939, 938t
for typhoid fever, 457
Dexamethasone test, 934
Dextroamphetamine, for daytime sleepiness, 230
Dextromethorphan
for cough, 235
poisoning, 152t
Diabetes insipidus, 923
central, 7, 276t, 277, 923
drug-induced, 8, 1138t
gestational, 923
nephrogenic, 7, 276t, 277–278, 788, 923
treatment of, 7–8, 924–925
Diabetes mellitus, 942
cardiovascular disease and, 1120
clinical features of, 942–943
depression in, 1078
diagnosis of, 942, 943t
nephropathy, 805, 945
neuropathy in, 1016, 1061
retinopathy in, 296, 297f
risk factors for, 943t
of treatment of, 943–947, 944t–946t, 1120
hospitalized patient, 946–947, 946t
type 1, 942
type 2, 942
in women, 1129
Diabetic ketoacidosis, 21, 100, 943, 947
laboratory values in, 100f, 101
treatment of, 19, 101, 102t
Dialysis, 796
for acute renal failure, 793
hemodialysis, 797
for hypercalcemia, 962t
peritoneal, 797
Diarrhea, 254
from altered intestinal motility, 254
C. difficile-associated disease, 461
chronic, physical examination in, 255t
from decreased absorptive state, 254, 259t
drug-induced, 1137t–1138t
exudative, 254
hemorrhagic adenovirus, 583
infectious, 254–255, 255t, 451
inflammatory, 452, 456
noninflammatory, 451, 452t
pathogens causing, 452t
penetrating, 452t
irritable bowel syndrome, 840, 842t
metabolic acidosis in, 17t, 18
nosocomial, 431
osmotic, 254, 256
in returned traveler, 1117
secretory, 254
stool examination, 256
treatment of, 256, 257f, 258f
Disaccharide, 312
Diastolic failure, 730
Diazepam
for alcohol withdrawal, 1098
dosage and action of, 1086t
for isoniazid poisoning, 150t
for multiple sclerosis, 1041
for muscle spasms, 123
for myocardial infarction, 702
for nerve agent exposure, 170t, 171
poisoning, 143t
for tetanus, 529
for vertigo, 214t
Dichloralphenazone, for migraine, 186t
Dicloxacillin
for auricular cellulitis, 304
for streptococcal infections, 498
Dicyclomine
for diverticulitis disease, 842
for irritable bowel syndrome, 841
poisoning, 138t
Didanosine, for HIV/AIDS, 607t
Dietary reference intake (DRI), 39
Diethylcarbamazine, for filariasis, 652
Diethylstilbestrol, 342t
Diffuse large B cell lymphoma, 358, 380–381
Diffuse large B cell lymphoma, 358, 380–381
Diffuse white matter disease, 996t, 1000–1001, 1001f
DiGeorge’s syndrome, 883
Digitalis
for heart failure, 732t
for mitral stenosis, 678
Digitalis toxicity, 722t, 733–734
Digital rectal exam, 387, 399–400, 400f, 1123t, 1124
Digoxin
for arrhythmias, 728t, 736
for atrial fibrillation, 726
for heart failure, 732–733
Digoxin (Cont.):
- for mitral regurgitation, 679
- for supraventricular arrhythmias, 704
- for tachyarrhythmias, 722t–723t
Digoxin-specific antibody fragments, 141t
Dihydroergotamine, for migraine, 185t–186t, 187t
Diltiazem
- for aortic dissection, 738
- for arrhythmias, 728t
- for atrial fibrillation, 726
- for hypertension, 695t
- for hypertrophic cardiomyopathy, 686
- for mitral stenosis, 678
- for myocardial infarction, 701
- for poisoning, 140t
- for supraventricular arrhythmias, 704
- for tachyarrhythmias, 722t–723t
- for unstable angina, 711
- for Wolff-Parkinson-White syndrome, 729
Diluting agent, for radionuclide contamination, 174
Dimenhydrinate
- for nausea and vomiting, 245
- for vertigo, 214t
Dimercaprol
- for arsenic poisoning, 155t
- for heavy metal poisoning, 157t, 159t
Diocetyl sodium sulfosuccinate, for hemorrhoids, 844
Diphenhydramine
- for allergic rhinitis, 880
- for anaphylaxis, 117
- for antivenom reaction, 122
- for extrapyramidal reactions, 149t
- for poisoning, 138t, 153t
- for urticaria/angioedema, 879
Diphenoxylate
- for diarrhea, 256
- for inflammatory bowel disease, 838
Diphenyldimethane, for irritable bowel syndrome, 841
narcotic abuse, 1099
Diphtheria, 501
- Diphtheria antitoxin, 502
- Diphtheria-tetanus vaccine, 438t
Diphtheria toxoid, 501
Diphtheria vaccine, 503
Diphyllobothriasis, 657
Dipyridamole
- for premenstrual syndrome, 85
- for thrombosis, 338
Disease prevention, 1103
- immunization, 1107
- U.S. Preventive Services Task Force recommendations, 1106t
Disequilibrium syndrome, dialysis, 797
Disopyramide
- for angina pectoris, 715
- for arrhythmias, 727t
- for hypertrophic cardiomyopathy, 686
- for tachyarrhythmias, 726
Disseminated intravascular coagulation (DIC), 332–335
Distributive shock, 59t, 60t
Disulfiram, for chronic glomerulonephritis, 808
- for chronic obstructive pulmonary disease, 10, 244t
- for cor pulmonale, 735
- for diabetic nephropathy, 806
- for edema, 243, 243t
- for heart failure, 731, 732t, 733t, 735
- for hypertension, 695–696, 695t, 697t, 796
- for mitral regurgitation, 679
- for myocardial infarction, 705, 706t
- for nephrolithiasis, 828t
- for pulmonary hypertension, 745
- for restrictive cardiomyopathy, 686
- for tricuspid regurgitation, 683
Divalproex, for generalized anxiety disorder, 1082
Diverticular disease, 841
- asymptomatic, 841
- hemorrhage in, 842
Diverticulitis, 841–842
Diverticulosis, 261, 263
Dizziness, 211
DLCO (diffusing capacity of lung), 749–750
DNA-dependent tyrosine kinase gene, 882
Dobutamine
- for anaphylaxis, 117
- for beta blocker poisoning, 140t
- for calcium channel blocker poisoning, 140t
- for cardiac glycoside poisoning, 141t
- for heart failure, 734, 734t
- for hypervolemic shock, 92t
- for myocardial infarction, 705, 706t
- for pulmonary edema, 68
- for shock, 62, 62t, 66
Doxetaxel, 341t
Docusate salts
- for angina pectoris, 138t
- for minimally invasive procedures, 706t
- for myocardial infarction, 702
Dopamine
- for anaphylaxis, 117
- for beta blocker poisoning, 140t
- for calcium channel blocker poisoning, 140t
- for cardiac glycoside poisoning, 141t
- for heart failure, 734, 734t
- for increased intracranial pressure, 92t
- for myocardial infarction, 705, 705t, 706t
- for shock, 62, 62t, 707
- for sympatholytic poisoning, 139t
Dopamine agonists
- for Parkinson’s disease, 1003
- for hyperprolactinemia, 920
- for Parkinson’s disease, 1003–1004, 1005t–1006t
Dorsal root ganglionopathy, paraneoplastic, 407–408, 408t
Dothiepin, for migraine prevention, 187t
Double vision, 217, 218t, 293
- monocular, 217
Doxepin
- for angina pectoris, 715
- for arrhythmias, 727t
- for tachyarrhythmias, 726
Dosage and adverse effects of, 138t, 141t, 1086t
- for pain, 36t–37t
Doxorubicin
- for bladder cancer, 392
- for breast cancer, 376, 378
- for Burkitt’s lymphoma leukemia, 360
Drug-induced illness (Cont.): myopathy, 1074, 1075t, 1140t myositis, 1140t nausea and vomiting, 245t, 341t–342t, 343–344, 1137t nephritis, 810–812, 811t, 1138t nephropathy, 1138t nephrotic syndrome, 1138t neutropenia, 329, 344 obesity, 940 optic neuritis, 1139t oral conditions, 1137t pancreatitis, 1138t pancytopenia, 1135t peptic ulcer disease, 1138t pericarditis, 1136t peripheral neuropathy, 341t, 1138t pill-related esophagitis, 252 pseudotumor cerebri, 1139t pulmonary edema, 1136t pulmonary fibrosis, 341t–342t pulmonary infiltrate, 1136t pure red cell aplasia, 1135t purpura, 1134t renal tubular acidosis, 1138t retinopathy, 1139t schizophrenic-like reactions, 1140t seizure, 990t, 1139t serum sickness, 1132t sexual dysfunction, 1132t SIADH, 341t skin disorders, 319, 1134t sleep disorders, 1140t stroke, 1139t thrombocytopenia, 332, 344, 1135t thromboembolism, 1136t thyroid disease, 1132t toxic epidermal necrolysis, 1134t treatment of, 343–344 urinary calculi, 1138t urinary tract obstruction, 1138t urticaria, 1134t vestibular disorders, 1139t weight loss, 248t

Drug monitoring, therapeutic, reference values for laboratory tests, 1157t–1159t

Drug overdose, 130. See also Poisoning reference values for laboratory tests, 1157t–1159t treatment of, 133–160, 134t, 136t–159t Drusen, 296, 296f DTaP vaccine, 503, 1108t–1109t Dual-energy x-ray absorptiometry, 967, 967t Duchenne dystrophy, 1068 Ductal carcinoma in situ, 376 Duke criteria, for infective endocarditis, 442, 443t Duloxetine dosage and adverse effects of, 1086t for pain, 36t, 57t for polymyoneuropathy, 1061 Duodenal ulcer, 831–834 833t Durable attorney for health care, 47 Duree-Salmon staging, for multiple myeloma, 362t Dysautonomia, 1013, 1018 Dysbetaipoproteinemia, 969t, 974 Dysentery, 452t, 453 amebic, 460–461 Dysfunctional uterine bleeding, 952 Dyskinesia, 1004 Dyslipidemia, 968 in diabetes mellitus, 945–946 metabolic syndrome, 699, 700t Dysmenorrhea primary, 954 secondary, 954 Dyspepsia, 246 functional, 246 peptic ulcer disease, 246 Dysphagia, 249, 1024 esophageal, 250 oropharyngeal, 250 in terminally ill patient, 52t Dysphonia, 1024 Dyspnea, 231 approach to, 68f, 232f, 233 ARDS, 69 cardiac vs. pulmonary, 232t paroxysmal nocturnal, 228, 233 pulmonary edema, acute, 66 in terminally ill patient, 49, 53t treatment of, 49, 49t Dysomnia, 223 focal, 223 generalized, 223 idiopathic torsional, 223

E Ear disease anaerobic infections, 533 drug-induced, 1139t external ear infections, 304 hearing loss, 297 middle ear infections, 305 Eastern equine encephalitis, 595, 596t–597t Eating disorder, 1093 clinical features of, 1093–1094 treatment of, 1094–1095, 1095f in women, 1129 Ebola virus infection, 110, 599 Ebstein anomaly, 677 Echinocandins, 620 Echinococcosis, 656 Echinocysts, 321 Echocardiography, 669 in aortic disease, 671, 672t, 736, 738 in cardiac mass, 670, 672t in cardiomyopathy, 684, 684t chamber size and ventricular performance, 669 clinical uses of, 669t, 670, 671f in congenital heart disease, 671, 674 in coronary artery disease, 713–714, 714t in cor pulmonale, 735 2-D echo, 669t, 670f Doppler, 669x normal values in adults, 1168t in endocarditis, 442 in heart failure, 730 in myocardial infarction, 701 in myocarditis, 687 in pericardial disease, 670, 672t, 688, 691, 691f in pericardial effusion/tamponade, 112
in pulmonary embolism, 770
in pulmonary hypertension, 742–743
stress, 669t, 671
transesophageal, 669t
in valvular heart disease, 670, 671f, 672t, 678
Echolalia, 223
Echovirus infection, 588. See also Enteroviral infection
Ectasy (MDMA), 6
Ecthyma gangrenosum, 110, 478, 516–517
Ectoparasites, 657
Ectopic atrial contractions, 721f
Ectopic ventricular contractions, 721f
Eczema, 315
asteatotic, 311f
drug-induced, 1133t
dyshidrotic, 310f
hand, 310f
Eczema herpeticum, 565
Edema, 240, 242f
drug-induced, 241t, 342t
generalized, 241–242
in heart failure, 730
idiopathic, 242
localized, 241
lymphedema, 742
lead system, 666f
mean axis in, 665
in myocardial infarction, 178, 666–667, 667f, 668f, 689t, 700, 709
in myocarditis, 687
in pericardial disease, 688
in pericarditis, 688, 689t, 690f, 691
in poisoning, 133
PR interval, 666
in pulmonary hypertension, 742
QRS interval, 666
QT interval, 666
rhythm, 665
ST-T waves, 667–669
in subarachnoid hemorrhage, 89
in tachyarrhythmias, 720, 721f, 722t–725t
in valvular heart disease, 678
in variant angina, 716
Electrocochleography, 298
Electroconvulsie therapy, 1079
Electrodiagnosis
of mononeuropathy, 1062t–1064t
of muscle disease, 1068
of peripheral neuropathy, 1059–1060
Electroencephalography (EEG)
in brain death, 79
in coma, 79
in seizures, 900–991
in status epilepticus, 98
Electrolyte balance, 3
Electrolytymagrometry, 211
Elephantiasis, 652
Eletriptan, for migraine, 185t, 187t
Elliptocytes, 321
Enalapril/enalaprilat
for heart failure, 733t
for hypertensive emergencies, 1044f
Encephalitis. See also specific types
acute, 1042
approach to, 1042, 1043f–1044f
arthivirus, 595, 596f–597f
cytomegalovirus, 573
tosavirus, 590
HSV, 565
insect-borne disease, 595
measles, 584
paraneoplastic, 407, 408f, 409t
viral, 1047t, 1048
diagnosis of, 1049, 1049f
Encephalitis. See also specific types (Cont.):
pathogens, 1048
treatment of, 1049–1050
Encephalopathy
hepatic, 874
hypoxic-ischemic, 96, 97f
Endocarditis
culture-negative, *Bartonella*, 526t, *p. 527*
acute, 109t, 111, 440
causes of, 440
definite, 442
diagnosis of, 442, 443t
enterococcal, 444t, 446, 500–501
gonococcal, 470t
HACEK group, 445t, 511
noncardiac manifestations of, 441–442
nosocomial, 442, 492
parvalvular, 442
pathogenesis of, 440–441, 441f
possible, 442
prevention of, 447–448, 447t
prophylaxis before dental procedures, 447t, 448
prophylaxis in congenital heart disease, 677
staphylococcal, 445t, 446, 491–492, 496
streptococcal, 443, 444, 499–500
subacute, 440
prophylaxis in congenital heart disease, 677
Endocrine disease
adrenal, 933
diabetes mellitus, 942
drug-induced, 1132t
hypothermia in, 128t
leukocytosis in, 330
muscle disorders in, 1074
nausea and vomiting in, 245t
paraneoplastic, 405
pituitary, 917, 923
reproductive system disorders
female, 952
male, 947
shock in, 59t
thyroid, 925
tumors of GI tract and pancreas, 389
weight loss in, 248t
Endodermal sinus tumor, 393
End-of-life care, *p. 46. See also Terminally ill patient*
Endometrial cancer, 396t, *p. 397*
Endometritis, 465
Endophthalmitis
*Candida*, 621
*Klebsiella*, 515
Endoscopic retrograde cholangiopancreatography, 846t, 848, 852
Endoscopic variceal ligation, 873
Endoscopy
in gastropathies, 834
in GI bleeding, 260, 262
in peptic ulcer disease, 832
Enterviridae, for HIV/AIDS, 606, 614t
Enoxaparin
for deep venous thrombosis prevention, 741
for myocardial infarction, 701–702
for thrombotic disorders, 336
for venous disease, 741
for venous thromboembolism, 770
for venous thrombosis prevention, 731
Entacapone, for Parkinson’s disease, 677
Enzyme immunoassay (EIA), 411
Eosinopenia, 331
Eosinophilia, 330
drug-induced, 1134t
pulmonary infiltrates with, 776
Epiglottitis, 306
Epidemic disease, 431
Epidemic inclusion cyst, 310f
Epidermiditis, 463
chlamydial, 471
treatment of, 463–464, 470t
Epidermal abscess
neck pain in, 198
*S. aureus*, 491
spinal, 95, 109t, 483, 1029
Epidural hematoma, 93
spinal, 95, 1029
Epilepsy, 988
sleep disorders in, 227
status epilepticus, 98
treatment of, 992t–994t, 994–995
Epinephrine
for anaphylaxis, 117
for antivenom reaction, 122
for beta blocker poisoning, 140t
for calcium channel blocker poisoning, 140t
for cardiac glycoside poisoning, 141t
for heart failure, 734t
for hymenoptera sting, 127
for MAO inhibitor poisoning, 138t
Epiphysitis, brucellosis vs. tuberculosis, 523, 523t
Epirubicin
for gastric cancer, 381
toxicity of, 341t
Episcleritis, 294
Eplerenone
for aldosteronism, 935
for heart failure, 733t
for hyperaldosteronism, 21
for hypertension, 695t
for myocardial infarction, 707
Epley procedure, 213
Epoprostenol
for pulmonary hypertension, 745
for systemic sclerosis, 889
Eprodysate, for amyloidosis, 915
Epstein-Barr virus infection,
cancer associated with, 353, 575–576, 576t
mononucleosis, 574–577, 576t
posttransplantation lymphoproliferative disease, 575, 577
in transplant recipients, 800
Epitifibatide
for myocardial infarction, 711
for thrombotic disorders, 338
for unstable angina, 711
Erectile dysfunction, 950, 951f
Ergot alkaloid poisoning, 137t
Ergotamine
for cluster headache prevention, 187
for migraine, 185t, 187t
for poisoning, 137t
Erlotinib
for lung cancer, 374
for pancreatic cancer, 389
toxicity of, 342t
Erosion (skin lesion), 313t
Ertapenem, for pneumonia, 766t, 767t
Eruptive xanthoma, 973
Escherichia coli
E. coli O157:H7, 459, 514
toenteroaggregative and diffusely adherent (EAEC), 514
toenteropathogenic (EPEC), 514
toenterotoxigenic (ETEC), 514	
toextraintestinal (ExPEC), 513
tointestinal, 514
toostemyelitis, 485t
Shiga toxin-producing/enterohemorrhagic (STEC/HEEC), 458, 514
Escalatopram, 1086t
Esmolol
for aortic dissection, 738t
for arrhythmias, 727t
for hypertensive emergencies, 698t
for MAO inhibitor poisoning, 138t
for poisoning, 140t
for sympathomimetic poisoning, 136t
Esophageal cancer, 379
adenocarcinoma, 379–380
squamous cell carcinoma, 379–380
Esophageal inflammation, 252
Esophageal manometry, 250
Esophageal motility disorders, 250
Esophageal pain, 175t, 176f, 178
Esophageal spasm, 251
Esophageal ulcer, 253
Esophageal varices, 873
prevention of initial bleed, 874
treatment of
acute bleeding, 873–874
prevention of recurrent bleeds, 874
Esophagitis, 252
Candida, 252
eosinophilic, 252–253
HSV infections, 566, 568t
pill-related, 252
viral, 252
Esophagogastroscopy, 250, 380, 873
Esophagus, rupture of, 177f
Estazolam poisoning, 143t
for Bartonella infections, 526t
for campylobacteriosis, 458
for cellulitis, 479t
for chancroid, 476
for C. pneumoniae infections, 563
for C. psittaci infections, 563
diptheria, 502
preventive treatment, 503
for H. pylori eradication, 247
for human bite infections, 119t
indications for, 426t
for leprosy, 553
for Lyme borreliosis, 550
for lymphogranuloma venereum, 471
for nausea and vomiting, 246
for pertussis, 510
for pharyngitis, 304t
for relapsing fever, 553
resistance to, 426t
Erythroplakia, 367
Erythropoiesis, 281
Erythropoietin, decreased level of, 324
Erythropoietin therapy
for anemia, 328, 344
for chronic kidney disease, 795–796
Eschar, 201, 478
Escherichia coli infection
E. coli O157:H7, 459, 514
toenteroaggregative and diffusely adherent (EAEC), 514
toenteropathogenic (EPEC), 514
toenterotoxigenic (ETEC), 514
toextraintestinal (ExPEC), 513
tointestinal, 514
toostemyelitis, 485t
Shiga toxin-producing/enterohemorrhagic (STEC/HEEC), 458, 514
Estradiol, 1086t
Estradiol benzoate
for breast cancer, 378
for endometriosis, 676
for menopause, 676
for sexual dysfunction, 1086t
Estrogen
for endometriosis, 676
for menopause, 676
for sexual dysfunction, 1086t
Estrone
for breast cancer, 378
for endometriosis, 676
for menopause, 676
for sexual dysfunction, 1086t
Estrone/estradiol ratio, bone marrow, 323
Estrone sulfate, for breast cancer, 378
for endometriosis, 676
for menopause, 676
for sexual dysfunction, 1086t
Estrone/sulfate ratio, bone marrow, 323
Estrus, 280t
Estramustine for prostate cancer, 401
toxicity of, 341t

Estrogen therapy
for amenorrhea, 953
for hypopituitarism, 922t
for menopausal symptoms, 957
oral contraceptives, 957
for osteoporosis, 967

Etanercept
for ankylosing spondylitis, 897
for psoriasis, 314
for psoriatic arthritis, 898
for rheumatoid arthritis, 887

Ethacrynic acid for edema, 243t

Ethambutol
for nontuberculous mycobacterial infec-
tions, 548–549
for tuberculosis, 541, 543t

Ethanol
for AGMA inducer poisoning, 147t

Ethchlorvynol poisoning, 144t

Ethosuximide
for seizures, 992t–993t

Ethylene glycol poisoning, 17t, 18–19, 147t

Ethylestradiol/norethisterone, for GI telang-
iectasis, 263

Etomidate poisoning, 144t

Etoposide
for AML, 346
for extragonadal germ cell tumor, 402
for lung cancer, 371
for testicular cancer, 394

Exanthem, enterovirus, 590

Exchange transfusion, 44, 160

Excoriation, 313t

Exemestane
for breast cancer, 378
for toxicity of, 342t

Exenatide
for diabetes mellitus, 289, 290t

Fatigue
chronic fatigue syndrome, 290
drug-induced, 289, 289t
in cancer patient, 150
in myalgia, viral disease, 594–595
in returned traveler, 1117

Fever
approach to, 200–201, 435–436, 435f
causes of, 200
in cancer patient, 115
with myalgia, viral disease, 594–595
with rash, 200

Fenofibrate, for hyperlipidemia, 972t

Fentanyl
narcotic abuse, 1099
for pain, 36e–37t

Fever
approach to, 200–201, 435–436, 435f
in cancer patient, 115
causes of, 200

Fibrinogen deficiency, 334

Fibrinolytic therapy
for myocardial infarction, 701, 702f, 703f
for thrombotic disorders, 338
for venous thromboembolism, 772
Fibromyalgia, 908, 1078
Fifth disease, 587
Filaria, 421, 651
- lymphatic, 652
- nocturnally periodic, 652
- subperiodic, 652
Finasteride
- for prostate cancer prevention, 1124
- for prostate hyperplasia, 399
Fire coral, 122
Fisher syndrome, 1061
Fish oil supplementation
- for hyperlipidemia, 972t
- for IgA nephropathy, 252, 317, 464, 621
- preventive treatment, 621
- for coccidioidomycosis, 630
- for cryptococcosis, 626
Flucortisone, for adrenal insufficiency, 115
Flucytosine, for cryptococcosis, 626
Fludarabine
- for CLL, 356
- for follicular lymphoma, 357
- for idiopathic thrombocytopenic purpura, 335
- toxicity of, 341t
Fludrocortisone
- for Addison’s disease, 936
- for hypoadosteronism, 937
- for orthostatic hypotension, 1019
- for SIADH, 925
Fluid absorption, in GI tract, 253
Fluid restriction
- for hypovolemia, 406
- for SIADH, 114, 925
Fluid retention, drug-induced, 1136t
Fluke infection
- blood flukes, 420t
- liver (biliary) flukes, 654
- lung flukes, 654
Flumazenil, for sedative-hypnotic poisoning, 143t
Fondaparinux
- for thrombotic disorders, 337
- for venous thromboembolism, 770
Food poisoning
- bacterial, 453
- clostridial, 541
- S. aureus, 492
Foot, muscles and innervation of, 980t–981t
Foramen magnum, lesions near, 1027
Forearm, muscles and innervation of, 980t–981t
Formoterol, for asthma, 754
Fosamprenavir, for HIV/AIDS, 613t
Fosphenytoin, for status epilepticus, 99f
Fournier’s gangrene, 533
Foxglove, 141t
Fracture, osteoporotic, 965–966, 966t
Francisella tularensis infection. See Tularemia
Fresh-frozen plasma (FFP), 44–45
for bleeding disorders, 335
- for warfarin reversal, 336
Friedreich’s ataxia, 1009–1010
Frontotemporal dementia, 995, 997t, 998, 1001
Frostbite, 128, 129t
Frovatriptan, for migraine, 185t, 187t
Frozen shoulder, 910
Fungal infection, 618
- diagnosis of, 411
Fungus ball, 302
Furosemide
for ascites, 272
for edema, 243t
for heart failure, 731, 733t
for hypercalcemia, 406, 962t
for hyperkalemia, 15t
for hypertension, 695t, 698
for myocardial infarction, 705, 706t
for pulmonary edema, 68
for SIADH, 114
Furuncle, 490
Furunculosis, 316
Fusariosis, 632
Fusobacterium
infection, 632
Gabapentin
for generalized anxiety disorder, 1082
for menopausal symptoms, 957
for migraine prevention, 188t
for multiple sclerosis, 835
for polyneuropathy, 1061
for seizures, 994t
Gait analysis, 986
Galactorrhea, drug-induced, 1132t
Gallbladder, drug-induced, 1132t
Gallamine, for Alzheimer’s disease, 1000
Gallstones, 175t
Gametocyte, 636
Gamma-glutamyltranspeptidase (GGT), 269
Gamma knife radiosurgery, 1020–1021,
1032
Gamma radiation, 171
Ganciclovir
for cytomegalovirus infections, 574
for viral esophagitis, 252
Gardasil, 398
Gardner’s syndrome, 381, 384, 384t
Gas exchange, disturbances of, 749
Gas gangrene, 108t, 111, 477, 480t, 531–532
Gastrectomy, 381, 833
Gastric aspiration, 148t
Gastric atrophy, 834
Gastric cancer, 380
adenocarcinoma, 380–381
diffuse infiltrative, 380
intestinal type, 380
staging of, 382t
superficial spreading, 380
Gastric lavage, 135, 831
Gastric tumor, benign, 381
Gastric ulcer, 831–833
Gastrinoma, 389, 390t, 391, 835
Gastroenteritis
Aeromonas, 516
campylobacteriosis, 458
Gastroesophageal reflux disease (GERD), 246
sleep disorders in, 228
Gastroesophageal varices, 260, 263
Gastrointestinal bleeding, 259
anemia in, 326
drug-induced, 1138t
lower GI tract, 261–263, 262f
upper GI tract, 260–263, 261f
Gastrointestinal cancer, 379
Gastrointestinal decontamination, 135
Gastrointestinal disease
cholecystitis
acute, 845
chronic, 847
choledocholithiasis/cholangitis, 847
cholelithiasis, 844
cirrhosis, 868
colonic angiodysplasia, 843
colon polyps, 383
diarrhea, infectious, 451
diverticular disease, 841
drug-induced, 1137t–1138t
endocrine tumors, 389
esophageal varices, 873
gastric tumors, 381
gastropathies, 834
hepatic failure, 858
hepatitis
acute, 854
chronic, 859
infections in immunocompromised patients, 434, 436t
inflammatory bowel disease, 836
intestinal parasites, 421
intestinal pseudoobstruction, 842
irritable bowel syndrome, 840
listerial, 507
liver tumors, 388
mesalazine, 585
nausea and vomiting in, 245t
pain in, 175t, 176f, 179t
pancreatitis, 849
peptic ulcer disease, 831
portal hypertension, 872
primary sclerosing cholangitis, 848
small-bowel tumors, 382
in travelers, 1117
tuberculosis, 540
vascular, 843
weight loss in, 247, 248t
Zollinger-Ellison syndrome, 835
Gastrointestinal function, normal, 253, 1167t
Gastrointestinal stromal cell tumor (GIST), 380
Gastrointestinal telangiectasia, 263
Gastropathies, 834
erosive, 834
Gastroscopy, 381
Gefitinib
for lung cancer, 374
toxicity of, 342t
Gemcitabine
for bladder cancer, 392
for breast cancer, 379
for pancreatic cancer, 389
Gemfibrozil, for hyperlipidemia, 972t
Gemifloxacin, for pneumonia, 766t
Gemtuzumab ozogamicin, 342t
Generalized anxiety disorder, 1082, 1088
Generalized disease of the newborn, enterovirus, 590
Genital herpes, 464, 475, 565
features of genital ulcers, 467t
treatment of, 475, 479t, 567t–568t
Genital lesion, ulcerative, 466, 467t
Genital warts, 844
Genitourinary tract cancer, 391
Gentamicin
for Abiotrophia infections, 501
for bacterial meningitis, 1046t, 1047t
for Bartonella infections, 526t
for brucellosis, 523
for enterococcal infections, 501
for gram-negative enteric bacteria infections, 516
indications for, 426t
for infective endocarditis, 444t–445t, 446
for listerial infections, 508
for pelvic inflammatory disease, 466
for plague, 164t, 526
for pneumonia, 767t
resistance to, 426t
for sepsis/septic shock, 65t, 107t
for staphylococcal infections, 496
for streptococcal infections, 499
for tularemia, 165t, 524
for urinary tract infections, 819t
German measles. See Rubella
Germ cell tumor, 395
extragonadal, unrecognized, 402
paraneoplastic syndromes in, 409t
GHB, 132t, 144t
for daytime sleepiness, 230
Giant cell arteritis, 217, 892
Giardiasis, 420t, 421, 454
treatment of, 468
Gilbert’s syndrome, 265, 268t
Gingivitis, 532
necrotizing ulcerative, 532
Gingivostomatitis, HSV infections, 564
Gittelman’s syndrome, 788
Glanders, 518–521, 520t
Glaucoma, 216f, 295, 295f
acute angle-closure, 294
drug-induced, 1139t
open-angle, 295
Glimepiride, for diabetes mellitus, 945t
Glucagon
for beta blocker poisoning, 140t
for calcium channel blocker poisoning, 140t
for hypoglycemia, 105
Glucagonoma, 389, 390t, 391
Glucocorticoids, adrenal, 933
Glucocorticoid therapy
for acute disseminated encephalomyelitis, 1041
for acute renal failure, 793
for adult T cell leukemia/lymphoma, 260
for amiodarone-induced thyrotoxicosis, 931
for amyloidosis, 915
for anaphylaxis, 117
for ankylosing spondylitis, 897
for ataxia, 1010
for autoimmune hemolysis, 329
for autoimmune hepatitis, 867
for brain tumor, 1031
clinical uses of, 938, 938t
for CLL, 356
for dermatitis, 315
for eczema, 315
epidural, for back pain, 196
for Epstein-Barr virus infections, 577
for erythema nodosum, 318
for fever, 201
for gout, 904
for histoplasmosis, 629t
for hymenoptera sting, 127
for hypercalcemia, 113, 962t
for increased intracranial pressure, 92t
for inflammatory bowel disease, 838
for inflammatory myopathy, 1072
for interstitial lung disease, 775
for larva migrans, 649
for leishmaniasis, 644
for lichen planus, 314
for meningococcal infections, 505
for minimal change disease, 804
for muscular dystrophy, 1071
for myasthenia gravis, 1066
nasal, for allergic rhinitis, 880
for optic neuritis, 217
for osteoarthritis, 902
for parainfluenza virus infections, 583
for pityriasis rosea, 314
for polymyopathy, 1061
for primary sclerosing cholangitis, 849
for pseudogout, 906
for psoriasis, 314
for psoriatic arthritis, 898
for reactive arthritis, 900
for rosacea, 318
for sarcoidosis, 912
for schistosomiasis, 654
for Sjögren’s syndrome, 891
postinfectious, 801
poststreptococcal, 280, 801
rapidly progressive, 785, 802
with anti-GBM antibodies, 802–803
causes of, 802t
immune complex-associated, 802
pauci-immune, 802–803
in SLE, 803
Glossopharyngeal neuralgia, 1023
Glucocorticoid therapy
for acute disseminated encephalomyelitis, 1041
for acute renal failure, 793
for adult T cell leukemia/lymphoma, 260
for amiodarone-induced thyrotoxicosis, 931
for amyloidosis, 915
for anaphylaxis, 117
for ankylosing spondylitis, 897
for ataxia, 1010
for autoimmune hemolysis, 329
for autoimmune hepatitis, 867
for brain tumor, 1031
clinical uses of, 938, 938t
for CLL, 356
for dermatitis, 315
for eczema, 315
epidural, for back pain, 196
for Epstein-Barr virus infections, 577
for erythema nodosum, 318
for fever, 201
for gout, 904
for histoplasmosis, 629t
for hymenoptera sting, 127
for hypercalcemia, 113, 962t
for increased intracranial pressure, 92t
for inflammatory bowel disease, 838
for inflammatory myopathy, 1072
for interstitial lung disease, 775
for larva migrans, 649
for leishmaniasis, 644
for lichen planus, 314
for meningococcal infections, 505
for minimal change disease, 804
for muscular dystrophy, 1071
for myasthenia gravis, 1066
nasal, for allergic rhinitis, 880
for optic neuritis, 217
for osteoarthritis, 902
for parainfluenza virus infections, 583
for pityriasis rosea, 314
for polymyopathy, 1061
for primary sclerosing cholangitis, 849
for pseudogout, 906
for psoriasis, 314
for psoriatic arthritis, 898
for reactive arthritis, 900
for rosacea, 318
for sarcoidosis, 912
for schistosomiasis, 654
for Sjögren’s syndrome, 891
Glucocorticoid therapy (Cont.):
for SLE, 803, 886
for spinal cord compression, 95
steroid preparations, 938–939, 938t
for systemic mastocytosis, 881
for systemic sclerosis, 889
for taeniasis solium and cysticercosis, 656
for vertigo, 214t
Glucocorticoids:
for inflamed eye, 294
for trichinellosis, 649
for vasculitis, 893
for vertigo, 214t
Gluconate, for hyperkalemia, 15t
Glucosamine and chondroitin, for osteoarthritis, 902
Glucose-lowering agents, oral, 944–945, 945t
Glucose-6-phosphate dehydrogenase deficiency, 326, 327t, 328–329
Glucose therapy
for hypoglycemia, 105
for salicylate poisoning, 149t
Gluten-free diet, 1010
Glutethimide poisoning, 144t
Glyburide, for diabetes mellitus, 945t
Glycocholic breath test, 256
Glycolytic defects, 1073
Glycylcyclines, 424
Goiter, 926, 931
nontoxic, 931
toxic multinodular, 928–930, 931
Gold compounds, for rheumatoid arthritis, 887
Golytely, 135
Gonadotropin(s)
deficiency of, 919t, 922, 922t
hypersecretion of, 919t, 920–921
Gonadotropin-releasing hormone deficiency, 947
Gonococcemia, 201
Gonorrhoea, 468
anorectal, 469
arthritis, 469, 481–482
cervicitis, 465, 468
disseminated infection, 469, 470t
epididymitis, 463, 470t
ocular, 469
pelvic inflammatory disease, 465, 469, 470t
pharyngeal, 469
in pregnancy, 469
proctitis, 468
treatment of, 463, 470t
urethritis, 463–464, 468
Goodpasture’s syndrome, 807t
Goserein, for prostate cancer, 401
Gout, 903
Gouty arthritis, acute, 903–904
GP IIb/IIIa antagonists
for myocardial infarction, 711
for unstable angina, 711
Graft-versus-host disease, 44
Grain(s), 537
Grain dust, 758
Gram-negative bacilli
enteric, 513
miscellaneous, 522
Gram’s stain, 411, 412f, 482
Granisetron, for nausea and vomiting, 246
Granulocyte colony-stimulating factor, 343t, 368
Granulocyte-macrophage colony-stimulating factor, 343t
Granuloma inguinale, 476
Granulomatous disease, leukocytosis in, 330
Granuloma venereum, 476
Graphesthesia, 985
Graves’ disease, 928–930
Graves’ ophthalmopathy, 1074
Gray (radiation unit), 171
Griseofulvin, 620
for dermatophyte infections, 317
Growth hormone, 917, 918f
deficiency of, 919t, 922, 922t
hypersecretion of, 919t, 920–921
therapy for weight loss, 248
Guanabenz poisoning, 139t
Guanfacine, for tics, 224
Guillain-Barré syndrome, 1016, 1061
Gumma, 473
Gynecologic cancer, 395
Gynecomastia
drug-induced, 342t, 1132t
evaluation of, 949f
paraneoplastic, 405t
H
HAART therapy, 606
HACEK group infection, 511, 512t
endocarditis, 445t
Haemophilus ducreyi infection. See Chancroid
Haemophilus influenzae infection, 508
epitlottitis, 509
Hib, 508
meningitis, 508–509
nontypable strains, 508–509
pneumonia, 509
Haemophilus influenzae type b vaccine, 438t, 509, 1108t–1109t
Haemophilus species infection. See HACEK group infection
Hallucinations
drug-induced, 1140t
hypnagogic, 229t, 230, 230t
Hallucinogens, 131t
Haloperidol
for delirium, 50t
dosage and adverse effects of, 139t, 1091t
for nausea and vomiting, 49, 245
Haloprogen, for dermatophyte infections, 317
Hand, muscles and innervation of, 980t–981t
Hand-foot-and-mouth disease, 590
Hand hygiene, 429, 493, 591
Hantavirus hemorrhagic fever with renal syndrome, 110
Hantavirus pulmonary syndrome, 111, 598
Harris and Benedict formula, 39, 39f
Headache, 183. See also specific types
causes of, 183t
drug-induced, 1138t
symptoms suggesting serious underlying disorder, 184t
Head and neck cancer, 367
infections in cancer patients, 433t
local disease, 368
locally advanced disease, 368
oncologic emergencies, 112–113
paraneoplastic syndromes in, 405t, 406
prevention of, 368, 1125
recurrent or metastatic, 368
Head and neck infection, anaerobic, 532
Head louse, 658–659
Head trauma, 91, 996t, 998
approach to, 93
hearing loss in, 297
increased intracranial pressure in, 90
intracranial hemorrhage in, 82t
post-concussion headache, 183t, 187–189
subarachnoid hemorrhage in, 88
Health care-associated infections, 428
Health care worker, HIV/AIDS in, 617–618
Hearing aid, 297–298, 300
Hearing loss, 212–213, 297
approach to, 297–298, 299f
causes of, 298–300
drug-induced, 300, 1139t
noise-induced, 301
prevention of, 301
sensorineural, 297–298, 300

treatment of, 300–301
Heart
chamber size and ventricular performance, 669
noninvasive examination of, 669
physical examination of, 661
Heartburn, 246
Heart disease. See also Cardiovascular disease
cardiac mass, 670, 672t
computed tomography in, 672t, 673
congenital. See Congenital heart disease
cyanosis in, 239, 240t
depression in, 1078
drug-induced, 342t, 1135t–1136t
dyspnea in, 231–233, 232t
echocardiography in, 669
edema in, 241
diastolic, 662t, 664f, 665
ejection click, 664
midsystolic click, 665
opening snap, 664
S1 through S4, 661–662
Hematemesis, 259
Hematin, for porphyria, 977
Hematochezia, 260
Hematocrit, 280
Hematologic disease
bleeding disorders, 332
blood smear, 321
bone marrow examination, 322
drug-induced, 1134t
fatigue in, 289t
leukocytosis and leukopenia, 329
red cell disorders, 323
reference values for laboratory tests, 1142t–1144t
thrombotic disorders, 336
Hematomyelia, 96
Hematopoietic cell transplant
for amyloidosis, 915
for CLL, 356
for follicular lymphoma, 357
infections in recipients, 436–437, 436t
vaccination of recipients, 438t, 439
Hematuria, 280, 392–393, 787, 806–807
approach to, 279f
causes of, 278t
gross, 280
microscopic, 280
Heme preparations
for acute intermittent porphyria, 977
for erythropoietic porphyria, 978
Hemianopia
bitemporal, 215, 216f
homonymous, 215, 216f, 220t
Hemiballismus, 223
Hemiblock, 667f
Hemicrania, paroxysmal, 189
Hemicrania continua, 189
Hemifacial spasm, 1022–1023
Hemiparesis, 80, 93, 220t, 221f
systolic, 662t, 664f, 665
Heart rate, 665
Heart sounds, 662f, 663
effects of physiologic and pharmacologic interventions, 663t
erection click, 664
mid systolic click, 665
opening snap, 664
S1 through S4, 663–664
Heart transplant, infections in recipients, 437–439
Heat stroke, 201
drug-induced, 203
exertional, 201
non exertional, 203
Heavy chain deposition disease, 812t
Heavy metal poisoning, 154t–160t
Height, ideal weight for height, 40t
Heinz bodies, 322
Helicobacter pylori infection
detection of, 832, 832t
eradication of, 247, 832, 833t
indigestion, 246
lymphoid malignancies and, 355
peptic ulcer disease, 831
Helmith ectoparasites, 657
Helmith infection, 648
intestinal, 421
Hemapheresis, 46
Hematemeses, 259
Hematin, for porphyria, 977
Hematocrit, 260
Hematologic disease
bleeding disorders, 332
blood smear, 321
bone marrow examination, 322
drug-induced, 1134t
fatigue in, 289t
leukocytosis and leukopenia, 329
red cell disorders, 323
reference values for laboratory tests, 1142t–1144t
thrombotic disorders, 336
Hematomyelia, 96
Hematopoietic cell transplant
for amyloidosis, 915
for CLL, 356
for follicular lymphoma, 357
infections in recipients, 436–437, 436t
vaccination of recipients, 438t, 439
Hematuria, 280, 392–393, 787, 806–807
approach to, 279f
causes of, 278t
gross, 280
microscopic, 280
Heme preparations
for acute intermittent porphyria, 977
for erythropoietic porphyria, 978
Hemianopia
bitemporal, 215, 216f
homonymous, 215, 216f, 220t
Hemiballismus, 223
Hemiblock, 667f
Hemicrania, paroxysmal, 189
Hemicrania continua, 189
Hemifacial spasm, 1022–1023
Hemiparesis, 80, 93, 220t, 221f
systolic, 662t, 664f, 665
Heart rate, 665
Heart sounds, 662f, 663
effects of physiologic and pharmacologic interventions, 663t
erection click, 664
mid systolic click, 665
opening snap, 664
S1 through S4, 663–664
Heart transplant, infections in recipients, 437–439
Heat stroke, 201
drug-induced, 203
exertional, 201
non exertional, 203
Heavy chain deposition disease, 812t
Heavy metal poisoning, 154t–160t
Height, ideal weight for height, 40t
Heinz bodies, 322
Helicobacter pylori infection
detection of, 832, 832t
eradication of, 247, 832, 833t
indigestion, 246
lymphoid malignancies and, 355
peptic ulcer disease, 831
Helmith ectoparasites, 657
Helmith infection, 648
intestinal, 421
Hemapheresis, 46
Hematemeses, 259
Hematin, for porphyria, 977
Hematocrit, 260
Hematologic disease
bleeding disorders, 332
blood smear, 321
bone marrow examination, 322
drug-induced, 1134t
fatigue in, 289t
leukocytosis and leukopenia, 329
red cell disorders, 323
reference values for laboratory tests, 1142t–1144t
thrombotic disorders, 336
Hematomyelia, 96
Hematopoietic cell transplant
for amyloidosis, 915
for CLL, 356
for follicular lymphoma, 357
infections in recipients, 436–437, 436t
vaccination of recipients, 438t, 439
Hematuria, 280, 392–393, 787, 806–807
approach to, 279f
causes of, 278t
gross, 280
microscopic, 280
Heme preparations
for acute intermittent porphyria, 977
for erythropoietic porphyria, 978
Hemochromatosis, 44, 975
HFE-associated, 975, 976f
screening for, 975f

Hemodialysis
complications of, 797, 797t
for hyperkalemia, 15t
intermittent, 793
for poisoning, 137t, 143t, 147t, 148t, 149t, 151t, 160
for tumor lysis syndrome, 116

Hemoglobin
abnormal, 239, 326, 326t
blood concentration, 280
unstable variants, 326

Hemolysis
leukemoid reaction in, 330
leukoerythroblastic reaction in, 330

Hemolytic anemia,
classification of, 326t
drug-induced, 1135t
microangiopathic, 825

Hemolytic pattern
α-hemolysis, 497
β-hemolysis, 497
γ-hemolysis, 497

Hemolytic uremic syndrome (HUS), 326t, 459, 824–826

Hemoperfusion
for methylxanthine poisoning, 137t
for sedative-hypnotic poisoning, 143t

Hemophilia A, 334–335
Hemophilia B, 334–335

Hemoptysis,
235, 238f

Hemorrhage.
See also specific types and sites
with extensive transfusion, 333
leukoerythroblastic reaction in, 330

Hemorrhagic fever, viral, 110, 596
Hemorrhagic fever with renal syndrome, 598

Hemorrhoids, 310f, 844

Hemostatic disorders, 335

Hemothorax, 780

Henbane, 138

Henoch-Schönlein purpura, 803, 807t, 892

Heparin
for arterial embolism, 739
for deep venous thrombosis prevention, 741
for DIC, 335
for myocardial infarction, 701–702, 711
for thrombotic disorders, 336–337, 337t
for unstable angina, 711
for venous disease, 741
for venous thromboembolism, 770–771
preventive treatment, 731

Heparin-induced thrombocytopenia, 332, 334, 770

Hepatic artery embolization, 389

Hepatic disease.
See Liver disease

Hepatocellular carcinoma, 388

Hepatotherapeutic disorders, liver function tests in, 268t
Hepatocellular carcinoma, 388

Hepatitis
acute, 859
depression in, 1078
grading of, 859
staging of, 859
toxic/drug-induced, 858
viral, 854, 855t, 858

Hepatitis A
acute, 854, 855t, 856f
prevention of, 854

Hepatitis A vaccine, 438t, 854, 865, 1108t–1112t, 1115t, 1116t

Hepatitis B
acute, 854, 855t, 856f
chronic, 864, 865t–867t
prevention of, 857

Hepatitis B, 887

Hepatitis B immune globulin, 856

Hepatitis B vaccine, 438t, 856, 1108t–1112t, 1115t, 1116t

Hepatitis C

Hepatitis D, 855t, 857

Hepatitis E, 855t, 857

Hepatitis E virus infection, 310f, 311, 475, 564
acyclovir-resistant, 568–569, 568t
Bell’s palsy, 1021–1022
eye infection, 565, 568t
interstitial, 565
oral-facial, 564, 567t–568t
proctitis, 468
reactivation of, 564
skin disease, 316
treatment of, 316, 475, 479t, 566–569
vulvar infections, 566, 568t
whitlow, 565, 568t

Hepatitis virus infection, 564

Hepatitis zoster, 310f, 311, 316, 570
neck pain in, 198
treatment of, 316, 479t, 571

Hepatitis zoster vaccine, 571

Herpetic infection, 309
Herpesvirus test, 576

Herpesvirus infection, 564

Herpes zoster, 310f, 311, 316, 570
neck pain in, 198
treatment of, 316, 479t, 571
Herpes zoster vaccine, 571
Herpetiform lesion, 309

Hirsutism,
955, 956f

Histoplasmosis, 627
acute pulmonary, 627, 629t
African, 628
chronic cavitary, 628, 629t
CNS disease, 629t
mediastinitis, 628
progressive disseminated, 627–628, 629t
remission of, 628, 629t
Histotoxic hypoxia, 96
Histrionic personality disorder, 1084
HIV/AIDS, 600
  acute retroviral syndrome, 604–605
  advanced HIV disease, 602
  asymptomatic infection, 605
  chronic and persistent infection, 601–602
  clinical features of, 604–605, 604t
  cytomegalovirus infections in, 573–574
  depresion in, 1078
  diagnosis of, 603, 603f
  epidemiology of, 601
  etiology of, 600–601
  fever of unknown origin in, 199–200
  health care workers and, 617–618
  hormones, ectopic production of, 405
  infection in, 433t
  laboratory monitoring of, 603–604
  laboratory monitoring of, 603–604
  neoplasms in, 605
  pathophysiology and immunopathogenesis of, 601–602
  Pneumocystis (P. carinii) infections in, 633
  postexposure prophylaxis, 617–618
  prevention of, 618, 1117
  primary infection, 601–602
  secondary infectious diseases in, 605, 617
  symptoms of, 605
  treatment of, 605
  antiretroviral therapy, 606–617, 607t–615t, 617t
  prevention of secondary infections, 617
  principles of, 616t
  tuberculosis and, 538–540, 542, 545t–546t
  vascular myelopathy, 1029
  in women, 1129
  HIV entry inhibitors, 606, 614t–615t
  HIV vaccine, 618
  Hodgkin’s disease, 535t, 361, 575
    infections in, 433t
    paraneoplastic syndromes in, 409t
    staging of, 363, 363t
    vaccination in, 438t
  Homocysteine, 1120
  Hookworm infection, 649, 650, 1117
  Hormones, ectopic production of, 405
  Hornet sting, 126
  Hospitalized patient. See also Nosocomial infections
  care of
    acid-base balance, 3
    admission orders, 1
    critical care medicine, 30
    electrolyte balance, 3
    end-of-life care, 46
    imaging, 22
    pain and its management, 34
    palliative care, 46
    parenteral nutrition, 41
    procedures performed by internists, 25
    transfusion and pheresis therapy, 44
  Howell-Jolly bodies, 321
  H₂ receptor antagonists
    for erosive gastropathies, 834
    for peptic ulcer disease, 833
  Human bite, 118, 119, 478, 511
  Human herpesvirus 6 infection, 571
  Human herpesvirus 7 infection, 571
  Human herpesvirus 8 infection, 353, 571
  Human papillomavirus (HPV) infection, 476
  cervical cancer and, 398
  warts, 317
  Human papillomavirus (HPV) vaccine, 398, 477, 1110–1113t, 1125
  Human respiratory syncytial virus (RSV) infection, 582
  Human T-lymphotropic virus infection, 353
  Hunt-Hess Scale, for subarachnoid hemorrhage, 88t
  Huntington’s disease, 223, 998, 1002
  Hyaluronic acid
    for heart failure, 731, 733t
    for hypertension, 698, 698t
    for myocardial infarction, 706–707
  Hyaluronic acid
    for dialated cardiomyopathy, 685
  Hydrocephalus
    normal-pressure, 998, 1001
    in subarachnoid hemorrhage, 89–90
  Hydrochlorothiazide
    for diabetes insipidus, 8
    for edema, 243t
    for heart failure, 733t
    for hypertension, 695, 695t
  Hydrocodone
    for dyspnea, 49t
    for hemoptysis, 238
  Hydrocortisone
    for Addison’s disease, 936
    for adrenal insufficiency, 115
    for hypopituitarism, 922t
    for inflammatory bowel disease, 838
    for meningococcal infections, 505
    for myxedema coma, 928
    for sepsis/septic shock, 66
    steroid preparations, 938–939, 938t
  Hydrocodone
    for dyspnea, 49t
    for myxedema coma, 928
    for sepsis/septic shock, 66
    steroid preparations, 938–939, 938t
  Hydrodactylycortone, for syncope, 210
  Hydrogen sulfide, 145t
  Hydroxychloroquine
    for malaria prevention, 640t
    for porphyria cutanea tarda, 977
    for Q fever, 559
    for rheumatoid arthritis, 887
    for Sjogren’s syndrome, 891
    for SLE, 886
    for SLE, 119, 882
    5-Hydroxyindoleacetic acid, urinary, 389
  Hydroxyprogesterone, for endometrial cancer, 397
  Hydroxyurea
    for cervical cancer, 398
    for sickle cell anemia, 328
    for systemic mastocytosis, 881
    toxicity of, 341t
Hypoglossal nerve, 984
disorders of, 1024

Hypoglycemia, 103, 104f, 210
diagnosis of, 103–104, 105t
drug-induced, 103, 1132t
paraneoplastic, 405, 405t
reactive, 103f
Hypoglycemic unawareness, 103–104

Hypogonadism, 953
hypogonadotropic, 947
primary, 947, 949
secondary, 947, 949
treatment of, 948

Hypohidrosis, 1013

Hypokalemia,
approach to, 11f
causes of, 9t, 10
drug-induced, 10, 1133t

Hypomagnesemia, 963, 964

Hypomania, 1080
drug-induced, 1140t

Hyponatremia,
acute symptomatic, 6–7
approach to, 4f
chronic, 5–7
drug-induced, 1133t
euromuscular, 3, 4f, 6
hypervolemic, 3, 4f, 5–7
hypovolemic, 3, 4f, 5
paraneoplastic, 406
in subarachnoid hemorrhage, 89
treatment of, 6–7

Hypoparathyroidism, 963–964

Hypophosphatemia,

Hypophosphatemia, 946

Hypopituitarism, 921, 922t

Hypopnea, 783

Hypoponatremia, 3
acute symptomatic, 6–7
approach to, 4f
chronic, 5–7
drug-induced, 1133t

Hypomagnesemia, 963, 964

Hypovolemia, 3
in myocardial infarction, 706, 707f, 708
orthostatic. See Orthostatic hypotension

Hypothalamic hormones, 918f

Hypothermia, 127

drug-induced, 128t
risk factors for, 127, 128t
therapeutic
for hypoxic-ischemic encephalopathy, 98
for increased intracranial pressure, 92t
for stroke, 84
treatment of, 128

Hypothyrombinaemia, drug-induced, 1134t

Hypothyroidism, 925, 926, 827f
clinical or overt, 926
depression in, 1078
edema in, 242
muscle disorders in, 1074
primary, 926, 926t
secondary, 926, 926t
subclinical or mild, 926
transient, 926, 926t

Hypoxemia, 71–72, 743t, 749, 782
approach to, 750f
mechanisms of, 750

Hypoxia, 96
histotoxic, 96
hypoxic-ischemic encephalopathy, 96

Hysterectomy, 398

Hysterical fainting, 210

Ibandronate, for osteoporosis, 967
Ibritumomab tiuxetan
for follicular lymphoma, 357
toxicity of, 342t

Ibuprofen
for frostbite, 129, 129t
for migraine, 185t
for narcotic withdrawal, 1100
for pain, 36–37t
for pericarditis, 688
for SLE, 886

Ibutidine
for arrhythmias, 728t
for Wolff-Parkinson-White syndrome, 729

Icterus. See Jaundice

ICU patient. See Critically ill patient

Idarubicin
for AML, 346
toxicity of, 341t

Idebenone, for ataxia, 1010

Idoxuridine, for HSV infections, 568t

Ilospamide
for cervical cancer, 398
toxicity of, 341t

IgA deficiency, isolated, 884

IgA nephropathy, 808

IgG subclass deficiency, 884

Ileal pouch-anal anastomosis, 840

Ileoproctostomy, 383

Ileus, drug-induced, 1137t–1138t

Imaging, diagnostic, 22, 484t

Imatinib
for CML, 349
for gastric cancer, 381
toxicity of, 342t

Imidazoles, 619
for dermatophyte infections, 317

Imipenem
for anaerobic infections, 534t
for cholecystitis, 847
for enterococcal infections, 501
for gram-negative enteric bacteria infections, 516
for human bite infections, 119t
indications for, 425t
for nocardiosis, 536t
for nontuberculous mycobacterial infections, 548
for P. aeruginosa infections, 519t
for pneumonia, 766t, 767t
resistance to, 425t

Imipenem-cilastatin
for pancreatitis, 851
for sepsis/septic shock, 65t
for urinary tract infections, 819t

Imipramine
dosage and adverse effects of, 138t, 141t, 1086t

Hypoxemia, 71–72, 743t, 749, 782
approach to, 750f
mechanisms of, 750

Hypoxia, 96
histotoxic, 96
hypoxic-ischemic encephalopathy, 96

Hysterectomy, 398

Hysterical fainting, 210

Ibandronate, for osteoporosis, 967
Ibritumomab tiuxetan
for follicular lymphoma, 357
toxicity of, 342t

Ibuprofen
for frostbite, 129, 129t
for migraine, 185t
for narcotic withdrawal, 1100
for pain, 36–37t
for pericarditis, 688
for SLE, 886

Ibutidine
for arrhythmias, 728t
for Wolff-Parkinson-White syndrome, 729

Icterus. See Jaundice

ICU patient. See Critically ill patient

Idarubicin
for AML, 346
toxicity of, 341t

Idebenone, for ataxia, 1010

Iodoxuridine, for HSV infections, 568t

Ilospamide
for cervical cancer, 398
toxicity of, 341t

IgA deficiency, isolated, 884

IgA nephropathy, 808

IgG subclass deficiency, 884

Ileal pouch-anal anastomosis, 840

Ileoproctostomy, 383

Ileus, drug-induced, 1137t–1138t

Imaging, diagnostic, 22, 484t

Imatinib
for CML, 349
for gastric cancer, 381
toxicity of, 342t

Imidazoles, 619
for dermatophyte infections, 317

Imipenem
for anaerobic infections, 534t
for cholecystitis, 847
for enterococcal infections, 501
for gram-negative enteric bacteria infections, 516
for human bite infections, 119t
indications for, 425t
for nocardiosis, 536t
for nontuberculous mycobacterial infections, 548
for P. aeruginosa infections, 519t
for pneumonia, 766t, 767t
resistance to, 425t

Imipenem-cilastatin
for pancreatitis, 851
for sepsis/septic shock, 65t
for urinary tract infections, 819t

Imipramine
dosage and adverse effects of, 138t, 141t, 1086t
Imipramine (Cont.):
for noncardiac chest pain, 250
for pain, 36t–37t
Imiquimod
for HPV infections, 476
for warts, 317
Immune globulin, intramuscular, for hepatitis A, 854
Immune-mediated myelopathy, 1029
Immunization, 1107
of immunosuppressed patients, 438t, 439
recommendations for, 1104t–1105t
schedule
for adults, 1112t–1115t
for children, 1108t–1111t
for travelers, 1107, 1116t
Immune-complex disorders, 46
Immune-mediated myelopathy, 1029
Immunization, 1107
of immunosuppressed patients, 438t, 439
recommendations for, 1104t–1105t
schedule
for adults, 1112t–1115t
for children, 1108t–1111t
for travelers, 1107, 1116t
Immunodeficiency disease
definition of, 881
diagnosis of, 882t
immunoglobulin deficiency syndromes, 883
leukopenia in, 331
primary, 881
secondary, 881
severe combined immunodeficiency, 881
T cell immunodeficiency, 883
Immunodeficiency with hyper IgM, X-linked, 884
Immunofluorescent stain, 411
Immunoglobulin deficiency syndromes, 883
Immunohemolytic anemia, 327–328
cold antibody, 327
warm antibody, 327
Immunology, reference values for laboratory tests, 1145t–1156t
Immunoproliferative small-intestinal disease (IPSID), 382
Immunosuppressive agents
for inflammatory bowel disease, 838
for liver transplant, 872
for renal transplant, 799–800
Impetigo, 316, 477
bullous, 316, 477
streptococcal, 498, 498t
Impetigo contagiosa, 477
Inclusion body myositis, 1072, 1073t
India ink, 411
Indigestion, 246
Indinavir, for HIV/AIDS, 612t
Indomethacin
for ankylosing spondylitis, 897
for pain, 36t–37t
for pericarditis, 688
for reactive arthritis, 900
Indomethacin-responsive headache, 189
Infant botulism, 529–530
Infections
leukemoid reaction in, 330
lymphocytosis in, 330
monocytosis in, 330
neutrophilia in, 329
skin disease, 316
weight loss in, 248t
Infectious disease. See also Sepsis; specific diseases and pathogens
diagnosis of, 411
antigen detection, 411
culture, 411–413
microscopy, 411
fatigue in, 289t
focal infections with fulminant course, 109t, 111
in immunocompromised host, 432, 800
medical emergencies, 105
treatment of, 106, 107t–109t
Infectious mononucleosis
cytomegalovirus, 573
Epstein-Barr virus, 574–577, 576t
Infectious myelopathy, 1029
Inferior vena cava filter, 772
Infertility
female, 958
male, 949
Inflammatory bowel disease, 836
Crohn’s disease, 837
diagnosis of, 837–838, 896f
enteropathic arthritis, 907
epidemiology of, 836, 836t
extraintestinal manifestations of, 838
treatment of, 838, 839f, 840
ulcerative colitis, 837
Infliximab
for ankylosing spondylitis, 897
for inflammatory bowel disease, 840, 907
for psoriatic arthritis, 898
for rheumatoid arthritis, 887
Influenza, 577
avian, 111, 577–578
complications of, 578
epidemic and emerging problems, 431
pneumonia, 578
prevention of, 580–581
treatment of, 579–580, 579t
Influenza vaccine, 438t, 580–581, 1108t–1112t, 1114t
recommendations, 580t
Influenza virus
antigenic variation, 577
as bioweapon, 167
Insect-borne disease
protozoan infections, 636
viral infections, 593
Insecticide poisoning, 142t
Insomnia, 226, 229t
adjustment (acute), 227
drug-induced, 227
long-term (chronic), 227
psychophysiological, 227
rebound, 227
short-term, 227
sleep-offset, 227
sleep-onset, 227
transient, 227
Insulin
combinations, 944t
long-acting preparations, 944t
short-acting preparations, 944t
Insulina, 103, 104f, 105t, 389, 390t
Insulin resistance syndrome. See Metabolic syndrome

Insulin therapy
for beta blocker poisoning, 140t
for calcium channel blocker poisoning, 140t
for diabetes mellitus, 943–947, 944t, 946f
for diabetic ketoacidosis, 102t
for hyperglycemic hyperosmolar state, 101–102
for hyperkalemia, 15t

Integrase inhibitors, for HIV/AIDS, 606, 615t

Interferon-alpha therapy
for carcinoma tumor, 389
for chronic hepatitis B, 864
for essential thrombocytosis, 351–352
for follicular lymphoma, 357
for islet-cell tumors, 391
for kidney cancer, 393
for melanoma, 365
for membranoproliferative glomerulonephritis, 805
for Zollinger-Ellison syndrome, 836

Interferon-beta therapy, for multiple sclerosis, 1039

Interferon therapy
for adult T cell leukemia/lymphoma, 260
for HSV infections, 568t
for squamous cell carcinoma, 366
for squamous cell carcinoma, 366
toxicity of, 342t

Interleukin-2 therapy
for kidney cancer, 393
for melanoma, 365
toxicity of, 342t

Internal contamination, radiation, 172

International travel. See Travelers

Internist, procedures commonly performed by, 25

Intestinal decompression, 843

Intestinal motility, 253
altered, 254

Intestinal pseudoobstruction, 842
primary, 843
secondary, 843

Intraabdominal abscess, 449, 513

Intraabdominal infection, 448
clostridial, 531
Klebsiella, 515

Intracerebral hemorrhage, 88
in head trauma, 93
intracranial pressure in, 90
treatment of, 84–85

Intracranial aneurysm, 82t, 88

Intracranial hemorrhage, 80, 82t

Intracranial infection, 109t

Intracranial pressure (ICP)
increased, 90
clinical features of, 90
treatment of, 90–91, 92t
monitoring of, 91, 92f, 92t

Intracranial tumor, 1032

Intracytoplasmic sperm injection, 950, 958

Intraocular pressure, 295

Ipratropium
for COPD, 761–763
for cough, 235

Irtbesartan, for heart failure, 733t

Iridooculitis, 294

Iron
hemochromatosis, 975
poisoning, 147t

Iron-deficiency anemia, 324f, 325, 325t, 328

Iron overload, 44

Irritable bowel syndrome, 840, 841t, 842t

Ischemia, hypoxic-ischemic encephalopathy, 96

Islet-cell tumor
pancreatic, 389, 390t
paraneoplastic syndromes in, 405t

Isocarboxazid, 1087t

Isolation techniques, 429

Isometheptene, for migraine, 186t

Isoniazid
for nontuberculous mycobacterial infec-
tions, 548
poisoning, 150t
for tuberculosis, 541, 543t, 545t

Isoproterenol
for antipsychotic poisoning, 139t
for beta blocker poisoning, 140t
for calcium channel blocker poisoning, 140t
for membrane-active agent poisoning, 153t
for tachyarrhythmias, 725t

Isosorbide dinitrate
for atherosclerosis, 251
for angina pectoris, 715t
for esophageal spasm, 251

Isosorbide mononitrate, for angina pectoris, 715t

Isosporiasis, 420t, 456

Izotretinoin, for acne, 318

Ith mite, 658

Intravenous immunoglobulin
for C. difficile-associated disease, 462
for CLL, 356
for idiopathic thrombocytopenic purpura, 335
for immunoglobulin deficiency, 884
for inflammatory myopathy, 1072
for multiple sclerosis, 1041
for myasthenia gravis, 1066
for parvovirus infections, 588
for polyneuropathy, 1061
for RSV infections, 583
for streptococcal infections, 498t

In vitro fertilization (IVF), 958

Involucrum, 483

Iodine
radioactive, bioterrorism, 174
deficiency, 926t, 931
eccess, 928
iodoquinol, for amebiasis, 460
Ipecac, syrup of, 135, 155t
for COPD, 761–763
for cough, 235
Irbesartan, for heart failure, 733t

Iridocyclitis, 294

Iron
hemochromatosis, 975
poisoning, 147t

Iron-deficiency anemia, 324f, 325, 325t, 328

Iron overload, 44

Irritable bowel syndrome, 840, 841t, 842t

Ischemia, hypoxic-ischemic encephalopathy, 96

Islet-cell tumor
pancreatic, 389, 390t
paraneoplastic syndromes in, 405t

Isocarboxazid, 1087t

Isolation techniques, 429

Isomethopentene, for migraine, 186t

Isoniazid
for nontuberculous mycobacterial infec-
tions, 548
poisoning, 150t
for tuberculosis, 541, 543t, 545t

Isoproterenol
for antipsychotic poisoning, 139t
for beta blocker poisoning, 140t
for calcium channel blocker poisoning, 140t
for membrane-active agent poisoning, 153t
for tachyarrhythmias, 725t

Isosorbide dinitrate
for atherosclerosis, 251
for angina pectoris, 715t
for esophageal spasm, 251

Isosorbide mononitrate, for angina pectoris, 715t

Isosporiasis, 420t, 456

Izotretinoin, for acne, 318

Ith mite, 658
Itraconazole, 619  
for aspergillosis, 623, 624t–625t  
for blastomycosis, 631  
for candidiasis, 252, 621  
for coccidioidomycosis, 630  
for histoplasmosis, 629t  
for penicilliosis, 632  
for sporotrichosis, 631  
Ivermectin  
for larva migrans, 649  
for onchocerciasis, 653  
for pediculiasis, 658  
for scabies, 658  
for strongyloidiasis, 651  

J  
Japanese encephalitis, 595, 596t–597t  
Japanese encephalitis vaccine, 1116t  
Jarisch-Herxheimer reaction, 474  
Jaundice, 263  
approach to, 265f  
causes of, 264, 264t  
cholestatic conditions that produce, 267t  
drug-induced, 266t, 1137t–1138t  
hepatocellular conditions that produce, 266t  
obstructive, 268t  
JC virus, 1051  
Jellyfish sting, 122  
Jet-lag disorder, 226–227, 230  
Jimson weed, 138t  
Joint(s), muscles and innervation of, 980t  
Joint disease  
an aerobic infections, 533  
neuropathic, 908  
P. aeruginosa infections, 517  
Joint pain, 203  
an assessment of, 204–205, 204f  
diagnostic imaging in, 206–207, 207t  
in elderly, 207  
laboratory features in, 205–206  
physical examination in, 205  
Joint replacement surgery, 902  
Jugular foramen syndrome, 1024  
Jugular venous pulsation, 661, 662f  
Jimson weed, 138t  
Joint(s), muscles and innervation of, 980t  
Joint disease  
an aerobic infections, 533  
neuropathic, 908  
P. aeruginosa infections, 517  
Joint pain, 203  
an assessment of, 204–205, 204f  
diagnostic imaging in, 206–207, 207t  
in elderly, 207  
laboratory features in, 205–206  
physical examination in, 205  
Joint replacement surgery, 902  
Jugular foramen syndrome, 1024  
Jugular venous pulsation, 661, 662f  
Juvenile polyposis, 384, 384t  
Kidney cancer, 392  
infections in cancer patients, 433t  
oncologic emergencies, 113  
paraneoplastic syndromes in, 393, 405t  
Kidney disease. See Renal disease  
Kidney stones, 450  
Kingella kingae infection. See HACEK group  
Klebsiella granulomatis infection, 476  
Klebsiella infection, 514  
Klinefelter’s syndrome, 947  
Koplik’s spots, 584  
Korsakoff’s syndrome, 1097  
Kussmaul’s sign, 662  
Kwashorkor, 40  
Kyphoscoliosis, 231  

L  
Labetalol  
for aortic dissection, 738t  
for hypertension, 695t, 698, 698t, 822  
poisoning, 140t  
for sympathomimetic poisoning, 136t  
Laboratory tests, reference values for, 1141  
Labyrinthine dysfunction  
acute bilateral, 212–213  
acute unilateral, 212  
recurrent, 213  
Labyrinthitis, 212, 245t  
La Crosse encephalitis, 596t–597t  
Lactic acidosis, 17t, 18–19  
D-Lactic acidosis, 17t, 18–19  
Lactose hydrogen breath test, 256  
Lactulose  
for constipation, 48t, 259  
for hepatic encephalopathy, 874  
for irritable bowel syndrome, 842t  
Lacunar syndromes, 80, 85  
Lambert-Eaton myasthenic syndrome, 408t, 409, 409t  
Laminectomy, decompressive, 95  
Lamivudine  
for chronic hepatitis B, 858, 860t–861t, 864  
for HIV/AIDS, 608t  
Lamotrigine  
for bipolar disorder, 1080  
dosage and adverse effects of, 143t, 1092t  
for seizures, 992t–993t, 994t  
Lansoprazole, for H. pylori eradication, 833t  
Larva migrans  
cutaneous, 649  
ocular, 649  
visceral, 649  
Laryngeal cancer, 367  
Laryngeal palsy, 1024  
Laryngitis, 306  
Laser therapy  
for diabetic retinopathy, 296  
for glaucoma, 295  
Lassa fever, 110, 597–598  
Latex agglutination assay, 411  
Laxatives  
for constipation, 259  
for hemorrhoids, 844  
Lead poisoning, 156t–157t  
Leech infestation, 659  
Leflunomide  
for psoriatic arthritis, 898  
for rheumatoid arthritis, 888  
Left ventricular function, assessment by nuclear cardiology, 671, 672t
Legionella infection, 521
  specimen collection and transport, 418t
Legionnaires’ disease, 521
Leiomymoma
  gastric, 381
  small-bowel, 382
Leiomyosarcoma, gastric, 380–381
Leishmaniasis, 642
  cutaneous, 643–644
  mucosal, 643–644
  visceral, 643–644
Lemierre syndrome, 533
Lenalidomide, for myelodysplastic syndromes, 350
Leprudin
  for heparin-induced thrombocytopenia, 334
  for thrombotic disorders, 337
Leprosy, 542
  complications of, 544–545
  lepromatous, 544
  treatment of, 546–547
  tuberculoid, 544
Leptospirosis, 551
  anicteric, 552
  icteric, 552
Leriche syndrome, 738
Letrozole
  for breast cancer, 378–379
  toxicity of, 342t
Leucovorin
  for Pneumocystis infections, 634t
  preventive treatment, 635t
  for toxoplasmosis, 647
Leukapheresis, 46
Leukemia.
  See also specific types
  definition of, 352
  drug-induced, 341t
  infections in cancer patients, 433t
  monocytopenia in, 331
Leukemoid reaction, 330
Leukocytes
  inclusion and nuclear abnormalities, 322
  normal values in blood, 329t
Leukocytosis, 329
  drug-induced, 341t
  infections in cancer patients, 433t
  monocytopenia in, 331
Leukemia reaction, 330
Leukoplasty, 330
  drug-induced, 331
Leukoplakia, 367
  oral, 1125
Leuprolide
  for prostate cancer, 401
  toxicity of, 342t
Levetiracetam
  for seizures, 994t
  for tachyarrhythmias, 724t–725t
  for polyneuropathy, 1061
  for sarcoidosis, 536t
  for osteomyelitis, 485t
  for pneumonia, 766t, 767t
  for sepsis/septic shock, 65t
  for sinusitis, 303t
  for S. maltophilia, 518
  for staphylococcal infections, 494t
  for tuberculosis, 542
Levorphanol, for pain, 36t–37t, 38
Levetiracetam
  for alcohol withdrawal, 391
  for seizures, 994t
  for tachyarrhythmias, 724t–725t
  for polyneuropathy, 1061
  for sarcoidosis, 536t
  for osteomyelitis, 485t
  for pneumonia, 766t, 767t
  for sepsis/septic shock, 65t
  for sinusitis, 303t
  for S. maltophilia, 518
  for staphylococcal infections, 494t
  for tuberculosis, 542
Lia, human, 658
Lichenification, 313t
Lichenoid eruption, 313t
  drug-induced, 1134t
Lichen planus, 310f, 314
  lichen simplex chronicus, 311f
Liddle’s syndrome, 20
Lidocaine
  for antidepressant poisoning, 141t
  for antipsychotic poisoning, 139t
  for arrhythmias, 727t
  for cardiac glycoside poisoning, 141t
  for membrane-active agent poisoning, 153t
  for polyneuropathy, 1061
  for tachyarrhythmias, 724t–725t
  for paresis, 894
  for peripheral neuropathy, 1125
  for polyneuropathy, 1061
  for sarcoidosis, 536t
  for osteomyelitis, 485t
  for pneumonia, 766t, 767t
  for sepsis/septic shock, 65t
  for sinusitis, 303t
  for S. maltophilia, 518
  for staphylococcal infections, 494t
  for tuberculosis, 542
Ligase IV gene, 882
Light chain deposition disease, 812t, 813
Lightning muscle cramps, 223
Lightning reflex, 223
Lightning reflex, 223
Limficoliosis, 313t
Limb girdle dystrophy, 1071
Limbic encephalitis, paraneoplastic, 407, 408t
Linear skin lesion, 309
Lindazol
  adverse reactions to, 428
  for enterococcal infections, 501
  for MRSA infections, 479t
  for nocardiosis, 536t
  for osteomyelitis, 485t
  for pneumonia, 766t, 767t
  for sepsis/septic shock, 65t
  for sepsis/septic shock, 65t
  for sinusitis, 303t
  for S. maltophilia, 518
  for staphylococcal infections, 494t
  for tuberculosis, 542
Lioresal, for multiple sclerosis, 1041
Lipase, serum, 849
Lipemia retinalis, 973
Lipodystrophy syndrome, 606
Lipodystrophy syndrome, 606
Lipoma, small-bowel, 382
Lipoprotein analysis, 968–970, 969t
Lipoprotein lipase deficiency, 969t, 973
Lipid replacement therapy, 309
Liquid nitrogen, for warts, 317
Lisinopril
  for heart failure, 733t
  for hypertension, 695t
Lithium, 1093
  for bipolar disorder, 1080
  for cluster headache prevention, 187
  dosage and adverse effects of, 8, 151t, 1092t
Liver abscess, 450
  amebic, 460–461
  streptococcal, 501
Liver biopsy, percutaneous, 309
Liver biopsy, percutaneous, 309
Liver disease
  alcoholic, 869
  benign tumors, 388
Liver disease (Cont.):
coagulation disorders in, 334–335
drug-induced, 1137t–1138t
hepatobiliary imaging in, 270
jaundice in, 263
Liver failure
acute, 858
adverse prognostic indicators, 859
fulminant, 90
sleep disorders in, 228
Liver flap, 224
Liver function tests, 266f, 267, 268t
Liver transplant, 858–859, 862t, 870, 871, 915, 978
for ascites, 272
contraindications to, 872t
immunosuppressive agents for, 872
indications for, 871t
infections in recipients, 439
medical complications after, 872
Lobeline, 142t
Local anesthetics, 146t, 153t
Lockjaw, 528
Löffler’s syndrome, 650
Löfgren’s syndrome, 911
Loperamide
for diarrhea, 256, 1117
for irritable bowel syndrome, 841, 842t
for narcotic withdrawal, 1100
for traveler’s diarrhea, 453
Lopinavir/ritonavir, for HIV/AIDS, 613t
Loratadine, for allergic rhinitis, 880
Lorazepam
for alcohol withdrawal, 1098
for delirium, 50t
dosage and action of, 1089t
for dyspnea, 49t
for myocardial infarction, 702
for nausea, 49
for status epilepticus, 99f
Losartan
for heart failure, 733t
for hypertension, 695t
for systemic sclerosis, 889
Lovastatin, for hyperlipidemia, 972t
Low back pain, 189
acute, 193–196, 194f–195f
causes of, 190–191
visceral, 193, 193t
chronic, 196
examination of, 190, 191t
risk factors for structural cause, 192t
types of, 190
Low back strain/sprain, 192
Lower esophageal sphincter, disorders of, 251
Low-molecular-weight heparin
for thrombotic disorders, 336, 337t
for venous disease, 741
for venous thromboembolism, 770–771
Loxapine, 1091t
Lubiprostone, for irritable bowel syndrome, 842t
Ludwig’s angina, 532
Lumbar disk disease, back pain in, 190
Lumbar puncture, 27, 28f, 416t
Lumbar puncture headache, 189
Lumpectomy, 376
Lung abscess, 533, 767
Lung biopsy, 774
Lung cancer, 368
adenocarcinoma, 369, 372t–373t
bronchoalveolar, 374
causes of, 369, 756–757
diagnosis of, 751
epidermoid (squamous), 369
large cell, 369
non-small cell, 372t
oncologic emergencies, 112–113
paraneoplastic syndromes in, 369, 405t, 406–407, 409t
prevention of, 1124
screening for, 1122
small cell (oat cell), 369, 371–374, 372t
staging of, 369–371, 370t–371t
treatment of, 371–374, 372t–373t
Lung disease. See also Respiratory disease
anerobic infections, 533
cor pulmonale, 735
cyanosis in, 239, 240t
diffuse parenchymal, 231
dyspnea, 231–233, 232t
environmental, 756
inorganic dusts, 757
occupational exposures, 757
organic dusts, 758
toxic chemicals, 758
fatigue in, 289t
interstitial, 772
with alveolitis, inflammation, and fibrosis, 772, 773t
in connective tissue disorders, 775–776
drug-induced, 774
with granulomatous reaction, 772, 773t
necrosis, 535, 536t
nontuberculous mycobacterial infections, 547
pulmonary hypertension in, 743t
Lung transplant
for COPD, 762
infections in recipients, 439
Lung volume(s), 747f
Lung volume reduction surgery, 762
Lupus, drug-induced, 1131t
Luteinizing hormone, 917, 918f
Lyme borreliosis, 125, 549, 558
arthritis, 550–551
disseminated infection, 550–551
localization, 549
persistent infection, 550–551
Lymphadenitis, in tuberculosis, 539
Lymphadenopathy, 283
diseases associated with, 284t
drug-induced, 1135t
due to hyperplasia, 284–285
due to infiltration, 285
in HIV/AIDS, 605
Lymphadenectomy, 774
Lymphedema, 742
Lymphocutaneous syndrome, nocardiosis, 535, 536t
Lymphocytic choriomeningitis, 594
Lymphocytic leukemia, chronic (CLL), 355
staging of, 355, 356t
Lymphocytosis, 330
Lymphoepithelioma, 367
Lymphogranuloma venereum, 468, 471
features of genital ulcers, 467
Lymphoid leukemia/lymphoma
acute (ALL), 353t, 354f, 359
adult T cell leukemia/lymphoma, 360
acute lymphoblastic leukemia and lymphoblastic leukemia, 359
chronic, 353t, 354f, 355
Lymphoid malignancy, 352
classification of, 352, 353t
diagnosis and staging of, 355
incidence and etiology of, 352–355, 354f
Lymphoma, 352, 572.
See also specific types
aggressive, 353t, 355, 357
definition of, 352
indolent, 353t, 355, 357
infections in patients, 433t
oncologic emergencies, 112–113
primary CNS, 1033
Lymphopenia, 331
Lymphoproliferative disease
posttransplantation, 575, 577
X-linked, 884
Lynch syndrome, 384, 384t
M
Macular degeneration, 215, 216f, 296, 296f
dry, 296
wet, 296
Macule, 313t
Maculopapular rash, 106, 200
Magnesium, serum, arrhythmias and, 704
Magnesium citrate
for constipation, 48t
for poisoning, 135
Magnesium hydroxide (Milk of Magnesia)
for constipation, 48t
for irritable bowel syndrome, 842t
Magnesium therapy
for antipsychotic poisoning, 139t
for cardiac glycoside poisoning, 141t
for hypomagnesemia, 965
for membrane-active agent poisoning, 153t
for torsades de pointes, 725t
Magnetic resonance angiography, in stroke, 80, 85
Magnetic resonance imaging (MRI) in coma, 79
in heart disease, 672t, 673
hepatobiliary, 270, 846t
indications for, 24
in myocardial infarction, 701
neuroimaging, 986, 987t
in osteomyelitis, 484t
in poisoning, 133
in respiratory disease, 751
in spinal cord disorders, 94–95
utility of, 24
Malabsorption syndromes, 256
causes of, 259t
drug-induced, 1137t–1138t
Malaria, 421, 636
cerebral, 109t, 636
in children, 637
diagnosis of, 420t
in pregnancy, 637
prevention of, 639, 640t–641t, 1116
transfusion, 637
treatment of, 637–639, 638t–639t
Malassezia infection, 631
Malathion, for pediculiasis, 658
Maldigestion, 259t
Male gender, cardiovascular disease and, 1120
Malingering, 1084
Malnutrition, 39
ascites in, 272
eye disease in, 294
MALT lymphoma, 355, 380–382, 835
Mammography, 375
screening, 375–376, 1122, 1123t
Mandibular positioning device, 784
Mania, 1080
drug-induced, 1140t
Manic depressive illness. See Bipolar disorder
Mannitol therapy
for increased intracranial pressure, 90–91, 92t
for poisoning, 135
for stroke, 83
MAO inhibitor poisoning, 138t, 152t
Marasmus, 40
Maraviroc, for HIV/AIDS, 606, 615t
Marburg virus infection, 110, 599
March hemoglobinuria, 328
Marie-Strumpell disease. See Ankylosing spondylitis
Marine envenomations, 122
invertebrate, 122–123
vertebrate, 123
Marine poisoning, 123
Mastectomy
bilateral prophylactic, 1124
for breast cancer, 376
Mastitis, staphylococcal, 491
Mastocytosis, systemic, 880, 880t
Mastoiditis, 305
M component, 360–361
Measles vaccine, 585
Measles virus infection, 584
atypical measles, 585
CNS disease, 584–585
gastrointestinal disease, 585
postexposure prophylaxis, 585
respiratory disease, 584
subacute sclerosing panencephalitis, 585
Mebendazole
for ascariasis, 650
for enterobiasis, 651
for hookworm, 650
for trichinellosis, 649
Mechanical ventilation. See Ventilatory support
Mechlorethamine, 341t
Mecazine
for nausea and vomiting, 48, 245
for vertigo, 214t
Mediastinal mass, 781
Mediastinitis, 781
Mediastinoscopy, 752
Medical emergencies. See Emergencies, medical
Medicinal leech, 659
Mediterranean spotted fever, 110, 555
Medrol, for anaphylaxis, 117
Medroxyprogesterone
for amenorrhea, 953
for menopausal symptoms, 957
Toxicity of, 342t
Mefloquine, for malaria, 638t
Preventive Treatment, 639, 641t
Megestrol
for endometrial cancer, 397
for weight loss, 248
Meglumine antimonate, for leishmaniasis, 643
Melanoma, 364
Acral lentiginous, 364–365
Lentigo maligna, 364
Metastatic, 365
Nodular, 365
Paraneoplastic syndromes in, 409t
Superficial spreading, 364
Melarsoprol, for sleeping sickness, 646
Melena, 259
Meleney’s gangrene, 533
Melioidosis, 518, 520t
Melphalan
for amyloidosis, 915
for multiple myeloma, 361
Toxicity of, 341t
Memantine, for Alzheimer’s disease, 1000
Mendelson’s syndrome, 533
Ménière’s disease, 213, 214t, 300
Meningioma, 216f, 1033, 1034f
Meningitis
acute, 1042
Approach to, 1042, 1043f–1044f
Acute bacterial, 1042
Clinical Features of, 1044
Laboratory features of, 1044–1045, 1045t
Pathogens, 1042, 1047t
Treatment of, 1045, 1046t, 1047t
Aseptic
Enterovirus, 590
HSV, 565–566, 567t–568t
Poliovirus, 589
Bacterial, 108t, 111
Chronic, 1052
Approach to, 1052–1055
Causes of, 1053, 1054t, 1055t
Clinical features of, 1052, 1053t
Coccidioidomycosis, 630
E. coli, 513
Enterococcal, 501
Gonococcal, 470t
H. influenzae, 508
Listerial, 507
Lumbar puncture, 27–28, 28f
Meningococcal, 504–506
Mollaret’s, 566
Pneumococcal, 487–488
Streptococcal, 500
Viral, 1046
Pathogens, 1047t
Treatment of, 1048
Meningococcal infection, 504, 506t
Meningitis, 504–506
Respiratory disease, 504
Meningococcal vaccine, 438t, 505–506, 506t, 1108t–1112t, 1115t, 1116t
Meningoencephalitis, 643
Cryptococcal, 623, 626
Listerial, 507
Menopause, 956
Sleep disorders in, 228
Mental status exam, 979, 979t
Meperidine
for cholecystitis, 847
Narcotic Abuse, 1099
For pain, 36t–37t
For pancreatitis, 851
Poisoning, 152t, 153t
Meprobamate poisoning, 144t
Megalalga preaesthetica, 1063t
6-Mercaptopurine
For Burkitt’s lymphoma, 359–360
For inflammatory bowel disease, 838
Mercury poisoning, 158t–159t
Meropenem
For anaerobic infections, 534t
For bacterial meningitis, 1046t, 1047t
For B. cepacia infections, 518, 520t
For brain abscess, 1051
For cholecystitis, 847
Indications for, 425t
For meningococcal infections, 506t
For P. aeruginosa infections, 519t
For pneumonia, 767t
Resistances to, 425t
Merozoite, 636
Mesalamine enema, for inflammatory bowel disease, 838
Mesenteric arteriography, 260, 873
Mesenteric insufficiency, chronic, 843
Mesenteric ischemia, acute, 843
Mesothelioma, 757
Metabolic acidosis, 16
Anion-gap, 17t, 18–19, 21
Causes of, 16–18, 17t
Drug-induced, 17t, 1133t
Hyperchloremic, 19
Non-anion-gap, 17t, 18, 21
Metabolic alkalosis, 19, 20f
Chloride-resistant, 19–20, 20f
Chloride-responsive, 19–20, 20f
Metabolic disease
Abdominal pain in, 179t
Drug-induced, 1132t
Weight loss in, 248t
Metabolic syndrome, 699
NCEP-ATPIII 2001 and IDF criteria for, 700t
Metabolism disruptors, 132t
Metapneumovirus infection, 583
Metformin
For diabetes mellitus, 944–945, 945t
For obesity, 940
Methadone, 1099
For narcotic withdrawal, 1100
For opioid maintenance, 1100
For pain, 36t–37t, 38
Methanol poisoning, 17t, 18–19, 148t
Methemoglobinemia, 239
Methemoglobin inducers, 146t
Methamphetamine, for nephro lithiasis, 828t
Methimazole, for thyrotoxicosis, 928–929
Methotrexate
for ankylosing spondylitis, 897
for bladder cancer, 392
for head and neck cancer, 368
for inflammatory bowel disease, 840
for inflammatory myopathy, 1072
for multiple sclerosis, 1039
for polyneuropathy, 1061
for primary sclerosing cholangitis, 849
for psoriasis, 314
for psoriatic arthritis, 898
for reactive arthritis, 900
for rheumatoid arthritis, 887
toxicity of, 341t
for vasculitis, 894
Methyl cellulose, for irritable bowel syndrome, 842t
Methyldopa, for hypertension, 698
Methylene blue, for methemoglobin, 146t
Methylphenidate
for daytime sleepiness, 229t, 230
Methylprednisolone
for asthma, 756
for multiple sclerosis, 1039, 1041
for optic neuritis, 217
for renal transplant rejection, 799
steroid preparations, 938–939, 938t
Methylsergide
for migraine prevention, 188t
poisoning, 137t
Methylxanthine poisoning, 137t
Metoclopramide
for H. pylori eradication, 247
for migraine, 186t
for nausea and vomiting, 246
for systemic sclerosis, 889
Methylene blue, for methemoglobin, 146t
for myotonic dystrophy, 1071
MHC class II deficiency, 883
Micafungin, 620
for candidiasis, 621
Miconazole, 620
for candidiasis, 464
Microaerophilic bacteria, 528
Microbial bioterrorism, 160, 432
CDC category A agents, 161t, 162–167
CDC category B agents, 161t, 167
CDC category C agents, 161t, 167
features of bioweapons, 161t
prevention and preparedness, 167
Micrographia, 1002
Micronutrient deficiency, 43t, 44
Microscopic polyangiitis, 892
Microscopy, diagnostic, 411
Midazolam
for delirium, 50t
for dyspnea, 49t
for increased intracranial pressure, 92t
poisoning, 143t
for scorpion sting, 126
for status epilepticus, 99f
Midodrine
for hepatorenal syndrome, 274
for orthostatic hypotension, 1019
Mifepristone, for emergency contraception, 957
Miglitol, for diabetes mellitus, 945t
Migraine, 183, 183t
diagnosis of, 184t
sleep disorders and, 227
vertigo in, 213, 214t
visual loss in, 215
Migrating motor complex, 253
Milk alkali syndrome, 19
Milorone
for heart failure, 734t, 735t
for myocardial infarction, 705, 705t
Miltefosine, for leishmaniasis, 643–644
Milwaukee shoulder, 906
Mineral(s)
for mineral deficiencies, 43t
trace, reference values for laboratory tests, 1160t
Mineralocorticoids, 933
Mineral oil, for constipation, 259
Minimal change disease, 804
Mini-mental status examination, 979t, 995
Mini-transplant, 356
Minocycline
for actinomycosis, 538
for pelvic inflammatory disease, 466
for rheumatoid arthritis, 898
for systemic sclerosis, 889
for osteomyelitis, 485t
for trichomoniasis, 464
for urethritis in men, 463
Metapyrone, for ectopic ACTH syndrome, 407
Mexiletine
for arrhythmias, 727t
for myotonic dystrophy, 1071
for MHC class II deficiency, 883
for polyneuropathy, 1061
for vasculitis, 894
for migraine prevention, 188t
poisoning, 137t
Methylxanthine poisoning, 137t
Metoclopramide
for H. pylori eradication, 247
for migraine, 186t
for nausea and vomiting, 246
for systemic sclerosis, 889
Methylene blue, for methemoglobin, 146t
for myotonic dystrophy, 1071
MHC class II deficiency, 883
Micafungin, 620
for candidiasis, 621
Miconazole, 620
for candidiasis, 464
Microaerophilic bacteria, 528
Microbial bioterrorism, 160, 432
CDC category A agents, 161t, 162–167
CDC category B agents, 161t, 167
CDC category C agents, 161t, 167
features of bioweapons, 161t
prevention and preparedness, 167
Micrographia, 1002
Micronutrient deficiency, 43t, 44
Microscopic polyangiitis, 892
Microscopy, diagnostic, 411
Midazolam
for delirium, 50t
for dyspnea, 49t
for increased intracranial pressure, 92t
poisoning, 143t
for scorpion sting, 126
for status epilepticus, 99f
Midodrine
for hepatorenal syndrome, 274
for orthostatic hypotension, 1019
Mifepristone, for emergency contraception, 957
Miglitol, for diabetes mellitus, 945t
Migraine, 183, 183t
diagnosis of, 184t
sleep disorders and, 227
vertigo in, 213, 214t
visual loss in, 215
Migrating motor complex, 253
Milk alkali syndrome, 19
Milorone
for heart failure, 734t, 735t
for myocardial infarction, 705, 705t
Miltefosine, for leishmaniasis, 643–644
Milwaukee shoulder, 906
Mineral(s)
for mineral deficiencies, 43t
trace, reference values for laboratory tests, 1160t
Mineralocorticoids, 933
Mineral oil, for constipation, 259
Minimal change disease, 804
Mini-mental status examination, 979t, 995
Mini-transplant, 356
Minocycline
for actinomycosis, 538
for pelvic inflammatory disease, 466
for rheumatoid arthritis, 898
for systemic sclerosis, 889
for osteomyelitis, 485t
Minocycline (Cont.):
  resistance to, 426t
  for staphylococcal infections, 493, 494t
Mirtazapine, 1086t
Misoprostol, for erosive gastropathies, 834
Mithramycin, 342t
Mitochondrial myopathies, 1074
Mitomycin
  for anal cancer, 878
  toxicity of, 342t
Mitotane, for adrenal carcinoma, 934
Mitoxantrone
  for multiple sclerosis, 1039
  for prostate cancer, 401
  toxicity of, 341t
Mitral regurgitation, 662t, 678, 680f
  echocardiography in, 671f
  in myocardial infarction, 708
Mitral stenosis, 662t
  echocardiography in, 671f
  treatment of, 678, 679f
Mitral valve prolapse, 662t, 680
Mittelschmerz, 954
Mixed anaerobic infection, 532
Mixed connective tissue disease, 890
MMR vaccine, 438t, 585–586, 1108t–1113t
MMRV vaccine, 585
Mobilizing agent, for radionuclide contamination, 174
Modafinil
  for circadian rhythm disorders, 230
  for daytime sleepiness, 229t, 230
  for depression, 50
Moh’s micrographic surgery, 366
Molindone, 1091t
Molluscum contagiosum, 477
Monkey bite, 118, 119t
Monoamine oxidase inhibitors (MAOI), 1087t, 1088
Monoclonal gammopathy of uncertain significance (MGUS), 361
Monocytopenia, 331
Monocytosis, 330
Mononeuritis multiplex, 1061
Mononeuropathy, 1055, 1062t–1064t, 1065
Mononeuropathy multiplex, 1061
Montelukast
  for allergic rhinitis, 880
  for asthma, 755
  for urticaria/angiodyema, 879
Mood disorder, 1077
Mood stabilizers, 1092t, 1093
MOPP-ABV regimen, for Hodgkin’s disease, 364
MOPP regimen, for Hodgkin’s disease, 364
Moraxella catarrhalis infection, 510
Morbiliform lesion, 309
Morganella infection, 516
Morphine
  for dyspnea, 49t
  for increased intracranial pressure, 92t
  for myocardial infarction, 702, 711
  narcotic abuse, 1099
  for pain, 36t–37t, 38
  for pulmonary edema, 68
  for unstable angina, 711
Mortality, age-specific, 1103, 1104–1105t
Mosquito-borne viral infection, 593
Motion sickness, 214t, 245, 245t
Motor exam, 984
Motor fluctuations, 1004
Motor neuron disease, 1010
  etiology and investigation of, 1012t
  lower motor neurons, 219t, 220t, 1011t
  secondary, 1011t
  sporadic, 1011t
  upper motor neurons, 219t, 220, 220t, 1011t
Motor unit disorders, 220, 220t
Movement disorders, 222
  insomniania and, 227
Moxifloxacin
  indications for, 427t
  for Legionella infections, 522
  for pneumonia, 766t, 767t
  resistance to, 427t
  for tuberculosis, 542
Mucormycosis, 626
  pulmonary, 627
  rhinocerebral, 111, 626–627
Mucositis, acute necrotizing ulcerative, 532
Mucous membranes
  dry, in terminally ill patient, 53t
  in malnutrition, 41
Mucous patch, 472
Multifocal motor neuropathy with conduction block, 1011, 1011t
Multi-infarct dementia, 1000–1001
Multiorgan system failure, 32
Multiple cranial nerve palsies, 1024
Multiple endocrine neoplasia type 1, 389, 835–836, 959
Multiple myeloma, 355, 360
  glomerular disease in, 807t
  infections in patients, 433t
  oncologic emergencies, 113
  paraneoplastic syndromes in, 405t
  staging of, 361, 362t
Multiple sclerosis (MS), 1035
  acute (Marburg’s variant), 1041
  clinical features of, 1035–1036
  clinical variants of, 1041
  definite, 1036t
  diagnostic criteria for, 1036–1037, 1036t
  disorders that mimic, 1037t
  facial nerve involvement in, 1022
  laboratory features of, 1037–1038, 1038f
  primary progressive, 1037, 1040f
  probable, 1036t
  progressive-relapsing, 1037
  relapsing-remitting, 1037, 1040f
  at risk for, 1036t
  secondary progressive, 1037, 1039, 1040f
  spinal cord involvement in, 1030
  treatment of, 1039–1041, 1040f
  acute relapses, 1039
  disease-modifying therapies, 1039
  progressive symptoms, 1039–1040
  symptomatic therapy, 1041
Multiple sleep latency test, 228, 229t
Mumps virus infection, 586
  orchitis, 587
  parotitis, 586–587
Munchausen’s syndrome, 1084
Mupirocin, 427t
Murmur. See Heart murmur
Murphy’s sign, 845
Muscle contracture, 1068
Muscle cramp, 1068
Muscle disease, 1068
approach to, 1068, 1069f–1070f
disorders of energy metabolism, 1072
drug-induced, 1074, 1075t, 1140t
endocrine and metabolic myopathies, 1074
inflammatory myopathies, 1072, 1073t
mitochondrial myopathies, 1074
muscular dystrophies, 1068
paraneoplastic, 408–409, 408t
periodic paralysis, 1074
Muscle relaxant poisoning, 138t, 139t, 144t
Muscle spasm, back pain in, 190
Muscular dystrophy
Duchenne, 1068
facioscapulohumeral, 1071
limb-girdle, 1071
myotonic dystrophy, 1071
ocularpharyngeal, 1072
Musculoskeletal complaints, 203
Musculoskeletal infection
E. coli, 513
S. aureus, 491
Mushrooms, poisonous, 138t, 142t, 858
M-VAC regimen, for bladder cancer, 392
Myalgia, 1068
drug-induced, 1140t
Myasthenia gravis (MG), 1065
differential diagnosis of, 1066
diplopia in, 217
paraneoplastic, 408t, 409t
treatment of, 1066–1067, 1067f
Myasthenic crisis, 1066–1067
Myelitis, paraneoplastic, 408t
Myelodysplastic syndrome, 325, 345t, 350
classification of, 348t–349t
prognostic scoring system for, 350, 350t
Myelofibrosis, 330
Myelography, 986
Myeloid leukemia
acute (AML), 344
classification of, 345t
chronic (CML), 347
response criteria for, 348t
Myelopathy. See also specific types
retrovirus-associated, 1029
Myelophthisis, 330
Myeloproliferative syndrome, 351
leukocytosis in, 329–330
Myelosuppression, drug-induced, 341t–342t
Myceloma, 302
Mycobacterium abscessus infection, 548
Mycobacterium chelonae infection, 548
Mycobacterium fortuitum infection, 548
Mycobacterium kansasii infection, 548
Mycobacterium marinum infection, 549
Mycobacterium tuberculosis infection.
Mycophenolate mofetil
immunosuppression for renal transplant, 800
for inflammatory myopathy, 1072
for myasthenia gravis, 1066
for SLE, 803, 886
Mycoplasma genitalium infection, 471
cervicitis, 465
urethritis in men, 463
Mycoplasma hominis infection, 471
arthritis, 471
bacterial vaginosis, 471
pelvic inflammatory disease, 465, 471–472
urethritis, 471
Mycoplasma pneumoniae infection, 560
Myotic aneurysm, 88
Myelitis, paraneoplastic, 408t
Myelodysplastic syndrome, 325, 345t, 350
classification of, 348t–349t
with isolated del(5q), 348t–349t
N
Nadolol
poisoning, 140t
for variceal bleeding, 263
for vasovagal syncope, 210
Nafcillin
- for bacterial meningitis, 1046t, 1047t
- for cellulitis, 479t
- for infective endocarditis, 445t
- for osteomyelitis, 485t
- for perichondritis, 304
- resistance to, 425t
- for sepsis/septic shock, 65t
- for staphylococcal infections, 494t

Nailbed, in cyanosis, 239

Nail lesions, 311

Naloxone
- for membrane-active agent poisoning, 153t
- for opiate overdose, 1100
- for sympatholytic poisoning, 139t

Naltrexone
- for alcoholic rehabilitation, 1098
- for primary biliary cirrhosis, 871

Naproxen
- for migraine, 185t
- for pain, 36t–37t

Naratriptan, for migraine, 185t, 187t

Narcissistic personality disorder, 1084

Narcolepsy, 226, 228, 229t

Narcotic(s)
- for abdominal pain, 182
- for frostbite, 129, 129t
- for migraine, 186t

Narcotic abuse, 1099
- clinical features of, 1099–1100
- prevention of, 1101
- treatment of, 1100–1101
  - drug-free programs, 1101
  - opiate antagonists, 1100–1101
  - opioid maintenance, 1100
  - overdose, 1100
  - withdrawal, 1099–1100

Nasal swab, 414t

Nasopharyngeal cancer, 367, 575–576, 576t

Nasopharynx
- S. pneumoniae carriage, 486

Nataglinide, for diabetes mellitus, 945t

Natalizumab, for multiple sclerosis, 1039

Nausea and vomiting
- causes of, 244–245, 245t
- in terminally ill patient, 48

Neatorameicus infection. See Hookworm infection

Neck infections, 307

Neck pain, 196

Neck weakness, 1024

Necrotizing fasciitis, 108t, 110, 477, 478
- mixed anaerobic-aerobic infection, 533
- streptococcal, 497–498, 498t
- treatment of, 479t–480t, 480

Necrotizing myelopathy, acute, 408

Nedocromil sodium, for asthma, 755

Nefazodone, 1092

Negri bodies, 592

Neisseria gonorrhoeae infection. See Gonorrhea

Neisseria meningitidis infection. See Meningococcal infection

Nelfinavir, for HIV/AIDS, 612t

Nematocysts, 122

Nematode infection
- filarial worms, 651
- intestinal, 649
- tissue nematodes, 648

Neomycin, for hepatic encephalopathy, 874

Neonatal disease
- cytomegalovirus infections, 573
- generalized disease of the newborn, 590
- HSV infections, 566, 568t
- streptococcal infections, 500

Neostigmine poisoning, 142t

Nephrectomy, 393

Nephritic syndrome, 280, 801

Nephritis
- acute interstitial, 810, 811t
- chronic interstitial, 811
- drug-induced, 810–811, 811t, 1138t

Nephrolithiasis
- stone composition, 826–827

Stone composition, 826–827

Nephrosclerosis, arteriolar

Nephrosis, arteriolar

Neoplasms
- brain, 1039
- gastrointestinal, 1041
- lymphatic, 1043

Neopterin, for megaloblastic anemia, 671

Neuroborreliosis, 550

Neurocysticercosis, 655–656

Neurogenic shock, 59t

Neuroimaging, 986, 987t, 994

Neuroleptic malignant syndrome, 1039

Neurologic disease
- abdominal pain in, 179t
- ataxia, 1007
- autonomic nervous system disorders, 1013
- brain abscess, 1050
- cranial nerve disorders, 1020
- in critically ill patient, 33
- cytomegalovirus infections, 573
- dementia, 995
- depression in, 1078
- diptheria, 502
- hypertoxemia, 502
- drug-induced, 341t, 1138t–1139t
- encephalitis, acute, 1042

Neurocysticercosis, 655–656

Neurogenic shock, 59t

Neuroimaging, 986, 987t, 994

Neuroleptic malignant syndrome, 203, 1092

Neurologic disease
- abdominal pain in, 179t
- ataxia, 1007
- autonomic nervous system disorders, 1013
- brain abscess, 1050
- cranial nerve disorders, 1020
- in critically ill patient, 33
- cytomegalovirus infections, 573
- dementia, 995
- depression in, 1078
- diptheria, 502
- drug-induced, 341t, 1138t–1139t
- encephalitis, acute, 1042

Nephrin, for membranoproliferative glomerulonephritis, 1039

Nephrine,

Nephrine syndrome, 280, 801

Nephritis
- acute interstitial, 810, 811t
- chronic interstitial, 811
- drug-induced, 810–811, 811t, 1138t

Nephrolithiasis
- stone composition, 826–827

Nephritic syndrome
- ascites in, 273t
- causes of, 804, 804t
- drug-induced, 1138t
- evaluation of, 806t

Nerve agents, 169, 170t
- clinical features of exposure, 169
- treatment of, 169–171, 170t

Nerve gas, 142t

Nervous system tumor, 1031

Neptunium, 829

Nephrin, for membranoproliferative glomerulonephritis, 1039

Nephrine,

Nephrine syndrome, 280, 801

Nephritis
- acute interstitial, 810, 811t
- chronic interstitial, 811
- drug-induced, 810–811, 811t, 1138t

Nephrolithiasis
- stone composition, 826–827

Neurology, 986

Neurolymphomatosis, 444

Neurologic disease
- abdominal pain in, 179t
- ataxia, 1007
- autonomic nervous system disorders, 1013
- brain abscess, 1050
- cranial nerve disorders, 1020
- in critically ill patient, 33
- cytomegalovirus infections, 573
- dementia, 995
- depression in, 1078
- diptheria, 502
- drug-induced, 341t, 1138t–1139t
- encephalitis, acute, 1042
- epilepsy, 988

Epstein-Barr virus infections, 575

Fatigue in, 289t

HSV infections, 565–566, 568t

in HIV/AIDS, 605

Hypothermia in, 128t

in leprosy, 546

Lyme borreliosis, 550

in malnutrition, 41
meningitis
  acute, 1042
  chronic, 1052
motor neuron disease, 1010
multiple sclerosis, 1035
myasthenia gravis, 1065
paraneoplastic, 407, 408t
Parkinson’s disease, 1002
progressive multifocal leukoencephalopathy, 1051
seizure, 988
sleep disorders in, 227
spinal cord disease, 1026
tuberculosis, 540
tumors of nervous system, 1031
varicella-zoster virus infections, 570
weight loss in, 248t

Neurologic examination, 979
  anatomic localization of problem, 985t, 986
  coordination and gait, 986
  cranial nerve exam, 979
  in head trauma, 93
  in low back pain, 190, 191t
  mental status exam, 979, 979t
  motor exam, 984
  reflexes, 984
  sensory exam, 985
Neuromuscular blockers, 31
Neuromuscular junction disorders, 219t, 220t
Neuromyelitis optica, 217, 1041
Neuropathy. See specific types paraneoplastic, 408t, 409t
Neuroprotection, for stroke, 84
Neurosyphilis, 473, 474t, 475
Neutron particles, 171
Neutrophilia, 329
in cancer patient, 115
Febrile, 331
approach to, 435–436, 435f
infections, 518
P. aeruginosa infections, 455
Nefazodone, 1045
Nistic, 658–659
Nitazoxanide
  for cryptosporidiosis, 455
  for giardiasis, 455
Nitrates
  for angina pectoris, 714–715, 715t
  for heart failure, 731, 733t
  for myocardial infarction, 705–706
  poisoning, 146t
Nitrite poisoning, 146t
Nitrofurantoin
  for cystitis, 818t
  for urinary tract infection prevention, 817
Nitrogen mustard, 168
Nitrogen oxides, poisoning, 146t
Nitroglycerin
  for anal fissures, 844
  for angina pectoris, 714–715, 715t
  for ergot alkaloid poisoning, 137t
  for hypertensive emergencies, 698t
  for myocardial infarction, 702, 705, 705t, 706t, 711
  for systemic sclerosis, 889
  for unstable angina, 711
Nitroprusside
  for aortic dissection, 738, 738t
  for ergot alkaloid poisoning, 137t
  for heart failure, 734, 734t
  for hypertension, 698t, 822
  for MAO inhibitor poisoning, 138t
  for mitral regurgitation, 680
  for myocardial infarction, 705, 705t, 706t, 708
Nitrosourea, 341t
Nocardiosis, 535, 536t
  eye infections, 535, 536t
  pulmonary disease, 535
  skin/soft tissue infections, 535, 536t
  Nodule (skin lesion), 201, 313t, 478
  Noma, 532
Non-Hodgkin’s lymphoma, 354f, 355
  international prognostic index for, 358, 358t
Nonpolyposis syndrome, 384, 384t
Nonsteroidal anti-inflammatory drugs
  (NSAID)
    for ankylosing spondylitis, 897
    for calcium apatite deposition disease, 907
    for cholecystitis, 847
    for chronic fatigue syndrome, 291
    for colon cancer prevention, 1124
    for colonic polyps, 383
    for diabetes insipidus, 8
    for enteropathic arthritis, 907
    for erythema nodulare, 318
    for fever, 201
    for fibromyalgia, 909
    for gout, 904
    for low back pain, 196
    for migraine, 184, 185t
    for osteoarthritis, 902
Nonsteroidal anti-inflammatory drugs (NSAID) (Cont.):
- for osteonecrosis, 909
- for pain, 36t–37t, 38, 955
- for psoriasis, 898
- for reactive arthritis, 900
- for rheumatoid arthritis, 887
- for SLE, 886
- for systemic mastocytosis, 881
- for tension headache, 186

Nontuberculous mycobacterial infection, 547
- disseminated disease, 548
- lung disease, 547

Norepinephrine
- for beta blocker poisoning, 140t
- for calcium channel blocker poisoning, 140t
- for increased intracranial pressure, 92t
- for MAO inhibitor poisoning, 138t
- for shock, 62, 62t
- for subarachnoid hemorrhage with vasospasm, 89
- for sympatholytic poisoning, 139t

Norovirus infection, 431
- diarrhea, 454

Nortriptyline
- dosage and adverse effects of, 1086t
- for pain, 36t–37t, 38
- for smoking cessation, 1127

Nutritional status, assessment of, 39
- decision tree for initiating, 42f
- enteral nutrition, 42–43
- parenteral nutrition, 43

Octreotide
- for acromegaly, 921
- for carcinoid tumor, 389
- for esophageal varices, 874
- for hepatorenal syndrome, 274
- for islet-cell tumors, 391
- for variceal bleeding, 263

Ondansetron
- for nausea and vomiting, 246, 343

Orchidectomy, 394
Pancreatic endocrine tumors, 389
Pancreatic enzyme replacement, 853
Pancreatic exocrine insufficiency, 852–853, 853t
Pancreatic necrosis, 852
Pancreatic pseudocyst, 852
Pancreatitis, 849
acute, 849
causes of, 850t
complications of, 851–852
risk factors that adversely affect survival, 851t
ascites in, 273t
chronic, 852
complications of, 853
TIGAR-O classification of, 853t
diagnosis of, 587
drug-induced, 1138t
interstitial, 849
necrotizing, 849
Pancytopenia, drug-induced, 1135t
Panic disorder, 1081, 1088
Panitumumab, for colorectal cancer, 387
Pantoprazole
for erosive gastropathies, 834
for H. pylori eradication, 833t
Papillary necrosis, 817
Pappenheimer bodies, 321
Pap smear, 397–398, 1123t, 1125
Papule (skin lesion), 313t, 478
Papulosquamous disorder, 314
Paracentesis, 28, 107
Paracoccidioidomycosis, 631
Paragonimus infection. See Fluke infection, lung flukes
Parafibromin, 954
Paracoccidioidomycosis, 631
Paraganglioma. See Neurofibromatosis, type 1
Paraganglioma, pheochromocytoma
Paraganglioma, pheochromocytoma
Paraganglioma, pheochromocytoma
Paragonimus infection. See Fluke infection, lung flukes
Parainfluenza virus infection, 583
Paralysis, 218
periodic, 1074
site of responsible lesion, 219, 219t
Paralytic shellfish poisoning, 124
Paraneoplastic syndromes
emergent, 113
diagnosis, 405
neurologic, 407, 408t
Paraneoplastic syndromes
diagnosis of, 407
neurologic, 407, 408t
Paroxysmal nocturnal hemoglobinuria, 323, 326, 326t
Paroxetine
for depression, 50
dosage and adverse effects of, 1086t
for irritable bowel syndrome, 841
for menopausal symptoms, 957
for vasovagal syncope, 210
Paroxysmal nocturnal hemoglobinuria, 323, 326, 326t
Parvovirus B19 infection, 587
Patch (skin lesion), 313t
Patch tests, 312
Peginterferon
for chronic hepatitis B, 860t–861t, 864
for chronic hepatitis C, 864, 865t–866t
Pelger-Hüet anomaly, 322
Pelvic infection, anaerobic, 533
Pelvic inflammatory disease (PID), 465, 469
causes of, 465, 469–470
pain in, 954
treatment of, 466, 470t
Pelvic pain, 953
acute, 954
causes of, 953–954, 954t
chronic, 954
cyclic, 954, 954t
noncyclic, 954, 954t
Pemetrexed
for lung cancer, 371
toxicity of, 341t
Pemoline, for depression, 50
Penciclovir, for HSV infections, 568t
Penetrating radiation, 171
Penicillamine
for lead poisoning, 159t
for nephrolithiasis, 828t
for rheumatoid arthritis, 887
for systemic sclerosis, 889
Penicillina, penicillin G/penicillin V
for actinomycosis, 538
for anaerobic infections, 534
for bacterial meningitis, 1046t, 1047t
for clostridial infections, 108t, 480t, 532
diabetes, 502
for enterococcal infections, 501
for HACEK group infections, 512t
indications for, 425t
for infective endocarditis, 444t
for leptospirosis, 553
for meningoocccal infections, 107t, 506t
for necrotizing fasciitis, 108t, 479t
for osteomyelitis, 485t
for parichondritis, 304
for pharyngitis, 304t
for pneumococcal infections, 488
resistance to, 425t
for rheumatic fever prevention, 678
for rodent bite infections, 120t
for staphylococcal infections, 493, 494t
for streptococcal infections, 498t, 499–500
for syphilis, 474t
for tetanus, 529
Penicilliosis, 632
INDEX

Pentamidine
for *Pneumocystis* infections, 634t, 635
preventive treatment, 635t
for sleeping sickness, 646
Pentobarb coma, 92t
Pentobarbital
poisoning, 143t
for status epilepticus, 99f
Pentostatin, 341t
Pentoxifylline
for alcoholic liver disease, 870
for arteriosclerosis, 739
Peptic ulcer disease (PUD), 389, 831
bleeding in, 260
causes and risk factors for, 831
diagnosis of, 835t
drug-induced, 1138t
duodenal, 831–833
gastric, 831–833
treatment of, 832–834, 833t
*Pectostreptococcus* infection, 532
Percutaneous coronary intervention (PCI), 701, 702f, 711, 712t, 716, 717t
Percutaneous needle aspiration, of lung, 752
Pergolide
for Parkinson’s disease, 1006t
poisoning, 137t
Pericarditis
acute, 688
causes of, 688t
chest pain in, 175t, 177f, 178
laboratory features of, 688, 689t, 690f
constrictive, 112, 689, 692t
laboratory features of, 691, 691f
drug-induced, 1136t
enterovirus, 590
in myocardial infarction, 708
in tuberculosis, 540
Perichondritis, 304
Perihepatitis, 465
Perimenopause, 956
Perimeter, 215
Perinephric abscess, 450
Periodic leg movements of sleep, 226–227
Periodic paralysis, 1074
hyperkalemic, 1074
hypokalemic, 1074
Periodontal disease, 511, 532
Periorbital edema, 241
Peripheral edema, 730
Peripheral nerves, cutaneous areas supplied by, 982f–983f
Peripheral neuropathy, 1055
approach to, 1055–1058, 1056f
autonomic involvement in, 1016, 1018t
causes of, 1057, 1060t
classification of
by fiber type, 1057, 1058t
by histopathology, 1057, 1059t
by time course, 1057, 1059t
clinical features of, 1057t
diagnosis of, 1057t, 1058–1060
drug-induced, 341t, 1138t
mononeuropathy, 1062t–1064t, 1065
motor-predominant, 1011t
paraneoplastic, 408t, 409, 409t
polyneuropathy, 1055, 1058
weakness in, 219t, 220t
Peripheral vascular disease, 739
arteriosclerosis of arteries, 739
Peristalsis, 225
Peritoneal carcinomatosis, in women, 402
Peritoneal dialysis, 160, 793, 797
complications of, 798, 798t
Peritoneal disease
ascites in, 271
pain in, 179t
Peritoneal fluid, paracentesis, 28–29
Peritonitis, 448
*E. coli*, 513
primary bacterial, 272, 448
pyogenic, 273t
secondary, 448, 449
tuberculous, 273t
Peritonsillar abscess, 532
Permethrin cream
for pediculiasis, 658
for scabies, 658
Peroneal nerve entrapment, 1064t
Perphenazine, 1091t
Personality disorder, 1084
cluster A, 1084
cluster B, 1084
cluster C, 1084
Persius, 509
catatarrhal phase of, 510
convalescent phase of, 510
paroxysmal phase of, 510
Petechiae, 106
Peutz-Jeghers syndrome, 381, 384t, 385
Pharmacologic stress testing, 713–714, 714t
Pharyngitis
acute, 306
Epstein-Barr virus, 575
HSV, 564
streptococcal, 497, 498t
treatment of, 304t, 497, 498t
Pharyngoconjunctival fever, 583
Phenazopyridine, 146t
Phenelzine, 138t, 1087t
Phenobarbital
poisoning, 143t
for seizures, 994t
for status epilepticus, 99f
Phentolamine
for hypertensive emergencies, 698t
for sympathomimetic poisoning, 136t
Phenylephrine
for heart failure, 734t
for increased intracranial pressure, 92t
poisoning, 136t
for shock, 62, 62t
for subarachnoid hemorrhage with vaso-
spasm, 89
Phenylpropanolamine, 136t
Phenytoin
for antidepressant poisoning, 141t
for cardiac glycoside poisoning, 141t
for multiple sclerosis, 1041
for myotonic dystrophy, 1071
for pain, 36t–37t
for poisoning, 143t
for seizures, 992t–993t, 994t
for status epilepticus, 99f
for trigeminal neuralgia, 1020
Pheochromocytoma, 693–694
Pheochromocytoma, 693–694
Pheresis therapy, 44
Phlebotomy, 283, 351, 975, 977
Phobic disorder, 1083
Phosphofructokinase deficiency, 1073
Photodermatitis, drug-induced, 1134t
Physostigmine
for anticholinergic poisoning, 138t
for membrane-active agent poisoning, 153t
poisoning, 142t
Pigment gallstones, 844
Pill rolling, 1002
Pilocarpine
for glaucoma, 294
poisoning, 142t
for Sjögren’s syndrome, 891
Pindolol, 140t
Pink eye, 294
Pinta, 551
Pinworm. See Enterobiasis
Pioglitazone, for diabetes mellitus, 945t
Piperacillin
for osteomyelitis, 485t
for otitis externa, 305
Piperacillin-tazobactam
for anaerobic infections, 534t
indications for, 425t
for osteomyelitis, 485t
for P. aeruginosa infections, 519t
for peritonitis, 448
for pneumonia, 766t, 767t
resistance to, 425t
for septic shock, 107t
Piracetam, for myoclonus, 224
Pitting, 287
Pituitary adenoma, 917
ACTH-secreting, 917, 919t, 934–935
gonadotropin-secreting, 919t, 921
growth hormone-secreting, 917, 919t,
920–921
hormonal evaluation of, 919t
macroadenoma, 917
microadenoma, 917
prolactin-secreting, 917, 919–920, 919t
thyroid-stimulating hormone-secreting,
919t, 921, 928
Pituitary apoplexy, 917, 919
Pituitary disease
anterior pituitary, 917
hormone hypersecretion syndromes, 919, 919t
posterior, 923
Pituitary hormones, 917, 918f
Pituitary tumor, 216f, 296–297, 917
Pityriasis rosea, 310f, 314, 572
Pivmecillinam, for shigellosis, 459
Pizotifen, for migraine prevention, 188t
Plague, 106, 478, 525
as bioweapon, 163, 164t, 526
bubonic, 525–526
pneumonic, 163, 164t, 525–526
septicemic, 525–526
treatment of, 164t, 526
Plantar reflex, 984
Plaque (lesion of MS), 1035
Plaque (skin lesion), 313t
Plasma cell disorders, 353t, 354f, 360
Plasmacytoma, 361
Plasma exchange
for acute renal failure, 793
for multiple sclerosis, 1039
Plasmapheresis, 46
for acute renal failure, 793
for autoimmune hemolysis, 329
for myasthenia gravis, 1066
for polyneuropathy, 1061
for primary biliary cirrhosis, 871
for thrombotic microangiopathy, 826
for thrombotic thrombocytopenic purpura,
335
for vasculitis, 894
Plasmodium infection. See Malaria
Platelet clumping, 322
Platelet disorders, 332
platelet function disorders, 334–335
Plateletpheresis, 46
Platelet transfusion, 45
for thrombocytopenia, 344
Platinum compounds, 341t
for breast cancer, 379
Pleural biopsy, 752
Pleural effusion, 767, 777
approach to, 779f
causes of, 778t
chyllothorax, 780
exudative, 777, 778t
malignant, 778–780
in pancreatitis, 852
parapneumonic, 777–778
related to pulmonary embolism, 780
thoracentesis, 26–27, 26f
transudative, 777, 778t
Pleuritis, tuberculous, 780
Pleuronecrosis, 780
Pleurodynia, enterovirus, 590
Pleuroneophilia, anaerobic, 533
Plummer’s nails, 928
Pneumatic compression stockings, 89
Pneumococcal infection, 486
endocarditis, 488
meningitis, 487–488
otitis media, 487
pneumonia, 487–488
Pneumococcal vaccine, 438t, 488–489,
1108t–1112t, 1115t
Pneumocystis infection, 633
prevention of, 635, 635t
pneumocystis pneumonia, 634–635, 634t
Pneumonia, 764
acute interstitial, 774
adenovirus, 583
aspiration, 533
causes of, 764
community-acquired, 491, 764
antibiotic therapy, 765, 766t
complications of, 766–767
site of care, 765, 766t
C. pneumoniae, 563
cryptogenic organizing, 774, 776
cytomegalovirus, 573–574
E. coli, 513
eosinophilic, 774, 776
gram-negative enteric bacteria, 516
health care-associated, 764, 767
hemoptysis in, 236
H. influenzae, 509
hospital-acquired, 769
human RSV, 582
influenza virus, 578
Klebsiella, 515
laboratory features of, 765
M. catarrhalis, 510
measles virus, 584
M. pneumoniae, 560
nocardiosis, 535, 536t
nosocomial, 429–430, 430t, 491
P. aeruginosa, 517, 519t
pathophysiology of, 764
pneumococcal, 487–488
Pneumocystis, 633
S. aureus, 491
secondary bacterial, 578
streptococcal, 498, 498t, 500
toxoplasmosis, 646
varicella-zoster virus, 570–571
ventilator-associated, 74, 430t, 517, 767
pathogenetic mechanisms, 768t
prevention of, 768t
treatment of, 767t, 768
Pneumonia Severity Index, 765
Pneumonitis
HSV infections, 566, 568t
hypersensitivity, 774–775, 776
croting, 533
Pneumothorax, 177f, 774, 780
Podagra, 903
Podoflox, for HPV infections, 476
Podophyllin
for HPV infections, 476
for warts, 317
Poikilocytosis, 321
Poison control center, 123, 160
Poisoning
diagnosis of, 130–133, 131t–132t
heavy metals, 154t–160t
marine, 123
reference values for laboratory tests, 1157t–1159t
treatment of, 133–160, 134t, 136t–159t
enhancement of elimination, 134t, 160
prevention of poison absorption, 134t, 159
Polio virus infection, 588
meningitis, 589
paralytic disease, 589
postpolio syndrome, 589
Poliovirus vaccine, 438t, 589, 591,
1108t–1111t
Polyangitis, microscopic, 892
Polyarthritis, glomerular disease in, 807t
Polyarthritis nodosa, 891
Polyarthropathy, parvovirus, 587
Polychondritis, relapsing, 908
Polycythemia vera, 283, 295
Polyethylene glycol-containing solution
for constipation, 259
for irritable bowel syndrome, 842t
Polymyalgia rheumatica, 909
Polymyositis, 1072, 1073t
Polyomyxin-bacitracin-neomycin, for eye infections, 294
Polymyxin E (colistin)
indications for, 427t
for P. aeruginosa infections, 520t
resistance to, 427t
Polyneuropathy, 1055, 1058
acute inflammatory demyelinating, 1061
chonic inflammatory demyelinating, 1061
Poly(s) colonic. See Colonic polyps
gastric, 381
Polyositis syndromes, 381
hereditary, 383, 384t
Polysomnography, 229t
Polystyrene sulfonate
for diabetic nephropathy, 806
for hyperkalemia, 796
Polyuria, 276t, 277, 277f
Pontiac fever, 521
Porphyria, 976
acute intermittent, 976, 1016
erthropoietic, 976, 977
hepatic, 976
Porphyria cutanea tarda, 977
Porphyromonas infection, 532
Portal hypertension, 287, 872
complications of, 873
hepatic, 873t
posthepatic, 873t
prehepatic, 873t
Portuguese man-of-war injury, 122
Posaconazole, 619
for aspergillosis, 623
for mucormycosis, 627
Positive end-expiratory pressure (PEEP), 71, 74
Post-concussion headache, 183t, 187–189
Postherpetic neuralgia, 316, 570–571
Postmenopausal hormone therapy, 956
Postmenopausal state, 1120
Postpolio syndrome, 589
Postradiation fibrosis, 198
Posttraumatic stress disorder (PTSD), 1083, 1088
Postural orthostatic tachycardia syndrome, 1018
Potassium, disorders of, 8
Potassium chloride
for hypokalemia, 10
for periodic paralysis, 1074
Potassium hydroxide preparation, 311, 411
Potassium iodide, for radioactive iodine exposure, 174
Potassium perchlorate, for amiodarone-induced thyrotoxicosis, 931
Pott's disease, 540
Pott's puffy tumor, 302
Powassan encephalitis, 596t–597t
2-Pralidoxime chloride for cholinergic poisoning, 142t
for nerve agent exposure, 170t, 171
Pramipexole for Parkinson's disease, 1006t
for restless legs syndrome, 227, 229t
Pravastatin, for hyperlipidemia, 972t
Praziquantel for echinococcosis, 657
for fluke infection, 654–655
for schistosomiasis, 654
for taeniasis solium and cysticercosis, 656
for tapeworm infection, 655
Prazosin for ergot alkaloid poisoning, 137t
for vasospastic disorders, 740
Precordial palpation, 662f, 663
Prednisolone for alcoholic liver disease, 870
for autoimmune hepatitis, 867
Prednisone for acute lymphoblastic leukemia and lymphoblastic lymphoma, 350
for alcoholic liver disease, 870
for autoimmune hepatitis, 867
for Bell’s palsy, 1022
for Burkitt’s lymphoma/leukemia, 360
for cluster headache prevention, 187
for gastric cancer, 381
for hirsutism, 955
for hypercalcemia, 962t
for hypopituitarism, 922t
for idiopathic thrombocytopenic purpura, 335
immunosuppression for renal transplant, 800
for inflammatory bowel disease, 838
for inflammatory myopathy, 1072
for interstitial lung disease, 775
for multiple myeloma, 361
for multiple sclerosis, 1039
for muscular dystrophy, 1071
for myasthenia gravis, 1066
for optic neuritis, 217
for pericarditis, 688
for Pneumocystis infections, 634t
for polymyalgia rheumatica, 909
for relapsing polychondritis, 908
for sarcoidosis, 912
steroid preparations, 938–939, 938t
for thyrotoxicosis, 930
for vasculitis, 894
Preexcitation syndrome. See Wolff-Parkinson-White syndrome
Pregabalin, 37t
for generalized anxiety disorder, 1082
for multiple sclerosis, 1041
Pregnancy ectopic, 954–955
gonorrhea in, 469
hypertension in, 698
listerial infections in, 507
malaria in, 637
streptococcal infections in, 500
syphilis in, 474t
toxemia of, 826
toxoplasmosis in, 646
travel during, 1117
Prehypertension, 1119
Preleukemia, 350
Premenstrual syndrome (PMS), 954–955
Presbycusis, 300
Pressure-control ventilation (PCV), 72, 73t
Pressure-support ventilation (PSV), 72, 73t, 74
Preventive medicine, 1103
Preventive Services Task Force, U.S., recommendations of, 1106t
Pneumocystis infections, 634t, 635
Primary (spontaneous) bacterial peritonitis, 488
Primary biliary cirrhosis, 870
Primary lateral sclerosis, 1011t
Primary sclerosing cholangitis, 848
Primidone for myoclonus, 224
poisoning, 143t
for seizures, 994t
for tremor, 222
Primitive neuro-ectodermal tumor, 1033
Prinzmetal’s variant angina, 716
Proamatine, for vasovagal syncope, 210
Probenecid for gonococcal infections, 470t
for gout, 905
for syphilis, 474t
Procaaminide for arrhythmias, 727t
for malignant hyperthermia, 203
for tachyarrhythmias, 724t
for Wolff-Parkinson-White syndrome, 729
Procaaine penicillin for diphtheria prevention, 502
for streptococcal infections, 498t
Prochlorperazine for migraine, 186t
for nausea and vomiting, 246, 343
for vertigo, 214t
Proctitis, 466, 471
HSV, 568t
Proctocolitis, 466
Progressive multifocal leukoencephalopathy (PML), 1051
Progressive systemic sclerosis, 775
Prolactin, 917, 917f
deficiency of, 919t
hyperlactemia of, 919, 919t
Prolactinoma, 297, 919–920
Promethazine, for vertigo, 214t
Prometrium, for amenorrhea, 953
Promyelocytic leukemia, acute, 344, 345t
Propafenone, for arrhythmias, 727t
Propionibacterium acnes infection, 532
Propofol for delirium, 50t
for increased intracranial pressure, 92t
poisoning, 144t
for status epilepticus, 99f
for sympathomimetic poisoning, 136t
Propoxyphene
narcotic abuse, 1099
poisoning, 153t
Propranolol
for aortic dissection, 738t
for hypertension, 695t
for methylxanthine poisoning, 137t
for migraine prevention, 188t
poisoning, 140t
for sympathomimetic poisoning, 136t
for thyrotoxicosis, 929
for tremor, 222
for variceal bleeding, 263
Propylene glycol poisoning, 17t, 18
Propylthiouracil, for thyrotoxicosis, 930
Prostascint scanning, 401
Prostate biopsy, transrectal ultrasound, 400, 400f
Prostate cancer,
oncologic emergencies, 113
osteoblastic bone metastasis, 404
prevention of, 1124
risk factors for, 1124
screening for, 1105t, 1122, 1123t
Prostatectomy, radical retropubic, 400–401
Prostate hyperplasia,
Prostate-specific antigen (PSA), 399, 400f, 1122, 1123t, 1124
bound, 400
free, 400
Prostatitis, 820
acute bacterial, 820
chronic bacterial, 820
Prosthetic device-related infection, 481–482, 492–493
Prosthetic-valve endocarditis, 492, 496
Protamine, to reverse anticoagulation, 336, 771
Protase inhibitors, for HIV/AIDS, 606, 611–614t
Protein-losing enteropathy, 272
Protein malnutrition, 40–41
Protein restriction, in renal failure, 796
Proteinuria,
nephrotic range, 279
Pseudallescheriasis, 632
Pseudocyst, pancreatic, 273t, 852
Pseudodementia, 999
Pseudolephedrine, for allergic rhinitis, 880
Pseudogout, 905
conditions associated with, 905t
Pseudohyponatremia, 5
Pseudomonas aeruginosa infection, 517
osteomyelitis, 485t
treatment of, 518, 519t–520t
Psychiatric disorder, 117
anxiety disorders, 1081
diagnosis of, 999t
drug-induced, 1140t
DSM-IV Axis I, 1077
DSM-IV Axis II, 1077, 1084
eating disorders, 1093
fatigue in, 289t
mood disorders, 1077
nausea and vomiting in, 245t
personality disorders, 1084
psychotic disorders, 1080
schizophrenia, 1080
sleep disorders and, 227
Treatment of, 1085
weight loss in, 248t
in women, 1129
Psychiatric medication, 1085
antidepressants, 1085
antipsychotics, 1088
anxiolytics, 1088
mood stabilizers, 1092t, 1093
principles of use of, 1085
Psychotic disorder, 1080
Pylilum
for diverticular disease, 842
for hemorrhoids, 844
for irritable bowel syndrome, 841, 842t
PTH(1–34), for osteoporosis, 967
Pubic louse, 658–659
Puddle sign, 271
Puerperal sepsis, 499
Pulmonary alveolar proteinosis, 776
Pulmonary angiography, 751
Pulmonary artery pressure, 748
Pulmonary disease. See Lung disease
Pulmonary edema, 241, 243
acute, 66
approach to, 68f
cardiogenic, 67–68
causes of, 67t
drug-induced, 1136t
noncardiogenic, 67t, 68
precipitants of, 67t
treatment of, 67–69
Pulmonary embolism, 769
chest pain in, 175t, 176, 177f
dyspnea in, 231
hemodynamic profiles in, 60t
hemoptysis in, 236
pleural effusion related to, 780
pulmonary hypertension in, 743t
thrombotic disorders, 336
treatment of, 336–338, 337t, 770–772, 772f
Pseudothrombocytopenia, 333
Pseudotumor cerebri, 216–217
drug-induced, 1139t
Psittacosis, 562
Psos abscess, 451
brucellosis vs. tuberculosis, 523, 523t
Psoriasis, 310f, 311f, 314
Psoriatic arthritis, 896, 897
patterns of joint involvement in, 898t
Prune juice, 48t
Pruritus ani, 844
Pseudomonas aeruginosa
infection, 844
Pulmonary embolism, 336
Pulmonary embolism, 769
chest pain in, 175t, 176, 177f
dyspnea in, 231
hemodynamic profiles in, 60t
hemoptysis in, 236
pleural effusion related to, 780
pulmonary hypertension in, 743t
thrombotic disorders, 336
treatment of, 336–338, 337t, 770–772, 772f
INDEX
1227
Pulmonary fibrosis
- drug-induced, 341t–342t
- idiopathic, 774, 775
- progressive massive, 758

Pulmonary function tests, 747, 751
- in asthma, 753–754
- in COPD, 759, 760t, 761
- in pulmonary hypertension, 743
- reference values for, 1169t–1170t

Pulmonary hypertension, 742, 749
- approach to, 744f
- arterial, 743t
- causes of, 743t
- in congenital heart disease, 675
- differential diagnosis of, 743–744
- laboratory features of, 742–743
- primary, 743
- venous, 743t

Pulmonary infiltrate
- drug-induced, 1136t
- with eosinophilia, 776

Pulmonary Langerhans cell histiocytosis, 774–775, 776

Pulmonary nodule, solitary, 371, 373f

Pulmonary rehabilitation, 761, 775

Pulmonary vascular resistance, 748

Pulmonic stenosis, 662t, 676

Pulmonic valve regurgitation, 662t

Pulseless disease, 738

Pulseless electrical activity, 57, 58f

Pulse oximetry, 749

Pulsus alternans, 661, 661f

Pulsus biferiens, 661, 661f

Pulsus paradoxus, 661, 661f

Pulsus parvus, 661, 661f

Pulsus tardus, 661, 661f

Pupillary signs, in coma, 78

Pure alexia, 225t

Pure red cell aplasia
- drug-induced, 1135t
- parvovirus infections, 588

Pure tone audiometry, 298

Pure word deafness, 225t

Purging behavior, 1093

Purine nucleoside phosphorylase deficiency, 883

Pureura, 201. See also specific types
- drug-induced, 1134t
- palpable, 319

Purpura fulminans, 108t, 110

Pustule, 313t

Pyelonephritis, 450, 815, 818t
- emphysematous, 817

Pyeloplasty, 833t

Pyomyositis, 481

Pyranthel pamoate
- for ascariasis, 650
- for enterobiasis, 651
- for hookworm infection, 650

Pyrazinamide, for tuberculosis, 541, 543t, 546t

Pyridostigmine
- for myasthenia gravis, 1066
- for orthostatic hypotension, 1019

Pyridoxine, for isoniazid poisoning, 150t

Pyridoxine deficiency, 43t

Pyrilamine, 138t
- for myasthenia gravis, 1066
- for orthostatic hypotension, 1019

Pyrimethamine
- for isosporiasis, 456
- for pneumocystosis prevention, 635t
- for toxoplasmosis, 647

Pyrogulaminic aciduria, 17t, 18–19

Pyruvate kinase deficiency, 326

Pyuria, 280, 787
- sterile, 787

Q

Q fever, 558
- acute, 559
- chronic, 559

Quadrantanopia, 220t

Quadrantopia, 216f

Quadriparesis, 220t, 221f

Quantitative sudomotor axon reflex test (QSART), 1016

Quetiapine
dosage and adverse effects of, 138t, 1091t
- for schizophrenia, 1081

Quinidine
- for arrhythmias, 727t
- for malaria, 637, 639t

Quinine
- for babesiosis, 107t, 642
- for malaria, 109t, 638t–639t

Quinolones
- for cystitis, 818t
- for tuberculosis, 543t
- for urinary tract infections, 818t–819t

Quinupristin-dalfopristin
- for enterococcal infections, 501
- indications for, 427t
- resistance to, 427t
- for staphylococcal infections, 493, 494t

Rabies, 118, 592
- encephalitic form, 592
- paralytic form, 593
- postexposure prophylaxis, 121, 593, 594f
- preexposure prophylaxis, 593
- prodrome, 592

Rabies immune globulin, 121, 593, 594f

Rabies vaccine, 121, 593, 1116t

Rad, 171

Radial neuropathy at spiral groove, 1063t

Radiation bioterrorism, 171
- acute radiation sickness, 172
- treatment of casualties, 173t
- types of exposure, 172
- types of radiation, 171

Radiation sickness, acute, 172, 173f

Radiation therapy
- for anal cancer, 388
- for bladder cancer, 392
- for brain tumor, 1032–1033
- for breast cancer, 379
- for cervical cancer, 398
- for colorectal cancer, 387
- complications of, 342t, 1035
- for endometrial cancer, 397
- for follicular lymphoma, 357
- for gastric cancer, 381
- for head and neck cancer, 368
- for Hodgkin’s disease, 363–364
leukopenia in, 331
for lung cancer, 371
for prostate cancer, 400–401
for spinal cord compression, 95, 113
for testicular cancer, 394, 394t

Radiculopathy
cervical, 197t
nonprogressive, 198–199
lumbosacral, 191t
subacute, 196

Radiography
in joint pain, 206–207, 207t
in osteomyelitis, 484t

Radioiodine
for nontoxic goiter, 931
for thyroid neoplasms, 932–933
for thyrotoxicosis, 928–930
for toxic adenoma, 932
for toxic multinodular goiter, 932

Radionuclide contamination, 174
Radionuclide scan
hepatobiliary imaging, 270
for osteomyelitis, 484t

Ragged red fibers, 1074

Raloxifene
for breast cancer prevention, 1122
for osteoporosis, 967
toxicity of, 342t

Raltegravir, for HIV/AIDS, 606, 615t

Ramipril
for heart failure, 733t
for hypertension, 695t

Ramsay Hunt syndrome, 1022

Recluse spider bite, 125

Recombinase activating gene deficiency, 882

Recommended dietary allowance (RDA), 39
Rectal cancer, 387

Red blood cell(s)
inclusions, 321–322
increased RBC mass, 351
morphology of, 321
RBC indices, 281–282

Red blood cell disorders, 323
anemia, 280, 323, 326
intracellular abnormalities, 326
maturation disorders, 325
membrane abnormalities, 326
polycythemia, 282

Red blood cell transfusion, 44
Red eye, 293, 293t

Referred pain, 34
abdominal pain, 179t
low back pain, 190
shoulder pain, 198

Reflexes, testing of, 984
Reflex sympathetic dystrophy, 1018
Refractory anemia, 348t–349t
with excess blasts, 348t–349t
with ringed sideroblasts, 348t–349t

Refractory cytopenia with multilineage dysplasia, 348t–349t

Rapid eye movement (REM) behavioral disorder, 226

Rapid shallow breathing index, 32

Rapid urease test, 832, 832t
Rasagiline, for Parkinson’s disease, 1004
Rasburicase, for tumor lysis syndrome, 116

Rat-bite fever, 118

Raynaud’s disease, 740t
Raynaud’s phenomenon, 740, 740t

Reactive arthritis, 896f, 899
Recurrent slide bite, 125

Recombinase activating gene deficiency, 882

Regurgitation, 244, 246
Rehydration, in diarrhea, 256
Reiter’s arthritis, 482
Reiter’s syndrome, 471

Relapsing fever, 553
chill phase of, 553
flush phase of, 553
louse-borne, 553
tick-borne, 553
Relapsing polychondritis, 908
Renal abscess, 450
Renal artery occlusion, 820
Renal artery stenosis, 821
approach to, 823f
clinical features of, 822, 822t
hypertension in, 698, 821–824
Renal artery thrombosis, 821
Renal arterioembolism, 821
Renal cancer. See Kidney cancer

Renal disease
approach to, 785
azotemia, 274
chronic classification of, 275t
treatment of, 795–796
clinical and laboratory database for, 786t
dialysis in, 796
drug-induced, 341t, 1138t
end-stage, 794
renal transplant in, 798
fatigue in, 289t
glomerular, 785, 801
hypertension in, 693, 694, 821–824
infections in immunocompromised patients, 434, 436t
metabolic acidosis in, 17t, 18
monoclonal immunoglobulins and, 812
1165t
renal tubular disease, 786t, 787–788, 808
nephrolithiasis, 786t, 788, 826
nephrotic syndrome, 786t, 787
reference values for renal function tests,
intrinsic, 789–791, 790t, 792t

Refractory anemia, 348t–349t

with excess blasts, 348t–349t

with ringed sideroblasts, 348t–349t

Renal failure
acute, 785, 786t, 789
approach to, 791–792, 792t
causes of, 790t
dialysis for, 793
Renal failure (Cont.):
postrenal, 789, 790t, 791
prerenal, 789, 790t, 791, 792t
chronic, 786t, 787, 794
causes of, 794–795, 794t
sleep disorders in, 228
slowing progression of, 796
edema in, 242
Renal transplant, 796, 798
complications of, 800
contraindications to, 799t
factors influencing graft survival, 799t
immunosuppressive therapy for, 799–800
infections in recipients, 437
rejection of, 799
Renal tubular acidosis, 17t, 788,
proximal (type II), 814
type IV, 814–815
Renal tubular disease, 786t, 787–788,
transport dysfunction in, 810t
Renovascular disease, 820
arteriolar nephrosclerosis, 824
renal artery occlusion, 821
in scleroderma, 824
sickle cell nephropathy, 826
thrombotic microangiopathy, 824
toxemia of pregnancy, 826
Repaglinide, for diabetes mellitus, 945t
Repositioning exercises, for vertigo, 213,
214t
Reproductive system disease
female, 952
male, 947
Reproductive tract infection, 462
Respiratory acidosis, 820
arteriolar nephrosclerosis, 824
renal artery occlusion, 820
renal artery stenosis, 821
renal vein thrombosis, 821
in scleroderma, 824
sickle cell nephropathy, 826
thrombotic microangiopathy, 824
toxemia of pregnancy, 826
Respiratory disease.
See also Lung disease
bronchoalveolar lavage in, 752
bronchoscopy in, 751–752
chest x-ray in, 751
computed tomography in, 751
diagnosis of, 751
drug-induced, 1136t
emergencies, 111
extraparenchymal, 748, 748t
infections in immunocompromised pa-
tients, 434, 436t
meningococcal, 504
M. pneumoniae, 560
MRI in, 751
nuclear medicine imaging in, 751
obstructive, 747–748, 748t
P. aeruginosa, 517
parenchymal, 748, 748t
pulmonary function tests in, 751
restrictive, 747–748, 748t
spumum exam in, 751
upper respiratory infections, 301
viral, 577
weight loss in, 248t
Respiratory failure, 71, 73t
hypercarbic, 71–72
hypoxic, 71–72
Respiratory function, 747
in coma, 79
disturbances of, 751
Respiratory muscle dysfunction, 231
Respiratory rate, 749
Respiratory syncytial virus (RSV), human.
See Human respiratory syncytial virus infection
Respiratory syncytial virus (RSV) immune globulin, 583
Respiratory tract, 414–415
Resting energy expenditure, 39
Restless legs syndrome, 227, 229t
Retching, 244
Reteplase, for thrombotic disorders, 338
Reticulocyte(s), 321
Reticulocyte index, 281
Retinal artery occlusion, 216f
Retinal detachment, 215, 216f
Retinopathy
diabetic, 296, 297t
drug-induced, 1139t
paraneoplastic, 408, 408t
Reverse SLR sign, 190
Reverse transcriptase inhibitors, for HIV/ AIDS, 606, 607t–610t
Rewarming
active, 128
external, 128
internal, 128
passive, 128
Reye’s syndrome, 578
Rhabdomyolysis, 280
Rheumatic (Sydenham’s) chorea, 223
Rheumatic fever, prophylaxis for, 678
Rheumatic heart disease, 678
Rheumatoid arthritis, 775, 780, 886
neck pain in, 198
Rheumatoid factor, 774, 887
Rhinitis, allergic, 879
Rhinovirus infection, 581
Rhizomucor infection. See Mucormycosis
Rhizopus infection. See Mucormycosis
Rhodococcus infection, 503
Ribavirin
for adenovirus infections, 583
for chronic hepatitis C, 864, 865t–866t
for human RSV infections, 582–583
for measles, 585
for membranoproliferative glomerulone-
phritis, 805
for viral hemorrhagic fevers, 165t
Richter’s syndrome, 355
Rickettsia africae infection, 555
Rickettsia akari infection, 555
Rickettsia conorii infection, 555
Rickettsial disease, 106, 108t, 110, 201, 554
flea- and louse-borne typhus, 556
Rickettsialpox, 555
Rickettsia prowazekii infection. See Typhus, epidemic
INDEX

Rickettsia rickettsii infection. See Rocky Mountain spotted fever

Rickettsia typhi infection. See Typhus, endemic murrine

Rifabutin, for tuberculosis, 541–542

Rifampin

adverse reactions to, 428

for anthrax, 164t

for arthritis, infectious, 482

for Bartonella infections, 526t

for brucellosis, 523

for diphtheria, 502

for human granulocytotropic anaplasmosis, 558

indications for, 427t

for infective endocarditis, 445t

for Legionella infections, 522

for leprosy, 546–547

for meningococcal disease prevention, 506t, 1045

for nontuberculous mycobacterial infections, 548

for osteomyelitis, 485t

for primary biliary cirrhosis, 871

for Q fever, 559

resistance to, 427t

for staphylococcal infections, 496

for tuberculosis, 541, 543t, 545t–546t

Rifapentine, for tuberculosis, 542

Rifaximin

for C. difficile-associated disease, 462

for diarrhea, 1117

for hepatic encephalopathy, 875

Rift Valley fever, 598

Right ventricular systolic pressure, 669

Riluzole, for ALS, 1013

Rimantadine, for influenza, 579t, 580

Ringer’s lactate, for cholera, 453

Rintavir, for HIV/AIDS, 611t

Rituximab

for autoimmune hemolysis, 329

for CLL, 356

for gastric cancer, 381

for idiopathic thrombocytopenic purpura, 335

for inflammatory myopathy, 1072

for lymphoma, 357–358

for membranous glomerulonephritis, 804

for rheumatoid arthritis, 888

for rheumatoid arthritis, 888

toxicity of, 342t

Rivastigmine, for Alzheimer’s disease, 1000

River blindness, 652

Rizatriptan, for migraine, 185t, 187t

Rocky Mountain spotted fever, 108t, 110, 200, 554

Rodent bite, 118, 120t

Rodent-borne viral infection, 593

Romano’s sign, 644

Romberg sign, 986

Ropinirole

for Parkinson’s disease, 1006t

for restless legs syndrome, 227, 229t

Rosacea. See Acne rosacea

Roseola infantum, 571

Rose spots, 457

Rosetting, 636

Rosiglitazone, for diabetes mellitus, 945t

Ross River virus infection, 596

Rosuvastatin, for hyperlipidemia, 972t

Rotavirus infection, diarrhea, 454

Rotavirus vaccine, 454, 1108t–1109t

Roteotide, for Parkinson’s disease, 1006t

Rouleaux formation, 342t

Roundworm infection. See also Nematode infection

intestinal, 420t

Rubella, 585

congenital rubella syndrome, 585–586

Rubella vaccine, 585

Rumination, 244

Russian spring-summer encephalitis, 596t–597t

Saccharomyces boulardii therapy, 462

Sacroiliitis, 898t

Salicylates

for osteoarthritis, 902

poisoning, 149t

Salicylic acid

for seborrheic dermatitis, 315

for warts, 317

Saline therapy

for hypercalcemia, 113, 406, 962t

for hyperglycemic hyperosmolar state, 101

for hypernatremia, 7–8

for hypokalemia, 4

for increased intracranial pressure, 92t

for membrane-active agent poisoning, 153t

for metabolic alkalosis, 20

for SIADH, 114

for tumor lysis syndrome, 116

Salmeterol, for asthma, 754

Salmonellosis, 456

nontyphoidal, 457

typhoid fever, 456–457

Salpingitis, 465, 469, 471

Samarium-153 EDTMP, 342t

Saquinavir, for HIV/AIDS, 611t

Sarcoma, paraneoplastic syndromes in, 405t

Sarcoidosis, 774, 910, 912f

acute, 912f

chronic, 912f

Sarcoplasma scabiei infestation. See Scabies

Sarin, 142t, 169–171

SARS coronavirus, as bioweapon, 167

Scabies, 658

Scale (skin lesion), 313t

Scar, 313t

Scar carcinoma, 366

Scarlet fever, 497

Scedosporiosis, 632

Schilling test, 256

Schistocytes, 321
Schistosomiasis, 391, 420t, 421, 653, 1117
   acute, 654
   chronic, 654
Schizoaffective disorder, 1081
Schizoid personality disorder, 1084
Schizophrenia, 1080
   drug-induced schizophrenic reactions, 1140t
Schizophreniform disorder, 1081
Schizotypal personality disorder, 1084
Schwannoma, 1033
   vestibular, 300
Scatica, 196
Sciatic neuropathy, 1064t
Scleritis, 294
Sclerodactyly, 889
Scleroderma. See Systemic sclerosis
Scombroid poisoning, 124
Scopolamine
   for nausea and vomiting, 48, 245
   poisoning, 138t
   for vertigo, 214t
Scorpionfish envenomation, 123
Scorpion sting, 126
Scotoma, 215, 216f, 295
Screening recommendations, 1103
Sea anemone injury, 122
Seborrheic keratosis, 311f
Secobarbital, 143t
Sedative-hypnotics, poisoning, 131t, 143t
Seizure, 988. See also Epilepsy
   absence (petit mal), 988, 988t, 992t–994t
   approach to, 988, 991f
   causes of, 989, 989t, 990t
   complex-partial, 988, 988t
   differential diagnosis of, 990t
   drug-induced, 990t, 1139t
   EEG in, 990–991
   febrile, 201
   generalized, 988, 988t
   neuroimaging in, 994
   partial, 988, 988t
   in poisoning, 135
   simple-partial, 988, 988t
   syncope vs., 210
   tonic-clonic (grand mal), 988, 988t,
   992t–994t
   treatment of, 992t–994t, 994–995
Selective serotonin reuptake inhibitors, 1085, 1086t
Selegiline
   for Alzheimer’s disease, 1000
   dosage and adverse effects of, 138t, 1087t
   for Parkinson’s disease, 1004
Selenium, for prostate cancer prevention, 1124
Selenium sulfide, for seborrheic dermatitis, 315
Semen analysis, 950
Seminoma, 393–394, 394t
Senna, for constipation, 48t
Sensitization, 34
Sensory exam, 985
Sensory level, 113
Sensory loss, 220t
Proprioceptive, 218
Sentinel loop, 850
Sentinel node biopsy, in breast cancer, 376
Sepsis, 63
   Aeromonas, 516
   without clear focus of primary infection, 106, 107t
   clostridial, 531
   infectious disease emergencies, 105
   post-splenectomy, 106, 107t
   puerperal, 499
   S. aureus, 491
   severe, 63
   with skin manifestations, 106, 107t–108t, 110
   with soft tissue/muscle findings, 108t,
   110–111
   treatment of, 64–66, 65t
Septic shock, 30, 31f, 59t, 60, 63, 106, 107t
   infectious disease emergencies, 105
   pathogenesis and pathology of, 63–64
   treatment of, 64–66, 65t
Sequestra, 483
Serositis syndrome, 152t
Serratia infection, 516
Sertraline
   dosage and adverse effects of, 1086t
   for vasovagal syncope, 210
Serum sickness, 201
   drug-induced, 1132t
Sevelamer, for hyperphosphatemia, 964
Severe acute respiratory infection (SARS), 581
Severe combined immunodeficiency, 881
   X-linked, 882–883
Sexual assault, 1130
Sexual dysfunction, drug-induced, 1132t
Sexually transmitted disease, 462
   in travelers, 1117
Shift work, 226, 230
Shigellosis, 458
   proctocolitis, 468
Shingles, 316, 570
Shock, 30, 58. See also specific types
   approach to, 31f, 59–60
   forms of, 59r
   in GI bleeding, 260
   hemodynamic profiles in, 60t, 61f
   high cardiac output/low systemic vascular
   resistance, 30, 31f
   hypovolemic, 30, 31f
   treatment of, 60–62, 62t
Shoulder
   adhesive capsulitis, 910
   muscles and innervation of, 980t–981t
Shoulder pain, 196
   causes of, 196–198
   mechanical, 198
   treatment of, 198–199
Shunting, hypoxemia in, 750
Sibutramine, for obesity, 940
Sick euthyroid syndrome, 930
Sickle cell anemia, 326, 328
   pathophysiology of sickle cell crisis, 327f
Sickle cell nephropathy, 826
Sickled cells, 321
Sick sinus syndrome, 717–718
Sideroblastic anemia, 325, 325t
Sigmoidoscopy, 387, 1123t
   in diarrhea, 256
   in GI bleeding, 261
   “Sign of the groove,” 471
Sildenafil
for achalasia, 251
for erectile dysfunction, 951
for systemic sclerosis, 889
Silicosis, 757
Simple phobia, 1083
Simvastatin, for hyperlipidemia, 972t
Sindbis virus infection, 596
Sinoatrial node dysfunction, 717
extrinsic, 717
intrinsic, 717
Sinusitis, 301
acute, 302
anaerobic, 533
aspergillosis, 622–623
bacterial, 302
chronic, 302
fungal, 302
Klebsiella, 515
M. catarrhalis, 510
nosocomial, 302
treatment of, 302, 303t
Sinus rhythm, 665
Sinus tachycardia, 704, 721f, 722t
Sirolimus, immunosuppression for renal transplant, 800
Sister Mary Joseph’s nodule, 271
Sitagliptin, for diabetes mellitus, 945t
Sjögren’s syndrome, 890
Skin, examination of, 309
Skin biopsy, 311
Skin cancer, 364
basal cell carcinoma, 366
melanoma. See Melanoma
prevention of, 364, 367, 1104t
screening for, 1123t
squamous cell carcinoma, 366
Skin disease
acne, 317
arrangement and shape of lesions, 309, 310f–312f
in cancer patients, 432
diagnosis of, 311–313
distribution of lesions, 309
drug-induced, 319, 342t, 1133t–1134t
eczematous, 315
history in, 310
lesion characteristics, 309, 310f–312f
in malnutrition, 41
papulosquamous, 314
primary lesions, 309, 313t
in returned traveler, 1118
secondary lesions, 309, 313t
sepsis-associated, 106
vascular disorders, 318
Skin infection, 316, 477
anaerobic, 533
clostridial, 531
P. aeruginosa, 518
S. aureus, 490–491, 496
in transplant recipients, 436t
treatment of, 479f–480t
Skin tag, 311f
Skull fracture, 91
Sleep, nonrestorative, 227
Sleep apnea, 226, 228, 228, 783, 784t
central, 228, 783
mixed, 228
obstructive, 228, 229t, 783, 784t
Sleep disorder, 226, 229t
drug-induced, 1140t
in women, 1130
Sleep hygiene, 227
Sleeping sickness, 645
East African, 645–646
West African, 645–646
Sleep paralysis, 229t, 230, 230t
Sleepwalking, 226
Slit-lamp examination, 215, 294
Slow low-efficiency dialysis, 793
Slow-reacting substance of anaphylaxis, 877, 877f
Small-bowel cancer, 382
Small-bowel tumor, 382
Smallpox
as bioweapon, 163–166, 164t
hemorrhagic, 166
malignant, 166
microbiology and clinical features of, 163–166
treatment of, 164t, 166
vaccination and prevention, 166
Smell, disorders of sense of, 1023, 1023t
Smoking, 369, 391–392
cough and, 234–235
pregnancy and, 234–235
prevention of, 1128
relative risks for current smokers, 1126t
Smoking cessation, 368, 374, 759, 775, 775, 1103, 1104t–1105t, 1118, 1124, 1126
approach to, 1126–1127
clinical practice guidelines, 1127, 1127t
methods of, 1127, 1127t
quit date, 1126–1127
Snakebite, 120t, 121
field management of, 121
hospital management of, 121–122
Snoring, 229
Social phobia, 1083
Sodium, disorders of, 3
Sodium bicarbonate
for AGMA inducer poisoning, 147t
for antidepressant poisoning, 141t
for antipsychotic poisoning, 139t
for iron poisoning, 147t
for membrane-active agent poisoning, 153t
for metabolic acidosis, 19
for methanol poisoning, 148t
for poisoning, 160
for salicylate poisoning, 149t
Sodium citrate, for metabolic acidosis, 19
Sodium deficit, 7
Sodium nitrite, for cytochrome oxidase inhibitor poisoning, 145t
Sodium phosphate enema, for constipation, 48t
Sodium restriction
for aldosteronism, 935
for ascites, 272
for cor pulmonale, 735
for edema, 243
for heart failure, 731, 735
Sodium restriction (Cont.):
- for hypertension, 694
- for restrictive cardiomyopathy, 686
- for vertigo, 213, 214t

Sodium stibogluconate, for leishmaniasis, 643

Sodium thiosulfate, for cytochrome oxidase inhibitor poisoning, 145t

Soft tissue infection, 477
- anaerobic, 533
- clostridial, 531
- HACEK group, 511
- Klebsiella, 515
- P. aeruginosa, 518
- S. aureus, 490–491, 496

Solid organ transplant infections in recipients, 437–438
vaccination of recipients, 439

Soman, 142t

Somatization disorder, 1083

Somatoform disorder, 1083

Somatostatinoma, 389, 390t, 391

Somatostatin therapy, for esophageal varices, 874

Somatotropin, for hypopituitarism, 922t

Sorafenib
- for kidney cancer, 922t
- toxicity of, 342t

Sorbitol
- for irritable bowel syndrome, 842t
- for paralytic shellfish poisoning, 124
- for poisoning, 135

Sotalol
- for arrhythmias, 728t
- poisoning, 140t

South American hemorrhagic fevers, 598

Soy-based products, 957

Spastic colon, 840

Specimen collection, 414t–419t
Specimen transport, 414t–419t

Spectinomycin, for gonococcal infections, 470t

Speech audiometry, 298

Spermatogenesis, 949–950

Sphincter, 125

Splenectomy, 288, 356, 450, 577
post-splenectomy infections, 106, 107t

Splenogenic, 450

diseases associated with, 286t–287t
mechanism of, 286t–287t, 287
tropical, 637

Spondylitis, 896f

Spondyloarthritides, 898t

Spondylitic myelopathy, 199, 1029

Sporotrichosis, 631
- disseminated, 631
- lymphocutaneous, 631
- osteoarticular, 631
- plaque disease, 631
- pulmonary, 631

Sporozoite, 636

Spotted fever
- mite-borne, 554
- tick-borne, 554

Spur cell anemia, 326

Staphylococcal infection, 489
- cellulitis, 478
- coagulase-negative staphylococci, 493
- endocarditis, 445t, 446
- food poisoning, 453
- treatment of, 493–496, 494t–495t

Staphylococcal scalded-skin syndrome, 477, 492

Staphylococcus aureus infection, 489
- bacteremia and sepsis, 491
- endocarditis, 491–492, 496
- impetigo, 316
- invasive disease, 490
- methicillin-resistant (MRSA), 65t, 477, 485t, 489–493, 494t–495t, 496
- musculoskeletal, 491, 496
- osteomyelitis, 483, 485t
prosthetic device-related, 492–493
respiratory tract, 491
risk of, 490
skin/soft tissue, 477, 490–491, 496
spinal epidural abscess, 95
toxin-mediated disease, 490, 492
treatment of, 493–496, 494t–495t
urinary tract, 492
Starvation, 40
Stasis ulcer, 311f
Stat DRIP (medication pneumonic), 2
Statins
for aortic stenosis, 681
for hyperlipidemia, 972t
for myocardial infarction, 711–712
for unstable angina, 711
Stauffer’s syndrome, 393
Stavudine, for HIV/AIDS, 608t
Steatorrhea, 256
Stellate ganglion blockade, 1019
Stenotrophomonas maltophilia infection, 518, 520t
Stenting, vascular
for angina pectoris, 716, 717t
for superior vena cava syndrome, 112
Stereognosis, 985
Sterilization, 957
Stevens-Johnson syndrome, 318, 1133t
Stiff-person syndrome, 408t
Streptobacillus moniliformis infection, 118
Streptococcal infection,
arthritides, 499–500
bacteremia, 498–499
brain abscess, 501
cellulitis, 498–500, 498t
empyema, 498, 498t
dendocarditis, 443, 444t, 499–500
eyrispelas, 316, 498, 498t
group A, 316, 497, 498t

group B, 499
groups C and G, 499
hemolytic patterns, 497
impeigio, 498, 498t
liver abscess, 501
meningitis, 500
necrotizing fasciitis, 497–498, 498t
neonatal, 500
nutritionally variant streptococci, 501
osteomyelitis, 485t
pharyngitis, 497, 498t
pneumonia, 498, 498t, 500
poststreptococcal glomerulonephritis, 801
in pregnancy, 500
puerperal sepsis, 499
scarlet fever, 497
toxic shock syndrome, 497, 498t, 499
urinary tract, 500
viridans streptococci, 501
Streptococcus pneumoniae infection. See Pneumococcal infection
Streptococcus pyogenes infection
eyrispelas, 478
necrotizing fasciitis, 478
Streptokinase
for myocardial infarction, 701
for thrombotic disorders, 338
Streptomycin
for Bartonella infections, 526t
for brucellosis, 523
for enterococcal infections, 501
for nontuberculous mycobacterial infections, 548
for plague, 164t, 526
for tuberculosis, 541
for tularemia, 165t, 524
Streptozotocin
for carcinoid tumor, 389
for islet-cell tumors, 391
for Zollinger-Ellison syndrome, 836
Stress testing, in coronary artery disease, 713–714, 713f, 714t
Stroke, 79
anatomic localization in, 81t
causes of, determination of, 85
drug-induced, 1139t
embolic, prevention of, 85–86, 87t
hemorrhagic, 80
ischemic, 80
causes of, 86t
treatment of, 81–84, 84t
prevention of, 85–87, 87t
risk factors for, 85, 87t
small-vessel, 80
treatment of, 80–85, 83f
Strongyloidiasis, 419t, 421, 650, 1117
Strontium-89 therapy, 342t
Struvite stones, 827, 828t
Stupor, 74
Subacute sclerosing panencephalitis, 585
Subarachnoid hemorrhage (SAH), 88
grading scales for, 88, 88t
headache in, 183t
with hydrocephalus, 89–90
lumbar puncture, 27–28, 28f
vasospasm in, 89
Subdural hematoma, 93
Substance abuse, 1104t
alcoholism, 1095
narcotic abuse, 1099
in women, 1130
Succimer, for heavy metal poisoning, 157t, 159t
Sucralfate
for erosive gastropathies, 834
for peptic ulcer disease, 833
Sudden death, 55
differential diagnosis of, 55t
Suicide, 1078, 1080
prevention of, 1104t–1105t
Suicide attempt, 130
Sulfacetamide, for eye infections, 294
Sulfadiazine, for toxoplasmosis, 647
Sulfadoxine-pyrimethamine, for malaria, 638t
Sulfasalazine
  for ankylosing spondylitis, 897
  for enteropathic arthritis, 907
  for inflammatory bowel disease, 838
  for psoriatic arthritis, 898
  for reactive arthritis, 900
  for rheumatoid arthritis, 887
Sulfinpyrazone, for gout, 905
Sulfonamides
  adverse reactions to, 428
  indications for, 426t
  poisoning, 146t
  resistance to, 426t
Sulfonylurea, for diabetes mellitus, 944, 945t
Sulfur granules, 537
Sulfur mustard, 168–169
Sulindac
  for colon cancer prevention, 1124
  for colonic polyps, 383
Sumatriptan
  for cluster headache, 187
  for migraine, 185t–186t, 187t
Sweat's syndrome, 201, 432
Swimmer's ear, 304, 518
Swimmer's itch, 478, 653
Swinging flashlight test, 215
Tachycardia, 717
Tadalafil, for erectile dysfunction, 951
Taeniasis saginata, 655
Taeniasis solium, 655
Takayasu's arteritis, 738, 892
Tamoxifen
  for breast cancer, 376, 378–379
  preventive treatment, 379, 1122
  for endometrial cancer, 397
  for melanoma, 365
  toxicity of, 342t
Tapeworm infection, 655
Tardive dyskinesia, 223, 1092
Target cells, 321
Target lesion, 309
Tarsal tunnel syndrome, 1064t
Taxanes, for prostate cancer, 401
Tazarotene, for psoriasis, 314
T cell immunodeficiency, 883
T cell receptor complex deficiency, 883
Td vaccine, 503
Teardrop cells, 321
Telangiectasia, 313t
Telavancin, for staphylococcal infections, 494t
Temazepam, 1089t
Temperature, 199
Temporary arthritis. See Giant cell arteritis
Temsirolimus
for kidney cancer, 393
toxicity of, 342t

Tendinitis
910
calcific, 910

Tendon reflexes, 219t

Tendon xanthoma, 970

Tenecteplase, for thrombotic disorders, 338

Tenofovir, for HIV/AIDS, 609t

Tension headache, 183t, 186

Teratogenesis, of cancer chemotherapy, 340–342

Teratoma, 393

Terazosin, for prostate hyperplasia, 399

Terbinafine, 620

Terbutaline poisoning, 136t

Terminally ill patient, 46
anorexia in, 52t
apnea in, 53t
care during last hours, 50–51, 52t–53t
clinical courses in last days, 51f
congestion in, 48
death rattle in, 52t
dehydration in, 52t
delirium in, 50, 53t
depression in, 49–50
dysphagia in, 52t
dyspnea in, 49, 53t
fatigue in, 52t
incontinence in, 53t
mucosal membranes in, 53t
nausea and vomiting in, 48
pain management in, 47
physical symptoms of, 47, 47t
psychological symptoms of, 47, 47t
withdrawal of care, 33

Testicular cancer, 393, 394t

paraneoplastic syndromes in, 405t

Testosterone deficiency, 947–949
Testosterone therapy
for androgen deficiency, 948
for hypopituitarism, 922t

Tetanus, 118, 528
generalized, 528–529
local, 529
neonatal, 528–529

Tetanus and diphtheria toxoid (Td), 529

Tetanus booster, 121

Tetanus immune globulin, 529

Tetracycline
for acne, 318
adverse reactions to, 424
for C. pneumoniae infections, 563
for C. psittaci infections, 563
for H. pylori eradication, 833t
for intestinal pseudoobstruction, 843
for malaria, 109t, 638t
for syphilis, 474t
for tularemia, 524

Tetralogy of Fallot, 677

Tetraethylthiuram disulphide, for Wilson’s disease, 978

Thalassemia, 325–326, 325t, 328
Thalidomide
for leprosy, 547
for multiple myeloma, 361

Theophylline
for asthma, 754–755
for COPD, 761–762
poisoning, 137t
Thermoregulatory sweat test, 1016
Thiamine deficiency, 43t
Thiamine therapy, for alcohol withdrawal, 1098
Thiazolidinedione, for diabetes mellitus, 945, 945t
Thigh, muscles and innervation of, 198

Thoracentesis, 26, 26f, 752

Thoracic outlet syndrome, disputed, 198
true neurogenic, 198

Thoracic spine disease, chest pain in, 176f, 178

Thoracotomy, video-assisted (VATS), 752, 775

Throat specimen, collection and transport of, 414t

Thrombocytopenia, 332, 333f
drug-induced, 332, 344, 1135t

Thrombocytopenic purpura
idiopathic (ITP), 332, 335
thrombotic (TTP), 333, 335, 459, 824–826
treatment of, 335

Thrombocytosis, 333

Thyroidectomy, 932

Thyroid function tests, 929

Thyroiditis
silent, 928–930
subacute, 928–930, 930f

Thyroid nodule, 933f
Thyroid-stimulating hormone, 917, 918f
deficiency of, 919t, 922, 922t
hypersecretion of, 919t, 921
Thyroid storm, 928, 930
Thyrotoxic crisis, 928, 930
Thyrotoxicosis, 925, 928, 929f
amiodarone-induced, 931
Thyrotoxicosis, 925
for hypopituitarism, 922t

Tiagabine
for generalized anxiety disorder, 1082
poisoning, 143t
for seizures, 994t

Tic(s), 223
Ticarcillin-clavulanate
for anaerobic infections, 534t
for sepsis/septic shock, 65t
for S. maltophilia infections, 518, 520t
for urinary tract infections, 819t

Tic douloureux. See Trigeminal neuralgia
Tick, removal of, 125
Tick bite, 124
Tick paralysis, 124
Ticlopidine, for thrombotic disorders, 338
TIGAR-O classification, of pancreatic disease, 853t
Tigecycline
for enterococcal infections, 501
for Klebsiella infections, 515
for staphylococcal infections, 493, 494t

Tilt-table test, 1016
TIMI Risk Score, 709–710, 711f

Tinzaparin, for venous thromboembolism, 770

Tobramycin
indications for, 426t
for P. aeruginosa infections, 519t
for pneumonia, 767t
resistance to, 426t
for sepsis/septic shock, 65t
Tokes, muscles and innervation of, 790t–791t
Tolcapone
for Parkinson’s disease, 1004
for P. aeruginosa infections, 519t
Toltenamic acid, for migraine, 185t
poisoning, 187t
for seizures, 992t–993t, 994t
Topoisomerase inhibitors, 341t
Topotecan, 341t
Torsades de pointes, 725t
Torsemide, for heart failure, 733t
Torticollis, 223
Tosilumab
for follicular lymphoma, 357
toxicity of, 342t
Tourette syndrome, 223
Toxemia of pregnancy, 826
Toxic adeno, 932
Toxic epidermal necrolysis, 477
drug-induced, 1134t
Toxoplasmosis, 646
CNS disease, 646
congenital, 646–647
diagnosis of, 420t
ocular, 647
pneumonia, 646
in pregnancy, 646
prevention of, 647
Tracheobronchitis
human RSV, 582
M. catarrhalis, 510

Tramadol
narcotic abuse, 1099
for osteoarthritis, 902
for pain, 36t–37t
poisoning, 152t
Trandolapril, for heart failure, 733t
Transaminases, 268, 268t
Transfusion therapy,
for AML, 346
autologous transfusion, 45
complications of, 44, 45t
plasma components, 45
platelet transfusion, 45
red blood cell transfusion, 44
whole blood, 44
Transjugular intrahepatic portosystemic shunt (TIPS), 263, 272, 874

INDEX
Transplant recipient
cytomegalovirus infection in, 573
infections in, 436, 800
Transsphenoidal surgery, 919, 934
trans-Tretinoic acid, for AML, 346
Transsternal potassium gradient, 10, 11f, 13f
Transurethral microwave thermotherapy
(TUMT), 399
Transurethral resection of prostate (TURP), 399
Tranylcypromine, 138t, 1087t
Trastuzumab
for breast cancer, 379
toxicity of, 342t
Travelers
gastrointestinal illness, 1117
HIV-infected, 1117
immunizations for, 1107, 1116t
insect-borne disease prevention, 1116
malaria prevention, 1116
pregnant, 1117
problems after return, 1117–1118
sexually transmitted diseases in, 1117
Traveler's diarrhea, 451, 454
prevention of, 1117
Trazodone
dosage and adverse effects of, 1087t
for PTSD, 1083
Trichinellosis, 648
Trichomoniasis, 464
Triclabendazole, for liver flukes, 654
Tricuspid regurgitation, 662t, 683
Tricuspid stenosis, 662t, 683
Tricuspid valve endocarditis, 442
Tricuspid valve prolapse, 662t
Tricyclic antidepressants, 1086t, 1088
for irritable bowel syndrome, 842t
for migraine prevention, 184
poisoning, 141t, 149t, 152t, 153t
for polyneuropathy, 1061
Trientine, for Wilson’s disease, 978
Trifluoperazine, 1091t
Trifluorothymidine, for HSV infections, 568t
Trigeminal nerve, 982
sensory divisions of, 1020f
Trigeminal neuralgia, 189, 1020
Trigeminal neuropathy, 1021, 1021t
Trigger points, 1020
Triglycerides, 968
Trihexyphenidyl
for dystonia, 223
for Parkinson’s disease, 1004
Triiodothyronine, 925
Treprostinil, for pulmonary hypertension, 745
Trichloroacetic acid, for HPV infection, 476
Trichomonas vaginalis, 619
for dermatophyte infections, 317
Trichinellosis, 648
Trichloroacetic acid, for HPV infection, 476
Trichomoniasis, 464
Triclabendazole, for liver flukes, 654
Tricuspid valve endocarditis, 442
Tricuspid valve prolapse, 662t
Tricyclic antidepressants, 1086t, 1088
for irritable bowel syndrome, 842t
for migraine prevention, 184
poisoning, 141t, 149t, 152t, 153t
for polyneuropathy, 1061
Trientine, for Wilson’s disease, 978
Tuberculosis (Cont.):
- gastrointestinal disease in, 540
- genitourinary, 540
- HIV/AIDS and, 538–540, 542, 545t–546t
- meningitis in, 540
- miliary disease, 540
- multidrug-resistant, 538
- nosocomial, 432
- pericarditis in, 540
- pleural involvement in, 539, 780
- postprimary, 539
- prevention of, 542
- primary, 539
- pulmonary, 539
- skeletal disease in, 540
- treatment of, 541–542, 543t
- latent infection, 542, 544t–546t

Tuberoeruptive xanthoma, 974
Tuberous sclerosis/lymphangioleiomyomatosis, 774
Tuberous xanthoma, 970
Tube thoracostomy, 778
Tubulointerstitial disease, 808
Tubulointerstitial nephritis and uveitis syndrome, 811
Tularemia, 106, 118, 201, 478, 524
- as bioweapon, 165t, 166
- oculoglandular, 524
- oculopharyngeal and gastrointestinal, 524
- pulmonary, 524
- treatment of, 165t, 524–525
- typhoidal, 524
- uceloruglandular/glandular, 524

Tumor (skin lesion), 313t
Tumor lysis syndrome, 116, 359
Tumor-suppressor genes, 339
Turcot’s syndrome, 384, 384t
Turner’s sign, 849
Twitching, 984
Two-point discrimination, 985
Tympanic membrane perforation, 298–300
Tympanometry, 298
Typhoid fever. See Enteric fever
Typhoid vaccine, 1116t
Typhus endeminc murine (flea-borne), 556
- as bioweapon, 165t, 166
- oculoglandular, 524
- oculopharyngeal and gastrointestinal, 524
- pulmonary, 524
- treatment of, 165t, 524–525
- typhoidal, 524
- uceloruglandular/glandular, 524

U
Ulcer, 313t
- cutaneous, 201, 478
- genital, 466, 467t
Ulcer (skin lesion), 313t
Ulcerative colitis, 837
- epidemiology of, 836, 836t
- extraintestinal manifestations of, 838
- treatment of, 838, 839f, 840
Ulcerative pharynx, 1062t
Ultrasonography
- diagnostic, 24
- endoscopic, 380, 846t, 847
- hepatobiliary, 270, 846f, 847–848
- neuroimaging, 987t
- in osteomyelitis, 484t
- in pancreatitis, 851–852

renal, 794
- in stroke, 85
- venous, 770
Undecylenic acid, for dermatophyte infections, 317
Underweight, 939t
Undulating fever, 522–523
Unfractionated heparin
- for thrombotic disorders, 336
- for venous thromboembolism, 770–771
Unstable angina, 709
TIMI Risk Score for, 709–710, 711f
- treatment of, 709–712, 710f
Upper respiratory infection (URI), 301, 303t–304t
Urare nephropathy, 903
Urea breath test, 832, 832t
Ureaplasma infection, 471
Ureidoaceticillin, for cholecystitis, 847
Uremia, 276, 794, 795
Uremic syndrome, 795
Ureteral obstruction, 830
Urethral syndrome, 464
Urethritis, 815
- chlamydial, 471
- gonococcal, 464, 468
- in men, 463
- nongonococcal, 463, 471, 482
- treatment of, 463, 816–817
- in women, 464
Uric-acid lowering agents, 903
Uric acid stones, 827, 828t, 904
Uricosuric drugs, for gout, 905
Urinalysis, 816
- reference values for specific analytes, 1163t
Urinary incontinence, in terminally ill patient, 53t
Urinary tract incontinence, in terminally ill patient, 53t
Urinary retention, 399
Urinary stones, drug-induced, 1138t
Urinary tract infection, 786t, 787, 815
- acute, 815
- in cancer patients, 434
- candidiasis, 620
- catheter-associated, 816
- causes of, 815, 818–819t
- complicated, 819t
- E. coli, 513
- enterococcal, 500
- gram-negative enteric bacteria, 516
- Klebsiella, 515
- nosocomial, 429, 430t
- P. aeruginosa, 518, 520t
- prevention of, 817
- Proteus, 515
- S. aureus, 492
- streptococcal, 500
- treatment of, 816–817, 818t–819t
Urinary tract obstruction, 786t, 788, 829, 830f
- drug-induced, 1138t
Urinary tract abnormalities
- asymptomatic, 786t, 787, 806, 806t
- of volume, 276
- specimen collection and transport, 416t
- toxicologic analysis of, 133
Urethral tract, 416t
Urokinase, for thrombotic disorders, 338
Ursodeoxycholic acid
for primary biliary cirrhosis, 871
for primary sclerosing cholangitis, 849
Urticaria, for primary biliary cirrhosis, 871
for primary sclerosing cholangitis, 849
for drug-induced, 1134t
UV-B phototherapy, for pityriasis rosea, 314
Uveitis, 294
Uveitis, for drug-induced, 1134t
Uvulopalatopharyngoplasty, 784
Vaccination. See Immunization
Vaccine Adverse Event Reporting System (VAERS), 1107
Vaginal discharge, 464
Vagotony, for peptic ulcer disease, 833t
Valacyclovir
for Bell’s palsy, 1022
for HSV infections, 475, 479t, 567t–568t, 569
Valdecoxib, for pain, 36t–37t
Valganciclovir
for cytomegalovirus infections, 574
for viral esophagitis, 252
Valproate/valproic acid
for bipolar disorder, 1080
for migraine prevention, 188t
for myoclonus, 224
for posthypoxic myoclonus, 98
for poisoning, 143t
for posthypoxic myoclonus, 98
for seizures, 992t–993t, 994t
for status epilepticus, 99f
for seizures, 992t–993t, 994t
for status epilepticus, 99f
for toxic shock syndrome, 108t
Varicella vaccine, 571, 1108t–1112t, 1114t
Varicella-zoster immune globulin, 571
Varicella-zoster vaccine, 438t
Varicella-zoster virus infection, 569
chickenpox, 569
epidemic and emerging problems, 431–432
in immunocompromised host, 570
shingles, 570
Varicocle, 950
Variola major, 163–166
Variola minor, 163–166
Vascular dementia, 996t, 997t, 998, 1000
Vascular disease
abdominal pain in, 179t
gastrointestinal, 843
headache in, 183t
malabsorption in, 259t
peripheral, 738
skin diseases, 318
Vascular malformation, myelopathy in, 1029, 1030f
Vascular shunting, anatomic, 239
Vascular tone, disorders of, 280t
Vasculitis, 319, 891
approach to, 892, 893f
conditions that mimic, 894t
cutaneous, 319, 892
neuropathy in, 1061
primary vasculitis syndrome, 891–892
renal complications of, 826
secondary vasculitis syndromes, 892
treatment of, 319, 893–894
urticarial, 319
Vasoconstrictors, for heart failure, 734t
Vasodilators
for aortic regurgitation, 683
for heart failure, 734, 734t
for myocardial infarction, 705, 705t, 708
for pulmonary hypertension, 745
Vasopressin, 923
deficiency of, 922t
for heart failure, 734t
interarterial, for diverticulosis, 263
for shock, 62, 62t
Vasopressin antagonists, for hypotension, 7
Vasospasm, in subarachnoid hemorrhage, 89
Vasospastic disorders, 740
Venezuelan equine encephalitis, 596t–597t, 598
Venlafaxine
dosage and adverse effects of, 1086t
for menopausal symptoms, 957
for pain, 36t–37t
Venous disease, 740
Venous insufficiency, chronic, 741
Venous thromboembolism, 769
drug-induced, 1136t
Ventilation, disorders of, 781
Ventilation/perfusion lung scan, 743, 770
Ventilation/perfusion mismatch, 750
Ventilatory function, disturbances in, 747–748
extraparenchymal, 748, 748t
obstructive, 747–748, 748t
parenchymal, 748, 748t
restrictive, 747–748, 748t
Ventilatory support
in ALS, 1013
in ARDS, 70–71, 70f
care of ventilated patient, 31–32
complications of, 74
during COPD exacerbations, 763
for critically ill patient, 30
management of mechanically ventilated patients, 72–74
mechanical ventilation, 30
modes of mechanical ventilation, 72–74, 73t
monitoring of respiratory mechanics, 32
after nerve agent exposure, 169
in respiratory failure, 72–74, 73t
weaning from mechanical ventilation, 32
Ventricular aneurysm
in myocardial infarction, 708
pseudoaneurysm, 708
true, 708
Ventricular arrhythmia, in myocardial infarction, 704
Ventricular fibrillation, 721f, 724t
management of, 57f
in myocardial infarction, 704
Ventricular premature beats, 724t
Ventricular septal defect, 662t, 674
Ventricular septal rupture, 708
Ventricular tachycardia, 720, 721f, 724t, 726t
hypotensive, 57, 57f
in myocardial infarction, 704
in poisoning, 134–135
Ventriculoencephalitis, cytomegalovirus, 573
Verapamil
for angina pectoris, 715
for aortic dissection, 738
for arrhythmias, 728t, 736
for atrial fibrillation, 726
for cluster headache prevention, 187
for hypertension, 695t, 696–698
for hypertrophic cardiomyopathy, 686
for migraine prevention, 184, 188t
for mitral stenosis, 678
for myocardial infarction, 711
poisoning, 140t
for supraventricular arrhythmias, 704
for tachyarrhythmias, 722f–724t
for unstable angina, 711
for Wolff-Parkinson-White syndrome, 729
Verruca plana, 310f
Verruca vulgaris, 311f
Verrucous carcinoma, 366
Verruga (skin lesion), 528
Verruga peruana, 526t, 527
Vertebral disk herniation
central, 1023
acute, 1029
cervical disk, 196, 198
lumbar disk, 190
Ventral fracture, 192
Ventral metastasis, 192
Vertebrobasilar insufficiency, 215
Vertigo, 211, 214t, 297
central, 213, 213t
pathologic, 212
peripheral, 212–213, 212t
physiologic, 212
provocative tests to reproduce, 211
psychogenic, 213
Vesicants, 168
Vesicle (skin lesion), 313t, 477
Vesiculobullous eruptions, 200
Vestibular disorder
drug-induced, 1139t
vertigo, 211
Vestibular function tests, 211
Vestibular neuritis, 212
Vibrio cholerae
See also Cholera
Vibrio parahaemolyticus
Vibrio vulnificus
infection, 453
infection, 453
infection, 110, 477
Vidarabine
for HSV infections, 568t
Vincristine
for acute lymphoblastic leukemia and lymphoblastic lymphoma, 359
for Burkitt’s lymphoma/leukemia, 359
for gastric cancer, 381
for idiopathic thrombocytopenic purpura, 335
for multiple myeloma, 361
toxicity of, 341t
Vinorelbine
for breast cancer, 379
for lung cancer, 371
toxicity of, 341t
VIPoma, 389, 390t, 391
Viral disease
diagnosis of, 411
specimen collection and transport, 418t
Viral hemorrhagic fevers
as bioweapon, 165t, 166–167
treatment of, 165t
Viritelization, 955
Visceral abscess, 450
Visceral disease, back pain in, 193, 193t
Visceral spasm, 179t
Visual acuity, 215
Visual field mapping, 215, 216f
Visual loss, 293
acute, approach to, 215
chronic, progressive, 295, 295t
transient or sudden, 215
Vitamin(s)
reference values for laboratory tests, 1160t
for acute lymphoblastic leukemia and lymphoblastic lymphoma, 359
for Burkitt’s lymphoma/leukemia, 359
for gastric cancer, 381
for idiopathic thrombocytopenic purpura, 335
for multiple myeloma, 361
toxicity of, 341t
VIPoma, 389, 390t, 391
Viral hemorrhagic fevers
as bioweapon, 165t, 166–167
Vitamin A deficiency
anemia in, 325, 328
Vitamin C supplementation for macular degeneration, 296 for nephrolithiasis, 828
Vitamin D deficiency, 963, 968
Vitamin D supplementation for osteomalacia, 968 for osteoporosis, 967 for primary sclerosing cholangitis, 848 for psoriasis, 314
Vitamin E deficiency, 43t, 1009
Vitamin E supplementation for macular degeneration, 296 for menopausal symptoms, 957
Vitamin K deficiency, 43t, 334–335
Vitamin K supplementation for vitamin K deficiency, 335 for warfarin reversal, 336
Vitiligo, 310f
Vitreous detachment, 215–216
Vitreous hemorrhage, 216
Volume regulation, 3t
Volume status, assessment of, 4f
Vomiting. See Nausea and vomiting
von Hippel-Lindau disease, 392
von Willebrand disease, 334–335
Voriconazole, 619 for aspergillosis, 623, 624t for fusariosis, 632
Vulvovaginal infection, 464
VX gas, 142t, 169–171

Waldenström’s macroglobulinemia, 807t

Women’s health, 1128 Alzheimer’s disease, 1128 autoimmune disease, 1129 coronary heart disease, 1128 diabetes mellitus, 1129 HIV infection, 1129 hypertension, 1129 nicotine addiction, 1130 obesity, 1129 osteoporosis, 1129 pharmacology, 1129 psychiatric disease, 1129 sleep disorders, 1130 substance abuse, 1130 violence, 1130 Wood’s light examination, 312 Work hardening, 196 Wound infection specimen collection and transport, 417t surgical, 430–431, 430t Wrist, muscles and innervation of, 980t–981t

X
Xanthelasma, 970 Xanthoma, 970, 973–974 Xerostomia, 890–891 D-Xylose absorption test, 256 D-Xylose urinary excretion test, 852

Y
Yaws, 551 Yellow fever, 110, 599 Yellow fever vaccine, 1116t Yellow jacket sting, 126 Yersinia pestis infection. See Plague

Z
Zafirlukast for asthma, 755 for urticaria/angioedema, 879
Zalcitabine, for HIV/AIDS, 608t
Zaleplon
   for insomnia, 228
   poisoning, 143t
Zanamivir, for influenza, 579, 579t
   preventive treatment, 580–581
Zap70 kinase deficiency, 883
Zidovudine
   for adult T cell leukemia/lymphoma, 260
   for HIV/AIDS, 607t
Zieve’s syndrome, 868
Zinc deficiency, 43t
Zinc supplementation
   for hepatic encephalopathy, 875
   for macular degeneration, 296
   for Wilson’s disease, 978

Ziprasidone
   dosage and adverse effects of, 1091t
   for schizophrenia, 1081
Zoledronate
   for hypercalcemia, 113, 406, 962t
   for osteoporosis, 967
Zollinger-Ellison syndrome, 389, 390t, 835, 835t
Zolmitriptan, for migraine, 185t, 187t
Zolpidem
   for insomnia, 228
   poisoning, 143t
Zonisamide
   poisoning, 143t
   for seizures, 994t
Zoster ophthalmicus, 570–571